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Abstract
1. Effect of Statin Use on Acute Kidney Injury
Following Elective Cardiothoracic Surgery: A
Population Cohort Study in Denmark
J Bradley Layton,1 Malene K Hansen,2 Carl-Johan
Jakobsen,3 Jan J Andreasen,4 Vibeke E Hjortdal,5 Bodil
S Rasmussen,6 Abhijit V Kshirsagar,7 Ross J Simpson,7
Christian F Christiansen.2 1Epidemiology, University of
North Carolina at Chapel Hill, Chapel Hill, NC, United
States; 2Clinical Epidemiology, Aarhus Univeristy
Hosptial, Aarhus, Denmark; 3Anesthesia and Intensive
Care, Aarhus University Hospital, Aarhus, Denmark;
4Cardiothoracic Surgery, Aalborg University Hospital,
Aalborg, Denmark; 5Cardiothoracic and Vascular Sur-
gery, Aarhus University Hospital, Aarhus, Denmark;
6Anaesthesia and Intensive Care Medicine, Aalborg Uni-
versity Hospital, Aalborg, Denmark; 7Medicine, Univer-
sity of North Carolina at Chapel Hill, Chapel Hill, NC,
United States.
Background: Acute kidney injury (AKI) is a serious com-
plication of cardiac surgery. Clinical nonexperimental
studies have reported that statins, having pleiotropic anti-
inﬂammatory and plaque-stabilizing properties, may pre-
vent post-surgical AKI, yet methodological concerns raise
doubts about these results.
Objectives: To estimate the effect of initiating a statin
prior to elective cardiac surgery on post-surgical AKI.
Methods: We identiﬁed adults undergoing elective
cardiac surgeries in years 2006-2011 in the Western
Denmark Heart Registry which contains detailed patient
and surgical characteristics about cardiac surgeries.
Medication history and pre- and post-surgical serum
creatinine (sCr) measures were obtained from Danish
population-based registries. The presence of post-surgical
AKI was determined using Acute Kidney Injury Network
(AKIN) guideline criteria by comparing pre- and peak
post-surgical sCr levels measured during the 5 days
following surgery. Adjusted and standardized mortality
ratio weighted (SMRW) risk ratios (RR) and 95% conﬁ-
dence intervals (CI) were estimated for the risk of AKI
in patients who initiated a statin within 100 days prior to
surgery compared to those without prior statin use.
Analyses were stratiﬁed by surgery type: coronary artery
bypass grafting (CABG) and non-CABG surgeries (valve,
aorta, septum, other).
Results: We identiﬁed 6,699 surgeries; after the exclu-
sion of former and long-term statin users, we retained
1,907 CABG and 1,722 non-CABG patients. Of these
statin-naïve patients, half (50%) the CABG patients
newly initiated a statin prior to surgery, and 9% of non-
CABG patients did. AKI occurred in 25% of CABG
and 28% of non-CABG surgeries; the majority of AKI
(77%) was mild, AKIN stage 1. The adjusted RR for
the effect of statin initiation on AKI in CABG was
0.82 (95% CI: 0.68, 0.99); SMRW RR=0.76 (0.58,
1.00). In non-CABG surgeries: RR= 0.87 (0.66, 1.14);
SMRW RR=0.82 (0.61, 1.10).
Conclusions: Our study, employing a new user design
and rich clinical information, agrees with previous esti-
mates suggesting that pre-surgical statin initiation mod-
estly reduces post-surgical AKI, particularly in CABG
procedures.
2. Perioperative Utilization of Statins in Patients
Undergoing Intermediate to High Risk Non-Cardiac
Surgery
Elisabetta Patorno, Shirley Wang, Sebastian Schneeweiss,
Jun Liu, Brian Bateman. Division of Pharmaco-
epidemiology and Pharmacoeconomics, Brigham and
Women’s Hospital and Harvard Medical School, Boston,
MA, United States.
Background: Cardiac events are a major cause of peri-
operative morbidity and mortality in patients undergoing
non-cardiac surgery. Starting from early to mid 2000s a
growing body of literature has been produced on the
potential role of statins in reducing these events.
However, evidence remains inconsistent and little is
known regarding the use of perioperative statins in
clinical practice.
Objectives: To describe perioperative initiation of statins
before moderate- to high-risk non-cardiac elective
surgery in the US.
Methods: Using health care utilization data from a large
US healthcare insurer, we identiﬁed a cohort of patients
18 years old and older who underwent moderate- to
high-risk non-cardiac elective surgery. Perioperative
initiation of statins was deﬁned as initiation of therapy
within a 30-day assessment window before surgery, with
no prescriptions ﬁlled during the 180-day period prior to
the assessment window. We described rates of statin
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initiation over time and patient characteristics associated
with initiation.
Results: We identiﬁed 460,154 patients who underwent
moderate- to high-risk non-cardiac elective surgery
between 2003 and 2012 and had no statin prior to the
assessment window. Of those, 5,628 (1.2%) initiated a
statin within 30 days of surgery. The rate of initiation
progressively increased from 0.8 per 100 procedures in
2003 to 1.5 per 100 procedures in 2012. The increase
was more pronounced among patients with revised car-
diac risk index (RCRI) score ≥2 and patients undergoing
vascular surgery, with initiation rates equal to 7.4% and
14.9% respectively by the end of 2012. Compared to
non-initiators, statin initiators were older, more likely to
be male, had more frequently cardiovascular or renal
disease, and more often underwent vascular surgery.
Conclusions: The rate of statin initiation progressively
increased from 2003 to 2012, particularly among older
patients with higher RCRI and undergoing major vascu-
lar surgery. Research is needed to further deﬁne the risks
and beneﬁts of initiation of statins prior to surgery.
3. Pattern of Risks of Rheumatoid Arthritis among
Patients Using Statins: a Cohort Study with the
Clinical Practice Research Datalink
Hilda J De Jong,1,2,3 Jan Willem Cohen Tervaert,2,4 Arief
Lalmohamed,3 Frank De Vries,2,3 Rob J Vandebriel,1
Henk Van Loveren,1,2 Olaf H Klungel,3 Tjeerd Van
Staa.3,5 1National Institute for Public Health and the
Environment, Bilthoven, Netherlands; 2Maastricht
University Medical Centre, Maastricht, Netherlands;
3Utrecht University, Utrecht, Netherlands; 4Sint Franciscus
Gasthuis, Rotterdam,Netherlands; 5University of Southampton,
Southampton, Netherlands.
Background: Previous studies evaluating the effect of
statins on developing rheumatoid arthritis (RA) have
shown conﬂicting results.
Objectives: To examine the association between statin
use and the risk of RA in a large population-based cohort
in the United Kingdom (UK), with a special focus on de-
scribing the patterns of risks of RA during statin exposure.
Methods: A retrospective cohort study using the UK
Clinical Practice Research Datalink was conducted. All
patients aged ≥40 years, who had at least one prescription
of statins during the period 1995-2009 were selected and
matched by age, sex and date of ﬁrst prescription of
statins to controls (patients not using statins). All patients
were followed up for the development of RA. Patients
were considered as having a diagnosis of RA if the
ﬁrst-time diagnosis registered by general practitioners
was veriﬁed by the use of at least one prescription of
disease modifying anti-rheumatic drugs.The follow-up
period of statin users was divided into periods of current,
recent and past exposure, with patients moving between
these three exposure categories over time. Time-dependent
Cox models were used to derive hazard ratios of RA,
adjusted for disease history and previous drug use.
Results: The study population included 1,023,240
patients, of whom 511,620 received a prescription of
statins. No associations were found between RA and
current or past users of statins. However, in patients
who currently used statins, there were substantial
changes in the hazard rates of RA over time: hazard rates
were increased shortly after the ﬁrst prescription of
statins and then gradually decreased to baseline level.
The risk of developing RA was increased in patients
who recently used statins, as compared to non-users
(HRadj, 1.41; 95% CI: 1.12-1.79).
Conclusions: The risk of RA is substantially increased in
the ﬁrst year after the start of statins and then diminishes
to baseline level. These ﬁndings suggest that statins
might accelerate disease onset in patients susceptible to
developing RA. Alternatively, confounding by cardio-
vascular risk factors and diagnostic suspicion bias may
have inﬂuenced the ﬁndings.
4. Statin Use and Cholesterol Levels among US
Adults with Age-Related Macular Degeneration
(AMD): Findings from the 2005-2008 National
Health and Nutrition Examination Survey (NHANES)
R A Cantrell,1 C I Kiu Weber,2 P Delmar,2M Gleeson,3
Q Doan.3 1Genentech, Inc., South San Francisco,
CA, United States; 2Roche Ltd., Basel, Switzerland;
3Outcomes Insights, Inc., Westlake Village, CA, United
States.
Background: Age is a risk factor for both AMD and
cardiovascular disease (CVD). A growing body of litera-
ture indicates an involvement of lipids in the pathogene-
sis of AMD.
Objectives: To estimate a) mean HDL-C and LDL-C
levels, b) the prevalence of statin use and c) the relation-
ship between HDL-C and AMD in the US.
Methods: Individuals ≥40 years old who had completed
interview, examination and gradable retinal images
in NHANES 2005-2008, a population-based national
cross-sectional survey, were included in this analysis.
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Diagnosis of any AMD (e.g., early, geographic atrophy,
or exudative) was based on grading of fundus photo-
graphs. Statin use was based on self-report. HDL-C was
measured directly in serum, and LDL-C was calculated
using the Friedewald calculation in participants who
had fasted. Analyses were conducted using survey
weights to account for the complex NHANES sampling
design, oversampling and survey non-response. Logistic
regression was used to evaluate the association between
systemic HDL-C and AMD after adjusting for age, sex,
race, education, body mass index, smoking, health insur-
ance, history of CVD, hypertension and statin use.
Results: 5,512 participants met inclusion criteria. For
each of the following measures, we estimated the values
for those with AMD and those without AMD:
• prevalence of statin use: 36.6% (95%CI: 31.4-41.9%)
vs. 25.7% (95% CI: 23.5-27.8%)
• meanHDL-C: 56.7mg/dL (95%CI: 55.1-58.4mg/dL)
vs. 53.8mg/dL (95% CI: 53.0-54.5mg/dL)
• meanLDL-C: 119.1mg/dL (95%CI: 112.6-125.6mg/dL)
vs. 119.5mg/dL (95% CI: 117.7-121.4mg/dL)
• percentage with HDL-C <40mg/dL: 17.5% (95%
CI: 13.7-21.2%) vs. 20.1% (95% CI: 18.7-21.6%)
The adjusted odds ratio for any AMD was 1.01
(95% CI: 1.00-1.02) per 1mg/dL higher HDL-C
level (p = 0.01).
Conclusions: These results provide nationally represen-
tative estimates of the prevalence of statin use and
average HDL-C and LDL-C levels among patients with
and without AMD in the US as well as an estimate of
the association between systemic HDL-C levels and risk
of AMD.
5. Statin Initiation in a Closed Cohort of U.S. Women
over Two Decades
Tracy L Kinsey,1 Til Stürmer,1 Robert J Glynn.2
1Department of Epidemiology, University of North
Carolina, Chapel Hill, NC, United States; 2Division
of Preventive Medicine, Brigham and Women’s
Hospital, Boston, MA, United States.
Background: Understanding drivers of statin use that
are not captured in claims data is important in
pharmacoepidemiologic studies of statins.
Objectives: To describe predictors of statin initiation
with respect to secular trends and use in primary and
secondary prevention in a cohort of U.S. women initially
free of cardiovascular disease (CVD).
Methods: We identiﬁed new statin use among 39,876
women enrolled in the Women’s Health Study from
1993-95 and followed through 2011. Women completed
annual questionnaires, 13 of which included statin use.
Initiation was deﬁned as the ﬁrst report of use in initial
non-users. Logistic regression models were ﬁtted to
predict initiation overall, among those with and with-
out prior CVD, and separately within 1994-2000 and
2002-2010, corresponding to National Cholesterol
Education Program Adult Treatment Panel-II (ATP-II)
and ATP-III guidelines, respectively. Covariates were
age, body mass index, self-reported total cholesterol
(TC), menopausal status, education, smoking, exercise,
race, alcohol use, multivitamin use, diabetes, hypertension,
CVD, cerebrovascular events, and calendar time.
Results: Prevalent use was 3% at inception and 43% in
2011. Of 38,608 baseline non-users, 17,451 (45%)
initiated statins during follow-up. The annual proportion
initiating increased steadily over time from 2% to 6%.
Key predictors in the overall model were TC (adjusted
OR (95% CI) 5.6 (5.4, 5.9) for >240 vs. <200mg/dl),
diabetes (2.7 (2.5, 2.8)), CVD (1.8 (1.7, 2.0)), hyperten-
sion (1.6 (1.6, 1.7)), and calendar time (2.7 (2.6, 2.9)
for >2002 vs. <1997). The overall c-statistic was 0.75.
In models for ATP-II and ATP-III periods, respectively,
ORs were 14.5 (12.4, 16.9) and 3.9 (3.6, 4.1) for TC,
2.0 (1.7, 2.4) and 2.8 (2.6, 3.1) for diabetes, and 2.8
(2.2, 3.7) and 1.7 (1.5, 1.9) for CVD; in models for
primary and secondary prevention ORs were 5.8 (5.5,
6.1) and 2.4 (1.9, 3.1) for TC, and 2.7 (2.5, 2.9) and 1.9
(1.5, 2.5) for diabetes.
Conclusions: Initiation was driven more heavily by TC
and CVD under ATP-II, while diabetes was a stronger
predictor under ATP-III. The role of TC in statin initia-
tion is diminished in more recent times, as well as in
secondary prevention settings.
6. Pharmacoepidemiologic and In Vitro Evaluation
of Potential Drug-Drug Interactions of Sulfonylureas
with Fibrates and Statins
Hedi Schelleman,1 Xu Han,2 Colleen M Brensinger,1
Sara K Quinney,3 Warren B Bilke,1,4 David A
Flockhart,2 Lang Li,5 Sean Hennessy.1,4 1Center for
Clinical Epidemiology and Biostatistics, Perelman
School of Medicine at the University of Pennsylvania,
Philadelphia, PA, United States; 2Division of Clinical
Pharmacology, School of Medicine at Indiana
University, Indianapolis, IN, United States; 3Department
of Obstetrics and Gynecology, School of Medicine at
Indiana University, Indianapolis, IN, United States;
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4Center for Pharmacoepidemiology Research and
Training, Perelman School of Medicine at the University
of Pennsylvania, Philadelphia, PA, United States;
5Department of Medical and Molecular Genetics,
School of Medicine at Indiana University, Indianapolis,
IN, United States.
Background: Hypoglycemia is a common side effect
of sulfonylureas and could be exacerbated by interac-
tions with concomitant medications. Inhibition of drug
metabolism by cytochrome P450 (CYP) enzymes is
one of the most common mechanisms for drug-drug
interactions.
Objectives: To examine whether the initiation of ﬁbrates
or statins in sulfonylurea users is associated with severe
hypoglycemia, and to examine in vitro the inhibition of
CYP enzymes by statins, fenoﬁbrate and glipizide.
Methods: We used Medicaid data to conduct nested
case-control studies. All person-time exposed to sulfo-
nylureas was included for all enrollees 18 years and
older. Cases were current users of sulfonylureas who
were hospitalized or treated in an emergence department
(ED) for hypoglycemia. The index date was the date of
hospital admission or ED visit. Fifty controls without
hypoglycemia were selected randomly for each case,
matching on index date and state. Case and controls were
considered exposed to ﬁbrates/statins if a ﬁbrate/statin
was dispensed 1-30 days before the index date. Condi-
tional logistic regression was used to calculate overall
and time-stratiﬁed odds ratios (ORs) and 95% conﬁdence
intervals (CIs). We also characterized in vitro the
inhibition of CYP enzymes by statins, fenoﬁbrate, and
glipizide, and estimated area under the concentration-
time curve ratios (AUCRs) for drug pairs.
Results: We found elevated adjusted overall ORs for
glyburide-fenoﬁbrate (OR 1.84, 95% CI 1.37-2.47) and
glyburide-gemﬁbrozil (OR 1.57, 95% CI 1.25-1.96).
The apparent risk did decline over time as might
be expected with a pharmacokinetic interaction.
Fenoﬁbrate was a potent in vitro inhibitor of
CYP2C19 (IC50 = 0.2 μM) and CYP2B6 (IC50 = 0.7
μM), a moderate inhibitor of CYP2C9 (IC50 = 9.7
μM). The predicted AUCRs for fenoﬁbrate-glyburide
and gemﬁbrozil-glybuiractions interactions were only
1.09 and 1.04, suggesting that CYP inhibition is
unlikely to explain such an interaction.
Conclusions: Use of fenoﬁbrate or gemﬁbrozil together
with glyburide was associated with elevated overall risks
for severe hypoglycemia. CYP inhibition seems unlikely
to explain this observation.
7. Does a Risk Management Plan Increase Safety
Monitoring for the Use of Tumor Necrosis Factor-
alpha Inhibitors?
Meng-Ju Chan,1 Chien-Ning Hsu,1,2 Yen-Hsia Wen,1
Yu-Chin Lily Wang.2 1School of Pharmacy, Kaohsiung
Medical University, Kaohsiung, Taiwan; 2Department
of Pharmacy, Kaohsiung Chang Gung Memorial
Hospital, Kaohsiung, Taiwan.
Background: The Risk Management Plan (RMP),
including baseline evaluation and follow-up safety
monitoring of tumor necrosis factor-alpha inhibitors
(TNFi) was recommended by Taiwan FDA in early
2012, but the compliance of RMP application remained
unknown.
Objectives: To assess differences in screening rates of
viral hepatitis and tuberculosis infection before and after
RMP in the practice setting.
Methods: A cross-sectional study was conducted using
patient level data from a large medical center in Taiwan
from 1/2010 to 11/2013. Patients with at least one
prescription of TNFi (etanercept, adalimumab and
golimumab) were identiﬁed based on electronic dispens-
ing records. Based on the earliest date of prescription in
the dataset, TNFi users were classiﬁed into pre- and
post-RMP groups (cut-point 1/1/2012). Safety monitor-
ing tests (liver function, B/C viral hepatitis, tuberculosis)
were retrieved 6months before and after the earliest
prescription for TNFi users. Multivariate logistic regres-
sion was employed to determine the independent effect
of RMP and other factors associated with the likelihood
of safety monitoring.
Results: Of 1128 patients (n = 531 in pre- and 597 in
post-RMP group), 41% were male with mean age 49.9
(±14.3) years at ﬁrst prescription. Screening rates
increased from 32.2% in pre- to 61.3% in post-RMP for
hepatitis B, 32.2% to 54.3% for hepatitis C, and 60.3%
to 76.4% of chest X ray for tuberculosis screening.
Tests for liver function, abdominal ultrasound and
tuberculosis remained no differences. Factors signiﬁcantly
associated with hepatitis B (HBs Ag) screening were RMP
(OR=2.5), concomitant cyclosporine (OR=0.6); hepatitis
C (anti-HCV Ab) was related with RMP (OR=2.5),
concomitant leﬂunomide (OR=1.7) and penicillamine
(OR=0.2), hepatitis B carrier (OR=12.8); chest X ray
was related with RMP (OR=2.5), concomitant sulfasalazine
(OR=1.5) and penicillamine (OR=0.2). Specialty effect
varied depending on test.
Conclusions: The launch of RMP was associated a
signiﬁcant increase in TNFi safety monitoring rates. Test
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was associated with background uses of DMARD and
risk of viral hepatitis, and specialty.
8. Cost-Efficacy of Biologic Therapies for Moderate
to Severe Psoriasis from the Perspective of the
Taiwanese Healthcare System
Ching-Chi Chi,1,2 Shu-Hui Wang.3 1Department of
Dermatology, Chang Gung Memorial Hospital, Chiayi,
Taiwan; 2College of Medicine, Chang Gung University,
Taoyuan, Taiwan; 3Department of Dermatology, Far
Eastern Memorial Hospital, New Taipei, Taiwan.
Background: Biologic therapies are more effective for
psoriasis but also more costly when compared to con-
ventional therapies.
Objectives: To compare the cost-efﬁcacy of etanercept,
adalimumab, and ustekinumab therapies for moderate to
severe psoriasis in a Taiwanese setting.
Methods: We conducted a meta-analysis of randomized
placebo-controlled trials to calculate the incremental
efﬁcacy of etanercept, adalimumab, and ustekinumab for
at least 75% reduction in the Psoriasis Area and Severity
Index score (PASI 75). The base, best, and worst case in-
cremental cost-effectiveness ratio (ICER) for one subject
to achieve PASI 75 were calculated for economic analysis.
Results: The 1-year ICER per PASI 75 responder was
US$39,709 (best scenario US$36,400; worst scenario
US$43,680), US$23,711 (best scenario US$22,633;
worst scenario US$25,319), and US$26,329 (best scenario
US$24,780; worst scenario US$27,623) for etanercept,
adalimumab, and ustekinumab, respectively. The corre-
sponding 2-year ICER per PASI 75 responder was US
$71,973 (best scenario US$65,975; worst scenario US
$79,170), US$62,665 (best scenario US$59,817; worst
scenario US$66,914), and US$52,657 (best scenario US
$49,560; worst scenario US$55,247), respectively.
Conclusions: In a Taiwanese setting, both adalimumab
and ustekinumab had a lower 1-year cost per PASI 75
responder, while ustekinumab had the lowest 2-year cost
per PASI 75 responder.
9. Regional Differences in Utilisation of Biologicals
in Portugal
Joelle M Hoebert,2 Soﬁa Oliveira-Martins,3 Hubert GM
Leufkens,1 José Cabrita,3 Helder Mota-Filipe,3
Patrick C Souverein.1 1Division of Pharmacoepidemiology
& Clinical Pharmacology, Utrecht Institute for
Pharmaceutical Sciences, Utrecht University, Utrecht,
Netherlands; 2National Institute for Public Health and
the Environment (RIVM), Bilthoven, Netherlands;
3Faculty of Pharmacy, University of Lisbon, Lisbon,
Portugal.
Background: In Portugal policy measures have been
taken in 2008 with the objective to create a national
database including all patients treated with biologics for
rheumatic diseases, to allow for a better monitoring of
their efﬁcacy, access and safety.
Objectives: To describe use of biologics in Portugal and
compare utilisation patterns between regions.
Methods: Data were used from the Portuguese data-
base of consumption of biologic agents, as maintained
by INFARMED between 2008 and 2011. The dataset
compiles information from 32 hospitals/clinics and
contains details on patient characteristics, diagnosis,
details on prescribed biologic, date of initial treatment
of the disease and origin of care (local/large hospital).
We identiﬁed all patients starting treatment with
biologics in this period. Patient and biologics utiliza-
tion characteristics were assessed and compared
between regions. Persistence with biologics was
assessed at 12months.
Results: We identiﬁed 2831 starters of biologics (56.8%
females, mean age 48 years (SD 15) with median
duration of follow-up of 16months. The most frequent
indication was rheumatoid arthritis (39.2%). The major-
ity of patients were prescribed etanercept (55.2%) or
adalimumab (26.3%), but regional differences were
present with adalimumab being prescribed more often
(48.1%) in the south-central area (Alentejo). During
follow-up, just 3.2% of patients switched biologics.
After one year, 31% (523/1687) of patients were
persistent with treatment, but persistence ranged
between 10.4% in the southern part of Portugal to
37.7% in the Lisbon and surrounding area. The
proportion of patients treated locally (as compared to
larger hospitals) increased from 20.7% in 2008 to
47.5% in 2011. There was no difference between in
persistence between patients treated locally or in
larger hospitals.
Conclusions: This ﬁrst analysis within the Portugese
national register of biologics users revealed interesting
differences between regions in type of biologic pre-
scribed and persistence with treatment. Furthermore,
the increase in the proportion of users starting treatment
outside main hospitals suggests better accessability to
these agents.
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10. Risk of Incident Heart Failure among Established
Rheumatic Arthritis Patients Treated with TNF-alpha
Inhibitors in Taiwan
Tzu-Chieh Lin,1,2 Yea-Huei Kao Yang,1,2 Swu-Jane
Lin.2,3 1Institute of Clinical Pharmacy and Pharmaceuti-
cal Science, National Cheng Kung University, Tainan,
Taiwan; 2Health Outcome Research Center, National
Cheng Kung University, Tainan, Taiwan; 3Department
of Pharmacy Administration, University of Illinois at
Chicago, Chicago, United States.
Background: Although US FDA has requested to add
the precaution on potential risk of heart failure into the
package insert of TNF-alpha inhibitors, it remains
unclear whether use of them increases the risk of
heart failure.
Objectives: To examine the association between TNF-
alpha inhibitors therapy and risk of heart failure
among established rheumatic arthritis (RA) patients
in Taiwan.
Methods: A retrospective cohort analysis was
conducted, and incident RA patients who received the
catastrophic illness certiﬁcation were retrieved from
the National Health Insurance Research Database
(NHIRD) during 2001-2009. Patients aged below
18 years, had cancer or heart failure claims during
baseline period were excluded. Ever use of TNF-alpha
inhibitors (etanercept/adalimumab) was treated as a
time-dependent variable by counting process. Each
patient was followed from RA diagnosis till heart
failure occurred (retrieved from inpatient claims), death
or end of the study (2010/12/31). We used multivariate
time-dependent Cox modeling to compare the risk of
heart failure between use and non-use of TNF-alpha
inhibitors. Results were examined in series sensitivity
analyses and subgroup analyses.
Results: From 2001-2009, there were 24,523 incident
RA patients included in our cohort. Among them,
3,123 (12.7%) patients ever exposed to TNF-alpha
inhibitors. Results of time-dependent Cox analysis
showed that ever use of TNF-alpha inhibitors was
not associated increase risk of heart failure (adjusted
HR, 0.71; 95%CI, 0.40-1.26). Consistent results
were found in uni-directional time-dependent analysis
(adjusted HR, 0.73; 95%CI, 0.48-1.12) and propen-
sity-score matching analysis (adjusted HR, 0.84; 95%
CI, 0.45-1.58).
Conclusions: No excess risk of heart failure was found in
RA patients using TNF-alpha inhibitors in Taiwan.
11. Development of an Algorithm to Identify
Denosumab 60 Milligram Users in Health Insurance
Claims Data
Veena Thyagarajan,1 Fei Xue,2 Betsey Gardstein,3
Kathleen Skerry,3 Cathy W Critchlow,2 Cheryl Enger.1
1Epidemiology, Optum, Ann Arbor, MI, United States;
2Center for Observational Research, Amgen, Inc.,
Thousand Oaks, CA, United States; 3Epidemiology,
Optum, Waltham, MA, United States.
Background: Denosumab is approved in the United
States (US) for patients at high fracture risk due to post-
menopausal osteoporosis, androgen deprivation therapy
for non-metastatic prostate cancer, and adjuvant aroma-
tase inhibitor therapy for breast cancer, with a dosage of
60 milligrams (mg) every 6months. The lack of a
procedure code speciﬁc to denosumab 60mg creates
challenges in identifying denosumab 60mg users within
healthcare databases.
Objectives: To develop an algorithm to identify
denosumab 60mg users and describe frequency of
potential off-label use in the US using an administrative
database of a large US healthcare insurer.
Methods: Patients with a denosumab-speciﬁc or non-
speciﬁc administration claim during the early period
of denosumab 60mg availability in the US (01 June
2010 - 31 March 2012) were classiﬁed as deﬁnite,
probable, possible, and non- denosumab 60mg users
with an algorithm based on claims patterns consistent
with potential use. Medical record review conﬁrmed a
sample of deﬁnite, probable, and possible users and
the positive predictive value (PPV) was estimated.
Potential off-label use based on claims was evaluated
among the combined population of deﬁnite and proba-
ble users and among chart-conﬁrmed users.
Results: The PPV of the claims-based algorithm
varied among deﬁnite, probable, and possible users
(17.8%-95.8%). Requiring an osteoporosis, bone/cartilage
disorder or osteoporotic fracture claim after excluding can-
cer claims prior to a denosumab-speciﬁc administration
code gave the highest PPV (95.8%), followed by requiring
denosumab 60mg National Drug Code on the same claim
as a denosumab-speciﬁc or non-speciﬁc administration
code (88.2%). Potential off-label use was identiﬁed in
approximately 25% of deﬁnite and probable users. Medical
record review for chart-conﬁrmed denosumab 60mg users
classiﬁed as off-label showed evidence of on-label diagno-
ses not captured in claims.
Conclusions: Denosumab 60mg users are accurately
identiﬁed in claims with a combination of treatment and
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diagnosis codes. Claims-based analyses may overesti-
mate the proportion of potential off-label use due to
under-recording of on-label diagnoses.
12. Payer-Level Differences in the Response to
Regulatory Actions Regarding Bevacizumab
Stacie B Dusetzina,1,2,5 Aaron N Winn,2 Haiden A
Huskamp,3 G Caleb Alexander,4 Nancy L Keating.3
1Division of General Medicine and Clinical Epidemi-
ology, University of North Carolina at Chapel Hill,
Chapel Hill, NC, United States; 2Health Policy
and Management, University of North Carolina at
Chapel Hill, Chapel Hill, NC, United States; 3Health
Care Policy, Harvard Medical School, Boston,
MA, United States; 4Epidemiology, Johns Hopkins
School of Public Health, Baltimore, MD, United
States; 5Lineberger Comprehensive Cancer Center,
University of North Carolina at Chapel Hill, Chapel Hill,
NC, United States.
Background: Based on promising early trial results
the U.S. Food & Drug Administration approved
bevacizumab (bev) in Feb 2008 via an accelerated
approval process. In Nov 2011 the FDA revoked bev’s
breast cancer indication as later evidence suggested an
unfavorable risk-beneﬁt proﬁle. The Centers for
Medicare and Medicaid Services (CMS) announced their
intention to continue covering bev for breast cancer,
although later, some contractors who make local cover-
age determinations for Medicare announced they would
no longer cover it. Some private insurers announced
intentions to only cover bev on a case-by-case basis.
Objectives: We examined payer-speciﬁc trends in
bevacizumab use to determine the role of coverage
policies in reducing bevacizumab use following the
FDA’s indication withdrawal.
Methods: We used IMS Health LifeLink CMS-1500
claims from Feb 2008–Sep 2012.We evaluated bev use
as a proportion of infused chemotherapy by person-
month for breast cancer claims paid by Medicare or
commercial insurance (N = 131,114 unique women).
We grouped states into 10 local area coverage groups
(LACG) to evaluate whether Medicare local coverage
determinations would impact changes in bev use. We
used modiﬁed Poisson regression and GEE to account
for repeated measures.
Results: The proportion of breast cancer patients with
chemotherapy who received bev prior to the FDA’s
actions was higher among Medicare enrollees than
commercial enrollees (16% vs 9%). After November
2011, bev use among commercially-insured patients
decreased by nearly 50% (RR: 0.52, 95%CI:0.49-0.56)
while use among Medicare patients decreased by only
11% (RR:089, 95%CI:0.84-094). Among Medicare
beneﬁciaries, we observed signiﬁcant variation in bev
use across LACGs, with steep declines in some LACGs
(RR: 0.21, 95%CI:0.17-0.37) and increasing use in others
(RR:1.39, 95%CI:1.21-1.60).
Conclusions: We found pronounced differences in bev
use among the commercially insured as compared with
those on Medicare. However, in Medicare, bev use varied
by LACG suggesting the important inﬂuence that reim-
bursement and coverage policies may have in mediating
the effect of regulatory events such as safety advisories
or label changes.
13. Antipsychotics and Mortality: Adjusting for
Mortality Risk Scores to Address Confounding by
Terminal Illness
Yoonyoung Park,1,2 Jessica Franklin,2 Sebastian
Schneeweiss,2 Raisa Levin,2 Stephen Crystal,3 Tobias
Gerhard,3,4 Krista Huybrechts.2 1Department of
Epidemiology, Harvard School of Public Health,
Boston, MA, United States; 2Division of Pharma-
coepidemiology & Pharmacoeconomics, Brigham and
Women’s Hospital; Harvard Medical School, Boston,
MA, United States; 3Center for Health Services
Research on Pharmacotherapy, Rutgers University,
New Brunswick, NJ, United States; 4Ernest Mario
School of Pharmacy, Rutgers University, Piscataway,
NJ, United States.
Background: Earlier studies have documented a greater
risk of death associated with conventional compared to
atypical antipsychotics both in the community and
nursing home (NH) setting. Concern remains that the
association is not causal, but due to residual confounding
by patient frailty and terminal illness.
Objectives: To address this concern, we evaluated
whether adjustment for prognostic indices developed to
predict mortality in NH populations affected the
magnitude of the previously observed associations.
Methods: A merged dataset of Medicaid, Medicare, the
Minimum Data Set (MDS), the Online Survey Certiﬁca-
tion and Reporting system, and the National Death Index
in the US for 2001-2005 was used. The cohort included
dual-eligible subjects ≥ 65 years who initiated antipsy-
chotic treatment in a NH. Three mortality risk scores
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(MRIS, MMRI-R, and ADEPT) were derived for each
patient using baseline MDS data, and their performance
was assessed using c-statistics and goodness-of-ﬁt tests.
The impact of adjusting for these prognostic indices in
addition to propensity scores (PS), which account for a
broad range of mental and medical illness and other
healthcare utilization, on the antipsychotic-mortality
association was evaluated using Cox models with and
without adjustment for disease risk scores.
Results: In our cohort of 75,445 NH patients, each score
showed moderate discrimination for 6-month mortality
with c-statistics ranging from 0.61 to 0.63. There was
no evidence of lack of ﬁt. Imbalances in risk scores
between conventional and atypical antipsychotic users
overall, suggesting potential confounding, were greatly
reduced within PS deciles. Accounting for each score in
the Cox model did not change the relative risk estimates:
HR=2.24 with conventional PS adjustment vs. 2.20,
2.20, 2.22 after further adjustment for the three risk scores.
Conclusions: Our study supports earlier ﬁndings that
conventional antipsychotics are associated with higher
6-month mortality than atypical antipsychotics. Although
causality cannot be proven based on non-randomized
studies, this study adds to the body of evidence rejecting
alternative explanations for the observed association.
14. Mediators of the Causal Pathway to Mortality in
Older Adults Who Use Antipsychotics
John W Jackson,1,2 Tyler J VanderWeele,2 Deborah
Blacker,2,3 Sebastian Schneeweiss.1,2 1Medicine, Divi-
sion of Pharmacoepidemiology & Pharmacoeconomics,
Brigham and Women’s Hospital and Harvard Medical
School, Boston, MA, United States; 2Epidemiology,
Harvard School of Public Health, Boston, MA, United
States; 3Psychiatry, Massachusetts General Hospital
and Harvard Medical School, Boston, MA, United
States.
Background: Observational studies of older adults
show higher mortality for ﬁrst-generation antipsychotics
(FGAs) than their second-generation counterparts
(SGAs), but the actual mechanism is unclear.
Objectives: To quantify how much of the mortality
difference between FGAs and SGAs is mediated by
stroke, ventricular arrhythmia, acute myocardial infarc-
tion, venous thromboembolism or pulmonary embolism,
pneumonia, other bacterial infections, and hip fracture.
Methods: A cohort of new users of oral antipsychotics
(9,060 FGAs and 17,137 SGAs) enrolled in Medicare
and pharmacy assistance programs were followed from
the date of dispensing for 180 days or until death.
Medical events were assessed using diagnostic and pro-
cedure codes on inpatient billing claims. For the individ-
ual and combined set of medical events (mediators), we
estimated the total, direct and indirect effects of antipsy-
chotic type (FGA versus SGA) on mortality using the
risk ratio scale (RR), their 95% conﬁdence intervals
(CI), and the percent mediated on the risk difference
scale. A maximum likelihood approach and predictive
value weighting were used to address potential misclassi-
ﬁcation of the medical events in claims data.
Results: During follow-up there were 3,199 deaths, 862
cardiovascular events, 675 infectious events, and 491
hip fractures. The crude risk for each medical event
ranged from 0.44% to 2.17%. FGA users had higher mor-
tality than SGA users (total effect, RR= 1.15; 95%CI
1.08, 1.23). After accounting for the low sensitivity in de-
tecting medical events (modeled as 0.5, non-differential),
the proportion mediated for the combined set of medical
events increased from 4% to 21%–involving stroke (6%),
ventricular arrhythmia (5%), myocardial infarction (3%),
pneumonia (4%), and hip fracture (2%)–but the indirect
effect did not reach statistical signiﬁcance (RR= 1.03;
95%CI 0.97, 1.09). Similar results were obtained under
a differential misclassiﬁcation model with lower sensitiv-
ity (0.3) among those who died during follow-up.
Conclusions: The adverse events considered here
partially explained the mortality difference between
FGA and SGA users. Other pathways or residual bias
may contribute to this ﬁnding.
15. Concomitant Use of Nonsteroidal Anti-
Inflammatory Drugs (NSAIDs) during Antipsychotic
Treatment in Incident Cases of Schizophrenia and
Risk of 1-Year Psychiatric Hospitalizations
Ole Koehler,1 Ole Mors,1 Liselotte Petersen,2
Christiane Gasse.2 1Research Unit P, Aarhus University
Hospital, Risskov, Denmark; 2National Centre for
Register-Based Research, Aarhus University, Aarhus,
Denmark.
Background: Adjunctive use of nonsteroidal anti-
inﬂammatory drugs (NSAIDs) and COX-2 inhibitors
may improve early phase treatment effects of antipsy-
chotics (APs), but clinical trials are still rare. Only one
observational study investigating deterioration as indi-
cated by changes in AP treatment has been performed.
Objectives: To study 1-year psychiatric hospitalization
rates among incident cases of schizophrenia (SZ)
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treated with APs with and without concomitant
NSAID/COX-2 use.
Methods: Population-based cohort study linking Danish
national registries of all incident SZ patients (ICD-10:
F20.X) between 1997 and 2006. Use of APs and NSAIDs
prior to and after SZ-diagnosis were identiﬁed and
treatment intervals calculated. Hazard rate ratios (HRR)
with 95% conﬁdence intervals adjusted for important
covariates were estimated using Cox regression analysis.
Results: Of 12,124 incident SZ patients (42.6% women)
ﬁlling at least one prescription for an AP within the
subsequent year, 863 (7.1%, 51.6% women) used
NSAIDs concomitantly. NSAID users were older
(median: 45.8 years) compared to patients using AP only
(34.8 years). Crude 1-year incidence rates for SZ-
hospitalizations were 650.2 per 1,000 person months
(PMs) among AP only users (3,287 hospitalizations;
5055.6 PMs) compared with 1586.5 per 1,000 PMs
among AP users in combination with NSAIDs (99
hospitalizations; 61.2 PMs). The adjusted HRR was
2.35 (95% CI: 1.63; 3.38). Ibuprofen (HRR=2.22
(1.37; 3.61)), diclofenac (HRR= 3.91 (1.85; 8.26)) and
COX-2 inhibitors (HRR= 2.85 (0.39; 20.71)) increased
the risk for psychiatric hospitalization with SZ. Concom-
itant use of NSAIDs was associated with a mortality risk
of HRR= 2.98 (0.14; 64.37).
Conclusions: We observed no overall decreased risk of
hospitalizations due to SZ during the ﬁrst year of AP
treatment among NSAID users with no differences be-
tween single NSAID compounds. Somatic comorbidity
resulting in prescription of NSAIDs may partly explain
the higher risk for psychiatric deterioration. Our results
indicate that NSAID use among incident SZ patients
may require increased awareness of physicians.
16. Incidence of Weight Gain with Seroquel XL™ in
Primary Care in England: Results from an Observation
Post-Marketing Cohort Study
Deborah Layton,1,2 Miranda Davies,1,2 Vicki Osborne,1,2
Saad AW Shakir.1,2 1Drug Safety Research Unit,
Southampton, United Kingdom; 2University of Ports-
mouth, Portsmouth, United Kingdom.
Background: Weight gain is an independent risk factor
for developing type 2 diabetes (T2DM) in patients whose
baseline risk for developing T2DM is already elevated.
Antipsychotics (APs) have been associated with gains
in weight. A Risk Management Plan developed for
quetiapine extended release (Seroquel XL™), included a
Modiﬁed Prescription-Event Monitoring (M-PEM) study
to examine the safety and use of quetiapine XL as
prescribed in primary care in England. Study objectives
included the evaluation of known and generate signals
of potential risks.
Objectives: To describe the prevalence and time to onset
of weight increase in patients (pts) using quetiapine XL.
Methods: An observational, population-based cohort
design using the technique of M-PEM. Pts were identi-
ﬁed from dispensed prescriptions (Rx) issued by GPs
Sep2008-Feb2013. Questionnaires were sent to GPs
12months after each individual pts’ 1st Rx for event in-
formation recorded in medical charts. Incidence densities
(IDs) were calculated for months (m)1, 2-6 & 7-12 inclu-
sive. In M-PEM negative ID differences (IDd) +95%
Conﬁdence Interval (CI) between periods are indicative
of signals of delayed onset events whilst positive ID dif-
ferences are indicative of signals of early onset events.
The cumulative incidence (CumI + 95%CI) for events
(inc free text event MedDRA PT: weight increased)
was calculated using survival methods.
Results: Final cohort n = 13,276; median age 43 yrs (IQR
33, 55). There were 282 reports of ‘weight increased’,
complete case (n = 105) CumI was 1.0% (95%CI
0.8,1.2); median onset 7months. The IDds for m1 - m2-
6 [-1.1(95%CI -1.9, -0.3)] & m1 - m7-12 [-0.8 (95%CI
-1.5, -0.0)] were signiﬁcantly different. A sensitivity
analysis allocating median person time at risk where
event date was missing estimated CumI as 2.7% (95%
CI 2.4,3.0).
Conclusions: The negative ID differences suggest that
reports of weight increase is more frequently reported
as duration of treatment increases. This result appears to
be a possible signal of an association between weight
increased and quetiapine XL. Prevalence may be
underestimated because of missing event dates and a
narrow case deﬁnition.
17. Detecting Potential Adverse Reactions of Sulpiride
in Schizophrenic Patients by Prescription Sequence
Symmetry Analysis
Edward Chia-Cheng Lai,1,2 Jyun-Hong Chen,6 Cheng-
Yang Hsieh,1,3 Swu-Jane Lin,4 Yea-Huei Kao Yang.1,5
1Institute of Clinical Pharmacy and Pharmaceutical
Sciences, National Cheng- Kung University, Tainan,
Taiwan; 2Duke Clinical Research Institute, Duke
University School of Medicine, Durham, United States;
3Department of Neurology, Tainan Sin-Lau Hospital,
Tainan, Taiwan; 4Department of Pharmacy Administration,
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College of Pharmacy, University of Illinois at Chicago,
Chicago, IL, United States; 5Health Outcome Research
Center, National Cheng-Kung University, Tainan,
Taiwan; 6Institute of Nuclear Energy Research, Atomic
Energy Council, Executive Yuan, Taiwan.
Background: Previous studies have demonstrated
sulpiride to be signiﬁcantly more effective than
haloperidol, risperidone and olanzapine in schizo-
phrenic treatment; however, only limited information
is available on the potential risks associated with
sulpiride treatment.
Objectives: This study attempts to provide information
on the potential risks of sulpiride treatment of schizo-
phrenia, especially with regard to unexpected adverse
effects.
Methods: Patients with schizophrenia aged 18 and
older, newly prescribed with a single antipsychotic
medication from the National Health Insurance
Research Database of Taiwan in the period from 2003
to 2010 were included. A within-subject comparison
method, prescription sequence symmetry analysis
(PSSA) was employed to efﬁciently identify potential
causal relationships while controlling for potential
selection bias.
Results: A total of 5,750 patients, with a mean age of
39, approximately half of whom were male, constituted
the study cohort. The PSSA found that sulpiride
was associated with extrapyramidal syndromes (EPS)
(adjusted SR, 1.73; 95% CI, 1.46-2.06) and
hyperprolactinemia (12.04; 1.59-91.2). In comparison,
EPS caused by haloperidol has a magnitude of 1.99
when analyzed with PSSA, and hyperprolactinemia
caused by amisulpride has a magnitude of 8.05,
respectively. Another ﬁnding was the unexpected
increase in the use of stomatological corticosteroids,
emollient laxatives, dermatological preparations of
corticosteroids, quinolone antibacterials, and topical
products for joint and muscular pain, after initiation
of sulpiride treatment.
Conclusions: We found sulpiride to be associated with
an increased risk of EPS and hyperprolactinemia, and
the potential risk could be as high as that induced by
haloperidol and amisulpride, respectively. Additionally,
our study provides grounds for future investigations
into the associations between sulpiride and the in-
creased use of additional drugs for managing adverse
effects, including stomatological, dermatological, and
musculoskeletal or joint side effects, constipation,
and pneumonia.
18. Course and Outcome of Clozapine Treatment in
Patients with Incident Schizophrenia in Denmark
Christiane Gasse,1 Aske Astrup,1 Henrik Støvring,2
Theresa Wimberley.1 1National Centre for Register-
based Research, Aarhus University, Aarhus V, Denmark;
2Public Health-Institute of Biostatistics, Aarhus University,
Aarhus C, Denmark.
Background: Clozapine is the drug of last resort in
treatment-resistant schizophrenia (TRS).
Objectives: To describe course and outcomes of cloza-
pine (CLZ) treatment in patients with schizophrenia (SZ).
Methods: Population-based cohort study using Danish
national registry data of all adult patients with an incident
diagnosis of SZ between Jan 1, 1996 and Dec 31, 2006
and at least one prescription for CLZ after SZ diagnosis
by Dec 31, 2010. Follow-up (FU) started at ﬁrst prescrip-
tion of CLZ and ended at emigration, death or Dec 31,
2010. Based on prescription data we constructed
episodes of CLZ treatment during FU. We extracted
outcomes from hospital registries. We estimated
Kaplan-Meier curves for selected outcomes during ﬁrst
current CLZ treatment episodes or during total FU.
Results: Among 8632 incident SZ cases, 1134 used CLZ
(42% women) with 7644.3 person years (PYs) of FU,
representing 3922.6 PYs of current and 3731.7 PYs of
past use of CLZ. The ﬁrst CLZ treatment episode had a
median of 155.5 days with 25% exceeding 445 days.
The median number of treatment episodes was 14 (inter
quartile range = 7-26). Extreme treatment resistance,
i.e. failure to resume CLZ after discontinuation occurred
in 3.6% patients after the ﬁrst treatment episode, in 3.4%
after the second, and in 4.2% after the third; 88.8% patients
had more than three treatment episodes. The probability of
psychiatric admission within two years after CLZ initiation
was 35.6% during the ﬁrst treatment episode and 54.5%
during total FU. Probability of augmentation within three
months of CLZ initiation with antidepressants was
49.4%, 37.6% with antiepileptics, 67.0% with other
antipsychotics, and 57.8%with benzodiazepines. Probabil-
ity of death during the ﬁrst CLZ treatment episode was
0.7% within ﬁve years after CLZ start. Of side effects,
ketoacidosis was registered in 4/1134, agranulocytosis in
1 case, ileus in 6 cases, incident diabetes in 56 patients
during FU.
Conclusions: First study in Denmark to describe the
complexity and dynamics of CLZ treatment in TRS over
an extended period, which is an essential pre-requisite for
identifying patient characteristics and predictors of
clozapine treatment response.
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19. Improving Empirical Variable Selection in
Propensity-Score Models with High-Dimensional
CovariateSpaceUsingHealthcareDatabases
Sebastian Schneeweiss, Wesley Eddings, Robert J Glyn,
Jessica M Franklin. Division of Pharmacoepidemiology,
Harvard Medical School, Brigham and Women’s
Hospital, Boston, MA, United States.
Background: Algorithmic approaches to confounding
adjustment have distinct methodological advantages for
rapid cycle analytics across a network of healthcare
databases.
Objectives: Better identiﬁcation of outcome predictors
may improve automated variable prioritization, particu-
larly in settings of few events.
Methods: Using 5 published cohort studies from
diverse databases, we implemented the standard high-
dimensional propensity score (hdPS V2) algorithm with
500 variables and decile adjusted outcome models to
estimate treatment effects among drug initiators and com-
pare with expected effects. The original variable selection
procedure based on the estimated bias of each variable if
it was omitted using unadjusted associations between
confounder and exposure (RRCE) and disease outcome
(RRCD) was augmented by alternative strategies. These
included bias formulas with increasingly adjusted RRCD
estimation, including models considering all (>1500)
variables jointly (LASSO, penalized regression); using
prediction statistics or likelihood ratios for covariate
prioritization; directly estimating the propensity score
with all variables, or directly ﬁtting an outcome model
without PS using all covariates jointly.
Results: In 5 empirical examples the tested augmentations
of the existing hdPS did not further improve estimation
compared with RCT ﬁndings except for fully-adjusted
Bayesian RRCD estimation which performed numerically
better in 2 of 5 examples in terms of bias (1.5% and
3.6%) and never worse. The augmentation of the bias for-
mula via LASSO-estimated RRCD performed poorly in all
settings as did outcome modeling using LASSO or Ridge.
Prediction or likelihood ratio test-based covariate prioriti-
zation did not improve estimation over association-based
prioritization. Variation in code granularity and interaction
terms did not improve estimation.
Conclusions: Overall, hdPS performance is robust in
many settings and minor improvements in the hdPS
variable selection are technically possible using penal-
ized regression particularly when outcomes are rare.
The empirically inferior performance of LASSO needs
further testing.
20. Penalized Regression for Fitting High Dimensional
Propensity Score Models in Small Samples
Carl de Moor,1,2 Ed Malka.1 1Epidemiology, IMS
Health, Alexandria, VA, United States; 2College of
Health and Human Services, UNC Charlotte, Charlotte,
NC, United States.
Background: Confounder adjustment strategies in
pharmacoepidemiology often employ high-dimensional
propensity score modeling, where hundreds of
potential confounders are used to estimate propensity
scores. This approach is made possible by the
availability of large numbers of variables and large
patient populations that exist in electronic data
sources. However, in some circumstances patient
numbers are small relative to the number of con-
founders, posing problems of statistical separation
and inadequate degrees of freedom. Penalized regression,
including LASSO, ridge, and elastic net regression,
penalizes model complexity and provides stable regression
estimates even when the number of confounders exceeds
the sample size.
Objectives: To evaluate the performance of modeling
high dimensional propensity scores in small samples
using penalized regression in terms of bias and mean
squared error.
Methods: Simulation studies were conducted to
evaluate the performance of penalized regression
(LASSO, ridge and elastic net) as a means of
estimating propensity scores compared with traditional
logistic regression. Study design features were varied
including the ratio of exposed sample size to
confounders, ratio of true confounders to noise,
strength of confounding, and correlation among
confounders.
Results: Performance of penalized regression was similar
to traditional logistic regression when the ratio of
exposed sample size to confounders was large. When
the ratio was low, performance exceeded traditional
logistic regression. LASSO performed best with
correlated confounders, and ridge regression performed
best with independent cofounders. Elastic net provided
a robust method that performed well in most scenarios,
even when the number of exposed sample size was half
the number of confounders.
Conclusions: Penalized regression is a robust approach
for estimating high dimensional propensity score models
when the ratio of exposed sample size to confounders
is low.
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21. Improving Propensity Scoring through Machine
Learning
John A Rigg,1 Huma Lodhi,1 John Gregson,2 Joseph
Kim.1,2 1Real-world Evidence Solutions, IMS Health,
London, England, United Kingdom; 2Department of
Medical Statistics, London School of Hygiene & Tropical
Medicine, London, England, United Kingdom.
Background: Propensity scores (PS) are a popular
method to adjust for confounding bias in estimation of
treatment effects. PS are almost always based on logistic
regression (LR) despite its well-known potential limita-
tions concerning model speciﬁcation. Moreover, consid-
eration is seldom given to the impact of exposure
misclassiﬁcation to results using PS based on LR.
Objectives: To assess whether the accuracy of treatment
effects may be improved through a range of advanced
machine learning algorithms, Support Vector Machines
(SVMs), used to compute PS; to assess whether the
optimal SVM speciﬁcation differs according to the nature
of confounding; to assess whether treatment effects are
more accurate with SVMs than LR with differential and
non-differential exposure misclassiﬁcation.
Methods: A hypothetical study cohort was simulated
(N= 2,000) using Monte Carlo sampling for a binary
outcome, a binary exposure and ten binary or continuous
covariates. Nine scenarios were created; seven scenarios
differing by non-linear and/or non-additive confounding
and two scenarios differing by differential or non-
differential exposure misclassiﬁcation. PS were based on
LR and SVMs – single, boosted and bagged speciﬁcations.
Optimal SVM parameter settings were identiﬁed using
cross-validation. Performance metrics included the percent
bias in the treatment effect and the average standardized
difference in absolute mean of covariates between treated
and non-treated (a measure of covariate balance).
Results: SVMs provided more accurate treatment effect
estimates and better covariate balance than LR, especially
in the presence of non-linear and non-additive confound-
ing. There was generally no substantive difference between
both ensemble SVM methods, except for a notably supe-
rior performance by bagged compared to boosted SVMs
with differential exposure misclassiﬁcation.
Conclusions: SVMs provide a highly promising solution
to reducing treatment effect bias and ensuring covariate
balance in the presence of confounding bias and differen-
tial exposure misclassiﬁcation. These advanced algo-
rithms out-performed LR and pharmacoepidemiology
would beneﬁt from their more widespread adoption.
22. Propensity Score Matching and Unmeasured
Covariate Imbalance: A Simulation Study
M Sanni Ali,1,2 Rolf HH Groenwold,1,2 Svetlana V
Belitser,1 Arno W Hoes,2 A de Boer,1 Olaf H Klungel.1,2
1Division of Pharmacoepidemiology and Clinical
Pharmacology, Utrecht Institute for Pharmaceutical
Sciences, University of Utrecht, Utrecht, Netherlands;
2Julius Center for Health Sciences and Primary
Care, University Medical Center Utrecht, Utrecht,
Netherlands.
Background: Selecting covariates for adjustment or
inclusion in propensity score (PS) analysis is a trade-off
between reducing confounding bias and a risk of ampli-
fying residual bias by unmeasured confounders.
Objectives: To assess the covariate balancing properties
of PS matching with respect to unmeasured covariates
and its impact on bias.
Methods: Simulation studies were conducted in binary
covariates, treatment and outcome data. In different
scenarios, instrumental variables (IV, i.e., variables
related to treatment but not to the outcome or other
covariates), risk factors (variables related only to the
outcome), unmeasured covariates, and confounders
with various associations among each other were
considered.Treatment effects estimates (risk ratio)
were derived after PS matching using Poisson
models; balance for each covariate was checked
before and after matching using the absolute
standardized difference.The choice of covariates for
the PS model was compared with respect to bias in
the treatment-outcome relation and balance of
(unobserved) covariates.
Results: PS matching improved balance of measured
covariates included in the PS model but exacerbated the
imbalance of the unmeasured covariate that was
unrelated to measured covariates compared to the full
unmatched sample. Inclusion of instrumental variables,
independent of unmeasured covariates, exacerbated the
imbalance in unmeasured covariates and ampliﬁed the
residual bias. However, including instrumental variables
that were associated with unmeasured covariates
improved the balance of unmeasured covariates and
reduced bias. When the PS model included variables
related to the outcome, exclusion of instrumental
variables that were related to unmeasured covariates
exacerbated the balance of unmeasured covariates and
increased the bias.
Conclusions: In choosing covariates for a PS model, the
pattern of association among covariates has substantial
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impact on other covariates’ balance and the bias of the
treatment effect.Investigators should not rely only on
covariate association with treatment or outcome but
should take into account possible associations among
covariates and explore the balance of other covariates
after PS matching.
23. Use of Propensity Score Methodology to Assess
Comparability of Treatment Groups in a Registry
Program
Kenneth J Rothman,1 Menno V Huisman,2 Gregory
YH Lip,3 Hans-Christoph Diener,4 Sergio J Dubner,5
Chang-Sheng Ma,6 Kristina Zint,7 Christine Teutsch,7
Nils Schoof,7 Miney Paquette,8 Eva Kleine,7 Dorothee
B Bartels,7 Jonathan Halperin.9 1Epidemiology, Boston
University School of Public Health, Boston, MA,
United States; 2Department of Thrombosis and
Hemostasis, Leiden University Medical Center,
Leiden, Netherlands; 3Haemostasis Thrombosis &
Vascular Biology Unit, Centre for Cardiovascular
Sciences, University of Birmingham, Birmingham,
United Kingdom; 4Department of Neurology, Universit
Hospital Essen, Essen, Germany; 5Arrhythmia and
Electrophysiology Service, Clinica y Maternidad Suizo
Argentina, Buenos Aires, Argentina; 6Department of
Cardiology, Beijing AnZhen Hospital, Capital Medical
University, Beijing, China; 7Boehringer Ingelheim
Pharma GmbH&Co. KG, Ingelheim amRhein, Germany;
8TCM GLORIA-AF Registry, Boehringer Ingelheim
Canada Limited, Burlington, ON, Canada; 9Clinical
Cardiology Services, Mount Sinai School of Medicine,
New York, United States.
Background: Propensity scores (PS) are commonly used
to account for measured confounding factors in compara-
tive studies of treatment options. In the Global Registry
on Long-Term Oral Antithrombotic Treatment in Patients
with Atrial Fibrillation (GLORIA-AF), we used propen-
sity scores in Phase II of the registry program to assess
comparability of patients receiving different treatments
regarding their baseline characteristics, before initiating
longitudinal data collection to perform comparative
analyses between the treatments.
Objectives: During Phase II we evaluated comparability
of baseline patient characteristics for newly diagnosed
AF patients receiving either dabigatran or vitamin-K
antagonists (VKA) by examining PS distributions.
Methods: Speciﬁcally, we measured the proportion of
patients within the region of overlap of the PS distribu-
tions. When data collection was started dabigatran was
a new treatment and it was expected that patient charac-
teristics might initially differ, resulting in limited overlap.
The proportion of patients in the region of overlap was a
key determinant in the decision when to start the large
scale safety and effectiveness comparison in Phase III
of GLORIA-AF. If 95% of patients were in the overlap-
ping region, Phase III would be initiated for a speciﬁc
region. The ﬁrst analysis was done for North America.
Results: In the North American analysis, 536 patients
initiating dabigatran were compared with 488 patients be-
ginning VKA. The proportion of patients in the overlap-
ping region of PS was 99.3% for the PS model containing
a pre-speciﬁed subset of risk factors for stroke and bleed-
ing. When we included all baseline characteristics in the
model, the proportion of patients in the region of overlap
was only slightly lower (96.3%). Either result was
sufﬁcient to proceed to Phase III.
Conclusions: We employed PS to assess comparability
of anticoagulant treatment groups in this large registry
program to help determine when to begin a comparative
study assessing safety and effectiveness. This approach
may have applications in other types of population-based
registry studies as well.
24. Applying High Dimensional Propensity Score
(HDPS) in a Exploratory Data Analysis with a US
Claims Database for Recent Medicinal Products
Bing Cai, Sundaresan Murugesan, Jamie Geier,
Andrew Bate. Epidemiology, Pﬁzer Inc, New York,
United States.
Background: HDPS is a semi-automatic method used in
active surveillance to evaluate potential safety signals.
The Observational Medical Outcomes Partnership
(OMOP) experiment applied and evaluated the method
using well-established drug-outcome pairs with extensive
literature support. Currently, it is unknown how well
such evaluations would generalize to recently approved
and marketed products.
Objectives: To conduct a pilot study for implementing
the HDPS method for exploratory data analysis, investi-
gating the performance of the method for adalimumab
(Humira®), a biologic disease-modifying antirheumatic
drug (bDMARD) which is approved for the treatment
of rheumatoid arthritis.
Methods: We applied the HDPS method to the original
Optum database and the database in OMOP common
database model (CDM), employing a new user design
with a 12-month washout period. Other bDMARDs
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served as a control group. Events evaluated included:
acute myocardial infarction, gastrointestinal perforation,
herpes zoster, interstitial lung disease, and pneumonia.
Odds Ratios (OR) adjusted for propensity score with
SMR method and regression were calculated.
Results: The majority of HDPS analysis results had ORs
less than 1, except GI perforation (1.51 [95% CI 1.47-
1.71]), and herpes zoster (1.01 [95% CI 0.91-1.12]),
using CDM data and propensity scores as the predictor
variables for the logistic regression; analyses of original
databases or with CDM with an SMR weighted method
resulted in ORs less than 1. For other outcomes evalu-
ated, ORs varies with data format as well as the analysis
methods. Speciﬁcally, estimated ORs for lymphoma and
pneumonia were substantially larger with the CDM
database than with the original database.
Conclusions: We were able to implement the HDPS for
exploratory analysis of a recently marketed products.
Our HDPS methodological analysis did not ﬁnd any
signals of disproportional recording of adalimumab with
any study outcome compared with other bDMARDs.
25. Increased Risk of Hip Fracture Associated with
Dually-Treated HIV/Hepatitis B Virus Coinfection
Dana D Byrne, Craig W Newcomb, Dena M
Carbonari, Melissa S Nezamzadeh, Kimberly BF
Leidl, Maximilian Herlim, Yu-Xiao Yang, Sean
Hennessy, Jay R Kostman, Mary B Leonard, Russell
Localio, Vincent Lo Re III. Perelman School of
Medicine, University of Pennsylvania, Philadelphia,
PA, United States.
Background: HIV and hepatitis B virus (HBV) infection
are each associated with reduced bone mineral density,
but it is unclear whether HIV/HBV coinfection is associ-
ated with an increased risk of fracture.
Objectives: To determine whether dually-treated HIV/
HBV patients have a higher incidence of hip fracture
compared to treated HBV-monoinfected, antiretroviral
therapy (ART)-treated HIV-monoinfected, and HIV/
HBV-uninfected patients.
Methods: We conducted a retrospective cohort study
among 4,156 dually-treated HIV/HBV-coinfected, 2,053
treated HBV-monoinfected, 96,253 ART-treated HIV-
monoinfected, and 746,794 randomly sampled uninfected
persons within the U.S. Medicaid populations of
California, Florida, New York, Ohio, and Pennsylvania
(1999-2007). Coinfected patients were matched on pro-
pensity score to persons in each comparator cohort.
Weighted survival models accounting for competing risks
were used to estimate cumulative incidences and hazard
ratios (HRs) with 95% conﬁdence intervals (CIs) of
incident hip fracture for dually-treated coinfected
patients compared to: 1) HBV-monoinfected receiving
nucleos(t)ide analogue or interferon alfa therapy, 2)
HIV-monoinfected on ART, and 3) randomly selected
uninfected persons.
Results: Dually-treated coinfected patients had a higher
cumulative incidence of hip fracture compared to ART-
treated HIV-monoinfected (at 5 years: 1.49% versus
1.07%; adjusted HR, 1.40 [95% CI, 1.05-1.87]) and
uninfected (at 5 years: 1.48% versus 0.83%; adjusted
HR, 1.83 [95% CI, 1.33-2.51]) persons. The cumulative
incidence of hip fracture was higher among coinfected
than treated HBV-monoinfected patients (at 5 years:
0.70% versus 0.27%), but this difference was not statisti-
cally signiﬁcant in competing risk analysis (adjusted HR,
2.62 [95% CI, 0.92-7.51]).
Conclusions: Among U.S. Medicaid enrollees, the risk
of hip fracture was signiﬁcantly higher among dually-
treated HIV/HBV-coinfected patients than ART-treated
HIV-monoinfected and uninfected persons. Future stud-
ies should examine mechanisms for bone disease as well
as interventions and therapies to prevent fractures among
coinfected patients.
26. Antiretroviral Adherence among Patients Enrolled
in an AIDS Drug Assistance Program
Jenna Parrett,1 Alice C Thornton,2 Emily S Brouwer.1
1Pharmacy Practice and Science, University of
Kentucky, Lexington, KY, United States; 2Infectious
Diseases, University of Kentucky, Lexington, KY,
United States.
Background: Adherence to antiretroviral (ARV) treat-
ment is critical to reducing viral load thereby reducing
morbidity, mortality and transmission. Currently there is
uncertainty regarding how the United States Patient
Protection and Affordable Care Act (ACA) will affect
AIDS Drug Assistance Programs (ADAP) nationally as
well as whether ADAPs foster positive patient behaviors
and outcomes, such as increased medication adherence in
a predominantly rural, underserved population like the
state of Kentucky.
Objectives: To quantify adherence to ARVs among
patients enrolled in the Kentucky AIDS Drug Assistance
Program (KADAP) and explore factors that may be
related to increased adherence in this population.
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Methods:We collected pharmacy records on patients en-
rolled in KADAP that also had exposure to ARVs in the
year 2011. Patients that did not have at least two medica-
tion ﬁlls were excluded from the analysis. To measure
antiretroviral adherence we calculated the medication
possession ratio (MPR). We used multivariate logistic
regression models to examine the relationship between
near perfect adherence MPR> 95% and patient factors
including, age, race, sex, as well as clinic location as a
proxy for mail-order delivery of medication.
Results: Overall there were 1,784 patients enrolled in
KADAP between January 1, 2011 and December 31,
2011. The study population was 81% male, 62% white,
and a median age of 47 years (Interquartile Range
[IQR]: 39-53). Patients were prescribed a median of 3
antiretrovirals (Full Range: 1-9). The median MPR was
92 (IQR: 77, 99). In multivariate models, age and race
were clinically and statistically signiﬁcant predictors of
obtaining an MPR> 95% with white and older patients
more likely to achieve perfect adherence (Odds Ratio
[OR]: 1.14, 95% Conﬁdence Interval [CI]: 1.04, 1.26
and OR: 1.48, 95% CI: 1.21, 1.82 respectively). Clinic
location was not a statistically signiﬁcant predictor of
adherence.
Conclusions: Our results demonstrate that on average,
KADAP patients have a lower MPR than that required
to maintain a very low viral load. Strategies to maximize
adherence as healthcare policies related to HIV treatment
and care undergo signiﬁcant change is paramount.
27. Adherence to Antiretroviral Drugs and Its
Determinants among Human Immunodeficiency
Virus(HIV) Patients Attending HIV Clinic in a
Teaching Hospital in Nigeria
Chioma Stella Ejekam,1,2 Adebayo Temitayo
Onajole,1 Charles C Okany,2,4 OA Lesi,2,3 ES
Oridota.1 1Department of Community Health, Lagos
University Teaching Hospital, Lagos, Nigeria; 2PEPFAR
Clinic, Lagos University Teaching Hospital, Lagos,
Nigeria; 3Department of Medicine, Lagos University
Teaching Hospital, Lagos, Nigeria; 4Department of
Hematology, Lagos University Teaching Hospital,
Lagos, Nigeria.
Background: Adherence is the engaged and accurate par-
ticipation of a patient in a plan of care, in relation to ARV
(Antiretroviral), it means taking ARV on time, every time
as prescribed. With ARV, anything less than a near perfect
adherence to treatment can result to diminishing efﬁcacy
of the drug with subsequent development of viral strains
that are resistant. This study becomes relevant as adher-
ence has emerged as both the major determinant and the
Achilles’ heel of treatment success.
Objectives: This study aimed at determining the factors
contributing to adherence to ARV among HIV patients
attending the HIV Clinic.
Methods: This was a cross sectional descriptive study. A
systematic random sampling technique was used to select
300 people living with HIV/AIDS of about 1600 attend-
ing the clinic in one month and who were at least
6months on ARV drugs. Structured interviewer adminis-
tered questionnaire was used to collect data on patients
socio-demographics, knowledge of HIV and ARV drugs,
assessment of adherence (using keeping to timing of their
drugs and missed doses in a 3-day period as key indica-
tors) and quality of care. A 3-day patient self-report is a
relatively simple and universally acceptable efﬁcient
method of assessing adherence in clinical practice. Data
was analyzed using Epi info for windows version 3.5.1.
and statistical signiﬁcance set at p< 0.05.
Results: Findings showed 75% of the respondents
were females. 78% had secondary and post secondary
education. Only 34% adhered to the prescribed time of
taking drugs and 76% had optimal adherence (did not
miss their drugs in 3 days). The commonly cited
reasons for missing prescribed dosing and timing of
drugs were: simply forgetting 51%, left drug at home
23%, uncomfortable social environment 17%. The
common facilitators were the use of mechanical
devices as reminders 58% and making ARV part of
daily routine 43%.
Conclusions: The ARV adherence rates in this study
were comparable with those seen in developed and devel-
oping countries. Good patient counseling and education,
strengthening the use of reminder tools and treatment
partners are recommended.
28. Predictors of Receiving Guideline Recommended
Antiretroviral Treatment: Type of Provider Influences
the Provision of Optimum HIV Treatment
Emily S Brouwer, Sarah Wixson, Daniela C Moga.
Pharmacy Practice and Science, University of
Kentucky, Lexington, KY, United States.
Background: Randomized clinical trials of combination
antiretroviral therapy (cART) have informed the use of
speciﬁc antiretrovirals (ARV) and their combination for
optimizing therapeutic efﬁcacy. Given these advances,
HIV-infected patients must have access to and receive
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the most appropriate ﬁrst-line cART to minimize long-
term treatment resistance and failure.
Objectives: To examine factors that impact receiving
initial guideline recommended cART within a cohort of
insured patients receiving care in the United States (US).
Methods: We established an employed, commercially
insured, population-based cohort of HIV patients receiv-
ing a new ARV in the US between January 2007 and
December 2009. HIV patients were identiﬁed through
ICD-9 codes (042) or a national drug code for any of the
FDA approved ARVs. The primary outcome was deﬁned
as a claim for a prescription containing recommended
cART consisting of two nucleoside reverse transcriptase
ARVs and either a non-nucleoside reverse transcriptase
inhibitor, protease inhibitor, or an integrase strand transfer
inhibitor. Monotherapy, dual therapy, and triple nucleo-
side regimens were not considered recommended cART.
Multivariate logistic regression models including patient
demographic and provider characteristics evaluated pre-
dictors of receiving recommended cART.
Results: There were 2,316 HIV patients that received a
new ARV. Patients were 57% white, 79% male with a
median age of 42 years (Interquartile Range:35-49).
Overall, 66% of the population received recommended
cART. Receiving care from an infectious disease (ID)
specialist was the strongest predictor of receiving
recommended cART (Odds Ratio:1.47 (95% Conﬁdence
Interval:1.38, 1.56). Men, those with less than a high
school education, and younger individuals were also
more likely to receive recommended cART (p< 0.01).
Conclusions: Many HIV-infected patients are not
prescribed recommended cART. Treatment established
by an ID specialist is an important factor in determining
optimum cART. Increased communication and training
of all healthcare providers will insure patients receive
the most durable ﬁrst-line regimen.
29. Seasonal Variation in Penicillin Use in Brazil
and Mexico: An Analysis of the Impact of Over-
the-Counter Regulations
Yared Santa-Ana-Tellez,1 Aukje K Mantel-Teeuwisse,1
Hubert GM Leufkens,1 Veronika J Wirtz.2,3 1WHO
Collaborating Centre for Pharmaceutical Policy &
Regulation, Utrecht Institute for Pharmaceutical
Sciences (UIPS), Utrecht, Netherlands; 2Center for
Global Health and Development, Boston University,
Boston, MA, United States; 3Center for Health
Systems Research, National Institute of Public Health,
Cuernavaca, Mexico.
Background: The seasonal variation in the use of
antibiotics has been associated with their inappro-
priate use.
Objectives: In order to explore if restrictions lead to
more appropriate use, the objective of this work is to
measure the changes in the seasonal variation in the use
of penicillins before and after the OTC sales restrictions
in Mexico and Brazil.
Methods: We used retail quarterly sales data, provided
by IMS Health, of antibiotics and antihypertensives from
the private sector in Mexico and Brazil, from the ﬁrst
quarter of 2007 to the ﬁrst quarter of 2013. The unit of
analysis was the daily deﬁned dose per 1000 inhabitants
days (DDD/TID). We used interrupted time-series
models for the total use of penicillins and by active
substance, using the antihypertensives as reference. We
added interaction terms to estimate changes in trend,
level and the variation in use between quarters (or
seasons) after the OTC regulation. We examined the
presence of autocorrelation of residuals and corrected it
if present using autoregressive models.
Results: The use of penicillins accounted for 37% out
of the total use of antibiotics in both countries. The
most used penicillin was amoxicillin, followed by
amoxicillin combined with clavulanic acid, and ampi-
cillin (minimal use in Brazil). Before the OTC restric-
tion, the seasonal variation in penicillin use in Mexico
and in Brazil was 1.1 and 0.8 DDD/TID, respectively.
In Mexico, we estimated a signiﬁcant decrease after
the OTC restriction in the seasonal variation of 0.4
DDD/TID (-63%) mainly due the changes in seasonal
variation of amoxicillin (-34%) and ampicillin (-93%).
The seasonal variation in Brazil did not change signif-
icantly neither in the overall use of penicillins nor by
active substance.
Conclusions: The policies to restrict OTC sales of antibi-
otics led to a decrease in seasonal variation in Mexico but
not in Brazil, which may indicate that inappropriate use
of penicillins diminished after the regulations were
enforced in Mexico. For Brazil the increasing use of
penicillins together with no change in seasonal varia-
tion suggests that further efforts need to be undertaken
to reduce their inappropriate use.
30. The Effects of Obesity on the Comparative
Effectiveness of Linezolid and Vancomycin in
MRSA Pneumonia
Aisling R Caffrey,1,2 Eunsun Noh,1,2 Haley J Morrill,1,2
Kerry L LaPlante.1,2 1Infectious Diseases Research
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Program, Veterans Affairs Medical Center, Providence,
RI, United States; 2Department of Pharmacy Practice,
College of Pharmacy, University of Rhode Island,
Kingston, RI, United States.
Background: Methicillin-resistant Staphylococcus
aureus (MRSA) has become a leading cause of pneu-
monia. Numerous reports have evaluated different
treatment options for MRSA pneumonia, however,
there is limited data on MRSA pneumonia outcomes
in obese patients.
Objectives: To evaluate the effectiveness of Linezolid
(LZD) compared to Vancomycin (VAN) for the
treatment of MRSA pneumonia in a national cohort
of obese Veterans.
Methods: This national retrospective cohort study in-
cluded obese patients (body mass index ≥ 30) admitted
to Veterans Affairs hospitals with MRSA-positive
respiratory clinical cultures between 2002 and 2012.
Patients initiating either LZD (intravenous or oral) or
VAN (intravenous), but not both, in the hospital were
selected for inclusion. Exclusion criteria included death
or discharge within 2 days of treatment initiation and
exposure to more than 2 consecutive days of antibiotic
therapy with MRSA activity prior to or during treatment
with LZD/VAN. Propensity matching and adjustment of
Cox proportional hazards regression models quantiﬁed
the effect of LZD compared with VAN on time to
hospital discharge, intensive care unit discharge, 30-day
mortality, inpatient mortality, 30-day readmission, and
30-day MRSA re-infection.
Results: We identiﬁed 124 LZD and 2,872 VAN
patients. Although several baseline variables differed
signiﬁcantly between the treatment groups, balance
was achieved within propensity score quintiles and
between propensity matched pairs (LZD=102, VAN=102).
Time to discharge was signiﬁcantly lower in the LZD
group in unadjusted analyses (Hazard Ratio [HR]
0.74, 95% Conﬁdence Interval [CI] 0.59-0.92) and
non-signiﬁcantly lower in propensity adjusted (HR
0.85, 95% CI 0.68-1.06) and propensity matched
analyses (HR 0.73, 95% CI 0.46-1.15). The inpatient
(28%) and 30-day (29%) mortality rates were high,
but similar between treatment groups. No signiﬁcant
differences were observed in unadjusted, adjusted, or
matched Cox proportional hazards models for the
other outcomes assessed.
Conclusions: The real-world comparative effectiveness
of LZD was similar to VAN for treating culture-
conﬁrmed MRSA pneumonia in obese patients.
31. Use of Triptans and Risk of Hemorrhagic Stroke
in Women
Klaus K Andersen,1 Christian Dehlendorff,1 Charlotte
Skriver,1 Søren Friis,1 Tom S Olsen.2 1Statistics,
Danish Cancer Society Research Center, Copenhagen,
Østerbro, Denmark; 2Stroke Unit, Frederiksberg
Hospital, Copenhagen, Frederiksberg, Denmark.
Background: Migraine has been associated with an
increased risk of ischemic stroke. Whether this also
applies to hemorrhagic stroke is uncertain. Triptans are
mainly prescribed for treatment of migraine attacks and
may thus serve as a proxy for diagnoses of migraine.
Objectives: To determine whether the use of triptans is
associated with an increased risk of hemorrhagic stroke
in Danish women between 15 and 60 years of age.
Methods:We followed the entire Danish female popula-
tion between the age 15 and 60 years during the period
2003 to 2011. We obtained information on current use
of triptans and hospitalization for stroke from nationwide
registries. Furthermore, we recorded information on
education, age, calendar time, and loss to follow-up.
We deﬁned current use of triptans as redeeming at least
one prescription of triptans (ATC codes, N02CC01-7)
within the previous year. Stroke subtype was deﬁned as
either ischemic or hemorrhagic based on CT or MRI.
The association between triptan use and risk of stroke
was analyzed by applying log linear Poisson models
adjusting for age, calendar time and educational level
and with person-time at risk as an offset. Analyses were
run for ischemic and hemorrhagic stroke separately.
Results: The study population contributed with a total
28,4 million person-years and a total of 5,369 strokes,
of which 4,998 were ischemic and 381 were hemor-
rhagic. Triptans use constituted 0,5 million person-years
(1.7%) and was inversely u-shaped with a maximum of
4.3% at age 50. Current use of triptans was not associated
with an overall risk of ischemic stroke, RR 1.10 (95% CI
0.96-1.26) compared to non-users. In contrast, current
use of triptans was associated with an increased risk of
hemorrhagic stroke (RR, 1.77; 95% CI, 1.17-2.67). In
absolute terms, the increased risk of hemorrhagic stroke
associated with triptans was 3.5 (1.6-5.4) cases per
100.000 person-years.
Conclusions: Risk of hemorrhagic stroke was almost
2-fold increased in women using triptans. This may
indicate that migraine is associated with an increased risk
of hemorrhagic stroke, however, an effect mediated by
triptans cannot be excluded. Although the relative risk
estimate was high, the absolute risk was minimal.
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32. Women’s Perception of Risks in Pregnancy
Irene Petersen,1 Rachel McCrea,1 Angela Lupattelli,2
Michael Twigg,3 Hedvig Nordeng.2 1Primary Care
and Population Health, UCL, London, United Kingdom;
2University of Oslo, Oslo, Norway; 3University of East
Anglia, Norwich, United Kingdom.
Background: Pregnancy is an important period in many
women’s lives and a period where they may consider
their own health as well as that of their future child. How-
ever, sparse information is available on their perception
of risks in pregnancy.
Objectives: To estimate and compare:
(1) women’s baseline perception of the risk of giving
birth to a child with a birth defect.
(2) perceived risk scores for a range substances
including commonly prescribed and over the counter
medication as well as selected food items.
(3) the associations between perceived risks and
maternal characteristics, their views about medica-
tion, their drug use during pregnancy and country
of residence.
Methods: A multinational web-based population study
of pregnant women and new mothers was conducted in
2011-12 in Europe, America and Australia. Women used
a numeric rating scale to score the teratogenic risk of 13
substances: paracetamol, antibiotics, antidepressants,
thalidomide, swine inﬂuenza-vaccine, over the counter
(OTC) agents against nausea, blue veined cheese, eggs,
ginger, cranberries, alcohol in the ﬁrst trimester, smoking
and dental X-ray. We estimated baseline risk perception
of birth defect, derived sum scores for risk perception
and used multilevel regression analyses to examine asso-
ciations of women’s characteristics and risk perception.
Results: Overall, 9,459 women aged between15-55 were
included in the study. Nearly 80% perceived the baseline
risk of birth defect to be low (less than 5%). Women rated
alcohol and smoking on par with thalidomide (median
scores: 10 out of 10) followed by antidepressants and
dental X-rays (median scores: 8 out of 10). Few women
2749/9459 (29%) knew of thalidomide, but 80% of
those who did rated it very harmful. The perception of
risk of medicine varied by country, age, level of
education and profession. Women who used medicine
in pregnancy had a lower perception of risk compared
to those who did not.
Conclusions: Most women perceived baseline risk of
birth defects to be low (less than 5%). Alcohol and
smoking were considered as harmful as thalidomide
followed by antidepressants and dental X-rays. Risk
perception varies by country, age, level of education
and profession.
33. Procedure-Related Issues Associated with the
Nexplanon Contraceptive Implant: Interim Results
from the Nexplanon Observational Risk Assessment
Study (NORA)
Suzanne Reed, Klaas Heinemann. Berlin Center for
Epidemiology and Health Research (ZEG), Berlin,
Germany.
Background: Nexplanon is a subdermal contraceptive
implant containing the progestogen etonogestrel. In
contrast to Implanon, it contains barium sulfate to
facilitate its localization and a new applicator to aid
correct insertion. Issues involving Nexplanon have not
previously been adequately assessed.
Objectives: To characterize the frequency of insertion-,
localization- and removal-related events and their
clinically signiﬁcant consequences among Nexplanon
users in the USA during standard clinical practice.
Methods: The Nexplanon Observational Risk Assess-
ment Study is a large, prospective, non-interventional,
observational cohort study that follows new users of
Nexplanon after their recruitment by health care profes-
sionals (HCPs). Baseline and follow-up data are collected
via questionnaires. Data analysis includes characterizing
the frequency of procedure-related events.
Results: There were 6,046 insertions by 405 HCPs
through October 2013. 77 HCPs (19% of HCPs) reported
182 issues involving 167 patients (2.8% of insertions).
Insertion-related issues (and number of insertions in-
volved) included: difﬁculty removing protection cap
(85) or sliding needle to its full length (28), implant
sticking out of skin (19), difﬁculty moving purple
slider to the back (14) or unlocking the purple slider
(5), needle visible after insertion (2), needle inserted
too deep (2) or too superﬁcial (1), injury to nerve/
blood vessel (1) and other issues (25). Patients
reported 37 issues affecting the implant arm shortly
after insertion: severe pain (5 patients), pins and
needles/numbness (18 patients), altered strength/
movement (3 patients), other problems (11 patients).
At follow-up, 161 patients reported a Nexplanon
removal, commonly for menstrual/bleeding problems
(132 patients). Removals were successful with no hos-
pitalization. There was one pre-treatment pregnancy
and one in-treatment pregnancy.
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Conclusions: Nexplanon was successfully inserted in
97% of study participants without a problem. Patient-
reported issues involving the implant arm were rare.
Menstrual/bleeding problems were the most common
reason for early Nexplanon removal.
34. Unwanted Pregnancies in Women Using
Intrauterine Devices: Final Results from the
EURAS-IUD Study
Klaas Heinemann, Sabine Moehner, Thai Do Minh.
ZEG-Berlin, Berlin, Germany.
Background: Intrauterine devices (IUDs) are a well-
accepted and widely used method of contraception and
have shown high contraceptive efﬁcacy in clinical trials.
Complications associated with unintended pregnancies
during IUD use have previously been poorly described.
Objectives: The primary objective of the analysis is to
determine the rate of unwanted pregnancies in women
using IUDs and describe associated complications.
Methods: Large, comparative, multinational, prospec-
tive, non-interventional cohort study with new users of
different types of IUDs: LNG-IUDs and copper IUDs.
The combined cohort included more than 60,000 women
in six European countries (Germany, Austria, UK, Fin-
land, Poland and Sweden). The study was conducted
from 2006 to 2013. Both the women and their treating
physicians received a follow-up questionnaire 12months
after enrolment. All patient-reported outcomes of interest
were validated by the women’s treating physicians. A
multifaceted 4-level follow-up procedure ensured low
loss to follow-up rates. The analysis was based on Cox
regression models comparing the cohorts.
Results: 61,448 women were recruited (70% LNG-
IUDs, 30% copper IUDs). Women in the LNG-IUD
cohort were slightly older (37.4 yrs vs 33.3 yrs). A total
of 118 contraceptive failures have been reported
(26 LNG-IUD, 92 copper IUD), giving a Pearl Index
(PI) of 0.06 for LNG-IUD and a PI of 0.52 for copper
IUD. The hazard ratio adjusted for age, BMI and
parity for LNG-IUD vs. copper IUD was 0.16 (95% CI:
0.10-0.25). The risk for contraceptive failure in
LNG-IUS users compared to copper IUD users remained
substantially and statistically signiﬁcantly lower in all age
groups except for women aged between 40 and 50 years,
for whom statistical signiﬁcance could not be shown.
21 pregnancies (7 LNG-IUD, 14 copper IUD) were
ectopic pregnancies, giving an adjusted hazard ratio
of 0.26 (95% CI: 0.10-0.66).
Conclusions: The contraceptive failure rate for both
cohorts was low, with LNG-IUD having a signiﬁcantly
lower contraceptive failure rate compared with copper-
IUD. Physicians should have a high index of suspicion
for extra-uterine gravida if they suspect a pregnancy
under IUD use.
35. Rates of Opioid-Managed Pelvic Pain after
Sterilization by Implanted Device vs. Tubal Ligation,
U.S. 2005-2011
Mitchell M Conover,1 Jennifer M Wu,2 Alan C Kinlaw,1
Jennifer O Howell,2 Michele Jonsson Funk.1 1Epidemiol-
ogy, UNC Gillings School of Global Public Health,
Chapel Hill, NC, United States; 2Obstetrics and
Gynecology, UNC School of Medicine, Chapel Hill,
NC, United States.
Background: Hysteroscopic sterilization (HS) is a
relatively new alternative to laparoscopic sterilization
(aka tubal ligation, LS), in which coils are implanted in
the fallopian tubes. Recent case reports suggest an
increased risk of abdominal/pelvic pain after HS.
Objectives: To compare rates of opioid-managed pelvic
pain in the 6months after HS vs LS.
Methods: Using inpatient, outpatient and pharmaceutical
claims from Truven Health’s MarketScan database, we
identiﬁed women age 18-49 who had HS (CPT: 58565)
or LS (CPT: 58670, 58671). We identiﬁed pelvic pain
requiring opioids based on ≥2 ICD-9 diagnoses of
abdominal pain (789.0x) or dysmenorrhea (625.3) and
≥2 prescription ﬁlls for opioids. Outcomes were censored
at disenrollment or 180 days. We excluded those with <6
months of prior continuous enrollment, a prior steriliza-
tion, a prior diagnosis of pelvic pain or prior opioid use.
We ﬁt propensity score (PS) models using logistic
regression with these baseline predictors: age, number
of prescriptions, excess menstruation, vaginal prolapse,
ﬁbroids, ovarian cysts, obesity, diabetes, and hospitaliza-
tion. We used Cox proportional hazards models to esti-
mate hazard ratios (HR) comparing HS to LS with 95%
conﬁdence intervals (CI) in PS-matched and inverse-
probability of treatment weighted (IPTW) analyses.
Results: We identiﬁed 65,345 eligible women (HS
n = 23,079 [35.3%], LS n = 42,266 [64.7%]). Of those,
210 women (0.32%) experienced the outcome within
6months (HS n = 67 [0.29%]; LS n = 143 [0.34%]). HS
patients were somewhat less likely to experience the out-
come than those with LS (crude HR=0.89, 95%CI: 0.67,
1.19). In PS-matched analysis (n = 46,066), there was no
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difference in the rate of opioid-managed pelvic pain
(HR= 0.91, 95%CI: 0.66, 1.26). The result was similar
in the IPTW analysis (HR= 0.96, 95%CI: 0.72, 1.27).
Conclusions: In the largest study to date of adverse
outcomes after hysteroscopic sterilization, we found no
evidence of higher rates of pelvic/abdominal pain
requiring opioids during the 6months after hysteroscopic
versus laparoscopic sterilization.
36. Persistent Opioid Use Following Cesarean
Delivery: Patterns and Predictors among Opioid
Naı¨ve Women
Brian T Bateman,1,2 Jessica M Franklin,1 Katsiaryna
Bykov,1 Krista F Huybrechts,1 Michael A Fischer,1
Niteesh K Choudhry.1 1Division of Pharma-
coepidemiology & Pharmacoeconomics, Department of
Medicine, Brigham & Women’s Hospital and Harvard
Medical School, Boston, MA; 2Department of Anesthesia,
Critical Care and Pain Medicine, Massachusetts
General Hospital, Boston, MA.
Background: Opioid-related death in women has in-
creased 5-fold over the past decade. For many women,
their initial opioid exposure will occur in the setting of
routine medical care. Approximately 1 in 3 deliveries in
the US is by cesarean and opioids are commonly pre-
scribed for post-surgical pain management.
Objectives: To determine the risk that opioid naïve
women prescribed opioids after cesarean delivery will
become consistent prescription opioid users in the year
following delivery and to identify predictors for this
behavior.
Methods: We identiﬁed women in a database of
commercial insurance beneﬁciaries who underwent
cesarean delivery and were opioid naïve in the year prior
to delivery. We used trajectory models to identify
groups of patients with distinct patterns of opioid ﬁlling
during the year following cesarean delivery. We then
constructed a multivariable logistic regression model to
identify independent risk factors for membership in the
persistent user group.
Results: 285 of 80,127 (0.4%) opioid naïve women be-
came persistent opioid users following cesarean delivery.
Persistent users could be predicted using demographics,
baseline comorbidity and characteristics of the index
prescription (c statistic = 0.74). Compared to patients
whose initial prescription was for ≤3 days supply, those
with a days supply of either 4-5 days or ≥6 days had a
higher risk of persistent use (adjusted odds ratio (aOR),
95% conﬁdence interval (CI) of 1.43 (1.07 - 1.93) and
1.92 (1.33 - 2.77), respectively). Compared to patients re-
ceiving an initial prescription for a total daily dose of
<81mg of morphine equivalent, those with a daily dose
of >112.5mg of morphine equivalent were also signiﬁ-
cantly more likely to become persistent users (aOR 1.42
(1.03 - 1.96)). Other signiﬁcant predictors included a
history of substance abuse, tobacco use, back pain,
migraines, and antidepressant or benzodiazepine use.
Conclusions: A small but important and identiﬁable
proportion of opioid naïve women become persistent
prescription opioid users following cesarean delivery.
Characteristics of the initial opioid prescription were
strong and potentially modiﬁable risk factors for
persistent use.
37. Antibiotic Use among Dutch Pregnant Woman and
the Development of Toddler Asthma: the Influence of
Confounding
Bianca Mulder,1 Koen B Pouwels,1 Nynke CM
Schuiling-Veninga,1 Jens Bos,1 Tjalling W de Vries,2
Susan S Jick,3,4 Eelko Hak.1,5 1PharmacoEpidemiology
& PharmacoEconomics, University of Groningen,
Groningen, Netherlands, Netherlands; 2Department
of Pediatrics, Medical Center Leeuwarden,
Leeuwarden, Netherlands, Netherlands; 3Department
of Epidemiology, Boston University School of
Public Health, Boston; 4Boston Collaborative Drug
Surveillance Program, Boston, Lexington, United
States; 5Department of Epidemiology, University
Medical Center Groningen, Groningen, Netherlands,
Netherlands.
Background: Recent studies have reported an increased
risk of asthma in children after prenatal exposure to
antibiotics, notably during third trimester due to altered
vaginal bacterial ﬂora. Associations could have been in-
ﬂuenced by unmeasured confounders.
Objectives: To assess the association between antibiotic
use during pregnancy and the development of toddler
asthma with a confounding minimizing crossover(case-
sibling) design. Secondary we wanted to assess the inﬂu-
ence of time-invariant confounding by comparing results
with a case-control design.
Methods: We conducted this study using a linked
mother-infant subset of the University Groningen pre-
scription database IADB.nl. We conducted both a cross-
over study in which 1,228 children with asthma were
compared to their own siblings without asthma, and a
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traditional matched case-control study. Maternal expo-
sure was deﬁned as at least 1 day of supply of sys-
temic antibiotics during pregnancy. Children were
considered to have asthma if they received at least 3
prescriptions for anti-asthma medication within a year
before the ﬁfth birthday. Conditional logistic regres-
sion was used to estimate crude and adjusted odds
ratios (aOR). Sensitivity analyses were performed to
estimate the potential inﬂuence of unobserved time-
varying confounders.
Results: The crossover analysis only showed an in-
crease in the toddler’s asthma risk if antibiotics were
used in the third trimester of pregnancy (aOR 1.37
(95%CI 1.02-1.83)). The matched case-control study
yielded a similar increase in the toddlers asthma risk
after exposure in the third trimester (aOR 1.40(95%CI
1.15-1.47)). In addition, use of antibiotics, indepen-
dent of trimester of pregnancy, was associated with
an aOR of 1.46 (95%CI 1.33-1.58) in the matched
case-control study.
Conclusions: Prenatal exposure to antibiotics in the
third trimester of pregnancy is associated with a small
increased risk of childhood asthma. This association did
not appear to be inﬂuenced by time-invariant confounders
such as genetic predisposition. However the inﬂuence of
time-variant confounders, such as disease severity, cannot
be ruled out.
38. Genital Herpes Infection and Its Treatment in
Relation to Preterm Delivery among 662,913 Births
De-Kun Li,1,2 Marsha A Raebel,3 T Craig Cheetham,4
Craig Hansen,5 Lyndsay Avalos,1 Hong Chen,1 Robert
Davis.5 1Division of Research, Kaiser Foundation
Research Institute, Kaiser Permanente, Oakland, CA,
United States; 2Department of Health Research and
Policy, School of Medicine, Stanford University,
Stanford, CA, United States; 3Kaiser Permanente
Colorado Institute for Health Research, Denver, CO,
United States; 4Pharmacy Analytical Services, Kaiser
Permanente, Downey, CA, United States; 5Center for
Health Research Southeast, Kaiser Permanente
Georgia, Atlanta, GA, United States.
Background: Risk factors for preterm delivery (PTD),
the leading cause of infant mortality and morbidity, are
largely unknown.
Objectives: To examine the risk of genital herpes infec-
tion and the effect of anti-herpes medications during
pregnancy in relation to PTD.
Methods: A multicenter member population-based
retrospective cohort study was conducted based on
advanced comprehensive electronic medical records,
including clinical and pharmacy databases. Four Kaiser
Permanente (an integrated health care delivery system)
regions were included: Northern and Southern California,
Colorado, and Georgia. The study population consisted
of 662,913 mother-newborn singleton pairs. Pregnant
women were classiﬁed into three exposure groups: those
with a diagnosis of genital herpes infection without
treatment, those treated with anti-herpes medications,
and controls (no herpes diagnosis or treatment). Births
with gestational age less than 37 complete weeks
(259 days) were considered as preterm. Logistic regres-
sion for repeated measurements (GEE model) was used
to obtain point and interval estimates of association
(odds ratios and 95% conﬁdence interval) after control-
ling for confounders.
Results: After controlling for potential confounders,
compared to controls, having a diagnosis of genital her-
pes infection without treatment during 1st or 2nd
trimester was associated with more than double the risk
of PTD: odds ratio (OR) =2.23, 95% conﬁdence interval
(CI): 1.79-2.76. The association was stronger for PTD
due to premature rupture of membrane (OR= 3.18) and
early PTD (OR= 2.87). In contrast, anti-herpes treatment
during pregnancy reduced PTD risk to essentially that
observed in the control group (OR= 1.10, 95% CI:
0.88-1.36]).
Conclusions: This study revealed an increased risk of
PTD associated with untreated genital herpes infection,
and a beneﬁt of anti-herpes medications in mitigating
the adverse effect of genital herpes infection on PTD.
Given the high prevalence of pregnant women with
seropositive herpes infection, identifying and treating
those with genital herpes infection may reduce PTD risk
among pregnant women.
39. Erythromycin in Early Pregnancy and Fetal
Safety: A Register Based Nationwide Cohort Study
Jon T Andersen,1 Nadia L Andersen,2 Arendse Torp-
Pedersen,1 Vanja Cejvanovic,1 Henrik E Poulsen,1 Espen
Jimenez-Solem.1 1Laboratory of Clinical Pharmacology,
Copenhagen University Hospital Bispebjerg, C, Denmark;
2Mental Health Center Copenhagen, Copenhagen,
Denmark.
Background: Contradictive results have been reported
concerning the fetal safety of the antibiotic erythromycin
during pregnancy. Recently a Swedish study found an
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increased risk of heart defects in children born to
women exposed to erythromycin during early pregnancy.
Furthermore, another macrolide, clarithromycin, has
been associated with an increase in miscarriage when
used in early pregnancy.
Objectives: The aim of the study was to investigate the
fetal safety of erythromycin when used in the ﬁrst
trimester of pregnancy.
Methods: We conducted a nationwide cohort study in-
cluding all women in Denmark with a known conception
between 1997 and 2010. The Medical Birth Register was
used to identify all records of births, stillbirths, neonatal
death, preterm birth and low Apgar score and the
National Hospital Register was used to identify all
women with a record of miscarriage or induced abortion.
Prescription data was obtained from the National Pre-
scription Register. An adjusted Cox proportional hazards
regression model was used to estimate the hazard ratio
(HR) of miscarriage and multivariable logistic regression
was used to estimate the odds ratio (OR) of major
congenital malformations, stillbirth, neonatal death,
preterm birth and low Apgar score at birth in women
exposed to erythromycin in the ﬁrst trimester compared
to unexposed.
Results: We identiﬁed 1279840 pregnancies of whom
9067 women redeemed a prescription of erythromycin
in the ﬁrst trimester. The OR of any major malformation
was 0.91 (CI95% 0.80-1.05) and the OR of major heart
defects was 0.95 (CI95% 0.74-1.23). We found no
increased OR in any EUROCAT subgroupings. The HR
of having a miscarriage after exposure to erythromycin
was 1.03 (CI95% 0.96-1.10). There was no increased risk
of stillbirth (OR= 1.03 (CI95% 0.73-1.46)), neonatal
death (OR= 1.38 (CI95% 0.94-2.01)), preterm birth
(OR= 1.05 (CI95% 0.98-1.13)) or low Apgar score
(OR= 1.06 (CI95% 0.97-1.15)).
Conclusions: We found no association between expo-
sure to erythromycin in the ﬁrst trimester of pregnancy
and miscarriage, any major malformations, major heart
defects, stillbirth, neonatal death, preterm birth or low
Apgar score compared to unexposed.
40. Antiepileptic Drug Use before, during and after
Pregnancy: A Study in 7 European Regions
Rachel Charlton,1 Ester Garne,2 Hao Wang,3 Kari
Klungsøyr,4,5 Sue Jordan,6 Amanda Neville,7 Anna
Pierini,8 Anne Vinkle Hansen,2,9 Anders Engeland,4,5
Rosa Gini,10 Daniel Thayer,6 Karen Tingay,6H Jens Bos,3
Aurora Puccini,11 Anne Marie Nybo Andersen,9 Helen
Dolk,12 Lolkje de Jong-van den Berg.3 1University
of Bath, Bath, United Kingdom; 2Hospital Lillebaelt,
Kolding, Denmark; 3University of Groningen,
Groningen, Netherlands; 4The Norwegian Institute of
Public Health, Bergen, Norway; 5University of Bergen,
Bergen, Norway; 6University of Swansea, Swansea,
United Kingdom; 7Emilia Romagna Registry of Birth
Defects, Ferrara, Italy; 8National Research Council,
Pisa, Italy; 9University of Copenhagen, Copenhagen,
Denmark; 10Agenzia Regionale di Sanità della Toscana,
Tuscany, Italy; 11Emilia Romagna Region Health
Authority, Bologna, Italy; 12University of Ulster, Belfast,
United Kingdom.
Background: Antiepileptic drugs (AEDs) are used to
treat epilepsy and increasingly mental health conditions.
During pregnancy, the beneﬁts and risks of speciﬁc
AEDs need to be weighed.
Objectives: To describe utilisation patterns of AEDs
before, during and after pregnancy in 7 population-based
electronic healthcare databases.
Methods: A common protocol was implemented across
7 databases in Denmark, Norway, the Netherlands, Italy
(Emilia Romagna/Tuscany), Wales, and the Clinical
Practice Research Datalink representing the rest of the
UK. Women with a pregnancy between 2004 and 2010
were identiﬁed in each database. All AED prescriptions
issued (UK) or dispensed (non-UK) in the 6months
before, during or 6months after pregnancy were
identiﬁed. AED prescribing patterns were evaluated,
including the prevalence of prescribing, the selection of
AEDs, changes in prescribing over time and co-prescribing
of folic acid.
Results: 966,649 women with 1,230,733 births were
identiﬁed. Overall, during the 6months before preg-
nancy, the prevalence of AED prescribing was 0.63%
(CI950.61-0.64). During pregnancy this fell to 0.50%
(CI950.49-0.51), ranging from 0.43% (CI950.33-0.54) in
the Netherlands to 0.60% (CI950.54-0.66) in Wales. In
all databases, prescribing declined during the ﬁrst and
second pregnancy trimesters. In Denmark, Norway and
the two UK databases lamotrigine was the AED most
commonly prescribed, whereas in the Italian and Dutch
databases the older AEDs including valproate, phenobar-
bital and carbamazepine were the most frequently
prescribed. A gradual increase in the use of lamotrigine
was observed during the study period in Italy and the
Netherlands. In all databases, less than a third of women
prescribed AEDs during the 3months before pregnancy
were also prescribed high dose folic acid (>0.5mg)
during the same time period.
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Conclusions: The regional differences in prescribing
patterns identiﬁed suggest different use and interpretation
of the scientiﬁc evidence base, and are unlikely to reﬂect
informed choices of women. The low co-prescribing of
folic acid may indicate that many pregnancies are
unplanned and women taking AEDs are not receiving
complete preconception care.
41. Medications and Other Risk Factors for 2nd
and 3rd Degree Hypospadias in the National Birth
Defects Prevention Study, 1997-2009
Jennita Reefhuis,1 Sander Groen in ‘t Woud,1,2 Iris van
Rooij,2 Marleen van Gelder,2 Richard Olney,1 Suzan
Carmichael,3 Nel Roeleveld.2 1National Center on
Birth Defects and Developmental Disabilities, Centers
for Disease Control and Prevention, Atlanta, GA,
United States; 2Radboud University Medical Center,
Nijmegen, Netherlands; 3Stanford University, Berkeley,
CA, United States.
Background: Hypospadias is a birth defect in boys in
which the opening of the urethra is not at the tip of the
penis, but somewhere along the ventral side. It occurs
in approximately 5 out of every 1000 male births and is
generally subdivided into three phenotypes. Some evi-
dence suggests etiological heterogeneity among subtypes.
Objectives: To assess whether differences exist in the fac-
tors associated with second and third degree hypospadias.
Methods: Data for 1997-2009 were derived from the
National Birth Defects Prevention Study (NBDPS), a
large, multi-state, population-based, case-control study
in the United States. We assessed the association between
a wide variety of maternal and pregnancy-related factors
and isolated second and third degree hypospadias to iden-
tify potential differences between the two phenotypes.
Medications assessed included clomiphene citrate, oral
contraceptives, antihypertensive medication, thyroxine,
and folic acid. Logistic regression was used to calculate
crude and adjusted odds ratios including a random effect
by study center.
Results: In total, 1547 second degree cases, 389 third de-
gree cases, and 5183 male controls were included in our
study. Third degree cases were more likely than second
degree cases and controls to be delivered very preterm
(16%, 5% and 2% respectively), to have a very low birth
weight (22%, 5%, and 1% respectively), and to be small
for gestational age (42%, 15% and 7% respectively). As-
sociations with both second and third degree hypospadias
were observed for maternal age, race/ethnicity, family
history, parity, fertility treatment, plurality, and
hypertension during pregnancy and its treatment. Risk
estimates were generally higher for third degree
hypospadias except for family history.
Conclusions: Our results indicate a stronger role for
factors associated with placental insufﬁciency in third
degree hypospadias than in second degree hypospadias.
As most risk factors were associated with either both or
neither phenotype, the underlying mechanism is likely
similar in both phenotypes. Stratiﬁcation by phenotype
may result in more appropriate effect estimates for the
hypospadias subtypes.
42. Statins during Pregnancy and the Risk of
Congenital Malformations: A Cohort Study
Brian T Bateman,1,3 Sonia Hernandez-Diaz,2
Helen Mogun,1 Michael A Fischer,1 Krista F Huybrechts.1
1Division of Pharmacoepidemiology & Pharmaco-
economics, Department of Medicine, Brigham &
Women’s Hospital and Harvard Medical School,
Boston, MA; 2Department of Epidemiology, Harvard
School of Public Health, Boston, MA; 3Department of
Anesthesia, Critical Care, and Pain Medicine,
Massachusetts General Hospital, Boston, MA.
Background: Statins are the most commonly used class
of medication to treat hyperlipidemia. Statins have been
designated by the U.S. Food and Drug Administration
as Category X (i.e., they are contraindicated in
pregnancy). Existing human studies based on registries
and spontaneous reports have been inconsistent in their
ﬁndings regarding the teratogenic potential of statins.
As the prevalence of cardiovascular disease risk factors
in women of reproductive age rises and as the indications
for statin therapy expand, it is important to understand
whether it is safe to use these medications in patients
who may become pregnant.
Objectives: To examine the risk of major congenital
malformations associated with ﬁrst trimester statin
exposure.
Methods: We used a cohort of 886,996 completed preg-
nancies linked to liveborn infants of women enrolled in
Medicaid from 2000 to 2007. We examined the risk of
major congenital malformations and organ-speciﬁc
malformations associated with ﬁrst trimester exposure
to a statin, which was deﬁned based on a ﬁlled prescrip-
tion during this exposure window. The reference group
consisted of women without a statin dispensing during
the ﬁrst trimester. Propensity score matching in a 1:3
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ratio was used to control for potential confounders in-
cluding maternal demographics, obstetric and medical
conditions, and exposure to other medications.
Results: There were 1,152 (0.13%) women dispensed a
statin during the ﬁrst trimester. The prevalence of
malformations in the statin exposed was 6.33% compared
to 3.54% in the non-exposed (odd ratio (OR) 1.84, 95%
conﬁdence interval (CI) 1.45 to 2.33). After controlling
for confounders, the OR for any malformation was 1.05
(95% CI 0.78 to 1.39). There were no signiﬁcant increases
in any of the organ-speciﬁcmalformations assessed. Results
were similar across a range of sensitivity analyses.
Conclusions: Maternal use of statins early in pregnancy
was associated with a higher risk of malformations. How-
ever, the increase in risk was no longer present after
adjusting for confounders. Our results suggest that ﬁrst
trimester statin exposure does not confer a signiﬁcant risk
of congenital malformations in the offspring.
43. Validation of Pancreatic Cancer Diagnosis Claims
Within SEER-Medicare
Mary E Ritchey, Jinghua He, Samuel S Engel,
Mellissa Yong, Kimberly G Brodovicz. Merck &
Co., Whitehouse Station, NJ, United States.
Background: Validation of insurance claims data can be
difﬁcult when data have been de-identiﬁed for research
purposes; patient chart reviews are often needed to
conﬁrm diagnoses. The Surveillance, Epidemiology,
and End Results (SEER)-Medicare database provides a
unique resource in which conﬁrmed cancer diagnoses
from cancer registries are already available within de-
identiﬁed patient records.
Objectives: To assess the proportion of conﬁrmed diag-
noses associated with two commonly used algorithms
for pancreatic cancer.
Methods: We identiﬁed patients in the 5% Medicare
sample within the SEER-Medicare database who had
two ICD-9-CM diagnoses claims of pancreatic cancer
(most common algorithm) between 2001-2007. A 2nd
less stringent algorithm of one diagnosis claim of
pancreatic cancer was also applied. We then assessed
the proportion of pancreatic cancer patients identiﬁed
through claims who were also conﬁrmed pancreatic
cancer cases within SEER data. Since pancreatic cancer
has a very poor prognosis, we identiﬁed differences in
subsequent follow-up time between conﬁrmed and
unconﬁrmed cases.
Results: Of the 590 people with no other cancer and at
least one month enrollment prior to ICD-9-CM diagnosis
of pancreatic cancer, only 368 (62.4%) had conﬁrmed
pancreatic cancer in SEER. Among patients with other
cancers, a similar proportion (66%) was conﬁrmed. By
year, the proportion of conﬁrmed pancreatic cancer
ranged 52-68% with no noted trend (p = 0.238). Among
conﬁrmed pancreatic cancer cases, the mean time to
death was 291 days (median 182 days) vs a mean of
511 days (median 238 days) among unconﬁrmed cases.
Similar results were noted with the less stringent
algorithm.
Conclusions: SEER-Medicare provides cancer registry
data for validation of claims-based cancer diagnoses.
SEER-conﬁrmed pancreatic cancer cases may follow a
different trajectory post-diagnosis than unconﬁrmed
pancreatic cancer cases based on diagnosis claims alone.
The common algorithm of two ICD-9-CM diagnoses of
pancreatic cancer does not provide high accuracy in
identifying patients with conﬁrmed pancreatic cancer
within SEER-Medicare. Research of pancreatic cancer
using claims data should include conﬁrmation of diagnosis.
44. An Analysis of Biomarker Testing and Appropri-
ate Treatment Among Women with Breast Cancer
Using Oncology EMR Data
Kathleen A Foley, Leigh G Hansen, Richard Bizier.
Truven Health Analytics, Ann Arbor, MI, United States.
Background: Personalized treatment for biomarker-
speciﬁc breast cancer is a reality. However, real-world
research has lagged behind due to lack of data sources
capturing testing, results, and drug treatment.
Objectives: This study uses a new oncology electronic
medical record (EMR) database to examine testing, doc-
umentation of results, and appropriate treatment among a
cohort of women treated for breast cancer in community
oncology practices in the U.S.
Methods: The Truven Health MarketScan® Oncology
EMR Database was used to select patients diagnosed
with breast cancer between July 1, 2011 and September
30, 2013 who had at least 2 visits and known disease
stage. Biomarker tests and results for estrogen receptor
(ER), progesterone receptor (PR) and human epidermal
growth factor receptor 2 (HER2) were observed along
with patients’ drug treatment.
Results: 57,660 women met inclusion criteria. Docu-
mented biomarker testing varied by disease stage and
test. ER testing was >90% for women with stage 0 - II;
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80% for stage IV patients. More than 87% of women
with stage 0-III and 75% with stage IV had a PR test.
HER2 testing was documented in 82% with stage 0,
77% with stage I-II, 76% in stage III, and 66% with stage
IV. Overall, 74%, 56%, and 2% of women respectively
who were ER positive, HER2 positive, and HER2 nega-
tive received biomarker speciﬁc treatment. Treatment
rates varied by disease stage, with >81% of stage IV
women receiving appropriate treatment for ER positive
and HER2 positive cancer. Among HER2 negative stage
IV women, appropriate treatment was 16%. 6%, 12%,
and 14% of patients respectively had a biomarker result
that was not consistent with ER positive, HER2 positive,
or HER2 negative treatment received.
Conclusions: Documentation of appropriate testing
varied both by the type of test and disease stage. Quality
improvement programs aimed at documentation as well
as appropriate treatment may beneﬁt patients treated in
U.S. community oncology practices.
45. Comparative Persistence to Oral Hormonal
Agents in Women with Breast Cancer
Edward Chia-Cheng Lai,1,2 Winson Y Cheung,3
Yinghong Zhang,2 Soko Setoguchi.2 1Institute of
Clinical Pharmacy and Pharmaceutical Sciences,
National Cheng- Kung University, Tainan, Taiwan;
2Duke Clinical Research Institute, Duke University
School of Medicine, Durham, United States; 3Division
of Medical Oncology, British Columbia Cancer Agency,
Vancouver, BC, Canada.
Background: In addition to tamoxifen, a number of
other oral anti-cancer agents are used in breast cancer,
including steroidal (exemestane) and non-steroidal
aromatase inhibitors (anastrozole, letrozole). Measuring
persistence integrates patients’ and clinicians’ judgments
of efﬁcacy, safety, and tolerability into a global measure-
ment that reﬂects their evaluation of therapeutic beneﬁts
in relation to undesirable effects. Nowadays, persistence
to these various drugs have not been directly compared.
Objectives: To compare the persistence to anastrozole,
letrozole, exemestane, and tamoxifen in women with
breast cancer in a real word setting.
Methods: We conducted a retrospective cohort study
using the U.S. Medicare data of female patients who were
incident users from 2006 to 2009 of any of the following
agents: anastrozole, letrozole, exemestane, and tamoxi-
fen. Patients were considered non-persistent on their drug
if they failed to reﬁll their medication within 60 days
from the anticipated end of supply date of their preceding
prescription or if they received a drug different from their
index medication. Cox regression models were con-
structed to examine the relationships between clinical
characteristics and time to non-persistence for each of
the agents.
Results: We identiﬁed 5,150 women initiating an oral
hormonal agent: 2352 (46%) anastrazole, 1401 (27%)
letrozole, 248 (5%) exemestane, and 1149 (22%) tamox-
ifen. For the entire study cohort, the mean age was
76.4 years and the majority (88%) were White. Discon-
tinuation of hormonal agents was highly prevalent in
the cohort (49% of patients). This occurred most
commonly with exemestane (65%) and least frequently
with tamoxifen (42%). In a Cox regression model with
tamoxifen as the reference group, exemestane was
correlated with the highest risk of non-persistence (HR
1.93, 95% CI 1.63-2.30) followed by letrozole (1.47,
1.32-1.64) and anastrozole (1.14, 1.03-1.27).
Conclusions: The study demonstrated that the persis-
tence were worse in patients receiving aromatase
inhibitors when compared with tamoxifen. Additional
research should focus on elucidating the association
between non-persistence to hormonal therapy and
breast cancer speciﬁc outcomes.
46. Elderly Breast Cancer Patient’s Pill Burden and
Adherence to Hormonal Therapy
Kitaw Demissie,1 Joel N Swerdel,1 Kim M Hirshﬁeld,2
Sheenu Chandwani,1 George G Rhoads.1 1Epidemiology,
Rutgers School of Public Health, Piscataway, NJ, United
States; 2Medicine, Rutgers Robert Wood JohnsonMedical
School, New Brunswick, NJ, United States.
Background: Elderly patients suffer from multiple
comorbidities resulting in a high pill burden and complex
regimens which may lead to non-adherence to hormonal
therapy for breast cancer.
Objectives: To determine the non-breast cancer
treatment related pill burden and its association with
non-adherence to hormonal therapy.
Methods: The Surveillance, Epidemiology and End
Results linked Medicare data from 2007-2010 was used
for this analysis. Medicare Part D contains prescription
reﬁlls data. Patients who initiated hormonal therapy after
invasive breast cancer diagnosis were included. Pill
burden was estimated by the average number of pills
taken daily during the period between time of breast
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cancer diagnosis and initiation of hormonal therapy and
was categorized into four groups: none (0 pills/day),
low (>0-3 pills/day), intermediate (>3-5 pills/day) and
high (>5 pills/day). A medication possession ratio of
<0.8 deﬁned non-adherence. Analysis was stratiﬁed by
race (Whites and Non-Whites) and time of initiation of
hormonal therapy after breast cancer diagnosis (within 8
and> 8months).
Results: In the overall sample (n = 25,899), 6.6% had
none, 44.9% low, 23.7% intermediate and 24.8% high
pill burden. Non-adherence to hormonal therapy was
seen in 27.2% [95% Conﬁdence interval (CI): 26.7% to
27.7%] of patients in the ﬁrst year and remained similar
thereafter. In patients who initiated hormonal therapy
within 8months of breast cancer diagnosis, pill burden
was not associated with non-adherence. In contrast, in pa-
tients who initiated hormonal therapy after 8months,
higher pill burden was associated with non-adherence to
hormonal therapy. For example, in Whites, in compari-
son to the none pill burden group [proportion of non-
adherence = 0.25; Relative Risk (RR) = 1], the proportion
of non-adherence was 0.30 (RR=1.23; 95% CI 1.05 to
1.43) in the low, 0.33 (RR= 1.33; 95% CI: 1.12 to
1.58) in the intermediate and 0.26 (RR= 1.05; 95% CI:
0.87 to 1.26) in the high pill burden groups. A similar
non-signiﬁcant trend was seen among Non-Whites.
Conclusions: Special attention should be given to
adherence issues in elderly patients with comorbidities
who are initiating hormonal breast cancer therapy.
47. The Impacts of Competing Risks on Assessing
the Association between Switch and Interruption of
Adjuvant Hormone Therapy in Breast Cancer
Women
Kun-Pin Hsieh,1,4 Li-Chia Chen,2 Kwok-Leung
Cheung,3 Yi-Hsin Yang.1 1School of Pharmacy,
College of Pharmacy, Kaohsiung Medical University,
Kaohsiung, Taiwan; 2Division for Social Research in
Medicines and Health, School of Pharmacy, Univer-
sity of Nottingham, Nottingham, United Kingdom;
3Division of Breast Surgery, School of Graduate
Entry Medicine & Health, University of Nottingham,
Derby, United Kingdom; 4Department of Pharmacy,
Kaohsiung Medical University Hospital, Kaohsiung,
Taiwan.
Background: Switching adjuvant hormone therapy (HT)
due to suboptimal efﬁcacy (recurrence or progression) or
adverse effects often jeopardizes HT persistence in the
treatment of breast cancer (BC) women. However, there
is no population-based study incorporating mortality
and recurrence as competing risks (CR) in assessing
association between switching and interruption of
adjuvant HT.
Objectives: This study aimed to explore the impacts of
CR on the association between switching and interrup-
tion of adjuvant HT in BC women by comparing
Kaplan-Meier (KM) survival analysis and CR analysis.
Methods: This cohort study used the Taiwan Health
Insurance Research Database from 2003 to 2011. BC
women were grouped by initial HT and whether HT
was switched before the ﬁrst interruption, including
Tamoxifen (Tam), Tam/switch (S), Aromatase inhibi-
tors (AIs), and AIs/S, and followed to the ﬁrst inter-
ruption, i.e. gap of over 180 days between coverage
of two HT prescriptions, or study end. For each group,
probability of interruption was analyzed by KM sur-
vival analysis and CR analysis. Adjusted hazard ratios
(HR) of interruption were estimated by Cox regression
considering covariates of diagnosed age groups,
Charlson Comorbidity Index score, primary BC
treatment, adjuvant BC therapy and modiﬁed Cox
regression (CR analysis) with additional covariates of
mortality and recurrence.
Results: Proportions of the 37,391 included patients in
the four groups were: Tam 64.9%, Tam/S 20.7%, AIs
9.9% and AIs/S 4.6%. Interruption rates over 5 years
in CR analysis were about 10% lower than KM
analysis, except for the Tam group. Comparing Cox
and modiﬁed Cox regression, the HRs for Tam/S were
2.17 (95%CI: 2.03-2.32) vs. 1.54 (95%CI: 1.40-1.69),
for AIs/S were 2.33 (95%CI: 2.08-2.61) vs. 1.55
(95%CI: 1.33-1.82).
Conclusions: Switching adjuvant HT is associated with
increased risk of interruption, however, when competing
risk events exist, absolute risk of interruption might be
overestimated in standard survival analysis. CR analysis
provides an objective measure of switch-related HT
interruption in BC women.
48. Prognostic Impact of Tumor MET Expression
among Patients with Stage IV Gastric Cancer: A
Danish Cohort Study
Rune Erichsen,1 Michael A Kelsh,2 Kelly S Oliner,3
Karsten B Nielsen,4 Trine Froslev,1 Anne-Vibeke
Laenkolm,5 Morgan Vyberg,6 John F Acquavella,2
Henrik T Sorensen.1 1Department of Clinical Epidemiol-
ogy, Aarhus University Hospital, Aarhus, Denmark;
2Center for Observational Research, Amgen, Thousand
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Oaks, CA, United States; 3Medical Sciences, Amgen,
Thousand Oaks, CA, United States; 4Molecular
Pathology, R&D, Dako, Glostrup, Denmark; 5Department
of Pathology, Slagelse Hospital, Slagelse, Denmark;
6Institute of Pathology, Aalborg University Hospital,
Aalborg, Denmark.
Background: Recent clinical trial data indicate a
poor prognosis for patients with gastric cancer and
positive tumor mesenchymal epithelial transition
factor (MET) protein expression. MET expression
also has been associated with poorer disease progno-
sis in other cancers.
Objectives: We investigated the prevalence of MET-
positive (MET-pos) stage IV gastric cancers and 1 year
survival using historical medical registry data to evaluate
prevalence and prognostic signiﬁcance in the general
population.
Methods: We identiﬁed patients with stage IV gastric
cancer in a single institution in Northern Denmark
from 2003-2010. From these patients, we collected
archived (formalin ﬁxed parafﬁn-embedded) cancer
specimens and analyzed MET protein expression by
immunohistochemistry (MET-pos if ≥25% of tumor
cells showed membrane staining). We calculated the
prevalence of patients with MET-pos tumors and
the associated 95% conﬁdence interval (CI) using
Jeffrey’s method. We estimated overall survival using
the Kaplan-Meier method and computed mortality rate
ratios comparing MET-pos to MET-negative (MET-neg)
patients using Cox proportional hazards models adjusted
for age, gender, and Charlson Comorbidity Index scores
(score of 0, 1-2, and 3+, excluding gastric cancer from
the Index).
Results: 101 patients with stage IV gastric cancer were
included in the study; 55% (95% CI: 46%-65%) had
MET-pos tumors. Patients with MET-pos tumors were
younger at diagnosis than patients with MET-neg tumors
(median age 65 vs 68 years), included more men, showed
higher comorbidity levels, had more poorly differentiated
cancers, and were less likely to undergo surgery or
chemotherapy. In patients with MET-pos tumors,
one-year survival was 18% compared to 39% in
patients with MET-neg tumors (mortality rate ratio =
2.3, 95% CI: 1.4-3.9).
Conclusions: Prevalence of MET-pos stage IV gastric
cancers was similar with that seen in clinical trials.
Survival was much worse in these patients than in
MET-neg patients suggesting the MET pathway is a
logical target for therapeutic intervention.
49. Comparative Effectiveness of Drug-Eluting Stents
for Patients with Coronary Diseases: A Nationwide
Population-Based Study in Taiwan
Grace Hui-Min Wu,1,2 Yu-chiao Wang.1 1Division of
Health Technology Assessment, Center for Drug
Evaluation, Taipei, Taiwan; 2Department of Physical
Therapy and Assistive Technology, National Yang-Ming
University, Taipei, Taiwan.
Background: Various types of coronary drug-eluting
stents (DESs) have been reimbursed by the National
Health Insurance (NHI) at the same rate with bare-metal
stents (BMSs) under a balanced-billing scheme (BBS).
However, the comparative effectiveness of DESs remains
unclear.
Objectives: This study aims to investigate the
comparative effectiveness between DESs and BMSs,
and also between different types of DESs including
biolimus- (BES), everolimus- (EES), paclitaxel- (PES),
sirolimus- (SES), and zotarolimus- (ZES) eluting stents,
and endothelial progenitor cell-capturingstents (EPC).
Methods: A retrospective cohort study was conducted
using the National Health Insurance Claims Database.
First-time users of BMSs and various types of DESs
aged above 40 years old during 2006 and 2011 were
enrolled and were followed up until the end of 2012.
BMSs users and DESs users were matched by propen-
sity score. Death and acute myocardial infarction
(AMI) were assessed.
Results: Among 23,010-pair BMSs and DESs users,
DESs users have lower risks of AMI (HR: 0.73, 95%
CI: 0.68, 0.78, p< 0.001) and death (HR: 0.90, 95%CI:
0.85, 0.94, P< 0.001) than BMSs users. Among 24,320
DESs users, ZES (35.6%), PES (23.7%), EES (19.7%)
were the most common types of DESs, whereas EPC
was the least one (3.7%). All types of DESs users have
similar AMI risks. However, compared with PES users,
the earliest DESs covered by NHI, SES and ZES users
were associated with increased risks of death (adjusted
HR of SES vs. PES: 1.75, 95% CI: 1.14, 2.67, p = 0.01;
adjusted HR of ZES vs. PES: 1.49, 95% CI: 1.06, 2.08,
p = 0.02). EPC users also have increased risk of death
but without signiﬁcant (p = 0.162). BES and EES users
have slightly lower but not signiﬁcant risk of death than
PES users (p = 0.642, and p = 0.804).
Conclusions: Based on our population-based study,
DMSs users were associated with lower risk of AMI
and deaths compared with BMSs. Moreover, the risk of
death may differ across different types of DMSs.
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50. Real-World Effectiveness of Primary ICDs Im-
planted during Unplanned Medicare Hospitalizations
Chih-Ying Chen,1,2 Garrick C Stewart,3 Lynne W
Stevenson,3 Deepak L Bhatt,2,3,4 Manisha Desai,5 John
D Seeger,1,2 Lauren Williams,1 Jessica J Jalbert,1,2 Soko
Setoguchi.1,2,6 1Division of Pharmacoepidemiology and
Pharmacoeconomics, Department of Medicine, Brigham
and Women’s Hospital, Boston, MA; 2Harvard Medical
School, Boston, MA; 3Division of Cardiovascular
Medicine, Brigham and Women’s Hospital, Boston,
MA; 4VA Boston Healthcare System, Boston, MA;
5Quantitative Sciences Unit, Stanford University School
of Medicine, Palo Alto, CA; 6Duke Clinical Research
Institute, Durham, NC.
Background: Beneﬁts of Implantable Cardioverter
Deﬁbrillators (ICD) for primary prevention are well
established in ambulatory HF population, but unclear
among hospitalized patients.
Objectives: To examine clinical effectiveness of primary
ICDs in Medicare patients receiving the device during
unplanned hospitalizations for HF or other acute
conditions.
Methods: Linking data from the CMS ICD registry, a
nationwide heart failure (HF) registry, and the Medicare
ﬁles (2004-2009), we identiﬁed 23,111 hospitalized
patients ≥ 66 years of age with ejection fraction ≤35%
who were eligible for primary ICDs from the ICD regis-
try (ICD patients) or the HF registry (non-ICD patients).
We used a latency analysis to address the potential bias
due to ICD recipients being healthier. Cox proportional
hazard models were used to derive crude and high-
dimension propensity score (hdPS)–adjusted hazard
ratios (HRs) for all-cause mortality and sudden cardiac
death (SCD) from 180 days after index implantation or
discharge.
Results: The average follow-up in our study population
was 2.8 years. Although patients who received ICDs
during non-elective hospitalizations for cardiac or non-
cardiac causes had lower crude mortality (40% at 3 years,
95% CI: 38%-41%) than those who did not receive an
ICD during their index hospitalization (60% at 3 years,
95% CI: 60%-61%), ICD recipients did not have a signif-
icantly different adjusted risk of mortality (hdPS-adjusted
HR=0.91; 95% CI: 0.82-1.00) or SCD (hdPS-adjusted
HR=0.95; 95% CI: 0.78-1.17) compared with non-ICD
recipients. ICD use was associated with 16% lower risk
of death (95% CI = 0.72-0.99) among patients greater
than 81 years of age. No other signiﬁcant treatment
heterogeneity was noted.
Conclusions: After accounting for confounding and
selection bias, ICD use among Medicare patients
receiving primary ICD during unplanned hospitalization
for HF or other reasons was not associated with compara-
ble survival beneﬁts as what was observed in the
landmark trials. Future research is warranted to further
identify subgroups of older patients who are more or less
likely to beneﬁt from ICDs in order to reﬁne current
practice guidelines and reimbursement criteria.
51. Concomitant Use of Clopidogrel with Calcium
Channel Blockers and Cardiovascular Outcomes in
Patients Received Percutaneous Coronary Intervention
Chen- Yu Wang,1 Fei-Yuan Hsiao,1 Zhen-Fang Lin,2
Li-Jiuan Shen.1 1Graduate Institute of Clinical Pharmacy,
National Taiwan University, Taipei; 2School of Pharmacy,
National Taiwan University, Taipei.
Background: Some pharmacokinetic studies have re-
ported that calcium channel blockers (CCBs) reduce the
activity of clopidogrel, but studies assessing clinical out-
comes in patients receiving both drugs are very limited.
Objectives: The objective of this population-based
cohort study was therefore to investigate risks of
recurrent hospitalization for cardiovascular events in
patients received percutaneous coronary intervention
who require ongoing clopidogrel therapy with or
without CCBs.
Methods: Using the 2004-2009 Taiwan’s National
Health Insurance research databases, we identiﬁed 4072
patients ﬁrst admitted for acute coronary syndrome
(ACS) and received PCI. We further limited our study
subjects as those who received medications for secondary
prevention for ACS recommended by recent guidelines
(i.e.β-blockers, (ACEI/ARB) and statins).Multivariable
logistic regression analyses were conducted to assess
(re-hospitalization for ACS) in patients receiving
clopidogrel therapy with or without CCBs.
Results: Among patients who used clopidogre, concom-
itant use of CCBs was associated with a reduced risk
of CV outcomes after adjusting for age, gender, and
comorbidities,(adjusted odds ratio (OR) 0.46 [95%
conﬁdence interval (CI)0.32-0.64]). In addition, there
is no difference between CCBs with and without
P-glycoprotein (P-gp) inhibiting property. Compared
to P-gp inhibiting CCBs, the adjusted OR of risk of
CV outcomes for non P-gp inhibiting CCBs is 0.89
[95%CI 0.48-1.63]. These ﬁndings are consistent in
patients who used clopidogrel alone.
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Conclusions: In conclusion, this population-based
cohort study found that concomitant use of clopidogrel
and CCBs in patients received PCI after ACS was not
associated with an increased risk of cardiovascular
outcomes.
52. Integration of Healthcare Delivery System
Characteristics into Pharmacoepidemiologic Research:
An Analysis of Acute Stroke Care Effectiveness
Mark O Loveless,1 Andrew Wilson,2 Stephen Agbor,2
Drew Levy,3 Aaron WC Kamauu.2 1Alpha ~R Systems,
Portland, OR, United States; 2Anolinx, LLC, Salt Lake
City, UT, United States; 3Genentech, Inc, South San
Francisco, CA, United States.
Background: The treatment of acute ischemic stroke
(AIS) is heavily time-dependent and thus inﬂuenced by
the effectiveness of the care delivery system. Elucidating
the impact of the capabilities of the stroke care teams on
treatment outcomes is challenging due to the complexity
of the care delivery environment.
Objectives: Use formal epidemiologic analysis com-
bined with social network modeling of individual stroke
care teams to describe the critical system characteristics
of high-performing units in a real-world hospital system.
Methods: Individual facility characteristics and variation
of treatment delivery (thrombolytic medication) were
analyzed and compared between study sites. A critical
path analysis was created for each care site based on a
standard acute stroke care process model. Formal and
informal stroke care teams were mapped using network
analytic software (Gephi).
Results: Analysis of stroke care data in 12 hospitals
revealed heterogeneity in the institution-level parameters,
with 5 hospitals meeting criteria for all 7 institution-level
parameters and the remaining 7 hospitals range from 1-3
parameters. Additionally, the proportion of acute stroke
patients receiving thrombolytic treatment varied between
hospitals, ranging from 0-7% of AIS cases with at least
one rt-PA medication record. We also observed prelimi-
nary relationships between institution-level parameters
and rt-PA Treatment Rate. Results of critical path
analysis, combined with mapping of the individual stroke
team network interactions, system-level structures and
processes associated with the use of thrombolytic therapy
will be presented.
Conclusions: Existing healthcare delivery system data is
robust for evaluating medical outcomes, but may lack
necessary indicators of delivery system performance. A
network model of real world stroke care teams may
provide new insights into the key system-level barriers
for the rapid delivery of thrombolytic therapy.
53. Preadmission Use of Angiotensin-Converting
Enzyme Inhibitors or Angiotensin Receptor Blockers
and 30-Day Stroke Mortality
Jens Sundbøll,1,2 Morten Schmidt,1,2 Erzsébet Hovath-
Puho,1 Christian F Christiansen,1 Lars Pedersen,1 Hans
E Bøtker,2 Henrik T Sørensen.1 1Department of
Clinical Epidemiology, Aarhus University Hospital,
Aarhus, Denmark; 2Department of Cardiology, Aarhus
University Hospital, Aarhus, Denmark.
Background: The prognostic impact of angiotensin-
converting enzyme inhibitors (ACE-Is) or angiotensin
receptor blockers (ARBs) on stroke mortality remains
unclear.
Objectives: To examine whether preadmission use of
ACE-Is or ARBs is associated with improved short-term
mortality following ischemic stroke, intracerebral hemor-
rhage (ICH), and subarachnoid hemorrhage (SAH).
Methods: We conducted a nationwide population-based
cohort study using medical registries in Denmark. We
identiﬁed all patients with a ﬁrst-time inpatient diagnosis
of stroke between 2004 and 2012 and their comorbidities.
We deﬁned ACE-I/ARB use as current use (last prescrip-
tion redemption <90 days before hospital admission),
former use, and nonuse. Current use was further classi-
ﬁed as new or long-term use. We used Cox regression
modeling to compute 30-day mortality rate ratios
(MRRs) with 95% conﬁdence intervals (CIs), controlling
for potential confounders.
Results: We identiﬁed 100,043 patients with a ﬁrst-time
stroke. Of these, 83,736 patients had ischemic stroke,
11,779 had ICH, and 4,528 had SAH. For ischemic
stroke, the adjusted 30-day MRR was reduced in cur-
rent users compared with nonusers (0.87, 95% CI:
0.82-0.91). We found no reduction in the adjusted
30-day MRR for ICH (0.95, 95% CI: 0.88-1.04) or
SAH (1.00, 95% CI: 0.84-1.20), comparing current
users with nonusers. No association with mortality was
found among former users compared with nonusers.
We identiﬁed no notable modiﬁcation of the association
within sex or age strata.
Conclusions: Preadmission use of ACE-Is/ARBs was
associated with reduced 30-day mortality among patients
with ischemic stroke. We found no association among
patients with ICH or SAH.
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54. Severe Malabsorption Associated with Olmesartan:
A French Nation-Wide Cohort Study
Myriam Mezzarobba,1 Mickael Basson,1 Alain Weill,1
Philippe Ricordeau,1 Allemand Hubert,1 Alla François,1
Franck Carbonnel.2 1French National Health Insurance
Fund, Paris, France; 2Service de Gastroentérologie,
Hôpitaux Universitaires Paris Sud, CHU de Bicêtre,
APHP, Université Paris Sud, Le Kremlin Bicêtre,
France.
Background: Several cases of severe sprue-like
enteropathy have been reported in patients treated with
Olmesartan medoxomil, an angiotensin II receptor blocker
(ARB) approved for the treatment of hypertension.
Objectives: To assess in a large nation-wide patient
cohort the risk of severe intestinal malabsorption
associated with olmesartan, compared with ARBs other
than olmesartan or ACEIs.
Methods: We identiﬁed adult patients who started ARB
or ACEI treatment between 2007 and 2012 from the
claim database of the main insurance scheme of the
French national health insurance (SNIIRAM), which
covers approximately 53.1 million inhabitants of France,
and the national hospital discharge database (PMSI).
Patients with a history (assessed over 12months prior to
treatment initiation) of hospitalization for intestinal
malabsorption or celiac disease serology testing or
gluten-free dietary product prescription were excluded.
Severe intestinal malabsorption was deﬁned by hospitaliza-
tion with a discharge diagnosis of intestinal malabsorption
(ICD-10 code K90). Rate ratios were estimated with a
Poisson regression model adjusted for age and sex.
Results: 4,546,680 patients summing up to 9,010,303
person-years were included. 218 events were observed.
Compared with ACEI, the adjusted rate ratio of severe in-
testinal malabsorption associated with olmesartan was
2.27 (95% conﬁdence interval 1.59-3.23, p< 0.0001).
This adjusted rate ratio varied with treatment duration:
less than 1 year RR=0.68 (0.35-1.33, p = 0.3), between
1 and 2 years RR= 3.35 (1.68-6.68, p< 0.001), 2 years
or more RR= 10.27 (4.86-21.71, p< 0.0001). Compared
with other ARBs, the rate ratio of severe intestinal
malabsorption associated with olmesartan intake was
3.04 (95% CI 2.13-4.34, p< 0.0001). The risk of severe
intestinal malabsorption was not signiﬁcantly different
between patients who were prescribed ARBs other than
olmesartan and ACEIs.
Conclusions: Olmesartan was associated with an
increased risk of severe intestinal malabsorption. The
increased risk appears after one year of treatment and
reaches 10.3 after 2 years of olmesartan. ARBs other than
olmesartan were not associated with an increased risk of
severe intestinal malabsorption.
55. Instrumental Variable Analysis Using Multiple
Databases: An Example of Antidepressant Use and
Risk of Hip/Femur Fracture
Md Jamal Uddin,1 Rolf HH Groenwold,1,2 Anthonius
de Boer,1 Helga Gardarsdottir,3 Elisa Martin,4
Gianmario Candore,5 Svetlana V Belitser,1 Arno W
Hoes,2 Kit CB Roes,2 Olaf H Klungel.1 1Division of
Pharmacoepidemiology and Clinical Pharmacology,
University of Utrecht, Utrecht, Netherlands; 2Julius
Center for Health Sciences and Primary Care, Univer-
sity Medical Center Utrecht, Utrecht, Netherlands;
3Department of Clinical Pharmacy, University Medical
Center Utrecht, Utrecht, Netherlands; 4BIFAP, Pharma-
coepidemiology and Pharmacovigilance Division, Medi-
cines for Human Use Department Agencia Española de
Medicamentos y Productos Sanitarios (AEMPS), Madrid,
Spain; 5European Medicines Agency (EMA), London,
United Kingdom.
Background: Instrumental variable (IV) analysis can
reduce bias due to unmeasured confounding, yet it has
not been widely used in pharmacoepidemiologic studies.
Objectives: To assess the performance of several IVs
across multiple databases in a study of antidepressant
use and risk of hip/femur fracture (HF).
Methods: Information on adult patients with at least
one prescription of a selective serotonin reuptake inhibitor
(SSRI) or tricyclic antidepressant (TCA) during 2001-2009
was extracted from three European databases: THIN (UK,
n = 570139), BIFAP (Spain, n = 250865), and Mondriaan
(Netherlands, n = 22474). Conventional Cox model and
two-stage IV analysis were applied to estimate the risk of
HF associated to initiation of SSRI vs. TCA. IVs were
created using the proportion of SSRI prescriptions per
practice (PSP) or using the number, one (PPP1), ﬁve
(PPP5) or ten (PPP10), of previous prescriptions by a
physician. Quantitative methods (e.g. correlation (r),
standardized difference (SDif)) were used to assess the
validity of IVs. 95% conﬁdence intervals (CI) in IV
analysis were estimated using bootstrapping.
Results: Conventional analysis showed that SSRI use
was associated with an increased risk of HF in BIFAP
and THIN, hazard ratio (HR) 1.35 [95%CI 1.18-1.56]
and 1.35 [1.26-1.44], respectively and similarly in
Mondriaan (though not signiﬁcant), HR 1.36 [0.86-2.15].
The IVs PSP (THIN and BIFAP) and PPP10 (THIN and
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Mondriaan) were strongly associated (r> 0.15) with
SSRI prescribing and independent of confounders
(SDif< 0.10). IV analysis based on these variables
showed that SSRI use was not associated with an increased
risk of HF: HR 1.09 [0.75-1.60] and 2.75 [0.97-7.10] for
the PSP in THIN and BIFAP, respectively; and 1.16
[0.70-1.92] and 1.67 [0.15-27.7] for the PPP10 in THIN
and Mondriaan, respectively.
Conclusions: Conventional analysis showed an in-
creased risk of HF for SSRI users, whereas IV analysis
showed that SSRI did not indicate a clear association
with an increased risk of HF compared to TCA.
Performance of IVs varied across databases and estimates
from IV analysis are imprecise, indicating that this null
effect should be interpreted cautiously.
56. Using Simulation to Explore the Properties of IV
Bias Amplification and Unmeasured Confounding
Jonathan V Todd,M Alan Brookhart. Epidemiology,
Gillings School of Global Public Health, The University
of North Carolina at Chapel Hill, Chapel Hill, NC,
United States.
Background: Recent research has explored the phenom-
enon of bias ampliﬁcation from adjustment for instru-
mental variables (IV) and near instrumental variables
(NIV). Analysts may encounter situations where there is
a potential trade-off between avoiding error from adjust-
ment for IV and NIV, and error from failing to adjust for
a confounder.
Objectives: We used simulation to explore these two
sources of error with a variety of adjustment sets.
Methods: We assumed treatment and outcome were
conditionally Bernoulli distributed given covariates, with
the logit of the mean given by a linear function of the
simulated covariates (and exposure for the outcome).
We created one true IV with a uniform distribution and
three NIV, one speciﬁed using a normal distribution
and two with a Bernoulli distribution. NIV were deﬁned
as having an association with the exposure and an
extremely weak association with the outcome. Ten
confounders were simulated using normal and Bernoulli
distributions, with varying parameter values. We esti-
mated bias, variance, and mean squared error (MSE)
using eight adjustment sets. We simulated 1000 cohorts
each with a sample size of 1000.
Results: Our true value for the coefﬁcient corresponding
to exposure was -0.2. The model adjusting only for con-
founders (leaving out the IV and NIVs) performed the
best (MSE=0.0301). MSE increased as more NIV were
added to the adjustment set. The model that failed to
adjust for a strong confounder (β= 1.2) performed
demonstrably worse (MSE=0.0656) than did the model
including three NIV but properly adjusting for the strong
confounder (MSE=0.0346). However, the model failing
to adjust for a moderate confounder (β= 0.25) performed
better (MSE= 0.0307) than models that included at least
one NIV.
Conclusions: Using a simulation strategy incorporating a
broad range of confounders, IV, and NIV, we found that
the avoidance of strong confounding was of greater
importance with regards to MSE than bias ampliﬁcation
from adjustment. However, adjustment for the IV and
NIV resulted in higher MSE than failure to adjust for
a moderate confounder. Both residual confounding
and bias ampliﬁcation were sources of substantial
systematic error.
57. Instruments and Doubly Robust Estimation: Bias
and Efficiency Compared to Conventional Estimators
Michele Jonsson Funk, Virginia Pate, Til Stürmer.
Dept of Epidemiology, University of North Carolina,
Chapel Hill, NC, United States.
Background: In conventional estimation, including
instruments increases variance and may induce bias.
Omitting a near instrument can also lead to bias. The
doubly robust (DR) estimator is theoretically unbiased
as long as one of the component models is correctly
speciﬁed. Would the doubly robust property protect
against bias if the instrument is only included in one of
the component models?
Objectives: To evaluate the DR estimator and conven-
tional estimators in scenarios involving instruments.
Methods: We simulated a dichotomous instrument (Z),
dichotomous treatment (X), and continuous outcome
(Y); some scenarios included effect measure modiﬁcation
(EMM) by Z or residual confounding. Z was a pure or
near (weak effect on Y) instrument. We simulated 5000
iterations, each of n = 5000. We estimated the average
treatment effect using DR, inverse probability of treat-
ment weighted (IPTW), g-computation, and maximum
likelihood estimators. All models were ﬁt with and with-
out Z. We calculated mean bias, variance, and mean
squared error (MSE) across all iterations.
Results: In the base scenario (no residual confounding,
no effect of Z on Y, no EMM), all estimators were
unbiased (<1%); including Z in any component model
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increased variance and MSE, as expected. In the presence
of residual confounding, all estimates which included Z
were more biased, including the DR estimator when Z
was in one or both models. If Z was a near instrument,
failing to include it in at least one of the models resulted
in bias (up to 10%) in all estimators. This was offset by a
decrease in variance; MSE was minimized by omitting Z.
If Z was an EMM, all estimates which did not include Z
were biased. Including Z in any DR component model
eliminated bias. MSE was minimized by including Z,
despite the decrease in efﬁciency.
Conclusions: Including Z in one or both models had sim-
ilar effects on bias and efﬁciency of DR and conventional
estimators, for better and worse. All of these estimators
require analysts to weigh potential bias ampliﬁcation,
weak effects of Z on the outcome, and/or EMM by Z.
58. Evaluating Different Physician’s Prescribing
Preference Based Instrumental Variables in the
Study of Beta2-Agonist Use and the Risk of Acute
Myocardial Infarction
Md Jamal Uddin,1 Rolf HH Groenwold,1,2 Anthonius de
Boer,1 Ana Afonso,1 Paola Primatesta,3 Claudia Becker,4
Svetlana V Belitser,1 Arno W Hoes,2 Kit CB Roes,2
Olaf H Klungel.1 1Division of Pharmacoepidemiology
and Clinical Pharmacology, University of Utrecht,
Utrecht, Netherlands; 2Julius Center for Health
Sciences and Primary Care, University Medical Center
Utrecht, Utrecht, Netherlands; 3Global Epidemiology,
Novartis Pharma AG, Basel, Switzerland; 4Basel
Pharmacoepidemiology Unit, Division Clinical Phar-
macy & Epidemiology, University of Basel, Basel,
Switzerland.
Background: Instrumental variable (IV) analysis with
physician’s prescribing preference (PPP) as an IV has
been used to control for unobserved confounding in
pharmacoepidemiology. PPP can be deﬁned in several
ways, but it is unclear how different PPPs perform across
databases.
Objectives: To assess the validity of the IV PPP in two
general practice (GP) databases in the study of inhaled
long-acting beta2-agonist (LABA) use and the risk of
acute myocardial infarction (AMI).
Methods: Information on adult patients with a diagnosis
of asthma and/or COPD and at least one prescription of
an inhaled short-acting beta2-agonist (SABA)/LABA/
muscarinic antagonist (MA) was extracted from the
British Clinical Practice Research Datalink (CPRD,
n = 490499), and the Dutch Mondriaan (n = 27459) GP
databases. Conventional Cox model and two-stage IV
analysis were applied to estimate the effect of LABA
vs. non-LABA (SABA/MA) on the risk of AMI. PPPs
were deﬁned by the proportion of LABA prescriptions
per practice (PLP) or previous single (PPP1), or ﬁve
(PPP5), or ten (PPP10) prescriptions by a physician.
Quantitative methods (e.g. correlation (r), odds ratio
(OR), standardized difference (SDif)) were used to assess
the validity of the IVs. 95% conﬁdence intervals (CI) for
IV estimates were estimated using bootstrapping.
Results: LABA was not associated with an increased risk
of AMI, adjusted hazard ratio 0.96 [95%CI 0.89-1.02]
(CPRD) and 1.18 [0.97-1.43] (Mondriaan) in conven-
tional Cox model and 0.95 [0.55-1.63], 1.24 [0.40-3.60],
and 1.24 [0.47-3.09] in IV analyses with PPP10
for CPRD, and PPP5 and PPP10 for Mondriaan,
respectively. PLP, PPP1 and PPP5 in the CPRD and
PPP1 in Mondriaan were weakly associated with
LABA (r< 0.15 or OR< 2). Also, observed confounders
were imbalanced (SDif> 0.10) across PLP levels in
Mondriaan.
Conclusions: LABA use was not associated with an
increased risk of AMI compared to non-LABA. Validity
of IV depends on the deﬁnition of IV and the database in
which it is applied. We recommend researchers to gener-
ate several possible IVs, assess their validity, and report
the estimate(s) from the most valid IV.
59. The Performance of Different Disease Risk Score
Methods for Estimating Unbiased Odds Ratio in the
Presence of Multiple Confounders
Chien-Chang Lee,1,2,3 Chen-Fang Chen.1 1Department
of Emergency Medicine, National Taiwan University
Hospital, Taipei; 2Department of Emergency Medicine
and Department of General Medicine, National
Taiwan University Hospital Yunlin Branch, Douliou;
3Department of Epidemiology, Harvard School of
Public Health, Boston.
Background: The disease risk score (DRS) is the
probability of a speciﬁc outcome conditional on observed
variables in the nonexposed population. The use of the
DRS is aimed to result in balancing potential con-
founders between case and controls in a case-control
study. Little is known about the performance of DRS
methods for estimating odds ratios.
Objectives: To ﬁnd out the performance of different
disease risk score methods for estimating unbiased odds
ratio in the presence of multiple confounders.
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Methods: The DRS was calculated from the full cohort.
We performed a series of Monte Carlo simulations to as-
sess the performance of stratifying on the DRS, adjust-
ment of DRS in regression model, DRS matching, and
inverse probability of disease weighting (IPDW) using
the DRS to estimate odds ratios. For the simulated sam-
ple, we set 3 outcome prevalence, 0.05, 0.1, and 0.15,
and 3 true exposure odds ratio, 1, 1.5, 2. We ﬁrst com-
pared the proportion of bias adjustment between different
methods. Then we assessed precision and mean-squared
error (MSE) of the effect estimates under disease risk
score adjustment methods.
Results:When the true odd ratio is 1, all 3 DRS methods
except DRS matching had comparable performance to
traditional regression model. When the true odd ratio in-
creased to 1.5 or 2, only stratiﬁcation and DRS adjust-
ment in model have comparable performance. When the
outcome prevalence increase from 0.05 to 0.1 the perfor-
mance of DRS weighting improved, but still is inferior to
stratiﬁcation and DRS adjustment in model. When the
outcome prevalence set to be 0.2, stratiﬁcation, adjust-
ment, and weighting have comparable performance but
the estimates by matching method still have signiﬁcant
residual bias. The weighting method has signiﬁcant
higher MSE than other three methods across three out-
come prevalence and different effect sizes.
Conclusions: Our simulation study suggest when out-
come is rare, DRS covariate adjustment or stratiﬁcation
methods have better performance in eliminating bias.
Weighting method can be used when outcome prevalence
and effect size is high. DRS matching has inferior perfor-
mance in our simulation sample.
60. Accounting for Cumulative Exposure Effects in
Comparative Effectiveness and Safety Analyses
Michal Abrahamowicz,1,2 Rolina D van Gaalen,1 Marie-
Pierre Sylvestre,3,4 Marie-Eve Beauchamp.2 1Department
of Epidemiology, Biostatistics, and Occupational Health,
McGill University, Montreal, QC, Canada; 2Division of
Clinical Epidemiology, McGill University Health Centre,
Montreal, QC, Canada; 3Research Centre, University
of Montreal Hospital Centre, Montreal, QC, Canada;
4Department of Social and Preventive Medicine,
Universite de Montreal, Montreal, QC, Canada.
Background: Observational comparative effectiveness
(CER) studies require accounting for time-varying
patterns of drug dosage [1]. The true mechanism by
which past and current doses affect the risk is usually
unknown. It varies depending on the pharmacodynamics/
pharmacokinetics of the drug, and likely includes
cumulative effects of past doses. Yet, current CER
studies typically rely on ad hoc simple conventional
exposure metrics, e.g. ‘current dose’ or ‘any use in
the past 3months’.
Objectives: (1) To develop and validate a ﬂexible
method for testing the difference between effectiveness
of alternative treatments, while accounting for their
cumulative effects. (2) To compare type I error rates
and power of the proposed test with tests based on
conventional exposure models.
Methods: We expanded our ﬂexible weighted cumula-
tive exposure (WCE) model [2] to permit simultaneous
estimation of the cumulative effects for two or more
time-varying exposures. We developed procedures to dis-
criminate between hypotheses of (i) no difference in ef-
fectiveness, (ii) different strengths of the cumulative
effects, or (iii) different ways treatment effects cumulate
with increasing use of drugs. 1,000 hypothetical cohorts
of incident users of two drugs were simulated assuming
different true effects, and analyzed using Cox models
with alternative exposure metrics, including the WCE
model [2]. Model-based likelihood ratio tests were then
used to discriminate between hypotheses (i)-(iii).
Results: Type I error rates of all tests were close to 0.05.
The proposed ﬂexible tests, which account for cumula-
tive effects, yielded systematically higher power than bi-
nary models and outperformed all conventional tests
when drug-speciﬁc weight functions differed, e.g. from
18% power for the test based on simplistic ﬁxed-in-time
groupings of users of drug A vs. B, and 45% power for
the conventional time-varying ‘current use’ model-based
test, to 84% for the WCE-based test.
Conclusions: Flexible modeling of the effects of time-
varying drug exposures may enhance statistical power
and accuracy of CER analyses.
[1] Sylvestre MP & Abrahamowicz M. Stat Med
2009;28:3437-53.
[2] Abrahamowicz M et al. Stat Med 2012;31:1014-30.
61. Use of Antidepressants and Age: A Comparatively
High Risk of Suicide Attempts but Not of Suicide
among the Young
Fabian Termorshuizen,1,2 Marco P Boks,3 Hugo M
Smeets,4 Eibert R Heerdink.5,6 1Julius Center for Health
Sciences and Primary Care, Utrecht University, Utrecht,
Netherlands; 2Health Promotion and Epidemiology,
Municipal Health Service Utrecht, Utrecht, Netherlands;
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3Psychiatry, University Medical Centre Utrecht, Utrecht,
Netherlands; 4Achmea Health Insurance, Amersfoort,
Netherlands; 5Pharmacoepidemiology & Clinical Phar-
macology, Utrecht Institute for Pharmaceutical Sciences,
Utrecht, Netherlands; 6Altrecht Institute for Mental
Health Care, Utrecht, Netherlands.
Background: The United States Food and Drug Agency
(FDA) as well as the European Medicines Authority
(EMA) have issued a number of advisory warnings
regarding a possible link between antidepressants (ADs)
and suicide behavior among young persons.
Objectives: To investigate the rates of (fatal) suicide
attempts associated with use of ADs at different
ages.
Methods: By linking insurance claims with the death
register of Statistics Netherlands (2001-2011), rates
of fatal suicides and suicide attempts were estimated
during episodes of AD use and intermittent episodes
of no use over a broad age range. The inﬂuence of
age on the comparison of rates of fatal suicides in ep-
isodes of use with episodes of no use was tested by
inclusion of terms for {age x episode} interaction in
a Cox regression model. For suicide attempts, a
Poisson regression model was applied with individual
episodes of AD use and no use as the units of analy-
sis. Dependence of the duration of episodes within the
same patient was taken into account by inclusion of a
random intercept.
Results: For 232,561 patients with at least one new
AD prescription after at least 1 year of no use, 590
suicides and 2,939 suicide attempts were registered.
During episodes of use compared to episodes of no
use, the rates of suicide (8.5 vs. 3.1/10,000 pyrs.)
and suicide attempts (68.8 vs. 28.1/10,000 pyrs.) were
signiﬁcantly higher. For suicide attempts, the Rate
Ratio (RR) during AD use compared to no use
decreased from 3.62 (95%CI: 2.84-4.62) among those
aged under 24 to 1.86 (1.47-2.37) among those aged
over 60 (p for interaction {age x episode}< 0.001).
A similar age dependency was observed when
restricting use of ADs to SSRIs or to the later years
(>5 years) after the ﬁrst registered AD. For suicide,
no statistically signiﬁcant age dependency of the HR
was established (P = 0.9063).
Conclusions: Episodes of AD are indicative of high
suicide behavior risk, especially at young age. At
young age, use of ADs may be less effective for
prevention of suicide behavior, which necessitates
intense clinical monitoring.
62. Drug Use Patterns and Characteristics of Elderly
Users of Antidepressants in Germany
Kathrin Jobski, Niklas Schmedt, Tania Schink, Edeltraut Garbe.
Clinical Epidemiology, Leibniz Institute for Prevention
Research and Epidemiology - BIPS GmbH, Bremen,
Germany.
Background: Antidepressants (ADs) are frequently used
in elderly patients; however, knowledge on characteris-
tics and drug use patterns of elderly users of speciﬁc
AD classes and drugs is scarce.
Objectives: To investigate characteristics and drug use
patterns of elderly AD users in Germany.
Methods: Using data from the German Pharmaco-
epidemiological Research Database (GePaRD) we identi-
ﬁed a cohort of persons aged 65 years or older with at
least one AD dispensation between 2005 and 2009. Co-
morbidity and co-medication was assessed in the year
prior to cohort entry and for co-medication also during
follow-up. We examined if patients used two or more
ADs concurrently or switched to other AD drugs or clas-
ses. Additionally, we calculated the median duration of
AD use and evaluated if treatment was discontinued. In
a subgroup analysis these measures were also calculated
for patients with depression.
Results: During the study period 490,114 persons aged
65 years or older received at least one AD. Median age
at cohort entry was 72 years, 73% were female and 52%
had a diagnosis of depression. Over 70% of patients en-
tered the cohort with a tri- or tetracyclic AD (TCA),
followed by 20% receiving a selective serotonin inhibitor
(SSRI) as index AD. Amitriptyline most often led to
cohort entry (21%), followed by opipramol (16%) and
citalopram (12%). Median treatment duration for any
AD was 85 days and varied between 33 days for doxepin
users and 392 days in patients entering the cohort with
sertraline. Discontinuation of treatment was found in
26% of patients ranging from 15% in SSRI users to more
than 30% in patients receiving TCA. For 12% of all AD
users, concurrent use or switch was identiﬁed. Compared
to the whole cohort, treatment in patients with depression
was longer (median 126 days), and concurrent use or
switch were more common (16%).
Conclusions: Drug use patterns of AD assessed in a large
cohort of elderly Germans varied substantially across
drug classes and drugs. Compared to the whole cohort,
patients with depression showed different patterns.
Overall, the high proportion of AD users treated with
TCA compared to other AD classes was remarkable.
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63. Treatment Patterns among US Veterans Treated
with Selegiline Transdermal System
Scott L DuVall,1,2,3 Kimberly B Portland,4 Terry
Painter,4 Andrew Wilson,5 Stephen Agbor,5 Aaron WC
Kamauu.5 1VA Salt Lake City Health Care System, Salt
Lake City; 2University of Utah School of Medicine, Salt
Lake City; 3University of Utah School of Pharmacy,
Salt Lake City; 4Mylan Specilaty, LP, Basking Ridge;
5Anolinc LLC, Salt Lake City.
Background: Depression is a substantial problem and
ﬁrst-line therapies are not always effective for patients.
Monoamine oxidase inhibitors (MAOIs) can be useful
for patients with atypical depression or who do not
respond to ﬁrst-line treatments. However, MAOIs are
infrequently prescribed due to adverse issues with food
interactions requiring dietary restrictions. A relatively
new transdermal delivery mechanism for the MAOI
selegiline, approved by the FDA in 2006, signiﬁcantly
reduces the need for such restrictions.
Objectives: This study examines treatment patterns
among US Veterans treated with selegiline transdermal
system (STS).
Methods: This study used electronic medical record data
from the Department of Veterans Affairs (VA) between
January 1999 and July 2012. Eligible patients needed at
least one prescription for STS and 180 days baseline
healthcare coverage in VA prior to initial prescription
date. 719 patients met these criteria. Treatment patterns
were explored for STS-treated patients with a diagnosis
of major depressive disorder, bipolar disorder, Alzheimer’s
disease, and Parkinson’s disease.
Results: 78% of VA patients prescribed STS were age
45years old or over, 83% were male, and 75% were white.
Less than 5% of patients had STS as their initial
antidepressant. 86% switched to STS from one or
more other antidepressants, with the majority of pa-
tients switching medications within 90 days of initial
antidepressant prescription. Close to 25% of patients
had STS as the ﬁnal antidepressant prescribed, while
other patients switched again to different antidepres-
sants. There was a consistent upward trend in the
number of prescriptions per patient across time across
the spectrum of disorders.
Conclusions: STS was prescribed to patients in the
context of complex, highly-personalized care. Although
fewer than 5% of patients receiving STS had it as their
initial antidepressant, almost 25% had STS as the ﬁnal
antidepressant prescribed during the study period, possi-
bly indicating positive patient response.
64. Neighborhood Material and Social Deprivation and
Adherence to Antidepressant Treatment in Depression
Sophie Lauzier,1 Hichem Kadachi,1 Jocelyne Moisan,1
Marie-Josée Fleury,2 Alain Lesage,3 Alain Vanasse,4
Josiane Courteau,4 Jean-Pierre Grégoire.1 1Chair on
Adherence to Treatments, CHU de Québec Research
Center, Laval University, Québec, QC, Canada;
2Douglas Mental Health University Institute Research
Center, McGill University, Montréal, QC, Canada;
3Fernand-Seguin Research Center, Institut Universitaire
en Santé Mentale de Montréal, Montréal, QC, Canada;
4Groupe PRIMUS, Étienne-Lebel Research Center,
Université de Sherbrooke, Sherbrooke, QC, Canada.
Background: Adherence to antidepressant (AD) treat-
ment is suboptimal for a high proportion of individuals
diagnosed with depression. Deprivation could be a
barrier to medication adherence.
Objectives: To assess the effect of material and social
deprivation on persistence and compliance with AD treat-
ment in the context of the Quebec (Canada) public drug
plan’s goal of providing equitable access to prescription
medications.
Methods: Using Quebec administrative health data, we
conducted a cohort study including individuals aged ≥18
years, newly diagnosed with depression between 1
January 1997 and 31 December 2006 and enrolled in
the public drug plan 1 year before and 2 years following
depression diagnosis. Neighborhood material and social
deprivation were measured using indices built and
validated using the Quebec population. Based on
Canadian practice guidelines, individuals were consid-
ered persistent if they had an active AD claim 240 days
after treatment initiation. Among those who persisted,
individuals were considered compliant if they had an
AD for ≥ 80% of the days. Log-binomial regressions
were used to calculate adjusted prevalence ratios
(aPR) and their 95% conﬁdence intervals (CI) compar-
ing the proportions of individuals persistent and
compliant in the most deprived levels to those in the
least deprived levels.
Results: Among the 65,453 individuals exposed to an
AD in the year following a new diagnosis of depression,
54% persisted for the minimum recommended period of
240 days. Among persistent individuals, 74% had an
AD for ≥ 80% of the days. Material deprivation had no
effect on persistence (aPR comparing the most deprived
to the least deprived = 0.98; 95%CI: 0.96-1.01) or on
compliance (aPR= 0.98; 0.96-1.00). Results for social
deprivation were similar.
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Conclusions: Persistence and compliance did not differ
according to deprivation levels. This suggests that the
Quebec public drug plan may achieve its goal of provid-
ing equal access to prescription medications.
65. Understanding Inconsistent Results from Obser-
vational Pharmacoepidemiological Studies: the Case
of Antidepressant Use and Risk of Hip Fracture
V Abbing-Karahagopian,1 P Souverein,1 E Martin,2
C Huerta,2 F de Abajo,3,4 H Leufkens,1,5 G Candore,6
Y Alvarez,6 J Slattery,6M Miret,7 G Requena,4M Gil,2
R Groenwold,8 R Reynolds,9 R Schlienger,10
M de Groot,1 OH Klungel,1,8 T van Staa,1,11 T Egberts,1,12
MLDe Bruin,1,5 H Gardarsdottir.1,12 1Division of Pharma-
coepidemiology & Clinical Pharmacology, Utrecht
University, Utrecht, Netherlands; 2Bifap Research Unit,
Agencia Española de Medicamentos y Productos
Sanitarios (AEMPS), Madrid, Spain; 3Department of
Biomedical Sciences, School of Medicine, University of
Alcalá, Alcalá, Spain; 4Unit of Pharmacology, Depart-
ment of Biomedical Sciences, School of Medicine, Univer-
sity of Alcalá, Alcalá, Spain; 5MEB, Medicines Evaluation
Board, Utrecht, Netherlands; 6EMA, European Medicines
Agency, London, United Kingdom; 7Merck KGaA,
Geneva, Switzerland; 8Julius Center for Health Sciences
& Primary Care, UMCU, Utrecht, Netherlands; 9Depart-
ment of Epidemiology, Pﬁzer, New York, United States;
10Global Clinical Epidemiology, Novartis Pharma AG,
Basel, Switzerland; 11London School of Hygiene &
Tropical Medicine, London, United Kingdom; 12Depart-
ment of Clinical Pharmacy, UMCU, Utrecht, Netherlands.
Background: Results from multiple observational
studies on the same exposure-outcome association may
be inconsistent due to variations in methodological,
clinical and health care system factors.
Objectives: In the context of the Pharmaco-
epidemiological Research on Outcomes of Therapeutics
by a European Consortium (PROTECT) project, we eval-
uated the impact of applying a common study protocol
and statistical analysis plan on the consistency of results
from cohort studies on antidepressant (AD) use and the
risk of hip/femur fracture (HFF).
Methods: Three new user cohorts, including adult
patients receiving an AD between 2001 and 2009, were
constructed in three primary care databases (Spanish
BIFAP, Dutch Mondriaan and UK THIN). AD treatment
episodes were constructed and divided into current,
recent and past use. Patients were followed until ﬁrst
HFF, death, loss to follow-up or end of study. Potential
confounders included comedications and comorbidities.
Hazard ratios (HR) and 95% conﬁdence intervals (CI)
were estimated for the association between current SSRI
and TCA use and HFF using time-dependent multivari-
able Cox proportional hazard models, using past use as
reference.
Results: The crude HRs for current SSRI use were 2.48
(CI 2.22, 2.78), 2.40 (CI 1.44, 4.00) and 2.10 (CI 1.94,
2.27) and for current TCA 2.01 (CI 1.61, 2.50), 2.52
(CI 1.30, 4.92) and 2.39 (CI 2.17, 1.63) in BIFAP,
Mondriaan and THIN, respectively. The adjusted HR
for SSRI use was higher in Mondriaan (3.27; CI 1.93,
5.53) than BIFAP (1.63; CI 1.45, 1.83) and THIN
(1.72; CI 1.59, 1.87). This difference may be mainly
explained by an interaction between SSRI and age in
Mondriaan. The adjusted HR for TCA use and fracture
was 1.28 (CI 1.02, 1.60), 1.98 (CI 1.00, 3.92) and 1.32
(CI 1.20, 1.46) in BIFAP, Mondriaan and THIN,
respectively.
Conclusions: Applying similar study methods to differ-
ent populations and data sources may still produce
different results. Some of these differences may express
real (or natural) variance in the exposure-outcome co-
occurrences. However, consistently similar methods also
enable the identiﬁcation of relevant effect modiﬁers.
66. (Non)availability of Dosage Instructions in
Electronic Health Care Databases and Exposure
(mis)classification: the Example of Antidepressants
Patrick C Souverein,1 Helga Gardarsdottir.1,2 1Division
of Pharmacoepidemiology & Clinical Pharmacology,
Utrecht Institute for Pharmaceutical Sciences, Utrecht
University, Utrecht, Netherlands; 2Dept. Clinical
Pharmacy, University Medical Center Utrecht, Utrecht,
Netherlands.
Background: Pharmacoepidemiological studies often
require detailed information on drug use patterns over
time. However, many health care databases lack informa-
tion on the prescribed dosage regimen, making it difﬁcult
to estimate duration of drug use adequately.
Objectives: To assess the inﬂuence of methods used to
deﬁne duration of a single antidepressant (AD) prescrip-
tion on exposure (mis)classiﬁcation.
Methods: From the Dutch PHARMO-RLS database, all
patients initiating ADs in 2001 were selected. Two
methods were used to estimate the theoretical duration
of an AD prescription; M1) using the actual dosage regi-
men and number of units dispensed and M2) assuming
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use of 1 deﬁned daily dose per day. Treatment episodes
were constructed allowing for a 30 day gap between pre-
scriptions. Median duration of use (days) for the ﬁrst AD
treatment episode and persistence rates at 182 days were
compared for both methods using Mann-Whitney U and
Chi-square tests. Subsequently, we studied the impact
of type of AD on these measures.
Results: 28,948AD initiators were included (67.0% fe-
male, mean age 47.9 [Standard Deviation 16.4]) years.
The median duration of the ﬁrst AD treatment episodes
was 102.0 (Interquartile range 303.0) days using M1
and 80.0 (290.0) days using M2 (p< 0.001). Patients
starting TCAs had signiﬁcantly longer (p< 0.001)
median treatment episodes duration when using M1 com-
pared to M2 (44.0 vs. 19.0 days, respectively). However,
no signiﬁcant difference (p = 0.64) was found for the me-
dian duration for patients initiating SSRIs when using
M1 (139.0 days) compared to M2 (137.0 days). AD
persistence at 182 days was higher using M1 (38.1% vs.
35.7%, p< 0.001) However, among patients initiating
on TCAs the 182 day persistence was higher for M1
(27.1% vs. 10.9%, p< 0.001), but no difference was
found for SSRI initiators (44.2% vs 44.3%).
Conclusions: Dose assumptions that are made due to
lack of information on prescribed dose can lead to expo-
sure misclassiﬁcation when estimating antdepressant use,
speciﬁcally for TCAs. How this misclassiﬁcation inﬂu-
ences risk estimates in pharmacoepidemiological studies
needs further investigation.
67. A Paradigm Shift for Screening Individual Case
Reports: Accounting for Quality and Content
Ola Caster,1,2 Kristina Juhlin,1 Sarah Watson,1
G Niklas Norén.1,3 1Uppsala Monitoring Centre, Uppsala,
Sweden; 2Department of Computer and Systems
Sciences, Stockholm University, Stockholm, Sweden;
3Department of Mathematics, Stockholm University,
Stockholm, Sweden.
Background: Disproportionality analysis is the current
state of the art for ﬁrst-pass screening of collections of in-
dividual case reports, as a triage for clinical assessment.
This purely quantitative approach naïvely disregards the
quality and content of reports.
Objectives: To develop a screening algorithm that
incorporates report quality and content; and to compare
its performance to that of disproportionality analysis.
Methods: The algorithm, denoted vigiRank, was devel-
oped as a shrinkage regression model for the prediction
of emerging safety signals. Training data consisted of
reporting patterns in VigiBase on 264 drug-adverse drug
reaction pairs for historical European labelling changes
and 5280 randomly selected negative controls. Data up
until a point determined by the start of the European
Medicines Agency’s review was used. 13 potential
predictors were considered, capturing aspects of strength
of evidence that range from primarily clinical, e.g. the
number of reports with positive rechallenge, to entirely
quantitative, such as a disproportional reporting rate.
Other examples include the number of informative reports,
the number of reports with a case narrative, the number of
recent reports, the number of reports without co-reported
drugs, and the geographic spread as measured by the num-
ber of contributing countries. The predictive performance
of vigiRank was measured as area under the receiver
operating characteristics curve (AUC), and compared to
that of the disproportionality metric IC025, and screening
based on raw numbers of reports.
Results: In order of decreasing coefﬁcients, regression
selected the following predictors for vigiRank: informa-
tive reports, recent reports, disproportionality, reports
with narrative, and geographic spread. It obtained a mean
AUC of 0.775 in ﬁve-fold cross-validation, compared to
0.736 for IC025 (p< 0.001) and 0.707 for raw numbers
of reports.
Conclusions: Relative to today’s methods, accounting
for multiple aspects of strength of evidence in a predic-
tive model like vigiRank has clear conceptual and empir-
ical advantages in identifying emerging safety signals.
68. Sequential Analysis After a Signal in Safety
Surveillance of Drugs or Vaccines
Bruce H Fireman, Edwin M Lewis. Division of
Research, Kaiser Permanente, Oakland, CA, United States.
Background: Sequential analyses are designed to stop
after a signal. Yet in sequential safety surveillance as
done by Mini-Sentinel or the Vaccine Safety Datalink,
relevant data would keep accumulating after a signal. If
so, there can be good reasons to continue statistical tests
while also evaluating possible biases.
Objectives: Simulate surveillance that does not stop after
a signal and continues testing until the planned end.
Clarify the interpretation and use of post-signal tests.
Methods: By simulation, we examined the performance
of post-signal tests in scenarios which varied the inci-
dence, the relative risk (RR), and the number of stages
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(“looks”). The overall chance of a false positive signal
was kept at .05 using 1-sided exact binomial tests with
a ﬂat Pocock threshold. A signal prior to the last stage
of surveillance was deemed an “early” signal. We
examined the proportion of early signals that would be
withdrawn if (and only if) the nominal test at the last
stage yields a p-value above 0.05.
Results: In a 10-look design, the threshold needed to
keep below .05 the overall chance of a false positive
signal was a nominal p-value below .0190. If the true
RR was 1.0, the chance of signaling early was .0454.
After early Type 1 errors, the drug-outcome association
tended to weaken, and it usually weakened so much that
the nominal p-value not only re-crossed the stringent
threshold (p = .0190 in this scenario), it also rose above
.05. When the criterion for withdrawing a signal was a
nominal p above .05 at the ﬁnal stage of surveillance,
55.5% of false early signals were withdrawn.
As expected, only a small percentage of valid signals
were withdrawn. The higher we made the true RR, and
the higher was the design’s power, the rarer it occurred
that a true signal was withdrawn. When the true RR
was 2.0, and power was 80%, only 2.2% of early signals
were withdrawn. In scenarios with 90% power, only 1%
or fewer of early signals were withdrawn.
Conclusions: If relevant data continue to accumulate af-
ter a safety signal, post-signal tests can limit the costs of
false alarms without undermining the advantages of
timely signals about real safety problems.
69. Comparative Analysis of Pharmacovigilance
Systems in Five Asian Countries
Jude Nwokike, Elisabeth Ludeman, Melissa Thumm,
Louis An. USAID Systems for Improved Access to
Pharmaceuticals and Services (SIAPS) Program, Center
for Pharmaceutical Management, Management Sciences
for Health, Arlington, VA, United States.
Background: Strong pharmacovigilance (PV) systems
are essential to prevent patient harm and achieve de-
sired health outcomes, but in some Asian countries,
PV activities are limited. To better understand how
PV systems promote public health in Asia, the
USAID-funded SIAPS Program, led by Management
Sciences for Health, conducted a comparative analysis
of PV systems in Bangladesh, Cambodia, Nepal, the
Philippines, and Thailand.
Objectives: The aims of the study were to benchmark the
status of national PV systems, identify replicable and
successful experiences, map the contributions of donor
agencies, and recommend options to enhance the
capacity and performance of PV and post-market surveil-
lance systems.
Methods: SIAPS reviewed PV systems in the region,
conducted individual country assessments, and performed
a comparative analysis of results from individual country
studies. The assessment was conducted using a indicator-
based PV assessment tool developed previously with
USAID funding. The data for each country were collected,
analyzed, and scored across ﬁve PV system components:
governance, policy, law & regulation; systems, structure,
& stakeholder coordination; signal generation & data man-
agement; risk assessment & evaluation; and risk manage-
ment & communication. Countries that met >60% of the
requirements for each component were classiﬁed as
meeting the standard requirements for that component.
Results: Thailand has the strongest PV system achieving
>60% in all ﬁve components, the Philippines in four,
Cambodia in three, and Bangladesh and Nepal in just
one. PV legislation is in place and adverse event (AE)
forms are available, but not standardized. Opportunities
for regional collaboration and data sharing for decision
making are lacking. Only Thailand and the Philippines
implement consumer reporting of AEs. Across all coun-
tries there is limited capacity for active surveillance.
Conclusions: This assessment demonstrates that while
PV activities are being implemented in the ﬁve Asian
countries, they are limited and in some cases, insufﬁcient.
Although most of the countries assessed lack fully
functional PV systems, national and global efforts are
underway to improve their capacity and performance.
70. SAFEGUARD Results: Analysis of Pharma-
covigilance Databases
Lorna Hazell,1 Niklas Schmedt,2 Lorenza Scotti,3 Ingrid
Leal,4 Gianluca Triﬁro,4,5 Miriam Sturkenboom,4 Saad
Shakir.1 1Drug Safety Research Unit, Southampton,
United Kingdom; 2Leibniz Institute for Prevention
Research and Epidemiology - BIPS GmbH, Bremen,
Germany; 3Univeristy of Milan Bicocca, Milan, Italy;
4Erasmus University, Rotterdam, Netherlands; 5Depart-
ment of Clinical and Experimental Medicine, University
of Messina, Messina, Italy.
Background: The SAFEGUARD project aims to inte-
grate evidence from different sources to assess risks
for selected cardiovascular, stroke, pancreatic and blad-
der outcomes with non-insulin blood glucose lowering
drugs (NIBGLD).
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Objectives: To identify NIBGLDs with disproportionate
reporting for these outcomes in pharmacovigilance
databases.
Methods: Data were analysed for reports received in the
FDA’s Adverse Event Report System (FAERS) and
EudraVigilance (EV) between 2004 and 2012. Outcomes
were deﬁned by groups of MedDRA ‘preferred’ terms.
Diabetes (DM) subsets included reports involving at least
one NIBGLD ‘suspect’. Proportional Reporting Ratios
(PRR) and Reporting Odds Ratios (ROR) were
calculated for 29 NIBGLDs and 9 outcomes. Signals
of disproportionate reporting (SDRs) were deﬁned by
lower conﬁdence level of the PRR/ROR>=1 and
exposed cases>=3. For each database, analyses were
repeated in the whole database and DM subset using
narrow and broad case deﬁnitions. PRRs were
computed over time to identify the method providing
earliest SDR detection.
Results: Around 3 million reports were analysed for each
database. DM subsets comprised 123,930 and 93,596 re-
ports in FAERS and EV respectively. Highest propor-
tions of reports were seen for exenatide, rosiglitazone
and metformin in FAERS and for metformin,
rosiglitazone and sitagliptin in EV. SDRs were found
mainly for cardiovascular and stroke outcomes with
rosiglitazone and, for bladder cancer and heart failure
with pioglitazone. For gliptins and GLP-1 agonists,
SDRs were found for pancreatic outcomes. Most other
SDRs were detectable only in the whole database
analysis, not within the DM subset. No substantial
differences were found using PRRs versus RORs. Of
the 65 SDRs detected in the DM subset, some were
only found (37.5%) or found earlier (33%) in FAERS.
Broad case deﬁnitions detected SDRs earlier in 20%
of SDRs.
Conclusions: SDRs identiﬁed within the DM subset
were largely as expected from current knowledge. SDRs
detected using the whole database may be false signals
confounded by indication. Further examination (signal
assessment) is required to evaluate signals generated by
such methods or propose further studies to answer
questions raised.
71. Beyond Traditional “Observed Versus Expected”
Analyses: A Sensitivity Analysis Integrating Uncer-
tainties Around Reporting Bias and Background
Incidence Rate
Lionel Van Holle, Olivia Mahaux, Vincent Bauchau.
Vaccine Clinical Safety and Pharmacovigilance,
GlaxoSmithKine Vaccines, Wavre, Belgium.
Background: The observed number of spontaneous re-
ports post immunization related to a condition under
monitoring is sometimes compared with the expected
number, based on the background incidence rate of that
condition in the vaccinated population in an “observed
versus expected” analysis (OE). The main sources of
uncertainty are the fraction of cases actually reported
(underreporting) and the background incidence rate for
the vaccinated population.
Objectives: Develop a sensitivity analysis to cope with
the uncertainties and allow rapid but well informed deci-
sion-making by manufacturers or regulatory authorities.
Methods: Instead of traditionally presenting the results
of an OE as an estimate along with conﬁdence limits
and potentially under different scenarios, we visually
present the results of the OE in an OE-plane with as
x-axis the background incidence rate and, as y-axis
the percentage of cases actually reported.
Results: The OE plane allows the visual determination of
how much hidden bias would need to be present to alter
the observed OE qualitative conclusion. It determines
under what range of background incidences and
underreporting the observed number of spontaneous
reports for the condition under monitoring is lower than
expected at the desired conﬁdence level.
Conclusions: Depending on how plausible this range
is, a conclusion regarding a potential excess of
observed cases versus the expected can be drawn.
The framework also allows regulatory authorities to
draw their own conclusion should they ﬁnd another
range of background incidence rates and reported
fraction more relevant.
72. Validation of Signal Impact Assessment Tool in
Order to Explore Pharmacovigilance Signals’ Follow-
Up Actions
Leàn Rolfes,1,2 Judith Kolfschoten,3 Florence van
Hunsel,1,2 Eugene van Puijenbroek,1 Kees van
Grootheest.1,2 1Netherlands Pharmacovigilance Centre
Lareb, ‘s-Hertogenbosch, Netherlands; 2University of
Groningen, Groningen, Netherlands; 3Utrecht Univer-
sity, Utrecht, Netherlands.
Background: To determine which actions are advisable
for signals arising from a spontaneous reporting system,
the Netherlands Pharmacovigilance Centre Lareb uses a
Signal Impact Assessment Tool (SIAT). It categorizes
signals into one of four categories: strong/moderate sig-
nal strength and similarly health impact. This SIAT has
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not been validated yet. For a study which explored
follow-up actions of pharmacovigilance signals, a
validated tool was desirable.
Objectives: Validation of a Signal Impact Assessment
Tool.
Methods: In the SIAT, signal strength is assessed based
on: strength of the cases, disproportionality of the associ-
ation in the Lareb and WHO database and information
available in literature. The health impact is assessed
based on: seriousness of the reports, duration the drug
is marketed, type of users and the nature of the indication.
For validity testing judgments of a panel of three
pharmacovigilance assessors was used as a ´gold stan-
dard’. A Delphi method was used to achieve agreement.
In phase 1 of our study the panel assigned a weighting
for each item included in the SIAT. Subsequently, they
rated 20 signals in one of the four categories. The 20 sig-
nals were also scored by two researchers using the weight
adjusted SIAT. Panel judgments were compared with the
SIAT-score. In phase 2 this process was repeated with 20
new signals. Inter- and intra-observer variability of the
SIAT were also tested. The Cohen’s Kappa coefﬁcient (κ)
was calculated to measure the degree of agreement. A κ of
at least 0.61 was considered to be needed for good validity.
Results: Validity did not meet predeﬁned criteria:
κ phase 1= 0.78, κ phase 2= 0.36. Differences were found
for signal strength and health impact. Inter- and intra-
observer variability was good, κ of respectively 0.78 and
0.72. Most differences were related to signal strength.
Conclusions: Testing of the SIAT showed low validity
in the second phase. Discussion revealed that personal
experiences and interpretation play a great role in the
panel judgments. Although criteria used in SIAT can
be used as an aid for signals characterization, the
SIAT-scores should not be decisive in the decision
making process.
73. A Guide to Guidelines. A Symposium Sponsored by
the Public Policy Committee
Jesper Hallas,1 Kenneth J Rothman,2 Kiyoshi Kubota,3
Stella Blackburn,4 Alejandro A Navarro,5 Gerald Dal
Pan.6 1Clinical Pharmacology, University of Southern
Denmark, Odense C, Denmark; 2RTI Health Solutions,
Research Triangle Park, NC, United States; 3Department
of Pharmacoepidemiology, Graduate School of
Medicine, Tokyo, Japan; 4Quintiles, London, United
Kingdom; 5RTI Health Solutions, Barcelona, Spain;
6Ofﬁce of Surveillance and Epidemiology, FDA, Silver
Spring, United States.
Background: There is a plethora of available guidelines
for the conduct of pharmacoepidemiological research.
These guidelines can be very useful for researchers, reg-
ulators or for employees within pharmaceutical industry.
However, there is also a risk that guidelines can become
too prescriptive, thus entailing a slow development of the
discipline or that conduct of pharmacoepidemiological
research becomes cumbersome with too many general re-
quirements that serve little purpose. Also, with the large
number of available guidelines, there may be conﬂicting
rules, and it can be a challenge to maintain overview.
Description: We will cover some of the recent
developments in guidelines for classical pharmaco-
epidemiological research; ISPE’s new revision of Good
Pharmacoepidemiology Practice, ENCEPP’s Code of
conduct, ENCEPP’s Guide of Methodological Standard
and FDA’s guidance regarding studies using electronic
healthcare data. For each guideline, we will describe their
aim and focus and scope, their target audience, their content,
whether they should be perceived as prescriptive or guiding
and the plans for future developments and maintenance.
74. Academic Detailing: Putting Pharmacoepidemiology
into Practice
Jerry Avorn,1 Stephen Chapman,2 Frank May,3 Loren
Regier,4 Debra Rowett.3 1Division of Pharmaco-
epidemiology and Pharmacoeconomics, Brigham and
Women’s Hospital, Department of Medicine, Boston, MA,
United States; 2School of Pharmacy, Keele University,
Keele, Staffordshire, United Kingdom; 3Drug and
Therapeutics Information Service, Repatriation General
Hospital, Daw Park, South Australia, Australia; 4RxFiles
Academic Detailing Service, Saskatoon City Hospital,
Saskatoon, SK, Canada.
Background: More than two decades have passed since
research-based academic detailing concepts evolved into
ongoing support programs for health professionals.
Academic detailing is non-commercial, evidence-based
interactive educational outreach. Pharmacoepidemiology
has played a large role in the success of these initiatives.
Trusting relationships formed between academic de-
tailers and physicians have become a spearhead for many
clinical practice improvement strategies. This symposium
will review the way pharmacoepidemiology has in-
formed academic detailing-led public health improve-
ment programs.
Objectives: (1) To provide an overview of the evidence
for, and operations of academic detailing-led clinical
practice improvement programs worldwide.
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(2) To discuss academic detailing program topic
material preparation, key message formulation, and the
place of pharmacoepidemiology training for informing
discriminating analysis of published biomedical research
ﬁndings.
(3) To review training methods and ongoing support
structures used for academic detailers in the ﬁeld.
(4) To summarise pharmacoepidemiological and other
techniques used in evaluating outcomes from academic
detailing-led programs for clinical practice improvement.
Description: This symposium addresses the current
global state of academic detailing for clinical practice im-
provement. A number aspects of pharmacoepidemiology
which underpin the discipline of academic detailing will
be examined. (1) The complexities of preparation of
academic detailing topic materials and key messages
based on published literature and comparative effective-
ness research; (2) The nature and structure of empathic,
persuasive communication used by academic detailers;
(3) The consistent ‘service’ approach which fosters
positive relationships between academic detailers and
their client healthcare practitioners; (4) The knowledge-
base acquisition and skills-training necessary for aca-
demic detailers to be able to credibly present their key
messages as well as the balance of beneﬁts and harms
associated with alternative approaches to clinical care;
(5) Challenges associated with pharmacoepidemiological
evaluation techniques for ongoing non-experimental
design programs.
75. Biospecimens From Asia in Pharmacoepidemiology
Research: Opportunities and Challenges in a Global
Environment
Arnold KW Chan,1 Bruce Carleton,2 Daniel FC Tsai,1
Mao Mao.4 1Medical Research, National Taiwan
University, Taipei City, Taiwan; 2Pediatrics, University
of British Columbia, Vancouver, Canada; 3WuXi AppTec,
Shanghai, China.
Background: Pharmacoepidemiologists are dealing
more with data derived from biospecimen analysis
(vaccines, genomics, biologics). In Asia, there are
speciﬁc issues related to access to specimens, specimen
access, procurement, and transportation, in addition to
acquisition of specimen-related data that affect academic,
industry and regulatory sectors.
Objectives: (1) To become familiar with the speciﬁc
challenges, opportunities, and recent advances related to
access to biospecimens or biospecimen-derived data in
research that occurs in Asia.
(2) To understand the motivations, ethical issues, and
underlying rationale behind policy decisions relating
access to biospecimen or biospecimen-related data, and
how this may help frame future access requests.
Researchers wanting additional expertise in the sharing
of biospecimens in Asian countries for research from
academics, industry, or regulatory bodies, particularly in
the ﬁelds of molecular pharmacogenomics, biologics,
vaccines, and databases will beneﬁt.
Description:
• Dr. Chan (moderator, 5min): Introduction.
• Dr. Carleton (15min), who has academic initiatives
across multiple continents will frame the (i) beneﬁts from
global access to biospecimens/biospecimen data related
to pharmacogenomics, vaccines, and biologics; and (ii)
challenges encountered related to biospecimen access,
particularly in Asian countries, such as China and Japan.
• Dr. Tsai (15min; International Network of UNESCO
Chair in Bioethics, Taiwan) will frame the ethical and prac-
tical issues related to biospecimen procurement and pro-
cessing across multiple countries in Asia, including the
international non-proﬁt perspective.
• Dr. Mao (15min; President, Asian Cancer Research
Group (ACRG)) will discuss collaborative biospecimen-
related research in Asia, including China, Taiwan, Hong
Kong, Singapore, and Korea, including an industry
perspective. He will discuss the drafting of Regulations
of Genetic Materials in China. Examples will be provided
from ACRG collaborations.
• Panel Discussion: (40minutes) Dr. Chan will moder-
ate a directed question-and-answer session for the panel,
with emphasis on audience participation.
76. Challenges in Risk Minimization Evaluation:
CIOMS Working Group IX Consensus and Recent
Field Experience
Yola Moride,1 Elizabeth Andrews,2 Susana Perez-
Gutthann,3 Montse Soriano-Gabarró,4 Stephen Heaton,5
Kiliana Suzart-Woischnik,4 Zdravko Vassilev,6 June M
Raine.7 1Faculty of Pharmacy, Université de Montréal,
Montreal, Canada; 2RTI Health Solutions, Durham,
United States; 3RTI Health Solutions, Barcelona, Spain;
4Global Epidemiology, Bayer Pharma AG, Berlin,
Germany; 5Global Pharmacovigilance, Bayer Pharma
AG, Berlin, Germany; 6Global Epidemiology, Bayer
Healthcare Pharmaceuticals, Whippany, NJ, United
States; 7Vigilance Risk Management of Medicines,
Medicines and Healthcare Products Regulatory Agency,
London, United Kingdom.
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Background: As part of the evaluation of the overall
effectiveness of European additional Risk Minimization
Measures (aRMM) and the United States Risk Evalua-
tion and Mitigation Strategies (REMS), two types of
indicators may be considered: process indicators,
including physician and patient knowledge and
awareness of product risks and actions that should be
taken to assure safe use of a medicine; and, whenever
possible, outcome indicators, aiming to provide an
overall estimate of the level of risk control attained
with a RMM.
Objectives: To provide an update on the upcoming
CIOMS Working Group IX consensus on risk minimiza-
tion evaluation and to describe challenges faced by
studies evaluating aRMM/REMS, with a main focus on
process indicators.
Description: The ability to apply robust study methodol-
ogy is challenged by numerous factors. For studies of
knowledge and behavior, challenges include lack of
baseline information on risk behavior as well as adequate
ascertainment and representativeness of study popula-
tions. For studies assessing outcome indicators, chal-
lenges include the dearth of pre-existing data sources
that include the necessary exposure, outcome, and
confounder information and adequate choice of relevant
outcomes. We will present the views of 4 key stake-
holders providing speciﬁc examples on the trade-offs
made between the ideal and practical study designs to
minimize bias and maximize generalizability of study
results while addressing regulatory requirements and
expectations. This will be followed by a panel/audience
discussion and sharing of experiences.
• S. Perez-Gutthann: Chair, welcome, goals and intro-
ducing speakers.
• Y. Moride: CIOMS Working Group IX consensus:
General principles for risk minimization evaluation
and ﬁeld experience.
• E. Andrews: Methodological considerations for the
design and implementation of risk minimization evalu-
ation studies assessing process indicators
• M. Soriano-Gabarró: Experiences and challenges with
risk minimization evaluation studies: Assessing risks
in diverse prescriber and patient populations.
• J. Raine: Regulatory perspective on risk minimization
evaluation.
77. Gender Differences in Pharmacoepidemiology
Björn Wettermark,1 Yea-Huei Kao Yang,2 Karin
Schenck-Gustafsson,1 Vera Vlahovic-Palcevski,3 Mia
von Euler,1 Soko Setoguchi-Iwata.4 1Centre for
Pharmacoepidemiology, Karolinska Institutet, Stock-
holm, Sweden; 2National Cheng Kung University,
Tainan, Taiwan; 3University of Rijeka, Rijeka, Croatia;
4Duke University School of Medicine, Durham, NC,
United States.
Background: Rational drug use implies that “patients
receive medications appropriate to their clinical needs,
in doses that meet their own individual requirements,
for an adequate period of time, and at the lowest cost
to them and their community”. Individual requirements
may also indicate sex and gender. While it is evident
that biological differences, commonly referred to as
sex differences, should be considered when prescribing
medicines, it is more disputable if it is rational to let
socio-cultural differences, commonly referred to as
gender differences, affect the prescription patterns.
Sex- and gender differences in drug utilization have
been demonstrated in several pharmacoepidemiological
studies. Some differences may be explained by varia-
tions in disease patterns while others seem to indicate
inequities and under- or over use of certain drugs. A
session on gender differences at ICPE would provide
an excellent opportunity to discuss the study ﬁndings
in relation to the evidence of gender difference in
clinical pharmacology and epidemiology, thus meeting
the need of healthcare professionals to promote the best
treatment for all patients regardless of sex.
Objectives: To provide an overview of current knowl-
edge concerning sex and gender differences in clinical
pharmacology and epidemiology. Examples will be
given on pharmacoepidemiological studies followed by
a discussion on future directions.
Description: The symposium will be moderated by
professor Mikael Hoffmann (Sweden) and professor
Yea-Huei Kao Yang (Taiwan).
(1) Sex differences in pharmacodynamics and pharma-
cokinetics (15min, Mia von Euler, Sweden)
(2) Sex differences in disease epidemiology (15min,
Vera Vlahovic-Palcevski, Croatia)
(3) Drug utilization studies on sex and gender
differences – where do we stand (20min, Björn
Wettermark, Sweden)
(4) Moving beyond the descriptive studies – what
pharmacoepidemiological studies ought to be done
(20min, Soko Setoguchi, United States).
(5) Panel debate and discussion with the audience
on the key areas to focus on in the future and sug-
gestions (20 min).
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78. Impact of Methodological Choices on Findings
from Pharmacoepidemiological Studies: Final Results
of the IMI-PROTECT (Pharmacoepidemiological
Research on Outcomes of Therapeutics by a European
ConsorTium) Project
Olaf Klungel,1,3 Mark de Groot,1 Helga Gardarsdottir,1,2
Ruth Brauer,4 Lamiae Grimaldi-Bensouda,5 Xavier
Kurz,6 Christiane Gasse,7 Robert Reynolds.8 1Pharmaco-
epidemiology & Clinical Pharmacology, Utrecht Institute
of Pharmaceutical Sciences (UIPS), Utrecht University,
Utrecht, Netherlands; 2Clinical Pharmacy, University Med-
ical Center Utrecht, Utrecht, Netherlands; 3Julius Center
for Health Sciences and Primary Care, University Medical
Center Utrecht, Utrecht, Netherlands; 4London School of
Hygiene and Tropical Medicine, London; 5LA-SER, Paris;
6European Medicines Agency, London; 7School of
Business and Social Sciences, Aarhus Universitet, Aarhus;
8Pﬁzer, New York.
Background: Pharmacoepidemiological (PE) research
should provide consistent, reliable and reproducible
results to contribute to the beneﬁt-risk assessment of
medicines. IMI-PROTECT aims to identify sources of
methodological variations in PE studies using a common
protocol and analysis plan across databases (including
independent replication studies). In addition, differences
by design, applied to a same drug-adverse event (AE)
pair in different databases are examined. Results from
PE studies will be evaluated on 7 drug-AE pairs (i.e. 1.
antibiotics and acute liver injury; 2. antidepressants and
hip fracture; 3. benzodiazepines and hip fracture; 4. anti-
convulsants and suicide/suicide attempts; 5. calcium
channel blockers and malignancies; 6. inhaled long-
acting β2 agonists and acute myocardial infarction; 7. a
negative control study: antibiotics and acute myocardial
infarction) conducted in 7 European and 1 US electronic
databases. These are: the CPRD and THIN from the UK,
the Danish national registries, the Dutch Mondriaan
project (NPCRD, AHC), the Spanish BIFAP, the French
PGRx and the US InVision Datamart.
Objectives: To review and understand the methodologi-
cal issues encountered in these studies and to draw
conclusions about their relevance for future PE research.
Description: In follow up to a session at ICPE Montreal
which presented selected preliminary results from cohort
studies only, we will present ﬁnal data from association
studies in the various databases using different designs
including cohort, case-control, case-crossover, and self-
controlled case series for some drug-AE pairs. The major
methodological issues such as choice of study design,
analytical methods to control for confounding, variation
in operational deﬁnitions of exposure, outcome and
confounders across databases with different coding
systems will be discussed. Recommendations for future
PE research will also be presented.
Program:
(1) Introduction to IMI-PROTECT
(2) Results from PE studies on drug-ae associations
(3) Main recommendations from PROTECT
(4) Panel discussion.
79. The New ISPE Vaccine Special Interest Group
(VAXSIG): Helping to Advance the Global Vaccine
Agenda
Huifeng Yun,1 Hak Eelko,2 Ajit Pal Singh,3 Jan
Bonhoeffer,4,5 Daniel Weibel,6 Miriam Sturkenboom.6
1Department of Epidemiology, Universy of Alabama at
Birmingham, Birmingham; 2PharmacoEpidemiology &
PharmacoEconomics, University of Groningen, University
Center for Pharmacy, Groningen; 3Clinical Affairs and
Regulatory, International Vaccine Institute, Seoul;
4Brighton Collaboration Foundation, Basel, Switzerland;
5University Children’s Hospital, Basel, Switzerland;
6Erasmus University Medical Center, Rotterdam, The
Netherlands.
Background: The biotechnology and informatics revolu-
tions create new opportunities for a) the development of
vaccines against major killers such as HIV, malaria, and
TB; and b) accurately assessing the risks and beneﬁts of
immunizations across the life cycle of a vaccine, from
pre- to post-licensure.
Objectives: To advance this exciting agenda synergisti-
cally with stakeholders and prioritize the opportunities
(and challenges) for ISPE VAXSIG based on discussion
of the following timely presentations.
Description: Introduction of VAXSIG and Moderators
(Miriam Sturkenboom & Huifeng Yun).
• Ajit Pal Singh: A pilot model of web-based adverse
events following immunization tool.
To support the introduction of new vaccines and
manage vaccine safety concerns in resource limited
countries, the new web based tool is being developed
by the International Vaccine institute for diverse existing
data collection, collation, transmission, analysis and feed-
back systems.
• Jan Bonhoeffer: Performance testing of pediatric
signal detection methods in surveillance systems.
Several methods for signal detection in spontaneous
reporting systems have been developed; but they are not
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tailored for use in pediatric populations. We present re-
sults of a systematic performance testing of a slate of
methods in this setting.
• Daniel Weibel: PREVENT: infrastructure for
rigorous vaccine safety studies in low and middle
income countries (LMIC).
Vaccination exposure, morbidity outcome, and
demographic data have been collected within different
infrastructures in Africa. We evaluated the quality of
such available surveillance systems for use in: 1)
observational post-licensure vaccine safety studies, and
2) future scale up for rapid vaccine beneﬁt - risk surveil-
lance and hypothesis testing in LMIC.
• Eelko Hak : European Universal Inﬂuenza Vaccine
(UNISEC) project
The conventional annual inﬂuenza vaccination
strategy may result in cost-inefﬁciency and poor
protection if mismatched. UNISEC is designing phase
IIb studies to evaluate the safety, immunogenicity and
cross-seasonal clinical efﬁcacy of two universal
inﬂuenza vaccines.
80. Risk of Hip Fractures Associated with
Benzodiazepines: Applying Common Protocol To a
Multi-Database Nested Case-Control Study. The
PROTECT Project
Gema Requena,1 John Logie,2 Rocío González-
González,3 Helga Gardarsdottir,4,5 Ana Afonso,4 Patrick
C Souverein,4 Elisa Martin Merino,3 Nada Boudiaf,2
Consuelo Huerta,3 Andrew Bate,6 Yolanda Alvarez,7
Luis A García-Rodríguez,8 Robert Reynolds,9 Raymond
G Schlienger,10 Mark CH de Groot,4 Olaf H Klungel,4
Francisco J de Abajo.11 1Unit of Pharmacology,
Department of Biomedical Sciences, University of Alcalá,
School of Medicine, Madrid, Spain; 2Observational Data
Analytics Worldwide Epidemiology, R&D Projects,
Clinical Platforms & Sciences, GlaxoSmithKline,
Uxbridge, Middlesex, United Kingdom; 3BIFAP Research
Unit, Spanish Agency of Medicines and Medical Devices,
Madrid, Spain; 4Division of Pharmacoepidemiology &
Clinical Pharmacology, Utrecht University, Utrecht,
Netherlands; 5Department of Clinical Pharmacy,
University Medical Center Utrecht, Utrecht, Netherlands;
6Epidemiology, Pﬁzer Ltd, Walton Oaks, Dorking Road,
Tadworth, United Kingdom; 7Risk Management,
European Medicines Agency (EMA), London, United
Kingdom; 8Pharmacoepidemiology, Spanish Center for
Pharmacoepidemiological Research (CEIFE), Madrid, Spain;
9Epidemiology, Pﬁzer Research & Development, New York,
United States; 10Global Clinical Epidemiology, Novartis
Pharma AG, Basel, Switzerland; 11Clinical Pharmacology
Unit, University Hospital Príncipe de Asturias, Madrid, Spain.
Background: The association between benzodiazepines
(BZD) and hip fractures has been estimated in several
observational studies although diverse methodologies
and deﬁnitions have hampered comparability.
Objectives: To evaluate the discrepancies in the risk
estimates of hip/femur fractures associated with BDZs
across different databases and to assess the impact of
different matching strategies.
Methods: A case control study nested in a cohort of BZD
users, examining their association with the risk of hip/
femur fracture between 2001 and 2009, was performed
within 3 databases, the BIFAP (Spain), the CPRD (UK)
and the Mondriaan (Netherlands) database. A risk set
sampling matching was performed using two strategies:
1) controls matched by age (up to ± 2 years), sex and time
in the cohort (up to ± 6months) and 2) controls selected
with the smallest Manhattan distance according same
matching factors. Co-morbidity and co-medication ad-
justed OR and (95% conﬁdence intervals) were estimated
for current use (up to 30 days after last supply) vs. past
(>60 days after current use) using conditional logistic
regression models. Sensitivity analysis was performed
in CPRD including matching by general practice (GP).
Results: Adjusted ORs (matching 1) for current use were
1.14 (1.03-1.27) in BIFAP; 1.32 (1.22-1.42) in CPRD,
and 1.34 (0.63-2.82) in Mondriaan. Matching 2 resulted
in ORs of 1.09 (1.03-1.27), 1.29 (1.17-1.42) and 1.28
(0.60-2.71) in BIFAP, CPRD and Mondriaan respec-
tively. In CPRD, adding GP-practice as a matching
factor to matching strategy 1 increased the OR to
1.46 (1.35-1.59).
Conclusions: By applying a common protocol, the
estimated risk of hip/femur fractures associated to BZD
was consistent between studies. The different matching
strategies did not inﬂuence the risk estimates substan-
tially, however the inclusion of GP-practice as matching
factor should be carefully considered in further studies.
Acknowledgments: This research received support from
the Innovative Medicine Initiative Joint Undertaking
through the PROTECT project.
81. Effect of Allopurinol on Cardiovascular Outcomes
in Hyperuricemic Patients: A Cohort Study
Kasper S Larsen,1,2,3 Anton Pottegård,1,2 Hanne M
Lindegaard,3 Jesper Hallas.1,2 1Clinical Pharmacology,
Institute of Public Health, University of Southern
Denmark, Odense, Denmark; 2Department of Clinical
Chemistry & Pharmacology, Odense University Hospital,
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Odense, Denmark; 3Department of Rheumatology, Odense
University Hospital, Odense, Denmark.
Background: Hyperuricemia and gout have been associ-
ated with increased cardiovascular risk. Allopurinol is an
effective urate lowering drug. Whether lowering of uric
acid (UA) by allopurinol improves the cardiovascular
risk in hyperuricemic patients remains to be established.
Objectives: To investigate the effect of allopurinol on
cardiovascular outcomes in hyperuricemic patients in an
observational setting.
Methods: We had access to a study population
consisting of all patients with high UA levels from
1992 to 2010 from Funen County, Denmark (approxi-
mately 480,000 residents). We linked four registries; all
blood samples, all in- and outpatient contacts in hospi-
tals, all reimbursed prescriptions and causes of death.
We identiﬁed all allopurinol users and matched them
1:1 to non-users of urate lowering therapy (ULT) who
had similar UA levels, by using propensity scores. Haz-
ard ratios were calculated using competing risk regres-
sion model, with respect to AntiPlatelet Trialist´s
Collaboration (APTC) composite outcome and all-cause
mortality.
Results: Among 65,971 patients with hyperuricemia we
found 7,133 patients on allopurinol treatment. In the pro-
pensity score matched cohort we found a hazard ratio
(HR) of 0.89 (95% conﬁdence interval [CI] 0.81 –
0.98) for the APTC composite outcome among allopuri-
nol treated compared with non-ULT treated. The
corresponding HR for all-cause mortality was 0.68
(95% CI 0.62 - 0.75).
Conclusions: Allopurinol treatment is associated with a
decreased cardiovascular risk among hyperuricemic
patients. The ﬁnding in this study supports an aggressive
approach to prescribing allopurinol.
82. Opioids and Breast Cancer Recurrence: A Danish
Population-Based Cohort Study
Deirdre P Cronin-Fenton,1 Mette Nørgaard,1 Uffe Heide-
Jørgensen,1 Thomas P Ahern,2 Timothy L Lash,3 Peer
Christiansen,4,5 Bent Ejlertsen,5,6 Per Sjøgren,6 Henrik
Kehlet,7 Henrik T Sørensen.1 1Department of Clinical
Epidemiology, Aarhus University Hospital, Aarhus,
Denmark; 2Department of Surgery, University of
Vermont, Burlington, VT, United States; 3Department of
Epidemiology, Emory University, Atlanta, United States;
4Department of Surgery P, Aarhus University Hospital,
Aarhus, Denmark; 5Danish Breast Cancer Cooperative
Group, Copenhagen, Denmark; 6Department of
Oncology, Rigshospitalet, Copenhagen, Denmark;
7Section for Surgical Pathophysiology, Rigshospitalet,
Copenhagen, Denmark.
Background: In theory, lack of pain relief following sur-
gery for breast cancer may suppress natural killer cells,
increasing the risk of breast cancer recurrence (BCR).
On the other hand, opioids may also inhibit cell-mediated
and humoral immunity, introducing apoptosis.
Objectives: To investigate the association between post-
diagnosis opioid use and BCR among Stage I-III breast
cancer patients.
Methods: We identiﬁed incident Stage I-III breast
cancer cases diagnosed 1995-2008 in Denmark, and
reported to the Danish Breast Cancer Cooperative
Group registry. Opioid prescriptions were ascertained
from the Danish National Prescription Registry.
Follow-up began on the date of breast cancer primary
surgery and continued until the ﬁrst of BCR, death,
emigration, or 31/12/2012. We used Cox proportional
hazards regression models to estimate the hazards ratio
and 95% conﬁdence intervals (HR & 95%CI) for
opioid prescriptions overall, and weak (codeine,
dextropropoxyphene, tramadol) versus strong opioids
(all others), and BCR, adjusting for potential con-
founders (age, menopausal status, stage, histologic
grade, estrogen receptor status, surgery type, pre-
diagnosis hormone replacement therapy, myocardial
infarction, congestive heart failure, cerebro- and periph-
eral vascular disease, rheumatoid arthritis, osteoarthritis,
and concurrent prescriptions for aspirin, and simva-
statin). We treated opioid prescriptions as a time-
varying exposure lagged by one year, and in sensitivity
analyses, lagged by two years. All statistical tests were
two-sided.
Results: We identiﬁed 34,188 patients, with a total of
283,666 person-years of follow-up. Median follow-up
was 7.1 years. 47% of the patients received opioid
prescriptions. Ever use of opioids had no effect on
the rate of ten-year BCR in both crude and adjusted
analyses (crude HR = 0.98, 95%CI = 0.91, 1.05;
adjusted HR = 1.00, 95%CI = 0.93, 1.08), with similar
results in the sensitivity analyses (crude HR = 1.00,
95%CI = 0.93, 1.08; adjusted HR = 1.01, 95%CI = 0.93,
1.10). Estimates for strong and weak opioids were
also similar.
Conclusions: Findings from this large prospective
cohort study do not suggest an association between
opioid prescriptions and rate of BCR.
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83. Intrauterine Devices and the Risk of Uterine Perfo-
rations: Final Results from the EURAS-IUD Study
Klaas Heinemann, Sabine Moehner, Thai Do Minh.
ZEG-Berlin, Berlin, Germany.
Background: Uterine perforation is a potentially serious
complication of intrauterine device (IUD) use. The
absolute risk of uterine perforation associated with
levonorgestrel-releasing IUDs (LNG-IUD) is unknown.
It is also unknown whether the perforation rate is higher
with this IUD than with copper IUDs.
Objectives: Aim of the study is to determine the uterine
perforation rate in women using Intrauterine Devices
(IUD).
Methods: Large, comparative, multinational, prospec-
tive, non-interventional cohort study with new users of
different types of IUDs: LNG-IUDs and copper IUDs.
The combined cohort included more than 60,000 women
in six European countries (Germany, Austria, UK, Fin-
land, Poland and Sweden). The study was conducted
from 2006 to 2013. Both the women and their treating
physicians received a follow-up questionnaire 12months
after enrolment. All patient-reported outcomes of interest
were validated by the treating physicians. A multifaceted
follow-up procedure ensured low loss to follow-up rates.
The analysis was based on Cox regression models.
Results: 61,448 women were recruited (70% LNG-
IUDs, 30% copper IUDs). In total, 61 perforations
with LNG-IUD (1.4 per 1,000 insertions (95% CI:
1.1-1.8)) and 20 with copper IUD (1.1 per 1,000
insertions (95% CI: 0.7-1.7)) occurred. The risk ratio
(RR) adjusted for age, BMI, breastfeeding and parity
was 1.61 (95% CI: 0.96 – 2.70). 63 of the 81 perforations
were associated with previously suspected risk factors
for perforation. Breastfeeding at time of insertion led
to a six-fold increase in total perforation risk (RR 6.1,
95% CI: 3.6-9.6), with no differences between
LNG-IUD and copper IUD users. None of the perfora-
tions led to serious illness or injury to intra-abdominal
or pelvic structures.
Conclusions: Perforation rates for intrauterine devices
are low. The adjusted RR for perforation comparing
LNG-IUD and copper IUDs was 1.6. An association of
this magnitude identiﬁed in observational research is
too low to discriminate among bias, confounding,
causation, and chance as alternative explanations.
Perforation rates were signiﬁcantly higher among women
breastfeeding at the time of insertion compared to those
not breastfeeding.
84. Prevalence of Potentially Inappropriate Medication
Prescribing Among Older US Adults Using STOPP
Criteria
Marcela Jirón,1 Virginia Pate,2 Michele Jonsson Funk,2
Til Stürmer.2 1Technology and Pharmaceutical Sciencies,
Faculty of Chemical and Pharmaceutical Sciences,
University of Chile, Santiago, Chile; 2Epidemiology,
Gillings School of Global Public Health, University of
North Carolina, Chapel Hill, North Carolina, United States.
Background: Potentially inappropriate medications
(PIM) increase the risk of adverse effects of drugs in
older adults. STOPP Criteria have been used internation-
ally to identify PIM but US data are lacking.
Objectives: To determine prevalence of PIM among US
older population using STOPP Criteria.
Methods: We used fee-for-service Medicare Parts A, B,
and D claims data from 2007-2011 to estimate the prev-
alence of PIM in the US population aged ≥65 years.
PIM was deﬁned by STOPP Criteria, including diagnoses
or conditions present in the previous calendar year. We
estimated the point prevalence of PIM within each
calendar month by dividing the number of older adults
with ≥1 PIM during the month by the number of adults
ﬁlling ≥1 prescription. We report the prevalence and used
generalized estimating equations (GEE) to account for
the dependence of multiple monthly observations of a
single person in the estimated 95% conﬁdence intervals
(CI). A multivariable model was performed to estimate
adjusted Relative Risk (RR) and CI.
Results: A total of 23,223, 23,565, 23,670, 22,727 and
24,782 patients were included during 2007, 2008, 2009,
2010 and 2011, respectively. The majority (56.7%) of
patients were 75 years or older, 65.6% were women, and
85.5% were white. The point prevalence of PIM was
19.2% (CI: 18.8-19.7) in 2007, 19.2% (CI: 18.7-19.6)
in 2008, 18.9% (CI: 18.5-19.4) in 2009, 19.2% (CI:
18.8-19.7) in 2010 and 18.7% (CI: 18.2-19.1) in 2011.
Compared to patients age 65-69, those 80-84 and ≥85 were
slightly more likely to receive a PIM (RR 1.13, CI 1.06-1.21
and RR 1.08; CI 1.02-1.16, respectively). Patients with ≥1
emergency visit in the previous 12months (RR 1.53; CI
1.48-1.59) were more likely to receive a PIM than those
with none. The most common PIMs included drugs
affecting musculoskeletal system (20%) and drugs that
adversely affect those prone to falls (19.7%).
Conclusions: Approximately one in 5 older US adults
received at least one PIM. The PIM prevalence was lower
than it has been reported using Beers Criteria 2012.
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Drugs affecting musculoskeletal system and drugs that
adversely affect fallers were found to have the highest
potential for PIM.
85. Use of Antipsychotics and Risk of Acute Respira-
tory Failure in COPD: A Case-Crossover Study
Meng-Ting Wang, Che-Li Chu, Bi-Juian Wu. School
of Pharmacy, National Defense Medical Center, Taipei,
Taiwan.
Background: The evidence of antipsychotic-induced
respiratory failure is limited in case reports. This poten-
tial harmful effect from antipsychotic use is of particular
concern in patients with chronic obstructive pulmonary
disease (COPD).
Objectives: To evaluate whether or not antipsychotic use
was associated with an increased risk of ARF in COPD
patients.
Methods: This is a case-crossover study analyzing data
from the Taiwan National Health Insurance Research
Database during 2000-2008. We identiﬁed patients with
any diagnosis of ARF (ICD-9-CM codes 518.81,
518.82, 518.84) concurrently accompanied with an
intubation procedure or ventilator use from emergency
care or inpatient care among COPD patients aged
40 years. The 1-60 days and 181-240 days before the
ARF event were deﬁned as the case period and control
period, respectively. The odds ratios (ORs) for antipsy-
chotic exposure in the case period compared with that
in the control period were estimated using conditional
logistic regressions.
Results: A total of 5,300 COPD patients encountering
ARF were included for the analysis, with a mean age of
74.5 years and a median follow-up of 3.1 years.
Compared with nonuse, any use of antipsychotics was
associated with a 1.54-fold (95% CI, 1.25-1.90) in-
creased ARF risk after adjustment for the potential
confounders. Typical and atypical antipsychotics carried
a 1.37-fold (95% CI, 1.07-1.76) and 1.87-fold (95% CI,
1.30-2.68) increased risk of ARF, respectively. Parenteral
administration of antipsychotics (adjusted OR 2.01; 95%
CI, 1.02-3.97) seemed to be associated with a higher
ARF risk than oral administration (adjusted OR 1.50;
95% CI, 1.20-1.87). A dose-dependent response was
observed: antipsychotics prescribed at an average daily
dose equivalent to olanzapine≥ 10mg/day incurred a
2.58-fold (95% CI, 1.72-3.87) increased risk of ARF,
whereas the risk was attenuated with decreasing
daily doses.
Conclusions: Use of antipsychotics is associated with an
increased risk of ARF in COPD patients. Healthcare
professionals should be cautious about this risk in COPD
patients on antipsychotics, especially for those receiving
parenteral administration or high doses of antipsychotics.
86. A Prospective Multicenter Study of the Incidence
of Adverse Drug Events in Saudi Arabia: The
(ADESA) Study
Hisham Aljadhey,1 Mansour A Mahmoud,1 Michael D
Murray,2 David W Bates.3 1Medication Safety Research
Chair, College of Pharmacy, King Saud University,
Riyadh, Saudi Arabia; 2Purdue University and
Regenstrief Institute, Indianapolis, United States;
3Harvard Medical School and Brigham and Women’s
Hospital, Boston, United States.
Background: Few studies have investigated the epide-
miology of adverse drug events (ADEs) in developing
countries.
Objectives: To determine the incidence of ADEs and as-
sess their severity and preventability in Saudi hospitals.
Methods: We performed a prospective cohort study of
patients admitted to medical, surgical and intensive care
units of four hospitals in Riyadh, Saudi Arabia. Incidents
were collected by pharmacists and reviewed by two
independent clinicians. Reviewers classiﬁed the identi-
ﬁed incidents into ADEs, potential ADEs (PADEs) and
medication errors and determined their severity and
preventability.
Results: Medical charts of 4041 patients were reviewed
by clinical pharmacists and complete data for 3985
patients were analyzed. The mean age of patients in the
analytic cohort was 43 (±19.5) years. A total of 1676
incidents were identiﬁed by pharmacists during
medical chart review. Clinician reviewers accepted
1531 (91.4%) of the incidents found by pharmacists
(245 ADEs, 677 PADEs and 609 medication errors with
low risk to cause harm). The incidence of ADEs was 6.14
per 100 admissions (95% CI, 5.4-6.9) and 7.75 per 1000
patient days (95% CI, 6.8 – 8.7). ADEs were most
common in the intensive care units 149 (60.8%) followed
by medical 67(27.3%) and surgical units 29(11.8%). In
terms of severity, 129 (52.7%) of the ADEs were
signiﬁcant, 91 (37.1%) were serious, 22 (9%) were life-
threatening and 3 (1.2%) were fatal. Preventable ADEs
accounted for 85 (34.7%) of all ADEs. Preventable
ADEs most commonly occurred at the prescribing stage
75 (88.2%).
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Conclusions: We found that ADEs were common in
Saudi hospitals, especially in intensive care, and they
cause signiﬁcant morbidity. Many are preventable.
Future studies should focus on investigating the root
causes of ADEs at the prescribing stage and development
and testing of interventions to minimize the risk of harm.
87. Understanding Pharmacy Compounding in the
Retail Setting: Practice and Role of Pharmacists in
Singapore
Yuen-Teng Choo,1 Cheong Hian Goh,2 Mui-Ling Tan,1
Wai-Ping Yau.1 1Department of Pharmacy, National
University of Singapore, Singapore, Singapore; 2Health
Sciences Authority, Singapore, Singapore.
Background: Currently, medicinal products can be
customized and prepared for patients via compounding
services provided by pharmacists. Little is known about
retail compounding pharmacists and how they safeguard
public health.
Objectives: To evaluate the practice and role of pharma-
cists who provide retail compounding services.
Methods: A cross-sectional face-to-face interview study
was conducted between December 2013 and January
2014 on retail compounding pharmacists in Singapore.
An adapted and pre-tested interview guide consisting of
16 open-ended questions was used to obtain information
on pharmacists’ background, challenges faced, and their
pharmacy operations and practices during compounding.
Responses were transcribed verbatim for qualitative anal-
ysis. Descriptive statistics were also generated to summa-
rize the data.
Results: Of the total 11 retail compounding pharmacists
in Singapore, 63.6% (n = 7) were interviewed, of whom
71.4% (n = 5) were below age 40 and 85.7% (n = 6)
received their pharmacy training locally. All had prior
practice in a retail pharmacy setting, with a median
of 11 years of professional practice (4 - 47 years).
Knowledge and skills in compounding were acquired
through pharmacy education (100%), on-the-job training
(100%), from references (71.4%) and other pharmacists
at work (57.1%). Most (71.4%) explained that
compounding is still a manual process in practice. Key
challenges faced included the length of time required to
compound medications, the need to build up knowledge
in compounding and to meet patients’ and doctors’
expectations. To safeguard public health, they had
established procedures and practices in place to ensure prod-
uct safety through counterchecking during compounding,
ensuring appropriate shelf-life of compounded products
and maintaining adequate hygiene levels in compounding
premises.
Conclusions: Retail compounding pharmacists provide
an exclusive professional service catered to patients’
needs. Despite compounding being a manual operation
in practice and posing potential challenges, our ﬁndings
show that pharmacists do have proper measures and con-
trols to ensure the safety of compounded medications.
88. Is There Geographic Variation of the Frequency
and the Profile of Adverse Drug Reactions?
Krunal Pawar, Tanja Tran, Joerg Hasford. IBE, Dept. for
Med. Informatics, Biometry and Epidemiology, Ludwig
Maximilians Universitaet, Muenchen, Germany.
Background: Different population characteristics, co-
morbidities and comedications may result in different
ADR proﬁles and frequencies across countries. Such dif-
ferences might have an impact on risk minimisation
activities.
Objectives: We aimed to ﬁnd out whether the proﬁle of
ADRs of Imatinib indicate geographic variation.
Methods: The literature search in English used the fol-
lowing key words: prospective study, chronic myeloid
leukemia, Imatinib, adverse event, adverse drug reaction,
safety. All prospective studies with adults who received
400mg Imatinib/day were included if they provided
quantitative data on ADRs. ADRs were grouped using
the System-Organ-Classes (SOCs) of the WHO. ADR
proﬁles were constructed by calculating the relative
frequencies of the SOCs for each study.
Results: We identiﬁed 13 prospective studies,
representing patients from EUROPE, the USA and Asia
(Japan and India) with 2424 CML patients from 13
countries. The ADRs reported were classiﬁed in 16
SOCs. Seven SOCs were reported most often: body as
a whole - general disorders; gastro-intestinal system
disorders; muskulo-skeletal system disorders; platelet,
bleeding and clotting disorders; red blood cell disorders;
skin and appendages disorders; white blood cell and
reticuloendethelial system disorders. These SOCs
showed similar relative frequencies except for skin and
appendages disorders, which were reported more fre-
quently in Asia than in Europe and the USA. Differences
were seen too for ADRs of the cardiovascular and the
central nervous system, both were reported more often
in Europe and in the USA. ADRs which were reported
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more often in Asia than in Europe and the USA were
liver, biliary, and urinary system disorders. Metabolic
and nutritional ADRs were reported in Europe and the
USA only. Vascular (extra cardiac), and special senses
ADRs were reported in Europe and Asia only.
Conclusions: There was considerable geographic variation
concerning frequencies and proﬁles of ADRs in eight differ-
ent SOCs between Europe, Asia, and the USA. Our results
thus indicate that there is considerable geographic variation
in drug safety issues which deserve more attention.
89. Rates of Opportunistic Infections in Psoriatic
Arthritis Patients Compared to Non-Psoriatic Arthritis
Patients
Katrina W Hagberg,1 Lin Li,1 Michael M Peng,2
Susan Jick.1 1Boston Collaborative Drug Surveillance
Program, Boston University School of Public Health,
Lexington, MA, United States; 2PV and Epidemiology,
Celgene, Berkeley Heights, NJ, United States.
Background: There are few treatments available for
psoriatic arthritis (PA). This study was conducted in
support of a NDA ﬁling for a new PA drug.
Objectives: To estimate the rate of opportunistic
infections in patients with PA in comparison with non-
PA patients.
Methods:We conducted a cohort study using the United
Kingdom Clinical Practice Research Datalink (CPRD)
that included patients with a ﬁrst PA diagnosis recorded
in 1988-2012. We matched PA patients to up to 10
patients with no diagnoses of psoriasis or PA on age,
sex, general practice, and calendar time. All patients were
required to have ≥1 year of recorded history prior to
cohort entry (ﬁrst PA diagnosis or matched date in
the non-PA patients). Cases were patients with a
diagnosis of an opportunistic infection any time on or
after cohort entry (including pneumocystis pneumonia,
cryptospodiosis, tuberculosis, diseases due to
mycobacteria, bartonellosis, leukoencephalopathy, candi-
diasis, cryptococcis, other mycoses, cytomegaloviral
disease, herpes simplex, herpes zoster, human papilloma
virus, viral hepatitis, Epstein-Barr virus, histoplasmosis,
and toxoplasmosis). Patients were followed until the
end of the study period, end of practice registration,
death, or until ﬁrst opportunistic infection diagnosis.
We estimated cumulative incidence rates with 95%
conﬁdence intervals (CI) and risk (cumulative hazard
function) using the Kaplan Meier method for each cohort
and tested risk differences using a log-rank test.
Results: Rates of opportunistic infections were higher in
PA patients (N= 8,677) compared to non-PA patients
(N= 86,413) [24.6/1,000 person-years (PY) (95% CI
23.3–25.9) compared to 17.7/1,000 PY (95% CI 17.1–
18.1)]. The analyses of cumulative hazards yielded a
statistically signiﬁcant difference between the PA and
non-PA cohorts (p< 0.0001). In both cohorts, rates were
more than double for females compared to males, and
highest in the youngest and oldest age groups. Most
infections were cryptospodiosis, cryptococcosis, or other
mycoses.
Conclusions: The rates of opportunistic infections were
higher in PA patients in comparison to non-PA patients.
90. Increased Benzodiazepine Abuse Among HIV-
Infected Individuals in the United States
Sarah E Wixson, Emily S Brouwer. Pharmacy
Practice and Science, Institute for Pharmaceutical
Outcomes and Policy, University of Kentucky, Lexington,
KY, United States.
Background: The HIV-infected population has a high
prevalence of psychiatric disorders often coexisting with
drug and alcohol dependence. Symptoms associated with
psychiatric disorders are frequently managed with benzo-
diazepines (BZDs), a class of medication often abused.
Objectives: The objective of this research was to exam-
ine whether HIV-infected patients were more likely to
engage in problematic BZD use than their uninfected
counterparts.
Methods: We established a privately insured, popula-
tion-based cohort of patients in all 50 states and
Washington DC ﬁlling a BZD prescription between
January 2007 and December 2009. We included patients
between 19 and 64 years of age with at least one
healthcare claim in 2007 followed by a claim in 2008
or 2009. Patients were considered HIV-positive if they
had an HIV related claim in 2007 (ICD-9 code 042).
BZD use was identiﬁed using national drug codes. Prob-
lematic BZD use was deﬁned as a BZD prescription ﬁll
with a daily dose of at least 40 diazepam milligram
equivalents. Bivariate analyses examined the relationship
between HIV-infection and problematic BZD use.
Multivariate logistic regression models adjusted for
baseline covariates estimated adjusted odds ratios (OR)
and associated 95% conﬁdence intervals (CI).
Results: Overall, 831,358 patients were included in the
sample, of which 3,447 were HIV-infected. Among
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patients ﬁlling a BZD prescription HIV-infected patients
were more likely than uninfected patients to be male
(84% vs 32%), black (8% vs 4%), and have been
diagnosed with depression (24% vs 20%) or insomnia
(11% vs 8%). HIV-infected patients were also more
likely than uninfected patients to have problematic BZD
use (14% vs 10%). Adjusted for baseline covariates,
HIV-infected patients had 1.30 times the odds of
problematic BZD use than uninfected patients (OR:
1.30 95% CI: 1.18, 1.44).
Conclusions: We demonstrated that HIV-infected
patients are more likely to engage in problematic BZD
use than uninfected patients. Given that substance abuse
is linked to suboptimal HIV-medication adherence and
subsequently poor health outcomes, it is necessary to
develop interventions to manage substance abuse in this
at-risk population.
91. Disease Burden of Hospitalized Influenza Patients:
A Database Analysis in 2007 – 2012
Shih-Chen Chang, Jeffrey M Harris, Andrew McKee,
Roman Barbalat, Tracy Burgess, Jose M Trevejo.
Genentech Inc., South San Francisco, CA, United
States.
Background: Serious inﬂuenza infections may require
hospitalization, data describing the burden of inﬂuenza-
associated hospitalizations (IAH) in the US are lacking.
Objectives: To estimate the incidence, clinical outcomes
and case fatality of IAH over a 5-year period.
Methods: Premier Perspective inpatient data, composed
of >5 million annual discharges from >500 U.S hospi-
tals was analyzed. Hospital-speciﬁc projection weights
were applied to project to the national total discharges.
The ﬂu seasonal year was deﬁned from May 1st to the
followed year of April 30th. IAH was deﬁned if a patient
had an ICD-9 diagnosis of ﬂu in discharge records or
received ﬂu medicine during hospitalization.
Results: Around 29% of IAH were ascertained through
primary diagnosis, 26% through secondary diagnosis,
and 45% through receiving medicine for ﬂu treatment
only, without any corresponding ﬂu diagnoses. The
projected incidence varied across years: the highest
incidence was 304,785 in the pandemic season of
12009-2010, slightly higher than 274,000 from CDC
surveillance report. The median length of stay (LOS)
was 4 days, and remained stable over the 5-year period.
The LOS was higher in patients with (8 d) than without
(3 d) an ICU stay. Around 26% of the patients had an
ICU stay, with ~18% admitted to the ICU on admission
day; the rate was higher in adults (28%) than in children
(18%), and increased over the 5-year period, from 17% in
2007-2008 to 29% in 2011-2012. Around 16% of the
patients were on a mechanical ventilator; the rate is
higher in adults (18%) than in children (8%), and in-
creased over the 5-year period, from 9% in 2007-2008
to 19% in 2011-2012. The in-hospital case fatality rate
was 4%, and was higher in patients who stayed in the
ICU (13%) than those who did not (0.9%). These clinical
outcomes did not appear to be different in the pandemic
2009-2010 year from the other years.
Conclusions: In summary, the disease burden of IAH is
substantial, and a considerable proportion of patients
were observed to receive medicine for ﬂu treatment only,
which needs to be further considered when deﬁning IAH
in an administered healthcare database.
92. Etiologic Features of Stevens-Johnson Syndrome
(SJS) and Toxic Epidermal Necrolysis (TEN) with
Ocular Involvement
Kotone Matsuyama,1 Chie Sotozono,2 Mayumi Ueta,2
Satomi Sakabayashi,1 Shigeru Kinoshita.2 1Dept. of
Project Management, Translational Research Informat-
ics Center, Kobe, Japan; 2Department of Ophthalmol-
ogy, Kyoto Prefectural University of Medicine, Kyoto,
Japan.
Background: SJS/TEN can affect anybody at any age as
a consequence of adverse drug reactions. A variety of
drugs can cause SJS/TEN. There has been no epidemio-
logical study to analyze the relations of etiologic factors
to ocular severity of SJS/TEN.
Objectives: This study objective is to identify correlation
of ocular severity to speciﬁc etiologic factors of
Stevens-Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN).
The primary outcome was the severity of ocular
surface complication. The presence or absence of
chronic sequelae of ocular surface was deﬁned as the
secondary outcome.
Methods: Ocular severity at the onset was compared to
the patients’ age, sex, causative drugs, systemic ﬁndings,
treatment, and clinical sequelae.
Results: In this study, we obtained detail medical
records of 112 SJS/TEN from both dermatologists and
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ophthalmologists, and multivariate analysis (decision tree
by the chi-squared automatic interaction detection
algorithm) revealed that NSAIDs as the causative drug
and the patient’s age (<45) are predictable factors of
severe ocular involvement whereas anti-convulsants,
anti-biotics and the patient’s age (=> 45) are predictable
factors of slight ocular involvement. The patient’s age
and non-steroidal anti-inﬂammatory drugs (NSAIDs) as
the causative drugs signiﬁcantly correlated with ocular
severity (logistic regression analysis: P = 0.0151 and
P = 0.0126, respectively). Furthermore, all TEN cases
who had severe ocular involvements are diagnosed as
TEN with spots and cases with other type of TEN had
no interaction with severity of ocular involvements.
Conclusions: At the onset of SJS/TEN, much attention
should be needed to ocular involvement in the young
patients with the causative drug of NSAIDs. We also
should consider early intervention with steroids for SJS
or TEN with spots patients with inﬂammatory ﬁndings
in mucocutaneous junction to prevent severe ocular
involvements.
93. Childhood Atopic Dermatitis and Antidepressant
Drug Use in Young Adults: A Nationwide Population-
Based Cohort Study
Jette L Riis,1 Mette Deleuran,1 Christian Vestergaard,1
Morten Olsen.2 1Department of Dermatology, Aarhus
University Hospital, Aarhus; 2Department of Clinical
Epidemiology, Aarhus University Hospital, Aarhus.
Background: Atopic dermatitis (AD) is a pruritic inﬂam-
matory skin disease of varying severity affecting up to
20% of children in afﬂuent countries. It may have
substantial impact on quality of life. Furthermore, the
pro-inﬂammatory cytokines involved in AD development
may also be involved in the pathogenesis of mood
disorders. We thus hypothesize that the risk of mood
disorders is increased in AD patients.
Objectives: To estimate the risk of antidepressant drug
use in young adults with a history of atopic dermatitis
compared with a general population cohort.
Methods: Using the Danish National Patient Registry,
we identiﬁed all children born in Denmark from January
1, 1980 to December 31, 1995 with hospital diagnosed
AD before the age of 15 years. Using the Danish Civil
Registration System we identiﬁed 10 comparison cohort
members per patient matched on year of birth and
gender. Redeemed prescriptions for antidepressant drugs
were identiﬁed in a nationwide prescription database
established in 1995. A unique personal identiﬁer enabled
unambiguous data linkage and virtually complete follow
up. Patients and comparison cohort members were
followed from 15 years of age until redemption of a
prescription for antidepressant drugs, death, emmigration,
or end of study on December 31, 2012. We computed
cumulative incidence of antidepressant drug use at
20 years of age. Using Cox proportional hazards regres-
sion we estimated the hazard ratio (HR) of antidepressant
drug use of AD patients compared with the general popu-
lation cohort, while adjusting for gender and year of birth.
Results:We identiﬁed 11,481AD patients with a median
age of 3 years at diagnosis (49% male). The cumulative
incidence of antidepressant drug use at 20 years of age
was 7.6% (95% conﬁdence interval (CI) 7.1 – 8.2%)
among AD patients and 5.3% (95% CI 5.1 – 5.4%) in
the comparison cohort. The adjusted HR for antidepres-
sant drug use of AD patients compared with the general
population cohort from 15 to 33 years of age was 1.26
(95% CI: 1.19 – 1.33).
Conclusions: Childhood hospital diagnosed AD is
associated with increased risk of antidepressant drug
use in early adulthood.
94. Epidemiology of Hepatic Impairment among
Diabetes Patients in Japan
Chia-Hsien Chang, Motonobu Sakaguchi. Pharma-
covigilance, Takeda Pharmaceutical Company Limited,
Osaka, Japan.
Background: Because little information has been carried
out on the epidemiology of hepatic impairment among
Type 2 diabetes mellitus (T2DM), assessing possible
drug-induced liver injury is challenging in the drug
development process and post-marketing in Japan.
Objectives: To estimate the prevalence of hepatic
impairment and its risk factors admitted for hepatic
disease among DM patients.
Methods: This cohort consists of the adults with DM
and/or receiving any hypoglycemic agents (sulfonylurea,
biguanide, thiazolidinediones, alpha-glucose inhibitor,
glinides, dipeptidyl peptidase-4 inhibitors, GLP-1 ana-
logue and insulin) during 2010-2012. We identiﬁed the
hepatic admission from a record-based healthcare
database managed by Medical Data Vision Ltd. The
events were classiﬁed into virus hepatitis, alcoholic
hepatitis, liver cirrhosis or hepatocarcinoma, fatty liver,
drug-related hepatitis, biliary disease and other causes
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of hepatic diseases by pre-deﬁned criteria. All analyses
were conducted by using SAS 9.3 software.
Results: A total of 356,071 patients contributed 555,320
person-years were identiﬁed, of which 20,804 (5.8%)
patients admitted for hepatic disease were found during
follow-up. Annual prevalence of hepatic impairment in
the baseline from 2010 to 2012 were 9.7%, 9.5% and
10.1%, respectively. DM patients with pre-existing liver
disease had higher prevalence of hypertension,
dyslipidmia, renal disease, biliary disease and gastric
ulcer. Incidence of hepatic admission ranged from 22.9
(95% conﬁdence interval (CI), 22.4-23.3) with normal
liver function to 216 (95% CI, 211-220) with pre-existing
liver disease per 1,000 person-years. The main reasons
for admission were liver cirrhosis/ hepatocarcinoma,
followed by virus hepatitis and other cause hepatitis.
The predicting risk factors for admission include pre-
existing liver disease [adjusted hazard ratio (95% CI),
7.70 (7.48-7.92)] and the use of known hepatoxic drug
[adjusted hazard ratio (95% CI), 2.26 (2.16-2.36)].
Conclusions: The annual prevalence of hepatic impair-
ment among T2DM patients in Japan is 10%. Patients
with pre-existing liver disease had signiﬁcant higher
risk for hepatic admission compared to those without
liver disease.
95. Prevalence and Demographic Characteristics of
Acromegaly in the United States
R A Cantrell,1 R Walls,2 N Singh,1 P Napalkov,1 A
Surinach,3 Y Mu,1 E Fisheleva.4 1Genentech, Inc., South
San Francisco, CA, United States; 2 F. Hoffmann-La
Roche Ltd, Basel, Switzerland; 3Genesis Research,
Hoboken, NJ, United States; 4Roche Products Ltd,
Welwyn Garden City, United Kingdom.
Background: Acromegaly is a rare chronic disease
associated with increased mortality resulting from exces-
sive hormone production caused primarily by a pituitary
adenoma. To our knowledge, there are no published
prevalence data in the US currently available.
Objectives: To estimate the prevalence and describe the
demographic characteristics of patients with acromegaly
in the US.
Methods:We used US data from the GE Centricity (GE)
electronic health record database and the Thomson
Reuters MarketScan (MS) health insurance claims
databases, including Commercial Claims (CC), Medicare
(MC) and Multi-State Medicaid (MD) databases. In GE,
acromegaly patients were identiﬁed between 2000-2012
with ≥1 claim for acromegaly (ICD-9-CM 253.0),
excluding cases with unconﬁrmed initial diagnosis.
In MS, acromegaly patients were identiﬁed between
2000-2011 in CC and MC and between 2006-2011 in
MD with a) ≥2 claims 30 days or more apart for acromeg-
aly (ICD-9-CM 253.0) during 1 year after the ﬁrst
acromegaly diagnosis, or b) ≥1 claim for acromegaly
(ICD-9-CM 253.0) and ≥1 claim for pituitary adenoma
(ICD-9-CM 237.0 or 227.3) during 1 year after the ﬁrst
acromegaly diagnosis. Prevalent cases were all patients
with continuous eligibility (MS) or activity record (GE)
in the year of interest including eligible cases identiﬁed
in prior years with ≥1 acromegaly record in the year
of interest.
Results: The prevalence of acromegaly (cases per
million) as of 2011 in MarketScan was estimated to be
48.9 in CC, 63.8 in MC and 45.5 in MD while the
prevalence as of 2012 was estimated to be 60.4 in GE.
Across all databases, females represented 47.9%-52.2%
of acromegaly patients. The average (median) age
for acromegaly in CC and GE databases that cover
demographically representative populations was 45.5 (48)
and 45.2 (48) years, respectively. Caucasians accounted
for 80% in GE, the only database in this study with
representative race data.
Conclusions: To our knowledge, this is the ﬁrst study to
report acromegaly prevalence and demographic charac-
teristics from large and diverse patient populations in
the US.
96. Health Outcomes for Older Australians After
Transient Ischaemic Attack (TIA) or Ischaemic
Stroke (IS)
Janet K Sluggett,1 Gillian E Caughey,1 Michael B Ward,2
Andrew L Gilbert.1 1Quality Use of Medicines and
Pharmacy Research Centre, University of South
Australia, Adelaide, South Australia, Australia; 2School
of Pharmacy and Medical Sciences, University of South
Australia, Adelaide, South Australia, Australia.
Background: Use of acute stroke treatments and
secondary stroke prevention medicines has doubled since
release of Australia’s ﬁrst stroke guidelines in 2003. It is
unclear if improvements in quality of care are translating
into improved health outcomes.
Objectives: To compare health outcomes for TIA and
IS patients hospitalised in 2003–2004 with those
hospitalised in 2008–2009.
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Methods: A retrospective cohort study was conducted
using the Australian Government Department of
Veterans’ Affairs claims database. Subjects aged ≥65
years with a ﬁrst-ever hospitalisation for TIA or IS
during 2003–2004 or 2008–2009 were followed for
2 years to determine time to next admission for stroke,
myocardial infarction (MI), death and a composite
outcome of stroke, MI or death. Cox proportional hazards
models were used to estimate hazard ratios (HR) and
95% conﬁdence intervals (CI) for association between
study year and outcome, using age as the primary time
scale and adjusting for gender, residential status and
comorbidities.
Results: 2238 TIA and 2288 IS patients hospitalised
during 2003–2004 and 1883 TIA and 1984 IS patients
hospitalised during 2008–2009 were included. Compari-
son between cohorts showed patients admitted during
2008–2009 were older (TIA: median age 85 vs 82 yrs;
IS: 86 vs 82 yrs) with a greater number of comorbid
conditions (including atrial ﬁbrillation, TIA: 23% vs
18%; IS: 39% vs 31%) and more complications during
the hospital stay. Compared to those hospitalised
during 2003–2004, adjusted analyses showed patients
hospitalised later had no difference in risk of stroke
(TIA: HR 0.86, 95% CI 0.68–1.09; IS: HR 1.02, 95%
CI 0.82–1.27), MI (TIA: HR 1.17, 95% CI 0.84–1.64;
IS: HR 0.95, 95% CI 0.62–1.44), death (TIA: HR 1.00,
95% CI 0.88–1.14; IS: HR 0.98, 95% CI 0.89–1.09) or
the composite endpoint of stroke, MI or death (TIA:
HR 1.01, 95% CI 0.90–1.13; IS: HR 1.00, 95% CI
0.91–1.10) during follow-up.
Conclusions: Although patients hospitalised later were
likely to be at higher risk of poor health outcomes, no sig-
niﬁcant differences were observed. Improvements in care
may be positively impacting on patient health outcomes.
97. Cataract in Cystic Fibrosis Patients
Nicholas J Everage,1 Yan Bai,2 Brett Loop,2 Nataliya
Volkova,2 Nan Liu,1 Cheryl Enger.3 1Optum Epidemiol-
ogy, Waltham, MA, United States; 2Vertex Pharmaceuti-
cals Incorporated, Boston, MA, United States; 3Optum
Epidemiology, Ann Arbor, MI, United States.
Background: Ocular changes in cystic ﬁbrosis (CF)
patients may result from various etiological factors,
potentially leading to an increased risk of cataract.
Objectives: This study was designed to determine the
incidence and prevalence of cataract among CF patients
versus a general population (GP) cohort.
Methods: This was a retrospective cohort design using
data from the Optum Research Database. The study
period was from 01 Jan 1994 to 31 Aug 2012 and
included patients with both medical and pharmacy
coverage. The CF cohort consisted of patients with ≥1
inpatient claim with an ICD-9-CM (ICD-9) diagnosis
(dx) code 277.0x, ≥2 CF outpatient claims, and/or ≥1
pharmacy ﬁlls of dornase alfa with a CF outpatient claim.
Each CF patient was frequency matched to 100 GP
patients based on age, gender, and calendar year of
cohort entry. Cataract was identiﬁed using an ICD-9 dx
for cataract (366.xx) or congenital cataract (743.3x), or
a procedure code indicating cataract treatment. The point
prevalence as of 31 August 2012; incidence rates (IRs);
incident rate ratios (IRRs) based on Poisson regression
models; and 95% conﬁdence intervals (CIs) of cataract
were computed. The IRs and IRRs were stratiﬁed by
age and gender.
Results: 5,574 patients with CF were matched to
525,960 GP patients. On 31 Aug 2012, 4.8% (95% CI:
3.8-6.0) of CF patients had evidence of cataract vs.
2.8% (95% CI: 2.7-2.9) in the GP. The IR of cataract
for the CF cohort was 5.8 (95% CI: 4.8–7.1) per 1,000
person-yrs compared with 3.3 (95% CI: 3.2–3.4) in the
GP. The unadjusted IRR comparing the CF with the GP
cohort was 1.8 (95% CI: 1.5–2.2) and decreased to 1.5
(95% CI: 1.2–1.8) after adjustment for age, gender,
cohort entry year, corticosteroid use in follow-up and/or
at baseline, number of drugs dispensed, and diabetes
and hypertension diagnoses. When stratiﬁed by age, the
unadjusted cataract IRR comparing CF to GP cohorts
was highest for those 21-35 yrs (3.3, 95% CI: 1.7–6.5).
For gender, the IRRs comparing the CF with the GP
cohort was 2.0 (95% CI: 1.5–2.8) for males and 1.3
(95% CI: 1.0–1.7) for females.
Conclusions: The data suggest that patients with CF
have an increased cataract risk as compared to the GP
cohort, which also increased by age.
98. Longitudinal Analysis of Dengue Fever Infections
Reported in the UK between 2002 – 2013 Using the
Health Improvement Network (THIN) Primary Care
Database
David Ansell, Caroline O’Leary, Ahmed Nasser.
CSD MR UK, London, United Kingdom.
Background: In the UK, dengue fever is a travel associ-
ated viral infection which is endemic in over 110
countries and is transmitted through a mosquito vector.
Infection may develop into severe dengue which can lead
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to death. There is currently no licensed immunisation to
protect against infection, although vaccines are in devel-
opment. In 2009 the Health Protection Agency (HPA) in
England commenced monitoring the prevalence, so there
is no longitudinal data on UK rates.
Objectives: This study describes the rates of infections
by year and the demographic characteristics of those
acquiring dengue fever, recorded in a UK primary care
database over 10 years. It contrasts these rates with the
4 years of data produced by the HPA mandatory data
collection.
Methods: The THIN primary care database contains 12
million patients with 3.8 million active patients in 2012.
An observational, retrospective study was conducted
from 1/1/2002 – 31/12/2012. All patients with a coded
diagnosis of dengue fever in this period were included.
The variables were: age, gender, ethnicity, social depriva-
tion score and month of diagnosis.
Results: There were 168 patients recorded with a diagno-
sis of dengue fever. The annual rates of dengue fever
pmp in THIN from 2002 – 2013 were 4.0, 3.7, 7.9, 5.3,
3.3, 6.5, 5.0, 1.9, 7.4, 5.8, 5.8 respectively. The 4 years
of HPA data from 2009 to 2012 were very similar to
THIN rates (2.9, 7.1, 3.9, 5.9). 58% of patients
were males. The percentage by age bands 0 – 19, 20-39,
40 – 59, 60+ were 8%, 48%, 30%, 14% respectively.
79% of UK patients presenting with Dengue fever
were from the least socially deprived population groups
(upper 2 quintiles).
Conclusions: Between 2002 – 2013 there was year to
year variability in dengue infection rates, although the
UK travellers have seen no rise in rates of dengue fever
during this period. The 4 years of HPA reported rates
are very similar to THIN rates. Infection was reported
more frequently in males, and almost half of infections
occurred in the 20 – 39 year age group. This may just
reﬂect their greater propensity to travel to affected
destinations.
99. Regional Variation in Serum Urate amongst
Patients Recruited for the Febuxostat Versus Allopurinol
Streamlined Trial (FAST)
RobertW Flynn,1 Claudine G Jennings,1 Isla SMackenzie,1
George Nuki,2 Ian Ford,3 Thomas M MacDonald.1
1Medicines Monitoring Unit, University of Dundee,
Dundee, United Kingdom; 2University of Edinburgh,
Edinburgh, United Kingdom; 3Robertson Centre for Biosta-
tistics, University of Glasgow, Glasgow, United Kingdom.
Background: The FAST trial is an international
multicentre randomised clinical trial in gout patients with
one or more cardiovascular risk factors. Incidence of gout
is known to vary on a regional basis.
Objectives: To determine whether there is a regional
variation in baseline serum urate levels amongst gout
patients screened for the FAST trial.
Methods: This study used cross-sectional data collected
at screening as part of FAST. Patients are recruited to
FAST from 6 regions of the UK (Dundee, Edinburgh,
Glasgow, Aberdeen, Nottingham & the Highlands) and
Southern Denmark. Eligible patients are aged 60 or over,
currently taking allopurinol for chronic hyperuricaemia
and have at least one additional cardiovascular risk factor.
The outcome measure for this study was serum urate level
measured at the screening visit. We use a generalised linear
model to establish whether there was a difference between
regions in the baseline serum urate adjusted for baseline
covariates. To compare centres we calculated an adjusted
mean serum urate for a hypothetical 65-year-old, non-
smoking, non-alcohol drinking, male patient with normal
renal function, a BMI of 25kg/m2, on an imputed zero dose
of allopurinol, and on no other relevant co-prescribed
medication. Analyses were done using SAS 9.3.
Results: By January 2014, 1490 patients had been
screened and were eligible for FAST: 289 from Dundee,
239 from Edinburgh, 94 from Glasgow, 118 from
Aberdeen, 257 from Nottingham, 18 from the Highlands
and 475 from Southern Denmark. The region that
patients were recruited from was not signiﬁcantly
associated with serum urate level (p = 0.310). The
adjusted means for each centre were as follows:
Dundee 411μmol/L (95% CI 395 to 428), Edinburgh
406μmol/L (95% CI 389 to 423), Glasgow 397μmol/L
(95% CI 378 to 416), Aberdeen 411μmol/L (95% CI
392 to 430), Nottingham 414μmol/L (95% CI 397 to
430), Southern Denmark 414μmol/L (95% CI 396 to
432), the Highlands 408μmol/L (95% CI 375 to 440).
Conclusions: After adjustment for baseline covariates,
we found no evidence of regional variation in serum urate
levels in patients screened for FAST.
100. Prevalent Conditions among Elderly and Non-
Elderly Patients with Type 2 Diabetes (T2DM)
Catherine Ntabadde,1 Mary E Ritchey,1 Zhiwen Liu,1
Michael Senderak,1 Samuel Engel,1 Ravi Shankar,1
Kimberly G Brodovicz.1 1Merck & Co, North Wales,
PA, United States.
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Background: Elderly patients (>65 years), particularly
those with T2DM, are at increased risk of comorbidities,
and are consequently more medically complex than non-
elderly patients.
Objectives: To examine prevalence proportions (PPs) of
T2DM-related conditions among elderly and non-elderly
patients at three points in their treatment: initiating
monotherapy (MONO); escalating from mono- to dual
therapy (DT); escalating from non-insulin-based therapies
to insulin use (INSULIN).
Methods: PPs were estimated in the year prior to index
date of initiating/escalating therapy in Truven Health
MarketScan (MS) claims data in 2006-2012, and overall
differences were assessed via average standardized
absolute mean difference (ASAMD) and compared via
standardized differences (SD).
Results: We assessed 589,951 MONO (23% elderly),
48,245 DT (29% elderly) and 9,460 INSULIN patients
(22% elderly). As expected, cardiovascular conditions
(CVDCs) were among the highest PPs in all three groups.
For MONO, the highest PPs were for fracture, peripheral
arterial disease (PAD), angina, edema in lower extremi-
ties, stroke/TIA, and heart failure (elderly % =12.8,
10.1, 8.2, 8.0, 6.9, 5.1, respectively; non-elderly
%=15.3, 3.1, 3.3, 4.9, 1.9, 1.6, respectively). Higher
PPs were generally seen in elderly for DT and INSULIN.
The ASAMD between MONO elderly and non-elderly
was 0.103. However, large SDs ranging from 0.12 to
0.31 were noted for PAD, stroke/TIA, angina, chronic
kidney disease, heart failure, osteoporosis, benign
prostatic hyperplasia, edema and bladder cancer. For
DT, elderly continued to have more comorbidities than
non-elderly (ASAMD=0.093) and INSULIN were more
different (ASAMD=0.137). SDs for CVDCs increased
from 0.18-0.30 in MONO/DT to 0.25-0.38 in INSULIN.
Conclusions: SDs and ASAMD indicate that elderly pa-
tients had modestly higher proportions of comorbidities
than non-elderly patients. Differences remain as patients
progress to DT or INSULIN. Quantifying variations and
accounting for age (via adjustment or stratiﬁcation) may
be useful for researchers to interpret outcome studies
and assist clinicians in understanding applicability of
research ﬁndings to their patient population.
101. Incremental Direct and Indirect Cost of Untreated
Vasomotor Symptoms (VMS)
Philip Sarrel,1 Patrick Lefebvre,2 Marie-Hélène Lafeuille,2
Jonathan Gravel,2 Mei Sheng Duh,2 Peter Aupperle,3
David Portman.4 1Department of Obstetrics andGynecology
and Psychiatry, Yale University School of Medicine, New
Haven, CT, United States; 2Analysis Group, Inc., Boston,
MA, United States; 3Noven Pharmaceuticals Inc., New York,
NY, United States; 4Columbus Center for Women’s Health
Research, Columbus, OH, United States.
Background: Most women with moderate to severe
VMS are untreated.
Objectives: To evaluate the healthcare resource use,
work loss, and cost burden associated with untreated
VMS using a large employer database.
Methods:An analysis of health insurance claims (1999-2012)
from 69 self-insured US companies was conducted. Adult
women with ≥1 diagnosis for VMS (ICD-9: 627.2)
continuously enrolled for ≥6months before the ﬁrst
VMS claim (index date) were matched 1:1 with controls
(no-VMS) women using a propensity scores algorithm.
Women with pregnancy-related diagnoses or receiving
VMS treatment were excluded. Healthcare resource
utilization and work productivity loss (disability +
medically-related absenteeism) were compared between
cohorts using incidence rate ratios (IRRs) and conditional
Poisson models. Mean per-patient-per-year (PPPY)
direct and indirect costs were also calculated and
compared between cohorts using non-parametric
(bootstrap) methods.
Results: The untreated VMS and control cohorts
(n = 252,273 in both, including 35,933 with disability
coverage) were matched and balanced with respect to
age (mean = 56 years), region, payer type, industry type,
beneﬁciary status, year of index date, history of a recent
hysterectomy and baseline menopause-related diagnoses.
During the ﬁrst 12months following the index date,
untreated VMS women had signiﬁcantly higher all-cause
and VMS-related healthcare resource utilization than
controls (e.g., 82% and 121% higher for all-cause and
VMS-related outpatient visits, respectively). Average
direct costs PPPY were also signiﬁcantly higher for
untreated VMS women (direct cost difference [95% CI]:
$1,346 [$1,249; $1,449]). Untreated VMS women also
had 57% more indirect work productivity loss days than
controls, corresponding to an incremental indirect cost
PPPY associated with untreated VMS of $770 (95% CI:
$726; $816).
Conclusions: This large study showed that untreated
VMS is associated with a signiﬁcantly higher frequency
of outpatient visits, and an incremental direct and indirect
cost per women of $1,346 and $770, respectively. These
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results substantiate the need for additional treatment
options for VMS.
102. Clinical Characteristics of Patients with Lupus
Nephritis
Huifang Liang,1 Jennifer H Lin,1 Sudhakar Manne,1
Ryou Nakaya,2 Motonobu Sakaguchi,2 Ali Hariri.1
1Takeda Development Center Americas, Inc., Deerﬁeld,
IL, United States; 2Takeda Pharmaceutical Company
Limited, Osaka, Japan.
Background: Limited data are available on clinical
characteristics of patients with lupus nephritis (LN) from
large observational databases.
Objectives: To describe baseline characteristics of
patients with LN using the U.S. GE Centricity EMR
database up to 2013.
Methods: This study identiﬁed LN patients 18 years or
older based on a diagnosis of systemic lupus erythemato-
sus (SLE) and at least two records of renal diseases two
or more weeks apart. A minimum of one year of registra-
tion before diagnosis (the ﬁrst date of having both SLE
and renal disease diagnosis) was required. Eligible
patients were classiﬁed into group 1 (those with SLE
diagnosed before or on the same date as nephritis), or
group 2 otherwise. The most recent measures of
estimated glomerular ﬁltration rate (eGFR), urinary red
blood cell (RBC) cast, and total cholesterol at baseline,
as well as a medical history of type 2 diabetes mellitus
(T2DM), myocardial infarction (MI), stroke, or cancer
were assessed. These characteristics were further
compared between two groups of patients.
Results: A total of 961 LN patients (mean age 53 years,
women 85%) were eligible for the study, with 71%
in group 1. Among patients with known renal
function (n = 768), the percentage of patients with eGFR
(ml/min/1.73m2) ≥90, 60-89, 30-59, and< 30 was 14%,
22%, 44%, and 20%, respectively. About half of the
patients with available urinary RBC cast test (n = 356)
had positive results, and 14% of those with total
cholesterol values (n = 433) had hypercholesterolemia
(total cholesterol≥ 240mg/dL). For medical histories,
T2DM appeared to be most prevalent (21%) in all patients,
compared with stroke (9%), MI (3%), and cancer (3%).
Finally, group 2 patients appeared to be older, and had a
higher prevalence of renal dysfunction and T2DM.
Conclusions: To our knowledge, this is the ﬁrst study
assessing clinical characteristics of LN patients using a
large EMR database. Consistent with previous evidence,
our study ﬁndings show that LN patients are mainly
women, have high prevalence for decreased renal
function, T2DM and hypercholesterolemia.
103. Epidemiology of Parkinson’s Disease in China
Wilson HH Low,1 Siau Lin Yee,1 Soraya Azmi,1 Lan
Ge,2 Dominique Milea.3 1Azmi Burhani Consulting,
Petaling Jaya, Selangor, Malaysia; 2Lundbeck (Beijing)
Pharmaceuticals Consulting Co. Limited, Bejing, China;
3Lundbeck Singapore Pte. Ltd., 101 Thomson Rd, United
Square, Singapore, Singapore.
Background: Parkinson’s disease (PD) is a well-known
neurodegenerative disorder that affects up to 1% of the
world population aged 65 to 69 and up to 3% of those
aged 80 and above. China is the most populous nation,
with rapidly increasing elderly population, but informa-
tion on the epidemiology of PD in China from English
publication is limited.
Objectives: To review studies that investigated the
epidemiology and mortality of PD in China in English
and Mandarin.
Methods: A structured literature review on published
articles in both English and Mandarin languages was
conducted. Literature search was conducted using
PubMed, Cochrane, Wan Fang, and VIP databases.
Articles published between 2000 and 2013 were selected.
The inclusion criteria included studies on Chinese
population based in China only and studies that reported
epidemiology or mortality of PD. Four reviewers (two
for each language) independently selected and reviewed
the articles.
Results: The prevalence of PD varied in different parts of
China, ranging from 0.09% to 3.7%. The prevalence of
PD in China increased from 15 per 100,000 in 1991 to
>500 per 100,000 in 2005. Prevalence of PD in urban
areas was reported higher compared to rural areas. A
study reported low PD awareness among patients,
especially in the rural areas (68%) compared to the urban
areas (37%). The same study also reported 63% of the PD
patients did not receive treatment with levodopa
regardless of their disease awareness. Our review also
showed that the prevalence of PD increased with age.
The incidence of PD in China was reported to be 0.9%
(95% CI 0.6-1.4%) in 2006. A study with a mean
follow-up duration of 11.3 years reported PD mortality
rate of 29.2%. Another study with a follow-up duration
of 1.64 years reported PD mortality rate of 11.4%.
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Conclusions: Based on the current review ﬁndings, the
prevalence of PD in China has gradually increased over
the years but the prevalence rate is comparable than those
reported in Western countries. However, due to the sheer
population size in China, PD poses a signiﬁcant social
and economic burden to the country.
104. Adverse Drug Events in Medical and Surgical
Patients of an Academic Hospital
Hisham Aljadhey,1 Mansour A Mahmoud,1 Thamir
Alshammari.2 1Medication Safety Research Chair,
College of Pharmacy, King Saud University, Riyadh,
Saudi Arabia; 2College of Pharmacy, Hail University,
Hail, Saudi Arabia.
Background: Patient safety and the quality of healthcare
have been the focus of healthcare policy makers for
several decades.
Objectives: To identify the incidence of adverse drug
events (ADEs) and assess their severity and preventabil-
ity in medical and surgical patients.
Methods: This was a prospective cohort study con-
ducted in two surgical and three medical units of a 900
beds academic hospital for a period of four month.
Incidents were collected by pharmacists and reviewed
by one physician and one clinical pharmacist indepen-
dently. These incidents were further classiﬁed into
ADEs, potential ADEs and medication errors. The
severity and preventability of the incidents were also
determined.
Results: Majority of the patients 496 (61.8%) were
admitted to medical units, while 306 (38.2) patients were
admitted to the surgical unit. A total of 241 incidents
were identiﬁed by pharmacists; reviewers accepted 187
incidents and excluded 54 incidents. Of the accepted
incidents 127 (67.9%) were from medical units and 60
(32.1) from the surgical units. The incidence of ADEs
in the medical units was 7.3 per 1000 patient days and
7.6 per 100 admissions, while the incidence of ADEs in
surgical units was 3.1 per 1000 patient days and 2.6 per
100 admissions. The incidence of preventable ADEs
was 2.5 per 1000 patient days in the medical units and
0.7 per 1000 patient days in the surgical unit. The
incidence of potential ADEs was 11.9 per 1000 patient
days in medical units and 12.6 per 1000 patient days in
surgical units. The incidence of medication errors with
low risk to cause harm was 5.2 per 1000 patient days in
medical units and 7.9 per 1000 patient days in the
surgical unit.
Conclusions: The incidence of ADEs is higher in the
medical units while potential ADEs and medication
errors with low risk of harm are most common in the
surgical units.
105. Severity and Patient Reported Outcomes of Dry
Eye Disease in Taiwan
Hsu-Chih Chien,1 Po-Ting Yeh,2 Sun-Huei Tseng,3
Wei-Li Chen,2 Yu-Chih Hou,2 I-Jong Wang,2 Hsiao-Sung
Chu,2 Kwong Ng,4 Yea-Huei Kao Yang,1 Fung-Rong
Hu.2 1Institute of Clinical Pharmacy and Pharmaceutical
Sciences, National Cheng Kung University, Tainan,
Taiwan; 2Department of Ophthalmology, National Taiwan
University Hospital, Taipei, Taiwan; 3Sun-Huei Tseng Eye
Institute, Tainan, Taiwan; 4Regional Market Access,
Allergan Singapore Pte Ltd, Singapore, Singapore.
Background: Dry eye disease (DED) is one of the most
common reasons for visiting ophthalmologists. As
clinical signs and symptoms of DED are poorly corre-
lated, patient-reported outcomes play an important role
in the diagnosis and treatment eligibility of DED.
Objectives: This study aimed to evaluate DED severity
and treatment response reported both by patients and cli-
nicians in a real world setting in Taiwan.
Methods: This cross-sectional study was conducted in a
tertiary referral center in Taipei and a local ophthalmol-
ogy private clinic in Tainan from August 2013 to
November 2013. DED patients with at least one positive
Schirmer’s test result in any one eye within last year were
enrolled.
To assess DED severity, patients were asked to com-
plete the validated Chinese version of the Ocular Surface
Disease Index (OSDI) questionnaire. Bilateral corneal
signs and staining results of patients were recorded at
the time of visit. DED severity was graded by the
clinicians.
To evaluate response to dry eye treatment, patients
completed the Subject Global Assessment scale and
clinicians also independently assessed patients using the
Clinician Global Impression scale.
Results: We recruited 466 DED patients with 316 from
the tertiary referral center and 150 from the local private
clinic. The mean age is 60.82 years, with 25% male
patients (n = 117). Based on clinician assessment, 88%
of the patients were graded as level 1 or 2 severity (mild),
9% as level 3 (moderate) and 3% as level 4 (severe).
Based on OSDI, 26% patients had normal ocular
surfaces (0-12 points), 21% with mild dry eye disease
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(13-22 points), 17% with moderate severity (23-32 points)
and 36% with severe (33-100 points) DED.
According to clinician assessment, 47 (10%) patients
were unchanged on their symptoms as compared with
baseline and 407 (88%) patients were improved. In
contrast, 219 (48%) patients reported their DED
symptoms were almost the same after treatment and
160 patients (34%) reported their symptoms improved.
Conclusions: We found marked differences in the level
of DED severity and treatment response reported by
patients compared to that assessed by clinicians. Such
disparity may result in less than optimal treatment of
DED in some patients.
106. Global Incidence of Acute Lymphoblastic Leukemia,
2003-2007
Aaron J Katz, Victoria M Chia, Michael A Kelsh.
Center for Observational Research, Amgen, Inc.,
Thousand Oaks, CA, United States.
Background: Acute lymphoblastic leukemia (ALL) is a
rare malignancy with a bimodal incidence distribution
that peaks sharply in early childhood and rises gradually
in late adulthood. Previous literature suggests the
incidence of ALL may vary by geographic region and
between afﬂuent and developing nations; however,
literature on the epidemiology of ALL has been limited
and is generally outdated.
Objectives: To describe the incidence of childhood
and adult ALL among selected countries between 2003
and 2007.
Methods: Using the Cancer in Five Continents Volume
X database, we obtained country-speciﬁc case counts of
ALL (International Classiﬁcation of Diseases, 10th
Revision code C91.0) and at-risk person time accrued
over the 2003 to 2007 period to calculate crude, age-
speciﬁc (in 5-year age groups), and age-standardized
incidence rates expressed per 100,000 person-years
(PY). Incidence rates of childhood (0-14 years), adult
(15 years and older), and total ALL were calculated
for select countries from six distinct geographic regions
(i.e., Africa, Asia, Europe, North America, Oceania, and
Central/South America).
Results: Between 2003 and 2007, the median age-
standardized incidence rate (ASIR) of childhood ALL
among selected countries was 3.63 per 100,000 PY;
country-speciﬁc ASIRs of childhood ALL were lowest
in Egypt (2.08), China (2.53), and Israel (2.56) and
highest in Singapore (4.37), Australia (4.39), and Costa
Rica (4.44). The median ASIR of adult ALL was 0.79
per 100,000 PY; country-speciﬁc ASIRs of adult ALL
were lowest in Sweden, Saudi Arabia, and Switzerland
(0.59 each) and highest in Costa Rica (1.31) and
Colombia (1.52). The median ASIR of ALL overall
was 1.48 per 100,000 PY with country-speciﬁc ASIR
estimates ranging from 1.07 in Egypt to 2.12 in Costa
Rica. Overall, ASIRs of ALL were highest in Oceania
and North America and lowest in Africa and Asia.
Conclusions: Consistent with previous literature, inci-
dence of childhood, adult, and total ALL varied across
countries and geographic regions from 2003 to 2007.
Differences in diagnostic techniques, disease awareness,
and completeness of ALL capture in population-based
cancer registries may have contributed to the variation
of incidence observed.
107. Prescriptions, Nonmedical Use and Emergency
Department Visits of ADHD Stimulants
Lian-Yu Chen,1,3 Rosa Crum,2 Eric C Strain,2G Caleb
Alexander,3 Christopher N Kaufmann,1,3 Ramin Mojtabai.1
1Mental Health, Johns Hopkins Bloomberg School of Public
Health, Baltimore, MD, United States; 2Department of
Psychiatry, Johns Hopkins School of Medicine, Baltimore;
3Center for Drug Safety and Effectiveness, Johns Hopkins
Bloomberg School of Public Health.
Background: There are growing concerns about the
nonmedical use of attention deﬁcit hyperactivity disorder
(ADHD) stimulants. However, little is known regarding
the temporal trend in prescription, nonmedical use and
emergency department (ED) visits involving these
medications and their associations.
Objectives: To investigate the relationship between
trends in prescriptions, nonmedical use of, and ED visits
for Adderall (dextroamphetamine-amphetamine) and
methylphenidate among adults and adolescents.
Methods: Data are from three representative national
surveys between years 2006-2011: National Disease
and Therapeutic Index (NDTI, ofﬁce-based practices’
survey), National Survey on Drug Use and Health
(NSDUH, population survey of substance use), and Drug
Abuse Warning Network (DAWN, survey of ED visits).
Association of quarterly treatment visits, nonmedical
use, and ED visits were examined by ordinary least
square (OLS) regression. Source for misused stimulants
(NSDUH) and reasons for ED visits (DAWN) were
examined by cross tabulation.
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Results: In adolescents, visits in which Adderall or
methylphenidate were prescribed decreased over the
years; whereas, nonmedical use of Adderall remained
stable and nonmedical use of methylphenidate declined
0.16% per year. No apparent trend of ED visits involving
either drug was noted in adolescents. In adults, prescrip-
tion visits for Adderall remained stable while nonmedical
use and ED visits both increased by approximately
0.10% over the period and were strongly associated.
Prescriptions, nonmedical use, and ED visits involving
methylphenidate did not change in adults. For both drugs,
the major source across age groups was a friend or
relative. In two-thirds of the cases, the friend or relative
had obtained the medication through prescriptions from
a doctor.
Conclusions: Although prescriptions for Adderall
among adults did not change in 2006-2011, both its
nonmedical use and related ED visits increased signiﬁ-
cantly. Physician’s prescriptions were the major source
of the nonmedically used drug. Prevention strategies
should target drug diversion routes as well as education
on the adverse consequences of ADHD stimulants.
108. Medical Comorbidities and Drug Utilization of
Sickle Cell Disease Patients in a Large US Health-
Claims Database
Lauren Oliva, Made Wenten, Jin Wang, Anne Dilley.
Safety and Beneﬁt Risk Management, Biogen Idec,
Cambridge, MA, United States.
Background: Sickle cell disease (SCD) is well recog-
nized but relatively uncommon. As such, the epidemiol-
ogy of SCD has rarely been studied, and information on
medical comorbidities and drug utilization are limited.
Objectives: To describe the demographic, comorbid
conditions, and drug utilization among SCD patients in
a sample of the insured US population.
Methods: SCD patients were selected from a large US
insurance claims database from January 1, 2004 to June
31, 2013. SCD patients were deﬁned as those with at
least one or more ICD-9 codes for sickle cell disease or
trait (282.4x, 282.5 or 282.6x). Controls were selected
matched on year of birth, gender, total time in the
database, pharmacy beneﬁt eligibility and geographic
region. Comorbidities were classiﬁed using the Clinical
Classiﬁcation System (CCS) developed by the Agency
for Health Research Quality (AHRQ) which groups
ICD-9 codes into clinical categories. Odds ratios (OR)
and 95% conﬁdence intervals comparing comorbidities
in cases and controls were calculated. Medications
were grouped into drug classes using the USC classiﬁca-
tion system.
Results: Among the 37,130 SCD patients in the
database, the mean age was 32 years. Common comorbid
conditions included respiratory infections (67%); other
upper and lower respiratory disease (49% and 38%,
respectively); disease of the female genital organs and
disease of the urinary system (48% and 47% respec-
tively); and eye disorders (47%). A small proportion of
SCD patients were prescribed hydroxyurea in the
database. Additionally, concomitant medications included
codeine and combination products (61%); macrolide
antibiotics (55%); penicillins (52%); anti-arthritics
(44%); and cephalosporin antibiotics (36%).
Conclusions: SCD occurs rarely in the US population
but is associated with substantial comorbidity. The distri-
bution of comorbid conditions and concomitant medica-
tions observed in the US insurance claims database
were similar to what is commonly associated with SCD
in the literature. Further investigation of these comorbid
conditions relative to non-SCD patients is currently
underway.
109. Risk Modification of Dementia in Patients Aged
≥75 Years - Influence of PPIs
Britta Haenisch,1,2,3 Klaus von Holt,1 Birgitt Wiese,4
Karl Broich,2 Frank Jessen,1,3 Gabriele Doblhammer,5,6,7
Wolfgang Maier.1,3 1German Center for Neurodegenera-
tive Diseases (DZNE), Bonn; 2Federal Institute for
Drugs and Medical Devices (BfArM), Bonn; 3Depart-
ment of Psychiatry, University of Bonn, Bonn; 4Institute
for General Practice, Hannover Medical School,
Hannover; 5Institute for Sociology and Demography,
University of Rostock, Rostock; 6Max Planck Institute
for Demographic Research, Rostock; 7German Center
for Neurodegenerative Diseases (DZNE), Rostock.
Background: Drugs that modulate the risk for dementia
in the elderly are of potential interest for dementia
prevention. Proton pump inhibitors (PPIs) are widely
used for the treatment of gastrointestinal diseases, but
information on the risk of dementia is lacking.
Objectives: To investigate the inﬂuence of PPI medica-
tion on the risk of dementia.
Methods: Data were derived from the German Study on
Aging, Cognition and Dementia (AgeCoDe) of the
German Competence Network Dementia. AgeCoDe is a
longitudinal multi-center study in primary care patients
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recruited at six study sites in Germany by general
practitioners’ (GP) medical record registries. Inclusion
criteria comprised age 75 or older, absence of dementia
at recruitment, and regular contact with the GP. The
association between drug use and incident dementia is
analyzed using time-dependent Cox regression. The
model is adjusted for potential confounding factors
including age, sex, education, ApoE4 status, further
medication, and comorbidities. The replication analysis
was done applying routine claims data of the German
public health insurance fund AOK.
Results: Patients receiving PPI medication (omeprazole,
pantoprazole, esomeprazole, lansoprazole, or rabeprazole)
had a signiﬁcantly increased risk for incident dementia
compared to non-users. This result is compatible with
recent ﬁndings in mouse models where PPIs were shown
to augment brain amyloid beta (Aβ) levels, probably due
to a modulation of Aβ production. Aβ plaques are one of
the major signs in brains of demented Alzheimer patients.
Conclusions: Due to the burden of dementia in public
health and the lack of curative medication, the ﬁnding
provides indication for dementia prevention.
110. The Inappropriate Prescribing of Antibacterial
Medicines in Sudan; a National Study at National
Health Insurance Fund Setting
Isam Eldin Mohammed Ali Mustafa. Pharmaceutical
Services, National Health Insurance Fund, Khartoum,
Sudan.
Background: The irrational use of medicines is a
common problem worldwide. Recent literature revealed
that more than 50% of all medicines are prescribed
inappropriately which results in serious public health
problems like antimicrobial resistance. However, the
extent of irrational antibacterials at National Health
Insurance Fund (NHIF), Sudan is not well identiﬁed.
Objectives: To determine the pattern of antibacterial
medicines prescribing at primary healthcare facilities of
NHIF, Sudan.
Methods: The study followed the method developed by
the WHO/INRUD.
• Design: retrospective study
• Setting and study population: Twenty primary
health centres were selected from 5 states that represented
the ﬁve geographical regions of the Sudan, then 2401
patients encounters were withdrawn from these centres
by systematic random sampling from the year 2012.
• Outcome measure(s): Medicines Prescribing Indicators:
percentage of encounters with antibacterials prescribed
adjusted for age, sex and diagnosis.
Results: On average the percentage of encounters with at
least one antibacterial is 64% (ranged from 43% in
patients aged over 55 years, to 84% in children under ﬁve
years old). The patient’s age was negatively correlated
with the percentage of encounters with an antibacterial
prescribed ((r = -0.288, N = 2270, p< 0.01, two tails),
while there were no signiﬁcant differences in prescribing
behavior of doctors for males or females ( t = 0.919,
p = 0.35, two tails). A one-way analysis of variance
revealed signiﬁcant differences between the groups of
diagnosis in the percentage of antibacterials prescribed
(F = 91.39, p = 0.000).The main causes of antibacterials
prescribing were upper respiratory tract infections,
urinary tract infections, typhoid fever and gastro-
intestinal disorders. Interestingly, 45% of patients with
malaria received antibacterials.
Conclusions: There is over use of antibacterials
which reﬂects the urgent need for development and
implementation of antibiotics policy and Standard
Treatment guidelines especially for management of
respiratory infections, urinary tract infections and
typhoid fever.
111. Predictors of G-CSF Prophylaxis in the First
Cycle of Chemotherapy in Non-Hodgkin’s Lymphoma
Patients
Julius Asubonteng,1 Sally Wetten,2 Pieternella J
Lugtenburg,3 Lucy DeCosta,2 Zsolt Szabo,4 John H
Page.5 1Department of Epidemiology, University of
Pittsburgh, Pittsburgh, United States; 2Amgen Ltd,
London, United Kingdom; 3Erasmus MC Cancer
Institute, Rotterdam, Netherlands; 4Amgen GmbH, Zug,
Switzerland; 5Amgen Inc, Thousand Oaks, United States.
Background: International guidelines recommend pri-
mary prophylaxis with granulocyte-colony stimulating
factors (G-CSF) for patients who are assessed to be at
high (≥20%) risk of experiencing febrile neutropenia
(FN), to support treatment with myelosuppressive
chemotherapy. However, G-CSF use varies widely in
clinical practice even in high risk patients. There have
been several publications investigating predictors of FN
but few on predictors of G-CSF prophylaxis.
Objectives: The main objective of this analysis was to
identify predictors of G-CSF prophylaxis in the ﬁrst cycle
of chemotherapy in order to improve our understanding
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of the relationship between G-CSF use and FN in Non-
Hodgkin’s Lymphoma (NHL) patients.
Methods: This is a post-hoc analysis of data from IM-
PACT NHL, an observational cohort study. The
analysis was performed on the subset of prospectively
enrolled adults with any histological type of NHL treated
with (R)-CHOP. The relationship between baseline
patient characteristics and G-CSF prophylaxis in the ﬁrst
cycle of chemotherapy was examined using logistic
regression. Multivariable models were adjusted for age,
gender, country, performance status, histology and
regimen type.
Results: A total of 1187 patients were included in the
analysis, of whom 49% received G-CSF prophylaxis in
the ﬁrst cycle. In bivariable analyses, factors signiﬁcantly
associated with G-CSF prophylaxis included older age,
country, no bone marrow involvement, dose-dense regi-
men, investigator assessed high FN risk, DLBCL histol-
ogy, poor ECOG performance status, higher planned
cycles, chemotherapy dose, AST, CRP, LDH, and lower
serum albumin, haemoglobin and glucose. In multivari-
able analyses, investigator-assessed high FN risk (OR
2.9, 95% CI 2.1-4.0), <8.8mmol/L glucose (OR 1.7,
95%CI 1.0-2.8), <3x109/L ANC (OR 1.3, 95%CI 1.1-
2.0), and >400 U/L LDH (OR 1.4, 95% CI 1.0-1.9) were
associated with use of G-CSF prophylaxis.
Conclusions: In addition to well known risk factors for
FN, country, glucose and LDH appear to be predictors
of G-CSF prophylaxis in the ﬁrst cycle of NHL patients
receiving (R)-CHOP. These factors should be considered
when interpreting G-CSF use in clinical practice.
112. Do Case-Only Designs Yield Consistent Results
Between Them and Across Different Databases (DB)?
Hip Fractures Associated with Benzodiazepines
(BZD) as a Case Study
Gema Requena,1 John Logie,2 Elisa Martin,3 Consuelo
Huerta,3 Rocio González-González,3 Nada Boudiaf,2
Arturo Álvarez,3 Andrew Bate,4 Luis A García-
Rodríguez,5 Robert Reynolds,6 Raymond G Schlienger,7
Mark CH de Groot,8 Olaf H Klungel,8 Francisco J de
Abajo,1,9 Ian Douglas.10 1Unit of Pharmacology,
Department of Biomedical Sciences, University of
Alcala, Madrid, Spain; 2Observational Data Analytics
Worldwide Epidemiology, R&D Projects, Clinical
Platforms & Sciences, GlaxoSmithKline, Uxbridge,
Middlesex, United Kingdom; 3BIFAP Research Unit,
Spanish Agency of Medicines and Medical Devices,
Madrid, Spain; 4Epidemiology, Pﬁzer Ltd, Tadworth,
United Kingdom; 5Pharmacoepidemiology, Spanish
Center for Pharmacoepidemiological Research (CEIFE),
Madrid, Spain; 6Epidemiology, Pﬁzer Research &
Development, New York, United States; 7Global Clinical
Epidemiology, Novartis Pharma AG, Basel, Switzerland;
8Division of Pharmacoepidemiology & Clinical Pharma-
cology, Utrecht University, Utrecht, Netherlands;
9Clinical Pharmacology Unit, University Hospital
Príncipe de Asturias, Madrid, Spain; 10Non-Communica-
ble Disease Epidemiology, London School of Hygiene &
Tropical Medicine (LSHTM), London, United Kingdom.
Background: The case crossover (CXO) and self-
controlled case series designs (SCCS) are increasingly
used in pharmacoepidemiology. In both designs relative
risk estimates are obtained within persons rather than
between persons thus implicitly controlling for ﬁxed
confounding variables.
Objectives: To examine the consistency of relative risk
estimates of hip/femur fractures (HF) associated with
the use of BZD across case-only designs and across two
different DB, when same protocol and analytical methods
are applied.
Methods: CXO and SCCS studies were carried out in
BIFAP (Spain) and CPRD (UK). For the CXO, exposure
to BZD was divided into non-use, current (up to 30 days
after the end of last supply), and recent (1-60 days after).
A case moment with four control moments (each 90 days
apart) were deﬁned from index date (HF); odds ratios
(OR; 95%CI) of current use vs. non-use were estimated
using conditional logistic regression with adjustment for
co-medications (AOR). For the SCCS, exposure to
BZD was divided similarly, but current use was
subdivided into:1-30; 31-60; 61-182; 183-365; and >365
days. A conditional Poisson regression was used to
estimate incidence rate ratios (IRR; 95%CI) of current
use as compared to non-use, adjusted for age. To
investigate possible event-exposure dependence we also
evaluated the relative risk excluding a pre-exposure time
of 30 days.
Results: In the CXO current use of BZD was associated
with an increased risk of HF in both DB, BIFAP
[crude OR= 1.70 (1.50-1.92); AOR= 1.47 (1.29-1.67)]
and CPRD [crude OR=1.75 (1.60-1.92); AOR= 1.55
(1.41-1.67)]. In the SCCS IRRs for the ﬁrst current
period was 0.79 (0.68-0.92) in BIFAP and 1.42
(1.27-1.59) in CPRD. However, when we removed the
30 day pre-exposure period from non-use, the IRR for
ﬁrst current period was 1.40 (1.21-1.62) in BIFAP and
1.59 (1.42-1.78) in CPRD.
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Conclusions: CXO designs yielded consistent results
across DB, while SCCS did not. However, once we
accounted for the event-exposure dependence, estimates
derived from SCCS were more consistent across DBs
and with CXO results.
113. Use of Antidepressant Medications in Depressed
Older Adults and Predictors of Discontinuation of
Antidepressant Use
Eunsun Noh, Brian J Quilliam. University of Rhode
Island, College of Pharmacy, Kingston, RI, United
States.
Background: Major depressive disorder is highly
prevalent in the United States and increases morbidity
and mortality particularly in older adults. National
guidelines suggest 12-18 months of antidepressant
treatment for depressed patients to maximize the beneﬁts
of treatment; however, patterns of medication use
according to the guidelines are less well understood,
especially in older adults who are at higher risk of
adverse drug events.
Objectives: To describe the patterns of antidepressant
medication use by community-dwelling older adults and
examine the predictors of antidepressant medication
treatment discontinuation in older adults covered by
Medicare programs.
Methods: We performed a large nationally representa-
tive cross-sectional study using the Medicare Current
Beneﬁciary Survey (MCBS) data from 2004 to 2008.
We estimated a 6-month discontinuation rate of
antidepressant medications in older adults who initiated
antidepressant treatment following diagnosis with
depression. We further developed a multivariable logistic
regression model to identify predictors of discontinuation
of antidepressant medication.
Results: We found that less than 5% of older adults in
Medicare programs were diagnosed with major depres-
sion between 2006 and 2008. Nearly 1 in 2 depressed
older adults were treated with antidepressant medications
and 19.2% initiated medication after diagnosis. Of
these new users of antidepressant medications, 30.3%
discontinued medication therapy within 180 days of the
treatment starting. The discontinuation rate at 6month
was higher in the SSRI/SNRI users (34.9%) compared
to the TCA/other antidepressant users (21.2%). Living
in a metropolitan area was a signiﬁcant predictor of
antidepressant discontinuation (adjusted odds ratio = 3.5;
95% conﬁdence interval, 1.2-10.2).
Conclusions: Older adults tend to persist in antidepres-
sant medication use. The descriptive information
obtained in this study can provide points of discussion
for physicians and other healthcare providers when they
are working with older adults regarding barriers to
persistence in antidepressant use.
114. Therapeutic Inertia and Intensified Treatment
in Diabetes Prescription Patterns: A Nationwide
Population-Based Study
Huang Li-Ying,1 Shau Wen-Yi,1 Su Syi,2 Lai Mei-Shu.3
1Division of Health Technology Assessment, Center for
Drug Evaluation, Taipei, Taiwan; 2The School of
Healthcare and Management, Kainan University, Taipei,
Taiwan; 3Institute of Epidemiology and Preventive
Medicine, College of Public Health, National Taiwan
University, Taipei, Taiwan.
Background: Clinical guidelines based on empirical
evidence emphasize the fact that aggressive drug therapy
can mitigate or prevent the occurrence of diabetes-related
complications; however, many physicians fail to
prescribe appropriate drug therapy for the control of the
disease.
Objectives: This study sought to measure therapeutic
inertia by characterizing prescription patterns using
secondary data obtained from the nationwide Diabetes
Pay-for-Performance Project (DM-P4P) in Taiwan.
Methods: This retrospective cohort study employed data
related to diabetes patients participating in the DM-P4P
between 2006 and 2008. Hemoglobin A1c (A1c) results
were used to evaluate therapy modiﬁcations adopted in
response to poor control of diabetes (A1c values between
7% and 11%). We then examined the modiﬁcation of
therapy based on poor A1c control results to elucidate
the issue of therapeutic inertia.
Results: A total of 168,876 diabetes patients (899,135
A1c results) presenting A1c values between 7% and
11% were adopted in this study. Prescription patterns
were used to assign patients to a therapeutic inertia group
or intensiﬁed treatment group. A total of 61.5% of the
patients underwent modiﬁcations in therapy as a result
of poorly controlled A1c levels, indicating the
presence of therapeutic inertia in 38.5% of the cases.
The most common treatment modiﬁcation involved
prescribing additional drugs from other therapeutic
classes (68.3%), followed by increasing dosages of
previously prescribed medications. Analysis of prescrip-
tion patterns revealed that combination therapy was more
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commonly administered to patients in the intensiﬁed
treatment group. In the therapeutic inertia group, 9.6%
of the patients were not provided any drugs for the
control of the disease.
Conclusions: Among the patients in this study, 38.5%
were subject to therapeutic inertia. The proportion of
patients in the intensiﬁed therapy group who had been
prescribed more than two types of drugs was much
higher than that observed in the non-intensiﬁed therapy
group. Further studies are required to investigate how
factors related to patients and health care providers
inﬂuence therapeutic inertia.
115. AHRQ/HCUPNet-Derived Pharmacoepidemiologic
Evidence on Ventilation-Associated Iatrogenic
Pneumothorax
Yelizaveta Torosyan,1 Qianlai Luo,1,2 Sarah Hoffman,1,2
Danica Marinac-Dabic.1 1Division of Epidemiology,
Center for Devices and Radiological Health, CDRH/
FDA, Silver Spring, United States; 2The University of
North Carolina of Chapel Hill, Chapel Hill, United States.
Background: Our preliminary AHRQ/HCUPNet ﬁndings
(ICPE 2013) showed that in-hospital death rates in
patients on ventilatory support during the last decade
were decreasing in patients on mechanical ventilation
(MV), but not in patients on CPAP. The relatively
high in-hospital mortality among CPAP patients was
accompanied by the increasing rate of Iatrogenic
Pneumothorax (IP). We suggested a possible role of
the pneumothorax-related genetic markers in ventilation-
induced lung injury.
Objectives: The second phase of the project is focused
on a more detailed analysis of other modifying factors
that can affect the development of IP in patients on
ventilatory support.
Methods: NIS data (2002-2011) were used to analyze all
records on IP (ICD9: 512.1) and ventilatory procedures
(ICD9: 93.90 for CPAP; ICD9: 967.1 and 967.2 for MV
96 h and MV> 96 h, respectively). Multivariate logistic
regression was used to identify IP predictors in patients
on ventilatory support.
Results: In the last decade, only the MV> 96 h-
associated IP rate slightly decreased from 1.53% to
1.46%, remaining, however, much higher than
corresponding IP rates in patients on MV< 96 h and
CPAP (0.74-0.84% and 0.38-0.43%, respectively). In
addition to ventilation type, IP rates in MV/CPAP
patients were affected by demographic factors. The
highest IP rates were found in White females: 1.89% on
MV> 96 h, 0.98% on MV< 96 h, and 0.46% on CPAP.
The increased odds ratios (95% CI) for IP were as
follows: MV> 96h – 3.83 (3.65, 4.01), MV< 96h – 1.94
(1.85, 2.03), and female gender – 1.18, (1.15, 1.22).
Non-White ethnicities were associated with lower risk of
IP. Sleep apnea was found as a frequent comorbidity
which, however, did not increase IP risk.
Conclusions: These ﬁndings suggest the need for further
research on IP predictors to identify genetic and non-
genetic markers that can be used for individualizing
ventilatory support and assessing safety of ventilatory
devices.
116. Disparities in Oral Antidiabetic Agents for Newly
Diagnosed Type 2 Diabetes in Taiwan
Chia-Hung Liu,1,2 Chia-Hsuin Chang,1,3 Shu-Ting
Chen,1 Mei-Shu Lai.1,4 1Graduate Institute of Epidemiol-
ogy and Preventive Medicine, College of Public
Health, National Taiwan University, Taipei, Taiwan;
2Department of Family Medicine, Taipei Medical
University-Shuang Ho Hospital, Ministry of Health and
Welfar, New Taipei City, Taiwan; 3Department of
Internal Medicine, National Taiwan University Hospital,
Taipei, Taiwan; 4Center for Comparative Effectiveness
Research, National Center of Excellence for Clinical
Trial and Research, National Taiwan University
Hospital, Taipei, Taiwan.
Background: Metformin is recommended to be the ﬁrst
of choice as the initial oral pharmacologic agent for type
2 diabetes without contraindications since the 2006
consensus statement from the American Diabetes
Association and the European Association for the Study
of Diabetes. There are limited studies to explore the
prescription patterns of oral hypoglycemic agents for
newly diagnosed type 2 diabetes.
Objectives: To describe the temporal trends of different
oral hypoglycemic agents, and to determine the patient’s,
the physician’s and the medical facility’s factors
associated with using non-metformin prescriptions as
the initial treatment.
Methods: Millions of the National Health Insurance
claims data between 2006 and 2010 were randomly
sampled yearly. Newly diagnosed type 2 diabetes were
deﬁned as outpatients initiating oral antiglycemic
agents during the study period. Oral antidiabetic agents
included metformin, sulfondylureas, thiazolidinediones,
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meglitinides, alpha-glucosidanse inhibitors, and dipeptidyl
peptidase-4 inhibitors and were presented in frequency.
The multilevel logistic regression was used to examine
which covariates, in patient’s, physician’s and medical
facility’s levels, would be associated with prescription
disparities.
Results: From 2006 to 2010, the overall rate of non-
metformin prescriptions in new oral hypoglycemic
prescriptions dropped from 43.8% to 26.2 % (5-year
decreasing rates 40.1%). Low decreasing rates (<30%)
of non-metformin prescriptions in 5 years were observed
in patients aged over than 85 (16%), patients with low
income (24.1%), patients’ DCSI (28.3%), doctors’ age
over than 55 (26.8%), and medical facilities in remote
area (20.4%). The incident oral hypoglycemic prescrip-
tions from male or older patients, older doctors, non-
endocrinologists, ordinary or rural cities, and for-proﬁt
hospitals were signiﬁcantly associated with non-
metformin formula.
Conclusions: The prescription patterns of initiating oral
hypoglycemic agents are changing and obeying the
ADA/EASD recommendation in Taiwan, and a discrep-
ancy in prescription patterns still exists. Further studies
are needed to conﬁrm that continue medical education
will diminish this disparity.
117. Differential Healthcare Utilization in Metformin
Versus Sulfonylureas Users Pre- and Post-Initiation
Jin-Liern Hong, Michele Jonsson Funk, Jennifer L Lund,
Virginia Pate, Til Stürmer. Department of Epidemiology,
Gillings School of Global Public Health, University
of North Carolina at Chapel Hill, Chapel Hill, NC,
United States.
Background: Differential healthcare utilization may lead
to biased detection of cancer. Little is known about
whether healthcare utilization differs between initiators
of metformin (MET) versus sulfonylureas (SU).
Objectives: Examine patterns of physician visits and
cancer screening tests in MET and SU initiators in the
180 days pre- and post-initiation.
Methods: We used 2007-2010 US Medicare claims
and enrollment data to identify new users of MET
(n = 63,790) or SU (n = 24,301), age 65+ years, with no
diagnosis of cancer or renal disease within 180 days prior
to initiation. Patients were excluded if they died or
disenrolled within 180 days after initiation. Healthcare
utilization included physician visit, blood glucose tests,
and cancer screening tests. We reported the frequency of
each event in the 180 days pre- and post-initiation of
MET and SU. We also estimated the risk difference (RD)
comparing MET to SU weighted by age, sex, and race.
Results: MET users were younger (72 vs 74years), more
likely to be female (61% vs 59%) and white (81% vs
78%), compared with SU users. More MET than SU users
had physician ofﬁce visits before (91% vs 86%; RD: 6.1,
95%CI: 5.8-6.5) and after initiation (97% vs 94%; RD: 1.5,
95%CI: 1.3-1.7). MET users were more likely than SU users
to have a glucose test before (22% vs 18%, RD: 3.7, 95%CI:
3.3-4.2), but not after initiation (25% vs 27%, RD: -1.7, 95%
CI: -2.1 to -1.2). MET users were also more likely than SU
users to have cancer screening tests pre- and post-initiation,
especially for mammography. In women initiating MET
and SU, 20% and 13% had a mammogram before initiation
(RD: 5.9, 95%CI: 5.4-6.4), and 22% and 15% did after initi-
ation (RD: 5.1, 95%CI: 4.6-5.7), respectively.
Conclusions: Our results indicate differential healthcare
utilization between MET and SU pre- and post-initiation.
Cancer screening pre-initiation would tend to decrease
while cancer screening post-initiation would tend to
increase the incidence of cancer during follow-up.
Researchers need to be aware of the potential for more
screening pre-initiation when interpreting the beneﬁcial
ﬁndings of MET on cancer incidence.
118. The Pattern and Prescription Cost of Diabetes in
a Municipal Hospital in Ghana
Archibald Nii Boye Okotah. Ghana Health Service
(GHS), Accra, Ghana.
Background: Diabetes mellitus is a non communicable
disease with major health implications. The associated
risks of complications in diabetes contribute signiﬁcantly
to its high cost of treatment not only to the patient but
also the society at large. This study explores the pattern
and the cost of medicines prescribed for diabetic patients
at a Municipal Hospital in Ghana.
Objectives:
• To explore the pattern of prescription
• To determine the cost of medicines prescribed for
diabetic patients.
Methods: A retrospective sampling procedure was used
to randomly select 100 diabetic cases from the hospital
(Ho Municipal Hospital) data base system within the
period of January to December, 2011. Only OPD cases
of diabetes were involve in the study. In all, a total of
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588 prescriptions from the diabetic cases selected were
encountered. With the aid of excel and SPSS (vers 20),
the data generated was analysed and appropriate
measures of centrality and percentages determined. The
costs of medications were determined using the National
Health Insurance medicines list. Costs were however
discounted by 3% over a ﬁve year period.
Results: The data reveal a 100% written diagnosis for
all prescriptions encountered. The average number
of drugs per prescription was 6.0. About 61% of the
diabetic patients were also diagnosed with hypertension.
Biguanides (95%) were the commonest oral
hypoglycaemic agent prescribed while calcium channel
antagonists (60%) was the commonest antihypertensive
prescribed. The average cost of medications per prescrip-
tion was GHC 38.8 Ghana cedis (approximate, USD
20.5), were as the average total cost of medications per
diabetic case for the entire year was GHC 228.15 Ghana
cedis (approximate, USD 120).
Conclusions: The cost of treating diabetes was found to
be expectedly high, particularly due to the high number
of drugs encountered per prescription. Most diabetic
patients were also found to be hypertensive.
119. Treatment Patterns and Comorbidities in Adult
Patients Treated for Gaucher Disease in the US
Stephanie Tcherny-Lessenot,1 Lili Wang,1 Taylor Wang,1
Cristina Chang,2 Juhaeri Juhaeri.1 1Pharmacoepidemiology,
Global Pharmacovigilance & Epidemiology, Sanoﬁ,
Bridgewater, NJ, United States; 2Medical Department,
Sanoﬁ, Taipei, Taiwan.
Background: Information on concomitant medications
and comorbid conditions in Gaucher disease patients
are very limited in literature but these conditions may
impact patient management through speciﬁc risk proﬁle
and potential drug interactions.
Objectives: To estimate treatment patterns (acute or
chronic use of different drugs) and the prevalence of
comorbidities in adult patients treated for Gaucher disease.
Methods: In this retrospective cohort study using
MarketScan® database, the study population was deﬁned
as all adult patients with at least one prescription of
imiglucerase, velaglucerase alfa, taliglucerase alfa, and/
or miglustat from January 2003 to June 2012. Primary
outcomes were frequency of concomitant diseases
(such as cardiac events, depression and/or anxiety disor-
ders, respiratory infections) and concomitant prescribing
of potent CYP3A and/or CYP2D6 inhibitors where
chronic use was deﬁned as> 15 days.
Results: There were 168 adult patients treated for
Gaucher disease in the MarketScan® database, of whom
40.5% were men, 25% below 30, 29.2% 50-64 and
4.8% 65 years old or over. About 7.1% had at least one
claim of diagnosed respiratory infection and 3.6% of
depression and/or anxiety disorders within six months
prior to the initiation of Gaucher disease treatment. The
overall utilization of CYP2D6 and CYP3A inhibitors in
patients treated for Gaucher disease was limited (moder-
ate CYP3A inhibitors in 12.0%, strong CYP3A inhibitors
in 2.4%, moderate CYP2D6 inhibitors in 2.4%, strong
CYP2D6 inhibitors in 5.4%). Concomitant use of moder-
ate CYP3A inhibitors was more frequently related to
non-chronic use of antibiotics or antifungal agents for
systemic use prescribed for less than 15 days. Concomi-
tant use of strong CYP2D6 inhibitors was more fre-
quently related to chronic use of antidepressants
prescribed for15 days or more.
Conclusions: This study, through an evaluation of treat-
ment patterns and comorbidities in patients treated for a
rare disease over a 10 years period in a US large database,
provides reassuring ﬁndings for patient management in
term of low frequency of comorbidities and limited use
of concomitant drugs.
120. Anti-Diabetic Medication Pattern during
Inpatient Care for Patients with Diabetes in West
China Hospital
Sheyu Li,1 Chuan Yu,2 Yun Li,1 Rui Zhang,3 Qingtao
Hou,1 Tao Zheng,3 Yi Ma,3 Miye Wang,3 Na Su,4 Ting
Wu,5 Xia Sheng,6 Nan Li,3 Guanjian Liu,2 Yong Huang,3
Xin Sun,2 Haoming Tian.1 1Department of Endocrinol-
ogy and Metabolism, West China Hospital, Sichuan
University, Chengdu, Sichuan Province, China;
2Cochrane Center, West China Hospital, Sichuan
University, West China Hospital, Sichuan University,
Chengdu, Sichuan Province, China; 3Health Informatics
Center, West China Hospital, Sichuan University,
Chengdu, Sichuan Province, China; 4Department of
Pharmacy, West China Hospital, Sichuan University,
Chengdu, Sichuan Province, China; 5Epidemiology Asia
Paciﬁc Unit, Merck Research Laboratories, MSD China,
Beijing, China; 6Department of Informatics IT, Merck
Research Laboratories, Merck Sharp & Dohme Corp.,
Beijing, China.
Background: Few studies investigated the anti-diabetic
medication pattern of diabetic inpatients using Electronic
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medical record (EMR) database in China, which is
considered different with those in outpatient department.
Objectives: To investigate the prescription pattern of oral
antihyperglycemic agents (OAHAs)and insulin of diabetic
inpatients.
Methods: All inpatients with diagnosis of diabetes
discharged from West China Hospital between 2009
and 2012 were identiﬁed from the EMR database.
Baseline information including demographics, diagnoses,
prescription and healthcare resource utilization were
collected.Diabetic patients were identiﬁed by text
diagnosis and classiﬁed according to ICD-10. Medication
pattern was analyzed using the prescriptions at last day of
inpatient care before discharge.
Results: A total of 42186diabetic patients (59.67%
males)were identiﬁed with the median age of 65(IQR,
56-74) years and median length of stay of 11 (IQR, 7-17)
days.73% patients hadat least once AHAprescription
record; while 27% did not haveany AHA record with
the possible reason of self-bringAHAsor unstructured
prescription which cannot be captured currently.
Among the 24194 (57.4%) AHA usersprescribed at
last day of inpatient care, 35.5% (n = 8597)only used
OAHAs, in which 67.9%, 29.5% and 3.6% used 1, 2 and
3 types of OAHA, with the highest frequency of α-
glucosidase inhibitors (AGI, 52.2%), AGI &sulfonyl-
urea (SU, 30.1%), and AGI &Biguanide& SU (68.6%),
respectively;48.1% (n = 11642) only used insulin, in
which 37.8%, 5.5%, 32.7%, 19.6% and 4.4% used
bolus, basal, basal-bolus, premix and others, respectively,
with analogues as the most frequently used for bolus,
basal and basal-bolus treatment;and 16.4% (n= 3955) used
combination of both.Among patients treated withOAHAs
only, insulin only and their combination,there was
signiﬁcant difference on length of stay (11(7-17), 12(8-19),
13(8-20) days; P< 0.01, ANOVA).
Conclusions: The majority of diabetic inpatients were
prescribed OAHAs only and insulin only.The patients
treated with combined OAHAs and insulin had longer
length of stay.Patients without AHAprescription records
need to be conﬁrmed and used in caution.
121. Three Years Antibacterial Consumption in the
Indonesian Public Primary Health Care Center: The
Aplication of ATC/DDD and DU90% Method To
Monitor Antibiotic Use
Ivan Surya Pradipta, Elis Ronasih, Arrum Dyah
Kartikawati, Hartanto Hartanto, Rizki Amelia, Eli Halimah,
Ajeng Diantini, Keri Lestari, Rizky Abdulah. Pharmacol-
ogy and Clinical Pharmacy, Faculty of Pharmacy,
Universitas Padjadjaran, Bandung, Jawa Barat, Indonesia.
Background: The high use of antibacterials in Indonesia
led to the high opportunity on the irrational use of its. In
Indonesia, primary public health care center is a health
facility most visited by patients.
Objectives: This study aimed to determine patterns of
antibacterial use at public primary health care center in
a district of Indonesia during 2008-2010.
Methods: An observational study was conducted during
March until June 2011 to obtain pattern of antibacterial
use at public primary health care centers in a district of
Indonesia during January 2008- December 2010. The data
were obtained from the medicine use report from the
District of health ofﬁce. Antibacterial use with Anatomical
Therapeutic Chemical (ATC) code J01 was obtained, then
processed using Deﬁned Daily Doses (DDD) method with
DDD/1000 patients per day as a unit measurement. The
number of patients was obtained from the total visiting
patients in that research period. The data were analyzed
with descriptive statistical and the highest use segment
identiﬁed with Drug Utilization 90% (DU90%) method.
Results: There were fourteen antibacterial that use in 61
public primary health care centers. The total of antibacterial
use during 2008-2010 is 871.36 DDD/1000 patients/day.
Declining data showed in the antibacterial use 2008-2010,
there were 367.05 DDD/1000 patients/day in 2008, 343.21
DDD/1000/patients/day in 2009, 161.11 DDD/1000-
patients/day in 2010. Amoxicillin, sulphametoxazol, tri-
methoprim, isoniazid, ciproﬂoxacin, and tetracycline were
the most commonly used antibacterials. The data showed
that the average use per visit was as high as 24.41 DDD.
Conclusions: A decrease on the antibacterial use was
observed during 2008-2010, however the antibacterial
use per patient visiting was high. The high average
DDD of antibacterials use can be use as an early signal
for the irrational of antibacterial use. Qualitative study
and antibiotic policy are needed to control antibacterial
use and to formulate an effective intervention model that
can improve the rational use of antibacterial.
122. Using Drug Case Studies for Individual Case
Management to Enhance Appropriateness of Vancomycin
and Amikacin
Ming-Shen Lin, Jen-Wei Liu, Chun-Yu Wang. Pharmacy,
Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
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Background: We reviewed the usage of drugs for a
6-month period in terms of the deﬁned daily dose
(DDD), and found that there is an increasing trend in the
use of vancomycin and amikacin. While the rate of resis-
tant pathogens have not increased, serum concentration
measurements show an increasing number of cases of drug
dosing outside therapeutic drug concentrations. This
indicates that inappropriate drug dosing may be raising
the percentage of medication errors. Hence we wish to
propose strategies to improve this situation.
Objectives: We used drug case studies for individual
case management in the hope to comprehensively assess
and monitor drug use.
Methods:We reviewed “Daily Antibiotic Use Report” to
examine the daily use of vancomycin and amikacin.
The clinical pharmacist in charge then collected
patient’s information and made an initial evaluation. If
it was appropriate, follow-up and monitoring was
recommended. If the recommendation was not accepted,
the information was then passed onto to the infection
control specialist or the drug use evaluation committee
to determine suggestions for improvement.
On the other hand, we used a cloud operating system to
record the information for each case and to remind the
case management personnel and clinical pharmacist in
charge to continue follow-up.
Results: From the period between July 2013 to
December 2013 there were a total of 302 infection control
measures undertaken in relation to vancomycin and
amikacin. Two hundred and ﬁfty were related to vancomy-
cin and 52 related to amikacin. Four hundred and eighty-
eight recommendations were made by clinical pharmacists.
Categories as follows: continuous monitoring (54.5%),
dosage adjustments (28.5%), discontinuation (15.2%) and
change in therapy (1.8%). In terms of acceptance of
recommendations, 79% were accepted and 21% were not.
Cases of which side-effects may result in harm to patient
decreasing by 44% when compared to last year.
Conclusions: Current evaluations show that pharmacist’s
interventions can decrease inappropriate dosing and
therapy, and the use of vancomycin and amikacin for
treatment of non-susceptible bacterium.
123. Inappropriate Initial Dosing of Fluconazole in
Patients with Candidemia
Wen-Liang Lin, Pheng-Ying Yeh-Liu, Hui-Jen
Chang. Department of Pharmacy, National Cheng Kung
University Hospital, Tainan, Taiwan.
Background: Infectious Diseases Society of America
Guideline recommends starting ﬂuconazole with 800mg
(12mg/kg) loading dose and followed by 400mg
(6mg/kg/day) maintenance dose for candidemia. The
clinical practice in accordance with the recommendation
has not been well investigated.
Objectives: To explore the incidence of inappropriate ini-
tial ﬂuconazole dosing in patients with candidemia and to
identify variables associated with inappropriate dosages.
Methods: This was a retrospective cohort study in a
tertiary medical center of hospitalized adult patients with
candidemia prescribed ﬂuconazole. Appropriateness of
initial ﬂuconazole dosing was evaluated at start of
ﬂuconazole therapy after primary blood culture report
of yeast-like organism or as pre-emptive therapy. Patients
treated with ﬂuconazole for other fungal infections before
the onset of candidemia were excluded. The primary
outcome was the proportion of inadequate loading dose
and subsequent maintenance dose (adjusted for renal
impairment) of ﬂuconazole based on body weight. The
secondary outcome was variables associated with
inadequate ﬂuconazole doses. Univariate statistics were
used to compare variables between groups and followed
by multivariate logistic regression.
Results: A total of 131 patients were included during
9-month period. Fluconazole therapy started after
primary yeast blood culture report in 123 (94%) patients.
One hundred and thirteen (86%) patients received less than
12mg/kg loading dose of ﬂuconazole. Subsequent mainte-
nance dose was less than 6mg/kg/day in 38 (29%) patients.
Body weight per 1-kg increment (odds ratio, 1.08; 95%
conﬁdence interval, 1.04 to 1.13; P< 0.001) was associ-
ated with increased risk of inadequate subsequent mainte-
nance ﬂuconazole doses. There was no factor associated
with inadequate loading dose of ﬂuconazole.
Conclusions: The proportion of suboptimal loading dose
of ﬂuconazole in patients with candidemia was high.
Increased body weight was signiﬁcant predictor of
inadequate subsequent maintenance ﬂuconazole doses.
124. Different Use of Antibiotics in Rural and Urban
Regions in the Netherlands, an Observational Drug
Utilization Study
Josta de Jong,1 Jens HJ Bos,1 Tjalling W de Vries,2 Lolkje
TW de Jong-van den Berg.1 1Pharmacoepidemiology
and Pharmacoeconomics, University of Groningen,
Groningen, Netherlands; 2Pediatrics, Medical Centre
Leeuwarden, Leeuwarden, Netherlands.
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Background: The overuse of veterinarian antibiotics in
cattle farming is suspected to be a factor causing
resistance in humans.
Objectives: We investigated whether people living in
rural areas, assuming that they are more often in contact
with cattle than people in urban areas, use more
antibiotics or more frequently need an new course of
antibiotics.
Methods: Using the prescription database IADB.nl we
compared antibiotic use of patients living in rural areas
to patients living in urban areas. We also followed
cohorts of antibiotic users, determining the patients,
who need a second antibiotic within 14 days after the start
of a course.
Results: In rural areas the yearly prevalence of using
antibiotics was higher than in urban areas (2009: 23.6%
versus 20.2% (p< 0.001). In rural areas more adult
patients needed second antibiotic courses within 14 days.
Conclusions: People use more antibiotics and adults
more frequently need a second antibiotic course within
14 days in rural areas compared to urban areas. These
ﬁndings could be consequences of exposure to resistant
bacteria transmitted from farm animals.
125. Perspectives and Experiences of Community
Pharmacists about Antibiotic Dispensing in Riyadh,
Saudi Arabia
Hisham Aljadhey,1 Mohammed Al-Dhaeﬁ,1 Mansour A
Mahmoud,1 Aziz Sheikh.2 1Medication Safety Research
Chair, College of Pharmacy, King Saud University,
Riyadh, Saudi Arabia; 2The University of Edinburgh
Center for Population Health Sciences, Edinburgh,
United Kingdom.
Background: The dispensing of antibiotic without
prescription has been observed in many countries, includ-
ing Saudi Arabia. This may increase problems associated
with inappropriate use of antibiotics and lead to adverse
drug events and antibiotic resistance.
Objectives: We explored the perspectives and experi-
ences of community pharmacists regarding dispensing
of antibiotics without prescription.
Methods: A qualitative study of community pharmacies
sampled from across the ﬁve regions of Riyadh city
(i.e. North, West, East, South and Middle). Interviews
were conducted by a trained researcher with one
pharmacist in each community pharmacy. All interviews
were audio-recorded, transcribed verbatim and then
independently coded and analyzed by two researchers.
Results: A total of 16 pharmacists out of 22 participated
in the study (response rate 73%). Fourteen out of 16
pharmacists indicate that they dispensed antibiotics
without prescription. The reported indications for
dispensing antibiotic included fever, sore throat, tonsilli-
tis, urinary tract infections, common cold and cough. The
most common antibiotic dispensed was amoxicillin.
Further exploration of the causes of dispensing antibiotic
without prescriptions revealed three main themes. Factors
contributing to the dispensing of antibiotic included
requests for speciﬁc antibiotics by name, ignoring of phar-
macist advice that antibiotics were not indicated, and ﬁnan-
cial considerations. Factors perceived by pharmacists as
contributing to consumers demands for antibiotics without
prescription included, lack of conﬁdence in physicians,
easy access to community pharmacies, and time pressures.
In contrast, factors perceived by pharmacists as inhibiting
dispensing of antibiotics included complicated cases and
an incomplete patient medical history.
Conclusions: Pharmacists reported that antibiotics are
frequently dispensed without prescription, a combination
of public education, professional training and state
regulation are likely to be important to ensuring more
appropriate community dispensing and use of antibiotics.
126. Systemic Antimicrobials Consumption and
Expenditures in Russian Multi-Profile Hospitals: the
Results of Multicenter Trial
Maksim V Polyakov,1 Yuliya A Belkova,1 Svetlana A
Rachina,1 Roman S Kozlov,1 Vladimir M Mischenko,1
Ivan A Zakharenkov,1 Alﬁya I Abubakirova,2 Boris V
Berezhanskiy,3 Ekaterina V Eliseeva,4 Irina A
Kopylova,5 Shamil Kh Palyutin,6 Uliana S Portnyagina,7
Olga V Pribytkova,8 Evgeniy K Samuylo,9 Nadezhda A
Zubareva.10 1Smolensk State Medical Academy, Smo-
lensk, Russian Federation; 2Republic State Hospital
Named G.G. Kuvatov, Ufa, Russian Federation; 3City
Clinical Hospital #36, Moscow, Russian Federation;
4Vladivostok State Medical University, Vladivostok,
Russian Federation; 5Bryansk City Hospital #1, Bryansk,
Russian Federation; 6Yaroslavl State Medical Academy,
Yaroslavl, Russian Federation; 7Hospital #2 – Centre
for Emergency Medicine, Yakutsk, Russian Federation;
8Regional Clinical Hospital #3, Chelyabinsk, Russian
Federation; 9RAS Central Clinical Hospital, Moscow,
Russian Federation; 10Perm State Medical Academy,
Perm, Russian Federation.
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Background: Data on systemic antimicrobials (AM)
consumption and expenditures are essential for optimising
AM use in inpatient settings.
Objectives: To assess systemic AM consumption and
expenditures in multi-proﬁle hospitals in different regions
of Russia.
Methods: On-line database (OPTIMA Project) was devel-
oped tomonitor systemicAMconsumption and expenditures
in multi-proﬁle hospitals of 8 Russian cities: Vladivostok
(#2), Moscow (#3, #7), Yaroslavl (#4), Chelyabinsk (#5),
Perm (#6), Ufa (#8), Bryansk (#9), Yakutsk (#10) for one
year period (2009). Aggregate data on AM use were
expressed in numbers of DDD/100 bed-days (DBD).
Results: AM consumption rates in centers #2-10 were:
20.6, 25.8, 34, 65.1, 23.8, 40.2, 31.5, 45.5, 85.7 DBD,
average 40.2 DBD; AM expenditures were: €154358,
€75760, €201549, €312325, €161108, €151875,
€430974, €162776, €396240, average € 236576. The
majority of AM were qualiﬁed as 1st and 2nd line agents,
but improper AM consumption and expenditure rates (%)
were quite high: 14.9/0.5, 2.7/0.3, 23.6/7.2, 14.3/16.8,
1.2/0.3, 10.9/13.1, 67.3/18.7, 24.9/61.3, 1.7/3, average -
17.7/12.6, respectively. Penicillins, cephalosporins III,
carbapenems, quinolones, aminoglycosides, nitroimidazoles
consumption and cost shares (%) were: center #2 – 7.2/6.6,
46.8/43.9, 7.4/33.1, 17.2/4.6, 8.1/0.7, 1.7/0.3; #3 – 35.7/
14.4, 17.9/19.3, 0.6/30.5, 9.3/9.3, 1.6/0.4, 3.4/3.4; #4 – 22/
14.5, 29.7/12.8, 1.3/29.9, 7.3/13.7, 9.3/3.4, 2.6/2.3; #5
– 40.9/23.8, 23.6/38.7, 0.1/4.9, 7.7/10.7, 6.6/3.5, 6.3/
4.1; #6 – 12.7/13.4, 36.5/30.6, 0.9/21.2, 12.2/7.5, 4.9/1,
9.9/3.9; #7 – 5.7/1.8, 35.7/20.4, 1/23.7, 27.9/34.6, 1/0.4,
10.2/5.2; #8 – 16.5/9.4, 29/20.8, 1.7/38, 7.3/8.7, 12.5/2.8,
8.8/3.2; #9 – 45.4/21, 9.7/39.8, 0.1/11.3, 10.9/5.6, 7.4/
2.8, 5/3.5; #10 – 10.1/14.5, 61.9/26.6, 0.7/23.8, 13.3/5.9,
2/0.9, 5/3.6; average – 24.7/27.7, 29.7/17.4, 0.7/15.1,
14.4/18.4, 6.2/5, 7.2/6.3, respectively.
Conclusions: AM consumption and expenditures vary
signiﬁcantly in different regions of Russia. The highest
AM consumption was accounted for cephalosporins III,
penicillins and quinolones; the highest expenditures -
for penicillins, quinolones and cephalosporins III.
127. Comparison of Outpatient Antibiotic Use Between
Portugal and 5 European Countries in 2012 – There Is
(Much) Room for Improvement!
Carla Torre, José Guerreiro, Marta Gomes, Suzete Costa.
Centre for Health, Evaluation & Research (CEFAR),
National Association of Pharmacies, Lisboa, Portugal.
Background: In the landscape characterized by the
limited availability of novel antibiotics for human use
combined with the rising rates of antibiotic resistance,
antibiotic consumption (AC) surveillance and quality
benchmarking by comparison, acting as a stimulator to
quality improvement, is considered of great importance.
In Portugal, the National Program for Prevention and
Control of Infection and Antimicrobial Resistance is
one of the key national health programs and an
Intersectoral Alliance for the Preservation of Antibiotic
was launched in 2011.
Objectives: To perform a cross-country comparison on
outpatient antibiotic patterns use, between Portugal (PT)
and ﬁve European countries.
Methods: Cross-national outpatient systemic antibiotic
(ATC: J01) use data for 2012 was compared between
PT and 5 European countries (Denmark, UK, the
Netherlands (NL), Norway and Sweden). Data from PT
was retrieved from hmR Pharmacy Sales Information
System, a representative nationwide sell-out database. Data
from other countries was obtained from open-access
databases for each country. Main outcome measure was
the deﬁned daily dose (DDD) per 1000 inhabitants per
day (DHD). Quality of outpatient use was assessed by
European Surveillance of Antimicrobial Consumption
(ESAC) drug quality indicators for outpatient antibiotic use.
Results: In 2012, in PT, the overall AC in DHD was
22.68 (twofold higher than in the NL, which had the low-
est AC: 10.44), followed by UK (18.09) and by Denmark
(16.40). The highest quinolone (J01M) consumption was
observed in PT (10.94%) and the lowest in UK (2.05%).
In Portugal, the ratio broad/narrow-spectrum AC was
35.69 - the highest among the studied countries (values
ranged between 0.17 in Sweden to 7.98 in the
Netherlands).
Conclusions: These ﬁndings highlight that in Portugal,
efforts to improve outpatient antibiotic use quality,
focusing on the AC reduction, particularly of the broad-
spectrum antibiotics, seems to be essential. An increased
antibiotic awareness and structured policies involving all
key actors – patients, pharmacies and physicians - are an
unquestionable need.
128. Empirical Antimicrobial Therapy or Directed To
Hemoculture and Mortality in Patients with Sepsis in
ICU: A Retrospective Cohort
Camila Schultz Cordeiro,1 Celso Nakagawa,2 Luciane
Cruz Lopes.1 1Pharmaceutical Science, University of
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Sorocava, Sorocaba, Sao Paulo, Brazil; 2Infectology,
Pontiﬁcia University Catholic, Sorocaba, Sao Paulo, Brazil.
Background: Sepsis is associated with high rates of
mortality in ICU (Intensive Care Unit). The broad spectrum
antibiotic therapy and is more preferably used. However,
there is a risk of bacterial resistance, which could increase
mortality and the effectiveness of antimicrobial agents.
Objectives: To assess efﬁcacy and safety of targeted
antimicrobial therapy for blood culture results compared
with empiric broad-spectrum therapy for the treatment
of adult ICU patients with a diagnosis of sepsis, severe
sepsis or septic shock caused by any microorganism.
Methods: A retrospective cohort analysis of medical
records and laboratory data. Were selected records of
patients with sepsis, severe sepsis and septic shock
caused by any microorganism, with a positive blood
culture result, submitted or not to antibiotic therapy prior
to their admission to the ICU at two hospitals in the state
of São Paulo. The primary outcome measures include:
ICU mortality up to 28days and mortality or discharged
at the end of hospitalization. Secondary endpoints include
duration of hospitalization, duration of ICU stay, multi-
drug resistance and resistance to antimicrobial agents.
Results: Of the 314 patients diagnosed with sepsis, severe
sepsis and septic shock were eligible for the study 92. Most
patients underwent standard broad-spectrum therapy (empiri-
cal) (82.61 %). There were no signiﬁcant differences
(p< 0.05) between the clinical data of the two populations
(gender, age, comorbidities and APACHE II). Treatments
directed to the results of blood cultures were not different as
those for empirical therapy in relation to the outcomes studied.
Preliminary data indicate no differences between therapies.
Conclusions: We can’t specify which of these therapies
are effective at reducing mortality in patients with sepsis.
129. Analysis of Prescriptions Before and After
Intervention of Evidence-Based Drug Formulary in
Private Hospital in South Sumatra, Indonesia: A
Quasi-Experimental Study
Erna Kristin,1 Iwan Dwiprahasto,1 Dwi Indria Anggraini,2
Jarir At Thobari,1 Alﬁ Yasmina.3 1Pharmacology, Faculty
of Medicine, GadjahMadaUniversity, Yogyakarta, Daerah
Istimewa Yogyakarta, Indonesia; 2Pharmacology, Faculty
of Medicine, Lampung University, Bandar Lampung,
Lampung, Indonesia; 3Pharmacology, Faculty ofMedicine,
LambungMangkurat University, Banjarmasin, Kalimantan
Selatan, Indonesia.
Background: Expenditures for prescriptions drugs
continue to increase, prompting hospital to adopt
evidence-based drug formulary.
Objectives: To analyze prescription before and after
implementation of evidence-based formulary in private
hospital in South Sumatra, Indonesia.
Methods: Design: A quasi-experimental study
Setting: Data was extracted from electronic patient
records from the medical record at the private
hospital in South Sumatra, Indonesia, before intervention
(2010-2011 data, 113.002 prescriptions) and after
intervention (2012 data, 32.103 prescriptions).
Exposures or interventions: Evidence-based drug
formulary
Main outcome measures: Generic usage, drugs cost per
patient, average number of drug per patient, list of drug
prescribed, the use of antibiotics
Statistical analysis: analysis of variance.
Results: Compared before intervention, generic drug us-
age was signiﬁcantly increased (17% to 45%, p< 0.001)
after intervention. Drug cost spent per patient was
signiﬁcantly decreased (IDR 329,536.41 to IDR
147,456.55, p< 0.001). Average number of drug per
patient was signiﬁcantly decreased (4.7 to 3.2). List of
drugs prescribed by doctors was signiﬁcantly decreased
from 1229 to 941. The use antibiotics were change.
Before intervention, the most widely use of antibiotics
were amoxicillin + clavulacic acid (16.9%), cefuroxime
(14.2%), clindamycin (12.3%) ceﬁxime (12.1%) and
cefadroxil (9.8%). After intervention, the most widely
use of antibiotics were ciproﬂoxacin (20.2%), cefadroxil
(12.7%), clindamycin (12.7%), ceﬁxime (10.5%) and
levoﬂoxacin (8.2%). After intervention 5 high use
antibiotics were amoxicillin + clavulacic acid (16.9%),
cefuroxime (14.2%), clindamycin (12.3%) and cefadroxil
(9.8%).
Conclusions: Intervention of evidence-based drug
formulary in hospital decreased cost per patient, average
number of drug per patient and list of drug prescribed.
The usage of generic drugs was increased and the use
of antibiotics were changed.
130. Endocrine Therapy for Breast Cancer Patients in
South Africa
Yaser T Bazargani, Anthonius de Boer, Hubertus
GM Leufkens, Aukje K Mantel-Teeuwisse. Utrecht
Institute for Pharmaceutical Sciences, Utrecht University,
Utrecht, Netherlands.
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Background: Endocrine therapy (tamoxifen and
aromatase inhibitors (AIs)) has been shown to reduce
the risk of recurrence and death in estrogen receptor
positive(ER+) breast cancer patients.
Objectives: The aim of this study is to assess access to
these medicines by comparing the estimated number of
ER+ breast cancer patients with actual use in a middle
income country (South Africa).
Methods: Total annual sales data of tamoxifen and AIs
for the period 2005-2012 (except 2010,2011) was
retrieved from the IMS Health database. The data was
converted into years of patient treatment using the
deﬁned daily does (DDD) for each medicine. The annual
number of new cases of breast cancer patients per
ethnicity was estimated using the national cancer registry
reports of South Africa (2000-2005). The proportion of
South African ER+patients was based on literature. The
estimates were then stratiﬁed for menopausal status and
disease stage. The total number of patients needing
endocrine therapy was calculated assuming a 5-year treat-
ment period. Scenario analyses were performed to com-
pare utilization rates in different treatment combinations.
Results: Annual utilization of tamoxifen and AIs
increased from 12,274 to 16,492 and from 1,961 to
6,106 patients treated per year during the study period,
respectively. Assuming that all the ER+ patients had
been treated with (1) only tamoxifen or with (2) either
tamoxifen or AIs, the median proportion of patients
receiving treatment was 62% and 85%, respectively.
Assuming that (3) only premenopausal patients were
treated with tamoxifen and post-menopausal patients
with AIs, all premenopausal patients were fully treated
while only 38.5% of postmenopausal patients were
treated. If in similar situation (4) post-menopausal
patients were treated with tamoxifen or AIs (1:1 ratio),
a median of 92% of premenopausal and 77% of postmen-
opausal patients were treated.
Conclusions: According to our data access to treatment
in patients with ER+ breast cancer has improved over
the study period. Besides, the more realistic scenarios
(2 and 4) suggest that endocrine therapy was sufﬁciently
available for the patients in the last two years of
the study.
131. Utilization Trends of Anti-Tumor Necrosis Factor
Therapy in Taiwan
Meng-Ju Chan,1 Chien-Ning Hsu,1,2 Yen-Hsia Wen,1
Yu-Chin Lily Wang.2 1School of Pharmacy, Kaohsiung
Medical University, Kaohsuing, Taiwan; 2Department
of Pharmacy, Kaohsiung Chang Gung Memorial
Hospital, Kaohsiung, Taiwan.
Background: Clinical trials have suggested that
initiation of tumor necrosis factor inhibitors (TNFi)
improves disease control in patients with chronic
inﬂammatory disease. Because of signiﬁcant cost, TNFi
was under restricted reimbursement criteria in Taiwan,
critical utilization review helps to ensure the clinical
value of new a biological product.
Objectives: To examine the trend and pattern of TNFi
utilization in the practice setting in Taiwan.
Methods: A cross-sectional study was conducted
using patient-level data from a large medical center in
Taiwan from 1/2005 to 11/2013. Patients (n = 72,891)
with either a prescription of TNFi (etanercept,
adalimumab, golimumab) or a diagnosis with TNFi
labeled indications were analyzed. TNFi labeled indica-
tion were rheumatoid arthritis (RA), psoriasis, ankylosing
spondylitis (AS) and Crohn’s disease (C). The annual
incidence rate of TNFi initiation was estimated,
demographics and pattern distribution of indication
among TNFi new users were assessed using descriptive
statistical analyses.
Results: Of 1,765 TNFi users with labeled indications,
4% of them aged< 18 and 50% of them ranged 45-60
years old and 38% of them were male patients. The most
frequent indication of use was RA (69%), following by
AS (22%), and 12% of users with more one indications.
The annual incidence of TNFi use gradually increased
from 0.48% in 2006 to 1.57% in 2013. The number of
new users increased mainly due to AS from 13 in 2006
to 83 in 2013, psoriasis from 19 in 2006 to 77 in 2013,
RA from 56 in 2006 to 174 in 2013. Only 26% new users
(n = 450) received persistent therapy over 2 years (with a
permissible gap between two reﬁlls <60 days).
Specialists of rheumatology, allergy and immunology
were responsible for 81% TNFi users, dermatology
14% and pediatrics 4%. There were 3% of TNFi users
with off-labeled indications.
Conclusions: Initiation of anti-TNF therapy in-
creased over the study period, and the increase was
varied by indication. Few new users continued
therapy for >2 years, reﬂecting the difference be-
tween trial setting and real-world experience. The
study results emphasize the need for studying effec-
tiveness and appropriateness of long-term use of
anti-TNF therapy.
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132. Trends in the Use of Maintenance Immunosup-
pressive Drugs among Liver Transplant Recipients in
Taiwan: A Nationwide Population-Based Study
Chia-Chen Hsu,1 Ying-Yu Huang,1 Yuh-Lih Chang,1,2
Che-Chuan Loong,3 Yeuh-Ching Chou.1,2,4 1Department
of Pharmacy, Taipei Veterans General Hospital, Taipei,
Taiwan; 2Department and Institute of Pharmacology,
National Yang-Ming University, Taiwan; 3Department
of Surgery, Taipei Veterans General Hospital, Taipei,
Taiwan; 4College of Pharmacy, Taipei Medical
University, Taipei, Taiwan.
Background: Liver transplantation in Taiwan has been
developed nearly thirty years. It has become an important
and effective treatment option for end-stage liver disease,
irreversible acute hepatic failure, and early stage
hepatocellular carcinoma in Taiwan. However, there is
limited information in the literature on the trends in the
use of maintenance immunosuppressants after liver
transplantation in Taiwan.
Objectives: The aim of this study is an analysis of trends
in the use of maintenance immunosuppressants after liver
transplantation in Taiwan.
Methods: We conducted a retrospective nationwide
population-based study utilizing National Health
Insurance Research Database to analyze the prescribing
patterns of immunosuppressants used in new Taiwanese
liver transplant recipients from 2000 to 2009.
Results: A total of 1,686 patients received an iso-
lated liver transplantation and their prescriptions of
immunosuppressants were analyzed. The major
immunosuppressive therapy among liver transplant
recipients was calcineurin inhibitors (CNI) based
combination. The most prescribed CNI has been shift
from cyclosporine to tacrolimus during the study
period. Tacrolimus-based regimen notable increased
from 23.3% in 2000 to 77.5% in 2009 based on
prescription level. Azathioprine has been almost
replaced by mycophenolate acid. Furthermore, the
use of sirolimus was rare before 2004, and it
increased from 0.1% in 2004 to 8.7% in 2009. In
the ﬁrst 3months after liver transplantation, a total of
17 different regimens were used in 2009, compared
with 7 regimens in 2000.
Conclusions: In conclusion, two combined regimen
with tacrolimus and mycophenolate acid became the
most common used immunosuppressive therapy after
liver transplantation. Furthermore, we revealed the trend
toward individualized immunosuppressive regimen in
Taiwanese liver transplant recipients.
133. Utilization Evaluation of Anticancer Drugs as
Adjuvant and Neo-Adjuvant Therapy in the
Management of Breast Cancer: A Study from a
Developing Country
Himanshu Patel,1,2 Richard Samuel,1 Parthasarathi
Gurumurthy.1,2 1Pharmacy Practice, JSS College of Phar-
macy, Mysore, Karnataka, India; 2Clinical Pharmacy,
JSS Medical College Hospital, Mysore, Karnataka, India.
Background: Pharmacotherapy of breast cancer has
become intricate due to complexity of disease,
limitedclinical evidences, multiple treatment modalities
and patient preferences.
Objectives: To assess utilization pattern and appropriate-
ness of anticancer drugs as adjuvant and neo-adjuvant
therapy in patients of breast cancer.
Methods: In a prospective study medication orders of
patients on chemotherapy for breast cancer were
reviewed and patients were interviewed to assess
treatment pattern and its appropriateness in a specialty
oncology hospital. Clinical stage of the disease, tumor
characteristics, drug selection, dose, route, administration
technique and anti-emetics used were reviewed with
respect to standard international recommendations to
evaluate the appropriateness of the chemotherapy.
Results: 100 patients were followed over six months.
Anthracycline-based regimens were used often (92%)
compared to cyclophosphamide, methotrexate and 5-FU
regimen (6%). Targeted therapy was prescribed to only
2 of 6 patients with HER2 positive tumor. Endocrine
therapy, as either anti-estrogens or aromatase inhibitor
was prescribed for 18 (100%) patients with hormone
responsive tumor and for 7 of 13 patients with unknown
hormone response status. Selection of chemotherapy
regimen was appropriate in 94% patients. Cost of the
therapy was the limiting factor to select an appropriate
regimen in the remaining patients. Doses of anti-cancer
agents were not calculated as per body surface area
during subsequent cycle in 22% cases. Inappropriate
administration of drugs was due to excess dilution of
drugs (25%) and improper infusion time (29%). Choice
of anti-emetics was inappropriate in 38% cases and they
were used at higher doses in 35% cases.
Conclusions: Selection of anti-cancer agents was as
recommended in standard international recommendations.
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However, inappropriate administration of anticancer
agents was observed. Appropriate training to nurses may
improve the delivery of chemotherapy.
134. Persistence on Disease Modifying Anti-Rheumatic
Drugs Among Taiwan Established Rheumatoid
Arthritis Patients
Yi-Han Liu,1 Tzu-Chieh Lin,1,2 Yea-Huei Kao Yang,1,2
Hui-Jen Chang.3 1Institute of Clinical Pharmacy and
Pharmaceutical Sciences, College of Medicine, National
Cheng Kung University, Tainan, Taiwan; 2Health
Outcome Research Center, National Cheng Kung
University, Tainan, Taiwan; 3Department of Pharmacy
Services, National Cheng Kung University Hospital,
Tainan, Taiwan.
Background: Rheumatoid arthritis (RA) is a chronic,
progressive autoimmune disease. Disease-Modifying
Antirheumatic Drugs (DMARDs) are the major treat-
ment, early initiation can improve prognosis of patients.
Although DMARDs are efﬁcacious and highly recom-
mended, literature reported that adherence to and persis-
tence on treatments are generally poor.
Objectives: To evaluate persistence on DMARDs among
established RA patients in Taiwan.
Methods: We conducted a retrospective cohort study by
analyzing the National Health Insurance Research Data-
base of Taiwan from 2001 to 2010. RA patients identiﬁed
by ICD-9 code 714.0 and issued with Catastrophic Illness
certiﬁcation for the ﬁrst time between 2002 and 2009
were included. We deﬁned the application date for
Catastrophic Illness certiﬁcation as index date, and the
prescription of DMARDs were retrieved from outpatient,
inpatient and contracted pharmacy claims. We considered
treatment discontinuation while the last prescription ﬁll is
expected to be exhausted without any subsequent reﬁll in
30days. To evaluate the length of the persistence, we
calculated the time to discontinuation after the index date.
Results: A total of 20,138 patients with RA were
included. The average age was 54 (SD, 14.1) years old,
and female patients accounted for 77.18%. During the
1st-year-period after the index date, 67.52% of patients
discontinued the DMARDs therapy. The median
persistence was 98 days. No signiﬁcant difference was
found between female and male patients. The persistence
of younger patients was poorer than the elders.
Conclusions: A large proportion of RA patients experi-
enced discontinuation, the persistence on DMARDs is
not optimal either. Further studies are needed to conﬁrm
related factors.
135. Outpatient Use of Oral Anticancer Drugs in the
Permanent Sample of the French Healthcare Insurance
Database (2006-2011)
Julien Bezin, Régis Lassalle, Sophie Broussy, Pernelle
Noize, Nicholas Moore, Annie Fourrier-Réglat. Univ.
de Bordeaux, INSERM U657, CHU de Bordeaux, CIC
Bordeaux CIC1401, Bordeaux, France.
Background: Few data on use of oral anticancer drugs
are available in France.
Objectives: Estimate use of oral anticancer drug in
outpatients from data of the permanent sample of the
French healthcare insurance database from 2006 to
2011 and describe the characteristics of treated patients.
Methods: Repeated cross-sectional study from 2006 to
2011 in the 1/97th permanent representative sample of
the French national healthcare insurance database
(EGB). Drugs of interest were all oral anticancer drugs
identiﬁed in the database using the Anatomical Therapeu-
tic Chemical classiﬁcation. For each year from 2006 to
2011, the prevalence (at least one dispensation for a
given subject) and the incidence (at least one dispensa-
tion but none during the previous year) of oral anticancer
drug dispensations in outpatients were estimated.
Results: The annual prevalence of oral anticancer drug
use in the EGB database increased from 3,727 patients
in 2006 to 4,094 in 2011. During the same period, there
was little variation of annual incidence use: 1,415
patients in 2006 and 1,394 in 2011. Incidence of oral
cytotoxic chemotherapy use was 232 patients in 2006
and 274 in 2011; of oral targeted therapy: 22 and 146;
of oral hormonal anticancer drugs: 1,218 and 1,034. For
incident users, there was little variation in age (median
[IQR]: 60 years [40; 74] in 2006, 62 years [46; 75] in
2011), in sex ratio (68% female in 2006, 69% in 2011),
or in administrative registration for cancer (Affections
de Longue Durée, ALD: 46% in 2006, 48% in 2011).
Conclusions: The annual prevalence of oral anticancer
drug use in outpatients increased from 2006 to 2011;
annual incident use was relatively constant. Less than
half of incident users had administrative registration for
cancer, which suggests that precaution should be taken
when using this for identiﬁcation of cancer patients. For
pharmacoepidemiological studies of these drugs the high
frequency of oral hormonal anticancer drug use suggests
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that the EGB database could be considered; the
infrequent use of oral targeted therapies and oral
cytotoxic chemotherapy suggests that the full health
insurance database (SNIIR-AM) should be employed.
136. Safety and Efficacy Conversion from Twice-Daily
Tacrolimus (Prograf) to Once-Daily Prolonged-
Release Tacrolimus (Adavagraf) in Stable Liver
Transplant Recipients
Chiu-Yen Li,1 Chih-I Wu,1 Yao-Li Chen,2 Sock-Ping
Ng,1 Su-Yu Chien.1 1Department of Phamarcy,
Changhua Christian Hospital, Changhua, Taiwan;
2Transplantation Center, Changhua Christian Hospital,
Changhua, Taiwan.
Background: Tacrolimus has become the ﬁrst-line
immunosuppression in liver transplant programs. Once-
daily tacrolimus offers a more convenient dosage
regimen and adherence while reducing rejection rate.
Objectives: The aim of this study was to analyze the
safety and efﬁcacy ratio of 1:1 dosage conversion from
twice-daily Prograf to once-daily Adavagraf in stable
liver transplant regimen.
Methods: This observational study includes 40 liver
transplant patients conducted in Changhua Christian
Hospital. We retrospectively review preconversion data
for 12months and prospectively conducted a follow-up
postconversion conditions for an additional 12months.
Conversion was based on a 1:1 proportion. Tacrolimus
concentration level and laboratory data were recorded
based on pre- and post-conversion, which includes serum
creatinine (SCr), estimated glomerular ﬁltration rate
(eGFR), GOT and GPT. T-test was conducted to com-
pare the differences between pre- and post-conversion.
Results: Average age of the 40 patients observed was
67±3.3years. The average number of serum creatinine,
eGFR, GOT and GPT collected pre- and post-conversion
was 38 and 34 respectively. SCr and eGFR was 1.16±0.02
pre- versus 1.17±0.04mg/dL post-conversion (P=0.25)
and 68.28±1.46 pre- versus 69.49±4.23mL/min/1.73m2
post-conversion (P = 0.18) respectively. GOT and GPT
was 34.55 ± 3.82 pre- versus 35.48 ± 3.28 U/L post-
conversion (P = 0.27) and 36.72 ± 3.35 pre- versus
35.83 ± 3.22 U/L post-conversion (P = 0.26) respectively.
The average number of tacrolimus concentration level
collected pre- and post-conversion was 23 and 22 respec-
tively. The mean standard deviation of tacrolimus was
0.83 pre- (range from 3.81 to 6.57) versus 0.34 ng/mL
post-conversion(range from 2.92 to 4.04).
Conclusions: Results from our study illustrates that the
liver and renal function remain unchanged within the
12months follow-up. The variation in tacrolimus concen-
tration level is much lower in a once daily regimen. We
conclude that switching to a once-daily tacrolimus is
safe, while having the advantage of adherence improval.
137. Blood Cell, Renal and Liver Function Monitoring
among Psoriasis Patients Who Initiated Methotrexate
Use in Taiwan
Hsin-Chun Chou,1 Wen-Wen Chen,1 Wei-Ming Ke,1
Pi-Hui Chao,1 Fei-Yuan Hsiao.2,3,4 1Taiwan Drug Relief
Foundation, Taipei; 2Graduate Institute of Clinical
Pharmacy, National Taiwan University, Taiepei; 3School
of Pharmacy, National Taiwan University, Taipei;
4Department of Pharmacy, National Taiwan University,
Taipei.
Background: Lower dose methotrexate (MTX) therapy
is used for psoriasis. Pancytopenia and thrombocytopenia
were reported with low dose MTX therapy in Taiwan. On
account of its potential myelosuppression, regular
monitoring blood cell, renal and liver function is essential.
Objectives: This study aimed to investigate the evalua-
tion rate of blood cell, renal and liver function among
psoriasis patients after they initiated their MTX use.
Methods: From Taiwan’s National Health Insurance
research database (NHIRD), we identiﬁed 1,896 psoriasis
patients who initiated MTX use between 2000 and 2011.
Patient’s and physician’s characteristics, as well as initial
MTX dose and blood cell test, renal and liver function
test conducted in different time periods before and after
MTX initiation were observed.
Results: Nearly two-thirds of our study subjects were
male. More than 40% were aged 30-49. 1,080 (57.0%)
and 612 (32.3%) patients received their ﬁrst MTX pre-
scription from dermatology and rheumatology physicians
respectively. And, 45.5% and 29.9% of these MTX pre-
scriptions were prescribed in medical centers and metro-
politan hospitals. Among 1,831 MTX ﬁrst-time receivers
in outpatient settings, over 80% of them had initial MTX
dose between 2.5 and 15mg weekly. Evaluation of blood
cell, renal and liver function in the posterior 90 days of
MTX initiation were conducted in 96 (5.1%), 71 (3.7%)
and 91 (4.8%) patients respectively. 498 (26.3%) patients
had folic acid supplement during MTX treatment.
Conclusions: Closely monitoring blood cell, renal and
liver function is relevant for the prevention of adverse
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events induced by MTX. This population-based study
disclosed the inadequate safety management of low dose
MTX therapy in psoriasis patients in Taiwan.
138. Treatment Patterns for Anemia among
Breast Cancer Patients Treated with Chemotherapy
in 2000-2013
Hairong Xu,1 Langfang Xu,2 John H Page,1 Kimberly
Cannavale,2 Roberto Rodriguez,3 Chun Chao.2 1Center
for Observational Research, Amgen Inc., Thousand
Oaks, CA; 2Department of Research and Evaluation,
Kaiser Permanente Southern California, Los Angeles;
3Department of Hematology Oncology, Kaiser
Permanente Southern California, Los Angeles.
Background: Anemia is a common complication of
chemotherapy that can cause clinically important
symptoms and reduced quality of life. It is unclear how
management of chemotherapy induced anemia (CIA)
has evolved over time given the changes in the US
prescribing information, reimbursements, and implemen-
tation of a risk evaluation and mitigation strategy
(REMS) for the use of erythropoiesis-stimulating agents
(ESAs).
Objectives: To describe treatment trends and current
treatment patterns for CIA between calendar periods
2000-2013.
Methods: Incident breast cancer patients (pts) who
developed grade II-IV CIA (i.e. hemoglobin (Hb)
<10 g/dL) were identiﬁed from Kaiser Permanente
Southern California Health Plan (n = 1110). We
estimated the proportions of anemia episodes with ESA
use and red blood cell (RBC) transfusion in three
calendar periods (P1-3): January 2000-Dec 2006 (P1),
January 2007-24 March 2010 (P2), 25 March 2010-June
2013 (P3). We also estimated the hemoglobin
concentrations within 7 days preceding use of ESA and
transfusion. Differences between calendar periods were
assessed for proportions treated and for hemoglobin
concentration prior to CIA treatment. Standard errors
were estimated with use of GEEs and mixed models
respectively.
Results: The observed grade II-IV anemia episodes were
578 (468 pts) in P1, 345 (288 pts) in P2, and 431 (360
pts) in P3. Proportion of anemia episodes with ESA use
decreased from 2006 to 2013 (25% in P1, 20% in P2,
and 4% in P3). An increased trend of transfusion use
was observed over time (4% in P1, 8% in P2, and 12%
in P3), with the most evident changes observed in grade
III-IV (Hb< 8 g/dl) anemia episodes (10 % in P1, 41%
in P2, and 56% in P3). We observed signiﬁcant lower
Hb levels (g/dL) prior to ESA use [mean (SD): 9.9
(1.1) in P1; 9.6 (0.9) in P2; 8.9 (1.0) in P3]. No differ-
ences in Hb concentrations prior to transfusion use were
observed [mean (SD): 8.7 (1.1) in P1; 8.0 (1.4) in P2;
8.1 (0.7) in P3].
Conclusions: The study indicates that along with the
decreased use of ESA, utilization of RBC transfusion
has increased signiﬁcantly over time. The implementa-
tion of ESA REMS appears to have impacted the
management of CIA.
139. Treatment Patterns for Anemia among Patients
with Non-Hodgkin Lymphoma Treated with Chemo-
therapy in 2000-2013
Chun Chao,1 Langfang Xu,1 John H Page,2 Kimberly
Cannavale,1 Roberto Rodriguez,3 Hairong Xu.2
1Department of Research and Evaluation, Kaiser
Permanente Southern California, Los Angeles; 2Center
For Observational Research, Amgen Inc., Thousand
Oaks; 3Department of Hematology Oncology, Kaiser
Permanente Southern California, Los Angeles.
Background: Anemia is a common complication of
chemotherapy that can cause clinically important
symptoms and reduced quality of life. It is unclear how
management of chemotherapy induced anemia (CIA)
has evolved over time given the changes in the US
prescribing information, reimbursements, and implemen-
tation of a risk evaluation and mitigation strategy
(REMS) for the use of erythropoiesis-stimulating agents
(ESAs).
Objectives: To describe treatment trends and current
treatment patterns for CIA in patients (pts) diagnosed
with non-Hodgkin lymphoma (NHL) from 2000 to 2013.
Methods: Incident NHL pts who developed grade II-IV
anemia (hemoglobin <10 g/dl) during chemotherapy
were identiﬁed from Kaiser Permanente Southern
California Health Plan (n = 416; SEER stage: localized
22%, regional 19%, and distant 59%).We estimated the
proportions of anemia episodes with ESA use and red
blood cell (RBC) transfusion by anemia severity in three
calendar periods: January 2000-Dec 2006 (P1), January
2007-24 March 2010 (P2), 25 March 2010-June 2013
(P3). We also estimated the hemoglobin concentrations
in the 7 days before ESA /transfusion. Differences
between calendar periods were assessed for proportions
treated and for hemoglobin concentration prior to CIA
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treatment. Standard errors were estimated with use of
GEEs and mixed models respectively.
Results: The observed grade II-IV anemia episodes were
313 (213 pts) in P1, 144 (102 pts) in P2, and 140 (106
pts) in P3. Proportion of anemia episodes with ESA use
decreased from 2006 to 2013 (P1: 34%; P2: 22%; and
P3: 6%). An increased trend of transfusion use was
observed (P1:12%; P2: 22%; and P3:27%), with the most
evident changes observed in grade IV (Hb <6.5 g/dl)
anemia episodes (P1: 14%; P2: 75%; and P3: 67%).
There were no differences in the hemoglobin concentra-
tions prior to ESA use [mean (SD): 9.6 (1.1) in P1; 9.6
(1.2) in P2; 9.7 (0.8) in P3] and RBC transfusion
use [mean (SD): 8.2 (1.0) in P1; 8.2 (1.2) in P2; 8.1
(0.7) in P3].
Conclusions: The study indicates that along with the
decreased utilization of ESA, utilization of red blood cell
transfusion has increased signiﬁcantly over time in NHL
patients receiving chemotherapy.
140. Utilisation and Baseline Risk of Bleeding in
Patients Prescribed Rivaroxaban: Interim Results from
a Post-Marketing Observational Cohort Study
Vicki Osborne,1,2 Miranda Davies,1,2 Deborah Layton,1,2
Saad AW Shakir.1,2 1Drug Safety Research Unit,
Southampton, United Kingdom; 2School of Pharmacy
and Biomedical Science, University of Portsmouth,
Portsmouth, United Kingdom.
Background: Rivaroxaban is a novel oral anticoagulant,
which was newly indicated in 2011 for the prevention of
stroke and systemic embolism in non-valvular atrial
ﬁbrillation (AF) and treatment and prevention of deep
vein thrombosis and pulmonary embolism in the UK.
This post-marketing Modiﬁed Prescription-Event
Monitoring study is part of the risk management plan to
investigate the use of rivaroxaban in clinical practice,
with particular emphasis on the characterisation of the
bleeding risk proﬁle of patients prescribed rivaroxaban.
Objectives: To advance the understanding of the patient
population prescribed rivaroxaban in the primary care
setting.
Methods: An observational, population-based cohort
design based on review of medical charts (secondary data
collection). Patients were identiﬁed from dispensed
National Health Service prescription data for rivaroxaban
between Dec 11- Oct 13 (interim data lock date). Data
was collected from the prescribing general Practitioners
(GPs) via postal questionnaires sent at least 3-months
after 1st prescription for rivaroxaban was dispensed to
gather information on baseline characteristics.
Results: Interim cohort = 1109 patients, median age
75 yrs (IQR: 63,83). Rivaroxaban was most frequently
prescribed for Non-Valvular AF (58.7% cohort). The
majority of patients were started on a dose of 20mg once
daily (56.5%) and few doses outside of those licensed
were reported (n = 8). Some patients were reported to
have a history of or predisposition to bleeding (3.1%
and 0.9% respectively). Eleven patients were reported
to have a haematological disorder at baseline.
Concomitant use of ketoconazole (n = 1) and ritonavir
(n = 1) was reported, though this is not recommended
due to increased risk of bleeding.
Conclusions: The interim analysis shows that
rivaroxaban is largely being prescribed within the terms
of the license in general practice in England. Risk factors
for haemorrhage were reported in some patients, but
prevalence was low. This analysis provides information
on interim data, has undergone minimal data cleaning
and will become obsolete when validation and follow-
up are complete for the ﬁnal analysis.
141. Trends in Cardiovascular Risk Factors and
Change over Time across Education Levels, and the
Influence from Medicine Use and Gender. The Tromsø
Study 1994-2008
Anne Elise Eggen,1 Ellisiv B Mathiesen,2,3 Inger
Njølstad,1 Bjarne K Jacobsen,1 Tom Wilsgaard.1
1Department of Community Medicine, UiT The Arctic
University of Norway, Tromso, Norway; 2Department
of Clinical Medicine, UiT The Arctic University of
Norway, Tromso, Norway; 3Department of Neurology
and Neurophysiology, University Hospital of North
Norway, Tromso, Norway.
Background: Cardiovascular risk factors, as total
cholesterol and blood pressure, are inversely correlated
with socioeconomic status (SES). Both risk factors are
falling in high-income regions.
Objectives: The aim of this study was to analyse differ-
ences in cardiovascular risk factors across education
groups, whether educational differences in risk factor
levels have changed over time, and whether any such
changes were related to gender or use of medicines.
Methods: Data from participants (30-74 years) of the
Tromsø Study in 1994-5 (n = 22,108) and in 2007-8
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(n = 11,565). Blood samples, measurements, and self-
reported educational level and medicine use were collected.
Results: The use of antihypertensives and lipid lowering
drugs increased considerably in both sexes and age
groups in the time period, and use of lipid lowering drugs
was practically non-existent in 1994.
Differences in risk factor levels across education
groups were persistent for all risk factors over time, with
a more unfavourable pattern in the lowest education
group. The exception was cholesterol with the reduction
being largest in the lowest educated, resulting in
weakened educational trends over time. While a signiﬁ-
cant educational trend in cholesterol persisted among
the non-users of LLD, no educational trend in cholesterol
was found among the LLD users in 2007-8.
The strongest educational trends were found for daily
smoking and body mass index (BMI). In 2007-8 the odds
for being a smoker was ﬁve times higher among the
lowest educated compared to the highest educated. In
men, the odds for being in the highest quintile of the
BMI distribution were in 2007-8 almost doubled in the
lowest compared to the highest educated. The lowest
educated women had 6.2mmHg higher mean systolic
BP than the highly educated, mean BMI of 26.4 kg/m2
and smoking prevalence of 37.7%.
Conclusions: The difference across education groups for
cholesterol levels decreased, while the educational gap
persisted over time for the other risk factors. Use of
LLD seemed to contribute to the reduction of social
differences in cholesterol levels.
142. Drug Utilization Studies of Antihypertensive
Drugs for Hospitalized Patients with Hypertension in
Shenyang
Jian Gong,1 Wen Pan,2,3 Feng Guo,4 Kaishun Bi.1
1Department of Clinical Pharmacy, Shenyang Pharma-
ceutical University, Shenyang, China; 2Liaoning Center
for Disease Control and Prevention, Shenyang, China;
3Chinese Journal of Public Health, Shenyang, China;
4Department of Pharmaceutical Toxicology, China
Medical University, Shenyang, China.
Background: Since 30 years ago, antihypertensive drugs
have been proven to control hypertension effectively and
prevent the complications. In China, epidemical data
showed that hypertension patients in hospital are
different from those in community. In hypertension
patients in hospital, antihypertensive drugs utility ratio
is 28.2%, but the hypertension control ratio is only
8.1%. Here on the basis of our previous studies of the
inpatients, we evaluate the utilization of antihypertensive
drugs in this population.
Objectives: To study the drug utilization of antihyperten-
sive drugs by hospitalized patients with hypertension for
increasing the level of rational drug use in Shenyang.
Methods: From March 2004 to December 2013, data of
6000 hospitalized patients with hypertension were ran-
domly selected from 6 hospitals in Shenyang. For antihy-
pertensive drug classiﬁcation the Anatomical Therapeutic
Chemical (ATC) system was used. The data of drug
utilization was evaluated by deﬁned daily dose (DDD).
Results: The rate of metoprolol use was 29.34%. The
ﬁrst 3 places of DDDs of 29.34% were nifedipine,
imidapril, and telmisartan. The ﬁrst 3 places of DDDc
of 29.34% were esmolol, benidipine, and arotinolol.
Drug utilization index was approximately equal to 1 were
amlodipine, valsartan, and arotinolol.
Conclusions: Irrational drug utilization of antihyperten-
sive drugs for hospitalized patients with hypertension still
existed in the hospitals in Shenyang.
143. Utilization of Oral Anticoagulants in Patients
with Non Valvular Atrial Fibrillation
Layla Saliba,1 Pierre Mondoly,2 Alexandre Duparc,2
Marc Delay,2 Philippe Maury,2 Anne Rollin,2 Violaine
Calmels,3 Atul Pathak,2 Alessandra Bura-Riviere,4
Jean-Louis Montastruc,1 Haleh Bagheri.1 1Clinical
Pharmacology, Toulouse University Hospital, INSERM
U1027, Toulouse, France; 2Cardiology, Toulouse
University Hospital, Toulouse, France; 3Pharmacy,
Toulouse University Hospital, Toulouse, France;
4Angiology, Toulouse University Hospital, Toulouse,
France.
Background: Atrial Fibrillation (AF) is the most
frequent heart chronic arythmia. Its thromboembolic risk
justiﬁes the use of oral anticoagulants such as Vitamin K
Antagonists (VKA) or New Oral AntiCoagulants
(NOAC). NOAC are more recent, easier to use, but less
known than VKA.
Objectives: To describe the factors associated with
NOAC prescription.
Methods: This study was performed in Toulouse on a
cohort of patients from consultations in rythmology
followed from February to April 2013, treated with
VKA or NOAC for AF. A multivariate model was
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performed using logistic regression to describe the
factors associated with NOAC prescription and the
discontinuation of the anticoagulant.
Results: Among the 140 patients included, 92 (66%)
were treated with VKA and 48 (34%) with NOAC.
Recent AF diagnosis (OR 7.52 IC95% [2.41-23.29],
p =0.001), previous exposure to VKA (17.11 [4.48-60.91],
p< 0,001) and lack of Anti-Platelet Agents (APA)
exposure (7.69 [1.22-50.00], p = 0.030) were associated
to NOAC prescription. Discontinuation of the antico-
agulant (n = 36) was associated to NOAC intake (2.71
[1.21-6.08], p = 0.016).
Conclusions: NOAC are less prescribed than VKA in
patients treated with APA. NOAC switch to VKA was
not systematic in patients diagnosed for a long time.
However, INR values were stable in most of patients
treated with VKA at the switching to NOAC. A more
powerful study would conﬁrm the factors associated with
NOAC prescription.
144. Withdrawn by Author
145. Pharmacoeconomic Aspects of Angiotensin II
Receptor Blockers in Patients with Essential
Hypertension
Viet Thanh Truong,1 Cornelis Boersma.2 1Pharmacy,
Laval University, Quebec, QC, Canada; 2University of
Groningen, Groningen, Netherlands.
Background: Hypertension is regarded as one of main
risk factors for morbidity and mortality related to cardio-
vascular complications. Frequently prescribed antihyper-
tensive agents include diuretics, angiotensin-converting
enzyme inhibitors (ACEIs), beta-blockers, angiotensin
II receptor blockers (ARBs) and calcium channel
blockers (CCBs), depending on stages and severity of
the disease. ARBs represent the newer drugs compared
with other conventional agents. Cost-effectiveness
analyses of these drugs can help to better treatment
outcomes.
Objectives: To evaluate the cost-effectiveness of some
commonly used ARBs for the hypothetical population
based on clinical trials and evaluate the cost of these
ARBs in the real life Dutch settings in patients with
essential hypertension.
Methods: The cost-effectiveness analysis was performed
using the Weibull-based accelerated failure time model
for the predictions of cardiovascular events in 1, 3, 5, 7,
10, 15, 20 years with clinical data from the studies by
Giles et al. for the hypothetical population of 100 000
patients with essential hypertension. Drug cost and
cardiovascular complications were discounted at 4.0%
and 1.5% respectively. The outcomes were presented by
net cost per cardiovascular complication averted. For
the real life Dutch settings, drug cost was calculated with
the data recorded at pharmacies from IADB.nl for the
period 1998-2007 and on the basis of drug cost estimates
in 2008 values.
Results: Compared with placebo, complications averted
by olmesartan, losartan and valsartan were 931, 696
and 800 respectively after 5 years; 1375, 994 and 1177
after 10 years; 1507, 1054 and 1287 after 15 years. The
net costs per complication averted by olmesartan,
losartan and valsartan amounted to about €39 000, €56
000, €39 000 respectively after 5 years; €20 000, €30
000 and €20 000 after 10 years; €14 000, €22 000 and
€14 000 after 15 years. The mean daily cost of treatment
with olmesartan, losartan and valsartan amounted to
€0.73, €0.80 and €0.75 respectively for the washout
period of 180 days.
Conclusions: Among three ARBs, olmesartan was more
cost-effective than losartan and valsartan.
146. Preadmission Use of Calcium Channel Blockers
or Beta-Blockers and 30-Day Stroke Mortality
Jens Sundbøll,1,2Morten Schmidt,1,2 Erzsébet Hovath-Puho,1
Christian F Christiansen,1 Lars Pedersen,1 Hans E Bøtker,2
Henrik T Sørensen.1 1Department of Clinical Epidemiology,
Aarhus University Hospital, Aarhus, Denmark;
2Department of Cardiology, Aarhus University Hospital,
Aarhus, Denmark.
Background: The prognostic impact of calcium channel
blockers (CCBs) and beta-blockers (BBs) on stroke
mortality remains unclear.
Objectives: To examine whether preadmission use of
CCBs or BBs is associated with improved short-term
mortality following ischemic stroke, intracerebral hemorrhage
(ICH), and subarachnoid hemorrhage (SAH).
Methods: We conducted a nationwide population-based
cohort study using medical registries in Denmark. We
identiﬁed all patients with a ﬁrst-time inpatient diagnosis
of stroke between 2004 and 2012 and their comorbidities.
We deﬁned CCB/BB use as current use (last prescription
redemption <90 days before admission), former use, and
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nonuse. Current use was further classiﬁed as new or long-
term use. We used Cox regression modeling to compute
30-day mortality rate ratios (MRRs) with 95% conﬁdence
intervals (CIs), controlling for potential confounders.
Results: We identiﬁed 100,043 patients with a ﬁrst-time
stroke. Of these, 83,736 patients had ischemic stroke,
11,779 had ICH, and 4,528 had SAH. Comparing current
users of CCBs or BBs with nonusers we found no associ-
ation with mortality for ischemic stroke (adjusted 30-day
MRR 0.97, 95% CI: 0.92-1.03 and 1.01, 95% CI: 0.96-
1.07, respectively), ICH (1.05, 95% CI: 0.95-1.16 and
0.95, 95% CI: 0.87-1.04, respectively), or SAH (1.06,
95% CI: 0.86-1.30 and 0.89, 95% CI: 0.71-1.11, respec-
tively). However, among current users of CCBs aged
<60 years we found a reduction in 30-day MRR for
ICH (0.63, 95% CI: 0.43-0.94), driven by the effect
among new users (0.41, 95% CI: 0.19-0.88). As well,
we found a reduction in ICH mortality among current
users of BBs aged between 60-69 years (0.71, 95% CI:
0.56-0.91), driven by the effect among long-term users
(0.67, 95% CI: 0.50-0.89). No association with mortality
was found among former users of CCBs or BBs
compared with nonusers.
Conclusions: Preadmission use of CCBs or BBs was not
associated with 30-day mortality among patients with
ischemic stroke, ICH, or SAH. However, a reduction in
mortality following ICH was observed among new users
of CCBs aged <60 years and long-term users of BBs
aged between 60-69 years.
147. Effects of Pitavastatin on Glucose and Lipid
Metabolism in Nondiabetic Patients in a Taiwan
Medical Center
Yu-Chuan Tsai, Chien-Hui Chen, Su-Yu Chien.
Department of Pharmacy, Changhua Christian Hospital,
Changhua, Taiwan.
Background: Statin therapy is effective for reduction of
cardiovascular events and is generally safe and well
tolerated. Pitavastatin has a potent LDL-C-reducing
activity. However, a number of clinical trials have
highlighted a potential association between statin therapy
and an increased risk of developing type 2 diabetes.
Objectives: This study was to evaluate the effects of
pitavastatin on glucose and lipid metabolism in nondiabetic
patients with dyslipidemia.
Methods: The retrospective study of patients receiving
pitavastatin was conducted in Changhua Christian
hospital between June 2013 and January 2014. Study partic-
ipants were nondiabetic outpatients, plasma glucose and
lipid measurements at baseline and again after treatment.
The changes from baseline in glucose metabolism (fasting
plasma glucose, and hemoglobin A1C) and serum lipids
(low-density lipoprotein cholesterol (LDL-C), high-density
lipoprotein cholesterol (HDL-C), triglyceride, and total cho-
lesterol) were compared by performing a paired t-test.
Results: A total of 31 patients were enrolled. 32.1% and
67.9% of patients receiving 2mg/day and 4mg/day of
pitavastatin. The mean duration of the follow-up period
was 157.7 ± 40.6 days. The mean age of patients was
58.6 ± 10.8 years, and 35.5% were male. The average
fasting plasma glucose, hemoglobin A1C, LDL-C,
HDL-C, total cholesterol and triglyceride at baseline
were 100.0±11.5mg/dl, 5.8±0.5%, 140.7±29.9mg/dl,
47.4±13.2mg/dl, 224.0±33.7mg/dl and 146.8±116.5mg/dl,
respectively. After pitavastatin treatment, there were
no signiﬁcant increases in fasting plasma glucose
(+1.3mg/dl, p = 0.43), hemoglobin A1C (+0.02%,
p = 0.89) and HDL-C (+1.6mg/dl, p = 0.22). The signiﬁ-
cant reductions were observed in LDL-C (-31.6mg/dl,
p< 0.001), total cholesterol (-50.2mg/dl, p< 0.001) and
triglyceride (-31.4mg/dl, p = 0.02).
Conclusions: The short-term study showed that pitavastatin
does not signiﬁcantly inﬂuence the glucose regulation and
is effective in decreasing LDL-C, total cholesterol and
triglyceride in nondiabetic patients with dyslipidemia.
148. Calcium Channel Blockers and Gingival Over-
growth: An Intensive Pharmacosurveillance Monitoring
in Chiang Mai, Thailand
Kannika Thiankhanithikun,1 Surapon Nochaiwong,1
Thitima Makaew,2 Pison Sribundit.3 1Pharmaceutical
Care, Faculty of Pharmacy, Chiang Mai University,
Chiang Mai, Thailand; 2Community Pharmacy, Hang
Dong Hospital, Chiang Mai, Thailand; 3Consumer
Protection, Chiang Mai Provincial Public Health Ofﬁce,
Chiang Mai, Thailand.
Background: Calcium Channel Blockers (CCBs) are
widely prescribed for the pharmacological management
of various cardiovascular disorders. Several studies
revealed that gingival overgrowth (GO) is one of the
most cumbersome Adverse Drug Reaction (ADR) of
CCBs. However, the prevalence of this condition remains
uninvestigated in Thailand.
Objectives: To gain insight into the prevalence of
gingival overgrowth of CCBs in daily practice, via an
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intensive ADR monitoring program based at Chiang Mai
Pharmacosurveillance Center, Thailand.
Methods: Within the Chiang Mai Pharmacosurveillance
System Database, ambulatory patients treated with CCBs
were intensively monitored for GO, deﬁned as WHO
Adverse Reactions Terminology (WHOART) code 0296,
through September 2013. A patient was classiﬁed as
having GO if symptoms were present and a dentist had
conﬁrmed the diagnosis. Association between CCBs and
GO was assessed and reported by pharmacists. Only
reports ranked at least “possible” according to Naranjo’s
causality assessment criteria were considered.
Results: Among the follow-up assessment period, 3,850
cases were intensively monitored via 16 community-
hospitals. Within the study population, we identiﬁed
100 case patients with deﬁnite GO [2.60 %; 95%
conﬁdence intervals (95% CI) 2.12-3.15]. Ninety-six
cases were associated with amlodipine-usage [2.81 %],
and four cases were associated with nifedipine-usage
[0.91 %]. The average deﬁned daily dose (DDD) in
accordance with WHO anatomical therapeutic chemical
classiﬁcation system in GO group was 1.25 (range 0.5-4).
Most of them were deﬁned as “non-serious”, required oral
hygiene counseling and periodontal scaling.
Conclusions: Prevalence of GO in an intensively moni-
tored patients was found to be 2.60 %. With the increas-
ing of CCBs users, physicians, dentists, and pharmacists
need to make a cooperated and early detection programs
to reduce the complication of CCB-induced GO.
149. Adverse Drug Reaction Reports for Cardiometa-
bolic Drugs from Sub Sahara Africa: A Study in
VigiBase
Derbew F Berhe,1,2 Kristina Juhlin,3 Kristina Star,3 Flora
M Haaijer-Ruskamp,1 Kidane Michael,4 Katja Taxis,5
Peter GM Mol.1,6 1Clinical Pharmacy and Pharmacol-
ogy, University Medical Center, Groningen, Netherlands;
2Pharmacy, College of Health Sciences, Mekelle Univer-
sity, Mekelle, Tigray, Ethiopia; 3WHO Collaborating
Centre for International Drug Monitoring, Uppsala Mon-
itoring Center, Uppsala, Sweden; 4Pharmacovigilance
Center, FMHACA, Addis Ababa, Ethiopia; 5Pharmaco-
therapy & Pharmaceutical Care, Faculty of Mathematics
and Natural Sciences, University of Groningen, Gro-
ningen, Netherlands; 6Dutch Medicines Evaluation
Board, Utrecht, Netherlands.
Background: Many pharmacovigilance centers have
been established in Sub Sahara Africa (SSA) in recent
years. Their focus has been on ADRs to drugs for
communicable diseases. Little is known about ADRs
caused by drugs for cardiometabolic diseases, although
its burden is increasing rapidly in SSA.
Objectives: Identify characteristics of cardiometabolic
ADR reports in SSA comparing those with reports from
the rest of the world (ROW).
Methods: Reports on suspected ADRs of cardiometabolic
drugs (ATC: A10 [antidiabetes], B01 [antithrombotics]
and C [cardiovascular]) were extracted from the WHO
Global Individual Case Safety Report database, VigiBase
(1992-2013). We used vigiPoint, a logarithmic-odds ratios
(logOR) based method to study disproportional reporting
between SSA and ROW. To identify the most case deﬁn-
ing features, characteristics were only considered relevant
if the lower limit of the 99% conﬁdence interval> 0.5.
Results: In SSA, 3,773 (9%) of reported ADRs were for
cardiometabolic drugs compared to 18% in ROW. Of
these, 79% originated from South Africa and 81% were
received after 2007. Most reports were for drugs acting
on the renin-angiotensin system (36% SSA & 14%
ROW), lipid modifying agents (18% & 20%), antidia-
betics (14% & 18%), antithrombotics (13% & 20%)
and calcium channel blockers (5.1% & 7.4%).
Physicians reported ADRs more frequently (83% SSA
vs 50% ROW; logOR 2.2 [99CI 2.1;2.3]) in SSA.
Reports were more often for patients 18-44 years old
(logOR 0.95 [99CI 0.80;1.09]) or had a non-fatal
outcome (logOR 1.16 [99CI 1.10;1.22]). We found
disproportional reporting for a cluster of 6 ADRs (cough,
angioedema, lip swelling, face oedema, swollen tongue,
throat irritation) related to ACE-inhibitors and for
enalapril and perindopril; as well as for 2 other ADRs
(drug ineffective, blood glucose abnormal) and 4 drugs
(rosuvastatin, nifedipine, insulin glulisine and insulin lispro).
Conclusions: ADR reporting for cardiometabolic drugs
has sharply increased in SSA in recent years. The reports
clearly show the well-known differential ADR proﬁle of
ACE-i in the black population. Our data would also
suggest that other drugs show different risk proﬁles,
e.g some insulins.
150. The Use of Pillbox and Time in Therapeutic
Range Among New Users of Warfarin: A Propective
Cohort Study
Stéphanie Dumas,1 Étienne Rouleau-Mailloux,2 Nawal
Bouchama,1 Halima Lahcene,1 Jean-Claude Tardif,2
Mario Talajic,2 Marie-Pierre Dubé,2 Sylvie Perreault.1
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1Faculty of Pharmacy, University of Montréal, Montréal,
QC, Canada; 2Beaulieu-Saucier University of Montreal
Pharmacogenomics Centre, Montréal Heart Institute,
Montreal, QC, Canada.
Background: Warfarin, a widely prescribed oral antico-
agulant, is well known to have a narrow therapeutic
index. Many studies conﬁrmed that adherence helps to
achieve a stabilization of the INR, but little data is
available on the impact of the use of a pillbox.
Objectives: The objective of this study is to evaluate the
association between the use of a pillbox among new
warfarin-users and time in therapeutic range (TTR).
Methods: This study was based on a prospective cohort
of new warfarin-users which aims to assess the genetic,
clinical and environmental risk factors associated with
the effectiveness and safety of warfarin. Demographic
and clinical data were collected among a subgroup of
702 patients who began the treatment between May 1st,
2010 and Aug. 31st, 2012 at one of 18 hospitals in
Quebec, Canada. Patients were followed-up each three
months up to a year after the initiation of warfarin. Our
outcome was the TTR and it was tested using a mixed
linear model to allow for repeated measures.
Results: Mean age was 70.0 ± 11.6, 60.1% were men,
79% had atrial ﬁbrillation as a primary indication for
warfarin, 67.9% had hypertension and 61.1% had
dyslipidemia. Of these patients, 47.2%, 53.1%, 56.1%
and 60.4% used a pillbox at 3, 6, 9 and 12months,
respectively. Patients who used their own pillbox
(approximately 75% of pillbox users) had a higher TTR
than non-users (3.7%, p = 0.03). These results were
adjusted for the INR target, age, number of concomitant
drugs and patient-reported dose of warfarin as these co-
variates were signiﬁcantly associated with the outcome.
Conclusions: There is a signiﬁcant association between
the use of a pillbox prepared by the patient and a higher
TTR. The use of this device may improve the stability
of patients taking warfarin.
151. Excellent Outcome of Intensive Medical Care
for Type B Aortic Dissection – A Single-Center
Retrospective Study
Shih-Han Wang,1 Chaw-Chi Chiu,2,3 Jiann-Woei
Huang,2 Chung-Yu Chen,4 Yaw-Bin Huang.4,5 1Master
Program in Clinicla Pharmacy, School of Pharmacy,
Kaohsiung Medical University, Kaohsiung, Taiwan;
2Division of Cardiovascular Surgery, Kaohsiung Medical
University Hospital, Kaohsiung, Taiwan; 3School of
Medicine, Kaohsiung Medical University, Kaohsiung,
Taiwan; 4School of Pharmacy, Kaohsiung Medical
University, Kaohsiung, Taiwan; 5Department of Pharmacy,
Kaohsiung Medical University Hospital, Kaohsiung,
Taiwan.
Background: Stanford type B aortic dissection (TBAD)
is a life-threatening disease associated with high rates of
mortality. Anti-impulse medical therapy has remained
the preferred treatment for uncomplicated TBAD, but
mortality of TBAD using intensive medical care is still
unclearly in Asian population.
Objectives: To estimate mortality of TBAD patients with
intensive medical care in a single medical center.
Methods: We conducted a retrospective chart review of
patients over 18 years old diagnosed TBAD from 2011
to 2012. The cohort was followed until death, last chart
record, or end of follow-up (12/31/2013). We deﬁned
intensive medical care as systolic blood pressure (SBP)
110mmHg and heart rate(HR)< 60 beats/min when
patients admitted to cardiovascular surgery intensive care
unit. β-blockers and/or calcium channel blockers (CCBs)
were ﬁrst prescribed to control SBP and HR. Patients
returned for follow-up monitoring and 3-month interval
contrast computed tomography scanning after discharge.
We identiﬁed baseline characteristics and death by
reviewing chart, and using descriptive statistics to
summarize the baseline characteristics and mortality.
Results: We identiﬁed 44 TBAD patients (mean age 64,
86% male) with intensive medical care, 27% patients had
intramural hematoma, 41% patients were current
smoker, and the length of observation was 20.0months
(SD= 11.9). The most common comorbidities for TBAD
were hypertension (93%), diabetes (14%), and coronary
artery disease (14%). During the study period, patients
average used 2.7 different antihypertensive drugs, most
were b-blockers (89%), CCBs (73%), and angiotensin
receptor blockers (39%). The in-hospital mortality and
1-year mortality were 2.4% and 5.0%, respectively.
According to previous studies, in-hospital mortality and
1-year mortality were about 10% and 30%. We found
that mortality is lower in our study.
Conclusions: Our results show that mortality of TBAD
under intensive medical treatment is lower than previous
studies. Further studies will be carried out in a longer
period to investigate the reasons, including other relevant
outcomes, such as AD-related mortality and late aortic
reoperation rate.
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152. A Population-Based Study of the Drug Interaction
between Clarithromycin and Statins
Bita Mesgarpour,1,2 Ghazaleh Gouya,1 Harald Herkner,3
Berthold Reichardt,4 Michael Wolzt.1 1Department of
Clinical Pharmacology, Medical University of Vienna,
Vienna, Austria; 2Pharmaceutical Policy Research
Centre, Tehran University of Medical Sciences, Tehran,
Islamic Republic of Iran; 3Department of Emergency
Medicine, Medical University of Vienna, Vienna,
Austria; 4Burgenländische Gebietskrankenkasse, Eisenstadt,
Austria.
Background: Co-administration of clarithromycin,
known as a potent inhibitor of CYP3A enzyme, and some
HMG-CoA reductase inhibitors (statins), known to be
CYP3A enzyme substrates, may increase plasma concen-
tration of statins. Clarithromycin is also metabolized by
CYP3A4 and may compete with these statins for the
enzyme. Therefore, co-administration of these two
medications may increase the risk of adverse events.
Objectives: To determine whether the concomitant use of a
statin with clarithromycin is associated with serious outcomes.
Methods: We established a retrospective cohort of adult
patients in the Regional Health Insurance Institution of
Burgenland, Austria who ﬁlled a prescription for
clarithromycin from Jan. 1, 2010 to July 30, 2012. We
deﬁned exposed patients as those who were treated with
clarithromycin and had overlapping treatment with a
statin at least for one day as opposed to unexposed
controls who had been prescribed clarithromycin with
no statins. Outcome was deﬁned as a composite of
hospital admission or death within 30 days after starting
clarithromycin. We used logistic regression to model
association between the outcome and the exposure to
statins. We allowed for within patient correlation by
including a random effects error term and adjusted for
potential confounding by including predeﬁned covariates
into the model and tested for ﬁrst order interactions.
Results: Among 28,484 prescriptions of clarithromycin,
we identiﬁed 2,317 patients exposed to co-administered
statins. Statin and clarithromycin co-administration was
associated with 2.3 times increased odds of death or
hospitalisation (95% conﬁdence interval [CI] 1.9- 2.7).
This effect was almost entirely explained by, age,
diabetes and cardiovascular disease (multivariable
adjusted odds ratio [OR] 1.01, 95%CI 0.84–1.21). The effects
did not differ signiﬁcantly by CYP3A enzyme metabolised
statins type (simvastatin, lovastatin, pravastatin and atorva-
statin versus rosuvastatin and ﬂuvastatin, p=0.39).
Conclusions: Among patients receiving clarithromycin,
concomitant therapy with statins was not causally associ-
ated with an increased risk of hospitalisation and death.
153. Regional Variations in Physician Case Volume
and Outcomes for Carotid Artery Stenting (CAS) vs.
Carotid Endarterectomy (CEA)
Hiraku Kumamaru,1,2 Jessica J Jalbert,2,3 Louis L Nguyen,4
Soko Setoguchi.5 1Epidemiology, Harvard School of Public
Health, Boston, MA, United States; 2Division of
Pharmacoepidemiology and Pharmacoeconomics, Brigham
and Women’s Hospital, Harvard Medical School, Boston,
MA, United States; 3LA-SER Analytica, LA-SER
Analytica, NY, NY, United States; 4Department of
Vascular and Endovascular Surgery, Brigham and
Women’s Hospital, Harvard Medical School, Boston,
MA, United States; 5Duke Clinical Research Institute,
Durham, NC, United States.
Background: Greater physican case volume for carotid
endarterectomy (CEA) and carotid artery stenting
(CAS) are associated with more favorable outcomes.
After the 2005 National Coverage Determination
reimbursing CAS for Medicare beneﬁciaries, CAS is
now performed throughout the US, but the number is still
small. We hypothesized that CAS was more likely to be
performed by low case volume physicians compared to
CEA in some geographic areas, causing regional varia-
tions in clinical outcomes.
Objectives: To evaluate regional variations in physician
case volume for CAS and CEA and its association with
regional mortality risk.
Methods: We identiﬁed inpatient CEA and CAS proce-
dures and performing physicians in 2007-2008 Medicare
ﬁles. We calculated physician case volume as the number
of past-year CAS or CEA and classiﬁed physicians with
<10 cases as low volume. We calculated the proportion
of CAS or CEA procedures performed by low case
volume physicians in each hospital referral regions
(HRRs), an empirically deﬁned regional health care
markets, and categorized HRRs into 5 levels (0-20,
21-40, 41-60, 61-80, >80%) based on the proportion.
We compared 30-day mortality risk for CAS and CEA
across HRRs with different proportions of low case
volume physicians.
Results: We identiﬁed 94,838 and 13,430 Medicare
beneﬁciaries in 306 and 280 HRRs undergoing CEA
and CAS, respectively. HRRs with greater proportion of
low case volume physicians were much more prevalent
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for CAS than for CEA (median proportion: 0.8
(IQR:0.5-1.0) vs. 0.2 (IQR:0.1-0.3)). For CAS, we
observed a decreasing trend in 30-day mortality risk as
the proportion of low case volume physician in HRRs
decreased (from 2.6% in >80% group to 1.3% in 0-20%
group) but not for CEA. This trend persisted after
confounder adjustment.
Conclusions: Compared to CEA, physician case volume
for CAS remains low in many US regions. HRRs with
greater proportions of CAS performed by low case
volume physicians had increased risk of 30-day mortality.
Dissemination of newly introduced procedures such as
CAS may beneﬁt from careful planning of physician
selection and regionalization.
154. Treatment with Statins and Fibrates in Chinese
Type 2 Diabetes Mellitus Patients Initiating Hospital-
ization at the Qingdao Endocrine and Diabetes
Hospital from 2006 to 2012 in Qingdao, China
Lei Zhang,2 Xiaoli Wu,1 Weiguo Gao,1 Qing Qiao,3
Niklas Hammar,3 Claudia Cabrera,4 Yanhu Dong,2 Jia
Wei.1 1R&D information China, Astrazeneca, Shanghai,
China; 2Qingdao Endocrine and Diabetes Hospital,
Qingdao, China; 3Observational Research Centre, Payer
& Real World Evidence, Global Medicine Development,
Astrazeneca RD, Molndal, Sweden; 4Global Regulatory
and Patient Safety Quality Assurance, Global Medicine
Development, Astrazeneca AB, Molndal, Sweden.
Background: Few studies were performed to examine
dyslipidemia management in Chinese patients with type
2 diabetes (T2DM).
Objectives: To study the frequency of prescriptions of
lipid lowering drugs to patients with T2DM who were
hospitalized in the Qingdao Endocrine and Diabetes
Hospital for the ﬁrst time from 2006 to 2012 and to
identify factors that may affect treatment selections.
Methods: Electronic medical records (EMR) of 12,361
(6,696 men) T2DM patients, who were newly admitted
to the Hospital, were collected and analyzed. Information
on demographic, anthropometric and laboratory measure-
ments, and lipid lowering drugs administrated to patients
were extracted from EMRs. Diagnoses of diabetes,
dyslipidemia, and cardiovascular events were based on
international standard diagnostic criterion.
Results: On average, 63% of patients were prescribed
statins, 11% ﬁbrates, and only 0.4% with both. Only
2 patients received ezetimibe treatment, and 25% of
patients with elevated lipid didn’t receive any medica-
tions. This observed treatment pattern was not substan-
tially changed over past 6 years. Social Medical
Insurance (SMI) beneﬁciaries received more statins
(64%) than those who were covered by commercial
insurances (61%, X2 = 19.37, p = 0.03). The treatment
decision didn’t appear to be associated with baseline
measures collected upon admission to the Hospital
(gender, occupation, education, prior history of cardio-
vascular disease, current diagnosis of coronary heart
disease or peripheral artery atherosclerosis, body mass
index, glucose or blood pressure).
Conclusions: In this diabetic patient cohort, statins
monotherapy was most frequently observed, followed
by ﬁbrates monotherapy. The rate of dual medication
with statins and ﬁbrates was extremely low. SMI beneﬁ-
ciaries were more likely to receive a prescription of
statins. The treatment pattern remained unchanged
throughout the study period. It is noticed that a quarter
of the diabetic patients with elevated lipid didn’t receive
any lipid lowering treatment during their hospitalization.
155. Evaluation for Statin Usage in Taiwan by Using
National Health Insurance Claim Database
Grace Hui-Min Wu,1,2 Yu-chiao Wang,1 Yong-chen
Chen.1,3 1Division of Health Technology Assessment,
Center for Drug Evaluation, Taipei, Taiwan;
2Department of Physical Therapy and Assistive
Technology, National Yang-Ming University, Taipei,
Taiwan; 3Graduate Institute of Life Sciences, National
Defense Medical Center, Taipei, Taiwan.
Background: HMG-CoA reductase inhibitors (statins)
have become major drug expenditure of the National
Health Insurance (NHI) in Taiwan.
Objectives: The study aims to evaluate the statins usage
by using NHI claim database to ensure its utilization both
complying with evidence-based medicine, and being in
an efﬁcient way while considering the treatment cost.
Methods: Systematic review was conducted to investi-
gate the comparative efﬁcacy, and safety of the six
current NHI-covered statins including atorvastatin,
ﬂuvastatin, lovastatin, pravastatin, rosuvastatin, and
simvastatin. Following the clinical practice in Taiwan,
reduction in low-density lipoprotein cholesterol (LDL-C)
levels was chosen as the efﬁcacy indicator. Based on the
comparative efﬁcacy, the daily cost of statins was
compared. Utilizations of the six statins were examined
using the NHI claim database during 2001 to 2011.
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Results: The equivalent therapeutic doses in terms of
LDL-C reduction between different statins have been
established by one recent well-conducted meta-analysis.
Accordingly, the daily costs of statins with similar
potency have been found varied widely; some statins
which reduce LDL-C less are more costly than those
which reduce LDL-C more. During 2001 to 2011, the
total expenditure of statins increased rapidly as the total
claims of statins increased. The market share changed
largely as atorvastatin and rosuvastatin have got reim-
bursed successively in 2001 and 2005, and then became
the two dominant statins, which together accounted for
60% of the total consumption in 2011. The mean daily
dose of atorvastatin sharply increased right after its
higher dose product entered into the market. Generic
product of some statins are commonly prescribed, how-
ever, the expenditure did not reduce much after generic
substitution because the price difference between generic
and brand statins is not large (~20%).
Conclusions: The daily cost of statins does not corre-
spond to its potency in terms of LDL-C reduction well,
and the commonly prescribed statins were not those with
the lowest cost given similar potency. These indicate the
efﬁciency of statins usage may need further improvement.
156. Patterns of Chronic Use of Angiotensin-
Converting Enzyme Inhibitor or Angiotensin Receptor
Blocker in Pre-Dialysis Chronic Kidney Disease
Patients with Anemia
Chi-Tai Yen,1,2 Ming-Cheng Wang,1,3 Tzu-Chieh Lin,1
Yea-Huei Kao Yang.1 1Institute of Clinical Pharmacy
and Pharmaceutical Sciences, National Cheng Kung
University, Tainan, Taiwan; 2Internal Medicine, Ministry
of Health and Welfare Tainan Hospital, Tainan, Taiwan;
3Internal Medicine, National Cheng Kung University
Hospital, Tainan, Taiwan.
Background: Angiotensin-converting enzyme inhibitor
(ACEI) or angiotensin receptor blocker (ARB) is the
main therapy to retard chronic kidney disease (CKD)
progression. The information of actual and persistent
use of ACEI or ARB in pre-dialysis patients with anemia
was scarce.
Objectives: To investigate the patterns of chronic use of
ACEI or ARB in pre-dialysis CKD patients with anemia.
Methods:We included 36,673 pre-dialysis CKD patients
with anemia from the national health insurance research
database from 2002 to 2009, and the index date was the
initiation of erythropoietin (EPO) use. According to the
reimbursement schemes, EPO is only reimbursed for
CKD patients if their serum creatinine levels were
greater than 6mg/dl and hematocrit levels were less
than 28%. We excluded patients receiving dialysis
therapy or renal transplants during the baseline
period. Each patient was followed from index date
till entering dialysis, death or the end of the study.
Chronic ACEI or ARB users were deﬁned as the last
persistent use of ACEI or ARB before entering
dialysis, with length of duration longer than 90 days
and gap less than 30 days.
Results: 14,851 of 36,673 patients (40.5%) were ACEI
or ARB chronic users. They were younger (mean age
62.9 years), more prevalent in DM (60.4%), HTN (70.8%
with more than 3 antihypertensive) and cardiovascular
disease comparing with total pre-dialysis patients with
anemia. We further divided chronic ACEI or ARB users
into four groups by the time point of consistent use: >
90days before index date(15.6%), ≤ 90days before index
date(9.8%), ≤ 90days after index date(23.3%), > 90days
after index date(51.3%). The median length of persistent
use was 224 days, 261 days, 280 days, and 294 days,
respectively. Patients in the 4th group were younger, had
less comorbid condition and less usage of diuretics, insulin
and statin as compared to the other 3 groups.
Conclusions: 30% of pre-dialysis CKD patients with
anemia consistently used ACEI or ARB before entering
dialysis, and patients with less usage of diuretics, insulin
and statin had the most persistent use.
157. The Incidence of Actinic Keratosis and Risk of
Non-Melanoma Skin Cancer in Taiwan
Chi-Feng Hsieh,1 Weng-Foung Huang,1 Yi-Ting
Chiang.1 1Institue of Health and Welfare Policy,
National Yang Ming University, Taipei, Taiwan;
2Institue of Health and Welfare Policy.
Background: Actinic keratosis (AK), also known as
solar keratosis, are common lesions representing a step
in the development of squamous cell carcinoma. The
AK brought the growing numbers of affected people
and the economic burden of treatment. It is important to
treat patients with actinic keratosis to prevent malignant
conversion. However, there is no population-based study
focusing on the Actinic keratosis regarding among Asian
population.
Objectives: To investigate the incidence, the distribu-
tion, and the treatment types of AK in Taiwan. The risk
of AK to malignant neoplasm were also evaluated.
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Methods:We designed a nationwide retrospective cohort
study using the 2000 Longitudinal Health Insurance
Database (LHID) to study this during 1999 to 2010.
The inclusion criteria were as follows: (1) patients who
had one outpatient visits with a diagnosis of AK Interna-
tional Classiﬁcation of Disease-Clinical (ICD-9-CM)
code (702.0) identiﬁed by dermatologist; (2) patients
who had at least two outpatient visits or one hospital
admission with a diagnosis of AK. The Cox proportional
hazards model was used to evaluate whether AKs is an
important risk factor for skin malignant neoplasm.
Results: The overall incidence rate for AK from 2000 to
2010 ranged from 2.27 to 3.75 per ten thousands people.
We found the incidence rate for AK for those aged 65
and older (range from 7.76 to 14.04) was higher than
those less than 65 years old (range from 1.24 to 2.67).
Fifty night percent were female, 45.1% were elderly
people, 54.9% lived in southern Taiwan and others area,
48.2% had cryotherapy surgery, 8.0 % had electro
cauterization, 8.8% had excision of skin, and 4.6% had
excision of facial skin. Thirty-six patients of skin
malignant neoplasm were identiﬁed after diagnosis of AK.
Conclusions: The AK incidence rate was low in general
population but particular high in elderly population in
Taiwan. Our ﬁndings warrants further investigation into
the relationship between actinic keratosis treatments and
the NMSC in Asians and may affect the approach we take
toward primary prevention of NMSC in Asians with AK.
158. Compliance with Pregnancy Prevention Recom-
mendations in 7,663 French Women of Childbearing
Age Exposed to Acitretin
Fanny Raguideau,1 Myriam Mezzarobba,2 Mahmoud
Zureik,1 Alain Weill,2 Philippe Ricordeau,2 François
Alla.2 1Departement of Epidemiology of Health
Products, French National Agency for Medicines
(ANSM), Saint-Denis, France; 2Department of Public
Health Studies, French National Health Insurance
Fund for Employees (CNAMTS), Paris.
Background: Acitretin is an oral synthetic aromatic
analogue of retinoic acid available in most European
countries since 1988. It’s used mainly for treatment of
severe forms of psoriasis. Like all systemic retinoids,
acitretin is teratogenic. Due to transesteriﬁcation of
acitretin to etretinate, a metabolite with longer half-life,
in presence of ethanol, pregnancy should be avoided
for at least 2 years after treatment discontinuation.
Strict pregnancy prevention in female acitretin users of
childbearing age is required.
Objectives: To assess compliance with pregnancy preven-
tion recommendations, speciﬁcally looking at pregnancy
testing (PT) compliance and pregnancy occurrence.
Methods: A cohort of 7,663 women aged 15-49 years
initiating an acitretin treatment from January 2007 to
December 2012 was identiﬁed using French SNIIRAM
(reimbursement data) and PMSI (hospitalisations data)
databases. Pregnancy Tests (PTs) were identiﬁed from
reimbursed serum (β) HCG laboratory PTs. In order to
fulﬁl PT criteria, patients who started treatment needed
to have a PT performed 3 or fewer days before they
bought acitretin. Pregnancies were identiﬁed based on
hospital stay related to a pregnancy or outpatient’s
medicinal abortion.
Results: A pregnancy test was performed in only 11% of
initiation and rarely performed during treatment or during
the 24months period following treatment discontinua-
tion. Compliance to the pregnancy prevention recom-
mendations seemed somewhat better by dermatologists
while remaining very weak, with a PT performed in
15.0 % of initiation (vs. 3.6% for general practitioners, p
0.001). Moreover, 357 pregnancies were reported
corresponded to 25 pregnancies per 1,000 person-years
at risk of teratogenicity.
Conclusions: This study showed the non-compliance of
pregnancy prevention recommendations of acitretin
treatment in France. Physicians, pharmacists and patients
should be better informed about acitretin’s risk of teratoge-
nicity and these pregnancy prevention recommendations.
159. Utilization Pattern of Phosphodiesterase Type 5
(PDE5) Inhibitors for Erectile Dysfunction among
Commercially Insured Adults in the United States
Wei Liu,1 Philipp Dahm,2 Tobias Gerhard,3 Patrick
Antonelli,1 Joseph Chris Delaney,4 Almut G
Winterstein.1 1Pharmaceutical Outcomes and Policy,
University of Florida, Gainesville, FL, United States;
2Urology, University of Florida, Gainesville, FL, United
States; 3Institute of Health, Health Care Policy and
Aging Research, Rutgers University, New Brunswick, NJ,
United States; 4Epidemiology, University of Washington,
Seattle, Washington, United States.
Background: With the emergence of Phosphodiesterase
type 5 (PDE5) inhibitors, erectile dysfunction (ED)
has become an increasingly recognized and widely
treated condition. However, only limited information is
available regarding real-world utilization pattern of
PDE5 inhibitors.
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Objectives: The objective of this study was to evaluate
utilization pattern using commercial health plan data for
patients using PDE5 inhibitors for management of ED.
Methods: This was a retrospective analysis conducted in
the MarketScan® Commercial Claims and Encounter
(CCAE) data from 1998-2007. Adult patients 18-64
years old with an initial or recurrent pharmacy dispensing
claim of sildenaﬁl, vardenaﬁl, or tadalaﬁl were identiﬁed.
Descriptive analysis examined the prevalence, incidence
of use, switching and dose titration associated with index
medication selection.
Results: There were about 4.4 million pharmacy claims
for PDE5 inhibitors during 1998-2007 for 610,433
individuals in the CCAE data. The overall prevalence
of PDE5 inhibitor use increased by 44% from 16.4
(1998) to 29.5 (2007) per 1,000 male adult members.
The incidence of PDE5 inhibitor use increased from
11.5 new prescription ﬁlls per 1,000 person-years in
1998 to 18.6 per 1,000 person-years in 2007. Both
prevalence and incidence of use increased in elder
patients. Tadalaﬁl was increasingly being marketed to
patients since it was approved by the FDA in 2003.
About 60% of patients reﬁlled their PDE5 inhibitor
prescription within 6months after they initiated the
therapy. Only 4-6% of PDE5 inhibitor users switched
medication during the same period regardless of which
PDE5 inhibitor they were prescribed initially.
Conclusions: The study suggested that there is a wide
adoption and use of PDE5 inhibitor for ED among
commercially insured adults in the United States. Future
prospective studies are required to evaluate the compara-
tive safety and effectiveness of these medications.
160. A Survey on the Utilization Pattern and Adverse
Events of Oral Contraceptives in Korean Women Aged
20 to 49 Years
Hye-Yeon Um,1 Hyun-Jung Kim,1 Hyun-Joo Jung,1
Sun-Young Jung,1 Byung-Joo Park.1,2 1Korea Institute
of Drug Safety and Risk Management, Seoul, Republic
of Korea; 2Department of Preventive Medicine, Seoul,
Republic of Korea.
Background: Safety issues of contraceptives have been
raised continuously by safety letters, media reports and
so on. Thus, we conducted the survey on drug utilization
patterns and adverse events in prior contraceptive users.
Objectives: The aim was to estimate the utilization
patterns and the safety of oral contraceptives including
oral contraceptive pills(OCPs) and Emergency contra-
ceptive pills(ECPs).
Methods: We conducted telephone interview survey for
1,500 women aged 20-49, who have ever used OCPs or
ECPs. The participants were selected by proportionally
allocated stratiﬁed sampling according to the age and
regional distribution of whole Korean population. A
standard questionnaire was composed of three parts
including social-demographic characteristics, drug usage
pattern and adverse events experience. We classiﬁed
research participants into three groups as only OCPs
users group, only ECPs users group and both users
group. The sample proportions were calculated using
the data and population parameters were estimated using
95% conﬁdence intervals.
Results: Of 1,500, 1,139(75.9%, 95% CI : 73.8-78.1)
respondents were only OCPs users, 88(5.9%, 95% CI :
4.7-7.1) respondents were only ECPs users and 273
(18.2%, 95% CI : 16.2-20.2) respondents were both
users. 416(27.7%, 95% CI : 25.5-30) respondents
experienced adverse events which occurred after taking
OCPs or ECPs. 293(25.7%, 95% CI : 23.2-28.3) of only
OCPs users, 13(14.8%, 95% CI : 7.4-22.2) of only ECPs
users and 110(40.3%, 95% CI : 34.5-46.1) of both users,
have experienced adverse events more than once. The
most commonly reported adverse event was nausea.
Conclusions: Among all respondents, the proportion of
only OCPs users was higher than only ECPs users. About
one third of oral contraceptive users experienced adverse
events induced by OCPs or ECPs. Further studies will be
needed to estimate more valid estimates of proportion of
women using oral contraceptives in general population
using more representative sample, and to evaluate causal
association between oral contraceptives use and adverse
events using cohort study design.
161. The Risk of Major and Any (non-Hip) Fracture
after Hip Fracture in the United Kingdom: 2000 – 2010
Corinne Klop,1 Deborah Gibson-Smith,1 Petra JM
Elders,2 Natasja van Schoor,3 Paco MJ Welsing,4 Hubert
GM Leufkens,1 Nicholas C Harvey,5 Tjeerd P van Staa,1
Frank de Vries.1 1Utrecht Institute for Pharmaceutical
Sciences, Utrecht University, Utrecht, Netherlands;
2Department of General Practice, VU University Medi-
cal Center, Amsterdam, Netherlands; 3Department of
Epidemiology and Biostatistics, VU University Medical
Centre, Amsterdam, Netherlands; 4Julius Center for
Health Sciences and Primary Care, University Medical
Center Utrecht, Utrecht, Netherlands; 5MRC Lifecourse
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United Kingdom.
Background: Hip fractures are associated with subse-
quent fractures, particularly in the year following initial
fracture. Age-adjusted hip fracture rates have stabilized
in many developed countries, but secular trends in subse-
quent fracture remain poorly documented.
Objectives: To examine secular trends (2000 – 2010)
and determinants for the risk of a subsequent major and
any (non-hip) fracture after hip fracture.
Methods: Patients ≥50 years with a hip fracture between
2000-2010 were extracted from the United Kingdom
Clinical Practice Research Datalink (n = 30,516). Patients
were followed from the date of hip fracture until the
occurrence of a major (spine, forearm, upper arm) fracture
or right censoring (death, withdrawal from the database or
end of data collection [31 December 2011]), whichever
came ﬁrst. This was done separately for any (non-hip) frac-
ture. Cumulative incidence probabilities (%) and adjusted
Hazard Ratios (aHRs) with 95% Conﬁdence Intervals
(95% CIs) for subsequent major and any (non-hip) fracture
were calculated by Kaplan-Meier life-table analyses and
time-dependent Cox regression, respectively.
Results: Within one year following hip fracture 2.7%
and 8.4% of patients sustained a major or any (non-hip)
fracture and 21.5% died. The cumulative incidence
probability for a major or any (non-hip) fracture in-
creased to 14.7% and 32.5% after ﬁve years. The most
important risk factors for a subsequent major fracture
within one year were female gender (aHR 1.90; 95%
CI: 1.51-2.40) and older age (70-79 years compared with
50-59 years) (aHR 1.60; 95% CI 1.04-2.49). The annual
risk of subsequent major and any (non-hip) facture was
stable until 2007 after which there was a sharp increase.
Conclusions:The risk of sustaining amajor or any (non-hip)
fracture in the year after hip fracture is small when compared
with competing mortality. From a clinical point of view re-
ducing mortality should have priority. However, given the
recent rise in secondary fracture rates and the substantial risk
of subsequent fracture in the longer term, fracture prevention
is clearly indicated for patients with a longer life expectancy.
162. Use of Non-Steroidal Anti-Inflammatory Drugs
and Risk of Chronic Kidney Disease in Subjects with
Type 2 Diabetes Mellitus
Ya Wen Huang,1 Hui Ju Tsai,1 Yueh Han Hsu,2 Yu Kang
Chang,1 Jia Sin Liu,1 Chih Cheng Hsu.1 1Institute of
Population Health Sciences, National Health Research
Institutes, Miaoli County, Taiwan; 2Department of
Internal Medicine, Ditmanson Medical Foundation
Chia-Yi Christian Hospital, Chia-Yi City, Taiwan.
Background: At present, our understanding about whether
the use of non-steroidal anti-inﬂammatory drugs (NSAIDs)
can lead to kidney dysfunction remains inconclusive.
Objectives: In the present study, we aimed to investigate
the temporal relationship between NSAIDs use and the
development of chronic kidney disease (CKD) in
subjects with type 2 diabetes mellitus (T2DM).
Methods:
• Design: We conducted a retrospective cohort
study using the data from the Longitudinal Health
Insurance Database for the year 2005 (LHID2005)
that was derived from the National Health Insurance
Research Database (NHIRD) of 2005.
• Setting: A total of 57,463 subjects aged 20 and above
and with T2DM were included in this study.
• Main outcome measures: Subjects with newly
diagnosed CKD.
• Statistic analysis: We applied multivariate propor-
tional hazards models to determine the temporal rela-
tionship between NSAIDs use and CKD development.
Results: We observed a signiﬁcant temporal relationship
between NSAIDs use and CKD development in subjects
with T2DM. Compared to subjects not taking any NSAIDs
in 2007, subjects taking NSAIDs for at least 90 days in
2007 had a higher risk of CKD development (adjusted
hazard ratio (AHR)= 1.29; 95%CI: 1.20–1.40). In
subgroup analyses, subjects (irrespective of age, sex, vari-
ous comorbidities, and use of antihypertensive drugs, aspi-
rin, or acetaminophen) taking NSAIDs for at least 90 days
were more likely to develop CKD than subjects taking
NSAIDs for less than 90 days or not taking NSAIDs.
Conclusions: The results suggest that there is a positive
temporal relationship between NSAIDs use and increased
risk of CKD in subjects with T2DM. The use of NSAIDs
should be based on clinical evaluations of beneﬁts and
risks, and should be prescribed with caution, particularly,
among subjects at high-risk for CKD.
163. Comparing Prescribing Pattern between Bisphos-
phonate and Raloxifene in Osteoporosis Patients
Jungmee Kim,1 Joongyub Lee,2 Ju-Young Shin,3
Hong-Ji Song,4 Nam-Kyong Choi,2 Byung-Joo Park.3
1Department of Preventive Medicine, College of Medicine,
Seoul National University, Seoul, Republic of Korea;
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2Medical Research Collaborating Center, Seoul National
University Hospital and Seoul National University
College of Medicine, Seoul, Republic of Korea; 3Korea
Institute of Drug Safety and Risk Management, Seoul,
Republic of Korea; 4Department of Family Medicine,
College of Medicine, Hallym University, Chuncheon,
Republic of Korea.
Background: Primary osteoporosis is irreparable in such
aspect that it results from aging and postmenopausal change.
Objectives: While medication is the major approach in
managing osteoporosis, this study aims to evaluate the
prescription pattern of two major osteoporosis treatments,
bisphosphonate and raloxifene in Korea using the Health
Insurance Review and Assessment Service-National
Patients Sample (HIRA-NPS) database of the year 2010.
Our concern is the proportion of two medications and the
characteristics of two groups including their comorbidities,
types of healthcare institutions, and physician’s specialties.
Methods: The HIRA-NPS database is a representative
database of the total population, stratiﬁed and systematic ran-
dom sampled for gender and age consisting 1,457,409, that
is, 3% of the overall population. The study subjects were
osteoporosis patients with both diagnosis of primary osteo-
porosis and prescriptions of bisphosphonate or raloxifene.
Results: The ﬁnal subjects were 29,025 and 92.3% were
women. There were more women and younger patients in
the raloxifene group and the comorbidities were similar in
both groups except that bisphosphonate recipients had
higher numbers of secondary osteoporosis related underly-
ing conditions and osteoarthritis. The proportion of breast
cancer patients was about the same between the two groups.
While bisphosphonates were more prescribed in primary
care clinics, raloxifene was more prescribed in tertiary care
institutions. Themajority of prescriptions of both drugs were
issued from the orthopedics and that proportion was higher
in the bisphosphonate group. The regional distribution of
both prescriptions showed difference among different cities
and provinces regardless of the percentage of Medical Aid
population or social and economic infrastructure.
Conclusions: There were some differences in demo-
graphic and clinical characteristics between bisphospho-
nate and raloxifene recipients.
164. Research on Asian Psychotropic Prescription
Patterns for Antidepressants II: REAP–AD 2013
Shu-Yu Yang,1 Mian-Yoon Chong,2 Yi-Hsin Yang,3
Shih-Ku Lin,1 Kuan-Pin Su,4 Tsung-MingHu.5 1Department
of Pharmacy, Taipei City Hospital, Taipei, Taiwan, Taiwan;
2Chang Gung Memorial Hospital, Kaohsiung, Taiwan,
Taiwan; 3Kaohsiung Medical University, Kaohsiung,
Taiwan, Taiwan; 4China Medical University Hospital,
Taichung, Taiwan, Taiwan; 5Yuli Veterans Hospital,
Hualien, Taiwan, Taiwan.
Background: Antidepressant use in Asia is poorly docu-
mented. This is a part of the international collaborative study
“Research on Asian Psychotropic Prescription Patterns for
Antidepressant II, REAP-AD 2013”. To assess the trend and
change of psychotropic drug use for patients with depression.
Objectives:The present studywill review the prescription pat-
terns of antidepressants in different countries/regions in Asia.
Methods: The survey was conducted in China, Hong
Kong, India, Indonesia, Korea, Malaysia, Singapore,
Taiwan, and Thailand on January 1 - May 31, 2013 using
the uniﬁed research protocol and questionnaire. The rates
of use of older (pre 1990) vs. newer antidepressants
patients at participate centres was compared. Demographics,
treatment setting, depressive symptoms, and clinical factors
associated with preferential use of newer drugs were tested
in descriptive weighted and multivariate analyses.
Results: Overall, 1,247 patients with ICD-10 diagnosis in
Depressive Episode and Recurrent Depressive Disorder
(F32 & F33) were recruited. Newer antidepressants were
included in the treatment regimens of 94.2% of study sub-
jects and patients in China (99.6%) were most use the drug.
Prescription for newer drugs was independently associated
with the patients in Southern (Odds: 0.17; 95% CI:
0.05-0.52; P = 0.0019) & South-Eastern Asia area (Odds:
0.24; 95% CI: 0.14-0.41; P< 0.001), emotional (Odds:
1.70; 95% CI: 1.05-2.75; P = 0.0316) & vegetative
symptoms (Odds: 0.50; 95% CI: 0.30-0.85; P = 0.0104),
but not with characteristics factor or treatment setting
(P> 0.05). While the older drugs was found independently
associated in South-Eastern Asia area (Odds: 2.88; 95%
CI: 1.30-6.35; P = 0.0089), and vegetative symptoms
(Odds: 2.67; 95% CI: 1.28-5.57; P = 0.0088).
Conclusions: Demographic area and depressive symp-
tom signiﬁcant to inﬂuence antidepressant choice more
than clinical factors such as sex, age, treatment setting.
165. The Insomnia Treatment, Drug Usage and
Their Side Effects in Taiwan: Analysis of 2009-2011
Nationwide Health Insurance Database
Ching-Hu Chung. Department of Medicine, Mackay
Medical College, New Taipei City, Taiwan.
abstract88
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
Background: Insomnia is one of the most common
complaints of patient in general medical practice.
Hypnotics/sedatives for treatment of insomnia were the
most frequently used psychotropic drugs in Taiwan.
Objectives: We aimed to study the usage, DDD, side
effect of hypnotics/sedatives for insomnia control in
Taiwan.
Methods: Insomnia patients were selected by Interna-
tional Classiﬁcation of Disease, Ninth Revision, Clinical
Modiﬁcation (ICD-9-CM) diagnostic criteria (ICD-9
code 7805, 78050, 78051, 78052, 78059). Hypnotics/
sedatives identiﬁcation was according to the Anatomical
Therapeutic Chemical classiﬁcations. Prevalence of
insomnia/hypnotics and sedatives usage and comedication
were studied.
Results: The prevalence of insomnia was 3.97%-4.27%,
and among these patients 54.60-55.64% was prescribed
hypnotics/sedatives as their medication in year 2009 to
2011. The fracture rate (7.06%vs 3.62% in year 2010)
and usage of drugs for constipation (16.79%vs 9.32%
in year 2010) among hypnotics/sedatives treated patients
was signiﬁcantly higher than insomnia patients without
hypnotics/sedatives treatment. The DDD of hypnotics/
sedatives was also increased over time. The study
suggests hypnotics/sedatives may have abuse potential
and falls/ related injuries remain a concern for patient
safety. Constipation was a comment adverse effect
among these hypnotics/ sedatives treated patients.
Conclusions: Hypnotics/sedatives may possess moderate
abuse potential, falls/related injuries and constipation that
limits their clinical utility.
166. Resource Utilisation of Patients with Alzheimer’s
Disease in Taiwan
Yong-Chen Chen,1,2 Raoh-Fang Pwu,1,3 Yu-Chiao
Wang,1 Yi-Ju Chen,1 Robert Chao-Jen Huang,1 Jung-
Chun Wang,1 Grace Hui-Min Wu.1,3 1Division of Health
Technology Assessment, Center for Drug Evaluation,
Taipei, Taiwan; 2Graduate Institute of Life Sciences,
National Defense Medical Center, Taipei, Taiwan;
3School of Health Care Administration, Taipei Medical
University, Taipei, Taiwan; 4Department of Physical
Therapy and Assistive Technology, National Yang-Ming
University, Taipei, Taiwan.
Background:As the population is aging quickly,Alzheimer’s
disease (AD) becomes an increasing burden to the society
and the National Health Insurance (NHI) in Taiwan.
Objectives: The study aims to investigate the direct
medical costs for caring AD patients from the NHI’s
viewpoint.
Methods: According to the reimbursement scheme of the
NHI, AD drugs including acetycholinesterase inhibitors
(AChEIs), for mild to moderate AD patients, and
memantine, for moderate to severe AD patients, are
available only to those who have been conﬁrmed as AD
patients with careful medical evaluation. Patients who
had been started on AChEIs or memantine therapy for
the ﬁrst time during 2007-2011 were identiﬁed, and were
followed till the end of 2011, drug withdrawal or drug
change from AChEIs to memantine), or death, whichever
came ﬁrst. During the follow-up, the direct medical costs
including outpatient visits, inpatient care, and acquisition
fee of AChEIs or memantine were analyzed.
Results: During the period of receiving pharmacotherapy
for AD, the annual total medical costs were 82,135 NTD
for AChEIs group (n = 16,732) and 69,742 NTD for
memantine group (n = 1,100). In AChEIs group, 29%,
45%, and 27% of total medical costs were spend for drug,
outpatient, and inpatient care respectively, and the
corresponding ﬁgures for memantine group are 16%,
47%, and 37%. The average annual cost of AChEIs was
around 2.15-fold of memantine. The inpatient costs of
AChEIs group was lower than memantine group, as its
annual hospitalization rate (30.3%) was signiﬁcantly
lower than memantine group (38.1%). After drug
withdrawal, total medical costs decreased in AChEIs
group (67,031 NTD), but increased in memantine group
(109,998 NTD) resulting from large increases in hospital-
ization rates (51%) and inpatient costs (75,068 NTD) in
memantine group.
Conclusions: From NHI’s viewpoint, during the period
of pharmacotherapy, outpatient visits in combination
with AD drug costs were the major burden of total
medical costs, especially in AChEIs group; however,
after drug withdrawal, hospitalization instead became
the major burden, especially in memantine group. Further
studies on other indirect costs for caring AD patients
were needed.
167. Use of Psychotropic Medication for People
with Learning Disability or Autism in England: A
Descriptive Study Using the Clinical Practice Research
Datalink
Rachael Boggon,1 Gyles Glover,2 Keith Ridge,3 Ray
Avery.3 1Clinical Practice Research Datalink, London;
2Public Health England, Cambridge; 3NHS England, Leeds.
abstract 89
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
Background: In May 2011, the British Broadcasting
Corporation Panorama programme revealed criminal
physical and psychological abuse of patients with
learning disabilities and challenging behaviour at
Winterbourne View private hospital. The Department of
Health’s response included a commitment to commission
a wide ranging review of the prescribing of antipsychotic
and antidepressant medication for patients with challeng-
ing behaviour.
Objectives: The study has four related objectives:
(1) To identify the extent of primary care prescribing of
psychotropic agents amongst patients with learning
disability or autism
(2) To identify the recorded indication, including
challenging behaviour
(3) To describe prescribing patterns
(4) To explore differences in these patterns between
subgroups of patients based on demographics,
diagnosis, geographical region and ﬁnancial year.
Methods: The Clinical Practice Research Datalink
primary care data will be used to identify a cohort of pa-
tients with learning disability or autism. For each psycho-
tropic, a list of approved indications and recommended
dosages will be constructed based on information in the
British National Formulary. Periods of psychotropic use
will be calculated for each patient by drug class and dosage
regimen. The extent of antipsychotic prescribing, with and
without an approved indication, and below or above
recommended dosages, will be described. Periods of use
of multiple drug classes will also be reported. Results will
be stratiﬁed by demographics, diagnoses, region and year.
Results: The formal data analysis will commence in April
2014. It is estimated that 25,000 patients with learning dis-
ability and 17,000 patients with autism will be included.
Full results will be presented at the conference, including
detailed methodologies for the identiﬁcation of indications.
Conclusions: This study will describe the primary care
prescribing of psychotropic medication in patients with
learning disability or autism using the Clinical Practice
Research Datalink primary care database.
168. Disease Progression, Treatment Patterns, and
Outcomes in Schizophrenia Over a 3-Year Period:
Results from the Cohort for the General Study of
Schizophrenia (CGS)
Jessica J Jalbert,1,2 Michel Rossignol,3,4 Frederic Rouillon,5,6
Bernard Astruc,7 Benoit David,3 Jacques Benichou,3,8
Lucien Abenhaim,9 Lamiae Grimaldi-Bensouda.3,10
1LA-SER Analytica, New York, NY, United States; 2Weill
Cornell Medical College, New York, NY, United States;
3LA-SER Research, Paris, France; 4McGill University,
Montreal, QC, Canada; 5Centre Hospitalier Sainte-Anne,
Université Paris V René Descartes, Paris, France;
6INSERM U894, Hôpital Sainte Anne, Paris, France;
7Faculté de Médecine Cochin Port-Royal, Eutelmed
SAS, Paris, France; 8Unité Inserm 657, Centre
Hospitalier Universitaire de Rouen, Rouen, France;
9LA-SER, London, United Kingdom; 10Conservatoire
National des Arts et Metiers, Paris, France.
Background: CGS is a large, prospective cohort study
designed to better understand schizophrenia outcomes
and epidemiology in France.
Objectives: To describe disease progression, treatment
patterns, and hospitalization rates in CGS patients, over
3 years.
Methods: Between 2005-2011, 96 psychiatric centers
recruited 1,388 patients aged 15 to 65 years meeting
DSM-IV schizophrenia criteria. At baseline and semi-
annually, data was collected on sociodemographics,
comorbidities, body mass index (BMI), psychotropic
medications, disease severity (Clinical Global Impression
[CGI] score), psychiatric hospitalizations, and deaths.
We grouped atypical and typical antipsychotics (AP) as
short-acting (SA) or long-acting (LA) and calculated
yearly psychiatric hospitalization rates per 100 person-
years.
Results: At cohort entry, mean age was 38.7 years,
68.9% were men, average maximum CGI score was 5.8
(SD= 0.8), 46.1% were hospitalized in the past year.
27% were taking LA atypical, 50.3% SA atypical,
18.1% LA typical, and 29.6% SA typical APs. 31.8%
were on AP polytherapy (<1% taking 5 or more APs)
and 2.1% were not treated with APs. Nearly 75% of
patients were followed 3 years. Prevalence of AP use
decreased slightly (<5%) for all groups except SA
atypicals (54.7% at 3 years). Patients not on APs
increased to 12.0% at 3 years. At each time point, AP
treatment interruption incidence was more stable and less
common for LA APs (usually <5%) than for SA APs
(3.6% to 29.8% for atypicals and 2.1% to 19.9% for
typicals). AP polytherapy prevalence was stable. Patients
discontinuing all APs spent, on average, almost one year
unexposed to APs. Over 3 years, CGI scores, mean BMI,
and prevalence of most comorbidities were stable.
Hospitalization rates were: 53.8 (95% CI: 49.9-57.8) the
ﬁrst year, 54.8 (95% CI: 50.5-59.4) the second year,
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and 52.9 (95% CI: 48.5-57.6) the third year. There were
30 (2.2%) patients who died (10 suicides) and 40
(2.9%) suicide attempts.
Conclusions: Comorbidities, BMI, disease severity, and
hospitalizations rates of patients with schizophrenia were
very stable over 3 years with frequent treatment adaptations.
169. Factors Associated with the Use of Pain Manage-
ment-Related Medications among the Non-Cancer
Elderly Patients Ever Utilized Traditional Chinese
Medicine Services: A Retrospective Population-Based
Cohort Study
Hsiang-Wen Lin,1,2 Li-Ping Chen,3 Chih-Hsueh Lin,4
Che-Yi Chou,5 Hsin-Hui Tsai.2 1School of Pharmacy
and Graduate Institute, China Medical University,
Taichung, Taiwan; 2Department of Pharmacy, China
Medical University Hospital, Taichung, Taiwan;
3Graduate Institute of Acupunture Science, China
Medical University, Taichung, Taiwan; 4Department of
Family Medicine, China Medical University Hospital,
Taichung, Taiwan; 5Department of Internal Medicine,
China Medical University Hospital, Taichung, Taiwan.
Background: The acupuncture is one of common
approaches to manage pain.
Objectives: The aim of this study was to explore the
factors associated with the incidence use of pain manage-
ment medications among the non-cancer elderly who
ever utilized Traditional Chinese Medicine (TCM)
services in Taiwan.
Methods: The retrospective cohort study was conducted
using two-million random samples of Taiwan National
Health Insurance Research Databases. Those elderly
patients without cancers and ever utilized TCM services
in 2008 were evaluated for their usages of acupuncture
and Chinese medications in the ﬁrst half of 2009 and
the incidence use of pain management-related medica-
tions in the last half of 2009. The pain management-
related medications included pain medications
(e.g., narcotics, NSAIDs), muscle relaxants (e.g., benzodi-
azepines), and neuroleptic agents (e.g, Gabapentin). The
demographics, diseases, and health care utilization were
potential contributing factors of interest. The univariate
and multivariate logistic regression tests were performed to
explore the factors associated with the incidence use of pain
management-related medications.
Results: Of 44,589 non-cancer elderly patients who
ever utilized TCM services in Taiwan in 2008, 12,520
(32.3%) ever utilized acupuncture services in the ﬁrst
six months in 2009. After adjusting for factors, those
TCM use elderly who ever use of acupuncture, male,
with cerebral vascular diseases, rheumatic diseases,
osteoarthritis, lower back pain,ever utilized more
outpatient visits and inpatient visits, and Western medi-
cations tended to newly use of pain management-related
medications. In contrast, those TCM use elderly who
were aged more than 85, ever use Chinese medications,
with diabetes mellitus, liver diseases, and with more
incomes tended not to newly use pain management-
related medications.
Conclusions: More attention should be made toward the
tendency of using pain management-related medications
among those elderly patients who had certain diseases
and utilized more health services, including acupuncture.
170. Association between Antipsychotic Treatment and
Risk of Hip Fracture in Subjects with Schizophrenia
Yu-Ting Tsai,1 Chi-Shin Wu,2,3,4 Chia-Ming Chang,5
Ya-Wen Huang,1 Hui-Ju Tsai.1,6,7 1Division of
Biostatistics and Bioinformatics, Institute of Popula-
tion Health Sciences, National Health Research
Institutes, Zhunan, Taiwan; 2Department of Psychia-
try, Far Eastern Memorial Hospital, New Taipei
City, Taiwan; 3College of Public Health, National
Taiwan University, Taipei, Taiwan; 4Department of
Psychiatry, National Taiwan University Hospital,
Taipei, Taiwan; 5Department of Psychiatry, Chang
Gung Memorial Hospital, Lin-Kou & Chang Gung
University, Taipei, Taiwan; 6Department of Medical
Genetics, College of Medicine, Kaohsiung Medical
University, Kaohsiung, Taiwan; 7Department of
Pediatrics, Feinberg School of Medicine, Northwestern
University, Chicago, IL, United States.
Background: Although a certain number of studies have
reported decreased BMD in subjects with schizophrenia
compared to healthy controls, limited studies have been
designed and conducted to examine the association
between hip fracture and antipsychotic medication use,
particularly in subjects with schizophrenia.
Objectives: To investigate the association between anti-
psychotic treatment and risk of hip fracture in subjects
with schizophrenia.
Methods: Design: We conducted a nested case-control
study to investigate the association between antipsy-
chotic treatment and risk of hip fracture in subjects
with schizophrenia.
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Setting: A total of 605 cases with hip fracture and
2,828 matched controls were identiﬁed from 2002 to
2011 using the National Health Insurance Research
Database in Taiwan.
Main outcome measures: Schizophrenia subjects aged
20 years and older and with newly diagnosed hip fracture.
Statistic analysis: We performed conditional logistic
regression models (with and without covariates adjust-
ment) to estimate the effect of antipsychotics on risk of
hip fracture, according to antipsychotic exposure status,
classes, binding afﬁnity, and daily dose, respectively.
Results: Current antipsychotic use was associated with
an increased risk for hip fracture (adjusted odds ratio
(AOR) = 1.69; 95% conﬁdence interval (CI): 1.34-2.14).
Among current users, new users had a higher risk of
hip fracture (AOR=4.55; 95% CI: 1.96-10.56) than past
users (AOR= 1.24; 95% CI: 0.91-1.69). In addition, a
signiﬁcant increased risk of hip fracture was noted in
schizophrenia subjects with ﬁrst-generation antipsychotic
use, but not in those with second-generation antipsy-
chotic use.
Conclusions: These results extended previous ﬁndings
and demonstrate an increased risk of hip fracture associ-
ated with antipsychotic use in schizophrenia subjects.
Further investigation is needed to dissect the underlying
mechanisms related to the effect of antipsychotic use on
hip fracture in subjects at risk.
171. Healthcare Utilization Prior to Self-Poisoning:
Variation by Age and Gender
Fei-Yuan Hsiao,1 Shu-I Wu,2 Chia-Yi Wu.3 1Graduate
Institute of Clinical Pharmacy, National Taiwan
University, College of Medicine, Taipei; 2Department
of Psychiatry, Mackay Memorial Hospital, Taipei;
3Department of Nursing, National Taiwan University,
College of Medicine, Taipei.
Background: Empirical evidence of age and sex
variations in service utilization and its related factors in
people with self-poisoning is scarce.
Objectives: The aim of the study was to describe service
use patterns before the ﬁrst self-poisoning episodes
focusing on differences in age and gender.
Methods: We identiﬁed 3,465 people with a veriﬁed
discharge diagnosis related to self-poisoning from
1997-2006 in the National Health Insurance Research
Database, Taiwan. Medical disorders, psychiatric
diagnoses, psychoactive medications and health service
use within one year of the episodes were compared by
gender and age, i.e. under (younger) or over (elder)
65 years old.
Results: Young women (<65 years) were found to seek
non-psychiatric outpatient services more than young
men, especially in the prior month of SP (<65 years
old: female 61.7% vs. male 50.5%, p< 0.001). In
contrast, more men contacted the emergency care than
women in the previous month (<65 years old: male
9.9% vs. female 6.7%, p = 0.002) and year before the
episode of SP (>= 65 years old: male 39.8% vs. female
29.3%, p = 0.006). Young females were prescribed
more antipsychotics, antidepressants, and anxiolytics,
with nearly half receiving anxiolytics in year prior to
self-poisoning.
Conclusions: The ﬁndings of the current study suggest
that the young women who self-poisoned for the ﬁrst
time utilized more non-psychiatric outpatient services
and were prescribed with more psychotropic medications
than other groups. This gender disparity needs to be
explored in greater detail to help prevent self-poisoning
at an early stage.
172. Differences in ADHDMedication Usage Patterns
in Children and Adolescents from Different Ethnic
Backgrounds in the Netherlands
Els F van den Ban,1,3 Patrick C Souverein,2 Herman van
Engeland,3 Hanna Swaab,4 Toine CG Egberts,2,5 Eibert
R Heerdink.2,5 1Youth Division, Altrecht Institute for Men-
tal Health, Utrecht, Netherlands; 2Pharmacoepidemiology
& Clinical Pharmacology, Utrecht Institute for Pharma-
ceutical Sciences, Utrecht, Netherlands; 3Child and
Adolescent Psychiatry, University Medical Centre Utrecht,
Utrecht, Netherlands; 4Clinical Child and Adolescent
Studies, Leiden University, Leiden, Netherlands; 5Clinical
Pharmacy, University Medical Centre Utrecht, Utrecht,
Netherlands.
Background: ADHD medication use in children and
adolescents has increased over the past decades in many
countries. Differences in incidence and prevalence of
ADHD medication use between ethnic groups have been
reported. Whether there are also differences in usage
patterns is, however, largely unknown.
Objectives: To determine whether there are differ-
ences in usage patterns of ADHD medication among
native Dutch, Moroccan, Turkish and Surinam
children and adolescents in The Netherlands between
1999-2010.
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Methods: A cohort of patients under 19 years of age
diagnosed with ADHD was evaluated for ADHD
medication use. Incident use and discontinuation of
ADHD medication was measured for ethnicity (native
Dutch, Moroccan, Turkish and Surinam) and adjusted
for age, gender and socio-economic status. Cox-
regression analyses were usd to calculate Hazard Ratios
for the risk of early discontinuation.
Results: A total of 817 children with a diagnosis of
ADHD was identiﬁed. A higher proportion of ADHD
diagnosed Moroccan (32%) and Turkish (42%) patients
never used ADHD medication compared to Dutch
natives (21%). One ﬁfth of native Dutch and Turkish
patients already used ADHD medication before the
ADHD diagnosis date. Almost all patients that used
medication initiated on immediate release methylpheni-
date (80%). Discontinuation of ADHD medication
within 5 years was highest in Moroccan (HR 2.4 [95%
CI 1.8-3.1]) and Turkish (HR 1.6 [95% CI 1.1-2.6])
patients. A sensitivity analysis with a postal code
matched comparison between Dutch natives and non-
natives showed similar results, suggesting this effect is
not explained by socio-economic status.
Conclusions: Differences are found in ADHD medication
prescribing and use between ethnical groups. Native Dutch
and Turkish patients start more frequently with ADHD
medication before the ADHD diagnose date, which can
be an indication of differences in either referral patterns
and/or access to care. A higher percentage of Moroccan
and Turkish patients never start using ADHD medication
at all and if they start using medication, discontinuation
rate is higher compared to Dutch natives and Surinams.
173. Evaluating the Safety of Atypical Antipsychotic
Drugs among Patients in Jos University Teaching
Hospital
Rachel U Odesanya, Moses D Audu, Silas
Fwangshak. Pharmacovigilance and Drug Safety
Centre, Pharmacy Department, Jos University
Teaching Hospital (JUTH), Jos, Plateau, Nigeria;
Psychiatry Department, Jos University Teaching
Hospital, Jos, Plateau, Nigeria; Pharmacovigilance
and Drug Safety Centre, Pharmacy Department, Jos
University Teaching Hospital, Jos, Plateau, Nigeria.
Background: Atypical antipsychotics are used to treat
symptoms of psychosis; and they may cause adverse drug
events (ADEs) in patients. Incidences of ADE can reduce
adherence to drug therapy or even harm patients, hence
evaluating their safety is important to guide management.
Objectives: To evaluate the safety of atypical antipsy-
chotics among patients in Jos University TeachingHospital.
Methods: This is a retrospective cohort study of randomly
selected 118 psychiatric in/out patients on atypical antipsy-
chotics in JUTH carried out 1stJanuary-31st July, 2013.
Data was obtained directly from patients including their
case notes using Profoma and analyzed with SPSS.17.
Results: Majority of the patients were males (60%) with
age ranging from 10-70 years and 21-30 years as modal
class age range of 36.4% and most of the participants
were students. Only three atypical antipsychotics are
presently in use in JUTH: olanzepine (50%), risperidone
(40.7%) and clozapine (9.3%). ADEs that occurred in
more than 50% include:sedation/drowsiness, speech
difﬁculty, confusion, blurred vision, weight gain, and
depression. Less frequently experienced ADE(in <50%
of patients) include:dry mouth, urinary retention, muscle
rigidity, increase heart rate, menstrual problem, delayed
ejaculation, suicidal attempt, insomnia, hypersalivation,
tardive dyskinesia, convulsion, stroke, gynaecomastia.
Blood glucose level and full blood count were monitored
in <20% while Liver Function Tests, Urea & Electro-
lytes were not done for any patient.
Conclusions: Nearly all patients experienced adverse
drug events(ADEs). ADEs include:drowsiness, suicidal
attempt, convulsion and stroke. Required laboratory tests
to monitor and evaluate safety of antipsychotics were
carried out in only <20% of patients. We advocate safety
surveillance to prevent harm and improve safety of
atypical antipsychotics.
174. Trends in Volume and Mortality in Carotid
Endarterectomy (CEA) After Introduction of Carotid
Artery Stenting (CAS) in Medicare Population
Hiraku Kumamaru,1,2 Jessica J Jalbert,2,3 Louis L
Nguyen,4 Jun Liu,2 Marie D Gerhard-Herman,5 Chih-
Ying Chen,2 Lauren A Williams,2 John D Seeger,2
Jessica M Franklin,2 Soko Setoguchi.6 1Epidemiology,
Harvard School of Public Health, Boston, MA, United
States; 2Division of Pharmacoepidemiology and
Pharmacoeconomics, Brigham and Women’s Hospital,
Harvard Medical School, Boston, MA, United States;
3LA-SER Analytica, NY, NY, United States; 4Department
of Vascular and Endovascular Surgery, Brigham and
Women’s Hospital, Harvard Medical School, Boston,
MA, United States; 5Department of Cardiovascular
Medicine, Brigham and Women’s Hospital, Harvard
Medical School, Boston, MA, United States; 6Duke
Clinical Research Institute, Durham, NC, United States.
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Background: Following the 2005 National Coverage De-
termination reimbursing CAS for Medicare beneﬁciaries,
the number of CEA procedures declined. We hypothesized
that the reduction in CEAs resulted in lower case volumes
for individual surgeons, leading to worse outcomes.
Objectives: To assess the decline in the surgeon case vol-
ume for CEA and its association with patients’ outcome.
Methods: We identiﬁed inpatient CEA (2001-2008) and
CAS (2005-2008) procedures and CEA performing
surgeons in Medicare data. We calculated surgeon case
volume as the number of CEAs performed in the year
prior to the procedure. We assessed yearly trends in: 1)
rate of CEA and CAS performed among Medicare bene-
ﬁciaries, 2) surgeon case volume distribution for CEA, 3)
characteristics of patients undergoing CAS or CEA, and 4)
30-day post-CEA mortality overall and by volume
category. We also predicted the counterfactual 30-day
mortality for CEA patients in years 2003-2008 if the
2001-2002 case volume distribution had been maintained,
to evaluate the impact of the decreased case volume.
Results: Among 450,727 CEA patients, those undergo-
ing CEA in later years were older and had higher propor-
tions with prior strokes and comorbidities than in earlier
years. Those undergoing CAS (N= 27,726) were sicker
and slightly older than CEA patients. Rate of CEA proce-
dures per 10,000 beneﬁciaries declined after 2002 (from
17.6 in 2002 to 12.6 in 2008), as did median case volume
for the surgeons (27 in 2002 to 21 in 2008). Overall
30-day mortality improved from 1.4% (95% CI: 1.4-1.5)
in 2001-2002 to 1.2% (95% CI:1.1-1.3) in 2007-2008,
and this improvement occurred in all volume categories.
Greater case volume was associated with lower 30-day
mortality throughout the years, with almost constant
relative risks between the volume categories. Predicted
counterfactual mortality in later years was almost identical
to that observed, suggesting negligible impact of the
decreased case volume on mortality.
Conclusions: Rate of CEAs decreased substantially from
2001 to 2008, as did surgeon CEA case volumes. These
changes did not adversely impact 30-day mortality of
CEA Medicare patients.
175. Drug Use Patterns of Elderly Neuroleptic Users in
Germany
Niklas Schmedt, Kathrin Jobski, Tania Schink, Edeltraut
Garbe. Clinical Epidemiology, Leibniz Institute for
Prevention Research and Epidemiology - BIPS GmbH,
Bremen, Germany.
Background: Neuroleptics (NLs) are frequently used in el-
derly patients, but little is known on characteristics and drug
use patterns of elderly users of speciﬁc NL classes and drugs.
Objectives: To investigate characteristics and patterns of
elderly NL drug users in Germany.
Methods: We conducted a cohort study in the German
Pharmacoepidemiological Research Database (GePaRD)
and identiﬁed all persons aged 65 years and older with a
NL dispensation between 2005 and 2009. Co-morbidity
and co-medication was assessed in the year prior to co-
hort entry and for co-medication also during follow-up.
After construction of NL treatment episodes, we obtained
the percentage of concurrent users of two or more NLs,
of switchers to other NLs and of treatment discontinua-
tion among users of NL drug classes and individual
drugs. In addition, we calculated the median (ME) dura-
tion of NL treatment. In subgroup analyses these mea-
sures were also calculated for incident NL users and
patients with dementia and psychoses.
Results: Overall, 302,998 persons received at least one
NL. The median age at cohort entry was 77 years and
68.6% were female. 67.4% entered the cohort with a con-
ventional NL, 30.4% with an atypical NL and 2.2% with
both classes. Among individual NLs, melperone most of-
ten led to cohort entry (21.7%), followed by
promethazine (16.4%), sulpiride (11.6%) and risperidone
(9.9%). The median treatment duration for any NL was
22 days and varied between NL classes and individual
drugs. Only 8.6% of all NL users were identiﬁed as concur-
rent users or switchers and 28.2% of patients had
discontinued treatment. Patients with dementia were older
(ME 82years) and had shorter treatment duration (ME
20days) whereas patients with psychoses were younger
(ME 73years) and treated longer (ME 51days). Switch
and concurrent use of different NLs was most common in
patients with psychoses (7.1% and 18.0%, respectively).
Conclusions: Characteristics and drug use patterns of
speciﬁc NL classes and drugs assessed in a large cohort
of elderly Germans varied substantially depending on
indication. This should be considered in comparative
safety studies and investigated more closely for indica-
tions besides dementia and psychoses.
176. Characteristics of Patients with DepressionWho Ini-
tiate Antidepressant and Benzodiazepine Therapy Simul-
taneously, Compared with Antidepressant Monotherapy
Greta A Bushnell,1 Alice White,1 Til Stürmer,1 Bradley
N Gaynes,2 Virginia Pate,1 Deborah Azrael,3 Matthew
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Miller.3 1Epidemiology, Gillings School of Global Public
Health, University of North Carolina, Chapel Hill, NC,
United States; 2Psychiatry, University of North Carolina
School of Medicine, Chapel Hill, NC, United States;
3Health Policy and Management, Harvard School of
Public Health, Boston, MA, United States.
Background: Co-initiation of antidepressants (AD) and
benzodiazepines (BZD) has been recommended for
patients with depression, particularly when anxiety or in-
somnia is present. AD and BZD have been independently
associated with fracture risk and motor vehicle accidents.
Objectives: To determine how often and in what
situations co-initiation occurs; to determine the rate of
fractures and motor vehicle accidents during concomitant
AD and BZD use.
Methods: We examined coincident new use of AD and
BZD by United States adults with depression, aged
≥25, from 1998-2010. Data came from the LifeLink
Health Plan Claims Database. Co-initiation was deﬁned
as ﬁlling a prescription for a BZD the same day as the
index AD; new use was deﬁned as not having ﬁlled a
prescription for AD or BZD in the year prior to AD initi-
ation. BZD deﬁned as Alprazolam, Chlordiazepoxide,
Clorazepate, Diazepam, Lorazepam, or Oxazepam. We
compared patient characteristics, prescription details,
and persistence by co-initiating status. We looked at rates
of unintentional injury (hospitalized hip, arm fractures
and motor vehicle accidents) for co-initiators and initia-
tors of AD monotherapy.
Results: Co-initiation occurred in 5% (n = 15,988) of
319,920 adults with depression who started AD therapy.
Compared to initiators of an AD alone, co-initiators were
younger (<50 years: 66% vs. 61%) and more likely to
have anxiety (40% vs. 19%), depression diagnosed
30 days prior to initiation (88% vs. 77%), and fewer
comorbidities. Most index BZD were for Alprazolam
(60%) or Lorazepam (34%); 67% of co-initiators ﬁlled
only 1 BZD prescription. Crude AD 6-month persistence
was 45% in co-initiators and 48% in initiators of an AD
alone. Unadjusted rates of unintentional injury within
3months were 7.3/1000 persons-years (27 events) in
co-initiators and 9.2/1000 (652 events) in initiators of
an AD alone.
Conclusions: In this population of insured adults with
depression, 5% co-initiated an AD and one of the
included BZD. Short BZD use and low events limited
our ability to assess the association between co-initiating
status and unintentional injuries during concomitant use.
177. Follow-Up of Psychoactive Drug Use in Newly
Diagnosed Patients with Autism Spectrum Disorder
(ASD) in Quebec (Canada)
Caroline Croteau,1 Laurent Mottron,2 Marc Dorais,3
Jean-Éric Tarride,4 Sylvie Perreault.1 1Faculty of
Pharmacy, University of Montréal, Montréal, QC,
Canada; 2Psychiatrie, Hôpital Rivière des Prairies,
Montreal, QC, Canada; 3Statistics, StatSciences,
Montréal, QC, Canada; 4Health Sciences, Mac Master
University, Hamilton, ON, Canada.
Background: Medication use in people with PDD has
been reported to increase over time in both the US and
also to a lesser extent, in the UK. Polypharmacy is also
common as many neuropsychiatric co-morbidities have
been reported in this population.
Objectives: To characterize the temporal course of
psychoactive drug utilization in a cohort of newly diag-
nosed autistic individuals.
Methods: A cohort was built using the provincial public
healthcare insurance program (RAMQ) databases. Newly
diagnosed subjects with ASD were selected (≥2
diagnoses (separate dates) with ICD-9 codes: 299.X,
excluding 299.2) between January 1998 and December
2010. Cohort entry was the date of ﬁrst diagnosis
conﬁrmed by the absence of ASD diagnosis in previous
5 years. Participants aged≥ 26 years or those not covered
by the RAMQ drug plan in the year preceding cohort
entry were excluded. Demographic and clinical patient
characteristics were assessed at cohort entry. Drug use
proﬁles (anticonvulsants, antipsychotics, antidepressants,
anxiolytics, ADHD drugs) were evaluated for 5 years of
follow-up. Impact of age groups on drug use proﬁles
and variations over time were analyzed using generalized
estimating equations methods.
Results: A cohort of 2,989 subjects was identiﬁed (male:
80.2%; median age: 6 years). Prior to ASD diagnosis,
35.8% received at least 1 psychoactive drug. At 1-year
of follow-up, 44.9% of participants were receiving at
least 1 psychoactive medication, which increased to
53.2% by 5 years. Overall, ADHD drug use was most
common in patients aged 1-5 and 6-12 years whereas
antipsychotics were most common in adolescents
(13-17 years) and young adults (18-25 years). The effects
of age group on the use of the different drug classes were
statistically signiﬁcant (p< 0.0001). We observed
signiﬁcant changes in drug use over time for all
psychoactive drug classes (increase or decrease), except
for anxiolytics.
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Conclusions: Psychoactive medication use increased
over the 5-year period among newly diagnosed ASD
people, whatever the age group. Optimal use of these
medications in the context of limited access to other types
of support modalities is discussed.
178. Characterization of Potential Pharmacodependence
of Zolpidem, Zopiclone and Zaleplone Users
Pei-Hua Hsieh,1,2 Chia-Yi Wu,3 Fei-Yuan Hsiao.1,2,4
1Graduate Institute of Clinical Pharmacy, National
Taiwan University, College of Medicine, Taipei,
Taipei, Taiwan; 2Department of Pharmacy, National
Taiwan University Hospital, Taipei, Taipei, Taiwan;
3Department of Nursing, National Taiwan University,
College of Medicine, Taipei, Taipei, Taiwan; 4School of
Pharmacy, National Taiwan University, College of
Medicine, Taipei, Taipei, Taiwan.
Background: Zolpidem, zopiclone and zaleplone (also
called as z-hypnotics) are widely used non-benzodiaze-
pine hypnotics which may be potentially associated
with pharmacodependence. Despite its wide use, very
few pharmacoepidemiology studies assessing the use of
z-hypnotics in the “real-world” setting.
Objectives: Using a nationally-representative database,
the objective of this study was to characterize users of
z-hypnotics and associated pharmacodependence.
Methods: Incident users of zolpidem, zopiclone and
zaleplone from 2001 to 2010 were identiﬁed from the
Longitudinal Health Insurance Database, Taiwan.
Patients were further categorized into three groups based
on their consumption behaviors of z-hypnotics. Speciﬁ-
cally, we identiﬁed “mild pharmacodependence” and
“severe pharmacodependence” groups if the same patient
receive more than two prescriptions of z-hypnotics within
one week and at the same day (at-risk behavior).
Results: A total of 242,412 incident z-hypnotic users dur-
ing the 10-year study period. Approximately 7% and 12%
of them were identiﬁed as “mild pharmacodependence”
and “severe pharmacodependence” groups. The propor-
tion of z-hypnotics users with “at risk behavior” decreased
overtime, with an decreased proportion of “mild
pharmacodependence” (2001:10.14% vs. 2011: 2.62%)
and “severe pharmacodependence” (2001:17.40% vs.
2011: 4.98%) groups. Moreover, one-third of patients in
the “severe pharmacodependence” received z-hypnotics
exceeding the labeled maximum daily dose. Overall, only
25% of users received their z-hypnotics prescriptions
from physicians specializing in psychiatry.
Conclusions: To our knowledge, our empirical study
was the ﬁrst one to characterize users of z-hypnotics
and potential pharmacodependence using claim database.
179. Testing the Robustness of Background Knowledge
Confounder Selection in a Case-Control Study
Johnny Kahlert,1 Reimar W Thomsen,1 Lars Pedersen,1
Morten Madsen,1 Niels Møller,2 Henning Beck-Nielsen,3
Henrik T Sørensen.1 1Department of Clinical Epidemiol-
ogy, Institute of Clinical Medicine, Aarhus University
Hospital, Aarhus, Denmark; 2Medical Department
M (Endocrinology & Diabetes) and Institute of
Clinical Medicine, Aarhus University Hospital, Aarhus,
Denmark; 3The Danish Centre for Strategic Research
in Type 2 Diabetes (DD2), Diabetes Research Centre,
Department of Endocrinology, Odense University
Hospital, Odense, Denmark.
Background: Logistic regression models are used to
adjust odds ratios (ORs) of an outcome associated with
an exposure, to control for the effect of confounding
variables. However, a long list of confounder candidates
may comprise nuisance variables that could dilute
exposure effects.
Objectives: In a reference study (REF), adjustment for
confounders based on clinical knowledge removed a
crude effect (OR= 1.36 [95% CI, 1.08; 1.69]) of incretin
use on the risk of acute pancreatitis (Thomsen et al.,
submitted). In the present analysis we examined whether
other criteria for confounder selection would lead to
different conclusions.
Methods: The analysis was carried out as an age-, gen-
der- and residence-matched (1:10) population-based
case-control study (12,868 pancreatitis cases and
128,680 controls subjects). In REF, 11 confounders were
examined: intake of lipid-lowering drug, oral glucocorti-
coid, azathioprine, anti-epileptics and nonsteroidal anti-
inﬂammatory drug, together with level of Charlson’s
Comorbidity Index (CCI) score and any history of
obesity, alcoholism, cancer, inﬂammatory bowel and
gallstone disease. We compared the ORs of acute
pancreatitis associated with incretin use in REF with
ORs obtained from four alternative models with
confounder selection according to statistical criteria:
Akaike Information Criterion (AIC), Bayesian Informa-
tion Criterion (BIC), Change In Estimate (CIE), and
Stepwise Regression with Backward Elimination (SB).
Results: The AIC model and the REF model comprised
the same variables. The most radical exclusion of
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variables emerged from the CIE model, which retained
only obesity and CCI score. Nevertheless, the adjusted
OR of incretin use changed only slightly using the CIE
model: 0.97 [95% CI, 0.77; 1.22] compared to 0.95
[95% CI, 0.75; 1.21] in REF, suggesting that most
candidate confounders did not further affect the associa-
tion between incretin use and occurrence of pancreatitis.
Shrinkage of regression coefﬁcients did not change the
OR or its precision.
Conclusions: Criteria for confounder selection other than
clinical knowledge did not change the conclusion of
REF, although the REF model probably included some
redundant confounders.
180. The Effect of a Comprehensive Approach to Blood
Product Management: Automated Decision Support,
Education, and Feedback
Keri J Donaldson,1 Thomas A Abendroth.1 1Center for
Quality Innovation, Penn State Milton S. Hershey
Medical Center, Hershey, PA, United States.
Background: Approximately 15 million units of red
blood cells (RBCs) are transfused annually in the U.S.
Though transfusions are often life-saving, they also are
associated with morbidity and increased mortality.
No single clinical ﬁnding or laboratory test can univer-
sally determine when RBC transfusion is indicated, but
current research suggests that more restrictive transfusion
criteria could improve clinical outcomes. By eliminating
transfusions without clear indication, we have reduced
patient risk and decrease intermittent shortages.
Objectives: To determine and compare the effectiveness
of: automated decision support, education, and a
feedback module, on blood product ordering.
Methods:We performed a descriptive analysis of current
blood product usage, deﬁned opportunities for improve-
ment, designed and implemented an online automated de-
cision support intervention, designed an educational
module, and designed a feedback evaluation tool to track
usage. The decision support module contains relevant
information (lab values, currency of the type and screen),
as well as current transfusion thresholds. The educational
module was designed to incorporate current guidelines
and clinical scenarios. The feedback was designed to
automatically track and compare blood use across
physicians and mid-levels. Rates of transfusion
adjusted for admissions where compared prior to and
after the intervention.
Results: The new decision support elements add less
than 15 seconds to electronic transfusion ordering,
decreasing the time required to review, and processing
time. For red cells alone, we decreased utilization by
9% (p< 0.01) for the year following this intervention.
This represents an annual savings of approximately
1,400 units of red cells, corresponding to $350K in
product acquisition costs plus $260K in transfusion
administration labor costs.
Conclusions: The novel decision support has decreased
our blood use while not effecting workﬂow. We will
launch the educational module at the start of the new
academic year, as will the feedback mechanism.
Impacts of these additional interventions will then be
compared.
181. Medication and Patient Safety in a Community
Teaching Hospital
Luis-MeaveGutiérrez-Mendoza,1,2AbrahamTorres-Montes,1,2
Elizabeth Ramírez-Hernández,2 Aldanely Padrón-Salas,1
Ricardo Villanueva-Alvarez,1 Viviana Juarez-Cruz.1
1Public Health Department, Faculty of Medicine,
Universidad Autónoma de San Luis Potosí, San Luis
Potosí, Mexico; 2Quality and Patient Safety, Hospital
Central “Dr. Ignacio Morones Prieto”, San Luis Potosi,
Mexico.
Background: The Institute of Medicine in 1999
attributed in the report To Err is Human: Building a Safer
Health System, more than 98,000 deaths a year due to
medical errors. The World Health Organization in 2009
highlighted that Incident in Medication/IV ﬂuids
problems can occur in all hospital environments and
integrated a classiﬁcation conceptual framework for the
International Classiﬁcation for Patient Safety.
Objectives: To determine the incidents related to
Medication/IV Fluids from January-December 2013 in a
community Teaching Hospital in San Luis Potosí, México.
Methods: A retrospective-descriptive study was
conducted in the Quality and Patient Safety Branch.
The information was collected from the “Incident Report
Format” during January-December 2013 in a 250-bed
Community Teaching Hospital, in San Luis Potosi,
Mexico. The population of responsibility is 1.7 million
of habitants and produced annually more than 17,500
discharges. Hospital is common for 19 residencies
programs, 5 bachelors and more than 1800 workers. A
database that integrated information regarding Medica-
tion/IV Fluids incidents in Microsoft Excel was created
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and Measures of Central Tendency and proportions were
used to describe the results using STATA V11.
Results: From January to December 2013 a total of 146
Incidents were reported to the Hospital Quality and
Patient Safety Branch. 32 cases (21.9%) were related to
Medication/IV Fluids and placed 2nd just below patient
falls 45 cases (31%). According to the WHO Incident
Type –Medication/IV Fluids the cases were classiﬁed
due to the following problems: Wrong Patient 3 (9.3%),
Wrong Drug 6 (18.75%), wrong Dose/Strength of
Frequency 3 (9.3%), Wrong Route 9 (28.1%), Wrong
Dispensing Label/Instruction 9 (28.1%), and adverse
drug reaction 2 (6.25%).
Conclusions: Incidents related to Medication/IV Fluids
are highly common in a community teaching hospital
environment. It is important to improve report culture
among health care staff to improve patient safety
strategies and minimize effects due to human error and
medication.
182. The Association between Long-Term Bisphospho-
nate Use and the Risk of Fracture among Females with
Osteoporosis in Taiwan
Chung-Hsuen Wu,1 Chi-Chuan Wang,2 Hsien-Tsung
Lu.3,4 1School of Pharmacy, College of Pharmacy,
Taipei Medical University, Taipei, Taiwan; 2School of
Pharmacy, National Taiwan University, Taipei, Taiwan;
3Department of Orthopedics, Taipei Medical University
Hospital, Taipei, Taiwan; 4Graduate Institute of
Medical Sciences, College of Medicine, Taipei Medical
University, Taipei, Taiwan.
Background: Bisphosphonates are effective to treat
osteoporosis and often recommended for patients with
fractures. Although bisphosphonates often serve as the
ﬁrst-line therapy, studies evaluating the long-term effect
of bisphosphonate use are limited.
Objectives: To evaluate the association between long-
term bisphosphonate use (i.e., treatment duration
5 years) and the risk of fracture among females with
osteoporosis aged 50 or older.
Methods: We conducted a retrospective cohort
study with a new bisphosphonate user design using the
2001-2011 National Health Insurance Research Database
(NHIRD). Females with osteoporosis aged 50 or older
without taking any bisphosphonate before the enrollment
period (January 1, 2002 to December 31, 2003) were in-
cluded. The date of the ﬁrst observed bisphosphonate
prescription during the enrollment period served as the
index date. Long-term bisphosphonate use was deﬁned
as a continuous bisphosphonate use for more than 5 years
without a reﬁll gap greater than 12months. Others were
deﬁned as regular users. We further excluded patients
with malignant neoplasms, non-speciﬁc hemangiomas,
and bone and plasma cell neoplasms at any time during
the study period. All patients were followed up for
8 years. The outcome was the time to the ﬁrst fracture.
Cox-proportional hazard models were used to analyze
the rate of fracture between long-term bisphosphonate
users and regular users.
Results: A total of 462 females were included in the
study and 13.4% of them were qualiﬁed as long-term
bisphosphonate users. After adjusting for age, long-term
bisphosphonate use was associated with a lower risk of
fracture but the result was not statistically signiﬁcant
(Hazard Ratio = 0.63, 95% Conﬁdence Interval: 0.37-1.07,
P-value = 0.09).
Conclusions: Female long-term bisphosphonate users
were not found to be associated with a lower risk of
fracture when compared with regular users. Further
investigation to the beneﬁts and risks associated with
long-term bisphosphonate use is warranted.
183. Evaluate the Effectiveness of Preventive Medicine
Curriculum among Medical Students of Public
Universities in Malaysia
Kavitha Devi,1 Shukry Zawahir,1,2 Mohd Fadli Mohd
Asmani,1 R Rekarani,1 Dashnilatha Permal,1 Redhwan
Ahmed Al-Naggar.3 1School of Pharmacy, Management
and Science University, Shah Alam, Selangor, Malaysia;
2Faculty of Medicine, University of Ruhuna, Karapitiya,
Galle, Sri Lanka; 3Population Health and Preventive
Medicine, Faculty of Medicine, Universiti Teknologi
MARA (UiTM), Shah Alam, Selangor, Malaysia.
Background: Preventive medicine training need to be
strengthened & development of evidence-based guide-
lines for low-middle income countries be a priority.
Objectives: To determine the knowledge, perception &
attitude of ﬁnal year medical students regarding the
content taught in the curriculum related to Preventive
Medicine among public universities in Malaysia &
explore socio-economic & demographic characteristics
inﬂuence on the effect.
Methods: A total number of 306 ﬁnal year students were
selected through proportionate to population method
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from randomly selected three public universities in
Malaysia. A validated, standard online questionnaire
was used to assess on the knowledge, perception &
attitude related to Preventive Medicine topics taught in
medical schools. Descriptive statistics, t-test & one-way
ANOVA test were done using SPSS V18.
Results:Majority of the respondents were females (64%)
with mean age 23 years old (SD 0.9) & were from urban
(80%) Malaysia. Each of all 19 knowledge & perception
variables showed higher percentages & combined mean
level of knowledge & perception regarding preventive
medicine among medical students (>77% & 81%
respectively) & mean 18.23 (SD 2.50) & 19.0 (SD 0.0)
respectively. Most of the respondents (>80%) believed
that it is important to learn all the preventive care areas
during their medical education, & all were satisﬁed with
preventive care training believed & it is important to
learn preventive care education & physician will need
to focus on preventive care in greater extent. They are
willing to offer preventive care services in the future
(97%). There was no statistically signiﬁcant inﬂuence
of socio-economical & demographic factors on mean
knowledge about preventive medicine, but there was a
signiﬁcant different between urban & rural (p = 0.021)
respondents.
Conclusions: In Malaysia, preventive care curriculum
among medical schools of public universities impart an
excellent knowledge, perception & believe about
preventive care practice. Medical students from rural
Malaysia are more knowledgeable in preventive care
medicine. In the current analysis only 84 included, data
analysis yet to be completed.
184. Evaluate the Effectiveness of Preventive Medicine
Curriculum among Pharmacy Students of Private
Universities in Malaysia
Dashnilatha Permal,1 Shukry Zawahir,1,2 Redhwan
Ahmed Al-Naggar,3 Eddy Yusuf.1 1School of
Pharmacy, Management & Science University, Shah
Alam, Selangor, Malaysia; 2Faculty of Medicine,
University of Ruhuna, Sri Lanka; 3Population Health
& Preventive Medicine, Faculty of Medicine,
Universiti Teknologi MARA (UiTM), Shah Alam,
Selangor, Malaysia.
Background: Prevention medicine will help in the
successful integration of prevention related topics into
the curriculum, which will add a much needed dimen-
sion, resulting in students’ being better prepared to
address the needs of their patients and the of community.
Objectives: To evaluate ﬁnal year pharmacy student’s
knowledge, perception & attitude regarding topics taught
in preventive medicine curriculum of private universities
in Malaysia and explore socio-economic & demographic
characteristics inﬂuence on the effect.
Methods: A total of 350 ﬁnal year students were selected
through proportionate to population method from
randomly selected ﬁve private universities in Malaysia.
A validated, standard online questionnaire was used to
assess on the knowledge, perception & attitude related
to Preventive Medicine topics taught in Pharmacy
schools. Descriptive statistics, t-test & one-way ANOVA
test were done by using SPSS version 18.
Results:Majority of the respondents were females (65%)
with mean age 24 years old (SD 2.7) & were from urban
(86%) Malaysia. Each of all 19 knowledge & perception
variables showed higher percentage & combined mean
level of knowledge & perception regarding preventive
medicine among pharmacy students (>88% & 96%
respectively), & 17.65 (SD= 2.44) & 19.00 (SD=0.0)
respectively. All the respondents believed that it is impor-
tant to learn all the preventive care areas during their
pharmacy education. Most of students satisﬁed with
preventive care training (89%), & believed it is important
to learn (89%), physician will need to focus on preven-
tive care in greater extent (100%) & they willing to offer
preventive care services in the future (92%). There was
no statistical signiﬁcant inﬂuence on knowledge and per-
ception about preventive medicine by socio-demographic
characteristic.
Conclusions: The preventive care curriculum of pharmacy
among private universities in Malaysia may impart excel-
lent knowledge, perception & believe about preventive
care practice. In the current analysis only 80 respondents
were included, since the data collection is still in progress.
185. Are Prescription Drugs Substitutes for Inpatient
Services? Evidence from Medicare Part D
Robert Kaestner,1 Cuiping Long,1 G Caleb Alexander.2
1Department of Economics, University of Illinois at
Chicago, Chicago; 2Department of Epidemiology, Johns
Hopkins Bloomberg School of Public Health, Baltimore.
Background: The creation of Part D was motivated, in
part, by the growing importance of prescription drugs in
preventing and treating diseases, and the growing costs
of buying prescription drugs. The relative dearth of
evidence on whether prescription drugs are substitutes
for other medical spending persists today.
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Objectives: To examine whether obtaining prescription
drug coverage through the Medicare Part D program
affected hospital admissions and inpatient expenditures
associated with those admissions for a variety of illnesses
such as congestive heart failure, stroke, dehydration and
chronic obstructive pulmonary disease).
Methods: Difference-in-differences (DID) analysis using
Medicare claims data (Medicare Provider Analysis and
Review, MEDPAR) from 2002 to 2009, which spans
the implementation of Medicare Part D in 2006. The
DID was used to compare changes in the use of, and
spending on, inpatient services pre- to post-Medicare Part
D for those who were more likely to gain prescription
insurance as a result of Medicare Part D to changes in
the use of, and spending on, inpatient services pre- to
post-Medicare Part D for those who were less likely to
gain prescription drug insurance.
Results: Gaining prescription drug insurance through
Medicare Part D was associated with a 8% decrease in
number of hospital admissions, 7% decrease in Medicare
payments for inpatient services per person. For heart-
related diseases, COPD, and dehydration, prescription
drug insurance was associated with decreases in the
number of admissions of in the range of 10% and 20%,
and was associated with decreased expenditures for these
admissions in the range of 15% and 25%. Reduced
hospital charges associated with increased prescription
drug coverage produced estimated aggregate savings of
approximately 2% of the total cost of Medicare Part D
in 2011.
Conclusions: Overall, gaining prescription drug insurance
through Medicare Part D was associated with a 8%
decrease in the number of admissions and a 7% decrease
in Medicare payments for inpatient services per person,
which substantially lowers the net cost of Medicare Part D.
186. Misuse, Abuse, and Diversion of Instanyl (Fentanyl
Nasal Spray) in France
Patrick Blin,1 Caroline Dureau,1 Stéphanie Lamarque,1
Marie-Agnès Bernard,1 Philip Robinson,1 Régis Lassalle,1
Adeline Grolleau,1 Cécile Droz,1 Nicholas Moore.1,2
1INSERM CIC Bordeaux CIC1401, Université de
Bordeaux, Bordeaux; 2CHU de Bordeaux, Bordeaux.
Background: Instanyl® (fentanyl nasal spray) received
European market authorisation in July 2009 for the man-
agement of breakthrough pain in adults already receiving
maintenance opioid therapy for chronic cancer pain, with
precise instructions on indications for use and dosage.
Objectives: To evaluate patient-reported misuse, abuse,
and diversion of Instanyl® in real-life in France.
Methods: Cross-sectional observational study of patients
with an Instanyl® dispensation from a non-hospital phar-
macy. An anonymous self-administered questionnaire was
distributed to patients at the time of drug dispensation
between 27 July 2011 and 12November 2012. The question-
naire collected data on indication, contraindications,
Instanyl® use, and previous completion of the questionnaire.
Results: Among the 272 eligible questionnaires (at least
one item completed in addition to age, gender, time since
ﬁrst prescription, and absence of previous completion of
the questionnaire), all patients were adult and 95%
declared misuse. Among the 160 patients who declared
having cancer, 94% declared misuse: 76% declared at
least one indication/contraindication misuse and 86% at
least one posology misuse. Widening the deﬁnition of
use for breakthrough pain to use for both breakthrough
and chronic pain in cancer patients, reduced the indica-
tion/contraindication misuse (63%), but when posology
misuse was also considered this did not markedly change
overall misuse (93%).
Abuse of Instanyl® (using the drug for emotional
reasons, relaxation, or sleep disorders) concerned 21
patients (15 with cancer, and 6 without); diversion
(passing the drug to another person) concerned 2 patients
(1 with cancer and 1 without).
Conclusions: Misuse of Instanyl® was widespread.
Nearly half reported not to have cancer, and among those
who did, only a few used this drug correctly. There seems
to be a communication deﬁcit as to the proper prescribing
of this drug, and its proper use when prescribed.
187. Is Preventive Medicine Curriculum among
Medical Students of Private Universities in Malaysia
Effective?
Rekarani Rajantharan,1 Shukry Zawahir,1,2 Redhwan
Ahmed Al-Naggar,3 Eddy Yusuf.1 1School of Pharmacy,
Management and Science University, Shah Alam,
Selangor, Malaysia; 2Faculty of Medicine, University of
Ruhuna, Sri Lanka; 3Faculty of Medicine, Universiti
Teknologi MARA (UiTM), Shah Alam, Selangor, Malaysia.
Background: Preventive medicine training need to be
strengthened and development of evidence-based guide-
lines for low-middle income countries be a priority.
Objectives: To determine the knowledge, perception and
attitude related preventivemedicine topics in the curriculum
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of medical students in the Malaysia’s private universities
and to explore the possible socio-demographic character-
istics inﬂuence on the effect.
Methods: The data involved 300 ﬁnal year medical
students which were randomly selected from ﬁve private
universities throughout Malaysia by proportionate to
population method.A validated, standard questionnaire
was used where to assess on the knowledge, perception
and attitude related to Preventive Medicine topics taught
in medical schools.Descriptive statistics, socio-economic
and demographic variables were used as the factor variables
in t-test and one-way ANOVA test using SPSS version 18.
Results: 2/3 of the respondents were females (68.8%)
with mean age 24 years old (SD 1.4) and from urban
Malaysia (95%).Parental education level was> secondary
level (96%) and having monthly household income RM
3000 (81%).19 knowledge and perception variables
showed higher level of knowledge and perception regard-
ing preventive medicine among medical students (95%
and 98%) and combined mean knowledge and perception
17.4 (SD 1.41) and 18.9 (SD 0.3).100% respondents
believed that it is important to learn all the preventive care
areas during their medical education. 84% students
satisﬁed with preventive care training and believed it is
important to learn 100%, physician will need to focus on
preventive care in greater extent and they willing to offer
preventive care services in the future (100%).There was
no statistical signiﬁcant inﬂuence on mean knowledge,
perception and attitude related preventive medicine by
socio-economical and demographic factors.
Conclusions: The preventive care curriculum among
Malaysia’s private universities may impart excellent
knowledge, perception and believe about preventive care
practice.Further studies being doneto investigate their
actual practice in the future.In the current analysis only
84 included, data analysis yet to be completed.
188. The Utilization Pattern of Glucocorticoids in
Taiwan Established Systemic Lupus Erythematous
Patients
Chun-Ming Chen,1,2 Yea-Huei Kao Yang,1 Tzu-Chieh Lin,1
Shu-Hua Tai,2 Hui-Jen Chang.2 1IInstitute of Clinical
Pharmacy and Pharmaceutical Sciences, College of
Medicine, National Cheng Kung University, Tainan,
Taiwan; 2Department of Pharmacy, National Cheng
Kung University Hospital, Tainan, Taiwan.
Background: Glucocorticoids are the mainstay of
therapy for SLE, but have been associated with the
development of hyperglycemia, coronary heart disease,
osteoporosis, osteonecrosis, and cataracts. The safe dose
of glucocorticoids has not been deﬁned, but daily dose
7.5mg of prednisone seem to minimize adverse effects.
Objectives: This study was aimed to investigate the prescrib-
ing patterns of glucocorticoids in Taiwan SLE patients.
Methods: This nationwide, population-based, retrospec-
tive cohort study used data from Taiwan National Health
Insurance Research Database. We identiﬁed patients
newly diagnosed with SLE during 2001-2005 and had
used glucocorticoids during the following 5 years. We
divided these population into two groups based on 5-year
cumulative dose of 13.69 g prednisone equivalent and
analyzed the prescribing patterns of glucocorticoids.
Results: A total of 4,520 incident SLE patients were
included. During the 5-year follow-up, the mean cumula-
tive and daily dose of glucocorticoid patients received
was 11.89 g and 6.51mg prednisone equivalent, respec-
tively. Patients received higher glucocorticoid dose (daily
dose of 11.4mg prednisone) in the ﬁrst year and
gradually reduced annually. Among these patients, 1047
were classiﬁed into high dose glucocorticoid users (5-year
cumulative prednisone dose> 13.69 gm) and received a
mean daily dose of 13.56mg prednisone. Also, these
patients more commonly used injectable glucocorticoids
and immunosuppressive agents and had higher rates of
disease ﬂare up.
Conclusions: In Taiwan, glucocorticoids are most
commonly used in SLE patients. Almost 32.6% of SLE
patients received high dose of glucocorticoids during
5 years after diagnosed. The adverse effects need to be
carefully monitored.
189. Evaluating the Impact of the Utah Clinical
Guidelines on Prescribing Opioids for Treatment of
Pain in Utah
Brian C Sauer,1,2 Chai-Chen Teng,1,2 Christy Porusnik,3
Erin Johnson,4 Robert Rolfs,4 Jonathan Nebeker.1 1SLC
HSR&D COIN (IDEAS 2.0), Veterans Health Adminis-
tration, Salt Lake City, UT, United States; 2Internal
Medicine Division of Epidemiology, University Utah,
Salt Lake City, UT, United States; 3Family Practice and
Medicine, University of Utah, Salt Lake City, UT, United
States; 4Utah Department of Health, Salt Lake City, UT,
United States.
Background: The leading cause of injury death in Utah
has been poisoning from prescription drugs – with
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opioid-related poisonings as the primary offender. As a
response, the State Legislature passed a Bill to establish
opioid quality of care guidelines. The primary goal of
the guideline is to seek balance between appropriate
treatment of pain and safe use of opioids.
Objectives: To quantify changes in opioid prescribing
and adverse events before guideline development
(pre-period) during development and media attention
(intermittent period) and after promulgation of the
Guidelines (post-period).
Methods: Multiple data sources were used for this
analysis including the Utah Controlled Substances
Database (CSD), Utah ED encounter database, and the
state medical examiner database. Process ﬂags included
the dual use of long-acting opioids or short-acting opi-
oids, combined use of benzodiazepines and long-acting
opioids, methadone titration. Outcome ﬂags included
the opioid related ED visits and deaths. Opioid users
were categorized as acute, intermittent, chronic or pallia-
tive. Flags were compared by opioid user type across the
pre-intervention period (07/2006-06/2007), intermittent
period (08/2007-07-2008), and post-period (04/2009-03/
2010). Risk ratios were computed to quantify changes
in the incidence of ﬂags among time periods.
Results: During each period there were approximately
380,000 acute uses, 32,000 chronic, 220,000 intermittent
and 5,000 palliative users. Most process and outcome
measures signiﬁcantly improved for chronic and intermit-
tent opioid users during the post-guideline periods.
Chronic users had the highest proportion of poly-
pharmacy and outcome ﬂags but also showed signiﬁcant
reduction in dual use of long-acting opioids, use of
benzodiazepines and long-acting opioids, opioid related
ED visits and opioid related deaths.
Conclusions: While the number of opioid users
remained constant across time periods, there has been a
decrease in unsafe use of opioids and opioid-related ad-
verse events in Utah since the opioid prescribing guide-
lines were promulgated and received media attention.
190. Examining the Impact of the Utah Opioid
Guideline Based Intensive Educational Intervention on
Opioid Prescribing in Utah
Brian C Sauer,1,2 Chai-Chen Teng,1,2 Christy Porusnik,3
Erin Johnson,4 Robert Rolfs,4 Jonathan Nebeker.1
1SLC HSR&D COIN (IDEAS 2.0), Veterans Health
Administration, Salt Lake City, UT, United States;
2Internal Medicine Division of Epidemiology, University
Utah, Salt Lake City, UT, United States; 3Family
Practice and Medicine, University of Utah, Salt Lake
City, UT, United States; 4Utah Department of Health,
Salt Lake City, UT, United States.
Background: As a response to the alarming increase in
opioid related deaths, the Utah State Legislature passed
a Bill to establish opioid quality of care guidelines. In
addition, the state sponsored a 20 credit Performance
Improvement Continuing Medical Education (PI-CME)
to teach prescribers about the new opioid prescribing
guidelines, how to access and use the Controlled
Substance Database (CSD) to check individual patients
and review their patient panel to assess improvements
in their prescribing patterns.
Objectives: To quantify changes in opioid prescrib-
ing and adverse events among providers who
received various levels of the PI-CME designed to
teach opioid prescribing guidelines and use of
promoted tools.
Methods: Providers voluntarily enrolled in the 3 Stage
course. Stage A involved generating a CSD report of
each provider’s patients during the past 6-weeks,
Stage B focused on the 6 tools for safe opioid use
and Stage C required participants to assess changes
in their prescribing. Multiple data sources were used
for this analysis including the CSD, Utah ED encoun-
ter database, and the state medical examiner database.
Process ﬂags included the dual use of long-acting
opioids or short-acting opioids, combined use of
benzodiazepines and long-acting opioids, methadone
titration. Outcome ﬂags included the opioid related
ED visits and deaths. Opioid users were categorized
as acute, intermittent, chronic or palliative. Flags were
compared between patients who completed different
stages of the educational intervention. Risk ratios were
adjusted using previous year prescribing ﬂags and
specialty.
Results: Stage A or higher was completed by 288
providers while Stage B or higher was completed by 95
providers. Approximately 8000 providers were not
exposed to the educational intervention. Providers
exposed to stage A or higher had a signiﬁcantly lower
incidence of dual long-acting and dual short-acting
opioids. They also had a signiﬁcantly lower incidence
of any process violation.
Conclusions: Providers who attended the intensive
educational intervention reduced the use of potentially
hazardous opioid prescribing.
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191. Use of Bipolar Disorder Medications Prior to
Diagnosis
Zhiwen Liu,1 Melissa Whipple,1 Jane Liao,1
Edward A Bortnichak,1 Mellissa Yong,1 Herve Besson.2
1Merck, Whitehouse Station, NJ, United States;
2Merck Sharp & Dohme, Oss, Netherlands.
Background: Bipolar disorder (BD) is not easy to
diagnose when it starts because the symptoms may seem
like separate problems, not recognized as part of a larger
problem.
Objectives: To identify and characterize subjects having
prescribed BD related medications prior to a BD
diagnosis (pre-treated BD subjects) using US healthcare
claims databases.
Methods:We identiﬁed subjects with a minimal 365-day
continuous medical and pharmacy enrollment period
prior to a BD diagnosis (BD index date) in the Truven
Health MarketScan Commercial & Medicare Supplemen-
tal Database with data up to 12/31/2011. Subjects
receiving at least one prescription for “atypical antipsy-
chotics”, “typical antipsychotics”, and/or “anti-manic
agents”(BD prescriptions) prior to their BD index date
were deﬁned as pre-treated while those not receiving
BD prescriptions were deﬁned as incident. Descriptive
statistics were calculated to characterize the pre-treated
and incident subjects.
Results: Approximately 42% out of a total of 199,257
BD subjects had a BD prescription prior to BD index
dates. Among the pre-treated, 74% had prescriptions for
anti-manic agents, 47% for atypical antipsychotics and
3.9% for typical antipsychotics prior to BD index date;
and the pre-treated subjects also kept similar prescription
patterns during the follow-up after BD index date. The
pre-treated subjects receiving anti-manic agents had the
longest pre-treated period beginning from 1st prescription
to BD index date (median 496 days vs. 393 days for
typical antipsychotics and 275 days for atypical antipsy-
chotics). Compared with incident subjects the pre-treated
consisted of more females and were older; furthermore,
the pre-treated group had higher baseline rates of mental
disorders and higher healthcare utilization during the
follow-up period.
Conclusions: It is common for subjects to have been
prescribed a BD related medication prior to a BD
diagnosis in our study population.BD diagnosis alone is
inadequate to determine a patient’s actual onset of
disease; and all related factors including BD medications
and other mental health conditions need to be considered
to better determine BD disease status.
192. Assessment of Appropriateness and Safety of
Dihydroergotoxine Use
Ching Yu Chang. Depeatement of Pharmacy, Ten-Chan
Medical Group, Ten-Chan Hospital, Taoyuan, Taiwan.
Background: As an ergot derivative, dihydroergotoxine
plays an important role in patient who with alzheimer’s
disease or dementia. According to restrictions on use of
medicines containing ergot derivatives from European
Medicines Agency(EMA), Taiwan Food and Drug
Administration(TFDA) posted about ergot derivative
drug safety information on August 2013.
Objectives: This study aimed to evaluate the appropri-
ateness and safety of dihydroergotoxine use, and propose
improvement plan.
Methods: This study is a retrospective study. We
backtracked the patient who has used dihydroergotoxine
from November 01, 2013 to January 31, 2014. According
to indication of dihydroergotoxine, we analyzed patient
who has or do not has indication about alzheimer’s dis-
ease or dementia.We also research if there is drug adverse
event between using of dihydroergotoxine. This study
use IBM SPSS 19 version to analysis the data.
Results: This retrospective study backtracked about 119
patient who has used dihydroergotoxine, since November
01, 2013 to January 31, 2014. There are 45(37.8%)
patients has alzheimer’s disease(ICD-9-CM code 331.0),
45(37.8%) patients has dementia((ICD-9-CM code 290.0,
290.1, 290.2, 290.3, 290.4, 291.2, 292.82, 294.1), and 29
(24.4%) patients has no related indication. According to
the hospital informed of nosocomial adverse drug reac-
tions, there is no patients due had adverse drug reactions
between using dihydroergotoxine produce.
Conclusions: According to the result, there are about 29
(24.4%) patients had no indication. Although there is no
patients due had adverse drug reactions between using
dihydroergotoxine produce, according to the results of
the analysis of the appropriateness of drug use still has
some place can be improved, so the hospital will be made
to improve the program for physicians prescribing
dihydroergotoxine, containing: (1)automatically indica-
tion windows (2)will pop an automatically warming win-
dows for no recommended use indication (3)will mark
the drug in the prescription to remind pharmacists to con-
ﬁrm whether there is an related indication with medicine.
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193. The Utilization and Safety of Abraxane for the
Treatment of Metastatic Breast Cancer in the USA:
Results from Health Insurance Claims Data
Caihua Liang,1 Ling Li,1 Cindy Duval,2 Amy Ko,2
Debra Patt,3 Deyanira Corzo,2 Cheryl Enger.4 1Epidemiology,
Optum, Waltham, MA, United States; 2Celgene Corporation,
Summit, NJ, United States; 3McKesson Specialty
Healthy/US Oncology, Houston, TX, United States;
4Epidemiology, Optum, Ann Arbor, MI, United States.
Background: Abraxane® (ABX) is an albumin-bound
formulation of paclitaxel approved for treatment of
metastatic breast cancer (MBC).
Objectives: To characterize the utilization and safety of
ABX for MBC treatment in the USA using health insur-
ance claims data.
Methods: Women aged ≥18 who initiated ABX for
MBC treatment were accrued from Optum Research
Database from 01/01/2005 to 09/30/2012. Patients were
required to have complete medical coverage and phar-
macy beneﬁts, ≥6months of continuous enrollment, and
a diagnosis of MBC (≥2 claims of BC diagnosis sepa-
rated by 30 days and ≥ 2 claims of metastatic spread)
prior to ABX initiation. The utilization of ABX in terms
of duration and number of administrations was character-
ized by line of therapy, regimen, and schedule. Overall
survival (OS), time to treatment discontinuation (TTD),
and major toxicities were described in a similar fashion.
Results: Among the 664 ABX patients, 172 (26%) initi-
ated ABX as the 1st line of therapy, 211 (32 %) as 2nd
line, and 281 (42%) as ≥3 rd line. Overall, 61% of patients
received monotherapy and 71% received weekly treat-
ment. The duration of ABX therapy in the 1st line was
longer and the total number of administrations was larger
than later lines of therapy. ABX was combined most
commonly with targeted therapy (22% with bevacizumab
and 9% with trastuzumab or lapatinib). Median OS was
17.4months (22.7, 17.4, and 15.1months in 1st, 2nd and
>3rd line, respectively) and 15.6months in those patients
≤50 years or with ≥3 metastases; median TTD was
6.1months (7.1, 6.6, and 5.3 in 1st, 2nd and >3rd line, re-
spectively). No new safety signal was identiﬁed.
Conclusions: In this healthcare system, the majority of
patients received ABX as a ≥2nd line of therapy,
prescribed as monotherapy and as weekly treatment.
The safety outcomes of ABX utilization observed in this
real-world setting appear consistent with those from
clinical trial data.
194. Patterns of Analgesic Initiation among Hemodialysis
Patients
Magdalene M Assimon, Anne M Butler, Lily Wang,
Abhijit V Kshirsagar,M Alan Brookhart. University
of North Carolina at Chapel Hill, Chapel Hill, NC,
United States.
Background: Pain is a common debilitating comorbid
condition of end-stage renal disease (ESRD), with approx-
imately 50% of hemodialysis (HD) patients reporting
problems with chronic pain. A key component of pain
management is pharmacologic treatment with analgesics.
Even though these medications are frequently prescribed
in the United States (US), data characterizing analgesic
use in the HD population is sparse.
Objectives: To describe patterns of prescription analge-
sic initiation in HD patients receiving treatment at a large
US dialysis provider from 2007-2010.
Methods: We conducted a retrospective analysis using
data from a large US dialysis provider linked with the
US Renal Data System, a national registry of HD patients
in the Medicare ESRD program. We identiﬁed patients
≥18 years of age who were receiving chronic HD for >9
months and had Medicare as their primary payer with
Part A, B and D coverage. Patients newly initiating anal-
gesics (opioids, non-steroidal anti-inﬂammatory drugs
(NSAIDs) and celecoxib) were identiﬁed after a 6month
washout period using Medicare Part D claims. Patterns of
analgesic initiation from 2007-2010 are described.
Results: Of 40,243 analgesic new-users (mean age = 59 ±
15 years, 50.5% male, 47.5% black), opioids were the
most common analgesic class initiated (90.7%), followed
by NSAIDs (8.5%), and celecoxib (0.8%). Among anal-
gesic initiators, opioid use increased from 89.6% in
2007 to 91.5% in 2010, whereas NSAID and celecoxib
use declined slightly. The majority of opioid initiators
received a combination product containing acetamino-
phen (87.5%) and nearly all opioid users received a
short-acting formulation (99.2%). The most commonly
prescribed opioids were hydrocodone (43.4%) and
oxycodone (14.2%). Ibuprofen (50.8%) and naproxen
(19.7%) were the most frequently initiated NSAIDs.
Conclusions: Among HD patients the vast majority of
analgesic initiators were prescribed opioids, particularly
hydrocodone and oxycodone. Given the wide use of
these agents and that some opioids demonstrate altered
pharmacokinetics in ESRD, future research is needed to
better understand the relative efﬁcacy and safety of
individual opioids in the HD population.
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195. Prevalence of Inappropriate Prescribing of
Inhaled Corticosteroids for Respiratory Tract
Infections in the Netherlands
Martina Teichert,1,2 Andre Wissenburg,2,3 Peter de Smet,1,2
Michel Wensing,2 Tjard Schermer.4 1Research &
Development, Royal Dutch Pharmacists Association
(KNMP), The Hague, Netherlands; 2Scientiﬁc Institute
for Quality of Healthcare (IQ Healthcare), Radboud
UMC, Nijmegen, Netherlands; 3SAL Apotheek,
Schuytgraaf, Nijmegen, Netherlands; 4Department of
General Practice/Family Medicine, Radboud UMC,
Nijmegen, Netherlands.
Background: Inhaled corticosteroids (ICS) are recom-
mended in prevailing guidelines for use in persistent
asthma and moderate to severe chronic obstructive
pulmonary disease (COPD). An Australian study showed
that 44% of patients with only one ICS dispensing and no
other respiratory medications (‘one off ICS’) were co-
dispensed oral antibiotics.
Objectives: To investigate the extend of one off ICS dis-
pensing with potential use in respiratory infections in the
Netherlands by a cross sectional study.
Methods: Data were obtained from a foundation that
collects dispensing data from community pharmacies.
Patients with at least one ICS dispensing in 2011 were
included. With logistic regression the inﬂuence of co-
dispensed oral antibiotics on receiving one-off ICS was
calculated.
Results: In 2011 within 845,068 ICS users in 1,725 phar-
macies 10% were dispensed one-off ICS, among which
12.9% together with oral antibiotics. This potential ICS
use for management of infections cost annually €555,000
and was mainly prescribed by General Practitioners,
mostly in ﬁxed combination with long acting b-agonists.
Co–dispensed oral antibiotics increased the chance to
receive a one-off ICS dispensing within all ICS users by
more than 5 times (OR 5.27, 95% CI 5.14 – 5.40).
Conclusions: In the Netherlands 1.3% of all ICS pre-
scribing was for management of respiratory infections.
196. Impact of Tuberculosis Treatment on Health-
Related Quality of Life of Pulmonary Tuberculosis
Patients: A Follow-Up Study
Muhammad Atif, Syed Azhar Syed Sulaiman,
Asrul Akmal Shaﬁe,MuhammadAsif, ZaheerUd-DinBabar.
Discipline of Clinical Pharmacy, Universiti Sains
Malaysia, Penang, Malaysia; Department of Pharmacy,
The Islamia University of Bahawalpur, Bahawalpur,
Punjab, Pakistan; Department of Pharmacy, Division of
Pharmacy Practice, University of Auckland, Auckland,
New Zealand.
Background: With regard to the impact of tuberculosis
(TB) treatment on health-related quality of life (HRQoL),
only two longitudinal studies from Asia are available in
literature, although none used widely acceptable HRQoL
assessment tool.
Objectives: The aim of this study was to evaluate the
impact of TB treatment on HRQoL of new smear positive
pulmonary tuberculosis (PTB) patients.
Methods: This was a follow-up of new smear positive
PTB patients who were diagnosed at the Penang
General Hospital between March 2010 and February
2011. All eligible PTB patients (i.e. literate and aged
≥18 years) were asked to self-complete the SF-36v2
questionnaire at the start of their treatment, and then
subsequently after the intensive phase and at the end
of the treatment. A score on a health domain or com-
ponent summary measure that was <47 norm-based
scoring (NBS) point was considered indicative of
impaired function within that health domain or
dimension. Likewise, an individual having mental
component summary (MCS) score ≤42 NBS point
was considered to be at the risk of depression.
Repeated measures ANOVA test was performed to
examine how the summary scores varied over time,
and to determine whether independent variables were
predictive of variability in the physical component
summary (PCS) and MCS scores over time.
Results: A total of 216 patients completed the SF-36v2
questionnaire at the start of their treatment. Out of these,
177 and 153 completed the questionnaire at the second
and third follow-ups, respectively. The mean PCS and
MCS scores at the start of the treatment, after the
intensive phase and at the end of treatment were <47
NBS points. More than 23% of the patients were at the
risk of depression at the end of their TB treatment.
Patient’s age and being a smoker were predictive of
differences in the PCS scores. Similarly, monthly
income, being a smoker and TB-related symptoms at
the start of the treatment were predictive of differences
in the MCS scores.
Conclusions: Although HRQoL improved with the
treatment, the scores on summary measures showed
compromised physical and mental health among study
patients even at the end of their TB treatment.
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197. Characteristics Associated with Use of Oral or
Inhaled Respiratory Medications at Initiation for
Patients with Chronic Obstructive Pulmonary
Diseases
Yaa-Hui Dong,1 Chia-Hsuin Chang,2 Shu-Ting Chen,3
Mei-Shu Lai.1,3 1Center of Comparative Effectiveness
Research, Center of Comparative Effectiveness
Research, National Center of Excellence for Clinical
Trial and Research, National Taiwan University
Hospital, Taipei, Taiwan; 2Department of Internal
Medicine, National Taiwan University Hospital, Taipei,
Taiwan; 3Graduate Institute of Epidemiology and
Preventive Medicine, College of Public Health, National
Taiwan University, Taipei, Taiwan.
Background: Chronic obstructive pulmonary disease
(COPD) is a substantial disease burden worldwide. In
terms of effectiveness and safety proﬁles, inhaled
respiratory medications rather than oral therapies is the
cornerstone of management of COPD. However, the
proportion of patients starting oral or inhaled respiratory
medications and characteristics associated with use of
which therapy are not well understood.
Objectives: To examine the proportion of individuals
starting oral or inhaled respiratory medications and
determinants of which therapy being given in patients
with COPD.
Methods: A cross-sectional study was conducted using
the Longitudinal Health Insurance Database 2005
derived from the Taiwan’s national health insurance
system. Patients who initiated respiratory medications at
the outpatient visits between January 1, 2001 and
December 31, 2010 and who were with COPD diagnosis
were identiﬁed. Association between use of oral versus
inhaled respiratory medications at initiation and baseline
demographic data was assessed by the multiple logistic
regression model, with covariates of patient-, physician-,
and hospital-level characteristics.
Results: A total of 23,189 COPD patients were included
in the analysis, 92.9% and 7.1% of whom initiated oral
and inhaled respiratory medications, respectively.
Female patients and individuals who were with age< 40
years, longer durations for COPD diagnosis, more
comorbidities, or lower incomes were more likely to
receive oral rather than inhaled respiratory medica-
tions. Also, patients who visited physicians who were
older, were not chest specialties, or did not serve at
the medical centers were more likely to being
prescribed oral therapies.
Conclusions: A vast majority of patients started oral
rather than inhaled respiratory medications in Taiwan,
which may be associated with patient-, physician-, and
hospital-level characteristics. Further strategies should
address these elements to improve the treatment patterns
for COPD patients.
198. Changes in Drug Prescriptions After the SMART
Trial – Secondary Data Analysis of Bavarian Asthma
Patients
Marietta Rottenkolber,1 Rainald Fischer,2 Luisa
Ibáñez,3,4 Joan Fortuny,5 Robert Reynolds,6 Roman
Gerlach,7 Martin Tauscher,7 Petra Thuermann,8,9 Joerg
Hasford,1 Sven Schmiedl.8,9 1Institute for Medical
Information Sciences, Biometry, and Epidemiology,
Ludwig-Maximilians-Universitaet, Munich, Germany;
2Medizinische Klinik und Poliklinik V, University
Hospital, Ludwig-Maximilians-Universitaet, Munich,
Germany; 3Fundació Institut Català de Farmacologia,
Hospital Universitari Vall d’Hebron, Barcelona,
Spain; 4Departament de Farmacologia, Terapèutica i
Toxicologia, Universitat Autònoma de Barcelona,
Barcelona, Spain; 5Novartis Farmaceutica S.A., Barcelona,
Spain; 6Epidemiology, Pﬁzer, New York, United States;
7National Association of Statutory Health Insurance
Physicians of Bavaria, Munich, Germany; 8Department of
Clinical Pharmacology, School of Medicine, Faculty
of Health, Witten/Herdecke University, Witten, Germany;
9Philipp Klee-Institute for Clinical Pharmacology,
HELIOS Clinic Wuppertal, Wuppertal, Germany.
Background: Following the publication of the
SMART trial (2006) which evaluated the safety of
salmeterol (long-acting beta-2-agonist (LABA)) in
asthma patients, drug authorities explicitly recommended
to use LABA only in patients receiving inhaled cortico-
steroids (ICS).
Objectives: We aim to describe LABA- and ICS-
related prescription patterns after the SMART trial in
Germany.
Methods: Patients documented in the Bavarian Associa-
tion of Statutory Health Insurance Physicians database
(covering 85% of the population, i.e. approximately
10.5 million people) were included if they had a diagno-
sis of asthma and at least one prescription of LABA and/
or ICS between 2004 and 2008. Annual period preva-
lence rates (PPRs) per 10,000 insured persons were
calculated for all LABA and ICS compounds separately.
For ﬁve mutually exclusive patient categories “concomi-
tant LABA and ICS users”, “switchers”, “non-concomitant
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LABA and ICS users”, “LABA users without ICS”, and
“only ICS user”, stratiﬁed analyses by calendar year, age
and sex were made. Cochrane Armitage test was used to
analyse trends over time.
Results: Highest annual PPRs were found for
budesonide (between 76 and 91 per 10,000 persons)
and the ﬁxed combination of salmeterol/ﬂuticasone
(between 62 and 73 per 10,000 persons). The fraction
of “concomitant LABA and ICS users” increased
signiﬁcantly from 52 to 58% within the study period,
whereas for “LABA users without ICS” a signiﬁcant
decrease from 6.5 to 5.4% was found. The fraction of
patients with at least one LABA prescription without
concomitant ICS was highest in elderly, male patients
(approximately 20%).
Conclusions: In a representative German population, we
found in general an increase in guideline-adherent LABA
prescriptions in terms of concomitant ICS prescribing.
Nevertheless, elderly men received a signiﬁcant number
of LABA presciptions without concomitant ICS which
might increase the risk for LABA-related adverse events.
(This research received support from the European
Innovative Medicine Initiative Joint Undertaking
through the PROTECT project).
199. Changes in Thiazolidinedione Utilization and
Outcomes Following Safety Warning and Risk
Evaluation & Mitigation Strategies (REMS) in Taiwan
Jason C Hsu,1,2 Dennis Ross-Degnan,2 Ching-Lan
Cheng,1 Anita K Wagner,2 Fang Zhang,2 Yea-Huei Kao
Yang,1 Li-Ling Liu,3 Hsueh-Yung Tai,3 Ke-Hsin Chen,3
Po-Wen Yang,3 Yi-Chen Juan,3 Christine Y Lu.2 1Institute
of Clinical Pharmacy and Pharmaceutical Sciences,
National Cheng Kung University, Tainan, Taiwan;
2Department of Population Medicine, Harvard
Medical School and Harvard Pilgrim Health Care
Institute, Boston, MA, United States; 3Division of
Drug, Food and Drug Administration, Ministry of
Health and Welfare, Taipei, Taiwan.
Background: Due to concerns over the possible increase in
cardiovascular risk, US and Taiwan FDAs implemented
safety warnings and Risk Evaluation & Mitigation
Strategies (REMS) programs for thiazolidinedione agents.
Objectives: To evaluate changes in thiazolidinedione use
and clinical outcomes following US FDA warnings for
thiazolidinedione and cardiovascular risk, Taiwan
rosiglitazone’s REMS and warnings for pioglitazone
and bladder cancer risk in the Taiwan population.
Methods: We obtained 2005-2011 claims data from
Taiwan’s National Health Insurance Research Database.
Using an interrupted time series design and segmented
regression, we estimated changes in monthly rates of
thiazolidinedione utilization. We also used survival
analysis and Cox proportional-hazards regression to
estimate the impacts of the interventions on time to index
prescription and cardiovascular-related events.
Results: There were relative reductions of 6.57% and
38.07% in prescribing and initiation rates of rosiglitazone
at 1 year following the US FDA boxed warnings compared
to expected rates. In contrast, there was no signiﬁcant
change in the use of pioglitazone. There was a relative re-
duction of 21% in prescribing of rosiglitazone following
Taiwan’s REMS, and a relative reduction of 12% in
prescribing of pioglitazone following its warnings and
bladder cancer risk. Further, we found signiﬁcant delays
in rosiglitazone prescription following both US FDA’s
warnings (HR=0.359) and Taiwan’s REMS (HR=0.022).
In contrast, time to pioglitazone prescription was shorter
following the US FDA’s warnings (HR=2.253). More-
over, there were signiﬁcant reductions in cardiovascular-
related event rates after the US FDA’s warnings (heart fail-
ure: HR=0.105; myocardial infraction: HR=0.152).
However, we did not detect signiﬁcant changes in hazard
ratios following Taiwan rosiglitazone’s REMS.
Conclusions: Rosiglitazone use reduced in Taiwan
following the US FDA’s thiazolidinedione’s safety
warnings; this may be associated with reductions in
cardiac adverse events. While Taiwan’s REMS for
rosiglitazone reduced use of this drug, there were no
changes in cardiac adverse events.
200. The Prescribing Pattern of Postnatal Steroids on
Preterm Infants in Taiwan
Tzu-Ling Kuo,1 Ching-Lan Cheng,1 Yea-Huei Kao Yang,1
Yung-Chieh Lin.2 1Institute of Clinical Pharmacy and
Pharmaceutical Sciences, National Cheng Kung
University, Tainan,Taiwan; 2Department of Pediatrics,
National Cheng Kung University College of Medicine
and Hospital, Tainan, Taiwan.
Background: The American Academy of Pediatrics rec-
ommends that use of postnatal steroid treatment for preterm
infants with chronic lung disease should be weight against
the potential adverse effect on neurodevelopment.
Objectives: The aim of this study was to analyze trends
in the use of postnatal steroids in Taiwanese preterm
infants over a 13-year period.
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Methods: We used population-based nationwide claims
database from 1999 to 2011 to estimate the change in
the use of systemic and inhaled steroids among preterm
infants. The preterm infants was deﬁned by ICD-9 code
765.0, 765.1 and V21.3. And we did a subgroup analysis
via birth-weight, separate in to two groups: other preterm
infants (birth weight of 1,000-2,499 g) and extremely
immature infants (birth weight of less than 1,000 g). Data
were analyzed in Chi-Square test for trend, and statistical
signiﬁcance was indicated by a p-value< 0.05.
Results: A total of 101,292 infants with 6,574 postnatal
steroid prescriptions were analyzed. The overall prescrip-
tion rate of steroids for infants decreased from 8.69% in
1999 to 4.43% in 2011 (P< 0.0001). The overall pre-
scription trend were similar in other preterm infants
(7.4% in 1999 vs. 2.5% in 2011, P< 0.0001), and in
extremely immature infants (28.5% in 1999 vs. 22.7%
in 2011, P = 0.0091). The prescription rate was higher
in extremely immature infants than in other preterm
infants (from 28.5% to 22.7% vs 7.4% to 2.5%). We also
observed a decline in prescribing of systemic steroids
(96.4% in 1999 vs. 86.0% in 2011) and increase in
inhaled steroid over time (3.6% in 1999 vs. 14.0% in
2011). The most frequently used medication in systemic
steroid was dexamethasone (49.2%-80.8 %), and in
inhaled steroid was budesonide (1.3%-15.6%).
Conclusions: Between 1999 and 2011, the prevalence of
postnatal steroid prescriptions in Taiwan has decreased.
Whether these changes affected rates of impaired
neurodevelopment requires further investigation.
201. Prescribing of Drugs in the Therapy of Acute
and Chronic Pain in Family Medicine Practice in
Croatia
Danijela Stimac,1 Meri Margreitner,2 Zvonimir Sostar.1
1Department for Public Health, Zagreb Institute of
Public Health, Zagreb, Croatia; 2General Practitioner,
Health Centre Zagreb East, Zagreb, Croatia.
Background: Medications are the most frequently
prescribed therapy for pain. The most prescribed drugs
in pharmacotherapy of pain are analgetics (N02) and
NSAIDs (M01). Utilization of these drug groups are very
high in Croatia.
Objectives: The aim of this study was to determine the
number and the type of prescribed oral analgesics and
NSAIDs, which are calculated on the Croatian Health
Insurance Fund, according to the diagnoses and to the
length of prescribing.
Methods: Data on the number and the type of prescribed
analgesics and NSAIDs, according to the generic name of
the drug, were obtained by a retrospective review using
e-health records of patients within the specialist outpa-
tient family medicine in the period from January 1 to
December 31, 2013.
Results: On the sample of the total number of patients
MSM (N= 1838), it was found that during the year
2013,the medication for pain was prescribed to 1305
(71 %) patients. Among these, 95.7 % of patients
received the medication for acute pain, and 4.1% for the
chronic pain. Medications were mostly prescribed for a
group of diseases of the musculoskeletal system, M00 -
M99, precisely 1115 (79.4 %). All patients who had
chronic pain ( 54 ), complained about the pain of the
musculoskeletal system, and 50 % had a lower back pain
M54. In the treatment of acute pain the most commonly
prescribed were the NSAIDs, of which ibuprofen with
32.7 %, the combination of tramadol - acetaminophen
with 17.7% and 14.2 % of tramadol. In the treatment of
chronic pain the NSAIDs were prescribed with 64%,
and 26% of tramadol - acetaminophen. 40.7 % of patients
in addition to NSAIDs and/or analgesics had a prescribed
anxiolytic, while in 16.6 % of patients antidepressants
were prescribed and in 3 % of analgesic treatment the an-
ticonvulsant was added. All patients with prescribed
NSAIDs in the treatment receive a gastroprotective drug.
Conclusions: This study conﬁrmed the high prevalence
of prescription of pain medications in the outpatient
GP. A family doctor has to recognize chronic pain and
to include Co-analgesics, and with NSAIDs to necessar-
ily prescribe a gastroprotective drug.
202. Utilization and Government Cost of Antisecretory
Drugs among Elderly in Australia and New Zealand
Suvimol Niyomnaitham,1,2 Alesha Smith.1,3,4 1School of
Pharmacy, University of Queensland, Brisbane, Queensland,
Australia; 2Faculty of Medicine Siriraj Hospital, Mahidol
University, Bangkok, Thailand; 3School of Pharmacy,
University of Otago, Dunedin, Otago, New Zealand; 4BPAC,
Dunedin, Otago, New Zealand.
Background: The marked increase of proton pump
inhibitors (PPIs) dispensed has replaced the use of
histamine-2-receptor antagonists (H2RA) in the last
decade. All 5 PPIs are available in Australia, whereas in
New Zealand only omeprazole, pantoprazole, and
lansoprazole are available. Cross jurisdictional compari-
sons of utilization and costs can lead to improve use
and reduce cost of these medications.
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Objectives: To compare government subsidized costs
and utilizations of antisecretory drugs in those ≥65 years
in Australia and New Zealand from 2008-2012.
Methods: In Australia, we extracted subsidized cost and
dispensing numbers in those aged ≥65years from the
Pharmaceutical Beneﬁts Scheme, a nationwide database.
Similar data in New Zealanders was obtained from the
National Pharmaceutical collection. In 2012, co-payments
are AUD5.80 and NZD3 per prescription in Australia and
New Zealand, respectively. We calculated the annual
utilization of each individual antisecretory drug by
converting to Deﬁned Daily Dose (DDD) per 1000popula-
tion per day. Changes in utilization and cost were analyzed
using a liner regression, followed by a t-test with level of
signiﬁcance at p< 0.05.
Results: Both PPI and H2RA utilization is higher in
Australia than New Zealand during study period. H2RA
makes up less than 10% of all antisecretory drug use in
both countries. The use of PPIs increased from 274 to
318 in Australia and 226 to 232 DDD/1000 population
aged ≥65 year/day in New Zealand between 2008 and
2012. Esomeprazole was the most frequently dispensed
PPI in Australia and accounted for 39% of all PPI use
followed by pantoprazole (27%) in 2012. While 87% of
PPIs dispensed in 2012 was omeprazole in New Zealand.
The Australian government spent AUD 360 million in
2012 on PPIs or 112 AUD/population aged ≥65 year
compared to 6.5 NZD/population aged ≥65 year for
New Zealand government. This cost difference can be
attributed to the 60% higher cost per DDD of esomeprazole
(AUD1.16) compared to omeprazole (AUD0.72).
Conclusions: In comparison to New Zealand, Australia
has a greater utilization and cost burden of antisecretory
drugs. This higher cost is likely to be due to the
expensive PPI, esomeprazole.
203. Hospital Length of Stay for Patients with Acute
Myocardial Infarction in China
Qian Li,1 Zhenqiu Lin,2 Frederick A Masoudi,3 Xi Li,4
Sonia Hernández-Díaz,1 Sudhakar V Nuti,2 Lingling Li,5
Qing Wang,4 John A Spertus,6 Harlan M Krumholz,2
Lixin Jiang.4 1Department of Epidemiology, Harvard
School of Public Health, Boston, United States; 2Center
for Outcomes Research and Evaluation, Yale University
School of Medicine, New Haven, United States;
3Division of Cardiology, University of Colorado Anschutz
Medical Campus, Aurora, United States; 4National
Clinical Research Center of Cardiovascular Diseases,
Fuwai Hospital, Chinese Academy of Medical
Sciences and Peking Union Medical College, Beijing,
China; 5Department of Population Medicine, Harvard
Medical School and Harvard Pilgrim Health Care
Institute, Boston, United States; 6Saint Luke’s Mid
America Heart Institute, Kansas City, United States.
Background: China is experiencing increasing burden of
care for acute myocardial infarction (AMI) in the face of
limited medical resources. Hospital length of stay (LOS)
is an important indicator of resource utilization.
Objectives: To examine the variation in LOS for AMI
across hospitals and over time in China and to identify
hospital characteristics that are associated with shorter LOS.
Methods: We used data from the Retrospective AMI
Study within the China Patient-centered Evaluative As-
sessment of Cardiac Events (China PEACE), a nationally
representative sample of patients hospitalized for AMI
during 2001, 2006, and 2011. Hospital-level variation
in risk-standardized LOS (RS-LOS) for AMI, accounting
for differences in case mix and year, was examined with
two-level generalized linear mixed models. A generalized
estimating equation model was used to evaluate
hospital characteristics associated with LOS. Absolute
differences in RS-LOS and 95% conﬁdence intervals
were reported.
Results: The weighted median and mean LOS was 13 and
14.6 days, respectively, in 2001 (n=1,901), 11 and
12.6 days in 2006 (n=3,553), and 11 and 11.9 days in
2011 (n=7,252). There was substantial variation in hospital
RS-LOS across the 160 hospitals, ranging from 9.2 to
18.1 days. Hospitals in the Central regions had on average
1.6 days (p=0.02) shorter RS-LOS than those in the Eastern
regions. All other hospital characteristics relating to capacity
for AMI treatment were not associated with LOS.
Conclusions: Although hospital LOS for patients with
AMI decreased over the past decade in China, it remains
long compared with international standards. Inter-hospital
variation is substantial even after adjusting for case-mix
and year. The implementation of standard clinical path-
ways may be helpful in further shortening LOS and
reducing unnecessary hospital variation.
204. Hospital Registry of Stroke or Transient Ischemic
Attack (LIS-2). Design and Prehospital Medical
Treatment Analyses
Sergey Yu Martsevich,1 Liubov Yu Drozdova,1 Natalia P
Kutishenko,1 Moisey L Ginzburg,2 Alexander Yu
Suvorov,1 Anna V Akinova,1 Natalia Yu Zhuravskaya.1
1Preventive Pharmacotherapy, National Research Center
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for Preventive Medicine, Moscow, Russian Federation;
2Lyubertsy District Hospital No. 2, Lyubertsy, Moscow
Region.
Background: The registry included all patients with
stroke, intracranial hemorrhage (IH) and transient ische-
mic attack (TIA),consecutively admitted to the Lyubertsy
district hospital No. 2.
Objectives: Estimation of social, demographic and
anamnestic characteristics of pts with cerebral stroke
(CS) as well as medical treatment received by the pts
before the reference CS in the hospital.
Methods: All the pts, regardless of age, sex, etc. admit-
ted to the hospital due to CS from 01.01.2009 to
31.12.2011 were included into the registry. Analysis of
social, demographic, anamnestic characteristics, assess-
ment of cardiovascular therapy before the reference CS
was performed.
Results: Among all included (N = 983), 37.0%
(n = 364) were men, 63.0% (n = 619) – women. Mean
age was 71.0 ± 9.9 years old. The rate of ischemic
stroke was 90.2% (n = 887), 6.0% (n = 59) pts had
TIA, while in 3.7% (n = 37) IH was diagnosed.
Common cardiovascular risk factors were analyzed
for all pts: 87.1% (n = 856) of pts had history of
hypertension, 26.8% (n = 264) had atrial ﬁbrillation
(AF). Diabetes mellitus (DM) rate was 20.8%
(n = 204). Among all the pts 12.7% (n = 125) were
smokers and 10.9% (n = 107) suffered from alcohol
abuse, 12.7% (n = 125) survived previous myocardial
infarction (MI), 22.3% (n = 219) had previous CS,
2.6% (n = 26) had previous TIA. In-hospital mortality
was 21.5% (n = 212). Typical cardiovascular risk
factors were estimated in the mortality group: 82.1%
(n = 174) had hypertension history, 41.5% (n = 88)
had AF, 22.6% (n = 48) had DM, 25.9% (n = 55)
survived CS earlier, 10.9% (n = 23) had previous
history of MI. Before the admission 6.1% (n = 60) of
all pts received antiplatelet agents, 26.9% (n=755) – ACE
inhibitors, angiotensin receptor blockers received 1.6%
(n=16), calcium channel blockers – 7.6% (n=75), 8.3%
(n=82) received diuretics, 9.8% (n=97) - β-blockers,3.6%
(n = 36) - antiarrhythmics. Statins and warfarin were
recommended to 6 pts (0.6%).
Conclusions: High prevalence of common cardiovas-
cular risk factors in pts with CS was revealed. Low
frequency of administration medical therapy with
proven inﬂuence on life-prognosis before the reference
CS was observed.
205. The Efficacy and Safety of Liraglutide for
Patients with Type 2 Diabetes Mellitus in Changhua
County, Taiwan
Lih-Jen Shyu, Ya-Mei Hsu, Sock-Ping Ng, Su-Yu Chien.
Department of Pharmacy, Changhua Christian Hospital,
Changhua, Taiwan.
Background: Liraglutide is a new, injectable Gluca-
gon-like Peptide -1 (GLP-1) receptor agonist which
leads to insulin releasing in the presence of elevated
glucose concentrations. According to the Institute for
Safe Medication Practices (ISMP), it’s classiﬁed as
“high alert medication” cause of possibly hypoglyce-
mic effect, pancreatitis and thyroid tumor. Therefore
we would like to known whether patients with type
2 diabetes mellitus (DM) get beneﬁt or harm from
liraglutide.
Objectives: To evaluate changes of glycated hemoglobin
(HbA1c), fasting blood glucose (FBG), body weight,
body-mass index (BMI) and adverse drug effects after
liraglutide treatment.
Methods: Patients with type 2 DM attending Changhua
Christian Hospital, prescribed liraglutide (4/1/2013-1/
31/2014) for at least 12weeks and assessed both at
baseline and post-initiation visit were included in the
study. The primary endpoint was change in HbA1c from
baseline. Secondary variables analyzed were FBG,
body weight, BMI, hypoglycemia, and other side effects.
All analyses were performed using Microsoft Ofﬁce
Excel 2010.
Results: A total of 38 patients with mean age
51.6 ± 10.5 years were identiﬁed. The mean HbA1c from
baseline to week 12 was decreased by 0.7%± 1.5%
(p< 0.01). Mean body weight was reduced by
1.4 ± 2.1 kg, BMI by 0.5 ± 0.7 (both p< 0.001).
However, mean FBG level was lowered by
16.1 ± 85.8mg/dL without statistically signiﬁcance
(p = 0.26). The most common sides effects reported
included diarrhea (7.9%), vomiting (5.3%), injection site
reactions (5.3%, such as pain and ecchymosis), hypogly-
cemia (2.6%). No pancreatitis and thyroid tumor episodes
were reported.
Conclusions: Our ﬁndings show that liraglutide
signiﬁcantly lowers HbA1c, body weight, and BMI
levels, but not fasting blood glucose after 12weeks of
treatment. It was accompanied by low incidence of
hypoglycemia.
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206. Adherence to Treatment Guidelines in Type 2
Diabetes (T2DM) Patients Treated with Metformin
(MET) Monotherapy with Suboptimal Glycemic
Control in Israeli Managed Care
Inbal Goldshtein,1 Kaan Tunceli,2 Larry Radican,2
Harvey Katzeff,2 Shengsheng Yu,2 Bernd Voss,2 Ofer
Sharon,2 Noga Gadir,2 Kimberly Brodovicz,2 Varda
Shalev,1,4 Gabriel Chodik,1,4 Avraham Karasik.3
1Epidemiology andDatabase Research,Maccabi Healthcare
Services, Tel aviv, Israel; 2Merck, Whitehouse Station, NJ,
United States; 3Tel Hashomer Hospital, Ramat gan, Israel;
4Tel Aviv University, Tel aviv, Israel.
Background: The 2013 ADA guidelines advocate
HbA1c< 7 % as a reasonable goal in T2DM and MET
as the preferred initial pharmacologic intervention. If
treatment goals with maximal MET dose are not achieved
within 3-6 months a second agent should be added,
tailored by patient proﬁle.
Objectives: This real world data study examined the
management of T2DM in response to suboptimal HbA1c
after MET monotherapy.
Methods: Using the computerized database of Maccabi
Health Services, a large Israeli HMO, we identiﬁed
T2DM patients on MET monotherapy for >3months
during 2009-2012 followed by an HbA1C ≥7.0% (index
event) prior to any treatment change in 12months follow-
up. Multivariate logistic regression and cox proportional
hazard models were used to identify baseline factors in
prior 12months associated with treatment change and
time to change at follow-up.
Results: Among 7705 eligible patients, 56% (n = 4336)
changed treatment within one year, either by increasing
MET dose (36%), adding a drug (60%), or switching to
a different medication (4%). After controlling for sex
and comorbidities, the strongest predictors of treatment
change were higher HbA1c (≥8.5% vs. 7-7.5%; odds
ratio (OR): 3.55 (95% CI 3.01-4.19), younger age (≥75
years vs. <55 years; OR: 0.48 (95% CI 0.40-0.57), and
a higher socioeconomic status (SES) (high vs. low SES;
OR: 1.37 (95% CI 1.21-1.54). Patients with risk factors
for cardiovascular disease (CVD) (hypertension or
obesity and dyslipidemia) were also, more likely, to
change treatment. Median time to change was 3months.
Time to add-on therapy was associated with similar
characteristics and factors.
Conclusions: This real world study indicates that treat-
ment change for patients treated with MET monotherapy
and not at goal is less than ideal, but is more common in
younger age groups, with higher baseline HbA1c, higher
SES, and CVD risk factors at baseline. Nevertheless,
there is still room for improvement by offering more
patients early add-on therapy.
207. Geriatric Homecare Patients’ Awareness on the
Side-Effects of NSAID Abuse
Andjelija Arandjelovic,1 Valentina Stankovic-Cekic.2
1Apoteka Nis, Nis, Serbia; 2Service for Home Treatment
and Medical Care, Nis, Serbia.
Background: Pain relievers are widely used by the
senior population among chronic patients. Chronic
diseases by themselves, as well as the pain that they
cause in patients, can signiﬁcantly affect the overall
quality of life. What is also signiﬁcant is the problem of
the side-effects of NSAID, as well as the consequences
of their frequent use or overuse.
Objectives: The goal of this paper was to inquire into the
awareness of these patients about the side-effects of
NSAID overuse, as well as to establish whether being
informed on the side-effects they still opt for using the
medication in question if their effect is pain relief.
Furthermore, a part of the research focused on the quality
of information the patients receive in the pharmacy by their
pharmacist on the nature of NSAID, as well as how often
the patients consult their pharmacist or doctor.
Methods: The paper includes a cross-section study on
161 home-treated chronic patients (59 male and 102
female) during doctor’s visit at their home at Nis, Serbia.
Patients were randomize chosen; they had to ﬁll out close
ended, anonymous questionnaires with 10 questions.
Data were collected from 01.11.2013 until 31.12.2013.
The target group consists of patients aged over 65,
chronic patients on palliative care.
Results: The results have shown a satisfactory level of
patient awareness, 76,4% of them knew side-effects of
NSAID abuse, but just 32,2% of them got pharmacist
assistance in the process of their informing. Also satisfac-
tory level information coming from their doctors, 52,2%
of respondents were informed on the overuse of
painkillers coming from the NSAIL group, but even
23,2% do not consult their doctors about pain medication
therapy. The study has also shown that the use of these
medications (44,1% of respondents) continues in spite
of their being aware of the consequential damage to the
gastro-intestinal tract if the medications are effective
against the pain.
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Conclusions: The study indicates that there exists a prob-
lem of NSAIL based medication overuse, as well as that
there also exists a determination in geriatric patients to
persist with their use despite the potential life-threatening
gastro-intestinal tract damage due to side-effects.
208. The Impact of Diabetes on Mortality in Non-ICU
Inpatients from a Chinese Tertiary Hospital
Chuan Yu,1 Sheyu Li,2 Yun Li,2 MiyeWang,3 Rui Zhang,3
Qingtao Hou,2 Yi Ma,3 Tao Zheng,3 Nan Li,3 Ting Wu,4
Na Su,5 Xia Sheng,6 Qianrui Li,2 Yong Huang,3 Xin
Sun,1 Haoming Tian.2 1Cochrane Center, West China
Hospital, Sichuan University, Chengdu, Sichuan
Province, China; 2Department of Endocrinology and
Metabolism, West China Hospital, Sichuan University,
Chengdu, Sichuan Province, China; 3Health Information
Center, West China Hospital, Sichuan University,
Chengdu, Sichuan Province, China; 4Epidemiology Asia
Paciﬁc Unit, Merck Research Laboratories, MSD
China, Beijing, China; 5Department of Pharmacy, West
China Hospital, Sichuan University, Chengdu, Sichuan
Province, China; 6Department of Informatics IT, Merck
Research Laboratories, Merck Sharp & Dohme Corp.,
Beijing, China.
Background: Diabetes is one of the most common
chronic diseases in China. However,it is not clear how
diabetes contributes to hospital mortality in China.
Objectives: To explore the impact of diabetes onmortality
in non-ICU inpatients from a Chinese tertiary hospital.
Methods: The study population was from the electronic
medical records (EMRs) database of West China
Hospital from Jan 2009 to Dec 2012, which consisted
of inpatients with discharge diagnosis of diabetes and
the reference group consisting of the ﬁrst 3 non-diabetic
inpatients after the selected diabetic patient based on the
sequential hospitalization unique ID. Demographic
characteristics, diagnoses, prescriptions, laboratory and
health care resource utilization were extracted. The diag-
noses of diabetes and its common comorbidities which
were reported to affect the prognosis of diabetes were
classiﬁed according to ICD-10. Outcome variable was
the mortality during the hospitalization. Logistic
regression model was used to explore the association of
diabetes with mortality, adjusting for common comorbid-
ities of diabetes, age, gender and lifestyles.
Results: A total of 41,187 patients with diabetes and
107,995 patients without diabetes were identiﬁed. Among
the diabetes group, median age was 65(IQR 56-74), and
24,557(60%) were males; while among the reference
group, median age was 51(IQR 39-64), and 58,716(54%)
were males. Multivariate logistic regression suggested that
patients with diabetes had an increased risk of mortality
(adjusted odds ratio, AOR:1.26;95%CI:1.11-1.43) even
after adjusting for the common comorbid conditions of
ischemic heart disease (AOR:1.69;95%CI:1.43-1.99),
chronic obstructive pulmonary disease (AOR:1.96;95%
CI:1.66-2.32), kidney failure (AOR:5.13;95%CI:4.41-
5.98), hepatic ﬁbrosis and cirrhosis (AOR:3.39;95%
CI:2.72-4.22), malignances (AOR:2.52;95%CI:2.22-2.85),
hypertension (AOR:0.93;95%CI:0.81-1.06) and depressive
episode (AOR:1.93;95%CI:0.98-3.79).
Conclusions: Diabetes may be independently associated
with higher risk of death in non-ICU inpatients after
adjusted for other diseases.
209. Drug Safety Education among Outpatient Using
Teriparatide:Improving Patients Care
Meichi Chang,1 Tzuyun Huang,1 Hsinlin Liang,1 KuoSheng
Fan.2 1Pharmacy, Kaohsiung Municipal United Hospital,
Kaohsiung, Taiwan; 2Chest Medical Department, Dalin Tzu
Chi General Hospital, Dalin, Taiwan.
Background: Pharmacists are responsible for providing
patient education and counseling on the appropriate use
of medicines to improve patients’compliance and reduce
medication-related problems.
Objectives: The aim of this study was to assess drug
safety education of teriparatide for outpatients.
Methods: A retrospective database analysis was
conducted among new users of teriparatide between July
2012 and December 2013.After completion of education
in patient and patient family member,pharmacists evalu-
ated the effectiveness of education and satisfaction by
questionnaires and direct observation of procedural
skills. Evaluations included general information, cogni-
tive function and questionnaires of satisfaction. Excel
was used for descriptive data analysis.Questionnaires
of cognitive function include effects and use skills and
adverse effects and precautions. Correct operation was
evaluated by direct observation of the procedural skills.
There were 10 items in the assessment protocol. In order
to ensure correct used,telephone tracking was provided
in the next day.
Results: Forty-eight patients (12 males and 36 females)
with osteoporosis and fracture were eligible for inclu-
sion.The age of the patients ranged from 54 to 94 years
(mean79.8 years).The most of respondents were patient
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family member (72.2%),and they had an university
education level (33%), followed by senior high school
(31%),junior high school (14%),elementary school
(14%), and illiterate (8%).Before education,all patients
or patient family member did not know how to use this
drug and adverse effects,13 patient family member knew
about drug effects, and only 1 patient knew drug precau-
tions.After receiving education,all patients understood
how to use teriparitate and knew drugs effects and
precautions.96% of patients were very satisﬁed,and 4%
were satisﬁed with the education processes and explana-
tion provided by the pharmacists.All patients were very
satisﬁed pharmacists’ attitudes and indicated that they
recognized the pharmacists as professionals,and next
time if they have any medication-related questions they
would ask the pharmacist.
Conclusions: Pharmacists improves knowledge about
the medicines use and potential side effects.
210. A Pilot Analysis of a Pharmacist Initiated Home
Medication Review Programme with Type 2 Diabetes
Patients in Penang, Malaysia
Ee Pin Chow, Mohamed Azmi Hassali. Discipline of
Social and Administrative Pharmacy, School of
Pharmaceutical Sciences, Universiti Sains Malaysia,
Gelugor, Penang, Malaysia; Discipline of Social and
Administrative Pharmacy, School of Pharmaceutical
Sciences, Universiti Sains Malaysia, Gelugor, Penang,
Malaysia.
Background: Continuity of care beyond the traditional
institutionalized healthcare setting has been advocated
for diabetes in many public health programmes around
the globe. In Malaysia, there is a lack of studies on the
effectiveness of such programmes for diabetes care.
Objectives: To evaluate the effectiveness of a home
medication review programme (HMR) for type 2 diabetes
patients from public primary centre in Penang, Malaysia.
Methods: A randomised controlled study was conducted
at primary clinic in Bukit Minyak. Eligible Type 2 diabe-
tes patients with HbA1c> 6.5%, taking ≥3 medications
who stayed at their own house were recruited and
randomly allocated into control and intervention group
by coin tossing. The control group received usual care
from the clinic whereas intervention group patients
received two additional home visits by a pharmacist.
During both visits, education on medications, life-style
modiﬁcations, assessment on patients’ adherence using
validated 8 items Morisky questionnaire and Michigan
Diabetes Knowledge Test questionnaire for knowledge
evaluation were performed. The primary outcomes
were medication adherence and level of knowledge.
Secondary outcomes included changes in HbA1c,FBS,
total cholesterol, patients’ satisfactions towards HMR
programme and direct cost saving from the programme.
Paired t-test was used to compare data before and after
HMR programme.
Results: A total of 150 patients were recruited and ran-
domly assigned in two groups. Fifty patients in the inter-
vention group and 69 in the control group completed the
study. Both groups showed no difference in baseline adher-
ence and knowledge score. After the 2 home visits there
were signiﬁcant improvements in the adherence score for
the intervention group (mean adherence score = 6.90,SD=
0.94) and the control group(mean adherence score = 4.05,
SD=1.51);t(117) = 11.78,p = 0.00.There was a signiﬁcant
improvement in knowledge score after HMR programme,
intervention group (mean knowledge score = 10.04,SD=
1.75) and the control group (mean knowledge score =
5.45,SD=1.89); t (117) = 13.66, p = 0.00.
Conclusions: Pharmacist-led home medication review
improved patients’ adherence and knowledge.
211. Predictors of Prescription Drug Importation by
United States Adults
Andrew R Zullo,1 David D Dore,1 Omar Galarraga,1 Tim
Rocafort,2 Vincent Mor.1 1Department of Health
Services, Policy, and Practice, Brown University
School of Public Health, Providence, RI, United States;
2Department of Pharmacy Practice and Science, Univer-
sity of Maryland School of Pharmacy, Baltimore, MD,
United States.
Background: Personal prescription drug importation
(PPDI) may result in exposure to counterfeit, adulterated,
or substandard medicines.
Objectives: Our objective was to identify predictors of
PPDI and develop a person-level predictive index.
Methods: We analyzed 2011 United States (US)
National Health Interview Survey data to estimate the
prevalence of PPDI among adults by sociodemographic,
diagnoses, self-reported health status, medical care
access, and health-related Internet usage characteristics
selected a priori. Unadjusted and multivariable preva-
lence odds ratios (PORs) were obtained through
survey-weighted logistic regression models to quantify
associations of the predictors and PPDI. We evaluated
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the inter-item correlation among predictors and aggre-
gated independent predictors into a composite score.
The score was created via summation of the number of
independent predictors possessed by each person.
Results: Characteristics in each domain–sociodemographic,
diagnoses/health status, medical care access, and health-
related Internet usage–predicted PPDI. The categorical
index score was predictive of PPDI, with PORs for the
number of predictors of: 5-6 vs. 0-4, 3.0 (95%CI:2.2-
4.1); 7-8 vs. 5-6, 4.0 (95%CI:3.3-4.9); and 9-12 vs. 7-8,
3.0 (95%CI:2.1-4.2). Multivariable PORs corresponding
to the strongest predictor in each domain were: ever
traveled outside the US since 1995 other than Canada,
Europe, Japan, Australia, and New Zealand vs. never, 2.5
(95%CI: 2.0-3.1); self-reported fair or poor health status
vs. excellent or good, 1.8 (95%CI: 1.4-2.4); no health
insurance vs. private insurance, 2.5 (95%CI: 1.9-3.1); ﬁlled
a prescription on the internet in the last year vs. did not, 2.5
(95%CI: 1.8-3.3).
Conclusions:We found that travel outside the US, fair or
poor health status, no health insurance, and ﬁlling
prescriptions on the Internet were strong predictors of
PPDI. The presence of multiple predictors improved
predictive ability and may be useful for targeting interven-
tions to reduce PPDI of potentially dangerous products.
212. Prevalence and Treatment of Pain in Emergency
Departments in the United States, 2000-2010
Hsien-Yen Chang,1 Matthew Daubresse,2,4 Stefan P
Kruszewski,3 G Caleb Alexander.2,4 1Department of
Health Policy and Management, Johns Hopkins
Bloomberg School of Public Health, Baltimore, MD,
United States; 2Department of Epidemiology, Johns
Hopkins Bloomberg School of Public Health,
Baltimore, MD, United States; 3Department of Mental
Health, Johns Hopkins Bloomberg School of Public
Health, Baltimore, MD, United States; 4Center for
Drug Safety and Effectiveness, Johns Hopkins
Bloomberg School of Public Health, Baltimore, MD,
United States.
Background: Efforts to improve the quality of pain
management in emergency departments have coincided
with extensive marketing and promotion of opioid
analgesics, sharp increases in opioid prescribing, and
increases in the morbidity and mortality associated with
prescription opioids. Emergency Departments play an
especially important role in efforts to improve the treat-
ment of pain while reducing epidemic rates of prescription
drug abuse and addiction.
Objectives: To describe changes in the prevalence and
severity of pain and prescribing of non-opioid analgesics
in U.S. emergency departments from 2000-2010.
Methods: Analysis of serial cross-sectional data regarding
emergency department visits from the National Hospital
Ambulatory Medical Care Survey. Visits were limited to
patients 18 years and older without malignancy. Outcome
measures included annual volume of visits among adults
with a primary symptom or diagnosis of pain; annual rates
of patient-reported pain severity; and predictors of non-
opioid receipt for non-malignant pain.
Results: Rates of pain remained stable, representing
approximately 45% of visits from 2000 through 2010.
Patients reported pain as their primary symptom twice
as often as providers reported a primary pain diagnosis
(40% vs. 20%). The percentage of patients reporting
severe pain increased from 25% (95% conﬁdence inter-
vals [CI] 22%-27%) in 2003 to 40% (CI 37%-42%) in
2008. From 2000 to 2010, the proportion of pain visits
treated with pharmacotherapies increased from 56% (CI
53%-58%) to 71% (CI 69%-72%), although visits treated
exclusively with non-opioids decreased 21% from 28%
(CI 27%-30%) to 22% (CI 20%-23%). The adjusted odds
of non-opioid rather than opioid receipt were greater
among visits for patients 18-24 years old (odds ratio
[OR] 1.35, CI 1.24-1.46), receiving fewer medicines
(OR 2.91, CI 2.70-3.15) and those with a diagnosis of
mental illness (OR 2.24, CI 1.99-2.52).
Conclusions: Large increases in opioid utilization in
emergency departments have coincided with reductions
in the use of non-opioid analgesics and an unchanging
prevalence of pain among patients.
213. Continuous Use of Medicines: Pattern and
Characteristics Associated among Participants of the
ELSA-Brasil Study
Roberta Carvalho de Figueiredo,1 Francisco de Assis
Acurcio,2 Sandhi Maria Barreto,2 Sotero Mengue,3 Maria
de Jesus Mendes da Fonseca.4 1Federal University of
São João Del-Rei, Divinópolis, Brazil; 2Federal
University of Minas Gerais, Belo Horizonte, Brazil;
3Federal University of Rio Grande do Sul, Porto
Alegre, Brazil; 4National School of Public Health,
Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Background: There has been growing interest in evalu-
ating the use of medicines and the determinants of this
use by populations. In Brazil, studies have shown high
rates of medicine use in all age groups; however, these
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are still scarce and carried a small portion of the popula-
tion in various regions of the country.
Objectives: This study aims to describe self-reported
use of continuous medicines by participants (35 to
74 years old) of the Brazilian Longitudinal Study of
Adult Health (ELSA-Brasil) baseline and to evaluate
the association with sociodemographic, health and
behavioral conditions.
Methods: Participants (n = 15,105) from the ELSA-
Brasil, a civil servant cohort from 6 different sites in
Brazil were asked about use of prescription and nonpre-
scription medicines, continuous and non-continuous use
medicines taken in the past two weeks. In this study, indi-
viduals taking continuously at least one medicine were clas-
siﬁed as users. Prevalence ratios (PR) and 95% conﬁdence
intervals (95%CI) were obtained by Poisson regression.
Results: The prevalence of continuous medicine use was
77.4%, and signiﬁcantly higher among women (83.2%)
than men (70.5%). Women and men took on average 2.1
(sd = 2.4) and 1.8 (sd = 2.3), respectively. After adjusting,
the prevalence of continuous use of medicine were signiﬁ-
cantly higher among the older, white, richer and more
educated individuals who had more comorbities and per-
ceived their own health as regular or bad. Additionally,
the prevalence of continuous use of medicine were also
higher among those former smokers and former alcohol
consumers. The most frequently used drug category was
cardiovascular, followed by nervous system and gastroin-
testinal tract and metabolism.
Conclusions: The study identiﬁed higher use of medi-
cines, especially by women. In general, factors associated
with the continuous use of medicines in this study were
similar to those observed in studies conducted in other
countries. Meanwhile, our results differ from those of other
studies by showing less frequent continuous use of medica-
tions among the poorer and less educated individuals.
214. Regional Variation in Strong Opioid Prescribing
in UK Primary Care Settings
Muna Adan,1 Li-Chia Chen,1 Roger Knaggs.1,2 1Division
for Social Research in Medicine and Health, University of
Nottingham, Nottingham, United Kingdom; 2Nottingham
University Hospital NHS Trust, Queen’s Medical Centre
Campus, Nottingham, United Kingdom.
Background: Prescribing of strong opioids has increased
in the past decade, yet there is limited empirical evidence
mapping the regional utilisation in primary care settings
in the UK.
Objectives: This study aimed to quantify strong opioid
prescribing in the 13 regions of the UK.
Methods: This cross-sectional study was conducted from
2000 to 2010 using data from the UK Clinical Practice
Research Datalink (CPRD). Prescriptions for four strong
opioids (morphine, buprenorphine, fentanyl and oxycodone)
were extracted and linked to patient’s medical records.
Adults patients (aged ≥18years) whowere prescribed strong
opioids during the study period were included. Number of
strong opioid prescriptions, number of users and number
of prescriptions per patients were repeatedlymeasured annu-
ally and stratiﬁed by the 13 regions in the UK.
Results: Over the 11 years, 2,677,942 strong opioid pre-
scriptions were issued to 178,645 adult patients (2% of
8,339,847 patients registered in CPRD). The annual
number of strong opioid prescriptions increased from
54,683 in 2000 to 507,511 in 2010; likewise the annual
number of strong opioid users increased from 9,480 to
53,653; and annual prescription rate increased from
5.77 to 9.46 prescriptions per patient. The highest preva-
lence of strong opioid users was found in North West
(12.67%), South West (11.00%) and South Central
(10.58%), and the lowest were in North East (2.24%)
and East Midlands (3.55%). The highest prescribing rate
(number of prescriptions per patient) was found in North
East (20.57), East Midlands (16.47) and the lowest was in
South Central (13.56) and South West (13.84).
Conclusions: Strong opioid prescribing varied in differ-
ent regions, with the highest rates found in regions with
the lowest prevalence users. These regions are also
known to be of higher deprivation than regions with the
lowest strong opioid prescribing rates. Further research
is needed to assess socioeconomic and behavioural
factors associated with the regional variation.
215. Attitudes in Antidepressants Use in Greece
Paraskevi Papaioannidou, Achilleas Ntaralas. Depart-
ment of Pharmacology, Medical Faculty, Aristotle
University of Thessaloniki, Thessaloniki, Greece.
Background: The use of antidepressants has increased
substantially during the last decade, and antidepressants
tend to be among the most prescribed medicines world-
wide. The use of generics in the Greek market of medi-
cines is generally lower than in other European
countries, and - under the current ﬁnancial crisis - the rise
in antidepressants sales in the Greek market has been
followed by an effort of the Greek authorities to encour-
age generic prescribing, in order to lower the constantly
increasing cost.
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Objectives: The purpose of this work was to study the
attitudes in antidepressants use, and to calculate the use
of generics in antidepressant sales in a sample from the
medicines market of Thessaloniki, the second largest city
in Greece.
Methods: A sample of antidepressants registered sales
was collected from the new registration system, which
has been applied during the last two years in Greece.
The sample corresponds only to a small amount of
sales from the market of Thessaloniki, as it comprised
the sales of a pharmacy during the years 2012 and
2013. All the classes of antidepressants and their rela-
tive ratios in the sales were estimated, and the percent-
age of generics in the sale of each medicine was
calculated out of a variety of brand names in each class
of antidepressants. The amount of medicines was esti-
mated in Deﬁned Daily Doses (DDDs) of the reference
drug and its generics.
Results: Selective Serotonin Reuptake Inhibitors (SSRIs)
and Serotonin-Norepinephrine Reuptake Inhibitors
(SNRIs) have displaced older antidepressants, corre-
sponding to 89% of total antidepressants sales (38,184
out of 43,523 DDDs). Generic use corresponded to
26% of total sales and varied greatly among various
SSRIs, being only 15% of ﬂuoxetine sale (1,064 out of
7,344 DDDs), 36% of sertraline sale (2,972 out of
8,236 DDDs) and reaching up to 53% of citalopram sale
(5,352 out of 10,060 DDDs).
Conclusions: In spite of the low percentage of generic
use in antidepressants sales, the percentage of generics
in citalopram use exceeded 50%, which is not usual
for the Greek standards. The use of generics in antide-
pressant therapy should be increased in Greece, in order
to lower the burden of medicines cost in the National
Health System.
216. Asthma Prevalence and Utilization of Antiasthmatic
Drugs among All Children in Stockholm, Sweden
Elin Dahlén,1,2 Ramin Zarrinkoub,2,3,4 Björn Wettermark.1,2
1Department of Medicin, Centre for Pharmacoepidemiology,
Karolinska Institutet, Stockholm, Sweden; 2Public
Healthcare Service Committee, Department of
Healthcare Development, Stockholm County Council,
Stockholm; 3Department of Neurobiology, Care Sciences
and Society, Centre for Family Medicine, Karolinska
Institutet, Huddinge, Sweden; 4Storvreten Primary Health
Care Centre, Stockholm, Sweden.
Background: Asthma is one of the most common
chronic diseases in children. Pharmacological treatment
is a keystone in asthma management, but there is limited
knowledge on the utilization of asthma drugs in entire
populations.
Objectives: Determine the prevalence of childhood
asthma in Stockholm and analyze the treatment.
Methods: This was a cross-sectional study on individual
patient data from an administrative health data register in
the Stockholm region, Sweden. Patients having asthma
were deﬁned as registered, at least once, with asthma
diagnosis (J45, ICD-10) between 2007 and 2012. The
prevalence of asthma was deﬁned as the number of
children (age 0-17) with registered asthma divided by
the number of children in Stockholm 2012.
Drug utilization was assessed by calculating the
number of children dispensed an asthma medicine in
2011 or 2012 divided by the number of inhabitants
2012. The asthma medicines studied were short-acting
β-2-agonsits (SABA), inhaled corticosteroids (ICS),
leukotriene receptor antagonists (LTRAs), long-acting
β-2-agonsits (LABA) and a ﬁxed combination of ICS &
LABA.
The comorbidity with allergy (J30.1-J30.4, H10.1,
T78.4), and atopic dermatitis (L20), was studied during
2007 and 2012.
Results: The total number of children with asthma was
36750, giving a prevalence of asthma of 8.1%. The prev-
alence was higher for boys (boys; 9.7% girls; 6.4%).
A total of 45784 children in Stockholm were dispensed
asthma medicines. Thus, the prevalence of antiasthmatic
drug use in children was 10.1%.
90% of the children with registered asthma diagnosis
had dispensed asthma medicines, at least once, between
2011 and 2012. Most children received SABA (92%),
77% received ICS, 28% received LTRAs, 16% a ﬁxed
combination and 1% LABA.
Allergy was found in 25% of the children with asthma.
The frequency of allergy increased by age and was
almost 50% for children aged 17. The comorbidity with
atopic dermatitis was highest for young children, with
an overall prevalence of 8% (varying from 2-10%).
Conclusions: The prevalence of asthma in our study was
in line with previous studies. Nine out of ten children
with a diagnosis of asthma had dispensed at least one
asthma medicine.
217. Bone Density Screening and Reduced Risk of Hip
Fracture: Effectiveness or Confounding?
Jie Zhang,1,2 Jeffrey R Curtis,2,1 Hong Zhao,1 Kenneth G
Saag,2 Meredith L Kilgore,3 Nicole C Wright,1 Huifeng
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Yun,1 Luqin Deng,1 Elizabeth Delzell.1 1Epidemiology,
University of Alabama at Birmingham, Birmingham,
AL, United States; 2Medicine (Division of Clinical Immu-
nology and Rheumatology), University of Alabama at
Birmingham, Birmingham, AL, United States; 3Health
Care Organization and Policy, University of Alabama
at Birmingham, Birmingham, AL, United States.
Background: Population-based bone density screening
using dual-energy x-ray absorptiometry (DXA) has
been associated with a signiﬁcant reduction in hip
fracture risk.
Objectives: To determine if the association between
DXA and hip fracture reduction may be confounded.
Methods: Using a random 5% sample of Medicare data
from 1999 through 2009, we identiﬁed a cohort of
women 65 year of age or older who had fee for service
coverage for a baseline period of 36 continuous months.
We excluded beneﬁciaries who had any bone density
test, osteopenia or osteoporosis diagnosis, or fracture
during the baseline period to increase the likelihood that
the DXA received was for screening purposes. Beneﬁcia-
ries were followed through the ﬁrst occurrence of
incidence of hip fracture, loss of fee for service coverage,
death, or December 31 2009. To evaluate the extent to
which the observed association may be attributable to
confounding, we used Cox regression to determine the
association of DXA with (1) subsequent hip fracture
and (2) other health outcomes presumably unrelated
to DXA, such as hospitalized acute myocardial infarc-
tion (AMI) and lipomas. Patients were censored if a
fracture at any site other than the hip occurred during
follow-up.
Results:We identiﬁed 551,418 eligible female beneﬁcia-
ries 65 or older. Receipt of DXA varied by age (≥85: 5%;
65-74: 29%), comorbidities (Charlson score ≥ 3: 15%; 0:
23%), and receipt of mammography (yes: 35%; no:
17%). Low hazard ratios (HR) indicating protective
effect of DXA were observed for severe outcomes,
such as all-cause mortality (HR 0.42; 95% conﬁdence
interval [CI]: 0.43-0.44), followed by hip fracture (HR:
0.58; 95% CI: 0.56-0.60), AMI (HR 0.70; 95% CI:
0.68-0.72), and stroke (HR: 0.73; 95% CI: 0.70-0.75).
In contrast, DXA was associated with increased risk of
relatively benign outcomes, such as hemorrhoids (HR:
1.48; 95% CI: 1.44-1.52) and lipomas (HR: 1.63; 95%
CI: 1.54-1.72).
Conclusions: The ﬁnding of protective associations
between DXA and other health outcomes, that were
comparable to that observed with hip fracture, suggests
substantial confounding (older and sicker beneﬁciaries
less likely to receive preventive health services).
218. Long Term Usage of Opioids by Chronic
Intractable Non Cancer Pain Patients in TAIWAN
from 2003 to 2012
Wen-Ing Tsay, I-Chen Cheng, Chih-Shiuh Chang,
Ping-Chang Hsu. Food and Drug Administration,
Ministry of Health and Welfare, Taipei, Taiwan.
Background: Chronic pain is an important and common
medical concern worldwide. Prescription opioid medica-
tions are widely used in the management of pain. In
Taiwan, If non-cancer patients with chronic intractable
pain need long-term treatment with opioids, they should
to be referred to medical centers or regional hospitals.
These patients must be reported to the Food and Drug
Administration, Ministry of Health and Welfare by the
hospitals and approved by the Review and Approval
Committee on Controlled Drugs for Medical Use
(RACCDMU). After the agreement of inspection by
RACCDMU, chronic intractable non-cancer pain (CINCP)
can receive opioids for long-term pain management.
Objectives: This survey analyzed opioids use among
CINCP patients to inform health management policy in
Taiwan.
Methods: There were 644 patients reported to
RACCDMU by 66 hospitals who acquired approval for
long-term use of opioids to treat CINCP from 2003 to
2012. This study provides descriptive information on
patient demographic and clinical characteristics as well
as opioid types used in CINCP patients.
Results: The sample included 62% males with a mean
age of 45.9 years. The average age of female was signif-
icantly older (53.8 years, p< 0.001). The most common
conditions associated with needs for pain management
included nervous system disease (30.7%), chronic
pancreatitis (15.6%), failed back pain syndrome (10.9%),
fractures (10.8%) and spinal cord injury (9.7%). The most
frequently used opioids were morphine (52.1%), fentanyl
(17.7%), and pethidine (13.1%).
Conclusions: Reasons for gender differences in man-
agement of CINCP need further investigation and
address whether females access to treatment is adequate.
Likewise, pethidine is not recommended worldwide
because of its’ side effects. “The Guideline of Pethidine
for Clinical Use” has been developed in 2011 by Taiwan
FDA and put into practice. Taiwan FDA will keep
monitoring the use of pethidine but also promoting the
established guideline.
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219. Over-the-Counter Aspirin Use, Comorbidities,
and Timing of Aspirin Therapy Initiation in Multiple
Myeloma Patients
Syd Phillips,1 Nancy A Brandenburg,2 Kimberley J
Woodcroft,3 Karen E Wells,3 Susan A Oliveria.1
1Epidemiology Research Group, New York, NY,
United States; 2Global Drug Safety and Risk Management,
Celgene Corporation, Berkeley Heights, NJ, United States;
3Department of Public Health Sciences, Henry Ford
Health Systems, Detroit, MI, United States.
Background: Current guidelines recommend that
multiple myeloma (MM) patients receiving lenali-
domide or thalidomide plus dexamethasone receive
venous thromboembolism (VTE) prophylaxis, with
type of prophylaxis based on the number of VTE risk
factors. Aspirin [acetylsalicylic acid (ASA)] therapy, a
common cardiovascular prophylaxis, may also provide
effective VTE preventive beneﬁt. Because the preva-
lence of current ASA use in persons ≥50 years is com-
mon (40%), it is important to understand its utilization
among MM patients.
Objectives: Estimate the prevalence of over-the-counter
(OTC) ASA use and describe comorbidities and timing
of its initiation among MM patients.
Methods: In the Henry Ford Health System, identiﬁed
patients ≥18 years, diagnosed with MM between 1/1/
2005-9/30/2012 from the tumor registry. Developed
a telephone survey, and contacted all eligible patients
to quantify OTC ASA use. Used medical record
review to assess comorbidities and timing of ASA
initiation. Patients’ characteristics, comorbidities, and
timing of ASA therapy are provided with descriptive
statistics.
Results: Identiﬁed 381 MM patients, of whom 177 were
eligible for the survey, and 67% (n = 119) responded.
The mean age was 64 years (standard deviation (SD)
11.6); 78% were aged≥ 55 years; 52% were female, and
69% were African American.
Thirty-nine percent (n = 46) of survey respondents
reported regular ASA use, of which 94% (n = 43 of 46)
reported daily use. The average daily dose was 114mg
(SD= 93) and 85% (n = 39 of 46) reported using the
81mg/day dose.
Of regular ASA users (39%; n = 46), 56% had
hyperlipidemia, 74% had hypertension, and 35% were
obese. Eleven percent started ASA therapy after their
MM diagnosis, in contrast, 35% started taking ASA prior
to their MM diagnosis. The timing of ASA initiation was
not documented in 52% of patients.
Conclusions: Our data indicate that 36% of MM patients
used OTC ASA daily. The most common comorbidities
were hyperlipidemia, hypertension, and obesity. In
addition to VTE risk factors, treating physicians should
be aware of ASA use for cardiovascular risk factors when
considering VTE prophylaxis in MM patients.
220. Ophthalmologists Practice Patterns on Perfor-
ming Intravitreal Injections in Europe
Kui Huang, Marla B Sultan, Duo Zhou, Charles S
Tressler, Jingping Mo. Pﬁzer Inc, New York, NY,
United States.
Background: Anti-VEGF agents have become the lead-
ing class of drugs for neovascular Age-related Macular
Degeneration (AMD) in the Europe since 2006. They
are all administered by intravitreal (IVT) injection.
Objectives: To better understand the practice patterns of
ophthalmologists administering IVT injections in Europe
when the use of IVT injection became a routine.
Methods: As part of a 2-year follow-up cohort study for
which the primary objective was to estimate the inci-
dence of pertinent ocular adverse events (POAEs) related
to IVT injections among neovascular AMD patients in
Europe, ophthalmologists completed a questionnaire at
baseline and one year after baseline.
Results: Of 125 ophthalmologists from 13 countries in
the study, 114 (91.2%) completed both the Baseline and
Follow-up Questionnaires between 2006 and 2012. Most
of these ophthalmologists were medical retina specialists
(43.0%); the median number of IVT injections performed
per month by them during the past year at the Baseline
was 20. The majority of them reported performing their
last IVT injection in an operating room or theater
(68.4%). When performing IVT injections, a large major-
ity of the ophthalmologists reported applying povidone –
iodine (90.4%) and topical antibiotics (66.7%) before
IVT injections, and topical antibiotics right after IVT
injections (89.5%) at the Baseline. In addition, 81.6%
reported using a sterile adhesive eye drape, and 80.7%
reported utilizing an eyelid speculum. For the Follow-
up Questionnaire, the median number of IVT injections
performed per month by these ophthalmologists had
increased to 35. The majority of them reported applying
povidone – iodine (72.8%) or topical antibiotics before
IVT injections (53.5%), topical antibiotics right after
IVT injections (74.6%), sterile adhesive eye drape
(65.8%) and an eyelid speculum (71.1%) on IVT
injections. In addition, this study also enrolled 501 AMD
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patients receiving a total number of 3,754 IVT injections
for AMD treatment. The incidence of POAEs was low
overall and consistent with the literature.
Conclusions: Ophthalmologists in this study became
experienced and skillful in IVT injections when the use
of IVT injections became routine procedure.
221. Temporal Changes in Polypharmacy, Hyper-
polypharmacy and Exposure to Anticholinergic and
Sedative Drugs: A Five-Year Study of Community-
Dwelling Older Men
Clara Leung,1 Sarah Hilmer,2,4 Sallie-Anne Pearson,1,3
Danijela Gnjidic.1,2 1Faculty of Pharmacy, University of
Sydney, Sydney, NSW, Australia; 2Sydney Medical
School, University of Sydney, Sydney, NSW, Australia;
3Sydney School of Public Health, University of Sydney,
Sydney, NSW, Australia; 4Royal North Shore Hospital
and Kolling Institute of Medical Research, Sydney,
NSW, Australia.
Background: Polypharmacy (≥5 concurrent drugs),
hyperpolypharmacy (≥10 concurrent drugs) and Drug
Burden Index (DBI) (cumulative measure of anticholin-
ergic and sedative drugs) exposures are associated with
adverse outcomes in older people. There is limited data
on changes in these drug exposures over time.
Objectives: To examine temporal changes in poly-
pharmacy, hyperpolypharmacy and DBI exposures, and
drug class level exposure, over ﬁve years in community-
dwelling older men.
Methods: We used data from the Concord Health and
Ageing in Men Project (CHAMP), a longitudinal cohort
of men aged ≥70 years recruited during 2005-2007,
Sydney, Australia. Participant information collected
included socio-demographics, functional measures and
medication inventory. Changes in polypharmacy, hyper-
polypharmacy and DBI exposures between baseline and
year ﬁve were compared using the McNemar’s test.
Results: We studied 926 of the 1,705 CHAMP partici-
pants for whom data was available at all 3 time points,
with median age of 75 (interquartile range 72-78) years.
At baseline, polypharmacy exposure was identiﬁed in
31.0% of participants, hyperpolypharmacy in 2.5% and
DBI in 22.1%. At year ﬁve, polypharmacy exposure in-
creased to 48.4%, hyperpolypharmacy to 7.5% and DBI
exposure to 32.4%. The prevalence of new exposure to
any of the drug measures was 2-5 times greater than the
prevalence of ceasing exposure at year ﬁve (p< 0.05).
Analgesics and cardiovascular drug classes contributed
most to higher prevalences of polypharmacy and
hyperpolypharmacy at year ﬁve. Of the DBI drug classes,
parasympatholytics, anticonvulsants, and psychothera-
peutics contributed most to the increasing DBI exposure
over ﬁve years.
Conclusions: Exposures to these high risk drug mea-
sures in our ‘survivor cohort’ increased over ﬁve years
with a signiﬁcant proportion of participants being
identiﬁed with new exposures. Future studies investi-
gating the implications of these measures on clinical
outcomes in older people should consider temporal
changes in drug exposures.
222. The Validity of a Patient-Reported Adverse Drug
Event Questionnaire Using Different Recall Periods
Sieta T de Vries, Flora M Haaijer-Ruskamp, Dick de
Zeeuw, Petra Denig. Clinical Pharmacy and
Pharmacology, University Medical Center Groningen,
Groningen, Netherlands.
Background: Patient-reports have an added value to
gain knowledge about the safety of drugs. Therefore, a
valid questionnaire is needed to assess patient-reported
adverse drug events (ADEs). The validity can be inﬂu-
enced by the recall period of such a questionnaire.
Objectives: To assess the validity of a patient-reported
adverse drug events (ADEs) questionnaire with recall pe-
riods of 3months and 4weeks.
Methods: A longitudinal study was conducted in which
patients being dispensed an oral glucose-lowering drug
were asked to report any potential ADEs they experi-
enced in a daily diary for a period of 3months. This diary
was used as the gold standard. Thereafter, they completed
an ADE questionnaire with either a recall period of
3months or 4weeks.
The validity of the questionnaire was assessed by
comparing ADEs reported in each version with those
reported in the diary at ADE class level and at individual
ADE level. At class level, a comparison was made using
the 1) primary System Organ Class (SOC) of the Medical
Dictionary for Regulatory Activities, and 2) other related
SOCs. Sensitivity and positive predictive value (PPV) were
calculated, including their 95% conﬁdence intervals (CI).
Results: In total, 78 patients participated. In the 3-month
group, 21 of the 39 patients (54%) reported in total 70
ADEs in the diary. Six of the 39 patients in the 4-week
group (15%) reported in total 7 ADEs in the last 4weeks
of the diary. The sensitivity and PPV for assessing ADEs
at primary class level with the questionnaire were low.
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For the 3-month group, the sensitivity was 33% (CI 21-
47%) and the PPV 51% (CI 34-69%). For the 4-week
group, the sensitivity was 33% (CI 4-78%) and the PPV
10% (CI 1-30%). Taking into account other related
SOC classes increased the sensitivity for the 3-month
recall group (38%; CI 25-52%). The sensitivity of
reporting the same ADE at individual level was 41%
(CI 30-54%) in the 3-month group and 43% (CI 10-82%)
in the 4-week group.
Conclusions: Regardless of the recall period and the
level of ADE comparison, the validity for assessing
ADEs was low with the patient-reported ADE question-
naire. Further reﬁnement is needed to improve the validity.
223. Analyzing the Short-Term Social Media Impact
of a Drug Safety Publication-A Case Study Approach
Ingrid S Sketris,1 Anatoliy Gruzd,1 Philip Mai,1 John M
Gamble,2 Colin Dormuth.3 1Dalhousie University,
Halifax, NS, Canada; 2Memorial Unviersity, St. John’s,
NL, Canada; 3University of British Columbia, Vancouver,
BC, Canada.
Background: Pharmacoepidemiologists generate research
about drug utilization, beneﬁts and risks. Its spread can be
measured using several metrics including by its incorpora-
tion into social media.
Objectives: To illustrate how using alternative metrics
can assess the social media impact of drug safety
research. We use the case study of a speciﬁc
publication “Use of high potency statins and rates of
admission for acute kidney injury: multicentre
retrospective observational analysis of administrative
databases” by Dormuth et al 2013.
Methods: We used two methods to generate alternative
metrics of impact of the March 19 2013 publication by
Dormuth et al in the BMJ. To monitor spread using the
DOI in social media platforms a specialized web tool,
Altmetric.com, was used. In addition, a semi manual
analysis of web search results using the meta- search
engine Carrot2.org and the visualization engine Touch-
graph were employed. The top level domain names and
geographic location of top 200 mentions of the article
as well as a hyperlink network of websites citing the
target or related articles were determined.
Results: The article by Dormuth et al was mentioned in
social media and mainstream media online. According
to Altmetric, which has tracked social media mentions
of 13,787 articles published in the BMJ (as of November
1, 2013), Dormuth et al. is ranked 72nd (92nd percentile)
compared to other articles of the same age and published
in the same journal. The article was mentioned by 26
Twitter users, 3 Facebook users, bookmarked by 26
Mendeley and 2 CiteULike users. The top three domains
were 39 .com, 13 .org and 9 .ca.
Conclusions: This case study demonstrates that social
media analysis can complement traditional measures to
assess the short term impact of a drug safety publication.
The rapid uptake and broad reach of the information
demonstrate its potential to provide medication risk infor-
mation to many stakeholders. Further work is needed to
determine the accuracy and the interpretation of the infor-
mation. Collaboration between pharmacoepidemiologists
and information and communication science professionals
can develop improved methods to communicate the
beneﬁts and risks of drugs.
224. A Qualitative Study Exploring Perspectives to-
wards Generic Medicines among Medical Specialists
and Consultants at a District Hospital in Malaysia
Zhi Yen Wong,1 Mohamed Azmi Hassali,2 Abduk Haniff
Yahaya,1 Fahad Saleem,2 Hisham Aljadhey,3 Tahir
Mehmood Khan.4 1Pharmacy Department, Hospital
Teluk Intan, Teluk Intan, Perak, Malaysia; 2School of
Pharmaceutical Sciences, Universiti Sains Malaysia,
Minden, Penang, Malaysia; 3College of Pharmacy, King
Saud University, Riyadh, Saudi Arabia; 4Department of
Pharmacy Practice, Discipline of Pharmacy, Monash
University, Bandar Sunway, Selangor, Malaysia.
Background: In Malaysia, generics have usually been
viewed as being inferior in quality and efﬁcacy when
compared to branded original drugs, especially by
medical doctors. Medical specialists are among the
highest ranked individuals in the hierarchy of the medical
profession and they are usually involved in decision
making for purchasing brand or generics.
Objectives: To investigate medical specialists’ knowl-
edge and the perception of generic medicine use in a
public hospital setting.
Methods: Qualitative in depth interviews were conducted
with specialists in a district public hospital in Perak
between 10 May 2013 and 7 June 2013. Semi-interview
guide consist of questions exploring physicians’ knowl-
edge, perception about generics and prescribing practices
was used. Ten specialists from different disciplines
(i.e. outpatient, emergency and trauma, orthopedic, medi-
cal, ophthalmology, psychiatry, pediatric, dental, obstetrics
and gynecology, ear, nose and throat) were recruited in
the interview though purposive sampling until saturation
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of themes occurred. Each one-to-one interview took an
average of 30–40 minutes and was conducted by a trained
interviewer. Interviews were audio taped, transcribed
verbatim and the transcripts supplemented with ﬁeld notes
taken during the interview and immediately afterwards.
The transcripts were then analysed with deductive content
analysis for qualitative data analysis.
Results: This study suggested that the specialists
interviewed lacked knowledge about the regulatory limits
of generics and the role of local regulatory authorities. The
specialists expressed concern about the quality, safety and
efﬁcacy of generics, especially in life-threatening
situations. The specialists also showed a mixed reac-
tion towards prescribing by using the generic names
of medicines.
Conclusions: Lack of knowledge regarding the regula-
tory limit of generics, concern about safety, quality and
efﬁcacy of generics still persists among the specialists
interviewed. This concern and misconception, if left
unattended, will have a negative impact on the develop-
ment of generic medicine policy in the future.
225. Practices and Self Confidence towards Antibiotic
Prescribing: An Exploratory Study Focusing Pre-
scribers in the District of Kota Setar, Kedah, Malaysia
Rabiatul Salmi Rezal, Mohamed Azmi Hassali, Fahad
Saleem. Discipline of Social and Administrative
Pharmacy, Universiti Sains Malaysia, Penang, Malaysia.
Background: Antibiotic consumption is one of the
factors contributing to the occurrence of antibacterial
resistant. Majority of their use were found at outpatient
settings where patients seek treatment for common respi-
ratory tract illnesses.
Objectives: The aim of this study was to evaluate prac-
tices and self conﬁdence towards antibiotic prescribing
among prescribers in the district of Kota Setar, Kedah,
Malaysia.
Methods: A cross-sectional descriptive survey design
was adopted to conduct the study. All prescribers from
10 healthcare clinics located in Kota Setar, Kedah,
Malaysia were targeted for the study. A pre validated
questionnaire was used for data collection. The study
results were analyzed descriptively using SPSS v 20.0.
Results: Out of 83 prescribers, 57 responded to the
survey with a response rate of 68.7%. The gender distri-
bution of the cohort was almost equal with mean age of
32.61 ± 6.48 years. Thirty ﬁve (61.4%) of the respondents
were medical ofﬁcers and 47 (84.2%) were working at
outpatient units. Although majority (n = 47, 85.9%) of
the prescribers were conﬁdent with their knowledge
towards antibiotics, 32 (56.2%) faced difﬁculties in
selecting the correct antibiotic for their patients. Conse-
quently, 43 (75.5%) of the respondents relied on the
opinion of their colleagues towards accurate antibiotic
prescription for their patients. Fifty ﬁve (96.4%) of the
respondents reported conferences and seminars as the
major source of information towards antibiotic followed
by information provided by their peers (N= 53, 92.9%).
Past prescribing experiences (98.2%), local prescribing
culture at the relative institutes (70.1%), fear of adverse
clinical outcomes (64.9%), and perceived patients’ demands
for antibiotics (38.6%) were reported as major inﬂuencers of
antibiotic prescribing by the study respondents.
Conclusions: Poor conﬁdence and negative attitude
towards antibiotics prescribing was reported among the
study respondents. Successions of medical education
are hereby recommended to develop conﬁdence and
certainty among the prescribers towards antibiotic use
in Kota Setar, Kedah, Malaysia.
226. A Qualitative Study Exploring Perspectives to-
wards Generic Medicines among Medical Specialists
at a District Hospital in Malaysia
Zhi Yen Wong,1 Mohamed Azmi Hassali,2 Fahad
Saleem,2 Abdul Haniff Mohd Yahaya,1 Hisham Hisham,3
Tahir Mehmood Khan.4 1Pharmacy Department, Hospital
Teluk Intan, Teluk Intan, Perak, Malaysia; 2School of
Pharmaceutical Sciences, Universiti Sains Malaysia,
Minden, Penang, Malaysia; 3College of Pharmacy, King
Saud University, Riyadh, Saudi Arabia; 4Department of
Pharmacy Practice, Discipline of Pharmacy, Monash
University, Bandar Sunway, Selangor, Malaysia.
Background: In Malaysia, generics have usually been
viewed as being inferior in quality and efﬁcacy when
compared to branded original drugs, especially by medi-
cal doctors. Medical specialists are among the highest
ranked individuals in the hierarchy of the medical profes-
sion and they are usually involved in decision making for
purchasing brand or generic drugs.
Objectives: The aim of the study was to investigate
medical specialists’ knowledge and the perception of
generic medicine use in a public hospital setting.
Methods: Qualitative in depth interviews were conducted
with specialists in a district public hospital in Perak be-
tween 10 May 2013 and 7 June 2013. Semi-interview
guide consist of questions exploring physicians’
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knowledge, perception about generics and prescribing
practices was used. Ten specialists from different disci-
plines (i.e. outpatient, emergency and trauma, orthopedic,
medical, ophthalmology, psychiatry, pediatric, dental,
obstetrics and gynecology, ear, nose and throat) were
recruited in the interview though purposive sampling
until saturation of themes occurred. Each one-to-one
interview took an average of 30–40 minutes and was
conducted by a trained interviewer. Interviews were
audio taped, transcribed verbatim and the transcripts
supplemented with ﬁeld notes taken during the inter-
view and immediately afterwards. The transcripts were
then analysed with deductive content analysis for
qualitative data analysis.
Results: This study suggested that the specialists
interviewed lacked knowledge about the regulatory limits
of generics and the role of local regulatory authorities. The
specialists expressed concern about the quality, safety
and efﬁcacy of generics, especially in life-threatening
situations. The specialists also showed a mixed reaction
towards prescribing by using the generic names of
medicines.
Conclusions: Lack of knowledge regarding the regula-
tory limit of generics, concern about safety, quality and
efﬁcacy of generics still persists among the specialists
interviewed. This concern and misconception, if left un-
attended, will have a negative impact on the development
of generic medicine policy in the future.
227. Prescribing Drug Use and Costs among Adult
Outpatients with Type 2 Diabetes in Taiwan: A
Nationwide Population-Based Study
Chi Wen Chiang,1 Chun Chi Chiu,2 Zon Min Lee,2 Yuh
Min Cheng.3 1Department of Pharmacy, Pingtung
Hospital, Ministry of Health and Welfare, Pingtung,
Taiwan; 2Department of Pharmacy, Kaohsiung Chang
Gung Memorial Hospital, Kaohsiung, Taiwan; 3Depart-
ment of Orthopaedic Surgery, Pingtung Hospital,
Ministry of Health and Welfare, Pingtung, Taiwan.
Background: Diabetes is one of the most common non-
communicable and epidemic diseases around the world.
It imposes a large economic burden on the healthcare
system.
Objectives: To describe the prescribing drug use and
costs among adult outpatients with type 2 diabetes (T2D).
Methods: A cross-sectional survey was implemented
using National Health Insurance Research Database
between 2009 and 2010. Adult outpatients who had
diagnoses of T2D and who had concurrent anti-diabetic
drug claim were identiﬁed. Drugs were identiﬁed and
classiﬁed by the National Drug Code and the AHFS
Pharmacologic-Therapeutic Classiﬁcation. Continuous
variables were described by means and standard
deviations and compared by using the t-test. Categorical
data were described by percentages and compared by
using the chi-square test. All statistical analyses were
conducted using the SAS 9.2 statistical software.
Results: During the 2-year period, a total of 44,938
outpatient visits met the study criteria. 50.3% were males.
The average age for women was 65.5 ± 11.9 years with
slightly higher than men. The average cost per prescrip-
tion for men is NT$1374.8 with signiﬁcantly more
than females (p = 0.018). Besides anti-diabetic drugs,
cardiac drugs are the most prescribed drugs, followed
by hypotensive agents.
Conclusions: The results of the present study can
provide related information about the prescribing drug
use and costs in adult outpatients with T2D.
228. Drug Discrepancy and Medication Error of Ad-
mitted Patients by Medication Reconciliation Process
Jaruwan Unin,1,2 Pramote Tragulpiankit,1 Thida
Ningsananda,3 Rattana Nilpetchploy.2 1Faculty of
Pharmacy, Mahidol University, Bangkok, Thailand;
2U-Thong Hospital, Suphan Buri, Thailand; 3The Asso-
ciation of Hospital Pharmacy (Thailand), Bangkok,
Thailand.
Background: Medication reconciliation is a systematic
process for obtaining a medication history, and using that
information to compare to medication order in order to
identify and resolve discrepancies but few medication
reconciliation studies are available in a community
hospital, in Thailand.
Objectives: To determine frequencies and characteristics
of drug discrepancy and medication error of admitted
patients by medication reconciliation process.
Methods: The study was a prospective observational
study and performed at the medical ward, U-Thong
Hospital, a 150-bed community hospital in Suphan Buri
Province, Thailand. Patients who were admitted during
June 1st and August 31th 2013 were selected and
conducted the best possible medication history list and
then reconciled the list to admission order by pharma-
cists. Drug discrepancy and medication error which is
deﬁned as unintentional discrepancy were detected.
Patient demography, frequency and characteristics of
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drug discrepancy and medication error were analyzed by
descriptive statistics.
Results: Total 108 patients were recruited and 50
(46.3%) patients were male. Those patients were
64.5 ± 14.9 years old on average and were taking a mean
of 7.6 ± 3.0 items of medications prior to admission.
Total 105 patients (97.2%) had at least one discrepancy
and found that 514 discrepancies were classiﬁed as an
intentional discrepancy by 72.4% (372) in 100 patients
(or 3.7 per patient), an undocumented intentional discrep-
ancy by 8.8% (45) in 24 patients (or 1.9 per patient) and
medication error by 18.9% (97) in 33 patients (or 2.9 per
patient), respectively. Total 97medication errors were clas-
siﬁed by omission of the drug and dosage/route/frequency
error type accounted by 71.1% and 14.4%, respectively.
Total 83 (85.6%) and 14 (14.4%) medication errors which
were categorized as category B and C, respectively based
on the National Coordinating Council for Medication Error
Reporting and Prevention (NCCMERP) index.
Conclusions: Drug discrepancy and medication error
commonly occurred at hospital admission. Most type
of medication error was omission error and potential
harm severity.
229. Drug-Related Hospital Readmission in Commu-
nity Hospital, Thailand
Jaruwan Unin,1,2 Pramote Tragulpiankit,1 Chaweewan
Moungnoi,2 Porntip Channalao.2 1Faculty of Pharmacy,
Mahidol University, Bangkok, Thailand; 2Department
of Pharmacy, U-Thong Hospital, Suphan Buri, Thailand.
Background: Drug-related problems are major concern
in public health but drug-related to hospital readmission
is no available data in community hospital in Thailand.
Objectives: To determine rate of hospital readmission
within 30-day and type of those drug-related problems.
Methods: The study was conducted by retrospective
electronic medical record review at a 150-bed community
hospital in Suphan Buri Province, Thailand. The patients
who were discharged during October 1st 2011 and March
31st 2012 were identiﬁed the patients with readmission
within 30-day after their discharge from the hospital.
Then, they were determined whether associated with
drug-related problems. The patient demography, the rate
of readmission and type of drug-related problems were
analyzed by descriptive statistics.
Results: Total of 5,114 medical records of discharged
patients were reviewed. It was found that 172 (3.4%)
patients were identiﬁed as readmission within 30-day
and 87 (50.6%) were male. The number of patients who
were readmitted within 30-day associated with drug-re-
lated problems were identiﬁed by 11 (6.4%) out of 172 pa-
tients. Eight out of 11 (72.7%) patients were age higher
than sixty-ﬁve years old and suffered from drug-associated
with hypoglycemia. Drug-related problems were catego-
rized by adverse drug reaction, noncompliance, dosage
too high, and needs additional drug therapy accounted by
5 (45.5%), 4 (36.4%), 1 (9.1%), and 1 (9.1%), respectively.
Conclusions: The hospital readmission associated with
drug related problems in the study seems to be not high
because the data based on medical chart review in the
study probably is insufﬁcient to evaluation whether
drug-induced. However, the study showed mostly drug-
related readmission associated with diabetic elderly
patients. Medicine management of this patient group
should be further studied.
230. Post Authorization Safety Studies (PASS):
Application of Prospective Observational Study
Methodology
Irene Pan,1 Amy Walton,2 Gretchen Dieck.2 1United
BioSource Corporation, Montreal, QC, Canada; 2United
BioSource Corporation, Blue Bell, PA, United States.
Background: A post authorization safety study (PASS)
is a study of a marketed drug or biologic conducted in
an effort to conﬁrm the safety proﬁle or identify potential
safety issues not identiﬁed in the controlled clinical trial
population. A PASS may be done voluntarily or in
response to requirements imposed by an approving
authority. According to the ENCePP website, there are
228 PASS protocols registered, of which 187 are
currently in active recruiting or planning status.
Objectives: To understand how PASS are being utilized
in current post-marketing research. To discuss key con-
siderations when designing and implementing a prospec-
tive observational PASS based on selected case studies.
Methods: A targeted search was conducted in PubMed
to identify all original research published in 2013 reporting
results from prospective PASS. The search was restricted
to English language publications. Abstracts of relevant
citations were reviewed to obtain the country of study, ther-
apeutic area, product, subject population and study design.
Results: The search returned 48 citations, containing 11
citations reporting results from prospective PASS.
Amongst the 11 studies, n = 4 (36.4%) were conducted
in Europe, n = 4 (36.4%) in Asia-Paciﬁc n = 1 (9.1%) in
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the United States, n = 1 (9.1%) in South America and
n = 1 (9.1%) globally. Sample sizes range from 10-7943
patients excluding 2 database analytics studies. Thera-
peutic areas include oncology, cardiology, endocrinol-
ogy, psychiatry and infectious diseases. Safety reporting
requirements vary by country, with the guidelines more
deﬁned in Europe (EU) and the US.
Conclusions: The purpose of the present review was not
to perform an exhaustive summary of all PASS protocols
but to gain information regarding study design that
provides the most valuable result. Results of this review
conﬁrm that different protocol designs are being used in
real-world data collection to meet speciﬁc safety surveil-
lance objectives. For prospective, observational PASS,
early determination of country speciﬁc requirements is
essential to ensure collection and reporting of robust data
in a timely manner.
231. European Drug Lists for Integration in a Decision
Support Tool for Optimization of Drug Therapy in
Older Persons
Anna Birna Almarsdottir,1,2 Shane Cullinan,3 Birna
Björg Masdottir,4 Stephen Byrne.3 1Institute of Public
Health, University of Southern Denmark, Odense,
Denmark; 2Faculty of Pharmaceutical Sciences, Univer-
sity of Iceland, Reykjavik, Iceland; 3School of Pharmacy,
University College Cork, Cork, Ireland; 4Division of
Finance and Information, Landspitali University
Hospital, Reykjavik, Iceland.
Background: The drug therapy aspect of a drug selec-
tion decision support and data collection tool requires
drug lists with prices that reﬂect the cost of medicines
to outpatients in six European countries in the SENA-
TOR project which is funded by EU FP7 programme.
Early in the project it was clear that no such European list
fulﬁlling requirements existed.
Objectives: To compile drug ﬁles with prices reﬂective
of societal costs using drug utilization research expertise
in collaboration with software programmers.
Methods: Informants (usually pharmacists) in each of
the six hospitals (Aberdeen-Scotland, Ancona-Italy,
Cork-Ireland, Madrid-Spain, Ghent-Belgium, and
Reykjavik-Iceland) were surveyed regarding information
for compiling the lists. The available lists were investigated
for the required elements. From this, prototype drug ﬁles
were created for each site.
Results: The most essential elements required for the
SENATOR engine were found to be ATC codes, drug
brand names, generic names, strength, and price per unit.
Hospital lists were found to be less reﬂective of costs
than outpatient lists but will supplement outpatient lists
for hospital only drugs. It was found that automated pric-
ing can be done for most drugs at the point of care, but it
is not essential to continually update the price lists for an
accurate economic evaluation for most drugs. Mapping
from BNF to ATC was done manually for one centre in
the study (Aberdeen).
Conclusions: Drug utilization expertise provided input
into the SENATOR decision support tool opening up
possibilities for compiling a pan-European drug list.
The lists compiled will facilitate the entry of drug data
by clinicians and at the same time provide reliable
pharmacoepidemiological data including: drugs the patient
was using at entry into the SENATOR trial and how this
changed during follow-up; ability to link ATC codes
reliably to the STOPP/START criteria for inappropriate
use of drugs in the elderly; and a way of calculating drug
costs that reﬂect reality in the outpatient setting.
232. Registry: Its Use in Real-World Data Collection
Irene Pan, Gretchen Dieck, Annette Stemhagen. Value
Demonstration, UBC: An Express Scripts Company,
Dorval, QC, Canada; Epidemiology & Risk Management,
UBC: An Express Scripts Company, Blue Bell, PA, United
States; Epidemiology & Risk Management, UBC: An
Express Scripts Company, Blue Bell, PA, United States.
Background: Registry has proven to be useful for post-
authorization safety studies (PASS) purposes due to its
design characteristics such as longer follow-up periods
and collection of patient-reported outcomes in addition
to clinical outcomes.
Objectives: To understand how registries are being
utilized in current post-marketing research.
Methods: A targeted search was conducted in
MEDLINE to identify all original research published in
2013 reporting results from registries. The search was
restricted to English language publications. Abstracts of
relevant citations were reviewed to obtain the country
of study, therapeutic area and registry design. A supple-
mentary search of registries listed on clinicaltrials.gov
was conducted to estimate the number of registries
currently ongoing.
Results: The search returned 136 citations, containing
128 citations reporting results from 116 unique registries.
Amongst the 116 registries, n = 43 (37.1%) were con-
ducted in Europe, n = 40 (34.5%) in the United States,
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n = 25 (19.8%) in Asia-Paciﬁc and n = 5 (4.3%) multi-
nationally. Most registries were studies in cardiology
(n = 76 [65.5%]), and n = 9 (7.8%) unique registries were
devoted to the study of pediatric patient populations.
21.6% of the registries were designed to investigate the
safety of a medical device or pharmaceutical agent, and
another n = 34 (29.3%) aimed to evaluate clinical out-
comes of surgical interventions.
According to clinicaltrials.gov, there are 747 registry
studies that are currently in active recruiting, or planning
status. At the time of this review, 410 registries are active
in North America and 247 in Europe.
Conclusions: The purpose of the present review was not
to perform an exhaustive summary of all registries but to
gain a snapshot of what has been published in a given,
recent year. Results of this review conﬁrm that different
registry designs are being used in real-world data
collection to meet speciﬁc research objectives, be it safety
monitoring, understanding disease natural history or
long-term clinical outcome evaluation. Further analysis
into the study characteristics will be presented to guide
stakeholders in choosing appropriate registry designs.
233. Post Authorization Safety Studies (PASS): Appli-
cation of Retrospective Chart Review Methodology
Dara Stein, Irene Pan, Krista A Payne. United BioSource
Corporation, Dorval, QC, Canada.
Background: While majority of PASS studies are
conducted in Western nations, other regions such as Asia
have acknowledged the importance of PASS. In the
absence of suitable databases, chart reviews can be used
to evaluate drug utilization and satisfy PASS requirements.
Objectives: Highlight design/operational considerations
for undertaking chart review PASS in Asia and other
regions and delineate strategies for resolution.
Methods: Critical review of seven chart reviews
conducted in Canada, United States and select European
(EU)/ROW countries that evaluated drug utilization and/
or clinical/safety outcomes was performed.
Results: All studies were PASS; 3 studies were man-
dated by regulators and 2 studies were non-mandated
(sponsor imposed). Sample sizes ranged from 125-2000
patients; number of study centers ranged from 12-300.
Therapeutic areas included oncology, cardiology,
intensive care and infectious diseases. PASS indication
determination at study outset for non-mandated studies
was challenging. Review of study objectives, country
speciﬁc regulations and sponsor SOPs guided decisions
for PASS indication in these instances. PASS safety
reporting requirements varied by country; when required,
expedited reporting of adverse events related to sponsor
products identiﬁed via chart review was undertaken.
PASS requirements for chart review studies are more
deﬁned in EU. Depending on country and sponsor, chart
review PASS may need to be registered on clintrials.gov
and EU PAS register. EU chart review PASS require
using a protocol template which must be submitted to
regulatory bodies; ENCePP protocol checklist should be
utilized. For studies looking at off-label product use,
protocol language must be written to minimize potential
response bias. In developing countries, culture variations
and languages need considerations.
Conclusions: For chart review PASS, early determina-
tion of country speciﬁc requirements is essential to
ensure collection and reporting of robust data in a timely
manner. Chart review design can be applied as PASS in
Asia and other regions to answer research questions
spanning drug utilization and clinical/safety outcomes.
234. Utilization Trend and Management of Oral
Anticancer Medicines Using Nationwide Pharmacy
Database and Questionnaire Survey at Pharmacies
in Japan
Osamu Takizawa, Hisashi Urushihara, Shiro Tanaka,
Koji Kawakami. Department of Pharmacoepidemiology,
Graduate School of Medicine and Public Health, Kyoto
University, Kyoto City, Japan.
Background: Cancer care in Japan is changing from
intravenous (IV) chemotherapy to oral anticancer medi-
cines (OAMs), from branded OAMs to generic OAMs,
from in-hospital care to outpatient care, from in-hospital
prescription to external prescription at pharmacies.
Objectives: This study aims to describe utilization
trend of OAMs and practice of pharmacists at pharmacies
in Japan.
Methods: We initially performed a cross-sectional drug
utilization study using administrative database of dispen-
sations at nationwide 489 pharmacies in Japan between
June 1, 2011 and May 31, 2012. Practice in the pharma-
cies was surveyed using questionnaires which consisted
of 29 items including background, training, medication
counseling, communication with prescribers, opinions
about generic OAMs.
Results: 31628 patients and 156904 dispensations were
identiﬁed in the database. The patients received drugs
for hormone therapy (n = 19899, 62.9%), anti-metabolic
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drugs (n = 9002, 28.5%), molecularly-targeted drugs
(n = 1716, 5.4%), alkylating compound drugs (n = 839,
2.7%), microtubular inhibitors (n = 148, 0.5%). 394
(80.6%) pharmacies responded to the questionnaires.
Their main prescribers were hospitals (66.7%) or clinics
(33.3 %). On average, the pharmacies dispensed at
1848.8 prescriptions daily and 60.2% of the pharmacists
received training on OAMs voluntarily. The contents of
counseling included adverse drug reactions, usage and
dosage, but 45.9% did not use materials for patients.
The major reason for queries to medical facilities was
usage and dosage inconsistent with the package insert.
Most of the pharmacies did not collect information on
laboratory measurements from patients or medical
facilities. With regard to generic OAMs, 48.7% of the
pharmacies commented on advantages in cost, but 50 %
were concerned about their efﬁciency, safety, and
steady supply.
Conclusions: About 90 % of OAMs dispensed at phar-
macies in Japan were drugs for hormone therapy and
anti-metabolic drugs. Our study suggests the importance
of pharmacy and clinic cooperation including sharing
medical records, in addition to training of pharmacists
and medication counseling.
235. Novel Methods of Adverse Event Detection Using
Electronic Health Record Data: A Critical Review of
the Literature
Christian M Rochefort.1,2 1Epidemiology, Biostatistics &
Occupational Health, McGill University, Montreal, QC,
Canada; 2Ingram School of Nursing, McGill University,
Montreal, QC, Canada.
Background: Adverse events (AE) are associated with
signiﬁcant mortality, morbidity and cost in hospitalized
patients. The increased use of electronic health records
(EHR), along with the development of automated
methods for encoding and classifying electronic data,
offers an exciting opportunity to develop novel methods
of AE detection.
Objectives: The purpose of this literature review was to
critically assess studies examining the accuracy of these
novel methods of AE detection.
Methods: Relevant studies, published in any languages,
were identiﬁed through an extensive search of the
PubMed database (1990-2014) using combinations of
selected keywords. Additional studies were identiﬁed
using bibliographic review of the key articles retrieved,
and the ‘related articles’ feature of PubMed. Studies were
included in the review if they: a) were conducted in an
inpatient setting, b) described an automated AE detection
method, and c) assessed the accuracy of the automated
method of AE detection in comparison with a gold
standard assessment of the medical chart. The methodo-
logical quality of each study was assessed using
published criteria.
Results: We identiﬁed 47 studies assessing the accuracy
of an automated method of AE detection. Studies based
solely on electronic triggers (e.g., abnormal laboratory
results or the prescription on an antidote drug) have low
sensitivity and positive predictive value. Studies using
either statistical or symbolic natural language processing
(NLP) achieved higher accuracy, with the best results
observed in studies combining both approaches. Natural
language processing promise improved accuracy by
allowing for the capture and classiﬁcation of the rich
information contained in free-text clinical narratives.
The methodological quality of the studies varied widely.
Conclusions: Automated methods of AE detection offer
a potentially more accurate and cost-effective alternative
to traditional methods. However, their accuracy varies
widely, thus limiting their widespread utilization in the
inpatient settings. Natural language processing techniques
applied on clinical narratives may greatly improve the
accuracy of automated AE detection.
236. Associations of Drug Burden Index with Falls,
General Practitioner Visits, and Mortality in Older
People
Prasad S Nishtala,1 Sujita W Narayan,1 Ting Wang,2
Sarah N Hilmer.3 1School of Pharmacy, University of
Otago, Dunedin, New Zealand; 2Department of Mathe-
matics and Statistics, University of Otago, Dunedin,
New Zealand; 3Royal North Shore Hospital, Kolling
Institute of Medical Research and Sydney Medical
School, University of Sydney, Sydney, Australia.
Background: Polypharmacy and use of medicines with
anticholinergic and sedative properties are common
among older adults. Exposure to medicines with anticho-
linergic and sedative properties, measured using the Drug
Burden Index, has been associated with functional
impairment in older people in Australia, USA, Finland
and UK.
Objectives: The main objectives of this study were on a
population level in people aged 65 years and over living
in New Zealand: (a) quantify each individual’s cumula-
tive exposure to anticholinergic and sedative medicines
using the Drug Burden Index; and (b) to examine the
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impact of Drug Burden Index scores on falls-related
hospitalisations, frequency of general practitioner visits,
and all-cause mortality.
Methods: The study used data extracted from Pharma-
ceutical Claims Data Mart (2011), National Minimum
Data set (2012), Births, Death and Marriages (2012)
and GP Visits (2012) for patient demographics,
hospitalisations and mortality. Cumulative anticholiner-
gic and sedative exposure was measured using the DBI.
Polypharmacy was deﬁned as ≥5 medicines dispensed
concurrently at any time during the study period.
Results: Amongst the study population (n = 537,387,
45% male), 43% were exposed to DBI drugs (95% Con-
ﬁdence Intervals (CI) =43.09-43.35). The odds of DBI
exposure for individuals with polypharmacy are 4.92
(95% CI = 4.86-4.98) times greater than that for individ-
uals without polypharmacy. DBI drugs were associated
with falls-related hospitalisations (IRR 1.56, 95% CI =
1.47-1.65) and greater number of GP visits (IRR 1.12,
95% CI = 1.12-1.12). Individuals with DBI >0 had a
1.28 times higher mortality risk (95% CI = 1.25-1.33).
Polypharmacy is also associated with a higher mortality
risk with a hazard ratio of 1.66 (95% CI = 1.59-1.73).
Conclusions: Polypharmacy and exposure to DBI
drugs were independently associated with falls-related
hospitalisations, frequency of GP visits, and risk of
mortality. On a population level, DBI may be useful as
a quality indicator to guide policy to improve prescribing
and optimise clinical outcomes in older people.
237. Drug Utilization Pattern for the Treatment of
Septic Shock in the ICU: A Comparison between
Survivors and Non-Survivors in a Tertiary Care
Teaching Institute
Anirban Hom Choudhuri, Rajeev Uppal. Department of
Anaesthesiology & Intensive Care, GB Pant Hospital &
Maulana Azad Medical College, New Delhi, Delhi, India.
Background: The critically ill septic shock patients in
the ICU are exposed to various types of medications.
Despite the best care, the mortality varies from 15 to 60
% in different parts of the world.
Objectives: To describe the drug utilization pattern in the
treatment of patients with septic shock in the ICU.
Methods: A retrospective cohort study of patients with
septic shock, who were treated in the ICU between
January 2012 and December, 2013. The ICU database
was used to identify the patients. The patient demographics
and characteristics were recorded. In addition, the number
and type of prescribed medications, type of infection, and
culture results were determined.
The main outcomes were the type of medication clas-
ses utilized and their comparison between the survivors
& non-survivors.
Results: During the study period, 109 cases were identi-
ﬁed. Upon presentation, the mean Acute Physiology and
Chronic Health Evaluation II (APACHE II) score was
22.5 (SD ±7.8), 93 (85.3 %) patients had leucocytosis,
and 84 (77.0 %) had positive cultures. The mean number
of medications prescribed per patient was 11.7 (SD ±4.7).
The most commonly prescribed medication classes were
proton pump inhibitors, carbapenems, BL/BLI combina-
tions and vasopressors prescribed in 101 (92.6 %), 75
(68.8 %), 64(58.7 %), and 91(83.4 %) patients, respec-
tively. Antifungals and blood products were prescribed
in 45 (41.2 %) and 77 (70.6 %) patients, respectively.
Medication usage were higher in non-survivors, com-
pared to survivors (12.6 ± 2.4 versus 9.7 ± 4.1), and in
patients with positive cultures (13.5 ± 1.9 versus 9.3 ± 3.6)
compared to patients with negative cultures.
Conclusions: In patients with severe sepsis and septic
shock, multiple medications were prescribed, and the
use of medications was higher in the non-survivors in
comparison to the survivors.
238. Development of Pharmacy-Based Patient Registry
for Long-Term Medication Use Monitoring
Manabu Akazawa,1 Shinichi Yamamura,2 Hiroyasu
Ogata.2 1Meiji Pharmaceutical University, Tokyo, Japan;
2Japanese Society for Applied Therapeutics, Tokyo,
Japan.
Background: Patients prescribed medications for longer-
term from a large hospital and despised them in a com-
munity pharmacy have been increased recently in Japan.
Those patients are required periodic monitoring by
healthcare providers to improve adherence and to ﬁnd
potential safety problems.
Objectives: A patient registry was created based on the
community pharmacies for evaluating role of pharmacists
on patient’s medication use with long-term prescriptions.
Current status of the registration and follow-up would be
reported.
Methods: Fourteen community pharmacies were in-
volved in this project. Patients prescribed medications
for 36 days or longer to treat their hypertension, hyperlip-
idemia or diabetes were selected and asked for
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participating in the patient registry. Patient records of
medication history, health conditions, lab-test results, life
style, and other healthcare service uses were registered
through an on-line database system. Pharmacists pro-
vided a regular contact with patients in the predetermined
ways such as home-visit, telephone-call, e-mail and etc.,
at least every 28 days. Changes in medication uses and
health conditions were monitored and recorded. Patient
outcomes of adherence and persistence to the medica-
tions as well as clinical effectiveness and safety would
be evaluated after completing one-year follow-up.
Results: As of February 1, 2014, about two months from
initiating the patient registry, 28 patients were registered
at 11 pharmacies. Average age of patients was 71 years
and 64% was male patients. Average duration of pre-
scriptions was 63 days when patients were registered.
More than 50% used 5 or more medications for chronic
conditions of hypertension, hyperlipidemia or diabetes.
A total of 17 pharmacist contacts were recorded during
2-month follow-up and no concerns of adherence or
safety were reported.
Conclusions: This is a ﬁrst patient registry created based
on community pharmacies in Japan. Data collected
through this registry would be used to evaluate roles of
pharmacists for monitoring long-term patient care and
medication use in the community.
239. The Incidence of Adverse Drug Events among the
Critically Ill Patients: A Prospective Multicenter
Study
Hisham Aljadhey,1 Mansour A Mahmoud. Medication
Safety Research Chair, College of Pharmacy, King Saud
University, Riyadh, Saudi Arabia.
Background: In the past few decades Adverse Drug
Events (ADEs) have received special attention from
healthcare professionals due to the associated mortality,
morbidity and additional healthcare cost. Critically ill
patients have been shown to be at higher risk for ADEs
in previous studies from developing countries. However,
this subject has received little attention from the develop-
ing countries.
Objectives: To determine the incidence of ADEs in the
critically ill patients and assess their severity and
preventability.
Methods: We conducted a prospective cohort study of
862 adult patients admitted to four intensive care units
(ICUs) of government, academic and private hospitals
over four months. Clinical pharmacists identiﬁed all
possible incidents and two clinicians independently
reviewed those incidents and had the privilege to either
accepted or rejected them. The included incidents were
then classiﬁed into ADEs, potential ADEs and medica-
tion errors. The severity and preventability of the
included incidents were also determined. Descriptive
data are expressed as number, Percentage, mean and
standard deviations.
Results: Medical records of 905 critically ill patients
were reviewed by clinical pharmacists. After excluding
incomplete data, a total 862 patients ﬁle were considered
for the ﬁnal analysis. The mean age was 50.1 (±21.1)
years. A total of 572 incidents were identiﬁed by pharma-
cists and clinicians reviewers accepted 530 (92.6%)
incidents. The incidence of ADEs was 17.3 per 100
admission (95% CI, 14.6-20.2) and 13.1 per 1000 patient
days (95% CI, 10.9–15.1). Regarding the severity of the
ADEs, 304 (57.4%) were signiﬁcant, 190 (35.8%) were
serious, 33 (6.2%) were life threatening and 3(0.6%)
were fatal. The incidence of preventable ADEs was 50
(33.6%) of all ADEs and most commonly occurred in
the prescribing stage 43 (86%).
Conclusions: We conclude that ADEs are common
among ICUs patients and often preventable. Intervention
should be designed to reduce the severity caused by
ADEs including morbidity. Future study should focus
on the cost of ADEs.
240. Drug Use Study of Heparin Using Japanese
Claim Data of Inpatients
Maki Noguchi, Ayumi Endo, Kaori Yamada,
Kazuhiro Matsui, Shinichi Watanabe. Ofﬁce of Safety
I, Pharmaceuticals and Medical Devices Agency,
Tokyo, Japan.
Background: Heparin is an anticoagulant commonly
used for treatment and prevention of thromboembolism,
or prevention of blood clot occurred by extracorporeal
circulation, dialyzed and others, however, this drug can
cause Heparin Induced Thrombocytopenia (HIT). Hepa-
rin is categorized into two types such as traditional
unfractionated (UF) Heparin, and novel low molecular
weight (LMW) Heparin, whose risk of HIT is known to
be lower than UF Heparin’s.
Objectives: To investigate the use of Heparin (UF or
LMW) and the risk of HIT among patients hospitalized
for lower limb surgery using Japanese claim data.
Methods: The Japanese claim data of inpatients called
Diagnosis Procedure Combination (DPC) data was
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used. The owner of these data, a DPC system vender,
performed all analysis by following the protocol pre-
pared by PMDA. The base population included about
1.5 million of patients hospitalized in 128 hospitals
during July 2010 to December 2012. Two targeted
populations were deﬁned by prescription of UF or
LMW Heparin given within 7 days after lower limb
surgery. Distribution of patient demographics, prescribed
duration after surgery, and the incidence proportion of
HIT were calculated.
Results: Among 1.5 million of the base population,
6,157 patients were prescribed UF Heparin and 3,596
patients were prescribed LMW Heparin within 7 days
after lower limb surgery. Their median ages were
76 years and 77 years in the patients prescribed UF and
LMW Heparin, respectively. As to prescribed durations,
4,143 patients (67.3%) were prescribed UF Heparin for
only one day. On the other hand, 3,515 patients
(97.7%) were prescribed LMW Heparin for 2-14 days.
The incidence proportions of HIT were 0.19% for UF
Heparin and 0.08% for LMW Heparin, which were lower
than those reported in previous studies.
Conclusions: This study investigated the utilization of
UF and LMW Heparin among patients hospitalized for
lower limb surgery using claim data. Although their
prescribed durations were different, there was not much
difference in the incidence proportion of HIT between
UF and LMW Heparin.
241. Utilization and Predictors of Ophthalmic Steroids
in Patients with Dry Eye Disease: A Nationwide
Population-Based Study in Taiwan
Mei-Chieh Chen,1 Chia-Hsien Chang,1 Yea-Huei Kao
Yang,1,2 Yi-Sheng Chang.3 1Institute of Clinical
Pharmacy and Pharmaceutical Sciences, College of
Medicine, National Cheng Kung University, Tainan,
Taiwan; 2Health Outcome Research Center, National
Cheng Kung University, Tainan, Taiwan; 3Department
of Ophthalmology, National Cheng Kung University,
Tainan, Taiwan.
Background: Ophthalmic steroids are used to relieve the
ocular surface inﬂammation, which participates in the
pathogenesis of dry eye disease (DED). However, a
large-scale population-based study on the use of
ophthalmic steroids in DED was lack.
Objectives: To investigate the utilization of ophthalmic
steroids in DED patients in Taiwan and analyze the
predictors associated with the long-term use of steroids.
Methods: A retrospective cohort study was conducted,
based on the claims data from 2004 to 2010. Patients with
a DED diagnosis (ICD-9 codes 370.33, 375.15, or 710.2)
receiving Schirmer’s test or/and having Sjögren’s
syndrome (recorded in the registry for catastrophic
illness) during 2005-2009 were included. All patients
were followed for one year from the ﬁrst DED diagnosis
to observe the pattern of steroid use. Multiple logistic
regression model was employed to evaluate the predic-
tors for long-term use of ophthalmic steroids.
Results: We identiﬁed 44,501 DED patients (26.5%
male) with a mean (±SD) age of 51.5 (±16.3) years.
There were 22,060 patients prescribed with ophthalmic
steroids within 30 days after DED diagnosis, and 6,338
were identiﬁed as long-term users (>= 3 bottles within
6months). Compared to short-term users, long-term users
were older (57.2 ± 16.7 vs. 49.9± 16.1 years) and had lon-
ger duration of steroid-use (7.4± 1.5 vs. 4.0 ± 1.6months).
Cornea transplant was the strongest predictor of the long-
term use (odds ratio 5.95).
Conclusions: Approximate 50% of DED patients were
prescribed with ophthalmic steroids, in which 28.7%
received the steroids for at least 6months. Drug safety
monitoring and counseling should be warranted once
ophthalmic steroids are initiated.
242. Longitudinal Changes of Polypharmacy in the
Elderly: A Population-Based Study over a 10-Year
Period in Taiwan
Wan-Hsuan Lu,1 Liang-Kung Chen,2,3 Fei-Yuan Hsiao.1
1Graduate Institute of Clinical Pharmacy, National
Taiwan University, Taipei, Taiwan; 2Center for
Geriatrics and Gerontology, Taipei Veterans General
Hospital, Taipei, Taiwan; 3Aging and Health Research
Center, National Yang Ming University School of
Medicine, Taipei, Taiwan.
Background: Polypharmacy is prevalent in the elderly.
Nevertheless, empirical data on the longitudinal changes
of polypharmacy is scarce.
Objectives: Using Taiwan’s National Health Insurance
Research Database (NHIRD), this population-based
study investigates longitudinal changes of polypharmacy
in the elderly over a 10-year period.
Methods: We identiﬁed 63,017 people who aged
65 years old and older in 2001 and divided those
into three groups (aged 65-74 (n = 41,192), 75-84
(n = 18,441) and 85+ (n = 3,384)). The numbers of drugs
prescribed to each study subject were measured every
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three months from 2001 to 2011 and grouped into ﬁve
categories: “0”, “1-4”, “5-8”, “9-12” and “13 + .”
Results: At cohort entry, most study subjects (35.6%)
used “1-4” drugs while at the end of the follow-up (the
10th year), most of them (34.3%) used “5-8” drugs.
Noteworthy, approximately 30% of the study subjects
used more than 9 drugs at cohort entry and the end of
the follow-up. The average number of drugs used increased
from 7.11 to 7.36. The trends of polypharmacy are differ-
ent across three elder populations. There is a slight increase
in the average number of drugs used by the youngest elder
group over the 10-year follow-up (age 65-74, 7.02 to 7.44).
In contrast, the average number of drugs used over the
10-year follow-up decreased for the other two groups
(age 75-84, 7.35 to 7.11 and age 85+, 6.97 to 6.20).
Conclusions: Different drug management strategies may
be warranted for different elderly populations since the
longitudinal changes of polypharmacy are very different
as suggested by our study.
243. Find the Risk of Drug Usage from the Surveil-
lance Results of the Electronic Media Advertisements
Chao-Yi Wang, Chia-Ping Liu, Ping-Chang Hsu,
Shwu-Huey Her, I-Hsuan Wu, Ming-Kung Yeh.
Food and Drug Administration, Ministry of Health and
Welfare, Taipei, Taiwan.
Background: Owing to the rapid advancement of
technology, the industries have employed strategies of
advertising and marketing to increase the product
visibility and acquire the immediate attention from their
customers. In Taiwan, the government has no regulation
on advertisements or commercial activities on food
products, thereby resulting in possibility of broadcasting
false information or exaggerated product effects that
may mislead customers. Food and Drug Administration
surveillance on media in Taiwan may provide the
protection against the illegal advertisement.
Objectives: By analyzing the surveillance results of the
electronic media advertisements, we can reveal the
violations on different aspects and preferences of people
for the product contents and functionalities. These
analyses will provide information to improve the health
education and correct concepts of medicine usage.
Methods: Analyzing the surveillance results of electronic
media advertising from 2011 to 2013 will provide a
better understanding of the common violations on
advertising and products aspect through various types
of media platforms.
Results:We found the mostly illegal advertised products
were food, followed by cosmetics, and Chinese medicine
on TV and the internet. On the radio broadcasting, the
mostly illegal advertised products were food, followed
by Chinese medicine. To be more precisely, the weight
loss commercials have the highest rate (23.17%),
followed by skin care (22.87%) in television advertising.
On the other hand, the radio advertising has the highest
illegal advertising rate on the pharmaceutical products
of cardiovascular circulation (26.3%), followed by drugs
of musculoskeletal aspects (19.50%). In internet advertis-
ing, products for skin cosmetics (40.18%) had the highest
illegal advertising rate, followed by drugs for blood
circulation (11.77%).
Conclusions: The Ministry attempts to prevent customers
from being misled through strengthening the annual sur-
veillance on advertisement of medicaments, cosmetic and
food products. In addition, the Ministry has advocated
the correct concepts of usage of medicaments to customers.
244. Use of Ezetimibe in Australia
Samantha A Hollingworth,1 Remo Ostini,2 David
Michael,2 Jennifer Martin,3 Tett Susan.1 1School of
Pharmacy, The University of Queensland, Brisbane,
QLD, Australia; 2School of Population Health, The
University of Queensland, Brisbane, QLD, Australia;
3School of Medicine, The University of Queensland,
Brisbane, QLD, Australia.
Background: Ezetimibe reduces absorption of dietary
and biliary cholesterol by inhibiting its transport
across the intestinal wall. Ezetimibe receives public
subsidy in Australia from the Pharmaceutical Beneﬁts
Scheme (PBS) for very restricted indications (authori-
sation required).
Objectives: To analyse the subsidised utilisation of
ezetimibe in Australia.
Methods: Utilisation of the ﬁve ezetimibe products (indi-
vidual and combined with simvastatin) between 2004 and
2012 were extracted using PBS item reports, downloaded
from Medicare Australia website. The deﬁned daily dose
(DDD) for ezetimibe is 10mg. DDD were calculated per
1000 inhabitants of Australia per day (DDD/1000/day)
for each calendar year.
Results: Ezetimibe as a sole active ingredient was the
most commonly dispensed formulation (0.25 up to 4.19
DDD/1000/day, from 2004 to 2012), followed by the
two combination products containing ezetimibe and
higher doses: 40mg (0.21 up to 1.50 DDD/1000/day
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from 2006 to 2012); and 80mg (0.16 up to 1.39 DDD/
1000/day from 2006 to 2012) of simvastatin. The two
combination products with ezetimibe and lower doses
(10mg and 20mg) simvastatin, subsidised since 2009,
were not widely dispensed (together 0.32 DDD/1000/
day in 2012). The average yearly increase in utilisation
between 2006 and 2012 was 25% and the increase in
costs to government was 32%.
Conclusions: Ezetimibe use has increased rapidly in
Australia since receiving public subsidy. Although the
indications for subsidy are very restricted there appears
to have been quite widespread use, with total use of
ezetimibe in all forms at 7.40 DDD/1000/day by 2012.
Latest guidelines still question the value of ezetimibe
use so further investigation is needed in Australia about
whether the public spending on this medication is
justiﬁable for the potential improvement in population
health outcomes.
245. Appropriate Prescribing of Medications among
Diabetic Medicare Patients Treated by Nurse
Practitioners or Physicians
Yong-Fang Kuo,1 Nai-Wei Chen,1 Mukaila A Raji.2
1Preventive Medicine and Community Health, University
of Texas Medical Branch, Galveston, TX, United States;
2Internal Medicine, University of Texas Medical Branch,
Galveston, TX, United States.
Background: The growing number of older Americans
with diabetes being cared for by nurse practitioners
(NPs) has raised questions about quality of prescribing
practice of NPs. Are there differences in how NPs and
physicians prescribe medications known to reduce the
risk of diabetes complications? Are NPs and physicians
similar in the rate of avoidance of medications considered
inappropriate in the elderly? Answering these questions
can inform development of guidelines to improve
diabetes care.
Objectives: We assess appropriate prescribing practice
by NPs vs. physicians on the use of: a) statin and
angiotensin converting enzyme inhibitor (ACEI) or
angiotensin receptor blockers (ARB), b) potentially
inappropriate medications (PIMs), and c) antimicrobials
(e.g. co-trimoxazole) known to interact adversely with
sulfonylureas.
Methods: Medicare data was used to identify diabetes
patients cared for by either NPs or physicians. We
excluded patients in health maintenance organization.
We included patients with continuous Medicare part A,
B, and D coverage in 2009. We used the Beers criteria
2003 list of inappropriate medications to deﬁne PIMs.
Multivariable logistic regressions models were built to
assess the differences in medication use between two
groups adjusted for age, gender, race, social economic
status, comorbidity and other confounders.
Results: Patients cared for by NPs were less likely to
receive statin (OR: 0.94, 95% CI = 0.90 – 0.98) but
were equally likely to receive ACEI/ARB (OR: 0.99,
95% CI = 0.95 – 1.03). No signiﬁcant difference was
seen between NPs and physician (12.8% vs. 12.9%)
on concurrent use of adversely-interacting antimicrobials.
There was also no signiﬁcant difference in the rate
of PIMs use by patients cared for by NPs (32.2%) or
physicians (30.1%).
Conclusions: Our study showed that NPs and physicians
were similar in quality of appropriate prescribing for
elderly patients with diabetes. This ﬁnding may somewhat
reduce concerns about the safety of the care provided by
NPs. More research is needed on reducing the high PIMs
use by both NPs and physicians.
246. Using Routinely Collected Administrative Health
Claims Data to Improve the Uptake of Primary
Healthcare Services
Vanessa T Le Blanc,1 Andrew L Gilbert,1 Lisa M Kalisch
Ellett,1 Nicole L Pratt,1 John D Barratt,1 Emmae N
Ramsay,1 Mhairi M Kerr,1 Robert Peck,2 Graeme Killer,2
Elizabeth E Roughead.1 1Quality Use of Medicines and
Pharmacy Research Centre, Sansom Institute, School of
Pharmacy and Medical Sciences, University of South
Australia, Adelaide, Australia; 2Australian Government
Department of Veterans’ Affairs, Canberra, Australia;
3Australia.
Background: The Veterans’ Medicines Advice and
Therapeutics Education Services (MATES) program
aims to improve the health care of the veteran population.
The Australian Government Department of Veterans’
Affairs administrative claims data are used to provide
direct patient-based feedback to medical practitioners.
The feedback is supported with educational material
developed by a clinical panel and overseen by a national
editorial committee. Interventions target, on average,
40,000 veterans, 10,000 doctors and 8,500 pharmacists.
Objectives: To evaluate the impact of the Veterans’
MATES interventions targeting healthcare services that
were known to be under-utilised; one targeted bone
mineral density testing, two targeted Home Medicines
Reviews (HMRs), one targeted dose administration aids,
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and one targeted tests and care plans associated with
diabetes care.
Methods: Segmented regression analysis was used to
estimate the effect of each intervention taking into
account the baseline trend prior to the intervention. A
log-binomial generalised estimating equation was used
with an AR (1) error structure to account for correlation
between months, clustered by patient.
Results: All interventions were effective in increasing
the use of targeted services. For diabetes, the intervention
was associated with an increase in HbA1c testing RR
1.17 (95% CI 1.14-1.19), microalbuminuria testing RR
1.08 (95% CI 1.04-1.11) and care plans (RR 1.21 (95%
CI 1.13-1.29). For osteoporosis, bone mineral density
testing increased in women RR 1.40 (95% CI 1.20-1.63)
and men RR 2.62 (95% CI 1.96-3.5). Home medicine
reviews increased in both interventions RR 1.10 (95%
CI 1.01-1.20) and RR 1.41 (95% CI 1.33-1.50) as did
the use of dose administration aids RR 3.10 (95% CI
2.95-3.27).
Conclusions: Routinely collected health claims data
can be used to increase the use of under-utilised
health services.
247. Assessment of Clinical Features and Medical
Treatment of Patients with Atrial Fibrillation in
Outpatient Registry in Moscow
Sergey Yu Martsevich, Natalia P Kutushenko, Liubov
Yu Drozdova, Arthur R Navasardyan, Alla V Zakharova.
Preventive Pharmacotherapy, National Research Center
for Preventive Medicine, Moscow.
Background: Atrial ﬁbrillation (AF) is the most com-
mon arrhythmia and associated with poorer prognosis.
However, clinical features of such patients (pts) may vary
in different populations and different regions.
Objectives: To characterize clinical features and medical
treatment of pts with AF according to registry data.
Methods: The data of PROFILE registry was used. This
registry includes all patients who applies for specialized
medical consultation in the outpatient consulting depart-
ment for cardiovascular diseases (CVD) of the National
Research Centre for Preventive Medicine in Moscow.
Results: 671 patients (constantly registred in Moscow)
with different CVD were included into PROFILE registry
consecutively during 15months period (2012-2013). AF
was diagnosed in 99 (14,7%)pts, 56,6 % of them had
paroxysmal AF. Pts with AF were older than pts without
AF. Comparing anamnesis of the pts with and without
AF no difference was found in the presence of CVD risk
factors (arterial hypertension, smoking, lipid disorders)
and diabetes mellitus. Obesity was more common in pts
without AF (29,5%) vs pts with AF (17,2%, p = 0.016).
The presence of coronary heart disease, peripheral vascu-
lar disease and their complications was equal in patients
with and without AF. However, congestive heart failure
was signiﬁcantly more common in pts with AF than in
pts without AF (30,3% and 19,9%, p = 0,028). In the
group of pts with AF 9,1% survived stroke; in the group
of pts without AF stroke survived only 2,8% (p = 0,006).
There was a tendency towards higher prevalence of
gastrointestinal bleedings in anamnesis in pts with AF
(9,1% and 4,4%, p = 0,084). 29% of pts with AF were
taking warfarin, 20% - novel oral anticoagulants
(dabigatran and rivaroxaban).
Conclusions: PROFILE registry revealed that patients
characteristics were similar to those in other registers of
CVD diseases performed in Russia. However, frequency
of anticoagulation in PROFILE registry appeared to be
many times higher.
248. Do Rational Use Meet Reality in a Country
Under Financial Assistance Program for Cost-Saving
Expenditures? The Two Sides of the Portuguese Coin
Carla Torre, José Guerreiro, Marta Gomes, Suzete Costa.
Centre for Health, Evaluation & Research (CEFAR),
National Association of Pharmacies, Lisboa, Portugal.
Background: The Memorandum of Understanding
(MoU) signed in 2011, between the Portugal(PT) and
the European Commission, International Monetary Fund
and the European Central Bank, imposed the establish-
ment and monitoring of several prescribing guidelines.
Objectives: To perform a cross-country comparison of
utilization patterns of ambulatory high expenditure
therapeutic groups between PT and six European
countries focusing on quality prescribing indicators
(e.g. ﬁrst-line uptake) and a cost-saving scenario analysis
using potentially more rational prescribing patterns in
PT. To investigate the impact of PT prescribing guide-
lines set forth by the MoU.
Methods: Cross-national drug utilization with 2012 data
from: PT,Denmark,UK,Finland,the Netherlands,Norway
and Sweden. Analysis comprised Oral Antidiabetic
Drugs(OAD)(A10B), Antihypertensives(AHT)(C02,C03,
C07,C08&C09), Lipid-Lowering Drugs(LLD)(C10AA
&C10BA02), Proton Pump Inhibitors(PPI)(A02BC),
Oral Anticoagulants (B01AA,B01AE&B01AF) and
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Antiepileptics-Carboxamide der.(N03AF). Data from
PT was retrieved from hmR Pharmacy Sales Information
System, a nationwide database with representative ambula-
tory data. Data from other countries was selected from
open-access databases in each country. Cost-saving
analysis:average annual cost per deﬁned daily dose
(DDD) from PT and simulations to measure the
impact on total expenditure of studied European
utilization patterns (%DDD)vs PT pattern. Segmented
regression analyses were set up to investigate the im-
pact of PT guidelines in the use for OAD,AHT,LLD
and PPI (ref per:Jan2010–Sep2013).
Results: PT has the highest consumption of DPP-4 ﬁxed-
dose combinations (25.1%) Angiotensin Reception
Blockers (32.3%) and Rosuvastatin (19.4%).Annual
cost-savings were estimated in scenarios of more rational
prescribing: e.g.111.6M€, 83.5M€ when simulating the
Dutch OAD and the Danish AHT prescribing patterns,
respectively. Overall, the PTprescribing guidelines had
no impact on ﬁrst-line drugs uptake.
Conclusions: It is crucial to optimize prescribing patterns
in PT, in order to achieve a more rational drug use and a
sustained control of pharmaceutical expenditure.
249. Surveillance of New Drug Adoption in Australia
Using Primary Care EHR Data
Malcolm B Gillies,1 Margaret Williamson,1 Alistair
Merriﬁeld,1 Stephen Morrell,2 Nancy Huang.1
1MedicineInsight, NPS MedicineWise, Surry Hills,
NSW, Australia; 2School of Public Health and Commu-
nity Medicine, University of New South Wales, Sydney,
NSW, Australia.
Background: Patterns of new drug adoption in primary
care vary greatly. For example, in 2008 more than 100
000 Australians were exposed to varenicline within
12months of its introduction. Early awareness of rapid
adoption would help prioritise work to ensure safe and
effective prescribing.
Objectives: To quantify the speed of new drug adoption
in Australian primary care in 2012 and give population-
level exposure estimates for intervention planning and
post-market surveillance.
Methods: MedicineInsight is an Australian national
primary health care panel collecting electronic health re-
cord data. It enables timely measurement of practitioners’
adoption of new drugs and their responses to prescribing
guidelines. This analysis is based on data from 53
practices, 738 prescribers and ~250 000 patients.
We analysed MedicineInsight data on drugs that were
ﬁrst made available under the Australian reimbursement
scheme in 2012, estimating the monthly proportion
of primary care physicians who had ever prescribed
each new drug. We also counted patients starting
each new drug during its ﬁrst six months and one year
of availability.
Results: Apixaban, linagliptin, rasagiline and ticagrelor
were prescribed by at most 5% of prescribers during
the ﬁrst 6months of subsidised availability. The most
commonly prescribed were linagliptin (0.06 / 1000
consultations) and ticagrelor (0.04 / 1000 consultations).
Over 12months, the proportion of doctors who had
ever prescribed each new drug increased linearly, and
the extrapolated national exposure for each drug was
10 000 patients.
Conclusions: None of the drugs introduced in 2012 was
taken up as rapidly as varenicline. This matched expecta-
tions as, except for ticagrelor, all were ‘me too’ drugs or
for lower prevalence conditions; the rate of ticagrelor
adoption was perhaps slowed because cardiologists are
generally the initiators of antiplatelet prescribing.
Coupled with adverse-event surveillance and an
understanding of doctors’ reasons for new drug adoption,
this type of analysis can form the basis of a forecasting
tool, supporting population health interventions to
improve the safety and quality of prescribing for newly
introduced drugs.
250. Sex Differences in Utilization of Nervous System
Drugs in Sweden and Taiwan
Mia von Euler, Maria Sperling, Ching-Lan Cheng,
Yea-Huei Kao Yang, Björn Wettermark. Clinical Science
and Education, Södersjukhuset, Karolinska Institutet,
Stockholm, Sweden; Institute of Clinical Pharmacy and
Pharmaceutical Sciences, National Cheng Kung Univer-
sity, Tainan, Taiwan; Centre for Pharmacoepidemiology
and Clinical Pharmacology, Karolinska Institutet,
Stockholm, Sweden.
Background: Sex differences in drug utilization have
been demonstrated in several therapeutic areas. While
some differences may be explained by varying disease
prevalence between the sexes when other causes are less
obvious.
Objectives: To identify sex differences in the utilization
of nervous system drugs in Sweden and Taiwan.
Methods: A retrospective cross-sectional study using
data from national registries. The Swedish Prescribed
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Drug register, including all drugs dispensed to the
Swedish population was used. A one million cohort
randomly sampled from all the beneﬁciaries in the
National Health Insurance Research Database (NHIRD)
in Taiwan was used, which covered almost the entire
population (99.6 %) and included all drugs dispensed at
contracted pharmacies. The one million cohort was
similar to the entire population in terms of gender and
age distribution.
The proportions of men and women who had been dis-
pensed at least one prescription of Nervous system drugs
in 2010 were compared between the countries.
Results: The age distribution of the population was
similar in Sweden and Taiwan. Women were more likely
to use nervous system drugs in general except for ADHD
medicines which were used by 6.6 and 5.9 patients/1000
patient years for men and women, respectively in Taiwan
and in 6.8 and 3.9 patients/1000 patient years for men
and women, respectively in Sweden. The largest
difference between the sexes was found for migraine
medications in both countries, reﬂecting that more
women than men suffer from the disease. The utilization
was 2.4 and 5.5 patients/1000 patient years in Taiwan
and 4.4 and 15.6 patients/1000 patient years for men
and women, respectively in Sweden. Women used
proportionally more Parkinson, antidementia, anxiolytic,
and antidepressant drugs in Sweden than in Taiwan while
antipsychotic medicines were used in proportionally
more women in Taiwan.
Conclusions: Some differences in drug utilization
between men and women such as migraine or ADHD
treatment can be related to differences in disease
patterns. However, antipsychotic medicines are used
unproportionally more in women in Taiwan while
anxiolytic and antidepressants are more used by Swedish
women. Further studies are warranted.
251. Evaluation of Control Activities of Antibiotic
Prescribing Practices and Multidrug-Resistant Bacteria
in Healthcare Organizations of Paris City and Inner
Suburbs
J-Frederic Westphal. Regional Agency of Health, Paris,
France.
Background: The areas of control of antibiotic prescrib-
ing practices (APP) and multidrug-resistant bacteria
(MRB) in French healthcare organizations (HO) are
managed by committees for nosocomial infection
control. The committee of each HO must provide a
computer-based annual report of its activities to the
French Ministry for Health.
Objectives: The aim of the study was to review the
scores obtained by all the HO concerned by the annual
report in Paris city and inner suburbs in 2012.
Methods: Evaluation of the reports was performed by the
Regional Agency of Health, a dependency of the
Ministry of Health.
In each area, evaluation included the global score
(decreasing from A to E) and the numerical scores
recorded in the three sections (Organization, Means,
Actions) structuring each area. These sections include
the items of pre-deﬁned policies that HO must fulﬁll in
their control activities.
Results: The annual reports of 205 HO (comprising
43,546 beds) were examined, including 31 university
hospitals (UH), 37 general hospitals (GH), 68 private
clinics (PC), 50 rehabilitation or long-term care facilities
(R/LTCF), and 19 psychiatric hospitals (PSYH).
In the MRB control area, distribution of the global
scores in HO was: A 33.5%, B 29%, C 17.5%, D 12%,
and E 8%, vs., respectively, 70%, 17%, 11%, 1,5%, and
0.5% in the APP area. Proportion of the combined scores
A and B in the APP or MRB control area was, respec-
tively, 87% and 62% (p <0.001).
Distribution of the combined higher scores A and B
according to the type of HO was: 64% in UH, 65% in
GH, 59% in PC, 66% in R/LTCF, and 53% in PSYH
for the MRB control area, vs., respectively, 90%, 87%,
92%, 86%, and 68% for the APP area.
Numerical scores recorded in the sections Organiza-
tion, Means, and Actions were maximal in, respectively,
73,5%, 13,5%, and 52% of HO for the APP area vs.
60,5%, 46%, and 32% for the MRB area.
Conclusions: Review of APP or MRB control activities
in the 2012 report from the 205 HO of Paris and inner
suburbs highlights perfectible results and the need for
some interventions in a number of HO.
252. Analysis of Essentiality of the Medicines from the
“Popular Pharmacy Program in Brazil”
Sueli Miyuki Yamauti, Silvio Barberato-Filho, Luciane
Cruz Lopes. Pharmaceutical Sciences Post Graduate
Course, University of Sorocaba, UNISO, Sorocaba, São
Paulo, Brazil.
Background: Essential medicines are considered as a
human right by the World Health Organization should
be selected with quality, having affordable prices with
reliable health systems and sustainable ﬁnancing to facil-
itate access by citizens. Popular Pharmacy Program in
Brazil (PFPB) was designed to expand the population’s
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access to a list of essential drugs in primary health care,
through co-payments or subsidies, offering an equal
service for all users or non-users of public health services.
Objectives: To analyze the selection of medicines from
the Popular Pharmacy Program in Brazil (PFPB) as to
the essentiality.
Methods: Cross-sectional descriptive design. The cast of
medicines of PFPB, the year 2012, was compared to the
lists of national reference (List of Essential Medicines
2010 - Rename) and international (18th Model List of
Essential Medicines of the World Health Organization -
EML), the lists of medicines government funded (Com-
ponents of Financing Blocks Pharmaceutical Assistance)
and the list of medicines produced by ofﬁcial pharmaceu-
tical laboratories of Brazil.
Results: The cast of PFPB contains 87 active ingredients
(119 pharmaceuticals products), where 19.3% and 52.9%
are not listed neither in nor Rename and nor in EML,
respectively. Some of these products have been excluded
in previous revisions of these reference lists (15 in the
Rename and 10 in the EML). The ofﬁcial pharmaceutical
laboratories produce 59.7% of the products of cast of
PFPB, including 15 items that are not in the Rename
and 33 missing in the EML. It was also found that 16%
of pharmaceutical products are not PFPB medicines used
in primary health care.
Conclusions: The cast features the PFPB nonessential
medicines and are not destined for primary health care,
contrary to the purpose of this program. We recom-
mend reviewing this list since ofﬁcial pharmaceutical
laboratories are prioritizing the production of these
medicines.
253. Influenza Vaccination According to Dementia
Diagnosis in French Nursing Homes
Adeline Gallini,1,2,3 Virginie Gardette,1,2,3 Maryse
Lapeyre-Mestre,1,2,3 Philipe De Souto Barreto,2,3 Bruno
Vellas,1,2,3 Sandrine Andrieu,1,2,3 Yves Rolland.1,2,3
1University of Toulouse, Toulouse, France; 2Toulouse
University Hospital, Toulouse, France; 3INSERM
UMR1027, Toulouse, France.
Background: Despite inﬂuenza vaccination being rec-
ommended for all people ≥65 years, some data suggest
that subjects with dementia are less frequently vacci-
nated than their non-demented peers in the commu-
nity. However, there is no data about vaccination
uptake according to dementia status in nursing homes
(NHs) in France.
Objectives: We aimed to compare the prevalence of
inﬂuenza vaccination according to dementia diagnosis
in French NHs in 2010-2011.
Methods: Design: Cross-sectional study
Setting: South-western France, winter 2010-2011. We
used baseline data from the IQUARE study (a controlled
trial aiming to investigate the effect of an educational
support to NH staff on the quality of care provided).
5036 residents (in 175 NHs) ≥65 years were assessed.
Outcomes: Vaccination status for the 2010-2011 season,
reported by medical staff.
Exposures: Dementia referred to a diagnosis made by a
specialist (neurologist, geriatrician or psychiatrist) and
reported in the medical charts (n = 1602). In a sensitivity
analysis, dementia diagnosis could have been made by
another physician (726 additional cases).
Analysis: In a multiple mixed-effect logistic regression
model, accounting for a NH random effect, we investigated
vaccination status according to dementia, controlling for
the residents’ demographics, comorbidities and disability
levels.
Results: Residents with dementia were more frequently
vaccinated (92.0%, 95%CI:[90.6-93.6]) than residents
without dementia (87.7%, 95%CI:[86.5-88.9]). Control-
ling for age, gender, comorbidities (e.g. heart failure,
chronic respiratory disease, renal failure, diabetes,
hypertension…), disability levels, accommodation in a
special care unit…, inﬂuenza vaccination was more
likely in residents with dementia than in residents without
dementia (OR=1.42, 95%CI:[1.09-1.85], p = 0.0096).
This result remained stable in the sensitivity analysis
(OR=1.53 (95%CI: [1.21-1.95])).
Conclusions: We did not observe any underuse of inﬂu-
enza vaccination in subjects with dementia in French
NHs. Furthermore, dementia represented an independent
predictor of vaccination receipt. Further analyses will be
conducted to investigate whether NH characteristics
could partly explain this result.
254. Sex, Gender and Drugs – A Tool for Gender-
Conscious Prescribing
Desirée Loikas,1,2 Emma Hultén,1 Linnéa Karlsson,1
Seher Korkmaz,1 Fadiea Al-Aieshy,3 Mia von Euler,4
Björn Wettermark,1,2 Eva Andersén Karlsson,1 Karin
Schenck-Gustafsson.5,6 1Public Healthcare Services
Committee, Stockholm County Council, Stockholm,
Sweden; 2Centre for Pharmacoepidemiology and
Clinical Pharmacology, Karolinska Institutet, Stockholm,
Sweden; 3Division of Clinical Pharmacology, Karolinska
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University Hospital Solna, Stockholm, Sweden;
4Karolinska Institutet Stroke Research Network at
Södersjukhuset, Department of Clinical Science and
Education, Södersjukhuset, Karolinska Institutet,
Stockholm, Sweden; 5Centre for Gender Medicine,
Karolinska Institutet, Stockholm, Sweden; 6Department
of Medicine, Cardiology Unit, Karolinska Institutet,
Stockholm, Sweden.
Background: Sex and gender are important factors to
consider when prescribing drugs since there may be
differences between men and women in drug effects, side
effects and drug utilization. However, drug evaluation
studies are often lacking sex- and gender analysis and
physicians have no support for sex- and gender-
conscious prescribing.
Objectives: The establishment of a knowledge database
with evidence based information on sex- and gender
aspects on drug treatment to facilitate a sex- and gender-
conscious prescribing.
Methods: Sex- and gender-speciﬁc information on
drug substances is compiled from systematic literature
searches in medical databases and short summary
texts are written for each substance. The texts are
complemented with data from the Swedish Prescribed
Drug Register, including all drugs dispensed to the
Swedish population, to describe the utilization pattern
in the Swedish population with focus on sex differences.
After an extensive review process by senior clinical
experts and the expert groups of the regional Drug and
Therapeutic Committee in Stockholm County Council,
the texts are published in the knowledge database “Sex,
Gender and Drugs”, freely available via the web site
www.janusinfo.se/genus.
Results: The knowledge database “Sex, Gender and
Drugs” provides concise and structured information on
sex- and gender related aspects of drug treatment and
whether there is something to take into consideration
regarding drug selection and dosage related to patient
sex. Drug statistics adds information on the utilization
patterns in men and women and can indicate possible
unequal drug treatment. To date the database contains in-
formation on about 50 substances within the therapeutic
areas cardiology and neurology, covering antithrombotic
agents, antiepileptics, anti-parkinson drugs, psycho-
leptics and psychoanaleptics. The database will continu-
ally be ﬁlled with information on more substances.
Conclusions: To the best of our knowledge, this is the
ﬁrst initiative to collect evidence-based information
about sex- and gender aspects on drug treatment into a
searchable tool. The database aims to facilitate a sex-
and gender-conscious prescribing, resulting in a better
drug treatment for the patients.
255. Comparison of Medication Use in Taipei with
Non-Taipei City by Beers Criteria in Elderly Based
on the National Health Insurance Research Database
in Taiwan
Mei-Hsiouh Guan, Su-Yu Yang, Li-Chi Chen.
Pharmacy, Taipei City Hospital, Taipei.
Background: Taiwan’s population moves from ‘aging’
to ‘aged’ and most of the elderly require medical care
and medications as well. With the data base of the
National Health Insurance Research Database in 2009,
we would like to identify the potentially inappropriate
medications in Taipei and non-Taipei city by Beers
Criteria in elderly.
Objectives: This study aims to compare of medication
use in Taipei with non-Taipei in elderly by Beers Criteria
in elderly to see if there’s difference in capital city and
non-capital city.
Methods: A cross-sectional survey was implemented
using the National Health Insurance Research Database
from January to December in 2009. Evaluated the out-
patients aged sixty-ﬁve and older that visited clinics by
Beers Criteria to identify the potentially inappropriate
medications. Age, gender, number of medications, dura-
tion of prescriptions, hospital type, and complications
of patients were analyzed as well.
Results: A total of 27,485,169 patients were included,
4,073,046 (14.82%) were in Taipei and 23,412,132
(85.18%) were in non-Taipei city. The average age was
74.98 (SD: 6.79); 75.7 (SD: 7.14) and 74.84 (SD: 6.71)
in total, Taipei and non-Taipei City respectively. The
average number of medications per prescription was
4.11(SD: 2.15); 4.3 (SD: 2.3) and 4.1 (SD: 2.1) in
total, Taipei and non-Taipei City. A total number of
medication use was 27,485,169; 4,073,046 and
23,412,123 in total, Taipei and non-Taipei respectively
the whole year. Evaluated by Beer Criteria, 53.53%
was potentially inappropriate medications and it was
50.07% in Taipei and 54.13% in non-Taipei City. The
top potentially inappropriate medication was diclofenac
both in total and in non-Taipei City, and was zolpidem
in Taipei.
Conclusions: The average number of medications
per prescription was higher in Taipei than in non-Taipei
City, but the percentage of potentially inappropriate
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medications was lower in Taipei than in non-Taipei
City. The top potentially inappropriate medication
was same in non-Taipei City and total but different
with Taipei.
256. Erythropoietin Stimulating Agent Prescribed
Pattern for the Incident Uremia Patients in Taiwan
An-Bang Wu,1,2 Tzu-Chieh Lin,2,3 Ming-Cheng
Wang,1,2 Yea-Huei Kao Yang.2,3 1Division of
Nephrology, Department of Internal Medicine, National
Cheng Kung University Hospital, Tainan, Taiwan;
2Institute of Clinical Pharmacy and Pharmaceutical
Science, National Cheng Kung University, Tainan,
Taiwan; 3Health Outcome Research Center, National
Cheng Kung University, Tainan, Taiwan.
Background: Erythropoietin stimulating agent (ESA)
corrected the renal anemia and improved the outcome
of uremia patients. However, high hemoglobin target
with more ESA dose may also be associated with poor
survival.
Objectives: To evaluate the prescribing pattern of ESA
for the incident uremia patients in Taiwan.
Methods: Incident uremia patients from January 2002 to
December 2009 were identiﬁed from the Registry for
Catastrophic Illness Database of National Health Insur-
ance Research Database (NHIRD). For incident uremia
patients in each year, the ﬁrst year’s total ESA consump-
tion after dialysis was measured by deﬁned daily dose
(DDD) per inhabitant per year, if the patient survived
more than one year after dialysis. For those patients
survived more than two or three years, the second or
third year’s total ESA consumption was measured as
the same method.
Results: A total of 84,385 patients were found in the
NHIRD during the study period. The mean age was
63.2 ± 14.3 years, and 50.95% of patients were male.
From 2002 to 2009, the ﬁrst year’s total ESA consump-
tion increased from 144 DDD to 193 DDD per inhabitant
per year. The second year’s ESA consumption increased
from 161 DDD to 201 DDD per inhabitant per year. The
third year’s ESA consumption increased from 163 DDD
to 200 DDD per inhabitant per year. Compared the ﬁrst
year’s consumption, male and older (more than 80 years)
patients had lower ESA usage.
Conclusions: During the study period, the ESA dose for
the incident uremia patients increase gradually. Male and
older incident uremia patient had relative low dose of
ESA in their ﬁrst year of dialysis.
257. Using Administrative Healthcare Data to Study
the Treatment of Inflammatory Bowel Disease in the
Region of Stockholm, Sweden
Thomas Cars,1,3 Mikael Lördal,2 Björn Wettermark.3,4
1Dept. Medical Sciences, Uppsala University, Uppsala,
Sweden; 2Centre for Digestive Diseases, Division of
Gastroenterology, Karolinska University Hospital,
Stockholm, Sweden; 3Public Healthcare Services
Committee Administration, Stockholm County Council,
Stockholm, Sweden; 4Centre for Pharmacoepidemiology,
Department of Medicine, Karolinska Institutet, Stockholm,
Sweden.
Background: Inﬂammatory bowel disease (IBD) is a
chronic inﬂammation in the digestive tract. IBD primarily
includes Crohn’s disease and ulcerative colitis with a
combined prevalence of about 0.65 % in Sweden. There
is no medical cure but several medications have proven
to be effective in helping to control the disease.
Objectives: To develop a model using healthcare admin-
istrative data on consultations, diagnoses, procedures and
drugs to analyze the drug therapy of IBD.
Methods: A cohort of IBD naïve patients during 2011
was created using the Stockholm regional health care
data warehouse (VAL). This cohort was followed for
two years from date of inclusion with focus on drug ther-
apy. Data on dispensed drugs and anti-TNFα-antibodies
administered at hospitals were retrieved from the data
warehouse.
Results: A total number of 628 newly diagnosed patients
were selected (282 with Crohn’s disease and 346 with
ulcerative colitis). The mean age was 39,1 years and
44,3 years for Crohn’s and ulcerative colitis respectively.
The gender distribution was 51,1 % women in Crohn’s
disease and 48,0 % women in ulcerative colitis. During
the ﬁrst two years after the ﬁrst diagnosis of Crohn’s
disease, 5-ASA preparations, systemic glucocorticoids,
immunomodulators and anti-TNFα-antibodies were used
by 44,7 %, 44,0% 38,3% and 18,4 % respectively. For
patients with ulcerative colitis, 5-ASA preparations,
systemic glucocorticoids, immunomodulators and anti-
TNFα-antibodies were used by 82,7 %, 43,6%, 19,1 %
and 8,4 % respectively. For patients initiated with anti-
TNF therapy the mean time from ﬁrst registered
diagnosis to anti-TNFα-antibodies was 365 days (median
275 days) for Crohn’s disease and 328 days (median
252 days) for ulcerative colitis.
Conclusions: This study shows the possibility to analyse
treatment patterns of IBD using administrative healthcare
data. Additional analyses using clinical data is needed to
further evaluate the quality of treatment.
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258. An Audit of Prescriptions from the Dental
Outpatients Department of a Tertiary Hospital in
Ado-Ekiti, South-West Nigeria
Joseph O Fadare,1 Obitade Obimakinde.2 1Department of
Pharmacology, Ekiti State University, Ado-Ekiti, Ekiti,
Nigeria; 2Department of Dentistry, Ekiti State University,
Ado-Ekiti, Ekiti, Nigeria.
Background: The audit of prescriptions serves to review
the use of medicines whether rational or otherwise. It
could also serve as a template for possible intervention
among prescribers.
Objectives: The aim of this study was to assess the pre-
scription pattern in patients attending the dental clinic
of a tertiary hospital in Ado-Ekiti, South-West Nigeria.
Methods: A retrospective study was done using the med-
ical records of patients who attended the dental clinic of
the teaching hospital between January 1 and June 30,
2013. Apart from bio-demographic data, the diagnoses
and the list of prescribed drugs and their dosages were
also retrieved and used for analysis.
Results: A total of 607 prescriptions were analyzed with
female patients accounting for 314 (51.7%). Periodontal
and gum disease was the diagnosis in 414 (70.5%) of
the patients, followed by pulpitis (49/8.3%) and dento-
alveolar abscess (43/7.3%). A total of 2178 drugs were
prescribed for the study population during the period
with a mean of 3.6 ± 0.7. Antimicrobials were the most
frequently prescribed class of drugs with 1163 (53.4%),
followed by analgesics (612/28.1%) and ascorbic acid
(363/16.7%). Amoxicillin was the most frequently
prescribed (564/ 48.5%) followed by Metronidazole
(561 /48.2%). Prescription by generic name was done
in 43.8 ± 11.2% of all prescribed drugs.
Conclusions: Polypharmacy, prescribing by brand
names and over-prescribing of antibiotics were some
of the problems found in this study. There is a need
for continuing education of the prescribers to address
these lapses.
259. Medication Utilization in the Palestine Refugee
Population in the Middle East: A Cross-Country
Comparative Analysis
Dima Qato. Pharmacy Systems, Outcomes and Policy,
University of Illinois, chicago.
Background: There is limited information on the use of
medications in the Palestine refugee population in the
Middle East.
Objectives: The purpose of this study is to describe and
compare the utilization of medications overall and by
therapeutic category in the Palestine refugee populations
in Jordan, Palestine, Lebanon, and Gaza.
Methods: We analyzed aggregate consumption data on
medications derived from the UNRWA (United Nations
Relief and Works Agency) pharmacy records for 2012
overall and by country. UNRWA is the primary provider
of primary care services, including medications, to this
population. Utilization was calculated for each speciﬁc
medication and by therapeutic category. We used the
WHO deﬁned daily dose (DDD) methodology, to calcu-
late utilization deﬁned as DDDs per 1000 persons.
Results: In 2012, there were substantial differences in the
utilization of medications in the Palestine refugee popula-
tion in the Middle East, particularly for medications for
non-communicable diseases (NCD), analgesics and men-
tal health. For example, the mean utilization of antihyper-
tensives and antidiabetes agents awas 195 DDDs/100
persons with hypertension (HTN) and 157 DDD/100
persons with diabetes (DM), respectively; the utilization
was lowest in the West Bank at 121 DDDs (HTN) and
95 DDDs (DM) and highest in Gaza at 240 DDDs
(HTN) and 250DDDs (DM). However, the use of analge-
sics (8.7DDDs/1000 persons overall) was highest in West
Bank (14.2 DDDs) and lowest in Jordan (2.6 DDDs).
Conclusions: These ﬁndings suggest differences in med-
ication utilization across the Palestine refugee population
in the Middle East that indicate potential undertreatment
in NCD and/or overtreatment with analgesics. Further
evaluation on the factors underlying these variations is
warranted.
260. Psychotropic Utilization in Ribeirao Preto, Brazil
Iahel Manon Lima Ferreira,1 Manuela Roque Siani
Morello,1 Leonardo Régis Leira Pereira,1 Marcela Jirón.2
1Department of Pharmaceutical Sciences, School of
Pharmaceutical Sciences of Ribeirão Preto of University
of São Paulo, Ribeirão Preto, SP, Brazil; 2Department of
Technology and Pharmaceutical Sciences, Faculty of
Chemical and Pharmaceutical Sciencies of University
of Chile, Santiago, Santiago, Chile.
Background: Psychotropic medications utilization has
been extensively described in developed countries, but
in developing countries like Brazil, data of psychotropic
consumption are lacking.
Objectives: The aim of the present study is to describe
the trends of psychotropic medication utilization in
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Ribeirao Preto, a 600.000-habitants city of the country-
side of São Paulo State – Brazil, between 2008 and 2012.
Methods: Dispensing data of the psychotropic drugs
available in the public health system (i.e. anxiolytics,
hypnotics and sedatives, antidepressants, antipsychotics)
were obtained from the district drug database. Drugs
were classiﬁed through the Anatomical Therapeutic
Chemical classiﬁcation. Data were expressed in DDD
per 1,000 inhabitants per day (DDD/1000/day).
Results: There was a 30.9% increase in the dispensing of
psychotropic medications in Ribeirao Preto between
2008 and 2012. Main increases were seen in antidepres-
sants (46.4% increase) and hypnotics and sedatives
(32.1% increase). The most consumed groups of psycho-
tropic were antidepressants (54.6% of total DDD/1000/
day between 2008 and 2012; from 22.2 DDD/1000/day
in 2008 to 32.5 DDD/1000/day in 2012), and anxiolytics
(19.4% of total DDD/1000/day between 2008 and
2012; from 8.5 DDD/1000/day to 8.1 DDD/1000/day)
Fluoxetine, sertraline and diazepam were the most
frequently dispensed psychotropic medications during
the study period.
Conclusions: Psychotropic utilization increased mark-
edly in Ribeirao Preto between 2008 and 2012, mainly
due to antidepressants consumption. Further research to
examine sociodemographic characteristics and the appro-
priateness of this medication treatment in this population
are needed.
261. Rational Usage of Medicines at the Public Heath
Facilities in Rajasthan, India
Ravi Kumar Balu,1 Preeti Kumar,2 Maulik Chokshi,1
Sakthivel Selvaraj.2 1Indian Institute of Public Health-
Delhi, Gurgaon, Haryana, India; 2Public Health
Foundation of India, New Delhi, Delhi, India.
Background: The concept of rational use has always
taken a backseat inspite of the availability of state spe-
ciﬁc essential drug list and standard treatment guidelines.
Drug prescription plays a vital role in health care delivery
has a major inﬂuence in the procurement process which
will act as a major ﬁnancial barrier, by procuring unnec-
essary drugs and preventing procurement of the other
essential medicines that is needed for the system.
Objectives: We conducted a prescription analysis to
examine the drug usage and prescription behavior in
public health facilities. The analysis will help us in under-
standing how much of generic drugs are being prescribed
as against the existing brand speciﬁc drug.
Methods: This study was conducted in the state of
Rajasthan across ﬁve districts using the prescription slips
from the users of public health facilities at the primary
health care centers, community health center, district
hospital and medical college with 20-25 prescription
from each facility. We collected around 3129 prescrip-
tions and analyzed on the average number of drugs
prescribed in each encounter, percentage encounters
when antibiotics prescribed, percentage of drugs pre-
scribed by generic name, percentage of syrups prescribed,
percentage of injectable prescribed, percentage of single
dose versus ﬁxed dose drug and percentage of vitamins
prescribed across the district.
Results: In an average across the state 3.29 drugs were
prescribed per counter and 98% of these drugs were with
generic names, 30% of the drugs were of antibiotics, 7%
of them were injections, 9% of them was of syrup
preparation, 3% were vitamins and 89% of the drugs
were prescribed as a single ﬁxed drug. All the drugs
prescribed were a part of the essential drug list for the
state of Rajasthan, India.
Conclusions:With more focus towards the movement of
the generic drugs into the existing health system, the
analysis has helped us in understanding how well generic
drugs are being prescribed in the public health system
and the pattern of antibiotics use in public health facilities
in the state which could be used to derive protocols for
rational usage of antibiotics in health facility based on
the level of care.
262. Interactions between Pharmaceutical Company
Representatives and Physicians in Jos, Nigeria
Maxwell LP Dapar,1 Comfort N Sariem,1 Isaac O Abah,2
Meshak SA Dayol,3 Noel N Wannang.4 1Clinical
Pharmacy, University of Jos, Jos, Plateau, Nigeria;
2Pharmacy, Jos University Teaching Hospital, Jos,
Plateau, Nigeria; 3Pharmacy, Plateau State Specialist
Hospital, Jos, Plateau, Nigeria; 4Phrmacology, University
of Jos, Jos, Plateau, Nigeria.
Background: Rapid increase in the number and
complexity of pharmacotherapeutic agents together
with aggressive marketing and high spending on
promotional activities of Pharmaceutical Company
Representatives (PCRs) present a challenge to
physicians’ prescribing choices.1 Studies have shown
that up to 90% of doctors meet with PCRs at least
once in two weeks. Moreover, PCRs have been
ranled as the ﬁrst or second most important source
of drug information2.
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Objectives: to determine the nature PCRs’ activities in
terms of the type and frequency of meeting with
physicians and to measure the attitudes of doctors
towards interaction with PCRs.
Methods: The study was a cross sectional questionnaire
survey in two University teaching hospitals and one
Government tertiary hospital in Jos, North-Central
Nigeria. Descriptive statistics for currents interaction of
PCRs with physicians and attitudes of physicians to these
interactions were analysed.
Results: 126 doctors participated in the study. Majority
were between ages 20-49 years. Similarly, in terms of
work experience, 39% had less than ﬁve years, 30% be-
tween six to ten years and 19% had between 11 and
15years. Twenty one percent of the respondents were house
ofﬁcers while 54% and 20% were residents and consultants
respectively. Only 24% of study participant were aware of
the existence of hospital or departmental policies guiding
interaction of doctors with PCRs. Notwithstanding, 95% re-
ported interacting with PCRs of which 55% met PCRs at
least once a week in one-on-one sessions during (Table 1).
Respondents generally perceived their interaction with
PCRs as being beneﬁcial to patients and they expressed
positive attitudes towards PCR activities (Table 2).
Conclusions: This study identiﬁed an overall positive
perception of PCRs’ activities among physicians. PCRs
have the potential to exert substantial inﬂuence on
prescribing decisions with little or no regulatory
framework for their interaction with the physicians. It is
essential to generate more robust data to add to the
evidence base needed inform policy and regulation of
PCRs for better prescribing behaviours that would ensure
overall patient safety.
263. What Makes Prescribers Switch to Fixed-Dose
Combination Therapy for Japanese Hypertensive
Patients?
Makiko Kusama,1 Shigeki Zeniya,2 Katsushi Fukuoka,3
Manabu Akazawa.2 1Graduate School of Pharmaceutical
Sciences, The University of Tokyo, Tokyo, Japan; 2Meiji
Pharmaceutical University, Tokyo, Japan; 3Nihon
Chozai, Tokyo.
Background: Angiotensin receptor blocker (ARB)-
based ﬁxed-dose combination (FDC) drugs with calcium
channel blockers (CCB) was ﬁrst marketed in 2010 in
Japan. Since then, cost saving effects and deregulation
on prescription-terms may have attributed to the
preference to FDC drugs, but on the other hand there
are patients who still use separate forms.
Objectives: In this study we aimed to investigate what
factors impact the switching from seperate form co-ther-
apy to FDCs, such as economic impact of the patients’
monthly drug cost, comorbidities, deregulation of pre-
scription-terms and emergence of generic drugs, as well
as other patient attributes.
Methods: Claims data from 44 community pharmacies
located in Tokyo (Nihon Chozai Pharmacies) were used
to identify 8713 chronic ARB users from Dec 2009 to
March 2013, of which 4702 patients were under chronic
ARB/CCB co-treatment. Prescription-based claims data
was analyzed with a view to perform COX hazard analy-
sis on switching to FDC during this observation period.
Results: Of the chronic ARB users, the proportion of
patients using CCB, beta blockers, hyperlipidemia
drugs, and diabetes drugs were 69.6%, 12.4%, 50.6%,
and 30.7%, respectively. Of the 4702 ARB/CCB co-
therapy patients, the ratio of FDC users increased over
the period (from 2.6% to 13.5%), which began to
increase after the ﬁrst ARB/CCB-FDC was marketed
(2010/4/16), and increased dramatically after the
deregulation of (2010/12/10), but not by the emergence
of generic ARB drugs (2012/6/22). Prescription-term of
ARB based FDCs increased from 14 days (maximum
prescription days by law) to 46.8 days after the
deregulation.
Conclusions: Switching to FDC drugs was strongly
enhanced by the de-regulation of prescription-terms but
not by the emergence of generic ARB drugs. More
factors such as adherence, monthly drug cost,
pharmacy/clinical attributes would be incorporated into
our ﬁnal model.
264. Investigation of Drug Safety Information of
Ethnic Medicine from 622 Drug Instructions in
Guizhou
Chen Ao,1 Lei Xiaoqing.2 1Center for ADR Monitoring
of GuiYang, GuiYang, GuiZhou, China; 2GuiYang
Institue for Food and Drug Control, GuiYang, GuiZhou,
China.
Background: In recent years, with the rapid develop-
ment of Chinese medicine industry, Guizhou Province
has built the “city of ethnomedicine”, and promoted
the developing of the pharmaceutical industry. The
pharmaceutical industry has been considerable devel-
opment in Guizhou. This paper investigated 622
instructions of ethnic medicine of Guizhou, and
provided the drug safety research data reference to
the pharmaceutical industry.
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Objectives: To analysis the instruction of ethnic medi-
cine from 622 Drug Instructions in Guizhou, to provide
reference for perfection ethnic drug package inserts.
Description: A total of 622 package inserts of athnic
medicine were collected from pharmaceutical companies,
and analyzed on adverse reactions, contraindication, drug
interaction and so on.
Results: There is 9.16% adverse reactions was
detailed. And that of contraindication marked the “not
yet clear” was 64.31%. The rate of the medication accu-
rately marked for pregnant and lactating women, pediat-
ric patients and geriatric patients was 36.50%,49.36%
and 23.63%, respectively. The rate of the medication
accurately marked for drug interaction and pharmacoki-
netic was 45.34% and 0.32%, respectively.
Conclusions: The contents of ethnic medicine are far
from perfect, which should draw attention to better
management.
265. Persistence Rate and Adherence Level To Oral
Antidiabetics and Their Associated Determinants
Patrice Simard,1 Louise Roy,2 Marc Dorais,3 Brian
White-Guay,1 Agnès Räkel,4 Sylvie Perreault.1 1Faculty
of Pharmacy, University of Montréal, Montreal, QC,
Canada; 2Nephrology, Hospital Centre of the University
of Montréal -Hôpital St-Luc, Montreal, QC, Canada;
3Statistics, StatSciences, Montreal, QC, Canada;
4Endocrinology, Hospital Centre of the University of
Montreal -Hôpital St-Luc, Montréal, QC, Canada.
Background: Intensive glucose control was associated
with a 25% lower rate of microvascular complications
after 10 years of treatment. However, there is limited
evidence addressing persistence rates and adherence level
in real-time drug use in patients taking Oral Antidiabetic
Agents (OAD).
Objectives: To evaluate the persistence rate and adher-
ence level of new OAD users as well as their relation to
patients’ demographic and clinical characteristics.
Methods: A 160,231-patient cohort was built from
prescription records in the Québec public healthcare
insurance program database. Patients aged 45-85 years
old who received at least one OAD prescription between
January 2000 and October 2009 were included. New
users were deﬁned as having no OAD prescribed in the
2 years preceding cohort entry. The cohort entry was
deﬁned by the ﬁrst OAD prescription date. Persistence
rate was deﬁned by allowing a 50% grace period for
renewal. Drug adherence was estimated using MPR.
The cumulative persistence rate was estimated using a
Kaplan-Meier analysis. Cox regression models were used
to estimate the rate ratio of ceasing OAD. Logistic regres-
sion models were used to establish the relation between
non-adherence level and their determinants.
Results: Patients had a mean age of 67 years, 49% were
men, 52% had a cardiovascular disease, 78% had hyper-
tension and 59% had dyslipidemia. Persistence decreased
to 51% after 1 year but the proportion of patients who
reﬁlled an OAD during the year after cessation ranged
from 73 to 91%. Adherent patients (MPR≥ 80%)
accounted for 67% after 1 year. Hypertension (0.84-0.87),
dyslipidemia (0.85-0.88) and cerebrovascular disease
(0.89-0.99) were associated with higher persistence rates,
whereas microvascular risk factors such as urologic proce-
dure (1.01-1.17) and viral infectious diseases (1.09-1.27)
demonstrated lower rates. Similar results were observed
for adherence.
Conclusions: Barriers to persistence rate and adherence
level occur early in the course of OAD therapy. Adherence
is a key factor in determining the success of various thera-
peutic approaches, thus greater attention should be paid to
this aspect which may result in improved patient outcome.
266. Investigating Time-Varying Factors Associated
with Lipid Lowering Medications for Primary CVD
Prevention Using Multistate Markov Modeling
Suzanne L West,1 Barry S Eggleston,1 Marianne
Kluckman,1 Amanda Hansen,2 Eric Solano,1 Kenneth
LaBresh,2 Vincent Bufalino,2 Michael F O’Toole.2 1RTI
International, RTP, NC, United States; 2Advocate
Medical Group/Midwest Heart Specialists, Oak Brook,
IL, United States.
Background: Clinical trial evidence shows that statins
are efﬁcacious for primary prevention of cardiovascular
disease (CVD) in those with elevated low-density
lipoprotein cholesterol (LDL-c). There is little information
on these medications for primary prevention using “real
world” data and time-varying covariates such as hyperten-
sion (HTN), diabetes (DM) and anti-platelet medications,
and coronary artery disease (CAD) development.
Objectives: Using 15- years of electronic medical record
data from a cardiology practice, identify covariates
associated with transitions to revascularizations such as
percutaneous coronary intervention or coronary-artery
bypass grafting among patients with elevated LDL-c
but no pre-existing CAD.
Methods: We used multistate Markov modeling to
investigate covariate effects on transition probabilities
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into 4 states: elevated LDL-c, drug use but LDL-c still
>100mg/dL, LDL-c <100mg/dL with drugs, and ≥1
revascularizations. To identify key variables for the
transitions, we used stepwise Cox modeling with time-
dependent covariates and static variables. Using the
multistate model estimates as inputs, we did simulations
to estimate revascularization rates given hypothetical
patient characteristics such as presence of DM.
Results: Of the 300,000 patients ever seen, only 34,000
were >40 years with untreated elevated LDL-c and at
≥1 measure of cholesterol and blood pressure; 21,335
patients had sufﬁcient outcomes data. Median age was
72 years, 56.4% were males, 22% had DM, and 32.6%
had smoked. Those with medically-treated CAD or
taking DM or platelet aggregation inhibitors had shorter
transition times to revascularization. Based on simulating
a 5-year trajectory for 1,000 patients, those with DM
experienced more revascularizations than those without
DM, and more than the population average.
Conclusions: Our transition and simulation modeling
aligns with clinical experience. Older patients with DM
and CAD were treated more aggressively as indicated
by shorter transition durations. Such modeling techniques
indicate that evidence-based care alters the natural
disease process, thus bending the disease curve.
267. Dimension Reduction and Shrinkage Methods
for Improving High Dimensional Disease Risk Score
Estimation in a Historical Cohort
Hiraku Kumamaru,1,2 Joshua J Gagne,2 Robert J Glynn,2
Soko Setoguchi,3 Sebastian Schneeweiss.2 1Epidemiology,
Harvard School of Public Health, Boston, MA, United
States; 2Division of Pharmacoepidemiology and Pharma-
coeconomics, Brigham and Women’s Hospital, Harvard
Medical School, Boston, MA, United States; 3Duke
Clinical Research Institute, Durham, NC, United States.
Background: Multivariable confounder adjustment in
studies of newly marketed drugs can be limited by small
numbers of exposed patients. Disease risk scores (DRSs)
developed in a historical cohort of comparator patients
may overcome this problem.
Objectives: To compare strategies for high dimensional
(hd-) DRS development in historical data for outcome
prediction in a concurrent cohort.
Methods: Using United HealthCare claims data, we
identiﬁed a historical cohort of warfarin initiators
between Oct.2007-Sep.2010. In a 1-year baseline period,
we empirically identiﬁed the 500 strongest univariate
predictors of each outcome: death, ischemic stroke, and
major hemorrhage. We developed hd-DRS models using
4 regression approaches (unreduced (UR), principal com-
ponent (PC), ridge, lasso) from pre-deﬁned risk factors,
established risk scores, demographics, and the empiri-
cally selected predictors. We applied the models to the
concurrent cohort of dabigatran and warfarin initiators
between Oct.2010-Jun.2011 and assessed the models’
discrimination (c-statistics) and calibration (Hosmer-
Lemeshow [HL] test). We compared the hd-DRSs to
models from established risk scores alone (combined
comorbidity score (CCS), CHADS2, and HAS-BLED).
Results: Among 17,555 patients in the historical cohort,
we observed 448 deaths within 180 days, and 171 strokes
and 562 hemorrhages within 365 days. In the concurrent
cohort of 2,845 warfarin and 1,268 dabigatran initiators,
we observed 92 deaths, 41 strokes and 147 hemorrhages.
C-statistics for the death DRSs in the concurrent cohort
were 0.75 for UR, 0.86 for PC, 0.86 for ridge and 0.86
for lasso. C-statistics for stroke DRSs were 0.46, 0.66,
0.66, and 0.66, and for hemorrhage DRSs were 0.53, 0.66,
0.68, and 0.67, respectively. All models except UR had
good calibration (HL p> 0.05) for all outcomes. Models
based on established risk scores had lower c-statistics
(CCS 0.85; CHADS-2: 0.64; HAS-BLED: 0.65).
Conclusions: Historically developed hd-DRSs with
dimension reduction and shrinkage methods showed
substantial predictive improvement compared to unreduced
models and performed modestly better than models from
risk scores alone.
268. Diabetogenic Effects of Atypical Antipsychotics –
Exploration of Measurement Bias
Almut G Winterstein,1,2 Rhonda Cooper-DeHoff,3 Paul
Kubilis,1 Gregory A Nichols,4 Joseph A Delaney.5
1Pharmaceutical Outcomes and Policy, University of
Florida, Gainesville, FL, United States; 2Epidemiology,
University of Florida, Gainesville, FL, United States;
3Pharmcotherapy and Translational Research, Univer-
sity of Florida, Gainesville, FL, United States; 4Kaiser
Permanente Center for Health Research, Portland, OR,
United States; 5Epidemiology, University of Washington,
Seattle, Washington, United States.
Background: Using electronic health record data
from Kaiser Permanente Northwest (KPNW) we
found increased surveillance of blood glucose (BG)
in patients exposed to antihypertensives, statins, and
atypical antipsychotics (AP) posing concerns about
measurement bias.
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Objectives: To compare estimates of diabetogenic
effects of AP using billing-like data (only diagnoses,
which are assumed to correspond to positive BG tests,
are known) versus electronic health record testing data
(both negative and positive BG results are known).
Methods: We enrolled nondiabetic patients age 35-65
years from KPNW at their ﬁrst fasting plasma glucose
(FPG) <126mg/dL between 1997 and 2010 (index date).
DM cases were deﬁned by a FPG ≥126mg/dL, random
plasma glucose ≥200mg/dL, or HbA1c ≥7.0%. We
deﬁned exposure to AP, antihypertensives, statins and
antidepressants for each week of follow-up based on
dispensed days’ supply. Fixed covariates (deﬁned at in-
dex date) included gender, smoking, calendar year, age,
body mass index, blood pressure, lipid panel results,
and FPG. We used two alternative interval-censored
Weibull proportional hazard models to examine AP
diabetogenic effects using right-censoring (model 1) at
end of follow-up (BG testing and negative BG results
unknown, n = 133,004) and (model 2) last negative test
(testing frequency is known, n = 101,432).
Results: Our cohort included 2498 AP users and 7891
DM cases. Diabetogenic effects of APs were estimated
at 1.76 (95% CI 1.44-2.16) in model 1 and 1.55 (1.27-1.91)
in model 2.
Conclusions: APs showed a signiﬁcant association with
DM onset. Failure to consider testing frequency resulted
in 38% bias introduced by increased surveillance of
patients taking APs.
269. Construction of Treatment Episodes in Elderly
Neuroleptic and Antidepressant Users
Niklas Schmedt, Kathrin Jobski, Tania Schink,
Edeltraut Garbe. Clinical Epidemiology, Leibniz
Institute for Prevention Research and Epidemiology -
BIPS GmbH, Bremen, Germany.
Background: Neuroleptics (NLs) and antidepressants
(ADs) are frequently used in elderly patients. In the
absence of information on prescribed daily doses, the
length of treatment episodes (TEs) has to be estimated.
Objectives: To investigate the number and length of TEs
among elderly NL and AD users.
Methods: We conducted two cohort studies in the
German Pharmacoepidemiological Research Database
(GePaRD) and identiﬁed all persons aged 65 years and
older with at least one NL or AD prescription between
2005 and 2009. First, TEs were constructed for individ-
ual drugs assuming a supply of the number of the
dispensed deﬁned daily doses (DDDs) plus 150% of the
number of dispensed DDDs. All prescriptions of the
same drug with a dispensation date during the estimated
supply of the previous prescription were combined to
one TE. We obtained the number of TEs as well as the
respective median durations among users of NL and
AD classes and drugs. In addition, we conducted sub-
group analyses in NL users with dementia and psychoses
and AD users with depression and varied the percentage
of the added DDD supply.
Results: Overall, 302,998 and 490,114 persons received
at least one NL and AD, respectively. The median
number of TEs was 2 for NLs and 1 for ADs. It varied
substantially for individual NLs but was more homoge-
nous for ADs. The median length of TEs was 22 days
for NLs and 70 days for ADs and differed widely
between drug classes and individual drugs. Compared
to the whole NL cohort, the median length was shorter
in patients with dementia (17 days) and longer with
psychoses (26 days). In patients with depression the
median length was also longer (85 days) compared to
the whole AD cohort. With higher percentages added to
the DDD supply, no cut-off point was found for NL
and AD classes and drugs at which the incline of the
median length of TEs ﬂattened.
Conclusions: Numbers and lengths of TEs varied for
different drug classes and drugs and across indications.
Our results might serve as reference for planning drug
utilization and safety studies on NL and AD use in
elderly patients. Further research should focus on the
appropriate deﬁnition of the length of NL and AD treat-
ment episodes based on DDDs.
270. Manual Versus Automated Coding of Free-Text
Self-Reported Drug Use in the 45 and Up Study: A
Validation Study
Danijela Gnjidic,1,2 Sallie-Anne Pearson,1,3 Sarah
Hilmer,2,4 Jim Basilakis,5 Fiona Blyth,2,6,7 Emily
Banks.7,8 1Faculty of Pharmacy, University of Sydney,
Sydney, NSW, Australia; 2Sydney Medical School,
University of Sydney, Sydney, NSW, Australia; 3Sydney
School of Public Health, University of Sydney, Sydney,
NSW, Australia; 4Royal North Shore Hospital and
Kolling Institute of Medical Research, Sydney, NSW,
Australia; 5School of Computing, Engineering and
Mathematics, University of Western Sydney, Sydney,
NSW, Australia; 6Centre for Education and Research
on Ageing (CERA), Concord Hospital, Sydney, NSW,
Australia; 7The Sax Institute, Sydney, NSW, Australia;
8National Centre for Epidemiology and Population
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ACT, Australia.
Background: Large-scale cohort studies commonly
include self-reported drug use information. However,
manual coding of free-text data is often prohibitively re-
source-intensive. Automated methods are used increas-
ingly to code free-text drug data, but research on the
validity of these methods is limited.
Objectives: To examine the accuracy of automated cod-
ing of previously keyed in free-text drug data compared
to manual coding of hand written free-text responses.
Methods: We selected a random sample of 500 partici-
pants enrolled in the 45 and Up Study. Manual coding
involved drug experts: keying in free-text responses;
converting listed drugs to generic names; and mapping
to ATC codes. Using keyed in free-text responses entered
by non-experts, the automated approach mapped entries
using the Australian Medicine Terminology (AMT) data-
base and converted drugs to generic names and assigned
corresponding ATCs.
Results: Using manual coding, 1,402 free-text entries
were recorded: 1,282 drugs were mapped to correspond-
ing ATC codes; 95 entries could not be mapped to an
ATC code (73 entries were non-speciﬁc and 22 were
supplements without ATC codes); and 25 entries were
blank. Overall, there was 81% agreement between
manual and automated entries. Of the drug entries that
mapped to ATC codes, there was 79% (1,014/1,282)
agreement based on 7-digit ATC codes and 82%
(1,046/1,282) agreement based on 5-digit ATC codes.
Conclusions: Our ﬁndings suggest that there is excellent
agreement between the automated and manual coding
methods for measuring the free-text self-reported drug
data. Future work will examine the agreement for speciﬁc
drug and drug classes to inform drug exposure analyses
in pharmacoepidemiological studies.
271. Composite Testing in Pharmacovigilance: The
Benefit of Window Shopping
Rolina D van Gaalen,1 Michal Abrahamowicz,1,2 David
L Buckeridge.1 1Department of Epidemiology, Biostatis-
tics, and Occupational Health, McGill University,
Montreal, QC, Canada; 2Division of Clinical Epidemiol-
ogy, McGill University Health Centre, Montreal, QC,
Canada.
Background: Time to signal detection in pharma-
covigilance may depend strongly on the method chosen
to model the exposure. Yet, the true relationship between
past drug use is often unknown and the risk of adverse
events may involve cumulative or delayed effects. It is
unlikely that the estimation model that correctly speciﬁes
the association will be selected.
Objectives:We used simulations to assess the timeliness
of signal detection in prospective pharmacovigilance
using simultaneous testing of multiple exposure models
of different effect durations and conditional on different
representations of exposure.
Methods: We generated cohorts with drug/AE associa-
tions of different complexities and durations of effect.
For each cohort, and at each testing point, we ﬁt multiple
parametric and ﬂexible spline-based estimation models.
We retained each p-value and assessed model ﬁt using
the AIC. We grouped the estimation models into 3
subsets containing (i) parametric and spline-based
models, (ii) parametric models only, and (iii) spline-
based models only. To “decide” if and when sufﬁcient
evidence existed to reject H0, for each subset of models
we separately compared (a) the lowest of the model-
speciﬁc p-values and (b) an AIC-weighted combined p-
value against thresholds that held constant the false
positive rate. We used Kaplan-Meier curves to compare
timeliness of these algorithms with a “correct” estimation
model, i.e., that correctly speciﬁed the associated used to
generate the data.
Results: For a simulated effect that was only harmful, the
subset with parametric estimation models alone was the
most timely, with the same median detection time as of
the perfectly speciﬁed estimation model alone. The
subset with spline-based estimation models alone was
the most timely when the simulated effect was not always
harmful. In all cases, the median detection times of the
subset consisting of all estimation models either was
equivalent to the best subset, or was slightly longer.
Combined p-values had slightly faster times to detection
in cases with longer simulated effect durations.
Conclusions: Time to detection in pharmacovigilance
may be reduced by simultaneously testing multiple
estimation models.
272. Evaluation of Analytical Method Performance
Using Self-Controlled Case Series
Jasmanda Wu,1 Ling Zhang,1 Patrick Caubel,1 Wanju
Dai,1 Cristina Chang,2 Dennis Shao,2 Juhaeri Juhaeri.1
1Global Pharmacovigilance and Epidemiology, Sanoﬁ,
Bridgewater, NJ, United States; 2Medical Department,
Sanoﬁ-Aventis Taiwan/Hong Kong/Mauau, Taipei, Taiwan.
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Background: Previous analyses conducted using a cohort
study showed tricyclic antidepressant (TCA) users were
1.5 times more likely to develop acute myocardial infarc-
tion (AMI) than those who did not receive TCA. In this
study, we examined the association between TCA and
AMI using a self-controlled case series (SCCS).
Objectives: To compare analytical method performance
using SCCS in a US claims database and simulated
dataset OSIM2 for examining the association between
TCA and AMI.
Methods: The InVision DataMart (United HealthCare,
formerly LabRx) database and OSIM2 were used. Study
population included eligible participants who had an
AMI diagnosis and were prescribed at least one TCA pre-
scription during 01/01/2007-12/31/2011 and 01/01/2004-
12/31/2008 for InVisonDataMart and OSIM2, respec-
tively. Each individual’s observation time was divided
into exposure periods as follows: fully exposed periods,
followed by 1-30, 31-60 and 61-90 days after the end
of a treatment period. All other periods of time were
classiﬁed as unexposed periods. Rate ratios (RR) to
compare the rate of events during exposed periods with
the rate during unexposed periods were estimated using
conditional Poisson regression.
Results: There were 3,094 and 1,193 TCA users
identiﬁed for SCCS in the InVision DataMart and
OSIM2 database, respectively. The mean age was older
in the InVision DataMart databases (InVision Datamart:
59.6 ± 12.7, OSIM2 50.6 ± 11.4). TCA users in the
InVision DataMart database also had more comorbidi-
ties, including hypertension, diabetes, and coronary heart
disease. The RR for AMI among all patients prescribed
TCA was 1.20 (95%CI 1.01-1.42), compared fully
exposed with unexposed periods in the InVision
DataMart. During 90 days periods after TCA treatment,
the RRs were marginally signiﬁcant. In the OSIM2,
exposure to TCA did not have an increased risk of AMI
(RR=0.87, 95%CI 0.80-0.95). Overall, we did not
observe a strong association between AMI and TCA
use using SCCS in our analyses.
Conclusions: The TCA-AMI pair combination did not
meet some SCCS assumptions. SCCS design may not
be suitable for examining the TCA-AMI association.
273. Application of Multivariate Statistical Methods to
the Assessment of Drug Abuse Potential Based on
Spontaneously Reported Adverse Events
Manfred Hauben,1,2,3 Cynthia Arons,4 Eric Hung,1 Sian
Ratcliffe.4 1Pﬁzer, New York, NY, United States; 2New
York University Medical Center, New York, NY, United
States; 3New York Mediccal College, Valhalla, NY,
United States; 4Pﬁzer, Groton, CT, United States.
Background: Prescription drug abuse is a complex
public safety problem. Addressing this problem requires
new/newly applied methods for the detection and
monitoring of abuse.
Objectives: To explore the use of multivariate statistical
techniques in detecting and monitoring drug abuse
potential by evaluating the ability of such methods to
appropriately compare/group/classify drugs based on
patterns of spontaneously reported abuse-related adverse
events (AEs).
Methods: Multivariate statistical techniques including
correspondence analysis, factor analysis, hierarchical
cluster analysis and discriminant analysis were applied
to AE data in the US FDA AERS database for scheduled
and non-scheduled CNS drugs. AEs associated with drug
abuse, including terms in the MedDRA Drug Abuse
SMQ and other terms generally considered by those in
the ﬁeld as indicative of abuse, were prespeciﬁed. AEs
were also clustered into medically meaningful categories
to improve some of the analyses. Drugs were grouped
based on US DEA scheduling status.
Results: Discriminant analysis demonstrated good
performance in predicting drug scheduling class based
on the pattern of spontaneously reported abuse-related
AEs. Correspondence analysis, factor analysis, and
hierarchical cluster analysis provided some further
insights on the similarity/differences/distances between
drug scheduling classes.
Conclusions: This preliminary evaluation of the use of
multivariate statistical techniques for assessing drug
abuse potential suggests that at least some of these tech-
niques may be useful tools in determining the types of
AEs to look for with a given drug scheduling classiﬁca-
tion and may be useful in monitoring postmarketing AE
reports for indications of drug abuse.
274. Health Outcomes and Medical Effectiveness
Research (HOMER): A Systematic Approach to
Exploring Hill’s Causal Viewpoints in Observational
Data
Patrick Ryan,1 Martijn Schuemie,1 David Madigan,2
Marc Suchard,3 Paul Stang,1 J Marc Overhage,4 Christian
Reich,5 Mark Khayter,6 Abraham Hartzema,7 Bill
DuMouchel,8 Jesse Berlin.1 1Janssen Research and
Development, Titusville, NJ, United States; 2Columbia
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University, New York, NY, United States; 3UCLA, Los
Angeles, CA, United States; 4Siemens Healthcare,
Malvern, PA, United States; 5AstraZeneca, Waltham,
MA, United States; 6Ephir, Boston, MA, United States;
7University of Florida, Gainesville, FL, United States;
8Oracle Health Sciences, Miami, FL, United States.
Background: Austin Bradford Hill outlined nine
viewpoints when considering causal effects, but to date,
there has been no systematic use of observational data
to explore these viewpoints for a given drug-outcome
association.
Objectives: To develop observational analyses that
systematically enable efﬁcient evidence generation and
evaluation for each of Hill’s causal viewpoints, and to
implement a proof-of-concept system (HOMER) that
demonstrates how these analyses can be integrated into
an exploratory visualization framework.
Methods: Using MarketScan claims data and GE/
Quintiles EHR data in the OMOP Lab, analyses were
executed across 165 positive controls and 234 nega-
tive control drug-outcome pairs. Strength of associa-
tion was estimated using cohort, case-control, and
self-controlled designs. Performance was measured
by AUC, bias, and coverage, and used for empirical
calibration. Consistency was assessed as heterogeneity
across methods, databases, and patient subgroups.
Temporality was explored through plots of co-
occurrences of drugs and outcomes. Plausibility and
experiment were demonstrated by summary of case
series from of review of patient proﬁles. Coherence
was established by comparing observational results
with analysis of spontaneous data, literature, labeling
and biomedical ontologies. Biological gradient was
established through standardized dose-response analy-
ses. Speciﬁcity and analogy were assessed through
systematic summaries of effects across drug classes
and disease groups. Visualizations representing these
analyses are shown in a single dashboard.
Results: Supplementing traditional epidemiologic analy-
ses from observational data with systematic extraction of
other causal viewpoints provides additional evidence that
can strengthen conﬁdence in true positive ﬁndings and
minimize false positives.
Conclusions: Observational data can be used to explore
all of Hill’s causal viewpoints. A large-scale analytics
platform is feasible for enabling interactive exploration
of drug-related effects, and represents a substantial
opportunity for expanding the efﬁciency, effectiveness
and reliability of epidemiologic evaluations.
275. Determination of Shrinkage Parameters in
Spontaneous Reporting System in China
Jia He, Xiaofei Ye, Jing Wang, Xiaojing Guo.
Department of Health Statistics, Second Military
Medical University, Shanghai, China.
Background: Signal detection by the current commonly
used disproportionality methods is not stable when the
expected frequency is small. Statistical shrinkage method
can enhance the signal stability and reduce false positive
signal number detected by disproportionate signal detec-
tion methods.
Objectives: We aimed to detect ADR signals from
national spontaneous reporting system of China and
explore appropriate shrinkage parameters to reduce the
number of false-positive signals.
Methods: Statistical shrinkage is the regularisation of an es-
timate by evaluating several parameters simultaneously. Dis-
proportionate analysis method is based on observation(O)
frequency and expected(E) frequency ratio. When OE ratio
exceeds a critical value, a signal is determined. In this study
we simulated shrinkage parameters value from 0 to 5 at in-
terval of 0.1. National Adverse Drug Reaction spontaneous
reporting system database in China in the year 2010-2011
were explored to get the most appropriate parameter values.
Results: Shrinkage can make a lot of signal disappeared
and we analyze the disappearance of the signals with
speciﬁc index including observed frequency distribute,
expected frequency distribute and the number of signals
reduced. We found that the speciﬁc index for PRR,ROR,
IC disproportionality measures appear segmentation point
when shrinkage parameter value in the 0.1-0.6. Disappear-
ance of the signal for comparison with drug instructions
We use the adverse drug reaction instructions as the gold
standard to determine the authenticity of the signal
disappears. Finally, the most appropriate parameter values
were determined on the basis of the false positive rate of
disappearance of the signal.
Conclusions: Shrinkage, as a statistical method, is used
in the ADR signal detection with its unique advantage.
It can enhance the signal stability and reduce false
positive signal number detected by disproportionate
signal detection methods.
276. Treating Analysis of Dose Flexibly Within a
Post-Authorisation Safety Study of an Atypical
Antipsychotic
Deborah Layton,1,2 Ian Ratcliffe,1 Sarah Clarke,1 Saad
AW Shakir.1,2 1Drug Safety Research Unit, Southampton,
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United Kingdom; 2University of Portsmouth, Portsmouth,
United Kingdom.
Background: In treating mental health conditions individ-
ual dose titration of antipsychotics (AP) is required. Thus
robust analytical approaches are needed to describe such pat-
terns of change. A Risk Management Plan was developed
for quetiapine extended release (Seroquel XL™) by theman-
ufacturer, including a Specialist Cohort Event Monitoring
(SCEM) study (Observational Assessment of Safety in
Seroquel–OASIS) to examine it’s safety and use as
prescribed in mental health care setting in England. Study
objectives included examining posology and titration.
Objectives: To explore methods for analysis of repeated
dose measurements over time.
Methods: An observational cohort design with quetiapine
immediate release (IR) as the comparator. Exposure data
were derived from forms completed at treatment start
(index) and 12+ weeks post index by specialists for
patients identiﬁed Dec 2009-Dec 2012. The relationship
of dose with time, by formulation, was explored by 2
methods calculating: 1)group-level bi-weekly mean model
dose from univariate person-period data; 2)exploratory
empirical and ﬁtted within-person OLS dose trajectories.
Results: The cohort comprised 869 patients. The mean
modal dose increased every 2week period from index
to end of study period, the difference highest in ﬁrst
period reﬂecting dose titration. Temporally sequenced
empirical dose trajectories informed little on this general
trend. Individual growth parameters obtained by ﬁtting
separate within-person OLS regression models for dose
as a function of linear time were: mean index dose XL
(302.2) SD (170.2) with rate of change 2.1mg/day; IR
(172.0) SD (122.6) with rate of change 3.7mg/day.
Conclusions: Both approaches take advantage of the
longitudinal data structure and multiple waves of data
in SCEM. However, group-level analysis introduces an
artiﬁcial time structure whilst individual growth model-
ling offers a more ﬂexible framework to explore within-
and between- individual dose patterns over time. The
results suggest that specialists’ AP dosing regimens are
individualised, but accordingly the potential for con-
founding on estimates of adverse events by time-varying
exposure should be considered.
277. Performance of the High-Dimensional Propen-
sity Score Algorithm When In-Hospital Medico-
Administrative Data Are Unavailable
Jason R Guertin,1 Elham Rahme,2,3 Colin R Dormuth,4
Alexis Matteau,1 Louis-Mathieu Stevens,1 Jacques
LeLorier.1 1Pharmacoeconomic and Pharmacoepide-
miology Unit, Research Center of the Centre Hospitalier
de l’Université de Montréal, Montreal, QC, Canada;
2Research Institute of the McGill University Health
Centre, Montreal, QC, Canada; 3McGill University,
Montreal, QC, Canada; 4University of British
Columbia, Vancouver, BC, Canada.
Background: High-dimensional propensity scores (hdPS)
utilize information from both inpatient and outpatient
databases. Access to both inpatient and outpatient data-
bases may be difﬁcult to obtain in certain jurisdictions
due to patient conﬁdentiality, and impossible in others.
Objectives: The objective of this study is to assess the
performance of the hdPS method in the adjustment for
confounding by indication in situation where in-hospital
medico-administrative data are not available.
Methods: Performance of the hdPS method was exam-
ined in the context of the risk of new-onset diabetes
mellitus among patients exposed to moderate versus
high-dose statins using the Quebec publicly funded
medico-administrative databases (including both the pub-
lic insurance database and the hospitalisation database).
We used the hdPS algorithm in order to calculate
patients’ individual hdPS using two sets of high-
dimensions; 1) 6 high-dimensions provided from both
databases (hdPS1), 2) 4 high-dimensions provided only
by the public insurance database (hdPS2). We created
two sets of matched sub-cohorts, in which 1 patient
initiated on a high-dose statin was matched to 1 patient
initiated on a moderate-dose statin. Patients’ hdPS1 was
used as the matching variable within the ﬁrst matched
sub-cohort and patients’ hdPS2 was used as the matching
variable within the second matched sub-cohort.
Standardized differences (SDD) were used to examine
the level of balance achieved between patient subsets
regarding 19 key confounders. SDD >0.1 indicated
the presence of imbalance.
Results: Substantial imbalance was observed within 8
of the 19 examined key confounders among the
unmatched cohort. Matching on either the hdPS1 or
the hdPS2 achieved balance within all 19 examined
key confounders. SDD obtained within both sub-
cohorts were similar (absolute differences in SDD
between both sub-cohorts were <0.003 in 15 out of
the 19 examined confounders).
Conclusions: Performance of the hdPS method in control-
ling for confounding by indication was not diminished
when the in-hospital data was hidden supporting its use
in studies where in-hospital data are unavailable.
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278. Performance of Disease Risk Score Matching in
Nested Case-Control Studies
Rishi J Desai, Robert J Glynn, Joshua J Gagne.
Division of Pharmacoepidemiology and Pharma-
coeconomics, Department of Medicine, Brigham and
Women’s Hospital & Harvard Medical School, Boston,
MA, United States.
Background: Matching in case-control studies with
stratiﬁed analyses improves statistical efﬁciency by
ensuring a constant distribution of controls to cases
across strata. In theory, matching on a disease risk score
(DRS) should result in better efﬁciency than matching
on discrete variables, but this has not been investigated.
Objectives: To compare the performance of DRS-
matching versus standard age- and sex- (AS-) matching
in nested case-control (nCC) studies.
Methods: We generated simulated data for 1000
hypothetical cohorts of 20000 patients with a binary
exposure, a time-to-event outcome, and 12 covariates: 6
confounders (4 binary and 2 continuous), 4 binary expo-
sure only determinants, 2 binary outcome only determi-
nants. Scenarios were deﬁned by different combinations
of exposure (0.1, 0.25, 0.50) and outcome (0.01, 0.05)
incidence. Each cohort was comprised of 2 sub-cohorts
of 10000 patients: a historical and a current sub-cohort.
We calculated DRS from the historical sub-cohort and
conducted nCC studies in the current sub-cohort using
incidence density sampling with 2 matching strategies –
AS-matching (using a continuous and a binary con-
founder representing age and sex) and DRS-matching –
using conditional logistic regression. We compared the
performance of the strategies on relative bias, mean
squared error (MSE), mean standard error, coverage
probability, and empirical power.
Results: Under all scenarios, DRS-matching yielded
lower MSE and mean standard errors compared to AS
matching (e.g., 0.15 v. 0.17 & 0.39 v 0.40 respectively
in the 0.1, 0.01 scenario). Coverage probability was
close to 0.95 for both strategies under all scenarios
(range: 0.947-0.961). Under most scenarios, DRS-
matching resulted in greater empirical power compared
to AS-matching. At lower outcome incidence, DRS-
matching resulted in lower relative bias compared to
AS-matching (e.g., 7.30 v. 17.12 in the 0.1, 0.01 scenario).
At higher outcome incidence, relative bias was similar
with the two strategies (e.g., 3.42 v. 3.10 in the 0.1,
0.05 scenario).
Conclusions: DRS–matching in nCC was more statis-
tically efﬁcient than AS-matching overall and resulted
in less bias at lower outcome incidence in our speciﬁc
simulations.
279. Strategies for Modeling the Relationship between
a Biomarker and a Binary Outcome
Yanli Li, John H Page.Center for Observational Research,
Amgen Inc, Thousand Oaks, CA, United States.
Background: In many clinical situations, biomarkers are
predictors of binary outcomes that are absorbing events.
Several statistical models may be used to model the
relationship between the biomarker and such events. We
conducted a Monte Carlo simulation study to determine
the optimal statistical method to study such relationships
when the duration of the biomarker at different levels is
predictive of the clinical event.
Objectives: To estimate Monte Carlo mean bias, mean
square error, relative efﬁciency, and coverage probability
for each of the combination of two exposure modeling
methods (biomarker level and interaction between bio-
marker level and duration [area]) and two speciﬁcations
of outcome (logistic and hazards models).
Methods: We conducted 1000 Monte Carlo simulations
of 2000 subjects who had a temporary decrease in
biomarker levels (consistent with multivariate normal
distribution with an autoregressive correlation structure)
over time where the area above the biomarker curve
(below a given threshold) is a predictor of the binary
outcome (consistent with an exponential failure time
distribution ~ log hazard ratio per unit area = 0.7). We
modeled the relationship between biomarker and risk
of binary event with logistic regression (up to time
event occurs, using generalized estimating equations
for variance estimation) and with Cox proportional
hazards model with time varying covariates to model
hazard of event. Exposure was modeled as previously
stated.
Results: Mean bias, mean square error, coverage proba-
bility of the log hazard ratio using biomarker level and
biomarker area were 1.00, 1.047, 0.00 and -0.02, 0.003,
0.94 respectively. Mean bias, relative efﬁciency, cover-
age probability of the log odds ratio using biomarker
level and biomarker area were 1.07, 1.163, 0 and 0.13,
0.019, 0.26 respectively.
Conclusions: A proportional hazards model with time
updated exposure is appropriate for estimating the rela-
tionship between a biomarker and a binary outcome
when the duration of biomarker below or above a thresh-
old is a predictor of outcome. Researchers should think
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carefully about the underlying biological mechanisms to
appropriately model exposure.
280. Covariate Balance When Matching on Disease
Risk Scores in Cohort Studies
Joshua J Gagne, Rishi Desai, Robert J Glynn,
Katsiaryna Bykov, Hiraku Kumamaru, Sebastian
Schneeweiss. Division of Pharmacoepidemiology and
Pharmacoeconomics, Department of Medicine, Brigham
and Women’s Hospital and Harvard Medical School,
Boston.
Background: Matching on propensity scores (PS) in
cohort studies balances confounding by balancing
covariates between exposure groups. In contrast, theory
suggests that cohort matching on disease risk scores
(DRS) balances confounding, but not necessarily each
covariate. This assertion has not been empirically
demonstrated.
Objectives: To evaluate covariate balance empirically
after matching on DRS in a cohort study.
Methods: Using US Medicare and prescription drug
claims data, we identiﬁed a concurrent cohort of
raloxifene and alendronate initiators between Jan. 1998,
when raloxifene entered the market, and Dec. 2005. We
identiﬁed a historical cohort of alendronate initiators
between Oct. 1995 and Dec. 1997 in which we developed
a DRS model, with 53 covariates, to predict a composite
fracture outcome. We applied the DRS model to estimate
fracture risk for all patients in the concurrent cohort and
1:1 matched raloxifene and alendronate initiators on the
DRS. Using the same covariates, we ﬁt a PS model in
the concurrent cohort and separately 1:1 matched
initiators on the PS. We used absolute standardized
differences (ASD) to measure individual covariate
balance and Mahalanobis (M-) distance to assess overall
balance across the set of covariates before and after
matching on each score. We also compared hazard
ratios (HRs) for fracture comparing raloxifene to
aldenronate in the concurrent cohort before and after
matching on each score.
Results: In the unmatched cohort, 11 (21%) of covariates
were imbalanced, as deﬁned by an ASD of >0.10; the
M-distance was 0.7241. In the DRS-matched cohort, 11
(21%) covariates were imbalanced, but these were not
all the same covariates that were imbalanced in the
unmatched cohort; the M-distance was 0.5741. PS-
matching resulted in balance in all 53 covariates; the
largest ASD in any covariate was 0.03 and the M-
distance was 0.0809. The HR was 0.77 (95% CI,
0.69-0.85) in the unmatched cohort, 0.91 (0.79-1.04)
in the DRS-matched cohort, and 0.92 (0.81-1.05) in
the PS-matched cohort.
Conclusions: Whereas PS-matching achieved excellent
covariate balance, DRS-matching did little to balance
covariates; yet matching on either score resulted in
similar confounding control.
281. Measurement Bias in Billing Data – A Simulation
Study
Almut G Winterstein,1,2 Paul Kubilis.1 1Pharmaceutical
Outcomes & Policy, University of Florida, Gainesville,
FL, United States; 2Epidemiology, University of Florida,
Gainesville, FL, United States.
Background: Billing data provide information about
diagnoses but not necessarily the underlying testing,
leaving concerns about measurement bias. For example,
more frequent blood glucose testing in the exposed will
increase the probability for diabetes mellitus detection;
if testing frequency is unknown, comparisons between
exposed and unexposed may be biased.
Objectives: To evaluate the validity of Cox and Weibull
proportional hazards models with and without interval
censoring in presence of measurement bias.
Methods: We established a simulated cohort of 1000
exposed subjects with disease testing every 30 days
(SD: 4 days) and 1000 unexposed subjects tested every
180 days (SD: 24 days). Disease incidence was consistent
across groups with 1 event per 10 years of follow-up
(expected HR= 1.0). We assumed 5 censoring events/
10 years of follow-up and censored follow-up entirely
after 4 years. We compared model ﬁts and results of
1000 simulated data sets for (1) Cox regression on time
to ﬁrst positive test and right-censoring at the end of
follow-up (similar to information in billing data lacking
information on testing), (2) Cox regression on time to
ﬁrst positive test and right-censoring at the last negative
test, (3) interval-censored Weibull regression on time
between last negative and before ﬁrst positive test with
right censoring at the end of follow-up, and (4) interval-
censored Weibull regression on time between last
negative and before ﬁrst positive test with right-censoring
at the last negative test.
Results: With the simulated testing and censoring
parameters, 21.7% of subjects did not have a negative
test. Results for the 4 models were: (1) HR=1.39 (95%
CI 1.29-1.50), (2) 1.04 (0.97-1.11), (3) 1.34 (1.24-1.44),
and (4) 1.0 (0.93-1.08).
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Conclusions: In this scenario of pronounced measure-
ment bias, failure to integrate information on negative
tests resulted in biased effect estimates. Use of interval
censoring had only a subtle bias-correcting effect.
282. The Use of Complementary Medicines for
HIV-Infected Children in Lagos, Nigeria
Kazeem A Oshikoya,1 Mubarak Hassan,2 Ibrahim A
Oreagba,2 Olayinka O Ogunleye,1 Idowu O Senbanjo.3
1Pharmacology, Lagos State University College of
Medicine, Ikeja, Lagos, Nigeria; 2Pharmacology, College
of Medicine, University of Lagos, Idiaraba, Lagos,
Nigeria; 3Paediatrics and Child Health, Lagos State
University College of Medicine, Ikeja, Lagos, Nigeria.
Background: Complementary medicine (CM) use is
common among children with chronic illnesses, account-
ing for substantial out of pocket expenditures from their
parents. Among children with human immunodeﬁciency
virus (HIV) infection, data is scarce on the proﬁle of
CM use.
Objectives: To determine the prevalence, pattern of use,
parental sources of information, perceived beneﬁts, cost,
and adverse effects of CM.
Methods: Parents or caregivers of HIV-infected
children attending the paediatric HIV- clinic in a teaching
hospital in Lagos, Nigeria, were randomly selected and
interviewed with a semi-structured (open- and close-
ended) questionnaire. The information obtained included
the demography of both the patients and their parents or
guardians and the type of CM, if any, used by the
patients; the sources, cost, perceived beneﬁts and adverse
effects of the CM used. Extracted from the case ﬁles were
the clinical details of the patient including baseline and
current viral loads and CD4+ counts, and current
medications, including antiretroviral therapy (ART) and
co-prescribed medicines for opportunistic or concurrent
infection.
Results: A total of 187 parents and caregivers were
interviewed. Most of the parents and caregivers (181;
96.8%) have used CMs for their children. Mind-body
interventions (181; 36.6%) and biological products
(179; 36.2%) were frequently used. Relatives, friends
and neighbours inﬂuenced CM use in 37.1% of the
children. CMs were used mostly to treat weight loss
(79; 43.7%), cold (40; 22.1%), and fever (39; 21.6%).
There was no signiﬁcant difference between the change
in the mean viral load for HIV-infected children using
biological products and those using non-biological CM
(1100.7 ± 588.6 copies and 1311.7 ± 658.8 copies,
respectively; P = 0.885). Similarly, there was no signiﬁ-
cant difference between the change in the mean CD4+
counts of HIV-infected children using biological prod-
ucts and those using non-biological CM (828.5 ± 482.0
cells mm-1 and 800.4 ± 422.0 cells mm-1, respectively;
P = 0.492). Speciﬁc adverse effects of CMs reported were
vomiting (14), diarrhoea (14) and nausea (13).
Conclusions: CM use is common among HIV-infected
children in Lagos.
283. Predictors of Broad Spectrum Antibiotics Use in
Children in a Nigerian Hospital
Chukwuemeka M Ubaka,1 Chinwe J Eneaji,2 Chinwe V
Ukwe.1 1Clinical Pharmacy and Pharmacy Management,
University of Nigeria, Nsukka, Enugu, Nigeria;
2Peadiatric Pharmacy, Enugu State University of Technol-
ogy Teaching Hospital, Enugu, Nigeria.
Background: Utilization of antibiotics among children
in developing countries has not been fully studied and
factors inﬂuencing the prescription of broad spectrum
agents in poor resource settings remain largely unknown.
Objectives: To evaluate the quality and predictors of
broad spectrum antibiotics prescription among children
in a Nigerian referral hospital.
Methods: Folders and prescriptions of children (under
12 years) from 2010 to 2011 in Enugu State University
of Technology Teaching Hospital were randomly sampled.
Prescriptions with antibiotics or at least an infection were
sorted, coded and entered into the SPSS version 16 for
statistical analysis. Quality of use was assessed using
WHO prescribing indicators while predictors of use
assessed using logistic regression.
Results: Cephalosporins were the most prescribed
antibiotics and the mean (SD) number of antibiotics
per prescription visit was 1.21(0.44) with nearly half
(45%) of the children receiving antibiotics as injections.
Only 27% of the drugs were prescribed as generics
and just 58.3% were listed on the essential drugs list.
Broad spectrum antibiotics were mostly prescribed
(50.5%), signiﬁcantly inﬂuenced by factors such as
higher cost of the antibiotic [odds ratio = 0.15, 95%
CI (0.09-0.25)], high cost of other drugs [odds ratio =
0.581, 95% CI (0.40-0.84)], not being listed on the
EDL [odds ratio = 2.13, 95% CI (1.45-3.14)] and being
an injection [odds ratio = 0.43, 95% CI (0.30-0.63)].
Cost/DDD showed cephalosporins as the most costly
antibiotic compared to others with ten antibiotics making
up the DU90%.
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Conclusions: Utilization of antibiotics in this hospital
was not in compliance with WHO guidelines. The factors
that drive the prescription of broad spectrum antibiotics
in children in this setting calls for concern and some form
of intervention.
284. Determination of a Possible Association between
Human Papillomavirus (HPV) Vaccination and
Migraine
Tessa M Schurink-van ‘t Klooster,1 Maria AJ de Ridder,2
Jeanet M Kemmeren,1 Johan van der Lei,2 Frans
Dekker,3 Miriam Sturkenboom,2 Hester E de Melker.1
1Center for Infectious Disease Control, National Institute
for Public Health and the Environment, Bilthoven,
Netherlands; 2Medical Informatics, Erasmus Medical
Center Rotterdam, Rotterdam, Netherlands; 3Public
Health and Primary Care, Leiden University Medical
Center, Leiden, Netherlands.
Background: Since the introduction of the bivalent HPV
vaccine in the Netherlands, a notable event reported in
the passive surveillance system is migraine.
Objectives: Assess a possible association between HPV
vaccination and newly diagnosed migraine.
Methods: Potential incident migraine cases were se-
lected from a population-based medical record database
Dutch GPs (i.e. IPCI). Cases were selected if the record
contained the ICPC-code N89 or ‘migrai*’ in the free text
within the years 2008-2010. Selected cases were
manually validated and coded. Girls born in 1993-1997
(i.e. who were eligible for HPV vaccination in 2009/2010)
from the IPCI database were linked to the vaccination
registry Praeventis to determine their HPV vaccination
status. Age and gender speciﬁc incidences of migraine in
the post-vaccination period (2009/2010) were compared
to the pre-vaccination period (2008). Self-controlled case
series (SCCS) analysis was used to compare potentially
high-risk periods (6, 4 and 2weeks after each dose) with
non-high-risk periods. Furthermore, a cohort analysis was
conducted to compare incidences of migraine in vaccinated
and unvaccinated girls.
Results: In the study period, 448 migraine cases
(certain + uncertain) have occurred. Higher, but not
statistically signiﬁcant, incidences of migraine were seen
for 12-16 year olds (for both girls and boys) in the post-
vaccination period (2009/2010) compared to the pre-
vaccination period (2008). The RR for migraine in the
high-risk period of 6weeks following each dose versus
non-high-risk period was 4.3 (95% CI 0.69-26.6) for
certain migraine and 2.9 (95% CI 0.71-11.7) for certain
and uncertain migraine. Decreasing the high-risk period
to 4 and 2weeks showed generally comparable results.
Furthermore, IRRs for migraine in monthly periods
following vaccination compared to migraine in unvacci-
nated girls ranged from 0.0 to 3.0, however none was
statistically signiﬁcant.
Conclusions: No statistically signiﬁcant association
between HPV vaccination and newly diagnosed migraine
was found. However, numbers of cases were rather low.
Including higher number of cases will be possible in the
future to further study a possible association.
285. Stimulant Effectiveness on Driving Citations and
Crashes of Children with ADHD
Almut G Winterstein,1,2 Tobias Gerhard,3,4 Paul
Kubilis,1 Jon Shuster.5 1Pharmaceutical Outcomes &
Policy, University of Florida, Gainesville, FL, United
States; 2Epidemiology, University of Florida, Gainesville,
FL, United States; 3Institute for Health, Health Care
Policy, and Aging Research, Rutgers University, New
Brunswick, NJ, United States; 4Ernest Mario School of
Pharmacy, Rutgers University, New Brunswick, NJ,
United States; 5Biostatistics, University of Florida,
Gainesville, FL, United States.
Background: Observational and driving simulator
studies suggest that ADHD causes higher risk-taking
behavior, decreased attention and greater risk for car
accidents, but little is known about the effectiveness of
respective pharmacological treatment.
Objectives: To evaluate the effectiveness of central
nervous stimulants on driving outcomes in adolescents
and young adults with ADHD.
Methods: We established the study cohort by linkage of
Florida Medicaid fee-for-service billing data and Divi-
sion of Motor Vehicle (DMV) records to obtain informa-
tion on driver licensure, citations and crashes. Eligible
subjects entered the cohort after their 15th birthday, an
in- or outpatient diagnosis for ADHD, and issuance of a
driver’s license (DL). Follow-up ended at end of eligibil-
ity, >12months without ADHD diagnosis, DL expira-
tion/suspension, age 21 or the study endpoint. Two
endpoints were ascertained from DMV records: crashes,
and citations for active driving violations. We deﬁned ex-
posure based on days’ supply plus 25% including meth-
ylphenidate, mixed amphetamine salts and atomoxetine.
We used logistic regression to estimate propensity scores
(PS) based on socio-demographic characteristics, sub-
stance abuse (DUI or ICD9 code), DL learner’s permit
status, 2000 population size in county of residence, and
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countywide total annual daily vehicular miles traveled
per total miles of paved road. Cox proportional hazards
regression was used to estimate stimulant effects while
adjusting for PS, valid DL status >1 year, and time-
dependent exposure to antidepressants, antipsychotics,
anticonvulsants, anxiolytics and alpha-agonists.
Results: 2161 subjects had a total of 71 crashes and 338
citations. Hazard ratios for stimulants were HR=1.01
(95% CI 0.61-1.70) for crashes and 0.86 (0.68-1.09) for
citations. Antidepressants showed a signiﬁcant associa-
tion among all included psychotropics with HR=0.29
(0.11-0.81) for crashes and 0.68 (0.50-0.95) for citations.
Conclusions: Stimulants showed no effect on citations
and crashes. The effect of antidepressants might be due
to parental driving restrictions.
286. Antipsychotic Initiation and Stability of Foster
Placement Among Youth with Disruptive Behaviors
Ming-Hui Tai, Susan dosReis. Pharmaceutical Health
Services Research, University of Maryland, Baltimore,
MD, United States.
Background: Antipsychotic medications are increasingly
prescribed for youth with attention-deﬁcit hyperactivity/
disruptive behavior disorders(ADHD/DBD). Disruptive
behaviors are prevalent in foster youth and a common
reason for foster placement transitions. If antipsy-
chotics effectively control the disruptive behaviors
then youth in foster care would experience fewer
transitions. To date, no study has examined the associ-
ation between antipsychotic initiation and stability of
foster placement.
Objectives: To examine the association between antipsy-
chotic initiation and time to ﬁrst foster care placement
transition during the 180-day follow-up among youth
with ADHD/DBD.
Methods: Child welfare and Medicaid administrative
data from January 2010 through May 2013 were used
to identify a new user cohort of youth who initiated
antipsychotics (index date) any time in 2010-2012. The
cohort had (1) continuous foster care enrollment 180 days
before and after the index date, (2) any ADHD, conduct
disorder, oppositional deﬁant disorder, or impulsive
control diagnosis, and (3) no antipsychotic 180 days
before the index date. The comparison group had no
antipsychotic use in 2010-2012 but met all other inclu-
sion criteria for the new user cohort. Cox proportional
hazard models were used to estimate the risk of time to
foster care placement transitions.
Results: Of 676 youth with ADHD/DBD, 42 were new
antipsychotic users and 634 were nonusers. On average,
youth were 14 years old, 62% male, and 92% black.
The unadjusted HR for antipsychotic initiation on the risk
of placement transition was 2.7(95% CI = 1.8-4.1). HRs
were similar after controlling for demographic and
clinical characteristics. HRs of antipsychotic initiation
remained signiﬁcant but reduced 23% after foster
care characteristics were accounted for (HR = 2.0
[95% CI = 1.3-3.0]).
Conclusions: The increased risk of foster care placement
transition, despite treatment suggests that further study
is needed to determine the comparative effectiveness of
antipsychotic management for disruptive behavior,
adjusting for underlying severity.
287. Long-Acting β2 Agonist Without Concomitant
Inhaled Corticosteroids in Children with Asthma in
Primary Care
Marjolein Engelkes,1 HettieM Janssens,2 Johan C de Jongste,2
MiriamCJMSturkenboom,1 KatiaMCVerhamme.1 1Medical
Informatics, ErasmusMC,Rotterdam,Rotterdam,Netherlands;
2Pediatric Pulmonology, ErasmusMC-Sophia, Rotterdam,
Netherlands.
Background: (Inter)national guidelines discourage use
of long-acting beta2 agonists (LABAs) without concom-
itant inhaled corticosteroids (ICS). The extent to which
LABA monotherapy actually occurs is uncertain.
Objectives: To evaluate prescription patterns of LABA
without ICS (=LABAmono) and LABA combined
with ICS (in 1 inhaler = LABAfx or in 2 separate =
LABAapart) in children with asthma. Additionally, to
identify risk factors associated with LABA monotherapy.
Methods: Population based cohort study using the IPCI
database, a Dutch primary care database containing the
complete medical records of more than 1 million patients.
All children with physician diagnosed asthma, aged 5-18
years between 2000-2012, were identiﬁed and validated.
The annual prevalence was calculated per 100 patient
years (PY), among children using asthma therapy in that
calenderyear, stratiﬁed by age and gender. Use of LABA
was investigated as either LABAfx or LABAapart or
LABAmono.
Results: The asthma cohort consisted of 14,304 children
with 35,000 PY of follow-up. The overall annual
prevalence was for LABAtotal 27.8/100PY, for
LABAfx 24.3/100PY, for LABAapart 2.9/100PY and
for LABAmono 1.8/100PY. LABA prescribing increased
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with age, and was higher in girls compared to boys after
the age of 13 years. Use of LABAmono and LABAapart
decreased with calendar time with prevalences of 1.44/
100PY and 1.52/100PY in 2011. Children receiving
LABAmono were older at time of the ﬁrst LABA
prescription and the proportion of children never consult-
ing a specialist was higher compared to LABAapart. The
severe asthma exacerbation rate was lower in children
receiving LABAmono compared to LABAapart, suggest-
ing less severe asthma.
In children receiving LABAapart, LABA exposed
days were covered with ICS in almost 100% (IQR
(91.9-100), which was stable over calendertime.
Conclusions: In Dutch pediatric primary care, LABA
prescribing as a separate inhaler has declined, but still
occurs in a small percentage. Despite (inter)national
guidelines, prescription of LABAmono continues to
occur in children with asthma.
288. Healthcare Databases for Paediatric Studies: A
Report from the GRiP Network Global Survey
Carmen Ferrajolo,1,2 Osemeke Osokogu,1 Cassandra
Nan,3 Yolanda Brauchli Pernus,3 Daniel Weibel,1
Katia Verhamme,1 Madlen Gazarian,4 Ian CK Wong,5
Hidefumi Nakamura,6 Jan Bonhoeffer,3,7 Carlo
Giaquinto,8 Miriam JCM Sturkenboom.1,9 1Medical
Informatics, Erasmus University Medical Center,
Rotterdam, Netherlands; 2Experimental Medicine,
Pharmacology Section, Campania Regional Center of
Pharmacovigilance and Pharmacoepidemiology, Second
University of Naples, Napoli, Italy; 3Brighton Collabora-
tion Foundation, Basel, Switzerland; 4School of
Medical Sciences, Faculty of Medicine, University of
New South Wales, Sidney, Australia; 5Pharmacology
and Pharmacy, Centre for Safe Medication Practice
and Research, University of Hong Kong, Hong Kong,
China; 6National Center for Child Health and Develop-
ment, Tokyo, Japan; 7University Children’s Hospital,
Basel, Switzerland; 8Paediatrics, University Hospital,
Padua, Italy; 9Epidemiology, Erasmus University
Medical Center, Rotterdam, Netherlands.
Background: A global federation of available healthcare
databases on infants, children, and adolescents could
provide currently missing power and data comparability
to improve knowledge on disease burden, and drug/
vaccine use and safety.
Objectives: To identify and describe globally automated
healthcare databases as a ﬁrst step to create a collabo-
rative network.
Methods: In frame of the Global Research in Paediatric
(GRiP) network (http://www.grip-network.org), we
performed a web-based survey among all databases
that were identiﬁed through manual revision of the
pharmacoepidemiology/pharmacovigilance conference
abstracts, the Bridge.to.Data database or by direct
knowledge of the GRiP network members. The survey
solicited information on the database contact, available
population, exposure and outcome, as well as access,
governance and sharing possibilities.
Results: A total of 125 databases were identiﬁed globally
(Europe, North- and South-America, Asian/Paciﬁc area,
and Africa) and were invited to participate to a survey.
To date, 61 answers were received (49%), with 52% of
respondents (N= 32) agreeing to collaborate with the
GRiP network in future pharmacoepidemiology studies.
Collaborating databases are located in 8 different
European countries (N= 21), in 4 Asian/Paciﬁc area
countries (N= 5), in Canada (N= 4) and in the US
(N= 2); one is available in more than one country. The
data sources comprise a total of 40 million children (<18
years). Sixteen databases capture outpatient data and
9 have both, outpatient and inpatient data from primary
care physicians and/or insurance claims. Immunization
data are available in 22 databases. Patient-level linkage
between drug/vaccine prescription and outcome data is
feasible for all collaborating databases.
Conclusions: Identiﬁed databases agreeing to collaborate
in a unique global network hold an enormous potential
for improving paediatric pharmacoepidemiological
studies. A ﬁrst step towards a collaborative approach is
being made by characterizing available databases and
scope and type of available data. Identiﬁcation and
participation requests will continue, while ﬁrst proof of
concept studies on the use of antibiotics will start.
289. Off-Label Prescription in Pediatric Patients in
Bandung City, Indonesia
Rizky Abdulah, Miski A Khairinisa, Ami A Pratiwi,
Ivan S Pradipta, Eli Halimah, Ajeng Diantini,
Keri Lestari. Department of Pharmacology and
Clinical Pharmacy, Faculty of Pharmacy, Universitas
Padjadjaran, Bandung, West Java, Indonesia.
Background: Off-label medication is often used in the
treatment of pediatric patients. It, however, should be
restricted due to the lack of evidence related to the
efﬁcacy and safety. Little is known about the frequency
of off-label drug use or the degree of scientiﬁc evidence
supporting this practice in Indonesia.
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Objectives: To investigate the off-label prescribing prac-
tice to pediatric patients in Bandung City, Indonesia.
Methods: We conducted a retrospective and population
based study to a total of 10.748 prescriptions for 0-5
years old pediatric patients from 14 selected community
pharmacies in 2012, and analyzed for its off-label used.
Results: 20.85% of the total prescriptions contain at least
one off-label drug. Furthermore, 7% of the total 16.516
prescribed drugs were categorized as off-label. From all
of the prescribed drugs, domperidone, dioctahedral smec-
tite, and doxycycline were the most off-label prescribed
drugs in term of age, dosage, and contra indication,
respectively.
Conclusions: This is the ﬁrst study that show signiﬁcant
number of off-label drugs prescribed for children in Indo-
nesia, therefore, efforts should be made to scrutinize un-
der evaluated off-label prescribing that may compromises
patient safety.
290. Epidemiology of Rotavirus Gastroenteritis (RGE)
in Young Children in Rural Guangxi, China
Yi Nong,1 Xu Yang,2 Yimei Wu,2 Qinglin Yang,2 Yan
Liang,2 Minmei Chen,1 Zhaojun Mo,1 Shusen Liu,3
Christopher Mast,4 Rongcheng Li.1 1Guangxi Center
for Disease Control and Prevention, Nanning, China;
2Sanjiang County Center for Disease Control and
Prevention, Liuzhou, China; 3Epidemiology Asia
Paciﬁc Unit, Merck Research Laboratory, Beijing,
China; 4Epidemiology, Merck Research Laboratory,
North Wales, PA, United States.
Background: There are few population-based studies
assessing the epidemiology of RGE in rural China.
Objectives: The goal of this study was to estimate RGE
attack rate in a mountainous region of Guangxi, China.
Methods: An active surveillance program attempted to
enroll all acute gastroenteritis (AGE) cases among
children< 5 years of age seeking medical care at 26
village clinics and 4 township/county hospitals during
the rotavirus (RV) season (Nov 2012 - Apr 2013). The
AGE case deﬁnition was>=3 loose or watery stools in
a 24-hour period prior to the clinic visit. The catchment
area covered ~3800 children aged< 5 years in the 26
villages. For enrolled cases, stool samples were collected
and demographic and clinical questionnaire/assessments
were administered. Stool was assayed for RV antigen
using EIA. AGE severity was assessed using the Vesikari
clinical scoring system.
Results: Totally 624 AGE cases were recruited, and stool
samples were collected from 589 (94%) of them. The
overall proportion of RV+ cases was 38.3% and peaked
at 58.2% in Jan 2013. Children aged< 24months
accounted for 70.8% of all-cause AGE cases. The overall
attack rate (AR) of RGE in the study population was
5.9% (95% CI: 5.2, 6.7) but varied by age: 11.9% (95%
CI: 10.3, 13.7) in children aged< 24 mos, and highest
in children aged 6 - 12 mos: 15.7% (95% CI: 11.8,
20.2). The proportion of mild, moderate and severe clin-
ical characteristics among AGE cases was 49%, 41% and
10%, respectively. Severe cases had greater likelihood of
being RV+ than mild cases (54% vs 35%).
Conclusions: This active population-based surveillance
study demonstrated that RGE is associated with a high
attack rate and signiﬁcant proportion of 2012-13 seasonal
AGE cases in the rural Guangxi, China.
291. Adveras Effect of Reactions in Time of Hospital
Stay and Delay in Pediatric Patients with Chemother-
apy Leukemia
Fabiola Patricia Medina Barajas,1 Fernando Antonio
Sanchez Zubieta,2 Sergio Sanchez Enriquez,1 Carmen
Zavala Sanchez,2 Ana Rosa Rincon Sanchez.1 1Phar-
macology, Universidad De Guadalajara, Guadalajara,
Jalisco, Mexico; 2Pharmacy, Hospital Civil De
Guadalajara, Guadalajara, Jalisco, Mexico.
Background: Adverse drug reactions in the U.S. repre-
sent 4.7% of hospital admission. In the European Union
is estimated to be 11.5 % to 16 % of hospitalizations
are due to ADRs. It has been reported that 46.3 % of
patients hospitalized ADR attributed to treatment with
antineoplastic agents and immunosuppressants.
Objectives: To assess the effect of adverse drug reactions
in the hospital stay and the time between cycles of chemo-
therapy during the consolidation phase of the treatment pro-
tocol of acute lymphoblastic leukemia in pediatric patients.
Methods: Prospective cohort study. On the factor of
exposure to adverse drug reactions as outcome variable
and the length of hospital stay and the time between
chemotherapy cycles. The sample was 43 research
subjects, alpha 0.05 and beta of 80 %. Inclusion criteria
were patients with a diagnosis of acute lymphoblastic
leukemia treatment protocol initiated in the consolidation
phase in remission. 1-15 years old. The study was
approved by the ethics committee.
Results: 44 and 46 cases were included. In the group
exposed found that the average length of stay per
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treatment cycle was 7.1 days +/- 3.5, and while in the
unexposed group was 4 days +/-0.2 days. RR 18.81,
p0.03, for the group of patients exposed to adverse
drug reactions and hospital stay during the administra-
tion of chemotherapy. Regarding the average time
between chemotherapy cycles in patients exposed was
18 days with a SD of 3.2 days, while for the group of
unexposed patients was 14 days with a SD of 4.2 days.
An RR of 1.62 with p = 0.005 for patients exposed to
adverse drug reactions and the time between chemo-
therapy cycles was found.
Conclusions: It is detected mainly ADRs type A. Can be
predictable and preventable in some cases. This condition
provides an opportunity to implement strategies to mini-
mize the effect it has on the length of hospital stay and
the time that elapses between chemotherapy cycles.
We note that the majority of ADRs were mild to mod-
erate severity. We believe that this favors the clinical
management of these is insufﬁcient to avoid having an ef-
fect on the length of hospital stay and the time elapsed
between chemotherapy cycles.
292. PMSI Database Consultation: Evaluation of
Hospital Stay Length for Infantile Haemangioma
in France Previous To and Subsequent To Propran-
olol Use
Charles Taieb. Public Health, PFSA, Paris, France.
Background: Infantile haemangioma (IH) appears in the
ﬁrst few days of life, and develops over time. Certain
types of IH cause signiﬁcant functional impairment and
aesthetic.
Objectives: The objective of this work was to estimate
(in children under the age of two years) hospital stay
length for IH previous to and subsequent to introduction
of propranolol as haemangioma treatment.
Methods: Analysis of the PMSI database covered two
periods: the ﬁrst previous to propranolol use (2006) and
the second more recent (2011) during which use of
propranolol became widespread. In the PMSI database,
haemangioma can be found under primary diagnosis (or
related) or associated, it is normal to carry out economic
assessments on the PD.
Results: In 2006, 1,205 children were admitted to
hospital for IH, thus generating 1,758 hospital stays.
Day hospital admissions represent 24%. In 2011, 1,712
children were admitted to hospital for IH, thus generating
2,136 hospital stays,. Day hospital admissions represent
30%. The average length of stay, with haemangioma as
primary diagnosis, decreased from 2.44 days in 2006 to
1.16 days on average in 2011, representing a 50%
decrease. We note that DRG differ between 2006 and
2011, suggesting that the diagnosis is best determined.
Conclusions: Infantile haemangioma has a signiﬁcant
medical and ﬁnancial impact. A recent assessment con-
ducted in France in ﬁve hospitals treating IH, considered
that the average cost of treatment (according to the health
insurance fund) of children with haemangioma reached
€6,407.00 on average. The highest expenditure item
was hospitalisation at an average cost of €5,337.00
(equivalent to 83% of the total average cost). A reduction
in the length of hospital stays, subsequent to propranolol
use, of almost 50% as demonstrated by the PMSI, should
have a signiﬁcant effect on treatment costs.
293. Medical and Economic Impact of Infantile
Haemangioma in France Previous To Propranolol Use
Charles Taieb. Public Health, PFSA, Paris, France.
Background: Infantile haemangioma is a common
lesion affecting around 10% of children. At least 30%
of haemangiomas require treatment.
Objectives: Estimate the cost of treatment of IH previ-
ous to introduction of propranolol in the treatment of
haemangioma.
Methods: Observational multicentric retrospective
study at ﬁve expert centres treating children with
haemangioma. The ﬁrst 10 patient records, from each
centre, of patients having been diagnosed, between the
age of one and ﬁve months before 31/12/2007, with a
haemangioma measuring >1.5 cm in diameter, having
already received corticosteroid treatment, were identiﬁed
and selected.
Results: 53 children were included. Haemangioma was
mixed (cutaneous and subcutaneous) in 69.0% of
children, and was located on the head and neck in
88.7% of cases. Complications arose in 75.5% of
children. 83.0% of the children underwent additional
tests in view of diagnosis and treatment of haemangioma.
Tests most often included an MRI-scan (39.6%), an
ophthalmological examination (30.2%) or heart ultra-
sound (32.1%). A dermatologist followed the patients in
71.7% of cases. 69.8% of the children were admitted to
hospital at least once for their haemangioma and 17.0%
had laser treatment. The average cost of treatment
(according to the health insurance fund) of children
with haemangioma was high, reaching €6,407.00 on
average. The highest expenditure item was hospitalisation
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at an average cost of €5,337.00 (equivalent to 83% of the
total average cost).
Conclusions: IH has a signiﬁcant medical and ﬁnancial
impact, requiring relatively heavy medical treatment
(numerous medical consultations with various specialists,
frequent additional tests, long-term medication and
surgery and laser treatment), the impact being even more
signiﬁcant the more serious the haemangioma. Introduc-
tion of propranolol in the treatment of IH should reduce
treatment costs appreciably, notably by reducing the
length of the hospital stays.
294. Infantile Haemangioma: A Burden for Families
Charles Taieb. Public Health, PFSA, Paris, France.
Background: Before Propanolol was discovered, the
children suffering from infantile haemangioma (IH) was
treated almost exclusively systemic corticosteroids.
Objectives: The objective of this study was to describe the
care and the burden of IH before the discovery of propranolol.
Methods: 26 families, in which one child suffered from
IH, before Propranolol became available, agreed to
answer questions on management of their child’s
haemangioma, and on the effect of the disease on their
family and professional life.
Results: The children suffering from IH was mainly and
almost exclusively systemic corticosteroids (96.2%),
combined with laser treatment for one child and with
Vincristine for another child. Only one child was treated
with topical corticosteroids alone. In 80%of cases, the
treatment was started immediately after the diagnosis,
and all children took their treatment daily. For 38.5%,
the treatment was changed later on for various reasons:
-Lack of effectiveness (40%); -Continuing treatment
(40%); -Relay treatment (10%). All families cited at least
one effect of the disease on the professional life of one or
both parents. The mother was more affected in most
cases (62%). 8% of families cite one or several effects
for both parents. The main psychological difﬁculties
they had to face were, in order of frequency: how others
saw them (88%); guilt (64%); anxiety with respect to
scarring/healing (52%); suffering (28% ). For 69% of
the parents, their child’s haemangioma (C’sH) had an
effect on their sleep; for 57% their C’sH made their
family life complicated; for 50% their C’sH had an effect
on their career; for 38% their C’sH took its toll on the
couple; for 81% people’s reactions to their C’sH weighed
on them; for 57% their C’sH disrupted their life.
Conclusions: The advent of Propanolol revolutionised
medical treatment of IH. A International study is ongoing
and aims to determine of it has an effect on the burden
felt by families.
295. Adolescent Asthmatics’ Needs and Preferences
Regarding Medication Counseling: Results from
Online Focus Groups
Ellen S Koster,1 Daphne Philbert,1 Liset L van Dijk,2
Tjalling W de Vries,3 Marcel L Bouvy.1 1Pharmaco-
epidemiology & Clinical Pharmacology, Utrecht
University, Utrecht, Netherlands; 2Nivel, Utrecht,
Netherlands; 3Medical Centre Leeuwarden, Leeuwarden,
Netherlands.
Background: In adolescents, non-adherence is a major
problem and leads to uncontrolled disease.
Objectives: To assess adolescents needs and preferences
regarding counseling and support with focus on use of
new media.
Methods: Asthmatic adolescents needs and preferences
were examined by means of moderated asynchronous
online focus group (OFG) over a one week period. Two
OFGs were created: early (age 12-13 years) and late
adolescence (age 14-16 years). A new question was
introduced by the researchers on each ﬁrst ﬁve days.
Participants were asked to respond anonymously to the
questions introduced by the researcher and to each
other’s comments. Questions concerned adherence be-
havior in general and needs and preferences in adherence
support with focus on new digital media (mobile technol-
ogy, social media, health games). Patients were recruited
through community pharmacies.
Results: In total, 192 adolescents were selected from 13
pharmacies and requested for participation. Fourteen
returned informed consent (7.3%) of which all 14 partic-
ipated in OFGs. Older participants were more actively
engaged in the discussions. Forgetting was mentioned
as important reason for not using medication as
prescribed and some adolescents mentioned the lack of
perceived need or lack of perceived effect of medicines.
Participants described different supportive roles for their
parents (reminding, ﬁlling prescriptions). Use of health
games was not perceived useful, whilst other new media
such as smartphone applications were suggested as
solutions to support medication intake behavior.
Furthermore, participants were generally positive about
the OFG methodology and sharing of online experiences.
Older participants were more actively engaged in the
OFG discussion.
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Conclusions: It is important to ﬁnd ways to improve ad-
herence that easily ﬁt into adolescents’ daily life. Adoles-
cents are highly engaged in technology and frequently
communicate through new digital media. Our ﬁndings
lay the foundation for future intervention development.
In order to develop patient-centered interventions to
improve medication adherence in adolescents, it is
important to embed these patient perspectives.
296. Pediatric Drug Safety Surveillance in Italian
Pharmacovigilance Network: An Overview over the
Years 2001-2012
Carmen Ferrajolo,1,2 Annalisa Capuano,1 Francesco
Rossi,1 Ugo Moretti,3 Gianluca Triﬁrò,2,4 Carmela
Santuccio.5 1Experimental Medicine, Pharmacology Sec-
tion, Campania Regional Center of Pharmacovigilance
and Pharmacoepidemiology, Second University of
Naples, Napoli, Italy; 2Medical Informatics, Erasmus
University Medical Center, Rotterdam, Netherlands;
3Clinical Pharmacology Unit, University of Verona,
Verona, Italy; 4Clinical and Experimental Medicine, Uni-
versity of Messina, Messina, Italy; 5Pharmacovigilance
Ofﬁce, Italian Medicines Agency, Roma, Italy.
Background: Regulatory actions in pediatrics are mainly
based on data mining in Spontaneous Reporting Systems
(SRS). Understanding structure and scope of these
databases and their strengths and limitations is crucial for
their correct use and interpretation for signal detection.
Objectives: To explore pediatric ADR reports on the
Italian SRS database over the last decade.
Methods: Reports of suspected ADRs related to children
and adolescents were extracted from the Italian SRS from
2001 to 2012. MedDRA terms and WHO-ATC classiﬁ-
cation were used to group ADR reports by suspected
drug classes and affected system/organ. Characteristics
were analysed within speciﬁed pediatric age-categories
and compared with adult ADR reports.
Results: Among 123,129 selected reports, 8,338 (6.8%)
concerned pediatrics, with males more involved than
females up to 11 years of age (52% vs. 48%), thereafter
reversed. 30% of pediatric reports were serious and of
these, 75% required hospitalization, mainly in very
young children. Most of the reports were issued by hospi-
tal physicians (62%), followed by pharmacists (10%),
while reports from family pediatricians accounted only
for 8%. Irrespective of the event, the most frequently im-
plicated drug categories were antiinfectives for systemic
use (n = 3,743, 45%), drugs acting on nervous system
(1,304, 15%), and antiinﬂammatory drugs (849, 10%).
As compared to adult reports, the pediatric group showed
a higher proportion of reports concerning respiratory sys-
tem drugs (7.8 vs 2.0%, respectively) and a lower propor-
tion for drugs acting on the blood (1.5 vs 10.4%) and on
cardiovascular system (1.0 vs. 12.0%). At single com-
pound-level, the mostly suspected drugs were different
among children and adults and, in several cases, with
respect to the same drug, ADRs were more serious in
adults than in children.
Conclusions: This descriptive study of Italian SRS re-
ﬂects real safety concerns for drugs used in pediatrics.
Because of the low number of reports by pediatricians,
speciﬁc learning programs should be adopted to
stimulate their drug safety monitoring. Since of age-
differences, pediatric drug safety needs to be assessed
in age-speciﬁc setting.
297. Adverse Drug Reactions of Spontaneous Reports
in Shanghai Pediatric Population
Jia He, Hui Li, Xiaojing Guo, Xiaofei Ye, Hong Jiang.
Department of Health Statistics, Second Military Medical
University, Shanghai, China.
Background: Knowledge of drug safety in the pediatric
population of China is limited.
Objectives: This study was designed to evaluate adverse
drug reactions (ADRs) in children reported to the sponta-
neous reporting system (SRS) of Shanghai in 2009.
Methods: Crude ADR reports submitted to Shanghai
SRS in 2009 for individuals aged from birth to 17 years
(including 17 years) were included. Data were analyzed
with respect to age, gender, category of ADR (System
Organ Class [SOC]), the severity of reports and type of
reporter.
Results: Amale overrepresentation was observed regard-
ing the total number of reports. The most frequently
reported group of drugs were vaccines (42.15%). Skin
rash and fever were the commonest symptoms reported
in the total pediatric dataset. The proportion of children
that suffered from a serious ADR was 2.16% and that
for drug related deaths was 0.34%. And we found that
the multiple drug exposure experienced a high proportion
of serious ADRs compared with the single drug use
(χ2 = 15.99, P< 0.0001). Sixty-ﬁve percent of ADRs
were for children less than 6 years of age. And more than
half of reports were from doctors.
Conclusions: In our study, consumers were more likely
to report new ADRs though they appear to contribute a
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relatively small percentage of total reports. We propose
that patients would take an active role in reporting ADRs.
More researches are needed in order to achieve better
understanding the characteristics of ADRs in pediatric
population of China.
298. Adverse Reactions in Children: French Data
François Krabansky, Malak Abou Taam, Baptiste
Demailly, Emmanuelle Herlem, Marie-Paule Roux,
Thierry Trenque. Department of Pharmacovigilance
and Pharmacoepidemiology, Reims University Hospitals,
Reims, France.
Background: French paediatric data are available
describing the frequency of adverse drug reactions
(ADR) in this speciﬁc population.
There is an under report of the adverse events occurred
in children. This population is excluded from the pre
marketing clinical trials.
Objectives: To analyze the most frequently reported
drugs in children between 1 and 18 years old.
Methods: All cases of serious ADR involving children
spontaneously reported to the French PharmacoVigilance
Database (FPVD) during four years were reviewed. For
all cases, we studied the patient characteristics and the
characteristics of the ADR.
Results: 4 682 reports of serious adverse events were
recorded between 2010 and 2014 in children.
The mean age was 11.1 +/- 5.4 years old, the sex ratio
was 0.87.
The most frequent suspect drugs were the acetamino-
phen (n: 164; 3.5%), isotretinoin (n: 154; 3.3%), HPV
vaccine (n: 154; 3.3%), immunoglobulins (n: 132;
2.8%) and ibuprofen (n: 126; 2.7%). By therapeutic clas-
ses, the most reported was the vaccine (n: 682; 14.6%)
the second was the antibiotics (n: 514; 11%) the third
was antineoplasic agents (n: 347; 7.4%) followed by the
analgesic (n: 321; 6.8%) the immunosuppressive drugs
(n: 310; 6.6%) antiepileptics (n: 240; 5.1%) non steroidal
anti-inﬂammatory drugs (n: 232; 4.9%) contraceptives
(n: 201; 4.3%) and drugs for acne (n: 157; 3.3%).
Anti infectious drugs (n: 670; 14.3%) produced signif-
icant number of serious ADR.
There were 9 555 serious adverse events, the most
frequent was skin effects (n: 2324; 24.3%), nervous
effects (n: 1707; 17.9%) and gastrointestinal effects
(n: 1241; 13%).
Conclusions: The importance of the vaccines report is
surprising. It could have a part of notorious bias
explaining this result. The distribution of the adverse
events is a reﬂect of the prescribing practices in France,
especially the vaccines which are mandatory or highly
recommended in the child population.
299. Inhaled Corticosteroids for Preschool Children –
A Norwegian Register Study
Øystein Karlstad,1 Knut Øymar,2 Kari Furu,1 Wenche
Nystad.1 1Division of Epidemiology, Norwegian Institute
of Public Health, Oslo, Norway; 2Department of Pediat-
rics, Stavanger University Hospital, Stavanger, Norway.
Background: Inhaled corticosteroids (ICS) is the
cornerstone of asthma treatment, but there is lack of
documentation for ICS in preschool children regarding
whowill beneﬁt from ICS treatment, and there may be a risk
of side effects like linear growth retardation. Asthma is
difﬁcult to diagnose at this age and there are no strict criteria
for which pre-schoolers should receive treatment with ICS.
Objectives: Examine extent of use and prescription
patterns for ICS in pre-schoolers (0-5 years) regarding
time trends, speciality of prescriber, and how treatment
with ICS is continued over time.
Methods: Data on dispensed ICS (R03BA, R03AK) to
preschoolers were retrieved from the complete, nation-
wide Norwegian Prescription Database (NorPD) during
2004-2013. For analyses of time trends, data were
analyzed as one-year cross-sections. Longitudinal analy-
ses of age at starting ICS treatment, discontinuation and
re-initiation were performed. Results were stratiﬁed by
age and gender.
Results: One-year prevalence of ICS use increased for all
age groups and gender from 2004-2010. Prevalence was
highest in 2-year olds and was higher among boys than
girls for all ages. Higher shares of the youngest children
received only one prescription per year. In longitudinal
analyses of children born in 2005, 45-63% received ICS
in the ﬁrst year following their initial ICS prescription.
Among children starting use of ICS in their ﬁrst two
years of life, 12-17 % received ICS in each year up to
5 years age. 31% of pre-schoolers received ICS from
paediatric specialists, 14% from other specialists, and
55% from physicians without specialty (2012).
Further analyses of data from 2012-2013 and longitu-
dinal analyses will be performed and presented.
Conclusions: Use of ICS in preschool children increased
in the period 2004-2010 and was highest in the early pre-
school age. Few children were receiving ICS throughout
preschool age.
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300. Serious Adverse Drug Reactions Associated with
Pneumococcal Vaccine: Experience in Thailand
Pakawadee Sriphiromya. Health Product Vigilance
Center, Nonthaburi, Thailand.
Background: The pneumococcal vaccine prevents pneu-
mococcal disease and infections from the Streptococcus
pneumoniae bacteria including pneumonia, meningitis,
and septicemia. The vaccine is not in the vaccine moni-
toring program. Adverse drug reaction (ADR) can occur
when using vaccine and there have been many factors
to make patients have chance to get ADR such as drug
interaction, elderly or underlying disease like hepatic or
renal function impairment in patients. Explore the risk
factors in Thai population is not well established but
necessary for improve patient care and generate risk
minimization in both population and individual level.
Objectives: This study is aimed to describe and charac-
terize ADRs associated with pneumococcal vaccine in
Thai patients, particularly serious adverse event as World
Health Organization deﬁnition criteria.
Methods: Retrospective observational study is the se-
lected design for this study (5 years). Exposure variables
are Pneumococcal vaccine used. Outcome variables are se-
rious ADRs which happened within the study period after
Pneumococcal vaccine use. Other important variable such
as sex, co morbidity, multiple drugs used are evaluated.
Results: A total of 68 reports related to Pneumococcal
vaccine were reported. 65% were female. 23% of these
were serious cases. Of these 1.5% was fatal or life threat-
ening. Serious reactions were found as anaphylactic
shock, pulmonary hemorrhage and cellulitis. Skin reac-
tions were reported in most of ADRs (i.e. rash, urticaria).
Conclusions: Serious reactions from Pneumococcal vac-
cine in Thai patients were anaphylactic shock, pulmonary
hemorrhage and cellulitis. Even less serious reactions were
reported, some made fatal and life threatening outcome.
Due to Pneumococcal vaccine has currently not been in the
vaccine intensive monitoring program, further speciﬁc mon-
itoring may be proposed to manage serious risk in Thailand.
301. Design of Randomized, Double-Blind, Controlled,
Multi-Centre Phase IIb Trials as Part of the EU-
Funded UNISEC Project to Assess the Safety,
Immunogenicity and Clinical Efficacy of Cross-
Seasonal Universal Influenza Vaccines with or Without
Pandemic Influenza Vaccine in Healthy Adults
Heng Liu,1 Stuart Robinson,2 Tamar Ben-Yedidia,3
Wilson Caparros-Wanderley,2 Tanya Gottlieb,3 Ron
Babecoff,3 Ed Schmidt,4 Anke Huckriede,5 Eelko Hak.1
1PharmacoEpidemiology and PharmacoEconomics,
University of Groningen, Groningen, Netherlands;
2SEEK, London, United Kingdom; 3BiondVax, Ness
Ziona, Israel; 4Pharmaceutical Technology and
Biopharmacy, University of Groningen, Groningen,
Netherlands; 5Department of Medical Microbiology,
University Medical Center Groningen, Groningen,
Netherlands.
Background: Current inﬂuenza vaccines mainly
induce immune responses against viral membrane
glycoproteins, which undergo continuous mutations
through antigenic drift. To prevent immune escape,
annual vaccination with the latest predicted viral
strains is adopted. Such vaccination strategy is incon-
venient and cost-inefﬁcient. Moreover, poor protective
effectiveness is observed when there is antigenic
mismatch between vaccine strains and actual epi-
demic strains. This is especially of concern during a
pandemic outbreak, when large populations are
affected by the newly re-assorted viral strain derived
from antigenic shift.
Objectives: To design phase IIb studies to evaluate
the safety, immunogenicity and cross-seasonal clinical
efﬁcacy of two universal inﬂuenza vaccines (Flu-v
and M-001) targeting different conserved epitopes of
inﬂuenza viruses. The tested epitopes are identiﬁed
from the viral surface glycoproteins as well as the
viral internal (structural) proteins. Moreover, these
epitopes are consistently expressed on both inﬂuenza
A and B viruses.
Methods: In two separate trials, a total of 1500 healthy
adults will be recruited from multiple centers in Europe
and randomized to receive placebo or the tested inﬂu-
enza vaccines at low or high antigen doses through a
double-blind procedure. Two parenteral administrations
will be given with a 21 day interval. In one trial, addi-
tional administrations of pandemic inﬂuenza vaccine
will be given 21 and 42 days after the second adminis-
tration. Clinical symptom scores and adverse events
(AEs) will be collected from AE diary card. Humoral
and cellular immune correlates of protection will be
assessed. The (severity of) incident RT-PCR-conﬁrmed
inﬂuenza infection will be recorded over two subsequent
inﬂuenza seasons.
Conclusions: Universal inﬂuenza vaccines are urgently
needed to increase protection among vulnerable groups.
Vaccine trial design needs to incorporate safety,
correlates of protection and clinical efﬁcacy.
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302. Tolerability Survey of a Two-Dose Pandemic
Vaccine [Focetria®], Administered after the Seasonal
2009-2010 Inﬂuenza Vaccination in the Netherlands
Sarah Godefrooij,1,2 Nicoline AT van der Maas,1 Hester
E de Melker,1 Jeanet M Kemmeren.1 1Centre for
Infectious Disease Control, National Institute for Public
Health and the Environment, Bilthoven, Netherlands;
2Health Sciences, VU University Amsterdam, Amsterdam,
Netherlands.
Background: During the 2009 inﬂuenza A (H1N1) pan-
demic, pandemic vaccine [Focetria®] was used in the
Netherlands as a preventive measure. However, extensive
information about the tolerability of this new adjuvanted
inﬂuenza vaccine was lacking.
Objectives: To assess the tolerability of the pandemic
inﬂuenza A(H1N1) vaccine, administered in a two-dose
regime after the seasonal vaccination in November -
December 2009.
Methods: In this dynamic cohort study, adults aged 18 or
older, living in the center of the Netherlands and who
were eligible for inﬂuenza vaccination, were asked for
participation. After agreement (n = 3251), they were
asked to report in questionnaires the local and systemic
adverse events (AEs) that developed within one week
after seasonal and pandemic inﬂuenza vaccinations,
respectively. Proportions of local and systemic AEs were
calculated with 95%CI. Risks were calculated by means
of a logistic GLMM.
Results: 5553 questionnaires were returned. Participants
experienced signiﬁcantly less local reactions after the
ﬁrst dose of the pandemic vaccine than after the seasonal
vaccine (OR 0.47; 95%CI 0.38-0.57 for women, and OR
0.62; 95%CI 0.48-0.80 for men). The same applied for
systemic AEs in women (OR 0.69 95%CI 0.57-0.84).
For men, no decreased risk for systemic AEs was found
(OR 0.99; 95%CI 0.77-1.26). Both men and women
experienced less local (OR 0.53; 95%CI 0.38-0.70 and
OR 0.34; 95% CI 0.27-0.42, respectively) and systemic
(OR 0.48; 95%CI 0.35-0.65 and OR 0.45; 95% CI
0.35-0.56, respectively) AEs after the second dose of
the pandemic vaccination compared to the seasonal
vaccination.
Conclusions: This study shows signiﬁcant lower
frequencies of AEs following the two-dose pandemic
vaccine compared to the seasonal 09/10 inﬂuenza
vaccine, and most events were mild to moderate.
However, the tolerability of the pandemic vaccine may
be inﬂuenced by the seasonal inﬂuenza vaccine that pre-
ceded the ﬁrst dose of pandemic inﬂuenza vaccine.
303. Assessment of Vaccination Rates among Children
Within the Humedica EHR Database, 2007-2013
Anthony P Nunes, Florence T Wang, Yan Ding,
Robin C Clifford, Nancy D Lin. Epidemiology, Optum,
Waltham, MA, United States.
Background: Electronic health records (EHR) may serve
as a source of detailed clinical notes and measures,
capturing vital signs, lab values and rationale behind
medical decisions. The Humedica EHR Database is a
new health information platform which pools clinical
data from the EHRs of 195 hospitals, >40,000 physi-
cians, and 28,600,000 patients in the U.S., representing
information from integrated delivery networks as well
as single provider practices. In addition to information
on diagnoses, procedures, medications, and laboratory
results, physician notes can be queried using natural
language processing.
Objectives: As a ﬁrst step toward assessing the research
potential of the Humedica EHR Database for immuniza-
tion safety evaluation, we characterize the availability
of information on childhood immunizations and related
documentation (e.g., select adverse events) from the
structured clinical information within this database.
Methods: Using a de-identiﬁed 5% random sample of the
Humedica EHR Database spanning January 2007-March
2013 (n= 987,538), we identiﬁed children with at least
one well-baby visit prior to 1 year of age and at least one
well-child visit between age 1-3 years. Childhood immuni-
zations (DTaP, PCV, IPV, Hib) occurring on or prior to the
last observed well-child visit were identiﬁed on the basis of
CPT codes. Indicators were created for the occurrence of at
least 1 vaccination and for up-to-date status for speciﬁc
vaccine series among children aged 1-3 years.
Results: A total of 8,929 children were identiﬁed, of
whom 90% had 1+ doses of DTaP, 85% had 1+ IPV,
90% had 1+ PCV, and 89% had 1+ Hib. 71%, 63%,
70%, and 80% of children had 3+ DTaP, 3+ IPV, 3+
PCV, and 2+ Hib, respectively.
Conclusions: Childhood vaccination rates observed in
the Humedica EHR Database are lower than national
coverage estimates and are consistent with single
provider immunization record-based assessments.
Supplementation of existing structured data with clinical
notes from free text ﬁelds may provide valuable
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information for safety surveillance in appropriately
deﬁned study populations of interest.
304. Impact of Vaccine Effectiveness on Signal
Detection Based on Disproportionality
Lionel Van Holle, Iris De Ryck. Vaccine Clinical Safety
and Pharmacovigilance, GlaxoSmithKline Vaccines,
Wavre, Belgium.
Background: Vaccines have different levels of efﬁcacy
and effectiveness. Furthermore, the chance of exposure
to the pathogen(s) targeted by a speciﬁc vaccine varies
greatly. Consequently, the proportion of lack of efﬁcacy
events (LOEEs) reported in spontaneous reporting
systems (SRS) differs between vaccines.
Objectives: Evaluate whether the disproportionality
measures for events not indicating LOE are affected by
the different proportions of LOEEs between vaccines.
Methods: We used the Standardized MedDRA Query
(SMQ) LOE for identifying LOEEs. We redesigned the
classical 2x2 contingency table used in disproportionality
into a 2x3 table integrating the SMQ LOE as a masking
class of events. For the Proportional Reporting Ratio
(PRR), we deﬁned a masking ratio that quantiﬁes the
masking effect induced by LOEEs.
Results:Within the GlaxoSmithKline (GSK) SRS, 52.6%
of the events reported after vaccination against varicella in-
fection were LOEEs, whereas for the other GSK vaccines
the proportion of LOEEs among reported events was only
5.7% on average. The masking ratio induced by LOEEs
was quantiﬁed as (1-0.057)/(1-0.526) = 1.989. Thus, for
the varicella vaccine, the PRR estimates for non-LOEEs
are twice as small as they would have been if all 20
reported LOEEs had been removed from the SRS before
calculating the PRR for each MedDRA Preferred Term.
Conclusions: The masking effect induced by LOEEs
may be important for vaccines presenting a high propor-
tion of LOEEs compared to the other vaccines in the
SRS. The masking ratio allows a precise estimation of
the magnitude of this bias and a potential correction.
305. Detection and Validation Strategy of Herpes
Zoster (HZ) Cases for a Vaccine Effectiveness Study
in a Managed Care Organization Database
Patricia Saddier,1 John Hansen,2 Joan Bartlett,2 Edwin
Lewis,2 Bruce Fireman,2 Laurie Aukes,2 Morgan Marks,1
Roger Baxter.2 1Epidemiology Department, Merck Sharp
& Dohme, Corp., Whitehouse Station, NJ, United States;
2Kaiser Permanente Vaccine Study Center, Oakland, CA,
United States.
Background: Zostavax™, a live zoster vaccine, is approved
in many countries for the prevention of HZ and postherpetic
neuralgia (PHN), its main long-lasting pain complication.
Duration of protection is being assessed through a long-term
vaccine effectiveness study conducted in a U.S. managed
care organization. Thousands of HZ cases are expected to
occur over the anticipated ~15years of study surveillance.
Objectives: To design an optimal strategy for the detection
and validation of HZ cases that minimizes medical chart
review while maximizing positive predictive value (PPV).
Methods: First, an informal chart review of >300 poten-
tial cases was performed to get a good understanding of
the varying existing HZ disease management situations.
Using combinations of diagnosis, treatment and procedure
codes from the managed care organization’s computerized
healthcare databases, these clinical situations were trans-
lated into corresponding mutually exclusive diagnosis
“buckets”. All potential HZ cases were then automatically
classiﬁed into one of these buckets. Representative sam-
ples of medical charts from each bucket were reviewed
and diagnosis was adjudicated by physicians according
to a pre-speciﬁed procedure to assess PPV.
Results: A total of ~41,000 potential HZ cases occurred
among the managed care organization’s members 50 years
of age or older in 2007-2012. A majority (~90%) were
classiﬁed into diagnosis buckets for which the PPV was
>90% while ~10% of potential HZ cases will require var-
ious levels of medical record review for conﬁrmation. This
includes ~4% that were hospitalized, ~3% that may
have consulted for PHN but not for the acute HZ episode,
and~ 3% that had only 1 diagnosis code without antiviral
therapy or indication of differential diagnosis.
Conclusions:HZ diagnosis as determined by the proposed
strategy will have excellent speciﬁcity without requiring
extensive resources. The reliability of this strategy will
need to be evaluated over time, in both vaccinated and
unvaccinated subjects, to assess possible drift and adjust
it as needed to changes in standard of care.
306. Effectiveness of the 2009 Pandemic H1N1
Influenza Vaccines in Preventing H1N1 Infection: A
Meta-Analysis
Songul Bozat-Emre,1 Xibiao Ye,1,2 Adrienne Morrow,1
Natalie Casaclang,1 Salaheddin M Mahmud.1,2 1Vaccine and
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University of Manitoba, Winnipeg, MB, Canada;
2Winnipeg Regional Health Authority, Winnipeg,MB, Canada.
Background: Effectiveness of the pandemic H1N1
(pH1N1) vaccines in preventing H1N1 infection during
the 2009 pandemic season remains controversial despite
many epidemiological studies.
Objectives: We aimed to conduct a systematic meta-
analysis of epidemiological studies to examine both the
strength and the consistency of association, and to
explore sources of variability between studies.
Methods: We searched multiple computerized literature
databases for studies published from January 1st, 2009
to October 31st, 2013. We also screened the bibliogra-
phies of the identiﬁed publications for additional
citations. The outcomes were laboratory-conﬁrmed
H1N1 infection, inﬂuenza related illnesses, and hospital-
ization due to laboratory-conﬁrmed H1N1 infection, and
the exposure was receipt 2009 pH1N1 vaccine. Two
researchers independently reviewed the studies meeting
our inclusion criteria. We derived pooled vaccine effec-
tives (PVE) using random effects models, and used
Cochran’s Q test and I2 to assess for heterogeneity
among the pooled studies. We also performed additional
subgroup analyses to explore other sources of the hetero-
geneity between the combined studies.
Results:We screened 460 articles and identiﬁed 43 eligible
studies. The adjuvanted pH1N1 vaccine had a PVE of 93%
(95%CI 80-98%) in preventing laboratory-conﬁrmed H1N1
infection, 56% in preventing hospitalization with labora-
tory-conﬁrmed H1N1 infection, and 13% in preventing
inﬂuenza-related illnesses. Consistently, the unadjuvanted
pH1N1 vaccine was moderately effective against these
outcomes. Overall, pH1N1 vaccines were particularly
effective among the pediatric (age <18years) population
(PVE 98%, 95%CI 62-100%) and among countries located
in the northern hemisphere (PVE 88%, 95%CI 77-94%).
Conclusions: The current epidemiological evidence suggests
the effectiveness of the 2009 pH1N1 vaccine in preventing
laboratory-conﬁrmed H1N1 infection, especially among the
pediatric population and in the northern hemisphere.
307. Linkage of the Vaccination Registration
Praeventis with the IPCI Medical Record Database
in the Netherlands - A Pilot Study
Jeanet M Kemmeren,1 Johan van der Lei,2 Petra Oomen,1
Hester E de Melker,1 Miriam Sturkenboom.2 1Center for
Infectious Disease Control, National Institute for Public
Health and the Environment, Bilthoven, Netherlands;
2Medical Informatics, Erasmus Medical Center Rotterdam,
Rotterdam, Netherlands.
Background: Linkage of GP consultations from a
population-based medical record database i.e. the
Interdisciplinary Processing of Clinical Information
(IPCI) with vaccination data of children from the
vaccination registry (Praeventis) is a potential tool for
safety and effectiveness research.
Objectives: The purpose of this study is to conduct the
feasibility and reliability for linkage of these two
registries.
Methods: Children aged 0-5 years with the diagnosis
febrile convulsion or limb fracture registered in IPCI in
the period 2005-2008 were linked to vaccination data of
the same time period in Praeventis. These diseases are
chosen because of their expected true positive (febrile
convulsions) or true negative (limb fracture) relationship
to vaccination. Linkage was based on birth date, four
digit postal code, ﬁrst character of the ﬁrst name and
gender. The data were analyzed by means of a self-
controlled case series design.
Results: The results indicated a signiﬁcant relationship
between DTaP-IPV/(-Hib) whether or not combined with
pneumococcal vaccination and the occurrence of febrile
seizures (RR= 8.2 95% CI 2.0 to 34.1). The same applies
for MMR vaccination (RR=6.5, 95% CI 2.4 to 17.8). No
children with a limb fracture were diagnosed in the risk
period after vaccination.
Conclusions: The results of this linkage study conﬁrm
the known true-positive relation between vaccination
and febrile convulsion and the true-negative relation
between vaccination and limb fracture. So, linking
Praeventis with IPCI seems to be a valid tool for
effectiveness and safety studies with a limited follow-up
period.
308. Safety of Rotavirus Vaccines: Analysis of Adverse
Events Reported Under Reexamination System and
Spontaneous Reporting System in Korea
Je-Yon Kim,1 Jong-Mi Seong,1 Byung-Joo Park.1,2
1Drug Safety Information II, Korea Institute of Drug
Safety and Risk Management, Seoul, Republic of
Korea; 2Department of Preventive Medicine, Seoul
National University College of Medicine, Seoul, Republic
of Korea.
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Background: Rotavirus vaccines (Rotateq(RV5), Rotarix
(RV1)) are new drugs in 6 years of intensive monitoring
under reexamination system in Korea. Safety issues arose
regarding adverse events (AE) such as intussuception
associated with these vaccines. For safer use of rotavirus
vaccines, better understanding of postmarketing safety
proﬁle of rotavirus vaccines is needed.
Objectives: The aim of this study was to detect serious
and unexpected signal of the two rotavirus vaccines using
KAERS (Korea Adverse Event Reporting System)
database. We assessed whether serious adverse events
(SAE) or unexpected events occurred after the vaccination.
Methods:We assessed reports submitted under reexami-
nation system and domestic spontaneous reports between
1989 and December 2013. We analyzed the frequency of
SAE reports and identiﬁed intussuception cases. Propor-
tional reporting ratio (PRR) was also used to detect
signals of RV5 and RV1. An event which met following
criteria was deﬁned as signal; PRR ≥ 2, chi-squared ≥ 4,
number of report ≥ 3. We then assessed whether the
detected signals were listed on the labels or not.
Results: Between 1989 and December 31, 2013, KAERS
received 457,190 reports in total. For RV5, 1,185 reports
were received and 1,499 reports for RV1. There were
24 SAE after RV5 vaccination including intussuception
(3 reports) and Kawasaki disease (1 report). Among 40
detected signals for RV5, 22 events were not listed on
the label including upper respiratory infection (PRR
33.23), asphyxia (3.93), infection viral (2.00). There
were 46 SAEs after RV1 vaccination, also including
intussuception (1 report) and death (1 report). The
number of unexpected events for RV1 was 32, including
upper respiratory infection (PRR 342.12), pharyngitis
(64.88), pneumonia (49.39).
Conclusions: The serious and unexpected AEs detected
need further monitoring. The reported intussuception
were low; however, a substantial number of reports indi-
cate signs and symptoms possibly suggestive of gastroin-
testinal illness. The signal for intussuception requires
further evaluation to determine whether the drug plays a
part in the development of gastrointestinal illness.
309. Adverse Events Following Rabies Pre- and Post-
Exposure Prophylaxis in Taiwan, July–December 2013
Wan-Ting Huang,1 Chi-Hsi Chang,1 Wei-I Huang,2
Ding-Ping Liu.1 1Taiwan Centers for Disease Control,
Taipei, Taiwan; 2Taiwan Drug Relief Foundation,
Taipei, Taiwan.
Background: Taiwan eliminated canine rabies and has
been considered rabies free since 1961. In July 2013,
the agricultural authorities identiﬁed three rabid ferret-
badgers captured in 2012. In response to the re-
emergence, Taiwan Centers for Disease Control (TCDC)
issued guidance on rabies pre- (PrEP) (three doses of
cell-culture vaccines [CCVs] on days 0, 7, and 28) and
post-exposure prophylaxis (PEP) (ﬁve doses of CCVs
on days 0, 3, 7, 14, and 28, with or without rabies
immune globulin [RIG]) as part of the contingency plans.
Objectives: To characterize adverse events (AEs) in
rabies PrEP and PEP recipients.
Methods: TCDC and Taiwan Food and Drug Adminis-
tration collaborated on the national passive vaccine safety
surveillance. We reviewed reports of AEs after RIG or
rabies CCVs, for the period from July to December
2013. We also provided assistance on the management
of potentially serious adverse events (SAEs) and assessed
compliance with subsequent PrEP or PEP administration.
Results: The overall reporting rate was 4.7 per 10,000
vaccine doses administered. Of the 23 AE reports, none
were classiﬁed as anaphylaxis, Guillain-Barré syndrome,
or acute disseminated encephalomyelitis. The two SAE
reports involved a boy, aged 2 years, hospitalized for
acute bronchiolitis 2 days following the third PEP dose
of CCV; and a male, aged 66 years, with signiﬁcant
weight loss in 6 days following the ﬁrst PEP dose of
CCV and diagnosed with pulmonary tuberculosis.
Among the 21 nonserious reports, the most frequently
reported AEs were rash (n = 8), dizziness (n = 5), and
pruritus (n = 4). Seven (30%) patients, including four
PEP recipients who reported nonserious AEs, did not
complete the required vaccination series.
Conclusions: Most reported AEs were nonserious and
consistent with those identiﬁed during clinical trials or
postlicensure studies. The risk of acquiring rabies must
be carefully considered before PEP discontinuation.
310. The Association Between Pneumococcal Vaccine
and Thrombocytopenia in Elderly Patients with
Chronic Obstructive Pulmonary Disease: A Case-
Crossover Study
Piyameth Dilokthornsakul,1,2 Todd A Lee.2 1Center of
Pharmaceutical Outcomes Research, Faculty of Pharma-
ceutical Sciences, Naresuan University, Muang,
Phitsanulok, Thailand; 2Center for Pharmacoepidemiology
and Pharmacoeconomic Research, College of Pharmacy,
University of Illinois at Chicago, Chicago, IL, United States.
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Background: Pneumococcal vaccine is recommended
for elderly patients with chronic obstructive pulmonary
disease (COPD). Several previous studies revealed the
association between pneumococcal vaccines and
thrombocytopenia but some did not show the association.
A controversy over the risks of pneumococcal vaccine on
thrombocytopenia still remains.
Objectives: This study aimed to determine the associa-
tion between the pneumococcal vaccine and thrombocy-
topenia related emergency department (ED) visit or
hospitalization in elderly patients with COPD.
Methods: A case-crossover study using a claim database
was undertaken. COPD patients aged 65 or older who
visited ED or admitted with thrombocytopenia were
included. The event of interest was thrombocytopenia
related ED visit or hospitalization. A window period for
determining pneumococcal vaccine receipt was 35 days.
A case period was day1to day35 before the event. Two
referent periods were day71 to day105 and day366 to
day400 before the event. Conditional logistic regression
was used to determine the association. Sensitivity
analyses were performed by varying the window period
to 7, 14, and 70 days.
Results: A total of 3,864 patients were included. Patients
were on average 78.2 ± 8.8 years of age with 59.35% of
male. A total of 15 patients (0.39%) received the vaccine
during case period and 19 patients (0.49%) received the
vaccine during referent periods. After adjusting for
inﬂuenza vaccine receipt, the risk of pneumococcal
vaccine on thrombocytopenia [odds ratio (OR)] was
1.62 [95% conﬁdence interval (95%CI); 0.82-3.20]. For
sensitivity analysis, the ORs were 5.26 (1.02-27.28),
2.37 (0.79-7.05), and 0.87 (0.55-1.38) for 7, 14, and
70 days of window periods, respectively.
Conclusions: In elderly patients with COPD, pneumo-
coccal vaccine has a trend to increase risk of ED visit
or hospitalization with thrombocytopenia, especially in
the ﬁrst 7 days of receiving the vaccine. Healthcare
providers should be aware of the risk and closely monitor
patients who recently receive pneumococcal vaccine.
311. Uptake of Influenza Vaccination in Elderly People:
Impact of Dementia Diagnosis
Adeline Gallini,1,2,3 Virginie Gardette,1,2,3 Sandrine
Andrieu,1,2,3 Maryse Lapeyre-Mestre.1,2,3 1University of
Toulouse, Toulouse, France; 2Toulouse University
Hospital, Toulouse, France; 3INSERM UMR1027,
Toulouse, France.
Background: Guidelines recommend inﬂuenza vaccina-
tion for every person aged 65 years or more in France.
Few studies have shown a lower uptake of inﬂuenza
vaccination in elderly people with dementia than in the
elderly without dementia in the UK and the US.
Objectives: We aimed to compare rates of vaccination
between elderly people with and without dementia in a
representative sample of the French population.
Methods: We conducted a closed cohort study in the
Echantillon Généraliste de Bénéﬁciaires (claims from a
1/97th random sample of the French population).
Exposed subjects were 65 years or older and identiﬁed
with an incident dementia between 1/07/2007 and 31/
08/2008 (registration with chronic condition ALD15;
≥ 2 dispensing of any antidementia drugs; diagnosis in
F00-F03, G30, G31 (ICD10 codes) during≥ 1 hospital
stay). Unexposed subjects were a 1/10th random
sample of subjects 65 years or older without dementia. Vac-
cination status (dispensing of a drug with ATC code in
J07BB) was recorded until 31/12/2012 or subject’s death
or institutionalization. Annual prevalence of vaccination in
exposed and non-exposed subjects was estimated for the 4
following vaccination seasons. We will perform a multivar-
iate analysis of associated factors to vaccination uptake.
Results: Patients with dementia (n= 451) were older
(mean: 82.0 years ± 6.5 vs. 75.7 ± 6.9; p< 0.0001) and
more frequently female (69% vs. 62%; p = 0.002) than sub-
jects without dementia (n= 5339). During the 1st vaccina-
tion season following baseline, vaccination coverage was
70.4% vs. 69.5% in subjects with and without dementia,
respectively. Controlling for age, patients with dementia
tended to be less vaccinated than subjects without dementia
(Odds Ratio OR=0.85; 95%CI [0.67-1.07]). This OR
remained stable for the 3 following vaccination seasons.
Conclusions: Controlling for age, we did not observe a
lower inﬂuenza vaccination uptake among French elderly
patients with dementia compared to elderly subjects
without dementia living primarily in the community. This
result must be conﬁrmed by the multivariate analysis of
factors inﬂuencing vaccination.
312. Design and Feasibility of a Study Using the
Clinical Practice Research Datalink General Practice
OnLine Database (CPRD GOLD) To Assess the Risk
of New Onset of Auto-Immune Diseases (NOAD)
Following Administration of the Human Papillomavirus
(HPV)-16/18 AS04-Adjuvanted Vaccine
Dominique Rosillon,1 CorinneWillame,1 Manel Pladevall,2
Julia Zima,1 Judith H van den Bosch,3 Eveline Bunge,3
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Tjeerd van Staa,4 Rachael Boggon,5 Laurence Baril.1
1GlaxoSmithKline Vaccines, Wavre, Belgium; 2RTI Health
Solutions, Barcelona, Spain; 3Pallas Health Research
and Consultancy, Rotterdam, Netherlands; 4London
School of Hygiene and Tropical Medicine, London,
United Kingdom; 5CPRD Research Group, London,
United Kingdom.
Background: The HPV-16/18 AS04-adjuvanted vaccine
is indicated for protection against cervical cancer. When
assessing the risk of rare events such as NOAD in
vaccinated populations, large computerised clinical
databases could be a valuable alternative to prospective
ﬁeld studies.
Objectives: To assess the feasibility of using CPRD
GOLD to evaluate the risk of NOAD in adolescent and
young adult women aged 9–25 years in the UK, after ad-
ministration of the HPV-16/18 AS04-adjuvanted vaccine.
Methods: This observational study (NCT01953822)
deﬁnes 4 cohorts (65,000 subjects each) in CPRD
GOLD: 1 exposed female cohort (receiving ≥1 dose of
HPV-16/18 vaccine Sep2008–Aug2010); and 3 unex-
posed cohorts: 1 concurrent male, 1 historical
(Sep2005–Aug2007) male and 1 historical female. The
male cohorts are internal controls for changes over time
in reporting NOAD. Cases of pre-speciﬁed AD (using
CPRD GOLD clinical terms) will be captured using
pre-deﬁned algorithms and conﬁrmed by blinded inde-
pendent experts by reviewing subject proﬁles, free text
and hospital episode statistics available. Study feasibility
was performed before study start.
Results: The feasibility assessment conﬁrmed that CPRD
GOLD contains a sufﬁcient number of eligible subjects to
deﬁne the 4 cohorts. Overall incidence rates of NOAD in
the target population were close to estimates previously
reported. Case ascertainment of a random sample of 55
potential cases of auto-immune disease (AD) classiﬁed
13 cases as non-conﬁrmed AD (including 7 cases of
uveitis/iritis), 4 as non-AD, and 38 as conﬁrmed AD.
The positive predictive value of the algorithms was 69%.
Conclusions: CRPD GOLD is an adequate resource to
assess the risk of rare events such as NOAD in a large
vaccinated population. This feasibility assessment
showed the need to have a robust case ascertainment
method to increase clinical endpoint speciﬁcity. The
positive output from this assessment resulted in study
initiation (now ongoing).
Funding: GlaxoSmithKline Biologicals SA.
313. Impact of Right Truncation in Studies of Drug
Safety during Pregnancy
Sonia Hernández-Díaz,1 Brian Bateman,2,3 Krista
Huybrechts.2 1Department of Epidemiology, Harvard
School of Public Health, Boston, MA, United States;
2Division of Pharmacoepidemiology and Pharmaco-
economics, Brigham and Women’s Hospital; Harvard
Medical School, Boston, MA, United States; 3Department
of Anesthesia, Critical Care, and Pain Medicine,
Massachusetts General Hospital, Boston,MA, United States.
Background: Right truncation occurs when follow-up
ends with unknown outcomes (e.g., terminations with-
out fetal autopsy) or before an outcome can occur
(e.g., preterm delivery before preeclampsia develops).
It can affect both opportunity for exposure (e.g., third
trimester exposures in relation to outcomes associated with
shorter gestation) and outcome classiﬁcation (e.g., longer
follow up after birth allows identiﬁcation of subclinical
congenital defects).
Objectives: To illustrate how sensitivity analyses can be
used to quantify the impact of right truncation.
Methods: In a cohort of pregnancies with live births
from 2000-2007 US Medicaid data, among the 100,942
women with depression, we calculated the relative risk
(RR) and 95% conﬁdence intervals (CI) of cardiac
defects associated with selective serotonin reuptake
inhibitors (SSRIs) use during the ﬁrst trimester with
propensity score adjustment to control for potential
confounders. We quantiﬁed the potential selection bias
introduced by missing terminations. Informed by the
literature, the probability of termination was assumed
to be 20% for fetuses without a cardiac malformation
(i.e. for social reasons), and 30% for fetuses with cardiac
malformations; with ranges considered around these
estimates. We examined the effect of SSRI users having
termination frequencies for malformations from 20%
lower to 20% higher than non-users.
Results: The adjusted RR for any cardiac defect was 1.06
(95% CI 0.93-1.22). The combination of the four
selection probabilities resulted in broad ranges for the
magnitude of the potential selection bias. Only under
extreme scenarios of at least 45% of infants with
cardiac malformations terminated among non-SSRI
users and 65% terminated among SSRI users would the
RR be >1.2.
Conclusions: The differences in the proportion of termi-
nations among women with depression on SSRIs vs.
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those untreated within levels of covariates used in the ad-
justment would have to be unrealistically strong in order
to dilute the previously hypothesized RR of 1.5 or higher.
Bias in RR estimates can be introduced if the outcome af-
fects retention into the cohort. The magnitude of the po-
tential bias can be quantiﬁed using sensitivity analyses.
314. Comparative Safety of Depression Treatments in
Late Pregnancy for the Neonate
Krista Huybrechts,1 Brian Bateman,1,2 Raisa Levin,1
Helen Mogun,1 Sonia Hernández-Díaz.3 1Division of
Pharmacoepidemiology and Pharmacoeconomics,
Brigham and Women’s Hospital, Boston, MA, United
States; 2Department of Anesthesia, Critical Care, and
Pain Medicine, Massachusetts General Hospital, Boston,
MA, United States; 3Department of Epidemiology, Harvard
School of Public Health, Boston, MA, United States.
Background: Selective serotonin reuptake inhibitor
(SSRI) antidepressant use near delivery has been associated
with an increased risk of neonatal withdrawal syndrome.
Since severe depression often requires pharmacologic treat-
ment, a clinical relevant question is whether speciﬁc antide-
pressants are associated with different risks.
Objectives: To evaluate the safety of depression treat-
ments in late pregnancy for the neonate.
Methods:We identiﬁed a cohort of 949,504 pregnancies
among women enrolled in Medicaid from 2000-2007.
Women were classiﬁed according to pharmacy dispens-
ings as exposed to SSRI and non-SSRI therapy during
the 3rd trimester. Women with no dispensing for antide-
pressants at any point during pregnancy were deﬁned as
unexposed. We estimated propensity scores (PS) based
on mental and medical conditions - which might be asso-
ciated with illicit exposure to medications that cause
withdrawal - and licit medications which may cause neo-
natal withdrawal. Neonatal withdrawal was deﬁned as the
presence of ICD-9 779.5 in infant claims within 30 days
following delivery. The risk of neonatal intensive care
unit (NICU) admissions was also evaluated. We esti-
mated relative risks (RR) and 95% conﬁdence intervals
(CI) stratiﬁed by PS.
Results: The risk for neonatal withdrawal was 1.9 per
1,000 among women unexposed to antidepressants.
Compared to unexposed women, the RR for neonatal
withdrawal among women exposed to SSRIs was 6.2
(CI: 5.5-6.9); it was 13.3 (10.1-17.5) for serotonin-
norepinephrine reuptake inhibitors (SNRIs) and 12.4
(8.9-17.3) for tricyclic antidepressants. After stratifying
on PS, the RRs were 2.2 (1.8-2.6), 3.0 (1.7-5.5), and
2.8 (1.4-5.6) respectively. Within antidepressant users,
compared to SSRIs, the adjusted RRs were 1.1 (0.8-1.7)
for SNRIs and 1.5 (1.0-2.2) for tricyclic antidepressants.
The risk of NICU admission was increased 30%-50%
by all antidepressants.
Conclusions: In this population of low income individ-
uals in the US, neonates born to women on antidepres-
sants had an elevated risk of withdrawal syndrome and
NICU admission. The association was found for all
antidepressant classes and was partially explained by
concomitant use of other psychotropic medications.
315. Teratogenicity of Selective Serotonin-Reuptake
Inhibitors and Venlafaxine – A Population-Based
Study of 2.3 Million Births in Five Nordic Countries
Kari Furu,1 Helle Kieler,2 Bengt Haglund,2 Helga
Zoega,3 Mika Gissler,4 Mette Nørgaard.5 1Norwegian
Institute of Public Health, Oslo, Norway; 2Karolinska
Institutet, Stockholm, Sweden; 3University of Iceland,
Reykjavik, Iceland; 4National Institute for Health and
Welfare, Helsinki, Finland; 5Aarhus University Hospital,
Aarhus, Denmark.
Background: Several studies have evaluated teratogenic-
ity of the selective serotonin-reuptake inhibitors (SSRIs)
with conﬂicting results. Only few studies have included
sufﬁcient numbers to examine the association of speciﬁc
SSRIs or venlafaxine and speciﬁc birth defects.
Objectives: By using a large cohort from ﬁve Nordic
countries we examined whether use of selective serotonin
reuptake inhibitors (SSRIs) or use of venlafaxine during
early pregnancy are associated with increased risks of
speciﬁc birth defects.
Methods: We conducted a study linking nationwide
health register data from the Nordic countries including
all live born singletons between 1996 and 2010. By means
of logistic regression analyses prevalence of major birth
defects following maternal use of SSRIs or venlafaxine
were compared with those found for infants unexposed
in utero. The main focus was on cardiac defects.
Results: Among 36,772 infants exposed to any SSRI,
1,357 (3.7%) had a birth defect diagnosis compared with
3.1% of the 2,266,875 infants not exposed to any antide-
pressants in utero (adjusted odds ratio (OR) 1.13; 95%
conﬁdence interval 1.06 to 1.20). The adjusted ORs for
use of any SSRI were 1.15;1.05 to1.26 for cardiac birth
defects, and 1.17;1.05 to1.31 for septal defects. All types
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of SSRIs seemed to increase the risk of right ventricular
outﬂow tract obstruction with adjusted ORs ranging from
1.40; 0.81 to 2.42 to 2.54; 1.31 to 4.90. Citalopram and
sertraline were both associated with increased risk of
clubfoot, and sertraline also with increased risk of anal
atresia. Use of venlafaxine did not increase the risk of nei-
ther cardiac birth defects overall nor septal defects. We
found no increased risk of hypospadias, limb-reduction,
craniosynostosis, or cystic kidneys associated with
exposure to any SSRIs.
Conclusions: In this large dataset we observed a small
increase in prevalence of cardiac birth defects, particu-
larly right ventricular outﬂow tract obstructions, among
infants exposed to SSRIs in utero.
316. Use of Antidepressants during Pregnancy and the
Risk of Pregnancy-Induced Hypertension
Fianne MAM van Loveren,1 Monique Boekema,1 Eelko Hak,1
Jens HJ Bos,1 Jan G Aarnoudse,2 Catharina CM Schuiling-
Veninga.1 1Pharmacoepidemology & Pharmacoeconomics,
University of Groningen, Groningen, Netherlands; 2Obstet-
rics and Gynaecology, University Medical Center
Groningen, Groningen, Netherlands.
Background: Pregnancy-induced hypertension (PIH) is
possibly caused by an increased activity of the sympatic
nervous system. Previous studies have suggested that
inhibition of the re-uptake of serotonin and norepinephrine
by selective serotonin re-uptake inhibitors (SSRIs) and
tricyclic antidepressants (TCAs) could contribute to this
increased activity.
Objectives: To assess the association between the use of
antidepressants (ADs) and the development of pregnancy-
induced hypertension.
Methods: Using the prescription database IADB.nl we
conducted a case-control study among pregnant women
between 1995 and 2012. Cases were deﬁned as> 1
dispensed prescription of an antihypertensive drug (meth-
yldopa, dihydralazine, ketanserin, labetalol, niﬁdepine)
after 20weeks of gestation. Controls were matched for
age at time of giving birth. Only ﬁrst and singleton
pregnancies of women not using any antihypertensive drug
during 6months before pregnancy till 20weeks of gesta-
tion were included. Exposure was deﬁned as> 1 dispensed
prescription of an antidepressant during pregnancy.
Logistic regression analysis was used to estimate odds
ratios (OR) and their corresponding 95% conﬁdence
intervals (95% CIs). Subanalyses were conducted for
class of AD (TCA, SSRI, other) and duration of AD use
(1-30, ≥ 31 Deﬁned Daily Doses (DDDs)). As the exact
duration of gestation was unknown, all analysis were con-
ducted for 3 theoretical gestational ages (36, 38, 40weeks).
Results: A total of 312 PIH cases and 12480 controls
were included in the analysis (gestational age 36weeks).
The exposure rate among case and control pregnancies
was 3.2% and 1.5% respectively. The use of AD
increased the risk for developing PIH more than twice
(OR [95% CI] 2.24 [1.17-4.27]). Signiﬁcant associations
(OR [95% CI]) were also found for the subgroups TCA
(3.39 [1.04-11.08]), SSRI (2.23 [1.03-4.81]) and≥ 31
DDDs (2.38 [1.16-4.90]). Increasing the theoretical
gestational age showed comparable results.
Conclusions: Prolonged use of ADs during pregnancy ap-
peared to be associated with an increased risk of developing
PIH. When balancing the beneﬁt and risks of using these
drugs during pregnancy, this should be taken into account.
317. Use of Antidepressants and Induced Abortions:
Population Based Case-Control Study from Three
Nordic Countries
Helle Kieler,1 Kari Furu,2 Mika Gissler,3 Mette
Noergaard,4 Unnur Valdimarsdottir,5 Bengt Haglund.1
1Centre for Pharmacoepidemiology, Department of Med-
icine, Solna, Karolinska Institutet, Stockholm, Sweden;
2Division of Epidemiology, Norwegian Institute of Public
Health, Oslo, Norway; 3National Institute for Health and
Welfare, Drugs and Pregnancy, THL, Helsinki, Finland;
4Department of Clinical Epidemiology, Aarhus Univer-
sity, Aarhus, Denmark; 5Centre of Public Health Science,
University of Iceland, Reykjavik, Iceland.
Background: Use of antidepressants during pregnancy is
increasing. Knowledge concerning risks of congenital
malformations in association with use of antidepressants
is inconclusive. Risks might be underestimated if induced
abortions are not considered. Conversely, women on
antidepressants might terminate their pregnancy because
of fear concerning teratogenic effects.
Objectives: To assess whether use of selective serotonin
reuptake inhibitors (SSRIs), tricyclic antidepressants,
mirtazapine, venlafaxine and other antidepressants is
associated with risks of late induced abortion.
Methods: We conducted a case-control study, including
as cases 14 902 women with induced abortion week 12
through 23 and 148 929 matched controls with a later
induced abortion than their index case or subsequently
giving birth. Information on ﬁlled prescriptions during
abstract 167
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
pregnancy and the reason for abortion (fetal malformations,
or maternal ill health or socio-economic disadvantage) was
obtained from the national health registers in Finland,
Norway and Denmark, 1996 to 2007. Odds ratios associ-
ated with use of speciﬁc antidepressant during pregnancy
were estimated using multivariate logistic regression
analysis and adjusting for use of other teratogenic drugs.
Results: At least one prescription of antidepressants
was ﬁlled by 550 of the cases (3.7 percent) compared
with 3 275 of the controls (2.2 percent). Use of any
type of antidepressants was associated with induced
abortions due to maternal ill health or socio-economic
disadvantage (odds ratio 2.2, 95% conﬁdence interval
2.0 to 2.5). Induced abortion due to fetal malformations
was associated with use of mirtazapine (2.2, 1.1 to 4.5)
There was no association between use of any of
the other antidepressants and induced abortion due to
fetal malformations.
Conclusions: Use of any type of antidepressants was
associated with late induced abortions due to maternal
ill health or socio-economic disadvantage. Except for
mirtazapine there were no associations with induced
abortions due to fetal malformations.
318. Withdrawn by Author
319. Electronic Health Data Capture of Clinical
Evaluation and Pancreatic Cancer (PC) Diagnosis
(DX) in Patients with Type 2 Diabetes (T2DM)
Mary E Ritchey, Yong Chen, Jinghua He, Samuel S
Engel, Weifeng Xu, Mellissa Yong, Kimberly G
Brodovicz. Merck & Co., Whitehouse Station, NJ,
United States.
Background: Electronic health data have been used to
evaluate PC risk associated with T2DM therapies.
However, these data may not capture complete patient
(pt) experience. Understanding data capture related to
PC dx is critical to assessing detection bias (DeB).
Objectives: Assessed capture of PC dx precursors
(i.e. imaging, abdominal pain (ABDP), jaundice (JAUN),
other signs/symptoms, risk factors, related conditions and
labs) in four groups: pts with conﬁrmed PC (SEER only, no
evaluation (eval) of T2DM), pts with T2DM (T2, no eval of
PC dx), pts with T2DM and subsequent PC dx (T2PC, no
eval of therapy), pts with T2DM on metformin initiating
sitagliptin or other therapy (DT, no eval of PC). Groups
represent pts with/without expectation of data capture;
DT allows evaluation of DeB.
Methods: Evaluated precursors in 3 databases: CPRD
(UK general practice) and MarketScan (MS, US Claims)
in 2006-2012; SEER-Medicare (SEER-US Claims,
only conﬁrmed PC) in 2001-2007. In T2, precursors
assessed for 18months after ﬁrst one seen; in T2PC,
18months prior to PC dx; in DT, imaging/labs assessed
in 18months after start of 2nd therapy and other
precursors in 12months prior. Assessed differences in
precursors for sitagliptin vs other therapies in DT.
Results: Imaging was captured in SEER and MS-T2PC
but rarely seen in CPRD-T2PC. In SEER, ABDP (67%)
and JAUN (24%) were common; all precursors noted in
>5% of pts. In T2PC, ABDP, JAUN and other precursors
were noted less often. As expected, in T2, no precursor was
>5% (most had no precursors). In DT, imagingwas seen in
16% in MS but 1% in CPRD. ABDP (12% MS, 4%
CPRD) and JAUN (8% MS; 2% CPRD) were noted infre-
quently. Differences between therapies were not noted.
Conclusions: PC precursors were seen in SEER, but less
commonly in T2PC in MS and CPRD. Limited documen-
tation was available in T2 and no differences were noted
by treatment in DT. Low proportions of precursors in DT
may reﬂect poor documentation, thus presence or
absence of DeB cannot be conﬁrmed due to (evidently)
incomplete data capture. We recommend obtaining
supplemental data when using electronic health data
for PC dx.
320. Proteinuria Testing Among Patients with
Diabetes Mellitus Is Associated with Bladder Cancer
Diagnosis: Potential for Unmeasured Confounding in
Studies of Pioglitazone and Bladder Cancer
James D Lewis,1 Laurel Habel,2 Charles Quesenberry,2
Ronac Mamtani,1 Tiffany Peng,2 Warren B Bilker,3
Monique Hedderson,2 Lisa Nessel,4 David J Vaughn,1
Brian L Strom,5 Assiamira Ferrara.2 1Medicine, Univer-
sity of Pennsylvania, Philadelphia, PA, United States;
2Division of Research, Kaiser Permanente Nothern
California, Oakland, CA, United States; 3Biostatistics and
Epidemiology, University of Pennsylvania, Philadelphia,
PA, United States; 4Center for Clinical Epidemiology and
Biostatistics, University of Pennsylvania, Philadelphia,
PA, United States; 5Rutgers Biomedical and Health
Sciences, Rutgers University, NJ, United States.
Background: The observed association between
pioglitazone and bladder cancer could be causal or due
to bias in the design of prior studies. We hypothesize that
proteinuria testing may lead to detection bias if routine
test results for proteinuria lead to a full urinalysis.
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Objectives: To determine whether patients treated
with pioglitazone are more likely to be tested for
proteinuria and to have a positive test, if a positive
proteinuria test is associated with completion of a full
urinalysis, whether completion of the urinalysis is
associated with subsequent bladder cancer diagnosis,
and the extent of bias that may result from failure to
adjust for proteinuria testing.
Methods: We re-analyzed a cohort of patients with diabe-
tes mellitus within Kaiser Permanente Northern California.
Logistic and Cox regression adjusted for age, sex, race, and
smoking were used to assess the association of proteinuria
testing with pioglitazone use, subsequent full urinalysis,
and diagnosis with bladder cancer.
Results: Patients treated with pioglitazone were more
likely than others with diabetes to undergo testing for pro-
teinuria (p< 0.001). The proportion of positive tests for
proteinuria was also higher among pioglitazone treated pa-
tients (OR=1.41, 95 CI 1.36-1.46). A positive proteinuria
test was positively associated with completion of a urinal-
ysis in the following 6months (OR=1.78, 95% CI 1.73-
1.85). Negative and positive proteinuria test results were
inversely (hazard ratio 0.63, 95% CI 0.52-0.75) and posi-
tively associated (hazard ratio 2.45, 95% CI 2.12-2.82)
with bladder cancer risk, respectively. However, adjust-
ment for negative and positive proteinuria testing reduced
the magnitude of association between pioglitazone and
bladder cancer by only 5% to 10% (ever use HR 1.06 to
1.01; >4 years of use HR 1.38 to 1.28).
Conclusions: Proteinuria testing may be a confounder in
studies of pioglitazone and bladder cancer, but does not
fully explain the association between pioglitazone and
bladder cancer in this cohort. Optimal adjustment for pro-
teinuria testing likely requires knowledge of the test result.
321. The Risk of Colorectal Cancer in Patients with
Type 2 Diabetes: Associations with Treatment Stage
and Obesity
Paulus JHL Peeters,1 Marloes T Bazelier,1 Hubert GM
Leufkens,1 Frank de Vries,1,2 Marie L De Bruin.1
1Division of Pharmacoepidemiology & Clinical Pharma-
cology, Utrecht University, Utrecht, Netherlands; 2Depart-
ment of Clinical Pharmacy and Toxicology, Maastricht
University Medical Centre, Maastricht, Netherlands.
Background: Type 2 diabetes mellitus (T2DM) has
been associated with colorectal cancer (CRC).
Chronic hyperinsulinemia may constitute a biologically
plausible explanation.
Objectives: To quantify the risk of CRC associated with
T2DM, and to evaluate additional associations between
CRC risk and T2DM treatment stage and duration of
obesity as indicators of chronic hyperinsulinemia.
Methods: We conducted a cohort study in the Clinical
Practice Research Datalink (1987-2012). All patients
(≥18 years) with at least one prescription for a noninsulin
antidiabetic drug (NIAD) or insulin (n = 300,039) were
matched (1:1) by birth year, sex, and practice to a
reference cohort without prior antidiabetic drug use.
Subjects were followed until the occurrence of CRC,
end of data collection, migration, or death. Cox propor-
tional-hazards models were used to derive adjusted
hazard ratios (aHR) and 95% conﬁdence intervals (CI).
Within the diabetic cohort we evaluated the effect of
treatment stages, based on antidiabetic drug use:
(1) current use of a single NIAD, (2) parallel use of two
or (3) more NIADs from different classes, (4) current
use of NIAD(s) combined with insulin, and (5) insulin
monotherapy. In addition, the effect of duration of
obesity (BMI ≥ 30 kg/m2) on CRC risk was determined
time-dependently during follow-up.
Results: After a median follow-up of 4.5 years, 2759
events were observed among T2DM patients (IR 1.7/
1000 py). The aHR for CRC among T2DM patients
was 1.26 (95% CI, 1.18-1.33) compared to the reference
cohort. Among T2DM patients, no association was found
with treatment stages. A trend of increased CRC risk was
observed with longer duration of obesity. Compared to
nonobese patients, an increased risk was found for
patients with recorded duration of obesity of 4 to 8 years
(aHR 1.21, 95% CI, 1.08-1.36) and over 8 years (aHR
1.29, 95% CI, 1.11-1.50).
Conclusions: T2DM was associated with a 1.3-fold
increased risk of CRC. Our results indicate that the risk
of CRC increases with duration of obesity among
T2DM patients. Future research could be directed at
determining whether the elevated risk observed here is
reversible through weight reduction.
322. Colorectal Cancer Risk in Metformin Initiators –
A Matched Cohort Study
Anne S Geier,1 Ina Wellmann,1 Jürgen Wellmann,1
Jessica M Franklin,2 Hiltraud Kajüter,3 Oliver
Heidinger,3 Georg Hempel,4 Hans-Werner Hense.1,3
1Institute of Epidemiology and Social Medicine,
Westfälische Wilhelms-Universität Münster, Münster,
Germany; 2Department of Medicine, Brigham and
Women’s Hospital, Havard Medical School, Division of
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Pharmacoepidemiology and Pharmacoeconomics,
Boston, MA, United States; 3Epidemiological Cancer Regis-
try of North Rhine-Westphalia, Münster, Germany; 4Institute
of Pharmaceutical and Medical Chemistry, Westfälische
Wilhelms-Universität Münster, Münster, Germany.
Background:Metformin (MET) has been associated with an
inhibition of colorectal cancer cell growth but observational
studies assessing the impact of MET use on colorectal cancer
risk in patients with type 2 diabetes reported conﬂicting ﬁnd-
ings. It was noted recently that the majority of these studies
suffered from time-related biases and other limitations.
Objectives: This study determined whether starting MET
is associated with colorectal cancer progression while
attempting to address the methodological shortcomings
of previous observational studies.
Methods: We conducted a matched cohort study linking
a disease management programme for type 2 diabetes
mellitus (DMP-DM2) with a population-based cancer
registry. The cohort was assembled from treatment-naive
patients who were enrolled between 2003 and 2009 and
who had no prior cancer diagnosis. MET initiators were
matched to up to three untreated controls by index dates
in terms of time since DMP enrolment, diabetes duration
at baseline, sex, age and BMI categories. Remaining im-
balances were redressed by including propensity score
weights in the estimation of hazard ratios in a Cox pro-
portional hazards model. Follow-up time was analyzed
a) in an as treated (AT) approach censoring for a new an-
tidiabetic therapy start or therapy discontinuation and b)
an intention-to-treat (ITT) approach.
Results: In AT analyses, 92 new colorectal cancer cases
occurred over 40,347 person-years of follow-up. Overall,
initiating MET was not clearly associated with colorectal
cancer risk (HR= 0.75, 95% CI [0.38-1.47]), however
natural cubic spline models indicated that cancer risk
was reduced in particular in the ﬁrst six months after
starting on MET and not later on. ITT analyses (148
cases, 64,648 person-years) conﬁrmed these results.
Conclusions: This study avoided immortal time bias and
time-lag bias and found indication of a possible initial short
term effect ofMETon cancer risk, which dissolved over time.
Study size limitations precluded more conclusive results.
323. Duration of Metformin Use and Risk of Prostate
Cancer in Men with Diabetes
Laurel A Habel, Stephen K Van Den Eeden, Lori C
Sakoda, Ninah S Achacoso, Charles P Quesenberry,
Tiffany Peng, Samantha F Ehrlich, Assiamira Ferrara.
Division of Research, Kaiser Permanente Northern
California, Oakland, CA, United States.
Background: Several observational studies have reported
a lower incidence of cancer, including prostate cancer,
among patients with diabetes treated with metformin.
Objectives: To examine the association between risk of
prostate cancer and duration of metformin use among
men with diabetes mellitus using methods that minimize
time-related biases.
Methods: We conducted a retrospective cohort study of
26,817 male health plan members of Kaiser Permanente
Northern California (KPNC) aged 40years or older who
were in the KPNC Diabetes Registry and completed a
mailed survey on health-related traits and behaviors in
1994 to 1996. Electronic pharmacy dispensing records were
used to identify prescriptions for diabetes medications.
Using the KPNC Cancer Registry, men were followed for
prostate cancer from 1997 to 2009 (median 8.2 years).
Men who had any invasive cancer diagnosed prior to 1997
(i.e., prevalent cancer) or who had used metformin prior to
1997 (i.e., prevalent users) were excluded. Cox regression
modeling, with age as the time scale, was used to estimate
relative risks (RR) of prostate cancer associated with dura-
tion of metformin use, adjusted for race/ethnicity; birth year;
income; education level; and BMI, alcohol use, smoking
status, diabetes duration, levels of hemoglobin A1c and
creatinine, and PSA testing (all evaluated prior to baseline);
and ever use of other types of diabetes medications.
Duration of metformin use, and ever use of other diabetes
medications, were modeled as time-dependent variables.
Results: During 233,002 person-years of follow-up,
1,165 patients were diagnosed with prostate cancer. The
crude and adjusted RRs for prostate cancer associated
with different durations of metformin use were almost
identical. The adjusted RR for ever use of metformin
was 1.07 (95% conﬁdence interval (CI) 0.93-1.23). The
adjusted RRs for <2.0, 2.0-4.9, and 5.0+ years of metfor-
min use were 1.14 (95% CI, 0.96-1.36), 1.00 (95% CI,
0.83-1.21), and 1.02 (95% CI, 0.82-1.26), respectively.
Conclusions: Our results do not support earlier ﬁndings of a
lower risk of prostate cancer associated with metformin use.
324. Exposure to Pioglitazone and Risk of the 10 Most
Common Cancers
Assiamira Ferrara,1 Charles P Quesenberry,1 James D
Lewis,2 Samantha F Erlich,1 Stephen K Van Den Eeden,1
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1Division of Research Kaiser Permanente Northern
California, Oakland, CA, United States; 2University of
Pennsylvania, Philadelphia, PA, United States; 3Rutgers
University, Newark, NJ, United States.
Background: Pioglitazone is a PPARγ agonist used to
treat diabetes. Studies suggest PPARγ agonists may have
either pro- or anti-cancer effects.
Objectives: To examine the association between
treatment with pioglitazone and risk of cancer at 10 sites
(prostate, breast, lung and bronchus, colon, non-
Hodgkin’s lymphoma, corpus uteri, pancreatic, kidney/
renal pelvis, melanoma, and rectum).
Methods: A cohort of 236,507 diabetic patients was
identiﬁed using the Diabetes Registry of Kaiser
Permanente Northern California (KPNC). They were
aged 40+ years at baseline (01/1997-06/2005) and were
followed up to 6/2012 for incident cancers by linkage
with the KPNC cancer registry. All prescriptions for
diabetes medications during the study period were identi-
ﬁed by the KPNC pharmacy database. Cox models were
used to provide point and interval estimates of the hazard
ratios (HR) associated with ever use of pioglitazone and
time since ﬁrst use, cumulative duration, and dose.
Measures of exposure to pioglitazone were treated as
time-dependent covariates.
Results: 38,190 patients were ever exposed to pioglita-
zone. In models adjusted for age, year of cohort entry,
use of other diabetes medications, sex, race, income,
current smoking, HbA1c and diabetes duration, the HRs
for risk of 8 of the 10 cancers associated with ever use
of pioglitazone ranged from 0.81 to 1.15 and all 95%
CIs included 1.0. Ever use of pioglitazone was associated
with increased risk of prostate cancer (HR= 1.13, 95% CI
1.02-1.26) and pancreatic cancer (HR =1.41, 95% CI
1.16-1.71); no clear pattern was observed with increasing
time since initiation, duration, or dose of pioglitazone.
The association with increased risk of pancreatic cancer
was the strongest in the ﬁrst year of pioglitazone therapy.
An increased risk of pancreatic cancer was also observed
for ever use of other diabetes medications (metformin,
insulin, and sulfonylureas).
Conclusions: The increased risk in pancreatic cancer
observed with ever use of pioglitazone and other
diabetes medication is likely explained by reverse
causality. The increased risk of prostate cancer
associated with ever use of pioglitazone needs further
investigation.
325. Disparities in the Use of Prescription
Medications: A Population-Based Approach
Dima Qato. University of Illinois, Chciago.
Background: Despite the importance of pharmaco-
epidemiologic studies in guiding pharmaceutical
policy, there are signiﬁcant limitations in the data
sources often, and increasingly, being used to examine
disparities in the use of prescription medications.
These data sources exclude information on individuals
that experience limited access to care. Therefore,
information derived from these data inadequately
inform policies aimed at improving access to prescrip-
tion medication in minority populations.
Objectives: To use nationally-representative, popula-
tion-based data to examine the use of prescription
medications by race/ethnicity and access to care in the
U.S. older adult population.
Methods: In-home interviews were administered
between June 2005 and March 2006 to 3,005 commu-
nity-residing individuals, ages 57–85 years, drawn from
a cross-sectional, population-based sample of the United
States. Prescription medication use was deﬁned as the use
of at least 1 prescription medication. Access to care was
deﬁned based on both insurance status and having a usual
source of care.
Results: Hispanic and Black older adults were signiﬁ-
cantly more likely to be uninsured and have no usual
source of care. Older adult individuals having a usual
source of care are signiﬁcantly (P< 0.05) more likely to
use prescription medications (85%) in comparison
to their counterparts without a usual source of care
(51%). These differences persist after accounting for
demographic and health status characteristics. Insured
individuals were also signiﬁcantly more likely to use
prescription medications (84%) compared to the
uninsured (71%). Differences in the use of prescription
medications by usual source of care were similar across
racial/ethnic groups. However, differences in use by
insurance status varied by race/ethnicity; Uninsured
Hispanics were signiﬁcantly less likely to use prescrip-
tion medications (57%) compared to their insured
counterparts (76%).
Conclusions: These ﬁndings suggest a population-based
approach using survey data enables a health equity
perspective that may better inform pharmaceutical policy
efforts aimed at improving the use of medicines in
minority populations.
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326. Racial/Ethnic Disparities in US Prescribing
Patterns of Sleep Medications from 1996-2010
Christopher N Kaufmann,1,3 Adam P Spira,1 Sarah L
Canham,1 Lian-Yu Chen,1,3G Caleb Alexander,2,3 Pia
Mauro,1 RaminMojtabai.1,3 1Department of Mental Health,
Johns Hopkins Bloomberg School of Public Health,
Baltimore, MD, United States; 2Department of Epidemiol-
ogy, Johns Hopkins Bloomberg School of Public Health,
Baltimore, MD, United States; 3Center for Drug Safety
and Effectiveness, Johns Hopkins Bloomberg School of
Public Health, Baltimore, MD, United States.
Background: The number of pharmacological options
for treating sleep disorders has grown over the past
20 years, but little is known about racial/ethnic disparities
in receiving these medications.
Objectives:We examined whether physician prescribing
patterns of sleep medications differed by the racial/ethnic
composition of physicians’ patient populations.
Methods:We combined data on physicians participating in
the National Ambulatory Medical Care Survey (NAMCS)
from 1996 to 2010. We categorized physicians as frequent
vs. infrequent prescribers of benzodiazepines (BZDs), non-
BZD sleep-aids, and sedating antidepressants (SADs).
Frequent prescribers were deﬁned as those in the top 10%
of prescribers of each medication class. We also categorized
physicians in terms of whether the majority of their patients
were non-Hispanic white, non-Hispanic black, Hispanic, or
other race/ethnicity. We limited our sample to physicians
who provided data on at least 10 patient visits.
Results: Our sample consisted of 13,602 physicians of
mostly non-Hispanic white patients, 706 non-Hispanic
black patients, 950 Hispanic patients, and 323 patients of
“other” race/ethnicity. After adjusting for ofﬁce setting,
geographic region, insurance, and physician specialty,
compared to physicians whose patients were mostly white,
those prescribing to mostly black patients had a lower odds
of being a frequent prescriber of BZDs (OR=0.37, 95%
CI= 0.20, 0.68), non-BZD sleep-aids (OR=0.32, 95%
CI= 0.18, 0.57), and SADs (OR=0.64, 95% CI= 0.38,
1.08). Similarly, those prescribing to mostly Hispanic
patients had a lower odds of being a frequent prescriber
of BZDs (OR=0.43, 95% CI= 0.24, 0.76), non-BZD
sleep-aids (OR=0.63, 95% CI= 0.42, 0.97), and SADs
(OR=0.48, 95% CI = 0.25, 0.91).
Conclusions: Compared to physicians of mostly non-
Hispanic white patients, those treating mostly non-Hispanic
black and Hispanic patients were substantially less likely to
be frequent prescribers of common sleep-aid medications. It
remains to be determined if these patterns are driven by
different clinical needs between these patient populations.
327. Sex Differences in Utilization of Cardiovascular
Drugs in Sweden and Taiwan
Desirée Loikas,1,2 Marlin Isteifo,1 Ching-Lan Cheng,3
Yea-Huei Kao Yang,3 Karin Schenck-Gustafsson,4,5 Björn
Wettermark,1,2 Mia von Euler.6 1Public Healthcare
Services Committee, StockholmCounty Council, Stockholm,
Sweden; 2Centre for Pharmacoepidemiology and Clinical
Pharmacology, Karolinska Institutet, Stockholm, Sweden;
3Institute of Clinical Pharmacy and Pharmaceutical
Sciences, Health Outcome Research Center, National
Cheng Kung University, Tainan, Taiwan; 4Centre for
Gender Medicine, Karolinska Institutet, Stockholm,
Sweden; 5Department of Medicine, Cardiology Unit,
Karolinska Institutet, Stockholm, Sweden; 6Karolinska
Institutet Stroke Research Network at Södersjukhuset,
Department of Clinical Science and Education,
Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
Background: Sex differences in drug utilization have
been shown in several therapeutic areas. Disparities in
disease prevalence may explain some differences while
other explanations are less obvious. International
comparisons are valuable to create more knowledge and
identify potential areas for improvement.
Objectives: To identify sex differences in the utilization
of cardiovascular drugs in Sweden and Taiwan.
Methods: A retrospective cross-sectional study using
data from national registries in Sweden and Taiwan.
The Swedish Prescribed Drug Register, including all
drugs dispensed to the Swedish population was used.
For the Taiwanese data, a one million cohort randomly
sampled from all the beneﬁciaries in the National Health
Insurance Research Database (NHIRD) covering almost
the entire population (99.6 %) and includes all drugs
dispensed at contracted pharmacies in Taiwan was used.
The proportions of men and women who had been
dispensed at least one prescription of antihypertensive
drugs, antithrombotic agents, and lipid modifying agents
in 2010 were compared between the countries. Differ-
ences between the sexes were calculated as relative ratios
(women/men) with 95% CI.
Results: The prevalence was considerably higher in
Sweden for all studied pharmacological groups (range
2-24 times higher across groups in women, 2-36 times
higher in men). More men than women were treated with
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ACE inhibitors (RR 0.79 in Sweden(S) and 0.86 in
Taiwan(T)), low dose acetylsalicylic acid (RR 0.87 in S
and 0.80 in T) and vitamin K antagonists (RR 0.68 in S
and 0.91 in T) in both countries. More women were
treated with diuretics (RR 1.56 in S and 1.18 in T) and
beta blocking agents (RR 1.10 in S and 1.43 in T) in both
countries. Lipid modifying agents were used more by
men in Sweden and more by women in Taiwan (RR
0.83 in S and 1.05 in T).
Conclusions: Both men and women in Sweden were
treated to a greater extent with all cardiovascular drugs
compared with men and women in Taiwan. Sex differ-
ences were similar for most pharmacological groups, ex-
cept for lipid modifying agents which were more
common among men in Sweden and among women in
Taiwan. More studies are needed to investigate explana-
tions behind these differences.
328. Cross-National Comparison of Prescribing Pat-
terns in Australian and Dutch Nursing Homes
Katja Taxis,1 Sjoerd Kochen,1 Sanne Geerens,1 Hans
Wouters,1 Froukje Boersma,4 Jan GMaring,3 Hans Mulder,2
Jugoslav Pavlovic,1 Gerard Stevens,5 Andrew JMcLachlan,5
Lisa Pont.5 1Pharmacotherapy and Pharmaceutical Care,
University of Groningen, Groningen, Netherlands; 2Clinical
Pharmacy, Wilhelmina Hospital, Assen, Netherlands;
3Clinical Pharmacy, Diaconessen Hospital, Meppel-
Hoogeveen, Netherlands; 4General Practice/Nursing
Home, University Medical Center Groningen, Groningen,
Netherlands; 5University of Sydney, Sydney, Australia.
Background: Prescribing quality is a major issue in nurs-
ing home patients. Few cross-national comparisons of pre-
scribing patterns have been carried out in this population.
Objectives: To compare prevalence of medication use in
nursing home patients between Australia and The
Netherlands.
Methods: An analysis of medication use based on
pharmacy dispensing data was undertaken for residents
in nursing homes in Australia (AU) and the Netherlands
(NL). The data included residents >65 years old who
remained in a high care nursing home in 2009 in AU
(n = 1,560) or NL (n = 2,037). Annual prevalence
was deﬁned as the dispensing of 1 or more prescriptions
for a drug during the study year expressed as percentage
of all residents. Multiple logistic regression was used
to calculate the prevalence odds ratios (OR) and
associated 95% conﬁdence intervals (CI), adjusted for
gender and age.
Results: The mean age of residents was 85.8 (SD 7.5)
(AU) and 82.8 (SD 7.5) (NL), the majority were female
(AU: 70.3%, NL: 68.2%). Residents used a mean of
11.4 (SD 5.3) (AU) and 10.8 (SD 7.0) (NL) drugs. The
prevalence of medication use was similar in the two
countries for most ATC groups. Major differences were
observed in the use of benzodiazepines (anxiolytics:
AU: 14.1%, NL: 27.8%, OR 0.41 (0.37-0.53)), osteopo-
rosis medication (AU: 51.2%, NL: 28.9; OR 2.56
(2.22-2.96)). Overall use of antipsychotics (AU: 37.7%,
NL: 40.3%; OR 0.91 (0.79-1.04)) was similar, but choice
of individual drugs differed, e.g. haloperidol (AU: 8.2%,
NL: 19.7%; OR 0.34 (0.27-0.42)) and risperidone (AU:
17.4%, NL: 7.3%; OR 2.86 (2.30-2.57)). Systemic
antibacterials (AU: 66.8%, NL 62.4%; OR 1.08
(0.93-1.24)) and cardiovascular system drugs (AU:
73.8%, NL: 72.9%; OR 1.05 (0.90-1.23)) overall were
similar but major differences were also found in the
choice of agents.
Conclusions: There are many similarities, but also
striking differences in prescribing patterns for nursing
home patients between Australia and the Netherlands.
Differences in policies, guidelines, education/training
and cultural beliefs are possible explanations. Investigat-
ing this further should improve our understanding of the
various inﬂuences on prescribing in nursing homes.
329. Bladder Antimuscarinics and Cognitive Decline in
Elderly Patients Enrolled in the National Alzheimer’s
Coordinating Center Cohort
Daniela C Moga,1,2 Erin Abner,2,3 Gregory Jicha.3,4
1Department of Pharmacy Practice and Science, College
of Pharmacy, University of Kentucky, Lexington, KY,
United States; 2Department of Epidemiology, College of
Public Health, University of Kentucky, Lexington, KY,
United States; 3Alzheimer’s Disease Center, Sanders-
Brown Center on Aging, University of Kentucky, Lexing-
ton, KY, United States; 4Department of Neurology,
College of Medicine, University of Kentucky, Lexington,
KY, United States.
Background: Previous research suggests that, in patients
with Alzheimer’s disease, bladder antimuscarinics
(BAM) produce cognitive changes; however, the
evidence is limited by the small number of patients tested
with limited follow-up.
Objectives: To evaluate the impact of BAM on cognition
in patients 65 and older enrolled in the National Alzheimer’s
Coordinating Center (NACC) cohort, an ongoing study with
comprehensive cognitive assessment of participants.
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Methods:We conducted a retrospective cohort study using
data from the NACC Uniform Data Set (2005–2013) for
patients 65+with complete medication information. Patients
were excluded in the presence of non Alzheimer’s disease
dementia. Prevalent and incident users were identiﬁed based
on self-reported medication use at each study visit.
Cognitive function (overall status, attention, language, and
executive functioning) wasmeasured based on the extensive
information collected yearly for cohort participants. To bal-
ance groups at baseline, incident users were matched with
up to 4 nonusers using propensity score (PS) methodology.
The PS model included demographic characteristics, living
situation, center, enrollment and assessment year, body
mass index, lifestyle related risk factors, urinary and fecal
incontinence status, cognitive status, level of independence,
comorbidities, and other medications used. We evaluated
the impact of BAM initiation on cognitive change between
two consecutive assessments as compared to nonusers.
Results: Of the 22,625NACC participants 65 and older, 744
were incident and 1278 were prevalent users. Our PS
matched sample included 672 incident users and 2504
nonusers. 10.27% of the BAM users, as compared to 7.63%
of the nonusers, showed cognitive decline (p=0.03). Of those
with mild cognitive impairment at baseline, 30% of the users
as compared to 22% of the nonusers experienced decline to
dementia at follow-up (odds ratio 1.53, 95% conﬁdence
interval: 1.02-2.31).
Conclusions: Our results show that BAM initiation causes
cognitive decline in patients enrolled in the NACC cohort
and raise question about their use, especially in those with
impaired cognition.
330. Utilization and Predictors of Active Surveillance among
Elderly Men with Low-Risk Localized Prostate Cancer
Huei-Ting Tsai,1 Arnold Potosky,1 George Philips,2
Katherine Taylor.1 1Oncology, Lombardi Comprehensive
Cancer Center, Georgetown University, Washington D.C.,
Washington, United States; 2Medicine, Lombardi
Comprehensive Cancer Center, Georgetown University,
Washington D.C., Washington, United States.
Background: Active surveillance (AS) has been proposed
as an alternative to active treatment (AT) to reduce
overtreatment and harm in localized prostate cancer with
low-risk of recurrence. Acceptance and predictors of AS
in U.S. general practice remain unclear.
Objectives: To determine the use of AS versus AT
among elderly men with incident localized prostate
cancer classiﬁed as low-risk of recurrence.
Methods: Using the U.S. SEER-Medicare database, we
conducted a retrospective cohort study of men 66 and older
diagnosed during 2004-2009 with incident localized prostate
cancer classiﬁed as low-risk of recurrence by the American
Urological Association. We deﬁned AS as men having at
least one prostate-speciﬁc-antigen test or re-biopsy and no
curative-intent treatment within 12months post diagnosis.
AT was deﬁned as men receiving radical prostatectomy
and radiation within 12months post diagnosis. We used gen-
eralized linear regression to model receipt of AS, accounting
for clustering of patients treated by the same physician.
Results: Our cohort included a total of 12,230 men with
localized prostate cancer classiﬁed as low-risk of recur-
rence and 26% of them chose AS in the ﬁrst year after
their diagnosis. We found a positive secular trend of
AS use (p< 0.0001). Compared to men 66-70 years
old, adoption of AS was higher in older men and
increased with age (OR= 1.27 for 70-74 year; 2.03 for
75-79 year; 6.17 for men over 80 years, p< 0.0001) or
men with two or more comorbidities (OR= 1.35, 95%
C.I. = 1.18, 1.54). Married men were less like to choose
AS (OR = 0.56, 95%C.I. = 0.51, 0.61). Compared to
registries in Paciﬁc region, uptake of AS was lower in
the East Coast (OR = 0.56, 95%C.I. = 0.50, 0.63) and
Mountain region (OR = 0.79, 95%C.I. = 0.65, 0.96).
Conclusions: Our data indicated that AS has increasingly
been adopted in U.S. general practice for managing men
with localized prostate cancer at low-risk of recurrence.
The adoption shows signiﬁcant geographic variation.
Patient characteristics played a larger role than physician
characteristics in choosing AS versus AT.
331. Avoiding “Crystal Ball” Epidemiology: The Case
of Low-Dose Aspirin and Major Bleeding
Jennifer L Lund,1 Til Sturmer,1 Erzsebet Horvath-Puho,2
Szimonetta Szépligeti,2 Lars Pedersen,2 Vera Ehrenstein,2
Henrik T Sorensen,2 John A Baron.3 1Department of Epi-
demiology, University of North Carolina at Chapel Hill,
Chapel Hill, NC, United States; 2Department of Clinical
Epidemiology, Aarhus University Hospital, Aarhus N,
Denmark; 3Department of Medicine, University of North
Carolina at Chapel Hill, Chapel Hill, NC, United States.
Background: Although information captured in large
healthcare databases is prospectively collected, data on
future events are available to researchers at study outset. Using
future events to deﬁne cohorts can lead to selection bias.
Objectives: We illustrate the impact of this bias by
replicating the methods from a safety study of low-dose
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aspirin and major bleeding published in JAMA (2012)
using Danish medical registries (2004-11).
Methods: As described in the JAMA study, we ﬁrst
identiﬁed Danes aged 30-95 years old who were new con-
tinuous aspirin users (those initiating aspirin andwhose last
prescription was<75days before hospitalization for major
bleeding or the end of follow-up) or never aspirin users
(never initiating aspirin during the entire study period), a
deﬁnition that uses future aspirin data to deﬁne both treated
and untreated cohorts. We computed major bleeding
incidence rates (IRs) and 95% conﬁdence intervals (CIs)
and estimated adjusted incidence rate ratios (aIRRs) for
the association between low-dose aspirin and major
bleeding, using Poisson regression models and propensity
score (PS) matching to adjust for measured confounders.
We then extracted cohorts ignoring future events and con-
ducted an “as-treated” analysis, censoring individuals at
the time their aspirin use changed (allowing prescription
gaps<120days), and implemented a PS matched analysis.
Results:When the JAMA study methods were replicated
using the Danish data, we identiﬁed 188,965 new contin-
uous users and PS-matched 156,605 of these individuals
to never users; major bleeding IRs in Denmark were 8.6
and 3.6 per 1,000 person-years (PY), respectively
(aIRR= 2.5, 95% CI: 2.4, 2.7). After extracting cohorts
ignoring future events, the as-treated bleeding IRs
decreased in the newly matched aspirin users
(n = 377,483) to 7.9 per 1,000 PY and increased in non-
users to 4.5 per 1,000 PY (aIRR= 1.7, 95%CI: 1.7-1.8).
Conclusions: Using future events to deﬁne cohorts may
threaten validity in database studies. In this setting, condi-
tioning on future aspirin use led to an overestimation of the
major bleeding IR in aspirin users and an underestimation
in non-users, resulting in an inﬂated relative risk estimate.
332. AUDIT-C Alcohol Misuse Screening Score and
Major Bleeding in Warfarin Therapy: An Evaluation
of Main Effects and Interaction with VKORC1
Genetic Status
Joshua A Roth,1 Katharine Bradley,1 Kenneth Thummel,2
David L Veenstra,3 Denise Boudreau.1 1Group Health Re-
search Institute, Group Health, Seattle, WA, United States;
2Department of Pharmaceutics, University of Washington,
Seattle, WA, United States; 3Department of Pharmacy,
University of Washington, Seattle, WA, United States.
Background: Warfarin is an anticoagulant that is highly
effective at reducing thrombotic event risk and is used by
>1 million Americans annually. However, major bleeding
adverse events are relatively common and create a barrier
to appropriate prescribing. Alcohol use and VKORC1
genetic variants both impact major bleeding risk in
warfarin patients. However, no studies have evaluated the
association between the commonly used AUDIT-C alcohol
misuse screening instrument and major bleeding, or an
interaction with VKORC1 status.
Objectives: Assess the association between AUDIT-C
score and major bleeding risk among warfarin users in a
community setting, and explore the interaction with
VKORC1 (1173G>A) genetic status.
Methods: We used a case-control design and recruited
patients from Group Health, an integrated healthcare sys-
tem in Washington State. Cases had a major bleeding
event while receiving warfarin. Similar patients using
warfarin on a randomly assigned index date and no major
bleeding in the prior year were selected as controls. We
identiﬁed major bleeding with a standard ICD-9
algorithm, validated events with chart review, obtained
AUDIT-C scores from a mailed survey, and determined
VKORC1 status from buccal swabs. We used multivari-
ate logistic regression to estimate major bleeding odds
ratios (OR) for patients with moderate/severe alcohol
misuse (AUDIT-C scores ≥5) relative to those with
scores <5, and stratiﬁed by VKORC1 status.
Results: In 265 cases and 305 controls with 3.4 and 3.7
mean years of warfarin use, screening positive for moder-
ate/severe alcohol misuse was associated with increased
major bleeding risk (OR= 2.10, 1.08-4.07). In stratiﬁed
analyses, the association was signiﬁcant in VKORC1
variants (OR=3.87, 1.56-9.59), but not in wild-type
(OR=0.62, 0.19-2.08) patients (multiplicative interac-
tion p = 0.04).
Conclusions: Our results demonstrate a strong associa-
tion between AUDIT-C score and major bleeding risk
in warfarin patients in a community setting, and particu-
larly among VKORC1 variants. These ﬁndings can
inform clinical management of warfarin major bleeding
risk in the context of alcohol use.
333. An International Comparison of Spontaneous
Adverse Event Reports and Potentially Inappropriate
Medicine Use Associated with Dabigatran
Lisa M Kalisch Ellet, Cameron J McDonald, John D Barratt,
Gillian E Caughey.Quality Use of Medicines and Pharmacy
Research Centre, Sansom Institute for Health Research,
School of Pharmacy and Medical Sciences, University of
South Australia, Adelaide, SA, Australia.
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Background: Clinical trial data and subsequent
meta-analyses have highlighted several safety concerns
potentially associated with use of the new oral anticoag-
ulant dabigatran. When compared to warfarin, meta-
analyses have shown that dabigatran is associated with
an increased risk of gastrointestinal haemorrhage. Little
is known about these safety issues associated with use
of dabigatran in clinical practice that may be reported in
spontaneous adverse event reports.
Objectives: To analyse spontaneous adverse event
reports associated with dabigatran from Australia, Canada
and USA and to examine concomitant medicine use.
Methods: Spontaneous adverse event national databases
from Australia, Canada and the USA were used to exam-
ine all reports of adverse events associated with
dabigatran from 1st August 2005 to 31st March 2013.
Disproportionality analysis was conducted for the
quantitative detection of signals using the USA database.
Concomitant medicine use was examined to identify
potentially inappropriate medicines which may place
the patient at increased risk for adverse events.
Results: There were a total of 1039, 1333 and 13788
spontaneous adverse event reports associated with
dabigatran from Australia, Canada and USA, respec-
tively. Gastrointestinal (GI) disorders were the most com-
monly reported adverse event, ranging from 27.5% for
Australia to 40.5% for USA. Of these, GI haemorrhage
accounted for 81.5% of Australian, 71.5% of Canadian
and 42% of USA GI disorder adverse event reports.
Positive signals for were conﬁrmed in the USA data (GI
haemorrhage; PRR 18.18, χ2 40993.51 and ROR 19.55
95% CI 18.77-20.36). Use of concomitant medicines
with the potential to increase bleeding risk across all
three countries ranged from 34.4% for Australia to
51.1% for the USA.
Conclusions: A large proportion of adverse events were
associated with concomitant therapies which may have
placed the patient at increased risk of harm. This highlights
the need for pharmacovigilance by the prescribing clinician
to minimise risk and ensure the safe and effective integra-
tion of dabigatran into routine clinical practice.
334. Intravenous Thrombolytic Therapy Is Beneficial
for Acute Stroke Patients with Renal Dysfunction
Cheng-Yang Hsieh,1,2 Chih-Hung Chen,3 Huey-Juan
Lin,4 Sheng-Feng Sung,5 Yea-Huei Kao Yang.1 1Institute
of Clinical Pharmacy and Pharmaceutical Sciences,
National Cheng Kung University, Tainan, Taiwan;
2Neurology, Tainan Sin Lau Hospital, Tainan, Taiwan; 3Neu-
rology, Hospital and College of Medicine, National Cheng
Kung University, Tainan, Taiwan; 4Neurology, Chi-Mei Med-
ical Center, Tainan, Taiwan; 5Neurology, DitmansonMedical
Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan.
Background: Several studies reported that renal
dysfunction (RD) was associated with poor stroke outcome
after intravenous thrombolytic therapy. However, the
effect of thrombolytic therapy has never been assessed in
stroke patients with RD.
Objectives: To compare the improvement of acute stroke
patients with RD who received thrombolytic therapy or not.
Methods: Based on stroke registry data of 4 hospitals in
Taiwan from 2007-2013, we retrospectively identiﬁed
acute stroke patients with renal dysfunction who were
admitted within 4.5 hours of onset and given intravenous
thrombolytic therapy or not. Renal dysfunction
was deﬁned as an estimated glomerular ﬁltration rate
(eGFR)< 60ml/min/1.73m2. The improvement of stroke
was deﬁned as the difference of National Institute of
Health Stroke Scale (NIHSS) score between admission
and discharge. The effect of thrombolytic therapy was
assessed in using a multivariable linear regression model.
Results: Of the 1,979 stroke patients with RD, 247 (12%)
received thrombolytic therapy. Patients receiving thrombo-
lytic therapy were younger but had higher pre-treatment
NIHSS score. After adjustment with age, pre-treatment
NIHSS score, blood glucose, and eGFR, the use of
thrombolytic therapy was associated with improvement
of stroke [coefﬁcient 1.7, 95% conﬁdence interval (CI)
1.1 to 2.3; p = 0.004]. Other factors signiﬁcantly associated
with improvement were pre-treatment NIHSS score
(coefﬁcient 0.11, 95% CI 0.09 to 0.14; p< 0.0001)
and per 10ml/min/1.73m2 decrease of eGFR (coefﬁcient
-0.58, 95% CI -0.41 to -0.74; p=0.0001).
Conclusions: Thrombolytic therapy is beneﬁcial and should
not be contraindicated in acute stroke patients with RD.
335. Adherence and Persistence to New-Users of
Dabigatran Among Patients with Non-Valvular Atrial
Fibrillation in an Administrative Claims Database
Meijia Zhou,1 Hsien-Yen Chang,2 G Caleb Alexander,1,2
Sonal Singh.1,2 1Department of Epidemiology, Johns
Hopkins Bloomberg School of Public Health, Baltimore,
MD, United States; 2Center for Drug Safety and
Effectiveness, Johns Hopkins Bloomberg School of
Public Health, Baltimore, MD, United States.
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Background: Dabigatran (pradaxa) is a direct thrombin
inhibitor recently approved by FDA for the treatment of
non-valvular atrial ﬁbrillation. Little is known regarding
whether patients are adherent or persistent to these
therapies, yet their safety and effectiveness depend on this.
Objectives: To examine the adherence and persistence to
Dabigatran among adults with atrial ﬁbrillation.
Methods: We used IMS Health’s LifeLink Health Plan
Claims Data from 2010 to 2012 to identify patients aged
18 years and older with prevalent non-valvular atrial
ﬁbrillation. We deﬁned the index date as the ﬁrst date
of qualifying use of Dabigatran. We restricted our
analysis to patients who had no exposure to any oral
anticoagulants within the six months prior to the index
date (new-users), and derived adherence and persistence
outcomes for continuously enrolled patient cohorts at
6months, 9months and 12months of follow-up. We
measured adherence using the medication possession
ratio (MPR), and deﬁned individuals with MPR’s
>=80% as adherent. We characterized persistence,
deﬁning individuals with gaps of 60-days or longer in
Dabigatran supply as failing to persist in their therapy.
Results: We identiﬁed 3376 atrial ﬁbrillation patients
treated with Dabigatran with at least 6months of follow-
up; of these, 68% used Dabigatran as the only oral antico-
agulant whereas the remainder ﬁlled prescriptions for at
least one other oral anticoagulant during the follow-up
period. Among those using Dabigatran alone (n= 2244),
31% were non-adherent with therapy, while 5% had gaps
of 60 days or greater. Among those observed for 9 (or 12)
months that used Dabigatran alone, rates of non-adherence
were 38% (42%), whereas 9% (14%) discontinued therapy
during follow-up. Rates of adherence and persistence were
similar when analyses were limited to patients with
incident atrial ﬁbrillation alone.
Conclusions: Our ﬁndings indicate that nearly one third
of patients on Dabigatran are non-adherent after 6months
of therapy. Future studies are needed to understand the
reasons for this non-adherence and how to mitigate them.
336. Utilization of Anticoagulants in Atrial Fibrillation:
Influences of Clinical Risk Scores in Real-World Practice
Julie C Lauffenburger,1 Joel F Farley,1 Denise H Rhoney,1
Anil K Gehi,2M. Alan Brookhart,3 Gang Fang.1 1UNC
Eshelman School of Pharmacy, University of North
Carolina at Chapel Hill, Chapel Hill, NC, United States;
2School of Medicine, University of North Carolina at
Chapel Hill, Chapel Hill, NC, United States; 3Gillings
School of Global Public Health, University of North
Caroling at Chapel Hill, Chapel Hill, NC, United States.
Background: Anticoagulants are used for prevention of
stroke or systemic embolism in atrial ﬁbrillation (AF). While
novel oral anticoagulants have emerged as alternatives towar-
farin, it is unknown how selection is determined in practice.
Objectives: To examine whether and to what extent
anticoagulant selection has been driven by clinical
predictions of stroke risk (treatment beneﬁt) and bleeding
risk (treatment harm) in real-world US practice.
Methods: A cohort of non-valvular AF patients newly-
initiating therapy after dabigatran availability in Oct 2010
were extracted from a nationwide database of commercial
and Medicare Part D supplement claims from 2009-2012.
Risk scores of ischemic stroke (CHADS2 and CHA2DS2-
VASc) and bleeding (ATRIA) were used to examine
associations with use. Baseline demographic, clinical, and
medication use characteristics were also measured as
covariates. Multivariable Poisson regression models
assessed the association between each risk score and antico-
agulant use, adjusting for covariates. Partial R-squares were
used to examine the variation in treatment selection
explained by the risk scores.
Results: In total, 64,936 patients were identiﬁed with 33%
initiating dabigatran. New dabigatran users were more likely
to be younger, male, and have comorbidities. Patients at in-
termediate stroke risk (CHADS2 or CHA2DS2-VASc=1)
were equally likely to receive warfarin and dabigatran
(RR, 95% CI: 0.97, 0.94-1.01), while warfarin selection
was signiﬁcantly associated with high ischemic stroke risk
(CHADS2 or CHA2DS2-VASc≥ 2) (RR, 95% CI: 0.91,
0.87-0.95). New users of dabigatran were signiﬁcantly less
likely to have high bleeding risk (ATRIA≥ 5) versus warfa-
rin (RR, 95%: 0.72, 0.69-0.76). The base model statistics
(including the covariates) was only marginally increased
by adding any risk score.
Conclusions: Bleeding risk was strongly associated with
selecting a speciﬁc anticoagulant. However, the extent of
selection explained by treatment harm prediction was
minimal. Providers appear to base selection on factors
other than predictions of treatment beneﬁt, which has
implications for studying comparative effectiveness.
337. Use of Pharmacologic Agents for the Secondary Pre-
vention of Osteoporotic Fracture: A Cross-National Study
SeoyoungCKim,1Mi-SookKim,2Gabriel Sanfélix-Gimeno,6
Hong Ji Song,3 Liu Jun,1 Isabel Hurtado,6 Salvador Peiró,6
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Joongyub Lee,5 Nam-Kyong Choi,5 Byung-Joo Park,2,4
Jerry Avorn.1 1Medicine, Brigham and Women’s Hospital,
Boston, MA, United States; 2Preventive Medicine, Seoul
National University, Seoul, Republic of Korea; 3Family
Medicine, Hallym University College of Medicine, Anyang,
Republic of Korea; 4Korea Institute of Drug Safety and Risk
Management, Seoul, Republic of Korea; 5Medical Research
Collaborating Center, Seoul National University Hospital,
Seoul, Republic of Korea; 6Center for Public Health
Research (CSISP-FISABIO), Valencia, Spain.
Background: Osteoporosis is common but generally
undertreated. While current osteoporosis management
guidelines recommend use of pharmacologic treatment
following hip fracture, the care of patients after hip
fracture has been suboptimal.
Objectives: To examine the use and adherence of
pharmacologic therapy for the secondary prevention of
osteoporotic fracture among patients hospitalized for
hip fracture in three countries with different health care
systems - the U.S., South Korea and Spain.
Methods: We conducted a cohort study of patients aged
≥65 years hospitalized for incident hip fracture in the US,
South Korea and Spain. Baseline characteristics were
assessed in 365 days prior to the index hip fracture.
Proportions of patients receiving ≥1 prescription of any
osteoporosis drugs after the index hip fracture were
calculated. Adherence to osteoporosis treatment was
measured as the proportion of days covered. Crude rates
of recurrent hip fracture were estimated.
Results: We identiﬁed 4,704 patients with hospitaliza-
tion for a hip fracture in the US Medicare, 6,700 in a
US commercial health plan, 57,631 in Korea, and
17,167 in Valencia, Spain. Mean age was 77-83 years
and 74-78% were women. Prior to the index hip fracture,
16-18% took ≥1 medication for osteoporosis. Within
90 days following the index hip fracture, only 11% (US
Medicare), 13% (US commercial), 39% (Korea), and
25% (Spain) received ≥1 prescription for osteoporosis.
Although oral bisphosphonates were most commonly
used across the countries, the use of oral bisphosphonates
decreased over the recent years. Among patients who
received at least 1 prescription for osteoporosis, the 1-year
adherence was 70% (USMedicare), 67% (US commercial),
43% (Korea) and 66% (Spain). Crude rate of recurrent hip
fracture per 1,000 person-years ranged between 20.5 (Spain)
to 43.9 (US Medicare).
Conclusions: Use of pharmacologic agents for the second-
ary prevention of osteoporotic fracture was generally low
but varied considerably across the countries. Adherence
to osteoporosis treatment was also suboptimal in all three
countries.
338. Patterns of Pharmacological Treatment for Osteopo-
rosis among Patients Qualified for Pharmacotherapy Ac-
cording to the National Osteoporosis FoundationGuidelines
Chi-Chuan (Emma) Wang,1 Chung-Hsuen (Alvin) Wu,2
Joel F Farley.3 1School of Pharmacy, National Taiwan
University, Taipei, Taiwan; 2School of Pharmacy, Taipei
Medical University, Taipei, Taiwan; 3UNC Eshelman
School of Pharmacy, University of North Carolina at
Chapel Hill, Chapel Hill, NC, United States.
Background: Even though pharmacotherapy have been
proven effective to reduce the risk of fractures, they are
often underused.
Objectives: To examine rates of and factors associated
with medication treatment for osteoporosis among post-
menopausal women and men aged 50 years or older who
were recommended for pharmacotherapy according to the
National Osteoporosis Foundation (NOF) guidelines.
Methods: This is a descriptive study using the 2005-2010
National Health and Nutrition Examination Survey
(NHANES). The study sample was limited to women and
men aged 50 years or older who completed both interviews
and physical examinations in the NHANES and met the
treatment criteria based on the NOF guidelines. Factors as-
sociated with medication treatment for osteoporosis were
selected based on the Andersen’s Behavioral Model of
Health Services Use, including predisposing factors (age,
gender, and race), enabling factors (health insurance and
household income), and need factors (long-term corticoste-
roid use, history of fractures, parental fractures, smoking
and alcohol use status, rheumatoid arthritis, low bone
density, general health status, and 10-year risk of fractures).
A logistic regression model was used to assess factors asso-
ciated with medication treatment for osteoporosis among
those who were qualiﬁed for pharmacological treatment.
Results: Around 16 million of elder men and women met
the NOF treatment criteria, but only 24% of them receiving
pharmacotherapy. Male gender (OR=0.20, 95% CI =
0.12-0.34) and lack of health insurance (OR=0.32, 95%
CI= 0.11-0.93) were two factors associated with lower
likelihood of pharmacotherapy. Long-term corticosteroid
use (OR=2.74, 95%=1.41-5.33), history of fractures
(OR=1.75, 95%=1.10-2.78), and low bone density (OR=
2.37, 95%=1.70-3.31) were three factors associated with
increased likelihood of medication treatment.
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Conclusions: Our results suggest that less than one-fourth
of the population recommended for pharmacotherapy re-
ceived medication treatment for osteoporosis. Clinicians
should be more aware of the unmet need for medication
treatment when treating patients with osteoporosis.
339. Distributed Analysis of Total Hip Arthroplasties
Using Six International Registries: Comparing the
Effects of Implant Bearing Surface and Size
Art Sedrakyan,1 Elizabeth W Paxton,2 Steven E Graves,3
Guy Cafri,2 Samprit Banerjee,1 Alejandro Allepuz,7 Leif
I Havelin,5 Susan Mehle,6 Susanna Stea,4 Denica
Marinac-Dabic.8 1Healthcare Policy and Research, Weill
Cornell Medical College, New York, NY, United States;
2Surgical Outcomes and Analysis, Kaiser Permanente,
San Diego, CA, United States; 3Australian Orthopaedic
Association’s National Joint Replacement Registry,
University of Adelaide, Adelaide, Australia; 4Emilia
Romagna Joint Registry, Istituto Ortopedico Rizzoli,
Bologna, Italy; 5The Norwegian Arthroplasty Register,
Department of Orthopaedic Surgery, Haukeland Univer-
sity Hospital, Bergen, Norway; 6Research Department,
HealthEast Care System, St. Paul, MN, United States;
7Catalan Arthroplasty Register - Registre d’Artroplàsties
de Catalunya (RACat), Barcelona, Spain; 8Center for
Device and Radiological Health, United States Food
and Drug Administration (FDA), Silver Spring, MD,
United States.
Background: Total hip arthroplasty (THA) is one of the
most common major surgeries in the US. However,
device failure affects substantial number of patients.
There is growing evidence that large size metal-on-metal
(MoM) implants fail and it’s unclear if this is applicable
to all large size implants. Ceramic-on-ceramic (C-C)
device failures are also reported.
Objectives: The purpose of this study is to compare
implant survival across bearing surfaces and sizes, and
to showcase the capacity of the International Consortium
of Orthopaedic Registries (ICOR); an unprecedented
collaboration of international registries and US Food
and Drug Administration.
Methods: Using a distributed registry data network that
does not require data centralization, primary THAs were
identiﬁed from six national registries from 2001-2010.
Osteoarthritis patients with primary uncemented THAs
were investigated. Metal on cross-linked polyethylene
(XLPE) implants were selected as controls. Linear mixed
models, with implant survival probability as the unit of
analysis, were used to compare large size MoM and
C-C as well as small size C-C implants with XLPE.
Various size comparisons were also performed.
Results: The cohort consisted of 40157 THAs (50.1%
men). We found that large size MoM are associated with
higher risk of failure relative to XLPE bearings (after 2-3
years: HR=1.42 (1.16, 1.75), 4-5 years: HR= 1.78 (1.45,
2.19), 6-7 years, HR= 2.15 (1.63, 2.83)). Smaller size
C-C bearings were also associated with higher risk of
failure (HR= 1.36 (1.09, 1.68)) but larger size C-C were
not different from XLPE. Larger size C-C implants failed
less often when compared to smaller size C-C implants
(HR=0.73 (0.60, 0.88)). Importantly, there were no
differences between sizes <32mm and 32mm or >32mm
in XLPE implants.
Conclusions: We demonstrate the potential of the
international research network and found consistent and
strong evidence worldwide that large size MoM implants
are associated with higher risk of revision when
compared to XLPE bearings. Smaller head size C-C are
also associated with higher revision when compared to
large head size C-C and XLPE bearings.
340. Shiny and New: Examining Patient and Physician
Utilization of Non-Oral Osteoporosis Medications in
Ontario, Canada
Andrea M Burden,1 Mina Tadrous,1 Lindsay Wong,1
Andrew Calzavara,2 Yan Yun Liu,1 Suzanne M
Cadarette.1 1Leslie Dan Faculty of Pharmacy, University
of Toronto, Toronto, ON, Canada; 2Institute for Clinical
Evaluative Sciences, Toronto, ON, Canada.
Background: Two non-oral osteoporosis drugs were
added to the public drug formulary in Ontario, Canada in
the last decade: annual zoledronic acid in 2006 under the
exceptional access program (modiﬁed 2012) and semi-
annual denosumab in 2012 under limited use criteria.
Objectives: We sought to describe the use and persistence
of zoledronic acid and denosumab since formulary addition.
Methods: Using Ontario administrative claims data, we
identiﬁed new users of zoledronic acid and denosumab
from formulary entry through to 2013. Descriptive
characteristics of prescribing physicians and patients
were summarized. The number of new patients and new
prescribing physicians were plotted by month and
examined over time. Time series analysis was used to
examine the impact of the formulary change to zoledronic
acid in 2012. Persistence with index therapy and switching
to different therapies were also examined.
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Results: We identiﬁed 1,508 zoledronic acid users (86%
female, mean age = 77) treated by 630 physicians (30%
specialist) and 16,736 denosumab users (97% female,
mean age= 79) treated by 2,904 physicians (11% special-
ist). More denosumab users had prior oral therapy (55%
vs. 34%), yet fewer received bone mineral density testing
(20% vs. 33%). In comparison to zoledronic acid (<5
new prescribers and physicians), uptake of denosumab
was rapid (>450 new prescribers and>1200 new patients)
in the ﬁrst two months on the formulary. Time series
analysis identiﬁed a signiﬁcant increase in zoledronic acid
use following a modiﬁcation to the limited use criteria. We
identiﬁed that 55% (denosumab) and 57% (zoledronic
acid) patients persisted beyond the ﬁrst year, and 30% of
zoledronic acid patients persisted for 3+ years.
Conclusions: We identify an increase in the prescribing
and use of zoledronic acid and denosumab. A provincial
formulary modiﬁcation that broadened access criteria for
zoledronic acid signiﬁcantly increased prescribing.
More than half of patients persisted with therapy beyond
the ﬁrst year, suggesting both zoledronic acid and
denosumab are enticing options for the treatment of
osteoporosis.
341. Mortality in British Hip Fracture Patients, 2000 –
2010: A Population-Based Retrospective Cohort Study
Corinne Klop,1 Paco MJ Welsing,4 Cyrus Cooper,2
Nicholas CHarvey,2 JohannesWJBijlsma,3 Petra JMElders,5
Hubert GM Leufkens,1 Frank de Vries.1 1Utrecht Institute
for Pharmaceutical Sciences, Utrecht University, Utrecht,
Netherlands; 2MRC Lifecourse Epidemiology Unit, Uni-
versity of Southampton, Southampton, United Kingdom;
3Rheumatology and Clinical Immunology, University
Medical Center Utrecht, Utrecht, Netherlands; 4Julius
Center for Health Sciences and Primary Care, University
Medical Center Utrecht, Utrecht, Netherlands; 5Depart-
ment of General Practice, VU University Medical Center,
Amsterdam, Netherlands.
Background: Hip fractures are a major public health
concern with high mortality rates and substantial costs.
However, data on recent trends in (excess) mortality after
hip fracture are scarce.
Objectives: To examine secular trends in mortality post
hip fracture and to compare this to the general population
from 2000 – 2010.
Methods: A population-based retrospective cohort study
was conducted within the United Kingdom Clinical Prac-
tice Research Datalink linked to death certiﬁcates for
57.7% of patients to determine the primary cause of
death. Patients with a ﬁrst hip fracture (n = 31,495) were
matched to up to four controls by age, sex, index date,
and practice. All subjects were followed for death, and
lifestyle, disease and medication history adjusted hazard
ratios (aHRs) were calculated.
Results: Overall, the cumulative mortality rate was 22%
one-year post hip fracture as compared to 7.8% in
controls. The one-year mortality risk after hip fracture de-
clined from 2009 and was 14% lower after, compared
with before 2009 (aHR 0.86, 95% CI: 0.81–0.92). The
decline was observed for males (≥75 years) and females
(≥85 years). Signiﬁcant contributors to the decline in
mortality post hip fracture were respiratory infections in
females as were cerebrovascular and malignant diseases
in males. However, the mortality risk remained unaltered
over the decade when compared to controls with a 3.5-fold
(95% CI: 3.3 – 3.7) and 2.4-fold (95% CI: 2.3 – 2.5)
increased risk in males and females respectively.
Conclusions: The one-year mortality risk after hip
fracture has declined over the last decade in the UK.
However, the difference in mortality risk between hip
fracture patients and the general population remained
unaltered. These observations highlight the need for the
continued implementation of evidence-based standards
for good hip fracture care.
342. Medicine Use and the Risk of Hip Fracture in the
Elderly: A Case-Crossover Study
Michael J Leach, Nicole L Pratt, Elizabeth E Roughead.
Quality Use of Medicines and Pharmacy Research
Centre, Sansom Institute, School of Pharmacy and
Medical Sciences, University of South Australia,
Adelaide, South Australia, Australia.
Background: Hip fracture is a serious injury that may be
triggered by multiple factors, including medicines. In
medicine safety research, a viable alternative to tradi-
tional observational study designs is the case-crossover
design. This design controls for confounding due to
within-person factors by comparing an individual’s
exposure just before an outcome with the same individ-
ual’s exposure at an earlier time.
Objectives: To evaluate the impact of medicine use on
the risk of hip fracture in elderly patients.
Methods: Data was sourced from the Australian Govern-
ment Department of Veterans’ Affairs (DVA) healthcare
claims database. The cohort consisted of DVA beneﬁciaries
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over 65 years who were admitted to hospital for hip fracture
between 2009 and 2011. We used the case-crossover design
to compare each patient’s medicine exposure during the
35 days before admission (hazard period) with their
medicine exposure between 70 and 105days before
admission (control period). Due to within-person matching,
conditional logistic regression was used to quantify associa-
tions between medicine use and hip fracture.
Results: There were 6435 hip fracture patients with a
median age of 88 years. The odds of hip fracture were
signiﬁcantly increased following exposure to antipsy-
chotics (odds ratio [OR] = 1.90, 95% conﬁdence interval
[CI] =1.45-2.49), opioids (OR=1.81, 95% CI=1.55-2.13),
antidepressants (OR = 1.76, 95% CI = 1.41-2.20) and
benzodiazepines (OR = 1.26, 95% CI = 1.07-1.47).
Conclusions: In this case-crossover study, antipsychotics,
opioids, antidepressants and benzodiazepines increased the
risk of hip fracture among elderly patients.
343. The Dual-Time-Adjusted Case-Crossover Design
Joshua J Gagne, Sebastian Schneeweiss, Shirley V Wang.
Division of Pharmacoepidemiology and Pharmaco-
economics, Department of Medicine, Brigham and
Women’s Hospital and Harvard Medical School, Boston.
Background: Self-controlled designs are immune to
time invariant confounding, but are susceptible to bias
due to exposure time trends at individual (e.g., sick stop-
per effects), and population (e.g., uptake of a new drug)
levels. Separate approaches have been developed to ad-
dress each source of bias in case-crossover designs, but
no approach exists to simultaneously adjust for both.
Objectives: To develop and demonstrate an approach to
simultaneously adjust for individual- and population-
level time trends in case-crossover analyses.
Methods: We combined principles of the case-time-
control design (CTC), which uses non-cases to measure
and adjust for population-level exposure time trends, and
the case-case-time-control (CCTC) design, which uses
cases exposed to a comparator drug to measure and adjust
for individual-level exposure time trends, into a single
approach that simultaneously addresses both sources of bias.
We demonstrate the approach by using it to mimic prospec-
tive monitoring of valdecoxib on 30-day myocardial
infarction (MI) risk, beginning at valdecoxib market ap-
proval, with celecoxib as a (not new to market) control drug.
Results: The proposed approach – the dual-time-adjusted
case-crossover (DTACC) design – is algebraically
equivalent to a ratio of two CTC odds ratios (ORs), with
the drug of interest in the numerator and the control drug
in the denominator. The use of the control drug addresses
individual-level time trend bias provided that the biases
are similar between the two drugs. The CTC aspect
addresses population-level trends. A naïve case-crossover
analysis of valdecoxib indicated high initial ORs
(e.g., 5.06; 95% CI, 3.01-8.51) due to a population-level
time trend, which was mitigated with the CTC (ﬁnal OR,
1.23; 1.03-1.44). The CTC OR for celecoxib indicated no
individual-level time trend (ﬁnal OR, 1.02; 0.91-1.14).
The ﬁnal DTACC OR was 1.24 (1.00-1.54) indicating a
slight triggering effect of valdecoxib on 30-day MI.
Conclusions: The DTACC design inherently addresses
time-invariant confounding through its self-controlled
nature, and simultaneously addresses biases due to
individual- and population-level time trends by combin-
ing the CTC and CCTC methods.
344. Adapting and Evaluating Self-Controlled Case
Series Method (SCCS) for Signal Screening of a
Recently Marketed Drug Using a US Claims Database
Xiaofeng Zhou, Rongjun Shen, Jamie Geier, Andrew Bate.
Epidemiology, Pﬁzer, NYC, NY, United States.
Background: Literature on the application of the SCCS
method and its feasibility for active drug safety surveillance
in an early signal screening framework is sparse. The
Observational Medical Outcomes Partnership has shown
promising results for the SCCS method in such a frame-
work, but focus of the method testing has primarily been
on well established products marketed for many years.
Objectives: To assess performance of SCCSmethod for a re-
cently marketed drug in an early signal detection framework.
Methods: Adalimumab (Humira®) for the treatment of
rheumatoid arthritis was selected as the drug of interest.
Six outcomes described in Humira USPI were selected:
Acute Myocardial Infarction, GI Perforation, Herpes
Zoster, Interstitial Lung Disease, Lymphoma, and
Pneumonia. Optum, a US claims database was used for the
study. Relative risk (RR)> 1 and lower bound 95% CI> 1
were used as a threshold.
Results: Univariate SCCS method highlighted 3 of the 6
outcomes of interest: Herpes Zoster (RR: 1.41 [95% CI
1.23-1.62]), Pneumonia (RR: 1.15 [95% CI 1.04-1.27]),
Lymphoma (RR: 1.43 [95% CI 1.02-2.01]). Secondary
analyses indicated that 1). estimates for most pairs varied
minimally when varying the risk periods, though
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“30days from exposure start” led to lower estimates overall;
2). restricting case inclusion criteria to “≥12months of
enrollment” resulted in similar estimates; to “12months
enrollment prior to the 1st event” resulted in bigger estimates
across all pairs, though none exceeded 2; and to “post
exposure only” produced unusual hike and unstable
estimates during the 1st two years of drug launch; 3). Multi-
variate SCCS produced similar estimates.
Conclusions: SCCS method testing indicated that
potential signals may be detected, but with imperfect
performance. Half of the outcomes of interest were
highlighted, which is aligned with USPI and published
literature. The results need to be interpreted with caution
as previous studies indicated that a RR <2 may lead to a
higher risk for false positives. Further work is needed to
build better understanding of signal screening capability
in observational data for new medical products.
345. The Use of Prior Event Rate Ratio Adjustment
Method for Controlling Unmeasured Confounding in
Pharmacoepidemiologic Studies: A Cautionary Note
Md Jamal Uddin,1 Rolf HH Groenwold,1,2 Tjeerd P van
Staa,3 Anthonius de Boer,1 Svetlana V Belitser,1 Arno
W Hoes,2 Kit CB Roes,2 Olaf H Klungel.1 1Division of
Pharmacoepidemiology and Clinical Pharmacology,
University of Utrecht, Utrecht, Netherlands; 2Julius
Center for Health Sciences and Primary Care, University
Medical Center Utrecht, Utrecht, Netherlands; 3London
School of Hygiene and Tropical Medicine, London,
United Kingdom.
Background: Unmeasured confounding is one of the prin-
cipal problems in observational pharmacoepidemiologic
studies. Prior event rate ratio (PERR) adjustment method
has been proposed to control for unmeasured confounding.
Objectives: To assess the performance of the PERR
method in realistic pharmacoepidemiologic settings.
Methods: Simulation studies were performed in several
scenarios with varying effects of prior events on the
probability of subsequent exposure, incidence rates, strength
of confounders in prior and post periods, and rate of
mortality/dropout. Exposure effects were estimated using
conventional rate ratio (RR) and PERR adjustmentmethods.
For the PERR method, the exposure effect is a ratio of two
RRs: RR post exposure initiation and RR prior to initia-
tion of exposure. In each simulation, the sample size
was 100000 and each scenario was replicated 10000
times. 95% conﬁdence intervals were estimated in a
non-parametric way using the 2.5 and 97.5 percentiles
of the 10000 estimates.
Results: The exposure effects from the PERR adjustment
method are highly biased when “prior” events inﬂuence
the probability of subsequent exposure or when
confounding differs considerably between prior and post
periods. For example, the RR ranged from 1.52 to 1.10
(true RR= 2.00) when the effect of prior events on the ex-
posure was RR 1.25 to 1.70, respectively. With a strong
effect of prior events on the exposure (e.g. RR= 1.70),
the bias of the estimates were more pronounced for
PERR method than for the conventional method. In such
case, even with a null exposure effect (RR= 1.00), the
estimates shifted away from the null. In all settings,
the conﬁdence intervals of the estimates were wider for
the PERR method than for the conventional method.
Conclusions: The PERR adjustment method has
signiﬁcant limitations; in particular situations, e.g. when
prior events strongly inﬂuence the probability of subse-
quent exposure, it can be more biased than conventional
methods. Hence, caution should be exercised when
applying this method and theoretical justiﬁcation
should be provided for underlying assumptions of the
PERR.
346. Controlling Time-Dependent Confounding by
Frailty: Restriction Versus Statistical Adjustment
Leah J McGrath,1 Alan R Ellis,2M Alan Brookhart.1
1Department of Epidemiology, Gillings School of Global
Public Health, University of North Carolina at Chapel
Hill, Chapel Hill, NC, United States; 2Cecil G. Sheps
Center for Health Services Research, University of North
Carolina at Chapel Hill, Chapel Hill, NC, United States.
Background: Non-experimental studies of preventive
interventions suffer from healthy user bias when patients
receiving the intervention are healthier in unmeasured
ways than apparently comparable patients not receiving
the intervention (e.g., when frailty in the untreated group
causes rapid health declines and adverse outcomes). In a
previous study of inﬂuenza vaccine effectiveness (VE) in
hemodialysis patients, the authors reported evidence of
this bias, which could not be controlled with available
healthcare claims data.
Objectives: To explore whether this confounding could
be controlled using a marginal structural model with
granular data collected at dialysis sessions, including
changes in clinical and laboratory parameters.
Methods: In a cohort of 43,840 adult hemodialysis
patients with claims data from the U.S. Renal Data
System and clinical data from a large dialysis provider,
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we estimated inﬂuenza VE before and during the 2005/06
inﬂuenza season. A Cox proportional hazards marginal
structural model accounted for time-dependent confound-
ing. To reduce bias, we incorporated frailty indicators,
measured confounders at different time intervals, and
progressively restricted the sample. We assessed residual
bias by estimating VE prior to inﬂuenza season, which
should be negligible.
Results: The pre-inﬂuenza hazard ratio (HR) from our
base model was 0.43 (95% CI: 0.39, 0.47). Incorporating
detailed clinical data in a time-dependent fashion did not
reduce bias, nor did measuring time-dependent covariates
in periods of 4 or 10 days versus 7. Requiring survival
into the follow-up period reduced bias (12week survival:
pre-inﬂuenza HR= 0.66 (0.46, 0.95)). Adding restrictions
on baseline and time-dependent covariates further
reduced bias (10week survival + covariate restrictions:
0.96 (0.64-1.44)) but reduced sample size, resulting in
wide conﬁdence intervals. With both a survival require-
ment and covariate restrictions, inﬂuenza season VE
estimates ranged from 6% (HR= 0.94 (0.74, 1.20)) to
11% (HR=0.89 (0.71, 1.12)).
Conclusions: The healthy user bias in the present study
could not be controlled through statistical adjustment
but was reduced greatly using restriction.
347. Comparator Choice in Diabetes Drug Studies:
Single Class or Non-User Comparator Group?
Kimberly G Brodovicz, Mary E Ritchey, Yong Chen,
Michael Senderak, Jane Liao, Cynthia J Girman,
Ravi Shankar, Zhiwen Liu, Samuel S Engel. Merck,
Whitehouse Station, NJ, United States.
Background: Many observational comparative drug
studies have a non-user group as the comparator. A
non-user group may not be homogeneous and treating it
as such may mask differences between the drug of
interest and speciﬁc comparators.
Objectives: To assess the heterogeneity of a non-user
comparison group by examining differences in
baseline characteristics of patients with type 2 diabetes
initiating sitagliptin (SITA) vs single drug class
comparison groups.
Methods: Patients starting mono-, dual, or triple therapy
with SITA, metformin (MET), a sulfonylurea (SU), or a
thiazolidinedione (TZD) were identiﬁed in MarketScan
(MS, US) and Clinical Practice Research Datalink
(CPRD, UK) (2006-2012). Demographic and clinical
characteristics were assessed up to 5 yrs before drug start.
Balance in characteristics was compared by standardized
differences (SD).
Results: In CPRD, the characteristics that differed
between SITA and each drug class varied by class and
treatment complexity. For example, in dual therapy
patients, compared to MET, SITA patients were less
likely to have renal disease (13.6% vs 20.4%, SD -
0.18), cataracts (6.9% vs 10.7%, SD -0.14), or stroke
(3.4% vs 6.1%, SD -0.12) but were similar to SU or
TZD patients for these conditions. Compared to TZD,
SITA patients were more likely to have retinopathy
(19.4% vs 14.8%, SD 0.12), less likely to be smokers
(28.7% vs 34.8%, SD -0.13) but were similar to SU or
MET patients on these characteristics. SITA patients
were younger compared to MET (mean 62 vs 69 years,
SD -0.50) and SU (mean 62 vs 64 years, SD -0.15) but
similar in age to TZD patients. In MS, fewer differences
were noted between comparators and treatment complex-
ity. The differences (e.g. renal events in SITA vs MET
dual therapy; heart failure, volume depletion, arrhythmia
in SITA vs TZD triple therapy) were in conditions
included in product labeling.
Conclusions: In comparative observational studies of
diabetes medications, we recommend assessment of single
drug classes for the comparator group, rather than a broad
non-user group, to determine if heterogeneity exists. When
there are differences by class, an overall non-users group
may mask the true associations being studied.
348. Comparing Estimation Strategies for Disease
Risk Scores: A Simulation Study
Richard Wyss,1M Alan Brookhart,1 Virginia Pate,2 Til
Stürmer.1 1Department of Epidemiology, Gillings School
of Global Public Health, University of North Carolina,
Chapel Hill, NC, United States; 2Cecil G. Sheps Center
for Health Services Research, University of North
Carolina, Chapel Hill, NC, United States.
Background: The disease risk score (DRS) is a summary
score that is advantageous for controlling confounding in
certain settings. Estimating the DRS in practice can be
challenging due to limitations when ﬁtting the DRS
within the same population where the treatment effect is
estimated. Recent strategies that use data from outside
the study population to model the DRS have been
proposed to overcome these limitations. There remains
uncertainty regarding which population is optimal for
modeling the DRS in various settings speciﬁc to large
database research.
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Objectives: To evaluate potential gains that can be
achieved when using external data to model the DRS in
a variety of practical settings.
Methods: We simulated various degrees of additivity
and linearity while varying the sample size. We ﬁt the
DRS model within three populations: the full cohort,
untreated individuals, and an external population of
untreated individuals. Each model included only main
effects for the covariates to reﬂect practical settings
where there is some misspeciﬁcation in the DRS model.
We compared the percent bias and standard error of the
effect estimates after stratifying on the estimated DRSs.
Results: Results were similar when DRS models were
correctly speciﬁed and sample sizes were large. When
the study size was small (N = 500), ﬁtting the DRS model
within an outside population resulted in slightly lower
percent bias compared to ﬁtting the DRS within the study
cohort of untreated individuals (difference in percent bias
ranging from 0% to 3%). When the DRS models
were misspeciﬁed, ﬁtting the DRS within external data
resulted in a slight improvement in percent bias
compared to ﬁtting the DRS within the full study cohort
(difference in percent bias ranging from 0% to 2%).
Conclusions: Beneﬁts from using external data to model
the DRS were modest in the scenarios evaluated.
Advantages of using external data may be more pro-
nounced in settings speciﬁc to newly introduced treat-
ment therapies. Future research will include evaluating
the relative performance of these estimation strategies
when comparing newly introduced oral anti-coagulant
medications to warfarin in reducing ischemic stroke
within the Medicare data.
349. Increasing Trend of Type 1 Diabetes in Dutch
Children and Adolescents (1998-2010)
Soulmaz Fazeli Farsani,1 Patrick C Souverein,1 Marja
MJ van der Vorst,2 Catherijne AJ Knibbe,3 Ron
MC Herings,4 Anthonius de Boer,1 Aukje K Mantel-
Teeuwisse.1 1Division of Pharmacoepidemiology and
Clinical Pharmacology, Utrecht Institute for Pharmaceu-
tical Sciences (UIPS), Utrecht University, Utrecht,
Netherlands; 2Department of Pediatrics, St. Antonius
Hospital, Nieuwegein, Netherlands; 3Department of
Clinical Pharmacy, St. Antonius Hospital, Nieuwegein,
Netherlands; 4PHARMO Institute for Drug Outcomes
Research, Utrecht, Netherlands.
Background: There is no recent data on the epidemiol-
ogy of type 1 diabetes (T1D) in Dutch children and
adolescents. To assess the incidence and prevalence of
T1D in children, which is reasonably rare, a large
population has to be monitored.
Objectives: To assess trends in the incidence and
prevalence of T1D in Dutch children and adolescents
aged 0-19 years.
Methods: A population-based cohort study was
conducted in the Dutch PHARMO-RLS that comprises
community pharmacy dispensing records linked to hospi-
tal admissions (1998-2010). Insulin prescriptions were
used as a proxy to identify cases of T1D. All children
and adolescents aged 0-19 years with at least two insulin
prescriptions were identiﬁed and the numbers of incident
and prevalent cases of T1D (numerators) were calculated
in each year. The incidence and prevalence of T1D were
calculated overall and for different sexes and age catego-
ries (age bands: 0-4, 5-9, 10-14, 15-19, and 0-14 years)
using the data from the Dutch Central Bureau of Statistics
as denominator.
Results: In 2010, the incidence and prevalence of T1D
was 31.6/100,000 person-years and 195.2/100,000
children, respectively. From 1998 to 2010, the overall
incidence and prevalence of T1D in Dutch children
increased by 62.9% and 87.9%, respectively. A similar
increasing pattern was observed for boys and girls. The
largest increase in the incidence and prevalence of T1D
was perceived for 15-19 years adolescents (140% and
93%, respectively). A sensitivity analysis restricted to
children 0-14 years showed a plateau and even a gradual
decrease in the incidence of T1D, mainly driven by a
decreasing trend in the 0-4 year old children. Overall,
there was an increase in the mean age at the onset of
T1D (from 10.9 in 1999 to 13.1 years in 2010).
Conclusions: Our study is the most recent population-
based study to investigate the incidence and prevalence
of T1D in Dutch children and adolescents. Both incidence
and prevalence of T1D nearly doubled from 1998 to 2010.
The increase in the number of new cases and older age at
the onset of the disease warrants further research to identify
environmental triggering factors of T1D.
350. Cancer Incidence among Infants in the United
States, 2000-2010
Logan Tyler,1 Jinghua He.2 1Epidemiology and
Biostatistics, Drexel University Schoool of Public
Health, Philadelphia, PA, United States; 2Epidemiol-
ogy, Merck Sharp & Dohme, North Wales, PA, United
States.
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Background: Infant cancers have long been a difﬁcult
area of study. The most recent report on US infant
cancer epidemiology was based on data from 1980s
to early 1990s.
Objectives: To provide an update-to-date report on
infant cancer incidence in US.
Methods: The study used the publicly available data
from the Surveillance, Epidemiology, and End Results
(SEER) program. Additional data on month of age at
diagnosis were requested. The study population of
interest was limited to children diagnosed with primary
malignant cancers within 1 year old during 2000-2010.
The ﬁndings on cancer incidence were further stratiﬁed
by age in month, sex, calendar year, and major cancer
types based on International Classiﬁcation of Childhood
Cancer (ICCC). All analyses were performed using
SEER Stat 8.1.2 software.
Results: From 2000-2010, a total of 3,032 newly diag-
nosed infant cancer cases were recorded in SEER. The
overall incidence rate is 237.6 per 1 million (/1M), which
remains largely the same among all the calendar years.
The risk is slightly higher in males than females (247.4/
1M vs. 227.3/1M). Neuroblastoma and other peripheral
nervous cell tumors are the most frequent cancer type
with an overall incidence rate of 52.4 /1M. They are
followed by leukemias (47.2 / 1M), general central
nervous system (CNS) tumors (35.2 per 1M), retinoblas-
tomas (26.4 per 1M), and germ cell tumors (20.6/1M).
The cancer type ranks largely the same between males
and females. The gross majority of cancers display peak
incidence in the ﬁrst month of life and then generally
decrease over the following 11months of infancy.
Conclusions: Our ﬁndings on infant cancer incidence are
consistent with the data reported in 1980s and early 1990s.
No signiﬁcant changes were detected after stratiﬁed by
calendar years, age in month, sex, and ICCC cancer types.
351. Chronic Comorbidities in Children and Adolescents
with Type 1 Diabetes
Soulmaz Fazeli Farsani,1 Patrick C Souverein,1 Marja MJ
van der Vorst,2 Catherijne AJ Knibbe,3 Anthonius de
Boer,1 Aukje K Mantel-Teeuwisse.1 1Division of
Pharmacoepidemiology and Clinical Pharmacology,
Utrecht Institute for Pharmaceutical Sciences (UIPS),
Utrecht University, Utrecht, Netherlands; 2Department
of Pediatrics, St. Antonius Hospital, Nieuwegein,
Netherlands; 3Department of Clinical Pharmacy, St.
Antonius Hospital, Nieuwegein, Netherlands.
Background: Limited quantitative data exist on the burden
of chronic comorbidities in children and adolescents with
type 1 diabetes (T1D). Such knowledge is necessary for
the development of guidelines and prevention programs.
Objectives: To determine the incidence of chronic co-
morbidities in children and adolescents with T1D and to
compare the risks with the diabetes-free children.
Methods:A population-based cohort study was conducted
using the Dutch PHARMO-RLS that comprises commu-
nity pharmacy dispensing records linked to hospital
admissions. Insulin prescriptions were used as a proxy to
identify incident cases of T1D. All patients (<19years)
with at least 2 insulin prescriptions (T1D cohort), and up
to 4 diabetes-free children with the same age and sex but
without any anti-diabetic prescription (reference cohort)
were sampled (1999-2009) and followed for a median of
5 years. The incidence of 9 common chronic comorbidities
was assessed using hospital admissions (ICD-9 codes),
and/or dispensing records (ATC codes). Cox proportional
hazard analysis was used to estimate the strength of the
association between T1D and comorbidities, expressed as
hazard ratios (HR (95% conﬁdence intervals (CI)), and to
assess effect modiﬁcation by age and sex.
Results: A total of 925 T1D patients and 3591 reference
children (49.3% girls, mean age 10.1 [SD 4.5] years) met
the inclusion criteria. T1D was associated with an
increased risk (HR (95%CI)) of thyroid disease 14.9
(6.8-32.5), non-infectious enteritis and colitis 5.9
(3.0-11.5), cardiovascular disorders 4.4 (3.1-6.1), mental
disorders 2.1 (1.4-3.0), epilepsy 2.0 (1.1-3.8), and
(obstructive) pulmonary disease 1.4 (1.1-1.7). The inci-
dences of other comorbidities (malignant disorders, anemia,
and migraine) were also higher in the T1D cohort compared
with the reference cohort, but not statistically signiﬁcant. No
effect modiﬁcation by age and sex was found.
Conclusions: Risks of 6 comorbidities were signiﬁcantly
higher in children and adolescents with T1D (during the
early years after diagnosis of T1D) compared with the
diabetes-free children and adolescents which conﬁrm
the necessity of applying regular monitoring programs
early after the diagnosis of T1D.
352. Antimuscarinic Utilization in the Pediatric
Population in the United States, 2000-2011
Alan Kinlaw,1 Jennifer Wu,2 Mitchell Conover,1
Virginia Pate,1 Michele Jonsson Funk.1 1Department of
Epidemiology, University of North Carolina at Chapel
Hill, Chapel Hill, NC, United States; 2Department of
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Obstetrics and Gynecology, University of North Carolina
at Chapel Hill, Chapel Hill, NC, United States.
Background: Antimuscarinics are ﬁrst line pharmaco-
therapy for overactive bladder. Oxybutynin is the only
one approved in the US, and it is approved for children
5 and older. There are no population-based estimates of
antimuscarinic utilization in children.
Objectives: To estimate rates and time trends of
antimuscarinic utilization in the pediatric population, and
to identify diagnoses and provider characteristics associ-
ated with children’s prescriptions for antimuscarinics.
Methods: We assessed longitudinal healthcare claims in
Truven Health Analytics’ MarketScan databases from
2000–2011 for individuals <18years of age, including
person-time only when children had prescription drug cover-
age. Using National Drug Codes, we identiﬁed prescriptions
for twelve antimuscarinic formulations and standardized
prescription length to 30days. We estimated utilization rates
per 100,000 person-months, rate ratios (RR), and 99%
conﬁdence intervals (CI). We described diagnoses and
provider type from the most proximate inpatient or outpatient
visit preceding prescription, within 30days.
Results: We identiﬁed 60,628 children with 270,184 pre-
scriptions among 34,416,978 children during 655,743,096
person-months of prescription coverage (rate: 41.2 prescrip-
tions per 100,000 person-months; 99%CI: 41.0–41.4).
Among children under 7 years of age, oxybutynin syrup
was the most common antimuscarinic (51.1%); for older
children, oxybutynin (63.6%) and tolterodine (19.5%) pills
were prevalent. Utilization varied by age and was highest
for ages 6-9 (rate: 66.6; 99%CI: 66.0–67.2). Utilization
was 32% higher for females than males (RR: 1.32; 99%
CI: 1.31–1.34). Use increased by 1.9% per calendar year
from 2000 to 2011 (99%CI: 1.7%–2.1). The most common
diagnoses were urinary frequency (9%), incontinence (8%),
urinary tract infection (8%), and nocturnal enuresis (6%).
Common providers were pediatricians (21%) and urologists
(19%); pediatric urologists were less common (2%).
Conclusions: Antimuscarinic utilization in children and ad-
olescents has increased and the highest rates were among girls
age 6-9 years. Additional research is needed regarding the
efﬁcacy and safety of these drugs in the pediatric population.
353. Prevalence of Pediatric Chronic Hepatitis C
Patients in the European Union (EU) in 2012
Shih-Chen Chang,1 Katie M Miller,1 Gregory Hooper.2
1EpiRPO, Genentech, South San Francisco, CA, United
States; 2PDI, Roche, Welwyn, United Kingdom.
Background: The HCV screening of blood donor products
became mandatory since 1992 in Europe and effectively
eliminated the risk of HCV infection through blood
transfusion. As of 2012, all children (<18) were born post
blood-donor-screening era, thus making mother-to-child
transmission (MTCT) of HCV the primary source of infec-
tion. Published studies are not readily available to estimate
current disease burden for this vulnerable population.
Objectives: To develop an algorithm to estimate the pediat-
ric HCV prevalence in the EU by considering contributing
factors, including vertical MTCT, horizontal transmission
in injecting drug users (IDUs), and immigration.
Methods: For MTCT, a published approach (Jhaveri et al,
J Pediatr 2006;148:353-8) was adapted to include number
of live births (surrogated by number of children), HCV
prevalence in pregnant mothers, MTCT rate, and spontane-
ous virus clearance rate. For immigrant children with
HCV, a similar approach was adapted using the number
of immigrant children andweighted prevalence in pregnant
mothers from the corresponding countries of origin.
For horizontal transmission in IDUs, only children ages
15-17 were considered, and the model included prevalence
of IDUs in adolescents and HCV prevalence amongst these
IDUs. Data resources used for this estimation model were
extracted from peer review studies, European vital statis-
tics, other surveillance data, and trends in international
migrants stock from the United Nations.
Results: Based on the model, in 2012, the total estimated
pediatric HCV prevalence in 27 EU & 4 member states
(Iceland, Norway, Liechtenstein, Switzerland) was 49.4
and 56.8 per 100,000 from the ages of 0-14 and 15-17,
respectively; with the majority of patients (~95%)
contributing to the estimate through MTCT.
Conclusions: A model based on a number of assump-
tions and extrapolations was developed to provide an
effective estimation. A well-designed screening study
would more accurately estimate the current pediatric
HCV prevalence in the EU, however, given the low
estimated prevalence in our model, it will require a large
screening study and this may not be cost-effective.
354. Association between Use of Asthma Drugs in
Children and Hepatotoxicity
Carmen Ferrajolo,1,2 Marjolein Engelkes,1 Katia MC
Verhamme,1 Gianluca Triﬁrò,1,3 Annalisa Capuano,2
Miriam CJM Sturkenboom.1,4 1Medical Informatics,
Erasmus University Medical Center, Rotterdam,
Netherlands; 2Experimental Medicine, Pharmacology
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Section, Campania Regional Center of Pharmacovigilance
and Pharmacoepidemiology, Second University of
Naples, Napoli, Italy; 3Clinical and Experimental
Medicine, University of Messina, Messina, Italy;
4Epidemiology, Erasmus University Medical Center,
Rotterdam, Netherlands.
Background: Hepatotoxicity in relation to asthma drugs is
rare. Some cases of hepatotoxicity have been described with
use of Leukotriene receptor antagonists (LTRA). Our research
on signal detection in children showed a new association be-
tween ﬂunisolide, an inhaled corticosteroid, and liver injury.
Objectives: To investigate the association between oral
and inhaled use of asthma drugs and hepatotoxicity in
children and adolescents.
Methods: A population-based case-control study was
performed over 2000-2008 combining three European
electronic primary care databases: The Integrated Pri-
mary Care Information database in the Netherlands, plus
the PEDIANET and the Health Search/CSD Longitudinal
Patient Database in Italy. Cases of hepatotoxicity in the
pediatric population (<18 years old) were identiﬁed and
validated in each database, retaining only idiopathic
cases. Up to 100 controls were matched to each case
based on age, gender and the date of case diagnosis
(index date). Use of antiasthmatics was classiﬁed as current
if a prescription for the drug of interest lasted until index
date or ended within 60 days prior to the index date.
Results:We identiﬁed 938 pediatric cases of hepatotoxicity
and these were matched to 93,665 controls. Signiﬁcant
unadjusted associations were found for current inhaled use
of β2-adrenergic agonists [OR 2.3 (95% CI, 1.6 to 3.4), cor-
ticosteroids (2.3, 1.7 to 3.2), cromoglicic acid/nedocromil
(3.3, 1.1 to 10.6) and oral use of LTRA (2.6, 1.1 to 5.8),
compared to non-use. When adjusting for concurrent use
of antibiotics, the association remained signiﬁcant only for
the use of β2-agonists and corticosteroids. Use of LTRA
was associated with an increased risk estimate of hepatotox-
icity (adj. OR 1.8, 0.8 to 4.0), but no longer signiﬁcant.
Conclusions: This study provides some evidence on the
hepatic safety of anti-asthmatics in children. Use of β2-
agonists and corticosteroids was associated with an increased
risk of hepatotoxicity, but additional studies will be needed to
verify that this is not due to residual confounding.
355. Use of Oral Contraceptives and Risk of Hemor-
rhagic Stroke in Denmark (2003 -2012)
Klaus K Andersen,1 Christian Dehlendorff,1 Charlotte
Skriver,1 Søren Friis,1 Tom S Olsen.2 1Statistics,
Bioinformatics and Registry, Danish Cancer Society
Research Center, Copenhagen, Denmark; 2Stroke Unit,
Frederiksberg Hospital, Copenhagen, Denmark.
Background: There is evidence that use of oral contracep-
tives (OC) is associated with an increased risk of ischemic
stroke. Whether there is an increased risk of hemorrhagic
strokes remains unclear since studies of this issue are few.
Increased risk of hemorrhagic stroke among OC users has
been reported in all ages in developing countries, whereas
in western countries only OC use above age> 35years
has been found to be associated with an increased risk.
Objectives: To determine whether use of OC increases
the risk of hemorrhagic stroke in Danish women between
age 15 and 50 years.
Methods: We followed the entire Danish female popula-
tion aged 15 to 50 years during the period 2003-2011. For
all women, we obtained information on current use of OC
and diagnoses of stroke from nationwide registries. Fur-
thermore, we recorded information on age, calendar time,
education, and loss to follow-up. We deﬁned current use
of OC as redeeming at least two OC prescriptions (ATC
group, G03A) within the previous year. The main out-
come was hospitalization for stroke. Stroke subtype was
deﬁned as either ischemic or hemorrhagic stroke based
on CT or MR-scan. The effect of OC on stroke was ana-
lyzed by applying log linear Poisson models adjusting for
age, calendar time and educational level and with person-
time at risk as an offset. Analyses were run for ischemic
and hemorrhagic stroke separately. Effects were reported
as relative risks (RR) with 95% conﬁdence intervals (CI).
Results: The study population contributed with a total 21,9
million person-years. We identiﬁed 2,333 strokes, of which
2,180 were ischemic and 153 were hemorrhagic. In total,
OC use constituted 3,7 million person years (17.1%). OC
use was most frequent in ages 20-25 years (68 %). Current
use of OC was associated with an increased risk of ischemic
stroke (OR, 1.42; 95% CI, 1.28-1.58), whereas we did not
observe an increased risk of hemorrhagic strokes associated
with current OC use (OR, 1.02; 95% CI, 0.68-1.54). No
effect measure modiﬁcation by age was found.
Conclusions: Current use of OC was associated with an
increased risk of ischemic, but not hemorrhagic, stroke,
irrespective of age.
356. Comparative Cardiovascular Safety of Testosterone
Formulations in the United States and United Kingdom
J Bradley Layton,1 Julie L Sharpless,2 Christoph R
Meier,3 Til Stürmer,1 Susan S Jick,4M Alan Brookhart.1
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Hill, United States; 2Medicine, University of North
Carolina, Chapel Hill, United States; 3Pharmaceutical
Science, University of Basel, Basel, Switzerland; 4Epide-
miology, Boston University, Boston, United States.
Background: Increases in testosterone use and reports of
adverse events have raised concerns about the cardiovas-
cular (CV) safety of testosterone. Testosterone is
available in several delivery mechanisms with varying
pharmacokinetics; injections cause spikes in testos-
terone levels, while transdermal patches and gels cause
more subtle but sustained increases. The comparative
safety of gels, injections and patches has not been
established.
Objectives: To determine the comparative CV safety of
testosterone injections, patches, and gels.
Methods: We identiﬁed new users of testosterone from
pharmacy dispensing or physician prescribing records in
commercial insurance (MarketScan) and Medicare claims
from the United States and general practitioner records
from the United Kingdom (CPRD) for the years 2000 -
2011. After a 180 day washout period, we followed users
for one year for the occurrence of: CV outcomes, including
myocardial infarction (MI), unstable angina (UA), stroke;
venous thromboembolism (VTE); all-cause hospitaliza-
tion; or mortality. We calculated adjusted hazard ratios
and 95% conﬁdence intervals (CI) using Cox proportional
hazard models comparing injection and patch to gel users
in an intent-to-treat analysis. Analyses were performed
separately in the three databases, tested for heterogeneity,
and uniform estimates were pooled.
Results: We identiﬁed 431,687 testosterone initiators:
36% injection, 9% patch, 55% gel. Medicare had a
majority of injection users (51%); MarketScan had
majority gel users (56%); CPRD had equal proportions
of injections and gels (~41%). Heterogeneity was not
observed among the three database estimates. Compared
to gels, injection users had higher hazard of CV events
(MI, UA, and stroke) (HR= 1.24, 95%CI: 1.15, 1.33),
hospitalization (HR=1.16, 1.13-1.18), and death (HR=
1.32, 1.14-1.54), but not VTE (HR= 1.06, 0.98-1.14).
Patches did not show increased hazard of CV events
(HR= 1.10, 0.93-1.31), hospitalization (HR= 1.03, 0.99-
1.07), or death (HR= 1.09, 0.83, 1.43).
Conclusions: Testosterone injections were associated
with a greater risk of CV events, hospitalizations, and
deaths compared to gels. Patches and gels had similar
risk proﬁles.
357. Dipeptidyl Peptidase-4 Inhibitors Do Not Increase
the Risk of Cardiovascular Events in Type 2 Diabetes
Seoyoung C Kim,1 Robert Glynn,1 Jun Liu,1 Brendan
Everett,1 Allison Goldﬁne.2 1Brigham and Women’s
Hospital, Boston, MA, United States; 2Joslin Diabetes
Center, Boston, MA, United States.
Background: Dipeptidyl peptidase-4 inhibitors (DPP4i)
are oral glucose-lowering drugs for type 2 diabetes mellitus
(T2D). While 2 recent clinical trials of T2D patients with
cardiovascular disease (CVD) at baseline showed no risk
of ischemic cardiovascular events associated with DPP4i,
1 trial showed an increased risk of hospitalization for heart
failure (HF) in the saxagliptin group.
Objectives: We evaluated the risk of CVD including
myocardial infarction (MI), stroke, coronary revasculari-
zation, and HF associated with DPP4i in T2D patients
with and without baseline CVD.
Methods: We conducted a cohort study using commer-
cial insurance claims data (2005-12). Among T2D
patients aged 40 years and older, initiators of DPP4i
combotherapy (DPP4i plus metformin) and non-DPP4i
combotherapy (metformin plus other non-DPP4i drugs)
were selected. Patients with cancer, end-stage renal
disease, dialysis, or use of insulin or glucagon-like
peptide 1 agonists at baseline were excluded. The
primary endpoint was a composite CVD outcome includ-
ing MI, stroke, coronary revascularization and HF. To
control for baseline confounders such as demographic
factors, comorbidities, medications, and health care
utilization, propensity score (PS)-matched Cox regres-
sion models compared the risk of CVD in DPP4i initia-
tors vs. non-DPP4i initiators with and without baseline
CVD. Sensitivity analysis compared DPP4i monotherapy
vs. non-DPP4i monotherapy.
Results: We included a total of 32,419 PS-matched pairs
of DPP4i and non-DPP4i combotherapy initiators. The
PS-matched HR for composite CVD was 0.90 (95%CI
0.77-1.06) for DPP4i vs. non-DPP4i combotherapy initi-
ators in patients with baseline CVD. The PS-matched HR
for composite CVD was 0.95 (95%CI 0.80-1.13) in
patients with no baseline CVD for DPP4i vs. non-DPP4i
initiators. The PS-matched HR for hospitalization for HF
was also not increased with DPP4i. Similarly, the sensi-
tivity analysis showed no CVD risk in DPP4i monother-
apy initiators with and without baseline CVD.
Conclusions: In this large cohort of T2D patients, initiating
DPP4i was not associated with an increased or decreased
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risk of CVD including HF compared to those initiating
non-DPP4i.
358. Risk of Out-of-Hospital Sudden Cardiac Death
with Use of Domperidone, Proton Pump Inhibitors,
and Metoclopramide
Alejandro Arana,1 Catherine Johannes,2 Cristina Varas,1
Kenneth J Rothman,2 Lisa J McQuay,3 Qing Yang,3
Daniel Fife.4 1Epidemiology, RTI-HS, Barcelona, Spain;
2Epidemiology, RTI-HS, Waltham, MA, United States;
3Epidemiology, RTI-HS, Research Triangle Park, NC,
United States; 4Epidemiology, Janssen Research and De-
velopment, LLC, Titusville, NJ, United States.
Background: Epidemiologic studies have linked
exposure to domperidone (DOM) with serious cardiac
arrhythmias, including sudden cardiac death (SCD), but
most of these studies were small, and data relating risk
to age, dose, and duration of use are limited.
Objectives: To clarify the risk of out-of-hospital SCD
with use of DOM.
Methods:We conducted a population-based case-control
study nested (NCC) within a cohort drawn from the UK
Clinical Practice Research Datalink (CPRD), linked to
mortality and hospital data in 2005-2011. Controls were
matched to SCD cases on age, sex, and practice. Risk of
SCD in users of DOM relative to risk among users of
proton pump inhibitors (PPI), metoclopramide (MET),
and no use at the index date was evaluated with
multivariable conditional logistic regression. We also
conducted case-crossover (CC) analyses to address
possible residual confounding by features of exposed
subjects.
Results: In the NCC analysis (3,397 SCD cases; 13,179
controls), the adjusted odds ratio (aOR) for SCD with
current use of DOM alone (31 cases and 55 controls)
compared with non-use of study medications (824 cases
and 4,690 controls) was 2.09 (95% CI, 1.16-3.74); for
oral MET, 4.29 (95% CI, 2.39-7.70); and for oral PPI,
1.32 (95% CI, 1.18-1.48). Compared with current MET
use, the aOR for current DOM use was 0.42 (95% CI,
0.19-0.94) and compared with current PPI use was 1.58
(95% CI, 0.88-2.52). OR estimates were higher in the
CC analysis than in the NCC analysis for DOM (3.33;
95% CI, 1.87-5.92) and for MET (4.78, 95% CI, 2.74-
8.36), but the OR for PPIs was near 1. There was a larger
effect for current use of DOM alone compared with non-
use among those aged> 60 years (aOR, 2.01; 95% CI,
1.12-3.62) than those aged 2-59 years, with a dose of
> 30mg/day (aOR, 4.52; 95% CI, 0.91-22.58) than lower
doses, and with duration of use< 16 days, (aOR, 6.18;
95% CI, 2.48-15.4) than≥ 16 days.
Conclusions: Susceptibility to SCD related to DOM
exposure appears to be increased in certain subgroups
of DOM users. The ﬁndings on MET were unexpected
and should be evaluated in further studies.
359. Association of Azithromycin and Ventricular
Arrhythmia: the ARITMO Project
Gianluca Triﬁro,1,2 Alessandro Oteri,1 Maria de Ridder,1
Peter Rijnbeek,1 Serena Pecchioli,3 GiampieroMazzaglia,3
Irene Bezemer,4 Edeltraut Garbe,5 Tania Schink,5
Elisabetta Poluzzi,6 Trine Frøslev,7 Miriam Sturkenboom.1
1Erasmus University Medical Center, Rotterdam;
2University of Messina, Messina; 3Health Search,
Italian College of General Practitioners, Florence;
4PHARMO Institute for Drug Outcomes Research,
Utrecht; 5Leibniz Institute for Epidemiology and Pre-
vention Research - BIPS GmbH, Bremen; 6Department
of Pharmacology, University of Bologna, Bologna; 7De-
partment of Clinical Epidemiology, Aarhus University
Hospital, Aarhus.
Background: A recent US study showed an increased
risk of cardiovascular death with azithromycin as
compared to amoxicillin. Using Penicillin V as compara-
tor, a following study did not conﬁrm this association in a
Danish young and middle age population.
Objectives: This population-based, multi-Country,
nested case-control study was aimed to evaluate the risk
of ventricular arrhythmia (VA) with azithromycin use.
Methods: Data source was a network of 7 healthcare da-
tabases (AARHUS/Denmark, GEPARD/Germany, HSD
and ERD/Italy, PHARMO and IPCI/Netherlands, and
THIN/UK), covering a population of around 35 million
European subjects from 1996 to 2010. In a cohort of
antibiotic users, VA cases were identiﬁed through
validated coding algorithms and matched to up to 100
controls by index-date (ID, i.e. date of VA onset), sex,
age and database. Exposure to azithromycin and other
antibiotics was categorized as: a) current (exposure at
ID or within 7 days prior); b) recent (exposure ended
between 7 and 90 days prior to ID); c) past (exposure
ended between 90 and 365 days prior to ID); and d) no-
use (no exposure within 365 days prior to ID). Odds ratio
(OR) of current use of azithromycin relative to either
no-use of any antibiotic or current use of amoxicillin was
estimated using multiple conditional logistic regression,
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while adjusting for confounders. Risk estimates were
reported for each database and for pooled data.
Results: Overall, 13,536 VA cases were identiﬁed, and,
of these, 30 were currently exposed to azithromycin and
1,026 to other antibiotics. As compared to no-use of
any antibiotic, current use of azithromycin (ORadj:
1.97; 95%CI: 1.35-2.86) was associated with a statisti-
cally signiﬁcant increase in VA risk. In comparison to
current use of amoxicillin, this risk disappeared (ORadj:
0.90; 95%CI: 0.48-1.71). Results from meta-analyses
of database-speciﬁc estimates conﬁrmed results from
pooled analysis.
Conclusions: The increase in VA risk with azithromycin
was not conﬁrmed in this European multi-database study.
The observed increase in the VA risk for azithromycin, as
compared to no-use, points towards confounding by indi-
cation due to acute effects of infections.
360. Risk of Hemorrhagic Stroke Associated with
Combined Use of Antidepressants and Non-Steroidal
Anti-Inflammatory Drugs
Ju-Young Shin,1 Mi-Ju Park,1 Mi-Hee Kim,1 Nam-
Kyong Choi,2 Joong-Yeup Lee,2 Byung-Joo Park.1,3
1Korea Institute of Drug Safety and Risk Management,
Seoul; 2Medical Research Collaborating Center, Seoul
National University College of Medicine/Seoul National
University Hospital, Seoul; 3Department of Preventive
Medicine, Seoul National University College of
Medicine, Seoul.
Background: It is generally believed that antidepressants
and non-steroidal anti-inﬂammatory drugs (NSAIDs) in-
crease the risk of abnormal bleeding. But little is known
about the risk of hemorrhagic stroke associated with
combined use of antidepressants and NSAIDs.
Objectives: To investigate the association between the
use of antidepressant with or without NSAIDs and the
risk of hemorrhagic stroke.
Methods: We conducted a retrospective cohort study
involving 5,059,438 patients who newly prescribed an
antidepressant medication between 2009 and 2012 using
the Korea Health Insurance Review and Assessment
Service (HIRA) database. Patients with prior cerebrovas-
cular diseases (ICD-10: I60-I68, G45, G46) during prior
365 days were excluded. Propensity-matched cohort
was constructed and ﬁnal study subject were two groups
of 1,863,244 new users of antidepressant with or without
NSAIDs. Outcome was deﬁned as the ﬁrst hospitalization
to the hemorrhagic stroke (ICD-10: I60-62). Incidence
Rate (IR) per 1,000 person-years and its 95% Conﬁdence
Interval (CI) were calculated assuming a Poisson distri-
bution. Cox regression models were used to estimate
the hazard ratios (HR) and their 95% CI for hemorrhagic
stroke in the propensity-matched cohort.
Results: Increased risk of hemorrhagic stroke was
observed among those on antidepressants with NSAIDs,
as compared with those on antidepressants alone (HR,
1.24; 95% CI, 1.15 to 1.34). Particularly, the risk of com-
bined use within 7 days appeared to be higher (HR, 1.68;
95% CI, 1.54 to 1.84). Use of Serotonin-Norepinephrine
Reuptake Inhibitors (SNRIs) showed the higher IR of hem-
orrhagic stroke (SNRIs alone: IR, 6.09; 95% CI, 4.61 to
8.06; SNRIs +NSAIDs: IR, 7.48; 95% CI, 5.91 to 9.47),
as compared with use of overall antidepressants use
(antidepressants alone: IR, 3.82; 95% CI, 3.59 to 4.05;
antidepressants +NSAIDs: IR, 4.45, 95%CI, 4.24 to 4.68).
Conclusions: Combined use of antidepressants and
NSAIDs was associated with increased risk of hemor-
rhagic stroke compared with antidepressants alone, espe-
cially within one week. More attention should be paid to
the patients who were treated with both drugs together.
361. Comparison of Chronic Disease Burden of
Chinese in US and in China: Findings from Two Large
Nationally Representative Surveys in US and China
Chenghui Li. University of Arkansas for Medical
Sciences, Little Rock, United States.
Background: Chinese Americans are a less studied
group due to low participation rate in clinical studies.
Data from Chinese population in Asian could provide
important implications for this population. However,
Chinese residing in US may differ signiﬁcantly from
Chinese residing in Asian in their disease burden and
disease progression due to dietary and lifestyle changes
and difference in environmental factors.
Objectives: Using two large nationally representative
survey databases in US and China, this study compares the
prevalence of chronic diseases between Chinese adult popu-
lations in China and those currently residing in the US.
Methods: Design: Data on Chinese population were
from 2011 China Health And Retirement Longitudinal
Study (CHARLS) Wave 1 survey and data on Chinese
in the US were from 2007-2012 National Health Inter-
view Survey (NHIS). Because of the limited sample size
of Chinese in NHIS, data from the 6 years were pooled.
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Adults aged 45 or older were included in this study.
Main outcome measures: Prevalence chronic conditions
(hypertension, diabetes, cancer, liver diseases, heart
diseases, stroke, arthritis, asthma) ascertained by an
afﬁrm answer to the question asking if a person was ever
been diagnosed with each of the conditions by a doctor.
Statistical analysis: Age-adjusted prevalence rates and
95% conﬁdence intervals were calculated.
Results: Among adult Chinese aged 45 or older, those
residing in the US have a higher prevalence of
hypertension (34.7%, 95% CI: 30.1-38.8%; vs. 24.9%,
95% CI: 23.6-26.1%), cancer (7.9%, 95% CI: 6.2-
10.0%; vs. 0.9%, 95% CI: 0.8-1.1) and asthma (7.0%,
95% CI: 5.1-9.6; vs. 3.8%, 95% CI: 3.3-4.2%) but lower
prevalence of arthritis (16.8%, 95% CI: 13.8-20.2%;
vs. 32.5%, 95% CI: 30.7-34.3%) compared to Chinese
in China.
Conclusions: Chinese residing in the US differ signiﬁ-
cant from the Chinese in China in term of their chronic
disease burden.
362. Safety of Anticholinergic Medications in the
Elderly: Anticholinergic Burden and Lower Urinary
Tract Symptoms (LUTS)
Lisa G Pont,1 JTH (Yannick) Nielen,2 Andrew
McLachlan,1 Danijela Gnjidic,1 Lewis Chan,1 Robert
Cumming,1 Katja Taxis.3 1University of Sydney,
Sydney, Australia; 2Maastricht University, Maastricht,
Netherlands; 3University of Groningen, Groningen,
Netherlands.
Background: Lower Urinary Tract Symptoms (LUTS)
are a signiﬁcant health issue for the elderly yet little is
known about the clinical relevance of anticholinergic
medication use on urinary function.
Objectives: To explore the relationship between anticho-
linergic burden and urinary outcomes (LUTS) in a cohort
of community dwelling older men.
Methods: A cross sectional survey of baseline data from
a longitudinal cohort of 1705 men aged over 70 years
resident in the Sydney metropolitan area was conducted.
Medication use (prescription and non prescription) and
urinary outcomes data (frequency, nocturia, inconti-
nence, post-void residual (PVR) volume, overall LUTS
severity and urinary quality of life (UQoL)) was collected
during scheduled clinic visits. Anticholinergic burden
was assessed using 4 scales (Anticholinergic Cognitive
Burden scale (ACB), Anticholinergic Drug burden Scale
(ADS), Anticholinergic Risk Scale (ARS), Anticholiner-
gic component of the Drug Burden Index (DBI-A)).
Ordinal regression with adjusted parameter estimates
was used to compare urinary outcomes with each scale.
Results: The mean participant age was 76.9 (±5.5) years.
Most participants were using at least one medication. With
the exception of the ADS and the ACB (κ=0.629) agree-
ment between scales to categorize anticholinergic burden
was poor (κ< 0.3). While an association was found
between LUTS severity and increasing anticholinergic
burden for all scales the scales varied in their relationship
with the individual urinary outcomes. ACB and ADS
demonstrated a relationship with increased frequency
(ACB: B=0.427, p = 0.002, ADS: B= 0.350, p = 0.005),
ARS and ADS showed an increase in PVR (ARS:
B=0.543, p = 0.043, ADS: B=0.487, p = 0.022). No
relationship between anticholinergic use and nocturia was
observed for any scale.
Conclusions: Agreement between commonly used scales
to measure anticholinergic burden was lacking with
respect to urinary function. However, in general, in-
creased anticholinergic burden was associated with
poorer outcomes of urinary function in a cohort of older
men, highlighting the need for caution when using these
medications in the elderly.
363. Oral Corticosteroids and the Risk of Serious
Infections in Patients with Elderly-Onset Inflammatory
Bowel Diseases
Paul Brassard,1 Alain Bitton,2 Alain Suissa,3 Liliya
Sinyavskaya,1 Valerie Patenaude,1 Samy Suissa.1
1Center for Clinical Epidemiology & Community
Studies, Jewish General Hospital, Lady Davis Institute
for Medical Research, Montreal, QC, Canada;
2Division of Gastroenterology, McGill University,
Department of Medicine, McGill University Health
Centre, Montreal, Canada; 3Department of Gastroenter-
ology, Rambam Health Care Campus, Technion-Israel
Institute of Technology, Haifa, Israel.
Background: Systemic corticosteroids are among the
most common anti-inﬂammatory treatments in elderly-
onset IBD patients. Steroid use and older age each
independently predisposes to infections and infections
increase mortality in hospitalized older IBD patients.
Objectives: To examine the relation between oral
corticosteroid treatment and serious infections in elderly-
onset IBD patients, and explore how the timing of
exposure affects the risk estimates.
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Methods: Using the healthcare databases (RAMQ and
MEDECHO) of the province of Quebec, Canada, we
conducted a population-based cohort study with a nested
case-control analysis. Incident IBD patients aged
66 years or over were identiﬁed from January 1st, 1996
to December 31st, 2009. Patients were followed until
end of study, date of death, end of drug coverage, or
the study outcome. Outcome was deﬁned as an occur-
rence of hospitalization with serious infection as primary
discharge diagnosis (index date). Exposure was deﬁned
as any oral corticosteroid dispensed during 6-month
period prior to the index date, and further classiﬁed as
current and past. Conditional logistic regression was
performed to estimate crude and adjusted rate ratios
(RRs) with 95% conﬁdence intervals (CIs).
Results: We identiﬁed 3,522 elderly-onset patients, of
which 564 cases with serious infections were identi-
ﬁed during a mean 4.4 years of follow-up (incidence
rate 3.7 per 100 per year) and matched to 2,646 con-
trols The rate of serious infections was signiﬁcantly
higher in those exposed to oral corticosteroids any
time during the 6-month period compared with non-
exposed (aRR 2.3; 95%CI 1.8 - 2.9). Those currently
exposed (within 45 days) had a higher risk (aRR 2.8;
95%CI 2.1 - 3.7). The residual effect of oral cortico-
steroids remained marginally statistically signiﬁcant
up to the 90 days period prior to the index date (aRR
1.7; 95%CI 1.0 - 2.7).
Conclusions: We found an excess relative risk for
serious infections in elderly-onset IBD patients on oral
corticosteroid therapy. Those with current exposure
demonstrated a higher vulnerability to infections.
364. Withdrawn by Author
365. Incidence of Barrett’s Esophagus and Esophageal
Adenocarcinoma in the United Kingdom and the
Netherlands: Did We Reach a Plateau?
Gwen MC Masclee,1,2 Preci M Coloma,1 Marcel de
Wilde,1 Ernst J Kuipers,2 Miriam CJM Sturkenboom.1,3
1Medical Informatics, Erasmus University Medical
Center, Rotterdam, Netherlands; 2Gastroenterology and
Hepatology, ErasmusUniversityMedical Center, Rotterdam,
Netherlands; 3Epidemiology, Erasmus University Medical
Center, Rotterdam, Netherlands.
Background: Barrett’s esophagus (BE) is a risk factor
for esophageal adenocarcinoma (EAC). Several studies
report increasing incidences of BE with substantial
variation and not considering detection bias.
Objectives: To determine age- and sex-stratiﬁed incidence
rates (IR) of BE and EAC.
Methods: Design:Cohort study from 2000-2012.
Setting:Two general practice databases in United
Kingdom (UK; THIN The Health Improvement
Network) and Netherlands (NL; IPCI Integrated
Primary Care Information).
Outcome: BE and EAC cases were identiﬁed using dis-
ease-speciﬁc READ codes (UK) and free-text search with
manual validation (NL).
Statistical analysis:Age-and sex-speciﬁc incidence
rates (IRs) were calculated for both BE and EAC.
Results: From the study population of 6,885,420 subjects
in UK we identiﬁed 12,312 incident BE and 40 (0.3%)
subsequent incident EAC cases. Among 1,487,191
subjects in NL 1,383 incident BE and subsequent 5
(0.4%) incident EAC cases occurred.
IR of BE increased linearly with age: 15.6/100,000
PYs (UK) and 23.7/100,000 PYs (NL) for patients aged
40-44 years, increasing to 85.6/100,000 PYs (UK) and
87.0/100,000 PYs (NL) for 70-74 years. In both UK
and NL, IR of BE was 2-4 times higher in males than
females across all age groups.
With respect to calendar time, the IR of BE
increased by 35% (UK) and 41% (NL) from 2000 to
2003, after which IRs remained stable until 2012. The
increase in IR of BE was not explained by increasing
number of gastroscopies; IR of BE/1,000 gastroscopies
in 2000: 29.1 and 26.4 and in 2011: 38.5 and 31.2 in
UK and NL, respectively. IR of EAC among the gen-
eral population was 2.9/100,000 PYS in UK, which
increased from 2.1 in 2000 up to 3.2 in 2011. IR of
EAC among BE subjects was 22.6/100,000 PYs in
UK and 80.1/100,000 PYs in NL. The one-year risk
of EAC among BE patients was 0.086% (95% CI:
0.04 – 0.17).
Conclusions: IRs of BE in the UK and NL increased
until 2003, but levelled off and were not explained by
detection bias. Around 0.3% of BE patients developed
EAC ≥1 year after BE diagnosis, with a one-year risk of
0.09%. The current increase in EAC incidence may
reﬂect the increase in BE incidence a decade ago.
366. Incidence of Drug-Induced Acute Liver Failure: A
Population-Based Study
David Goldberg,1,2,3,4 Kimberly Forde,1,2,3 Kevin
Haynes,2,3 James D Lewis,1,2,3,4 Dena Carbonari,2,3
Kimberly Leidl,2 Rajender Reddy,1MelissaNezamzadeh,2,3
Jason Roy,2,3 Daohang Sha,2 Amy Marks,5 Jolanda De
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Boer,5 Jennifer Schneider,5 Brian Strom,2,3,7 Douglas
Corley,5 Vincent Lo Re III.2,3,6 1Division of Gastroenterol-
ogy, University of Pennsylvania, Philadelphia, PA, United
States; 2Center for Clinical Epidemiology and Biostatis-
tics, University of Pennsylvania, Philadelphia, PA,
United States; 3Center for Pharmacoepidemiology
Research and Training, Perelman School of Medicine,
University of Pennsylvania, Philadelphia, PA, United
States; 4Leonard Davis Institute of Health Economics,
University of Pennsylvania, Philadelphia, PA, United
States; 5Division of Research, Kaiser Permanente
Northern California, Oakland, CA, United States;
6Division of Infectious Diseases, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, PA,
United States; 7Rutgers Biomedical and Health
Sciences, Newark, NJ, United States.
Background: Medications are a major cause of acute
liver failure in the United States, but there are no popula-
tion-based studies speciﬁcally evaluating the incidence of
acute liver failure arising from drug-induced liver injury.
Objectives: To conduct a population-based assessment
of the incidence and outcomes of drug-induced acute
liver failure.
Methods: We performed a retrospective cohort study
using data from the Kaiser Permanente Northern California
(KPNC) healthcare system between January 1, 2004
and December 31, 2010. The primary outcome was drug-
induced acute liver failure (coagulopathy and hepatic
encephalopathy without underlying chronic liver disease),
determined by hepatologists who reviewed medical records
of all KPNC members with inpatient diagnostic and
laboratory criteria suggesting potential acute liver failure.
Results: Among 5,484,224 members enrolled in KPNC
between 2004 and 2010, 669 were hospitalized with
inpatient diagnostic and laboratory criteria suggesting
potential acute liver failure. After medical record review,
61 (9.2%) were conﬁrmed to have acute liver failure, and
35 (57.4%) were identiﬁed as having a drug-induced
etiology (28 categorized as deﬁnite, 7 possible).
Acetaminophen was implicated in 20 (57.1%) drug-
induced acute liver failure events, dietary/herbal supple-
ments in six (17.1%), and antimicrobials in three (8.6%).
Six (17.1%) patients with drug-induced acute liver failure
died, six (17.1%) underwent liver transplantation, and 23
(65.7%) were discharged alive. The incidence rates of
deﬁnite drug-induced acute liver failure and acetamino-
phen-induced acute liver failure were 1.67 (95% CI:
1.11-2.42) events and 1.08 (95% CI: 0.64-1.70) events
per 1,000,000 person-years, respectively.
Conclusions: Drug-induced acute liver failure is uncom-
mon, but over-the-counter products and dietary/herbal
supplements are its most common causes. While
continued vigilance for liver injury from prescription
medications remains important, these data suggest that
closer attention to the hepatotoxicity of over-the-counter
medications, particularly dietary and herbal supplements,
is needed.
367. Identification of Type 2 Diabetes Mellitus in
Different Electronic Databases Within the SAFE-
GUARD Project
Ingrid Leal,1 Gwen MC Masclee,1 Lorenza Scotti,2
Giorgia De Berardis,3 Irene Bezemer,4 Miguel Gil,5
Elisa Martin,5 Cormac Sammon,6 Niklas Schmedt,7
John D Seeger,8 Gianluca Triﬁro,1,9 Serena
Pecchioli,10 Cristina Varas-Lorenzo,11 Mark M
Smits,12 Peter Rijnbeek,1 Miriam CJM Sturkenboom,1
Silvana Romio.1,2 1Medical Informatics, Erasmus
University Medical Center, Rotterdam, Netherlands;
2University Milano-Bicocca, Milan, Italy; 3Consorzio
Mario Negri Sud, Santa Maria Imbaro, Italy;
4PHARMO Institute, Utrecht, Netherlands; 5Spanish
Agency for Drugs and Medical Devices, Madrid,
Spain; 6University of Bath, Bath, United Kingdom;
7Leibniz-Institute for Prevention Research and Epide-
miology – BIPS GmbH, Bremen, Germany; 8The
Brigham and Women’s Hospital, Harvard Medical
School, Boston, United States; 9Department of Clini-
cal and Experimental Medicine, University of Messina,
Messina, Italy; 10Health Search, Italian College of
General Practitioners, Genomecdis, Florence, Italy;
11RTI Health Solutions, Barcelona, Spain; 12VU Uni-
versity Medical Center, Amsterdam, Netherlands.
Background: Diabetes mellitus has a prevalence of 8.3%
worldwide (2013), 90-95% type 2 (T2DM). Drugs for
T2DM are used chronically and often licensed based on
interim rather than hard outcomes. Electronic health care
records are an important tool to assess their safety. Mul-
tinational studies, such as SAFEGUARD (Spain:BIFAP;
Germany:GePaRD; Italy:Regional Databases (DB) of
Puglia and Lombardy, Health Search DB; Netherlands:
IPCI, PHARMO; UK:CPRD USA:Medicare) allow for
using heterogeneous exposure and treatment patterns.
The price to pay is the need to harmonize the event
extraction across different health systems, types of data-
bases and terminologies.
Objectives: To harmonize the identiﬁcation of T2DM in
the DB participating in SAFEGUARD and compare the
information used for its extraction.
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Methods: The data were extracted from 8 primary
care and claim European DBs with different charac-
teristics such as coding systems (ICD9, ICD10, ICPC,
READ), available information (diagnosis codes, drug
prescription/dispensing, laboratory data, free text)
and level of detail. The study period was DB speciﬁc,
ranging from 1999 to 2012. The age and database
speciﬁc incidence rate (IR) and standardized IR
(SIR) of T2DM (no diagnosis/treatment/laboratory
values recorded in the previous yr) were calculated
using a common script (Jerboa). The information used
for identiﬁcation of T2DM was reported by each data
source.
Results: From a source population of 49,746,014 sub-
jects and a total of 1,427,559 T2DM cases, the SIR of
T2DM in the ﬁrst harmonization cycle ranged between
241 to 623 per 100,000 PY, depending on the use of
diagnosis, dispensing and laboratory data. The rates
increased consistently with age in all DB with the highest
rates between 70 and 79 yrs. In claims DBs many cases
were identiﬁed through dispensing data, while diagnoses
and HbA1C values in GP DBs.
Conclusions: The inﬂuence of the type of information
by which T2DM is identiﬁed on the absolute occur-
rence rate is substantial. Safety assessments should
preferably be done within DB to reduce heterogeneity
due to variations in outcome and covariate coding,
prior to pooled analyses that might be conducted
meta-analytically.
368. Identification of Prediabetes, Healthcare
Utilization and Progression to Diabetes in CPRD
Jin-Liern Hong,1 Ann Marie McNeill,1,2 Jinghua He,2
Kimberly Brodovicz.2 1Department of Epidemiology,
Gillings School of Global Public Health, University of
North Carolina at Chapel Hill, Chapel Hill, NC,
United States; 2Department of Epidemiology, Merck,
Whitehouse Station, NJ, United States.
Background: Prospective studies indicate that 6-9% of
adults with impaired fasting glucose (IFG) progress to
diabetes (DM) within 1 year. However, few studies have
used real-world data to identify prediabetic patients, and
to characterize their healthcare utilization and disease
progression.
Objectives: 1) to assess the feasibility of using the
Clinical Practice Research Datalink (CPRD) to identify
prediabetic patients; 2) to describe their healthcare
utilization and progression from IFG to DM.
Methods: Prediabetic patients aged 25+ years were identi-
ﬁed during 2002-2012 based on initial fasting plasma
glucose (FPG) test (index date) of ≥6.1 and <7.0mmol/l.
Prior DM diagnosis or medications must be absent. The
patterns of FPG, HbA1c testing and primary care (PC)
visits in the following 2 yrs were described in 4 sequential
6-month intervals. DM onset during follow-up was deﬁned
by diagnoses and prescriptions. In a subgroupwith a subse-
quent FPG within 7-18 months after the index date, 1-yr
glycemic change (stable IFG, converted to DM or NG)
was further assessed at the FPG test closest to 1 yr after
the index date.
Results: A total of 113,796 IFG patients were identiﬁed
with a median age of 64 yrs and 46% were female. In
the following 2 yrs, 65%, 27%, and 71% had≥ 1 subse-
quent FPG, HbA1c test, and PC visit, respectively. The
frequencies in the 4 sequential 6-month intervals were
39%, 22%, 24% and 18% receiving a FPG test; and
40%, 25%, 29%, and 24% having≥ 1 PC visit, respec-
tively. 11% of IFG patients progressed to DM within
1 yr. The subgroup analysis of 57,319 patients with
≥1 subsequent FPG test within 7-18 months from the
index date, 32% of these patients remained in IFG,
while 48% and 21% converted to NG or DM,
respectively.
Conclusions: Amongst a population classiﬁed as IFG
from a single FPG test, 11% progressed to DM within
1 yr. Results indicate a low use of health services during
the 2-yrs following initial recognition of IFG, with
greatest utilization in the initial 6months. Early recogni-
tion of IFG using electronic health records provides
opportunities to target at-risk individuals for diabetes
prevention efforts.
369. Characteristics of Patients with Type 2 Diabetes
(T2DM) Captured in Administrative Claims and
Electronic Medical Records (EMR)
Mary E Ritchey, Samuel S Engel, Zhiwen Liu,
Catherine Ntabadde, Michael Senderak, Ravi Shankar,
Ying Qiu, Larry Radican, Swapnil Rajpathak, Kimberly
G Brodovicz. Merck & Co., Whitehouse Station, NJ,
United States.
Background: While EMR are generally seen as a
richer data source than administrative claims, the
EMR data that are available for research do not always
include in-depth clinician notes or capture the full spec-
trum of care. For patients with chronic conditions such
as T2DM, neither claims nor EMR may provide a full
clinical picture.
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Objectives: We sought to document the level of comor-
bidity burden of pre-speciﬁed T2DM complications and
demographics in both MarketScan (MS, US claims) and
CPRD (UK primary care EMR) in 2006-2012.
Methods: Documentation of 23 T2DM complications
and obesity was identiﬁed by prespeciﬁed algorithms.
Prevalences (PR) of T2DM complications were evaluated
in the year before therapy initiation/escalation and
estimated in three treatment categories (monotherapy,
dual therapy, insulin) in each database.
Results: PR trends of T2DM complications were similar
in the two data sources, with higher comorbidity
documentation in patients initiating insulin compared to
monotherapy and dual therapy. Differences in speciﬁc
PR were noted between the databases. Obesity was only
captured for surgical procedures in MS and was noted
in<0.1% in all three treatment categories; in CPRD, obe-
sity was documented more often in read codes (48-58%).
UTI was captured more frequently in CPRD: 4-6% vs 2%
in MS. Other complications were captured more
frequently in MS: fracture (11-15% MS vs 1% CPRD);
angina (4-7% MS vs 1% CPRD); peripheral artery
disease (4-7% MS vs 1% CPRD).
Conclusions: While PR trends between databases were
similar, noted dissimilarities may reﬂect geographic
variation (practice pattern differences) and/or differences
between claims and medical records with neither fully
capturing PR of T2DM complications in the year prior
to therapy change. Patients with T2DM have a high
comorbidity burden. In order to evaluate outcomes
associated with therapy choice decisions it is necessary
to understand the completeness of capture of comorbidi-
ties in each database evaluated.
370. Monitoring for Proteinuria in Patients with Type
2 Diabetes Mellitus in the U.K. Clinical Practice
Research Datalink
Paul Dolin,1 Huifang Liang,2 Carlos Vallarino,2 Sudhakar
Manne.2 1Takeda Development Centre Europe Ltd.,
London, United Kingdom; 2Takeda Development Center
Americas, Inc., Deerﬁeld, IL, United States.
Background: Patients with type 2 diabetes mellitus
(T2DM) are at risk of developing diabetic renal compli-
cations. National Institute for Health and Care Excellence
guidelines on diabetes recommend at least annual
monitoring of T2DM patients for proteinuria. It is
unknown if frequency of proteinuria testing varies by
age, sex, renal complications, or antidiabetic drug therapy.
Objectives: To describe proteinuria monitoring rate in
T2DM patients.
Methods: This study identiﬁed T2DM patients 40years or
older with the ﬁrst antidiabetic drug use in 2007-2013 (co-
hort entry) in the U.K. Clinical Practice Research Datalink.
At least one year of registration before and three months af-
ter cohort entry were required. A test was considered un-
dertaken if a medical or laboratory code indicated a
urinary albumin or protein test. For simplicity, analyses fo-
cused on time to ﬁrst proteinuria test. A monitoring rate
was calculated as the number of patients with at least one
proteinuria test during follow-up, divided by the sum of
time to the ﬁrst proteinuria test during follow-up, and dur-
ing substratum of the follow-up period.
Results: A total of 79,451 T2DM patients (mean age
63.1 years, men 57.3 %, mean follow-up 35.4months)
were included in the study, of whom 66,904 (84.2%)
patients had at least one proteinuria test during fol-
low-up. The monitoring rate for a ﬁrst test was 126
patients tested per 100 person-years. The rate was
higher in patients with renal complications (yes vs
no: 134 vs 125, during ﬁrst year of diabetic drug
therapy (ﬁrst year vs ≥ second year: 159 vs 128), and
those with more changes in drug regimen (no change
vs 1 change vs 2 changes vs 3+ changes: 120 vs
134 vs 138 vs 138). Higher rates were seen for
patients who were older (≥65 years vs <65 years:
137 vs 118), or male (men vs women: 130 vs 120).
Conclusions: The ﬁndings suggest the monitoring for
proteinuria is dependent on multiple clinical factors. Fur-
ther analyses are being undertaken to examine variation
by drug class and positivity of test results.
371. Characteristics of Patients with Type 2 Diabetes
Starting Sitagliptin vs. Other Oral Diabetes Medica-
tions and Propensity Score Balance
Kimberly G Brodovicz, Mary E Ritchey, Yong Chen,
Michael Senderak, Jane Liao, Samuel S Engel, Ravi
Shankar, Zhiwen Liu, Cynthia J Girman. Merck,
Whitehouse Station, NJ, United States.
Background: ppropriate nonrandomized drug compari-
sons rely on an assumption of treatment equipoise. But,
prior work shows patients with type 2 diabetes (T2DM)
starting sitagliptin (SITA) are older and have more co-
morbidities than patients starting other oral
antihyperglycemic agents (OAHA). This channeling can
lead to biased treatment effect estimates if patient charac-
teristics cannot be balanced.
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Objectives: To assess if channeling persists and if bal-
ance can be achieved through study design (stratiﬁcation)
or statistical analysis.
Methods: Patients with T2DM were identiﬁed from
MarketScan (US, MS) and the Clinical Practice
Research Datalink (UK, CPRD) (2006-2012). SITA
and OAHA new users were compared in 3 strata: mono
(MS only), dual, triple therapy. Demographic/clinical
characteristics within 5 years before therapy start were
assessed. Between-group balance was evaluated with
standardized differences (SD) and propensity score
(PS) methods.
Results: SITA users, vs. OAHA users, were generally
older with more comorbidities and physician visits. SITA
use increased from mono to triple therapy. Differences
were greatest in the mono strata. PS matching reduced
between-group differences, but available covariates
varied by database. As an example, in CPRD, SITA dual
users were more likely to be obese (20.2% vs. 12.5%, SD
0.21) and to visit their physician (mean 81 vs. 75 visits,
SD 0.13) and less likely to have chronic kidney disease
(CKD) (14.5% vs. 17.7%, SD -0.09) In MS, obesity
was reported for <0.5% of dual users; SITA dual users
were more likely to have CKD (9% vs. 5.9%, SD 0.12)
and to visit their physician (mean 51 vs. 46 visits, SD
0.12). After PS matching, all SDs were< |0.1|.
Conclusions: Channeling persists and any balance
achieved with PS methods is limited to available covari-
ates. Supplemental data are needed for critical missing
characteristics (e.g. BMI) to improve assessment of
balance across groups.
372. Baseline Characteristics of Patients with Type 2
Diabetes Initiating Sitagliptin or GLP-1 Receptor Agonists
Kimberly G Brodovicz, Mary E Ritchey, Yong Chen,
Michael Senderak, Jane Liao, Cynthia J Girman,
Ravi Shankar, Zhiwen Liu, Samuel S Engel. Merck,
Whitehouse Station, NJ, United States.
Background: DPP-4 inhibitors (DPP4i) and GLP-1
receptor agonists (GLP1-RA) are often referred to as
incretin mimetics. While DPP4i and GLP1-RA act on
the same metabolic pathway, these drugs regulate
glucose through different mechanisms and have different
beneﬁt-risk proﬁles that may inﬂuence their use.
Objectives: To determine if patients initiating sitagliptin
(SITA), a DPP4i, are different from patients initiating
exenatide (EXEN) or liraglutide (LIRA), GLP1-RAs.
Methods: Patients with type 2 diabetes initiating dual or
triple therapy with SITA, EXEN, or LIRA were identiﬁed
in MarketScan (MS, US) and Clinical Practice Research
Datalink (CPRD, UK) (2006-2012). Demographic and
clinical characteristics were assessed up to 5 years before
therapy start. Balance in characteristics were compared
by standardized differences (SD).
Results: Compared to patients initiating EXEN or LIRA
dual therapy, patients starting SITA dual therapy in
CPRD were older (mean years- S: 63, E: 56, L: 56) and
more likely to be women (S: 55.2%, E: 46.9%, L:
46.0%) or have history of acute pancreatitis (S:
0.6%, E: 0%, L: 0%). EXEN or LIRA dual therapy
starters were more obese (S: 20.2%, E: 42.3%, L:
34.5%), and had more physician visits (mean- S: 81,
E: 95, L: 97), medications (mean- S: 22, E: 27, L:
26), neuropathy (S: 3.6%, E: 5.9%, L: 5.8%), depres-
sion (S: 12.9%, E: 25.3%, L: 21.2%), and loop
diuretic use (S: 18.1%, E: 22.5%, L: 25.7%). Similar
patterns were seen in MS. SITA users in MS were
also more likely to have a history of heart failure (S:
7.4%, E: 5.0% L: 4.6%), stroke (S: 8.8%, E: 6.0%,
L: 4.0%), chronic kidney disease (S: 9.0%, E: 5.5%,
L: 5.3%), and beta-blocker use (S: 41.5%, E: 36.4%,
L: 34.6%). SD between SITA vs EXEN and SITA
vs LIRA were> |0.1|. Similar patterns were seen in
triple therapy patients.
Conclusions: The clinical proﬁle of patients prescribed
sitagliptin differs from those prescribed GLP-1 RA.
Some characteristics where these patients differ may be
important risk factors and confounders for many disease
outcomes. Comparative studies should analyze DPP4i
and GLP1-RA separately to appropriately control for
these differences.
373. Comparison of Matching on Key Confounders,
High-Dimensional Propensity Score (HDPS) and a
Combination of Both to Adjust for Confounding
Fei Xue,1 Patrick Ventura,1 Trevor McMullan,2 Paul
Petraro,1 Violeta Hennessey.2 1Center for Observational
Research (CfOR), Amgen, Inc., Thousand Oaks, CA,
United States; 2Global Biostatistics, Amgen, Inc.,
Thousand Oaks, CA, United States.
Background: Matching on HDPS is an efﬁcient way to
adjust for confounding when selecting a comparator
cohort. It is unclear, however, whether the efﬁciency of
HDPS to balance a large number of variables would re-
sult in residual confounding by known key confounders
if not individually matched on.
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Objectives: To compare the performance of 3 methods
of matching on: 1) key confounders; 2) HDPS; 3) both,
in balancing potential confounders when assessing Prolia
vs. bisphosphonate (BP) treatment in relation to
osteonecrosis of the jaw (ONJ).
Methods: Women ≥55 years and with a diagnosis or
treatment related to osteoporosis (OP) were identiﬁed
from the MarketScan database (2004 – 2012). HDPS of
receiving Prolia vs. BP following cohort entry was calcu-
lated based on ONJ risk factors and the most frequent
100 diagnoses, medications and procedures during the
prior 1-year. An equal number of BP users were selected
by random sampling or by matching on 1) key con-
founders, i.e., age, cumulative BP use, corticosteroid
use, poorly controlled diabetes and calendar time; 2)
quintiles of HDPS; or 3) a combination of both. The
distribution of baseline confounders was compared
between the Prolia and BP cohorts.
Results: We identiﬁed 2,578 Prolia users and 460,416 BP
users. With random sampling, 15 out of 25 covariates had
an absolute standardized difference (ASD) of ≥5 to 73%
and all were signiﬁcant (P≤ 0.05). After matching on the 5
key confounders, 4 covariates had an ASD of ≥5 to 10%
and 2 remained signiﬁcant (N of doctor visits and type II di-
abetes). After matching on quintiles of HDPS, 4 covariates
had an ASD of ≥5 to 8% (N of doctor visits, BP use (yes
vs. no), cumulative BP dose and BP duration) and all were
signiﬁcant. After matching on both quintiles of HDPS and
the 5 key cofounders, all 25 covariates including BP-related
covariates were balanced (ASD< 5% and P> 0.05).
Conclusions: Matching on HDPS proved to be success-
ful to balance the discrepancy in a large number of
covariates but may leave key confounders unbalanced.
Additional matching on key confounders may adjust for
such residual confounding and should be considered if
sample size permits.
374. Head to Head Comparison of the Propensity
Score and High-Dimensional Propensity Score
Matching Methods in Reducing Potential Indication
Bias
Jason R Guertin,1 Elham Rahme,2,3 Colin R Dormuth,4
Jacques LeLorier.1 1Pharmacoeconomic and Pharmaco-
epidemiology Unit, Research Center of the Centre
Hospitalier de l’Université de Montréal, Montreal, QC,
Canada; 2Research Institute of the McGill University
Health Centre, Montreal, QC, Canada; 3McGill Univer-
sity, Montreal, QC, Canada; 4University of British
Columbia, Vancouver, QC, Canada.
Background: Propensity score (PS) and high-
dimensional propensity score (hdPS) methods may be
used to control for confounding by indication.
Objectives: Our goal was to identify which method pro-
vided the best adjustment for confounding by indication.
Methods: Performance of both methods was examined
within the context of the risk of de novo diabetes among
patients exposed to moderate versus intensive dose
statins. A cohort of diabetes-free incident users of statins
was identiﬁed from the Quebec’s publicly funded
medico-administrative database (Full Cohort). Two sub-
cohorts were created among the patients selected within
the Full Cohort. In both cases, we matched one patient
initiated on an intensive dose to one patient initiated on
a moderate dose statin; patients’ PS was used as the
matching variable within the ﬁrst matched sub-cohort
(Matched PS Sub-Cohort) while patients’ hdPS was used
as the matching variable within the second matched sub-
cohort (Matched hdPS Sub-Cohort). Standardized
differences were used to examine the level of balance
achieved between patient subsets regarding 19 key con-
founders. Standardized differences >0.1 were considered
to indicate the presence of unbalance.
Results: Eight out of the 19 examined key confounders
were shown to be unbalanced within the Full Cohort
reﬂecting the presence of confounding by indication.
History of a percutaneous coronary intervention (stan-
dardized difference = 0.30) and history of a myocardial
infarction (standardized difference = 0.27), both in the
year prior to the initiation of a statin drug, showed the
greatest degree of imbalance. Matching on either the PS
or the hdPS achieved balance within all 19 examined
key confounders. Standardized differences were gener-
ally lower in the Matched hdPS Sub-Cohort than in the
Matched PS Sub-Cohort.
Conclusions: Although matching on the PS did improve
the balance within the patient characteristics compared to
the Full Cohort, it was inferior to the hdPS method. Our
results support the use of the hdPS method in subsequent
observational studies.
375. High-Dimensional Propensity Score Versus Lasso
Outcome Regression for Confounding Adjustment
Jessica M Franklin, Wesley Eddings, Jeremy A Rassen,
Robert J Glynn, Sebastian Schneeweiss. Division of
Pharmacoepidemiology and Pharmacoeconomics,
Brigham and Women’s Hospital and Harvard Medical
School, Boston, MA, United States.
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Background: The high-dimensional propensity score
(hdPS) algorithm can reduce bias in some nonrandomized
studies of treatment effect through empirical selection of
confounders. Lasso regression provides an alternative
confounder selection method and allows for direct model-
ing of the outcome in a high-dimensional covariate space
through shrinkage of coefﬁcient estimates.
Objectives: To compare the performance of hdPS to that
of a lasso outcome regression model for reduction of con-
founding bias.
Methods: We used a published study of the gastrointes-
tinal effects of nonsteroidal anti-inﬂammatory drugs as
the basis for a plasmode simulation study. We created
500 simulated datasets of 49,653 patients with a true odds
ratio (OR) treatment effect of 1.0, overall outcome risk of
5%, and confounding effects from demographics, 16 in-
vestigator-speciﬁed clinical characteristics, and select in-
teractions. In each dataset, we estimated exposure-based
and bias-based hdPS models with 500 variables plus
demographics. We then estimated treatment effect using
1) ordinary logistic regression on treatment and deciles
of hdPS and 2) lasso or ridge logistic regression on
treatment, demographics, and all 4800 variables screened
by hdPS. In the lasso and ridge models, shrinkage was
applied to all coefﬁcient estimates except for the coefﬁ-
cient on treatment, and cross-validation was used to
select the optimal shrinkage parameter.
Results: Lasso regression selected an average of 127
hdPS-derived variables for inclusion in the outcome
model with an inter-quartile range (IQR) of 102-147.
The crude median OR of 1.19 (IQR: 1.15-1.22) was
reduced to 1.05 (1.02-1.08) and 1.10 (1.06-1.13) by lasso
and ridge regression, respectively. Median ORs were
1.00 (0.97-1.03) and 0.99 (0.96-1.02) for exposure-based
and bias-based hdPS, respectively.
Conclusions: Lasso regression selected fewer variables
and produced treatment effect estimates that were more
biased than the hdPS approaches. Ridge regression,
which does not eliminate any variables, had the largest
bias. Expanded simulation scenarios that vary the number
and types of true confounders, instruments, and risk
factors are planned to test this result.
376. Trimming on Propensity or Disease Risk Scores
to Enhance Validity in the Design of Comparative
Effectiveness Studies
Robert J Glynn,1 Mark Lunt,2 Til Sturmer.3 1Division of
Pharmacoepidemiology & Pharmacoeconomics, Brigham
& Women’s Hospital, Boston, MA, United States; 2Arthri-
tis Research UK Epidemiology Unit, University of
Manchester, Manchester, United Kingdom; 3Department
of Epidemiology, University of North Carolina, Chapel
Hill, NC, United States.
Background: Three alternative trimming strategies can
focus causal inference in comparative effectiveness
studies on patients with equipoise and reduce bias from
non-overlap in covariate patterns between treatment
groups: Crump et al (2009) proposed trimming subjects
with absolute propensity score (PS) values< .1 or> .9;
Sturmer et al (2010) recommended asymmetric PS
trimming; and Walker et al (2013) proposed trimming
subjects in the tails of a preference score.
Objectives: To compare the amount of trimming obtained
from these three approaches, and its relationship to the
overlap in the c-statistic of the PS; to compare treatment
effects with varying or no trimming in simulations; and to
illustrate trimming on a disease risk score (DRS).
Methods: PSs were generated under alternative beta distri-
butions which yield PSs with widely varying c-statistics.
Simulations compared the impact of alternative trimming
strategies on estimated treatment effects. A real data com-
parison of the efﬁcacy of atorvastatin vs rosuvastatin was
used to illustrate the approaches, as well as an alternative
trimming strategy based on a DRS.
Results: Over a range of beta distributions, Crump’s ap-
proach trimmed over 40% of subjects when the c-statistic
was above .9, 20% with c-statistic of .8, and <1% when
the c-statistic was< .7. The approaches of Sturmer and
Walker trimmed higher percentages of subjects for
all simulated PSs (e.g. >50% trimmed with c-statistic
above .9), with Sturmer’s approach trimming fewer until
the c-statistic was about .65, below which Walker’s
approach trimmed fewer. In simulations with unmea-
sured confounding in the PS tails, the approaches of
Walker and Sturmer showed greater reductions in bias
relative to that of Crump, which was superior to un-
trimmed analysis. In the example dataset, trimming
on a DRS appeared to reduce bias relative to the un-
trimmed analysis.
Conclusions: Trimming at the study design stage can fo-
cus on the optimal study population for causal inference.
Trimming higher percentages of subjects through use of
the Sturmer or Walker approaches can reduce bias with
unmeasured confounders among subjects in the tails of
the PS or DRS.
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377. Antidepressant Use and Risk of Hip Fracture: A
Comparison of Marginal Structural Models, Conven-
tional Regression and Propensity Score Methods
M Sanni Ali,1,2 Rolf HH Groenwold,1,2 Svetlana V
Belitser,1 Patrick C Souverein,1 Helga Gardarsdottir,1,3
Arno W Hoes,2 A de Boer,1 Olaf H Klungel.1,2 1Division
of Pharmacoepidemiology and Clinical Pharmacology,
Utrecht Institute for Pharmaceutical Sciences, Univer-
sity of Utrecht, Utrecht, Netherlands; 2Julius Center
for Health Sciences and Primary Care, University
Medical Center Utrecht, Utrecht, Netherlands; 3Depart-
ment of Clinical Pharmacy, Division of Laboratory and
Pharmacy, University Medical Center Utrecht, Utrecht,
Netherlands.
Background: In observational studies of time-varying
treatment, conditioning on time-dependent confounders
that are affected by previous treatment using conven-
tional regression methods may adjust-away(indirect)
treatment effects.In the presence of unmeasured common
causes of confounders and outcome, it can also induce
collider-stratiﬁcation bias.
Objectives: To compare time-dependent propensity
scores, conventional Cox and marginal structural models
(MSM) in a study of selective serotonin reuptake inhibi-
tors (SSRI) and the risk of hip fracture (HF).
Methods: A cohort of patients with a ﬁrst prescription
for antidepressants (AD, SSRI or tricyclic antidepres-
sants, TCA) was extracted from the Dutch Mondriaan
GP database in the period 2001-2009.Potential con-
founders were ascertained when antidepressant use
changed over time or at six month intervals. Follow-up
began with the ﬁrst day of AD prescription and ended
at the occurrence of HF, death, unregistration with the
GP, or end of the study.Treatment effects were estimated
using time-varying Cox regression, PS stratiﬁcation, co-
variate adjustment, and inverse probability weighting
(MSM) to control for confounding. In MSMs, censoring
was accounted for by including inverse probability of
censoring weights (IPCW).
Results: The crude HR of HF in current SSRI users ver-
sus non-current SSRI users was 1.70 [95%CI 1.09-2.65].
Effects increased after confounder adjustment, PS stratiﬁ-
cation, and PS adjustment: HR 2.28 [1.45-3.59], 2.47
[1.54-3.95], and 2.51 [1.54-4.09], respectively.When
MSMs with stabilized weights were used, the HR was
1.34 [0.65-2.76] and 1.53 [0.81-2.93] with and without
accounting for censoring, respectively. After weight
truncation, the HR became 2.09 [1.31-3.35] and 2.37
[1.49-3.78] with and without accounting for censoring,
respectively.
Conclusions: When treatment and confounders are
time-varying, accounting for informative censoring can
materially inﬂuence effect estimates in addition to the
potential collider-stratiﬁcation and confounding bias that
arise due conditioning or stratiﬁcation on time-dependent
confounders.Hence, the use of methods such as MSMs is
recommended.
378. Preference and Propensity: Evaluating Oral
Treatment of Type 2 Diabetes (T2DM)
Mary E Ritchey, Yong Chen, Cynthia J Girman,
Kimberly G Brodovicz. Merck & Co., Whitehouse
Station, NJ, United States.
Background: Probability distributions such as propensity
scores (PS) are increasingly used to balance between treat-
ment groups in outcomes studies. In 2013, “preference”
was introduced as a method to address imbalance via
transforming the probability distribution to represent a state
of interchangeability or equipoise in clinical practice. Such
an assessment is useful in comparative effectiveness re-
search to better inform provider decisions and minimize
potential bias.
Objectives:We evaluated patients with T2DM augment-
ing therapy with either sitagliptin (SITA) or other oral
medication (OTH) and compared PS and preference
scores (PREF) for SITA vs OTH, vs metformin (MET),
vs sulfonylureas (SU), and vs thiazolidinediones (TZD).
Methods: We assessed patients in 2006-2012 in UK
general practice (CPRD). We estimated the probability
of receiving SITA as a function of pre-speciﬁed charac-
teristics and used this to develop PS and PREF. Covariate
balance of PS was conferred if average standardized
absolute mean difference (ASAMD) was <0.1 and for
PREF if 0.3<PREF< 0.7 for >50% of scores.
Results: The PS and PREF comparison of SITA vs OTH
was relatively balanced (ASAMD=0.0515; >95% of
SITA and OTH 0.3< PREF <0.7). PS appeared Gauss-
ian with peak around 0.1. By design, PREF peaked
around 0.5 and also appeared Gaussian. Similar results
were noted in SITA vs SU or TZD; but the visualized un-
derlying population represented in PS (not PREF) shifted
with each comparison. In SITA vs MET, there was
slightly more imbalance (ASAMD=0.0940; 0.3<PREF
< 0.7 = 79% SITA and 76% MET). Visualizations ap-
peared somewhat bimodal for MET, with a peak in PS
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around 0.1 PREF peak spread across 0.1-0.3. PS for
SITA skewed right while PREF skewed left.
Conclusions: PREF provided similar results to PS and
easier visualization of differences between groups. How-
ever, PS provided easier visualization of the underlying
patient populations compared. Both PS and PREF for
SITA vs OTH did not provide the nuanced informa-
tion seen within each class of comparator; yet, neither
accounted for changes over time. While PREF is
useful for evaluating imbalance, it should be used
in context with other tools for careful feasibility
evaluation.
379. Do Patients Initiate Therapy? Primary Non-
Adherence to Statins and Antidepressant in Iceland
Gudrun Thengilsdottir,1 Anton Pottegård,2,3 Anna B
Almarsdottir,1,2,3 Helga Gardarsdottir.4,5 1Faculty of
Pharmaceutical Sciences, University of Iceland,
Reykjavik, Iceland; 2Clinical Pharmacology, Institute of
Public Health, University of Southern Denmark, Odense,
Denmark; 3Department of Clinical Chemistry &
Pharmacology, Odense University Hospital, Odense,
Denmark; 4Department of Clinical Pharmacy, UMCU,
Utrecht, Netherlands; 5Division of Pharmaco-
epidemiology & Clinical Pharmacology, Faculty of
Science, Utrecht University, Utrecht, Netherlands.
Background: The term primary non-adherence (PNA)
refers to patients who receive a prescription for a
new treatment but never have that prescription dis-
pensed at a pharmacy and thus do not initiate drug
therapy.
Objectives: The objective was to assess the primary non-
adherence to statins and antidepressants in Iceland.
Methods: Data on patients receiving a new prescription
for a statin (ATC; C10AA) or an antidepressant (N06A)
from the general practitioner during 2009-2011 (Primary
Health Care database) was linked with dispensing histo-
ries from The Icelandic Prescription Database, a database
covering all drugs dispensed in Iceland. PNA was de-
ﬁned as not ﬁlling the new prescription within 365 days
from the prescribing date. Logistic regression was used
to estimate odds ratios (OR) with 95% conﬁdence
intervals (CI) to assess if patient characteristics such as
gender, age, patient group (general, pensioners, disabled)
and type of antidepressant (SSRI, TCA, other) or statin
(simvastatin, atorvastatin) were associated with PNA.
In addition, the time from issue until dispensing
was assessed.
Results: PNA for antidepressants was less common for
males (OR= 0.79; 95%CI 0.67-0.94) and more common
for those receiving other type of antidepressants
(OR= 2.06; 95%CI 1.67-2.54). Although not statistically
signiﬁcant, patients prescribed atorvastatin (OR= 1.61;
0.99-2.61) and those disabled were more likely to be pri-
mary non-adherent with OR= 1.29; 0.74-2.23 for statins
and OR= 1.19; 0.94-1.52 for antidepressants, respec-
tively. The majority of patients got their prescription dis-
pensed within 7 days from prescribing date, or 85% of
statin users and 87% of antidepressant users, respectively.
Conclusions: Although PNA for statins and antidepres-
sants in Iceland is low, it needs to be considered in pri-
mary health care and special attention should be paid to
vulnerable groups such as the disabled when prescribing
new drugs.
380. Patterns of Statin Prescribing for the Primary
Prevention of Cardiovascular Disease in People with
Severe Mental Illness
Ruth Blackburn,1 David Osborn,1 Irene Petersen,2
Kate Walters,2 Irwin Nazareth.2 1Division of Psychia-
try, University College London, London; 2Primary Care
and Population Health, University College London,
London.
Background: Severe mental illness (SMI) such as bipo-
lar disorder and schizophrenia is associated with excess
cardiovascular disease (CVD) morbidity and mortality,
which may indicate an unmet need for interventions to
prevent CVD. Statins are the most commonly prescribed
CVD drug, but uptake is unknown for individuals with
SMI.
Objectives: To quantify differences in new statin pre-
scribing for primary CVD prevention between individ-
uals with and without SMI.
Methods: We used data from The Health Improvement
Network (THIN) primary care database from 2007 to
2012 to describe differences in new statin prescriptions
in UK patients with and without SMI with no pre-
existing CVD conditions. Individuals aged 30-99 years
with a schizophrenia or bipolar disorder diagnosis were
selected and age and gender frequency-matched to ten
control patients in the same practice who did not have
an SMI diagnosis. Prescribing differences between indi-
viduals with SMI and controls were investigated in
Poisson regression models with new statin prescription
as the outcome. Models were adjusted for calendar time
or estimated CVD risk.
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Results: A total of 8,530 individuals with schizophrenia
and 7,561 with bipolar disorder and ten-times as many
controls were included in the study. Time-adjusted
Incidence Rate Ratios (IRR) for statin prescribing
amongst 30-59 year olds were; 1.92 (95% CI: 1.74-2.11)
for schizophrenia and 1.98 (95% CI: 1.78-2.2) for bipolar
disorder compared to controls without SMI. Individ-
uals aged 60-99 years with schizophrenia had lower
rates of statin prescribing than controls; IRR 0.75
(95% CI: 0.67-0.84), but there were no such difference
for bipolar disorder; IRR 0.99 (95% CI: 0.88-1.11). After
adjusting for estimated CVD risk, individuals with
schizophrenia (but not bipolar disorder) were less
frequently prescribed statins than controls; IRR 0.93
(95% CI: 0.87-0.98).
Conclusions: Evidence of disparity in statin prescribing
is apparent for older individuals with schizophrenia
(relative to controls without SMI), suggesting an unmet
need for statin prescribing in this group.
381. Drug Utilization Pattern in Children with Autism
Spectrum Disorder (ASD) in Asian Countries: A
Population Based Study
Ching-Lan Cheng,1 Kenneth KC Man,2 Yingfen Hsia,3
Yea-Huei Kao Yang,1 Ian CK Wong.2 1Institute of Clin-
ical Pharmacy and Pharmaceutical Sciences, National
Cheng Kung University, Tainan, Taiwan; 2Department
of Pharmacology and Pharmacy, The University of Hong
Kong, Hong Kong, Hong Kong; 3Centre for Paediatric
Pharmacy Research, University College London, School
of Pharmacy, London, United Kingdom.
Background: A recent study has reported an increase
rate of ASD in Chinese population. No current evidence
on medication use for ASD treatment in Chinese children
has been reported. There is need to investigate medica-
tion use in this population.
Objectives: The aim of this study was to investigate the
current pharmacological treatments patterns among a
cohort of children diagnosed with ASD in Taiwan (TW)
and Hong Kong (HK).
Methods: Patients who aged younger than 12 years old
with autism diagnosis (ICD-9-CM 299.xx) were
identiﬁed from the National Health Insurance Research
Database (NHIRD) and registry for catastrophic illness
between 2000 to 2010 in TW and the Clinical Data and
Reporting System (CDARS) database between 2001
and 2010 in HK. Based on literature review, agents found
to be possibly efﬁcacious of those patients were studied.
Psychotropic drug use was assessed within one year after
the ﬁrst diagnosis of ASD was recorded.
Results: A total of 11,825 (5,501 from TW; 6,324 from
HK) of ASD children were identiﬁed. The majority of
patients were boys (84.0% for TW; 87.2% for HK), and
median age at diagnosis were 5 years old in both areas.
2,354 patients (1,740 (31.6%) from TW, 614 (9.7%)
from HK) received at least one prescription of psychotro-
pic drug within the study period. There is variation of
prescribing pattern in TW and HK. In TW, the most com-
monly prescribed medications were stimulants (1,018 pa-
tients, 58.5%), antipsychotics (615 patients, 35.3%),
anxiolytics (477 patients, 27.4%), antidepressant (227 pa-
tients, 13.0%), and clonidine (128 patients, 7.4%). In HK,
stimulants was also the most commonly prescribed medi-
cation (506 patients, 82.4%), followed by antipsychotics
(133 patients, 21.7%), anxiolytics (78 patients, 12.7%),
and antidepressant (31 patients, 5.0%). Of these stimulants,
methylphenidate was the most commonly prescribed drug
in both TW and HK (70.1% in TW, 92.1% in HK).
Conclusions: This study showed one-third of ASD
children received medication treatment in TW whereas
it was only one-tenth of children received treatment in
HK. Further research is needed to evaluate the effective-
ness and safety of this utilization.
382. Withdrawn by Author
383. The Impacts of Non-Adherence on Hospitaliza-
tions in Patients with Schizophrenia in Thailand
Piyameth Dilokthornsakul,1 Oraluck Patanaprateep,2
Ronnachai Kongsakon,3 Nathorn Chaiyakunapruk.1,4
1Center of Pharmaceutical Outcomes Research,
Naresuan University, Muang, Phitsanulok, Thailand;
2Department of Health Informatics, Ramathibodi
Hospital, Mahidol University, Bangkok, Thailand;
3Faculty of Medicine Ramatibodi Hospital, Mahidol
University, Bangkok, Thailand; 4School of Pharmacy,
Monash University Malaysia, Selangor, Malaysia.
Background: Medication adherence is a crucial part for
management of patients with schizophrenia. There has
been an absence of study determining the impacts of
non-adherence on hospitalization in Thailand.
Objectives: This study aimed to determine the impacts of
non-adherence on hospitalization in patients with schizo-
phrenia in Thailand.
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Methods: A retrospective study using an electronic data-
base was undertaken. Patients with schizophrenia aged
18-65 who visited a University hospital and received
antipsychotics from 04/2011 to 10/2011 were included. Pa-
tients were longitudinally tracked for 2 years. The ﬁrst year
was used for assessing adherence bymedication possession
ratio (MPR). The second year was used for assessing
outcomes. Outcome was on schizophrenia-related and
all-cause hospitalizations. Logistic regression was used to
determine the impacts of non-adherence (optimal adher-
ence: MPR 0.8-1.2, non-adherence: <0.8) on the hospital-
izations, adjusting for propensity score (PS) and other
potential confounders.
Results: A total of 582 patients were included. The aver-
age age was 44.4 ± 11.0 years with 43.3%male. Around
55.2% of those patients received typical antipsychotics,
29.7% received atypical antipsychotics and 15.1% re-
ceived both. A total of 3 out of 224 patients (1.3%) were
hospitalized with schizophrenia in optimal adherence
group, while 10 of 140 (7.1%) were hospitalized in
non-adherence group. Based on propensity-adjusted mul-
tivariate logistic regression, the adjusted odds ratio was
5.78 (95% conﬁdence interval (CI); 1.49-22.40) for
schizophrenia-related hospitalization and 7.92 (95%CI;
2.15-29.16) for all-cause hospitalization.
Conclusions: The schizophrenia hospitalization of non-
adherence patients was higher than optimal-adherence
patients.
384. Discontinuation of Somatic Medication during
Psychiatric Hospitalisation
Heshu Abdullah-Koomees,1,2 Helga Gardarsdottir,1,3
Lennart J Stoker,2 Judith Vuyk,4 Toine CG Egberts,1,3
Eibert R Heerdink.1,3,4 1Pharmacoepidemiology &
Clinical Pharmacology, Utrecht University, Utrecht,
Netherlands; 2Department of Clinical Pharmacy,
Brocacef Ziekenhuisfarmacie, Den Dolder, Utrecht,
Netherlands; 3Department of Clinical Pharmacy, Uni-
versity Medical Center Utrecht, Utrecht, Netherlands;
4Division of Willem Arntz, Altrecht Institute for Mental
Health Care, Utrecht, Netherlands.
Background: Psychiatric hospitalisation can increase the
risk of discontinuation of pharmacotherapy. This may
negatively inﬂuence patients’ health.
Objectives: To investigate the association between psy-
chiatric hospitalisation and the discontinuation of somatic
medication.
Methods: A retrospective crossover study was performed
in patients admitted to a psychiatric hospital (index date)
between 2007-2009 in the Netherlands, and who were dis-
pensed somatic medication (oral antidiabetics, insulins,
lipid loweringmedication, anticoagulants, antithrombotics,
cardiovascular medication and acid and bowel relatedmed-
ication) during the three months prior to hospitalisation.
Discontinuation of somatic medication was investigated
at the following time points: index date, as well as 3, 6,
and 9months before the index date. Patients were classi-
ﬁed as discontinuers when ≥1 somatic medication was
discontinued after a time point of interest. Discontinuation
of somatic medication at index date was compared with
discontinuation at the time points before the index date.
Relative risks (RR with 95% CI) were estimated, overall
and stratiﬁed by patient characteristics (e.g. age and hospi-
talization duration), using Cox proportional hazards.
Results: 471 hospitalised patients were dispensed a
somatic medication during the 3months prior to hospi-
talisation. 38.9% of the patients were discontinuers on
the index date, while this was 21.7% on average on
the time points prior to hospitalisation. Patients had
almost twofold (RR = 1.88; 1.55-2.27) risk of
discontinuing any somatic medication on index date.
The risk was highest for patients <45 years (RR=
2.83, 1.92-4.18), those with short (<8 days)
hospitalisation duration (RR= 2.81, 1.87-4.21), and
those admitted to nonpsychogeriatric wards (RR=
2.45, 1.91-3.14).
Conclusions: Psychiatric hospitalisation is associated
with an almost doubled risk of discontinuation of somatic
medication. Future studies should address the inﬂuence
of such discontinuation of care on the patients’ somatic
and psychiatric diseases, whether the discontinuation is
intended or unintended and if the initial discontinuation
of somatic medication leads to discontinuation after
discharge.
385. Assessment of Prediabetes in the United Kindgom
CPRD and Its Association with Incident Cancers
Jin-Liern Hong,1 Ann Marie McNeill,1,2 Jinghua He,2
Kimberly Brodovicz.2 1Department of Epidemiology,
Gillings School of Global Public Health, University
of North Carolina at Chapel Hill, Chapel Hill, NC,
United States; 2Department of Epidemiology, Merck,
Whitehouse Station, NJ, United States.
Background: Prediabetes has been linked to increased
risk of certain cancers (pancreas, liver, breast) in prospec-
tive cohort studies. However, few studies have evaluated
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this association using population-based electronic health
record (EHR) databases.
Objectives: To estimate incident cancer risk among
adults classiﬁed with temporally-stable impaired fasting
glucose (IFG) or normoglycemia (NG) in the absence
of diabetes (DM) or DM, using data from Clinical
Practice Research Datalink (CPRD) 2002-2012.
Methods: Subjects were deﬁned as IFG or NG on the ba-
sis of 2 fasting plasma glucose (FPG) values, separated
by 7-18 months whose values were within the same gly-
cemic category (IFG ≥6.1 to <7.0; NG <6.1mmol/l) in
the absence of prior DM based on presence of diagnoses,
prescriptions, and A1C or FPG. Follow-up for outcomes
began on the day of the 2nd lab test until transfer out date
or end of 2012. Multivariable Cox PH regression was
used to estimate hazard ratios (HR) of each incident
event. Given established association between myocardial
infarction (MI) and dysglycemia, risks of MI associated
with IFG and DM relative to NG were also estimated
for comparison.
Results: Over a median 4 years of follow-up, adjusted
HRs (95%CIs) of cancer associated with IFG and DM
compared with NG were 1.23 (1.01- 1.51) and 1.06
(0.95-1.19) for breast; 1.29 (0.84-1.98) and 1.12 (0.88-
1.44) for kidney; 0.71 (0.57-0.90) and 0.93 (0.83-1.03)
for lung; and 2.23 (1.52-3.26) and 1.99 (1.57- 2.53) for
pancreas. Adjusted HRs (95%CIs) of incident MI were
1.12 (0.98-1.28) and 1.38 (1.29-1.48) comparing IFG
and DM to NG, respectively. Similar results were ob-
served when censoring occurred as subjects progressed
from one glycemic category to another (NG to IFG, NG
or IFG to DM).
Conclusions: Identiﬁcation of patients with IFG from
EHRs appeared feasible and this study yielded associa-
tions between glucose impairment and speciﬁc cancers
and MI largely consistent with ﬁndings from prior cohort
studies, suggesting patients with IFG, as well as DM,
may be at increased risk of speciﬁc cancers, particularly
of the breast and pancreas, compared to NG patients.
386. Adherence to Drug Treatment: A Practical Look
at Complex Measurement Issues
Jean-Pierre Grégoire,1 Petra Denig,2 Colin Dormuth,3
Gillian Caughey.4 1Chair on Adherence to Treatments,
CHU de Québec Research Center, Laval University Fac-
ulty of Pharmacy, Québec, QC, Canada; 2Department of
Clinical Pharmacy and Pharmacology, University
Medical Center Groningen, Groningen, Netherlands;
3Department of Anesthesiology, Pharmacology & Thera-
peutics, University of British Columbia, Vancouver, BC,
Canada; 4Quality Use of Medicines and Pharmacy
Research Centre, University of South Australia Sansom
Institute for Health Research, Adelaide, Australia.
Background: Patient adherence is a major determinant
to achieve expected beneﬁts from evidence-based drug
treatments. Which measure should we select to appropri-
ately describe or quantify adherence using patient-level
data? How can inadequate assessment of adherence lead
to biased ﬁndings?
Objectives: To make attendees aware of several critical
measurement issues in adherence research and propose
practical solutions to deal with those issues.
Description: The following measurement issues will be
discussed: how to deﬁne/select the adherence behavior
at target, how to select the measure the most appropriate
to the targeted behavior while taking care of the nature of
drug utilization data, how to deal with multiple drug reg-
imen and how to measure the healthy-adherer effect.
Jean-Pierre Gregoire will present on the different
types of adherence behavior (acceptance/initiation/
primary adherence, persistence, compliance/implementa-
tion) involved and on the importance of selecting mea-
surements and developing interventions based on the
speciﬁc behavior to target.
Petra Denig will present on the variation in adherence
patterns at the patient level, showing empirical examples
of different types of adherence observed in diabetes pa-
tients using multiple drugs. In addition, she will provide
examples illustrating the importance of measuring adher-
ence to co-prescribed drug treatments.
Colin Dormuth will present on an important topic for
those involved in comparative effectiveness studies: the
healthy-adherer bias. He will present examples of
healthy adherer bias in pharmacoepidemiologic studies
and discuss how researchers can predict the direction
and perhaps magnitude of this bias in their own
studies.
A short round of questions and discussion will follow
each presentation. Gillian Caughey will make wrap-up
comments.
387. Databases in China: Are We Ready Yet?
Xiaofei Ye,2 Siyan Zhan,3 Wei Zhou,1 Xin Sun.4
1Epidemiology Asia Paciﬁc Unit, Merck Research
Laboratories, Beijing, China; 2Department of Health Statis-
tics, Second Military Medical University, Shanghai, China;
3Department of Epidemiology and Statistics, Peking
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University Health Science Center, Beijing, China; 4Clini-
cal Research and Evaluation Unit; Chinese Evidence-
Based Medicine Center, West China Hospital, Sichuan
University, Chengdu, China.
Background: Lack of data is a major challenge for
pharmacoepidemiologic research in Asian countries.
The situation have improved signiﬁcantly in China with
varying forms of observational databases being con-
structed in recent years, which includes national and pro-
vincial spontaneously reported adverse event data,
hospital-based electronic medical records (EMR),
medical claims data, disease registries, and large cohort
studies or surveys. These databases together offer ample
research opportunities. However, there is not enough rec-
ognition on their availability and application towards
pharmacoepidemiologic studies. Their strengths and lim-
itations have not been systematically introduced.
Objectives: This workshop will present various types of
observational databases available in China, and discuss on
their strengths, limitations, and potential applications in ep-
idemiology studies. Case examples will be giving for differ-
ent databases. Researchers or students who have interest in
understanding the status of databases in China, and are
willing to collaborate with the Chinese investigators, will
beneﬁt from the presentations and panel discussions.
Description: The workshop will start with a short intro-
duction of the panel members, and continue with presen-
tations from 4 speakers, with approximately 15minutes
each. Theworkshopwill endwith 25min panel discussions,
including response to questions from audiences. The pre-
sentation topics of each panel member are as below:
(1) Dr. Xiaofei Ye will introduce the China National
spontaneous AE report dataset, and how it used for
data mining and signal detection in China
(2) Dr. Siyan Zhan will introduce various types of
registries in China, including disease registry, drug
registry, and health services registry
(3) Dr. Wei Zhou will introduce different types of EMR
databases in China, and discuss on the potential us-
age for future epidemiology studies
(4) Dr. Xin Sun will discuss the combination of EMR
with longitudinal study in the Chinese setting.
388. Challenges in Implementing Findings of Regulatory
Science to Evaluate and Improve the Drug Regulatory
System
Xavier Kurz,1 David Martin,2 Jarno Hoekman,3 Jacoline C
Bouvy,3 Andrew Roddam,4 Hans Ebbers,3 Hubert GM
Leufkens,3,5K Arnold Chan,6 Gerald Dal Pan,7 Robert
Reynolds,8 Marie L De Bruin.3,5 1Pharmacovigilance,
EMA, London, United Kingdom; 2CBER, FDA, Rockville,
MD, United States; 3Utrecht Institute for Pharmaceutical
Sciences, Utrecht University, Utrecht, The Netherlands;
4Medical Research, National Taiwan University Hospital,
Taipei, Taiwan; 5Medicines Evaluation Board, Utrecht,
The Netherlands; 6Worldwide Epidemiology, GSK, Uxbridge,
United Kingdom; 7CDER, FDA, Silver Spring,MD, United
States; 8Pﬁzer, New York, NY, United States.
Background: Several initiatives have been undertaken
to evaluate and improve the functioning of various
aspects of the drug regulatory system, including
pharmacovigilance. In an era of rapid decision cycles,
the next challenge is how and when to rapidly implement
the ﬁndings and assess their impact. There is a need to
identify which/when results are matured enough to form
a basis to implement changes in clinical practice and
decision-making.
Objectives: To present challenges faced by regulators,
industry and researchers in transferring results of regula-
tory science projects into practice and discuss the
dilemma between the needs for prompt action and
scientiﬁc validation.
Description: In the symposiumwewill present the results
of recently performed regulatory science studies from
IMI-PROTECT, Mini-Sentinel and Escher. Practical ex-
periences and different perspectives on how to implement
these results will be discussed with a multidisciplinary
panel as well as the audience.
(1) Introduction and aims of the symposium (Marie L
De Bruin, 5min)
(2) Lessons from four regulatory science projects:
(a) Matrix for assessing the regulatory impact of
IMI PROTECT (Xavier Kurz, 5min)
(b) Novel pathways for the marketing authorization
of medicines (Jarno Hoekman, 10min)
(c) Interpretation of results of Mini-Sentinel vaccine
studies (David Martin, 10min)
(d) Cost-effectiveness of pharmacovigilance (Jacoline
Bouvy, 10min)
(3) Practical experience from industry in implementing
regulatory science ﬁndings (Andrew Roddam,
10min)
(4) Discussion with panel and audience, including
different perspectives on implementation (chaired
by Bert Leufkens, 40min)
(a) Researchers perspective (K Arnold Chan)
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(b) Regulators perspective (Gerald dal Pan)
(c) Industry perspective (Robert Reynolds).
389. Guidelines and Recommendations for Comparative
Effectiveness Research (CER) Methods: International
Assessment and Exchange
Eunsun Noh,1,2 Nancy A Dreyer,3 Jeonghoon Ahn,4
Thamir M Alshammari,5 Mary E Ritchey,6 J Bradley
Layton,7 Aisling R Caffrey.1,2 1Department of Pharmacy
Practice, University of Rhode Island, College of Pharmacy,
Kingston, RI, United States; 2Providence Veterans Affairs
Medical Center, Providence, RI, United States; 3Quintiles
Real World & Late Phase Research, Cambridge, MA,
United States; 4National Evidence-based Healthcare Col-
laborating Agency, Seoul, Republic of Korea; 5University
of Hail, Saudi Arabia; 6Merk & Co, North Wales, PA,
United States; 7University of North Carolina, Chapel Hill,
NC, United States.
Background: Healthcare systems worldwide are being
challenged to provide better care with fewer resources.
As healthcare providers attempt to select the most
appropriate treatments for their patients, a lack of
supportive clinical data related to alternative treatments
negatively impacts this decision-making process. The
goal of CER is to quantify the beneﬁts and harms of
alternative treatments in order to identify evidence-based
healthcare practices that improve patient care. Despite the
renewed interest and subsequent rise in CER studies,
standardized approaches for the planning and conduct
of CER have not been established. Over the past ﬁve
years, eight CER methods guidance documents have
been published by organizations from the United States
(US). Since there are few published methods guides from
other countries, less is known about standard CER
practices internationally. As such, further discussion is
needed to understand the extent of international agree-
ment between recommendations.
Objectives: To explore the status of CER methods
regulations, guidelines, and accepted practices in Asia,
Europe, the Middle East, and the US. Since formal
methodological guidance can assist researchers in
applying accepted and appropriate CER methods, we will
compare and contrast CER methods recommendations
between regions.
Description: This symposium will assess the interna-
tional status of CER methods recommendations. For
each region, the speaker will describe the presence of
methodological regulations, recommended guidelines,
and/or standard practices for CER methods.
Furthermore, speciﬁc recommendations and/or accepted
practices will be presented. In a panel discussion, we
will review and discuss the following: 1) core recom-
mendations based on agreement between regions, 2)
approaches to reaching an international consensus of
best practices in CER methods, and 3) strategies for
guideline dissemination to areas with limited CER
resources. Speakers (15min): Europe (ND), Korea
(JA), Saudi Arabia (TA), United States (EN). Panel dis-
cussion with audience participation (30min): moderated
by MR and JBL.
390. Leveraging Electronic Health Data for Medical
Device Epidemiology: Approaches To Post-Market
Surveillance of Joint Replacement Surgery
Stephen Graves,1 Nicole Pratt,2 Liz Paxton,3 Tzu-Chieh
Lin,4 Maria Inacio.2 1Australian Orthopaedic Association
National Joint Replacement Registry, Adelaide, Australia;
2University of South Australia, South Australia, Australia;
3Kaiser-Permenente, San Diego, United States; 4National
Cheng Kung University, Tainan, Taiwan.
Background: Post-market surveillance (PMS) of
medical devices is critical to ensure patient safety in an
area of medicine with limited pre-market clinical safety
studies. Major device failures such as metal-on-metal
(MOM) articulation hips and PIP breast implants have
highlighted the need for active rather than passive
surveillance of high risk devices. Medical device
epidemiology has many unique features that distinguish
it from pharmacoepidemiology, including potentially more
complex exposure ascertainment and outcome assessment.
Safety issues after medical device implantation may be
due not only to the device but other factors such as
surgeon skill, complications of surgery, post-operative
care and concomitant pharmacological treatment. Limited
data sets used by registries have been effective for
identifying major device issues, however, linking with
additional data sources has the potential to considerably
enhance the value of registry data.
Objectives: To bring together the experts in medical de-
vice epidemiology to examine the utilization of various
data sources to optimize PMS of medical devices.
Description: Focusing on the surveillance of joint
replacement prostheses we will describe the unique
features of medical device epidemiology. Professor Steve
Graves, director of the Australian Joint Replacement
Registry will discuss the success and limitations of
device registries. Dr Tzu-Chieh, epidemiologist from
Taiwan National Cheng Kung University, will discuss
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the interaction between medicines and devices and give
the perspective from Asian countries about device PMS
in different ethnic populations. Registry data has identi-
ﬁed the higher failure rate with MOM hips, Dr Pratt from
the Center for Research Excellence in Medicines and
Devices in Australia, will discuss how health claims data
can be used to further investigate metal toxicity after
MOM hip procedures. Liz Paxton, director of Surgical
Outcomes and Analysis, Kaiser-Permanente, and Maria
Inacio will examine the use of electronic health data to
evaluate the inﬂuence of co-morbidity on outcomes of
joint replacement procedures.
391. PrimaryDataCollection inPharmacoepidemiology:
Design, Practical, and Methodologic Considerations
Jessica J Jalbert,1,2 Kiyoshi Kubota,3 Gurumurthy
Parthasarathi,4,5 Soko Setoguchi,6 Lamiae Grimaldi-
Bensouda.7,8 1LA-SER Analytica, New York, NY, United
States; 2Weill Cornell Medical College, New York, NY,
United States; 3Department of Pharmacoepidemiology,
University of Tokyo Graduate School of Medicine, Tokyo,
Japan; 4Clinical Pharmacy Services, JSS Medical College
Hospital, Mysore, India; 5Department of Pharmacy
Practice, JSS College of Pharmacy, Mysore, India; 6Duke
Clinical Research Institute, Durham, NC, United States;
7LA-SER Research, Paris, France; 8Conservatoire National
des Arts et Metiers, Paris, France.
Background: In modern pharmacoepidemiology (PE),
primary data collection is often reserved for questions
not amenable to study using existing data sources. It is
also used when databases are not available, as is the case
in some Asian countries. Design and execution of studies
using primary data collection can differ signiﬁcantly from
those using secondary data sources.
Objectives: To describe design, practical, and
methodologic considerations for safety and comparative
effectiveness studies using primary data collection.
Description: Using recent or ongoing studies as case
examples, the symposium will feature four 15-minute
presentations on approaches, challenges, and methodologic
considerations when designing, implementing, and
analyzing PE studies using primary data collection. A
30-minute panel discussion will focus on special consid-
erations for PE studies using primary data and how biases
may be avoided, detected, and, when possible, mitigated
(moderated by PG and SS).
The session will feature the following topics and
presenters (shown by initials):
(1) Introduction: Design and analytic considerations for
PE studies using primary data collection (KK)
(2) Practical Considerations: The Cohort for the General
study of Schizophrenia (CGS) and Pharmaco-
epidemiologic General Research Extension (PGRx) will
be used to illustrate approaches to limiting intervention
and selection bias, maximizing recruitment, minimizing
missing data, and methodologic challenges. (LGB)
(3) Use of Prescription Records for Drug Safety Monitor-
ing: Prescription-Event Monitoring in Japan (J-PEM),
currently inactive, suffered from serious selection bias.
A recent study involving primary data collection used
electronic prescription records in individual hospitals
to reduce selection bias. Other methods to improve efﬁ-
ciency and study limitations will be illustrated. (KK)
(4) Potential Pitfalls: A recent study using primary data
collection to assess peri-surgical treatment on
infectious complications will be used to illustrate
selection, diagnostic and intervention bias, loss to
follow-up, and residual confounding resulting from
failure to collect data on important covariates (JJJ).
392. Tracking of Adverse Drug Reactions in Social
Media: Current Status ofRequirements, Best Practices,
Methods and Tools
Massoud Toussi,1 Carl de Moor,2 Siva Nadarajah,3
Alasdair Breckenridge.4 1Epidemiology and Safety, Europe,
IMS Health, Paris La Défense, Ile-de-France, France;
2Epidemiology and Safety, US, IMS Health, Alexandria,
United States; 3Social Media, IMS Health, Parsippany,
United States; 4Deaprtment of Pharmacology, University
of Liverpool, Liverpool, United Kingdom.
Background: After realizing the potential of social
media, more and more life sciences and healthcare
companies have started initiating commercial social
media presence such as company sponsored Facebook
pages, Twitter handles, Blogs and Youtube Channels
to connect with healthcare professionals, patients, con-
sumers and investors. However, due to the interactive
nature of social media, the User Generated Content
(UGC) that gets generated on these initiatives require
24/7 monitoring to ensure Adverse Drug Reactions
(ADRs) and off-label use of the products are reported and
handled according to local regulations of each country.
Objectives: To explore regulatory requirements, best
practices and available tools and providers for collection
and mitigation of UGCs in social media.
Description: Currently, most regulatory authorities
including European national, EMA, as well as FDA
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are experimenting with how they can best use social
media to obtain information on both the safety and
effectiveness of regulated medicines from a population
of users who do not usually report such factors by
conventional means. Which form of social media are
most useful is also uncertain and how such informa-
tion can be used in regulation is also widely
discussed. Unsurprisingly, pharmaceutical industry is
also involved in such exercises.
This interactive and educational workshop is run by
speakers with academic, government, research and IT/
technology industry background. Speakers will ﬁrst ex-
plore the regulatory requirements needed for reporting
of ADRs through UGCs in different areas of the word
and provide their view point of how these regulations
may change over the next few years during an interactive
session. Best practices and methodological concerns will
be reviewed and discussed in a second part of the work-
shop. In the third part, different examples of available
tools and providers will be presented and their implica-
tions on the drug life cycle will be discussed.
Finally, the speakers will provide perspectives of
future requirements and the next generation tools in
this area.
393. Quantitative Benefit-Risk Assessment of the
Quadrivalent HPV Vaccine for the Prevention of
Anal Cancer in Males – Results
Lydie Marcelon,1 Thomas Verstraeten,2 Geraldine
Dominiak-Felden,1 François Simondon.1 1Department of
Epidemiology, Sanoﬁ Pasteur MSD, Lyon, France; 2P95,
Epidemiology and Pharmacovigilance Consulting and
Services, Leuven, Belgium.
Background: Despite a low incidence, 7600 new anal
cancer (AnCa) cases are estimated to occur each year in
Europe. Gardasil has been shown to be effective in the
prevention of vaccine type related anal intraepithelial
neoplasia, the precursor of AnCa. As 75-80% of AnCa
cases are human papillomavirus types 16 or 18 related,
up to 6000 cases could be prevented by Gardasil vaccina-
tion. The beneﬁt-risk (BR) proﬁle of Gardasil in females
is recognized as being positive but has been questioned
in males. We performed a quantitative assessment of the
BR balance of Gardasil among the male population,
including the protection against AnCa.
Objectives: To compare the beneﬁts and risks of Gardasil
in males to the alternative option of no vaccination.
Methods: The BR assessment used the multicriteria
decision analysis (MCDA) approach. A value tree and
effects table were derived from published and internal
Merck/SPMSD reports on vaccine efﬁcacy/safety. A panel
of independent experts in human papillomavirus (HPV)
related disease, HPV vaccination and BR modelling
validated the choice of studies, the value tree as well as
the weights. Hiview 3 software was used.
Results: TheMCDAmodel suggested a superior score for
Gardasil compared to no vaccination (BR score of 66 and
46, respectively). A ﬁrst sensitivity analysis showed that
a change in weight> 15 points was needed for any individ-
ual outcome to change the BR balance. Secondly, the overall
BR balance changed towards no vaccination only if the
weight assigned to the beneﬁts node would decrease
to below 10%. In ﬁve alternative models constructed
as additional sensitivity analyses Gardasil maintained
a better BR proﬁle compared to no vaccination, al-
though in the most pessimistic analysis, the difference
was only 5 points.
Conclusions: The quantitative MCDA model showed
that the use of Gardasil in males, with an indication of
preventing AnCa, has a superior BR score compared to
no vaccination. This ﬁnding was robust, as conﬁrmed
by a number of sensitivity analyses. These results suggest
that including AnCa as a new indication for males
would further improve the already positive BR proﬁle
of Gardasil.
394. Application of Targeted Maximum Likelihood
Estimation in Pharmacoepidemiology
Menglan Pang,1 Tibor Schuster,1,2 Kristian B Filion,1,3
Maria Eberg,1 Robert W Platt.2,4 1Centre For Clinical
Epidemiology, Jewish General Hospital Lady Davis
Research Institute, Montreal, QC, Canada; 2Department
of Epidemiology, Biostatistics and Occupational Health,
McGill University, Montreal, QC, Canada; 3Division of
Clinical Epidemiology, McGill University, Montreal, QC,
Canada; 4The Research Institute of the McGill University
Health Centre, Montreal, QC, Canada.
Background: Targeted Maximum Likelihood Estima-
tion (TMLE) has been proposed for estimating marginal
causal effects, allowing speciﬁcation of both the treatment
and outcome models. This approach has been shown to
be robust against misspeciﬁcation of either model
(double robustness). However, due to its theoretical
complexity, TMLE has not been widely used in
pharmacoepidemiology.
Objectives: To demonstrate the application of TMLE
in high-dimensional covariate settings, to incorporate
abstract 207
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
the use of high-dimensional propensity score (HDPS)
into TMLE, and to compare the performance of
TMLE to that of marginal structural models (MSMs)
by simulations.
Methods: We implemented the TMLE procedure in a
point-exposure study: statins and the 1-year risk of all-
cause mortality post-myocardial infarction using the
Clinical Practice Research Datalink. A range of known
potential confounders were considered, and empirical co-
variates were selected using the HDPS algorithm. Odds
ratios were estimated using TMLE and MSM and a vari-
ety of covariate selection strategies; results were com-
pared to those of a published meta-analysis. We then
used simulations to evaluate the performance of TMLE
and MSM in high-dimensional covariate settings based
on the study of statins and mortality.
Results: In the case study, TMLE, adjusting for the pre-
speciﬁed confounders and the HDPS covariates in either
the treatment model or the outcome model, provided
comparable estimates to those reported in the previous
meta-analysis. The simulation showed that the perfor-
mance of TMLE and MSM diverged when a large
amount of covariates were included in modeling the
treatment mechanism. We found irregular bias and large
standard errors by TMLE with correctly speciﬁed HDPS
treatment model.
Conclusions: HDPS can be used in TMLE to account
for confounding. Some differences in performance may
occur between the TMLE and MSM, even when used
in the same modeling approach, due to their different
use of the propensity score. Although TMLE is doubly
robust in general, we revealed that a near violation of the
positivity assumption in a high-dimensional covariate
setting might be problematic using TMLE.
395. Incidence of Gastrointestinal Perforation among
Patients with Crohn’s Disease and Those Patients
Dispensed with Anti-TNF Therapy
Xiaofeng Zhou, Yun Gu, Sundaresan Murugesan,
Andrew Bate. Epidemiology, Pﬁzer, NYC, NY, United States.
Background: Crohn’s disease (CD) is a relapsing
systemic inﬂammatory disease mainly affecting the
gastrointestinal tract. There is a lack of published literature
on the risk of gastrointestinal perforation (GIP), a serious
and potentially life-threatening condition, among patients
diagnosed with CD. In particular, the evidence of GIP risk
in those dispensed anti-tumor necrosis factor (anti-TNF)
drugs has been limited.
Objectives: To estimate the incidence rate (IR) of GIP
among CD patients overall and stratiﬁed by anti-TNF
user status.
Methods: Retrospective cohort study from 2002-2012 using
Optum, a US claims database. ICD-9, CPT-4, and NDC
codes were used to identify the patients with CD, GIP,
and exposure to anti-TNF drugs. Adult patients (≥18) with
at least 6months of enrollment, without GIP history before
the 1st CD diagnosis, and a minimum of 12month follow
up after 1st CD diagnosis were included in the study. Three
cohorts were created: 1) CD patients; 2) Anti-TNF experi-
enced CD patients; 3) Anti-TNF naïve CD patients.
Results: A total of 28,898 CD patients, 1459 anti-TNF
experienced patients, and 27,086 anti-TNF naïve patients
was identiﬁed. Patients in the anti-TNF experienced co-
hort were younger than those in the other two cohorts
(40 vs. 45 years) while gender distribution was the same
(56% females). The crude IRs of GIP among CD patients,
anti-TNF experienced patients, and anti-TNF naïve pa-
tients were 19.9 (95% CI: 19.0-20.8), 39.7 (95% CI:
33.1-47.6), and 18.5 (95% CI: 17.7-19.5) per 1000 per-
son years, respectively. The crude IR ratio of GIP for
anti-TNF users vs. nonusers was 2.1 (95% CI: 1.8-2.6)
without adjusting for potential confounding such as
disease severity.
Conclusions: This study adds evidence to the scarce
literature on the incidence of GIP among CD patients
and those dispensed anti-TNF drugs. It is unclear if the
increased risk of GIP in anti-TNF experienced patients
is due to the severity of CD, the exposure to anti-TNF,
or other confounders. Further research of the GIP risk
in this population including potential confounding
control, multiple database use, and medical chart review
of the outcome is suggested.
396. Idiopathic Thrombocytopenic Purpura After
Seasonal Influenza Vaccination
Chunfu Liu,1 Laura Polakowski,2 Hozefa A Divan,1 Yun
Lu,2 Hector Izurieta,2 Nandini Selvam.1 1HealthCore,
Inc., Wilmington, DE, United States; 2Center for Biologics
Evaluation and Research, Food and Drug Administration,
Rockville, MD, United States.
Background: Idiopathic thrombocytopenic purpura
(ITP) is known to occur after measles-mumps-rubella
(MMR) vaccination among young children. Although
there are some suggestions of an association between
ITP and seasonal inﬂuenza vaccination, these are
generally case studies.
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Objectives: To assess the association between seasonal
inﬂuenza vaccination and ITP occurring within 1-42 days
post-vaccination in a large health plan.
Methods: The study included members of all ages
from a large commercial health plan who received at
least one seasonal ﬂu vaccination during the 2006-
2009 ﬂu seasons (identiﬁed in claims data). Persons
with a claims diagnosis of ITP (code 287.31) were
further classiﬁed into persistent, chronic, acute (one-
time only and intermittent), and other, based on code
timing and frequency, and only acute cases were stud-
ied. Those with exclusionary diagnoses or exposure to
chemotherapy, blood products, radiation treatment or
platelet-depleting medication were excluded and those
with at least one ITP episode within 49 days prior to
and 84 days after receipt of an inactivated ﬂu vaccine
comprised the ﬁnal study population. A self-controlled
risk interval design applying conditional Poisson re-
gression was used to evaluate the association between
ﬂu vaccination and ITP, implicitly controlling for
time-invariant confounders. The risk interval was de-
ﬁned as 1-42 days after vaccination, with control inter-
vals of 8-49 days pre-vaccination and 43-84 days post-
vaccination.
Results: Among 3.1 million inactivated seasonal ﬂu
vaccinees and 2,966 with at least one ITP episode
during the 2006-2009 ﬂu seasons, 22 acute ITP patients
had at least one episode within 49 days prior to and
84 days after ﬂu vaccination. Inﬂuenza vaccination
was not associated with an increased risk of ITP (IRR=
0.74, 95% CI: 0.42-1.31 pre-vaccination control; IRR=
0.78, 95% CI: 0.43-1.40 post-vaccination control).
Similar results were found in sub-analyses that ex-
cluded ITP episodes of those who received same-day
MMR vaccine.
Conclusions: Inactivated seasonal inﬂuenza vaccination
is not associated with an increased risk of ITP among
members of a large health plan, providing further support
for the safety of ﬂu vaccines.
397. 30-Year Mortality Following Venous Thrombo-
embolism: A Population-Based Cohort Study
Kirstine K Søgaard, Morten Schmidt, Lars Pedersen,
Erzsébet Horváth-Puhó, Henrik T Sørensen. Department
of Clinical Epidemiology, Aarhus University Hospital,
Aarhus, Denmark.
Background: Studies on long-term mortality following
venous thromboembolism (VTE) are sparse.
Objectives: We examined 30-year mortality associated
with ﬁrst-time hospitalisation for VTE subtypes, and the
prognostic impact of age, comorbidity, and calendar
period of diagnosis.
Methods: We conducted a nationwide population-based
cohort study using data from Danish medical databases
(1980-2011). We identiﬁed patients with VTE, and
matched each patient with ﬁve individuals from the
general population without VTE, on gender and year
of birth. We computed 30-year mortality risk using
Kaplan-Meier method among patients with VTE [deep
venous thrombosis (DVT) or pulmonary embolism
(PE)]. We assessed mortality rate ratios (MRRs) with
95% conﬁdence intervals (CIs) using Cox regression
controlling for potential confounders. Stratiﬁed analyses
were performed according to age, calendar period, and
several covariates.
Results: We included 128 223 persons with a VTE
diagnosis (74 157 with DVT and 54 066 with PE), and
640 760 comparison cohort members. The mortality risk
for DVT and PE patients was higher than for
the comparison cohort, especially within the ﬁrst year
(30-day mortality risk: 3.0% and 31% vs. 0.4%; 31-364
day risk: 13% and 20% vs. 4.0%). VTE patients had a
2-fold increased MRR within 30 years compared with
persons in the comparison cohort [DVT: 1.55 (95% CI:
1.53-1.57); PE: 2.77 (95% CI: 2.74-2.81)]. The 30-day
MRR was 5.38 (95% CI: 5.00-5.80) for DVT and 80.87
(95% CI: 76.02-86.02) for PE. While these values declined
gradually, they remained 25%-40% increased within 1-10
years and 11-30 years. Over time, the 30-day MRR was con-
sistently 5 to 6-fold increased for DVT, but improved for PE
from 138 (95%CI: 125-153) in 1980-1989 to 36.08 (95%CI:
32.65-39.87) in 2000-2011.
Conclusions: Patients with VTE are at increased risk
of dying, especially within the ﬁrst year after diagno-
sis, but also during the entire 30-years of follow-up.
While 30-day mortality after DVT remained fairly
constant over the last three decades, it improved
markedly for PE.
398. Malignant Diseases in Swedish Person with
Heamophilia-A Longitudinal Registry Study
Susanna Lövdahl1,1 Karin M Henriksson,2,3 Fariba
Baghaei,4 Margareta Holmström,5 Erik Berntorp,1 Jan
Astermark.6 1Department of Clinical Sciences, Clinical
Coagulation Research Unit Lund University, Skåne Uni-
versity, Malmö, Sweden; 2Cardiovascular Epidemiology,
Department of Medical Science, Uppsala University
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Hospital, Uppsala, Sweden; 3AstraZeneca, Department
of Epidemiology, R&D, Mölndal, Mölndal, Sweden;
4Coagulation Centre, Department of Medicine/Hematology
and Coagulation Disorders, Sahlgrenska University Hospi-
tal, Gothenburg, Sweden; 5Coagulation Unit, Hematology
Centre, Karolinska University Hospital and Department
of Medicine, Stockholm, Sweden; 6Department of Hematol-
ogy and CoagulationDisorders, Skåne University Hospital,
Malmö, Sweden.
Background: Longitudinal data on co-morbidity in
subjects with heamophila are rare. We linked National
and local Registries (Malmö, Gothenburg and Stockholm)
of 1431 patients with heamophilia A or B (PWH) and
7150 matched controls.
Objectives: The aim of this study was to investigate the
occurrence of malignancies among persons with
haemophilia in Sweden as compared to matched controls.
Methods: All registered PWH in Sweden alive in
1968 and born before 2009 were identiﬁed. Informa-
tion was linked to the national Cancer-registry and ﬁve
age and sex matched controls for each person with
haemophilia was randomly chosen from the general
population. The incidence rate ratios of malignant
diseases were calculated per 1000 person-years as the
time from birth to death, emigration or end of study
with 95% Poisson conﬁdence intervals (CI).
Results: Of a total of 170 cancer diagnoses among PWH,
146 constituted primary cancers. Corresponding numbers
for controls were 676 and 611 respectively. The median
age of any ﬁrst cancer diagnosis for all severities of
haemophilia was 65.5 with min and max (12-87) and
68.0 (1-94) for controls. In the subgroup of persons with
severe haemophilia, the median age of any ﬁrst cancer
diagnosis was 46.0 (22-59) and 58.5 (4-83) for controls.
The incidence rate ratio of malignancies per PWH 1000
person-years (pyr) from 1972 through 2008 was 1.3, 95%
CI: (1.1, 1.5) vs controls. Corresponding subgroup analy-
ses with severe haemophilia the incidence rate ratio per
1000 pyr for malignancies between 1984 and 2008 was
1.8, 95%CI: (1.0, 3.1). Hematologicmalignancies including
lymphosarcom and leukemia were one of the most frequent
primary diagnosed cancer in PWH cohort (independent
of severity) N= 31, (2.2%) vs N=50 (0.7%) for con-
trols, p-value< 0.001. Prostate cancer was also one of
the most common primary diagnosed cancer for PWH,
31 (2.2%) and 179 (2.5%) for controls, p-value= 0.45.
Conclusions: As compared to matched controls, the
overall rate of malignant diseases was higher in persons
with haemophilia and hematologicmalignancies including
lymfosarkom and leukemia and prostate cancer constitute
their most common form of registered cancer diagnoses.
399. The Risk of Malignant Melanoma among Patients
with Multiple Sclerosis
Made Wenten, Sarah Gheuens, Sandra Richman,
Susan Eaton, Li Li, Anne Dilley. Safety and Beneﬁt
Risk, Biogen Idec, Cambridge, MA, United States.
Background: The pathogenesis of multiple sclerosis
(MS) involves an inappropriate immune response me-
diated by auto-reactive lymphocytes within the central
nervous system. While the association between auto-
immune disease and cancer is not fully understood,
auto-reactive T cells have been shown to inﬂuence
both the prevention and the advancement of cancer.
Multiple population-based studies have examined the
relationship between MS and cancer risk but none, to
our knowledge, have examined the relationship be-
tween MS and malignant melanoma (MM).
Objectives: To estimate the incidence, incidence rate,
and relative incidence rate of malignant melanoma in
MS patients and non-MS controls in a large US Health
Claims Database.
Methods: During the study period (January 1, 2004 to
December 31, 2012), MS patients were deﬁned as
those with at least two diagnosis codes for MS (ICD-
9 340). Two control subjects without a diagnosis code
for MS were selected for each case, matched on age,
gender, and follow-up time in the database. MM was
deﬁned as a patient with 2 or more inpatient or outpa-
tient claims for MM of the skin (ICD-9 172.X) with a
time period of 30 days or more between claims occur-
ring after the index MS diagnosis date. A Poisson re-
gression model was used to estimate the association
of MS and MM.
Results: We found a total of 77 and 207 incident MM
among MS cases and non-MS controls, respectively,
during the study period. This represents an incidence
rate of 79 per 100,000 person-years (MS cases) and
52 per 100,000 person-years (non-MS controls). After
adjusting for age, gender, and follow-up time, we
found a statistically signiﬁcant 48% increase in the rate
of MM in MS patients compared to non-MS controls
(95% CI: 1.14-1.92).
Conclusions: No studies, to our knowledge, have ex-
amined the association between MS and MM. This
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claims database study found that MS patients in the
US have a 48% increased rate of MM compared to
non-MS controls. A validation study using another
electronic health-records database is ongoing.
400. Combining Information from an Electronic
Healthcare Database and Spontaneous Reporting
Database for Enhancing Signal Detection
Alexandra C Pacurariu,1,2 PreciosaMColoma,1 Gianluca
Triﬁro,1,3 Sabine M Straus,1,2 Martijn Schuemie,1 Rosa
Gini,4 Ron Herings,5 Giampiero Mazzaglia,6 Gino
Picelli,7 Lorenza Scotti,8 Lars Pedersen,9 Johan van
der Lei,10 Miriam Sturkenboom.11 1Medical Informat-
ics, Erasmus University Medical Center, Rotterdam,
Netherlands; 2Pharmacovigilance, Dutch Medicines
Evaluation Board, Rotterdam, Netherlands; 3Clinical
and Experimental Medicine, University of Messina,
Messina, Italy; 4Agenzia Regionale di Sanità della
Toscana, Florence, Italy; 5PHARMO Institute, Utrecht,
Netherlands; 6Società Italiana di Medicina Generale,
Florence, Italy; 7Pedianet-Società Servizi Telematici
SRL, Padova, Italy; 8Statistics, Università di Milano-
Bicocca, Milan, Italy; 9Clinical Epidemiology, Aarhus
University Hospital, Aarhus, Denmark.
Background: Due to better sensitivity for common
multifactorial events, electronic healthcare databases
(EHR) may have additional value in traditional signal
detection, which is done with spontaneous reporting
systems (SRS). In order to beneﬁt from this additional
source of signals, an efﬁcient triage process must be in
place to overcome the high rate of false positives.
Objectives: The objective of this study is to propose a
novel way of combining the sensitivity in ﬁnding sig-
nals from an EHR-based system with the speciﬁcity of
a spontaneous reporting system.
Methods: We selected the outcome of myocardial in-
farction and performed signal detection in a network
of 7 European EHR databases (EU-ADR) by applying
a method speciﬁcally developed for this (Longitudinal
Gamma Poisson Shrinker). We then applied a triage
process that consisted of two steps: 1) testing for pos-
sible protopathic bias and 2) using the number of case
reports in SRS as a ﬁlter (minimum 3 cases received).
Changes in sensitivity and speciﬁcity after each triage
step were assessed. The conﬁrmed signals were consid-
ered the “gain” and were balanced against the false pos-
itives, namely “the cost” for the system. A set of positive
and negative test cases was constructed using data avail-
able literature and in the product information leaﬂet.
Results: Based on LGPS in the EU-ADR network we
identiﬁed a total of 457 potential signals: 76 were
‘conﬁrmed’ ADRs and 381 were classiﬁed as false
positive signals. After testing for protopathic bias we
lost 10.4% in sensitivity for a 10% gain in speciﬁcity,
after the second triage step we lose 5.2% sensitivity
for 10% gain in speciﬁcity. In total 35 ‘conﬁrmed’
associations were lost, while 289 false positives were
correctly discarded. The additional beneﬁt of using
EHR as an initial signal generation source is seen from
41 conﬁrmed signals, out of which 31 (75.6%) were
not ﬂagged in SRS using standard methods.
Conclusions: This study shows that for a common
multifactorial event such as AMI, the load of false pos-
itives associations from mining EHRs can be efﬁciently
reduced when using SRS data as additional source.
401. Preventable Drug Related Problems and Factors
That Affect Heart Failure Treatment at Maharaj
Nakorn Chiangmai Hospital
Poukwan Arunmanakul,1 Thanisa Kritsadathan,1 Thanyaluk
Poonninrat,1 Rungsrit Kanjanavanit.2 1Pharmaceutical Care
Department, Faculty of Pharmacy, Chiangmai, Thailand;
2Cardiology, Internal Medicine, Faculty of Medicine,
Chiangmai, Thailand.
Background: Heart failure patients can maintain their
health status by taking their heart medications. Lack of
compliance and nonadherence can lead to worsening
symtoms. Pharmacists as one of the health team in
heart failure clinic conducted medical reconcillation
and transfer the data to other professionals by write
down pharmacist notes in patients’ medical records.
Objectives: The purpose of this study is to determine
the preventable drug related problems and factors that
can cause worsening heart failure in patients.
Methods: The preventable drug related problem were
divided in to two categories; medical compliance and
health behavior, and another factor included patients’
diseases. The data was review from 107 heart failure
patients (407 visits) during 1 January - 31 December
2012 and was collected from pharmacist notes, patients’
proﬁle and medical records.
Results: There were 107 patients, 63.6% were men.
Most of the patients had follow up at heart failure
clinic 4.04 ± 1.99 visits per year and the average time
of worsening heart failure was 0.88 ± 1.51 times per
year. Medical compliance was the main problem found
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in this study. Twenty eight percent of the patients did
not follow the physicians’ order, 26.2 % did not know
the indication of their medication, 23.4% forgot to take
their medications, and 4.7% spontaneously stopped
taking medications according to adverse drug reactions.
Medical compliance problems always involve the main
drug therapy in heart failure such as ACEIs, beta-blocker,
and hydralazine. There were six patients who had taken
NSAIDs which are contraindication for heat failure.
37.4 % of the patients were found with health behavior
problems and 37.4% of patients might have had worsen-
ing heart failure from their uncontrolled underlying dis-
eases. Once the problems were found, the heart failure
team tried their best to solve the problem.
Conclusions: Since medical compliance and health
behavior are preventable factors, heart failure patients
should be well educated about their medications and
their disease stages, so they can get beneﬁt from ther-
apy and slow disease progression.
402. Association between Generic Substitution and
Refill Adherence to ACE-Inhibitors - Analysing the
Impact of Using Multiple Medications
Pernilla Jonsson,1,2 Anna K Jönsson,3 Eva Lesén,4 Ann-
Charlotte Mårdby,5 Karolina Andersson Sundell.2
1Nordic School of Public Health, Gothenburg, Sweden;
2Social Medicine, University of Gothenburg, Gothenburg,
Sweden; 3LinköpingUniversity, Linköping, Sweden; 4Nordic
Health Economics, Gothenburg, Sweden; 5Sahlgrenska
University Hospital, Gothenburg, Sweden.
Background: Generic substitution has led to economic
savings in many countries but there are reports of lower
adherence in particular among patients using multiple
medications.
Objectives: The aim was to analyze the impact of use
of multiple medications on the association between ge-
neric substitution and reﬁll-adherence to angiotensin-
converting-enzyme (ACE) inhibitors.
Methods: New users of ACE-inhibitors, starting between
1 July 2006 and 30 June 2007, were identiﬁed in the
Swedish Prescribed Drug Register. Reﬁll adherence was
assessed using the continuous measure of medication ac-
quisition (CMA). Effects on adherence of generic substitu-
tion and use of multiple medications were analysed using
linear regression, controlling for potential confounders.
Results: The study population included 42735 individ-
uals with a mean CMA of 88% (SD 3.4). Half of the
participants (51.2%) were exposed to generic substitu-
tion of the ACE-inhibitor. The highest CMA was ob-
served in the group exposed to both generic
substitution and use of multiple medications (118.2%),
compared to those exposed to one(generic substitution:
100.0%, use of multiple medications 87.3%) or none
of the factors(54.6%) (p< 0.05). Reﬁll adherence also
varied with age, household income, country of birth,
previous hospitalization and previous cardiovascular
diagnosis.
Conclusions: The results of this population based
register study indicate a positive association between
generic substitution, use of multiple medications and
reﬁll adherence among new users of ACE-inhibitors.
To what extent this is also reﬂected in self-reported
adherence and inﬂuenced by double medication needs
further studies using other approaches.
403. Effect of a Medication Adherence Program for
Long-Acting Injectable Atypical Antipsychotics on
Adherence and Psychiatric Hospitalizations
Frederic Rouillon,1,2 Jessica J Jalbert,3,4 Bernard Astruc,5
Michel Rossignol,6,7 Franck Bayle,8 Benoit David,6
Ryma Bennoune,6 Bernard Avouac,6 Lucien Abenhaim,9
Lamiae Grimaldi-Bensouda.6,10 1Centre Hospitalier
Sainte-Anne, Université Paris V René Descartes, Paris,
France; 2INSERM U894, Hôpital Sainte Anne, Paris,
France; 3LA-SER Analytica, New York, NY, United
States; 4Weill Cornell Medical College, New York, NY,
United States; 5Faculté de Médecine Cochin Port-Royal,
Eutelmed SAS, Paris, France; 6LA-SER Research, Paris,
France; 7McGill University, Montreal, QC, Canada;
8University Paris-Descartes, Paris, France; 9LA-SER,
London, United Kingdom; 10Conservatoire National des
Arts et Metiers, Paris, France.
Background: Long-acting injectable (LAI) atypical
antipsychotics are associated with increased adherence
and reduced hospitalization risk in schizophrenia.
Objectives: To evaluate the effect of a medication ad-
herence program (MAP) on adherence and psychiatric
hospitalization rates among schizophrenia patients taking
LAI risperidone (LAI-R).
Methods: Between 2009-2010, we recruited LAI-R
users aged 18 to 65 years meeting DSM-IV criteria for
schizophrenia and followed them 1year. The MAP
consisted of calling patients 48 h prior to their scheduled
LAI-R injections and within 3 days of a missed appoint-
ment. Centers applying MAP to ≥50% of scheduled
abstract212
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
patient injections were deemedMAP compliant. Adher-
ent patients received≥ 80% of their injections within
5 days of the scheduled date. Poisson regression was
used to derive crude and propensity score-adjusted rate
ratios (RR), comparing psychiatric hospitalization rates
among patients treated by MAP compliant vs. non-
compliant centers and adherent vs. non-adherent
patients.
Results: Of 506 patients recruited from 36 psychiatric
wards in France, 95.7% were followed up to 1 year
(mean age: 38.7; 64.6% males; 60.4% hospitalized in
the past year). The hospitalization rate over follow-
up was 32.5 per 100 person-years. Fifteen centers
treating 243 patients were MAP compliant and 21 cen-
ters treating 263 patients were not. Fewer general hos-
pitals were MAP compliant than specialty hospitals
(37.5% vs. 54.5%), as were centers with a larger num-
ber of psychiatric beds. Center MAP compliance was
associated with lower psychiatric hospitalization rates
(crude RR: 0.64 [95% CI: 0.44-0.93]; adjusted RR:
0.78 [95% CI: 0.47-1.27]). Nearly 75% of patients
were adherent to LAI-R. While patient adherence had
little impact on hospitalization rates (adjusted RR:
0.92 [95% CI: 0.59-1.44]), MAP compliance was
more effective among non-adherent (adjusted RR:
0.45 [95% CI: 0.16-1.28]) than adherent (adjusted RR:
0.88 [95% CI: 0.51-1.53]) patients.
Conclusions: MAPs may improve patient adherence
and reduce psychiatric hospitalizations, particularly
among patients with problems adhering to LAI antipsy-
chotic treatment regimens.
404. Associations between Generic Switch and
Adherence - Do Patients’ Discomfort, Need of
Information and Concerns about Medicine Influence
Adherence: A Combined Cross-Sectional Questionnaire
and Register Study
Jette Rathe,1 Dorte E Jarbøl,1 René dePont Christensen,1
Morten Andersen,1,2 Jens Søndergaard.1 1Research Unit
of General Practice, Odense, Institute of Public Health,
University of Southern Denmark, Odense, Denmark;
2Centre for Pharmacoepidemiology, Karolinska Institutet,
Department of Medicine, Solna, Stockholm, Sweden.
Background: Generic prescription drugs are bioequiv-
alent to their brand name versions, meaning that they
have the same qualitative and quantitative composition
of the active substances, but the drugs’ information
leaﬂets often vary substantially with regard to indica-
tion for drug use, adverse effects and interactions.
Additionally, differences in package forms among ge-
nerics may add to patients’ concerns about medication
and poor adherence among drug users. Some interview
studies have indicated that generic substitution can
cause lower adherence, but there is a lack of large-scale
quantitative studies measuring the magnitude of this
issue. In particular, there is a lack of studies on how
concerns, drug dispensing discomfort and need of in-
formation inﬂuence patients’ adherence among those
having had generic drug substitution.
Objectives: This study aimed to assess whether
switching of generic substitutable drugs is associated
with medication non-adherence with special focus of
the importance of patients’ concerns, drug dispensing
discomfort and need of information.
Methods: Cross-sectional survey comprising responses
from 2272 randomly selected persons aged 20 years or
older and living in the Region of Southern Denmark,
who had redeemed generically substitutable medicines
in September 2008. For each patient we focused on
the purchase of one generically substitutable drug
(index drug). We applied three scales from the ques-
tionnaire; discomfort with the medication dispensing
or label, need of information about the drug and spe-
ciﬁc concern about medicine. Drug adherence was
assessed by linkage of the questionnaires with Odense
PharmacoEpidemiologic Database (OPED). Data will
be analysed using linear regression and Cox regression.
Results: Analyses are ongoing and results will be pre-
sented at the conference.
Conclusions: This study will present information that
is important for future interventions aimed at improv-
ing adherence for patients having had generic drug
substitution.
405. Physician Adherence to Antihypertensive Drug
Treatment Guidelines and Cost of Antihypertensive
Drugs in Indian Setting
Kapil Gudala,1 Dipika Bansal,1 Anil Bhansali.2 1Pharmacy
Practice, National Institute of Pharmaceutical Education and
Research, Mohali, India; 2Endocrinology, Post Graduate
Institute of Medical Education and Research, Chandigarh,
India.
Background: Hypertension was found to be indepen-
dent risk factor of micro- and macrovascular complica-
tions in patients with diabetes. Established evidence
proved the efﬁciency of antihypertensives (AHT) in
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reducing important health outcomes in persons with
hypertension. Clinical guidelines are at the intersection
between research evidence and clinical actions that can
improve patient outcomes.
Objectives: The aim of the present study was to esti-
mate the prescribing pattern of AHT, adherence of phy-
sicians’ to the Joint National Commission (JNC) 7 and
cost of AHT in type 2 diabetes patients of north India.
Methods: Across-sectional study involving type 2 diabe-
tes patients with comorbid hypertension attending endo-
crinology clinic of a tertiary care hospital. Demographic,
disease and medication details were taken from medi-
cal records. Prescribing pattern was expressed in per-
centages. Adherence to the guideline was calculated
as a percentage of the total number of patients. The av-
erage drug acquisition costs (ADAC) were calculated
for each AHT class on a daily and annual basis.
Results: A total of 370 patients of mean age 45.2 + 8.4
were included. Mean duration of diabetes was found to
be 8.3 + 3.6 years. 23.2% and 76.8% patients received
mono- and poly therapy. Overall, ACE inhibitors
(ACEIs) were highly prescribed (49%), followed by
calcium blockers (CCB) (32%), beta-blockers (BB)
(27%), angiotensin receptor blockers (ARBs) (25%),
and diuretics (18%). Adherence to JNC 7 guidelines was
found to be 90.2%. The ranking in terms of ADAC of
AHT class is ACEIs>ARB>CCB>BB> diuretics.
Conclusions: Adherence to clinical guidelines was
high. However continuous surveillance is necessary
in AHT as evidence based guidelines update regularly.
406. Predictive Validity of Four Self-Reported
Measures of Medication Adherence in Patients with
Type 2 Diabetes
Arsène Zongo,1,2,3 Line Guénette,1,2,3 JocelyneMoisan,1,2,3
Jean-Pierre Grégoire.1,2,3 1Faculty of Pharmacy, Université
Laval, Québec, QC, Canada; 2Chair on Adherence to
Treatments, Université Laval, Québec, QC, Canada; 3Axe
Santé des Populations et Pratiques Optimales en Santé,
Centre de Recherche du CHU de Québec, Québec, QC,
Canada.
Background: Authors have recently observed that self-
reported adherence predicts 6-month glycemic control.
This ﬁnding presents an important clinical perspective
as instruments with demonstrated predictive validity
could then be used to identify patients whose glycemia
may or may not be subsequently controlled.
Objectives: To assess the predictive validity of four self-
reported measures of adherence on glycemic control
measured with HbA1c.
Methods: A survey conducted to assess factors associ-
ated with adherence to non-insulin antidiabetes drugs
in the Canadian province of Quebec serves as the back-
ground for the present study. Participants completed an
on-line questionnaire in which adherence to their treat-
ment was assessed using four self-report instruments:
the 4-item and 8-item Morisky Medication Adherence
Scales (MMAS-4/8), an adaptation of a 5-item scale
previously developed to be used with HIV patients
and a 5-point Likert single item scale developed by
our team. A sample of those who completed the ques-
tionnaire was then asked between 3 and 6months later
to measure their HbA1c.
We plotted a receiver operating characteristics
(ROC) curve for each adherence measure and glyce-
mic control (HbA1c ≤7% - >7%). The predictive per-
formance of each instrument was assessed using the
area under the ROC curve (AUC). AUC ranges from
0 to 1, with 0.5 indicating a no better than chance predic-
tion. Results were stratiﬁed according to diabetes dura-
tion (≤9y - >9y), as this variable is associated with
glycemic control.
Results: A total of 117 participants were studied. Non-
stratiﬁed analyses yielded an AUC of 0.515 (95% CI:
0.423-0.606) for the MMAS-4, 0.532 (0.431-0.633)
for the MMAS-8, 0.541 (0.452-0.629) for the HIV-
adapted scale, and 0.524 (0.441-0.607) for our scale.
In patients who have had diabetes for >9 years, the
HIV-adapted scale exhibited a signiﬁcant but moderate
AUC of 0.653 (0.523-0.784).
Conclusions: Overall all 4 self-reported measures of
adherence exhibited a poor validity at predicting gly-
cemic control.
407. Evaluation of Adherence To Therapy in Patients
with Chronic Kidney Disease
Smita Sontakke, Ritu Budania, Chaitali Bajait, Kavita
Jaiswal, Sonali Pimpalkhute. Pharmacology, Government
Medical College, Nagpur, India.
Background: Chronic kidney disease (CKD) is a
prolonged illness usually co-existing with diseases such
as hypertension, diabetes .Non-adherence is common in
CKD patients and can cause uncontrolled hypertension,
hospitalization, dialysis, increased medication and related
costs.
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Objectives: To evaluate adherence to medication and
study factors associated with non-adherence in CKD
patients.
Methods: A cross-sectional questionnaire based study
was conducted in Nephrology department of a super
speciality hospital. Indoor and outdoor patients, above
18 years of age, suffering from CKD since six months
or more were interviewed using self-designed, semi-
structured questionnaire to get information about ad-
herence to medication, diet restriction and lifestyle
modiﬁcation (n = 150). Morisky’s medication adherence
questionnaire was used to calculate overall adherence
scores.
Main outcome measures included incidence of non-
adherence and factors associated with non-adherence
to medication.
Logistic regression was used to assess variables
independently associated with non-adherence.
Results: Average number of medicines taken by each
patient was 8.0 + 1.612(mean + SD) per day. Non-
adherence to medication was reported in 53.3% patients.
Common causes of non-adherence were high cost of
medication(21.3%), complex dosing schedule (20%),
and fear of adverse effects (16%). Sixty-eight% patients
were not aware about importance of taking each medi-
cine. Sixteen% stopped taking medicines due to high
cost. Forty-two% patients suggested that government
should adopt measures to provide free medicines to poor
patients.
In Morisky’s medication adherence questionnaire
high, medium and low adherence was observed in
7.3%, 55.3% and 37.3% of patients, respectively. Factors
independently associated with non-adherence were age
above 40, more than two concurrent illnesses and intake
of more than four medicines daily.
Conclusions: Since majority of patients were not
aware about importance of taking each medicine,
creating awareness about the same is essential for
improving adherence to therapy. Measures to provide
free medicines to non-affording patients need to be
implemented since high cost was other major cause
of non-adherence.
408. Factors Affecting the Regular Admission of
Statins (according to the Register PROFILE)
Sergey Yu Martsevish, Oleg V Gaisenok, Alexandr V
Zagrebelniy. National Research Centre for Preventive
Medicine of the Ministry of Healthcare of the Russian
Federation, Moscow, Russian Federation.
Background: The problem of patients adherence to
prescribed therapy, highly relevant, and actively
studied.
Objectives: to analyze the factors inﬂuencing regu-
lar admission of statins, in a cohort of patients
with cardiovascular diseases (CVD), formed on the
rules of the register in a specialized medical center in
Moscow.
Methods: in this study included patients presenting to
the department of preventive pharmacotherapy from 1
May to 31 December 2011. During this period 274 pa-
tients was recorded. A specially designed questionnaire
was issued to each patient in order to assess patients ad-
herence to therapy. All patients answer the following
questions: do they know about the high level of choles-
terol (yes, no, unknown); a method of correction of
hypercholesterolemia they apply (diet, medication,
exercise, or otherwise); whether they accept drugs from
the group of statins (take regularly, do not accept, accept
infrequently). On the basis of responses received and the
evaluation of the regularity of reception of statins was
estimated concept of adherence to statin therapy.
Results: to determine the signiﬁcance of a number of
factors on their inﬂuence on the regularity of statins
admission in patients with CVD, we calculated OR,
95%CI for a number of features: the elderly patients
age (70 years) - OR 0.42, p = 0.01, CI [0.22, 0.82],
increasing the dose of statin therapy is more standard -
OR 0.49, p = 0.3, CI [0.17, 1.14]; stroke history - OR
2.01, p = 0.3, CI [0.63, 6.4], history of myocardial
infarction - OR 4.8, p = 0.002, CI [1.7, 13.2] .
Conclusions: the analysis of factors inﬂuencing the
regular admission of statins in patients with CVD,
according to the register PROFILE, the data obtained
indicate the advisability of holding of doctors of
additional educational program aimed at explaining
the reasonableness of reception of statins in elderly
high-risk patients, including survivors of stroke, if
necessary, dose adjustment above average therapeutic,
to achieve the target lipid levels.
409. Barriers to Medication Adherence among
Outpatients in Jos University Teaching Hospital
Rachel U Odesanya,1 Ngozi Oragwu.2 1Pharmacovigilance
and Drug Safety Centre, Pharmacy Department, Jos
University Teaching Hospital, Jos, Plateau, Nigeria;
2Pharmacy Department, JosUniversity TeachingHospital,
Jos, Plateau, Nigeria.
abstract 215
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
Background: Adherence is the major link between
medical practice and patient outcomes since drugs will
only work in patients who take them. It is known that
for every 100 prescriptions issued, only 25 to 30 are
taken appropriately.
Non adherence to medication therefore needs to be ad-
dressed by detecting the barriers to medication adherence
in an effort to make meaningful interventions aimed at
improving medication adherence among patients.
Objectives: To assess the level of medication non ad-
herence and to identify the factors/barriers to medication
adherence;to educate/counsel the patients in order to
promote adherence to medication.
Methods: A cross-sectional prospective study was
carried out for a period of 2months from June 2013 to
July 2013 at 6 outpatient departments at JUTH.
Patients visiting the departments were involved in the
study after taking their consent by completing a struc-
tured questionnaire consisting of socio-demographic
proﬁle, medication and health condition proﬁle, eight
item Morisky Medication Adherence scale and barriers
to medication adherence. A score greater than 2 obtained
on the Morisky Medication Aherence Scale was consid-
ered as “poor adherence (non adherence)” and scores
ranging from zero to two were considered as good adher-
ence. Subsequent interventions (education, counseling)
were made based on barrier(s) to medication adherence.
Data was analysed with Excel and SPSS 17.
Results: Out of 324 patients, 72 (22%) were non adher-
ent to medication. The most common cause of non-
adherent behavior was forgetfulness (32%). Chi square
test for categorical variables and adherence to medica-
tion was found to be positively associated with psychiat-
ric clinic patients, male gender, higher educational level,
absence of health insurance, fewer comorbidities, longer
duration of condition and therapy, asking questions and
satisfactory knowledge of medicines (p <0.05).
Conclusions: Although the rate of medication non ad-
herence was considerably low with forgetfulness being
the major barrier, this study reiterates the need for a
systematic assessment of adherence to medication
among patients alongside proffering adequate interven-
tions to promote adherence to medication.
410. A Medicines List Is a Simple Tool to Improve
Adherence
Yeqin Zuo, Leanne Atkins, Stephen Morrell, James Reeve.
1Evaluation, NPSMedicineWise, Sydney, NSW, Australia.
Background: To achieve the expected beneﬁts of
medicines, especially for chronic disease management,
consumers are expected to adhere to prescribed medicine
regimes.NPSMedicineWise has developed amedicines list
and, more recently, a medicines list app (MedicineList+) to
assist consumers in recording and managing their med-
icines, and to encourage better adherence.
Objectives: To examine the beneﬁts of keeping a
medicines list in improving adherence.
Methods: (1) Design: Cross-sectional population-
based survey commissioned to improve consumer
awareness, knowledge, attitudes and behaviours in re-
lation to medicines.
(2) Setting: Computer-aided telephone interview (CATI)
among people aged 16 years and over across Australia
(3) Main outcome measures: Adherence to pre-
scribed and non prescribed medicines among people
taking two or more medicines.
(4) Statistical analysis: The sample was weighted ac-
cording to the age, sex and geographic distribution of
the Australian census. Univariate analyses and multiple
logistic regression modelling of these factors in relation
to reporting adherence were conducted. Parsimonious
logistic regression models were also produced, using a
stepwise model building approach.
Results: 1500 people responded to the survey. There
was no signiﬁcant gender difference in reporting ad-
herence. There was a strong and highly signiﬁcant
(OR= 1.25 95% CI 1.14-1.38) positive association
between increasing age and the proportion reporting
adherence. There was a signiﬁcantly lower proportion
of respondents who speak a language other than English
at home (OR=1.71 95% CI 1.13-2.61), who reported
adhering to a medicine regime. Keeping a list of
medicines was strongly (OR=2.35 95% CI 1.28-3.28)
associated with the likelihood of reporting adherence.
Conclusions: Future programs aiming to improve ad-
herence to medicine regimes should focus on improv-
ing adherence in younger people and people with
English as their second language. Keeping a medicines
list is a simple tool that can improve adherence.
411. Association between Adherence to Secondary
Prevention Therapies and Mortality in Acute
Myocardial Infarction (AMI)
Tzu-Chi Liu,1 Yea-Huei Kao Yang,1 Ching-Lan Cheng,1
Cheng-Han Lee.2 1Institute of Clinical Pharmacy and
Pharmaceutical Sciences, National Cheng KungUniversity,
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Tainan, Taiwan; 2Department of Internal Medicine, Na-
tional Cheng Kung University Hospital, Tainan, Taiwan.
Background: Secondary prevention drugs following
AMI (acute myocardial infarction) has been proved
its efﬁcacy. Nevertheless, poor adherence to post-MI
medications has been documented. Currently there’s
no study investigating the adherence rate in Taiwan.
Objectives: To assess the adherence to secondary
prevention therapies after AMI in Taiwan.
Methods: We conducted a nationwide retrospective
cohort study using data from 1999-20009 Taiwan’s
National Health Insurance Research Database
(NHIRD). Patients aged between 18 and 100 years,
hospitalized with ﬁrst AMI between January 1, 2002
and September 30, 2007 and surviving at least 1 year
and 3months after hospitalization were identiﬁed and
were then separated into 2 groups according to ICD-9
code: STEMI and NSTEMI. All patients had to ﬁll at
least 1 of 4 study drugs (antiplatelet agents, beta-
blockers, ACEI/ARBs or statins) within 3months of
AMI hospital discharge. Medication adherence was
calculated as proportion of days (PDC) for each thera-
peutic group in 1 year following discharge. Adherence
was subdivided into 3 categories–high (PDC, ≥80%),
intermediate (PDC, 40%-79%), and low (PDC,<40%).
Results: During the study period, 20,952 STEMI
patients and 16,096 NSTEMI patients were identiﬁed
respectively. Overall, the rate of adherence to study
drugs was slightly lower in the NSTEMI group com-
pared with STEMI patients. After calculating the one
year PDC, in STEMI group, high adherence was
reached by 78.6% of patients taking antiplatelet agents,
63.0% taking beta-blockers, 61.9% taking ACEI/
ARBs, and 55.7% taking statins. In NSTEMI group,
high adherence was reached by 75.0% of patients taking
antiplatelet agents, 60.7% taking beta-blockers, 60.2%
taking ACEI/ARBs, and 53.7% taking statins.
Conclusions: 1-year compliance rates were suboptimal.
Our results indicate that there remains room to improve
implementation of secondary prevention therapies to
AMI patients.
412. The Investigation of Potential Prescription
MedicationsWaste in aMedical Center: A Pilot Study
Yi-Jung Chiang, Yen-Yu Hsieh, Wen-Hsin Chan,
Yi-Syuan Lai, Su-Yu Chien. Department of Pharmacy,
Changhua Christian Hospital, Changhua, Taiwan.
Background: Up to 99% Population in Taiwan are
covered with National Health Insurance. Affordable
co-payment and highly accessible medical institutions
not only provide convenient and high quality health
care service, but also result in patient hospital shopping
and drug expenditure going up quite substantially with
years. According to previous survey, in Taiwan, the
estimated amount of medications disposed was about
10 tons and the waste of money was over a hundred
million Taiwan dollars. Unfortunately, most doctors
don’t know patients never take the prescriptions.
Objectives: We initiated a pilot study to investigate
potential prescription medications waste in our hospital,
and analyzed the patterns of drugs disposal. Through the
survey, we tried to establish the investigational model,
ﬁnd the potential drug utilization problems in our hospi-
tal and fed the data back to doctors.
Methods: The study was initiated in a medical center
with about 5,500 outpatient visits per day.
Two investigators collected and recorded all unused
medications which were threw out by patients in the outpa-
tient pharmacy department, on 2014/01/02 to 2014/01/10.
Results: 36,861 pills were collected through 9 days.
The most common pharmacology categories were gas-
trointestinal (20.8%), cardiovascular (17.16%) and di-
abetes (13.12%), accounted for over 50% pill counts.
Anti-diabetes drug, metformin (5.94%;545 DDDs),
was the most common disposing drug. Total value of
collected drugs was 284,485 NT dollars. We also found
unusually large amounts of immunosuppressant (cyclosporine
and sulfasalazin), anti-epileptic drug (oxcarbazepine),
anti-parkinsonism drug (trihexyphenidyl) and anti-platelet
agent (clopidogrel).Most above drugs had special clinical
indications and were expensive; therefore we never con-
sidered there were so much unused medications before.
Conclusions: Through the investigation, we found
that there was a large amount of medication waste
among the patients in our hospital. The next step we
will evaluate the relationship between speciﬁc wasted
drugs and reasons to throw them out (unnecessary or
poor compliance), and then discuss these data with
doctors, to ﬁnd the potential solutions.
413. HIV/AIDS Clinical Care Program Certification
International: Pharmaceutical CareModel Established
and Efficacy Analysis
Shiue-Shiang Lin,1 Chun-Eng Liu,2 Yuan-Meng Liu,2
Su-Yu Chien.1 1Department of Pharmacy, Changhua
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Christian Hospital, Changhua, Taiwan; 2Division of Infec-
tious Diseases, Changhua Christian Hospital, Changhua,
Taiwan.
Background: Changhua Christian Hospital proactivity
initialized a HIV/AIDS care plan. This care plan is cer-
tiﬁed by JCI (Joint Commission International). Pharma-
cists are also involved in the whole medical team to help
build a HIV/AIDS pharmaceutical care model.
Objectives: The objective of the study was to create a
pharmaceutical care model to assess the impact of a
pharmacist intervention on the knowledge gained by
HIV/AIDS patients with regard to the disease, antire-
troviral drug use as well as adherence to treatment.
Methods: We enrolled the HIV infected persons from
June 2012 to April 2013, including criteria: aged over
18 years who agree to the services of the care model
and signed the explanatory memorandum of participa-
tion. Primary outcomes were antiretroviral adherence,
viral load, and CD4 cell count and secondary outcomes
included patient medication knowledge, antiretroviral
modiﬁcations, and safety.
Statistical analysis: Quantitative variables were com-
pared between pre-intervention and post-intervention
stages by using t-test and Categorical variables were
compared by using Chi-square test or Fisher’s exact test.
Results: Forty-four HIV/AIDS patients were included,
average age was 38 years, 82% were male and 72%
were antiretroviral drug users. The impact of a phar-
macist intervention was associated with statistically
signiﬁcant adherence improvements and improved viral
suppression.
Conclusions: Pharmacists involved in team work, play
an important role in the patient care of HIV-infected
persons by ensuring patient adherence to complex
treatment regimens and providing pharmaceutical care
model.
414. Pharmacist-Led Educational Interventions to
Improve Inhalation Technique in Pediatric Asthma
Patients
Hsin-Lien Lin, Sock-Ping Ng, Chien-Hui Chen, Su-Yu
Chien. Department of Pharmacy, Changhua Christian
Hospital, Changhua, Taiwan.
Background: Incorrect use of inhalers reduces beneﬁt
of the medication. Pediatric inhalant education is further
complicated by the fact that changes in a child’s
cognitive and psychosocial development can pro-
foundly affect medication use. Typically, counseling
involves a child and one or both parents or another
caregiver.
Objectives: The aim of this study were to determined
the effect of pharmacist-led educational intervention to
improve the inhalation technique in pediatric asthma
patients.
Methods: This prospective interventional study con-
ducted in our hospital during the period May to Dec
2013. We eligible asthma patient aged between 2 to
18 years. Pharmacist was described and demonstrate
all the steps necessary to perform the correct
technique to the patient and one or both parents or
another caregiver. Subsequently, patients were asked
to demonstrate inhalation technique. Evaluate the in-
halation technique with checklist consist of 9 crucial
steps. Based on the results, pharmacist will enhanced
the education for non-correct step. Patient will asked
to demonstrate inhalation technique during second
visit (after one week) and inhalation technique
assessment will be done at the same time. The
comparison of the inhalation technique assessment
was performed.
Results: A total of 32 patients included, 34% were fe-
male and 66% were male ( F:M ; 1:1.9). Median age
was 4 years, 21 (66%) aged between 2 to 6 years; 10
(31%) aged between 7 to 12 years. 23 (72%) patients
need aerochamber. 13 patients (40.6%) made at least
one error in performing their inhalation and dropped
to 4 (12.5%) from the ﬁrst to the second visit
(p = 0.01). The average number of errors dropped from
0.78 to 0.28 per patient(p = 0.004). The most common
errors at ﬁrst visit were failure to shake well before use
(22%), wait about half a minute between taking each
puff of medicine (16%). Failure to hold breath after
inhaling for 5 to 10 second (8%) is the error with no
improvement after second visit. Failure to breath out
slowly and fully for patients without aerochamber
have the same problem.
Conclusions: Pharmacist-led intervention was effec-
tive improving inhalation technique in pediatric
asthma patients.
415. Self-Reported Adherence To Antiretroviral
Therapy in Sub-Saharan Africa: A Meta-Analysis
Obinna Ikechukwu Ekwunife,1 Charles Ebuka Okafor.2
1Clinical Pharmacy and Pharmacy Management, Nnamdi
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Azikiwe University, Awka, Anambra, Nigeria; 2Depart-
ment of Pharmacy, National Orthopaedic Hospital, Enugu,
Nigeria.
Background: HIV is a major public health problem for
developing countries especially those in sub-Saharan
Africa. Fortunately, more HIV infected patients now
receive treatment thanks to increased efforts by donor
agencies. However, as treatment of HIV infection with
antiretroviral medications becomes a reality in this
region of the world, adherence to treatment regimen
becomes a challenge.
Objectives: This study aimed to: establish the percent-
age of self-reported adherence to antiretroviral therapy
(ART) in sub-Saharan Africa from 2003-2012; and to
identify barriers to adherence and strategies to improve
adherence.
Methods: A formal meta-analysis was conducted to
summarize the reported adherence rates in the individ-
ual studies. Forest plot was used to visualize the extent
of heterogeneity among studies. A measure of the
degree of inconsistency (I2) across studies was
conducted using Cochrane Q, moment-based estimate
of between studies variance and I2 measure. Sensitiv-
ity analysis was done using Monte Carlo Markov
chain simulation of variability.
Results: A total of 27 articles (full texts and abstracts)
that met the inclusion criteria out of the 41 relevant
studies were used in the meta-analysis. The adherence
rate ranged from a minimum of 30% to a maximum of
100%. The combined adherence in the analysis
showed an adherence of 88.11% (95% CI = 87.39% -
88.81%) in the ﬁxed effect model. For the heterogene-
ity of studies conducted, the Q statistic was very
large (Q = 705.50, df = 26, P< 0.0001; I2 = 96.3%).
Identiﬁed barriers to adherence include: depression,
centralized ART clinic, interruption in drug supply/
procurement, stigma, absence of social support, cost
of ART, complacency, forgetfulness and medication
related problems. Cost of ART (OR= 2.19; 95% CI =
1.65 – 2.90), Complacency (OR=5.25; 95% CI=2.89 –
10.80), and medication related problems (OR= 1.68;
95%CI = 1.28 – 2.22) were the strongest barriers to
adherence.
Conclusions: This study showed a good level of
adherence in sub-Saharan Africa. However, barriers
to adherence identiﬁed in this study could be
employed to improve adherence to a near perfect
level.
416. Enriching Persistence Prediction Models Using
Prior Adherence and Empirically Selected Claims
Data Components
Hiraku Kumamaru,1,2 Joshua J Gagne,2 Robert J Glynn,2
Soko Setoguchi,3 Sebastian Schneeweiss.2 1Epidemiology,
Harvard School of Public Health, Boston, MA, United
States; 2Division of Pharmacoepidemiology and
Pharamacoeconomics, Brigham and Women’s Hospital,
HarvardMedical School, Boston, MA, United States; 3Duke
Clinical Research Institute, Durham, NC, United States.
Background:Models to predict future drug persistence
in electronic healthcare data have modest performance.
Improvement from including measures of prior medica-
tion adherence and empirically selected predictors has
not been extensively evaluated.
Objectives: To investigate the added value of prior
medication adherence and empirically selected data
in predicting future persistence to oral anticoagulants.
Methods: Using United HealthCare claims data, we
identiﬁed a historical cohort of patients with atrial ﬁ-
brillation who initiated warfarin Oct.2009-Sep.2010.
We developed competing risks models to predict time
to warfarin discontinuation, deﬁned by a coverage gap
>30 days, using data components captured in a 1-year
baseline period: 1) demographics; 2) comorbidities
and medications; 3) CHADS2 score; 4) health service
utilization; 5) prior adherence to preventive medica-
tions; and 6) empirically selected predictors with data
reduction via principal component analysis. We ap-
plied the models with each data component to a con-
current warfarin and dabigatran initiator cohort
Oct.2010-Dec.2012, and assessed their discriminatory
ability using Harrel’s c-index.
Results: We identiﬁed 4,525 warfarin initiators in the
historical cohort and 6,214 warfarin and 3,319
dabigatran initiators in the concurrent cohort. The me-
dian follow-up was 122 days in the historical cohort
and 120 days in the concurrent cohort, during which
2,937 (65%) and 5,773 (61%) patients discontinued,
respectively. The demographics only model had a c-
index of 0.56 in the concurrent cohort. The addition
of each data component yielded c-indice of: CHADS2,
0.56; comorbidity and medications, 0.59; health ser-
vices utilization, 0.57; prior medication adherence,
0.58; and empirically selected predictors, 0.59. When
all data components were combined, the c-index was
0.60. The c-indices were similar between warfarin
and dabigatran initiators.
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Conclusions: Prior medication adherence and empiri-
cally selected predictors resulted in slight improve-
ments in discriminating between patients who will
discontinue anticoagulants and do not. However, even
after adding this information, model discrimination
remained modest.
417. Persistence to Osteoporosis Drugs Following an
Incident Osteoporotic Fracture: the PREFRAC Study
Corinne Klop,1 Paco MJ Welsing,2 Jetty A Overbeek,3
Patrick C Souverein,1 Hubert GM Leufkens,1 Johannes
WJ Bijlsma,4 Frank de Vries.1 1Utrecht Institute for
Pharmaceutical Sciences, Utrecht University, Utrecht,
Netherlands; 2Julius Center for Health Sciences and
Primary Care, University Medical Center Utrecht,
Utrecht, Netherlands; 3PHARMO Institute for Drug
Outcomes Research, Utrecht, Netherlands; 4Rheumatol-
ogy and Clinical Immunology, University Medical
Center Utrecht, Utrecht, Netherlands.
Background: Osteoporotic fracture is a devastating
disease associated with high risk of mortality and
subsequent fracture. Recurrent fractures and even
mortality can effectively be prevented by osteoporosis
drugs. However, persistence to osteoporosis drugs for
the secondary prevention of osteoporotic fracture has
not been determined.
Objectives: To determine persistence to osteoporosis
drugs in patients who initiated therapy following an
incident osteoporotic fracture.
Methods: A population-based cohort study was con-
ducted using data from the Dutch PHARMO Database
Network (January 2002 to December 2011). We iden-
tiﬁed all patients ≥ 50 years who initiated osteoporosis
therapy (bisphosphonates, strontiumranelate, raloxifene,
denosumab) within one year following their ﬁrst fracture
(hip, spine, forearm, upper arm). Kaplan-Meier life-table
analysis was used to calculate the cumulative incidence
probability (%) for persistence to osteoporosis drugs.
Discontinuation of osteoporosis drugs was deﬁned as a
treatment gap of> 90 days. Time-dependent Cox regres-
sion was used to estimate fully adjusted hazard ratios
(aHRs) with 95% conﬁdence intervals (95% CIs) for
determinants of discontinuation of osteoporosis drugs.
Covariates included age, sex, comorbidities including
the type of fracture, and drug use six months prior.
Results: A total of 976 patients initiated osteoporosis
drugs within one year after their ﬁrst fracture. Within
one year following initiation 74% (95% CI: 67% - 76%)
persisted with treatment, which had dropped to 39%
(95% CI: 35% - 44%) after ﬁve years. Determinants for
discontinuation of osteoporosis therapy included older
age ≥ 80 years (aHR 1.9; 95% CI: 1.4 – 2.5) (reference:
patients aged 60 – 69 years) and recent use of proton
pump inhibitors or H2-receptor antagonists (aHR 1.5;
95% CI: 1.2 – 1.9).
Conclusions: This study shows a major treatment
failure for the secondary prevention of osteoporotic
fractures; more than half of all patients had
discontinued treatment within the recommended
treatment duration of ﬁve years which was even
worse in the elderly.
418. Efficacy and Content Analysis of Adherence
Interventions to Enhance Oral Antidiabetic Adherence
(OAD) in Adults with Type 2 Diabetes: A Systematic
Review and Meta-Analysis
Hervé Tchala Vignon Zomahoun,1,2 Marijn deBruin,3
Laurence Guillaumie,2,4 Jocelyne Moisan,1,2 Jean-Pierre
Grégoire,1,2 Norma Perez,2 Lydi-Anne Vézina-Im,4 Line
Guénette.1,2 1Faculty of Pharmacy, Laval University, Québec,
QC, Canada; 2Chair on Adherence to Treatments, Centre de
Recherche duCHU,Québec, QC, Canada; 3Health Psychol-
ogy Group, Institute of Applied Health Sciences, University
of Aberdeen, Aberdeen, Scotland, United Kingdom; 4Faculty
of Nursing, Laval University, Quebec, QC, Canada.
Background: Adherence to OAD is suboptimal. OAD
adherence interventions are available but their overall
efﬁcacy has not yet been estimated. Also, in order to
develop effective interventions, it is important to explore
the behavior change techniques (BCTs) employed and
their contribution to pooled effect size.
Objectives: To estimate the pooled effect size of OAD
adherence-enhancing interventions and identify BCTs
applied that had a modifying effect on the pooled esti-
mate of effect sizes.
Methods:We performed a systematic review and meta-
analysis of RCTs conducted to evaluate the efﬁcacy of
adherence-enhancing interventions targeting adults re-
ceiving OADs. Articles were searched using PubMed,
Embase, Psych-Info, the Cochrane Library, CINAHL
PLUS, Current Contents Connect and Web of science,
and included articles references and relevant review
articles. Two authors independently selected eligible
articles and coded study details including BCTs applied
in intervention and control groups. Each intervention’s
effect size was estimated using Hedges’s g. Pooled
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effect size and its heterogeneity (Higgins I2) were esti-
mated using a random effect model. For BCTs only
applied in intervention but not in control groups, we
assessed their modifying effect on the pooled effect size
by comparing interventions in which a speciﬁc BCT
was applied with those in which it was not.
Results: A total of 10 studies were included. The
pooled effect size (g) was 0.21 (95%CI = -0.05–0.47;
I2 = 82%). Out of 8 BCTs analysed, cope with side
effects (P = 0.003) and general intention formation
(P = 0.006) had a modifying effect on the pooled effect
size. The pooled effect size of interventions, in which
cope with side effects was applied, was moderate
(g = 0.64; 95%CI = 0.31–0.96; I2 = 56%).
Conclusions: Our results suggest that interventions that
include helping people to cope with side effects, when
this was not done for control patients, are particularly
effective in improving adherence to OAD.
419. The Impact of Two Consecutive Prescription
Charges on Adherence to Chronic Medications in
the Irish General Medical Services Population
Sarah-Jo Sinnott,1 Stephen Byrne,2 Noel Woods,3 Helen
Whelton.4 1Department of Epidemiology and Public
Health, University College Cork, Cork, Ireland; 2Phar-
maceutical Care Research Group, School of Pharmacy,
University College Cork, Cork, Ireland; 3Centre for
Policy Studies, University College Cork, Cork, Ireland;
4School of Dentistry, University of Leeds, Leeds, United
Kingdom.
Background: Two prescription charges (50c per item
in 2010 and €1.50 per item in 2013) were introduced
on the Irish General Medical Services scheme, a means
tested public health insurance covering approximately
40% of the population.
Objectives: The aim was to assess the impact of two
charges on adherence to prescription medicines.
Methods: A longitudinal repeated measures design was
used. Nationally representative individual level data
were obtained from the centralised pharmacy claims
database (HSE PCRS) for intervention and comparator
groups. Two consecutive cohorts, which included new
users of anti-hypertensive, anti-hyperlipidaemic and oral
anti-diabetic drugs, were established to analyse the effect
of both charges. Follow up was at least 12months. The
outcome was adherence measured at monthly intervals.
Segmented regression with generalised estimating
equations was used. Sensitivity analyses according to
age, sex and essential/non-essential drug status were
conducted.
Results: Relative to the comparator group, signiﬁcant
decreases in adherence were observed immediately
after the introduction of the 50c charge. For anti-
hyperlipidaemic medicines, the reduction was 2.2%
(95% CI, 1.24% - 3.12%). For anti-hypertensive medi-
cines, the decrease was 4.8% (95% CI, 4% - 5.7%). For
anti-diabetic medicines adherence declined by 2.4%
(95% CI, 1.3% - 3.5%).Directly after the introduction
of the €1.50 charge, adherence to anti-hypertensive
medicines decreased by 5.1% (95% CI, 4.2% - 6.1%).
Reductions in adherence to anti-hyperlipidaemic med-
icines were non-signiﬁcant and were non-existent for
anti-diabetic medicines. Neither prescription charge
was associated with reductions in long-term (12months)
adherence for any drug group. A greater drop in adher-
ence to non-essential drugs was observed.
Conclusions: The introduction of the 50c charge had
a greater immediate effect on adherence to anti-
hyperlipidaemic and anti-diabetes medicines than the
increased charge, suggesting reducing price elasticity.
Further changes to cost-sharing policies in Ireland should
be informed by national and international evidence.
420. The Influence of Anxiety and Depression on
Barriers to Antiretroviral Treatment Adherence
Reported by People Living with HIV in Brazil
Celline C Almeida,1 Maria das Graças B Ceccato,1 Maria
InêsBNemes,2MarkDCGuimaraes,1 FranciscoAAcurcio.1
1Universidade Federal de Minas Gerais, Belo Horizonte,
Brazil; 2Universidade de São Paulo, São Paulo, Brazil.
Background: Psychiatric symptoms interfere with
behaviors of people living with HIV (PLHIV), such
as the ability to face barriers to treatment adherence.
Objectives: To evaluate the association between bar-
riers reported by PLHIV and symptoms of anxiety
and depression.
Methods: Cross-sectional national study of HIV-positive
adults under care in 17 AIDS referral services in Brazil.
Patients were proportionally sampled according to seven
Brazilian Regions, strata of service quality and total num-
ber of patients under antiretroviral therapy (ART) in each
service. Patients answered to three open-ended questions
about barriers and facilitators with ART. After content
analysis ﬁve major categories were identiﬁed: factors
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related to (i) social and economic issues, (ii) system and
healthcare team, (iii) ART, (iv) HIV infection, and (v)
patients. These categories, as well as the experience of
stigma reported, were associated with symptoms of
anxiety and depression using chi-square test with a
p-value≤ 0.05 considered signiﬁcant.
Results:We included 598 (61%males) adults. Patients
with anxiety symptoms (235) were more likely to
report barriers related to social and economic issues
(i.e., lack of social support, difﬁculty in getting a job,
and ﬁnancial constraints; p = 0.02), ART (i.e., adverse
events, incorporating ART into routine, and organoleptic
properties; p< 0.01), and experience of stigma (p< 0.01)
than those without these symptoms. Barriers related
to HIV infection (i.e., fear of status disclosure, non-
acceptance of disease, uncertainty about the future,
and comorbidities) were more reported by patients
with both anxiety (p< 0.01) and depression (p< 0.01)
symptoms. In addition, patients who reported barriers
related to system and healthcare team complained
about the lack of psychologists and psychiatrics in
AIDS services.
Conclusions: Symptoms of anxiety and depression
were associated with reported barriers to treatment
adherence. The results suggest that the health ser-
vices are not ready to deal with these psychiatric dis-
orders. Efforts need to be done to face HIV-related
stigma and to add mental health providers in AIDS
services.
421. Association between the Medicare Part D
Coverage Gap and Non-Adherence to Hormonal
Treatment for Breast Cancer
Joel Swerdel,1 Kitaw Demissie,1 Kim Hirshﬁeld,2
Sheenu Chandwani.1 1Epidemiology, Rutgers School of
Public Health, Piscataway, NJ, United States; 2Medicine,
Rutgers Robert Wood Johnson Medical School, New
Brunswick, NJ, United States.
Background: The survival beneﬁt of hormonal ther-
apy in the treatment of hormone receptor positive
breast cancer has been demonstrated in clinical trials
and is an integral part of the National Comprehensive
Cancer Network Treatment Guidelines. Cost of medi-
cation is a signiﬁcant economic burden for elderly
breast cancer patients with multiple comorbidities.
This may affect adherence to hormonal therapy, partic-
ularly in those who reach the Medicare coverage gap,
the portion of the beneﬁt schedule where patients pay
100% of drug costs.
Objectives: To determine if the Medicare Prescription
Drug coverage gap is associated with non-adherence
to hormonal therapy in elderly breast cancer patients.
Methods: The Surveillance, Epidemiology and End
Results linked Medicare data from 2007-2010 was
used. Patients who initiated hormonal therapy after
invasive breast cancer diagnosis were included.
Pill burden was estimated by the average number
of pills during the period between time of breast
cancer diagnosis and initiation of hormonal ther-
apy and was categorized into four groups: none
(0 pills/day), low (≥0-3 pills/day), intermediate
(≥3-5 pills/day) and high (>5 pills/day). Patients
who reached the Medicare coverage gap were deter-
mined by beneﬁt codes associated with each pre-
scription. A medication possession ratio of <0.8
deﬁned non-adherence.
Results: In the overall sample (n = 25,899), 64.1%
reached the Medicare gap. Analysis that accounted
for the effect of age revealed that the coverage gap
was associated with non-adherence to hormonal therapy
in the low, intermediate and high pill group categories.
The relative risks (RRs) and 95% Conﬁdence Intervals
(CIs) associated with reaching the coverage gap were
0.9 (95% CI 0.79-1.08) in the none, 1.08 (95% CI
1.02-1.14), in the low, 1.26 (95% CI 1.14-1.39) in the
intermediate and 1.30 (95% CI 1.15-1.48) in the high
pill burden categories.
Conclusions: These ﬁndings provide evidence sug-
gesting that the prescription coverage gap is a barrier
in maintaining adherence and has important policy im-
plications for elderly breast cancer patients utilizing
Medicare Part D.
422. Withdrawn by Author
423. The Discrepancy of Perceived Medication Use
Patterns among the Elderly from Patient-Related
and Health Professionals’ Perspectives
Hsiang-Wen Lin.1,2 1School of Pharmacy and Graduate
institute, China Medical University, Taiching, Taiwan;
2Department of Pharmacy, China Medical University
Hospital, Taichung, Taiwan.
Background: There were limited studies examined
the medication use behaviors, attitudes and awareness
in Taiwan.
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Objectives: The aim of this study was to explore the
differences of perceived medication use patterns among
the elderly from different perspectives.
Methods: Four instruments were developed for different
perspective to explore the factors associated with their
perception of elderly medication use. The modiﬁed
Morisky medication adherence scale was adapted to de-
velop a 9-items medication adherence with two parts
(any condition and chronic condition) in order to explore
the discrepancy of elderly mediation use patterns be-
tween different perspectives. Four perspectives were
concerned and grouped into patient-related (i.e., patients
and their caregivers) perspectives and health professional
(i.e., pharmacists’ and prescription physicians’) perspec-
tives. The patient-related perspective questions were al-
most all yes/no questions and professionals’ perspective
questions were frequency about their encounters.
Results: Of available respondents (165 elderly, 48 care-
givers, 15 physicians, 31 pharmacists), patients tend to
perceive their tendency to ever forgot but caregivers
tend to claim patients had difﬁculty to remember taking
any kind of medications for acute or chronic conditions
(p = 0.0001, 0.0013, respectively). Pharmacists reported
that more elderly patients tended to ever forgot and had
difﬁculty to remember taking any kind of medications,
comparing to that of physicians’ experience (p=0.0034,
0.0595, respectively). For chronic conditions, patients
tended to claim they were poor adhere than that from
caregivers’ perspective, expect for the discontinuation
and frequency of non-adherence. Pharmacists tended
to claim more elderly patients had troublesome to fol-
low-up physicians’ orders (p = 0.0012), while other re-
sponses were not different between two professionals’
perspectives.
Conclusions: There exists the divergence of perceived
medication use patterns betweens patient-related and
professionals’ perspectives. All these discrepancies
should be aware whenever facilitating medication rec-
onciliation from different perspectives.
424. Consumption of Rosiglitazone and Pioglitazone
Following Safety Warnings – A Time Series Inter-
vention Analysis in Portugal
Carla Torre, Marta Gomes, José Guerreiro. Centre for
Health, Evaluation & Research (CEFAR), National
Association of Pharmacies, Lisboa, Portugal.
Background: TheNissen&Wolski meta-analysis (2007)
raised concern about the increased risk of myocardial
infarction and death in patients treated with rosiglitazone.
In 2010, after additional studies, the European Medi-
cines Agency(EMA) decided to suspend the use of
rosiglitazone. In June 2011, the French MA decision
to suspend the use of pioglitazone raised again safety
concerns of this class, this time suggesting an increased
risk of bladder cancer. In Portugal(PT), little is known
about thiazolidinediones(TZD) consumption following
safety signals.
Objectives: To describe rosiglitazone and pioglitazone
utilization trends in PT, after EMA press-releases (EMA
PR) safetywarnings, from Jan 2005 to Sep 2010, and from
Jan 2005 to Dec 2013, respectively.
Methods: Drug consumption data(ATC:A10BG02,
A10BG03,A10BD03,A10BD04,A10BD05,A10BD06)
was estimated for the study period through the CEFAR
Pharmacy Sales Information System, a nationwide data-
base with representative drug dispensing data from am-
bulatory care. Main outcome measure was the deﬁned
daily dose(DDD) per 1000 inhabitants per day(DHD).
An auto-regressive, integrated, moving average model
(ARIMA) was set up to calculate changes in consump-
tion trends of rosiglitazone and pioglitazone (alone and
ﬁxed-dose combination). The safety warnings(4 and 5
EMA PR issued for rosiglitazone and pioglitazone,
respectively) were used as determinants.
Results: The total use of rosiglitazone increased from
0.34 DHD in Jan 2005 to 3.33 DHD in Jul 2007; since
July 2008 showed a negative trend (6m after EMA PR
3) up to withdrawal. Pioglitazone had a residual con-
sumption (1DHD) up to Mar 2008 and reached a peak
(2.45DHD) in Sep 2010 (rosiglitazone withdrawal).
Since Jun 2011, a slightly decreasing trend was ob-
served until Dec 2013 (1.39DHD). Only EMA PR 2
and 4 concerning Pioglitazone had reduced consump-
tion signiﬁcantly (p< 0.05).
Conclusions: Although TZD were not heavily marketed
in PT, rosiglitazone EMA PR had no immediate signiﬁ-
cant impact on prescription behavior. Only for pioglita-
zone, a slightly impact was observed. Overall, the
timing of the observed decreasing trends, did not coincide
with safety warnings.
425. Safety of Azithromycin Therapy in Patients
with High Cardiovascular Risk. A Meta-Analysis
of Randomized Controlled Trials
Ziyad S Almalki, Jeff J Guo. University of Cincinnati ,
College of Pharmacy, Cincinnati, OH, United States.
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Background: Azithromycin has an attractive safety
proﬁle in treating or preventing certain bacterial infections.
However, there is growing concern that Azithromycin
may be associated with increased cardiovascular risk and
lead to cardiovascular death in high risk patients.
Objectives: We therefore conducted a meta-analysis of
randomized Controlled trials to describe the cardiovascu-
lar risk proﬁle of those patients receiving Azithromycin.
Methods: The MEDLINE and Cochrane Central Reg-
ister of Controlled Trials databases were searched from
1991 to September 2013 using speciﬁc search terms for
English-language trials of comparing high baseline risk of
cardiovascular disease patients receiving Azithromycin
or placebo and have reported cardiovascular outcomes.
Abstracts from major scientiﬁc meetings were also
reviewed.In the analysis, Methods based on risk ratios
(RRs) was used. RR was calculated using a random-
effects model (because we assume that the treatment
effect in all the included studies are not identical) from
the RRs and 95% conﬁdence intervals (CIs) were used
for each end point in each study. Statistical heterogene-
ity scores were assessed with an I2test. Sensitivity
analyses were performed by removing some trials and
recalculating the combined RRs for the remaining
studies.
Results: 12 trials randomized a total of 15,588 patients
into two groups, treatment and placebo. Compared
with participants who had not taken azithromycin,
those who had taken azithromycin had an overall RR
of deaths of 0.877 (95% CI, 0.752–1.024; p = 0.97).
No heterogeneity was observed (I2 = 0). Similarly,
there was no difference in the pooled odds ratio for hos-
pitalization and clinical intervention [(RR, 1.005; 95%
CI, 0.922–1.094), p = 0.915, I2 = 0%] and [(RR, 0.999;
95% CI, 0.896–1.125), p = 0.984, I2 = 0%], respectively.
Conclusions: The ﬁndings of this systematic review
suggest that no relationship exists between azithromycin
and risk of cardiovascular in patients with high risk of
cardiovascular events.
426. Prevalence and Antimicrobial Resistance Pattern
of Community Acquired Pathogens Against Beta
Lactam Antibiotics Isolated from Residents of Holy
Makkah, Saudi Arabia
Abdul Haseeb,1 Hani Saleh Faidah,2 Abdul Rehman
Bakhsh,3 Abrar Al Anazi,4 WeamClinton,5 Nada Bogus,6
Mahmood Essam Uddin Raggal.7 1Clinical Pharmacy,
Faculty of Pharmacy, Umm Al Qura University, Holy
Makkah, Makkah, Saudi Arabia; 2Applied Medical Sci-
ences, Umm Al Qura University, Holy Makkah, Makkah,
Saudi Arabia; 3Medical Administeration, Ajyad Emer-
gency Hospital, Holy Makkah, Makkah, Saudi Arabia;
4Faculty of Pharmacy, Umm Al Qura University, Holy
Makkah, Makkah, Saudi Arabia; 5Faculty of Pharmacy,
Umm Al Qura University, Holy Makkah, Makkah, Saudi
Arabia; 6Faculty of Pharmacy, Umm Al Qura University,
Makkah, Makkah, Saudi Arabia; 7Department of Clinical
Pharmacy, Faculty of Pharmacy, Umm Al Qura Univer-
sity, Makkah, Makkah, Saudi Arabia.
Background: An emerging problem in health care is
antimicrobial resistance among most common
organisms responsible for severe community acquired
infectious diseases e.g. Pneumonia, Meningitis,
Urinary Tract infections. Inappropriate and overuse
of Antibiotics is one of the major reasons for antimicro-
bial resistance. To improve appropriate antimicrobial
therapy, there is a need of antibiotics use restrictions
based on site speciﬁc resistance pattern.
Objectives: This study aimed to observe prevalence of
most common community acquired organisms among
multiple nationalities residing in Holy Makkah and
conﬁrmed antimicrobial resistance exhibited by gram
positive and gram negative bacteria.
Methods: Pathogens were isolated from patients with
different acute illnesses visited two hospitals emergency
services in holy Makkah. All cultures received during
initial 48 hours of admissions were included in the study.
Results: The activity of nineteen beta lactam antibiotics
was tested against the bacterial isolates. The resistant
rates were high among gram negative bacteria. Highest
resistance observed against Augmentin (Amoxicillin/
Clavulaniz acid) among all isolated pathogens.
Klebsella Pneumonia having the higher resistance to
Augmentin15 ( 75 %) and Ampicillins 55 ( 95 %). This
higher resistance might be due to inappropriate use of
antibiotics in community and indirectly leads to the
failure of initial control of severe infectious diseases.
Conclusions: Despite extensive antimicrobial resis-
tance among various organisms, most of the organisms
interestingly found less resistant against some broad
spectrum organisms e.g. ceftriaxone, ertapenem,
Meropenem, Tazocin( Piperacillin/Tazobactam) and
can generate hypothesis to test their effectiveness in
initial control of severe community acquired infectious
diseases in Makkah region. Their effectiveness should
however be monitored and audited.
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Further studies are required to investigate antimicro-
bial resistance pattern in multi settings to generate
empirical guidelines for most common community
acquired infections.
427. Prevalence and Antimicrobial Resistance Pattern
of Community Acquired Pathogens Against Amino-
glycoside and Quinolones, Isolated from 2 Emergency
Settings from Multinational Patients, Holy Makkah,
Saudi Arabia
Abdul Haseeb,1 Hani Saleh Faidah,2 Abdul Rehman
Bakhsh,3 Maab Khalid Sultan,4 Maram Al Anazi,5
Fatima Al Juhani,6 Mahmood Essam Uddin Raggal.7
1Clinical Pharmacy, Faculty of Pharmacy, Umm Al Qura
University, Holy Makkah, Makkah, Saudi Arabia;
2AppliedMedical Sciences, UmmAlQura University, Holy
Makkah, Makkah, Saudi Arabia; 3Emergency Medicine,
Ajyad Emergency Hospital, Ministry of Health, Holy
Makkah, Makkah, Saudi Arabia; 4Faculty of Pharmacy,
Umm Al Qura University, Holy Makkah, Makkah, Saudi
Arabia; 5Faculty of Pharmacy, Umm Al Qura University,
Holy Makkah, Makkah, Saudi Arabia; 6Faculty of
Pharmacy, Umm Al Qura University, Holy Makkah,
Makkah, Saudi Arabia; 7Department of Clinical
Pharmacy, Faculty of Pharmacy, Umm Al Qura
University, Holy Makkah, Makkah, Saudi Arabia.
Background: Rapid initiation of appropriate antibi-
otics is critical to optimize patient outcome and limit-
ing adverse effects in patients and bacterial ecology.
This can be achieved through the development of local
antimicrobial resistance pattern, which facilitate
prescribers to select most appropriate antimicrobial
therapy and to prevent severity and trajectory of illness.
Objectives: This study aimed to observe prevalence of
most common community acquired organisms among
multiple nationalities residing in Holy Makkah and
conﬁrmed antimicrobial resistance exhibited by gram
positive and gram negative bacteria.
Methods: Pathogens were isolated from patients with
different acute illnesses visited two hospitals emergency
services in holy makkah.
All cultures received during initial 48 hours of
admissions were included in the study.
Results: A total of 374 bacterial pathogens were
isolated from bacterial cultures of patients visiting
emergency departments of two different hospitals.
Highest number of isolates were
Obtained from Saudi residents (n =177, 47.3 %),
Pakistanis (n=30, 8 %), Egyptians n=24, 6.4 %) and
least fromNigerian residents subsequently. Gram-negative
pathogens accounted for 280 (75 %) of the total isolates
while 94 (25 %) were gram-positive organisms.
The activity of three most common aminoglycoside
and four quinolones was tested against the bacterial
isolates. E-Coli were highly resistant tomost aminoglyside
antibiotics. A higher resistance to gentamycin were
recorded in E.Coli (ESBL producing) 3 (75 %) and
Proteus Mirabilus 12 (75 %).
Interestingly, Levoﬂoxacin showed lower resistance
against all organisms in study with highest resistance rate
of resistance 4 (100 %) to E.Coli and with lowest rate of
resistance 4 ( 44 %) to K.Pneumonia respectively.
Conclusions: Despite extensive antimicrobial resis-
tance among various organisms, some of the organisms
found less resistant to Levoﬂoxacin and Amikacin and
can generate hypothesis to test their effectiveness in
initial control of severe community acquired infectious
diseases in Makkah region.
428. A Meta-Analysis of the Harms Associated with
the Novel Oral Anticoagulants (NOACs) for Stroke
Prevention inAtrial Fibrillation (AF) and the Treatment
of Venous Thromboembolism (VTE) in the Elderly
Manuj Sharma, Victoria R Cornelius, Jignesh P Patel, J
Graham Davies, Mariam Molokhia. Primary Care and
Public Health Sciences, King’s College London, London,
United Kingdom; Institute of Pharmaceutical Science,
King’s College London, London, United Kingdom; NIHR
Biomedical Research Centre at Guy’s and St Thomas’
NHSFoundation Trust andKing’s College London, London,
United Kingdom.
Background: NOACs have undergone clinical trials
to investigate their efﬁcacy and harm for use in VTE
and AF. There is no pharmacological reason to suspect
the beneﬁt of these drugs is not maintained in the
elderly, however risks with their use warrants further in-
vestigation given greater comorbidities, polypharmacy
and altered pharmacokinetics in the elderly.
Objectives: To review the harm proﬁle of NOACs
against warfarin for an elderly population aged ≥75
years compared to those aged <75 years.
Methods: A systematic review was conducted for all
RCTs for NOACs for the treatment of VTE and AF that
hadwarfarin as a comparator and aminimum of 6months
patient follow-up. Eligible trial data was extracted
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independently by two researchers. Where outcome data
was unpublished, drug manufacturers, authors and large
regulatory bodies were contacted to obtain missing data.
Outcome data was collected on major bleeding (MB) and
clinically relevant bleeding (CRB) forNOACs andwarfarin.
Results: Eleven RCTs using edoxaban, apixaban,
rivaroxaban or dabigatran were identiﬁed with ten
reporting data for 28,318 elderly participants aged ≥75
years. Results based on pooled NOAC data compared
to warfarin suggest a similar risk of MB in those aged
≥75 (OR 0.75 95% CI 0.61-0.93) compared to MB in
those aged <75 (OR 0.67 95% CI 0.60-0.75). Prelim-
inary subgroup analysis by individual NOAC however
suggests a lack of consistency across the NOACs with
possibly greater risk of harm in the elderly with
dabigatran. Risks were similar for pooled CRB com-
pared to warfarin in those aged ≥75 (OR 0.83 95%
CI 0.69-0.99) compared to those aged <75 (OR 0.81
95% CI 0.73-0.90).
Conclusions: RCTs for NOACs in VTE and AF have
limited outcome data on bleeding for elderly participants.
Pooled data did not indicate different bleeding patterns in
the elderly compared to those aged<75, however analy-
sis by individual NOAC suggests that bleeding patterns
for some drugs may be distinct. Further evidence and
experience is needed to assess the beneﬁt risk balance
for individual NOACs in the elderly.
429. The Bleeding Risk with Warfarin-Based
Antithrombotic Regimen among Acute Coronary
Syndrome Patients with Atrial Fibrillation
Lai Yi-Shan,1 Cheng Ching-Lan,1 Yea-Huei Kao Yang,1
Ping-Yen Liu.2 1Institute of Clinical Pharmacology and
Pharmaceutical Sciences, National Cheng KungUniversity,
Tainan, Taiwan; 2Division of Cardiology, InternalMedicine,
National Cheng Kung University Hospital, Tainan, Taiwan.
Background: There are limited evidence about safety
of antithrombotic therapy in patients with acute coronary
syndrome (ACS) and atrial ﬁbrillation (AF).
Objectives: To compare the bleeding risk between
warfarin-based antithrombotic regimen and antiplatelet-
based (aspirin, clopidogrel or ticlopidine) regimen.
Methods:Weperformed a retrospective cohort study by
using the National Health Insurance Research Database
to identify ﬁrst-time admission ACS patients concomi-
tant with AF between 2001 and 2008. The primary out-
come was one year major bleeding-related admission
(gastrointestinal bleeding or intracerebral hemorrhage
(ICH)). The cox proportional hazards model were used
to calculate the adjusted bleeding risk.
Results: Total of 6,834 ﬁrst-time admission ACS pa-
tients with AF were enrolled in this cohort. Patients had
at least 1 prescription ﬁlled for warfarin were classiﬁed
into warfarin-based group.(N=1,150) Conversely, anti-
platelet-based group were had at least 1 prescription of
aspirin, clopidogrel or ticlopidine.(N=5,684). During
follow-up period, 418 (6.1%) patients experienced major
bleeding and the crude bleeding rate was higher in the
warfarin group (7.8%) than antiplatelet group (5.8%).
After adjustment for age, gender, CHA2D2S-VAS score
and HAS-BLED score, the difference between two
groups was statistically signiﬁcant and the hazard ratio
(95% conﬁdence interval (CI)) was 1.39 (1.10-1.76).
Moreover, this difference mostly came from ICH, and
the hazard ratio (95% CI) was 2.00 (1.11-3.61).
Conclusions: The bleeding complication was signiﬁ-
cantly higher in warfarin group than antiplatelet group,
especially for ICH.
430. Increased Bleeding Risk of Dabigatran Usgae
in Patient with Renal Impairment
Tzu -Yu Lin,1 Chi-Hua Chen,1 Yu-Jr Lin,2 Cheng-Hung
Lee.3 1Department of Clinical Pharmacy Service, Linkou
Chang Gung Memorial Hospital, Taoyuan, Taiwan;
2Biostatistical Center for Clinical Research, Linkou
Chang Gung Memorial Hospital, Taoyuan; 3Division of
Cardiology, Linkou Chang Gung Memorial Hospital,
Taoyua, Taiwan.
Background: Dabigatran is a new oral anticoagulant
and dose not require monitoring. However bleeding
is still the major concern with dabigatran usage espe-
cially patients with difference characteristics in clinical
trial such as older age, impaired renal function. There
is lack of sufﬁcient dosage recommendations for
patient with creatinine clearance below than 30ml/min.
Objectives: To identify the correlation between renal
impairment and bleeding episode in dabigatran on
dabigatran treatment.
Methods: This was a retrospective study. We utilized
electronic medical records of single medical center in
Taiwan to identify adult patients who claimed a pre-
scription of dabigatran from 2010/1 to 2013/9. The
primary outcome is bleeding. Bleeding cases were
screened by ICD-9 code for hospitalization or
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hemoglobin drop> 2 g/L and blood transfusion over 2
unit simultaneously. Bleeding cases were conﬁrmed
by chart review ﬁnally. We excluded cases who lack
of data of creatinine, body weight or high. Renal func-
tion was estimated by creatinine clearance using Cock-
croft Gault equation (CrCl mL/min) with lean body
weight. Bleeding risk associated with renal impair-
ment was estimated using the Cox proportional-hazards
models to calculate hazard ratios (HRs) and the 95%
conﬁdence intervals (CIs), while adjusting for age and
sex.
Results: A total number of 1150 dabigatran users were
identiﬁed initial and 407 patients were included in the
ﬁnal analysis. During follow up (median, 8months),
18 participants had bleeding events. There were 140
patients (30.6%) with CrCl below than 30ml/min. Pa-
tient with bleeding events were older age and impaired
renal function as compared to patients without bleeding
(mean age: 82.6 v.s. 75.5; CrCl: 44.59 v.s. 30.54mL/
minute). No bleeding event occurred in patients with
CrCl higher than 60mL/minute. Compared to patients
with CrCl below 30mL/minute, patient with CrCl be-
tween 30 ~ 60mL/minute had lower risk of bleeding
(Hazard ratio: 0.2621, 95% CIs: 0.0943 ~ 0.7288).
Conclusions: In this study we found that patients with
Clcr below 30ml/min treated with dabigatran may
have increasing risk of bleeding in clinical practice.
431. Low BodyMass Index Predictor for Dabigatran
Related-Bleeding
Tzu-Yu Lin,1 Chi-Hua Chen,1 Kuo-Chun Hung,2 Ming-
Shien Wen,2 Cheng-Hung Lee.2 1Department of Clinical
Pharmacy Service, Linkou Chang Gung Memorial
Hospital, Taoyuan, Taiwan; 2Division of Cardiology,
Linkou ChangGungMemorial Hospital, Taoyuan, Taiwan.
Background: Despite efﬁcacy and safety of the recent
oral anticoagulant dabigatran to prevent ischemic
stroke in patients with non-valvular atrial ﬁbrillation
(AF), information on the increased bleeding complica-
tion due to low body index has not been well deﬁned.
Objectives: To identify the correlation between body
mass index (BMI) and bleeding episode in patients
on dabigatran treatment.
Methods: We utilized electronic medical records of
single medical center in Taiwan from 2010/1 to
2013/9 to identify adult patients who diagnosed of
non-valvular AF and prescribed with dabigatran.
Study subjects were divided by three group based on
the three tertile of BMI. All patients were followed
up for bleeding complication. Bleeding cases were
screened by ICD-9 code for hospitalization or hemo-
globin drop> 2 g/L and blood transfusion over 2 unit
simultaneously. Bleeding cases were conﬁrmed by
chart review ﬁnally. The association between bleeding
risk and BMI was estimated using the Kaplan-Meier
regression among three tertile. The log rank test was
used to test the difference between survival curves.
Potentially confounding factors were included in a
stepwise multiple regression model. BMI was ex-
plored by Cox regression to calculate the hazard ratio
for bleeding risk.
Results: a total number of 1155 of dabigatran users
were identiﬁed. During follow up (median, 8months),
29 participants had bleeding events. Patients with low
BMI (below 23.5 kg/m2) had a signiﬁcantly higher
bleeding risk than other two groups (23.6 to 26.5,
and above 26.6 kg/m2) (post hoc p< 0.05). According
to multiple stepwise analysis, BMI, diabetes mellitus
and hypertension were independent predictors for
bleeding (DM, p =0.04; HTN, p = 0.03), while BMI
was the only signiﬁcant predictor of bleeding compli-
cation (hazard ratio 0.812, p <0.01).
Conclusions: Decreased BMI associate with increased
bleeding risk in patient with non-valvular AF. This
study result provides additional value to careful evalu-
ation the bleeding risk before starting dabigatran in
patients with low BMI.
432. Improving the Use of Lipid Lowering Treatment
in Primary Prevention: A Randomized Clinical Trial
Yolima Cossio,1,3 Eduardo Hermosilla,2,3 Francesc Fina,1,2
Daniel Prieto-Alhambra,2,3,4 Bonaventura Bolíbar.2,3 1Institut
Català de la Salut, Barcelona, Spain; 2SIDIAP (Information
System for the Advancement of Research in Primary Care),
Barcelona, Spain; 3IDIAP Jordi Gol Primary Care Research
Institute, Barcelona, Spain; 4Nufﬁeld Department of
Orthopaedics, Rheumatology, and Musculoskeletal
Sciences (NDORMS), University of Oxford, Oxford, United
Kingdom.
Background: The use of lipid-lowering therapies in
primary prevention is controversial and related to inad-
equate use in low-risk patients.
Objectives: To study the effect of electronic feedback
(using electronic medical records) to general practitioners
(GPs) on inadequate prescriptions of lipid-lowering agents.
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Methods: Design: Non-blinded cluster randomized
clinical trial.
Population: Patients registered in 279 primary care
centers in Catalonia (Spain), aged 35 to 74 years, with
no history of previous cardiovascular disease between
01/09/2011 and 31/07/2013.
Intervention: GPs in the intervention arm received an
electronic feedback about inadequate lipid-lowering
prescriptions, deﬁned as: 1.LDL cholesterol ≤240mg/dl
or 2. cardiovascular risk ≤10%, estimated using the
Spanish calibration of Framingham tool).
Main outcomes: 1.Withdrawing of inadequate lipid-
lowering treatments prescribed in the previous year
(DROP) and 2. Incidence of inadequate lipid-lowering
therapies newly initiated during the intervention (AVOID).
Statistical analysis aggregated at health professional
level was performed.
Results: We report preliminary results from the ﬁrst
3months of the study.
DROP: 42,403 lipid-lowering therapies were initiated
in primary prevention prior to the intervention, and 64%
of them were inadequate. The intervention group with-
drew 16.5% inadequate lipid-lowering therapies com-
pared to the control arm (15.4%) (p = 0.003). The risk
ratio of withdrawal of inadequate therapies for the inter-
vention group was 1.08 (CI%95: 1.03-1.15).
AVOID: After the intervention, 16,877 lipid-lowering
therapies were initiated. The incidence of inadequate
treatments started by GPs in the intervention group
(4.9 per 1000 persons) was reduced compared to GPs
in the control arm (5.5 per 1000 persons)(p ≤0.001).
Conclusions: Electronic feedback reduces inadequate
lipid-lowering therapies by both encouraging cessation
of previously started inadequate treatments and reducing
new inadequate prescriptions. Simple interventions using
electronic medical records platforms can help GPs
improve the use of long-term medications in primary
care settings.
433. Estimate of Venous Thromboembolism and
Related-Deaths Attributable to the Use of Combined
Oral Contraceptives in France
Aurore Tricotel, Fanny Raguideau, Cedric Collin,
Mahmoud Zureik. Department of Epidemiology of Health
Products, French National Agency for Medicines and
Health Products Safety (ANSM), Saint-Denis, France.
Background:Women using combined oral contracep-
tives are exposed to an increased risk of venous
thromboembolism.
Objectives: To estimate the number of venous throm-
boembolic events and related-premature mortality
(including immediate in-hospital lethality) attributable
to the use of combined oral contraceptives in women
aged 15 to 49 year-old between 2000 and 2011 in France.
Methods: French data on sales of combined oral
contraceptives and on contraception behaviours from
two national surveys conducted in 2000 and 2010 were
combined to estimate the number of exposed women ac-
cording to contraceptives generation and age. Absolute
risk of ﬁrst time venous thromboembolism in non-users
of hormonal contraception and increased risk of
thromboembolism in users vs. non-users of hormonal
contraception were estimated on the basis of literature
data. Finally, immediate in-hospital lethality due to
pulmonary embolism and premature mortality due to
recurrent venous thromboembolism were estimated
from the French national database of hospitalisation
and literature data.
Results: In France, more than four millions women are
daily exposed to combined oral contraceptives. The
mean annual number of venous thromboembolic events
attributable to their use was 2529 (778 associated to the
use of ﬁrst- and second-generation contraceptives and
1751 to the use of third- and fourth-generation contra-
ceptives), corresponding to 20 premature deaths (six
with ﬁrst- and second-generation contraceptives and
fourteenwith third- and fourth-generation contraceptives),
of which eight to nine immediate in-hospital deaths. As
compared to the use of ﬁrst- and second-generation
contraceptives, exposure to third- and fourth-generation
contraceptives led to a mean annual excess of 1167
venous thromboembolic events and nine premature
deaths (including three immediate in-hospital deaths).
Conclusions: Corrective actions should be considered
to limit exposure to third- and fourth-generation con-
traceptives, and thus optimise the beneﬁt-risk ratio of
combined oral contraception.
434. Are ECGMonitoring Recommendations before
Prescription of QT Prolonging Drugs Applied in
Daily Practice? The Example of Haloperidol
Miriam Warnier,1,2 Frans Rutten,2 Patrick Souverein,1
Arno Hoes,2 Anthonius de Boer,1 Marie De Bruin.1 1Utrecht
University, Utrecht, Netherlands; 2UMC Utrecht, Utrecht,
Netherlands.
Background: Monitoring of the QT duration by elec-
trocardiography (ECG) prior to treatment is frequently
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recommended in the label of QT prolonging drugs. It is,
however, unknown how often these risk minimisation
measures are being adhered to by general practitioners
in daily clinical practice.
Objectives: We assessed the frequency of ECG mea-
surements in patients where haloperidol was initiated
in primary care.
Methods: A prospective cohort study was performed
in the UK Clinical Practice Research Datalink. Patients
aged 18 years or older with a ﬁrst prescription of halo-
peridol between January 1, 2009 andMay 1, 2013 were
included. The proportion of ECGsmade was determined
in two blocks of four weeks; during the exposure period
when haloperidol was initiated, and during the control
period, one year before. Conditional logistic regression
analysis was applied to calculate the relative risk of hav-
ing an ECG in the exposure period compared to the con-
trol period. Subgroup analyses were performed to assess
the proportion of ECG measurements in patients with
one or more additional risk factors for QT prolongation.
Results: In total, 3420 patients were prescribed halo-
peridol during the exposure period, and 1.8% of them
had an ECG at treatment initiation, compared to 0.8%
during the control period (relative risk [RR] 2.4 [1.5-3.8]).
Of the patients with additional risk factors for QT pro-
longation 1.9% of the patients had an ECG at initiation
of the prescription, compared to 1.0% during the con-
trol period (RR 2.1 [1.2-3.5]).
Conclusions: Compliance with recommendations to
perform an electrocardiogram when starting a new QT
prolonging drug is extremely low, when haloperidol is
taken as an example.
435. Interferon β and Rate of Hospitalization Due to
Infections among Multiple Sclerosis Patients
Cynthia Jones, Jawad Hasan, Jin Wang, Gary Bloomgren.
Safety and Beneﬁt-Risk Management, Biogen Idec, Boston.
Background: Multiple sclerosis (MS) patients have
higher rates of hospitalization due to infections (serious
infections) than the general population and patients
without MS. The impact of MS disease-modifying
therapy (DMT) on serious infection rates among MS
patients is unknown.
Objectives: The objective of this study was to estimate
the incidence rate ratio (IRR) of serious infections
among MS patients exposed to Interferon β (INFβ)
therapy and MS patients unexposed to DMT within a
US claims database.
Methods: MS patients were selected from a large US
insurance claims database from 1 January 2004 to 31
December 2012. MS patients were identiﬁed as those
with two or more medical claims for MS, eligibility
for pharmacy beneﬁts, 12months of continuous enroll-
ment, and 12months without infection prior to the in-
dex date. The outcome was deﬁned as the ﬁrst serious
infection as classiﬁed using the Clinical Classiﬁcation
System. Exposure was deﬁned has having at least one
prescription claim for an INFβ DMT identiﬁed within
the claims database. Patients without DMT exposure
were considered unexposed. Incidence rates and IRRs
were calculated.
Results: Among the 39,289MS patients in the analysis,
26,289 had no prior exposure to DMT within the data-
base. There were 13,000 MS patients with INFβ expo-
sure. A total of 745 cases of serious infections were
identiﬁed, 683 in the unexposed group and 62 in the ex-
posed group. Comparing MS patients exposed to INFβ
to MS patients unexposed to DMT, estimates for seri-
ous bacterial (IRR: 0.74, 95% CI: 0.69 – 0.80) and viral
infections (IRR: 0.71, 95% CI: 0.65 – 0.76) were statis-
tically signiﬁcant. A larger difference was observed for
serious other infections, i.e. parasitic, (IRR: 0.43;
95% CI: 0.39 – 0.47).
Conclusions: The rate of serious infections is lower
among MS patients on INFβ therapy than among MS
patients without DMT. This lower rate with INFβ ther-
apy was consistent for both serious bacterial infections
as well as viral infections. It is unclear if this is a result
of INFβ therapy or due to other confounders.
436. Proportionality between Adverse Events Identified
in Spontaneous Reporting Databases and Population-
Based Estimates of Drug Exposure
Joseph Kim,1,2 Marion Gaskin,1 David Prieto-Merino,2
Wilhelmine Meeraus,3 Andrew Thomson,3 Adam Collier,1
Stephen JW Evans.2 1Real-world Evidence Solutions, IMS
Health, London, United Kingdom; 2Faculty of Epidemiol-
ogy and Population Health, London School of Hygiene &
Tropical Medicine, London, England, United Kingdom;
3Pharmacoepidemiology Research & Intelligence Unit,
Medicines and Healthcare Products Regulatory Agency,
London, England, United Kingdom.
Background: Disproportionality analysis (DPA) ef-
fectively assumes that the total number of adverse
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events (AEs) captured in spontaneous reporting data-
bases (SRDs) is a surrogate for exposure. Reporting
ratios (PRR, EBGM, etc) attempt to identify potential
signals under the assumption that these measures are
proportional.
Objectives: To examine the association between AEs
captured in a SRD with drug exposure estimated using
1) patient-level prescriptions for a sample of UK patients
and 2) sales data in the UK population.
Methods: Analysis was performed from 2000 up to
2012 (from market entry to withdrawal or a publicised
safety concern) in order to obtain stable estimates of
exposure for rosiglitazone (ROS), pioglitazone (PIO),
celecoxib (CEL) and clopidogrel (CLO). Counts of
spontaneous reports in the UK were obtained between
2000 and 2012 through the MHRA Yellow Card
Scheme (YC). Individual-level exposure was captured
using IMS Health UK Disease Analyzer (DA). Sales in-
formation for 2002-2012 (in kg) was obtained from IMS
Health MIDAS (MI). Time series of % yearly change
was calculated for counts of AE reports (d%YC), number
of patients prescribed (d%DA) and kg sales of each
drug (d%MI). Pearson correlation between these time
series was used as a marker of proportionality.
Results: We found 6082 cases of AEs were reported
to YC for the selected drugs over the study period.
DA found 39144 prescriptions were written for 7223
persons, and MIDAS showed 193708 kg of product
was sold. The Table shows the correlations between
series of percent yearly changes for each drug.
Between-series ROS PIO CEL CLO
d%DA - d%MI 0.974 0.732 0.973 0.985
d%YC - d%DA 0.772 0.484 0.870 0.385
d%YC – d%MI 0.724 0.454 0.314 -0.086
Internal consistency in the exposure datawas evidenced
by the strong correlations between sales and persons ex-
posed. Reports from YC were shown to be consistently
better correlated with prescriptions than with sales where
the magnitude of correlation varied by drug.
Conclusions: Our ﬁndings provide evidence to sup-
port the assumption that total AEs captured in SRDs
is proportional to drug exposure in the UK population.
437. Health Care Professionals’ Knowledge and
Attitudes of Drug Benefits and Risks in Africa
Derbew F Berhe,1,2 Katja Taxis,3 Flora M Haaijer-
Ruskamp,1 Peter GM Mol.1,4 1Clinical Pharmacy and
Pharmacology, University Medical Center Groningen,
Groningen, Netherlands; 2Pharmacy, College of Health
Sciences, Mekelle University, Mekelle, Tigray, Ethiopia;
3Pharmacotherapy & Pharmaceutical Care, Faculty of
Mathematics andNatural Sciences, University of Groningen,
Groningen, Netherlands; 4Dutch Medicines Evaluation
Board, Utrecht, Netherlands.
Background: Inappropriate drug use is a major global
challenge. In Africa, it may be even more widespread
for a number of reasons, especially limited resources.
Drugs may be prescribed by health care professionals
(HCPs) who have received little training on drug ben-
eﬁts, but especially risks.
Objectives: Review knowledge and attitudes of HCPs
on drug beneﬁts and risks in Africa.
Methods: We performed a systematic review in
Embase.com selecting original studies that evaluated
knowledge and attitudes of HCPs on modern or tradi-
tional medicines (drugs) in Africa following PRISMA
guidelines.
Results: We identiﬁed 71 papers studying HCP drug
knowledge; most (68%) originated from 3 countries;
i.e. Nigeria (29), South Africa (11) and Tanzania (8).
Methods used were quantitative surveys in 45 papers;
face-to-face interviews in 15, focus group discussions
in 4 and mixed designs in 7. Physicians were studied
in 24 (34%) papers, while 32 (42%) involved ≥2 types
of HCPs. 32 (45%) papers were on communicable dis-
eases (CD), 14 (20%) on non-communicable diseases
(NCD) and 25 (35%) had no speciﬁc disease focus.
A median of 120 (min 12; max 1440) HCPs were en-
rolled per study. Knowledge questions were answered
correctly by >66% of HCPs in 15 (21%) papers, be-
tween 33 and 66% in 39 (55%) papers and by <33%
in 17(24%) papers, respectively ‘good’, ‘reasonable’
or ‘poor’ knowledge. HCPs had ‘good knowledge’ in
29% of CD, 3% of NCD and in 1% of the papers with
no speciﬁc disease focus. 35 (49%) papers reported on
HCPs attitudes towards drugs. In 5 of 11 papers focus-
ing on drug beneﬁts the majority of HCPs considered
these beneﬁts important for their daily practice, while
this was in 3 out of 9 papers addressing drug risks,
and in 9 of 15 papers addressing beneﬁts and risks.
Conclusions: In our study few HCPs had ‘good’
drug knowledge that was possibly a bit better in
the area of CD. Although fewer studies evaluated at-
titudes, in papers adressing risks & beneﬁts HCPs
considered both more relevant for daily practice than
when considering risks or beneﬁts in isolation.
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Clearly, work is needed to improve knowledge. HCP
may be more likely to apply that knowledge if it
covers both beneﬁts & risks.
438. Used of Potentially Inappropriate Medications
amongOlder Outpatient with Long-TermPrescription
at a Medical Center in Taiwan
Huei-Chao Lee,1,2 Min-Ling Tsai,1,2 Kuo-Jen Lee,2,3
Mao-ChungWeng,2,3 Shiuan-Chih Chen.2,3,4 1Department
of Pharmacy, Chung Shan Medical University Hospital,
Taichung, Taiwan; 2Institute of Medicine, Chung Shan
Medical University, Taichung, Taiwan; 3Department of
Family and Community Medicine, Chung Shan Medical
University Hospital, Taichung, Taiwan; 4School of Medi-
cine, Chung Shan Medical University, Taichung, Taiwan.
Background: An updated version of Beers Criteria
(2012) is available to identify Potentially Inappropriate
Medications (PIM). However, studies describing PIM
prevalence and their determinants in Taiwan are lacking.
Objectives: To determine the prevalence and predic-
tors of PIM prescribing among older outpatients with
long-term prescription using the 2012 Beers criteria
and comparing it with 2003 version.
Methods: A cross-sectional study was conducted by
using medical records between September and December
2011 at a medical center in central Taiwan. Older patients
(≥65years) with long-term prescription (≥28days) were
included. PIM was deﬁned using 2012 Beers criteria
and 2003 version. Multivariate logistic regression analy-
sis was used to determine predictors of PIM prescribing.
Results: The results were based on data of 12,237
patients; more than half (55%) were females and the
mean (standard deviation [SD]) age of the patients
was 75.6 (6.7) years. Mean (SD) number of diagnoses
and medications were 4.7 (2.7) and 4.9 (2.8), respec-
tively. A total of 4,437 (36.2%) patients were prescribed
with≥ 1 PIM according to 2012 Beers Criteria, com-
pared with 20.4% according to 2003 version. The most
commonly prescribed PIM was Zolpidem (977, 23.7%)
followed by Dipyridamole (846, 20.5%), and Glyburide
(648, 15.7%). PIM predictors were advanced age (OR,
1.01, 95% CI, 1.01-1.02; p <0.001), higher number of
medication (OR, 1.29; 95% CI, 1.26-1.31; p <0.001),
and co-existing mental disease (OR, 2.18; 95% CI,
1.99-2.40; p <0.001).
Conclusions: There was a high prevalence of prescrib-
ing PIMs among older outpatients having long-term
prescription. Compared to the 2003 version, since the
lists are more similar to the current clinical use of
drugs, therefore, 2012 Beers Criteria has a higher sen-
sitivity to detect PIMs and is more suitable for current
use as a PIM assessed tool.
439. Validation of a Refined Health Related Quality
of Life Comorbidity Index in Populations through
Cross-Sectional Surveys
Huang-tz Ou,1 Steven R Erickson.2 1Institute of Clinical
Pharmacy and Pharmaceutical Sciences, National Cheng
Kung University, Tainan, Taiwan; 2Clinical, Social and
Administrative Sciences, College of Pharmacy, University
of Michigan, Ann Arbor, MI, United States.
Background: The Health related Quality of Life
(HRQL) Physical and Mental Comorbidity Indices (CIs)
are valid risk adjustment tools. It outperformed Charlson
Comorbidity Index (Charlson-CI) in predicting HRQL.
Objectives: To reﬁne the HRQL Physical and Mental
CIs into one single composite index which can be
feasible for risk adjustment in clinical research.
Methods: The 2009Medical Expenditure Panel Survey
(MEPS) in the United States was used for reﬁning the
CIs. The least absolute shrinkage and selection operator
(LASSO) was applied to select disease conditions sig-
niﬁcantly associated with HRQL. Conﬁrmatory Factor
Analysis (CFA) was employed to identify dimensional
structure of the CI. The validation in terms of prediction
accuracy for HRQL was investigated in the 2011
MEPS. The discriminative validation was evaluated
with the area under the receiver operating characteristic
curve and conducted using the 2012 US National Health
Interview Survey (NHIS). Three HRQL outcomes de-
ﬁned dichotomously in the NHIS were the perception
of poor health vs. fair, good or excellent health, the per-
ception of disabled vs. not disabled, and having
remained in bed for more than half the day due to illness
for injury for 30 days or more in the last year vs. in bed
less time.
Results: Fourteen clinical conditions were identiﬁed
by LASSO and categorized into 9 disease dimensions
by CFA. Statistical weights for individual dimensions
were derived based on the regression model predicting
HRQL. Disease dimensions with assigned weights re-
sulted in a composite CI score. In validation, the R2 in
the model using the reﬁned CI scores for predicting
HRQL was higher than that in the one with
Charlson-CI (0.21 vs. 0.08). The average prediction
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error in the model using the reﬁned CI was smaller
than that using Charlson-CI (0.018 vs. 0.021). The re-
ﬁned CI showed well discriminative ability (c statistics
were 0.90, 0.91, 0.85, respectively, for poor perceived
health, perceived disability, and 30 or more bed days).
Conclusions: Achieving satisfactory calibration and
discrimination indicated successful validation. Our re-
ﬁned HROL-CI is a valid risk adjustment for use in
HRQL studies.
440. Risk Factors of Colistin Nephrotoxicity and
Severe Nephrotoxicity in the Clinical Setting
Shin-Woo Kim, Hyun-Ha Chang, Su-Jung Kim, Jong-
Myung Lee. Internal Medicine, Kyungpook National
University Hospital, Daegu, Republic of Korea.
Background: Recently, multidrug resistant Gram nega-
tive bacteria emerged and became a problem in treating
bacterial infection. Colistin, an old antibiotic, used more
with this era of multi-drug resistant bacteria because
colistin still usually has activity against carbapenem resis-
tant Gram negative bacteria. However, nephrotoxicity
caused by colistin is a huge problem in the use of colistin.
Objectives:We investigated the risk factors of colistin
nephrotoxicity to avoid of this dreadful side effects in
the clinical setting.
Methods: Patients with colistin use over 3 daily deﬁed
dose (DDD) were extracted from electronic database of
an academic hospital in South Korea. Nephrotoxicity
was deﬁned as a over 150% increase and severe neph-
rotoxicity as a over 300% increase in serum creatinine
above baseline. Study period was between January
2011 and January 2014. We tested variables including
age, colistin amount with DDD, albumin level, base-
line serum creatinine, presence of diabetes, presence
of sepsis, total duration (days) of intravenous use, and
duration of use after occurring of nephrotoxicity.
Results: Total 154 cases were enrolled. Nephrotoxicity
occurred in 115 patients (74.7%). Mean age was 65.7
(standard deviation 16.6). Male was 102 (66.2%). Age
over 65 (OR=2.94, p0.001), total duration of intrave-
nous use 10 days (OR=3.5, p = 0.046), and DDD >20
(OR=6.76, p< 0.001) were resulted in the chi-square
test for nephrotoxicity. Logistic regression test revealed
DDD >20 (OR=55.6, p< 0.001) for the occurring
nephrotoxicity and duration of use after occurring of
nephrotoxicity> 2 days (OR=3.11, p = 0.011) for the
severe nephrotoxicity.
Conclusions: Nephrotoxicity of colistin in the clinical
setting is very common. Important risk factors are in-
creased amount of drug (as DDD) for the nephrotoxi-
city and continuous use after onset of nephrotoxicity
for the severe nephrotoxicity. Therefore early recogni-
tion of occurring nephrotoxicity and stopping use of
colistin is important to avoid possible bad outcome.
441. Anti-Tuberculosis Drug Induced Liver Injury in
a Regional Hospital
Shu-TzuChen,1 Sheng-KangHuang.2 1Pharmacy, Changhua
Hospital, Ministry of Health andWelfare, Puhsin Chang Hua
County, Taiwan; 2Pharmacy, ChanghuaHospital, Ministry of
Health and Welfare, Puhsin Chang Hua County, Taiwan.
Background: Many anti-tuberculosis drugs have the
potential to cause liver injury, and their use must be
contemplated in the setting of severe liver dysfunction.
Objectives: This study aimed to evaluate the incidences
of liver adverse reactions induced by anti-tuberculosis
drugs in a regional hospital.
Methods: This was a retrospective study in a regional
hospital from January 1, 2011 to December 31, 2013.We
collected data on adverse drug reaction department in a
regional hospital who are treatment by anti-tuberculosis.
Sample survey based on pulmonary tuberculosis patients.
Monitor liver function including Glutamyl Oxaloacetic
Transaminase(GOT),Glutamyl Pyrubic Transaminase
(GPT),bilirubin was performed before and after
anti-tuberculosis agent given were rospective criteria.
Results: The 255 patients included 183 male ( 71.8%)
and 72 female (28.2%) had adverse reactions by anti-
tuberculosis drugs. The 53 patients had adverse reac-
tions of abnormal liver function including asymptomatic
elevations liver enzymes (GOT, GPT) was 41.5%,
hyperbilirubinemia 34.0%, hepatitis 24.5%. Isoniazid
(INH),rifampicin(RMP) and Pyrazinamide (PZA) are
the anti-tuberculosis drug most often associated with
liver injury. Second-line anti-tuberculosis drug are less
commonly associated with liver injury. Regarding the
prognosis of liver dysfunction, most patients recovered
after changed their anti-tuberculosis treatment from
ﬁrst-line to scond-line anti-tuberculosis drug.
Conclusions: Prevention and treatment of adverse
drug reaction of anti-tuberculosis are very important.
Scheduled monitoring is effective in identifying
asymptomatic liver damage, reducing liver injury of
anti-tuberculosis treatment. Priorities for future studies
abstract232
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
the development of shorter and safer anti-tuberculosis
drug regimens.
442. Safety Information, Boxed Warning, and
Contraindications in Drug Labeling: A Comparison
of the USA, the UK, and Canada
Joud K Alfraih,1 Lama S Alfehaid,2 Hisham S Aljadhey,3,4
Thamir M Allshammari.4,5 1Pharmaceutical Care, Prince
Mohammad bin Abdulaziz Hospital, Riyadh, Saudi Arabia;
2College of Pharmacy, King Saudi bin Abdulaziz University
for Health Sciences, Riyadh, Saudi Arabia; 3College of
Pharmacy, King Saud University, Riyadh, Saudi Arabia;
4Medication Safety Research Chair, King Saud University,
Riyadh, Saudi Arabia; 5College of Pharmacy, University of
Hail, Hail, Saudi Arabia.
Background: Drug labeling considered as an essen-
tial source to provide safety information of certain
drug. It is expected that drug labels do not differ
markedly among countries. However, due certain fac-
tors, differences in safety information are existed
among regions.
Objectives: The current study attempts to quantitatively
determine the discrepancy of the safety information
between the USA, the UK and Canada.
Methods: This study was conducted using cross-sectional
design with quantitative survey of safety information
on randomly sample of medications. This study will
include labels of 400 drugs approved in the USA, the
UK, and Canada. A sample of 15 labels was evaluable
for analysis initially. Three outcomes were measured in
this study which are 1) the total safety information (SI),
2) contraindications information (CI), and 3) of boxed
warnings information (BW) in all labels.
Results: There was discrepancy in the way of presenting
and classifying the safety information ( CI, SI and BW)
over those three countries. As the number of wording
in adverse drug reaction section, the mean of the number
is more in the Canadian labels (number of words = 1,324)
compared to the USA and the UK labels, 974 and 506,
respectively. With respect to contraindication section,
USA labels have more wording, 78 followed by UK
labels and Canadian labels, 61 and 44, respectively.
As Canadian an UK labels were more readable and
arranged in tables comparing to the USA labels. Further,
Canadian and UK labels were similar in the information
on adverse drug reactions (ADRs), however, in the UK
label, ADRs are classiﬁed to common, rare, and very
rare which is not the case in the USA and Canadian
labels. Several medications are missing BW in the UK
or Canadian labels, while it is written in the USA labels.
In addition, USA labels have more detailed ADRs infor-
mation from clinical trials. This study is still ongoing
and under analysis for all 400 drugs.
Conclusions: There is imbalance in the safety infor-
mation between the studied countries, which lead to
substantial difference between them. These differences
could pose risk to patients in country with minimum
safety information.
443. Deployment and Evaluation of the Doctor-
Consulting System for Home-Care Cases (DSHC)
in a Medical Center
Yun-Chia Chang, Mei-Jr Huang, Shih-Jung Huang,
Jung-Chuan Ko, Chun-Yu Wan. Department of Phar-
macy, Shin Kong Wu Ho-Su Memorial Hospital, Taipei,
Taiwan.
Background: Older people need not only health and
medical care, but also extensive long-term care services.
Home-care service is a part of long-term care services.
Objectives: In order that doctors can get the sugges-
tion from pharmacists before prescription, we design
“Doctor-consulting System forHome-careCases (DSHC)”.
Doctors can see the recommendation on line and
patients can get appropriate medical services.
Methods: 1.Result of the acceptance rate of pharma-
cist reply forms as paper copies in patients medical
charts from physicians is statistically analyzed from
2010 to 2011.
2.After the deployment of DSHC, result of the
acceptance rate of inclusion of pharmacist reply forms
in online medical charts from physician is statistically
analyzed from 2012 to 2013.
As a retrospective study, we analyze and compare
response and acceptance rate by physicians before
and after the deployment of DSHC.
Results: The acceptance of Pharmacist recommenda-
tions by physicians through pharmacist reply forms
has shown an increasing trend.
Before the deployment of DSHC between March of
2010 and 2011, there were 116 patient case ﬁles served
as reference samples.
Out of 116 case ﬁles, 101 cases have ﬁlled in phar-
macist reply form to the physician.
61% of all inclusions was responded by physicians
and 81% of which was found to be useful.
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After the deployment of the DSHC between January
of 2012 and 2013, there were 110 patient case ﬁles
served as reference samples.
Out of 110 case ﬁles, 76 cases have ﬁlled in pharma-
cist reply form with medication recommendation to the
physician. 68% of which was responded by physicians
and there was an 87% of acceptance rate.
Conclusions: After deployment of DSHC, it provides a
better and quicker channel of communication between
pharmacists’ and physicians’.
This positive effect is reﬂected from physicians’ re-
sponse to recommendations and prescription alterations.
Even so, the system has not taken into account for
hospital transfer cases and patient that have not
continued further follow up.
Therefore, further efforts are needed to provide more
enhancements into pharmaceutical recommendation
efﬁciency.
444. Inappropriate Prescribing Defined By Start and
STOPP Criteria and Association with Adverse Drug
Events in Elderly Hospitalized Patients
Mohd Tauﬁq Azmy,1 Mathumalar Loganathan,1 Yahaya
Hassan,1 Noorul Aﬁdza Muhammad,2 Christopher Lee,3
Azmillah Rosman.4 1Faculty of Pharmacy,MARAUniversity
of Technology (UiTM), Shah Alam, Selangor, Malaysia;
2Department of General Medicine, Serdang Hospital,
Serdang, Selangor, Malaysia; 3Department of General
Medicine, Sungai Buloh Hospital, Sungai Buloh, Selangor,
Malaysia; 4Department of Medicine, Selayang Hospital,
Selayang, Selangor, Malaysia.
Background: The study is initiated as the result of
lack published data on Adverse Drug Events(ADE) re-
lated to inappropriate use of medicine and prescribing
among elderly patient in Malaysia and in the South
East Asia region generally.
Objectives: The main aim of the study is to provide
descriptive information on the prevalence of potential
inappropriate medications among elderly patient in
Malaysia and its association to Adverse Drug Events
(ADE). This study help to determine any possible Ad-
verse Drug Event causing hospitalization and incidence
in selected hospital settings in Malaysia.
Methods: This study is conducted using Prospective
Cross Sectional study design as hospitalized elderly
patients aged 65 years and above would be studied over
5months period of time in 3 national referral hospitals
in central Malaysia involving 3 different departments
(medical, surgical and orthopaedic). Inappropriate pre-
scribing and inappropriate medications use would be
determined using START and STOPP criteria. ADEs re-
lated to inappropriate medications are deﬁned and veri-
ﬁed by experts including medical specialists and
clinical pharmacists in each respected hospital. The asso-
ciation of ADE causing hospitalization to inappropriate
medication use as the result of inappropriate prescribing
is identiﬁed and rate of ADE avoidability is observed.
Results: Inappropriate prescribing determined by the
START and STOPP criteria showed a total of 125
(65%) from 191 elderly patients selected for the study.
60 (31.4%) inappropriate prescribing were detected by
START while the rest are from the STOPP criteria
(n = 65; 34%). Inappropriate prescribing assessed based
from the START and STOPP criteria are signiﬁcantly
associated to adverse drug events (ADE) related to hos-
pitalization (OR: 6.97, 95%CI: 2.59 – 16.73, p< 0.001).
Conclusions: Potential inappropriate medicines as the
result of inappropriate prescribing deﬁned by the
START and STOPP criteria are among the leading
causes and reasons of hospitalization among elderly
patients as the result of adverse drug events.
445. How the Transparency Data Regulations Are
Changing the Communication Regarding Benefit-Risk
of Medications
Sylvie Tomczyk. Drug Safety Medicine, EMD Serono,
Rockland, MA, United States.
Background: Access to Regulators documents is
effective for post-marketing data i.e. PSURs, RMPs;
and under evaluation for clinical trials. A broader
release, earlier, to a broader audience and its impact
on safety messages are debated.
Objectives: To highlight the changes occurring/
transforming the landscape of Risk-Beneﬁt communi-
cation following recent regulations from FDA and
EMA on pharmaceutical data Transparency from the
Pharmaceutical Companies perspective publishing these
clinical research and safety information, to the patients
and physicians receiving them.
Methods: Literature analysis and Pharmacovigilance
stakeholders feedback.
Results: Requests for post-marketing safety data range
from toxicology reports to PSUR and Risk manage-
ment plans, mainly from the pharma industry and
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lawyers. The information released is received with
mixed feedback, too early for the prescribers, and
mixed for patients. These requests create cumbersome,
delicate processes for Pharmaceutical Companies
without necessarily beneﬁting the Patient. As for clin-
ical trials data, although accepted in principle, differ-
ences on implementation exist between Regulators,
EMA especially on its Policy 70 and PhRMA/EFPIA
Pharmaceuticals associations. If the Drug Industry is re-
luctant to disclose all clinical data, how about the inves-
tigators helping them gathering the information, the
patients reporting outcomes directly from their smart
phones to the Companies database? With the Patient’s
voice heard at PRAC, FDA consultation, or BRACE
and at the age of news going viral around the globe in
seconds, innovative and collaborative ways of data shar-
ing among PV stakeholders are inevitable and beneﬁcial
to the Patient.
Conclusions: The commitment to proactively publish
data from clinical trials and from post-marketing was
anticipated to re/establish trust and conﬁdence in the
System. Although this will need further evaluation, the
principle of releasing this data is accepted. The
agreement on the magnitude of the data release
and when it occurs is still being debated. Innova-
tive ways to communicate Risk-Beneﬁt information
are on the rise, and changing the landscape of
traditonal Pharmacovigilance.
446. Useablity of Harm Profile Data in Product
Descriptions: AComparison between theUSandEurope
Victoria R Cornelius,1 Kun Liu,1 Janet Peacock,1 Manuj
Sharma,1 Odile Sauzet.2 1Dept Primary Care and Public
Health Sciences, King’s College London, London; 2AG
Epidemiologie and International Public Health, Universitat
Bielefeld, Bielefeld.
Background: Patients, prescribers, policymakers and
researchers require information on the beneﬁt and
harm of a drug to inform decision making. Comprehen-
sive and high quality publicly available data is limited.
Clinical trial data on harms in peer review journals are
notoriously inadequately reported despite being well
collected and recorded. Regulators require drug
manufacturer produce product information
documents (SmPC in Europe and USPI in US).
These documents contain comprehensive and poten-
tially valuable publicly available information on
harms. We reviewed the usefulness of the data pre-
sented and compare the harm proﬁle of the same drug
between documents.
Objectives: To assess the usability of harm data
contained in the SmPC and USPI and compare them.
Methods: Brand drugs included are antidepressants or
antiepileptic drugs evaluated in randomised trials of
neuropathic pain since 1965 and which are currently
marketed in both the United States and Europe. Data
extracted included; number of adverse events (AEs),
how AEs were selected for reporting and the
dictionary used for coding. In addition all AEs and risk
estimates were extracted along with the study design
the evidence was base on. The quality of the informa-
tion and the harm proﬁle between documents was
compared.
Results: Ten drugs were included. More USPIs than
SmPCs included the criteria for reporting AEs (9 v 3),
dictionary used (6 v3), information on risk by dose
(3 v 0) and risk by indication (8 v2). The estimated risk
of AEs was given on average for 71% USPI events ver-
sus 50% SmPC and the number of people the estimates
were based on were reported for 70% USPI events
compared to 38% SmPCs. The number of AE contained
in a documents ranged from 56 to 413. On average
95 more AEs were reported in the USPI compared to
the SmPC.
Conclusions: USPIs are more comprehensive but the
large volume of information makes the harm proﬁle
hard to assess, and whether these are meaningful
differences is under evaluation. The development of
core outcomes for adverse events and clear reporting
criteria would signiﬁcantly improve the usability of
this valuable and publicly available information.
447. Evaluation of theValue ofWebData forDetecting
Drug Adverse Events
Mei S Duh,1 Pierre Cremieux,1 Marc Van Audenrode,2
Francis Vekeman,2 Paul Karner,1 Philippe Giguere-Duval,2
Yongling Xiao,2 Joe Damron,1 Paul Greenberg.1 1Analysis
Group, Inc., Boston,MA, United States; 2Groupe d’Analyse,
Ltée, Montréal, QC, Canada.
Background: Data from support group websites and
social media postings have emerged as potential new
sources for detecting detect drug adverse events (AEs).
Leveraging web data for pharmacovigilance (PV)
requires understanding their strengths and weaknesses
relative to traditional PV sources.
Objectives: To assess the frequency and pattern of
online AE postings compared to traditional PV sources.
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Methods: We extracted web postings on atorvastatin
(AT) and sibutramine (SB) from Askapatient.com
(ASK), searches for AT from Google Trends, and AEs
associated with AT from MedWatch (MW). For AT,
we compared the timing of ASK comments, Google
searches, and MW reports related to pain (a well-known
side effect). For SB, we compared ASK comments to its
established risk-beneﬁt proﬁle.
Results: ASK contained 1064 patient postings for AT
(4/2001-1/2014), and the majority (55%) cited pain.
Among MW AT reports with source information,
62% came from health care providers, but less than
20% cited pain. The same share of MW patients and
ASK users were female (46%), but ASK users were
younger (mean age 53 vs 64 years). Both ASK and
MW reports were subject to stimuli: ASK pain reports
peaked during media coverage of personal stories,
while MW reports were more stable except for 2 peaks.
The trend in AT Google searches mirrored ASK.
As established by the US FDA, SB had an unfavor-
able risk-beneﬁt proﬁle, resulting in withdrawal of
the product in 2010 due to serious cardiovascular
events. ASK contained 277 postings (89% female,
mean age 37) for SB (6/2001-10/2012), only 3 cited
serious adverse cardiac effects, and its overall satis-
faction rating was 4/5. 83% of comments showed
positive sentiment (56% cited weight loss, 43% re-
duced appetite) and 86% showed negative sentiment
(37% cited dry mouth, 36% headache/dizziness, 31%
insomnia).
Conclusions: Web AE reporters tend to be younger.
Web sources are sensitive to publicity and dispropor-
tionately capture quality-of-life related AEs compared
to serious AEs. Web data appear to generate different
AE signals that may not always reﬂect reality, suggesting
that web data may complement but not replace current
PV sources.
448. A Regulators’ Challenge: the Transfer of New
Scientific Knowledge into Regulatory Practice. The
Example of PROTECT
Xavier Kurz, Peter Arlett. Pharmacovigilance Depart-
ment, European Medicines Agency, London.
Background: Public funding of research on medi-
cines raises legitimate questions on the impact of
such investments on innovation and beneﬁt-risk eval-
uation. Measurement of the success of PROTECT
(Pharmacoepidemiological Research on Outcomes of
Therapeutics by a European ConsorTium) includes
effective transfer of results into regulatory practice to
improve public health. It requires distinction between
outputs implementable immediately and those needing
maturation in the scientiﬁc community.
Objectives: To present and discuss the process and
outcome of a review of PROTECT results and their
implementation in regulatory activities.
Methods: PROTECT conducts research on data col-
lection from consumers, signal detection, methods in
pharmacoepidemiology and beneﬁt-risk integration
and representation. Deliverables were classiﬁed in 3
categories: 1) immediate impact, 2) potential for rapid
use in regulatory practice after consultation of main
stakeholders and concerned parties and 3) need for
additional scientiﬁc input, validation or peer review.
Results: Category 1 includes the SPC-ADR database
used in EU signal management and an inventory giving
access to EU health care datasources on drug utilisation
in 23 countries. Category 2 includes tools and methods
for signal detection (statistical measures, value of
thresholds, subgroup analyses, algorithms to identify
duplicates, best use of MedDRA, masking effects),
assessment of safety issues (estimation of public
health impact of ADRs) and beneﬁt-risk visualisa-
tion (selection and testing of graphical displays of
beneﬁt-risk). Category 3 includes tools and methods
to assess and reduce discrepancies between results from
safety studies, control for confounders, assess quanti-
tatively the beneﬁt-risk of medicinal products and
collect data from consumers.
Conclusions: We propose a framework for reviewing
the beneﬁts and applicability of results of a regulatory
science project into regulatory practice. This systematic
approach aims maximising its beneﬁts for innovation
and public health protection.
This research received support from the Innovative
Medicines Initiative Joint Undertaking through the
PROTECT project.
449. Study ofMedication ErrorsWhichMayOccur in
the Process of Electronic Prescription and Dispensing
Using Failure Mode and Effects Analysis (FMEA)
Massoud Toussi,1 Hélène Berthelot,2 Gérard Simon.2
1Epidemiology and Safety, Europe, IMS Health, Paris
La Défense, France; 2BDMC, Cachan, France.
Background: Medication errors are part of avoidable
iatrogenic harm. Computer assisted prescription and
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dispensing can prevent medication errors by providing
alerts on potential errors. However, in real life condi-
tions their effectiveness depends on the appropriate
inputs provided by healthcare professionals and the
drug database.
Objectives: To study the risks which may occur in
prescription and dispensing process and their effect on
the safety of medication.
Methods: FailureMode and Effects Analysis (FMEA) is
a method initially used in aviation and military for the
identiﬁcation of potential dysfunctions of a system. A
multidisciplinary team of experts withmedical, pharmacy
and medical informatics background described the pre-
scription and dispensing process into sub-processes. In
each sub-process the potential of different failure modes
were discussed and weighted using a score of 1 to 9
for probability of occurrence, severity of impact and
difﬁculty of detection of failure modes. A risk priority
number (RPN) was calculated by multiplication of the
above attributes. The ﬁnal RPN score was categorized
as critical (scores >200), moderate (scores 20 to 199)
and mild (scores <20).
Results: Prescription and dispensing software often
compare patient records against summaries of product
characteristics (SmPC) in a prescription to generate safety
alerts such as existence of contraindications, drug inter-
actions or dosage problems.
We identiﬁed 176 failure modes i.e. inability to detect
a problem by the software. This included 124 (70%)
critical, 40 (23%) moderate and 12 (7%) mild situations.
The most common failure modes were related to the in-
ability of detection of a dosage error (41 situations),
followed by inability of selection of the right medication
for the patient (31 situations). Among critical situations,
dose related failure modes (30 situations) were the most
common.
Conclusions: Heterogeneity of the language used in
drug SmPCs and suboptimal recording of patient
information in electronic medical records can lead
to the failure of prescription and dispensing soft-
ware in avoiding potentially fatal medication
errors.
450. Quantitative Benefit-Risk Assessment of the
Quadrivalent HPVVaccine for the Prevention of Anal
Cancer in Males – Method
Thomas Verstraeten,1 François Simondon,2 Geraldine
Dominiak-Felden,2 Lydie Marcelon.2 1P95, Epidemiology
and Pharmacovigilance Consulting and Services, Leuven,
Belgium; 2Department of Epidemiology, Sanoﬁ Pasteur
MSD, Lyon, France.
Background: Increasing interest exists on the appli-
cation of quantitative beneﬁt-risk modelling for the
evaluation of pharmaceutical products. Little or no
published experience exists in applying such methods
to vaccines.
Objectives: To assess the potential of the multicriteria
decision analysis (MCDA) approach to make a beneﬁt-
risk (BR) assessment of a vaccine.
Methods: We compared Gardasil for the prevention
of anal cancer in males to no vaccination, following
the guidance developed by Mussen et al. for applying
MCDA to pharmaceuticals, taking a regulator’s per-
spective. The effects table was derived from pub-
lished or internal Merck/SPMSD reports on Gardasil
efﬁcacy/safety. Effects were measured on a value
scale using linear value functions. Weights were
assigned by six independent international experts in
human papillomavirus (HPV) related disease, HPV
vaccination and BR modelling, as well as by SPMSD
experts. The ﬁnal weighted scores were integrated
into the model by a bottom-up approach, using
Hiview 3 software.
Results: The MCDA model found a positive BR
score for Gardasil compared to no vaccination
(BR score difference of 20). Both external and in-
ternal experts agreed that the MCDA method pro-
vided a good basis for a BR assessment, mainly
for its capacity to simultaneously assess multiple
beneﬁts and risks and its transparency on how ben-
eﬁts and risks are compared. The main challenges
were agreeing on the value tree that reﬂects the
speciﬁcities of vaccines such as indirect effects,
comparing immediate adverse effects to long term
beneﬁts, extracting effect estimates on a comparable
scale and for some outcomes ﬁnding the correct
comparator. Reaching a consensus on weights was
surprisingly less challenging.
Conclusions: This evaluation gives a ﬁrst indication
that a quantitative BR ratio assessment can be used
to evaluate the risks and beneﬁts of vaccination. Prior-
ities for further development should be designing a ge-
neric value tree for vaccines, integration of uncertainty
on the estimates into the model and developing
methods to solicit weights from other stakeholders in
vaccination (e.g. parents, prescribers).
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451. The Application of the Columbia Classification
Algorithm of Suicide Assessment (C-CASA) Algorithm
to Evaluate Suicidal Ideation and Behaviour Within
a Post-Authorisation Safety Study
Deborah Layton,1,2 Nasser Qayum,1 Vicki Osborne,1,2
Miranda Davies,1,2 Saad AW Shakir.1,2 1Drug Safety
Research Unit, Southampton, United Kingdom; 2University
of Portsmouth, Portsmouth, United Kingdom.
Background: Antipsychotics are associated with sui-
cidal ideation (SI) and behaviour (SB); however assessing
causality is challenging because of strong confounding
by indication.Tools to support identiﬁcation in Post
Authorisation Safety Studies (PASS) are vital to help
quantify incidence in at-risk groups. The FDA has
endorsed standard suicide terms for clinical trials, but
use in PASS has been limited. A Risk Management
Plan for quetiapine extended release (Seroquel XL™)
included a Modiﬁed Prescription-Event Monitoring
(M-PEM) study to examine the safety and use of
quetiapine XL prescribed in primary care in England. Ex-
ploratory objectives included evaluation of known risks.
Objectives: To evaluate use of C-CASA classiﬁcation
for suicide events reported in the M-PEM PASS.
Methods: An observational cohort design. Patients were
identiﬁed from dispensed prescriptions (Rx) issued by
GPs Sept 2008-Feb 2013; data from forms sent to GPs
12+ months (m) after each patient’s 1st Rx (index date)
and via followup. Suicide events were classiﬁed into mu-
tually exclusive C-CASA categories (SI, SB, self-injurious
behaviours -no suicidal intent (SIB)) by clinicians. De-
scriptive statistics and survival methods summarised
characteristics and onset of events<12m post index date.
Results: Final cohort = 13276; median age 43 yrs (IQR
33, 55). SI prevalence was 0.2% (23), 50% occurred by
day 66, 56.5 % (13) female, median age 31 yrs (IQR
27, 38); SB prevalence was 1.0% (132; 22 fatal); 50%
occurred by day 104; 63.6% (84) female; median age
38 (IQR 29,47). SIB prevalence was 0.3% (35); 50%
occurred by day 180; 80.0% (28) female; median age
31 yrs (27, 39). All cases had prior mental health condi-
tions. 2 cases of accidental overdose were not classiﬁed.
Conclusions: In ﬁrst 12m post index, SI was uncom-
mon whilst SB was common; both are listed as com-
mon (>1%). This study shows that assessing suicidal
events reported in PASS using C-CASA is feasible and
can help support post-marketing risk: beneﬁt evaluation.
Study limitations include subjectivity of GPs identifying
suicide-type behaviours and under-reporting.
452. Comparative Quantitative Benefit-Risk Assess-
ment of High- and Low-Dose Methylprednisolone in
Multiple Sclerosis Relapse Management
Ola Caster,1,2 I Ralph Edwards.1 1Uppsala Monitoring
Centre, Uppsala, Sweden; 2Department of Computer
and Systems Sciences, Stockholm University, Stockholm,
Sweden.
Background: High-dose methylprednisolone (HDMP)
is the recommended treatment for multiple sclerosis
(MS) relapses. However, its beneﬁts and risks have
never been jointly evaluated, and no proper comparison
to low-dose methylprednisolone (LDMP) exists.
Objectives: To determine whether HDMP (≥2,000mg
cumulatively during 31 days), LDMP (<1,000mg), or
no treatment is preferable in MS relapses.
Methods: Probabilistic decision analysis was used for
evaluation, measuring each alternative’s rate of preference
according to expected utility over 10,000 sampling
iterations. The analysis considered relapsing-remitting or
progressive MS patients in acute relapse, adopting a six-
month timeframe. Effectiveness was deﬁned as the proba-
bility of improving at least one point on the expanded
disability status scale within 30days, and estimated by
combining data from clinical trials in a hierarchical beta-
binomial model. The same method was used to estimate
the risk of experiencing any non-serious adverse effect.
Risk intervals for serious adverse effects were derived from
individual case reports and combined with a range of plau-
sible distributions. Probabilistic modelling driven by logi-
cally implied or clinically well motivated qualitative
relations was used to derive utility distributions, for differ-
ent degrees of risk aversiveness and relapse severity.
Results: HDMP was most effective (posterior median
0.64; 95% credibility interval 0.52-0.74), followed by
LDMP (0.47; 0.30-0.65) and no treatment (0.34; 0.23-
0.45). HDMP also generally carried highest risks. Over-
all, LDMP was the clearly worst option with a maximum
preference rate of 41% across all scenarios; however,
only limited data was available for this treatment alterna-
tive. Instead, HDMP and the no treatment alternative
interchanged as most preferred. HDMP’s preference rate
generally increased with lower risks for serious adverse
effects, lower degree of risk aversiveness, and more se-
vere relapses: yet it did not exceed 75% in any scenario.
Conclusions: Current treatment recommendations
should not be changed. More clinical research is needed
to establish ﬁrmer recommendations.
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453. Simulation Modelling for Quantitative Benefit
Risk: AnExample ofComparativeHarm forGlaucoma
Treatment
Andrew Maguire,1 Francisco J de Abajo.2 1OXON Epide-
miology Ltd, London, United Kingdom; 2Departamento de
Ciencias Biomédicas, Universidad de Alcala de Henares,
Madrid, Spain.
Background: A potential approach to beneﬁt risk
modelling is the use of event simulation models that
convert event probabilities, and uncertainty, into times
to event occurrence from which patient cohorts can be
simulated.
Objectives: To develop event simulation methods
and evaluate them via a worked example of glau-
coma treatment. The speciﬁc objectives are to dem-
onstrate how scenarios of comparative harm can be
quantiﬁed given differing scenarios of relative risk be-
tween timolol maleate and latanoprost. The outcomes
are heart failure “HF” and bronchoconstriction (COPD/
asthma). Incident and exacerbation, case fatality and
overall mortality are modelled. We also aim to demon-
strate how uncertainty can be incorporated and
communicated.
Methods: Rates of each outcome were calculated
over a 12month follow-up using Log-linear models
applied to all adults in THIN. Risk factor level spe-
ciﬁc regression coefﬁcients and standard errors
“SE”were used to randomly generate a risk for each
of the 17392 glaucoma patients in THIN. Events
were simulated using the Exponential distribution.
Multiple events were modelled by restarting the
simulation after the occurrence of an event. Case-
fatality used randomly assigned rates from published
rates and their SE. Other deaths were modelled using
national rates. Each patient was assigned a random
relative risk (RR: timolol vs. latanoprost): RR for
COPD/asthma exacerbation = 1.47 (95% CI:1.04-2.09);
HF = 1.33 (1.0-2.02). The simulation was repeated
1000 times.
Results: Exposing 10000 patients to timolol instead of
latanoprost would result in 33.5 (SD= 12.0) more HF
cases and 54.6 (SD= 12.6) more COPD/asthma cases
per year. Case fatalities resulted in a total increase in
overall mortality of 14.0 (SD= 24.5). Results are also
expressed probabilistically such that the chance that
latanoprost is better than timolol in terms of both
COPD/asthma and HF mortality is 77.9% compared
to being worse for both outcomes (0.4%).
Conclusions: This example is not a formal risk assess-
ment of glaucoma treatment. It demonstrates how the
risks and relative risks translate to absolute numbers
whilst accounting for multiple, competing outcomes
and uncertainty.
454. Effectiveness of Risk Minimisation Measures
for Vandetanib in Canada: A Process and Outcome
Evaluation
Yola Moride,1 Michael Kozmenko,2 Francesco Salvo,3
Alia Yousif,1 Sarah Frise.2 1Faculty of Pharmacy,
Université de Montréal, Montreal, QC, Canada; 2Patient
Safety and Medical Information, AstraZeneca Canada,
Mississauga, ON, Canada; 3Pharmacology, Université
Bordeaux 2, Bordeaux, France.
Background: Vandetanib (CAPRELSA®) has been
approved in Canada for the treatment of medullary
thyroid cancer. Important safety concerns consist of
QTc prolongation (QTP) /Torsade de Pointes (TdP),
Diarrhea and Rash. The risk minimisation measures
(RMMs) include communications to health care pro-
fessionals, restricted distribution program (RDP), and
mandatory prescriber education and certiﬁcation.
Objectives: To evaluate the effectiveness of the van-
detanib RMMs through a prospective drug utilisation
study (DUS) and a knowledge and understanding
(KAU) survey of prescribers.
Methods: All patients who initiated treatment with
vandetanib during the ﬁrst year post-launch were invited
to participate in the DUS. Appropriate prescriber’s actions
related to concomitant use of QT prolonging drugs were
evaluated at treatment initiation, 3months, 6months,
12months. Data sources included: i) Oncologist case
report form, ii) home pharmacy records, iii) patient
questionnaire. Assessment of appropriateness of con-
comitant drug use was performed against the product
label and the Arizona Centre for Education and Re-
search on Therapeutics (CERT) lists. All 15 certiﬁed
physicians who had enrolled at least one patient in the
RDP were contacted for the survey.
Results: At 12-month post-launch, 12 patients provided
data for the DUS. Drugs that were clearly associated with
QTP or TdP (i.e., listed in the product label and included
in the Arizona CERT lists) were discontinued or not pre-
scribed. When referencing the product label, two occur-
rences of sub-optimal prescribers actions were found;
these were related to use of central nervous system
medications, including opioids, antidepressants, and
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anxiolytics. Nine prescribers (64.3%) participated in
the KAU survey; all demonstrated adequate under-
standing of key safety messages. Approximately
50% of prescribers would not avoid prescribing a con-
comitant antidepressant; however, most would select
ﬂuvoxamine, which is not speciﬁcally listed as a med-
ication that should be avoided.
Conclusions: Overall, RMMs for vandetanib were
found effective in limiting exposure to concomitant
medications that prolong QTc or raise the potential
for TdP.
455. The Timing of Safety Regulatory Decisions Com-
pared with Cumulative Meta-Analysis’ Risk Estimates
Carlos Alves,1,2,3 Ana F Macedo,3 Francisco Batel
Marques.1,2 1Central Portugal Regional Pharmacovigilance
Unit, Centre for Health Technology Assessment and Drug
Research (CHAD), AIBILI - Association for Innovation and
Biomedical Research onLight and Image, Coimbra, Portugal;
2School of Pharmacy, University of Coimbra, Coimbra,
Portugal; 3Health Sciences Research Centre, University
of Beira Interior, Covilhã, Portugal.
Background: Meta-analysis is commonly used to as-
sess efﬁcacy endpoints. Although not frequently con-
ducted to assess safety issues, cumulative meta-analysis
has demonstrated that appropriate and timely decisions
could have been taken concerning cardiovascular events
associated with rofecoxib.
Objectives: This study aims at evaluating how risk
estimates generated from cumulative meta-analysis
performs over time for drugs having their beneﬁt/risk
ratio reevaluated due to safety issues and, additionally,
compare risk estimates with regulatory authorities’
conclusions.
Methods: Safety alerts which have been supported by
longitudinal, comparative studies (both experimentals
and/or observationals designs) were searched in the
websites of four major regulatory authorities. Data
from studies was included according to the year that
they ﬁrst became available. Random-effects model
was used to pool ORs over time and their respective
95% conﬁdence intervals.
Results: Seventeen alerts issued on 9 different safety
issues were included in this study. In 2008, proton
pump inhibitors (PPIs) were associated with an in-
creased risk for bone fractures (OR 1.25, 95% CI
1.00-1.55, P = 0.049; I2 = 83,9%); FDA included
labelling warnings in 2012. An increased risk for Clos-
tridium difﬁcile associated diarrhea was pooled for PPIs
in 2004 (OR 1.89, 1.19-3.02, P = 0.007; I2 = 54,4%);
FDA included labelling warnings in 2012. PPIs were as-
sociated with pneumonia in 2009 (OR 1.40, 1.06-1.85,
P = 0.017; I2 = 97,4%); in 2012 US FDA concluded that
B/R ratio should remain positive. Statins were associated
to an increased risk for diabetes (OR 1.07, 1.01-1.15,
P = 0.033; I2 = 0%) in 2008. EMA included labelling
warnings in 2012. The remaining cumulative meta-
analyses have not estimated increased risks earlier than
regulatory decisions.
Conclusions: This study demonstrates that meta-
analysis may help predicting iatrogenic risks. How-
ever, between-studies heterogeneity can considerably
affect the estimated results. Therefore, this technique
should not replace further assessments during bene-
ﬁt/risk ratio reevaluation due to safety issues.
456. A Unified Framework for Classification of
Methods for Benefit-Risk Assessment
Mehdi Najafzadeh,1 Sebastian Schneeweiss,1 Niteesh K
Choudhry,1 Kate Bykov,1 Kristijan Kahler,2 Diane P
Martin,2 Stephen Arcona,2 Joshua J Gagne.2 1Division
of Pharmacoepidemiology and Pharmacoeconomics,
Department of Medicine, Harvard Medical School, Boston,
MA, United States; 2Novartis Pharmaceuticals Corpora-
tion, East Hanover, NJ, United States.
Background: Patients, physicians, and other decision-
makers make implicit but inevitable trade-offs among
risks and beneﬁts of different treatments. Many methods
have been proposed to promote more transparent and
rigorous risk beneﬁt analysis (BRA). We propose a
framework for classifying BRA methods based on key
factors that matter most for patients and by utilizing a
common mathematical notation and compared their
results using a hypothetical example.
Objectives: To propose a framework for classifying
BRA methods based on key factors that matter most
for patients and by utilizing a common mathematical
notation.
Methods: We classiﬁed available BRA methods into
three categories: (1) un-weighted metrics, that use only
probabilities of beneﬁts and risks; (2) metrics that in-
corporate preference weights and that account for the
impact and duration of beneﬁts and risks; and (3) met-
rics that incorporate ad-hoc weights based on decision
makers’ opinions.We used two hypothetical antiplatelet
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drugs (A and B) and preference weights from the litera-
ture to compare the BRA methods within our proposed
framework.
Results: Unweighted metrics include number needed
to treat (NNT) and number needed to harm (NNH).
BRA using the NNT/NNH method resulted in -1.3%
net probability of beneﬁt of drug A versus B, suggesting
an unfavorable risk beneﬁt balance.Metrics that incorpo-
rate preference weights include those that use Maximum
Acceptable Risk, which resulted in an incremental net
beneﬁt (INB) of 4.6%; those that use relative-value ad-
justed life years, which resulted in an INB of 3.8%;
and those that use quality-adjusted life years, which
resulted in an INB of 5.4%. Metrics that incorporate
ad-hoc weights includeMulti-criteria Decision Analysis,
Beneﬁt-Less-Risk Analysis, Boers’ 3 by 3 table, the
Gail/NCI method, and the Transparent Uniform Risk
Beneﬁt Overview.
Conclusions: The proposed framework provides a uni-
ﬁed, patient-centered approach toBRAmethods classiﬁca-
tion. This framework facilitates comparisons of the types
of weights that are used across existing methods, a key
differentiating feature. Our ﬁndings suggest that existing
BRA methods share substantial core commonality.
457. Drug-Drug Interaction Alerts inHospital Setting:
Distribution, the Prevalence of Overrides, and
Prescriber Determinants
Tewodros Eguale,1,2,3 Diane L Seger,1,4 Sarah P Slight,1,5
MaryGAmato,1,6 Karen CNanji,1,7 NivethiethaManiam,1,4
Patricia C Dykes,1,4 Julie M Fiskio,1,4 David W Bates.1,2,4
1Division of General Internal Medicine, Brigham and
Women’s Hospital, Boston, MA, United States; 2Harvard
School ofMedicine, Boston,MA,United States; 3Department
of Medicine, McGill University, Montreal, QC, Canada;
4Partners Healthcare Systems, Inc., Boston, MA, United
States; 5School of Medicine, Pharmacy and Health,
The University of Durham, Durham, United Kingdom;
6MCPHS University, Boston, MA, United States; 7Depart-
ment of Anesthesia, Critical Care and Pain Medicine,
Massachusetts General Hospital, Boston,MA,United States.
Background: Computerized prescriber order entry
(CPOE) with clinical decision support can alert pre-
scribers to important drug-drug interactions (DDI),
but drug prescribers can override the majority of these
DDI alerts.
Objectives: To assess the distribution of DDI alerts
likely to prevent serious injuries, the reasons prescribers
gave for overriding these alerts, and to identify prescriber
determinants of alert overrides in hospital setting.
Methods:We extracted the DDI alerts with a potential
to prevent serious injuries from Brigham Women
Hospital between January 2009 and December 2011.
We calculated the frequency distribution of DDI alerts
and the proportion of overridden alerts by interacting
drug pair and overall. Physician characteristics were eval-
uated in relation to the likelihood of DDI alert override
accounting for clustering of patients within physician.
Results: There were 35,579 DDI alerts from 571 drug
pairs during the study period. The top 50 drug pairs
contributed to 80% of these DDI alerts. The most com-
mon DDI alerts included ibuprofen-ketorolac (12%),
diltiazem-simvastatin (8%), dalteparin-heparin (6.5%),
amlodipine-simvastatin (4.5%), and amiodarone-simvastatin
(3.9%). Overall, 25616 (68.2%) DDI alerts were overrid-
den by the prescribers with reasons such as ‘will monitor
as recommended’ (54%), ‘will adjust dose as recom-
mended’ (15.5%) and due to perceived lack of reason-
able alternative drug (1.6%). High degree of
variability was noted in DDI alert overrides: 17% for
dalteparin-heparin, 67% for simvastatin-verapamil,
and 90% for calcium-ceftriaxone interaction alerts.
Attending physicians (OR, 1.14, 95% CI, 1.01, 1.29)
and pharmacists (OR, 1.97, 95% CI, 1.30, 2.99) over-
rode DDI alerts more often than residents, and physi-
cian assistants overrode fewer DDI alerts than
residents. Compared to younger prescribers, older pre-
scribers overrode more DDI alerts.
Conclusions: Less than one tenth interacting drug
pairs accounted for the majority of DDI alerts. More
than two- third of DDI alerts which have potential to
prevent serious injuries were overridden and residents
and physician assistants overrode fewer DDI alerts.
458. ComparativeEffectivenessResearch ofMetformin-
Based Oral Hypoglycemic Therapy in Taiwan’s
Population-Based Database
Huang-Tz Ou, Yen-Ting Chen. Institute of Clinical
Pharmacy and Pharmaceutical Sciences, National Cheng
Kung University, Tainan, Taiwan.
Background: Metformin (MTF) is recommended as
the ﬁrst line of oral hypoglycemic agent (OHA) for
type 2 diabetes. Another OHA is needed to add-on
for patients with the failure control under MTF. Cur-
rent available add-on OHAs are sulphonylureas (SU),
meglitinide (MGT), thiazolidinediones (TZD) and
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acarbose (ACB). Although they were shown to be
effective in the control of HbA1C, their effectiveness
in preventing patients’ progress to macrovascular
complications was little investigated.
Objectives: To compare different MTF-based, dual
OHA regimens in reducingmacrovascular complications.
Methods: A retrospective cohort study was con-
ducted, based on Taiwan’s National Health Insurance
Research Database 1998-2011. Index date was deﬁned
as the ﬁrst date of MTF-based dual therapy start during
2001-2008. All patients were followed-up at least two
years from index date to observe macrovascular events.
Patient demographics, comorbidity at baseline and con-
current diseases during the follow-up were adjusted.
Results: We identiﬁed 12,572 type 2 diabetes under
MTF based, dual therapies, with a mean age of 59
(±12.3). Most patients were prescribed with MTF-SU
regimen (91.1%), followed by MTF-MGT (3.2%),
MTF-TZD (3.1%) andMTF-ACB (2.6%).Macrovascular
events were most seen in MTF-SU patients (19.9%),
followed by MTF-MGT (11.0%), MTF-TZD (9.3%) and
MTF-ACB (7.6%). The average duration of developing
macrovascular complications was longer in patients under
MTF-SU regimen (1,135 days) and shorter in those
prescribed with MTF-ACB regimen (580 days). Com-
paring to MTF-SU patients, the Number Needed to
Treat was highest in MTF-MGT (NNT=11) and lowest
in MTF-ACB (NNT= 8).
Conclusions: Although MTF-SU regimen seems to
prolong patients’ progress to macrovascular complica-
tions, other MTF-based dual regimens (i.e., ACB) may
be more effective in reducing the occurrence of the
complications.
459. Effect of BodyMass Index onChoice of Initiating
Diabetes Therapies
Mugdha N Gokhale,1 John B Buse,2 Til Sturmer.3
1Epidemiology, University of North Carolina, Chapel Hill;
2Medicine, University of North Carolina, Chapel Hill.
Background:While most diabetes drugs are associated
with weight gain, incretin based drugs glucagon-1 re-
ceptor agonists (GLP) and dipeptidyl peptidase 4 inhib-
itors (DPP) are thought to have a favorable or neutral
weight proﬁle. If obese patients are preferentially
channeled towards incretin drugs, comparative effec-
tiveness studies might be confounded if obesity affects
the outcome.
Objectives: Assess whether body mass index (BMI,
kg/m2) drives the choice of initiation of DPP vs
thiazolidinediones (TZD) and GLP vs insulin.
Methods: This study used data from the Cost and Use
ﬁles of the 2006-2009Medicare Current Beneﬁciary Sur-
vey, a nationally representative survey of the Medicare
enrollees. We identiﬁed two new-user cohorts – initiators
of DPP or TZD with no prescription of DPP or TZD in
the 6months before initiation and initiators of GLP or
insulin with no prescription of GLP or insulin in the
prior 6months. Information on age, sex, race and
BMI at baseline was collected from the survey. Age,
sex and race adjusted logistic regression models were
used to estimate the independent effects of BMI cate-
gories on the likelihood of initiating DPP vs TZD and
GLP vs insulin.
Results: In the DPP vs TZD comparison, there were
70 and 146 initiators of DPP and TZD with mean
age 72 and 69 years and mean BMI 32 and 30 respec-
tively. Obese patients (BMI>=30, N = 34 in DPP, 65
in TZD) were more likely to initiate DPP vs TZD com-
pared to patients with BMI< 30 (OR= 1.4, 95%CI
0.7-2.7) and this was even more pronounced for the pa-
tients with BMI>=35 (N=18 in DPP, 19 in TZD,
OR=3.2, 95%CI 1.5-7.2). In the GLP vs insulin
comparison there were 24 GLP initiators and 267 insu-
lin initiators with mean BMI 37 and 30 respectively.
Compared to patients with BMI <35, patients with
BMI>=35 (N=14 in GLP, 45 in insulin) were more
likely to initiate GLP vs insulin (OR 5.2, CI 2.1, 13.0).
Conclusions: Preliminary results indicate a positive
association between higher BMI (especially very high
BMI) and initiation of incretin mimetics. This has im-
plications for confounding control in studies assessing
comparative incidence of e.g., cardiovascular events or
adverse events like pancreatitis with incretin mimetics
versus other diabetes therapies.
460. Clinical Evaluation of Tigecycline in the Treat-
ment of Nosocomial Infection in a Hospital in Taiwan
Man-TzuMWu,1 Hsiang-Yin Chen,2 Li-Na Kuo,1 Kuei-Ju
Cheng.1 1Department of Pharmacy, Wan Fang Hospital,
Taipei Medical University, Taipei, Taiwan; 2Department
of Clinical Pharmacy, School of Pharmacy, Taipei, Taiwan.
Background: Clinical information of tigecycline use
in serious nosocomial infections is limited and the ef-
ﬁcacy is uncertain.
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Objectives: The aim of this observational, retrospec-
tive study was to assess the utilization pattern and the
effectiveness of tigecycline in a tertiary medical center
in Taiwan.
Methods: A retrospective study of the clinical and
microbiological outcome of all patients treated with
tigecycline for at least 48 hours over a 1-year period
was conducted in a 733-bed teaching hospital.
Results: Data from 133 patients with 149 cases of nos-
ocomial infection were analyzed in this assessment.
The mean APACHE II score at the initiation of tige-
cycline therapy was 22.5 ± 8.8 and the mean duration
of treatment was 11.4 ± 5.6 days. Pneumonia was the
most frequently diagnosed clinical indication for
tigecycline use (113 cases, 76%). An overall positive
clinical outcome was observed in 75 cases (50%).
Forty-seven percent (53/113) of pneumonia cases had
positive clinical outcome but only 18% (3/17) of bac-
teremia cases had positive clinical outcome. Multidrug-
resistant Acinetobacter baumannii (MDRAB) is the
most common organism for tigecycline therapy (n=59),
with a positive clinical outcome of 38% in tigecycline
mono-therapy, 66% in dual-therapy and 17% in triple-
therapy (p=0.031). APACHE II score equal to or greater
than 25 and admission to intensive care unit were identi-
ﬁed as predictive factors for negative clinical outcome.
The development of resistance was identiﬁed in 22
patients (15 %) during tigecycline treatment.
Conclusions: Our pneumonia-dominated study popu-
lation demonstrated a lower clinical improvement rate
of tigecycline compared to previous published data.
Tigecycline monotherapy is not recommended and co-
listin or cephoperazone/sulbactam combined with tige-
cycline seemed to yield good clinical outcome for
MDRAB infection.
461. Therapeutic Drug Monitoring and Pharmacoge-
netic Study of HIV-Infected Ethnic Chinese Receiving
Nevirapine -Containing Antiretroviral Therapy
Jin-Han Yang,1 Chien-Ching Hung,2 Ching-Hua Kuo,3,5
Bing-Ru Wu,4 Sue-Yo Tang,1 Wen-Chun Liu,2 Sui-Yuan
Chang,4 Shu-Wen Lin.1,2,5 1Graduate Institute of Clinical
Pharmacy, National Taiwan University, Taipei, Taiwan;
2Internal Medicine, National Taiwan University Hospital,
Taipei, Taiwan; 3School of Pharmacy, National Taiwan
University, Taipei, Taiwan; 4Clinical Laboratory Sciences,
National Taiwan University Hospital, Taipei, Taiwan;
5Pharmacy, National Taiwan University Hospital, Taipei,
Taiwan.
Background: Antiviral agent nevirapine (NVP) is a
non-nucleoside reverse transcriptase inhibitor. It is
the substrate of hepatic enzyme cytochrome P450
(CYP) 2B6 and CYP 3A, and transporter ABCB-1.
Literatures have shown that the gene polymorphism
(SNP) may determine the plasma concentration of
NVP, which may affect the treatment outcome conse-
quently. The most common side effects of NVP are
hepatotoxicity and skin rash, which may be related to
the plasma concentration of NVP.
Objectives: The aim of this study was to assess the
relationship between NVP plasma concentration and
the dosage and adverse effects in Taiwanese patients.
Methods: This prospective study is conducting at
National Taiwan University Hospital, and is currently
recruiting patients. NVP plasma trough levels in lead-in
andmaintenance periods were analyzed using a validated
HPLC method. Patients’ demographics, NVP levels,
SNP, dosage, and adverse effects were documented.
Results: Among 18 patients enrolled, median age was
25 years old (range: 18-49, interquartile range: 23-31).
Only 1 patient was female. A total of 22 trough concen-
trations were measured. Eight of which were measured
in lead-in period and 14 were in maintenance period.
Median trough level was higher in maintenance period
than in lead-in period (6.47 vs. 3.62 mcg/mL) although
trough level ranged widely from 2.07 to 17.31 mcg/mL
in the maintenance period. Among 12 patients whose
SNP were detected, 1 patient (8.3%) carried CYP2B6
SNP, 7 patients (58.3%) carried CYP3A5 SNP, and 3
patients (25%) carried ABCB1 SNP. Three patients de-
veloped grade 1 hepatotoxicity, and 3 patients had mild
skin rash. Multivariate analysis suggested NVP trough
level can be predicted by daily dose or weight-adjusted
dose but not SNP.
Conclusions: NVP plasma concentration was associ-
ated with daily dose and weight-adjusted dose. The re-
lationship between NVP plasma concentration and
adverse effects and SNP should be further studied.
462. Use of Granulocyte Colony-Stimulating Factor
and Neutropenic Events among Breast Cancer and
Non-Hodgkin’s Lymphoma Patients
Wan-Ting Lin,1,2 Tsun-Jen Wen,1 Shao-Chin Chiang,3
Li-Jiuan Shen,1,2 Fei-Yuan Hsiao.1,2 1Graduate Institute
of Clinical Pharmacy, National Taiwan University, College
of Medicine, Taipei, Taiwan; 2Department of Pharmacy,
National Taiwan University Hospital, Taipei, Taiwan;
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3Department of Pharmacy, Koo Foundation Sun Yat-Sen
Cancer Center, Taipei, Taiwan.
Background: Chemotherapy-induced febrile neutro-
penia (CIFN) is a potentially life-threatening compli-
cation of myelosuppressive chemotherapeutic agents.
Although clinical trials have demonstrated the beneﬁ-
cial effects of granulocyte colony-stimulating factor
(G-CSF) prophylaxis on reducing the risk of CIFN,
there are few studies estimating its effectiveness in
“real-world” clinical practice.
Objectives: The objective of this study was to explore
patterns of G-CSF prophylaxis and CIFN among
breast cancer and non-Hodgkin lymphoma (NHL) pa-
tients within a routine oncology hospital setting.
Methods: This is a retrospective observational cohort
study at a medical center in Taiwan. Eligible patients
were those who were older than 18 years, diagnosed
with breast cancer or NHL, and initiated a new chemo-
therapy regimen in 2010 and 2011. Outcome measure-
ments were percentage of patients receiving G-CSF for
“primary prophylaxis”, or “secondary prophylaxis”
and incidence of CIFN.
Results: A total of 2,768 and 886 chemotherapy cycles
from breast cancer and NHL patients were included.
The proportions of patients receiving primary or
secondary prophylaxis of G-CSF were very different
among chemotherapy cycles from two patient groups
(primary: breast 0.07% vs. NHL 26.0% and secondary:
breast 11.5% vs. NHL 35.0%). CIFN were less frequent
in breast cancer patients receiving G-CSF for primary
prophylaxis (primary: 0.50%, secondary: 0.94% and
no prophylaxis 0.71%). However, CIFN were less fre-
quent in NHL patients not receiving G-CSF (primary:
8.70%, secondary: 10.32% and no prophylaxis 4.62%).
Conclusions: At this cancer center in Taiwan, the use
of G-CSF and the incidence rates varies according to
the type of cancer. Differences in patient demo-
graphics, clinical proﬁles and chemotherapy regimens
received by different patient groups may be the possi-
ble risk factors, and need to be further analyzed.
463. A Retrospective Study of the Liver Transplan-
tation Recipients for Finding Risk Factors of Post-
Transplant Metabolic Syndrome (PTMS)
Kazuyuki Niki,1 Mayumi Hamada,1 Taizo Murata,2
Yasushi Matsumura,2 Hiroaki Nagano,2 Toshinori Ito,2
Etsuko Uejima.1 1Graduate School of Pharmaceutical
Science, Osaka University, Suita, Osaka, Japan; 2Graduate
School of Medicine, OsakaUniversity, Suita, Osaka, Japan.
Background: The prognosis of liver-transplant recip-
ients has to be thought in a long-term viewpoint now
because short-term transplant results have gotten better
by improvements of transplant techniques and progresses
of immunosuppressive therapies. However, post-
transplant metabolic syndrome (PTMS) is sometimes
caused by a long-term use of immunosuppressive drugs,
which deteriorates a prognosis of liver-transplant recipients.
Objectives: To identify factors for the prevention of
PTMS and make the prognosis better, we conducted a
retrospective chat review based on a medical record in
Osaka University Hospital. We conducted this study ac-
cording to the Osaka University Hospital Code of Ethics.
Methods: We conduct the study about patients who
were over 18 years old and undergone liver transplanta-
tion form August in 2007 to September in 2000 except
the patients who do not pass after transplantation for
ﬁve years (n = 61). We assessed backgrounds and bio-
chemistry test values of the patients for ﬁve years.
We focused on the biochemistry test values which
related to hypertension, diabetes, dyslipidemia and
hyperuricaemia as disease to lead to PTMS.
Results: The prevalence of hypertensions, diabetes, dys-
lipidemia and hyperuricaemia of the recipients after trans-
plantation had increased more than twice as much as that
before transplantation. Besides, we found the long term
prognosis of recipients whose calcineurin inhibitor (CNI)
had been changed inmid-coursewasworse comparedwith
those with no change of CNI. Therefore, it suggests that
the selection of the appropriate CNI at the beginning of
the immunosuppressive therapy might be important for
good prognosis in long-term of liver-transplant recipients.
Conclusions: There are no guidelines for the selection
of CNI in the immunosuppressive therapy as yet. We
suppose this study will be an evidence for formulating
the guidelines, which will bring about positive effects
to the prognosis of recipients after liver transplantation.
464. Inverse-Probability-of-Selection Weighting of
Rich Subsample Data Provides Informed Estimates
of Treatment Effects for a Larger Sample
Alan R Ellis,1M Alan Brookhart.2 1Cecil G. Sheps Center
for Health Services Research, University of North Carolina
at Chapel Hill, Chapel Hill, NC, United States; 2Depart-
ment of Epidemiology, Gillings School of Global Public
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Health, University of North Carolina at Chapel Hill,
Chapel Hill, NC, United States.
Background: Treatment effect estimates based on ad-
ministrative claims data may be biased due to unmea-
sured confounding.
Objectives: To demonstrate inverse-probability-of-
selection weighting (IPSW), using linked clinical data
on a subsample of observations, as a technique to reduce
bias in estimates for the full sample.
Methods: We conducted a retrospective cohort study of
adult hemodialysis patients using administrative data
from the U.S. Renal Data System (years 2004-2008)
and linked data on a subsample of observations from
the clinical database of a large dialysis provider. For each
person we made one observation, anchored on the ﬁrst
transferrin saturation lab test during the study period.
We used Coxmodels to examine the association between
1-month intravenous iron exposure (>200mg versus 1-
200mg) and hospitalization for infection during 90-day
follow-up, controlling for 43 covariates measured over
a 6-month baseline. We used the detailed subsample data
for our primary model and applied IPSWwith robust var-
iance estimation to make estimates for the larger sample.
We expected that naïve large-sample estimates would be
biased by unmeasured confounding; that the subsample
would resemble the larger sample; and that, like previous
ﬁndings, IPSW estimates would suggest a positive asso-
ciation between iron dose and infection.
Results: The clinical subsample (n=63,673) differed
slightly from the larger sample (n=310,484) before
weighting, but was very similar after weighting (average
standardized absolute mean difference on covariates
[ASAMD]=0.01, maximum=0.06). Unweighted subsam-
ple results were consistent with previous estimates from
similar data, aswas the IPSWestimate from the clinical sub-
sample (3,745 events; HR=1.04; 95% CI: 0.89, 1.20).
Conclusions: Although we could not assess bias directly,
our results were consistent with expectations. In cohort
studies with detailed subsample data, IPSW can provide in-
formed estimates of treatment effects for the larger sample.
465. Drug Safety Monitoring with a Self-Controlled
Design andTime-TrendAdjustmentsUsingDabigatran
and Warfarin as an Example
Shirley V Wang, Joshua J Gagne, Sebastian Schneeweiss.
Division of Pharmacoepidemiology andPharmacoeconomics,
Harvard Medical/Brigham and Women’s, Boston.
Background: Dabigatran is a novel oral anticoagulant
approved for stroke prevention in atrial ﬁbrillation
patients. Previously available anticoagulants such as
warfarin have narrow therapeutic windows and are
known to increase risk of bleeding.
Objectives: To compare short-term triggering effects of
dabigatran and warfarin on safety and effectiveness
endpoints using a case-crossover (CC) design, adjusting
for population level time-trends in exposure related to
uptake of dabigatran following market entry.
Methods: We used claims data from Optum Insight to
mimick rapid-cycle sequential surveillance. Surveillance
began after FDA approval of dabigatran and repeated
quarterly for 6 cycles. Outcomes were ischemic stroke
(IS) and intracerebral bleeding (BL).We used CC with
age, sex, time matched control-crossover adjustments
for time-trends in exposure. We deﬁned exposure to
dabigatran and warfarin during hazard (1-30) and refer-
ent windows (90-120) days prior to identiﬁed outcomes
and compared triggering effects of transient dabigatran
and warfarin exposure.
Results: CC odds ratios (OR) for dabigatran and BL
dropped from 12.0 to 2.7 over 6 monitoring periods;
the OR for dabigatran and IS declined from 5.5 to
3.4 over the same time period. Parallel declines in
OR for dabigatran were observed among cases of BL
or IS and their matched controls. After adjustment for
exposure time-trends, the OR for transient dabigatran
exposure and BL was 1.4 (0.5, 4.0), for IS 1.1 (0.7, 1.9).
CC OR for warfarin and BL were between 1.2-1.7 and
null for matched controls over the 6 monitoring periods.
Crossover OR among both cases and controls for warfarin
and IS were null.
By the 6th period, after adjustment for time trends, the
relative OR, 95% CI for transient dabigatran exposure
compared to warfarin on BL was 1.0 (0.3, 3.0); for IS
0.9 (0.5, 1.7).
Conclusions: High initial crossover estimates for
dabigatran among controls reﬂect time-trends in exposure
for a new to market medication. After adjustment for
time-trends, there was not evidence of a difference in
the triggering effect between transient dabigatran or war-
farin exposure on BL or IS within 6 monitoring cycles.
466. Aspirin for Primary Prevention of Cardiovascular
Disease in DiabetesMellitus – A Retrospective Cohort
Study in Taiwan
Ching-Ying Huang,1 Shun-Jin Lin,2 Wei-Hua Chen.3
1Master Program in Clinical Pharmacy, School of
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Pharmacy, Kaoshiung Medical University, Kaoshiung,
Taiwan; 2School of Pharmacy, Kaoshiung Medical Uni-
versity, Kaoshiung, Taiwan; 3Division of Cardiovascular
Medicine,KaoshiungMedicalUniversityHospital, Kaoshiung,
Taiwan.
Background: Diabetes mellitus (DM) is a high preva-
lence disease in many countries nowadays. How to
reduce complications of DM is an important issue.
Cardiovascular disease (CVD) is the leading cause of
morbidity and mortality in DM patients. Current guide-
lines recommend that aspirin is used for primary and
secondary prevention of CVD in DM. Compared to
secondary prevention with key evidence on its ben-
eﬁts, primary prevention is still controversial in
clinical use due to uncertain efﬁcacy and potential
risk in bleeding.
Objectives: To estimate the risk of myocardial infarct
(MI) associated with aspirin using for primary preven-
tion in patients with DM.
Methods: We use the Longitudinal Health Insurance
Database (LHID 2005) in Taiwan to conduct a popula-
tion-based retrospective cohort study, and enrolled
patients over 30 years old with newly diagnosed DM
from 1997 to 2010. The patients who used aspirin or
had any cardiovascular disease before the DM diagno-
sis were excluded. We followed the patients until MI,
death, last record, or end of follow-up (12/31/2010).
All of the patients were divided into aspirin group
and non-aspirin group, and deﬁned MI as primary out-
come. Cox regression models were used to estimate
the efﬁcacy of aspirin using for primary prevention
in DM patients.
Results: A total of 28,592 patients who were newly di-
agnosed DM in 1997-2010 were included. Mean age
was 53.63 years and 54.68% of patients were men.
The mean follow up time was 5.47 years. The baseline
characteristics showed that aspirin group had more risk
factors for CVD than non-aspirin group, including
older age and more hypertension. After adjusting for
age, sex, comorbidities and co-medications, aspirin
group had higher risk of MI compared with non-aspirin
group (HR= 2.91; 95% CI: 2.715-3.124, p< 0.0001).
Conclusions: Among DM patients, aspirin for primary
prevention was associated with an increase risk of MI.
Further studies will be carried out to include other
relevant outcomes, such as ischemic stroke and
haemorrhagic stroke.
467. Association between Statin Use and Cardiovas-
cular Mortality Decline at the Population Level in
the Netherlands 1994-2010
Maarten J Bijlsma,1 Fanny Janssen,2,1 Jens HJ Bos,1
Pieter Willem Kamphuisen,3 Stijn Vansteelandt,4 Eelko
Hak.1 1Department of Pharmacy, University of Groningen,
Groningen, Netherlands; 2Population Research Centre,
University of Groningen, Groningen, Netherlands; 3De-
partment of Vascular Medicine, University Medical Cen-
tre Groningen, Groningen, Netherlands; 4Department of
Applied Mathematics, Computer Science and Statistics,
Ghent University, Ghent, Belgium.
Background: There is ongoing debate about the deter-
minants of the decline in age-speciﬁc cardiovascular
mortality that has occurred in many Western countries
since 1970.
Objectives: We assessed the contribution of statin use
to the decline in cardiovascular mortality for the
Netherlands over the period 1994-2010.
Methods: We used aggregated mortality data from
Statistics Netherlands for the Netherlands as a whole
with ~16 million inhabitants and prevalence of drug use
in a representative drug dispensing database (iadb.nl)
covering ~ 500,000 persons annually. In the study pop-
ulation aged 50-83 years over the period 1994 to 2010,
we assessed the association between prevalence of
statin use with mortality rates from acute myocardial
infarction (AMI, ICD9-code 410), other ischaemic
heart disease (other IHD, ICD9-codes 411-414) and ce-
rebrovascular disease (ICD9-code 430-438) using a gen-
eralized linear model. We controlled for age, sex, birth
cohort, other cardiovascular drug use, and diabetes.
Results: One additional statin user per 100 person-
years in a half year period was associated with a de-
crease of 1.25% (95% CI: 0.93 to 1.53%) in the total
number of individuals that would have died because
of AMI in the same half year period. Corresponding
ﬁgures were 0.93% (CI: 0.42 to 1.43%) for other
IHD and 1.06% (CI: 0.70 to 1.42%) for cerebrovascular
diseases. In absolute numbers, this meant that statin use
was associated with a reduction of approximately 110
AMI deaths per 2.4 million person-years exposed to
AMI mortality on average throughout the study period.
Conclusions: Statin use appeared associated with a
decrease in cardiovascular mortality. Despite limita-
tions inherent to ecological studies, the study provides
evidence that at the population level lipid-lowering
abstract246
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
drugs play an important role in decreasing national
cardiovascular mortality rates.
468. Association between eGFR Decline and JNC7
Concordant Antihypertensive Treatment
Christopher G Rowan,1 Jeffrey A Spaeder.2 1Anceta Re-
search and Analytics, AmericanMedical Group Association
(AMGA), Alexandria, VA, United States; 2Quintiles,
Durham, NC, United States.
Background: The JNC7 guidelines advocate that
controlling blood pressure (BP) is key to reducing
the burden of hypertension-associated morbidity
and mortality. Renal dysfunction is an uncommon
yet important comorbidity associated with hyper-
tension. JNC7 advocates for the use of speciﬁc an-
tihypertensives based on hypertension stage and
comorbidities.
Objectives: To evaluate the association between eGFR
decline and being prescribed JNC7 discordant antihy-
pertensive therapy.
Methods: We conducted a retrospective cohort study
using EMR data from 11 medical groups in the US.
The study period was 2008–2011. The study cohort
included hypertensive patients following the ﬁrst
elevated BP in the EMR. All patients had an antihy-
pertensive prescription and a baseline and follow-up
serum creatinine values. JNC7 concordance was
evaluated during the six month follow-up period.
Using multivariable logistic regression, we estimated
adjusted the odds ratio and 95% conﬁdence interval
for receiving JNC7 discordant (vs. JNC7 concordant)
therapy with a 30% and 50% decline in eGFR (Mayo
quadratic formula). The models were adjusted for age,
sex, and diabetes.
Results: There were 8,096 stage 1 (n = 6,802) and
stage 2 (n = 1,294) hypertensive patients included.
JNC7 concordant therapy was prescribed in 74% and
45% of stage 1 & 2 patients, respectively. The overall
risk of a 30% and 50% decline in eGFR among stage 1
patients was 0.043 and 0.012, respectively. The overall
risk for stage 2 patients was 0.050 and 0.015, respectively.
The adjusted odds ratios (95% CI) for receiving
JNC7 discordant therapy and having a 30% or a
50% eGFR decline among stage 1 patients were
OR = 2.85 (2.21-3.68) and OR= 3.27 (2.03-5.26),
respectively. The adjusted odds ratios among stage
2 patients were OR= 0.72 (0.43-1.20) and OR= 0.82
(0.38-2.07), respectively.
Conclusions: Among patients with stage 1 hyperten-
sion, there was a signiﬁcant, 2 to 3 fold increased odds
of having a 30 to 50% decline in eGFR for patients
who received JNC7 discordant antihypertensive ther-
apy compared to stage 1 patients who received JNC7
concordant antihypertensive therapy. There was no
signiﬁcant association for patients with stage 2 hyper-
tension.
469. Comparative Efficacy and Safety of New Oral
Anticoagulants Versus Vitamin K Antagonists:
Rationale, Design and Baseline Characteristics of
the NACORA-BR Observational Study
Géric Maura,1 Pierre-Olivier Blotiere,1 Kim Bouillon,2
Cécile Billionnet,1 Philippe Ricordeau,1 François Alla,1
Mahmoud Zureik.2 1Département des Etudes en Santé
Publique, Caisse Nationale de l’Assurance Maladie et des
Travailleurs Salariés, Paris, France; 2Pôle Epidémiologie
des Produits de Santé, Agence Nationale de Sécurité du
Médicament et des Produits de Santé, Saint-Denis, France.
Background: Dabigatran and rivaroxaban, novel oral
anticoagulants (NOAC), have been shown to be at least
non-inferior to vitaminK antagonists (VKA) to safely pre-
vent ischemic events in large randomized trials. However,
to date, evidence on comparative effectiveness and safety
is insufﬁcient to ensure how well clinical trial results
would translate into everyday practice.
Objectives: To provide the rationale, design and base-
line characteristics of the NACORA-BR (NOAC and
Associated Risks - short term Risk/Beneﬁt assessment)
study, a observational study assessing efﬁcacy and
safety of NOAC in post-approval in France.
Methods: Using the French claims database (SNIIRAM)
linked to the hospital discharge database (PMSI), three
anticoagulant-naïve groups have been identiﬁed:
dabigatran- or rivaroxaban-treated patients, included be-
tween July and November 2012 and VKA-treated patients
as control group included between July and November
2011. In an intention-to-treat analysis, patients will be
followed from the ﬁrst prescription to December of their
respective year of inclusion. Potential differences in short-
term ischemic and major bleeding events will be evaluated
with a Cox model adjusted for baseline covariates.
Results: After excluding patients with contraindica-
tions, heart valves diseases and those treated for orthope-
dic procedures, we identiﬁed 12646, 10721 and 49837
patients for the dabigatran, rivaroxaban and VKA safety
cohort respectively. Cohort mean age (%women) was
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73.1±12.2 (46.6%), 68.1±15.3 (49.6%) and 68.2±15.8
(51.3%) respectively. Mean CHA2DS2-VASc score was
3.4±1.7, 3.3±1.7 and 3.5±1.8 respectively. A bleeding
factor (age ≥ 80, renal or hepatic chronic disease or
bleeding history) was found in 36.4%, 28.1% and
31.6% of the patients respectively.
Conclusions: Differences in indications between antico-
agulants and patient channeling in ‘real-world’ clinical
practice may explain differences in characteristics be-
tween treatment groups. Their impact on the association
betweenNOAC/VKA and subsequent adverse health out-
comes will be explored in a comparative outcome study.
470. Systematic Review of of Kudiezi Injection for
Acute Cerebral Infarction
Zhuo Lin, Wang Weiwei, Hu Jing, Wang Jing, Zhang
Yuelun. Department of Epidemiology and Bio-statistics,
Peking University Health Science Center, Beijing, China.
Background: Acute cerebral infarction is due to various
reasons, lead to the brain blood circulation obstacle, ische-
mia, hypoxia caused by brain ischemic necrosis, and then
develop into focal neurological symptoms and signs of dis-
ease. Themortality andmorbidity is high, and the incidence
is increasing quickly as time went on. It’s threating the
human health. The prevention of acute cerebral infarction
is the key to early diagnosis, timely and reasonable treat-
ment, prevention and control of lesion extension, improve
microcirculation, protect brain cells and so on. Kudiezi as
a kind of traditional Chinese medicine is playing a impor-
tant role in the treatment of cardiovascular disease. This
study is the ﬁrst try in China to analyze and evaluate
several independent research of Kudiezi injection in
treatment of acute cerebral infarction,so as to provide
reference for acute cerebral infarction clinical decision.
Objectives: To assess the efﬁcacy and safety of Kudiezi
injection for acute cerebral infarction.
Methods: All clinical studies of Kudiezi injection for
acute cerebral infarction (ACI) were searched from
Cochrane library, Medline, EMbase, CBM, CNKI, VIP
and Wanfang .Quality assessment and information
extraction were done by two independent screening.
The quality of the included documents was evaluated
by the Cochrane Collaboration’s tool for assessing risk
of bias and allocation concealment. Revman 5.1 software
was used for data analysis.
Results: A total of 9 randomized controlled trials with
906 patients were included, in which, only 1 study was
true RCT, while other studies did not mention alloca-
tion concealment, blind and loss-up information. Com-
pared with normal treatment measures, total effective
rate of 10 RCTs suggested that Kudiezi were more
effective with OR 3.74, 95%Cl[2.56,5.46]. Researches
with ADR/AE information of Kudiezi injection showed
that the symptoms of ADR/AE were moderate.
Conclusions: Kudiezi injection on the basis of con-
ventional treatment can improve the efﬁcacy of the
treatment of acute cerebral infarction. However, due
to the sample size of included studies were small and
of lower quality, conclusions above still need more
high-qualitied trials to be conﬁrmed.
471. Comparative Effectiveness of Different Oral
Antibiotics Regimens for Treatment of Urinary Tract
Infection in Outpatient Settings-A Cohort Study on
National Healthcare Administrative Database
Chien-Chang Lee,1,2 Meng-tse Gabriel Lee,1 Shih-Hao
Lee,1 Tse-Chih Chou.3 1Department of Emergency
Medicine, National Taiwan University Hospital, Taipei;
2Department of Emergency Medicine and Department
of General Medicine, National Taiwan University Hospital
Yunlin Branch, Douliou; 3Clinical Informatics and
Medical Statistics Research Center, Chang Gung Univer-
sity, Tao-Yuan.
Background: Urinary tract infections (UTIs) are one
of the most frequent bacterial infections encountered
in the female outpatient settings. However, there is
limited data on post-marketing outcome comparison
of different oral antibiotics regimens.
Objectives: This study compares the UTI treatment fail-
ure rate in patients receiving 5 different oral antibiotics.
Methods: We carried out a retrospective cohort study
using 2 million representative participants from the
National Health Informatics Project of Taiwan. The
subjects were longitudinally followed from 2005 to
2009. Treatment failure was deﬁned as a second anti-
biotic course, follow-up emergency room presentation,
or hospitalization for UTI. Multivariate regression and
a propensity score technique was used to compare
rates of treatment failure between patients that received
trimethoprim (n = 54796), ciproﬂoxacin (n = 4184),
levoﬂoxacin (n = 3142), oﬂoxacin (n = 5984) and
norﬂoxacin (n = 5569). 5 Subgroup analyses were con-
ducted: different sexes; age ≥ than 60 years old; with
(W)/without(WO) indwelling catheters; W/WO bed
ridden status and W/WO spinal cord injury.
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Results: UTI patients prescribed with norﬂoxacin
and oﬂoxacin have up to 30% lower composite
(inpatients + outpatients) and up to 45% lowered hospi-
talization treatment failure rate than patients prescribed
with trimethoprim. These statistically signiﬁcant re-
sults still remain in a sensitivity analysis by extending
the 30 days of treatment failure observation to 42 days.
However, there are no signiﬁcant differences in the
composite/inpatients treatment failure rate of ciproﬂox-
acin and levoﬂoxacin vs trimethoprim.
Conclusions: UTI patients show different treatment
failure rates when using different subgroup of oral
ﬂuoroquinolone. Norﬂoxacin and oﬂoxacin usage con-
sistently have lowered treatment failure rates. Further
subgroup analysis suggests that norﬂoxacin usage
has lowered treatment failure rates in female uncom-
plicated UTI patients. While, oﬂoxacin usgae has
lowered treatment failure rates in greater than 60 years
old complicated UTI patients, irrespective of sex.
472. Looking Both Ways Before Using the Disease
Risk Score (DRS): Performance of the DRS in a
Cohort with Known Selection Bias
Mina Tadrous,1 Muhammad M Mamdani,1,2,3 David N
Juurlink,2,3,4 Murray D Krahn,1,3,6 Linda E Lévesque,1,3,7
SuzanneMCadarette.1,3 1Leslie Dan Faculty of Pharmacy,
University of Toronto, Toronto, ON, Canada; 2Applied
Health Research Centre, Li Ka Shing Knowledge Institute,
St. Michael’s Hospital, Toronto, ON, Canada; 3Institute
for Clinical Evaluative Sciences, Toronto, ON, Canada;
4Institute of Health Policy, Management and Evaluation,
University of Toronto, Toronto, ON, Canada; 5Sunnybrook
Research Institute, Toronto, ON, Canada; 6Toronto Health
Economics and Technology Assessment (THETA) Collabo-
rative, Toronto, ON, Canada; 7Department of Community
Health and Epidemiology, Queen’s University, Kingston,
ON, Canada.
Background: Selection bias in Comparative Effec-
tiveness Research (CER) can arise when a new medi-
cation enters the market and is associated with higher
use in sicker patients. The Disease Risk Score (DRS)
has shown promise to efﬁciently adjust for known con-
founders in CER with newly marketed products.
Objectives: To examine the performance of the DRS
in a cohort with evidence of selection bias.
Methods: We examined a cohort of female new users
of bisphosphonates (alendronate and etidronate) ages
≥66 years from 2001-2008. Analysis of this cohort
suggested higher baseline fracture risk among
alendronate users (newer drug). We compared 1-year
hip fracture rates between agents using Cox-proportional
hazard models with alendronate as the referent. To
examine the impact of outcome deﬁnition on DRS
we varied the start date for outcome classiﬁcation from
0-(index) to 90-days after initiating therapy. DRS was cre-
ated in the whole cohort, divided into equal quintiles and
used as a stratiﬁcation variable. Results were compared to
propensity score (PS) and traditional multivariate models.
All hazard ratio estimates were compared to our base
analysis of a conventional multivariable Cox model with
outcome classiﬁcation starting 30-days after index.
Results: The cohort had 170,862 subjects with 2,740
events. The base analysis yielded non-signiﬁcant
differences between etidronate (HR=0.99;95%CI 0.90-
1.10) and alendronate. All DRS-based estimates were
shifted left towards zero away from the base analysis. Es-
timates ranged from (HR=0.95;95%CI: 0.87-1.04) when
using the 30-day outcome deﬁnition to (HR=0.87;95%
CI: 0.80-0.95) when outcome was classiﬁed on index.
PS results were similar to conventional analysis.
Conclusions: Selection bias and outcome classiﬁca-
tion were found to impact DRS-based estimates.
DRS use may exaggerate differences between newer
and older drugs, favoring older drugs which are used
in healthier patients. This exaggeration may be due
to a high level of correlation between exposure and
confounders caused by selection bias. Our ﬁndings
caution researchers using the DRS to be mindful of
possible selection bias and outcome classiﬁcation.
473. Effect of Conventional Enzyme-Inducing Anti-
epileptic Drugs on Cancer Mortality and Survival:
An Exposed-Unexposed Study of Carcinoma Breast
and Glioblastoma Multiforme
Gagandeep Singh,1 Ley Sander,2 Gail Bell.2 1Neurology,
Dayanand Medical College, Ludhiana, Punjab, India;
2Clinical & Experimental Epilepsy, UCL Institute of
Neurology, London, United Kingdom.
Background: People with cancer who also have epilepsy
andwho are prescribed conventional enzyme-inducing an-
tiepileptic drugs (EIAEDs) might experience pharmacoki-
netic interactions between the EIAEDs and anticancer
agents. This could lead to increased metabolism of the
anticancer agents and hence to reduced survival.
Objectives: To study the effect of use of conventional
EIAEDs (phenobarbital, phenytoin and carbamazepine)
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on survival duration in people with carcinoma breast and
those with glioblastoma multiforme.
Methods: A retrospective, exposed-unexposed study
matched on year of birth and gender was undertaken
in people with a diagnosis of either carcinoma breast
or glioblastoma multiforme using the source population
of the General Practice Research Database, UK. The
explanatory variable was exposure to conventional
EIAEDs following diagnosis of cancer. Individuals en-
tered a survival analysis using the KaplanMeier method
on the date of cancer diagnosis and were followed-up
until death, departure from practice or 31/12/2009.
Results: Hazard ratios for mortality were elevated in
people with carcinoma breast [2.1 (95% Conﬁdence
Interval 1.8 to 2.5)] who had used conventional
EIAEDs compared with those who did not. On the
contrary, mortality in people with glioblastoma
multiforme who used EIAEDs was not different from
those who did not. The causes of death in both EIAED
users and non-users with both carcinoma breast and
glioblastoma multiforme appeared to be similar.
Conclusions: The administration of EIAEDs is associ-
ated with reduced survival duration in people with
carcinoma breast but not glioblastoma multiforme.
474. Effectiveness, Tolerability and Impact on Qual-
ity of Life of Interventions Used for the Manage-
ment of Patients with Chronic Low Back Pain
Chirag s Shah,1 Dipika Bansal,2 Babita Ghai.3 1Pharmacy
Practice, SJMCollege of Pharmacy, Chitradurga, Karnataka,
India; 2Pharmacy Practice, NIPER, Chandigarh; 3PGIMER,
Chandigarh.
Background: Chronic low back pain (CLBP) with or
without radiculopathy is a major expensive, and dis-
abling condition around the globe. limited evidence
is available on efﬁcacy and safety of combinational
drug therapy for management of CLBP.
Objectives: To assess the prescribing pattern, efﬁcacy,
tolerance, quality of life and cost of the interventions
used for the management of CLBP.
Methods: An observational, non interventional ques-
tionnaire based study, performed in pain clinic in
tertiary care government hospital situated in north India.
To study efﬁcacy of treatment visual analogue scale
(VAS) was used to measured pain intensity. To study
impact of treatment on functional disability, quality of
life and psychological status, Modiﬁed Oswestry low
back pain Disability questionnaire (MODQ), SF- 12
questionnaire and Hamilton depression score (HDS)
were used respectively. All the score measured for the
follow-up period of three month with the interval of
initial one month and then three month.
Results: Total 48 patients (59 % male) were included
in our study with mean (SD) age of 42.07 (10.99)
years. Majority (92 %) were receiving combination
therapy including drugs from the class of antidepres-
sant and anticonvulsant. At baseline VAS and MODQ
median (IQR) value were 75 (52.5-87.5) and 53 (43-
60) respectively. After one month of treatment fol-
low-up, VAS and MODQ score was found to be 40
(36.3-61.3) and 44 (32-51) respectively which was
signiﬁcantly less (P value< 0.05) compare to base-
line. These difference was found insigniﬁcant in case
of SF-12 (P value = 0.085) and HDS score (P value =
0.082). 31 % of patient reported with side effect with
medication. Signiﬁcant (P value< 0.05) number of pa-
tients (47%) reporting sedation as major side effect with
pregabalin and gabapentin therapy. Lyrica[r] was the
highest prize brand with 54.89 INR/capsule for
pregabalin.
Conclusions: Neuropathic pain was found in majority
as revealed by disc bulging in MRI scan. Favorable
improvement was seen in the functional disability as
well as pain relief with combinational therapy. Treat-
ment of low back pain poses additional ﬁnancial
burden on patients.
475. Anticonvulsants or Antidepressants in Combi-
nation Pharmacotherapy for the Treatment of
Neuropathic Pain in Cancer Patients: AMeta-Analysis
Jia Guan, Shiro Tanaka, Koji Kawakami. Department of
Pharamacoepidemiology, Graduate School of Medicine
and Public Health, Kyoto University, Kyoto, Japan.
Background: NCCN guidelines recommended anti-
depressants and anticonvulsants as the ﬁrst-line adju-
vant analgesics for the treatment of cancer-related
neuropathic pain without sufﬁcient evidence.
Objectives: The purpose of this study is to investigate
the efﬁcacy and safety of anticonvulsants or antidepres-
sants in the combination pharmacotherapy in this setting.
Methods: Databases searched include Cochrane
Central Register of Controlled Trials, MEDLINE and
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EMBASE from inception to January 2014, with no
limits on language. The metaRegister of Controlled
Trials was also searched. Included were randomized
controlled trials, parallel or crossover design, compar-
ing anticonvulsants or antidepressants in the combina-
tion pharmacotherapy (experimental) with placebo,
active monotherapy, or combination pharmacotherapy
without anticonvulsants or antidepressant (control) for
neuropathic pain in cancer patients. Primary outcome
was mean difference of average pain from baseline to
end of follow-up using numerical rating scale (NRS)
with 0 representing no pain and 10 representing the
worst pain imaginable.
Results: Eight trials met inclusion criteria with a total
of 889 participants of whom 478 received experimen-
tal intervention. Four of the trials compared
gabapentin combined with other analgesics versus
controls, the other four trials concerned pregabalin,
duloxetine, lamotrigine and levetiracetam in combi-
nation pharmacotherapy as the experimental inter-
vention respectively. The duration of trials ranged
from 10 days to 10 weeks. Any kind of cancer
patients were included in six trials, and the other
two limited breast cancer.The mean difference of
average pain suggested a favorable association with
anticonvulsants or antidepressants in combination
pharmacotherapy compared with control (mean dif-
ference, -0.59; 95% conﬁdence interval, -1.23 to
0.05); however, substantial heterogeneity was pres-
ent (I2 = 79%).
Conclusions: As adjuvant analgesics, anticonvul-
sants and antidepressants showed a reduction of
neuropathic pain in cancer patients compared with
controls, but statistical signiﬁcance was not demon-
strated because of heterogeneity across trials.
476. Medication and Risk of Rehospitalization in
Bipolar Disorder: A Nationwide Cohort Study
Johan Reutfors,1 Jari Tiihonen,2 Lena Brandt,1 Louise
Scheen,1 Antti Tanskanen,2 Morten Andersen,1 Robert
Bodén.1,3 1Department of Medicine Solna, Centre for
Pharmacoepidemiology, Karolinska Institutet, Stockholm,
Sweden; 2Department of Clinical Neuroscience, Karolinska
Institutet, Stockholm, Sweden; 3Department of Neuroscience,
Psychiatry, Uppsala University, Uppsala, Sweden.
Background: Lithium, anticonvulsants and antipsy-
chotics (mood stabilizers; MS) are used to treat bipolar
disorder (BD) but knowledge is limited regarding their
relative effectiveness in preventing relapse.
Objectives: To compare the risk of rehospitalization
among patients with BD treated with different groups
of mood stabilizers.
Methods: Using the Swedish patient register, we
identiﬁed a complete cohort of patients who were
hospitalized with BD between 2006-2012. Individual
drug dispensing data was obtained from the Pre-
scribed Drug Register. A run-in period of one year
was used to exclude prevalent users of MS. Patients
who ﬁlled one or more prescription of a MS during
the ﬁrst 30 days post discharge were considered
exposed in an intention to treat analysis and were
followed up for one year. We estimated the relative
risk of psychiatric rehospitalization as hazard ratios
[HR] with 95% conﬁdence intervals [CI] using Cox
regression models and adjusting for sex, age, and
psychiatric comorbidity.
Results: Of 4764 patients with BD (57.2% women),
71.8% ﬁlled a prescription for a MS within the ﬁrst
month after hospitalization and 1587 patients
(33.3%) were rehospitalized within one year. Patients
who had used a MS had a lower risk of rehospitalization
(HR 0.87, CI 0.78-0.98) than the others.When comparing
outcomes for the 3421 patients who did ﬁll at least one
MS prescription, lithium appeared most favorable with a
HR for rehospitalization of 0.76 (CI 0.65–0.88) followed
by anticonvulsants with HR 0.87 (CI 0.75–1.00). Anti-
psychotics were associated with a non-signiﬁcantly
higher risk of rehospitalization.
Conclusions: Patients with bipolar disorder who are
treated with lithium may have the lowest risk of
rehospitalization.
477. Proton-Pump Inhibitors DoNot Impair (andMay
Modestly Help) Metformin’s Effectiveness
James H Flory,1 Kevin Haynes,2 Charles E Leonard,2
Sean Hennessy.2 1Endocrinology, Weill Cornell Medical
College, New York, NY, United States; 2Center for Clin-
ical Epidemiology and Biostatistics, Perleman School of
Medicine at the University of Pennsylvania, Philadelphia,
PA, United States.
Background: Metformin is the ﬁrst-line drug treatment
for type 2 diabetes. In order for metformin to work, it
needs to be taken up by the organic cation transporter
(OCT) system. A recent in vitro study found that pro-
ton-pump inhibitors (PPIs) inhibit OCT1, OCT2, and
OCT3, suggesting that PPIs might reduce metformin’s
effectiveness. Because use of PPIs in patients with
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diabetes is very common, this could be a clinically im-
portant effect.
Objectives: To assess whether PPI exposure altered
the clinical effectiveness of metformin.
Methods: A retrospective cohort study was performed
to assess the effect of PPI and metformin therapy, alone
and in combination, on glycosylated hemoglobin
(HbA1c). The primary outcome was the change in
HbA1c from the month prior to a new exposure to the
average 3 to 9months later. Changes in serum glucose
were also examined in sensitivity analysis.
Results: PPIs did not reduce the effectiveness of met-
formin, and indeed were associated with a modestly
better glycemic response by 0.14 HbA1c percentage
points (95% conﬁdence interval, -0.25 to -0.02). A
similar analysis using serum blood glucose as the out-
come also showed no evidence of a deleterious inter-
action. In addition, PPIs themselves had no direct
effect on HbA1c.
Conclusions: Despite a mechanistic basis for a poten-
tial drug-drug interaction, we found no evidence of a
deleterious interaction between PPI and metformin,
and some suggestion of a modest beneﬁcial effect. If
true, a beneﬁcial effect of PPIs on glycemic control
in users of metformin might be mediated through ame-
lioration of metformins’s gastrointestinal side effects
by PPIs.
478. Preference-Based Instrumental Variable (IV)
Methods in the Comparative Effectiveness of
Osteoporosis (OP) Medications in Women with
Postmenopausal Osteoporosis (PMO) Using the
MarketScan Database
Jane S Der,1MAlan Brookhart,1 Fei Xue.2 1Epidemiology,
University of North Carolina, Chapel Hill, NC, United
States; 2Center for Observational Research, Amgen, Inc.,
Thousand Oaks, CA, United States.
Background: IV methods may control for unmeasured
confounding in non-experimental studies. Few studies
have explored provider preference-based IVs in insur-
ance claims databases, where the provider identiﬁer is
unavailable in pharmacy claims (PC).
Objectives: To construct an IV based on provider
preference through linkage of PC to outpatient medical
claims (OMC) and to test the assumptions of the
IV method in assessing the potential effect of
bisphosphonate (BP) vs. other OP medications (OPM)
on the risk of osteoporotic fracture (Fx) in women
with PMO.
Methods: Women ≥55 years initiating a BP or OPM
(index treatment) were identiﬁed from the MarketScan
database (2000-10) and followed for incident osteopo-
rotic Fx. OMC, which include a provider identiﬁer
variable, were linked to PC by identifying a new pre-
scription ﬁll from the PC that occurred ≤30 days after
an ofﬁce visit in OMC. The prescribing provider’s
preference (IV=BP vs. other) was deﬁned by prior
prescriptions from the same provider in PC tracked by
linking to the OMC. Assumptions of the IV method
including the strength of the IV (its association with the
index treatment and osteoporotic Fx), the balance of
covariates across levels of the IV were assessed, and
the heterogeneity of treatment effect were evaluated.
Results: The strength of the IV (95% CI) was 2.15
(2.04, 2.25) and 0.14 (0.13, 0.15) on the relative and
absolute scales, respectively. The incidence rate ratios
(IRR) (95% CI) of osteoporotic Fx comparing index
treatment and IV were 1.05 (0.96, 1.14) and 1.07
(0.97, 1.18), respectively. The IRR for IV changed
minimally after adjusting for treatment. The imbal-
ances in measured confounders between treatment
groups were improved slightly by the IV. The strength
of the IV varied moderately by baseline covariates.
Conclusions: The strength of the IV derived by
linking PC to OMC in this study is comparable to
ﬁndings from a previous claims-based study, in which
physicians’ preference was derived by directly track-
ing PC. The performance of the IV needs further ex-
ploration in other populations and therapeutic areas.
479. Effect of Anti-Inflammatory Treatment on
Depression and Side Effects: A Systematic Review
and Meta-Analysis of Randomized Clinical Trials
Ole Koehler,1 Michael Benros,2 Merete Nordentoft,2 Ole
Mors,1 Jesper Krogh.2 1Research Unit P, University Hos-
pital, Risskov, Risskov, Denmark; 2Mental Health Centre
Copenhagen, Faculty of Health Sciences, University of
Copenhagen, Copenhagen, Denmark.
Background: Several studies have indicated antidepres-
sant effects of anti-inﬂammatory treatment; however, the
results have been conﬂicting and detrimental side effects
may contraindicate anti-inﬂammatory intervention.
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Methods: Searching CENTRAL, PubMed, EMBASE,
Psychinfo, and Clinicaltrials.gov, we conducted a system-
atic review and meta-analysis of randomized, placebo-
controlled trials assesing efﬁcacy and harmful effects of
anti-inﬂammatory intervention in adults with depressive
symptoms or depression. Standard mean differences (SMD),
random effects and Odds Rations (OR) were calculated.
Results: 14 trials (n = 6,262) were included, 10 on non-
steroidal anti-inﬂammatory drugs (NSAIDs) (n = 4,258)
and 4 on cytokine-inhibitors (n = 2,004). Anti-inﬂamma-
tory agents reduced depressive symptoms (SMD= -0.34;
95%-CI: -0.57 to -0.11; I2 = 90%) compared to placebo,
both in studies including patients with clinical depression
(SMD= -0.54; 95%-CI: -1.08 to -0.01; I2 = 68%) and
depressive symptoms (SMD= -0.27; 95%-CI: -0.53 to -
0.01; I2 = 93%). Clinical depression compared to depres-
sive symptoms or NSAIDs compared to cytokine-inhib-
itors did not explain the heterogeneity. Subanalyses
particularly emphasized antidepressant properties for
the selective COX-2 inhibitor celecoxib in general
(SMD= -0.29; 95%-CI: -0.49 to -0.08; I2 = 73%), on
remission (OR=7.89; 95%-CI: 2.94 to 21.17; I2 = 0%)
and response (OR=6.59; 95%-CI: 2.24 to 19.42;
I2 = 0%). 6 studies (n =2,523) reported on harmful
effects and we found no evidence of an increased num-
ber of gastrointestinal or cardiovascular events nor infec-
tions. All trials were associated with a high risk of bias
due to potentially compromised internal validity.
Conclusions: Anti-inﬂammatory agents, in particular
celecoxib, decreased depressive symptoms and de-
pression. We found no evidence indicating higher
number of harmful effects. However, the results were
associated with high heterogeneity making the mean
estimate uncertain. This supports a proof-of-concept
concerning use of anti-inﬂammatory agents in depres-
sion and identiﬁcation of subgroups that could beneﬁt
of this intervention might be warranted.
480. Comparison of Re-Hospitalization and Emergency
Room Visit Patterns Among Patients with Schizophre-
nia Receiving Paliperidone Palmitate or Oral Atypical
Antipsychotics in an Inpatient Setting
Marie-Hélène Lafeuille,1 Amanda Grittner,1 Erik Muser,2
John Fastenau,2 Mei Sheng Duh,3 Patrick Lefebvre.1
1Groupe d’Analyse, Ltée, Montréal, QC, Canada; 2Janssen
Scientiﬁc Affairs, LLC, Titusville, NJ, United States; 3Anal-
ysis Group, Inc., Boston, MA, United States.
Background: Inpatient care represents the primary
driver of costs associated with schizophrenia, accounting
for between one-third and two-thirds of the total direct
health care costs of patients with schizophrenia.
Objectives: To compare re-hospitalization and emer-
gency room (ER) visit patterns among patients with
schizophrenia receiving paliperidone palmitate (PP) or
oral atypical antipsychotics (AP) in an inpatient setting.
Methods: Hospital discharge and billing records from
the Premier Perspective Comparative Hospital Database
were analyzed for adult patients who had a schizophre-
nia-related hospitalization with either PP or oral AP
treatment (index hospitalization) between 1/2009 and
3/2012 and no evidence of prior treatment with other
long-acting AP. Patients with schizoaffective disorder
only were excluded. Patients using PP during their
index hospitalization were compared to those using oral
AP in terms of the frequency of re-hospitalizations and
ER visits using the Andersen-Gill Cox extension of
multivariate Cox proportional hazard models. Inverse
probability of treatment weights (IPTW) based on pro-
pensity scores were also used to control for differences
in baseline characteristics across cohorts.
Results: Several baseline characteristics differed
signiﬁcantly between the 394 PP and the 47,764 oral
AP patients. After using IPTW and controlling for time
since last schizophrenia-related hospitalization, as well
as for year, length of stay, number of APs, number of
mental disorder diagnoses, and discharge status of the
index hospitalization, hazard ratios for PP relative to oral
AP patients were 0.60 (p< 0.0001) and 0.71 (p< 0.0001)
for all-cause, and 0.74 (p< 0.0001) and 0.76 (p< 0.0001)
for schizophrenia-related ER visits and re-hospitaliza-
tions, respectively.
Conclusions: This hospital database analysis found
that schizophrenia patients using PP during their index
inpatient stay were associated with lower ER visit and
re-hospitalization rates as compared with those using
oral AP.
481. Above Standard Dose of Octreotide-LAR in
Patients with Neuroendocrine Tumors (NET) for
Control of Carcinoid Syndrome Symptoms: A Multi-
Center Retrospective Chart Review Study
Jonathan R Strosberg,1 Al B Benson,2 Lynn Huynh,3 Mei
Sheng Duh,3 Jamie Goldman,4 Vaibhav Sahai,2 Alfred W
Rademaker,2 MatthewHKulke.5 1Department of GI Oncol-
ogy, Mofﬁtt Cancer Center and Research Institute, Tampa,
FL, United States; 2Robert H. Lurie Comprehensive Cancer
Center of Northwestern University, Chicago, IL, United
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States; 3Analysis Group, Inc., Boston, MA, United States;
4Department of Internal Medicine, University of South
Florida, Tampa, FL, United States; 5Dana-Farber Cancer
Institute, Boston, MA, United States.
Background: Octreotide acetate for injectable suspen-
sion (OCT) is used in patients for control of carcinoid
syndrome (CS) and other symptoms of hormone
hypersecretion. In clinical practice, higher doses or
dose-frequencies have been used in some patients to
achieve CS symptom relief. This study aims to under-
stand the relationship between OCT doses above
30mg/4weeks and CS symptom improvement.
Objectives: This study aims to understand the rela-
tionship between OCT doses above 30mg/4weeks
and CS symptom improvement.
Methods: Medical records were abstracted for NET
patients with diagnosis of a carcinoid or pancreatic
endocrine tumor, ≥18 years old, and who had re-
ceived ≥1 dose of OCT (>30mg/4weeks) at three
large neuroendocrine tumor referral centers. Rea-
sons for dose-escalation and reports of ﬂushing
and diarrhea were abstracted for each patient
3months prior to and up to 12months following the
dose-escalation. Safety data were not collected and
assessed in this study.
Results:Medical records of 239 NET patients from 2000-
2012who had escalatedOCTdose above the standard dose
of 30mg/4weeks were evaluated. Of the evaluated pa-
tients, 53% were male, mean (SD) age at ﬁrst dose-escala-
tion was 60 (11) years, and mean (SD) time from OCT
initiation to ﬁrst dose-escalation was 1.7 (3.7) years.
The primary stated reasons for dose-escalation were car-
cinoid or hormonal syndrome (62%) or radiographic
progression (14%). The most common dose changes at
ﬁrst dose-escalation were 40mg/4weeks (71%) and
60mg/4weeks (18%). Of 90 patients in whom ﬂushing
was reported prior to dose-escalation, 73 (81%) were re-
ported to have experienced improvement/resolution of
their symptoms following the dose-escalation. Of 107
patients who were reported to have experienced diarrhea
before the ﬁrst dose-escalation, 85 (79%) were reported
to have experienced improvement/resolution post ﬁrst
dose-escalation.
Conclusions: A goal of improved symptom control is
a common reason for dose-escalation of OCT. This
retrospective chart review suggests that OCT dose
above 30mg/4weeks may result in improved CS
symptom control.
482. Vildagliptin Efficacy in Combination with
MetfoRmIn for EarlY Treatment of Type 2 Diabetes
Mellitus (VERIFY)
Wayne Huey-Herng Sheu,1 Stefano D Prato,2 James Foley,3
Wolfgang Kothny,4 Plamen Kozlovski,4 Päivi Paldánius,4
Michael Stumvoll,5 David R Matthews.6 1Department of
Internal Medicine, Taichung Veterans General Hospital,
Taichung, Taiwan; 2Department of Endocrinology and
Metabolism, Section of Metabolic Diseases, University of
Pisa, Pisa, Italy; 3Novartis Pharmaceuticals Corporation,
East Hanover, NJ, United States; 4Novartis Pharma AG,
Basel, Switzerland; 5Department of Medicine, University
of Leipzig, Leipzig, Germany; 6Oxford Centre for Diabetes
Endocrinology & Metabolism, University of Oxford,
Oxford, United Kingdom.
Background: Durability of good glycaemic control
may delay the development of diabetic complications
in patients with type 2 diabetes mellitus (T2DM).
Objectives: Early initiation of combination treatment
with oral anti-diabetic drugs (OADs) having comple-
mentary mechanisms of action may increase durability
of glycaemic control compared with stepwise addition
of OADs. Dipeptidyl pepetidase-4 inhibitors (DPP-4)
inhibitors such as vildagliptin are good candidates for
early use in combination with metformin as they are
weight neutral with no additional risk of hypoglycaemia.
Methods: About 2000 drug-naïve patients with T2DM
with HbA1c between 6.5%–7.5%, will be randomised in
VERIFY, a ﬁve-year, multinational, double-blind, paral-
lel-group study. The studywill test the hypothesis whether
early combination therapy with vildagliptin/metformin
will result in lower treatment failure rate or in lower rate
of loss in glycaemic control over time than with metfor-
min alone. Other objectives include evaluation of rate of
fasting plasma glucose progression, change in HbA1c
over time, time to insulin initiation, development / pro-
gression of diabetic complications, changes in body
weight, changes in HOMA-β/IR, safety and tolerability.
Insulin secretion rate and insulin sensitivity will be
assessed in annual standard meal-test. Patients will also
be evaluated for early changes in the vasculature,
microalbuminuria and retinal microaneurysms.
Results: VERIFY is the ﬁrst study to investigate the
long-term clinical beneﬁts of early combination treat-
ment versus the standard-of-care metformin followed
by addition of OADs.
Conclusions: VERIFY will provide valuable data on
the durability of glycaemic control, β–cell function,
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insulin resistance, safety and tolerability and explore
early changes in the vasculature of patients with T2DM.
483. Exploring the Factors Associated with Self-
Report of Health Status among the ElderlyDiagnosed
with Chronic Respiratory Diseases in Taiwan
Ching-Yuan Chang,1 Shan-Chieh Wu,1 Wei-Erh Cheng,3
Hsiang-Wen Lin.1,2 1School of Pharmacy and Graduate
Institute, China Medical University, Taichung, ROC;
2Department of Pharmacy, China Medical University
Hospital, Taichung, ROC; 3Division of Pulmonary and
Critical Care, Department of Internal Medicine, China
Medical University Hospital, Taichung, ROC.
Background: Chronic respiratory disease is one of
important causes of morbidity and mortality in the
elderly. While the proportion of elderly is increasing,
it is unclear how the chronic respiratory diseases
impact the elderly health status.
Objectives: The aim of the study was to explore the
factors associated with self-report of health status
among the elderly with chronic respiratory diseases
using nationwide survey data in Taiwan.
Methods: The study data was retrieved from the 2005
Taiwan National Health Interview Survey databases.
Those interviewees aged more than 65 years old, and
reported to have chronic respiratory diseases (e.g.,
asthma, chronic obstructive pulmonary diseases) were
compared with the counterparts after performing 1:1
matching using propensity scores for the selected
variables (e.g., demographic, health utilization, disease).
The univeriate and multivariate logistic regression
analyses were performed to explore the factors
associated with the dichotomous perceived health status
(worse or not), comparing to that in one-year ago and
others with the same age.
Results: Of 2,727 interviewees, 265 elderly were
diagnosed with chronic respiratory diseases. They
tended to report that their health status were worse
and less likely to do exercise and got ﬂu immunization
(all ps< 0.05). After controlling for the other factors,
those elderly patients with chronic respiratory
diseases, ever hospitalized (OR: 2.33, 95%CI:
1.44-3.78), and made outpatient visits (2.5,1.46-
4.308) tended to reported worse health, comparing
to one-year ago and others. Those elderly patients
with strokes and heart diseases tended to report
worse health, comparing to the others (3.848,
3.85-1.78; 1.894,1.15-3.11).
Conclusions: Those elderly patients ever made hospi-
talizations and outpatient visits tended to report worse
health statues. Some diseases might result in patients’
perception of health status different from the others.
Future prospective study is needed to explore the
rationales beyond, and the corresponding public health
strategies to provide better elderly care.
484. Comparative Treatment Failure Rates of Respi-
ratory Fluoroquinolones in the Treatment of Commu-
nity-Acquired Pneumonia: An Analysis of National
Representative Claims Database
Chien-Chang Lee,1,2 Meng-tse Gabriel Lee,1 Shih-Hao
Lee,1 Tse-Chih Chou.3 1Department of Emergency Medi-
cine, National TaiwanUniversity Hospital, Taipei; 2Depart-
ment of Emergency Medicine and Department of General
Medicine, National Taiwan University Hospital Yunlin
Branch, Douliou; 3Clinical Informatics and Medical Statis-
tics Research Center, Chang Gung University, Tao-Yuan.
Background: Penicillin, macrolide and ﬂuoroquinolone
are 3 common types of antibiotics used in the treatment of
community-acquired pneumonia (CAP). For patients with
comorbidities, current CAP treatment guidelines recom-
mend either respiratory ﬂuoroquinolone or β-lactam+
macrolide as the empirical antibiotic regimen.
Objectives: This study compares the treatment failure
rates of ﬂuoroquinolones/macrolide + penicillin vs
penicillin in CAP patients.
Methods: A retrospective cohort study was carried out
using the claims data from National Health Informatics
Project of Taiwan. 2 million subjects were longitudinally
followed from January 2005 toDecember 2007. Compos-
ite treatment failure rates were deﬁned by either one of the
following: a second antibiotic prescription, hospitalization
due to CAP and emergency department visit with a diag-
nosis of CAP. Multivariate regression and a propensity
score technique was used to compare rates of treatment
failure between patients that received levoﬂoxacin
(n=1602), moxiﬂoxacin (n=2100), penicillin (Amoxicil-
lin/clavulanate, or Ampicillin/sulbactam) (n=5049) and
macrolide (Azithromycin, or Clarithromycin) +Penicillin
(n=505). Two subgroup analyses were conducted in
patients: different sexes and age> than 65years old.
Results: Moxiﬂoxacin usage has up to 23% lower
composite (inpatient + outpatient) treatment failure
rate than penicillin and up to 25% lower composite
treatment failure rate than levoﬂoxacin. Subgroup
analysis on >65 years old inpatients found that
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moxiﬂoxacin usage has 35% lower treatment failure
rate than penicillin and 31% lower treatment failure
rate than levoﬂoxacin. We found no signiﬁcant differ-
ence in the composite or inpatient treatment failure
rates of levoﬂoxacin vs penicillin.
Conclusions: Out of the antibiotics studied,moxiﬂoxacin
usgae has the lowest composite treatment failure rates.
Taken together with the literature suggesting that
moxiﬂoxacin has better pharmacokinetics and lower
pneumonia resistance than levoﬂoxacin, we suggest
moxiﬂoxacin to be prescribed to Taiwanese CAP
patients with comorbidities.
485. Urinary Albumin Secretion in Type 2 Diabetes
Patients (T2DM) with Albuminuria Treated with
Sitagliptin as Add-On Therapy to Metformin: A
Real-World Data Study
Cheli Melzer Cohen,1 Gabriel Chodick,2 Avraham
Karasik,3 Larry Radican,4 Shengsheng Yu,5 Bernd Voss,6
Offer Sharon,7 Noga Gadir,8 Kimberley Brodovicz,9
Varda Shalev,10 Harvey Katzeff,11 Kaan Tunceli.12
1Maccabi Health Organization, Tel Aviv, Israel; 2Maccabi
Health Organization, Tel Aviv, Israel; 3Sheba Medical
Center & Tel Aviv University, Tel Aviv, Israel; 4Merck
Ltd, Whitehouse Station, NJ, United States; 5Merck Ltd,
Whitehouse Station, NJ, United States; 6Merck Ltd,
Whitehouse Station, NJ, United States; 7Merck Ltd, Hod
Hasharon, Israel; 8Merck Ltd, Hod Hasharon, Israel;
9Merck Ltd, Whitehouse Station, NJ, United States;
10Maccabi Health Organization, Tel Aviv, Israel; 11Merck
Ltd, Whitehouse Station, NJ, United States; 12Merck Ltd,
Whitehouse Station, NJ, United States.
Background: Reduction in Urine Albumin-to-Creati-
nine Ratio (UACR) by dipeptidyl peptidase 4 inhibitor
(DPP-4i) therapy was documented in clinical trials
among T2DM patients with albuminuria.
Objectives: To examine whether a similar effect occurs
in real-world we analyzed Maccabi database, a large Is-
raeli health maintenance organization (HMO)databases.
Methods: We identiﬁed 1248 eligible T2DM patients
with albuminuria who had sitagliptin added to their
metformin therapy for at least 120 days. Baseline
UACR, taken 4month before sitagliptin treatment
initiation was divided to three categories:30-100mg/gr
found in 54.3% (n= 643),100-300mg/gr in 26.3%
(n= 328) and >300mg/gr in 19% (n= 237). All pa-
tients had a second UACR after >60 days on sitagliptin
and an eGFR >45ml/min.
Results: A total of 523 (41.9%) patientsmoved to a lower
UACR category at follow-up, and 561 (45%) stayed at the
same baseline UACR category, while 164 patients
(13.1%) shifted to a higher UCAR category, 58%
(n=658) experienced a reduction of over 20% of their
baseline UCAR. HbA1c levels were reduced by 0.69%
(P< 0.001) from a baseline level of 8.2% (SD=1.4%).
In a multivariable model a baseline UACR of
>300mg/gr was associated with an odds ratio of
3.88 (95% CI: 2.40-6.25) for having at least 20%
UACR reduction compared with being in the lowest
category (30-100mg/gr).Males and obese patients
were signiﬁcantly less likely to achieve a 20% reduc-
tion in their UACR level. Changes in UCAR were
associated with changes in HbA1c (r = 0.208, p< 0.001)
but not with baseline HbA1c, namely,UACR was
signiﬁcantly (P< 0.01) improved even for patients with
no observed reduction in HbA1c.
Conclusions:A majority of T2DM patients with micro-
or macroalbuminuria treated with sitagliptin as add-on
therapy to metformin experienced a reduction in urinary
albumin excretion. The magnitude of improvement in
UACR was related to HbA1c reduction;however, the
reduction in UACR was clinically signiﬁcant even
when there was no reduction in HbA1c levels. Further
studies are needed to evaluate the possible mechanism
of glucose independent, DPP-4-dependent reduction
of albuminuria.
486. Use of High Dimensional Propensity Scores to
Control for Confounding in Assessing the Associa-
tion between Bone Density Screening and Hip
Fracture Risk
Jie Zhang,1,2 Jeffrey RCurtis,2,1 Hong Zhao,1 Luqin Deng,1
Kenneth G Saag,2 Meredith L Kilgore,3 Paul Muntner,1
Nicole C Wright,1 Elizabeth Delzell.1 1Epidemiology,
University of Alabama at Birmingham, Birmingham, AL,
United States; 2Medicine (Division of Clinical Immunology
and Rheumatology), University of Alabama at Birmingham,
Birmingham, AL, United States; 3Health Care Organization
and Policy, University of Alabama at Birmingham,
Birmingham, AL, United States.
Background: Younger and healthier individuals are
often more likely to receive screening and preventive
health services.
Objectives: To evaluate the use of high dimensional
propensity scores (HDPS) to control for confounding
in assessing the impact of screening with dual X-ray
absorptiometry (DXA) on hip fracture risk incidence.
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Methods: We conducted a retrospective cohort study
among female Medicare beneﬁciaries from a 5%
random sample from 1999 to 2009 who were ≥ 65
and had continuous fee for service coverage for ≥ 36
months (baseline period, follow-up started on month
37). We excluded beneﬁciaries who received a DXA,
had claim for osteopenia or osteoporosis, or had any
fracture during baseline to increase the likelihood that
the DXA received during follow-up was for screening
purposes. We divided the follow-up period into
6-month intervals; for each interval we calculated the
HDPS score using claims from the prior 12months;
we matched each beneﬁciary who received DXA
(index date: date of DXA receipt) in the interval to a
beneﬁciary who has not received DXA since start of
follow-up until index date. We compared the distribu-
tion of beneﬁciaries’ characteristics before and after
matching. We used Cox regression to assess the asso-
ciation between receipt of DXA and two outcomes,
hip fracture and all-cause mortality (censored if death
is preceded by a fracture within 30 days), in the origi-
nal and the matched cohort.
Results: The original cohort included 551,418 female
beneﬁciaries. Before matching, beneﬁciaries who
received DXA were younger and healthier than those
who did not receive DXA. After matching, characteris-
tics were balanced. The association between DXA and
hip fracture was attenuated from a hazard ratio (HR) of
0.58 (95% Conﬁdence Interval [CI]: 0.56-0.60) in the
original cohort to 0.77 (95% CI: 0.73-0.81) in the
HDPS-matched cohort; the HR for mortality was atten-
uated from 0.43 (95% CI: 0.42-0.43) to 0.60 (95% CI:
0.59-0.62).
Conclusions: Despite balanced characteristics after
HDPS matching, the association between DXA and
mortality exceeded that with hip fracture, indicative of
residual confounding.
487. On the Use of Propensity Score Method in
Case of Rare Exposure
DavidHajage,1 YannDe Rycke,3 Florence Tubach.2 1Epide-
miology and Clinical Research Department, Louis Mourier
Hospital, Assistance Publique-Hôpitaux de Paris (APHP),
Colombes, France; 2Epidemiology and Clinical Research
Department, Bichat Hospital, Assistance Publique-Hôpitaux
de Paris (APHP), Paris, France; 3Public Health Depart-
ment, Institut Curie, Paris, France.
Background: Observational studies led on large unse-
lected populations coming from medico-administrative
databases play a major role in pharmacoepidemiology.
Propensity score analyses are often used to take into
account confounding factors.
In post-marketing studies, the use of propensity
score methods could be difﬁcult, due to 1) the low
prevalence of exposure, and 2) the absence of signiﬁ-
cant confounders in the database, requiring additional
data collection for a large number of subjects.
Objectives: Simulation study comparing different
methods of subjects selection and analysis in the context
of non-interventional studies involving a rare exposure.
Methods:We simulated cohorts of 10000 subjects, with
varying prevalence of treatment (from 1% to 10%).
Treatment effect was evaluated on a time-to-event end-
point. Probability of exposure depends on a normally
distributed factor L which also affects event risk.
In each cohort, we applied 5 methods: naive
(Cox model without adjustment, method 1), multivar-
iate (adjustment for L, method 2) and propensity score
analysis (using inverse probability of treatment
weighting, method 3) of a representative sample of
the initial cohort, naive analysis after matching
(Cox model on exposed/non-exposed subjects
matched on L with varying threshold, method 4), and
propensity score analysis after matching (method 5).
Each method were applied to samples of increasing
size, to compare performances according to the number
of subjects requiring data collection for L.
Results: Propensity score analysis (method 3) is less
conservative than naive and multivariate analysis. Type
I error rate of method 4 is about 5 % whatever is the
sample size and prevalence, except for large matching
threshold. Method 5 was perfectly conservative even
in this situation. Analyses after matching are globally
more powerful than other methods. The propensity
score analysis of a representative sample was the most
biased method for low prevalence of exposure.
Conclusions: When the prevalence of exposure is
small, analyses of exposed/unexposed matched sub-
jects are unbiased and require less additional data
collection than analysis based on propensity score
applied to a representative sample of the initial cohort.
488. Marginal Structural Model Simulation: the
Effect of Omitting a Variable from the Outcome
Model When It Is Present in the Numerator Model
Alan R Ellis,1M Alan Brookhart.2 1Cecil G. Sheps
Center for Health Services Research, University of North
Carolina at Chapel Hill, Chapel Hill, NC, United States;
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2Department of Epidemiology, Gillings School of Global
Public Health, University of North Carolina at Chapel
Hill, Chapel Hill, NC, United States.
Background: Marginal structural models (MSMs)
are used to control for time-dependent confounding
by intermediate variables, which cannot be done
with standard regression models. The MSM litera-
ture is technical. A MSM simulation framework
would allow practical demonstration of MSM prin-
ciples and techniques, making MSMs accessible to
a wider audience.
Objectives: To develop a simple MSM simulation
template and use it to demonstrate an aspect of
MSM analysis.
Methods: SETTING: In a MSM, the denominator
model predicts the probability of the treatment received,
given baseline and time-dependent covariates. Observa-
tions are weighted by the inverse of this probability,
creating a pseudo-population in which treatment groups
are balanced on covariates. The numerator model can
include only baseline covariates, and also predicts the
probability of the treatment received. This probability
is multiplied by the inverse-probability-of-treatment
weight to create a stabilized weight. PROCEDURES:
We used the R programming environment to simulate
MSMs. First, we simulated a point-in-time treatment
using a logistic function of 3 continuous, normally
distributed covariates, x1-x3 (n = 1,000,000), and sim-
ulated an outcome as a Poisson function of covariates
and treatment. With all 3 covariates in the denomina-
tor model, we estimated stabilized weights in 3 ways:
(1) with no variables in the numerator or outcome
models, (2) with x2 in the numerator model but not
the outcome model, and (3) with x2 in both numera-
tor and outcome models. We repeated the simulation
using a longitudinal structure with 10 time points,
n = 100,000, and x2 as a time-varying confounder af-
fected by treatment.
Results: In the point-treatment and longitudinal scenar-
ios, treatment coefﬁcients for estimators 1, 2, and 3
were -0.5, -0.7, and -0.5, respectively (true value -0.5).
Conclusions: Only estimator 2, which omits a variable
from the outcome model when the variable is present
in the numerator model, is biased. Reports of MSM
analyses should conﬁrm that numerator variables were
included in the outcome model. Our simulation tem-
plate could be used to demonstrate other aspects of
MSM analysis.
489. Developing Alerting Thresholds for Active Drug
Safety Monitoring
Grace Wangge, Sebastian Schneeweiss, Robert J
Glynn, Joshua J Gagne. Pharmacoepidemiology and
Pharmacoeconomics, Brigham and Women Hospital/
Harvard Medical School, Boston, MA, United States.
Background: Current methods for active drug safety
monitoring focus on determining whether and when
to generate safety alerts indicating that a new drug
may be less safe than a comparator. Approaches are
needed to determine whether a new drug is less safer
than or equally safe as the comparator.
Objectives: To develop a framework for determining
which safety statements can be made about a new drug
andwhen they can bemade during prospectivemonitoring.
Methods: We developed a two-pronged approach to
establish alerting thresholds for active monitoring. First,
we adapted concept of setting non-inferiority (NI) mar-
gins for drug that has clinical trial data on safety outcome
and comparator of interest (“NI approach”). Second, we
summarized NI margins use in published randomized
trials(RCT) and reviewed publicly available data avail-
able on the US Food and Drug Administration’s website
to identify the type and magnitude of evidence used in
regulatory decisions involving withdrawals and black
box warnings between 2009 and 2013 (“benchmark
approach”). We applied the framework to a case study
of dabigatran vs. warfarin and major bleed.
Results: We provide formulas on both risk difference
(RD) and risk ratio (RR) for the NI approach that are anal-
ogous to NI margin setting in efﬁcacy trials, with thresh-
old based on the point estimate rather than the conﬁdence
intervals and using a maximum tolerable increase rather
than a preservation factor. For the benchmark approach,
the mode NI margin used in RCTs was RD 0.10 (range
0.01 to 0.80) and for RR was 1.25 (range 1.10 to 2.00).
Severe outcomes used lower range of values. The range
of point estimates used in black box warning and with-
drawal decisions was larger (RR 1.18 -7.30). Using the
NI approach to establish safety threshold for dabigatran,
we obtained an RR threshold of 1.51. Synthesizing cur-
rent post-marketing studies of dabigatran vs. warfarin
and the threshold indicated that dabigatran is as safe as
warfarin with respect to major bleed.
Conclusions: The proposed framework may be useful
for emerging active drug safety monitoring systems as
it expands the scope of safety statements that can be
made in such a system.
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490. Cognitive Health, Willingness to Live, and
Social Support but Not Physical Function May Be
the Source of Healthy User Bias
Soko Setoguchi,1 Lauren Williams,2 Chih-Ying Chen,3
Monera Wong,4 Melissa Clard,5 Winson Cheung,6 Edward
Chia-Cheng Lai.1,7 1Duke Clinical Research Institute,
Durhan; 2Brigham and Women’s Hospital, Boston;
3Massachusetts General Hospital, Boston; 4Brown Uni-
versity, Providence; 5British Columbia Cancer Agency,
Vancouver; 6Cheng Kong University, Tainan.
Background: One of the biggest threats to the validity
in observational comparative effectiveness research
(CER) for preventive medications and vaccines is
healthy user bias. Similar bias, namely healthy candi-
date bias has been observed in CER for assessing the
clinical effectiveness of implantable cardioverter
deﬁbrillators (ICDs) in heart failure (HF) patients.
Objectives: To assess if social, psychological, and
physical factors that are known to predict outcomes
in older patients are associated with preferences for
therapies in HF.
Methods: We identiﬁed ambulatory patients (age≥ 65)
from a community hospital and a tertiary care center,
who completed a structured survey asking their prefer-
ence to receive HF therapies, oral medication vs. ICD
after receiving information about HF and risk-beneﬁt
of therapies. We extracted demographic and comorbid
information from medical records. Factors associated
with frailty and worse outcomes in older HF patients in-
cluding physical and cognitive health, social support,
and willingness to live were assessed using validated
instruments, e.g., SF-12. We used modiﬁed Poisson
regression to assess the relationship between the
willingness to receive a therapy and these factors.
Results: Among 153 patients (52% female, 90% white,
mean age 76), the mean score (range) for physical func-
tion, cognitive health, social support and willingness to
live was 44 (0-100), 54 (0-100), 27 (7-35), and 4 (1-5).
When asked about preferences for therapies, 4% vs.
13% responded ‘not at all likely’ to receive medications
vs. ICDs. After adjusting for demographic, socioeco-
nomic, and comorbid factors, lower scores for cognitive
health (RR 0.94; 95% CI, 0.91-0.98), willingness to
live (RR 0.57; 0.43-0.76), and social support (RR
0.93; 0.88 -0.98) were associated with ‘not at all likely
to receive ICDs but physical function score was not
(RR 1.00; 0.96 -1.03). We found no association between
these factors and willingness to receive medications.
Conclusions: These social and psychological factors
are generally unmeasured in databases and likely to
be the source of healthy candidate bias in CER for
devices vs. medications.
491. Value of Information Methods for Choice of
Study Design
Drew G Levy,1 David C Norris.2 1Evidence Science &
Innovation--U.S. Medical Affairs, Genentech, Inc., South
San Francisco, CA, United States; 2David Norris Con-
sulting, LLC, Seattle, Washington, United States.
Background: Various study design options have
different information value (relevance, bias, precision,
timeliness) and cost proﬁles. Their relative ability to
contribute actionable evidence also depends on the spe-
ciﬁc scientiﬁc question, data quality, and characteristics
of the decision the study is intended to inform. Value of
information (VoI) methods have been proposed as a
systematic decision-analytic approach to choosing
study design, but methodologic and computational
challenges have been an obstacle for real-life problems.
Objectives: To provide an example of applied VoI-
based methods for choosing between study designs
using relative reduction in uncertainty as the utility
index for comparison.
Methods: We develop VoI in the framework of deci-
sion analysis. Epidemiologic and clinical processes
underlying populations are speciﬁed based on subject
matter knowledge and a simulated target population
generated. Realistic sampling of patients into various
study designs (e.g., RCTs, registries, EHRs) is
modeled, including consideration of issues such as
data quality, confounding by indication, applied analy-
sis methods, etc. The response variable most relevant
to effective decision making is carefully speciﬁed
and a parameterized prior distribution used to charac-
terize the uncertainty (relative credibility of values of
response) before new data are collected. Iterative sam-
pling of the source population for each candidate study
design is used to generate marginal expectations of
results from each design. The prior distribution is
updated with marginal summary of study results to
estimate a “posterior” distribution. The expected
reduction in uncertainty with new information is
compared among candidate designs.
Results: The prior distribution of the response and the
posterior distributions resulting from new information
from candidate study designs are represented graphically.
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The relative reduction in uncertainty and correspondence
to the true parameters in the simulation is assessed.
Conclusions: Formal quantitative decision analysis
based on expected VoI of various study designs is fea-
sibly practical and may support cost-effectiveness
evaluation of potential evidence generation with real
world data.
492. Outcomes of Outpatient Integrated Medical
Care Services across Times in a Medical Center
Hsiang-Wen Lin,1,2 Chih-Hsueh Lin,3 Chin-Kan Chang,4
Che-Yi Chou,6 Pin-Ting Chao,1 Chia-Nuan Hsu,5 Ling-Yu
Chang,5 Yow-Wen Hsieh,1,2 Jui Sung Hung,6 Wen-Liang
Huang,5,6 Der-Yang Cho.7 1Department of Pharmacy,
China Medical University Hospital, Taiching, Taiwan;
2School of Pharmacy and Graduate institute, ChinaMedical
University, Taichung, Taiwan; 3Department of Family
Medicine, China Medical University Hospital, Taichung,
Taiwan; 4Department of Rehabilitation, China Medical
University Hospital, Taichung, Taiwan; 5Department of
Medical Quality, China Medical University Hospital,
Taichung, Taiwan; 6Department of Internal Medicine,
China Medical University Hospital, Taichung, Taiwan;
7Department of Neurosurgeon, China Medical Univer-
sity Hospital, Taichung, Taiwan.
Background: The majority of patients with multiple
chronic diseases tended to visit single hospital persis-
tently, which accounted for 3.5% of all beneﬁciaries
and 19.3% of covered national health insurance
expenses in Taiwan.
Objectives: The aim of this study was to examine the
outcomes change across time in 2013 after
implementing the Integrated Medical Care (IMC) ser-
vices for loyal outpatients.
Methods: Among the listed 3271 patients, who were
loyal health care users with multiple chronic illnesses
and selected by National Health Administration, were
involved in IMC services in China Medical Univer-
sity hospital (CMUH) since April 2013. Such IMC
services were established to offer the patient-centered
integrated, geriatric and/or pharmaceutical care
clinics, in addition to via usual primary and specialty
clinics, in the outpatient units via clnical practitioners
since 2010. The outcomes, i.e., changes of outpatient
medical expenditure, number of outpatient visit,
emergency department (ED) visits, inpatient visits
(IP) and number of prescribed medication (Rx) in
CMUH across months in 2013, were examined to
compare with the ﬁrst month of implantation (April)
using nonparametric analysis approaches and time
series analysis.
Results: The changes of medical expenditures, number
of outpatient visits and Rx per person per month were
statistically signiﬁcant different (e.g., decreasing in
June, September and increasing afterward) and rela-
tively less, while comparing to that in April in 2013.
However, the numbers of IP and ED visits were not
statistically signiﬁcant different across months.
Conclusions: The change patterns of outcome indica-
tors across months in 2013 were various, while the
trends of total medical expenditures, number of outpa-
tient visit and prescribed medications were similar but
relatively less than that in April. Further evaluation for
such trends would be helpful to broadcast the changes
in 2014 whenever the IMC services are continuously
implemented in CMUH.
493. ENCePP-HTAWorking Group 2014 Survey of
Members Experience in Conducting Research to
Support HTA
Kevin Blake,1 Massoud Toussi,2 Xavier Kurz,1 Yvonne
Lis,3 Vera Ehrenstein,4 Nawab Qizilbash,5 Nicholas
Moore.6 1For the ENCePP-HTA Working Group
European Medicines Agency, London, United Kingdom;
2IMS Health, Paris, France; 3Parexel, London, United
Kingdom; 4Aarhus University Hospital, Aarhus,
Denmark; 5Oxon Epidemiology Ltd, London, United
Kingdom; 6University of Bordeaux, Bordeaux, France.
Background: The European Network of Centres
for Pharmacoepidemiology and Pharmacovigilance
(ENCePP) was established in 2007 by the European
Medicines Agency (EMA) in collaboration with
experts to further strengthen the post-authorisation
monitoring of the safety of medicinal products.
Capacity building is a key aspect of how this is
achieved. With the growing interest in incorporating
Health Technology Assessment (HTA) related
outcomes into post-authorisation studies (PAS), an
HTA working group (WG) of ENCePP has been
established. The mandate of this group includes
exploring capacity building for the conduct of studies
that meet the needs of regulators and HTA bodies.
Objectives: To report the results of a survey con-
ducted in Q2 2014 which determined speciﬁc aspects
of the competency of individual ENCePP centres to
conduct PAS that include HTA outcomes. The
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compiled results from individual centres on compe-
tence show capacity at a European level.
Methods: The survey sought to identify HTA research
experience and potentially relevant resources available
to accommodate the inclusion of HTA outcomes in
PAS, associated training needs and capacity. The
target audience were more than 200 researchers on
the ENCePP mailing list.
Results: The results of the survey are reported. They
will be of value in mapping current capacity to con-
duct research to support HTA and deﬁning needs for
further expansion. The responses will serve to assess
how the ENCePP Research Resources Database might
be updated to reﬂect the competencies of individual
centres. The results may also form the basis for the
development by the WG of a considerations paper on
practice in conducting PAS, e.g. in the form of dedicated
registries, that include HTA and drug safety outcomes
with a view to either developing a stand-alone good
practice guidance or integrating into existing guidance.
Conclusions: The ENCePP-HTA WG survey is a
unique collaborative exercise in mapping European ca-
pacity to undertake research that meets the requirements
of regulatory and HTA stakeholders. It will serve to un-
derpin further efforts of the group in terms of potentially
providing methodological insights into such research.
494. Medication Safety Improvement in Patients
Transferred from Emergency Room to Medical
Wards by Initiating Medication Reconciliation
Chia-Lin Lin,1 Chi-Hui Lee,1 Chin-Lon Lin,2,3 Ning-
Sheng Lai,4 Mei-Hua Chuang.1 1Department of Phar-
macy, Buddhist Dalin Tzu Chi General Hospital, Chiayi,
Taiwan; 2College of Medicine, Tzu Chi Univerity,
Hualien, Taiwan; 3Deparment of Cardiology, Buddist
Tzu Chi General Hospital, Hualien, Taiwan; 4Department
of Allergy, Immunology, and Rheumatology, Buddhist
Dalin Tzu Chi General Hospital, Chiayi, Taiwan.
Background: Medication reconciliation is one of best
methods used by pharmacists to collect the complete
medication proﬁles for patients. Studies showed that
prescriptions inconsistence occurred when patients were
transferred from one health care unit to another.To
improve patients’ medication safety, medication recon-
ciliation conducted by pharmacists is necessary.
Objectives: To improve patients’medication safety, medica-
tion reconciliationwas initiated at a regional teaching hospital.
Methods: This study was conducted at a regional teach-
ing hospital in Taiwan from August to November of
2013. The data from pharmaceutical care evaluation
forms from April to July of 2013 was used as the
control. Medication reconciliation was initiated for
patients admitted to medical wards from emergency
room. Pharmacists checked all prescriptions (including
formulary and non-formulary) took by patients from
hospital information system (HIS) before and after ad-
mitted. In addition, drug-drug interactions were evalu-
ated by comparing information through SQL database.
Results: A total of 30 prescription inconsistence was
caught by pharmacists after initiating medication
reconciliation. Interventions by pharmacists due to
inappropriate prescriptions were also increased from
1.4% to 2.8% (n = 52 vs. 98; p = 0.007). Types of
inappropriate prescriptions (before vs. after) were
duplicated therapy 9.6% vs. 21.4% (n = 5 vs. 21),
contraindicated uses 17.3% vs. 15.3% (n= 9 vs. 15), in-
correct dosages 17.3% vs. 15.3% (n= 9 vs. 15), drug-
drug interactions 17.3% vs. 12.2% (n= 9 vs. 12), and
incorrect dosage forms 19.2% vs. 8.2% (n= 10 vs. 8).
Conclusions: Results showed that initiation of medi-
cation reconciliation can improve safety uses of medi-
cations in patients who were transferred to different
health care units. Moreover, pharmacists were more
alerted to the inappropriate prescriptions and more
interventions were then performed. In the future, inte-
grations of patient counseling and follow-up tracking
system with HIS can make medication reconciliation
more effective used by pharmacists.
495. The Effectiveness Evaluation of Lasix, Albumin,
and Both Used in Liver Disease Patients with Ascites
Chiu-Ju Chen,1 Hey-Yu Wang.2 1Department of
Pharmacy, Chi-Mei Hospital, Tainan; 2Department of
Pharmacy, Chi-Mei Hospital, Tainan.
Background: Ascites is the most important complica-
tion of patients, the symptoms of liver diseases.
Diuretics like lasix are better choice to reduce ascites.
Objectives: The purpose of this study was to investigate
lasix, albumin, and both used in patients with liver dis-
ease syndrome, and comparing their serum concentration
of potassium, sodium, creatinine, albumin, and eGFR, in
order to assess the situation ascites improvement.
Methods: In a randomized clinical trial, were randomly
divided into four groups to select and seven cases of
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liver syndrome. Three treatment options are selected,
and at the end, each patient underwent three randomized
protocol. Non-parametric tests and analysis of data to be
collected and used SPSS statistical software.
Results: The differences in serum concentration of
potassium before and after administration of lasix, albu-
min, and both used were -0.51 ± 0.798, -0.85 ± 1.452,
and 0.34 ± 0.931, respectively; the differences in serum
concentration of sodium were 3.67 ± 4.267, -
18.72 ± 53.504, and -3.04 ± 5.765, respectively; the
differences in serum concentration of creatinine were -
0.79 ± 1.887, -0.22± 1.616, and -0.74 ± 3.159, respec-
tively; the differences in serum concentration of albumin
were 0.04± 0.350, -0.61± 0.773, and -0.63 ± 0.281,
respectively; the differences in serum concentration of
eGFR were 2.71 ± 13.067, 3.86 ±11.227, and -
4.17 ± 8.771, respectively, in the three therapy groups.
Conclusions:Our study showed that albumin for liver dis-
ease syndrome patients with ascites and no signiﬁcant im-
provement. However, lasix has signiﬁcantly improved.
Therefore, it is recommended that liver disease syndrome
patients with ascites do not use the high-priced of albumin.
496. Accounting for Treatment Complexity in Pro-
pensity Score Estimation: Case Study From T2DM
Mary E Ritchey,1 Yong Chen,1 Michele L Jonsson
Funk,2 Kimberly G Brodovicz.1 1Merck & Co.,
Whitehouse Station, NJ, United States; 2University of
North Carolina, Chapel Hill, NC, United States.
Background:Many patients with chronic diseases, in-
cluding type 2 diabetes (T2DM), require combination
therapy as the disease progresses. A comparison of
patients initiating a new medication does not typically
account for heterogeneity in treatment complexity.
Objectives:We evaluated typical, new user cohorts of
sitagliptin (sita) or non-DPP4 therapy compared to
new user cohorts stratiﬁed by treatment complexity
(mono-, dual or triple therapy).
Methods: We identiﬁed patients with T2DM initiat-
ing/augmenting therapy in 2006-2012 in US claims
(MarketScan). We estimated the probability of receiv-
ing sita as a function of demographic/clinical charac-
teristics in the total population and stratiﬁed by
treatment complexity. We evaluated covariate balance
via standardized differences (sd) and average standard-
ized absolute mean difference (ASAMD). We repeated
analyses in CPRD general practice data.
Results: We identiﬁed 773,752 eligible patients
(6.7% initiated sita); 68% with mono-, 22% dual,
and 10% triple therapy. Over 90% with sita could be
matched to non-DPP4 users. There was more sita use
with increasing treatment complexity. In the com-
bined cohort, ASAMD was initially 0.079 and de-
creased to 0.005 upon matching. Ten covariates had
sd 10%-51%; all were ≤2% after matching. Stratiﬁed
by complexity, sita and non-DPP4 users were more
similar before matching in the dual and triple therapy
cohorts (ASAMD 0.041 and 0.023, respectively).
Maximum sds were 16% and 6%, respectively.
Matching decreased ASAMD to 0.020 and 0.013, re-
spectively. Modest imbalance in the monotherapy
group (ASAMD= 0.108) improved with matching
(0.035). CPRD produced similar results for dual and
triple therapy and had too few initiators of sita mono-
therapy to obtain stable estimates.
Conclusions: Conditioning on treatment complexity
alone improved covariate balance in patients receiving
dual or triple therapy. Matching led to balance of char-
acteristics across treatment groups. Patients with T2DM
are heterogeneous and considering treatment complex-
ity may assist with confounding adjustment. Further
evaluation is needed with otherdiseases to note whether
treatment complexity warrants subgroup analysis.
497. A Propensity Score Matched Cohort Study to
Measure the Effects of Orlistat or Bariatric Surgery
on Health Outcomes in a General UK Population
Sample
Ian J Douglas,1 Krishnan Bhaskaran,1 Rachel L
Batterham,2 Liam Smeeth.1 1Non-Communicable Disease
Epidemiology, London School of Hygiene & Tropical
Medicine, London; 2Faculty of Medical Sciences, University
College London, London.
Background: The effectiveness of currently available
treatments for obesity on important health outcomes is
not well deﬁned.
Objectives: To measure the effect of bariatric surgery
or treatment with orlistat, on the risk of developing
type 2 diabetes, diabetes resolution, hypertension, car-
diovascular disease, fractures, cancers and obstructive
sleep apnoea.
Methods: We used electronic healthcare records from
the United Kingdom Clinical Practice Research
Datalink (CPRD). All patients with a record of bariat-
ric surgery or a prescription for orlistat, and with at
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least 12months prior registration (to ensure the treat-
ment was incident) were included. Propensity score
matching was used to match each patient receiving
orlistat or bariatric surgery to the patient with the
nearest score with no intervention. Cox regression
was used to estimate hazard ratios and 95% conﬁdence
intervals for each outcome.
Results: We identiﬁed 3,078 patients undergoing
bariatric surgery (median age 45y, 81% female, median
BMI 44.6kg/m2), and 100,701 receiving orlistat (median
age 46y, 76% female, median BMI 37.2kg/m2). Mean
follow time post intervention was 1.9 years for bariatric
surgery patients and 4.9years for patients receiving
orlistat. For hypertension, the HRs were 1.06 (1.03-1.10)
for orlistat vs untreated controls and 0.36 (0.27-0.49) for
bariatric surgery vs untreated controls. For commencing
ﬁrst oral antidiabetic treatment HRs were 1.19 (1.15-
1.24) for orlistat and 0.17 (0.11-0.25) for bariatric surgery.
Further results will be presented at the meeting for the
other outcomes listed.
Conclusions: Whilst bariatric surgery patients had a
reduced risk of developing hypertension or starting
treatment with an oral antidiabetic drug, there was
no evidence that orlistat protected patients from
these outcomes. Our results will help quantify the ef-
fects of widely used obesity treatments on important
clinical outcomes.
498. Indirect Comparison of Meta-Analysis Find-
ings on Adverse Treatment Outcomes: Impact of
Trial Heterogeneity and Effect Measure Selection
Aaron J Katz,1 Michael A Kelsh,1 Bin Yao,2 Dominik D
Alexander,3 Deborah Arrindell,4 Douglas L Weed.5
1Center for Observational Research, Amgen, Inc.,
Thousand Oaks, CA, United States; 2Puma Biotechnology,
Los Angeles, CA, United States; 3Exponent, Boulder,
CO, United States; 4Global Safety, Amgen, Inc., Thousand
Oaks, CA, United States; 5DLW Consulting Services,
LLC, Salt Lake City, UT, United States.
Background: Trial heterogeneity and effect measure
selection may affect conclusions drawn from indirect
comparisons of two or more treatments.
Objectives: To provide an empirical example of an
indirect comparison of adverse events between two
treatments whereby trial heterogeneity contributes to
rank reversal of treatment effect size such that choice
of effect measure inﬂuences decisions made about
the comparison.
Methods: We re-analyzed data from an indirect com-
parison of the risk of hypomagnesemia between two
anti-epidermal growth factors (EGFR), cetuximab
and panitumumab; the original study estimated meta-
risk ratios (meta-RRs) of hypomagnesemia using any
grade or grade 3-4 events reported in Phase III
randomized clinical trials for cetuximab (n = 8) and
panitumumab (n = 4). We calculated additional pooled
effect estimates including: 1) meta-risk differences
(meta-RDs) using the Mantel Haenszel ﬁxed-effects
model; 2) meta-RRs and meta-RDs restricting to grade
3-4 events; and 3) meta-RRs and meta-RDs further
restricting to colorectal cancer trials.
Results: Risk of any or grade 3-4 hypomagnesemia in
control and treatment arms varied noticeably across
trials; average risks in cetuximab and panitumumab
trials were 4.9% and. 1.1% in control arms and
19.2% and 17.2% in treatment arms, respectively.
Using these original risk estimates, rank reversal of
treatment effect size was observed; meta-RRs for
cetuximab and panitumumab were 3.87 and 12.55
while meta-RDs were 14.8% and 12.7%, respectively.
Rank reversal was not observedwhen trial characteristics
were more similar across treatments. Restricting to grade
3-4 events, meta-RRs for cetuximab and panitumumab
were 8.96 (95% CI, 4.68 to 17.16) and 17.04 (95% CI,
6.93 to 41.88) and meta-RDs were 4.5% (95% CI, 3.4
to 5.7) and 4.4% (95% CI, 3.4 to 5.4), respectively; fur-
ther restricting to colorectal cancer trials yielded
comparable results.
Conclusions: This empirical example highlights the
need for caution and careful evaluation of trial hetero-
geneity and effect measure selection when making in-
direct treatment comparisons including meta-analysis
of adverse events.
499. Comparative Effectiveness of Contemporary
Adjuvant Chemotherapy Options among Older Rectal
Cancer Patients
Jennifer L Lund,1 Hanna K Sanoff,2 Til Sturmer.1 1De-
partment of Epidemiology, University of North Carolina
at Chapel Hill, Chapel Hill, NC, United States; 2Depart-
ment of Medicine, University of North Carolina at
Chapel Hill, Chapel Hill, NC, United States.
Background: Guidelines for stage II and III rectal
cancer in the US recommend neoadjuvant chemoradi-
ation therapy (CRT), curative resection, and adjuvant
chemotherapy. This paradigm is based on early trials
without neoadjuvant CRT and extrapolations from
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colon cancer. Recent trials question whether adjuvant
chemotherapy decreases all-cause mortality in patients
treated with neoadjuvant CRT, and comparative
effectiveness studies of adjuvant chemotherapy in real
world rectal cancer patients is lacking.
Objectives: We examined whether adjuvant chemo-
therapy decreased all-cause mortality among a
contemporary cohort of older rectal cancer patients in
the US.
Methods: We identiﬁed a population-based cohort of
1,431 older (66+ years) non-metastatic rectal cancer
patients diagnosed from 2004-2009 using the Surveil-
lance, Epidemiology and End Results program
(SEER)-Medicare data, who underwent neoadjuvant
CRT or RT and surgery. Patterns of adjuvant chemother-
apy were described using binomial regression models
and the comparative effectiveness of: 1) any adjuvant
chemotherapy vs. no adjuvant chemotherapy and 2)
adjuvant oxaliplatin + 5-ﬂuorouracil (5-FU)/capecitabine
vs. 5-FU/capecitabine on all-cause mortality was
evaluated using Cox proportional hazards models after
propensity score (PS) matching.
Results: In total, 744 patients (52%) received adjuvant
chemotherapy; most were treated with oxaliplatin
(53%). Older age, lower stage, and being widowed
were associated with lower propensity for adjuvant
chemotherapy. After PS matching, adjuvant chemo-
therapy was associated with decreased mortality
(adjusted hazard ratio (aHR) = 0.71, 95% conﬁdence
interval (CI): 0.57, 0.89). Among patients receiving
adjuvant therapy, older age, earlier diagnosis year,
lower stage, and higher census tract poverty were asso-
ciated with lower propensity for oxaliplatin. The addi-
tion of oxaliplatin to 5-FU/capecitabine did not reduce
mortality after PS matching (aHR= 1.15, 95% CI:
0.78, 1.70).
Conclusions: Our results suggest that older non-metastatic
rectal cancer patients beneﬁt from adjuvant chemotherapy;
however, the addition of oxaliplatin may not provide
incremental beneﬁts.
500. Reduced Mortality in Thai Peritoneal
Dialysis Patients Using Angiotensin-Converting
Enzyme Inhibitors or Angiotensin Receptor Blockers:
A Propensity Score Analysis
Surapon Nochaiwong,1 Chidchanok Ruengorn,2 Setthapon
Panyathong,3 Yuraporn Kaisuwan,4 Sirisak Nanta.5 1De-
partment of Pharmaceutical Care, Faculty of Pharmacy,
Chiang Mai University, Chiang Mai, Thailand; 2De-
partment of Pharmaceutical Care, Faculty of Phar-
macy, Chiang Mai University, Chiang Mai, Thailand;
3Nephrology Unit, Nakornping Hospital, Chiang Mai,
Thailand; 4Nephrology Unit, Nakornping Hospital,
Chiang Mai, Thailand; 5Maesai District Hospital,
Chiang Rai, Thailand.
Background: Evidence suggests angiotensin-conv-
erting enzyme inhibitors (ACEIs) or angiotensin
receptor blockers (ARBs) may extend life in hemodi-
alysis patients. Whether such beneﬁt applies in perito-
neal dialysis (PD) is unclear in Thailand where most
ESRD patients (59%) use PD.
Objectives: Compare all-causes and cardiovascular
(CV) mortality, and safety, for ACEIs/ARBs users
and non-users on PD.
Methods: Subjects age ≥18 y with ﬁrst-ever PD of
≥3m from 2007-01-01 to 2012-07-31 were analyzed
in a retrospective cohort of the PD registry of
Nakornping Hospital, Chiang Mai, Thailand. Users of
ACEIs/ARBs of ≥3m were compared only to non-users.
Incidence density mortality per 1,000 patient-months
(1kp-m) was derived. Logistic regression of possible-
confounding factors at PD initiation--i.e. body mass
index, age, Charlson co-morbidity index, estimated
Glomerular Filtration Rate (eGFR), blood pressure,
serum potassium--resulted in propensity scores
predicting ACEIs/ARBs use, to control for time-
to-mortality by Cox hazard regression.
Results: Of 350 PD patients, 122 (34.9 %) received
ACEIs/ARBs. Follow-up was shorter in ACEIs/ARBs
users, 16.1m median (range 3.0-70.0) vs. 28.1m
(4.1-73.1). Both groups did not differ on entry eGFR
(5.4 vs. 5.6mL/min/1.73m2) and serum albumin
(3.3 vs. 3.3mg/dL).
All-causes crude mortality was signiﬁcantly lower in
ACEIs/ARBs users (7.9 per 1kp-m [95%CI 5.54-11.34])
vs. non-users (19.5 [15.8-24.10]). Survival (75th %ile)
was 38.0m (95%CI 23.0-49.0) in users vs. 15.0m
(10.0-18.5) in non-users. By adjusted hazard ratio
(HR), users had signiﬁcantly reduced all-causes mor-
tality (p = 0.001): HR 0.43 (95%CI 0.26-0.73), and
CV mortality (p =0.009): HR 0.24 (0.08-0.70).
Hyperkalemia was not more frequent in users
(33.9%) vs. non-users (35.0%). Erythropoietin re-
sistance caused by ACEIs/ARBs was not demon-
strated by frequencies of anemia requiring blood
transfusion -- 31.3% in users vs. 36.3% in non-
users (p = ns).
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Conclusions: ACEIs/ARBs appeared to decrease all-
causes and CV mortality in Thai PD patients, with
no obvious adverse effects.
501. Incidence of Diabetes Complications in Patients
on Insulin Analogues Against Those on Human
Insulin
Rosa Gini, Giuseppe Roberto, Francesco Cipriani,
Giuseppe Seghieri, Paolo Francesconi, Francesco Lapi.
Epidemiology, Regional Agency for Healthcare Services
of Tuscany, Florence, Italy.
Background: Insulin analogues (IA) possess beneﬁt
relative to human insulins (HI) in terms of glycemic
control. Little is known about the effect of IA vs. HI
in reducing the risk of long-term cardiovascular and
metabolic complications of diabetes.
Objectives: To assess the risk of diabetes-related
cardiovascular and metabolic complications associated
with IA against HI.
Methods: A nested case-control study was conducted
in Tuscany (Italy) using administrative databases. All
subjects who received an incident insulin prescription
(entry date) between January, 1, 2005 and December,
31, 2011 were followed until December, 31, 2012.
Outcomes were diabetes-related complications
(e.g., stroke, nephropathy, disglycemia), and subjects
who had registered an outcome before entry date
were excluded from the cohort. Subjects with less
than 1year of follow-up were excluded as well.
Cases were subjects who developed an outcome
during follow-up (index date). Up to 3 controls
were randomly selected for each case from the co-
hort after matching on sex, age (±5 years), entry
date (±3months) and duration of follow-up. The
date of the risk set was the index date for the
controls. Odds Ratio (OR), and 95% conﬁdence
interval (CI) of diabetes complications associated with
current use (within 1 year prior to the index date) of
IA versus HI was estimated by conditional logistic
regression after adjustment for selected comorbidities
(e.g. hypertension, other drugs for diabetes).
Results: Incidence rate of diabetes complications was
4.3 per 100 person-years at risk in the cohort of 6339
insulin new users, from which 817 cases and 2291
matched controls were identiﬁed. The average fol-
low-up time was 1.8 years (SD: 1.4). Compared with
HI users, OR and 95% CI was 0.88 (0.66 to 1.67),
1.20 (0.85 to 1.68) among IA or switchers,
respectively. These results were conﬁrmed when IA
users and users of different combinations (i.e., fast-acting
IA plus long-acting HI) were compared with HI users.
Conclusions: These results do not support a clinical
beneﬁt of treatment with IA versus traditional HI in
terms of cardiovascular and metabolic complications.
502. Radiographic and Endoscopic Diagnostic
Workup around Initiation of Oral Bisphosphonates
Xiaojuan Li,1 Yong Chen,2 Mugdha Gokhale,1 Julie
Chandler,2 Annie McNeil,2 Cynthia J Girman,2 Til
Stürmer.1 1Epidemiology, University of North Carolina,
Chapel Hill, NC, United States; 2Epidemiology, Merck
Sharp & Dohme Corp, North Wales, PA, United States.
Background: Use of oral bisphosphonates (OBs) has
been implicated with an elevated risk of esophageal
cancer in a 2009 US FDA case report. However,
results from subsequent studies evaluating the risk
have been conﬂicting. Gastrointestinal effects includ-
ing gastroesophageal reﬂux, a side effect of OBs,
may lead to differential diagnostic workup among
initiators of OBs and to differential detection of
preclinical esophageal cancer.
Objectives: To compare differences in diagnostic
workup including endoscopy and chest X-rays among
initiators of OBs and raloxifene (RA) before and
after initiation.
Methods: We used 2007-2013 Humana data to iden-
tify cohorts of initiators of OBs or RA who had Medi-
care Advantage Plans. Eligible new users were ≥66 at
initiation, continuously enrolled in Humana for ≥1
year, and had no claims for OBs or RA in the prior
6months. Monthly risks of diagnostic workup in the
two groups were compared using age, sex and race ad-
justed risk differences. Hazards of diagnostic workups
in the 6months post initiation were compared using
Cox proportional hazard models with standardized
mortality ratio weighting.
Results: There were 171,220 and 17,759 initiators of
OBs and RA, respectively. Compared with RA, OB ini-
tiators were older (74.4 [SD=5.9] vs. 73.4 [SD=5.7]),
more likely to have had a diagnosis of osteoporosis
(57.1% vs. 42.7%) and comorbid conditions, but less
likely to have had gastroesophageal reﬂux disorder
(20.6% vs. 22.8%). We observed only a small
adjusted monthly difference in X-rays and no adjusted
monthly difference in endoscopies between OBs and
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RA initiators in the 6months pre and post initiation.
The difference (%) for endoscopies was most
pronounced in the third month pre initiation -0.21
(95%CI: -0.33, -0.09). The adjusted hazard ratio of
diagnostic workups in the 6months post initiation
was 0.98 (95%CI: 0.85, 1.13) for endoscopies and
1.02 (95%CI: 0.94, 1.10) for X-rays.
Conclusions: Though we did not see evidence for
relevant differential diagnostic workup in this setting,
there was evidence for confounding which may
decrease validity in studies comparing OBs and RA
if not appropriately accounted for.
503. Using Refill Information to Improve the Perfor-
mance of Preference-Based Instrumental Variables
Jane S Der,1M Alan Brookhart,1 Cathy Critchlow,2
Vamshidar Goli,1,2 Fei Xue.2 1Epidemiology, University
of North Carolina, Chapel Hill, NC, United States;
2Center for Observational Research, Amgen, Inc.,
Thousand Oaks, CA, United States.
Background: Reﬁll information is available in many
U.S. insurance claims databases and could be used to
better determine incident medication use. Restricting
to new prescription (Rx) ﬁlls may affect the identiﬁca-
tion of physicians’ Rx preference as an instrumental
variable (IV) since new Rxs rather than reﬁlls would
be indicative of prescribing decisions.
Objectives: To evaluate the inﬂuence of reﬁlls on the
strength and assumptions of physician-preference IVs
in assessing the association between bisphosphonate
(BP) vs. other osteoporosis (OP) medications and the
risk of osteoporotic fracture (Fx) in women with
post-menopausal OP.
Methods: Women ≥55 years old initiating a BP or
other OP medication (index treatment) were identiﬁed
in the United Healthcare database (2008-11) and
followed for incident osteoporotic Fx. The IV was
deﬁned by the prescribing physician’s preference
(BP vs. other), characterized by last ﬁlled Rx (day IV) or
proportion ofﬁlledRxs during baseline (year IV). Assump-
tions of the IV method including the strength of the IV (its
association with the index treatment and osteoporotic Fx),
balance of baseline covariates across levels of the IV, and
heterogeneity of treatment effect were evaluated. Analyses
were conducted with and without index Rx reﬁlls.
Results: After restricting to new Rx ﬁlls, sample size
decreased by 4% for the day IV and by 2% for the year
IV. IV strength (95% CI) on the relative scale decreased
from 3.29 (3.05, 3.55) to 2.95 (2.73, 3.19) for the day
IV, and increased from 3.10 (2.89, 3.32) to 3.30 (3.07,
3.54) for the year IV. The IV strength (95% CI) on the
absolute scale was higher for the day IV at 0.17 (0.16,
0.19) and 0.16 (0.14, 0.17) than the year IV at 0.15
(0.14, 0.16) and 0.15 (0.14, 0.16) with or without reﬁlls,
respectively. Excluding reﬁlls yielded slight changes
when evaluating the assumptions of the IVs.
Conclusions: We found minimal differences in the
strength of the IVs and the evaluation of the IV
assumptions between analyses that included or ex-
cluded reﬁlls. The implications of reﬁll variables for
identifying preference-based IVs need to be further
evaluated in other therapeutic areas and populations.
504. The Impact of Insulin Glargine vs. Human
Insulin Use on Cancer Incidence
Anne S Geier,1 Ina Wellmann,1 Jürgen Wellmann,1 Jessica
M Franklin,2 Hiltraud Kajüter,3 Oliver Heidinger,3 Georg
Hempel,4 Hans-Werner Hense.1,3 1Institute of Epidemiol-
ogy and Social Medicine, Westfälische Wilhelms-
Universität Münster, Münster, Germany; 2Department of
Medicine, Brigham and Women’s Hospital, Havard
Medical School, Division of Pharmacoepidemiology and
Pharmacoeconomics, Boston, MA, United States;
3Epidemiological Cancer Registry of North Rhine-West-
phalia, Münster, Germany; 4Institute of Pharmaceutical
and Medical Chemistry, Westfälische Wilhelms-Universität
Münster, Münster, Germany.
Background: Several studies investigating the associ-
ation between insulin glargine and cancer risk reported
heterogeneous results, resulting in debates on study
design and analysis ﬂaws.
Objectives: Our study aimed to contribute to prior ev-
idence by applying robust pharmaco-epidemiological
principles to assess the impact of insulin glargine use
on tumor progression.
Methods: We used data from a disease management
programme for type 2 diabetes mellitus (DMP-DM2) to
identify cohorts of prevalent and ﬁrst-time users of insu-
lin glargine and human insulin and incident cancer cases
from a population-based cancer registry between 2003
and 2009. We matched insulin glargine users to up to
four human insulin users based on diabetes duration
and time from DMP-DM2 enrollment to treatment
start (+/-180 days) and estimated HRs using propen-
sity score weighted Cox proportional hazards models.
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We analyzed follow-up time a) in an as treated (AT)
approach censoring for a new insulin therapy start or
therapy discontinuation and b) an intention-to-treat
(ITT) approach.
Results: In the AT analysis, 248 incident cancers oc-
curred over 14,727 person-years of follow-up in the prev-
alent user cohort (ITT: 535 cases, 34,078 person years),
while 101 persons in the new-user cohort developed can-
cer over 4,944 person-years (ITT: 242 cases, 13,151 per-
son-years). Insulin glargine use was not associated with
an increased risk of malignancies (prevalent user cohort
HR=0.94, 95% CI [0.58-1.53]; new user cohort HR=
0.81, 95%CI [0.39-1.67]), ITT analyses revealed similar
HRs. Results were consistent for time-varying hazard
ratio analysis and sensitivity analyses that modiﬁed
induction and latency time.
Conclusions: This small scale study using an active
comparator cohort and including information on
diabetes duration found no altered cancer risk under
insulin glargine treatment.
505. Acute Pancreatitis in Type 2 Diabetic Patients
Treated with Dipeptidyl Peptidase-4 (DPP-4)
Inhibitor:APopulation-BasedNestedCase-Control Study
Hsin-Chun Chou,1 Wen-Wen Chen,1 Fei-Yuan Hsiao.2,3
1Taiwan Drug Relief Foundation, Taipei; 2Graduate
Institute of Clinical Pharmacy, College of Medicine,
Taipei; 3National Taiwan University Hospital, Taipei.
Background: Recent evidence has emerged that the
most recently approved oral antihyperglycemic agents,
the incretin-based drugs including dipeptidyl pepti-
dase-4 (DPP-4) inhibitors and glucagon-like peptide-
1 (GLP-1) analogs, may be associated with increased
risk of acute pancreatitis.
Objectives: This nested case-control study exam-
ined the association between use of dipeptidyl pep-
tidase-4 (DPP-4) inhibitor and acute pancreatitis
using Taiwan’s National Health Insurance Research
Database.
Methods: From the study cohort of type 2 diabetic
patients, we identiﬁed 1,957 acute pancreatitis cases
(patients who had been admitted with a diagnosis of
acute pancreatitis) and 7,828 age-, sex- and cohort
entry year- matched controls between 2000 and
2011. Multivariable conditional regression models
were used to estimate the association between use of
DPP-4 inhibitor and acute pancreatitis.
Results: The risk of acute pancreatitis among current
and past users of DPP-4 inhibitors were comparable
to non-users (current: adjusted odds ratio (aOR)
0.95; 95% conﬁdence interval (CI) [0.73-1.23]; past
users: aOR 2.32 [0.99-5.42]). Nevertheless, the
adjusted risks of acute pancreatitis were found to be
signiﬁcantly associated with patients with gallstone
disease (aOR 6.14 [4.93-7.65]), alcohol-related
disease (aOR 5.45 [4.13-7.18]), hypertriglyceridemia
(aOR 1.87 [1.32-2.65]), pancreatic disease (aOR
17.97 [11.02-29.30]), cancer (aOR 1.35 [1.06-1.72])
and higher Diabetes Complications Severity Index
(DCSI) score (DCSI 3-4: aOR 1.70 [1.38-2.10]; DCSI
=5: aOR 1.60 [1.23-2.09]).
Conclusions: This population-based study extends
previous evidence by exploring the potential associa-
tion between DPP-4 inhibitors use and risk of acute
pancreatitis in an Asian type 2 diabetic cohort. We
found that underlying diseases and severity of diabetes
but not DPP-4 inhibitors use were associated with
acute pancreatitis.
506. Risk of Spontaneous Bacterial Peritonitis
Associated with Gastric Acid Suppression
Chien-Chang Lee,1,2,3 Yi-Hsian Lin,1 Shih-Hao Lee,1
Tzu-Ting Chen,4 Meng-tse Gabriel Lee.1 1Department
of Emergency Medicine, National Taiwan University
Hospital, Taipei; 2Department of Emergency Medicine
and Department of General Medicine, National Taiwan
University Hospital Yunlin Branch, Douliou; 3Depart-
ment of Epidemiology, Harvard School of Public Health,
Boston; 4Institute of Epidemiology and Preventive Medi-
cine, National Taiwan University, Taipei.
Background: Increased susceptibility to infection has
been reported as a potential complication of gastric
acid suppression therapy.
Objectives: We aimed to assess the association of
gastric acid suppression therapy and the risk of sponta-
neous bacterial peritonitis in a national population of
patients with advanced liver cirrhosis.
Methods: We conducted a case-control study nested
within a cohort of 86,418 patients with advanced liver
cirrhosis, using the claims data from a 480,000 sample
of national health insurance beneﬁciaries. Cases were
deﬁned as ﬁrst outpatient or inpatient visit for a
primary diagnosis of SBP and were matched with
100 controls on age, gender, and year of SBP diagno-
sis. We built a disease risk score for prediction of SBP
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and used it for adjustment of confounding in a condi-
tional logistic regression model. Adjusted risk of
SBP associated with prior exposure to gastric acid
suppressants was calculated.
Results: From a cohort of 480,000 patients, 86,418
patients with advanced liver cirrhosis and 947 cases
of SBP were identiﬁed. Exposure to gastric acid
suppressants within 30 days of the event date was as-
sociated with an increased risk of SBP, with a disease
risk score adjusted RR of 3.89(95%CI 2.90-5.22) for
PPIs and 3.01(95%CI 2.33-3.89) for H2RAs. The risk
of SBP attenuated for recent use of PPIs 4.89(95%CI
3.43-6.97) or H22RAs 1.98(95%CI 1.46-2.70). Sensi-
tivity analysis using hospitalized SBP as the primary
outcome showed a risk for current use of PPIs (RR,
3.99; 95%CI 2.81-5.66) and current use of H2RAs
(RR 2.71; 95%CI 1.93-3.79). Higher cumulative days
of gastric acid suppression in the 90-day risk period
prior to the index date were associated with higher risk
of SBP (trend P< 0.0001). The adverse effect associ-
ated with use of PPIs appeared not to be modiﬁed by
age of 70 years or gender.
Conclusions: Among patients with advanced liver
cirrhosis, exposure to gastric acid suppressants was as-
sociated with an increased risk of SBP. Compared
with non-users, the association was strongest for
current PPI users.
507. Negative Control Study on the Risk of Acute
Myocardial Infarction Associated with the Use of
Antibiotics Using a US Database
Stephanie Tcherny-Lessenot,1,2 Yunxun Wang,3 Juhaeri
Juhaeri,2,3 Xavier Kurz,2,4 Laurent Auclert,2,5 Patrick Caubel.6
1Pharmacoepidemiology, Global Pharmacovigilance and
Epidemiology, Sanoﬁ, Chilly-Mazarin, France; 2PROTECT
WP6, IMI, Paris, France; 3Pharmacoepidemiology, Global
Pharmacovigilance and Epidemiology, Sanoﬁ, Bridgewa-
ter, NJ, United States; 4EMA, London, United Kingdom;
5QPPV Ofﬁce and PV Policy, Global Pharmacovigilance
and Epidemiology, Sanoﬁ, Chilly-Mazarin, France;
6Global Pharmacovigilance and Epidemiology, Sanoﬁ,
Chilly-Mazarin, France.
Background: This work was carried out as part of IMI-
PROTECT work package six (WP6) which aims to evalu-
ate if the tools proposed in work package two (WP2) are
speciﬁc enough not to detect an association that does not ex-
ist. For this purpose, the drug pair-event antibiotics (ATB)
and acute myocardial infarction (AMI) has been selected
from negative controls used in the OMOP experiment.
Objectives: This study aimed to assess if a case-control
design in a US claims database (Clinformatics) allowed
for detecting the absence of an association between ATB
use and AMI, which has been shown to be non-existent.
Methods: This study used a case-control methodology in
patients followed from 2004 to 2009. Cases were deﬁned
as ﬁrst recorded occurrence of AMI, and controls were
matched on age, sex, and calendar date of cohort entry. Ac-
cording to their exposure previous to the event date, pa-
tients were classiﬁed as current users (<30days), past
users ([365, 30), and non-users (>365 or no use). Cases
and controls were compared for ATB use and odds ratios
(ORs) were estimated using conditional logistic regression.
Results: A total of 20,344,233 patients in Clinformatics
were included as the study population from which
51,816 cases and 253,422 matched controls were identi-
ﬁed. Cases were >50 years old in 80% of cases, had
more often previous history of heart failure and diabetes,
previous use of statins and antidepressants than controls.
In the control group, use of ATB in the past year was
45.7% for any ATB, 20.0% for penicillins, 17.6% for
macrolides, 11.7% for cephalosporins, 5.1% for tetracy-
clines 2.7% for quinolones, and 0.3% for other antibi-
otics. The adjusted Odds Ratios of AMI for any ATB
were 1.38 [95%CI 1.33-1.43] for current users and 1.10
[95%CI 1.08-1.12] for past users compared to non-users.
Conclusions: This negative control study detected
Odds Ratios higher than 1 but smaller than 2 with nar-
row conﬁdence intervals. As described in OMOP,
small effects incur higher risk of false positives.
This research received support from the Innovative
Medicine Initiative Joint Undertaking through the
PROTECT project.
508. Does Use of Non-Steroidal Anti-Inflammatory
Drugs Affect the Risk of Incident Active Tuberculo-
sis Disease? A Nested Case Control Study on a
National Health Claim Database
Shih-hao Lee,1 Meng-tse Gabriel Lee,1 Yi-Hsian Lin,1
Chien-Chang Lee.1,2 1Department of Emergency Medi-
cine, National Taiwan University Hospital, Taipei;
2Department of Emergency Medicine and Department
of General Medicine, National Taiwan University
Hospital Yunlin Branch, Douliou.
Background: Mycobacterium tuberculosis (TB), the
causative bacteria pathogen, is one of the world’s most
devastating public health threats. To reduce the rate of
infection, we aimed to ﬁnd out whether commonly
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prescribed pain reliving drugs affect the risk of
incident active TB.
Objectives: To evaluate whether the use of non-
steroidal anti-inﬂammatory (NSAID) drugs affect the
risk of new incident of active TB disease.
Methods: A nested case control study was carried out
using the claims data from National Health Insurance
Research Database of Taiwan. 1 million patients were
longitudinally followed from January 1997 toDecember
2011. Patients with NSAIDs exposure were deﬁned by
having a prescription record of NSAIDS≥ 7 days. New
onset of active TB was deﬁned as, the record of the ﬁrst
diagnostic codes of TB plus the prescription of more
than two anti-TB medications for> 28 days. Non-selec-
tive NSAIDs target both COX-1 and COX-2 enzymes.
COX-2 inhibitor is considered selective NSAIDs.Multi-
variate regression and a disease risk score (DRS) tech-
nique were used to calculate risk of active TB disease.
Results: 4706 cases of new active TB and 470,600 con-
trols were identiﬁed. Current use of non-selective
NSAIDs was associated with 2.3 fold crude increase
and 1.9 fold DRS adjusted increase in risk of developing
TB. Recent and past use of non-selective NSAIDs was
associated with insigniﬁcant increase in risk of develop-
ing TB after DRS adjustment. However, current use of
Cox-2 inhibitor only caused 1.6 fold crude increase
and 1.3 fold DRS adjusted increase in risk of developing
TB. Subgroup analysis on non-selective NSAIDs found
that subjects<= 70 years of age had 2.2 fold DRS
adjusted increase in risk of developing TB. In addition,
female users of non-selective NSAIDs had 2.6 fold
DRS adjusted increase in risk of developing TB.
Conclusions: Our pilot results suggest that subjects
using non-selective NSAIDs have increase in risk of
developing active TB than subjects taking Cox-2 in-
hibitor. More research is required to validate our data
and rule out protopathic bias.
509. Does Systemic Corticosteroids Use Increase the
Risk of Incident Active Tuberculosis Disease? A
Nested Case Control Study on a National Health
Claim Database
Meng-tse Lee,1 Yi-Hsian Lin,1 Shih-Hao Lee,1 Chien-
Chang Lee.1,2 1Department of Emergency Medicine, Na-
tional Taiwan University Hospital, Taipei; 2Department
of Emergency Medicine and Department of General
Medicine, National Taiwan University Hospital Yunlin
Branch, Douliou.
Background: According toWorld Health Organization,
9.4 million people developed Mycobacterium tuberculo-
sis (TB) and 1.3 million died from the associated compli-
cation in 2009. To reduce the rate of infection, our goal is
to ﬁnd out whether the use of systemic corticosteroids
increases the risk of incident TB.
Objectives: To evaluate whether the use of systemic
corticosteroids increase the risk of incident active
tuberculosis disease.
Methods: A nested case control study was carried out
using the claims data from National Health Insurance
Research Database of Taiwan. 1 million patients were
longitudinally followed from January 1997 to Decem-
ber 2011. Index date referred to the ﬁrst date of TB
diagnosis. Patients with corticosteroids exposure were
deﬁned by receiving ≥ 7 days of prescription ending in
3 different time frames. First, current use, refer to pre-
scription that ended within 30 days of the index date.
Second, recent use, refer to prescription that ended
31 to 90 days prior to the index date. Third, past use,
refer to prescription that ended between 91 days and
1 year prior to the index date. Multivariate regression
and a disease risk score (DRS) technique were used
to calculate risk of active TB disease.
Results: 6229 cases of new active TB and 622,900
controls were identiﬁed. Increase in the risk of active
TB disease is inversely proportional to the time from
the last use of corticosteroids. Current use of cortico-
steroids caused 2.8 fold DRS adjusted increase in
active TB risk, followed by recent use of corticoste-
roids that caused 1.8 fold DRS adjusted increase in
risk. Past use of corticosteroids still caused 1.2 fold
DRS adjusted increase in TB risk. All the results are
statistically signiﬁcant (95% CI).
Conclusions: Our pilot results suggest that current, re-
cent and past use of systemic corticosteroids increase
the risk of incident active TB disease. Taken with the
known immunomodulation function of corticosteroids,
doctors should exercise caution when prescribing
systemic corticosteroids to patients at high risk of TB.
510. Mortality of Hydroxyethyl Starch Versus
Dextran for Resuscitation in Intensive Care
Lu-Hsuan Wu,1,2 Ching-Lan Cheng,1 Yea-Huei Kao
Yang.1 1Institute of Clinical Pharmacy and Pharmaceuti-
cal Sciences, National Cheng Kung University, Tainan,
Taiwan; 2Pharmacy, Taipei Tzu Chi Hospital, Buddhist
Tzu Chi Medical Foundation, Taipei, Taiwan.
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Background: Recently, randomized controlled trials
suggest use of hydroxyethyl starch (HES) to be associ-
ated with higher mortality when compared to crystal-
loid solutions.
Objectives: The aim of this cohort study was to deter-
mine the association between resuscitation with HES
compared with dextran (DEX), another colloid solu-
tion, and mortality among patients admitted in
intensive care unit.
Methods: We ﬁrst selected subjects aged >18 years
who were admitted to intensive care unit in a medical
center from 2010 to 2012. Patients who concurrently
received colloid solution (HES or DEX) and crystal-
loid solution were enrolled in our cohort. Patients
who died within 3 days after admission or used the
same colloid solution more than once within one
month were excluded. Retrospective chart review
was performed to collect baseline characteristics, and
clinical data. Primary endpoint was deﬁned as all-
cause mortality during therapy or within 14 days after
the last dose of the drug. Cox proportional hazard
model was performed to estimate the hazard ratio
and conﬁdence interval adjusting for shock, sepsis,
renal function, concurrent medications and Glasgow
coma scale (GCS).
Results: Our cohort included 1,479 patients, 1,394
were in HES group and 85 in DEX group. Except
sepsis (23.8% vs. 11.8%; p = 0.01) and concurrent
use of vasopressor (66.8% vs. 50.6%; p = 0.02), there
was no signiﬁcant difference in gender, age, shock,
renal function, and GCS between HES and DEX
group. The mortality rate was not signiﬁcantly differ-
ent between HES group and DEX group (adjusted
HR= 2.37, 95% CI: 0.97, 5.84). The results were
similar in subgroup analyses including those older
than 65 years (adjusted HR= 0.07, 95% CI: 0.94,
5.76), shock (adjusted HR= 0.06, 95% CI: 0.96,
5.84), sepsis (adjusted HR= 0.06, 95% CI: 0.97,
5.92), cardiovascular surgery (adjusted HR= 0.05,
95% CI: 0.99, 6.19), and acute kidney injury
(adjusted HR= 0.07, 95% CI: 0.95, 5.78).
Conclusions: In current study, there was no signiﬁcant
difference in mortality between HES and DEX in ICU
patients who were resuscitaed with crystalloid solutions.
511. Effect of Topical Steroids on the Eye
Michael D Murray,1,3 Shanshan Li,2 Evgenia Teal,3
Corey H Whitley.3 1Pharmacy Practice, Purdue
University, Indianapolis, IN, United States; 2Biostatistics,
Indiana University, Indianapolis, IN, United States;
3Regenstrief Center for Health Effectiveness Research,
Regenstrief Institute, Indianapolis, IN, United States.
Background: Instillation of glucocorticosteroids into
the eye to treat inﬂammatory conditions is a risk factor
for adverse ophthalmic problems including cataracts
and glaucoma. These effects are also noted with other
routes of delivery of glucocorticosteroids including
oral, parenteral, and inhaled.
Objectives: We wished to determine whether topical
glucocorticosteroids used to treat inﬂammatory disor-
ders of the skin might be associated with cataracts or
glaucoma.
Methods: We conducted a retrospective cohort study
of adult patients (18 years of age and older) exposed
to topical glucocorticosteroids compared to an age
and visit date matched cohort of patients from a large
inner-city health system in Indianapolis, Indiana,
USA. We followed patients until they developed a
cataract (ICD-9 code 366.x) or glaucoma (ICD-9 code
365.x), died, or had their last observed visit in the
health system. Patients in both the exposed and unex-
posed cohorts had no evidence of cataracts or glaucoma
the year prior to data collection. We used Kaplan-Meier
plots and Cox proportional hazards models to determine
the effect of glucocorticosteroids on either cataract or
glaucoma (primary endpoint) and each eye disorder
(secondary endpoints) controlling for age, visit date,
and other routes of glucocorticosteroid exposure and
to assess the effect of glucocorticosteroid potency. We
used a P value of< 0.05 for statistically signiﬁcance.
Results: We identiﬁed 39,736 subjects who were
exposed to topical glucocorticosteroids and a matched
cohort of 90,595 subjects who were unexposed. Times
in the health system prior to index dates were
9.0 ± 5.6 years and 7.8 years ± 5.4 years for the ex-
posed and unexposed cohorts (P< 0.0001). After con-
trolling for age, the date of visit, and exposure to other
glucocorticosteroids, topical glucocorticosteroids ex-
posure was associated with either cataract or glaucoma
(See ﬁgure, P< 0.0001; RR, 1.44; 95% CI, 1.38 to
1.51). The association with cataracts was predominant
(RR 1.24; 1.18 to 1.31) vs. glaucoma (RR 0.95; 0.86
to 1.04). More potent topical steroids had a stronger as-
sociation with cataracts (P = 0.016).
Conclusions: In this health system, topical steroids were
associated with a risk of cataracts but not glaucoma.
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512. Severity of Stroke in Women Using Oral
Contraceptives
Klaus K Andersen,1 Tom S Olsen.2 1Statistics, Bioinfor-
matics, Registry, Danish Cancer Society Research Center,
Copenhagen, Denmark; 2Stroke Unit, Frederiksberg
University Hospital, Copenhagen, Denmark.
Background: Use of oral contraceptives (OC) is associ-
ated with increased risk stroke. Severity of stroke differs
in regard to stroke type: (infarct/hemorrhage, throm-
botic/embolic, lacunar/cortical, etc) and cardiovascular
risk factor proﬁle. However, there is yet no knowledge
on severity of strokes associated with use of OC.
Objectives: To determine whether severity of strokes
associated with use of OC differs from that of other
strokes in Danish women between age 15 and 50.
Methods: During the study period January 1st 2003 to
December 31st 2011 we followed the entire Danish pop-
ulation of women between the age 15 and 50. For all
women information on current use of OC was obtained
from the nationwide registries. We deﬁned current use
of birth control pills as having at least two prescriptions
from the G03A group (ATC coding) within the previous
year. Information on hospitalization for stroke in the
study period was obtained from the Danish Stroke Regis-
ter designed to register all admissions for stroke in Dan-
ish hospitals with information on age, sex, stroke type
(ischemic/hemorrhagic), stroke severity (Scandinavian
Stroke scale, (SSS, 0 worst-58 best) and a cardiovascular
risk factor proﬁle. Information on socioeconomic posi-
tion was obtained from nation-wide registries.
Results: During the study period a total of 2364 women
aged 15- 50 years were hospitalized with stroke of
which 618 (26.1%) were current users of OC. Median
SSS of OC users was 48.0 and did not differ from that
of non-users (median SSS 48.3). From amultiple regres-
sion model, we found that after adjusting for age, stroke
subtype, socioeconomic position and current smoking
measured by SSSwas non-signiﬁcantly 0.6 points lower
in OC users than in non-users (p = 0.42).
Conclusions: Strokes in women using OC are as
severe as strokes in women not using OC.
513. A Pilot Study on the Impact of Severe Photosensi-
tivityReactions Linked toTopical Ketoprofen in Europe
Luigi Naldi,1,2 Simone Cazzaniga,1 Marie Laure
Kurzinger,3 Laurent Auclert,3 Mario Gori.4 1Centro Studi
GISED - FROM, Bergamo, Italy; 2USC Dermatologia,
AO Papa Giovanni XXIII, Bergamo, Italy; 3R&D, Global
Pharmacovigilance and Epidemiology, Sanoﬁ, Paris,
France; 4Menarini Ricerche S.p.A, Pomezia, Italy.
Background: The topical use of the drug has been
linked with photosensitivity reactions in spontaneous
reports and series of cases from contact dermatitis
clinics. To date, however, there has been limited infor-
mation on the risk of severe photosensitivity reactions
leading to hospitalization from topical ketoprofen use.
Objectives: To assess the prevalence of exposure to
topical ketoprofen in a sample of hospital controls; to
obtain estimates of the incidence of severe photosensi-
tivity leading to hospitalization in selected sampling
areas; to assess the impact of photosensitivity reactions
linked to topical ketoprofen in the general population.
Methods: A sample of patients of both genders, aged
18-74 years, consecutively admitted to hospitals in par-
ticipating centers for acute conditions or for elective
procedures not suspected of being related to medication
use was interviewed. All the hospital admissions due to
severe photosensitivity during one-year surveillance pe-
riod were also identiﬁed. One-month drugs exposure
prevalence rates and one-year incidence rates were cal-
culated along with their exact (Clopper-Pearson) 95%
conﬁdence intervals (CI). The population attributable
risk (PAR) percentage was used as a measure of health
impact on the general population.
Results: 920 controls were recruited, 370 in the
Lombardy region (Italy), 300 in the Paris metropolitan
area (France) and 250 in the Prague area (Czech
Republic). The overall one-month prevalence of
exposure to topical ketoprofen was 0.65% (95% CI,
0.24 to 1.42). A total of 8 severe photosensitivity cases
were reported, equal to 4.81 cases per 10 million
persons-year (95% CI, 2.07 to 9.48). The PAR was
equal to 11.92% (95% CI, -0.12 to 52.99).
Conclusions: The exposure rate as well as the incidence
rate of photosensitivity reaction leading to hospitaliza-
tion and linked to topical ketoprofen were low. The pilot
study suggests that the public health impact of these
adverse reactions can be considered as negligible.
514. Bisphosphonate (BP) Treatment and Renal
Impairment (RI) in Women with Postmenopausal
Osteoporosis (PMO) in UK
Fei Xue,1 Charles Wentworth,2 Paul Petraro.1 1Center for
Observational Research (CfOR), Amgen Inc., Thousand
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Oaks, United States; 2Analytic Consulting Solutions Inc,
Wakeﬁeld, RI, United States.
Background: BP, the most commonly used osteopo-
rosis medication (OPM), is not recommended for
patients with concomitant RI by FDA. However,
MHRA recognizes renal toxicity as an adverse event
only for IV BP, which is much less frequently used
than oral BP. It is unclear how BP treatment affects
renal function in clinical practice in UK.
Objectives: To describe the prevalence of concomitant
RI and the incidence rate (IR) of RI progression and
end stage renal disease (ESRD) in women with PMO
who initiated BP or other OPM or were untreated.
Methods: Women ≥55 years with ≥1 year of enroll-
ment in the UK THIN database (1995 – 2012) who
had received a diagnosis or treatment related to OP
were included in the PMO cohort. Initiators of BP
and other OPM were deﬁned by treatment with BP
or other OPM, respectively, without any OPM treat-
ment in the prior 1 year (baseline). Women who did
not receive any OPM were included in the untreated
cohort. All cohorts were followed for incident RI
progression [i.e., new RI or increase in chronic kidney
disease (CKD) stage] and ESRD (Stage 5 CKD). De-
scriptive analysis was conducted to address study
objectives.
Results: BP initiators (N = 90,685) had higher base-
line prevalence of Stage 1-2, Stage 3 and Stage 4-5
CKD (0.6%, 3.0% and 0.3%, respectively) than other
OPM initiators (N = 2,777) (0.1%, 0.2%, and 0.1%,
respectively) or untreated cohort (N = 57,024) (0.4%,
1.7% and 0.3%, respectively). The age-standardized
IR (95% CI) (/100,000 person-years) of RI progres-
sion and ESRD was higher in BP initiators [2903.9
(2586.0 – 3260.9), 28.3 (27.9 – 28.6), respectively]
than other OPM initiators [1911.9 (1751.2 – 2087.3),
10.0 (9.9 – 10.1), respectively] or the untreated
[1732.7 (1585.8 – 1893.2), 25.3 (25.0 – 25.5), re-
spectively]. Results remained similar in women with-
out prevalent RI but were less consistent in those
with RI.
Conclusions: Descriptive analysis suggested higher
prevalence of pre-existing RI and IR of RI progression
and ESRD in BP initiators than other OPM initiators
or untreated women with PMO in UK general practi-
tioner settings. The results are inconclusive given the
lack of adjustment for confounders, which warrants
further exploration.
515. Antipsychotic Drug and Seizure Risk among
Patients with Psychotic or Mood Disorder in Taiwan
Chi-Shin Wu,1,2,3 Sheng-Chang Wang,4 Shi-Kai Liu.5,6
1Department of Psychiatry, Far Eastern Memorial Hospi-
tal, New Taipei City, Taiwan; 2College of Public Health,
National Taiwan University, Taipei, Taiwan; 3Department
of Psychiatry, National Taiwan University Hospital and
College of Medicine, Taipei, Taiwan; 4Center of Neuro-
psychiatric Research, National Health Research Institutes,
Miaoli, Taiwan; 5Centre for Addiction and Mental Health,
Toronto, ON, Canada; 6Department of Psychiatry,
University of Toronto, Toronto, ON, Canada.
Background: Antipsychotic drugs are associated with
increased risk of seizure.
Objectives: To evaluate the seizure risk associated
with individual antipsychotics and receptor-binding
proﬁles of antipsychotics.
Methods: Design: A cohort study of the seizure risk in
patients with initiating antipsychotic treatment for
psychotic or mood disorder.
Setting: Using the Taiwan’s National Health Insur-
ance Research Database, patients aged ≥ 15 years and
used antipsychotic drug between January 1, 2001 and
December 31, 2009 were enrolled.
Main outcome measures: Firs-ever seizures were
identiﬁed through the emergency department visits
and hospitalization with a diagnosis of seizure (ICD-
9CM code: 333.2 (myoclonus), 345 (epilepsy), or
780.3 (convulsions).
Statistic analysis: Cox proportional hazard model
and propensity-score matched analyses were used to
evaluate seizure risk of individual antipsychotic drug,
compared with Risperidone. Comorbid neurological,
psychiatric, and medical disorder, concomitant medi-
cation use, and health system utilization were adjusted.
Results: A total of 1,867 seizures were identiﬁed
among 298,752 new episodes of antipsychotic treat-
ment. Compared with Risperidone, the risk of seizure
was increased for chlorpromazine (Hazard ratio [HR] =
1.65, 95% Conﬁdence interval [CI] = 1.25-2.17),
chlorprothixene (HR= 2.35 (1.27-4.32), clozapine
(1.78 [1.22-2.58]), haloperidol (1.67 [1.40-2.00]),
prochlorperazine (1.50 [1.19-1.88]), quetiapine (1.22
[ 1.01-1.49]), and thioridazine (2.06, [1.55-2.75]). In
addition, we found that antipsychotics with a high
binding afﬁnity of D2 dopaminergic and alpha 1 adren-
ergic receptors, and low binding afﬁnity of 5HT2C
serotoninergic was associated with a increased risk of
seizure than other types of antipsychotics.
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Conclusions: The study found that chlorpromazine,
chlorprothixene, clozapine, haloperidol, prochlorperazine,
quetiapine, and thioridazine were associated with higher
seizure risk the risperidone. In addition, the increased
seizure risk might be was associated with the binding
afﬁnity of D2 dopaminergic, alpha 1 adrenergic recep-
tors, and 5HT2C serotoninergic receptors.
516. An Observational Study of Upper Gastrointes-
tinal Tract Bleeding Events in Patients Taking
Duloxetine and Non-Steroidal Anti-Inflammatory
Drugs (NSAIDS): A Case-Control Analysis
HuLi,1 Yingkai Cheng,2 Jonna Ahl,1 Vladimir Skljarevski.1
1Eli Lilly and Company, Indianapolis; 2Former Eli Lilly
and Company, Indianapolis.
Background: Duloxetine is a selective serotonin norepi-
nephrine reuptake inhibitor (SNRI) that is approved in the
United States and in the European Union for several indi-
cations including depression, ﬁbromyalgia etc. Currently,
there is limited information on the association between
GI bleeding risk and concomitant use of duloxetine with
nonsteroidal anti-inﬂammatory drugs (NSAIDs).
Objectives: To determine whether the concomitant use
of duloxetine with NSAIDs or aspirin was associated
with an increased risk for upper gastrointestinal
(UGI) bleeding events as compared with taking these
analgesics alone.
Methods: Truven Health Analytics Marketscan data-
base was examined for hospital admissions of adult pa-
tients indexed from 1 January 2007 to 31 December
2011. Cases were patients with UGI hemorrhage or
peptic ulcer disease. Controls were randomly selected
from the remaining admissions to match 10:1 with cases
for age, gender, and date of admission. Prescription
medication exposure groups of interest were: 1) no ex-
posure to duloxetine, NSAIDs or aspirin; 2) duloxetine
only; 3) NSAIDs or aspirin only; 4) duloxetine +
NSAIDs or aspirin. Logistic regression and Relative
Excess Risk due to Interaction (RERI) was utilized to
estimate any increased risk of UGI bleeding for patients
prescribed these medications across these groups.
Results: There were 33,751 cases and 335,710
controls identiﬁed. Comparing groups 2 and 4, the
adjusted odds ratio was 1.03 (95% CI, 0.94, 1.12)
and the adjusted RERI was 0.352 (95% CI: -0.178,
0.724) for risk of UGI bleeds, neither of which support
an increased risk or an interaction between duloxetine
and prescription NSAID or aspirin for these events.
Conclusions: There was no evidence of an increased
risk for UGI bleeds when duloxetine was taken with
prescription NSAIDs or aspirin. There was also no
evidence of an interaction between duloxetine and
prescription NSAIDs or aspirin for an increased risk
of these events.
517. Fracture Risk among Depressed Patients Initi-
ating SNRIs vs SSRIs Antidepressants
Yi-han Sheu,1 Amy Lanteigne,1 Til Stürmer,2 Virginia
Pate,2 Deborah Azrael,1 Matthew Miller.1 1Harvard
Injury Control Research Center, Harvard School of
Public Health, Boston, MA, United States; 2Department
of Epidemiology, University of North Carolina, Chapel
Hiils, Chapel Hill, NC, United States.
Background: Serotonin-Norepinephrine Reuptake
Inhibitors (SNRIs) and Selective Serotonin Reuptake
Inhibitors (SSRIs) are associated with increased
fracture risk. No study has directly examined fracture
risk across these two antidepressants classes.
Objectives: To estimate the extent to which fracture
risks would differ if a cohort of depressed SNRIs
initiators were instead started on SSRIs.
Methods: Patients in the LifeLink Health Plan claims
database who initiated monotherapy with SNRIs or
SSRIs, 1998-2010, were assembled into cohorts by
propensity score (PS) matching up to two SSRI initia-
tors to every SNRI initiator (separately, for patients
aged 50-64 and 65+), resulting in cohorts of SNRI
vs. SSRI initiators with covariate distributions reﬂecting
that among SNRI initiators. The primary outcome of
interest was hip or arm fracture within one year of
starting antidepressant therapy. Censoring occurred at
discontinuation of the initial antidepressant, switching
to/augmenting with a second antidepressant, or end of
enrollment, whichever came ﬁrst.
Results: Among patients aged 50-64, 23,457 SSRI initi-
ators were PS matched to 11,744 SNRI initiators; 5,263
SSRI initiators aged 65+ were PS matched to 2,632
SNRI initiators. Among SNRI and SSRI initiators in
our younger cohorts there were, respectively, 22 and 27
fracture events; in our older cohorts, there were 29 and
45 events. A non-signiﬁcant trend towards higher frac-
ture risk among initiators of SNRIs (compared with initi-
ators of SSRIs) was observed: hazard ratio (HR) =1.58
(95% CI 0.8–1.8) for the younger cohort, and HR=1.27
(95% CI 0.8–2.0) for the older cohort. Higher baseline
fracture rates among older patients produced absolute
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risk differences that were clinically non-trivial, though
statistically not signiﬁcant (e.g., for every 94 patients
treated with SNRIs rather than SSRIs, we expect one
additional fracture event).
Conclusions: We report a non-signiﬁcant, but, if real,
non-trivial elevation of fracture risk among SNRI ini-
tiators, compared with initiators of SSRIs, particularly
among the older patients. Future studies with more sta-
tistical power are warranted.
518. Lamotrigine and the Risk of Severe Cutaneous
Adverse Drug Reactions :A Nationwide Cohort Study
Chi-Hsun Chen,1,2 Edward Chia-Cheng Lai,1 Ching-Lan
Cheng,1 Yea-Huei Yang Kao.1 1Institude of Clinical
Pharmacy and Pharmaceutical Sciences, Tainan, Taiwan;
2Center for Drug Evaluation, Taipei, Taiwan.
Background: Lamotrigine (LTG) was associated with
skin rash, the risk was related to the concomitant anti-
epileptic drugs (AEDs) & LTG dose. Sophisticated
dose titration schedule was recommended in the label
of LTG to lower the risk of rash; however, severe
cutaneous adverse reactions (SCARs) such as
Stevens-Johnson syndrome (SJS) and toxic epidermal
necrolysis (TENS) were still found in post-marketing
case reports. A safety review of pre-marketing clinical
trials identiﬁed only 4 cases of SJS; a formal
pharmacoepidemiological study is needed to evaluate
the risk of SCARs of LTG.
Objectives: To investigate the risk of SCARs of LTG
in Taiwan.
Methods: New users of LTG, deﬁned as no prescrip-
tion of LTG for 3 years before the 1st prescription of
LTG (index date), were retrieved from Taiwan National
Health Insurance Research Database (2005-2010). We
classiﬁed the new users into 4 Groups based on concom-
itant AEDs: Group 1, LTGmonotherapy; Group 2, LTG
with enzyme inducing AEDs; Group 3, LTG with
enzyme inhibiting AEDs; and Group 4, LTG with
other AEDs. Patients were followed up until occurrence
of SCAR events (deﬁned as ICD-9 code 695.1,
i.e. erythma multiforme, SJS and TENS), discontinu-
ation of LTG, 90 days after index date or the last
date of database. We used Cox proportional hazard
model to compare the risk of SCARs among groups
(Group 1 as reference). Covariates included age,
sex, indications (epilepsy or bipolar dosorder), ini-
tial dose of LTG and other co-medications related
to SCARs.
Results:We identiﬁed 28,488 new users and 73 events of
SCARs in the 4 groups; mean time to events from index
date was 40.15days (SD, 16.38). The event rate was
highest in Group 3 (5.62/1000 persons) and lowest in
Group 2 (1.57/1000 persons). Adjusted Hazard Ratio
was 2.70 (95%CI: 1.37-5.30) for Group 3, 0.56 for Group
2 and 1.40 for Group 4 as compared to LTGmonotherapy.
Conclusions: The risk of SCARs was higher in pa-
tients co-administrating LTG and enzyme inhibiting
AEDs than single LTG users. The ﬁndings warrant
further investigation of association of SCARs and
LTG dosage regimens.
519. Use of Low-Dose Aspirin and Prostate Cancer
Risk
Charlotte Skriver,1 Christian Dehlendorff,1 Michael
Borre,2 Klaus Brasso,3 Henrik T Sørensen,4 Klaus K
Andersen,1 Søren Friis.1 1Danish Cancer Society
Research Center, Danish Cancer Society, Copenhagen
Ø, Denmark; 2Department of Urology, Aarhus Univer-
sity Hospital, Aarhus N, Denmark; 3Department of
Urology and Copenhagen Prostate Cancer Center,
Rigshospitalet, Copenhagen Ø, Denmark; 4Department
of Clinical Epidemiology, Aarhus University Hospital,
Aarhus N, Denmark.
Background: Experimental studies have demonstrated
an antineoplastic effect of aspirin against prostate
cancer (PC). However, results of observational studies
are inconclusive.
Objectives: To evaluate whether use of low-dose aspirin
is associated with a reduced risk of PC among Danish men.
Methods: We conducted a nested case-control study
using data from Danish administrative and health regis-
tries. We identiﬁed all Danish men above 35 years with
a ﬁrst diagnosis of PC during 2000-2011. For each case
we sampled ﬁve population controls matched on birth
year and geographical region, using risk set sampling.
Ever-use of low-dose aspirin was deﬁned as≥ 2
prescriptions (ATC code: B01AC06). Conditional
logistic regression was used to estimate odds ratios
(OR) and 95% conﬁdence intervals (CI) of PC associ-
ated with low-dose aspirin use. We examined the effect
of recency, duration, and intensity of low-dose aspirin
use and stratiﬁed the case population by stage of PC at
diagnosis. The analyses were adjusted for age,
residency, educational level, income, diabetes, muscu-
loskeletal disorders and ever-use of high-dose aspirin,
non-aspirin non-steroidal anti-inﬂammatory drugs,
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statins, 5-alpha-reductase inhibitors, antidepressants/
neuroleptics, and selected cardiovascular drugs.
Results: We identiﬁed 37,195 cases and 185,971 pop-
ulation controls (median age: 71 years). Prevalence of
low-dose aspirin use was 27.8% and 28.5% among
cases and controls, respectively. The adjusted OR for
PC associated with ever-use of low-dose aspirin was
0.97 (95% CI 0.95-1.00). No apparent variation was
observed according to recency of low-dose aspirin
use or by stage of PC. In analyses deﬁning low-dose
aspirin use according to duration of use, ORs were
close to unity, except in analysis of long-term (≥10
years) low-dose aspirin use stratiﬁed according to esti-
mated average dose of low-dose aspirin (≥10 years use
in highest dosage tertile: OR 0.84; 95% CI 0.71-0.98).
Conclusions: Our study did not support a major pre-
ventive effect of low-dose aspirin (75-150mg) use on
PC, although long-term and highest intensity of low-
dose aspirin use was associated with a slightly reduced
risk of PC.
520. Anti-Epileptic Drug Prescriptions and Attempted
and Completed Suicide in Young Adults
Jesca Brouwer, Linda Wijlaars, Irene Petersen, Irwin
Nazareth. Primary Care and Population Health,
University College London, London, United Kingdom.
Background: Suicide was the leading cause of death in
England andWales among people aged 20 to 34 years in
2009. In 2008, the US Food and Drug Administration
issued a warning regarding a possible link between
increased suicidal behaviour and antiepileptic drugs
(AEDs), especially among people aged 5 to 24 years.
Objectives:We aimed to investigate the association be-
tween AED prescriptions and attempted and completed
suicides between 2000 and 2011 among young adults.
Methods: We used data from The Health Improve-
ment Network (THIN), a UK primary care database,
to identify young adults (aged 15-29 years) with a re-
cord of attempted or completed suicides. Only the ﬁrst
suicide attempt was included. AED exposure was de-
ﬁned as periods in which the cases were prescribed
AEDs included in the British National Formulary.
We performed self-controlled case series analyses,
stratiﬁed by indication (epilepsy, psychiatric disor-
ders, and other indications) and AED type, to estimate
incidence rate ratios (IRR) with 95% conﬁdence inter-
vals (CI).
Results: We identiﬁed 3105 attempted and 218
completed suicides. AED exposure was not associated
with suicide attempts (IRR 0.83, 95% CI: 0.58-1.19).
However, there was an overall increase in the rate of
suicide attempts one month before exposure (IRR
3.72, 95% CI: 2.18-6.37) compared to non-exposed
periods. This was observed speciﬁcally in people with
epilepsy (IRR 3.40, 95%CI: 1.18-9.82), psychiatric dis-
orders (IRR 3.80, 95% CI: 1.91-7.58), and in people
using carbamazepine (IRR 6.17, 95% CI: 2.34-16.29)
and lamotrigine (IRR 4.94, 95% CI: 1.78-13.74). Only
two people with a completed suicide record were pre-
scribed AEDs shortly before they committed suicide.
Hence, no subsequent analyses were performed.
Conclusions: AED prescription was not associated
with an increased risk of a ﬁrst suicide attempt in
young adults.
521. Association between Inhaled Corticosteroid
Use and Diabetes & Other Endpoints in Chronic
Obstructive Pulmonary Disease (COPD)
Robert W Flynn, Stuart Schembri, Adrian Hapca, Isla S
Mackenzie, Thomas M MacDonald.Medicines Monitoring
Unit, University of Dundee, Dundee, United Kingdom.
Background: Inhaled steroids (IS) at substantial daily
doses are often used in the treatment of COPD. IS
have been consistently associated with adverse effects
such as pneumonia, thrush and adrenal suppression.
However, there are conﬂicting reports on whether IS
are associated with increased incidence or worsening
of existing diabetes (DM). We investigated this in a
Dundee COPD population.
Objectives: The primary objective was to see if there
is an association between IS use and new onset DM
or the worsening of existing DM. Secondary endpoints
were inﬂuenza/pneumonia, fracture and cataracts.
Methods: COPD patients in Tayside are visited annu-
ally and their data, including demographics, spirome-
try, treatment, symptoms and outcomes are entered
into a managed clinical database. Prescription datasets
were used to determine IS exposure according to
equivalent daily doses of beclometasone. A DM
dataset was used to determine new DM diagnosis
and worsening of existing DM deﬁned as an increase
in glycosylated haemoglobin or the need for additional
DM medication. A Cox regression model was used to
determine the association between IS use and new DM
or worsening of existing DM after adjusting for
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potential confounders. A time dependent analysis of
exposure comparing time on versus off IS was
used to take into account patients changing their
exposure status during follow-up and to prevent immor-
tal time bias. Hospitalisation for inﬂuenza/pneumonia,
fracture and cataracts were the secondary endpoints.
Results: 4305 subjects (3243 exposed to IS, 1062 non
exposed) were eligible for the study. There were 239
cases of new DM and 265 cases of worsening DM. The
Hazard Ratio for the association between cumulative IS
exposure and new DM diagnosis was 0.70 (0.43-1.12),
that of worsening of existing DM was 0.57 (0.24-1.37).
There were 551 cases of inﬂuenza/pneumonia [HR 1.12
(0.93-1.35)]; 288 fractures [HR 1.08 (0.73-1.59)]; and
505 cataracts [HR 1.42 (1.07-1.88)].
Conclusions: There was no association between IS
use and either new onset DM or worsening of existing
DM. IS were associated with a small increased risk of
inﬂuenza/pneumonia and a larger risk of cataract.
522. Comparative Safety Profiles of Bevacizumab,
Ranibizumab and Pegaptanib in the Treatment of
Age-Related Macular Degeneration: the Analysis
of the WHO Database of Adverse Drug Reactions
Chiara Biagi,1 Valentino Conti,2 Marta Bonisolli,1
Mauro Melis,1 Elena Buccellato,1 Anna Covezzoli,3
Roberta Amato,3 Linda Pazzi,3 Mauro Venegoni,2
Alberto Vaccheri,1 Domenico Motola.1 1Department of
Medical and Surgical Sciences, Unit of Pharmacology,
University of Bologna, Bologna, Italy; 2Regional Centre
for Pharmacovigilance, Lombardy Region, Milan, Italy;
3Interuniversity Consortium - Health Care Systems
Department, CINECA, Bologna, Italy.
Background: The age-related macular degeneration
(AMD) is the major cause of visual impairment among
individuals older than 50 years in industrialized coun-
tries. In 2007 the anti-VEGFmonoclonal antibody for in-
travitreal use ranibizumab was marketed. In the literature
were already widespread evidence for the use of off-label
intravitreal bevacizumab, marketed as a systemic anti-
cancer therapy. Both are considered similar in terms of
efﬁcacy, while doubts remain about their safety proﬁle.
Objectives: Comparative analysis of the safety data of
ranibizumab, bevacizumab and pegaptanib on the
basis of reports of suspected adverse drug reaction
(ADR) in the database of the WHO, to contribute with
real life data at the discussion on the safety proﬁle of
these drugs.
Methods: ADR reports from January 2002 to Decem-
ber 2012 were selected from the WHO Vigibase.
Reporting Odds Ratio (ROR) as a measure of
disproportionality with conﬁdence interval of 95%.
The analysis was performed for drug-reaction pairs.
The comparison was performed for each of the three
drugs versus the other two. MedDRA terminology
for ADRs was used.
Results: 69.864 drug-reaction pairs were retrieved.
After elimination of duplicates, 56.617 pairs were
obtained. Bevacizumab’s ADR due to oncological
use were excluded. The ﬁnal analysis was performed
on 7753 pairs: 2069 for bevacizumab, 5130 for
ranibizumab and 554 for pegaptanib. Signiﬁcant RORs
was obtained for endophthalmitis and uveitis (1.90, CI
95% 1.48-2.43 and 10.62, CI 95% 6.62-17.05, respec-
tively) only for bevacizumab and for cerebrovascular
accident and myocardial infarction (1.54, CI 95%
1.14-2.10 and 1.73, CI 95% 1.18-2.53, respectively)
only for ranibizumab.
Conclusions: Our data show an increase in
disproportionality for cardiovascular ADRs in patients
treated with ranibizumab and for ocular reactions in
those treated with bevacizumab. These ﬁndings
suggest bevacizumab as ﬁrst choice for AMD therapy
due to its similar effectiveness compared to
ranibizumab, with a more favourable safety proﬁle.
523. Upper Gastrointestinal Bleeding in Patients
with Schizophrenia in the United States
Nadia Foskett, Suellen Curkendall, Nicole Princic,
Gregory Lenhart, Bogdan Balas, Smiljana Milosavljevic-
Ristic., Roche Prod Ltd, Welwyn Garden City, United
Kingdom; Truven Health Analytics, Bend, OR, United
States; Truven Health Analytics, Cambridge, MA, United
States; F. Hoffmann-La Roche, Pharmaceuticals Division,
Basel, Switzerland.
Background: Schizophrenia is a chronic disease with
substantial medical burden due in part to elevated
prevalence of somatic comorbidities compared with
the general population.
Objectives: Compare the rates of any upper gastrointes-
tinal bleeding (UGIB) and bleeding ulcer in patients with
schizophrenia to a matched group of patients without
schizophrenia& to evaluate risk factors for bleeding ulcer.
Methods: This retrospective cohort study used
MarketScan® claims databases (Medicaid, Medicare
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or commercial insurance) to select patients age ≥ 18
years diagnosed with schizophrenia from 1/1/2003-
10/31/2011. Incidence rates for UGIB and bleeding
ulcer were calculated for the schizophrenia cohort
and a matched non-schizophrenia cohort. Cox propor-
tional hazards regression model estimated the adjusted
hazard ratio for bleeding ulcer. A nested case-control
analysis was used to identify risk factors for bleeding
ulcer among patients with schizophrenia.
Results: Of the 224,351 patients with schizophrenia,
mean age was 44.8 years, 55.7% were male, and 83%
were covered under Medicaid. The incidence of any
UGIB in patients with schizophrenia was 7.9 per
1,000 person years (PY) compared to 5.9 per 1,000
PY in the patients without schizophrenia. The inci-
dence of bleeding ulcers in patients with schizophrenia
was 1.4 per 1,000 PY compared to 1.2 per 1,000 PY in the
patients without schizophrenia. The unadjusted risk ratio
for UGIB was 1.34 (1.28-1.41) and for bleeding ulcer
was 1.13 (1.01-1.26). The adjusted hazard ratio for bleed-
ing ulcer was not signiﬁcant [1.09 (0.97-1.22)]. Older
age, prior ulcers, cirrhosis, and use of thiazolidinediones,
anticoagulants, non-steroidal anti-inﬂammatory drugs,
selective serotonin reuptake inhibitors, corticosteroids,
histamine-2 receptor antagonists, and proton pump inhib-
itors were identiﬁed as leading to a signiﬁcantly increased
risk of a bleeding ulcer UGIB event among patients with
schizophrenia.
Conclusions: Risk of UGIB in patients with schizophre-
nia and potential risk factors for bleeding ulcer should be
considered in the management of these patients.
524. Diabetes Drugs and Acute Pancreatitis: A
Systematic Review of Observational Studies
Lorna Hazell,1 Manel Pladevall-Vila,2 Lorenza Scotti,3
Giorgia De Berardis,4 Cristina Varas-Lorenzo,2 Susana
Perez-Guttham,2 Miriam Sturkenboom,4 Saad Shakir.1
1Drug Safety Research Unit, Southampton, United Kingdom;
2Reserach Triangle Institute, Barcelona, Spain; 3Univeristy
of Milan Bicocca, Milan, Italy; 4Consorzio Mario Negri
Sud, Maria Imbaro, Italy; 5Erasmus University, Rotterdam,
Netherlands.
Background: The SAFEGUARD project aims to
evaluate the pancreatic safety of non-insulin blood
glucose lowering drugs (NIBGLD).
Objectives: To summarise evidence from published
observational studies on the risk of acute pancreatitis
(AP) in users of NIBGLD.
Methods: A systematic literature search was per-
formed in Pubmed and Embase (all years to May
2013). Eligible studies included cohort or case-control
designs comparing current/ever use of a NIBGLD with
non-use, or use of other NIBGLD. Risk effect
estimates for AP (as hazard, odds or risk ratios) were
summarised for each drug/class. Meta-analysis was
performed if these estimates were homogeneous
across studies. The Newcastle Ottawa Scale and the
RTI-Item Bank were used to assess study quality.
Results: Of the 605 articles retrieved, 9 were eligible
including: 5 cohort studies, 3 case-control studies and
one with mixed designs, using healthcare claims
(n = 7) or medical records databases (n = 2). Risk effect
estimates (95% conﬁdence limits) for AP versus non-
use were: 0.44 (0.31-0.62) for alpha-glucosidase
inhibitors (n = 1); ranged from 0.63 [0.47, 0.84] to
1.25 [0.86, 1.82] for sulfonylureas (n = 2), from 0.46
[0.35, 0.60] to 1.80 [0.40, 8.10] for biguanides (n = 3)
and from 0.63 [0.46, 0.86] to 1.25 [0.72, 2.17] for
thiazolidinediones (n = 2). Meta-analysis of cohort
studies provided a pooled risk ratio of 0.91 [0.74,
1.11] for exenatide (n = 5) and 0.91 [0.72, 1.15] for
sitagliptin (n = 2) versus use of other NIBGLD. In con-
trast, one case-control study reported an increased risk
associated with use of exenatide or sitagliptin com-
pared to non-users; OR 2.24 [1.36-3.69]. Methodolog-
ical limitations included lack of outcome validation,
immortal time bias and potential for channelling bias.
Conclusions: Observational studies included in this
systematic review are not conclusive regarding the risk
of acute pancreatitis in NIBGLD users. Only a small
number of studies were available for each drug. These
reported heterogeneous effect estimates, used very
different designs and had different methodological
limitations. Further large observational studies in users
of individual NIBGLD, speciﬁcally designed to
answer this important safety question, are required.
525. Total Cholesterol Level and Risk of Gastroin-
testinal Bleeding for Patient Taking Warfarin
Dahye Shin,1 Jin Soo Lee,2 Dukyong Yoon,1 Rae Woong
Park.1,3,4 1Department of Biomedical Informatics, Ajou
University School of Medicine, Ajou University, Suwon,
Republic of Korea; 2Department of Neurology, Ajou
University School of Medicine, Ajou University, Suwon,
Republic of Korea; 3Center for Clinical Epidemiology
and Biostatistics and Department of Biostatistics and
Epidemiology, Perelman School of Medicine at the
University of Pennsylvania, Philadelphia, PA, United
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States; 4Center for Pharmacoepidemiology Research and
Training, Perelman School of Medicine at the University
of Pennsylvania, Philadelphia, PA, United States.
Background: Warfarin is mostly used for prevention
of vascular diseases. Gastrointestinal bleeding (GIB)
is often complicated in patients taking them. Inverse
relationship between hemorrhagic stroke and serum
cholesterol has been reported in population-based
studies. However, long-term GIB risk due to low
serum cholesterol in patient receiving warfarin after
titration has not been elucidated.
Objectives: To investigate the relationship between
low serum cholesterol level and GIB risk in patients
taking warfarin.
Methods:We conducted a retrospective cohort study in
a university hospital between January 1996 and April
2013. All prescription records from outpatient and inpa-
tient data were used together. Patients who regularly
took warfarin prescriptions more than one month and
the proportion of day covered (PDC) greater than 0.8
were enrolled to the study. Patients who were co-
prescribed with statins that may alter cholesterol level
were excluded. We observed two years of follow-up
periods. The GIB event was deﬁned by ICD-10 (subdi-
visions .0-.6 of K20–K31). Mean of total cholesterol,
high-density lipoprotein (HDL), low-density lipoprotein
(LDL), triglyceride, aspartate transaminase (AST), ala-
nine transaminase (ALT) and creatine kinase (CK) level
during observation period were compared across GIB
event by t-test. Cox proportional hazard regression,
adjusting for age, sex, cholesterol, ALT, and target
therapeutic range (TTR), were conducted.
Results: A total of 2,306 patients were selected for
analysis. In t-test, triglyceride, AST and ALT levels
were signiﬁcantly lower in patients with GIB than
ones without event (p = 0.033, 0.004 and <0.001,
respectively). In Cox proportional hazard regression
model, cholesterol level (hazard ratio [HR] = 0.986
per mg/dL, 95% conﬁdence interval [CI], 0.973–
0.999) were associated with GIB risk. Age (HR= 1.038
per mg/dL, 95% CI, 0.9998–1.079), TTR (HR=1.004
per mg/dL, 95% CI, 0.985–1.023) and ALT (HR=0.978
per mg/dL, 95% CI, 0.937–1.020) didn’t show signiﬁcant
associated with GIB.
Conclusions: As with the intracranial hemorrhage,
inverse relationship between low serum cholesterol
level and GIB was observed in patients taking
warfarin.
526. The Risk of Acute Asthmatic Attacks Associated
with Different Dosage Forms of Non-Steroidal
Anti-Inflammatory Drugs: A Self-Controlled Case
Series Study
Yoshinori Takeuchi, Shingo Higa, Ayumi Endo,
Kazuhiro Matsui, Shinichi Watanabe. Ofﬁce of Safety I,
Pharmaceuticals and Medical Devices Agency (PMDA),
Tokyo, Japan.
Background: Our previous research in PMDA’s
MIHARI project revealed that self-controlled case
series (SCCS) could be applied for drug-safety eval-
uation with Japanese claims data. Although it is well
known that any NSAIDs may cause asthmatic attack,
few studies have evaluated the risk of asthmatic at-
tack associated with different dosage forms of
NSAIDs.
Objectives: To evaluate the association between the
incidence of acute asthmatic attacks and different
dosage forms of NSAIDs using SCCS method.
Methods: Design: SCCS.
Setting: The Japan Medical Data Center claims data-
base included 1.2 million patients (as of 2012) was used
for this research. Patients who experienced both exposure
of NSAIDs and acute asthmatic attack were included.
Exposures: Risk period was deﬁned as the duration
of NSAIDs prescription. Washout period was deﬁned
as 7 days after the end of Risk period. Control period
was period other than Risk or Washout periods. These
periods were deﬁned respectively for ﬁve different
dosage forms (injection, oral, suppository, ointment/
plaster and eye drop).
Main outcome measures: If inhalation procedure
and prescription start of inhaled β2 agonists were
recorded on the same day, it was deﬁned as the date
of occurrence of acute asthmatic attacks.
Statistical analysis: Conditional Poisson regression
models were used to calculate Incidence Rate Ratio
(IRR) and 95% Conﬁdence Interval (CI) of acute
asthmatic attacks in Risk or Washout periods relative
to those in Control period for each different dosage
form of NSAIDs.
Results: The IRR of acute asthmatic attacks in the
Risk period was 50.93 (95% CI, 36.37-71.33) with
injection, 26.37 (95% CI, 24.56-28.31) with oral,
27.05 (95% CI, 19.12-38.27) with suppository, 6.53
(95%CI, 5.35-7.96) with ointment/plaster and 1.94
(95%CI, 0.62-6.14) with eye drop forms of NSAIDs,
respectively.
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Conclusions: The risk of acute asthmatic attack
with different dosages of NSAIDs could be ranked
from high to low; in the following order, injection
oral≈ suppository> ointment/plaster forms. There
was no signiﬁcant increased risk of asthmatic attack
with eye drop forms of NSAIDs.
527. Adverse Drug Reactions in Hospitalized Pa-
tients: A Comparative Study of Intensive Care and
General Care Units
Joo-Hee Kim, Seung Hun Jang, Sunghoon Park, Yong
Il Hwang, Ki-Suck Jung. Department of Medicine, Hallym
University College of Medicine, Anyang, Republic of Korea.
Background: Adverse drug reaction (ADR) is deﬁned
as a harmful reaction associated with therapeutic uses of
given medications at a normal dosage. The incidence
and economic burden related to ADRs are increasing.
Patients in intensive care units (ICUs) are vulnerable to
ADRs because of complexity of patients’ diseases,
multi-organ dysfunction, high-number of medications
and complex drug regimens. However, these complexity
and variable clinical factors, patients in ICU are often
excluded from the evaluation of ADRs.
Objectives: The objective of this study is to determine
the clinical features, frequency, and causative drugs of
ADRs among patients in the ICUs in comparison with
those of ADRs in general wards (GWs).
Methods: A retrospective study was conducted from
Jan 2012 to Dec 2012 in both ICUs and GWs at a
tertiary university hospital. ADR data were collected
by medical personals using a computerized reporting
system. The causality of ADRs was assessed using
WHO-UMC criteria. Data were analyzed through
descriptive analysis and logistic regression.
Results: A total of 2,324 ADRs occurred in 1,319 pa-
tients, and 476 ADRs in 261 patients. The mean age
of the patients in ICUs and GWs were 63.5 ± 18.9
and 57.4 ± 19.2 years, respectively (p< 0.0001).
Overall, anti-infective agents were the most common
culprit drugs. However, the prevalence of cardiovas-
cular drugs as causative agents to ADRs was higher
in patients admitted to ICUs compared with those in
GW (p< 0.0001). Clinical manifestations were sig-
niﬁcantly different between the two groups. Patients
in ICUs presented hypotension, liver enzyme elevation,
diarrhea, and tachycardia. By contrast, patients in GWs
showed nausea, itching, and diarrhea. The proportion of
moderate to severe ADRs were signiﬁcantly higher in
ICU than in GW (p< 0.0001). Logistic regression
showed that the age was associated with the severity
of ADRs in ICU (OR=0.97).
Conclusions: The clinical features and prevalence of
ADRs in ICU were signiﬁcant different compared with
those of GWs. Closemonitoring of cardiovascular drugs
and liver function tests are recommended to detect
ADRs in ICU. Age was the only factor associated with
severity of ADRs.
528. Potential Drug-Drug Interactions in Oncology
Patients Receiving Anti-Cancer Drugs in a Tertiary
Medical Centre in Taiwan
Chin-Chin Ho,1 Chen-Chang Yang,2 Yueh-Ching Chou.3
1Institute of Environmental and Occupational Health Sci-
ences, National Yang-Ming University, Taipei, Taiwan;
2Department and Institute of Environmental and Occupa-
tional Health Sciences, National Yang-Ming University,
Taipei, Taiwan; 3Department and Institute of Pharmacol-
ogy, National Yang-Ming University, Taipei, Taiwan.
Background: Potential drug-drug interactions (DDIs)
may increase morbidity and mortality in oncology
patients, and may lead to hospital admissions.
Objectives: To investigate the frequency of potential
DDIs in prescriptions of cancer patients receiving che-
motherapy.
Methods: This was a retrospective study, and we
reviewed the prescriptions of inpatients attending onco-
logy ward from six cancer types (including breast cancer,
colorectal cancer, liver cancer, lung cancer, hematologic
cancer and cervical cancer) of a tertiary medical centre
in Taiwan. The classiﬁcation of potential DDIs was ac-
cording to Drug Interaction Facts. Drugs were screened
for signiﬁcance grade 1 and 2 DDIs by the warning
screen of the computerized physician order entry (CPOE)
system. In this study, we analyzed potential DDIs of
cancer chemotherapy. We used statistics to described
patients characteristics, frequency, and type of cancers.
The Statistical Package for the Social Sciences version
17.0 (SPSS, Inc., Chicago, IL) was used for all data.
Results: From January 2012 to June 2013, there were
9348 inpatients. There were 847 DDI prescriptions in
342 patients, including 111 pairs signiﬁcance grade 1
DDI and 736 pairs signiﬁcance grade 2 DDI. The odds ra-
tio (OR) of colorectal cancer, liver cancer and hematologic
cancer were 7.56 (p< 0.001), 2.45 (p< 0.001) and 1.53
(p< 0.001). The most common signiﬁcance grade 1 DDI
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involved 5-ﬂuorouracil (2.1%) and methotrexate (2.1%),
and signiﬁcance grade 2 DDI involved cisplatin (83.3%).
Conclusions: Approximately 10% inpatients of six
common cancer types were associated with a potential
DDI. Patients with colorectal cancer had higher risk
than other cancers.
529. Psychiatric Health Care Utilisation and Related
Costs in Newly Diagnosed Patients with Autism
Spectrum Disorder (ASD) in Quebec (Canada)
Caroline Croteau,1 Laurent Mottron,2 Marc Dorais,3 Jean-
Éric Tarride,4 Sylvie Perreault.1 1Faculty of Pharmacy, Uni-
versity of Montréal, Montréal, QC, Canada; 2Psychiatrie,
Hôpital Rivière des Prairies, Montréal, QC, Canada; 3Sta-
tistics, StatSciences Inc., Montréal, QC, Canada; 4Health
Sciences, Mac Master University, Hamilton, ON, Canada.
Background:Medication use in people with PDD has
been reported to increase over time in both the US and
also to a lesser extent, in the UK. Polypharmacy is also
common as many neuropsychiatric co-morbidities
have been reported in this population.
Objectives: To characterize psychiatric healthcare
utilization and its related costs in a cohort of newly
diagnosed ASD individuals.
Methods: A cohort was built using the provincial pub-
lic healthcare insurance program (RAMQ) databases.
Newly diagnosed subjects with ASD were selected
(≥2 diagnoses with ICD-9 codes: 299.X, excluding
299.2) between January 1998 and December 2010.
Cohort entry was the date of ﬁrst diagnosis without
ASD diagnosis in previous 5 years. Participants aged
26 years or those not covered by the RAMQ drug plan
in the year preceding cohort entry were excluded.
Demographic and clinical patient characteristics were
done at cohort entry. Healthcare utilisation associated
with a psychiatric diagnosis (physician and emergency
room visits, hospitalisations), psychoactive drug
use (anticonvulsants, antipsychotics, antidepressants,
anxiolytics, ADHD drugs) and total cumulative costs
were assessed during 5 years.
Results: Among the total cohort, 1227 patients had
5 years of follow-up (male: 80.3%; median age:
7 years). In the 1-year following diagnosis, the mean
number of visits to general practitioners was 1.6
whereas psychiatry related visits to specialists were
7.2 which decreased over time. Psychoactive drug uti-
lization was initially present in 49.3% of participants,
and increased to 53.2% at 5 years. The psychiatric hos-
pitalization rate was 10.4% in the 1-year of follow-up
with the highest rates seen in adolescents (20%) and
young adults (24%). Cumulative costs of psychiatric
health services and psychoactive drugs at 1-year of
follow-up were $547,568CAD and $600,433CAD,
respectively. Those costs were at $216,827CAD and
$934,381CAD at 5-years.
Conclusions:While cost related to psychiatric healthcare
services decreased by more than half in the 5 years of
follow-up, drug costs rose by 56%.Access to long term care
andmonitoring among the ASD population is discussed.
530. The Positive False Discovery Rate Method to
Control theMultiplicity Problem in Pharmacovigilance:
the SAFEGUARD Project
Lorenza Scotti,1 Silvana A Romio,1,2 Antonella Zambon,1
Lorna Hazell,3 Niklas Schmedt,4 Miriam Sturkenboom,2
Giovanni Corrao.1 1Department of Statistics and Quantita-
tive Methods, University of Milano-Bicocca, Milan, Italy;
2Erasmus University, Rotterdam, Netherlands; 3Drug
Safety Research Unit, Southampton, United Kingdom;
4Leibniz Institute for Prevention Research and Epidemiol-
ogy–BIPS GmbH, Bremen, Germany.
Background: Testing simultaneously the statistical
signiﬁcance in a large number of hypotheses could
increase the overall probability of rejecting at least a
true null-hypothesis (false positive signals). The
positive false discovery rate (pFDR) method accounts
for this multiplicity problem by controlling the propor-
tion of false positives.
Objectives: To control the number of false positive
drug-event signals using the pFDR method in the
SAFEGUARD project that aims to study the associa-
tion between each non-insulin blood glucose lowering
drugs (NIBGLD) and stroke, ventricular arrhythmia,
myocardial infarction, sudden cardiac death, pancre-
atic and bladder cancer and acute pancreatitis.
Methods: We analysed the adverse events reports
available in the FDA’s Adverse Event Report System
(FAERS) and in EudraVigilance (EV) between 2004
and 2012. The analysis was conducted considering
two event identiﬁcation criteria (narrow and broad)
and the set of all drugs with at least one adverse event
report as reference category For each drug-event com-
bination a Proportional Reporting Ratio (PRR) and a
one-sided test p-value were calculated (H0: log(PRR)
0 vs H1:log(PRR)> 0). The pFDR method was
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applied obtaining a q-value for each signal
representing the proportion of false positive signals
one would incur by accepting the null hypothesis of
the given test and every test with a smaller p-value.
A signal was considered signiﬁcant if the q-value
was< 0.05.
Results: Considering all drugs as reference, we ob-
served 51 and 59 signiﬁcant drug-event signals out of
171 and 184 comparisons in the EV system respectively
for the narrow and broad event deﬁnitions and 55 and 52
signiﬁcant drug-event signals out of 140 and 152 in
FAERS. After the application of the pFDRmethod, a re-
duction of 14% and 13% (narrow deﬁnition) and 17%
and 12% (broad deﬁnition) of the former signiﬁcant
signals was observed respectively in EV and FAERS.
Conclusions: The pFDR method could be used to con-
trol multiplicity in pharmacovigilance signal detection.
531. Rifampicin-Associated with Thrombocytopenia
in Dose Dependent Manner during Pulmonary Tub-
erculosis Treatment: A Case Report
Sen Mei Chen, Chen Szu Lai, Ping Ya Wang, Hao Chih
Hung, Ling Hui Chen, Hua Chi Chen. Taichung Tzu Chi
Hospital, Buddhist Tzu Chi Medical Foundation,
Taichung, Tanzi Dist, Taiwan.
Objectives: Rifampicin-associated with thrombocytope-
nia was documented previously,but Rifampicin-
associated with thrombocytopenia in dose dependent
manner is rarely reported.We presented an unusual
adverse event, a case of thrombocytopenia with petechiae
on groins and forearms may be caused by Rifampicin in
dose dependent manner.
Methods: A 76-year-old man suffered from dyspnea
and cough with yellowish sputum for several days
before admission.The results of sputum examination
showed to have acid-fast stain positive bacilli,and
PCR analysis revealed to beMycobacterium tubercu-
losis .Initiation of treatment with anti-tubercular
drugs including Ethambutol 800mg and Rifater
(Rifampicin 120mg,Isoniazid 80mg,Pyrazinamide
250mg) 4 tablets once daily,along with daily
Pyridoxine 20mg.Eleven days later,the patient
developed thrombocytopenia with petechiae. Anti-
Tubercular drug(Ethambutol 800mg and Rifater)
induced thrombocytopenia was suspected and then
was discontinued.Patient improved and was re-
exposed to the drugs one by one.After re-exposure
with Isoniazid,Ethambutol,Pyrazinamide, the platelet
count still maintain normal. Patient was suspected
of having thrombocytopenia due to Rifampicin in
dose dependent manner, and was re-challenge to
low dose of Rifampicin 300mg/day.The patient was
successfully treated with Isoniazid, Ethambutol,
Pyrazinamide and low dose of Rifampicin. No recur-
rence of the thrombocytopenia was noted.
Results:The onset of thrombocytopenia after administra-
tion of anti-tubercular drugs,the platelet count resumed to
normal limit after discontinuation of the drugs. After re-
exposure with Isoniazid,Ethambutol,Pyrazinamide and
low dose of Rifampicin, no recurrence of the thrombocy-
topenia was noted.Based on these observations from this
patient,Rifampicin-associated thrombocytopenic may be
in dose dependent manner.
Conclusions: This reported patient presented with Ri-
fampicin associated thrombocytopenia in dose dependent
manner.Physicians should be aware of the importance of
continuous supervision of patients on antituberculosis
treatment since all of them are capable of causing serious
thrombocytopenia during the course of therapy.
532. Drug Induced Liver Injury during TB Treatment
in Indonesia
JA Thobari,1 DA Perwitasari,2 UA Mulyani.3 1Faculty of
Medicine, Universitas GadjahMada (UGM), Yogyakarta,
Indonesia; 2Faculty of Pharmacy, Universitas Ahmad
Dahlan (UAD), Yogyakarta, Indonesia; 3Institute of
Research & Development, Ministry of Health, Republic
Indonesia, Jakarta, Indonesia.
Background: Tuberculosis are still a problem for
emerging countries such Indonesia. The program for
controlling and eliminations had been addressed on the
use of antituberculosis medicines. The safety proﬁle of
those drugs, particularly drug-induced liver injury
(DILI), has been studied, however, this information on
local or Indonesian capture is still minimum.
Objectives: To assess the proportion of drug-induced
liver injury (DILI) due to tuberculosis treatment
(TBT) among TB treated patients in Indonesia.
Methods: Prospective cohort study in 20 primary care
centers and 2 lung hospitals based setting were con-
ducted among adult’s TB patients who used standard
ﬁxed dose combination (FDC) regimens. Patients with
abnormal baseline AST and ALT level, lower hemo-
globin level and HIV positive were excluded. The
AST and ALT level were measured before treatment,
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and after intensive (2month) and maintenance
(6month) of treatment. DILI was deﬁned if AST/
ALT increasing above the upper normal limit.
Results: Two hundred and thirtythree subjects
were followed, 64.4% were male, age 39.7 years
(+/-.18.2), and 59.7% with underweight. The baseline
of AST and ALT were 21.8 (±8.9) and 19.2 (±11.1),
respectively. There were increased of DILI after
intensive phase (9.4%) compared to maintenance
treatment (14.6%) (p< 0.001). The DILI group
patients has signiﬁcantly higher increased of AST
and ALT after intensive treatment compared to non-
DILI (9.4 (±.0.7) vs. 23.8 (±.5.1), p< 0.001), and
(12.2 (±.0.9) vs. 52.3 (±.1.2), p< 0.001), respectively.
Similar with after maintenance phase of treatment.
This changed has still signiﬁcantly difference after
adjusting of age and BMI.
Conclusions: The incidence of drug-induced liver
injury is around 15% among TB pastients in Indonesia
who used standard ﬁxed dosed combination regimens.
The TB program need to increase awareness on this
potential liver injury related to TB drugs. Prospective
studies are needed to know the inﬂuence of genetic
polymorphism among DILI patients group.
533. Utility of Social Media Surveillance for Drug
Safety and Signal Detection Purposes
Brian Dreyfus,1 Jaidev Dasgupta,2 Andres Gomez-Caminero.3
1Bristol-Myers Squibb, Wallingford; 2Teranode, Westwood;
3Bristol-Myers Squibb, Hopewell.
Background: Access to safety data in the real world is
accompanied by delays of months to years. The avail-
ability of real time data from social media may be able
to provide more timely safety information. Thoughtful
review and communication of these data to different
stakeholders may allow for improved risk manage-
ment of the medications patients receive.
Objectives: This study was conducted to evaluate the
usefulness of social media for signal detection purposes.
Methods: The drug-event pairs, telaprevir (TLP) with
fatal skin reactions and boceprevir (BCP) with hyper-
sensitivity were selected. The labels (USPI) of TLP
and BCP were updated for these events in December
and November of 2012, respectively. Posts were cap-
tured from Facebook (FB), Twitter (TW), chat forums
and blogs (CF) from May 2012 through July 2013.
Posts were ﬁltered by the Medical Dictionary for
Regulatory authorities (MedDRA) ontology and a cus-
tom ontology of vernacular terms. The data were ana-
lyzed based on the number of posts per time period,
proportional reporting ratio (PRR), and content.
Results: 2775 CF, 1192 TW, and 43 FB posts for TLP
were included. BCP had 968, 724 and 30 posts respec-
tively. In the quarters (Qtr) before the USPI change for
TLP there were 58 and 60 posts for skin type events.
188 were in the Qtr of the change with 76% occurring
concurrently or following the USPI update. For BCP,
there were 29, 34, 41, 34 and 22 posts per Qtr for
hypersensitivity with no increase preceding the USPI up-
date. Most posts were not medically meaningful; primar-
ily with TW and FB. The PRR demonstrated the ability
to differentiate between the two products with regards
to speciﬁc adverse effects, e.g., skin reaction and anemia.
Conclusions: The study demonstrated that social media
provided useful insight on a patient’s experience with
treatment although many of the social media posts were
not relevant for drug safety purposes. The results did not
predict USPI changes; however, the analysis was limited
to only two drugs and a short observation time preceding
the events under study. A larger study is in progress to
establish if social media can identify safety signals.
534. Exploring Adverse Event Reporting Patterns of
Newly Approved Anti-Cancer Drugs in the Japanese
Adverse Drug Event Report (JADER) Database
Shinichi Matsuda, Kenji Hamada, Kotonari Aoki.
Drug Safety Data Management Department, Chugai
Pharmaceutical Co. Ltd., Tokyo, Japan.
Background: While the Japanese Adverse Drug Event
Report (JADER) database has become publicly available
since April 2012, the patterns and factors inﬂuencing
adverse drug reaction (ADR) reporting in Japan are
poorly understood. The Weber effect that was ﬁrst de-
scribed in UK is the well-known pattern of adverse event
reportingwith an increase in numbers and peak in the ﬁrst
2 years after marketing of a new drug, and then declining.
Objectives: To evaluate the validity of the Weber
effect in JADER database.
Methods: Nineteen anti-cancer drugs approved be-
tween 2004 and 2010 were used for the present study.
All these drugs were approved as the new-molecular
entities and the post-marketing all-case surveillances
were conducted as the post-approval commitments.
All reports in JADER were dated according to
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Pharmaceuticals and Medical Devices Agency
(PMDA) received date (quarter of the year). The num-
ber of ADRs for each drug per year from the time of
approval until 2012 was analyzed. Reporting patterns
were considered to demonstrate the Weber effect if
the peak was during the ﬁrst 2 years after product ap-
proval and then followed by a decline.
Results: Based on the reporting patterns, the drugs were
classiﬁed into three types: type W included drugs that
showed the Weber effect (42%); type N included drugs
that showed increase to a peak in a few years and
followed by a decline and increase again (53%); other
types (5%). Some of the second peaks in the type N drugs
were occurred after the approval of new indications.
Conclusions: Although the ADR reporting require-
ments are different between Japan and UK, the Weber
effect was conﬁrmed in 42% of drugs analyzed. In
Japan, the Early Post-marketing Phase Vigilance
(EPPV) and all-case surveillance could facilitate ADR
reporting after product approval. Our results imply that
interpretation of AE reporting or comparison between
drugs should be done with caution if there are regulatory
changes such as approval of new indications.
535. Bisphosphonate Therapy and Osteonecrosis of
the Jaw: A Case/Non-Case Study in the French
National Pharmacovigilance Database
Paul de Boissieu, Malak Abou Taam, Marie-Paule Roux,
Lukshe Kanagaratnam, Thierry Trenque. Department of
Pharmacovigilance and Pharmacoepidemiology, Reims
University Hospitals, Reims, France.
Background: Bisphosphonate related osteonecrosis
of the jaw (ONJ) have been described in 2003. Since,
ONJ were included in the summary of product
characteristics of bisphosphonates.
Objectives: The main objective of this study was to
investigate the association between exposure to
bisphosphonates and the risk of ONJ in the French
national pharmacovigilance database (FNPD).
Methods: We used a case/non-case methodology. All
cases of adverse drug reaction (ADR) involving ONJ
spontaneously reported to the FNDP from 1985 to
May 31st 2013 were reviewed. Cases were ONJ and
non-case were all other ADR recorded in the FNDP.
The reporting odds-ratio (ROR) was calculated with
the appropriate 95% conﬁdence interval (CI95%).
Cases of ONJ under bisphosphonates were described.
Results: A total of 143 reports associated with
bisphosphonates were collected. Patients were 67years
old (+/- 12), female (75%). Risk factors have been
identiﬁed in 122 cases (85,3%).The indication of
bisphosphonate therapy were : bone metastasis (44%), os-
teoporosis (23%), myeloma (15%) and others (18%). The
location of the ONJ was majority mandible (67%). The
evolutions were: persistence (61%), irreversible lesions
(11%), recovering in process (10%), recovered completely
(6%), death due to another cause (5%) and unknown (7%).
We have observed an increased risk of ONJ with the use
of bisphosphonates: ROR=3448 (CI95%: 1431-8417).
Conclusions: Treatment with bisphosphonates is
associated with an increased risk of ONJ. ONJ
development is multifactor and rare clinical entity
which remains poorly understood.
536. Dopamine Agonists: Time Pattern of Adverse
Effects Reporting in Australia
Samantha A Hollingworth,1 Treasure McGuire,1 David
Pache,1 Mervyn J Eadie.2 1School of Pharmacy, The
University of Queensland, Woolloongabba, QLD, Australia;
2School of Medicine, The University of Queensland, Herston,
QLD, Australia.
Background: While dopamine agonists (DA) are
effective in the control of Parkinson’s disease, their
use has recently decreased in Australia. This may be
a consequence of unusual adverse events reported with
ergot DAs being more widely appreciated.
Objectives: To examine the pattern of adverse event
(AE) reporting of DAs in Australia over two decades
and to determine if there is a class difference in the
spectrum of AEs with ergot and non-ergot DAs.
Methods: In Australia, there is voluntary reporting of
suspected AEs of therapeutic medicines by health
professionals and consumers. We analysed the case
listings of AEs obtained from the Australian Committee
on the Safety of Medicines (ACSOM) for bromocriptine,
cabergoline, pergolide, pramipexole and ropinirole; and
related them to drug utilisation as dispensed prescriptions
(1992-2012). The main outcome measures were nature,
frequency, onset, novelty, severity and outcome of AEs.
Results: The 220 suspected AEs reported fell into ﬁve
categories: (i) syncopal/ pre-syncopal, (ii) ﬁbrotic, (iii)
psychotic, (iv) obsessive-compulsive behaviours
(OCB) and (v) increased sleep. Of note were differen-
tial lag times between initial individual drug
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registration and reporting of these suspected AEs.
There was a lag of at least one year for ﬁbrotic reac-
tions and OCB compared to more contemporaneous
reporting of other AEs. Fibrotic reactions appear to
be class-type AEs of ergot DAs, whereas symptomatic
hypotensive reactions, psychosis and OCB occurred in
both ergot and non-ergot DAs, cabergoline and
pramipexole, respectively. Reports of syncopal and
pre-syncopal reactions seemed to diminish as ergot
DA use declined. Sleep pattern abnormalities were re-
ported too infrequently to permit conclusions.
Conclusions: Consistent with published literature, the
ACSOM data showed that ergot DAs share ﬁbrotic re-
actions as a class AE. The remaining categories of AEs
relate to individual medicines rather than a subclass.
537. Analysis of Safety Profiles between Iodinated
Contrast Media and Anaphylaxis Based on Korea
Adverse Event Reporting System
Yeonju Woo,1 Sooyoun Chung,1 Byung-Joo Park.1,2
1Korea Institute of Drug Safety & Risk Management,
Seoul, Republic of Korea; 2Department of Preventive
Medicine, Seoul National University, College of
Medicine, Seoul, Republic of Korea.
Background: Hypersensitivity to iodinated contrast
media(IOCM) occurs in 1-3% of patients. Anaphy-
laxis, one of this adverse event(AE), is uncommon
but serious, so it is need to investigate drug safety
proﬁles about IOCM.
Objectives: The aims of this study were to identify the
characteristics of IOCM induced anaphylaxis in Korea
and to compare the safety proﬁles of different IOCM.
Methods: This study conducted a retrospective,
disproportional analysis of the IOCM - including
iopromide, iohexol, iopamidol, iomeprol, ioversol,
iobitridol, iodixanol and diatrizoic acid - induced
anaphylaxis reports in Korea Adverse Event Reporting
System (KAERS) database from January 1, 1989 to
June 30, 2013. Safety proﬁles were compared between
different IOCM using the proportional reporting ratio
(PRR) and 95% conﬁdence interval (95% CI).
Results: A total of 362,689 reports, 38,040 (10.49%)
reports were related to the use of IOCM and total
59,330 AEs were reported. Of all AEs related to the
use of IOCM, 333 (0.56%) AEs were anaphyalxis
and the most frequently reported IOCM is iopromide
(178, 53.45%), followed by iohexol (45, 13.51%)
and iomeprol (33, 9.91%). Among the IOCM at least
three reported, disproportaionality of iodixanol (PRR,
4.00; 95%CI, 2.76-5.80), ioversol (PRR, 2.95; 95%
CI, 1.96-4.44) and iopromide (PRR, 2.92; 95% CI,
2.51-3.39) were higher caculated for IOCM induced
anaphylaxis than the other IOCM.
Conclusions: Our study shows that disproportaionality
was different between eight IOCMs and we expect that
this study would be used to research safety of IOCM. It
is need to further investigate incidence and mortality of
IOCM induced anaphylaxis using large scale insurance
claim data.
538. Knowledge, Perception Attitude About Adverse
Drug Reaction (ADR) and ADR Reporting Among
Pharmacy Students’ in Malaysian Private University
Mohamed Shukry Zawahir,1,2 Rodgne Alexius Sultan,1
Mohd Fadli Mohd Asmani,1 Eddy Yusuf.1 1School of
Pharmacy, Management and Science University,
Shah Alam, Selangor, Malaysia; 2Faculty of Medicine,
University of Ruhuna, Galle, Sri Lanka.
Background: ADRs have medical as well as eco-
nomic consequences, leading to increased patient
morbidity and mortality. Under reporting of ADR is
a huge health problem in Malaysia and the globe.
Objectives: To determine the knowledge, perception
and attitude of Pharmacy students at Management
and Science University (MSU), Malaysia on Pharma-
covigilance system and ADR reporting, and explore
demographic characteristics and clinical experience
inﬂuence on the effect.
Methods: This was cross sectional study; a pre vali-
dated questionnaire was used to assess the knowledge,
attitude and perception of pharmacy students at MSU.
Date were collected by face to face interview after
informed consent obtained. The response rate was
76% consisting of 80 participants. Data analyses were
done descriptively and t-test using SPSS version 18.
Results: Majority of the respondents (75%) were
females. The mean of respondents’ age was 22 (SD
1.64) & 20% of the respondents were exposed to clinical
attachment. During their clinical attachment about 16.3%
had experienced ADR reporting. The mean knowledge
about pharmacovigilance and ADR reporting was high
among the respondents 10.2 (SD=1.6) compared to that
of their perception 2.85 (SD=1.0) and attitude 3.7
(SD=1.3). The independent t-test results showed that
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socio-demographic and year of academic candidature
and clinical attachment at hospital have no signiﬁcant in-
ﬂuence on knowledge and perception and attitude of the
respondents, however awareness of Malaysian Adverse
Drug Reaction Advisory Committee has signiﬁcant in-
ﬂuence on knowledge about ADR reporting (p = 0.013).
Conclusions: Pharmacy students in this private institution
is having sufﬁcient knowledge about Pharmacovigilance
and ADR reporting. Pharmacy curriculum and delivery
system should be improved in order to increase
students’ perception, attitude and future practice on
ADR reporting. Further studies should be conducted
including many private institution in the country.
539. Side Effects Associated withAntiretroviral Therapy
(ART) in Nepal
Shyam P Lohani,1 Punita Rimal,1 Prakash Panta.2 1Nepal
Drug and Poison Information Center (NDPIC),
Kathmandu, Bagmati, Nepal; 2Medicine, Kathmandu Uni-
versity Medical School (KUMS), Dhulikhel, Kavre, Nepal.
Background: Approximately 50,200 adults and
children are living with HIV in Nepal. The total
ART coverage reached 23.7 % by December 2011,
and 6,051 adults, and 432 children were accessing
ART from 26 ART centers and 10 sub-ART centers
throughout the country.
Objectives: To examine the incidence of side effects
associated with ART intake as reported to the Nepal
Drug and Poison Information Center (NDPIC).
Methods: We analyzed retrospectively all queries
related to ART side effects to a NDPIC from 1st June
2006 to 30th May 2013. Data entry and analysis was
carried out using SPSS 16.0.
Results:A total of 195 consecutive cases were reported to
NDPIC. Seventy eight percentages of cases were males
(n=152) and remaining were female (22%, n=43). Ages
ranged from 22 to 56years, mean 35years (±10.00).
Combinations of fatigue (n=48), nausea (n=33),
vomiting (n=27) and headache (n=26) were the main
complaints. Other effects were dry mouth, diarrhea,
dizziness, skin rashes, confusion, fever, migraine, mood
swing, insomnia, loss of appetite, sleeping disorders, and
nightmares were the initial presenting symptoms. Time
to onset of side effects ranged from 30minutes to 8 hours
after taking antiretroviral drugs. Treatment was symp-
tomatic and supportive. In all cases, side effects were self
limiting and patients were continued of ART therapy.
Conclusions: Patients can develop numerous side ef-
fects within a relatively short time of initiating ART
therapy. In our experience, these reactions resolved
with supportive and symptomatic treatments; how-
ever, larger and more systematic investigation would
be helpful in delineating risk factors for severe reac-
tions or discontinuation of ART medicines. This issue
represents an important surveillance goal for drug and
poison information centers, which are encouraged to
coordinate with ART distribution centers and HIV
researchers in developing countries.
540. Case Review of Hypersensitivity Reactions Ass-
ociated with Platinum Antineoplastic Agents
Pei-Tzu Lin, Ching-Ling Tai. Pharmacy, Chiayi
Chang Gung Memorial Hospital of the C.G.M.F, Chiayi,
ROC, Taiwan.
Background: Platinum antineoplastic agents, includ-
ing cispltin, carboplatin and oxaliplatin, are one of
the ﬁrst line chemotherapy agents for ovarian, bladder,
head and neck, colorectal, and lung cancer. Incidence
of adverse drug reactions (ADRs) of platinum agents
increases when prolong use.
Objectives: Hypersensitivity reactions which would
increase the burden of patients and caregivers. To
analyze the characteristic of ADR associated with
platinum to make notiﬁcations to caregivers.
Methods: The data of retrospective study was claimed
from the Reporting System of Adverse Drug Reactions
from Jan 2000 to Dec 2012. Hypersensitivity reactions
associated with platinum agents were extracted by
material code and types of ADRs.
Results: 47 events that suspected ADR related
platinum agents were reported. 36 events(77%)were
hypersensitivity reactions. Baseline characteristic were
female(58%), outpatient therapy(58%) and younger
than 65 years old(67%).Oxaliplatin had 22 events
(61%);13 of them happened after 5th used and 9 of
them were within 3rd used and 10 events shifted to
other non-platinum agents.There were 12 events in
cisplatin; there was only one event suffered from
hypersensitivity at the 1st time, others happened
after the 6th time; that induced 2 events transfer to
non-platinum agents and 2 turned into carboplatin.
There were 2 events in carboplatin and they suffered
from hypersensitivity at the 13th and 25th and one
shift to non-platinum agents. The majority of symp-
toms were skin disorders (51%) and the 2nd relative
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symptoms was respiratory reactions(29%), such as
dyspnea, short of breathless and chest pain. By the
degree of severity, moderate that needed therapy
were 31 events(86%, others were mild that just
needed close monitoring.
Conclusions: Hypersensitivity usually appears after
multiple infusions that are different from other
medicines always happen at the ﬁrst time. Besides
discontinuing immediately, there are no speciﬁc
methods to conduct the reaction after that. In our
study, half of the patients had no shift to other
agents therapy.Caregivers and patients should be
monitored closely and informed the risk of
hypersensitivity regardless patients had be treated
or not.
541. Acute Topical β-Blocker Exposure in Asthma:
Meta-Analysis of Controlled Clinical Trials
Daniel R Morales,1 Bruce Guthrie,1 Brian J Lipworth,3
Cathy Jackson,2 Tobias Dreischulte.1 1Medical Research
Institute, University of Dundee, Dundee, United Kingdom;
2Medical School, University of St Andrews, St Andrews,
United Kingdom; 3Asthma & Allergy Unit, University of
Dundee, Dundee, United Kingdom.
Background: β-blockers may cause exacerbations in
patients with asthma. The risk varies according to drug
selectivity, dose of administration and is generally
greatest following acute exposure. Risk has been
quantiﬁed for oral but not topical β-blocker exposure
commonly used in the treatment of glaucoma.
Objectives: To evaluate changes in respiratory func-
tion following acute topical β-blocker exposure to
better inform their use in patients with glaucoma and
co-existing asthma.
Methods: A systematic review of MEDLINE,
EMBASE and CENTRAL databases identiﬁed all con-
trolled clinical trials evaluating acute topical β-blocker
exposure in asthma. Data were extracted and effect esti-
mates for changes in forced expiratory volume in one
second (FEV1) and symptoms were pooled using
ﬁxed-effect meta-analysis.
Results: A total of 10 clinical trials were identiﬁed.
Among patients unselected on the basis of prior
exposure, non-selective topical β-blockers caused falls
in FEV1 of ≥15% in 1 in 3 patients (risk difference
[RD] 0.35 95%CI 0.28-0.46, p< 0.001) and a mean
fall in FEV1 of -10.8% (95%CI -14.2 to -7.3, p
0.001). Among patients selected on the basis of prior
non-selective topical β-blocker sensitivity, selective
topical β-blockers caused falls in FEV1 of ≥15% in 1
in 3 patients (RD 0.35 95%CI 0.11 to 0.59,
p = 0.005) and a mean fall in FEV1 of -6.3% (95%CI
-11.7 to -0.8, p = 0.03). On the basis of 1 in 3 patients
being sensitive to non-selective topical β-blockers, se-
lective agents would be expected to cause signiﬁcant
falls in FEV1 of ≥15% in approximately 1 in 9 patients
unselected on the basis of prior exposure.
Conclusions: The use of non-selective topical β-blockers
poses a signiﬁcant risk to glaucoma patients with
co-existing asthma. Although better tolerated, selec-
tive topical β-blockers may still cause small signiﬁ-
cant changes in respiratory function in susceptible
patients with asthma.
542. Cases of Anaphylaxis Associated with the Use of
Drugs: Analysis of a Pharmacovigilance Database
Diogo Mendes,1,2 Carlos Alves,1,2,3 Francisco Batel
Marques.1,2 1Central Portugal Regional Pharmacovigilance
Unit, Centre for Health Technology Assessment and Drug
Research (CHAD), AIBILI - Association for Innovation and
Biomedical Research on Light and Image, Coimbra,
Portugal; 2School of Pharmacy, University of Coimbra,
Coimbra, Portugal; 3Health Sciences Research Centre,
University of Beira Interior, Covilha.
Background: Anaphylaxis is a systemic reaction with
an acute onset of illness, often life threatening, and
usually unexpected.
Objectives: This study is aimed at characterizing
cases of anaphylaxis spontaneously reported to the
Regional Pharmacovigilance Unit of Central Portugal
(UFC).
Methods: Spontaneous reports (SRs) of adverse drug
reactions (ADRs) received by the UFC between Janu-
ary 2001 and January 2014 were analyzed. Suspected
drugs were classiﬁed according to the Anatomical
Therapeutic Chemical (ATC) Classiﬁcation System.
ADRs were classiﬁed according to the MedDRA
dictionary (v.16.1). Causality was assessed using the
global introspection method. SRs containing ADRs
coded in the preferred terms (PT) “anaphylactic reac-
tion”, “anaphylactic shock”, “anaphylactoid reaction”,
or “anaphylactoid shock” were included in the study if
they had been assessed as possibly, probably or deﬁ-
nitely related to the suspected drug. Data processing
was performed using SPSS (v.17.0).
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Results: A total of 42 cases matched the inclusion
criteria; 31 (73.8%) were assessed as deﬁnitely, 10
(23.8%) as probably, and 1 (2.4%) as possibly related to
the suspected drug. The mean age (±SD) of the patients
was 58.2 (±17.2) years and 62% were female. The signs
and symptoms of anaphylaxis more frequently reported
were erythema (n=10; 9.3%), rash (n=8; 7.4%), hypo-
tension (n=7; 6.5%), dyspnea, feeling hot (each, n =6;
5.6%); back pain, pruritus (each, n =5; 4.6%), angio-
edema, bronchospasm, ﬂushing, malaise, tachycardia,
and throat tightness (each, n=3; 2.8%). Docetaxel
was the suspected drug more commonly associated
with cases of anaphylaxis (n=8; 19.0%), followed by
metamizole (n=5; 11.9%), oxaliplatin (n=4; 9.5%),
cetuximab (n=3; 7.1%), alteplase, and paclitaxel (each,
n=2; 4.8%).
Conclusions: Antineoplastic drugs were the most
frequently suspected ones associated with cases of
anaphylaxis. Further, dermatologic and respiratory
signs and symptoms were often observed. Healthcare
professionals should be aware of these features,
since an early recognition of these cases is critical
to the ﬁnal outcome.
543. Medications Prescribed and Occurrence of
Falls in Inpatient Setting
Ming-Fen Wu,1 Yen-Lin Chang,1 Wen-Shyong Liou,1
Sek-Kwong Poon,2 Li-Yin Chang.3 1Pharmacy, Taichung
Veterans General Hospital, Taichang, Taiwan; 2Internal
Medicine, Taichung Veterans General Hospital, Taichung,
Taiwan; 3Nursing, Taichung Veterans General Hospital,
Taichung, Taiwan.
Background: Medication usage has been identiﬁed as
a major risk factor for accidental falls.
Objectives: This study was to evaluate the association
between medications use and falls and identify
medications that may contribute to the risk of falls in
inpatient setting.
Methods: A retrospective case control study was
performed in a medical center in Central Taiwan. Data
were collected from nursing records and medical
records. Adult patients (≥20 years of age) admitted
between 1 July 2011 and 30 June 2013, experiencing
a fall at least 48 hours after hospital admission were
included in the case group. Each case was matched by
propensity score, according to the age (within 5 years),
sex, admission date (within90 days), patient care unit,
length of stay, and Charlson comorbidity index.
Medications administered within 48 hours before the
fall for the case group or designated fall date and time
for the control group were documented. Matched
case–control medications with ATC codes data were ex-
plored using logistic regression model.
Results: Of the 312 documented fall events, 211 pa-
tients met the inclusion criteria. Of those patients, 592
matched control patients on all criteria. The characteris-
tics of the two groups (case vs. control) were similar ex-
cept for dizziness/vertigo (p< 0.01), agitated, confused
or disorientated (p = 0.024), previous history of fall
(p< 0.01),and leg weakness(p = 0.046).The probability
of falls increased signiﬁcantly when the patients used
antidepressants (adjusted odds ratio [AOR] 2.002;
95% CI 1.15, 3.487; p = 0.014) and corticosteroids
([AOR] 2.023; 95% CI 1.422, 2.879; p <0.01).
Conclusions: In a sample of hospitalized patients, Anti-
depressants were signiﬁcantly associated with an in-
creased risk of falls, which is similar to other researches’
ﬁndings. These medications should be avoided when
alternatives exist. There are extensive studies for antide-
pressants, however, insufﬁcient researches for corti-
costeroids to support our ﬁnding. Further researches are
necessary to study the role of dosing, duration, and type
of corticosteroids in relation to the occurrence of falls.
544. Common Causative Agents of Nephrotoxicity
in a Regional Pharmacovigilance Center Based on
an Academic Hospital in Korea, 2009-2013
Shin-Woo Kim, Hyun-Ha Chang, Su-Jung Kim,
Jong-Myung Lee. Internal Medicine, Kyungpook
National University Hospital, Daegu, Republic of Korea.
Background: Nephrotoxicity caused by medications
induce prolongation of admission and difﬁculties of
patient care.
Objectives:We aimed to investigate the recent common
drugs that cause acute kidney injury.
Methods: A regional pharmacovigilance center based
on an academic hospital (Kyungpook national univer-
sity hospital) in South Korea reported the adverse ef-
fects of drugs to the national pharmacovigilance
center. We analyzed the agents of nephrotoxicity in
this report. Duration of adverse effect report was
between August 2009 and December 2013.
Results: Total reported cases were 372 cases
[probable (206, 62.0%), possible (110, 33.1%) and
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certain (16, 4.8%)]. According to ATC code (Anatom-
ical Therapeutic Chemical Classiﬁcation System),
J (antiinfectives for systemic use) 155 (46.7%), C
(cardiovascular system) 76 (22.9%), L (antineo-
plastic and immunomodulating agents)(especially
anticancer drug) 33 (9.9%), V (various)(especially
radiocontrast dye) 30 (9.0%), M (musculo-skeletal
system)(especially analgesics) 21 (6.3%), A (Ali-
mentary tract and metabolism)(especially oral
hypogycemics) 8 (2.4%), N (nervous system) 5
(1.5%), and H (systemic hormonal preparations,
excluding sex hormones and insulins)(especially
steroids) 4 (1.2%) were reported. Common antimi-
crobials caused kidney injury included glycopeptide
(42, 27.1%, vancomycin 36, teicoplanin 6), aminogly-
coside (22, 14.2%), colistin (25, 16.1%) amphotericin
B (22, 14.2%), and penicillins (17, 11.0%). Common
cardiovascular drug included loop diuretic (48. 63.2%)
and antihypertensives (25, 32.9%).
Conclusions: Recent common drugs causing neph-
rotoxicity are antibiotics (glycopeptide, aminoglyco-
sides, and colistin), diuretics, and radiocontrast dyes
in a regional pharmacovigilance center of Korea.
We have to be careful to use these kinds of drug
against nephrotoxicity in the clinical setting.
545. Baseline Risk Factors for Cardiovascular
Events: Differences between the USA and Russia
in a Study Population of Combined Oral Contra-
ceptive Users
Suzanne Reed, Klaas Heinemann, Juergen Dinger.
Berlin Center for Epidemiology and Health Research
(ZEG), Berlin, Germany.
Background: Risk of venous thromboembolism
(VTE) increases with COC use, and is compounded
by the existence of other risk factors, such as
obesity. Therefore, it is important to consider potential
confounding inﬂuences that pre-existing risk factors
could have on measurements of VTE risk. In
multinational studies, stratiﬁcation by country can
facilitate an understanding of important regional
differences that may inﬂuence the interpretation
of results.
Objectives: To describe the baseline characteristics of
new users of combined oral contraceptives in the USA
and in Russia.
Methods: The International Active Surveillance
Study – Folate in Oral Contraceptives Utilization
Study (INAS-FOCUS) is a prospective, controlled,
non-interventional long-term cohort study. New
users of combined oral contraceptives are recruited
in the USA and Russia by prescribing physicians.
Information is collected on patients’ demographics,
history of contraceptive use, personal and family
medical history, height and weight and lifestyle fac-
tors, such as smoking and exercise.
Results: A total of 37,991 women were recruited
through October 2013. First-ever users of COCs
comprise 70% of the study population in Russia
and 30% in the USA. Russian COC users have a
higher mean age (30.1 years) than American COC
users (25.6 years). American COC users have a
higher mean weight and mean BMI (71.5 kg and
26.7, respectively) than Russian COC users
(63.4 kg and 23.0, respectively). About 25% of
American COC users are obese compared to 5%
of Russians. Mean duration of OC use is shorter
in Russia (2.2 years) than the USA (4.8 years).
Over 30% of COC users in the USA had surgery
prior to study entry compared to 12% in Russia.
American COC users are more likely to use
medication regularly (18.8%) than Russians
(3.7%), and to have high blood pressure (USA:
2.3%; Russia: 1.0%). Cigarette smoking is more
common among Russian COC users (18.8%) than
Americans (14.9%).
Conclusions: Notable differences in cardiovascular
risk factors exist between American and Russian
COC users, such as age, BMI, treated hyper-
tension, smoking habits and use of concomitant
medication.
546. Improving Knowledge, Attitude and Practice of
Pharmacovigilance among Traditional Medicine
Practitioners in Lagos State, Nigeria
Ibrahim Oreagba,1,2 Khadija Ade-Abolade,2 Adeline
Osakwe,2 Olayinka Ogunleye,3 Kazeem Oshikoya.3
1Pharmacology Therapeutics and Toxicology, University
of Lagos, Lagos, Lagos, Nigeria; 2National Phar-
macovigilance Centre, National Agency for food and
Drug Administration and Control, Lagos, Lagos,
Nigeria; 3Department of Pharmacology, Lagos State
University, Lagos, Nigeria.
Background: In recent times, the use of herbal medi-
cines has increased and so monitoring of their safety
should be paramount. Poor reporting of adverse drug
reactions to herbal medicines may be attributed to the
absence of a vibrant monitoring system primarily
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caused by lack of knowledge of pharmacovigilance
and its practice; and poor attitudes by the practitioners.
It is therefore important to improve the knowledge,
attitude and practice of pharmacovigilance among
Traditional Medicine Practitioners.
Objectives: The study evaluated the impact of an
educational intervention on the knowledge, attitude
and knowledge of practice of pharmacovigilance among
Traditional Medicine Practitioners in Lagos State.
Methods: A cross-sectional study using a pre-tested
questionnaire to obtain baseline, immediate and one
month post-intervention information on knowledge,
attitude and practice of pharmacovigilance among the
respondents. The Paired T-Test and Analysis of Vari-
ance were used to compare the means of variables
during the study.
Results: Mean knowledge and attitude to
Pharmacovigilance scores signiﬁcantly improved by
the end of the study from 14.4 ± 4.3 to 16.7 ± 4.8
(P = 0.003) and 4.2 ± 0.6 to 4.6 ± 0.7 (P = 0.000)
respectively. However the improvement in knowledge
of practice of Pharmacovigilance was not sustained
as the P-value increased from 0.04 to 0.5. While
educational levels of the participants inﬂuenced the
impact of the intervention (P< 0.05), their gender
did not (P> 0.05).
Conclusions: Continual improvement of the
pharmacovigilance knowledge, attitude and practice of
Traditional Medicine Practitioners through regular edu-
cational interventions is necessary for their effective
participation in safety monitoring of herbal medicines.
547. Adverse Drug Event of Hospitalized Patients
from Multi-Hospitals in Thailand
Pramote Tragulpiankit,1 Narak Yeesoonpan,1 Thida
Ninsananda,2 AdCoPT Working Team,2 Busba
Chindavijak,1 Suvatna Chulavatnatol,1 Usa Chaikledkaew,1
Tikumpon Uaviseswong.1 1Faculty of Pharmacy, Mahidol
University, Bangkok, Thailand; 2The Association of
Hospital Pharmacy (Thailand), Bangkok, Thailand.
Background: An adverse drug event (ADE) includes
injuries caused by a drug whether from medication
error or appropriate usage [i.e. adverse drug reaction
(ADR)]. Although the number of ADR reporting
based on national pharmacovigilance scheme has been
increased, few natures of ADE studies from multi-
hospitals are available in Thailand.
Objectives: To determine the rate and characteristics
of ADE of hospitalized patients.
Methods: This study was conducted with an observa-
tional design by systematic chart review. Nine selected
provincial hospitals which there is a member of lead-
ing team of community of practice in ADR monitoring
under auspicious of the Hospital Pharmacy Associa-
tion (Thailand) across Thailand participated during
March to December 2012. The hospitalized patients
who admitted at medical wards were recruited by
convenience sampling. The ADE trigger tool which
consisted of modiﬁed 24 triggers were screened by
manual chart review and then suspected ADE was
determined. The rate of ADE occurring per 100 admis-
sions, per 1,000 patient-days and characteristics of
ADE in terms of 1) causing hospital admission whether
occurring during hospitalization 2) preventability 3)
severity 4) drug group causing and 5) organ affecting
disorder were analyzed using descriptive statistics.
Results: Total 149 ADE events from 144 patients out of
2,368 medical chart reviews were detected. The rate of
ADEs was 6.3% (95% CI: 5.3-7.3) and 13.7 (95% CI:
11.5-15.9) events per 1,000 patient-days. Total 53.7%
of ADE resulted in hospital admission. Seventy-two
ADEs or 48.3% (95% CI: 40.1-56.5) were classiﬁed as
preventable ADEs. Level F (i.e. is deﬁned as “harm that
contributed to or resulted in temporary harm to the pa-
tient and required initial or prolonged hospitalization”)
was accounted by 95 events (63.8%). Cardiovascular
drugs were common drug groups caused ADEs by 50
out of 155 drugs (32.3%). The most ADEs expressed
as endocrine disorders, gastrointestinal disorders and
skin disorders account by each 29 events (19.5%).
Conclusions: ADEs are not uncommon problem of
hospitalized patients. The preventing ADE should be
further developed.
548. Analysis in Adverse Reactions of Radiocontrast
Agent Using Association Rule Mining in Regional
Pharmacovigilance Center
Gyeong ImYu,1,5 YoonNyunKim,2Chang Sik Son,3Hyeok
Won Jang,4,5 Sang Hyon Kim,2,5 Dong Hoon Shin.1,5 1Pre-
ventive Medicine, School of Medicine, Keimyung University,
Daegu, Republic of Korea; 2Internal Medicine, School of
Medicine, Keimyung University, Daegu, Republic of Korea;
3Biomedical Informatics Technology Center, Keimyung
University, Daegu, Republic of Korea; 4Diagnostic Radiol-
ogy, School of Medicine, Keimyung University, Daegu, Re-
public of Korea; 5Regional Pharmacovigilance Center,
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Keimyung University Dongsan Medical Center, Daegu,
Republic of Korea.
Background: Adverse reactions of radiocontrast agent
probably involves direct cellular effects, enzyme induc-
tion, and activation of the complement, ﬁbrinolytic,
kinin, and other systems. In data mining, association
rule learning is a popular and well researched method
for discovering interesting relations between variables
in large databases.
Objectives: The purpose of this study was to ana-
lyze the adverse reactions of radiocontrast agent
using association rule mining (ARM) based on
Apriori algorithm.
Methods: The subjects were extracted from DSMD
Regional Pharmacovigilance Center. The ARMmethod
was used to analyze relationship of subject data. Total
subjects extracted 113 from DSMD Regional
Pharmacovigilance Center from January to April 2013.
Results: As a result of ARM, If Age< 60 yrs and
Itching then Urticaria (rule support, 23.89%; rule conﬁ-
dence, 79.41%; lift, 1.91). If Urticaria then Itching (rule
support, 40.71%; rule conﬁdence, 97.87%; lift, 1.78). If
Itching then Urticaria (rule support, 40.71%; rule
conﬁdence, 74.19%; lift, 1.78). If Iopromide then male
(rule support, 20.35%; rule conﬁdence, 54.76%; lift,
1.17). If Urticaria then male (rule support, 22.12%; rule
conﬁdence, 53.19%; lift, 1.13). If Age< 60 yrs and
Itching then male (rule support, 15.93%; rule
conﬁdence, 52.94%; lift, 1.13). If Urticaria and Itching
then male (rule support, 21.24%; rule conﬁdence,
52.17%; lift, 1.11). If male then Itching (rule support,
28.32%; rule conﬁdence, 60.38%; lift, 1.10). If Itching
then male (rule support, 28.32%; rule conﬁdence,
51.61%; lift, 1.10). If Urticaria then Age< 60 yrs (rule
support, 24.78%; rule conﬁdence, 59.57%; lift, 1.04).
If Urticaria and Itching then Age< 60 yrs (rule support,
23.89%; rule conﬁdence, 58.70%; lift, 1.02).
Conclusions: On Lift’s concepts showing, generated
Lift’s concepts of eleven in minimum support and con-
ﬁdence threshold of 15% and 50% level, respectively.
All Lift’s concepts suggested signiﬁcant result.
549. Use of Social Media in Pharmacovigilance:
Testing the Waters
Preciosa M Coloma, Benus Becker, Erik van Mulligen,
Jan A Kors. Medical Informatics, Erasmus MC University
Medical Center, Rotterdam, Netherlands.
Background: Social media is a phenomenon that is
increasingly becoming inﬂuential in health care.
Growing popularity of online communities and social
networks is stimulating exploration of these sources
for pharmacovigilance purposes,especially since new
EU pharmacovigilance legislation mandates use of all
available resources.
Objectives: To perform preliminary evaluation of the
potential contribution of mining social media for
pharmacovigilance using examples of drug-event
associations that have been ﬂagged as potential
signals: rosiglitazone and stroke/myocardial infarction;
and human papilloma virus (HPV) vaccine and prema-
ture ovarian failure.
Methods: Design/Setting: Publicly accessible data from
widely-used social media networking sites (Facebook,
GooglePlus,Twitter) were evaluated. Queries were also
executed via web search engines.
Main Outcome Measures:Social media sources
were characterised in terms of nature of data col-
lected/exchanged,year of establishment/country of or-
igin, volume of data (e.g., number of registered
users), language and user demographics,data access/
security, and identiﬁability of user information.The
search application programming interfaces (APIs)
for the selected sites were queried using relevant
key words from as far back as possible (varied
across sites).The subsequent mined results were
assessed manually for content and relevance to
pharmacovigilance.
Results: Social network data contained much dupli-
cation (as high as 96%) within and across different
sources and represented mostly links to news items
or websites of personal injury lawyers rather than
accounts of drug-related adverse experience.Geo-
graphical distribution of posts,number of posts
over time,and data from search engine queries sug-
gested possible trending in information coverage
and public sentiment. However, there was not
enough (retrospective) data from the evaluated
sources to provide relevant information for further
analyses.
Conclusions: Mining data from search engine
queries and social network sites may be useful
for suggesting emerging trends and public senti-
ment regarding potential drug safety issues, but
currently appears inadequate as basis for de novo
signal detection or reﬁnement. Further testing is
necessary.
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550. AComparison ofActiveAdverseEvent Surveillance
Systems Worldwide
Yu-LinHuang,1 JinheeMoon,1 Jodi B Segal.1,2 1Bloomberg
School of PublicHealth, JohnsHopkinsUniversity, Baltimore,
MD, United States; 2School of Medicine, Johns Hopkins
University, Baltimore, MD, United States.
Background: ADEs at low frequency will typically
not have been observed in pre-approval trials. Drug
regulatory agencies and industry are vigorously devel-
oping active surveillance systems for drugs, vaccines,
and medical devices to quickly identify therapies
causing harm to exposed patients.
Objectives: To describe the status of active surveillance
systems for ADEs worldwide.
Methods: Paired researchers reviewed published litera-
ture, as well as online sources, to identify existing
systems. Data was extracted into tables designed to
capture the key components of the active surveillance
systems. We reviewed and synthesized the information
across systems to identify common, and presumably,
essential features of active surveillance systems.
Results: We identiﬁed 9 active surveillance systems.
Each was designed for post-marketing surveillance of
pharmaceutical products (including vaccines), has a
goal of generating post-marketing drug safety infor-
mation, does not require personnel to initiate safety
reports, uses real-world data which are generated
from routine practice, and involves data from more
than a single institution. In the USA are Sentinel
Initiative and Vaccine Safety Datalink; in Canada
are Canadian Network for Observational Drug Effect
Studies and the Vaccine and Immunization Sur-
veillance in Ontario; in the EU are the EU-ADR Al-
liance and the Vaccine Adverse Event Surveillance and
Communication; in the UK are the VRMM in MHRA
and The Drug Safety Research Unit; in Asia is the
Asian Pharmacoepidemiology Network; in China is
the Shanghai Drug Monitoring and Evaluative System.
The surveillance systems all use administrative claims
or electronic medical records; some conduct
pharmacovigilance explicitly on behalf of a regulatory
agency, while others function more independently.
Conclusions: North America and Europe have the
most developed systems and most coverage of the
population; although some Asian countries are making
good advances. With the ever-increasing availability
of electronic data, active ADE surveillance should be
increasing feasible. This should translate to more rapid
signal detection, timely validation, and assurance that
drugs and vaccines are used safely.
551. Using New Information and Communication
Technologies (ICT) in Pharmacovigilance: Results
of a 2 Waves Survey Conducted in France in 2012
and 2013
Hubert Mechin,1 Benoit Martinet,1 Nathalie Beslay.2
1Drugee, Paris, France; 2Beslay+Avocats, Paris, France.
Background: Patients discuss a lot on social media
about their healthcare and about drugs they take, in
terms of efﬁcacy and safety (“Pharmacovigilance
2.0”). Risk Management and Pharmacovigilance
(PV) activities are more and more focusing on internet
and social media, recent regulation in this ﬁeld re-
quires that pharma companies pay more attention to
what is said and posted on social media and implement
digital methods to collect adverse drug reactions. We
are at the beginning of the digital revolution for
Pharmacovigilance activities and we are conducting
an annual survey to explore how pharma companies
will act according to these evolutions.
Objectives:
• To assess the safety and PV communication on
pharma company websites
• To identify PV process and usages on a digital
point of view.
Methods:
• Systematic screening of pharma company websites
in France (n = 77 in 2012 and 82 in 2013), 30% are
French companies, 70% are US or European companies
• Survey conducted within pharma company PV
managers in France with a 10 items online question-
naire (n = 27 respondents in 2012, 31 in 2013).
Results: Below is an extract of the survey results:
1/ Pharma company websites screening:
• Existing PV or safety section/page : 28/82 (34%) in
2013, vs 24/77 (31%) in 2012
• Online ADR data collection system : 10/82 (12%) in
2013, vs 6/77 (8%) in 2012
2/ Survey to PV responsible:
• Percentage of ADR coming from patients : 15% in
2013, vs 13% in 2012
• Usage of an ADR screening system on digital media
: 29% in 2013, vs 26% in 2012
• Speciﬁc website utilization for Risk Management
Plan : 50% in 2013, vs 44% in 2012.
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Conclusions: Only a third of pharma companies present
information about safety/risk/pharmacovigilance on their
corporate website, it has increased very slowly in 1 year.
Few companies have an online system for ADR
data collection.
Patients represent today between 13% to 15% of
declarant for ADR, this is a good starting point that
should increase year after year with the new EU
regulation and requirements
Lastly, 29% of pharma companies have a system in
place to screen digital media for potential PV reports.
552. MIHARI – Medical Information for Risk
Assessment Initiative Year 5
Chieko Ishiguro, Ayumi Endo, Kazuhiro Matsui,
Shinichi Watanabe. Pharmaceuticals and Medical
Devices Agency (PMDA), Tokyo, Japan.
Background: PMDA, the Japanese regulatory agency,
is being in a process of reinforcing and enhancing its
post-marketing safety measures as stated in its second
mid-term (FY 2009-2013) plan. MIHARI project has
started in PMDA since FY 2009 to develop a new safety
assessment system for post-marketing drugs using
Japanese medical databases and the update of MIHARI
in the last year of the second mid-term is reported.
Objectives: To develop a new safety assessment
system for post-marketing drugs using Japanese
medical databases.
Methods: The following 5 steps were applied to
multiple Japanese medical databases. 1) Establishment
of accessibility to multiple databases. 2) Evaluation of
each database by characterization studies, validation
studies, and other pilot studies. 3) Development of skills
to select appropriate study designs and statistical analy-
sis for each characterized database. 4) Practice about
real drug safety issues using the developed safety
assessment system. 5) Implementation of this system.
Results: In the ﬁfth year, MIHARI was at the fourth
and the ﬁfth steps described in the methods. Some
pilot studies about risk assessment and drug utilization
using claims data were performed in this year. Based
on the accumulated ﬁndings, knowledge, and expe-
riences from the previous pilot studies in the last
5 years, we summarized features of each database
available in Japan in order to make efﬁcient use of
those databases for the purpose of drug safety assess-
ment. We have started using these databases as inva-
luable sources of information for pharmacovigilance.
Conclusions: We established the framework to
commence operations of the novel safety assessment
system for post-marketing drugs using Japanese medi-
cal databases. We have achieved the goal of MIHARI
project successfully over this 5 years, and consequently
we will apply this framework to risk management of
drug safety in PMDA and make the system more
advanced in the next mid-term (FY 2014-2018).
553. Adverse Reactions of Cardiovascular Drugs in
Ukraine in 2011-2012
Oleksandr V Matvieiev,1,2 Olena I Koniaieva,1,2 Olena V
Matvieieva.2 1Clinical Pharmacology and Pharmaco-
therapy, Crimea State Medical University, Simferopol,
Crimea, Ukraine; 2Department of Post-Marketing
Vigilance, State Expert Center of Ministry of Health of
Ukraine, Kyiv, Ukraine.
Background: Death rate associated with cardiovacular
system is on the top in structure of deaths over the
world. Modern methods of pharmacotherapy have
signiﬁcantly decreased the lethality, loss of work ability
and improved quality of life but they may be dangerous
for patients due to adverse reactions (ADR).
Objectives: An aim of our study was to estimate rates
and speciﬁc patterns of ADR of drugs which inﬂuence
on cardiovascular system (cardiovascular drugs - CVD)
in Ukraine in 2011-2012.
Methods: Spontaneous reports about ADR sent by doc-
tors from all regions of Ukraine to national regulatory
agency and recorded in national database were ana-
lyzed. In 2011 1577 and in 2012 1904 reports about
ADR caused by CVD were obtained. During work we
also used ICD-10, and WHO causal classiﬁcation.
Results: A part of CVD reports in 2012 decreased in
comparison with 2011 from 17.7% to 16.3%
(p = 0,001) of all reports recorded in database. Most
frequently ADR were registered in females (67.4%).
Analysis of patients’ age revealed 2 risk periods for
CVD ADR: 59-63 and 70-74 y.o. About 15% of
reports informed about ADR of CVD prescribed for
treatment of non-cardiovascular pathology. Hyperten-
sion, coronary heart disease and cerebrovascular
pathology were leading ICD-10 classes. 2.8% of
patients had complicated allergy anamnesis. The lead-
ing CVD were: in “C01 – cardiac therapy” - isosorbide
dinitrate and amiodarone; in “C02 – hypotensives” –
urapidil and doxazosin; in “C03 - diuretics” –
indapamide and spironolactone; in peripheral
abstract292
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
vasodilators (C04) - pentoxyphilline and nicotinic
acid; in angioprotectors (C05) - Horse chestnut
extracts and quercetin; in beta-blockers (C07) -
bisoprolol (23.3%) and carvedilol (20.3%); in Ca2-
channel blockers (C08) – amlodipine and nifedipine;
in ACEI + sartans group (C09) – enalapril and
lysinopril (27.9% and 12.9%) and in hypolipidemic
drugs (C10) – atorvastatin and simvastatin. 92.2%
cases were not serious. Also we found signiﬁcant de-
crease in polypharmacy cases, mostly due to decrease
of cases with 4 and 5 accomponying drugs
(p< 0,0001). Also, we registered 5 lethal cases.
Conclusions: We have determined high-risk CVD
which need special attention of doctors of different
specialties.
554. Are Patients Ready to Take Part in the
Pharmacovigilance System – A Portuguese Prelimi-
nary Study Concerning Drug Reaction Reporting
Cristiano F Matos,1 Florence Pam van Hunsel,2 João J
Joaquim.1 1Farmácia, ESTESC-Coimbra Health School,
Instituto Politécnico de Coimbra, Coimbra, Portugal;
2Research & Analysis, Netherlands Pharmacovigilance
Centre Lareb, ‘s Hertogenbosch, Netherlands.
Background: New Pharmacovigilance legislation
allows patients to report ADRs directly to compe-
tent authorities in all EU member states. Patient
reporting is available in Portugal since July 2012.
In 2013 the National Pharmacovigilance System
(NPS) had received 3217 spontaneous ADR reports,
of which only 1.15% (n = 37) were reported by pa-
tients. Under-reporting remains a reality in Portugal,
although patient reporting could be one of the mea-
sures to reduce the rate of under-reporting by
healthcare professionals.
Objectives: The aim of this study was to describe the
attitudes and knowledge of the patients regarding spon-
taneous reporting and the reasons and patient opinions
that can inﬂuence patients ADR under-reporting.
Methods: A descriptive-correlational study was per-
formed looking for patient’s attitudes and knowledge
regarding spontaneous reporting. A 6-months survey
was conducted from June to November 2013 in
general adult patients from a community pharmacy in
Coimbra, Portugal, that used prescribed medicines or
OTC-drugs. Attitudes and opinions were surveyed in
a closed-answer questionnaire using a Likert scale.
Incomplete questionnaires and answers from Healthcare
professionals were excluded from data analysis. The
data were analyzed using descriptive statistics, χ2 tests
and Spearman’s correlation coefﬁcients.
Results: A total of 1084 questionnaires were collected
with a response rate of 81,1%, 948 completed question-
naires were selected for analysis. Of the respondents,
44.1% never heard about NPS. Younger people and
those with a higher education were signiﬁcantly more
likely to be aware of NPS. Only 1 patient had previously
reported an ADR directly to NPS. Reporting ADRs
indirectly through a HCP was preferred by 62.4%. The
main reasons for patients to do a spontaneous report
would be the severity of the reaction (81,1% agreed or
strongly agreed) and worries about their own situation
(73,4% agreed or strongly agreed).
Conclusions: Patients are most likely to do a spontane-
ous report about a severe reaction or if they are worried.
Good information on ADR reporting could increase the
number of reports from patients in Portugal.
555. Analysis of Adverse Drug Reactions in Hanyang
Univ. Hospital Drug Safety Center
Won Sun Jeon, Eun Jae Park, Kyoung Ok Lee, Hye
Young Kwak. Pharmacy, Hanyang Univ. Hospital,
Seoul, Republic of Korea.
Background: Pharmacovigilance is the pharmacological
science relating to the collection, detection, assessment,
monitoring, and prevention of adverse effects with
pharmaceutical products. Hanyang Univ. Hospital was
designated as Local Pharmacovigilance Center in January
2011 and established OCS adverse drug reactions (ADR)
reporting system.
Objectives: Through monitoring of ADR reporting
system, the objective is to achieve patient safety and
contribute to the active drug surveillance and quality
improvement of adverse event reporting.
Methods: This study was analyzed on the basis of
spontaneously reported ADRs in Hanyang Univ.
Hospital OCS(Order Communication System) from
January 2012 to December 2012. Analysis topics in-
clude patients analyzed, classiﬁed by symptoms of
adverse drug reactions, indications, causality assess-
ment, seriousness assessment and pathogenesis.
Results: The ADRs were reported in the elderly
over 65 years(64.9%) and children under the age of 12
(3.1%) who are vulnerable to adverse drug reactions.
abstract 293
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
The remaining 32% were between 12 to 65 years of age.
Frequently reported ADRs were gastrointestinal(42.5%),
hematological(13.5%), psychiatric/neurological(13.5%)
symptoms. Other symptoms were dermatologic, hepatic,
respiratory, cardiovascular, renal and systemic adverse
reactions. The frequencies of reported drug were 25%
for antibiotics, 16.2% for central nervous system
agents, 13.8% for antineoplastic agent, 8.7% for
opioids, 6.4% for cardiovascular agents, 4.7% for hor-
mones, 4.2% for diagnostic agents and others (pharmaco-
logic category classiﬁed by KIDS). Frequently reported
drugs were Fentanyl citrate(4.3%), Prednisolone(3.27%),
Flomoxef sodium(2.35%), Iopromide(2.18%). Causality
assessment of ADRs was based on the WHO-UMC cate-
gory by Korea institute of Drug Safety & Risk Manage-
ment (KIDS). We also assessed seriousness and
pathogenesis.
Conclusions: It is hard to say that the whole ADR was
reported since ADR report in the OCS is concentrated
in main department. Therefore, continuous public
relations and education are required to invigorate the
ADR report. Moreover, forecasting control system
for ADRs by adverse event signal detection should
be established in the future.
556. A Comparative Analysis of Adverse Drug Reac-
tions: Pre- and Post Regional Pharmacovigilance
Center in a Single Tertiary Hospital
Young-Hee Nam,1,3 Hee-Joo Nam,2,3 Jeong-Eun Song,3
Dong-Sub Jeon,1 Hye-Won Lee,1 Soo-Keol Lee.1,3
1Department of Internal Medicine, College of Medicine,
Dong-A University, Busan, Republic of Korea;
2Department of Pharmacy, Dong-A University Hospital,
Busan, Republic of Korea; 3Dong-A University Hospital
Regional Pharmacovigilance Center, Busan, Republic
of Korea.
Background: Spontaneous reporting of adverse drug
reactions (ADRs) is the basis of pharmacovigilance.
The number of ADRs has been signiﬁcantly increased
since the introduction of regional pharmacovigilance
centers (RPVC) in Korea.
Objectives: To compare the reporting and clinical
features of adverse drug reactions (ADRs) after
starting the RPVC in a single tertiary hospital.
Methods: ADR data were collected from April 2012 to
November 2013 in Dong-A university hospital in which
started the RPVC since February 2012. We compared
the ADR data before and after starting the RPVC.
Results: The total number of reported ADRs in-
creased from 396 to 1320. The most common
ADR reporters were doctors (66.2%), followed by
nurses (24%) which was signiﬁcantly increased
from 7.6% to 28.9%. The most common causative
drugs were antibiotics (64.6%), followed by miscel-
laneous drugs (21.7%), and nonsteroidal anti-in-
ﬂammatory drugs (14.9%) before RPVC, while
antibiotics (31%), miscellaneous drugs (29.8%),
and antituberculosis drugs (9.8%) after RPVC. The
most common clinical manifestations of ADRs were
cutaneous (63.6%), followed by hematologic abnor-
malities (40.6%) and general symptoms (22.2%), while
cutaneous (42.4%), gastrointestinal (24.3%) and
neurophsychiatric symptoms (18.1%) after RPVC.
Conclusions: The number of reported ADRs signiﬁ-
cantly increased since the introduction of RPVC in a
tertiary hospital. The ADR reporters had diversiﬁed,
and the causative drugs and clinical manifestations of
ADRs changed.
557. Evaluation of Statistical Measures for Adverse
Drug Interaction Surveillance
Kristina Juhlin,1 Daniel Soeria-Atmadja,1 Bharat
Thakrar,2 G Niklas Norén.1,3 1Uppsala Monitoring
Centre, Uppsala, Sweden; 2 F Hoffmann-La Roche,
Basel, Switzerland; 3Department of Mathematics,
Stockholm University, Stockholm, Sweden.
Background: Adverse drug interactions harm large
numbers of patients every year. Not all interactions
are known when drugs are launched, but individual
case reports may enable post-marketing detection.
Earlier analyses have indicated that statistical mea-
sures for interaction that use additive baseline models
perform better than those that use multiplicative
baseline models, but no broad evaluation has been
reported in the literature.
Objectives: Compare the sensitivity and speciﬁcity
of four statistical measures for adverse drug interac-
tion detection.
Methods: Four statistical measures for interaction
detection were evaluated in VigiBase®: one based on re-
gression with multiplicative baseline model (RegrMult),
one based on regression with additive baseline model
(RegrAdd), one shrinkage disproportionality measure
with multiplicative baseline model (IC3), and one
shrinkage disproportionality measure with additive
baseline model (Omega). The reference set for known
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interactions consisted of 74 established interactions and
29 pairs of drugs with an ADR for which there is no
empirical support for an interaction. The reference set
for emerging interactions included 324 adverse drug
interactions added to Stockley’s Interaction Alerts be-
tween 2007 and 2009, and 324x20 combinations with
two drugs that were not listed together as known to in-
teract in the same reference.
Results: For established interactions, Omega achieved
speciﬁcity 0.86 and sensitivity 0.39 compared to 0.86
and 0.36 for RegrAdd, 0.86 and 0.24 for IC3, and 0.71
and 0.30 for RegrMult. For emerging adverse drug inter-
actions Omega and RegrAdd achieved high speciﬁcity
but low sensitivity: 0.97 and 0.08 for Omega and 0.92
and 0.11 for RegrAdd, respectively. RegrMult and IC3
on the other hand performed worse than random.
Conclusions: Statistical interaction measures with
additive baseline models outperformed those with
multiplicative baseline models for both established
and emerging adverse drug interactions.
558. Study of Patients’ Potential as a Source for
Spontaneous Reporting Systems in Bulgaria
Hristina Lebanova, Ilko Getov. Medical University-Soﬁa,
Soﬁa, Bulgaria.
Background: Direct patient reporting of adverse drug
reactions (ADR) was introduced in Bulgaria in July
2012. Due to high rate of under reporting by health
professionals and lack of previous experience with
patient reports there is need to examine their potential
for participation.
Objectives: The aim of the study is to investigate the
knowledge and to assess patients’s potential as a source
of information for ADR spontaneous reporting system
in Bulgaria.
Methods: A sample of 254 patients were asked to partic-
ipate in the study by ﬁlling in a direct anonymous stan-
dardized questionnaire consisting of questions for social
and health status, previous experience with an adverse
drug reaction and knowledge of pharmacovigilance sys-
tem. Descriptive statistics and non-parametric tests were
used for the purposes of the analysis.
Results: 211 patients participated in the study with an
overall response rate of 83%. 14 of the questionnaires
were removed from further analysis during the valida-
tion process. 3% of the respondents have children with
chronic disease, 28% suffer from some chronic disease
themselves and 21% are caregivers for chronically ill
relatives. 77% of the participants claim to know what
an ADR is and the majority of them (64,5%) have
learned it from the patient leaﬂet followed by physi-
cians and internet. More than half of the interviewed
(57,3%) have previous experience with ADRs. All of
them have ported the ADR to their family physician
and in 73,9% of the cases treatment was changed
following no report to the national pharmacovigilance
center. 70,9% claim to need additional information for
ADRs and prefer to ask it from their physician or search
for it in internet. Only 21,3% know that they can report
ADRs directly to the national pharmacovigilance center.
The observed level of knowledge is higher in chronically
ill patients and parents with small children.
Conclusions: Patients in Bulgaria are not familiar with
the spontaneous reporting system and their role in it.
There is need of educational campaigns among
patients and health professionals to raise awareness
in direct patient reporting of ADRs.
559. Sample Size Calculations for Comparative
Pharmacoepidemiology Surveillance Studies in Hea-
lthcare Databases
Nicholas W Galwey,1 Michael C Irizarry,2 Ashley E
Wivel,3 Jennifer B Christian,3 Marilyn AMetcalf.4 1Statisti-
cal Consulting Group, GlaxoSmithKline, Stevenage, United
Kingdom; 2Medical - Neuroscience, Eli Lilly and Company,
Indianapolis, IN, United States; 3Clinical Evaluation Sci-
ence, GlaxoSmithKline, RTP, NC, United States; 4Beneﬁt-
Risk Evaluation, GlaxoSmithKline, RTP, NC, United States.
Background: Ongoing surveillance of medicine
safety after product launch poses well-known
challenges with regard to availability of data and its
interpretation; however, the use of claims data and
electronic medical record (EMR) databases offers the
prospect of new approaches.
Objectives: The objective of this work is to provide
guidance for estimating how long it will take to obtain
enough data to address a particular safety question at a
speciﬁed level of conﬁdence.
Methods:We present methods for making such predic-
tions, adapting efﬁcacy power calculations to address
non-inferiority. A speciﬁed degree of risk elevation
due to exposure is the null hypothesis to be rejected,
and a similar level of risk in exposed and unexposed
individuals is the alternative hypothesis.
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Results: If the duration of exposure in exposed
individuals and the follow-up time in unexposed
individuals are nearly equal and constant, the calcu-
lation can be expressed in terms of a risk ratio. If
they are highly variable, it should be expressed as
an incidence rate ratio.To determine the required
sample size, assumptions are made concerning the
background incidence rate and the ratio of unex-
posed to exposed individuals. Additional assump-
tions concerning the number of eligible patients
and the rate of uptake of the new medicine then
permit prediction of study duration. However,
assumptions should be checked over time and
predictions updated accordingly. Considerations re-
garding the clinical context (e.g. severity of event)
and potential confounders (e.g. early adopter effects,
channeling bias etc.) should be taken into account and
reﬂected in the predicted duration.
Conclusions: Predicting when there will be enough
data to address a particular safety question at a
speciﬁed level of conﬁdence using non-inferiority
estimation is challenging and based on many assump-
tions. These considerations need to be reassessed over
time based on real world data and predictions updated
accordingly.
560. Pharmacovigilance Reporting from Saudi Hos-
pitals: Survey of Pharmacovigilance Coordinators
Adel A Alharf,1 Saleh A Bawazir,1 Ali Alshahrani,1 Ghazi
Saeed,1 HishamAljadhey.2 1The National Pharmacovigilance
and Drug Safety Center, Saudi Food and Drug Authority,
Riyadh, Saudi Arabia; 2College of Pharmacy, King Saud
University, Riyadh, Saudi Arabia.
Background: The Saudi Food and Drug Authority
(SFDA) established the National Pharmacovigilance
and Drug Safety Center (NPC) in 2009. To encourage
reporting of adverse drug reactions to the SFDA,
pharmacovigilance coordinators were assigned in each
hospital with capacity of 150 beds or more.
Workshops and regular meetings are conducted to
train coordinators on the reporting of adverse drug
reactions (ADRs). However, the knowledge of
pharmacovigilance and experience of coordinators
with the SFDA is not known.
Objectives: To assess the knowledge of pharma-
covigilance coordinators in Saudi hospitals about
pharmacovigilance and ascertain their perspectives
about reporting adverse drug reactions to the
SFDA.
Methods: A validated survey was developed and sent
online to all pharmacovigilance coordinators in Saudi
hospitals. The survey investigated their knowledge
about ADRs, membership experience and reporting
barriers. A reminder by email was sent 3 days after
the ﬁrst contact. Descriptive analysis was conducted
using the SPSS statistical package.
Results: Forty three out of 70 coordinators completed
the survey (response rate of 61%). Fifty eight of the
responders were male. The majority (58%) reported that
they learned about pharmacovigilance from workshops
conducted by staff of the NPC in their hospitals. While
about half of the participants declared that being a
pharmacovigilance coordinator increased their daily
work, 91% of them believe that this task has improved
their knowledge towards drug safety. About 60% of
the participants revealed that they tend to report any
adverse drug reactions (ADRs) regardless of the severity
or expectedness while 30% tend to report only serious
ADRs. Sixty ﬁve percent faced challenges in reporting
ADRs such as limited cooperation from other healthcare
professionals (27%) and lack of time (22%).
Conclusions: This study explored experience and chal-
lenges faced by pharmacovigilance coordinators in Saudi
hospitals. Policy makers may elect to establish a national
network of pharmacovigilance coordinators to improve
the level and quality reporting of adverse drug reactions.
561. Potentially Inappropriate Medications Defined
by STOPP Criteria on Nursing Home Residents of
a Teaching Hospital in Taiwan
Li-Chai Chen,1 Pei -Yu Chen,1 Jian-Cheng Li,1 Pili
Chih-Min Mao.2 1Department of Pharmacy, ZuoYing
Branch of Kaohsiung Armed Forces General Hospital,
Kaohsiung, Taiwan; 2Clinical Pharmacy Division,
Department of Pharmacy, Kaohsiung Veterans General
Hospital, Kaohsiung, Taiwan.
Background: According to the nursing home practice
guideline, the pharmacist should provide drug regimen
review to the residents of nursing home at least once
every month.
Objectives: This study aimed to assess potentially in-
appropriate medicines (PIMs) deﬁned by new STOPP
(Screening Tool of Older Persons’ potentially inappro-
priate Prescriptions) criteria on nursing home residents
of a teaching hospital in Taiwan.
Methods:Weprospectively studied 74 patients, 65 years
or older, who were at nursing homes of a teaching
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hospital over a 12-month interval in Taiwan. Pharmacists
provided drug regimen review by STOPP criteria on
nursing home residents. The average age of residents
was 82.5 years old, 100% received drug therapy.
Results: On the average, these residents suffered from
3.5 diseases and took 8.7 medicines. 10.8 percent of
residents suffered at least one signiﬁcant drug-drug
interaction, 9.4 percent of residents suffered at least
one inappropriate dosage form, 77.0 % of residents
received at least one inappropriate drug for elderly by
STOPP criteria.
Conclusions: The results of this study demonstrated that
the model of drug regimen review by STOPP criteria is
workable and should be encouraged. PIMs by STOPP
criteria are signiﬁcantly associated with avoidable poten-
tially inappropriate medicines in older people on nursing
homes of a teaching hospital in Taiwan. Therefore, the
nursing home needs pharmacists’ service.
562. The Effectiveness Evaluation of CPOE Drug
Alerting System in NSAIDs Prescription for
Patients with Renal Impairment
Ching-Yao Cheng,1 Ying-Mei Liu,1 Wen-Shyone Liou,1
Ming-Ju Wu.2 1Pharmacy, Taichung Veterans General
Hospital, Taichung, Taiwan; 2Nephology, Taichung
Veterans General Hospital, Taichung, Taiwan.
Background: Drug safety alerts of computerized
physician order entry (CPOE) system with chronic
renal failure patients (stage 3 ~ 5) prescribing non-
steroidal anti-inﬂammatory drugs (NSAIDs) were
launch in TCVGH at June, 2011.
Objectives: To evaluate the efﬁcacy of alerting on
CPOE system when patients with chronic renal failure
stage 3~5 were prescribing NSAIDs, and the prevalence
of NSAIDs-related side effects, as changes in creatinine,
eGFR, anemia effect, as well as the behavior modiﬁca-
tion of prescribing medications.
Methods: Retrospective cohort study of inpatients
administered during 2010.01.01 ~ 2012.12.31 were
recruited. Patients’ demography, administrated days
and dosage of medication, departments, diagnosis of di-
abetes, hypertension and hyperlipidemia, creatinine and
eGFR of medication prescribing day were collected to
evaluate the acute kidney injury (AKI) and anemia.
Results: Totally 1137 patients were recruited, and there
were 593 and 544 cases at before (Group A) and post
(Group B) CPOE alerting system intervention stage, re-
spectively. The department that prescribed ketorolac in-
jection most was General Surgery (189, 16.6%), then
Neurosurgery (171, 15.0%). The cases matched AKI
deﬁnition from KDIGO before and after CPOE alter
system were 23 (3.9%) and 34 (6.3%), respectively.
Hemoglobin level dropped over 2 g/dL were counted
of 86 (17.7%) and 79 (18.0%), respectively. Patients
with hypertension were high risk of AKI when accumu-
lative dose of 30mg to 45mg intravenous ketorolac was
administered.(OR 11.62, 95% CI = 8.95-15.09).
Conclusions: Drug safety alerts of CPOE system with
chronic renal failure patients (stage 3 ~ 5) prescribing
non-steroidal anti-inﬂammatory drugs (NSAIDs) were
more important when medical risk management. More
aggressive and speciﬁc need of alerts system still
unmet for clinical practice.
563. Evaluation of the Relationship between BMI,
Body Fat Percentage and Waist to Hip Ratio in
Healthy Educated Young Indians
Dipika Bansal, Paleti S Ramakrishna. Pharmacy
Practice, NIPER, Mohali, Punjab, India.
Background: Overweight and obesity are commonly
deﬁned by the measurement of BMI. BMI recom-
mended by WHO as a simple marker to reﬂect total
body fat amount but limitation of the BMI is, as it
tends to ignore the distinction between fat and fat-free
mass and it just acts as index of weight excess, rather
than body fatness composition.
Objectives: To study the relationship between body
fat percentage, body mass index and waist to hip ratio
in healthy educated Indian adults of age between 20 to
30 years.
Methods: A total of 306 healthy educated volunteers
of age between 18 to 30 years of either sex were
included in the study (91 female and 215 male).
TANITA two compartment Body composition ana-
lyzer (Model: TBF-215) was used to estimate different
body composition parameters like Body Fat per-
centage, Fat Mass, Fat Free Mass, Basal Metabolic
Rate and Total Body Water by passing the electric
impulse through the subject foot. Anthropometric
measurements were taken by using Harpenden Baty
skinfold caliper and ﬂexible inelastic tape.
Results: 64.7% subjects are in normal range and
30.38% subjects are overweight and obese according
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to BMI.61.4% of subjects were at high risk for central
obesity according to waist to hip ratio.71 % fall in obese
range in considering body fat percentage. Waist-to-Hip
ratio correlated better with body mass index than with
body fat percentage (in men r = 0.821 and 0.341, and
in women r = 0.729 and 0.113; p< 0.01).The average
fat mass(kg)16.56 + 5.8, lean mass(kg) 44.1 + 6.9 and
fat mass to lean mass ratio 2.93 + 0.99 respectively.
Conclusions: Waist to hip ratio correlates better with
body mass index than body fat percentage. The preva-
lence of obesity using body fat percentage is higher than
that with waist-to-hip ratio and body mass index.
564. The Effectiveness of Varenicline Medication
Guide for Conveying Safety Information to Patients:
A 3-Year REMS Assessment Survey
Kandace L Amend,1 Muhammad Younus,2 Kenneth R
Petronis,2 Jingping Mo,2 Robert Gately,1 Cheryl Enger.1
1Epidemiology, Optum, Waltham, MA, United States;
2Epidemiology, Worldwide Safety and Regulatory, Pﬁzer
Inc., New York, NY, United States.
Background: Included in the varenicline Risk
Evaluation and Mitigation Strategies (REMS) is a
requirement by the FDA to periodically assess the
effectiveness of the medication guide (MG) as a tool
to inform patients about potential serious risks asso-
ciated with varenicline use.
Objectives: Using a patient survey, to assess patients’
understanding of serious risks associated with
varenicline use 3 years after implementation of the MG.
Methods: Varenicline users were identiﬁed between
October 2010 and March 2012 in a large US adminis-
trative claims database, and mailed a self-administered
questionnaire. Questions about the varenicline MG
focused on patients understanding of 4 potential risks:
neuropsychiatric symptoms, allergic reactions, skin
reactions, and cardiovascular disease (CVD). A de-
scriptive statistical analysis was conducted.
Results: A total of 3,238 patients received the survey
invitation; 19% responded (n = 606); and 601 surveys
were considered complete. Of survey completers,
92% recalled receiving the varenicline MG, and 80%
indicated they had read all or part of it. Survey completers
chose correct responses to at least one question on neuro-
psychiatric symptoms (88%); skin reaction (48%); aller-
gic reaction (62%); and CVD (82%). Slightly higher
proportions of patients who indicated that they had read
the MG had correct responses to the risk comprehension
questions than those who did not read it. Understanding
of the potential risks of neuropsychiatric symptoms, skin
and allergic reactions were evaluated in both the ﬁrst
(18months) and second (3 years) surveys; results were
similar at both time points.
Conclusions: This 3-year assessment of the effective-
ness of the MG as a component of the varenicline
REMS indicated a high proportion of patients remem-
bered receiving and reading the MG. The survey
showed a high level of understanding of the potential
risks of neuropsychiatric symptoms and CVD among
responders.
565. Real World Utilization and Management of
Adverse Events in Patients Treated with Direct
Acting Antivirals (DAAs) in a European Cohort of
Chronic Hepatitis C (CHC) Patients
Shirin Ahmed,1 Stephanie Chretin,2 T Christopher Mast.1
1Merck, Upper Gwynedd, PA, United States; 2MAPI,
Lyon, France.
Background: An observational post-authorization
safety study was established in Europe after the licen-
sure of Direct Acting Antivirals(DAA) for treatment of
Hepatitis C in 2011.
Objectives: To assess the utilization of DAAs and the
occurrence/management of pre-speciﬁed health out-
comes of interest (HOIs) under conditions of real-
world use.
Methods: An ongoing prospective primary data
collection cohort of genotype-1 CHC patients was
established in France, Germany, United-Kingdom
and Spain. Patients initiating therapy were enrolled in
the following groups:Pegylated interferon +Ribavirin
(P-R), PR +Victrelis™ and PR+ Incivo™. A prelimi-
nary analyses for drug utilization and HOI manage-
ment was based on 227 patients. Incidence of HOIs
was calculated over the ﬁrst 8-week treatment period
for a subset of 171 patients.
Results: Among all treated patients proportion of P-R
use was 8.4%(N= 19), PR +Victrelis™ was 48.8%
(N= 111) and PR+ Incivo™ was 42.7%(N= 97). For
the treatment groups of P-R, PR+Victrelis™ and PR+
Incivo™ the incidence per 1000 patient days for HOIs
was as follows- Anemia (<10 g/dl): 1.2[0.38;2.7], 4.8
[2.9;7.5] & 4.1[2.1;7.2]; Grade 3/4 Neutropenia: 0.71
[0.15;2.06], 2.2 [1.0;4.2] & 1.4[0.38;3.5]; Grade 3/4
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Thrombocytopenia:0.9[0.25;2.36], 1[0.27;2.50] & 1
[0.21;3.03] respectively.
For management of HOIs, 32/83 (39%) anemia epi-
sodeswere treatedwith ESA (65.6%) and/or ribavirin dose
reduction (53.1%) and/or transfusion (18.8%). The only
treatment for 2/33 (6%) neutropenia episodes was
G-CSF.3/16(19%)thrombocytopeniaepisodesweretreated
(2with drug dose reduction and 1with thrombopoietin). Of
serious rash episodes, 5/6 (83.3%) were treated.
Conclusions: DAA utilization was slightly higher
for Victrelis™ versus Incivo™. Incidence of Anemia
& Neutropenia seems to be higher in the Victrelis™
group compared to other treatment groups, however
the conﬁdence intervals are overlapping and results
are not deﬁnitive. Thrombocytopenia incidence
was similar in all groups. There were few cases of
serious rash. These are preliminary data that pro-
vide early insights into the real world use of DAAs
in Europe.
566. Management of Drug-Drug Interaction Alerts
for Clinical Decision Support in Outpatients
Chien Hao Su,1 Chien Ning Hsu,1,2 Shu Chen Tsai,1 Yu
Chin Lily Wang.1 1Department of Pharmacy, Kaohsiung
Chang Gung Memorial Hospital, Kaohsiung, Taiwan;
2School of Pharmacy, Kaohsiung Medical University,
Kaohsiung, Taiwan.
Background: It is well known that too many or
ambiguous alerts displayed for clinical decision
support (CDS) can lead to alert fatigue and cause
physicians to ignore and override clinically impor-
tant one.To ensure the efﬁcient drug-drug interac-
tion (DDI) warning for CDS, a 3-level of DDI
schema based on the severity and action required
to take for the DDI was used to improve original
coded way of DDI alerts on Sept. 1, 2010 in the
medical center, Taiwan.
Objectives: To assess the inﬂuence of the 3-level of
DDI alert (mild to severe) on a rate of prescription
changes inoutpatients.
Methods: A total of 1646 drug interaction pairs based
on Taiwan FDA MedWatch alerts and literature-based
evidence was set from 1/2010 to 12/2013. A expert
panel decided three levels of DDI alerts as: symbolic
coding (redicon) for the mild severity of DDI, pop-
out alert with narrative text for the moderate,and con-
traindicated combination therapy (prescription order
cannot be proceed in the electronic dispensing system)
for the severe level of DDI. This is a cross-sectional
study to assess prescription change rate in the medical
center outpatient setting from 1/2010 to 12/2013. The
annual rate of prescription change was measured as
number of prescription changed divided by the number
of prescription involved in the DDI alerts raised in year.
Analysis for the rate of changing combination therapy
for aliskiren-angiotensin converting enzymes inhibi-
tors/angiotensin-receptor blockers (ACEI/ARB) and
simvastatin-calcium channel blockers (CCB) was
performed in 1/2013-12/2013.
Results: The annual rate of prescription changeswas 6.3%
in 2010 (DDI alerts), substantially increased to 40.5% in
2011, 37.8% in 2012 and 33.9% in 2013.The rate of chang-
ing of aliskiren-ACEI/ARB interactions was 10.56%, and
39.45% excluding nephrologists’prescriptions. The rate of
changing combinationof simvastatin-CCB was 11.31%,
and 16.24% after alerts severity breakout by types of
CCB (dihydropyridine and non-dihydropyridine).
Conclusions: Prioritizing DDI alerts with clinical
relevance and physician’s specialty has the potential
to improve safety alerts for clinical decision support.
567. Ten Years Retrospective Review of Legal
Warnings in Thailand
Pakawadee Sriphiromya. Chulalongkorn University,
Bangkok, Thailand.
Background: Drug risk management (DRM) has many
tools for minimizing risk to patients. The example of
tools to control drugs’ risk are like Dear Healthcare
Professional Letters, box warning or special warning,
restricted use program and other tools like stimulated
spontaneous reporting system or cohort monitoring
events of interesting drugs. The box warning is one of
the DRM’s tools used for control drugs’ risk. Some
serious adverse drug reactions (ADR), probably emerge
after a drug has been marketed, and used in a larger
population. The surveillance system can monitor those
risks which may result in adjusting of boxed warning
to minimize risk throughout drug life cycle in drug use
system. Reviewing DRM’s tools can be the development
of effective mitigation tool in Thailand.
Objectives: The study was aimed to review all legal
warnings of Thai FDA after post marketing surveil-
lance to ascertain characteristics of them.
Methods: The study was cross-sectional review of all
legal warnings which were released from the Drug
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safety Advisory committee in the characteristic of
legal warnings and other relevant criteria which
conducted from year 2003 to 2011. The safety signals
or other factors which were trigger of legal warnings
releasing were also clariﬁed. Exclusion criterions were
any box warning of biologic products.The study set-
ting was at Health Product Vigilance center, Ministry
of Public Health, Thailand.
Results: A total of eight legal warnings were evaluated.
The legal warnings’ characteristic revealed the side ef-
fects, drug-drug interactions, drug-disease interaction,
and rare events of unpredictable ADRs. The most used
criteria in box warning was serious ADRs with allergic
or idiosyncratic effects which found in all warnings.
Conclusions: Recommendations of box warnings in
Thailand were the most used tool for DRM. The
standard criteria to release legal warning are needed.
The issue of consideration was the interesting trigger
of legal warnings.
568. Hypersensitivity Reactions to Andrographis
Paniculata Reported to the Health Product
Vigilance Center (HPVC) in Thailand
Wimon Suwankesawong,1 Surasak Saokaew,2 Unchalee
Permsuwan,3 Nathorn Chaiyakunapruk.2 1Health Product
Vigilance Center (HPVC), Food and Drug Administration,
Muang, Nonthaburi, Thailand; 2Center of Pharmaceutical
Outcomes Research (CPOR), Department of Pharmacy
Practice, Faculty of Pharmaceutical Sciences, Naresuan
University, Muang, Phitsanulok, Thailand; 3Department
of Pharmaceutical Care, Faculty of Pharmacy, Chiang
Mai University, Muang, Chiang Mai, Thailand.
Background: Andrographis is one of the herbal prod-
ucts that are widely used for various indications
including common cold and diarrhea. Hypersensitivity
reactions have been reported among subjects receiving
Andrographis paniculata. Understanding of character-
istics of patients, adverse events, and clinical out-
comes is essential for ensuring population safety.
Objectives: This study aimed to describe the character-
istics of hypersensitivity reactions reported in patients
receiving andrographis containing products in Thailand.
Methods: Thai Vigibase data from February 2001 to
December 2012 involving andrographis products were
used. Case reports were included for ﬁnal analysis if
they met the inclusion criteria; 1) reports with
andrographis being the only suspected cause, 2)
reports with terms consistent with the constellation of
hypersensitivity reactions, and 3) reports with terms
considered critical terms according to WHO criteria.
Descriptive statistics were used.
Results: A total of 248 case reports of andrographis-
associated adverse events were identiﬁed. Only 106
case reports contained andrographis herbal product as
suspected drug and reported at least one hypersensitiv-
ity reaction. Most case reports (89%) came from
spontaneous reporting system with no previously
documented history of drug allergy (88%). Of these,
18 case reports were classiﬁed as serious with 16 cases
requiring hospitalization. For ﬁnal assessment, the
case reports with terms consistent with constellation
of hypersensitivity reactions and critical terms were in-
cluded. Thirteen case reports met such criteria includ-
ing anaphylactic shock (n = 5), anaphylactic reaction
(n = 4) and angioedema (n = 4). Time to development
of symptoms ranged from 5minutes to 1 day. The
doses of andrographis used varied from 352mg to
1,750mg. Causality assessment of 13 case reports
were certain (n = 3), probable (8) and possible (2).
Conclusions: Our ﬁndings suggest that hypersensi-
tivity reactions have been reported among patients
receiving Andrographis paniculata. Healthcare pro-
fessionals should be aware of this potential risk.
Further investigation of the causal relationship is
needed.
569. A Review on Quality Surveillance Results of
Cosmetics in Taiwan
Meng-Hsuan Chung, Wei-Sheng Huang, Yu-Chang
Chang, Yu-Hsuan Chen, Ming-Shin Lee, Hwei-Fang
Cheng. Food and Drug Administration, Taipei.
Background: In order to have a clear understanding
of the trends on the product quality monitoring out-
come and regulatory control measures over the past
years, this study has put together the reports of nine
surveillance projects of cosmetics between 1982 and
2012.
Objectives: The ﬁndings of this study can be used
as reference in developing a more solid quality moni-
toring plan and management system on cosmetic
products in the future.
Methods: This study summarizes and discusses the
results of cosmetics quality research and surveillance
reports from the Annual Scientiﬁc Report of National
Laboratories of Food and Drug Administration, the
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Annual Scientiﬁc Report of Bureau of Food and
Drug Administration, and the Annual Report of
Food and Drug Research.The monitoring survey had
nine projects, including permanent wave, hair dye
products, phthalate esters, heavy metal, microorganism,
sunscreen products, hydroquinone, salicylic acid, and
methanol, chloroform and 1,4-dioxane.
Results: Results show that permanent wave, hair dye
products and phthalate esters have the highest average
non-compliance rates at 39.2%, 14.2% and 11.2%,
respectively, followed by the average non-compliance
rates of mercury, sunscreen products and microorganism
in order at 8.5%, 7.1% and 5.5%, and the remaining 4
projects averaging below 4.1%. Overall, the study
showed the non-compliance rates of permanent wave,
phthalate esters, mercury and hydroquinone have all de-
creased in previous year. When looking at surveillance
projects results after 2005, there was only one non-
compliance sample in lead, arsenic and cadmium whereas
the permanent wave, chloroform and 1,4-dioxane surveil-
lance projects fully complied with regulation standards.
Yet, the non-compliance rates of microorganisms pres-
ent in cosmetics, the ingredients in hair dye products
and sunscreen products were still high.
Conclusions: The government, industry and consumers
should work together to maintain the environment of
cosmetics safety. In addition, the high risk products will
be kept under watch by the government.
570. Conditional Approval from CHMP Is Associ-
ated with Increased Phase IV Epidemiology Study
Commitments
Philip A Spearpoint,1 Jack O Ziomek,1 Wenting Zhang,1
Anjan K Banerjee.1,2 1Development, Pope Woodhead
and Associates Limited, 1 Ramsey Road, StIves,
Cambridgeshire, United Kingdom; 2Institute of Biotechnol-
ogy, Cambridge University, Cambridge, Cambridgeshire,
United Kingdom.
Background: Conditional approval (CA) by the EMA
allows for marketing of pharmaceutical products with
limited clinical data for seriously debilitating, life-
threatening or rare diseases.
Objectives: To evaluate products approved via the
CA pathway using single-arm phase II data, assess
their regulatory and reimbursement approval out-
comes and map their post-authorisation commitments
for observational post-authorisation epidemiological
studies.
Methods: A search of the EMAwebsite was conducted
to identify medicines that received conditional approval
between 2006-2013. The evidence base for approval
(EU- EPARs) was analysed along with reports from
national reimbursement authorities of the UK, France,
Germany and Italy to understand the commitments for
post-authorisation observational studies.
Results: Six products received CA approval on the
basis of single-arm phase II studies (bretuximab,
ofatumumab, bosutinib, vismodegib, everolimus and
crizotinib). Data showed a clear pathway of endpoint
selection and further data generation post approval.
Nearly all products used Objective Response Rates
for approval. Further post-authorisation data-gathering
requirements were proposed or mandated for all
compounds, the majority utilising observational study
designs to conﬁrm safety data (often as part of en-
hanced pharmacovigilance commitments from the risk
management plan – RMP). Two compounds required
dedicated observational safety studies (brentuximab
and ofatumumab), with all other compounds requiring
further follow-up safety initiatives as part of on-going
clinical studies or further data generated in wider
patient populations to provide a substantiated evidence
base for safety and efﬁcacy.
Conclusions: Rigorous analysis of phase II data should
be undertaken relating response rate data to mortality or
morbidity outcomes, together with a clear plan for post-
authorisation observational studies. The likely future
trend of increased conditional approval is therefore
likely to be mirrored by a corresponding burden of
post-authorisation epidemiology study commitments.
571. The Effect of Acquisition with the Outcome
of Marketing Authorization Applications of New
Active Substances Submitted to the EMA
Cornelis A Van den Bogert,1 Patrick C Souverein,1 Michelle
Putzeist,1 Susan Janssen,2 Gerard H Koëter,3 Hubert GM
Leufkens.1 1Division of Pharmacoepidemiology & Clinical
Pharmacology, Utrecht Institute for Pharmaceutical Sci-
ences, Utrecht University, Utrecht, Netherlands; 2Division
of Nutrition, Medicines and Consumer Safety, National Insti-
tute for Public Health and the Environment (RIVM),
Bilthoven, Netherlands; 3Central Committee on Research in-
volving Human Subjects (CCMO), The Hague, Netherlands.
Background: Medicines in clinical development that
fail marketing authorization lead to ﬁnancial losses
and missed therapeutic opportunities. The effect of
acquisition is currently unknown.
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Objectives: To assess whether acquisition of new
active substances (NAS) was associated with the
outcome of aarketing authorization applications
(MAA).
Methods: We identiﬁed the originators of all NAS
evaluated by the EMA in 2009 and 2010 by a system-
atic crosscheck of online resources. Each NAS was
categorized as self-originated or acquired. Outcome
was a positive or a negative MAA. Characteristics were
described and compared between approved and failed
MAAs. We stratiﬁed by company size and therapeutic
area. Logistic regression analysis was used to assess
the strength of the association between acquisition status
and MAA outcome, expressed as adjusted odds ratio
(AOR) with 95% conﬁdence intervals (CI).
Results: We identiﬁed 68 NAS dossiers, of which 46
were self-originated and 22 were acquired. Twenty-
eight percent of the self-originated NAS had a negative
MAA outcome, compared to 45% of the acquired NAS.
Self-originated NAS consisted of more biologicals
compared to acquired NAS (59% vs. 23%; p = 0.01).
Antineoplastic NAS seemed to be associated with a neg-
ative MAA outcome, but the difference was not statisti-
cally signiﬁcant due to the small numbers (28% vs.
57%; p = 0.06). The multivariable model included the
variables acquisition (AOR 2.6, 95% CI 0.8-8.1), neo-
plastic therapeutic area (AOR 4.5; 95% CI: 1.2-16.6)
and previously approved elsewhere (AOR 1.7; 95%
CI: 0.9-3.0).
Conclusions: Acquired NAS had a higher probabil-
ity of a negative outcome of MAAs compared to
self-originated NAS. Also, antineoplastic NAS
seemed associated with a negative MAA outcome.
This ﬁnding needs further examination in a larger
sample, enabling further detailing of acquisitions.
Industry can take advantage of our ﬁndings by in-
troducing an independent assessment at the time of
acquisition such as the scientiﬁc advice procedure.
This may eliminate NAS with no therapeutic value
earlier in the development process and prevent
unnecessary and risky future clinical trials.
572. Case Study on a Violation of the Pharmaceuti-
cal Affairs Act: Illegal Commission of the Packing
Processing of Medicinal Products to a Food Factory
Hui-Ling Chen, Yu-Ting Huang, Chyn-Liang Huang,
Ming-Shin Lee, Hwei-Fang Cheng. Food and Drug
Administration, Food and Drug Administration, Taipei.
Background: To guarantee the quality of drugs made
available to the public, strict regulations were
established to regulate the manufacturing of medicinal
products. Under the Pharmaceutical Affairs Act, it re-
quires all companies that manufacture or package/label
drugs are required to subject the inspections conducted
by the Taiwan Food and Drug Administration (TFDA).
Objectives: The aim of this study is to review this vi-
olation event and its subsequent activities for future
improvement upon the current management system
on manufacturing of medicinal products.
Methods: A pharmaceutical manufacturer was reported
to TFDA for being against the regulation by outsourcing
their press-through packaging (PTP) process of drugs to
a food factory. A series of subsequent investigation
were initiated to collect relevant facts and evidence.
The TFDA conducted a for-cause inspection. The
evidence showed the food factory was involved in an
illegal drug packaging activity. In addition, judging
from the company’s accounting books, it indicated that
there were some other suspected pharmaceutical manu-
facturers also involved. The TFDA and local health
authorities initiated large scale inspections.
Results: The results of inspections revealed that 34 phar-
maceutical manufacturers and 154 drugs were involved.
The amount of recalled products was unprecedented huge
in history. The reasons why pharmaceutical manufac-
turers illegally outsourced their packaging process to a
food factory were the lack of either PTP packaging ma-
chines or its speciﬁc components/molds. The packaging
of drugs in a GMP non-compliant factory could place
consumers at risk. These convicted companies were
required to recall and destroy the products in a limited
period. To impel the recall, BNHI suspended their
product reimbursement plan. The local health authorities
issued warning notices to the hospitals or drugstores.
All suspected companies were sent to Tainan District
Prosecutors Ofﬁce.
Conclusions: By this violation event, actions had been
taken to improve the management on pharmaceutical
manufacturers and establishing a cooperation mechanism
between government units.
573. Acid-Suppressive Drug Use during Pregnancy
and the Risk of Atopic Dermatitis: A Crossover Study
Within the Clinical Practice Research Database
Bianca Mulder,1 Eelko Hak,1 Catharina CM Schuiling-
Veninga,1 Tjalling W de Vries,2 Susan S Jick.3,4
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1PharmacoEpidemiology & PharmacoEconomics, Univer-
sity of Groningen, Groningen, Netherlands; 2Department
of Pediatrics, Medical Center Leeuwarden, Leeuwarden,
Netherlands; 3Boston Collaborative Drug Surveillance
Program, Boston, Lexington, United States; 4Department
of Epidemiology, Boston University School of Public
Health, Boston, Lexington, United States.
Background: One previous study of our group reported
that acid suppressive drug use during pregnancy is associ-
ated with an increased risk for the development of atopic
dermatitis in children. However, reported associations
could have been confounded by unmeasured risk factors.
Objectives: The aim of this study was to assess the as-
sociation between prenatal exposure to acid-suppres-
sive drugs and the development of atopic dermatitis
in children by using a confounding minimizing
crossover design.
Methods: We conducted a bidirectional case-crossover
study within the Clinical Practice Research Database in
which 1,445 children with atopic dermatitis were
randomly matched to one of their own siblings with-
out atopic dermatitis. Children were deﬁned as having
atopic dermatitis if they had a diagnosis of atopic
dermatitis and at least 3 prescriptions for ointments
containing steroids or calcineurin inhibitors in the
year after diagnosis. We applied conditional logistic
regression to compute odds ratios (ORs) and 95%
conﬁdence intervals (95%CI).
Results: The percentage of exposure to acid suppressive
drugs amongst cases was 21.5% compared to 18.8%
amongst controls. After adjustments for gender, birth
order and maternal age at delivery the exposure to any
acid suppressive drug during pregnancy increased the
odds for developing atopic dermatitis by 34% (aOR
1.34; 95%CI: 1.05-1.71). Though not signiﬁcant, expo-
sure to the subgroup proton pump inhibitors conferred
an increased risk of 72% (aOR 1.72 95% CI: 0.62-4.79).
Conclusions: This study supports previous ﬁndings of
a small association between gastric acid suppression
during pregnancy and the development of atopic
dermatitis in children.
574. Association between Antibiotic Use and Birth
Defects Among Women Who Had Urinary Tract
Infections in the First Trimester of Pregnancy
Elizabeth Ailes,1 Suzanne Gilboa,1 Simerpal Gill,2
Cheryl Broussard,1 Krista Crider,1 RJ Berry,1 Tonia
Carter,3 Charlotte Hobbs,4 Jennita Reefhuis.1
1NCBDDD, Centers for Disease Control and Prevention,
Atlanta, GA, United States; 2Duchesnay Inc., Blainville,
QC, Canada; 3Marshﬁeld Clinic, Marshﬁeld, WI, United
States; 4College of Medicine, University of Arkansas
Medical Center, Little Rock, AR, United States.
Background: Previous studies reported associations
between antibiotics used to treat urinary tract infec-
tions (UTIs) and some birth defects; however, it is
unclear if these ﬁndings were due to antibiotic use,
infection or chance.
Objectives: Assess the relationship between antibiotic
use and birth defects among pregnant women with ﬁrst
trimester UTIs.
Methods: The National Birth Defects Prevention
Study is a multi-site, population-based, case-control
study of risk factors for major birth defects. Controls
included live-born infants without major birth defects.
We analyzed singleton pregnancies from 1997-2009
among non-diabetic women with UTIs from one month
before conception through the third month of preg-
nancy. To minimize potential confounding by indica-
tion, we restricted the analyses to women reporting
UTIs in early pregnancy and compared antibiotic users
to non-users. Logistic regression was used to estimate
associations between antibiotic use and birth defects,
after adjusting for maternal age, race/ethnicity, educa-
tion, and calendar year.
Results:We included 1770 case and 671 control mothers
with UTIs, of whom 1403 case (79%) and 521 control
mothers (78%) used antibiotics. Trimethoprim-sulfameth-
oxazole use was associated with oral clefts (Odds Ratio:
2.12, [95% CI: 1.01, 4.45]), esophageal atresia (4.13
[1.25, 13.67]), and hypospadias (5.92 [1.49, 23.58]).
Cephalosporin use was associated with anorectal
atresia/stenosis (6.27 [1.50, 26.26]), and macrolides
with cleft palate (5.16 [1.11, 24.04]). Inverse associa-
tions were observed between penicillin use and neural
tube defects (0.53 [0.30-0.95]) and use of multiple
antibiotics and cleft lip with cleft palate (0.32
[0.11-0.95]). Additional elevated but non-signiﬁcant
associations were observed, particularly for trimetho-
prim-sulfamethoxazole use.
Conclusions: To better inform clinical practice, stud-
ies are needed to conﬁrm these ﬁndings and examine
the relative safety of UTI antibiotic therapies during
pregnancy.
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575. Lamotrigine Use in Pregnancy and Risk of
Orofacial Cleft, an Update of EUROCAT
Lamotrigine Study
Hao Wang,1 Maria Loane,2 Ester Garne,3 Joan Morris,4
Vera Nelen,5 Babak Khoshnood,6 Anke Rißmann,7
Awi Wiesel,8 Mary O’Mahony,9 Anna Pierini,10
Elisa Calzolari,11 Miriam Gatt,12 Marian Bakker,13
Marie-Claude Addor,14 David Tucker,15 Kari Klungsoyr,16
Anna Latos-Bielenska,17 Jan PMejnartowicz,18 Karin Kallen,19
Ingeborg Barisic,20 Christine Verellen-Dumoulin,21
Bérénice Doray,22 Larraitz Arriola,23 Diana Wellesley,24
Amanda Neville,11 Lolkje TW de Jong-van den Berg,1
Helen Dolk.2 1University of Groningen, Groningen,
Netherlands; 2University of Ulster, Belfast, United
Kingdom; 3Region Syddanmark, Odense, Denmark;
4Queen Mary University of London, London, United
Kingdom; 5Provinciaal Instituut voor Hygiene, Antwerp,
Belgium; 6Institut National de la Sante et de la Recherche
Medicale, Paris, France; 7Otto-von-Guericke Universitat
Megdeburg, Magdeburg, Germany; 8Johannes Gutenberg
Universitat, Mainz, Germany; 9St Finbarr’s Hospital,
Cork, Ireland; 10CNR Institute of Clinical Physiology,
Pisa, Italy; 11Azienda Ospedaliero Universitaria di
Ferrara, Ferrara, Italy; 12G’mangia Gill, Malta, Malta;
13University Medical Centre Groningen, Groningen,
Netherlands; 14Registre Vaudois des Malformations,
Lausanne, Switzerland; 15SingletonHospital, Swansea,United
Kingdom; 16Medical Birth Registry of Norway, Bergen,
Norway; 17Polish Registry of Congenital Malformations,
Poznan, Poland; 18Uniwersytet Medyczny im. Karola
Marcinkowskiego w Poznaniu, Poland, Poland; 19Swedish
National Board of Health and Welfare and University of
Lund, Lund, Sweden; 20Klinika z a Djecje Bolesti Zagreb,
Zagreb, Croatia; 21Centre de Génétique Humaine Institut
de Pathologie et de Génétique, Charleroi, Belgium;
22Registre des Malformations Congenitales D’Alsace,
France; 23Registro Anomalias Congénitas CAPV,
Vitoria-Gasteiz, Spain; 24Princess Anne Hospital, South-
ampton, United Kingdom.
Background: Lamotrigine (LTG) is increasingly used
during pregnancy. A FDA warning was issued for an
association of LTG exposure and increased risk of
orofacial clefts (OCs), based on data from the North
American Antiepileptic Drug Pregnancy Registry
(Holmes, 2006; Holmes et al., 2008). The signal was
examined in the European Surveillance of Congenital
Anomalies (EUROCAT) antiepileptic-study database
(Dolk, 2008). No signiﬁcantly increased risk of OCs
was found relative to other malformations, either for
isolated orofacial clefts or for isolated cleft palate.
There has been no independent conﬁrmation of
increased risk of OCs in relation to LTG from all
studies in the literature combined (Dolk et al., 2012).
Objectives: To investigate whether ﬁrst trimester exposure
to LTG monotherapy is speciﬁcally associated with an in-
creased risk of OCs, using the EUROCAT antiepileptic-
study database including birth years up to 2010.
Methods: A population-based case-control study with
malformed controls was performed. The updated
EUROCAT antiepileptic-study dataset included 226,806
live births, stillbirths, or terminations with malformations
among 7.6 million births in 20 European countries from
1995 to 2010, more than twice the population of the orig-
inal study. Cases were 10,523 nonsyndromic OC registra-
tions, of whom 8,771 were isolated, and 3,789 cleft palate
(CP) of whom 2,984 were isolated. Controls were
144,914 non-chromosomal, non-OC registrations. We
compared ﬁrst trimester LTG vs no antiepileptics (non-
AED use), for mono and polytherapy.
Results: There were 181 LTG exposed (109 mono- and
72 polytherapy) registrations. The maternal age adjusted
odds ratios (ORs) for LTG monotherapy vs non-AED
use were 0.84 (95% CI 0.37-1.92) for OC relative to
other malformations, 1.01 (95% CI 0.44-2.30) for
isolated OC; 1.18 (95% CI 0.38-3.72) for CP, and
1.49 (95% CI 0.47-4.72) for isolated CP.
Conclusions: This update does not change the con-
clusion of the original study: we found no evidence
of an increased risk of isolated orofacial clefts rela-
tive to other malformations for LTG monotherapy
exposure in the ﬁrst trimester, nor any evidence of
an increased risk for isolated cleft palate.
576. Selective Serotonin Reuptake Inhibitor Use in
First Trimester Pregnancy and Risk of Congenital
Anomalies: A Register-Based Study in 12 European
Countries
Anthony Wemakor,1,2 Karen Casson,1 Ester Garne,3
Mariam Bakker,4 David Tucker,5 Babak Khoshnood,6
Vera Nelen,7 Mary O’Mahoney,8 Anna Pierini,9 Kari
Klungsoyr,10 Mariam Gatt,11 Marie-Claude Addor,12
Anke Rissmann,13 Larraitz Arriola,14 Lolkje de Jong-van
Berg,15 Helen Dolk.1 1Institute of Nursing and Health
Research, University of Ulster, Jordanstown, Co Antrim,
United Kingdom; 2School of Medicine and Health
Sciences, University for Development Studies, Tamale,
Ghana; 3Hospital Lillebaelt, Kolding, Denmark; 4Eurocat
Northern Netherlands, Department of Genetics, University
Medical Center Groningen, University of Groningen,
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Groningen, Netherlands; 5Public Health Wales, Swansea,
United Kingdom; 6Paris Registry of Congenital
Malformations, INSERM, Paris, France; 7Provinciaal
Instituut voor Hygiene, Antwerp, Belgium; 8Department
of Public Health, Cork, Ireland; 9CNR Institute of Clinical
Physiology, Pisa, Italy; 10Department of Global Public
Health and Primary Care, University of Bergen, Bergen,
Norway; 11Malta Congenital Anomalies Registry, G’mangia,
Malta; 12Service of Medical Genetics, Lausanne, Switzerland;
13Malformation Monitoring Centre, Medical Faculty
Otto-von-Guericke-University, Magdeburg, Germany;
14Registro Anomalias Congenitas, Vitoria-Gasteiz, Spain;
15Groningen University, Groningen, Netherlands.
Background: The Selective Serotonin Reuptake
Inhibitor (SSRI) antidepressants are widely prescribed
in pregnancy, but there is evidence that they may
cause congenital anomalies, particularly congenital
heart defects (CHD).
Objectives: To determine the speciﬁcity of association
between ﬁrst trimester pregnancy exposure to individ-
ual SSRIs and speciﬁc congenital anomalies (CAs).
Methods: Population-based case-malformed control
study covering 3.3 million births from 12 EUROCAT
registries 1995-2009. CAs included non-syndromic
livebirths, fetal deaths and terminations of pregnancy
for fetal anomaly (n = 42,839). Three groups of CA
were studied: CHD (n = 12,828), non-CHD “signals”
derived from the literature (n = 12,460), and other
subgroups of CA not previously associated with SSRIs
(controls, n = 17,046). First trimester SSRI exposure
was compared to no SSRI use. Odds ratios (OR) and
95% conﬁdence intervals (CI) were calculated
adjusting for registry, maternal age and birth year.
Results: SSRI use in ﬁrst trimester pregnancy was
associated with CHD overall (OR 1.38, 95% CI
1.05-1.82, n = 109); and with severe CHDs (OR
1.56, 95% CI 1.03-2.38, n = 29). Speciﬁc associa-
tions between SSRI and Tetralogy of Fallot (OR
3.36, 95% CI 1.67-6.75, n = 9), and Ebstein’s anomaly
(OR 8.23, 95% CI 2.91-23.28, n = 4) were detected.
Statistically signiﬁcant associations between SSRI and
four non-CHD signals (anorectal atresia and stenosis,
gastroschisis, renal dysplasia, clubfoot) were supported.
In all the statistically signiﬁcant associations identiﬁed
there was little evidence of SSRI type speciﬁcity.
Conclusions: These data support the previously
reported association between SSRIs and CHDs and a
number of other CAs but do not suggest speciﬁcity
of action in relation to SSRI type. This may indicate
confounding or a common mechanism of teratogenic
effect among SSRIs. Preconceptional and pregnancy
care for women should include weighing the beneﬁts
of SSRIs against the growing evidence of risk when
assessing treatment options.
577. Direct-from-Patient Information on Medication
Use: PROTECT Pregnancy Study Results
NancyADreyer,1 Shahrul Mt-Isa,2 Jonathan L Richardson,3
Maja Laursen,4 Priscilla A Zetstra-van der Woude,5
Lolkje de Jong-van den Berg,5 Ana Jamry-Dziuria,6
Simon HL Thomas,3 Stella CF Blackburn.7 1Scientiﬁc
Affairs, Quintiles Real-World & Late Phase Research,
Cambridge, MA, United States; 2Faculty of Medicine,
School of Public Health, Imperial College, London, United
Kingdom; 3Institute of Cellular Medicine, Newcastle
University, Newcastle, United Kingdom; 4Statens Serum
Institut, Copenhagen, Denmark; 5Pharmacoepidemiology
and Pharmacoeconomics, University of Groningen,
Groningen, Netherlands; 6Department of Medical
Genetics, Poznan University of Medical Sciences, Poznan,
Wielkopolska, Poland; 7Inspections andHumanMedicines
Pharmacovigilance, European Medicines Agency, London,
United Kingdom.
Background: The PROTECT Pregnancy Study is a
non-interventional, prospective study of pregnant
women who provide information about medication
use and key lifestyle factors at set intervals throughout
their pregnancy, and pregnancy outcome.
Objectives: This study was designed to pilot new
methods of collecting pharmacovigilance data in natural
language directly from reporters, whoever they are.
Methods: Pregnant volunteers were sought mainly via
the internet and leaﬂets in pharmacies. They were
provided with study information and could choose to
participate on-line or by phone using an interactive
voice response system (IVRS). Internet participants
could choose to provide data every 2 or 4weeks during
pregnancy. In Denmark and the UK we also sought
individual permission to link with electronic healthcare
records to compare the reports of prescribed medication
use, and where possible, birth outcomes.
Results: Following informed consent, 2521 pregnant
women from Denmark, the Netherlands, Poland, and
the United Kingdom were recruited. Of these, only
14 (0.5%) chose to provide data via IVRS. After study
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entry, 82% of “internet” women and 1 (7%) “IVRS”
woman went on to complete a detailed baseline
questionnaire. The choice of follow up period varied
between country, but overall 43% (range 28-49%)
chose every two weeks and 58%, (range 49-72%)
every 4weeks. To date, 38% have provided follow-
up data, despite all receiving reminders at each fol-
low-up time point. Limited information was available
as to why participants stopped participating as few
subjects completed the discontinuation forms, which
inquired about reasons.
Conclusions: Pregnant women can be recruited directly
to provide information for research via the internet but
recruitment for data provision by IVRS was poor. Our
research suggests additional tools are needed to enhance
retention of recruited volunteers. These results should
help guide future study designs using direct-to-patient
enrolment and follow-up. Additional research from
this project will examine self-reported medication use.
This research received support from the IMI JU
through the PROTECT project.
578. Discontinuation of Antipsychotic Medication in
Pregnancy: A Cohort Study
Irene Petersen,1 Rachel L McCrea,1 David PJ Osborn,3
Vanessa Pinfold,2 Ruth Gilbert,4 Phil J Cowen,5 Irwin
Nazareth.1 1Primary Care and Population Health, UCL,
London, United Kingdom; 2The McPin Foundation,
London, United Kingdom; 3Mental Health, UCL,
London, United Kingdom; 4Institute of Child Health,
UCL, London, United Kingdom; 5Warneford Hospital,
Oxford, United Kingdom.
Background:Women prescribed antipsychotics face the
dilemma on whether to continue medication in pregnancy
in terms of balancing potential teratogenic effects and
other adverse effects of the medication against the conse-
quences of a relapse of their illness. Previous research on
other psychotropic medications including antidepressants
and antiepileptic drugs suggests thatmanywomen discon-
tinue treatment in early pregnancy. However, limited
evidence exists on whether pregnancy is associated with
discontinuation of antipsychotic medication.
Objectives: To assess whether pregnancy is major
determinant for stopping antipsychotics and identify
characteristics of those who stopped antipsychotics
during pregnancy.
Methods:We identiﬁed 495,953 pregnant women from
The Health Improvement Network primary care
database. Kaplan-Meier plots were used to examine
time to last prescription in pregnant versus non-pregnant
women and Poisson regression to examine characteris-
tics of those who stopped treatment during pregnancy.
Results: Prescribing of atypical antipsychotics has been
increasing both before and during pregnancy, resulting
in an overall increase in prevalence of prescribing since
2007. Antipsychotics were more likely to be stopped in
pregnant than non-pregnant women. Only 107/279
(38%) of women on atypical antipsychotics and 39/
207 (19%) of women on typical antipsychotics before
pregnancy still received treatment at the start of third
trimester. Older women were more likely to continue
typical antipsychotic treatment in pregnancy (35+ ver-
sus <25years Risk Ratio: 3.09 [95% CI 1.76, 5.44]).
Likewise, those who received typical antipsychotics
for longer periods before were most likely to continue
treatment in pregnancy (12+ versus <6months: RR:
3.12 [95% CI 1.97, 4.95]). For atypical antipsychotics
length and dose of prior prescribing were also associated
with continuation in pregnancy.
Conclusions: Pregnancy was a major determinant of
cessation of antipsychotics. This may be explained by
concern about potential adverse effects of the drug, even
though these concerns need to be balanced against the
potential harm of inadequate treatment of psychoses
and other serious mental illnesses during pregnancy.
579. Trends in the Use of Anti-Epileptic Drugs
during Pregnancy in the Netherlands
Eugene van Puijenbroek, Loes de Vries,
Agnes Kant. Netherlands Pharmacovigilance Centre
Lareb, ‘s-Hertogenbosch, Netherlands.
Background: The use of anti-epileptic drugs (AEDs)
during pregnancy is associated with an increased risk
of birth defects. Since epilepsy itself is also associated
with potential risks for mother and child, an optimal
AED treatment is needed. Over the past years, the in-
troduction of new AEDs and the amendments of guide-
lines have changed the use of AEDs in this vulnerable
group of patients. The extend of the changes over time
in the Netherlands has not been studied before.
Objectives: To compare the use of different AEDs
in pregnant women over the past 10 years in the
Netherlands.
Methods: This retrospective cohort study data is
based on data from the register that is being used
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to submit Dutch cases to the EURAP study.
Pregnancies were included in which women were
exposed to an AED between January 2003 and
December 2012 either preconceptionally or during
the ﬁrst trimester. Binary logistic regression analysis
was used to compare the proportion of various
AEDs annually. Dependent variable was the year in
which conception took place; the AED and type of
epilepsy were covariates. In addition, the mean num-
ber of concomitantly used AEDs were calculated per
year and analyzed by ANOVA.
Results: A total number of 1,733 pregnancies in were
included in the analysis. The proportion of use of
levetiracetam and lamotrigine showed an upwards
trend from 6.2 and 16.0% in 2003 till 25.0 and
33.5% in 2012, with corresponding adjusted Odds
Ratio (OR) of 4.89 (95% CI 2.65-9.06) and 2.77
(95% CI 1.76-4.34) respectively. The proportion of
use of valproate and carbamazepine decreased from
28.4 and 28.4% in 2003 till 9.3 and 17.3% in 2013,
with an adjusted OR of 0.28 (95% CI 0.16-0.48) and
from 0.44 (95%CI 0.28-0.70) respectively. The use
of other miscellaneous AEDs decreased from 20.9%
to 14.9%, OR 0.61 (95%CI 0.38-0.98). The average
number of AEDs being used was 1.30 in 2003 and
1.24 in 2012 (p> 0.05).
Conclusions: The use of relatively safer AEDs
gradually increased over the past 10 years com-
pared to drugs more frequently associated with
congenital defects. The mean number of AEDs
used remained stable of the years. Our ﬁndings
are in line with advice provided in the literature
on the use of AEDs.
580. Outcomes of OpioidUse in Pregnancy: ADanish
Population-Based Study
Mette Nørgaard,1 Sussie Antonsen,1 Malene S Nielsson,1
Deirdre J Murphy,2 Rikke B Nielsen,1 Sabine M Apelt,3
Henrik T Sørensen.1 1Department of Clinical Epidemiology,
Aarhus University Hospital, Aarhus, Denmark; 2Trinity
College, University of Dublin, Dublin, Ireland; 3CertumCon-
sulting - Scientiﬁc Research, Oberbergkirchen, Germany.
Background: Few data exist on birth outcomes in
women who received opioid maintenance treatment
with methadone or buprenorphine during pregnancy.
Objectives: To examine adverse birth outcomes in
women exposed to methadone or buprenorphine
during pregnancy and to examine the risk of neonatal
abstinence syndrome (NAS) among neonates exposed
in utero to buprenorphine and methadone.
Methods: The study included all female Danish
residents with a live or a still-birth from 1997-2011.
We identiﬁed the study population, use of opioids
and opioid-substitution treatment, birth outcomes,
and NAS through medical registers. Birth outcomes
included preterm birth (<gestational week 38), low
birth weight (<2500 grams), small for gestational
age (weight below 2 standard deviations from the
sex- and gestational-week-speciﬁc mean), congenital
malformations, and stillbirths.
Results: Among 571,823 women who gave birth
during the study period, we identiﬁed 626 opioid users
(190 used buprenorphine only and 215 used metha-
done only). Compared with non-exposed, prenatal
opioid use was associated with greater prevalence of
preterm birth (prevalence ratios (PR) of 2.2 (95%
conﬁdence interval (CI): 1.6-3.1) in buprenorphine-
exposed and 3.6 (95% CI: 2.8-4.6) in methadone-
exposed), low birth weight (PR of 2.2 (95%
CI:1.5-3.3) in buprenorphine-exposed and 4.8
(95% CI: 3.8-6.1) in methadone-exposed), and
being small for gestational age (PR of 1.4 (95%
CI:0.6-3.2) in buprenorphine-exposed and 2.4
(95% CI:1.2-4.5) in methadone-exposed ). The
prevalence of congenital malformations was 8.0%
in buprenorphine-exposed, 11.3% in methadone-
exposed, and 4.3% in non-exposed. This corres-
ponded to PRs of 1.9 (95% CI: 1.2-3.0) in
buprenorphine-exposed and 2.6 (95% CI: 1.8-3.8)
in methadone-exposed. The risk of NAS ranged
from 7.0% in buprenorphine-exposed to 55.2% in
methadone-exposed neonates.
Conclusions: Maternal use of buprenorphine and
methadone during pregnancy was associated with
increased prevalence of adverse birth outcomes. The
risk of NAS was 8-fold higher in methadone-exposed
neonates than in buprenorphine exposed. We did not,
however, control for lifestyle factors or underlying
indication for opioid treatment.
581. Birth Outcomes after Exposure to Mebendazole
and Pyrvinium During Pregnancy – A Danish
Nationwide Cohort Study
Arendse Torp-Pedersen, Espen Jimenez-Solem, Henrik
E Poulsen, Jon T Andersen. Department of Clinical
Pharmacology, Bispebjerg Hospital, Tagensvej 20,
Copenhagen, Denmark.
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Background:Mebendazole and pyrvinium are anthel-
mintics used to treat infections with pinworms, a
common infection in children. Pinworms are easily
transmitted to close family, why treatment involves
the entire household. Other indications for treatment
with mebendazole are infections with hookworms, an
infection rare in Denmark, but endemic in some parts of
the world. WHO recommend deworming pregnant
women in the second and third trimesters in areas endemic
for soil-transmitted helminth infection, but still limited
safety data of anthelmintics during pregnancy exists.
Objectives: The purpose of this study was to investigate
the association between exposure to mebendazole or
pyrvinium during pregnancy, and the pregnancy out-
comes: congenital malformations, stillbirth, neonatal
mortality, and small for gestational age.
Methods: All births in Denmark between 1997 and
2007 were identiﬁed from The Danish Fertility
Database and included in the study. We identiﬁed the
maternal exposure using the date of redemption of a
prescription for mebendazole or pyrvinium through
The Danish National Prescription Registry. We
conducted logistic regression analysis adjusting for the
potential confounders: maternal age at conception,
parity, income, level of education, smoking, and gesta-
tional age. When analyzing the risk of congenital
malformations the exposure time window comprised
the ﬁrst trimester. For all other outcomes, we analyzed
risks associated with exposure throughout pregnancy.
Results: 713 667 births were included in the study.
We found 2567 mothers redeeming a prescription for
mebendazole and 1588 for pyrvinium. The rate of
congenital malformations, stillbirths, neonatal mortality,
preterm deliveries, and children born small for gesta-
tional age was not signiﬁcantly higher in mebendazole
or pyrvinium exposed pregnancies compared to the
unexposed pregnancies.
Conclusions: Exposure to mebendazole or pyrvinium
during pregnancy was not associated with any adverse
pregnancy outcomes.
582. NSAID Use during Pregnancy: Maternal
Characteristics and Prescription Patterns. A
Nationwide Cohort Study
Vanja Cejvanovic,1,2 Espen Jimenez-Solem,1,2 Henrik
Enghusen Poulsen,1,2,3 Jon Trærup Andersen.1,2 1Labo-
ratory of Clinical Pharmacology, Copenhagen Univer-
sity Hospital Rigshospitalet, Copenhagen, Denmark;
2Department of Clinical Pharmacology, Copenhagen
University Hospital Bispebjerg, Copenhagen, Denmark;
3Faculty of Health Sciences, University of Copenhagen,
Copenhagen, Denmark.
Background: Nonsteroidal anti-inﬂammatory drugs
(NSAIDs) are among the most widely used drugs
and are also used by pregnant women. Exposure
in early pregnancy has been associated with in-
creased risk of miscarriage and birth defects though
the ﬁndings are conﬂicting. It is therefore recom-
mended to use NSAID during the ﬁrst and second
trimester with precaution. NSAID use is contraindi-
cated during the third trimester since NSAID
exposure in late pregnancy has been associated with
adverse fetal effects.
Objectives: The aim of this study was to identify the
characteristics of pregnant women who redeemed at
least one prescription of an NSAID and evaluate pre-
scription patterns before, during and after pregnancy.
Methods: We performed a nationwide cohort study
identifying all registered pregnancies in Demark from
1997 to 2010. All births were identiﬁed using the
Medical Birth Registry. Information on women re-
deeming an NSAID was retrieved from the National
Prescription Register. We identiﬁed all women diag-
nosed with a disease of the musculoskeletal system
and connective tissue(ICD-10 DM group) using the
National Hospital Register.
Results: We identiﬁed 911569 pregnancies resulting
in a birth between 1997 and 2010. 24841(2.7%) were
exposed to an NSAID, mainly Ibuprofen, at some
point during pregnancy. NSAID exposed women were
more likely to have a disease of the musculoskeletal
system and connective tissue compared to unexposed.
NSAID exposure increased from 1997 until 2004 and
then decreased until 2010. We found that NSAID use
gradually decreased as pregnancy progressed and
increased again after delivery.
Conclusions: Our ﬁndings show that pregnant women
who redeemed at least one prescription of an NSAID
were more likely to have a disease of the musculo-
skeletal system and connective tissue compared to
unexposed. NSAID exposure decreased after 2004,
which could be explained by a warning from The
Danish Medicines Agency concerning a possible
risk to the fetus. Despite NSAIDs being contraindi-
cated in the third trimester 3264(0.4%) of the preg-
nancies in our cohort were exposed to an NSAID
during the third trimester.
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583. Combining Adverse Perinatal and Pregnancy
Outcomes Using a Latent Trait Model
Xuerong Wen,1 Kimford J Meador,2 Joseph C Delaney,3
Xuefeng Liu,4 Jeffrey Roth,5 Rich Segal,6 Robert
Egerman,7 Abraham Hartzema.6 1Department of
Medicine, University of Florida, Gainesville, FL, United
States; 2Department of Neurology & Neurological
Sciences, Stanford University, Stanford, CA, United
States; 3Department of Epidemiology, University of
Washington, Seattle, WA, United States; 4Department of
Biostatistics & Epidemiology, East Tennessee State
University, Johnson City, TN, United States; 5Family
Data Center, Division of Neonatology, University of
Florida, Gainesville, FL, United States; 6Department
of Pharmaceutical Outcome and Policy, University of
Florida, Gainesville, FL, United States; 7Department
of Obstetrics & Gynecology, University of Florida,
Gainesville, FL, United States.
Background: Application of latent variable model in
medical research is becoming increasingly popular. A
latent trait model (LTM) is developed to combine rare
birth defect (BD) outcomes in an index of infant
morbidity.
Objectives: The objective of this study is to employ a
LTM in a drug safety study to produce an overall
severity index of rare adverse perinatal and pregnancy
outcomes.
Methods: This study is based on four statewide, retro-
spective 10-year data sources: Florida Medicaid
claims, Florida Birth Vital Statistics, Florida Birth
Anomaly, and Florida Hospital Discharge Inpatient
and Outpatient from January 1, 1999 to December
31, 2009. The study cohort includes female Florida
Medicaid enrollees who delivered a live singleton
infant between 4/1/2000 and 12/31/2008. A healthy
control group was selected as comparison. Drug
exposure was deﬁned as any one dose of AEDs or
VPA dispensed during the period of 14 days before
the ﬁrst day of the mother’s last menstrual period to
the infant’s birth date. Four individual adverse out-
comes: BD, abnormal condition of new born (ACNB),
low birth weight (LBW), and pregnancy and obstetrical
complication (PCOC) were combined using a LTM to
generate an overall severity index. Unidimentionality, lo-
cal independence, internal homogeneity, and construct
validity were evaluated for the combined outcome.
Results: The study cohort consists of 3,183 mother-
infant pairs in the AED exposure group, 226 in the
VPA exposure group, and 43,956 in the healthy
control group. Compared to healthy controls, the
VPA exposed group has higher rate of BD (19.6% vs
10.5%, P< .0001), and similar rates of ACNB,
LBW, and PCOC, whereas, the AED exposed group
has a higher rate of BD (12.8% vs 10.5%, P< .0001),
ACNB (12.1% vs 7.8%, P< .0001), LBW (11.9% vs
8.4%, P< .0001), and PCOC (35.5% vs 27.7%,
P< .0001). The mean score of the combined outcome
in the AED group is signiﬁcantly higher (2.04 ± 0.02
vs 1.88 ± 0.01, P< .0001), while the VPA group is
not signiﬁcantly different from health controls.
Conclusions: LTM is an effective tool to combine rare
birth defect outcomes. However, evaluation of the
selected components is essential to ensure the validity
of the combined outcome.
584. Selective Serotonin Reuptake Inhibitors and Con-
genital Heart Anomalies: Comparative Cohort Studies
Irene Petersen,1 Stephen Evans,2 Louise Marston,1 Ruth
Gilbert,3 Irwin Nazareth.1 1Primary Care and Population
Health, UCL, London, United Kingdom; 2Medical Statis-
tics, London School of Hygiene and Tropical Medicine,
London, United Kingdom; 3Institute of Child Health,
UCL, London, United Kingdom.
Background: Adverse birth outcomes, in particular
congenital heart anomalies, have been associated
with antidepressant use in pregnancy, but ﬁndings
may have been confounded by other characteristics
of the women.
Objectives: (1) Identify the characteristics of women
who are prescribed SSRIs in pregnancy in contrast to
women who are not.
(2) Examine the associations between SSRIs
prescribed in pregnancy and congenital heart
anomalies.
(3) Examine the association between social and life-
style characteristics of pregnant women and congenital
heart anomalies.
Methods: Design: Comparative cohort design
including four cohorts of children of women with
and without different antidepressant exposures before
and during pregnancy using data from The Health
Improvement Network (THIN) primary care database.
Setting: Primary care in United Kingdom.
Participants: A population based sample of 209,135 pairs
ofwomen and their children including 5,154women receiv-
ing SSRIs before pregnancy, 2,776 receiving SSRI in
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pregnancy, 992 receiving other antidepressants and 200,213
not receiving antidepressants before or during pregnancy.
Main Outcome measures: Congenital heart anomalies.
Results: Less than 1% of children had a record of con-
genital heart anomalies within ﬁve years of birth and
there were no signiﬁcant differences related to antide-
pressant exposure in pregnancy. However, independent
of antidepressant prescribing, diabetes, increasing age,
obesity (BMI above 30), histories of alcohol and illicit
drug problems were associated with an increased risk
of having a child with congenital heart anomalies.
Conclusions: There was no difference in congenital
heart anomalies in children born to women with dif-
ferent antidepressant exposure status. However, we
conﬁrmed an increased risk of congenital heart anom-
alies in children of older women, with diabetes, obe-
sity and a history of alcohol and illicit drug problems
independent of the prescription of antidepressants.
Future research in this ﬁeld must account for these
characteristics. Based on existing evidence, advising
women to stop antidepressant treatment in pregnancy
may be counterproductive.
585. Lithium Prescribing during Pregnancy: A UK
Primary Care Database Study
Rachel L McCrea,1 Irwin Nazareth,1 David PJ Osborn,2
Steven Evans,3 Vanessa Pinfold,4 Phil J Cowen,5 Ruth
Gilbert,6 Irene Petersen.1 1Department of Primary Care
and Population Health, University College London,
London, United Kingdom; 2Division of Psychiatry,
University College London, London, United Kingdom;
3Department of Medical Statistics, London School of
Hygiene and Tropical Medicine, London, United
Kingdom; 4The McPin Foundation, London, United
Kingdom; 5Department of Psychiatry, University of
Oxford, Oxford, United Kingdom; 6Institute of Child Health,
University College London, London, United Kingdom.
Background: Women of childbearing age taking
lithium must decide whether to continue the medica-
tion if they conceive. Concerns about a possible risk
of congenital cardiac malformations need to be
balanced against the risk of a deterioration in maternal
mental health after stopping lithium, but the evidence
base is limited. We know little about how many
women stop or continue lithium during pregnancy.
Objectives: To determine the prevalence of lithium pre-
scribing during pregnancy and to assess whether
pregnancy is associated with discontinuation of lithium.
Methods: We identiﬁed women who were prescribed
lithium before and during pregnancy using data from
The Health Improvement Network (THIN) primary
care database. We used a Kaplan-Meier plot to exam-
ine time to last prescription in women who were being
prescribed lithium three months before pregnancy, and
likewise for a comparison group of nonpregnant
women. Finally, we described the characteristics of the
women prescribed lithium in pregnancy.
Results: Very few women were prescribed lithium
before they became pregnant: we identiﬁed 101 out of
495,624 pregnancies in which lithium was prescribed
in the six months beforehand. Pregnant women were
more likely to stop lithium than those who were not
pregnant. Of the 52 women we identiﬁed who were be-
ing prescribed lithium three months before pregnancy,
only 17 (33%) received further prescriptions after the
6th week of pregnancy (when the pregnancy was likely
to be known). However, most of these women contin-
ued treatment throughout pregnancy, and many were
initially prescribed an antidepressant (47%) or antipsy-
chotic (53%) in addition to lithium (compared to 34%
prescribed each drug in those who stopped).
Conclusions: Few women were prescribed lithium
before and during pregnancy. Pregnancy was
strongly associated with discontinuation of lithium.
Those who continued lithium in pregnancy were
more likely to be prescribed other psychotropic med-
ication. The high rate of discontinuation may be ex-
plained by concern over potential adverse effects on
the developing foetus. However, evidence on the
risks of lithium is needed so that women can weight
these against the risk of a deterioration in maternal
mental health.
586. Parental Exposure to Folic Acid Antagonists
During Reproductive Age in a National Sample
Kitaw Demissie,1 Matthew Cvitanovich,2 Bijal
Balasubramanian,2 Tefera Gezmu.3 1Epidemiology,
Rutgers School of Public Health, Piscataway, NJ, United
States; 2Epidemiology, University of Texas School of
Public Health, Dallas, TX, United States; 3Public Health,
Bloustein School of Planning and Public Policy,
New Brunswick, NJ, United States.
Background: In previous studies, maternal exposure
to folic acid antagonists was associated with adverse
pregnancy outcomes. More recent epidemiologic data
as well as evidence from animal studies suggest that
paternal exposure may inﬂuence the health of the fetus
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by transmission of environmental information through
the sperm’s epigenome.
Objectives: To determine the prevalence of exposure
to folic acid antagonists in a nationally representative
sample separately in women and men of reproductive
ages and among pregnant women.
Methods: The 2011 Medical Expenditure Panel Sur-
vey, a longitudinal survey that covers a representative
sample of the U.S. civilian non-institutionalized
population was utilized for this analysis. Appropriate
sample survey weights were applied to take into
account the complex sample design. Participants were
interviewed on the medication they are taking and
asked to show pill containers. Women (15 to 50 years)
and males (15 to 75 years) in the reproductive age
range as well as pregnant women were identiﬁed.
Results: Among women of reproductive age, 39.56%
[95% Conﬁdence Interval (CI): 38.43 to 40.70) were
exposed to at least one of the folic acid antagonists.
Exposure was highest in White (44.38%; 95% CI:
42.79 to 45.96), intermediate in African American
(34.84%; 95% CI: 33.02 to 36.67) and lowest in
Hispanic (29.50%; 95% CI: 27.67 to 31.34) women.
Among males, exposure was 27.20% (95% CI: 26.11
to 28.29). Exposure was highest in African Americans
(30.46; 95% CI: 28.90 to 32.03) as compared with
Whites (21%) and Hispanics (21%). In pregnant
women, exposure to at least one folic acid antagonists
was 44.50% (95% CI: 40.00 to 49.01) with the highest
exposure among pregnant whites (50.29%; 95% CI:
43.56 to 57.03), followed by Non-Hispanic African
Americans (45.29%; 95% CI: 37.64 to 52.95) and
Hispanics (34.11%; 95% CI: 27.52 to 40.70).
Conclusions: : In a nationally representative sample,
exposure to folic acid antagonists in both women and
men of reproductive ages as well as in pregnant
women was very high and deserves attention.
587. First Results of the Nationwide pREGnant
Register in the Netherlands
Eugene van Puijenbroek, Saskia Vorstenbosch, Agnes
Kant. Netherlands Pharmacovigilance Centre Lareb,
‘s-Hertogenbosch, Netherlands.
Background: At the time of marketing, knowledge on
the safety of the use of drugs during pregnancy is
still limited, as pregnant women are not included in
pre-marketing research. Also after marketing, collecting
information on drug use during pregnancy can be
bothersome. In 2013 the pREGnant project started in
order to develop and implement a national register
for medical drug use during pregnancy in the
Netherlands. This register will be used for signal
detection and conducting epidemiological studies. In
February 2014, a pilot study was started to test and
validate this register.
Objectives: To describe the ﬁrst results of the pilot
phase of the pREGnant register.
Methods: In pREGnant, exposure to medical drugs
and other potential risk factors are monitored prospec-
tively. Data are collected by means of web-based ques-
tionnaires and completed by pregnant women,
focusing on medical drug use, the health of the preg-
nant woman, pregnancy complications and outcomes,
and the health of the child. In the pilot phase, different
schemes for data collection are introduced in order to
choose the best practice for inclusion. During the pilot
phase, inclusion takes place at midwiferies and
hospitals.
Results: The method and approaches applied will be
discussed as well as the number and type of inclusions.
Based on the initial results of the validation studies
and the experiences with implementing data from
other data sources, possibilities for the deﬁnite system
for pREGnant be discussed.
Conclusions: The current lack of knowledge on the
teratogenic risks of many medical drug use often
hampers healthcare professionals in making evidence-
based decisions on whether or not the beneﬁcial effects
of treatment outweigh the possible risks for the develop-
ing foetus and the pregnant woman. The pREGnant reg-
ister will enable a systematic collection of information
and may ﬁll this gap of knowledge.
588. Validation of Major Congenital Malformations
(MCMs) in Infants of Mothers with Chronic Inflam-
matory Arthritis (cIA) and Psoriasis (PsO)
Wendy J Carman,1 Neil A Accortt,2 Li Zhou,1 Lauren
Sanders,1 Yessenia T Bartley,2 Mary S Anthony,2 Cheryl
Enger.1 1Epidemiology, OptumInsight, Waltham, MA,
United States; 2Center for Observational Research,
Amgen, Inc, Thousand Oaks, CA, United States.
Background: Claims data are a valuable screening
tool for the effective examination of congenital de-
fects. However, claims are not collected for research
and a diagnostic code does not conﬁrm disease.
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Objectives: To evaluate using MCM claims to screen
for the diagnosis of MCMs.
Methods: Using administrative claims from 1995
through June 2012, we identiﬁed pregnant women
with cIA, PsO, or general population comparators with
liveborn infants. Mothers were linked to the infants
covered by the same insurer. MCMs were identiﬁed
using ICD-9 diagnosis codes and medical records were
sought. Procured records were reviewed by a geneti-
cist to adjudicate the MCM claims. The percents of
infants that were chart conﬁrmed were calculated by
the body-system of the claim. Records with insufﬁcient
chart data to make a determination were excluded.
Results: From 3,523 pregnancies, we identiﬁed 518
pregnancies (14.7%) and 546 linked infants with
claims for ≥1 MCM. We sought medical records for
218 (39.9%) infants and procured records of 152
infants with 302 MCM claims. The records of 119
infants (78.3%) contained sufﬁcient data to determine
if the infant had ≥1 MCM. Body systems with the
highest proportion of infants conﬁrmed (PPV) were
chromosomal, 5/5(100%), oral facial, 4/5(80%), and
genitourinary 19/27 (70%).The most prevalent MCMs
were among infants with cardiovascular and circula-
tory claims, 19/45 (42%) conﬁrmed; 11/39(28%) with
musculoskeletal claims; and those with genitourinary
claims. Speciﬁc MCM claims with very low PPVs
include ostium secundum atrial septal defect and face
and skull deformities.
Conclusions: Our goal was to identify infants with
MCMs, thus we cast a wide net to identify MCM claims
and keep the sensitivity high. This resulted in low
conﬁrmation rates. Balancing sensitivity and PPV is
necessary depending upon the objectives of the particu-
lar project, but since the conﬁrmation of MCM claims
appears to vary by body system, the development of
speciﬁc claims-based algorithms may be warranted.
589. Epidemiology of Pre-Existing Diabetes in
Pregnancy from 2000-2006 among Medicaid
Patients in 29 US States
Caitlin A Knox,1 Richard Segal,1 Almut G Winterstein.1,2
1Department of Pharmaceutical Outcomes and Policy,
University of Florida, Gainesville, FL, United States;
2Department of Epidemiology, University of Florida,
Gainesville, FL, United States.
Background: The rapid rise of type 2 diabetes
mellitus (T2DM) also affects pregnant women at an
increasing rate. Published studies have been conﬁned
to small populations or select race/ethnicities and lack
accurate assessments of trends of pre-existing DM or
T2DM without inclusion of gestational DM in preva-
lence estimates.
Objectives: To examine annual trends in the preva-
lence of pre-existing diabetes in pregnant women in
Medicaid, and describe their demographic and clinical
characteristics.
Methods:We used Medicaid fee-for-service (FFS)
billing data (MAX) from 29 states in the US, to estab-
lish a retrospective cohort of pregnant women, age 12
to 55 years with ≥2 ICD-9-CM codes for pregnancy
and 12 of months continuous eligibility period before
pregnancy. Pre-existing diabetes was identiﬁed based
on ≥1 in- or ≥2 outpatient claims with ICD-9-CM
250.XX before pregnancy. We evaluated the preva-
lence of pre-existing diabetes during pregnancy, and
respective secular trends across the study period
(2000 to 2006), using linear regression.
Results: We identiﬁed 1,226,025 pregnancies in the
MAX database with 3.6% of cohort pregnancies hav-
ing pre-existing diabetes during the pre-pregnancy pe-
riod. There were 28,099 women with only diagnoses
for T2DM, 2,208 with T1DM only, 13,370 with diag-
noses for both or undetermined types. T2DM women
were on average older, had longer continuous eligibil-
ity in Medicaid, were Black, Non-Hispanic and had
higher prevalence of PCOS, chronic hypertension
and obesity when compared to non-diabetic women.
The annual prevalence of T2DM increased from
1.7% in 2000 to 3.3% in 2006 (p = 0.0170).
Conclusions: The prevalence of pre-existing T2DM in
pregnancies has almost doubled from 2000 to 2006.
Since we analyzed only FFS beneﬁciaries in Medicaid,
we may be underestimating the annual prevalence of
T2DM in pregnancy, due to the increasing enrollment
in managed care. Nevertheless, our ﬁndings emphasize
the need for evidence regarding the safety and effec-
tiveness of pharmacological treatment, especially oral
anti-diabetic agents used to treat T2DM in pregnancy.
590. Internet Advertisement Methods Provide Highest
Levels of Recruitment to a Pilot Study of Self-
Reported Medication Use and Pregnancy Outcomes
Jonathan L Richardson,1 Simon HL Thomas,1 Sally
Stephens,1 Anna Jamry,2 Anna Latos-Bielenska,2
Priscilla A Zetstra-van der Woude,3 Lolkje TW de
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Jong-van den Berg,3 Maja Laursen,4 Shahrul Mt-Isa,5
Valerie Bigouret-Hliva,6 Nancy A Dreyer,7 Stella CF
Blackburn.8 1Institute of Cellular Medicine, Newcastle
University, Newcastle-upon-Tyne, Tyne and Wear,
United Kingdom; 2Department of Medical Genetics,
Poznan University of Medical Sciences, Poznan,
Wielkopolska, Poland; 3Department of Pharmacy, Uni-
versity of Groningen, Groningen, Netherlands; 4Data
Delivery and Medicinal Product Statistics, National
Institute for Health Data and Disease Control,
Copenhagen, Denmark; 5Imperial Clinical Trials Unit,
Imperial College London, London, Greater London,
United Kingdom; 6Real-World and Late Phase Research,
Quintiles, St-Prex, Vaud, Switzerland; 7Real-World and
Late Phase Research, Quintiles, Cambridge, MA, United
States; 8Inspections and Human Medicines Pharma-
covigilance Division, EuropeanMedicines Agency, London,
Greater London, United Kingdom.
Background: Many women of reproductive age use
medications for which there is insufﬁcient data regard-
ing the embryonic or foetal effects following intrauter-
ine exposure. The continued surveillance of maternal
medication use in pregnancy is therefore vitally
important. However, many commonly used study
designs are limited by bias, confounding and/or cost.
The prospective collection of information directly
from pregnant women could address some of these
issues, provided adequate numbers of women are
willing to participate.
The PROTECT Pregnancy Study is a non-
interventional, prospective pilot study of medication
use and obstetric outcomes self-reported by a co-
hort of pregnant women recruited without health
care professional intervention. The study was con-
ducted in four EU countries: Denmark (DK), the
Netherlands (NL), Poland (PL) and the United
Kingdom (UK).
Objectives: To describe the effectiveness of advertis-
ing methods used to recruit participants into the study,
and compare the success of the various methods
employed between participating countries.
Methods: The main advertisement methods used in
each country included advertisements displayed on,
or sent in e-mails from pregnancy related websites,
leaﬂets displayed in health care institutions, and
non-direct interaction via a Facebook proﬁle. The
numbers of participants recruited by each adver-
tisement method were compared between the
countries to evaluate the international differences
in their success.
Results: At the time of this preliminary analysis 1,431
participants had enrolled in the study. Recruitment
data was available for 1,166 of these study
participants (DK – 505, NL – 263, PL – 22 and
UK – 376). In all countries advertisements displayed
on/sent from websites were the most successful
recruitment method (DK – 96%, NL – 93.5%, PL –
50.0% and UK – 94.1%) recruiting 94.0% of the total
study population.
Conclusions: This preliminary analysis suggests there
are signiﬁcant international differences in the success
of the various recruitment strategies. Full analysis to
be presented. This research received support from the
IMI JU through the PROTECT project.
591. Risks Versus Benefits of Medication Use
During Pregnancy: What Do Women Perceive?
Bianca Mulder,1 Nynke CM Schuiling-Veninga,1 Leonard
PMorssink,2Maarten J Bijlsma,1 Eugene van Puijenbroek,3
Jan G Aarnoudse,4 Eelko Hak,1 Tjalling W de Vries.3
1PharmacoEpidemiology & PharmacoEconomics, Univer-
sity of Groningen, Groningen, Nederland, Netherlands;
2Medical Center Leeuwarden, Leeuwarden; 3Netherlands
Pharmacovigilance Center Lareb, ‘s-Hertogenbosch;
4University Medical Center Groningen, Groningen.
Background: Understanding risk perception is es-
sential in designing good risk communication strat-
egies. It has been reported that women overestimate
the teratogenic risk of medication use, but these
studies didn’t include perceived beneﬁts and major
concerns of pregnant women regarding medication
use.
Objectives: The aim of this study was to evaluate the
perception of risks, beneﬁts and major concerns
regarding medication use during pregnancy.
Methods: Questionnaires were handed out to all preg-
nant women who attended a Dutch obstetric facility
for ﬁrst and second line care. Patients were asked to
score the beneﬁts of 7 drug groups on a scale from 1-7
(Beneﬁt-score (BS)). Second, patients were asked to rate
the probability and severity of an event occurring due to
use of the 7 drug groups on a scale from 1-7. Risk scores
(RS) were constructed by multiplication of the measures
of perceived probability and severity. To make the RSs
comparable to the BSs a square root extraction of the RS
was performed. Third, patients were asked about the
level of concern of different unfortunate events resulting
from medication use.
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Results: Results are preliminary
A total of 118 eligible women completed the ques-
tionnaire (response rate 77%). More than 80% of the
women used medication during pregnancy. Paraceta-
mol (RS = 2.0, BS = 4.7), antacids (RS = 2.8, BS= 4.2)
and antibiotics(RS = 3.3, BS = 4.6) were perceived
relatively low in risk and high in beneﬁt. Sedatives
(RS = 5.2, BS = 3.9) and NSAIDS (RS= 4.7, BS= 3.2)
were perceived relatively high in risk and low in
beneﬁt. Pregnant women were most concerned about
having a child with a congenital birth defect (38.1%),
a miscarriage (36.0%) or having a child with an
allergic disease (25.7%), respectively as a result of
drug use.
Conclusions: Though it has been reported that women
overestimate teratogenic risk of medication use, this
study showed that most of the drugs were perceived
relatively low in risk and high in beneﬁt. In addition
this study shows the different concerns women have
regarding medication use during pregnancy. Health
care providers in ﬁrst and second line care obstetric
facilities can take this into account when counselling
pregnant women.
592. Creating a Pregnancy Register for a UKPopulation
Rachael Boggon, Tim Williams. Clinical Practice
Research Datalink, London.
Background: Increased focus is being placed on in-
utero exposures with respect to pregnancy outcomes
and conditions manifested in children, including stud-
ies into teratogenic effects of drugs, which are chal-
lenging to investigate using traditional pre-marketing
methodologies for obvious reasons. The Clinical Prac-
tice Research Datalink (CPRD) provides GP data
(GOLD) linked to hospital and mortality data, within
which in-utero exposure and maternal and child out-
comes can be identiﬁed.
Objectives: The objectives are:
• Create a pregnancy register using CPRD GOLD
• Incorporate linked data to maximise effectiveness
and utility
• Validate results.
Methods: Women with delivery records in the CPRD
GOLD and linked databases were identiﬁed. Babies
born after the start of prospective data collection with
their own records in CPRD GOLD were identiﬁed. A
cartesian join of mothers to babies by family number
was undertaken and the optimal pair identiﬁed to
create a mother to live baby link. Women’s records
in all three databases were searched for evidence of
pregnancy to create the full pregnancy register.
Validation of the register was conducted via free text
searches and GP questionnaires.
Results: The mother to live baby link contains approx-
imately 700,000 mothers and over 1 million babies.
However, these records account for under 30% of
pregnancies in the register. Identifying additional
pregnancies, including mothers whose live births were
not linked to baby records and those with other birth
outcomes, results in a register that can be used for
a broader range of pregnancy related research. Full
results of the pregnancy register, incorporation of
linked databases and the validation exercises will
be presented.
Conclusions: The CPRD pregnancy register allows
studies of the teratogenic effects of drugs to be
conducted in a UK population. Long follow-up
allows for studies that require information in all
three trimesters, at delivery, through infancy and
into childhood.
593. Evaluation of Medication Use During Preg-
nancy in the Mini-Sentinel Distributed Database
Susan Andrade,1 Sengwee Toh,2 Marilyn Pitts,3 Monika
Houstoun,3 Katrina Mott,3 Katie Haffenreffer,2 Marsha
Reichman.3 1Meyers Primary Care Institute, Worces-
ter, MA, United States; 2Harvard Pilgrim Health Care
Institute, Boston, MA, United States; 3U.S. Food and
Drug Administration, Silver Spring, MD, United
States.
Background: The need for postmarketing surveillance
on medication use during pregnancy is well-recognized.
Mini-Sentinel is a pilot project sponsored by the U.
S. Food and Drug Administration to create an active
surveillance system to monitor the safety of FDA-
regulated medical products. The ability of Mini-
Sentinel to assess medication use during pregnancy
is currently unknown.
Objectives: To assess medication use among pregnant
women delivering a live born infant and a comparison
group of nonpregnant women.
Methods: We developed an algorithm based upon
other Mini-Sentinel and non Mini-Sentinel preg-
nancy-related projects to identify medication use
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during pregnancy in the Mini-Sentinel Distributed
Database. Diagnosis and procedure codes were used
to identify women ages 10 to 54 years delivering a
liveborn infant between January 1, 2001 and December
31, 2012. A comparison group of nonpregnant women
(not delivering a liveborn infant) with similar eligibility
criteria was identiﬁed. Use of select medications with
safety issues for use during pregnancy was identiﬁed
from outpatient dispensing data. The frequency of use
of the medications overall, and according to trimester
of use and select characteristics (calendar year, maternal
age group, pre-existing conditions and medication use)
was determined.
Results: Reusable, readily adaptable analytic code has
been distributed to 18 Mini-Sentinel Data Partners
encompassing an overall population of 153 million
individuals. The code can be easily modiﬁed to include
different lists of medications, time periods, age ranges of
women, diagnosis and procedure codes to identify
deliveries or pre-existing conditions, and various
enrollment criteria. We will describe the results of the
assessment (which will be available for presentation
by ICPE), including characteristics of the pregnant
and comparison groups and the frequency of use of
select medications.
Conclusions: Results of the assessment and
implications for the postmarket surveillance of the
safety of medication exposures during pregnancy
will be discussed.
594. Developing a Systematic Approach to Safer
Medication Use during Pregnancy: Summary of a
Centers for Disease Control and Prevention-
Convened Meeting
Cheryl S Broussard,1 Meghan T Frey,1,2 Sonia
Hernandez-Diaz,3 Michael F Greene,4 Christina D
Chambers,5 Leyla Sahin,6 Beth A Collins Sharp,7 Margaret
A Honein.1 1National Center on Birth Defects and
Developmental Disabilities, Centers for Disease Control
and Prevention, Atlanta, GA, United States; 2Oak Ridge
Institute for Science and Education, Oak Ridge, TN, United
States; 3Harvard School of Public Health, Boston, MA,
United States; 4Department of Obstetrics, Gynecology,
and Reproductive Biology, Harvard Medical School
and Massachusetts General Hospital, Boston, MA,
United States; 5Departments of Pediatrics and Family
and Preventive Medicine, University of California, San
Diego, La Jolla, CA, United States; 6Center for Drug
Evaluation and Research, U.S. Food and Drug Adminis-
tration, Silver Spring, MD, United States; 7Agency for
Healthcare Research and Quality, Rockville, MD,
United States.
Background: Medication use in pregnancy is
common, yet there is limited information available
about the safety or risk for the most frequently used
medications in pregnancy.
Objectives: To address existing information gaps that
limit informed clinical decisions on medication use in
pregnancy, the U.S. Centers for Disease Control and
Prevention (CDC) solicited expert input on a draft pro-
totype outlining a systematic approach to evaluating
the quality and strength of existing evidence for risks
associated with medication exposures in pregnancy.
Methods: The draft prototype was developed by CDC
scientists in collaboration with academic experts and
federal partners. It outlined a process for the systematic
review of available evidence and deliberations by a
panel of experts to inform clinical decision making
for the management of health conditions in pregnancy.
CDC convened an expert meeting in January 2013, and
meeting participants were divided into working groups
to discuss critical decision points within the prototype.
Work groups provided feedback on various sections of
the prototype including setting priorities for which ma-
ternal conditions to review, utilizing systematic review
methodologies, developing guidance, and disseminat-
ing information to women and providers.
Results: This presentation summarizes the meeting at-
tendees’ discussions about best practices for formulating
an expert review process, developing evidence summaries
and treatment guidance, and disseminating information.
Conclusions: There is clear recognition of the current
knowledge gaps and a strong collaboration of federal
partners, academic experts, and professional organiza-
tions willing to work together towards safer medication
use during pregnancy.
595. Female Kidney Transplant Patients Taking
Mycophenolate Analysis in a Southern Taiwan
Hospital
Pili Chih-Min Mao,1 Mei-Ing Chung,1 Eric Kin-Lap Lee,2
Pi-Lai Tseng.2 1Graduate Institute of Pharmaceutical
Sciences, School of Pharmacy, Kaohsiung Medical Uni-
versity, Kaohsiung, Taiwan; 2Department of Pharmacy,
Kaohsiung Veterans General Hospital, Kaohsiung.
Background: Pregnancy after solid organ transplanta-
tion is no longer uncommon. Mycophenolate mofetil
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(MMF), including mycophenolic Acid (MPA), is an
immunosuppressant. The use of MMF/MPA in trans-
plant patients has increased per year. However, there
is a change in the U.S. Food and Drug Administration
category of MMF/MPA from pregnancy Class C to D
(positive evidence of fetal risk) on October 2007.
Objectives: Time trend analysis of drug utilization
development for organ transplant patients could help
to follow the effect of regulatory changes on its
prescribing.
Methods: Consumption data were obtained via the
health reimbursement claims data ﬁles of ambulatory
care expenditure of the Kaohsiung Veterans General
Hospital (VGHKS), a 1300 bed medical center for
the period 2007-2012. Using Anatomical Therapeutic
Chemical (ATC) classiﬁcation codes (i.e. L04AA06)
we allocated to kidney replaced by transplant ICD-9
codes (i.e. V42). All the batch analysis was managed
and performed using the SPSS version 20 for
Windows.
Results: The overall medication consumption mea-
sured increased by 2.5%~ 4.8% between 2007 and
2012. Although the intensity of use (#deﬁned daily
doses, #DDDs) per year in the female reproductive
age group (15-50 years old) was lower the other
groups (e.g. male or female non-reproductive age).
The #DDDs per year of MMF/MPA use still increase
during the period of study.
Conclusions: Female patients of childbearing poten-
tial must receive contraceptive counseling and must
use effective contraception while taking MMF/MPA.
Pharmaceutical care for these patients should discuss
the risks and beneﬁts of MMF/MPA as well as alterna-
tive immunosuppressant therapy with their physicians
and patients.
596. Second Generation Antipsychotics and Risk
of Type 2 Diabetes in Publicly Insured Children
and Adolescents
Tobias Gerhard,1,2 William V Bobo,3 Mark Olfson,4
Christoph U Correll,5 Cecilia Huang,2 Stephen Crystal.2
1Ernest Mario School of Pharmacy, Rutgers University,
Piscataway, NJ, United States; 2Institute for Health,
Health Care Policy and Aging Research, Rutgers Univer-
sity, New Brunswick, NJ, United States; 3Mayo Clinic,
Rochester, MN; 4Department of Psychiatry, Columbia
University, New York, NY; 5Zucker Hillside Hospital,
New York, NY.
Background: Use of second generation antipsy-
chotics (SGAs) in youth has been associated with
a 3-fold increase in risk for type 2 diabetes.
Whether known differences in the short-term meta-
bolic proﬁles (weight gain, metabolic parameters)
of individual SGAs in this population translate into
a differential risk for type 2 diabetes remains
unknown.
Objectives: This study aims to estimate the compara-
tive risk for incident type 2 diabetes for individual
SGAs in publicly insured US youth.
Methods: We used Medicaid Analytic Extract data
from 45 US States for 2001-2009 to conduct a
retrospective cohort study among 511,398 youth
(age 2 to 24 years) newly started on risperidone
(n = 254,747), quetiapine (n = 106,788), aripiprazole
(n = 77,713), olanzapine (n = 55,349), or ziprasidone
(n = 16,801). New SGA treatment episodes required
180 days of eligibility without claims for any anti-
psychotic. Patients were excluded for serious gen-
eral medical illnesses, pregnancy, polycystic
ovarian syndrome or evidence of diabetes prior to
the index date. Study outcome was incident type
2 diabetes deﬁned by a validated algorithm (PPV =
83.9%). Cox proportional hazards models assessed
type 2 diabetes risk of individual SGAs compared
to risperidone (referent). Follow-up began at date
of ﬁrst SGA claim and was censored at study
outcome, SGA discontinuation/switch/addition,
age 25, end of study period, loss of eligibility or
death, whichever came ﬁrst. Propensity scores
(PSs) were used to adjust for a broad set of >150
covariates assessed during the 180-day pre-index
period.
Results: We observed 320 cases of incident type 2
diabetes during 193,793 person years of follow-up.
Treatment discontinuation was the predominant
censoring reason. PS-adjusted models showed no
signiﬁcant differences of any SGA compared to risper-
idone (quetiapine: HR 0.80, 0.58-1.10; aripiprazole:
HR 1.00, 0.70-1.42; olanzapine: HR 0.95, 0.64-1.41;
ziprasidone: HR 1.49, 0.90-2.49).
Conclusions: We observed no differences in type 2
diabetes risk between individual SGAs. Despite ex-
tensive adjustments, residual confounding from
channeling of high risk patients to SGAs perceived
to be less metabolically challenging cannot be ruled
out.
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597. Attention-Deficit/Hyperactivity Disorder
(ADHD) Pharmacological Treatment and Its Effect
on Accident and Emergency Admission Due to
Injury: A Self-Controlled Case-Series Study
Kenneth KC Man,1 Esther W Chan,1 Ian Douglas,2 Patrick
Ip,3 Wilfred HS Wong,3 David Coghill,4 Ian CK Wong.1
1Department of Pharmacology and Pharmacy, The
University of Hong Kong, Hong Kong, Hong Kong;
2Department of Non-communicable Disease Epidemiology,
London School of Hygiene and Tropical Medicine, London,
United Kingdom; 3Department of Paediatrics and
Adolescent Medicine, The University of Hong Kong, Hong
Kong, Hong Kong; 4Division of Neuroscience, School of
Medicine, University of Dundee, Dundee, United Kingdom.
Background: Attention-Deﬁcit/Hyperactivity Disorder
(ADHD) patients have a higher tendency to sustain
trauma requiring Accident & Emergency Department
(ED) visits. Evidence that ADHD patients on pharma-
cotherapy tend to have a lower ED admission rate
compared to those without medication is limited.
Objectives: To investigate the association between
ADHD drug treatment and Accident & Emergency
Department (ED) admission from injuries.
Methods: Design: Self-controlled case series study.
Setting: Patients aged 6 to 19 with at least one
prescription of Methylphenidate (MPH) and at least
one ED admission from injury in 2001 to 2013 were
identiﬁed (n = 5178) using Hong Kong Population-
based electronic medical records in the Clinical Data
Analysis & Reporting System (CDARS).
Main Outcome Measure: Relative incidence of
ED admission from injuries comparing exposed
and non-exposed periods was estimated. Individual
observation period commenced latest 1st January,
2001 or on patient’s 6th birthday, and ended earliest
31st December, 2013, on the patient’s 20th birthday
or the date of registered death. The Incidence Rate
Ratios (IRRs) and the corresponding 95% conﬁ-
dence intervals were calculated using conditional
Poisson regression.
Results: Among patients prescribed MPH, the rate of
ED admission from injuries was decreased during
exposed periods compared to non-exposed periods
(IRR= 0.91, 95%CI 0.86 to 0.97). Similar results were
observed if only the ﬁrst injury episode was counted
(IRR= 0.88, 95%CI 0.81 to 0.96). Sensitivity Analysis
was conducted by adding 1 to 10weeks after the end
of an exposed period which gave consistent results.
Conclusions: This study supports the hypothesis that
MPH can reduce the risk of injury-related ED admis-
sion in children and adolescents. Long term MPH
treatment prevents injuries in this group of high-risk
patients and this potential beneﬁt should be considered
in clinical practice.
598. Antidepressants and Risk of Suicide or Self-
Harm in Canadian Youth: A Study Involving a Com-
mon Data Model in Quebec and British Columbia
Larry L Lynd,1 Thierry Ducruet,2 Kathy Li,1 Marie
Tournier,3 Brian Greenﬁeld,4 Yola Moride.2 1Faculty of
Pharmaceutical Sciences, University of British Columbia,
Vancouver, BC, Canada; 2Faculty of Pharmacy,
Université deMontréal, Montreal, QC, Canada; 3INSERM
U657, Université Bordeaux, Bordeaux, France; 4Psychia-
try and Paediatrics, Faculty of Medicine, McGill
University, Montreal, QC, Canada.
Background: Use of antidepressants (AD) in children
and adolescents is controversial due to a possible in-
creased risk of suicide. Studies have been conducted
using healthcare databases, mainly restricted to hospi-
talized cases.
Objectives: To evaluate the rate of self-harm among
children (10-14 years) and adolescents (15-19 years)
who use ADs, and to compare rates across classes,
using a common data model.
Methods: A retrospective cohort study was conducted in
children and adolescents who initiated an AD treatment
between 1 Jan. 1997 and 31 Dec. 2008 (QC) or 2006
(BC). Hospitalized (BC, QC) and non-hospitalized
(QC) self-harm were studied. Data sources in-
cluded: prescription, medical services, hospitaliza-
tion databases. For hospitalized self-harm, cases
were identiﬁed using ICD-9 or ICD-10 codes, de-
pending on the year. For non-hospitalized self-
harm, a medical encounter at the emergency room
with an injury code followed by a psychiatric con-
sult was used as a proxy (validated). ADs were cat-
egorized into: Fluoxetine (only AD approved for
paediatrics in Canada), non-ﬂuoxetine SSRIs,
TCAs, Others. Multivariate logistic regression anal-
yses with high dimensional propensity scores were
conducted, with non-ﬂuoxetine SSRIs as reference.
Results: 51,868 (BC) and 28,200 (QC) AD users
were included : 70% were females, and 60% had re-
ceived a depression diagnosis. Rate of hospitalization
for self-harm was 38.15 and 19.23/1000 person-years
abstract 317
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
in BC and QC, respectively. Rates were higher
among adolescents (BC : 47.52; QC : 21.36) than
children (BC : 17.00, QC : 12.99). Median delay of
onset was 48 days for children and 41 for adolescents.
While there was no statistically signiﬁcant diffference
in risk associated with ﬂuoxetine relative to non-
ﬂuoxetine SSRIs, TCAs were associated with a lower
risk in BC (OR= 0.47; 95%CI : 0.31-0.72) and
Quebec for both hospitalized and non-hospitalized
cases (OR= 0.41; 95%CI: 0.30-0.46).
Conclusions: In two independent large cohorts, there
was no apparent differences in risk across ADs. Lower
risk of TCAs may be due to residual confounding
by indication, which will be addressed with self-
controlled analyses.
599. Trend in the Prescribing of Antipsychotics for
Children and Adolescents in Japan: A Descriptive
Epidemiological Study from the Large-Scale Phar-
macy Database
Sayuri Nakane,1 Chika Nishiyama,1 Kenji Kochi,1,2
YusukeOgawa,3 Toshiaki A Furukawa,3 Koji Kawakami.1
1Department of Pharmacoepidemiology, Graduate School
of Medicine and Public Health, Kyoto University, Kyoto,
Japan; 2Drug Development Division, Dainippon
Sumitomo Pharma Co., Ltd, Tokyo, Japan; 3Department
of Health Promotion and Human Behavior, Graduate
School of Medicine and Public Health, Kyoto University,
Kyoto, Japan.
Background: Although the action of antipsychotics
on children’s brain development has not been well
documented, antipsychotics are widely prescribed.
However, little is known about the temporal change
in the prescription patterns of antipsychotics to chil-
dren for a prolonged period.
Objectives: To describe the prevalence of antipsy-
chotics prescribed for outpatient children and adoles-
cents in Japan.
Methods: Design: A descriptive epidemiological
study. Participants: All outpatients aged 17 years
or younger receiving their ﬁrst antipsychotic pre-
scription from 2006 to 2012. Setting and Data
collection: Use of antipsychotics in children and
adolescents was described using dispensation re-
cords collected from 964 community pharmacies
in Japan. Measurements: age, sex, kinds and dos-
ages of antipsychotics, and their prescription pattern
(monotherapy vs polytherapy).
Results: During the study period, 10,511 patients were
included in this study. The number of patients which an-
tipsychotics were prescribed increased from 914 in 2006
to 1,884 in 2012 in this dataset. The mean (±SD) age de-
creased from 13.6 ± 3.4 in 2006 to 12.5 ± 3.7 in 2012.
The proportion of patients aged 0-6 years increased
from 5.1% in 2006 to 8.0% in 2012. The proportion of
male increased from 47.7% in 2006 to 59.0% in 2012.
There were increases in the proportion of monotherapy
from 86.8% in 2006 to 92.3% in 2012. Among mono-
therapies, second-generation antipsychotics (SGA)
monotherapy increased from 53.8% in 2006 to 78.3%
in 2012, whereas ﬁrst-generation antipsychotics (FGA)
monotherapy decreased from 33.0% to 14.0%. The
mean chlorpromazine equivalent (CPZ eq.) dose
decreased from 145.6 ± 204.8mg/day in 2006 to
122.0 ± 174.7mg/day in 2012. Surprisingly, 3.7% were
administered over 600mg/day of CPZ eq. dose.
Conclusions: Our study showed the prescription
patterns of antipsychotics in outpatient children and
adolescents. Given that children may be at higher risk
for side effects of antipsychotics, these ﬁndings have
broad public health warning.
600. Does Physicians’ Treatment of Pediatric
Depression Reflect Evidence-Based Practice?
Findings from a National Sample of Privately
Insured Children and Adolescents
Rene Soria-Saucedo,1 Heather J Walter,2 Howard Cabral,3
Mary Jane England,1 Lewis Kazis.1 1Health Policy and
Management, Boston University, Boston, MA, United
States; 2Psychiatry, Boston University School of Medicine,
Boston, MA, United States; 3Biostatistics, Boston Univer-
sity School of Public Health, Boston, MA, United States.
Background: An increasing number of psychotropic
medications have been marketed to physicians for the
treatment of depression in children and adolescents
(C&A), yet sparse to no empirical evidence deﬁni-
tively supports their effectiveness or safety. The opti-
mal approach should intend to maximize beneﬁt
while minimizing risk.
Objectives: To examine the frequency of six ap-
proaches to the treatment of depression with varying
degrees of empirical support in a national sample of
privately insured C&A.
Methods: Design: Retrospective observational study.
Study sample included 61,599 C&A with depression,
from a total of 6,225,600 privately insured C&A.
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Setting: A national 2009 privately insured sample of
C&A in the US.
Exposures: Six treatment options: combination treat-
ment (ﬂuoxetine and psychotherapy), ﬁrst line antidepres-
sant medication (ﬂuoxetine), second line antidepressant
medication, non-evidence based (newer antidepressants
and antipsychotics), and psychotherapy alone.
Main outcome: The likelihood of receiving six
different depression treatment options controlling for
demographics, insurance type, region, and illness
severity and complexity
Statistical analysis: Six mutually exclusive multivar-
iable logistic regression models.
Results: Only 58.4% of depressed C&A received at least
one type of depression treatment; 33.6% received psycho-
therapy alone; 24.8% received medication alone; and
2.7% received combination treatment. Of those depressed
C&A receiving medication, 24.8% received medications
unsupported by empirical evidence and 50.6 received
medications with equivocal support. Mental health spe-
cialists (MHS) were more likely to prescribe combination
treatment by approximately 9 fold (OR: 8.6; CI: 5.38-
14.01), compared to primary care physicians (PCP).
Conclusions: Large proportions of depressed C&A
are not receiving any treatment or are receiving
treatments unsupported or equivocally supported by
empirical evidence. Physicians should be guided by
evidence of safety and effectiveness when considering
treatment options for depressed youth.
601. Development of a Novel Approach to Assess Psy-
chotropic Polypharmacy in Administrative Databases
Xinyue Liu,1 Paul Kubilis,1 Regina Bussing,2 Almut G
Winterstein.1,3 1Pharmaceutical Outcomes and Policy,
College of Pharmacy, University of Florida, Gainesville,
FL, United States; 2Psychiatry, College of Medicine,
University of Florida, Gainesville, FL, United States;
3Epidemiology, College of Public Health & Health
Professions, Gainesville, FL, United States.
Background: The rise in pediatric psychotropic
polypharmacy has caused signiﬁcant public concern.
Traditional approaches to measure polypharmacy in bill-
ing data based on a minimum overlap of days’ supply of
ﬁlled prescriptions often fail to distinguish concomitant
from switching therapy. A novel approach to minimize
misclassiﬁcation of polypharmacy is needed.
Objectives: To develop and test an algorithm to
identify psychotropic polypharmacy in children with
attention deﬁcit/hyperactivity disorder (ADHD).
Methods: This approach is characterized by assessment
of prescription (re-)ﬁll pattern. Concomitant therapy is
assumed when both target drugs are dispensed repeat-
edly during active days’ supply (ADS) of each other,
e.g., the dispensing date of drug B occurs during drug
A’s ADS, the dispensing date of drug A occurs during
drug B’s ADS and the following dispensing date of drug
B also occurs during drug A’s ADS. Children aged 4-18
in 29 state Medicaid fee-for-service programs with ≥2
outpatient visits for ADHD in 2004 (n= 232485) were
followed through 2005-2006. Two stimulants (STIs), 4
SSRIs and 4 atypical antipsychotics (AAPs) formed
the drug pool to estimate polypharmacy prevalence.
Results: Using the novel metric and restricting the co-
hort to children with claims for 2 STIs (n = 37782), 2
SSRIs (n = 3384) or 2 AAPs (n= 16297), we estimated
the proportion of within-class polypharmacy at 3.0%,
2.6% and 18%. The proportion of children with
across-class polypharmacy among those with claims
for STIs + SSRIs (n = 11242), STIs +AAPs (n= 41682)
or SSRIs +AAPs (n= 4242) was 55%, 68% and 53%.
These estimates fell between polypharmacy estimates
derived from 60- or 30-day overlap deﬁnitions. These
were 1.6% or 14%, 0.71% or 7%, and 9.4% or 26%,
among children with pharmacy claims of 2 STIs, 2
SSRIs and 2 AAPs; and 36% or 69%, 47% or 77%,
and 33% or 63%, among children with pharmacy claims
of STIs + SSRIs, STIs +AAPs and SSRIs +AAPs.
Conclusions: The prevalence of polypharmacy deﬁned
by the novel approach was consistently between esti-
mates derived from 30- and 60-day overlap approaches.
The novel approach may be a promising metric to
overcome the high variability of traditional overlap
approaches.
602. Does a Cardiovascular Event Change Adher-
ence to Statin Treatment in Patients with Type 2
Diabetes? A Matched Cohort Design
Dianna de Vries,1 Petra Denig,2 Stefan Vegter,1 HJ Bos,1
Maarten J Postma,1 Eelko Hak.1 1Unit of Pharmaco-
Epidemiology & PharmacoEconomics, University of
Groningen, Groningen, Netherlands; 2Department of
Clinical Pharmacy and Pharmacology, University
Medical Center Groningen, Groningen, Netherlands.
Background: Statin treatment is associated with a
reduction in the risk of cardiovascular events. To be
effective, adherence is essential but this may be
inﬂuenced by the occurrence of a cardiovascular event
while being on treatment.
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Objectives: To assess the effect of an apparent ﬁrst
event on statin adherence rates in type 2 diabetes patients.
Methods: A matched cohort study was conducted
among type 2 diabetes patients initiating statin treatment
for primary prevention in the Groningen University
IADB.nl pharmacy database. Index patients who had a
drug-treated cardiovascular event (index date) after
statin initiation were matched to a reference patient
without such an event with similar gender, age at statin
initiation, initiation date, follow-up period and
adherence level before the event. Medication proxies
were used to identify apparent events. Adherence rates
were measured as percentages of days covered (PDC),
relative risks with 95% conﬁdence intervals (95%CI)
were calculated for shifts in adherence levels (non-
adherent, partial-adherent, full-adherent) around the
index date. Adherence rates around the index date
were evaluated using Wilcoxon signed ranks tests and
Mann-Whitney U Tests.
Results: We could match 375 of the 855 eligible index
patients. Index patients had on average a PDC of 81%
after the index date; reference patients had a PDC of
71% (P< 0.001) while both had a PDC of 79% before
the index date. Index patients were 4.5 times more likely
than reference patients to shift from non-adherent to
full-adherent [95%CI 1.1-18.8] and 1.8 times more
likely to shift from partial-adherent to full-adherent
[95%CI 1.2-2.6]. In the index group, 26% of patients
became more adherent after the ﬁrst cardiovascular
event. In contrast, 20% of patients became less adherent.
Conclusions: The occurrence of a drug-treated cardio-
vascular event appeared to avert the declining statin
adherence rate observed in diabetes patients without
such an event. On the other hand, one in ﬁve patients
became less adherent after the event, indicating that
there are still important beneﬁts to achieve by tailoring
the management of individual patients.
603. Factors Associated with Patients’ Adherence to
Antihypertensive Drug Classes in the UK
Amanj Baker, Li-Chia Chen, Rachel Elliott.Division for Social
Research in Medicines and Health, School of Pharmacy,
University of Nottingham, Nottingham, United Kingdom.
Background: Few studies have assessed factors
associated with patients’ adherence to antihyperten-
sive drug classes but mainly included new patients,
short follow up time, and dichotomous adherence
measures.
Objectives: To explore factors associated with adherence
to antihypertensive drug classes in new and existing
hypertensive patients.
Methods: A cohort study was conducted from April
2006 to March 2013 using the Clinical Practice Re-
search Datalink. Hypertensive patients were followed
up from the ﬁrst antihypertensive drug prescription
date to either study end, leaving dataset or death.
Spells of six antihypertensive drugs, i.e. diuretics,
beta-blockers (BB), calcium channel blockers
(CCB), angiotensin converting enzyme inhibitors
(ACEI), angiotensin receptor II blockers (ARB),
and ‘Others’ were identiﬁed. Proportion of days cov-
ered (PDC) was derived by dividing number of days
covered with an antihypertensive drug class, by
number of follow-up days in the spell. Association
between patients characteristics (age, gender,
Charlson comorbidity index [CCI] and new or
existing patients or user), follow-up time and class
PDCs was evaluated by Generalized Linear model
with gamma family and log link function.
Results: Overall, 371605 spells of antihypertensive
drug class were identiﬁed from 176835 existing
(55.5%) and new user (55.2%) patients’ prescriptions.
ACEIs accounted for 29.7% spells, followed by CCB
25.1%, diuretics 19.3%, BB 11.4%, ARB 10.7%, and
“Others” 3.8%. Median PDC for all spells was
93.9% (IQR: 47.3%, 100%), and PDCs< 80% was
found in 38.4% of the spells. The lowest proportion
of spells with PDC< 80% was in ARB (28.5%)
followed by ACEI (35.9%), and the highest was in
‘Others’ (47.3%). Class PDC increased with age
(0.3%, 95%CI: 0.2-0.4%), existing patients (2%,
95%CI: 0.8-3%), and existing drug users (13%, 95%
CI: 12-14%); while decreased with female (3.4%,
95%CI: 38-3%), CCI ≥ 2 (2%, 95%CI: 2.1-0.9%) and
follow-up year (1.4%, 95%CI: 1.6-1.3%).
Conclusions: Drug class, female, higher CCI, longer
follow-up and new patients and users jeopardise
adherence to antihypertensive drug classes, and further
interventions are needed to ensure those patients
maintain optimal adherence.
604. Factors Associated with β-Blocker Initiation
and Discontinuation among Seniors with Heart
Failure (HF)
Catherine Girouard,1,2,3 Jean-Pierre Grégoire,1,2,3 Paul
Poirier,2,4 Jocelyne Moisan.1,2,3 1Chair on Adherence to
Treatments, Université Laval, Quebec City, QC, Canada;
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2Faculty of Pharmacy, Université Laval, Quebec City, QC,
Canada; 3Axe Santé des Populations et Pratiques
Optimales en Santé, Centre de Recherche du CHU de
Québec, Quebec City, QC, Canada; 4Institut Universitaire
de Cardiologie et de Pneumologie de Québec, Quebec
City, QC, Canada.
Background: Most patients suffering from HF should
be exposed to β-blockers (bisoprolol, carvedilol and
metoprolol). Underexposure to these drugs has been
reported among seniors with HF. Factors associated
with β-blocker initiation and discontinuation among
seniors with HF are unknown.
Objectives: To assess factors associated with β-blocker
initiation and discontinuation among seniors with a ﬁrst
HF diagnosis.
Methods: Using the Quebec provincial administrative
databases, we conducted a population-based inception
cohort study that included all patients aged ≥65 with a
ﬁrst HF diagnosis who were naïve to β-blocker at time
of HF diagnosis. We assessed β-blocker initiation in this
cohort and discontinuation among those who had initi-
ated a β-blocker. We deﬁned discontinuation as the ﬁrst
gap in reﬁlling equal to twice the days’ supply of a claim
after β-blocker initiation. Stepwise Cox regression analy-
ses were used to calculate hazards ratios (HR) and to
identify factors associated with β-blocker initiation and
discontinuation. The input threshold was set to a p-value
0.1. Only variables that reached statistical signiﬁcance
(p-value <0.05) were kept in the ﬁnal model.
Results: Among the 91,131 seniors included 32,989
(36%) initiated a β-blocker. Among these, 15,408 (47%)
discontinued their β-blocker during the follow-up. Patients
diagnosed in a recent calendar year (year 2009: HR 2.11)
and those diagnosed by a cardiologist (HR 1.38) were
more likely to initiate a β-blocker whereas patients aged
≥90 (HR 0.65) and those with chronic obstructive pulmo-
nary disease (HR 0.66) were less likely. Patients with ≥9
medical consultations in the year before HF diagnosis
(HR 1.14) and those with dementia (HR 1.13) were more
likely to discontinue whereas the likelihood of discontinu-
ation was lower for those more recently diagnosed
(calendar year 2009: HR 0.74), those diagnosed during a
hospitalization (HR 0.88) and those exposed to another
β-blocker before HF diagnosis (HR 0.88).
Conclusions: Results suggest that patients with HF
underuse β-blockers. Those who might be perceived
by prescribers as being more complex to manage seem
to be the more vulnerable.
605. A Cross Country Comparison of the Impact of
Cost-Sharing Policies on Adherence to Prescription
Medicines
Sarah-Jo Sinnott,1 Helen Whelton,2 Jessica M Franklin,3
Jennifer M Polinski.3 1Department of Epidemiology and Pub-
lic Health, University College Cork, Cork, Ireland; 2School of
Dentistry, University of Leeds, Leeds, United Kingdom; 3Divi-
sion of Pharmacoepidemiology and Pharmacoeconomics,
Department of Medicine, Brigham and Women’s Hospital,
Harvard Medical School, Boston, United States.
Background: Little data are available regarding the
international generalizability of U.S. and Canadian
based evidence on the impact of cost-sharing on
medication adherence.
Objectives: To compare the impact of 2 similar cost
sharing policies, 1 in the U.S and 1 in Ireland, on
medication adherence.
Methods: A repeated measures longitudinal study design
was employed to measure individual drug adherence be-
fore and after the introduction of drug cost-sharing poli-
cies. The Irish policy introduced a 50c copayment/
prescription item in a publicly insured population in
2010. A similar policy occurred in the Massachusetts
Medicaid population in 2003. Prescription data were ob-
tained from centrally held pharmacy claims databases;
HSE-PCRS in Ireland and Medicaid Analytical Extract
in the U.S. New users of anti-hypertensive, anti-hyperlip-
idaemic and anti-diabetes drugs entered the cohort in the
6month period prior to introduction of the cost-sharing po-
lices and were followed for 12months post-policy change.
Segmented regression with generalized estimating equa-
tions and an autoregressive correlation structure was used.
Results: The Irish policy change resulted in a 3.9%
(95% CI, 2.91% - 5.02%) immediate drop in adherence
to anti-hypertensive drugs, whereas the U.S policy did
not affect anti-hypertensive adherence. Adherence to
anti-hyperlipidaemic drugs was insigniﬁcantly reduced
(-0.6235%, 95% CI, - 2.41% - 1.16 %) immediately
post-policy change in the U.S. However, adherence to
anti-hyperlipidaemic drugs was reduced in Ireland by
3.4% (95% CI, 2.25% - 4.62%).
Adherence to anti-diabetic drugs did not differ inter-
nationally post-policy change. There was no evidence
for international differences in the long-term impact
(12months) of policy changes.
Conclusions: Irish and U.S populations had different
changes in adherence to anti-hypertensive and anti-
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hyperlipidaemic drugs directly after implementation
of cost-sharing policies. However, similar changes
in adherence to anti-diabetic drugs were observed
between countries. These ﬁndings suggest that gen-
eralizability is not automatic. The unique aspects of
a setting should be considered when interpreting
evidence for policy.
606. Primary Care Prescriptions and Subsequent
Pharmacy Dispensing: A Population-Based Study
Daniel Prieto-Alhambra,1,2 Josep M Elorza-Ricart,1
Eduardo Hermosilla,1 Jordi Rodriguez-Ruiz,1 Leonardo
Mendez-Boo,1,3 Manuel Medina-Peralta.1,3 1SIDIAP
Database, Idiap Jordi Gol Primary Care Research Insti-
tute, Universitat Autonoma de Barcelona, Barcelona,
Spain; 2NDORMS, University of Oxford, Oxford, United
Kingdom; 3Primary Care, Institut Catala de la Salut,
Barcelona, Spain.
Background: There is a scarcity of data comparing
general practitioner (GP) prescriptions and subsequent
pharmacy dispensing data in a same population.
Objectives:We studied the proportion of GP prescrip-
tions (of a pre-speciﬁed list of drugs) collected from
any community pharmacy in the 3months following
the prescription date.
Methods: Design: Retrospective cohort study.
Setting: Data was obtained from the SIDIAP
database, which gathers primary care records and
pharmacy invoice data for >5.5 million people in
Catalonia, Spain.
Inclusion criteria: a random sample of 100,000
participants registered in SIDIAP was studied. New
users (deﬁned by GP prescriptions) of low-dose
aspirin (ATC B01AC06), simvastatin (C10AA01),
amoxicillin (J01CA04), or alendronate (M05BA04)
in June/2009-October/2012 were included.
Exclusion criteria: use of the study medication in the
previous 5months.
Measurements: The proportion (and 95%CI) of
prescriptions purchased in any community phar-
macy during the following 3months (June/2009 to
2012) was calculated assuming a binomial distribu-
tion. Yearly ﬁgures were estimated for the years
2009-2012.
Results: Amongst the selected 100,000 partici-
pants, 4,032 aspirin, 7,362 simvastatin, 21,488
amoxicillin, and 1,209 alendronate incident
GP prescriptions were identiﬁed. The proportion
of issued prescriptions subsequently dispensed
(in the following 3months) ranged from 87.6%
(IC95%: 84.6%-89.9%) in 2009 to 92.0% (90.6%-
93.3%) in 2011 for aspirin, from 91.4% (90.1%-
92.6%) in 2011 to 92.7% (91.5%-93.8%) in 2010
for simvastatin, from 86.4% (85.3%-87.4%) in
2009 to 90.1% (89.3%-90.8%) in 2012 for
amoxicillin, and from 84.9% (79.9%-89.0%) in
2009 to 90.8% (87.1%-93.4%) in 2010 for
alendronate. The latter was the drug with the
lowest overall proportion of prescriptions pur-
chased in the study period.
Conclusions: There is a strong correlation between
GP prescriptions and community pharmacy dispensa-
tions. Only 7% to 15% of the identiﬁed GP prescrip-
tions were not purchased. Alendronate was the drug
with the lowest proportion of purchases (over total
prescriptions) in our data.
607. Statin Adherence and Treatment LDL-Choles-
terol Response in Type 2 Diabetes Patients
Dianna de Vries,1 Jaco Voorham,1 Eelko Hak,2
Petra Denig.1 1Department of Clinical Pharmacy and
Pharmacology, University Medical Center Groningen,
Groningen, Netherlands; 2Unit of Pharmacoeconomics
& Pharmacoepidemiology, University of Groningen,
Groningen, Netherlands.
Background: In clinical practice statins are not
optimally used and lipid targets are not achieved in
at least a third of the patients. This lack of treatment
response could be due to undertreatment (low-dose
statin) and low adherence to treatment.
Objectives: To determine the relationship between
statin dose, adherence and LDL-cholesterol response
in new statin users.
Methods: This cohort study was performed using data
from the Groningen Initiative to Analyse Type 2
Diabetes Treatment (GIANTT) database. The relation
between adherence and LDL-cholesterol response
was assessed during the ﬁrst year of treatment with a
standard-dose statin using linear regression, adjusting
for covariates. The modifying effect of low-dose ver-
sus standard-dose was assessed in a propensity-score
matched cohort. Adherence was measured as the
medication possession ratio (MPR).
Results: In total 22% of the 8,282 new statin users
started on a low-dose, around 80% of them stayed on
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this low-dose during the ﬁrst year of treatment. These
patients did not differ in LDL-cholesterol level and
macro- and microvascular comorbidity compared to pa-
tients on standard-dose treatment. The mean adherence
was around 80% in both groups. The effect of adherence
on LDL-cholesterol response, measured in 1,797 pa-
tients, was dependent on the baseline LDL-cholesterol
level. With an average baseline LDL-cholesterol
level of 3.8mmol/l, an increase in adherence of 10%
resulted in an estimated decrease in LDL-cholesterol
of 0.2mmol/l. In the matched sample of 950 patients,
treatment dose modiﬁed the association between adher-
ence and LDL outcome. For adherence rates >80%
there was a signiﬁcant difference in effectiveness of
low-dose versus standard-dose statin treatment.
Conclusions: For patients with poor adherence rates
(MPR< 80%), lipid targets are difﬁcult to achieve
regardless of being on low-dose or standard-dose
treatment. For the majority of patients with an MPR
above 80%, the standard-dose treatment is more
effective than low-dose treatment making it easier to
achieve lipid targets.
608. Effect of Long-Term Aspirin Use on the Risk for
Neovascular Age-Related Macular Degeneration
Ruben G Duijnhoven,1,2 Redmer van Leeuwen,3 Sabine
M Straus,2,4 Saskia M Imhof,3 Arno W Hoes,5 Anthonius
de Boer,1 Marie L De Bruin.1,2 1Division of Pharma-
coepidemiology and Clinical Pharmacology, UIPS,
Utrecht University, Utrecht, Netherlands; 2Medicines
Evaluation Board (CBG-MEB), Utrecht, Netherlands;
3Department of Ophthalmology, UMC Utrecht, Utrecht,
Netherlands; 4Department of Medical Informatics,
Erasmus MC, Rotterdam, Netherlands; 5Julius Center
for Health Sciences and Primary Care, UMC Utrecht,
Utrecht, Netherlands.
Background: Results from several cohort studies
have indicated that long-term low-dose aspirin
(acetylsalicylic acid, ASA) use markedly increases
the risk for neovascular age-related macular degenera-
tion (nAMD). nAMD is a serious condition that causes
rapid decline in central-ﬁeld vision over the course of
days to weeks.
The studies currently available obtained data from
questionnaires, therefore lacking high-quality informa-
tion regarding exposure to low-dose ASA, and had
few nAMD cases.
Objectives: To quantify the risk for nAMD associated
with long-term low-dose ASA use.
Methods: A case-control study was conducted,
including all cases of nAMD in the period 1 January
1987 - 31 December 2012 aged 50 years and older
from the UK Clinical Practice Research Datalink
(CPRD) database. Cases were matched to up to ﬁve
controls on age, gender and general practice.
Conditional logistic regression was used to estimate
odds ratios for the risk of nAMD associated with
increasing durations of low-dose ASA use, adjusting
for smoking status, obesity, glaucoma, hypercholester-
olaemia, and lipid lowering medication, and cardio-
vascular diseases.
Results: 4,125 cases were matched to 20,173 con-
trols. Cases had a median age of 80.1 years and were
in majority female (64.7%). Overall, the risk for
nAMD associated with low-dose ASA use was a
small but signiﬁcantly increased adjusted risk of
1.12 (95% conﬁdence interval 1.03 - 1.21). We
observed a trend for increasing risk with prolonged
use: odds ratios were 1.06 (use for less than two-
and-a-half years; 95% CI 0.96 - 1.17), 1.07 (two-
and-a-half to ﬁve years; 95% CI 0.94 - 1.21), 1.17
(ﬁve to ten years; 95% CI 1.04 - 1.31), 1.23 (ten
to ﬁfteen years; 95% CI 1.05 - 1.45), and 1.33 (more
than ﬁfteen years; 95% CI 1.08 - 1.63), compared to
no ASA use.
Conclusions: Long-term use of low-dose ASA is
associated with an increased risk for nAMD. This risk
is lower than previously observed and small compared
to other risk factors and the beneﬁt-risk balance of
low-dose ASA for the prevention of cardiovascular
disease will not be impacted.
609. Preadmission Non-Steroidal Anti-Inflammatory
Drug Use and 30-Day Stroke Mortality
Morten Schmidt,1,2,3 Erzsébet Hovath-Puho,1 Christian
F Christiansen,1 Karin L Petersen,2 Hans E Bøtker,3
Henrik T Sørensen.1 1Department of Clinical Epidemi-
ology, Aarhus University Hospital, Aarhus, Denmark;
2California Paciﬁc Medical Center Research Institute,
San Francisco, CA, United States; 3Department of Cardi-
ology, Aarhus University Hospital, Aarhus, Denmark.
Background: The prognostic impact of non-aspirin
non-steroidal anti-inﬂammatory drugs (NSAIDs) on
stroke mortality remains unclear.
Objectives: We examined whether preadmission use of
nonselective NSAIDs and selective cyclooxygenase
(COX)-2 inhibitors inﬂuenced 30-day stroke mortality.
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Methods: In this nationwide population-based
cohort study, we used medical databases to identify
all ﬁrst-time stroke diagnoses in Denmark during
2004-2012 and to ascertain subsequent mortality.
We categorized NSAID use as current (prescription re-
demption within 60 days before hospital admission),
former, and non-use. Current use was further
classiﬁed as new or long-term use. Cox regression
was used to compute 30-day mortality rate ratios
(MRRs), controlling for potential confounding
through multivariate adjustment and propensity-
score matching.
Results:We identiﬁed 100,043 patients with ﬁrst-time
stroke, among whom 83,736 had ischaemic stroke,
11,779 had intracerebral haemorrhage, and 4,528 had
subarachnoid haemorrhage. After multivariate adjust-
ment, the 30-day MRR for ischaemic stroke was 1.14
(95% conﬁdence interval (CI): 1.03-1.27) for current
users of COX-2 inhibitors compared with non-users,
driven by the effect among new users (MMR=1.31,
95% CI: 1.13-1.52). The propensity-score-matched
analysis yielded similar results, with a 30-day MRR
for ischaemic stroke of 1.16 (95% CI: 1.01-1.34)
among current users and 1.28 (95% CI: 1.07-1.54)
among new users. Comparing different types of
COX-2 inhibitors, the MRR was driven by new
use of older traditional COX-2 inhibitors (1.30,
95% CI: 1.12-1.52) among which it was 1.51
(95% CI: 1.16-1.98) for etodolac and 1.21 (95%
CI: 1.01-1.45) for diclofenac. There was no associ-
ation for former users. Mortality from intracerebral
haemorrhage and subarachnoid haemorrhage was
not associated with use of either nonselective
NSAIDs or COX-2 inhibitors.
Conclusions: Preadmission use of COX-2 inhibitors
was associated with increased 30-day mortality fol-
lowing ischaemic stroke, but not haemorrhagic stroke.
Use of nonselective NSAIDs at time of admission was
not associated with mortality from ischaemic or
haemorrhagic stroke.
610. Chemoprevention of Esophageal Adenocarcinoma
among Patients with Barrett’s Esophagus
GwenMCMasclee,1,2 Preci M Coloma,1 Ernst J Kuipers,2
Miriam CJM Sturkenboom.3 1Medical Informatics,
Erasmus University Medical Center, Rotterdam,
Netherlands; 2Gastroenterology and Hepatology, Erasmus
University Medical Center, Rotterdam, Netherlands;
3Epidemiology, Erasmus University Medical Center,
Rotterdam, Netherlands.
Background: Studies have suggested that use of cer-
tain drugs such as non steroidal anti-inﬂammatory drugs
(NSAIDs), proton pump inhibitors (PPIs) and statins
may decrease the risk of esophageal adenocarcinoma
(EAC) among subjects with Barrett’s esophagus (BE).
However, some of these studies did not adjust for
important confounders or had methodological ﬂaws
such as immortal time bias.
Objectives: To estimate the risk of EAC among
patients with BE in relation to use of NSAIDs, statins
and PPIs by duration and dose.
Methods: Design: Nested case-control study. Controls
were matched on EAC diagnosis date by index density
sampling on age (±5 yrs), sex, year of BE diagnosis
(±1 yr) and database.
Setting: Two European primary care databases
(United Kingdom (UK); the Netherlands (NL)
(1996- 2013)
Exposure: NSAIDs, statins, PPIs, SSRIs, assessed
from BE date until index date.
Outcome: EAC and premalignant high-grade
dysplasia (HGD). Cases were adult persons
(≥18 years (yrs)) with EAC diagnosis ≥1 yr after
BE diagnosis.
Statistical analysis: Odds ratios (OR) with 95% CI
were calculated by conditional logistic regression
while adjusting for confounders (ORa).
Results: Within the BE cohort (n = 15,134), 45 EAC
(UK: 40, NL: 5) and 12 HGD cases (NL: 12) were
identiﬁed. NSAIDs were used by 29% of cases and
23% of controls. When adjusting for confounders,
OR for NSAID use was 1.2 (95%CI:0.6-2.5).
ORa for statin use (27% by cases; 35% by controls)
2-3 yrs was 0.7 (95%CI:0.4-1.5) and for> 3 yrs 0.5
(95%CI:0.1-1.7). When including HGD cases
(n = 57) ORa for NSAID use was 0.9 (95%CI:0.5-
1.8). Statin use for 2-3 yrs showed an ORa of 1.1
(95%CI:0.2-4.9) and >3 yrs 0.5 (95%CI:0.1-1.7).
Statin dose was inversely associated with EAC and
HGD (OR 0.7; 95%CI:0.2-2.3 for use ≥1.2 DDD per
day). PPIs did not signiﬁcantly decrease the risk of
EAC (ORa 1.1;95%CI:0.4-2.8)and EAC-HGD(ORa
0.9;95%CI:0.4-2.0).
Conclusions: NSAID use was associated with 5%
decrease in risk of HGD (but not EAC) among BE
patients, although this was not statistically signiﬁcant.
Longer duration of statin use was associated with a
decrease in risk of EAC and of EAC-HGD up to
52%, though not statistically signiﬁcant.
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611. Association of Individual Non-Steroidal Anti-
Inflammatory Drugs and Chronic Kidney Disease:
A Population-Based Case Control Study
Gianluca Triﬁrò,1 Ylenia Ingrasciotta,1 Francesco
Giorgianni,1 Janet Sultana,1 Daniele Ugo Tari,2
Margherita Perrotta,2 Claudio Linguiti,2 Andrea
Fontana,3 Fabio Pellegrini,3 Achille P Caputi.1
1Department of Clinical and Experimental Medicine,
University of Messina, Messina, Italy; 2Caserta Local
Health Service, Caserta, Italy; 3Unit of Biostatistics,
IRCCS “Casa Sollievo della Sofferenza”, San Giovanni
Rotondo (FG), Italy.
Background: Non-steroidal anti-inﬂammatory agents
(NSAIDs) are known to be nephrotoxic. Differences
in the risk of chronic kidney disease (CKD) among in-
dividual NSAIDs have not yet been investigated.
Objectives: To evaluate the association between the
use of individual NSAIDs and the risk of incident
CKD in a general population of Southern Italy.
Methods: The general practice Arianna database con-
tains data from 158,510 patients, registered with 123
general practitioners of Caserta. A population-based
case-control study was carried out. Incident CKD
patients were identiﬁed by searching for speciﬁc
ICD-9CM codes as cause of hospitalization, CKD-
relevant procedures undergone in hospital (dialysis),
drug prescriptions issued for a CKD-related indication.
The date of ﬁrst diagnosis of CKD was deﬁned as the
index date (ID). Up to 4 controls were randomly
selected and matched to each case by age (±3 years),
sex and ID. Multivariate conditional logistic regres-
sion was conducted to estimate the individual
NSAID-related CKD risk, during different risk win-
dows (any time, one year, 6, 3months prior to the
ID), by calculating odds ratios (ORs) together with
95% conﬁdence interval (CI) and adjusting for all
the potential confounders. Among current users of
NSAID (use within 90 days prior to ID), the effect
of cumulative exposure to NSAIDs (≤90, 91-180,
>180 days) any time prior to ID was calculated.
The linear increase of CKD risk per day/month of
NSAID cumulative exposure any time prior to ID
was assessed.
Results: Overall, 1,989 cases and 7,956matched controls
were identiﬁed. A statistically signiﬁcant increase in the
risk of CKD was observed for current users of ketorolac
(OR:2.48; 95%CI:1.43–4.30), piroxicam (OR:1.95; 95%
CI:1.19–3.21), meloxicam (OR:1.86; 95%CI:0.95–3.62).
A linear increased risk of 13% (OR:1.13; 95%CI:
1.03–1.24) was observed for each additional month of
therapy with piroxicam any time prior to ID.
Conclusions: Our data demonstrate that CKD risk
changes across different compounds and is higher for
high potency NSAIDs (ketorolac) and long term expo-
sure to oxicams, especially piroxicam which has the
largest half-life among NSAIDs.
612. Impact of Dose and Duration of Oral Glucocor-
ticoid Therapy on the Risk of Incident Type II
Diabetes in Patients with Rheumatoid Arthritis
Mohammad Movahedi,1 Marie-Eve Beauchamp,2 Kaleb
Michaud,3,4 Soﬁa Pedro,3 Michal Abrahamowicz,2,5 Will
G Dixon.1 1Arthritis Research UK Centre for Clinical
Epidemiology, Centre for Musculoskeletal Research, In-
stitute of Inﬂammation and Repair, The University of
Manchester, Manchester, United Kingdom; 2Division of
Clinical Epidemiology, McGill University Health Centre,
Montreal, QC, Canada; 3National Data Bank for Rheu-
matic Diseases, Wichita, KS, United States; 4Rheumatol-
ogy & Immunology, University of Nebraska Medical
Center, Omaha, United States; 5Department of Epidemi-
ology, Biostatistics, and Occupational Health, McGill
University, Montreal, QC, Canada.
Background: Glucocorticoids (GC) have a known as-
sociation with incident type II diabetes mellitus (DM).
However, the extent of the risk and its relationship
with dose and duration in patients with rheumatoid ar-
thritis (RA) are not known.
Objectives: To assess if and how the risk of DM,
varies with dose and timing of GC use.
Methods:We identiﬁed 2 cohorts of adult RA patients
from 1) a UK primary care research database (CPRD)
and 2) the US National Databank (NDB). NDB col-
lects information from patients through six-monthly
questionnaires with clinician validation. GC exposure
was identiﬁed from GC prescriptions in CPRD and
self reported exposure in NBD. DM in CPRD was de-
ﬁned as a READ code, at least two oral anti-diabetic or
abnormal blood results. In NDB, it was identiﬁed
through ﬁrst date of DM treatment and if no treatment
available by self-report. We used multivariable time-
dependent Cox models with conventional exposure
measures and a novel weighted cumulative dose
(WCD) model accounting for cumulative effects of
past doses, duration and timing, and compared the re-
sults from the 2 cohorts.
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Results: 21,962 and 19,297 patients were included in
CPRD and NDB, respectively, with median follow-
up of 5.4 and 3.4 years. The adjusted HR was 1.35
(1.21-1.50) and 1.32 (1.16-1.50) for current GC users
compared with non-users for CPRD and NDB, respec-
tively. Other conventional models (ever use, current
dose and cumulative dose) generated similar results
in the two datasets. The WCD model showed recent
use contributed most to current risk, with risk declin-
ing to zero for doses taken more than 6 (CPRD) or 12
(NDB) months in the past. In CPRD, use of 5mg
prednisolone equivalent (PEQ) for the last 1, 3 and
6months were associated with HRs of 1.20, 1.43
and 1.48, respectively, compared to non-use, while
30mg PEQ for 3 or 6 last months had a HR of 8.43
and 10.5. The corresponding NDB estimates were
similar.
Conclusions: GC use is a clinically important and
quantiﬁable risk factor for DM in RA patients, and
its impact depends on dose and treatment duration
within the last 12months. Consistency between the
two cohorts strengthens our ﬁndings.
613. Use of Glucocorticoids and Postoperative
Bleeding after Gastric Bypass Surgery
Sigrid B Gribsholt,1 Elisabeth Svensson,2 Stine Skovbo,2
Reimar W Thomsen,2 Bjørn Richelsen,1 Henrik T
Sørensen.2 1Department of Endocrinology and Internal
Medicine, Aarhus University Hospital, Aarhus, Denmark;
2Department of Clinical Epidemiology, Aarhus University
Hospital, Aarhus, Denmark.
Background: Roux-en-Y gastric bypass (RYGB) sur-
gery results in pronounced weight loss in severely
obese people, but also may be associated with compli-
cations and elevated mortality. Former research has
suggested that patients using glucocorticoids are at
higher risk of postoperative bleeding than patients
without such drug use.
Objectives: To investigate the association between
recent glucocorticoid use and risk of postoperative
bleeding after RYGB.
Methods: We conducted a nationwide cohort study of
all RYGB surgery patients in Denmark from 2006
through 2010. Using Danish medical databases, we
linked data on age, gender, surgical procedure, current
glucocorticoid use (redeemed prescription< 60 days
before surgery) or no current use (no prescription <60
days before surgery), preoperative comorbidity level
assessed by the Charlson Comorbidity Index, and
postoperative bleeding (within 30 days of surgery).
We computed odds ratios (ORs) for the association
between glucocorticoid use and bleeding with
corresponding 95% conﬁdence intervals (95% CIs),
adjusting for sex, age and comorbidity using logistic
regression.
Results: In total, 9,855 patients underwent RYGB. Of
these, 247 (2.5 %) were current glucocorticoid users
and 9,608 (97.5%) were non-users. A higher risk of
bleeding was observed among the glucocorticoid users
(2.4%) than among non-users (1.2%), the adjusted OR
was 2.0 (95% CI 1.1-3.6).
Conclusions: Use of glucocorticoids within 60 days
before RYGB was associated with a higher risk of
postoperative bleeding during 30 days follow up.
614. Statistical Natural Language Processing Can
Accurately Identify Venous Thromboembolism
(VTE) Events from Narrative Electronic Health
Record Data
Christian M Rochefort,1,2,3 Aman D Verma,1,3 David L
Bucheridge.1,3 1Epidemiology, Biostatistics & Occupa-
tional Health, McGill University, Montreal, QC, Canada;
2Ingram School of Nursing, McGill University, Montreal,
QC; 3Clinical & Health Informatics Research Group,
McGill University, Montreal, QC, Canada.
Background: Venous thromboembolisms (VTE),
which include deep vein thrombosis (DVT) and
pulmonary embolism (PE), are associated with
signiﬁcant mortality, morbidity and cost in hospital-
ized patients. To evaluate the success of preventive
measures, accurate methods for monitoring VTE
rates are needed. The increasing availability of
electronic health records and the advent of automated
methods for encoding and classifying narrative docu-
ments, such as natural language processing (NLP),
may help develop new methods for monitoring VTE
rates.
Objectives: To determine the accuracy of using statis-
tical NLP for identifying DVT and PE events from
electronic clinical data.
Methods: In this validation study, we randomly
sampled 2,000 radiology reports from patients with
a suspected DVT/PE event at an academic health
network in Montreal (Canada) over a 5-year period
(2008-2012). Each radiology report was manually
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coded to determine positive and negative cases of
DVT and PE; which served as our reference stan-
dard. Using a bag-of-words approach augmented
with semantic bi-gram features we trained two
parametrically optimized support vector machine
(SVM) models; one predicting DVT events, the
other predicting PE events. Training and testing
was performed with nested 10-fold cross-valida-
tion, and the average accuracy of each SVM model
was estimated.
Results: On manual review, 324 (16.2%) reports were
positive for DVT and 154 (7.7%) were positive for PE.
On average, the SVM model for DVT achieved a sen-
sitivity of 0.75 (95%CI: 0.68-0.83), speciﬁcity of 0.98
(98%CI: 0.97-0.99), and positive predictive value
(PPV) of 0.87 (95%CI: 0.81-0.93). On average, the
PE model achieved a sensitivity of 0.77 (95%CI:
0.69-0.85), speciﬁcity of 0.99 (95%CI: 0.98-1.00),
and PPV of 0.85 (95%CI: 0.74-0.95). The average
area under the curve was 0.96 (95%CI: 0.93-0.99)
for the DVT model, and 0.97 (95%CI: 0.95-0.99) for
the PE model.
Conclusions: Statistical NLP can accurately identify
VTE events from narrative radiology reports. The
SVM models that were validated in this study could
help hospitals monitor VTE rates, and evaluate the
success of preventive measures.
615. Validity of Current Procedural Terminology
(CPT) Codes and Natural Language Processing of
Infusion Notes to Identify Outpatient Infliximab
Infusion
Chao-Chin Lu,1,2 Chia-Chen Teng,1,2 Jianwei Leng,1,2
Grant Cannon,1,2 Tao He,1,2 David Harrison,3 Derek
Tang,3 Neel Shah,3 Brian Sauer.1,2 1VA Salt Lake City
Health Care System, Salt Lake City, UT, United States;
2Departments of Internal Medicine, University of Utah,
Salt Lake City, UT, United States; 3Amgen, Thousand
Oaks, CA, United States.
Background: Infusions of outpatient medications in-
cluding biologic Disease Modifying Anti-Rheumatic
Drugs (DMARDs) administered at Veterans Affairs
(VA) facilities are not consistently documented in the
pharmacy dispensing data. CPT and Healthcare Com-
mon Procedure Coding System (HCPCS) were used to
identify inﬂiximab infusion dates and doses. Natural
Language Processing (NLP) software was developed
to identify and extract information on inﬂiximab infu-
sions from progress notes.
Objectives: The objective was to compare the accu-
racy of three approaches to identify inﬂiximab
administration dates and infusion doses against a re-
ference standard established from the Veterans Affairs
Rheumatoid Arthritis (VARA) registry.
Methods: Inﬂiximab administration dates and infus-
ing doses were determined using three approaches:
CPT and HCPCS codes alone (CPT), NLP extraction
alone (NLP), and CPT and NLP combined (Combo).
Combo used the dose from NLP data when available.
Estimates based on these three methods were com-
pared to the information in the VARA registry (the ref-
erence standard) in which inﬂiximab infusion dates
and doses were veriﬁed by chart review. Accuracy
was deﬁned as the fraction of infusions with both
VARA-based infusion date and dose correctly identi-
ﬁed using one of the methods. Mean estimated infu-
sion doses were compared to VARA using two-tailed
t-test with α= 0.05.
Results: Accuracy was higher for the NLP and
Combo approaches (85%; 95% CI: 83%-87%), and
(91%; 95% CI: 90%-92%) respectively compared
to the CPT approach (60%; 95%CI: 58%-62%).
Mean dose (mg) and 95% CI based on NLP
(433.7; 95% CI: 426.5-441.0) and Combo ap-
proaches (424.7; 95% CI: 417.3-432.1) were similar
to VARA (432.9; 95% CI: 426.4-439.5). Mean dose
based on the CPT approach (337.0; 95% CI: 325.
9-348.0), however, was statistically different (p< .0001)
from VARA.
Conclusions: The results indicate that the CPT ap-
proach alone was not sufﬁcient to accurately identify
infusion dates and doses and NLP signiﬁcantly im-
proved the accuracy of estimating inﬂiximab infu-
sions. The highest level of accuracy was achieved
when we combined CPT and NLP approaches.
616. Linguistic Variability and Clinical Terminology
in a Large Dutch General Practitioners Database
Zubair Afzal,1 Martijn J Schuemie,2 Miriam CJM
Sturkenboom,1 Jan A Kors.1 1Department of Medical
Informatics, Erasmus University Medical Center,
Rotterdam, Zuid-Holland, Netherlands; 2Janssen Research
and Development LLC, Titusville, NJ, United States.
Background: The use of automated methods to
extract information from free-text narrative in
general practitioners (GP) records is hampered by
spelling variations and mistakes, speciﬁc abbreviations,
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and ill-formed and incomplete sentences. This com-
plicates the detection of clinical terms in text, pa-
tient identiﬁcation, and coding for pharmacovigilance
purposes.
Objectives: To quantify and resolve linguistic vari-
ability in free-text GP records, and assess the coverage
of three standard Dutch-translated terminologies.
Methods: We used IPCI (Integrated Primary Care In-
formation), a Dutch general practitioners database,
containing 339 million free-text entries of more than
1.6 million patients. Spelling variations of words were
detected and grouped based on similarity according to
the Damerau-Levenshtein editing distance. Potential
abbreviations were linked to candidate long-forms
using a modiﬁed Schwartz algorithm. To compute
the coverage of standard clinical terms (termin-
ologies), we used a term recognition tool, Peregrine,
with Dutch translations of MedDRA, MeSH, and
SNOMED-CT terminologies.
Results: IPCI contained almost 6 million textually-
unique words, which followed a Zipﬁan frequency dis-
tribution. Grouping by Damerau-Levenshtein distance
resulted in 1.6 million groups of similar words, reduc-
ing the total number of unique words by 73%. We
extracted 17,765 potential abbreviations and 182,633
candidate long-forms. SNOMED-CT had the best
coverage, with 26,570 unique concepts being detected
at least once in the database, while for MeSH and
MedDRA respectively 24,881 and 17,658 concepts
were found.
Conclusions: Our experiments showed that the IPCI
data has many term variations including spelling mis-
takes. Finding several long-forms for each potential
abbreviation indicates the ambiguity of abbreviations
used by GPs, highlighting the need for automated
disambiguation. Grouping similar words to get poten-
tially more useful terms, identifying standard and non-
standard abbreviations, and using standard termi-
nologies is needed to facilitate automated interpreta-
tion of the clinical text or help identify records for
manual review.
617. Generating and Evaluating a Propensity Score
Model Using Textual Features from Electronic
Medical Records
Zubair Afzal,1 Gwen MC Masclee,1 Miriam CJM
Sturkenboom,1 Jan A Kors,1 Martijn J Schuemie.2
1Department of Medical Informatics, Erasmus University
Medical Center, Rotterdam, Zuid-Holland, Netherlands;
2Janssen Research and Development LLC, Titusville,
NJ, United States.
Background: The high dimensional propensity scores
(HDPS) uses large numbers of covariates to better
control for confounding since these variables could
be proxies for unobserved factors that otherwise are
not considered. Generally, structured information is
used to construct the HDPS. Medical records comprise
mostly free text in the form of physician notes, dis-
charge summaries and specialist letters. In this study
we aim to explore whether unstructured text can be
used for construction of HDPS.
Objectives: To evaluate whether a high dimensional
propensity score model can be built from unstructured
textual features, using a large-scale regularized regres-
sion model.
Methods: Setting: IPCI (Integrated Primary Care In-
formation), a Dutch general practitioners database,
containing structured diagnosis and prescription infor-
mation as well as unstructured medical notes on more
than 1.6 million patients.
Exposure: All new users (no use in previous
6months) of non-selective NSAIDS and coxibs. All
word unigrams from patient entries in the last six
months prior to NSAID cohort entry were extracted.
Data was splitted in a separate training and test set to
evaluate predictive accuracy. A Bayesian binary re-
gression model using a Laplace prior with a variance
of 0.01 was used to generate the HDPS model.
Results: In total, we extracted 2,762,326 unigrams
from the electronic medical records of 487,275 new
users of traditional NSAIDs (n = 462,546) or coxibs
(n = 24729). After ﬁltering out less frequent unigrams
(frequency< 100), almost 95 thousand features
remained that entered the model. Initial results look
promising, with an area under the ROC curve of 0.72
on the test set. Using the Laplace prior, most of the
feature weights were zero.
Conclusions: Unstructured textual features can be
used to create a converging HDPS model, with
high predictive value for the reasons why the GP
would prescribe one class of drugs and not the
other. It will be tested how this automatically
selected model, performs in addressing confound-
ing by indication regarding the association between
coxibs and nsNSAIDs in relation to upper gastroin-
testinal bleeding.
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618. Handling Missing Exposure: A Simulation Study
Andrea V Margulis,1 Alejandro Arana.1 1RTI Health
Solutions, Barcelona.
Background:The presence and handling ofmissing data
are not always considered in pharmacoepidemiology.
Objectives: To evaluate different methods to handle
missing exposure in a simulated pharmacoepi-
demiology study.
Methods:We simulated 500 cohorts of n = 10,000 aged
40 years using publicly available age, sex and smoking
data from the EU. We simulated exposure (low, inter-
mediate, and high dose, and no exposure), associated
in a dose-response fashion with the simulated binary
outcome. Age, sex and smoking were confounding
factors. Missing values for exposure were generated at
random conditional on observed age and sex, and, in a
subset of simulations, outcome. Missingness was varied
to affect between 0 and 60% of the subjects.
In each cohort, we conducted 4 logistic regression
analyses with the main effects of age, sex, smoking
and exposure to estimate odds ratios (ORs) and 95%
conﬁdence intervals (CIs):
(1) Analysis in the complete dataset (gold standard)
(2) Complete case analysis in the dataset with missing
values
(3) Regression analysis in datasets completed via
multiple imputation, based on age, sex, smoking,
exposure and outcome
(4) Analysis #3 was repeated excluding the outcome
from the imputation model.
Results: Overall, 9% of the subjects had a low expo-
sure dose, 6% intermediate, and 1% high dose; the
outcome prevalence was 7%. In analysis 1, the ORs
for low, intermediate and high dose were 2, 3, and
3.5, respectively.
For exposure, the bias in CIs was larger for high than
for low dose, and increased with increasing prevalence
of missingness. ORs from analyses 2 and 3 were simi-
lar in all instances (difference< 10%). CIs in analysis 2
were generally narrower than in analysis 3.
In some instances, analysis 2 provided biased ORs
and CIs of the covariates without missing values.
Analysis 4 provided biased ORs and CIs for exposure.
Conclusions: In the conditions of this study, with
ORs for exposure between 2 and 3.5, ORs and CIs
from analyses 2 and 3 were not substantially biased
(<10%) for missingness up to 15%. Contrary to what
we hypothesized, CIs from analysis 3, which used data
from all subjects, were generally wider than those
from analysis 2, which only included the subset with
complete data. Analysis 4 should be avoided.
619. Assessment of Daily Dose of Domperidone in
the Clinical Practice Research Datalink (CPRD)
Using Multiple Information Sources
Alejandro Arana,1 Catherine Johannes,2 Cristina Varas,1
Kenneth J Rothman,2 Lisa J McQuay,3 Qing Yang,3
Daniel Fife.4 1Epidemiology, RTI-HS, Barcelona, Spain;
2Epidemiology, RTI-HS, Waltham, MA, United States;
3Epidemiology, RTI-HS, Research Triangle Park, NC,
United States; 4Epidemiology, Janssen Research and
Development, LLC, Titusville, NJ, United States.
Background: The correct assessment of drug expo-
sure is crucial to the validity of safety research. A
case-control study using CPRD GOLD data (2005-
2011) to assess the risk of sudden cardiac death related
to oral domperidone (DOM) use required a detailed
assessment of daily dose and duration.
Objectives: To assess dose and duration of exposure
to DOM, using all available data in the CPRD pre-
scription records, free-text ﬁeld, and a questionnaire
sent to CPRD physicians.
Methods: Numeric daily dose (NDD) in CPRD
GOLD prescription records is derived by an algorithm
using free-text instructions. We examined all recorded
NDD values for DOM prescriptions, compared them
with the dosage instructions in the free text, and
classiﬁed them as (1) reasonable NDD present or (2)
NDD value missing or insufﬁcient information. We
sent a questionnaire to CPRD physicians of patients
with DOM prescriptions closest to the index date with-
out an NDD recorded (n = 47) and, for veriﬁcation, for
a sample of patients with NDD recorded (n = 75). Only
CPRD physicians willing to participate in surveys
were included.
Results: Of the 336,782 DOM prescriptions, 75% had
NDD values; 71% of NDD values were 3 (indicating
tablets/day), and 4% had values ≥10 suggesting dose
in mg.
Of 119 physician questionnaires sent, 84 (71%)
were received, 37 of 44 (84%) for prescriptions with-
out NDD recorded in the CPRD GOLD and 47 of 75
(63%) for prescriptions with known NDD. Physicians
provided dose information for 34 of 37 (91%)
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prescriptions without NDD values and for 44 of 47
(94%) with known NDD values. Dose category as
derived from CPRD GOLD data was the same as
that derived from physician questionnaires for 91%
(95% CI, 79%-97%) of the prescriptions. Using all
sources of information, we were able to estimate
average daily dose for 241 of 246 subjects (98%)
exposed to DOM at the index date. Using only
NDD values recorded in CPRD GOLD would have
resulted in missing information for 54 DOM-exposed
subjects (22%).
Conclusions: Supplemental information can be useful
in estimating dose in CPRD GOLD when recorded in-
formation is not complete.
620. Impact of Direct-To-Consumer Advertising on
Asthma Prescriptions
Susan Hutﬂess,1 Matthew Daubresse,1 Yoonsang Kim,2
Rachel Kornﬁeld,2 Dima Qato,3 Jidong Huang,2 Kay
Miller,4 Sherry Emery,2 Caleb G Alexander.1 1Depart-
ment of Epidemiology, Johns Hopkins Bloomberg School
of Public Health, Baltimore, MD; 2Institute for Health
Research and Policy, University of Illinois at Chicago,
Chicago, IL; 3Department of Pharmacy Systems, Outcomes,
and Policy, University of Illinois at Chicago, Chicago, IL;
4Truven Health Analytics, Santa Barbara, CA.
Background: Advocates of Direct to consumer ad-
vertising (DTCA) argue that it enhances case-ﬁnding
and educates patients regarding common health
conditions. Opponents argue DTCA results in
over-prescribing of medications with unknown
safety proﬁles instead of safer and more effec-
tive alternatives.
Objectives: We sought to examine the association
between DTCA for the three advertised asthma
medications and prescription sales in the United States
during 2005 through 2009.
Methods: We linked Nielsen ratings from the top 75
US designated market areas (DMAs), representing
the average number of times advertisements for asthma
medications aired per household each month, with na-
tionally representative dispensing data for ﬂuticasone/
salmeterol (Advair™), montelukast (Singulair™), and
budesonide/formoterol (Symbicort™) from the IMS
Health National Prescription Audit. Population de-
nominators were derived from the Area Resource File.
We used multi-level Poisson regression models
accounting for nesting within DMAs to assess the
relationship between DTCA exposures and prescrip-
tions after adjustment for time and DMA-level
demographic characteristics.
Results: The median rate of dispensed doses for
advertised asthma medications per 100,000 individ-
uals increased from 386 in January 2005 to 497 in
December 2009. Each additional televised advertise-
ment exposure was associated with a 2% (95%
conﬁdence interval [CI], 1 to 5%) increase in average
prescription rates for the advertised medications,
although the effect varied. Both Singulair™ (6%,
95% CI 3 to 8%) and Symbicort™ (9%, 95% CI 3 to
16%) were associated with a statistically signiﬁcant
increase in dispensed prescription rates. However,
there was no association between DTCA and Advair™
(3%, 95% CI -1 to 6%).
Conclusions: A 2% increase in advertised asthma
prescription rates appears small, but equates to a
large volume of prescriptions. DTCA for Symbicort,
which was approved during the study period, had
the greatest impact on dispensed medications.
Understanding the beneﬁts and harms of DTCA
remains important given the impact of DTCA on
increasing medication utilization.
621. Lessons Learned on the Design of European
Post Authorisation Safety Studies (PASS): Review
of 18 Months of PRAC Oversight
Pierre Engel, Michelle Bulliard, Louise Parmenter,
Kathryn Starzyk, Nancy Dreyer. Real World and Late
Phase, Quintiles, Paris, France.
Background: Under the new Good PV Practices
(GVP) module VIII part of the 2010 EU
Pharmacovigilance (PV) legislation enforced in July
2012, all post-authorization safety studies (PASS) pro-
tocols either pursuant to an obligation imposed by a
Competent Authority as a condition of marketing
authorisation (MA) or voluntarily initiated (e.g., as part
of a risk management plan) are now being reviewed
by the PV Risk Assessment Committee (PRAC).
Objectives: The aim of this review is to provide for
the ﬁrst time ﬁgures on PASS designs based on reports
and data issued by the EMA and the EU-PAS register
hosted by the ENCePP.
Methods: We reviewed all monthly PRAC meeting
reports (section 7) and available data from the
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EU-PAS register for all protocols submitted from
July 2012 until February 2014. Compound, MA
holder, date of review, number of revisions, study
design, PRAC comments and endorsement status
were retrieved, analyzed and categorized. Missing
or inaccurate data were not included in the analysis.
Results: A total of 88 PASS protocols were evaluated
by the PRAC including 19 imposed PASS (21.6%).
Design classiﬁcation of 53 protocols was possible after
review. 47.2% were prospective PASS including 18
drug and 7 disease registries. Twenty retrospective
studies (mostly drug utilisation studies) were retrieved
utilising either medical chart review (n = 9) or EU
claims (n = 9). Six cross-sectional risk minimization
surveys and two PASS combining both retrospective
and prospective approaches were retrieved. Most
common comments highlighted by priority (i) an
inadequate study design (ii) the lack of statistical
analysis plan (iii) missing timelines, (iv) concerns on
sampling frame, enrollment strategy and ﬁnally (v)
biases and confounders not addressed.
Conclusions: The GVP module VIII supports the
same level of transparency, scientiﬁc and quality
standards for all PASS. It is therefore critical for all
MAH to have at their disposal consolidated feedback
from the PRAC, along with ISPE Good Phar-
macoepidemiology Practices and ENCePP guidance,
in order to anticipate possible design issues and
ultimately improve PASS quality to expedite endorse-
ment processes.
622. Hospital Based Electronic Medical Record
Databases in China
Wei Zhou,1 Ting Wu,1 Zhiwen Liu,2 Ronghua Chen.3
1E;pidemiology Asia Paciﬁc Unit, Merck Research Labo-
ratories, MSD China, Beijing, China; 2Departmetn of
Epidemiology, Merck Research Laboratories; Merck,
Whitehouse Station, NJ, United States; 3Heath IT/
Informatics, MSD China, Beijing, China.
Background: Hospital based Electronic Medical
Record (EMR) databases are widely used in China.
However, few of them have been used for epide-
miology research.
Objectives: To summarize the strength, limitations,
and possible applications of EMR databases in China.
Methods: We interviewed ﬁve different Health Infor-
matics Centers in 2012, using a self-developed
questionnaire, with detailed questions on the number
of available patients’ records, usage of diagnosis code,
drug prescription and dispense, medication, labora-
tory, discharges, and possible follow up information.
We summarized the strengths and limitations of these
databases for pharmocoepidemiology research. No
formal statistical analysis method was used.
Results: The 5 centers we interviewed were located in
Beijing, Shanghai, and Chengdu, with more than 35
million outpatient visits and 1.8 million inpatient
discharge annually. There are three major types of
EMR databases: 1) city wide hospital network EMR
databases, where the major tertiary and some se-
condary hospitals in the same city were linked together
with regular information exchange (i.e. Shanghai
Yilian database); 2) smaller scale hospital network,
where several afﬁliated hospitals from the same
university (i.e. Peking University Health Informatics
Center), hospitals in the same district of a city
(i.e. Shanghai Putuo District), or strategic alliance
hospitals that use the same EMR platform (i.e. West
China Hospital network) are linked;3) the single
hospital EMR (i.e. Peking University Renmin hospi-
tal). The main strength of the databases are: good
coverage of big populations across one or several
geographic areas, enriched information on diagnosis,
laboratory, treatment, and discharge. The main limi-
tations include: Data quality in EMRs is unknown
and not assessed, no clear guidance from government
on whether the EMR databases can be used for
research purposes, diagnosis or treatment codes are
not complete or standardized, outpatients data are
not readily available for use. The details of 3 types
of EMRs will be tabulated.
Conclusions: Few of the EMR databases in China are
readily available for epidemiology research. Addi-
tional work particularly the standardization of coding
are warranted.
623. Development of Thailand Rational Drug Use
Indicators
Penkarn Kanjanarat,1 Sirikwan Boriharn.2 1Pharmaceuti-
cal Care, Chiang Mai University, Chiang Mai, Chiang
Mai, Thailand; 2Strategic Development, Provincial Pub-
lic Health Ofﬁce, Chiang Mai, Chiang Mai, Thailand.
Background: Irrational use of drug poses major health
and ﬁnancial problems in Thailand. Though, rational
drug use (RDU) is promoted speciﬁc set of indicators
have not yet been developed to measure the impact.
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Objectives: This study aimed to develop rational drug
use indicators addressing quality of drug use in
Thailand.
Methods: Development of RDU indicators based on
RDU deﬁnition of Thailand National Essential Medi-
cine was composed of 4 steps:1) literature review, 2)
stakeholder survey, 3) expert review on scientiﬁc,
and 4) user review on technical and implication aspect.
Literature review of RDU indicators was conducted
from 1993-2010 from 3 main sources, WHO/INRUD
indicators of 1993, Ministry of Public Health, health
insurance, and research institutes in Thailand, and
PubMed. The indicators gathered from literature
review were categorized independently by 2 re-
searchers to 3 levels: national, health facility, and
prescribing. Then, a survey of stakeholders of drug
use was conducted using 4 criteria: validity, impor-
tance, data availability, and data quality. RDU indica-
tors were selected if the median => 4.00 on validity
and importance. Duplication were excluded. Expert
reviews were conducted to identify the ﬁnal set of
RDU indicators.
Results: We included 106 indicators from 18 reports
from literature review, 23 national, 24 health facility,
and 59 prescribing indicators. Stakeholder survey
selected 70 RDU indicators based on the inclusion
criteria. Scientiﬁc expert review excluded 20 indica-
tors not related to current clinical practice guidelines
in Thailand left 50 indicators. After technical review
of sensitivity and speciﬁcity, and practicality, 24
indicators were included with 4 national, 7 health
facility, and 13 prescribing indicators. The Thai RDU
indicators addressing antimicrobial use and resistance,
NED use, availability of independent source of drug
information, prescriber education and training, quality
of drug use in chronic diseases.
Conclusions: Thai RDU indicators was developed
with 24 indicators representing quality of drug use at
national, health facility, and prescribing level. Appro-
priate mechanisms should be developed to promote
the implementation of the Thai RDU indicators.
624. Prevalence of Suboptimal Processes of Care
Prior to Hospitalisation
Gillian E Caughey, Lisa M Kalisch Ellett. Quality Use
of Medicines and Pharmacy Research Centre, Sansom
Institute for Health Research, School of Pharmacy and
Medical Sciences, University of South Australia,
Adelaide, SA, Australia.
Background: Between 2% and 3% of all hospital
admissions in Australia are medication-related and it
is estimated that half are potentially preventable.
Clinical indicators identifying suboptimal processes
of care prior to hospitalisation would support improve-
ments in quality of care and with regular monitoring
may assist in reducing medication-related admissions.
Objectives: To identify the prevalence of hos-
pitalisations where suboptimal processes of care prior
to admission can be determined.
Methods: We developed a set of 21 indicators that
identiﬁed suboptimal processes of care which were
considered to be recognisable by a clinician as subop-
timal, with adverse outcomes that were foreseeable
and which could be identiﬁed and controlled.
Administrative claims data from the Australian
Government Department of Veterans’ Affairs were
used to examine the prevalence of the patterns of
suboptimal care. The study period was 1st July 2007
to 30th June 2012.
Results: Of 164,813 hospitalisations deﬁned by the in-
dicator set, involving 83,430 subjects, 25.2%
(n = 41,546) had suboptimal processes of care prior
to hospitalisation. Hospitalisations where subopti-
mal care was identiﬁed included; 19.7% of fracture
admissions in males occurred in men who had a
history of fracture or osteoporosis and no use of a
medicine for osteoporosis, 17.1% of chronic heart
failure hospitalisations occurred in those with
chronic heart failure who were not on an angioten-
sin converting enzyme inhibitor or angiotensin
receptor blocker, and 16.1% of hospitalisations for
asthma occurred in those who were using a
short-acting beta-agonist but who had not received
inhaled corticosteroids.
Conclusions: We assessed processes of care that were
validated by an expert panel as problems that
physicians should be able to identify as suboptimal
and avoid. We found gaps in quality of care prior to
admission, with up to 25% of identiﬁed hospital
events having suboptimal care prior to admission.
625. Understanding Patterns of Drug Utilization
Studies (DUS) Requested By the European Medi-
cines Agency (EMA)
Claudia Schroeder,1 Jacco Keja,2 Ben Hughes,2 Birgit
Ehlken,1 Massoud Toussi.3 1IMS Health, Munich,
Germany; 2IMS Health, London, United Kingdom;
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3Epidemiology and Safety, Europe, IMS Health, Paris La
Défense, Ile-de-France, France.
Background: In Europe the European Medicines
Agency (EMA) is responsible for the protection of
public health through the scientiﬁc evaluation and
supervision of medicines. Good Vigilance Practice
(GVP) established a clear regulatory framework for
drug safety monitoring and calls for the assessment
of the effectiveness of risk minimisation measures
(RMMs). Drug utilization studies (DUS) provide
simple metrics for the assessment of appropriate
drug use, and thus the implementation of RMMs.
Every DUS requested by EMA should be listed in
the EU-PAS, currently the e-register of the European
Network of Centers for Pharmacoepidemiology and
Pharmacovigilance (ENCePP).
Objectives: To describe patterns for drug use monitor-
ing in Europe and to understand the current require-
ments of EMA for DUS.
Methods: We combined three methods of data collec-
tion to characterise current requirements and patterns
for drug utilisation studies: 1) review of DUS listed
in ENCePP e-register between 2009 and 2013, 2) anal-
ysis of data elements on the EMA website and 3) inter-
views with experts from pharmaceutical companies,
facing requirements for conducting DUS.
Results: We identiﬁed a total of 27 DUS requested by
EMA between 2009 and 2013. Most frequent DUS
requests were observed in indications of hormonal
therapy (contraceptives) (n = 6, 22.2%) and metabolic
disorders (diabetes) (n = 5, 18.5%). The majority of
DUS was to be conducted in more than 3 countries
(n = 22, 81.5%). Almost half of all DUS included
more than 10,000 patients (n = 13, 48.1%). In 2013,
the vast majority of DUS were conducted through
databases (n = 24, 88.9%). Experts conﬁrmed an
increasing demand for DUS. In order to optimise the
RMMs, repetitive DUS in different points in time are
necessary.
Conclusions: Current and future EMA practice for
DUS seems to focus on new active substances,
particularly in diseases of high public health relevance.
To meet this demand, pharmaceutical companies are
required to propose more repetitive measurements of
the drug use. Since the vast majority of DUS are
conducted through databases we conclude that this
timely and efﬁcient method of data collection has
become the standard.
626. Comparison of Clinical Measures between
Those with and Without a Diagnosis of Diabetes
among Patients Prescribed Antidiabetic Drugs
Within the Humedica EHR Database
Donnie P Funch,1 Anthony P Nunes,1 Yan Ding,1 Robin
C Clifford,1 Nicholas J Everage,1 David D Dore.1,2
1Epidemiology, Optum, Waltham, MA, United States;
2School of Public Health, Brown University, Providence,
RI, United States.
Background: Within claims and electronic health
record (EHR) data, some antidiabetic drug (AD)
use occurs among patients without a diagnosis of
diabetes recorded on paid claims or providers’
billing records. The nonappearance of diagnoses
may indicate better disease control or other dif-
ferences associated with the absence of clinical
encounters for diabetes.
Objectives: To identify clinical differences between
patients with and without an administrative diagnosis
of diabetes among treated patients.
Methods: We identiﬁed all initiators of ADs from a
de-identiﬁed 5% random sample of ~ one million pa-
tients in the Humedica Research Database, a compila-
tion of EHR data from 195 hospitals, the practices of
>40,000 physicians, and 28.6 million patients. We
tabulated the initiators’ clinical attributes, stratiﬁed
by the presence of a baseline administrative diagnosis
of diabetes.
Results: Of the 15,115 initiators, 4,148 (27.4%) had
no diabetes diagnosis within 12months before drug
initiation, 999 (6.6%) had a diagnosis of type 1 diabe-
tes [T1D] and 9,968 (65.9%) had a diagnosis of type 2
diabetes [T2D]. The most common drugs at initiation
were metformin (49.3% undiagnosed, 12.5% T1D
and 52.6% T2D) and insulin (32.1% undiagnosed,
80.7% T1D and 24.5% T2D). There was a low
frequency of comorbid diagnoses among those with
no diabetes diagnosis (35% had none). Patients with
no diabetes diagnosis had a mean BMI of 32.7 (SD
8.1) compared to 29.9 (SD 7.8) for T1D and 33.2
(SD 7.7) for T2D. Undiagnosed patients had a
mean HbA1C of 6.7 (SD 1.6)) compared to 8.0
(SD 1.8) for T1D and 7.3 (SD 1.7) for T2D. Mean
eGFR for undiagnosed patients was 90.2 (SD 30.1)
compared to values of 89.8 (SD 33.7) for T1D and
85.0 (SD 27.0) for T2D. Mean serum creatinine
values were similar (1.3 for undiagnosed and T1D
and 1.2 for T2D).
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Conclusions: Patients prescribed ADs with no
administrative diagnosis of diabetes tended to
initiate on a ﬁrst line therapy and were less likely
to have comorbidities than diagnosed patients.
Undiagnosed patients had similar BMI levels to
T2D patients and lower HbA1c levels than diag-
nosed patients.
627. Patterns and Determinants of New First-Line
Antihyperglycaemic Drug Use in Patients with Type
2 Diabetes Mellitus
Anne S Geier,1 Ina Wellmann,1 Jürgen Wellmann,1
Hiltraud Kajüter,2 Oliver Heidinger,2 Georg Hempel,3
Hans-Werner Hense.1,2 1Institute of Epidemiology and So-
cial Medicine, WestfälischeWilhelms-Universität Münster,
Münster, Germany; 2Epidemiological Cancer Registry of
North Rhine-Westphalia, Münster, Germany; 3Institute of
Pharmaceutical and Medical Chemistry, Westfälische
Wilhelms-Universität Münster, Münster, Germany.
Background: Many patients with type 2 diabetes
mellitus are managed without medication for a certain
period of their diabetes duration. The provision of
antihyperglycaemic drug (AHD) treatment should be
initiated in accordance with evidence-based guidelines
to reduce diabetes-related complications.
Objectives: We evaluated the patterns and determi-
nants that inﬂuence the selection, timing and duration
of ﬁrst-line AHD in patients with diabetes type 2 in
Germany, focusing speciﬁcally on treatment-naive
AHD initiators.
Methods: Pharmacy dispensing claims data, con-
taining nine AHD groups with deﬁned daily dos-
ages (DDD), were linked with a cohort of patients
newly enrolled in a German Disease Management
Program for type 2 diabetes (DMP-DM2) between
2003 and 2009. We examined uptake of ﬁrst-line
pharmacotherapy in previously unmedicated pa-
tients and identiﬁed predictors of treatment initia-
tion as well as treatment modiﬁcation, that is,
switching or step-up therapy, using multivariable
regression analyses.
Results: There were 27,138 unmedicated patients with
type 2 diabetes and 43.7% of them were started on
AHD treatment during a median observed follow-up
of 2.8 years. Metformin accounted for 62% of newly
prescribed AHD in 2003 and more than 80% in 2009
while sulfonylureas accounted for only 10%. Initiating
metformin as ﬁrst-line AHD was associated with
younger age, higher BMI, lower HbA1c, and shorter
diabetes duration (multivariate p< 0.001 for all).
Therapy switch or step-up was signiﬁcantly less fre-
quent among metformin initiators than sulfonylurea
initiators (HR= 0.63, p< 0.001). Moreover, the me-
dian prescribed daily dose before therapy switch or
step-up was higher with sulfonylureas (1.33 DDD)
than metformin (0.85 DDD, p< 0.001).
Conclusions: In line with recent therapy guidelines,
current ﬁrst-line antihyperglycaemic treatment in
DM2 patients was increasingly based on metformin.
AHD initiators started on sulfonylurea were generally
more advanced in their disease and were started later
on primary pharmacotherapy. They needed more often
treatment modiﬁcation and received higher DDDs.
628. Incretin Therapy and Risk of Pancreatitis in
Type 2 Diabetes Mellitus: Systematic Review of
Randomized and Non-Randomized Studies
Ling Li,1,2 Jiantong Shen,3 Malgorzatax M Bala,4 Shanil
Ebrahim,5,6,7,8 Per Olav Vandvik,9,10 Jason W Busse,5,6
Lorena P Rios,11 German Malaga,12 Evelyn Wong,13
Zahra Sohani,5,14 Gordon H Guyatt,5,15 Xin Sun.1,5
1Chinese Evidence-based Medicine Center, West China
Hospital, Sichuan University, Chengdu, Sichuan, China;
2Department of Science and Research, First Teaching
Hospital of Tianjin University of Traditional Chinese
Medicine, Tianjin, China; 3School of Medicine, Huzhou
Teachers College, Huzhou, Zhejiang, China; 42nd
Department of Internal Medicine, Jagiellonian Univer-
sity School of Medicine, Krakow, Poland; 5Department
of Clinical Epidemiology and Biostatistics, McMaster
University, Hamilton, Canada; 6Department of
Anesthesia, McMaster University, Hamilton, ON,
Canada; 7Stanford Prevention Research Center, Depart-
ment of Medicine, Stanford University, Stanford, United
States; 8Department of Anaesthesia & Pain Medicine,
The Hospital for Sick Children, Toronto, ON, Canada;
9Norwegian Knowledge Centre for the Health Services,
Oslo, Norway; 10Department of Medicine, Innlandet
Hospital Trust, Gjøvik, Norway; 11Internal Medicine
Unit, Hospital Clinico FUSAT, Rancagua, Chile;
12Department of Medicine, Universidad Peruana Cayetano
Heredia, Lima, Peru; 13Department of Medicine, University
of British Columbia, Vancouver, Canada; 14Population
Genomics Program, McMaster University, Hamilton, ON,
Canada; 15Department of Medicine, McMaster University,
Hamilton, ON, Canada.
Background: Signiﬁcant concerns have arisen
regarding the risk of pancreatitis associated with the
use of incretin-based therapies.
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Objectives: To examine the association between
incretin therapy and the risk of pancreatitis.
Methods:We searched Medline, Embase, CENTRAL
and ClinicalTrials.gov to identify randomized con-
trolled trials (RCTs) and non-randomized studies
of adults with type 2 diabetes mellitus that com-
pared glucagon-like peptide-1 (GLP-1) receptor
agonists or dipeptidyl peptidase-4 (DPP-4) inhibi-
tors against placebo or active anti-diabetic medica-
tions. Paired reviewers independently screened for
eligible studies, assessed risk of bias, and extracted
data. We pooled data from RCTs using Peto odds
ratios (ORs) and qualitatively synthesized observa-
tional studies because of variation in outcome
measures.
Results: We included 59 studies (n = 348,624),
consisting of 55 RCTs (n = 33,350) and 4 observa-
tional studies (n = 315,274). Pooled estimates of 55
RCTs (at low or moderate risk of bias involving 37
pancreatitis events, raw event rate 0.11%) did not
suggest increased risk of pancreatitis of incretin agents
versus controls (OR 1.11, 95% CI 0.57 to 2.17). Sub-
group analyses by type of incretin agents suggested
similar results (GLP-1 vs. control: OR 1.05, 95% CI
0.37 to 2.94; DPP-4 vs. control: OR 1.06, 95% CI
0.46 to 2.45). Three retrospective cohort studies
(moderate to high risk of bias involving 1466 pancre-
atitis events, raw event rate 0.47%) suggested no
increased risk of pancreatitis with the use of either
exenatide (adjusted OR 0.93, 95% CI 0.63 to 1.36 in
one study, adjusted hazard ratio (HR) 0.90, 95% CI
0.60 to 1.50 in another) or sitagliptin (adjusted HR
1.00, 95% CI 0.70 to 1.30). However, a matched
case-control study with moderate risk of bias sug-
gested that the use of either sitagliptin or exenatide
was associated with increased odds of acute pancreati-
tis (adjusted OR 2.07, 95% CI, 1.36 to 3.13).
Conclusions: The available evidence suggests that
the risk of pancreatitis in patients using incretin
agents is very low, and provides little support for
the hypothesis that incretins may increase the risk
of pancreatitis.
629. Incidence of New Onset Type 2 Diabetes
(T2DM) with Seroquel XL in Primary Care in
England: Results from an Observational Post-
Marketing Cohort Study
Miranda Davies,1,2 Deborah Layton,1,2 Vicki Osborne,1,2
Saad AW Shakir.1,2 1Drug Safety Research Unit,
Southampton, United Kingdom; 2University of Portsmouth,
Portsmouth, United Kingdom.
Background: Antipsychotics (APs) have been
associated with gains in weight and hyperglycaemia.
A Risk Management Plan developed for quetiapine
extended release (Seroquel XL™), included a Modiﬁed
Prescription-Event Monitoring (M-PEM) study to
examine the safety and use of quetiapine XL as pre-
scribed in primary care in England.
Objectives: Study objectives included evaluation of
selected events - new onset T2DM.
Methods: An observational, population-based cohort
design. Pts were identiﬁed from dispensed prescriptions
(Rx) issued by GPs Sep2008-Feb2013. Data were
collected from forms sent to GPs 12months (m)after
each individual pts’ 1st Rx. T2DM cases were deﬁned
new onset if no prior medical history (pmh) of T2DM
was noted; drug-relatedness was not assessed.
Descriptive statistics summarised characteristics.
Crude cumulative incidence (CumI + 95%CI) of new
onset T2DM <12m post index was calculated using
survival methods (excluding cases where event date
was missing or data were conﬂicting); the impact of
missing event dates was explored by allocating
median event time of known to unknown.
Results: Final cohort = 13,276; median age 43 yrs
(IQR 33,55). Incidence of new onset T2DM was
0.8% (n = 108) during the total study period. Case
series analysis: median age 48 yrs (IQR 38,60);
63.0% (68/108) female; 26.1% (23/88) prescribed
concomitant anti-psychotics; 6.5% (7/88) had a history
of impaired glucose tolerance; 60.2% (53/88) pmh of
abdominal obesity; 50.0% (44/88) pmh of hyper-
lipidaemia. Complete case (n = 55) CumI was 0.5%
(0.4,0.7); median onset 7m.; sensitivity analysis
(n = 83) estimated CumI of 0.8% (0.6,1.0).
Conclusions: The incidence of new onset T2DM
within this study was 0.8% consistent with the product
labelling (uncommon, < 1%), and also previously
published results. The prevalence of pre-existing
hyperglycaemia in these new onset T2DM cases was
common, and thus cases were already at an elevated
risk status for development of T2DM, independent
of anti-psychotic exposure. Study limitations include
lack of information on current/prior risk factors
(e.g prior psychiatric history, prior AP use), and
missing event dates.
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630. Glitazone Antidiabetics and the Risk of
Parkinson’s Disease
Ruth Brauer,1 Krishnan Bhaskaran,1 Nishi Chaturvedi,2
David Dexter,3 Liam Smeeth,1 Ian Douglas.1 1Non-
Communicable Disease Epidemiology, London School
of Hygiene and Tropical Medicine, London; 2Institute
of Cardiovascular Sciences, University College London,
London; 3Centre for Neuroinﬂammation & Neurodegen-
eration, Imperial College, London.
Background: Recent in vitro and animal experiments
suggest that peroxisome proliferation-activated re-
ceptor gamma (PPARγ) agonist medications, such as
antidiabetic glitazone drugs, may prevent the onset
and progression of Parkinson’s disease (PD) by reduc-
ing the inﬂammation in the brain associated with the
disease process. To date, there are no human data on
this association.
Objectives: To estimate the rate ratio for PD in
people with diabetes, comparing individuals treated
with glitazones to people treated with other antidia-
betic drugs.
Methods: The study population for the cohort was
drawn from the United Kingdom Clinical Practice
Research Datalink (CPRD) from 1999 onwards.
Glitazone exposed patients were selected for inclusion
at receipt of their ﬁrst prescription (index date) and
were matched on the index date by age, sex, and
general practice with up to 5 non-glitazone users.
Patients were followed-up from their index date until
the ﬁrst recording of a PD diagnosis, transfer out date,
death or until the end of the study (August 2013). An
incidence rate ratio (IRR) was calculated using
Poisson regression.
Results: 40,824 glitazone-users were matched to
74,068 users of other diabetic medications. Patients
were followed-up for 5 years (median). 167
glitazone-users were diagnosed with PD compared to
296 users of other medications. The IRR, controlled
for age and sex, was 0.79 (95% conﬁdence interval:
0.66-0.96). Adjustments for potential confounding
variables, including smoking status, duration of
diabetes, and use of calcium channel blockers had no
material impact on the IRR.
Conclusions: In this diabetic population strong evi-
dence was found for a protective effect of exposure
to glitazones on the incidence of Parkinson’s disease,
suggesting that PPARγ agonists may be promising
targets for future research into the prevention and
treatment of PD.
631. Postmarketing Evaluation of the Safety of
Saxagliptin: An Interim Analysis
Kevin Haynes,1 Melissa S Nezamzadeh,1 Craig W
Newcomb,1 Jason Roy,1 Whitney Kite,1 Dena M
Carbonari,1 Sean Hennessy,1 Serena Cardillo,2 Cristin P
Freeman,1 Crystal N Holick,3 Daina B Esposito,3 Van
Staa Tjeerd,4 Bhullar Harshvinder,5 Brian L Strom,6 Lo
Re Vincent.1 1Biostatistics and Epidemiology, Perelman
School of Medicine, University of Pennsylvania,
Philadelphia, PA, United States; 2Medicine, Perelman
School of Medicine, University of Pennsylvania,
Philadelphia, PA, United States; 3HealthCore, Wilmington,
DE, United States; 4Clinical Practice Research Datalink,
London, United Kingdom; 5The Health Improvement
Network, Cegedim Strategic Data Medical Research,
London, United Kingdom; 6Rutgers Biomedical & Health
Sciences, Rutgers, The State University of New Jersey,
New Brunswick, NJ, United States.
Background: The comparative safety of saxagliptin in
real-world settings is unknown.
Objectives: To compare the risk of hospitalization for
acute kidney injury (AKI), acute liver failure (ALF),
major adverse cardiovascular events (MACE), serious
infection (INF), and severe hypersensitivity (HYP)
reactions in adult type 2 diabetic patients who initiated
saxagliptin compared to those initiating other oral anti-
diabetics (OAD).
Methods: Retrospective cohort study using 2009-
2011 data from US Medicare, the HealthCore Inte-
grated Research Database, Clinical Practice Research
Datalink, and The Health Improvement Network.
Inclusion criteria: ≥18 years of age, enrolled in
the database for at least 180 days, and newly pre-
scribed saxagliptin or an OAD in a class other than
DPP-4 inhibitor. Follow-up began on the date a
patient was ﬁrst prescribed or dispensed either
saxagliptin or other OAD and continued until the
earliest of: study endpoint (each outcome evaluated
separately), end of study data, or discontinuation
of index medication. Propensity scores were
developed within each database. Cox proportional
hazards regression was used to determine adjusted
hazard ratios (aHR) with 95% CIs of each outcome
in saxagliptin versus other OAD initiators, ad-
justing for propensity score.
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Results:We identiﬁed 23,699 new initiators of saxagliptin
and 220,569 new initiators of non-DPP-4 OADs across all
data sources. The incidence rates for AKI, ALF, CVD,
INF, and HYP reactions across all four data sources were
not statistically signiﬁcantly different between new initia-
tors of saxagliptin compared to those of other OADs. The
aHRs (95% CI) for the electronic outcome algorithms for
US Medicare (the largest data source) were:
AKI: 1.00 (0.79- 1.26)




Results were comparable in the other databases and
in analyses restricted to adjudicated events.
Conclusions: In this multiple database analysis,
saxagliptin was not statistically associated with an increased
risk of hospitalization for AKI, ALF, CVD, INF, or HYP
reactions. Analyses will continue to further evaluate the
comparative safety of saxagliptin in real-world settings.
632. Comparative and Clinical Effectiveness Studies
Based on Taiwan National Health Insurance
Research Database
I-Shou Chang,1 Mei-Shu Lai,2 Chung-Yi Li,3 Jung-Der
Wang,3 Li-Kwang Chen,4 Tzeng-Ji Chen.5 1National
Institute of Cancer Research /Center for Biomedical
Resources, National Health Research Institutes, ZhuNan,
Miaoli County, Taiwan; 2Institute of Epidemiology and
Preventive Medicine, College of Public Health, National
Taiwan University, Taipei, Taiwan; 3Department of
Public Health, College of Medicine, National Cheng
Kung University, Tainan, Taiwan; 4Institute of Pop-
ulation Health Sciences/Division of Health Policy
Research and Development, National Health Research
Institutes, ZhuNan, Miaoli County, Taiwan; 5Family
Medicine Department, Taipei Veterans General Hospital,
Taipei, Taiwan.
Background: As interrogating information from
databases is an important component in pharmaco-
epidemiological research, National Health Research
Institutes sponsors a 90minute symposium in the 30th
ICPE International Conference to share our experience
in using National Health Insurance Research Database
(NHIRD) to study important health issues in Taiwan.
Objectives: To share Taiwan experiences in using
health insurance database to perform health research
so as to beneﬁt researchers involved in the analysis
of large claims datasets.
Description: Taiwan launched a single-payer National
Health Insurance program on March 1, 1995. Approx-
imately 99.5% of Taiwan’s 23 million population were
enrolled in this program. Since year 2000, National
Health Insurance Research Database (NHIRD) derived
from this system by the National Health Insurance
Administration (NHIA), Taiwan, and maintained by
the National Health Research Institutes (NHRI),
Taiwan, has been provided to scientists in Taiwan for
research purposes. Using Taiwan NHIRD, the re-
searchers have published over 1000 papers; among
them many are in high impact international journals.
We highlight in this symposium some of the signiﬁcant
research works based on NHIRD.
This symposium is organized by Prof. I-Shou
Chang, chaired by Prof. Mei-Shu Lai, with Prof.
Chung-Yi Li serving as the discussant. Speakers and
topics are as follows:
(1) Prof. Jung-Der Wang on “Integration of epide-
miology with outcome research for health policy
decision: Empirical examples of combined use of
NHIRD with patients reported outcome.”
(2) Dr. Tzeng-Ji Chen on “Drug-relatedNHIRD research
at Taipei Veterans General Hospital, Taiwan.”
(3) Dr. LiKwang Chen on “Use health insurance data
to construct information for facilitating discussion
on appropriate goals of healthcare: some examples
regarding mechanical ventilation and dialysis.”
633. Confirmation of Medical Events (ME)
Identified from Existing Electronic Databases in
Pharmacoepidemiology (PE) Studies
Gerald Dal Pan,1 Vera Ehrenstein,2 Seeger John,3 Veena
Thyagarajan,4 Nicole C Wright,5 Hairong Xu,6 Fei
Xue.6 1Ofﬁce of Surveillance and Epidemiology, US Food
and Drug Administration (FDA), Silver Spring, MD,
United States; 2Department of Clinical Epidemiology,
Aarhus University Hospital, Aarhus, Denmark; 3Harvard
Medical School/Brigham & Women’s Hospital/Harvard
School of Public Health, Boston, MA, United States;
4Optum Epidemiology, Ann Arbor, MI; 5Department of
Epidemiology, University of Alabama at Birmingham,
Birmingham, AL, United States; 6Center for Observa-
tional Research (CfOR), Amgen Inc., Thousand Oaks,
CA, United States.
Background: Existing electronic databases represent
useful platforms to conduct PE studies. The data
generating mechanism can inﬂuence the reliability of
identiﬁed ME and the validity of analysis. The ability
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to conﬁrm potential ME may be necessary to draw
appropriate inferences from the study.
Objectives: To discuss considerations in conﬁrming
ME identiﬁed from databases with regard to regulatory
perspectives, methodological issues and real-world
experiences in various databases. Researchers from
regulatory agency, academia, service provider and
industry will share opinions on the best practice to
conﬁrm ME and use the conﬁrmation results.
Description: Reliable assessment of exposure, out-
come and covariates is critical for any PE study,
particularly drug safety studies where bias due to
misclassiﬁcation would lead to incorrect inferences
and jeopardize public health. Conﬁrmation of potential
ME through medical record review, or a linkage to
EMR or disease registries is often conducted to com-
plement existing databases. It may be conducted in a
targeted manner to address study-speciﬁc concerns
and may involve validation of algorithms in all or a
sample of the study population. In this symposium,
presenters will lead an in-depth discussion on the
necessity, approaches and operation of ME conﬁrma-
tion. The topics will cover validation of health
outcomes by Mini-Sentinel, special considerations
for drug safety studies, generalizability across
populations/time periods, PPV vs. sensitivity, evalua-
tion of new drugs/rare conditions, patient/provider
consent and HIPAA compliance, and access to speciﬁc
diagnostic data (e.g., radiographs and lab results), etc.
Agenda:
(1) Opening remarks (FX–5min)
(2) Regulatory perspectives and requirements
(GDP–15min)
(3) Methodological considerations (JS–15min)
(4) Acquisition of medical charts in the Medicare
database (NCW–15min)
(5) Assessment of new injectable and off-label use in
commercial claims (VT–15min)
(6) Assessment of new/rare events in multiple
Scandinavian national registries (VE – 15min)
(7) Panel Discussion: ME conﬁrmation to comple-
ment existing databases – challenges and opportu-
nities (10min).
634. Drugs and Devices: Challenges and Oppor-
tunities for the Evaluation of Combination Medical
Products
Michael E Matheny,1 Irene BMurimi,2,3 Mary E Ritchey,4
Ted Lystig,5 Myoung Kim,6 Danica Marinac-Dabic,2
Michael Steinbuch.7 1Department of Medicine, Vanderbilt
University Medical Center, Nashville, TN, United States;
2Division of Epidemiology, Center for Devices and Radio-
logical Health, Silver Spring, MD, United States; 3Depart-
ment of Pharmaceutical Outcomes and Policy, University
of Florida College of Pharmacy, Gainesville, FL, United
States; 4Comparative & Outcomes Evidence, Merck &
Co, North Wales, PA, United States; 5Strategic Scientiﬁc
Operations, Medtronic Inc, Minneapolis, MN, United
States; 6Medical Devices & Diagnostics, Johnson &
Johnson, New Brunswick, NJ, United States; 7Global
Safety Surveillance & Analysis, Procter & Gamble,
Cincinnati, OH, United States.
Background: Combination products are those thera-
peutic and diagnostic medical devices that are com-
bined with drugs and/or biological components. The
landscape for regulatory pre- and post-authorization
requirements has changed substantially over the last
few years, and this area is particularly complex be-
cause of multiple interacting domains that are critical
to consider during clinical use. We seek to explore
and highlight the challenges and opportunities of this
rapidly expanding product area.
Objectives: To explore recent developments, methodo-
logical challenges, national regulatory changes and clini-
cal examples with regards to pre and post-authorization
evaluation of combination products. This will include
highlighting issues unique to combination products
including: challenges in dealing with learning effects in
device implantation, medication and device exposure
considerations as well as the issues associated the devel-
opment and surveillance of these combination products.
Description: The symposium will consist of ﬁve talks
providing: 1) background and historical perspective on
combination medical products (Ritchey), 2) clinical
example within biodegradable drug eluting stents
(Matheny), 3) case example of a combination prod-
uct evaluated within a U.S post-marketing study
(Sansing), 4) presentation of a framework for con-
structing objective performance criteria for use in
pre-authorization studies of certain modiﬁcations
of combination products (Lystig), and 5) chal-
lenges surrounding the Evarrest ﬁbrin pad, a sterile
bio-absorbable haemostatic combination product
coated with two biological components (Kim). Pre-
sentations will be followed by a panel discussion
of opportunities for further development of epide-
miologic methods and strategies to address this
burgeoning ﬁeld. This abstract is submitted on be-
half of the Medical Device SIG.
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635. HOT, HOT, HOT and Getting HOTTER?-
Climate Change and Pharmacoepidemiology
Debra S Rowett,1 Richard Hill,2 Genevieve Gabb,3 Peng
Bi,4 Soko Setoguchi.5 1Drug and Therapeutics Informa-
tion Service, Repatriation General Hospital, Adelaide,
South Australia, Australia; 2Signal Investigation, Signal
Investigation, Ofﬁce of Product Review, Therapeutic
Goods Administration, Canberra, Australia; 3Depart-
ment of Medicine, Royal Adelaide Hospital, Adelaide,
South Australia, Australia; 4Discipline of Public Health,
School of Population Health, University of Adelaide,
Adelaide, South Australia, Australia; 5Duke Clinical
Research Institute, Durham, NC, United States.
Background: Advances in genomic analysis are
enabling more precise and personalized treatments
and the impact of medicines on health outcomes,
health service utilisation and safety is being realised
through data linkage and advances in pharma-
coepidemiology. However, an important variable
often not included is climate. With increasing fre-
quency and intensity of extremely hot weather, heat
exposure is presenting a threat to health and safety.
Global climate trends indicate that extreme heat
exposure is extending to a large area of the world.
Heat waves have killed more people during a typi-
cal year than ﬂoods, tornadoes, and earthquakes
combined. Older adults are especially vulnerable to
heat waves, not only because of age and pre-existing
medical conditions, but also because of the multiple
medications they take for comorbid conditions.
Studies indicate that, factors affecting heat health out-
comes included medication for mental disorders, heart
failure, diabetes or respiratory diseases.
A number of countries have operationalized
’National Heat Wave Plans’ as part of public health
campaigns to reduce morbidity and mortality.
Objectives: To generate discussion to inform public
health policy about medicine use during ’heatwaves’
and methods for pharmacovigilance and to plan for
drug use surveillance and detection of adverse drug
effects with changes in disease patterns and drug utili-
zation associated with climate change.
Description: Several speakers will present 1) to re-
view current data on climate change, 1) review the
existing and ongoing studies to assess the link between
extreme heat exposure and adverse drug events 3) the
impact of changing prevalence of drug use which may
contribute to morbidity and mortality during ’heat
waves’ in vulnerable population groups. (45min) A
panel will be formed to generate discussion which may
inform public health policy about medicine use during
’heatwaves’ and methods for pharmacovigilance and to
plan for drug use surveillance and detection of adverse
drug effects with changes in disease patterns and drug
utilization associated with climate change (45min).
636. How Do We Overcome Challenges of Diverse
Views in Multi-Displinary Collaboration on CER?
Cynthia J Girman,1 Sebastian Schneeweiss,2 Leona E
Markson,1 Til Stürmer,3 Stella Blackburn. 1Comparative
&Outcomes Evidence, Merck Research Laboratories, North
Wales, PA, United States; 2Medicine & Epidemiology,
Harvard Medical School, Boston, MA, United States;
3Epidemiology, University of North Carolina, Chapel Hill,
NC, United States.
Background: The perception of the potential
strengths and limitations that electronic health records
and Comparative Effectiveness Research (CER) bring
to evidence-based medicine varies signiﬁcantly across
different stakeholder groups. Issues such as CER feasi-
bility, level of pre-work needed before conducting
CER and precision of ﬁndings may be perceived dif-
ferently, along with timeliness, ability to proactively
communicate results, and costs of evidence genera-
tion. In particular, interpretation of what constitutes
valid results in the presence of imperfect data and
uncertain assumptions may be points of contention.
Cross-functional collaboration is essential to de-
velop the CER agenda and generate evidence that will
be useful for decision-makers, but rarely are different
perspectives directly discussed. Understanding these
perspectives and the rationale for such perspectives is
a ﬁrst step to overcoming challenges. While the per-
spectives of various stakeholders may be quite differ-
ent, usually there is common ground that create
opportunities for collaboration with few friction
points. Sometimes tools for assessing feasibility of
CER can be useful to make stakeholders more com-
fortable with conducting CER.
Objectives: To identify approaches that may be useful
in multi-displinary collaboration to understand per-
spectives and how to handle differing views on the
feasibility, design and interpretation of comparative
effectiveness research.
Description: Each panelist will discuss the type of
internal and external collaboration needed in their
organization(s) in order to design, conduct and
interpret CER. The key issues that lead to barriers to
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CER will be identiﬁed as well as potential strategies to
overcome these obstacles. Each panelist will be chal-
lenged to identify broad ways in which the perspectives
of collaobrations may be better understood. In addition,
panelists will comment on how to identify overlap of
interest such that agreement among essential collabora-
tors could be grown to accommodate the interests of
other parties involved. The workshop will be interac-
tive by polling for responses to dichotomous and mul-
tiple choice questions, relavant to the topic.
637. Improving the Science of Regulatory Decision-
Making – Advances in 2013/2014
Stanley A Edlavitch,2 Gerald J Dal Pan,2 June M Raine,3
Hubert G Leufkens,4 Byung-Joo Park,5 Jerry Avorn.6
1Psychiatry, UMKC School of Medicine, Kansas City,
MO, United States; 2Ofﬁce of Surveillance and Epidemi-
ology (OSE), Center for Drug Evaluation and Research,
US FDA, Silver Spring, MD, United States; 3Vigilance,
Risk Management of Medicines, Medicines and Health-
care Products Regulatory Agency, London, United
Kingdom; 4Division of Pharmacoepidemiology and
Clinical Pharmacology, Utrecht Institute of Pharmaceu-
tical Sciences, Utrecht, Netherlands; 5Korea Institute of
Drug Safety and Risk Management, Seoul, Republic of
Korea; 6Division of Pharmacoepidemiology and Phar-
macoeconomics, Harvard Medical School, Boston, MA,
United States.
Background: The US FDA, other regulatory agen-
cies, and academic programs worldwide are paying in-
creased attention to advancing regulatory science. In
2010, the NIH and FDA launched the Advancing Reg-
ulatory Science Initiative. In August 2011, the FDA
published “Advancing Regulatory Science at FDA: A
Strategic Plan”. In 2009 EMA launched a multina-
tional collaboration of 31 public, private and academic
groups, PROTECT. In 2013, the FDA and European
and Asian regulators initiated discussions on im-
proving international collaboration on regulatory science.
Though some progress had beenmade in collecting better
scientiﬁc information and analyzing data, most efforts
fail to address in depth how better data will be translated
into decision- making.
Objectives: (1) To understand the scope of current
US, non-US EU, E Asian and collaborative efforts
to improve regulatory science.
(2) To discuss how these efforts are addressing
scientiﬁc approaches to regulatory decision-making.
(3) To understand how scientiﬁc evidence, medical
practice, patient preferences, economics, politics, the
press, public opinion and other societal considerations
affect regulatory decisions.
(4) To become familiar with new scientiﬁc ap-
proaches to regulatory decision-making.
Description: For the last two years, this panel Drs.
Edlavitch (UMKC), Dal Pan (FDA), Raine (MHRA),
Leufkens (University of Utrecht), Avorn (Harvard)
and Park (Korean Institute of Drug Safety and Risk
Management) has convened to elucidate the
challenges and efforts to improve the science.
Discussion will review initiatives, such as the
FDA Sentinel efforts, the Observational Medical
Outcomes Partnership, the US Generic Drug Regu-
latory Science Initiative, the impact of US health
care reform legislation and it funding of compara-
tive effectiveness ﬁndings (PCORI) on drug
regulation and promotion? The panel will address
the question of whether initiative since the 29th
ICPE, have mproved or hindered the decision-
making process, how economic pressures, political
pressures, societal preferences, etc. have been inte-
grated into regulatory decision-making and identify
major expectations for the upcoming year.
638. International Collaboration on Pharmaco-
genomics in Epidemiology Research
Wei Zhou,1 Issam Zineh,2 Bruce Carleton,3 Fredrik
Nyberg,4 Wen-Hung Chung.5 1Epidemiology, Asia Paciﬁc
Unit, Merck Research Laboratories, China; 2Ofﬁce of
Clinical Pharmacology, US FDA; 3Pediatrics, University
of British Columbia, Canada; 4Epidemiology, AstraZeneca,
Sweden; 5Chang Gung Memorial Hospital, Taiwan.
Background: With the progress of the Human
Genome Project and increasing focus on personal-
ized medicine, pharmacogenomics (PGx) has
become more and more widely used in clinical
research. Validation and replication of ﬁndings is
of critical importance. Genetic differences at least
partially help explain individual or ethnic differ-
ences of some treatment responses and treatment-
related adverse reactions. PGx is the study of how
drug response varies in individuals, due to differ-
ences in their DNA. Recent examples include the
carbamazepine-induced serious skin reactions,
where HLA-B*15:02 is associated with SJS/TEN
in some Asian populations; and EGFR mutation
that predict the response to EGFR target therapies
among non-small cell lung cancers.
There has been lots of progress on international
collaborations on PGx research in recent years.
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Productive and active collaborations are essential to
moving research forward and require considerable
effort to ensure that any replication study for example
is as equivalent to the originally published study as
possible. International collaborations are critical,
especially for rare adverse events that have a signif-
icant impact on patient morbidity and/or mortality.
A genetic marker usually needs to be validated in
multiple independent populations with different
genetic backgrounds. Numerous international
consortia have been set up to foster the collabora-
tions, but are they working at maximal efﬁciency?
What are these Networks not accomplishing and
accomplishing well?
There are ongoing efforts to build national biobanks
in some countries, and link the genetic information
with patients’ electronic medical records in hospitals
or for use in large cohort studies. EMA, FDA, and
other regulatory agencies have published guidelines
on PGx in clinical drug development and/or post-
marketing pharmacovigilance. The importance of
epidemiology in PGx research cannot be under-
emphasized, given the accuracy of phenotypes is
critical for rigorous PGx analyses. International col-
laborations in genetic epidemiology is vital to deﬁn-
ing how relevant pharmacogenomics biomarker
ﬁndings are for use in clinical practice and how
best to interpret ﬁndings. It is highly unlikely that
genetic determinants alone are responsible for
drug-related harm, and certainly equally important
to recognize that single polymorphic variants are
also unlikely to deﬁne the occurrence of every ad-
verse drug reaction.
There are many important challenges in PGx
research, including ethical, legal, and policy issues
related to biological sample collection, shipment,
and usage; as well as analytical and methodological
issues.
Objectives: In this hot topic session, speakers from
different regions will share their experience and
views on the progress, issues, and suggestions
related to PGx in epidemiology research, with the
focus on best ways to enhance international collabo-
ration on PGx research.
Description: The workshop will start with a short in-
troduction of the panel members, and continue with
presentations from 4 speakers, with approximately
15minutes each. The workshop will end with 25min
panel discussions, including response to questions
from audiences. The presentation topics of each panel
member are as below:
Outline
(a) Introduction of the panel members (3min, Wei)
(b) Regulatory perspectives of PGx (15min, Issam
Zineh)
(c) International collaboration on pediatric PGx in
drug safety (Bruce Carleton, 15min)
(d) Incorporating PGx in multi-national clinical trials
and observational studies: industry perspective
(Fredrik Nyberg, 15min)
(e) Progress and issues of PGx research in Asia
(Wen-Hung Chung, 15min)
(f) Panel discussion: how to foster international
collaborations on PGx in epidemiology research
(25min, moderated by Wei)
639. Lithium Treatment and Risk for Dementia
Among Patients with Bipolar Disorder
Tobias Gerhard,1,2 Davangere P Devanand,3 Cecilia
Huang,1 Stephen Crystal,1 Mark Olfson.3 1Institute
for Health, Health Care Policy and Aging Research,
Rutgers University, New Brunswick, NJ, United
States; 2Ernest Mario School of Pharmacy, Rutgers
University, Piscataway, NJ, United States; 3Depart-
ment of Psychiatry, Columbia University, New York,
NY, United States.
Background: Lithium is a common treatment for
bipolar disorder. It has inhibitory effects on GSK-3, a
key enzyme in the pathogenesis of Alzheimer’s
disease, and has been hypothesized to protect against
development of dementia. Empirical evidence on this
topic has been mixed.
Objectives: To examine the association of lithium use
and dementia risk in a large cohort of publicly insured
older adults with bipolar disorder.
Methods: The study cohort was drawn from a merged
dataset of Medicaid and Medicare claims from 8
large US states for 2001-4, which provided infor-
mation on demographics, physician and hospital
services, and ﬁlled prescriptions. The cohort in-
cluded all individuals ≥50 years with a diagnosis
of bipolar disorder. Patients with dementia diagno-
sis or treatment during a 1-year baseline period
were excluded. Each day of follow-up was classi-
ﬁed according to cumulative lithium use during
the preceding 1-year period (categorized into 0,
1-60, 61-300, and 301-365 days). To guard against
potential biases (eg, confounding by indication,
healthy user effect), mood stabilizers other than
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lithium were evaluated analogously and served as a
negative control. Study outcome was a diagnosis of
dementia. Time-dependent Cox models assessed de-
mentia risk for lithium and mood stabilizers at var-
ious exposure levels (reference = 0 days of
exposure), controlling for demographic variables as
well as for diagnostic and medication history.
Results: 41,931 individuals met inclusion criteria.
1,538 (3.7%) had an incident diagnosis of dementia
during follow-up. Compared to non-use, continuous
lithium use during the prior year (301-365 days of
exposure) was associated with a 23% reduction in
dementia risk (HR 0.77; 95% CI, 0.60-0.99). No such
association was observed for intermediate or sporadic
lithium exposure (HR 1.04, 0.83-1.31 for 61-300
days; HR 1.07, 0.67-1.71 for 1-60 days) or for
any exposure level of the other mood stabilizers
(HR 0.98, 0.85-1.13 for 301-365 days; HR 1.05,
0.90-1.22 for 61-300 days; HR 1.26, 0.99-1.60 for
1-60 days).
Conclusions: Our ﬁndings are compatible with the
hypothesis that continuous lithium treatment may
reduce dementia risk and support further study of
lithium for this indication.
640. Incidence of Antipsychotic Use in Relation to
Diagnosis of Alzheimer’s Disease among Commu-
nity-Dwelling Persons: Nationwide Population
Based Study
Sirpa Hartikainen,1 Marjaana Koponen,1 Heidi Taipale,1
Anna-Maija Tolppanen,1 Jari Tiihonen,2 Antti
Tanskanen,2 Kristuna Johnell,3 Johan Fastbom.3 1School
of Phramacy, University of Eastern Finland, Kuopio,
Finland; 2Clinical Neuroscience, Karolinsak Institutet,
Stockholm, Sweden; 3Ageing Research Center,
Karolinsak Institutet, Stockholm, Sweden.
Background: Antipsychotics are frequently used to
treat behavioral and psychological symptoms of de-
mentia among persons with Alzheimer’s disease.
However, antipsychotic use has been associated with
mortality and serious adverse drug events including
hip fracture and stroke among older people with
dementia.
There is a lack of knowledge when antipsychotics
are prescribed for the ﬁrst time in the course of AD.
Objectives: To determine the incidence of antipsy-
chotic use in relation to diagnosis of Alzheimer’s dis-
ease (AD) among community-dwelling persons.
Methods: Nationwide register-based cohort study,
MEDALZ-2005. The study cohort consisted of all
community-dwelling residents in Finland diagnosed
with AD in 2005 and one matched control for each
person with AD. The mean age of the study sample
(n = 11,914) was 79.3 years in 2005 and 63.4% were
women. Data on all antipsychotics dispensed between
1995 and 2009 were extracted from the Finnish
National Prescription Register. The rate of new anti-
psychotic users per 100 person-years was calculated
for every six months up to 8 years before and 4 years
after AD diagnosis.
Results: During the follow-up, 2,084/5,957 (35.0%)
persons with AD initiated antipsychotic use. The
incidence of new users was four times higher among
persons with AD compared with the controls (IRR
4.22; 95% CI 3.82 to 4.65). The rate of new users
among persons with AD started to signiﬁcantly in-
crease two to three years before AD diagnosis
compared with the rate among the controls without
AD. The incidence of antipsychotic use was
highest during the ﬁrst six months after AD diag-
nosis (13.7 new users/100 person-years). Among
the controls the rate of new users (0.5 to 1.4 new
users/100 person-years) remained stable during
the 12-year follow-up.
Conclusions: Incidence of antipsychotic use starts
to increase already few years before AD diagnosis
which might be associated with early neuropsychi-
atric signs of AD. The highest rate of new users
occurs directly after AD diagnosis. This type of
prescribing practice is a concern as antipsychotics
have been associated with increased risk of serious
adverse drug events.
641. Psychotropic Use among Patients with Demen-
tia Receiving Donepezil in Japan
Kasumi Daidoji, Yukinori Sakata, Kenta Sumitomo,
Toshihisa Arai, Mika Ishii. Drug Fostering and
Evolution Coordination Department, Corporate Medical
Affairs Headquarters, Eisai Co., Ltd., Tokyo, Japan.
Background: Dementia patients are given various
psychotropics concomitantly with anti-dementia
drugs. Food and Drug Administration (FDA) has
issued an alert regarding the use of antipsychotics.
Guidelines on psychotropic use were also recently
established in Japan; however, few studies reported
the actual condition of concomitant psychotropic use
in a large group of patients nationwide.
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Objectives: To estimate the frequency, as well as
changes in the frequency, of concomitant use of
various types of psychotropics among patients with
dementia receiving donepezil in Japan.
Methods: Data from 6 prospective, observational,
post-authorization studies of patients receiving
donepezil conducted between 1999, the year the anti-
dementia drug donepezil was launched, and 2011 were
pooled for analysis. In all patients, donepezil had been
administered for 12 to 52weeks, and the presence or
absence of concomitant psychotropic use during the
administration period was investigated.
Results: A total of 9703 patients were analyzed
(65.2% women, aged 78.6 ± 7.5 years). The overall
proportion of concomitant psychotropic use was
25.4%. The number of concomitant psychotropics
used was one in 10.9% of patients, two in 7.7%, and
≥3 in 6.8%. The types of psychotropics used were as
follows: typical antipsychotics, 9.6%; atypical antipsy-
chotics, 4.4%; antidepressants, 5.8%; anxiolytics,
6.7%; and hypnotics, 11.4%(% does not sum up to
25.4% due to multiple use). By gender, the proportion
of use was 24.6% in men and 26.3% in women. By
age, the proportion was 30.4% in patients aged <65
years, 27.2% in those aged ≥65 years and <75 years,
25.7% in those aged ≥75 years and <85 years, and
25.2% in those aged ≥85 years. By time period, in
studies conducted between 1999 and 2004 vs. those
conducted between 2005 and 2011, the proportions
were 30.5% and 21.1%, respectively.
Conclusions: Concomitant psychotropic use was seen
in 25.4% of patients with dementia receiving
donepezil in Japan. The proportion of use between
men and women was comparable and tended to de-
crease with advancing age. Additionally, the overall
proportion decreased after the FDA issued its alert
in 2005.
642. Comparative Risk of Pneumonia among
Different Cholinesterase Inhibitors
Edward Chia-Cheng Lai,1,2 Monera Wong,3 Isao Iwata,4
Yinghong Zhang,2 Cheng Yang Hsieh,1,6 Yea-Huei Kao
Yang,1,5 Soko Setoguchi.2 1Institute of Clinical Phar-
macy and Pharmaceutical Sciences, National Cheng-
Kung University, Tainan, Taiwan; 2Duke Clinical Re-
search Institute, Duke University School of Medicine,
Durham, NC, United States; 3Geriatric Medicine,
Massachusetts General Hospital, Boston, MA, United
States; 4Division of Geriatric Medicine, University of
North Carolina at Chapel Hill, Chapel Hill, NC,
United States; 5Health Outcome Research Center,
National Cheng-Kung University, Tainan, Taiwan;
6Department of Neurology, Tainan Sin-Lau Hospital,
Tainan, Taiwan.
Background: Cholinesterase inhibitors (ChEI) have
been approved for the symptomatic treatment of mild
to moderate dementia; however, the overactivation of
muscarinic and nicotinic receptors from ChEI may
lead to compromise of the respiratory system and in-
crease the risk of pneumonia.
Objectives: To compare the risk of pneumonia
among elderly patients receiving different ChEIs,
i.e., donepezil, galantamine, and rivastigmine.
Methods: We conducted a retrospective cohort
study of new users of ChEI using 5% Medicare
data (2006-2009). Elderly patients aged 65 or older
were included. Pneumonia was deﬁned as the exis-
tence a primary diagnosis code of ICD-9-CM codes
480-486 listed as the primary diagnosis in hospital
claims or claims from emergency room (ER)
followed by dispensing for appropriate antibiotics.
We used Cox proportional hazard models to esti-
mate the risk of pneumonia. Numerous sensitivity
analyses including adjustments by high-dimensional
propensity scores (hdPS) were conducted to test the
results robustness.
Results: Among 35,570 new users of ChEIs
(30,174 donepezil, 1,176 galantamine, and 4,220
rivastigmine), a mean age was 82, 75% were fe-
male, and 82% were race white. The incident rate
of pneumonia was 51.9 per 1,000 person-year. The
pneumonia risk was signiﬁcantly lower by 24% in
patients started on rivastigmine compared with
those started on donepezil (hazard ratio [HR],
0.75; 95% CI, 0.60-0.93). The risk of the patients re-
ceiving galantamine (HR, 0.87; 95% CI, 0.62-1.23)
was not statistically different from that in donepezil
users. Hazard ratios from sensitivity analyses were
similar to the primary multivariate analyses.
Conclusions: The present study indicated that the risk
of pneumonia was lower in patients receiving
rivastigmine compared with patients receiving
donepezil. While our ﬁndings should be conﬁrmed
by larger study and other populations, rivastigmine
may be a better choice for patients who already have
a higher risk of pneumonia.
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643. Comparative Effectiveness of Antiepileptic
Drugs in Adult Patients with Epilepsy
Edward Chia-Cheng Lai,1,2 Cheng-Yang Hsieh,1,3 Soko
Setoguchi,2 Swu-Jane Lin,3 Yea-Huei Kao Yang.1 1Insti-
tute of Clinical Pharmacy and Pharmaceutical Sciences,
National Cheng- Kung University, Tainan, Taiwan;
2Duke Clinical Research Institute, Duke University
School of Medicine, Durham, NC, United States;
3Department of Neurology, Tainan Sin-Lau Hospital,
Tainan, Taiwan; 4Department of Pharmacy Administra-
tion, College of Pharmacy, University of Illinois at
Chicago, Chicago, IL, United States; 5Health Outcome
Research Center, National Cheng-Kung University,
Tainan, Taiwan.
Background: Epilepsy is a common disorder world-
wide and antiepileptic drugs (AEDs) are the essential
treatment for epilepsy. The International League
Against Epilepsy recommended persistence as the
primary measure of AED effectiveness measure.
However, no data exist to directly compare persistence
of antiepileptic drugs in Asian population in a real-
world setting.
Objectives: To compare effectiveness of AEDs in
adult patients with epilepsy.
Methods: A retrospective cohort study was con-
ducted using Taiwan’s National Health Insurance
Research Database. We included patients with epi-
lepsy aged 18 or older, who were newly prescribed
AEDs between 2005 and 2010. The primary
outcome was the persistence of AEDs, which was
deﬁned as by time to treatment changes, including
discontinuation, switching, hospitalization of epi-
lepsy, and disenrollment of database, whichever
came ﬁrst. Cox regression models were used to
estimate time to treatment changes. We used inverse
probability weighting (IPW) with high dimensional
propensity score (hdPS) to adjust for the differences
among groups.
Results: We identiﬁed 13,061 new users of AED
monotherapy with mean age of 58 years, 60% men.
After adjustment with hdPS-IPW, we generated 6
comparison groups of AED users (oxcarbazepine,
gabapentin, lamotrigine, topiramate, valproic acid,
phenytoin) with balanced baseline characteristics with
carbamazepine users (reference). The mean treatment
duration were ranged from 218.8 (gabapentin) to
275.9 (oxcarbazepine) days in the ﬁrst treatment year.
Persistence in patients receiving oxcarbazepine
(hazard ratio, 0.76; 95% CI, 0.72-0.80), valproate
(0.92; 0.88-0.95), lamotrigine (0.71; 0.63-0.79), and
topiramate (0.92; 0.85-1.00) were signiﬁcantly better
compared to carbamazepine. On the other hand,
phenytoin (1.09; 1.05-1.12) and gabapentin (1.05;
1.00-1.11) users were signiﬁcantly worse than
carbamazepine users.
Conclusions: The effectiveness measured as persistence
was varied among AEDs and better oxcarbazepine,
valproic acid, lamotrigine, and topiramate users but
worse in phenytoin and gabapentin users compared
with carbamazepine users in real-world practice set-
tings in Taiwan.
644. Recent Trends in Antiepileptic Drug Pres-
cribing in UK Primary Care
Jesca Brouwer, Irene Petersen, Irwin Nazareth, Linda
Wijlaars. Primary Care and Population Health, Univer-
sity College London, London, United Kingdom.
Background: The prevalence of persons ever diag-
nosed with epilepsy and prescribed anti-epileptic
drugs (AEDs) at least once increased from 0.9% to
1.2% between 1993 and 2007. In addition to epilepsy,
AEDs are also prescribed for psychiatric disorders and
neuropathic pain.
Objectives: We aimed to describe trends in the pres-
cribing of AEDs in UK primary care during 2000-2011.
Methods: We used electronic medical records of
patients who were registered for at least one year with
one of 535 practices included in The Health Improve-
ment Network (THIN), a UK primary care database.
We included all prescriptions for AEDs between
2000 and 2011. We determined prescription preva-
lence rates using Poisson regression by age group (in-
cluding people aged 0 – 100 years), sex, deprivation
quintile and indication (epilepsy, psychiatric disorder
(bipolar disorder or depression), and other).
Results: We included 7,145,564 people of whom
262,240 (3.7%) had received ≥1 AED prescription.
Prevalence rates doubled between 2000 and 2011 from
9.6 to 18.9 per 1,000 PYAR. Rates increased for all
age groups apart from 0–14 year olds. Of the six most
commonly prescribed AEDs, rates for carbamazepine
and phenytoin decreased, while lamotrigine, prega-
balin and gabapentin prevalence rates increased. Rates
for sodium valproate prescriptions remained stable
over time.
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Of the patients prescribed an AED, 27% had a diag-
nosis for epilepsy, 32% had a diagnosis for a psychiat-
ric disorder, and 41% had other indications. The
proportion of patients prescribed an AED for epilepsy
decreased over time.
For all six AEDs and for all three indications, prev-
alence rates increased with increasing deprivation,
with the exception of lamotrigine for epilepsy. Preva-
lence rates were higher for gabapentin, phenytoin
and pregabalin for indications other than epilepsy or
psychiatric disorders in the older age groups.
Conclusions: Between 2000 and 2011 the prevalence
of anti-epileptic drug prescriptions increased steadily.
This was mainly due to increasing prescription of
gabapentin and pregabalin, which were mostly pre-
scribed in older people for indications other than
epilepsy or psychiatric disorders.
645. Trends of Substance Misuse and Pharmaceuti-
cal Treatment Recorded in England and Wales Pri-
mary Care (1994-2012)
Hilary R Davies, Irene Petersen, Irwin Nazareth.
Primary Care and Population Health, UCL, London,
United Kingdom.
Background: Illicit drug use is a multifaceted public-
health problem. The United Kingdom has one of the
highest prevalence of illicit drug use in Europe. There
has been an overall reduction of overall illicit drug use
in the UK over the past 10 years. People who use illicit
drugs often seek help from their family doctors.
Objectives:To investigate the recording rate of illicit drug
use and pharmaceutical treatment in primary settings.
Methods: A cohort 16-64 years old was extracted
from The Health Improvement Network (THIN). First
recording rate of illicit drug use and pharmaceutical
treatment was estimated for each calendar year
(1994-2012). Poisson regression was ﬁtted to calculate
Incidence Rate Ratios (IRR).
Results: We identiﬁed 35,508 people with a record
of illicit drug use and 10,869 individuals with pre-
scriptions of pharmaceutical treatments. Males
(IRR 2.02, 95%CI:1.97–2.07), people aged 16-24
(16-24 versus 45-64: IRR 6.68, 95%CI:6.39–6.99) and
the most deprived (IRR 4.17, 95%CI:3.98–4.37)
were more likely to have a record of illicit drug
use. Males (IRR 1.23 95%CI:1.18-1.28), in the
age-group; 25-34 (25-34 versus 45-64: IRR 2.17
95%CI:2.03–2.33) and the most deprived (3.92
95%CI:3.58–4.30) were the groups more likely to
receive pharmaceutical treatment.
Conclusions: Family doctors in the UK record illicit
drug use and some individuals receive pharmaceutical
treatment. The demographics agree with national
surveys. However, more individuals are being treated
in community drug clinics than in primary care.
Family doctors could enhance their role in identiﬁca-
tion and possible treatment of illicit drug users.
646. Withdrawn by Author
647. Effect of Facility Opioid Treatment Availability
on Opioid Analgesic Overdose Deaths
Ting-Ying J Huang, Linda Simoni-Wastila. Pharmaceutical
Health Services Research, University of Maryland School of
Pharmacy, Balimore, MD, United States.
Background: Drug overdose deaths involving pre-
scription opioid analgesics (OAs) in the United States
have more than tripled since 1990.
Objectives: To examine the effect of facility opioid
treatment availability on OA overdose deaths.
Methods: This state-level ecological study used 2010
data from the National Vital Statistics System (NVSS),
the National Survey of Substance Abuse Treatment
Services (N-SSAT), the Treatment Episode Data Set-
Admission (TEDS-A) and the Census. The primary out-
come was the number of OA overdose deaths identiﬁed
from the NVSSmortality data using International Statis-
tical Classiﬁcation of Diseases, 10th Revision codes of
T40.2 to T40.4. The predicting variable was the number
of publicly-funded substance abuse treatment facilities
providing Opioid Treatment Programs (OTPs), as mea-
sured in the N-SSAT treatment facility information.
Need population covariates included the total number
of treatment admissions to publicly-funded substance
abuse treatment facilities reporting OAs as substance
problems, and associated demographics (median age,
% male and % nonwhite) from the TEDS-A client
characteristics. All measures were aggregated to the
state level. Geographic variation in rates of OA over-
dose deaths was mapped in quintiles. Rate ratios (RtRs)
were estimated by Poisson regression where state popu-
lation from the Census was used as the offset.
Results: In 2010, the crude rate of OA overdose
deaths ranged from 1.92 to 25.46 (mean 6.44) per
abstract 345
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
100,000 population. States with highest rates concen-
trated in the South and West. Number of treatment
facilities providing OTPs ranged from 0 to 81 (median
3). After adjusting for need population characteristics,
number of treatment facilities providing OTPs sig-
niﬁcantly lowered OA overdose deaths (RtR = 0.98,
95% conﬁdence interval = 0.97-1.00). The adjusted
rate of OA overdose deaths ranged from 2.66 to 9.52
(mean 6.08) per 100,000 population. After adjustment,
North Dakota and Louisiana changed from states with
the lowest to the highest rate of opioid analgesic over-
dose deaths.
Conclusions: States can play a central role in re-
versing the prescription opioid overdose epidemic by
ensuring better access to drug abuse treatment.
648. The Impact of Opioid Substitution Therapy on
Mortality Post-Release from Prison: A Retrospec-
tive Data Linkage Study
Louisa Degenhardt,1,2 Sarah Larney,1,3 Jo Kimber,1
Natasa Gisev,1 Michael Farrell,1 Timothy Dobbins,4
Don J Weatherburn,5 Amy Gibson,6 Richard Mattick,1
Tony Butler,7 Lucy Burns.1 1National Drug and Alcohol
Research Centre, University of New South Wales,
Sydney, New South Wales, Australia; 2School of Popula-
tion and Global Health, University of Melbourne,
Melbourne, Victoria, Australia; 3Alpert Medical School,
Brown University, Providence, RI, United States;
4National Centre for Epidemiology and Population
Health, Australian National University, Canberra,
Australian Capital Territory, Australia; 5New South
Wales Bureau of Crime Statistics and Research, Sydney,
New South Wales, Australia; 6Centre for Health Research,
University of Western Sydney, Sydney, New South Wales,
Australia; 7Kirby Institute, University of New South Wales,
Sydney, Australia.
Background: Prisoners have extremely elevated rates
of heroin dependence relative to the general popula-
tion, and are at high risk of mortality due to drug
overdose and suicide in the period post-release.
Objectives: To examine the impact of opioid substitu-
tion therapy (OST) for opioid dependence during and
after incarceration, upon mortality post-release.
Methods: A cohort was formed of all opioid dependent
people who enteredOST in New SouthWales, Australia,
between 1985-2010, and who following ﬁrst OST
entry, were released from prison at least once between
2000-2012. We linked data on OST history, court
appearances, prison episodes, and deaths. Demographics,
criminographic and treatment histories were examined;
crude mortality rates (CMRs) calculated according to re-
tention in OST; and multivariable Cox regressions for
post-release periods undertaken to examine the associa-
tion between OST exposure (a time dependent variable)
and mortality post-release, for which covariates were
updated per-release.
Results: A total of 16,453 people with a history of
opioid dependence were released from prison on
60,161 eligible prison releases during the study period.
Individuals were observed for 100,978 person-years
post-release, during which, 1,050 deaths occurred.
Most individual received OST sometime while incar-
cerated (76.5%) and individuals were receiving OST
in 40% of releases. Lowest post-release mortality
was among those continuously retained in OST post-
release (CMR at four-weeks post-release: 6.4 per
1,000PY; 95% CI: 5.2, 7.8), highest among those with
no OST (Four-week CMR: 36.7 per 1,000PY; 95% CI:
28.8, 45.9). Multifactorial models showed OST
exposure in the four weeks post-release reduced the
hazard of death by 75% (adjusted hazard ratio (HR):
0.25; 95%CI: 0.15, 0.52); OST receipt in prison had
a short-term protective effect that decayed quickly
across time.
Conclusions: In a study in NSW, Australia, we found
that OST in prison and post-release, reduces mortality
risk in the immediate post-release period. OST in
prison should be scaled up, and post-release OST con-
tinuation maximised.
649. Treatment Utilisation and Retention with Opioid
Substitution Therapy between 2001 and 2010: A
Comparison of Buprenorphine and Methadone Users
Natasa Gisev,1 Louisa Degenhardt,1,2 Sarah Larney,1,3
Timothy Dobbins,4 Briony Larance,1 Amy Gibson,5 Jo
Kimber,1 Tony Butler,6 Richard Mattick,1 Lucy Burns.1
1National Drug and Alcohol Research Centre, University
of New South Wales, Sydney, New South Wales, Australia;
2School of Population and Global Health, University of
Melbourne, Melbourne, Victoria, Australia; 3Alpert
Medical School, Brown University, Providence, RI, United
States; 4National Centre for Epidemiology and Population
Health, Australian National University, Canberra,
Australian Capital Territory, Australia; 5Centre for Health
Research, Univeristy of Western Sydney, Sydney, New
South Wales, Australia.
Background: Prior to the introduction of bupre-
norphine in 2001, methadone was the only subsidised
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form of opioid substitution therapy (OST) in Australia.
Retention in OST is challenging, with individuals
often cycling in and out of treatment.
Objectives: To track treatment entry, discontinuation
and re-entry with methadone and buprenorphine;
compare the characteristics of ﬁrst-time entrants com-
mencing methadone and buprenorphine; and deter-
mine the factors associated with retaining individuals
in their ﬁrst OST treatment episode.
Methods: Retrospective data linkage study based on
all 32,033 OST recipients registered in the New South
Wales, Australia, between 1st August 2001 and 31st
December 2010. These data were linked to records of
custody episodes (1st January 2000-31st March
2012). Characteristics of ﬁrst-time methadone and
buprenorphine users were compared descriptively.
Using exposure to methadone and buprenorphine
and the setting in which treatment was initiated
(community or prison) as a time-dependent covari-
ate, Cox proportional hazard models were used to
examine the factors associated with retaining individ-
uals in their ﬁrst OST treatment episode.
Results: There were 15,600 (48.7%) new treatment
entrants. Of these, 46% (n=7,183) commenced bupre-
norphine and 54% (n=8,417) methadone. Approxi-
mately half of all individuals (56%) who commenced
buprenorphine spent less than 3months in treatment,
compared to 30% who commenced methadone. Those
who commenced methadone also had higher treatment
retention at 12months (44%) compared to buprenorphine
(25%). Although retention with methadone was consis-
tently greater across all years, there was a 10-14%
increase in buprenorphine retention between 2001 and
2010. The risk of leaving a ﬁrst treatment episode was
highest among people receiving buprenorphine in the
community (adjusted hazards ratio 1.68, 95% conﬁdence
interval 1.61-1.76).
Conclusions: Individuals commencing methadone are
retained longer in treatment than those commencing
buprenorphine, independent of the treatment setting.
Further research is needed to identify ways in which
treatment retention can be improved.
650. The Misuse, Abuse and Diversion of Opioid
Replacement Therapies (ORT): A Study of
Street Abusers
Scott P Novak,1 Lynn Wenger,2 Lorvick Jennifer,2
Kral H Alex.2 1Behavioral Epidemiology, RTI Interna-
tional, Research Triangle Park, NC, United States;
2Urban Health, RTI International, San Francisco,
CA, United States.
Background: Buprenorphine suppresses cravings and
withdrawal symptoms of opioid dependence. These
pharmacological properties are believed to offer sig-
niﬁcant treatment advantages over existing opioid re-
placement therapies (ORT), such as methadone.
Community-based abuse liability studies are needed
to complement data from randomized clinical trials
and laboratory ‘challenge’ studies typically conducted
as part of the regulatory approval process for an ORT
medication.
Objectives: We estimate the overall prevalence of
misuse (self-treatment) and abuse (euphoria), as well
as diversion. We also seek to identify the psychosocial
predictors and examine differences between metha-
done and buprenorphine.
Methods: Computer Aided Interview (CAI) of adult
(ages 18+) injection drug users (n = 706) in San
Francisco. Targeted sampling methods were used
to recruit recent persons who inject drugs (PWID),
including those recently receiving outpatient drug
treatment (54%) in past 6m. Final sample character-
istics matched previous studies of PWID in SF,
including demographic (53% white, 79% male,
36% ages 30-44, 63% homeless) and behavioral
(13% HIV+) characteristics.
Results: Approximately 75%were candidates for ORT.
Over 30% of opioid addicts reported nonmedical (either
euphoria or self-treatment) use of methadone, compared
to 9% for buprenorphine. The prevalence of abuse was
higher for methadone (75%) than buprenorphine
(10%). More outpatient clients reported being treated
with methadone (50%) than buprenorphine (10%).
Among those receiving outpatient treatment and pre-
scribed methadone, approximately 50% abused their
own medication compared to virtually none (<1%) of
those being treated with buprenorphine. The signiﬁcant
predictors that differentiated between self-treatment
compared to euphoria were being out-of-drug-treatment,
co-occurring depression, PTSD, and high withdrawal
severity history.
Conclusions: Compared to buprenorphine, methadone
is more often prescribed to community-based street-
abusers, and appears to have a higher abuse liability
based on these self-administration data. These data
indicate that buprenorphine has a lower abuse liability,
even accounting for availability.
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651. When To Conduct Probabilistic Linkage vs.
Deterministic Linkage? A Simulation Study
Ying Zhu,1 Yutaka Matsuyama,1 Yasuo Ohashi,1
Soko Setoguchi.2 1The University of Tokyo, Tokyo, Japan;
2Duke Clinical Research Institute, Duke University School
of Medicine, Durham, NC, United States.
Background: Record linkage can enhance the validity
of database research. Deterministic linkage (DL)
requires exact match of records, which is simple to
implement but result in false negatives when data are
not accurately recorded; probabilistic linkage (PL)
potentially increases linkage rate but is more complex
and time-consuming and may result in false positives.
It is not well understood in what situations one method
outperforms the other.
Objectives: To 1) test the effects of linkage factors,
i.e. ﬁle size, missing and error rate, on the performance
of deterministic vs. probabilistic linkage and 2) to assess
the situations that one method outperforms the other.
Methods: We simulated a basic scenario of two
datasets (n = 10,000) with 60% overlap using ﬁve
non-unique identiﬁers commonly found in administra-
tive databases, which covered a range of distributions.
Each observation was assigned an error-free unique
personal identiﬁer (UPI). We introduced different
errors (0.5% to 5%) and omissions (0.5% to 5%)
to the variables. We then created 12 alternative sce-
narios by decreasing and increasing the ﬁle size
(1,000 to 50,000), ﬁle size ratio (1:1 to 1:20), miss-
ing rate (3 to 30%) and error rate (3 to 30%).
Finally, we linked the two datasets in each scenario
by DL and PL. We compared the linkage rate and
validity of all linkages against the true gold stan-
dard (UPI).
Results: Linkage validity was not affected by the
ratio of ﬁle sizes, but cutoff weight increased as
the ﬁle size increased. Linkage validity was com-
promised the most as the rates of error and missing
increased. When the overall error rate and missing
rate both reached 15%, the DL produced 1606 false
negatives and 44% linkage rate while PL generated
3 false positives and 55% linkage rate. PL
generated higher linkage rate, which was closer to
the true rate, and greater linkage validity than DL
in all scenarios.
Conclusions: Linkage validity was compromised as
the rates of missing and error increased, but was
not affected by ﬁle size. PL outperformed DL in
all scenarios when error/missing rates were 3-30%.
The linkage rate and validity of DL were acceptable
when rates of error and missing were very low
(i.e. 3%).
652. Performance of Methods for Linking Registry
Data to Insurance Claims When Unique Identifiers
Are Unavailable
StacieBDusetzina,1,2,5 Seth Tyree,4,5 Anne-MarieMeyer,3,4,5
William Carpenter.2,4,5 1Division of General Medicine and
Clinical Epidemiology, University of North Carolina at
Chapel Hill, Chapel Hill, NC, United States; 2Health
Policy and Management, University of North Carolina
at Chapel Hill, Chapel Hill, NC, United States;
3Epidemiology, University of North Carolina at
Chapel Hill, Chapel Hill, NC; 4ICISS, University of
North Carolina at Chapel Hill, Chapel Hill, NC,
United States; 5Lineberger Comprehensive Cancer
Center, University of North Carolina at Chapel Hill,
Chapel Hill, NC, United States.
Background: The IOM advocates ﬁlling important
knowledge gaps through comparative effectiveness
research using secondary data. Linking patient reg-
istries with other secondary data allows researchers
to incorporate rich clinical information into observa-
tional studies.
Objectives: To evaluate the performance of four alter-
native approaches to record linkage.
Methods: We evaluated four record linkage ap-
proaches: 1) SEER Medicare “gold standard”; 2)
deterministic with name and SSN; 3) deterministic
with encrypted identiﬁers; and 4) probabilistic. For
each model we began with full information and de-
creased the number of variables to mimic increasing
restrictions on identiﬁers (e.g., name, SSN). We use
the sensitivity, PPV and F-Measure to compare algo-
rithms. Cases: Individuals in the North Carolina
(NC) Central Cancer Registry diagnosed with colon
cancer between years 2007-2008 (N = 6,444). Claims:
Enrollment and claims data for beneﬁciaries in pri-
vately insured health plans in North Carolina between
2006-2009 (n = 3,747,250).
Results: Compared with the SEER Medicare algo-
rithm, the deterministic approach including SSN
resulted in lower sensitivities (87.1-88.4%) due to
missing SSNs for 11% of individuals. Once SSN
was removed, the sensitivity improved to 85.7-
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92.3%). Using only DOB, Last Name Soundex,
First Name Soundex, and Sex correctly identiﬁed
92% of matches, with speciﬁcity and PPV value
over 99%. The encrypted deterministic algorithms
performed similarly. The probabilistic approach
outperformed all deterministic algorithms. Using
full information, the probabilistic match sensitivity
was 97.9%. In all cases, algorithms relying solely
on DOB, residence, diagnosis, and sex had lower
sensitivity (<75%).
Conclusions: Straightforward and easy-to-employ de-
terministic algorithms demonstrated high speciﬁcity
and positive predictive value with acceptable sensitivity.
Deterministic matching on hash-encrypted variable
combinations performed as well as deterministic
matching on unencrypted variables. Probabilistic
matching outperformed deterministic methods. Beneﬁts
gained from probabilistic matching must be weighed
against the complexity of implementation.
653. Comparing Validity of Methods to Select
Appropriate Cutoff Weight for Probabilistic
Linkage Without Unique Identifiers
Ying Zhu,1 Chih-Ying Chen,2 Yutaka Matsuyama,1
Yasuo Ohashi,1 Jessica M Franklin,2 Soko Setoguchi.3
1The University of Tokyo, Tokyo, Japan; 2Brigham and
Women’s Hospital and Harvard Medical School, Boston,
MA, United States; 3Duke Clinical Research Institute,
Duke University School of Medicine, Durham, NC,
United States.
Background: Record linkage can enhance data
quality in comparative effectiveness research. Prob-
abilistic linkage, a method that allows partial match
of linkage variables, can overcome disagreements
arising from errors and omissions but also result
in false positive links. The validity of probabilistic
linkage in the absence of unique identiﬁes and
appropriate methods of cutoff weight selection are
not well understood.
Objectives: To 1) link two large databases via
probabilistic linkage with multiple non-unique
identiﬁers, and 2) assess three existing methods of
cutoff weight selection and validate them against
an internally derived gold standard using unique
identiﬁers.
Methods: We linked the Centers for Medicare and
Medicaid Services’ Implantable Cardioverter-
Deﬁbrillator Registry to the Medicare Provider
Analysis and Review inpatient ﬁles of year 2008
with multiple non-unique identiﬁers. We then tested 3
methods of cutoff selection, i.e. histogram inspection,
duplicate method, and odds formula. We validated these
methods against an internally derived gold standardwith
unique identiﬁers, calculating the associated validity
measures e.g. positive predictive value (PPV).
Results: Of the 64,890 registry records with an
expected linkage rate of 55% to 65%, 55% were linked
at cutoffs associated with 90% PPV and greater. The
histogram method and the duplicate method sug-
gested cutoff weights 13-15 and 14-15 respec-
tively, which were consistent with an internally
derived gold standard with unique identiﬁer (cutoff 15
for 90% PPV). In addition, the duplicate method made
accurate calculations of PPV if its assumption was
met. The odds formula suggested cutoff weight 22,
which was 4 points above the highest obtainable weight
of this linkage.
Conclusions: Probabilistic linkage using only non-
unique identiﬁers generated accurate linkages when the
cutoff was correctly chosen. When the method assump-
tion was met, the duplicate method in conjunction with
histogram inspection provided accurate cutoffs. The for-
mula method was overly conservative. Further studies
are needed to understand how linkage methods perform
with data of varying quality.
654. Incorporating Linked Outpatient Data to
Improve Confounding Control in a Study of In-
Hospital Medication Use
JessicaMFranklin,Wesley Eddings, Sebastian Schneeweiss,
Jeremy A Rassen. Division of Pharmacoepidemiology
and Pharmacoeconomics, Brigham and Women’s
Hospital and Harvard Medical School, Boston, MA,
United States.
Background: The Premier Perspectives database
captures diagnoses, procedures, and medications
from 20% of US hospitalizations and provides a
promising data source for studies of inpatient
medication use. However, inpatient recording of
confounders is limited.
Objectives: To evaluate strategies for incorporating
confounders recorded in outpatient claims data on a
subset of an inpatient study cohort.
Methods: We identiﬁed adults in Premier undergoing
percutaneous coronary intervention (PCI) in 2004-
2008 and exposed to either bivalirudin or heparin.
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Available confounders were assessed from inpatient
data, and patients were followed for up to 30 days after
their PCI for a repeat procedure. We then identiﬁed a
subset of these patients that were enrolled in
UnitedHealth for at least 90 days before PCI. In this
subset, we assessed 24 additional confounders from
outpatient claims, including comorbidities, prior
medication use, and service use intensity. Using
inpatient confounders only, we estimated propensity
score (PS)-adjusted risk ratios (RRs) in the primary
cohort and in the linked subset. We then applied
strategies that utilized both inpatient and outpatient
data: 1) PS-adjustment in patients with complete data
(the linked subset), 2) multiple imputation (MI) of
missing outpatient variables in the primary cohort,
and 3) PS calibration.
Results: Of 210,268 patients in the primary cohort,
3,240 (1.5%) were in the linked subset. Adjusting for
inpatient confounders reduced the estimated effect of
bivalirudin from a crude RR of 0.50 (0.48-0.53) to
0.71 (0.67-0.76). PS calibration and MI further
reduced the estimated effect to 0.76 (0.71-0.80) and
0.82 (0.75-0.89), respectively. In the complete case
analysis in the linked subset, crude, inpatient con-
founder-adjusted, and outpatient confounder-adjusted
RRs were 0.60 (0.38-0.95), 0.96 (0.45-2.03), and
1.17 (0.50-2.76).
Conclusions: Despite more than 98% missingness on
24 variables, MI successfully incorporated outpatient
confounders and yielded improved treatment effect es-
timates. Both PS calibration and MI were preferred
over complete case analysis, which led to small sample
size and very imprecise estimates.
655. Predicting Linkage Within a Validated Algo-
rithm That Identifies Mother-Infant Pairs Within
the Medicaid Analytic EXtract (MAX) Database
Caitlin A Knox,1 Kristin Palmsten,2 Soko Setoguchi,3
Richard Segal,1 Almut G Winterstein.1,4 1Department
of Pharmaceutical Outcomes and Policy, University of
Florida, Gainesville, FL, United States; 2Department of
Pediatrics, University of California, San Diego, CA,
United States; 3Duke Clinical Research Institute, Duke
University School of Medicine, Durham, NC, United
States; 4Department of Epidemiology, University of
Florida, Gainesville, FL, United States.
Background: Our previous research validated using the
Medicaid Case ID number and the delivery/birth dates to
link mothers to infants (sensitivity: 57.1%, speciﬁcity:
98.8% and PPV 86.6%) in the Florida Vital Birth Certiﬁ-
cates (FVBC). Research using theMedicaid Case ID num-
ber to link mothers to infants in the MAX is limited and
patient characteristics that shape this linkage is unknown.
Objectives: To identify factors inﬂuencing true mother-
infant linkage in the MAX database when using a vali-
dated Medicaid Case ID number linkage algorithm.
Methods: We identiﬁed all women aged 12-55 years
with a delivery claim, and all infants born in 1999-
2004 in FloridaMAX and linked via both social security
number and birth/delivery date to FVBC. Within MAX,
we linked mothers to infants by Medicaid Case ID
number and the delivery/birth dates and used a logistic
regression model to calculate the probability for true
linkage using maternal and infant characteristics.
Results: We identiﬁed 434,179 linked live births in
FVBC and MAX, and assessed 179,103 lives births
after excluding those that did not meet eligibility re-
quirements (e.g. non-valid Medicaid Case ID number).
We linked 72.7% of the identiﬁed live births via Medic-
aid Case ID number and delivery/birth dates, and 92.6%
of the linkages were true links. Characteristics that were
associated with true linkage include: term infants (OR
2.09; 95% CI: 1.99, 2.21), no siblings (OR 2.96; 95%
CI: 2.81, 3.12) compared to 1 sibling, mothers older
than 40 years at delivery versus mothers 20-29 years
old (OR 2.12; 95% CI: 1.85, 2.44), or 2004 delivery
year (OR 1.10; 95% CI: 1.02, 1.19) versus 1999
delivery year. Outpatient delivery claims (OR 0.54;
95% CI: 0.48, 0.61) and infants with a birth weight
<2500 g compared to infants with a birth ≥2500 g
weight had a lower likelihood for linkage.
Conclusions: Term infants, infants without living
siblings at birth, and women older than 40 years old
were more likely to result in true linkage. Attention
is warranted when using this mother-infant linkage
algorithm, as there is the potential to under-estimate
certain populations (e.g. preterm infants).
656. Accounting for Outcome Misclassification in
Pharmacoepidemiologic Studies
Xiaojuan Li,1 Nihan Potas,2 AnneMButler,1 Jess Edwards,1
Jason Fin,2M Alan Brookhart.1 1Epidemiology, Univer-
sity of North Carolina, Chapel Hill, NC, United States;
2Biostatistics, University of North Carolina, Chapel
Hill, NC, United States.
Background: Given a variety of different deﬁnitions
of outcomes, pharmacoepidemiologic studies commonly
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prioritize the one with highest speciﬁcity. Under as-
sumptions of non-differential misclassiﬁcation, bias
in the relative effect measures such as the risk ratio
(RR) will decrease with increasing speciﬁcity. How-
ever, the absolute effect measures such as the risk
difference (RD) are not guaranteed to be unbiased even
when speciﬁcity is perfect.
Objectives: To describe the use of methods to account
for outcome misclassiﬁcation when external validation
data are available and to demonstrate the importance
of sensitivity on the validity of absolute effect measures.
Methods: We illustrated the approaches using a cohort
of dialysis patients from the US Renal Data System data
1995-2010. Eligible patients were female, ≥65 at dialy-
sis initiation, had diabetes (N= 8,533) or glomerulone-
phritis (GN, N=1,302) as primary cause of end stage
renal disease (ESRD). We compared the 5-year inci-
dences for breast cancer between patients with different
primary cause of ESRD (GN= reference). Standardized
mortality ratio weighting was used to control for con-
founding. Correction of RR and RD were performed
by calculating the expected number of cases in the
weighted data using estimated sensitivity (47%), speci-
ﬁcity (>99%) from an external validation study assum-
ing non-differential outcomemisclassiﬁcation. The 95%
conﬁdence intervals (CI) of estimates were summarized
from 1000 bootstrapped resamples. Methods account-
ing for uncertainties in sensitivity and speciﬁcity will
also be presented at the Conference.
Results: In the weighted analysis, the adjusted RR
was 1.23 (CI 0.99, 1.53) and RD was 3.04% (CI
0.34%, 5.95%). The RR was similar after accounting
for misclassiﬁcation 1.24 (CI 0.98, 1.53), but the RD
was much higher 6.50% (CI 0.73%, 12.7%).
Conclusions: Prioritization of measures of algorithm ac-
curacy to identify outcomes should depend on the effect
measure of interest. To estimate absolute effect measures,
both sensitivity and speciﬁcity should be considered.
Correction approaches are easily implemented and should
be more commonly used in pharmacoepidemiologic
studies where outcome misclassiﬁcation is common.
657. Five-Year Safety Results from the ENCORE
Registry: Malignancies in Patients with Crohn’s
Disease Treated with Infliximab, Standard Therapy,
or Switched from Standard Therapy to Infliximab
G D’Haens,1W Reinisch,2 J-F Colombel,3 J Panes,4
S Ghosh,5 C Prantera,6 S Lindgren,7 DW Hommes,8
Z Huang,9 S Huyck,9 DK Chitkara.9 1Academic Medical
Center, Amsterdam, Netherlands; 2Medical University, Vi-
enna, Austria; 3Icahn School of Medicine at Mount Sinai,
New York, United States; 4Hospital Clinic I Provincial,
Barcelona, Spain; 5University of Calgary, Calgary, AB,
Canada; 6A.O. San Camillo Forlanini, Rome, Italy;
7University Hospital MAS, Malmö, Sweden; 8University of
California, Los Angeles, CA, United States; 9Merck Sharp
& Dohme, Kenilworth, NJ, United States.
Background: The long-term risk of lymphoprolifera-
tive disorders/malignancies (LPD/M) in patients with
Crohn’s disease (CD) who received biologics needs
to be determined. This 5-year study analyzed the risk
of LPD/M in CD patients receiving inﬂiximab (IFX)
vs standard therapy (STD).
Objectives: To determine the long-term risk of LPD/M
in CD patients who treated with IFX vs STD.
Methods: The European National Crohn’s Observa-
tional Registry (ENCORE) is a prospective, observa-
tional safety surveillance registry of CD patients
receiving IFX or STD or who switched from STD to
IFX after enrolment (S2IFX). Enrollment from clinical
practices in 9 EU countries occurred from 2003 to
2008; patients were followed for 5 years. The risk of
LPD/M was compared among the 3 groups. A
multivariate analysis of time to ﬁrst LPD/M event
was conducted to adjust for potential confounders.
Results: Of 2662 patients enrolled, 1541 were in the
IFX group, 298 in S2IFX and 1121 in STD group. Fol-
low-up patient-years (PYs) in these groups were 6417,
972 and 3750 respectively. The crude incidence per
1000 PYs (95% conﬁdence intervals [CI]) of any
LPD/M was 7.6 (5.6, 10.1), 8.2 (3.6, 16.2), and 5.6
(3.5, 8.6) in the IFX, S2IFX, and STD groups, respec-
tively. In a multivariate analysis of time to ﬁrst LPD/M
event, adjusting for age and disease duration, IFX was
not associated with a signiﬁcantly increased risk
(hazard ratio [HR] for IFX vs STD, 1.44 [95% CI,
0.86-2.42]). Age (continuous) and disease duration
(≥6 vs <6 years) were independently associated with
increased risk (HR= 1.05, 95% CI 1.03–1.06 and
HR= 2.09, 95% CI 1.22–3.56, respectively).
Conclusions: In the ENCORE registry, the IFX group
did not have a signiﬁcantly increased risk of LPD/M
after adjusting for potential confounders. The observed
differences in crude incidence rates may be due to
differences in age and disease duration between the
treatment groups.
abstract 351
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
658. Evaluation of Cancer Risk Following Use of
Becaplermin, a Topical Platelet-Derived Growth
Factor
Donald R Miller,1,2 Cindy L Christiansen,1,2 Daniel
Fife,3 Berlin A Jessie,3 Patricia Tremblay,4 Qing Shao,1,2
Madhuri Palnati,1 Graeme Fincke.1,2 1Center for Healthcare
Organization and Implementation Research, Edith Nourse
Rogers Memorial Veterans Hospital, Bedford, MA, United
States; 2Department of Health Policy and Management,
Boston University School of Public Health, Boston, MA,
United States; 3Pharmacoepidemiology, Johnson &
Johnson Pharmaceutical Research and Development,
Titusville, NJ, United States; 4Benchmark Senior Living,
Wellesley, MA, United States.
Background: Becaplermin (Regranex®) is a topical
formulation of recombinant human platelet derived
growth factor used to treat diabetic neuropathic
ulcers. Concerns that it may promote cancer were
heightened by reports from a postmarketing study
of higher cancer death rates in the highest exposure
group. This led to an FDA warning and call for
more evidence.
Objectives: To evaluate cancer risks with becaplermin
use in a large population of diabetes patients.
Methods: Using the Diabetes Epidemiology Cohorts,
a registry of all veterans with diabetes in healthcare
by the U.S. Dept. of Veteran Affairs (VA) since
1998, we studied cohorts of becaplermin initiators
and matched comparators, excluding all patients with
prior cancer. Follow-up extended for up to 11 years
to identify incident cancers, conﬁrmed by chart
review, and cancer deaths, identiﬁed from the National
Death Index. Risks were estimated using Cox
regression with adjustment for information from
medical, laboratory, and pharmacy records, as well
as patient surveys. We also conducted an instru-
mental variables (IV) analysis using clusters of
VA facilities as the instrument.
Results: In the total sample of 6,429 becaplermin
users and an equal number of comparison subjects,
we found no increase in risk of cancer death, with
HR (95% CI) from the fully adjusted model of 0.94
(0.76-1.18) for any use and 1.04 (0.73-1.48) for high
dose use. In the sample of 1,507 patients in each group
who completed a national survey, we again found no
increased risk of conﬁrmed incident cancer for non-
melanoma skin cancer (1.02 (0.64-1.61)) and for all
other cancers (1.06 (0.83-1.36)). These ﬁndings were
conﬁrmed in IV analysis and there was no evidence
for risk increases at any dose level, in any patient
subgroup, or with any speciﬁc cancer site. A slight
excess (10 vs. 4) of squamous cell carcinoma at the
ulcer site in becaplermin users was tempered by notes
from several charts that the largely verrucous lesions
may have been present before the treatment.
Conclusions: This study provides substantial evidence
for no increase in risk of incident cancer or cancer
mortality with becaplermin use, overall, or at the
highest doses.
659. Use of Non-Steroidal Anti-Inflammatory Drugs
(NSAIDs) and Risk of Non-Hodgkin’s Lymphoma
(NHL): A Systematic Review and Meta-Analysis
XibiaoYe,1,2,4Natalie Casaclang,1,4 SalaheddinMahmud.1,3,4
1Department of Community Health Sciences, Faculty of
Medicine, University of Manitoba, Winnipeg, MB, Canada;
2Research and Evaluation Unit, Division of Quality and
System Performance, Winnipeg Regional Health Authority,
Winnipeg, MB, Canada; 3Population and Public Health
Program, Winnipeg Regional Health Authority, Winnipeg,
MB, Canada; 4Vaccine and Drug Evaluation Centre, Uni-
versity of Manitoba, Winnipeg, MB, Canada.
Background: Epidemiological study ﬁndings re-
garding the association between use of NSAIDs and
risk of NHL have been inconsistent. Synthesizing the
evidence on the association will advance NHL
etiological research.
Objectives: We aimed to systematically review epide-
miological studies of the association and calculate
pooled relative risks using meta-analytic methods.
Methods: We searched several electronic literature
databases and registers to identify all studies of the
association. Identiﬁed studies were independently
reviewed by two researchers. We used a random
effects model to calculate pooled odds ratio (PORs).
Heterogeneity among studies was examined using
Cochran’s Q and I-squared tests; and sources of
heterogeneity were explored using subgroup and
meta-regression analyses.
Results: A total of 17 studies (12 case control studies
and 5 cohort studies), all adult studies, were included.
Use of NSAIDs was not associated with overall risk of
NHL (POR and 95% CI =1.04 [0.90-1.20]) or NHL
subtypes including B-cell lymphoma, T-cell lym-
phoma, follicular lymphoma, diffuse large B-cell
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lymphoma, chronic lymphocytic leukemia/small
lymphocytic lymphoma. Aspirin use was associated with
reduced risk of chronic lymphocytic leukemia/small
lymphocytic lymphoma (POR=0.73 [0.56-0.96]) but
not with the risk of all NHLs (POR=1.01 [0.88-1.15]).
Use of non-aspirin NSAIDs was associated with an
increased risk of NHL (POR=1.41 [1.01-1.97]) among
females only.
Conclusions: The epidemiologic evidence remains
inconclusive. Effects of NSAIDs may differ by drug
type, NHL histological type, and sex. More studies tak-
ing in consideration these differences and employing
sound epidemiologic designs are needed.
660. Calcium Channel Blockers and Cancer Risk
Using the UK CPRD
Lamiae Grimaldi-Bensouda,1,2 Mark de Groot,3
Robert Reynolds,4 Olaf Klungel,3 Michel Rossignol.1,5
1LA-SER, Paris, France; 2Conservatoire National des Arts
& Métiers, Paris, France; 3Faculty of Science, Division of
Pharmacoepidemiology & Clinical Pharmacology, Utrecht
University, Utrecht, Netherlands; 4National Institute for
Health Data and Disease Control, Copenhagen, Denmark;
5Department of Epidemiology, Biostatistics and Occupa-
tional Health, McGill University, Montreal, Canada.
Background: This study was part of the Pharmaco-
epidemiological Research on Outcomes (PROTECT)
project which aims at monitoring of the beneﬁt-risk
of medicines in Europe. Few epidemiological studies
have investigated the association between calcium
channel blockers (CCB) and cancer, and have pro-
vided contradictory evidence.
Objectives: To investigate whether CCB exposure
is associated with cancer risk and whether the
risk varies according to cancer subtype and duration
of exposure.
Methods: A population-based matched-cohort study
was conducted using data from the Clinical Practice
Research Datalink and National Cancer Registration
System. Eligible patients (18 to 79 years, over two
years primary care and prescription history) with ≥1
CCB prescription between 1996 and 2009 (CCBC)
were compared with two CCB unexposed cohorts: 1)
patients without CCB exposure (NCCBC), and; 2)
patients with no CCB and ≥1 other antihypertensive
prescription (AHTC). CCBC was compared with
NCCBC and AHTC according to cancer outcomes.
Conditional logistic cox-regression models estimated
multivariable hazard ratios (HR) and 95% conﬁdence
intervals (CI).
Results: There were 150,750 patients in the CCBC,
557,931 in the NCCBC, and 156,966 in the AHTC.
Cancer rates (crude per 1000 person-years) were
16.51, 15.75 and 10.62 for the CCBC, NCCBC and
AHTC respectively. Adjusted HRs (CI) of all cancer
for the CCBC compared to the NCCBC and AHTC
were 0.88 (0.86-0.89) and 1.01 (0.98-1.04) respec-
tively. Adjusted HRs (CI) of breast, prostate, and
colon cancer for the CCBC compared to the AHTC
were 0.95 (0.87-1.04), 1.07 (0.98-1.16) and 0.89
(0.81-0.98) respectively. Adjusted HRs (CI) of all
cancer for the CCBC compared to the NCCBC
were 0.88 (0.85-0.91), 0.98 (0.93-1.04), and 1.11
(0.98-1.27) for 0 to 5 years, 5 to 10 years, and ≥10
years of cumulative drug exposure respectively.
Conclusions: This study showed strong evidence that
CCB use is not associated with cancer. Shorter periods
of CCB exposure showed a small protective effect for
cancer, as did CCB exposure for colon cancer. Results
will be discussed in relation to other ﬁndings from
PROTECT work package two.
661. Spironolactone and Incidence of Cancers: A
Propensity Score Matched Cohort Study in the Clin-
ical Practice Research Datalink (CPRD)
Isla S Mackenzie, Alastair M Thompson, Li Wei,
Steve Morant, Thomas M MacDonald. Medicines
Monitoring Unit (MEMO), University of Dundee, Dundee,
United Kingdom.
Background: Spironolactone is widely used to treat
heart failure, high blood pressure and liver disease
and its use has increased in recent years. Spiro-
nolactone has various hormonal effects and historical
reports suggested possible links with increased risk
of certain types of cancer.
Objectives: Our a priori hypothesis was that spiro-
nolactone use may change the risk of certain
cancers. We investigated whether spironolactone
use was associated with the following pre-speciﬁed
primary outcomes: increased incidence of ovarian,
endometrial, pancreatic and colorectal cancers and
either increased or decreased incidence of prostate
cancer (based on biological plausibility); increased
incidence of renal cell, pharyngeal, thyroid and
myelomonoblastic/cytic leukaemias (based on previ-
ous publications).
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Methods: A pharmacoepidemiologicial propensity
score-matched cohort study was performed in the
CPRD between 1986 and 2013 to assess the effect of
spironolactone exposure on cancer incidence in the
UK population. Cox proportional hazards models were
used to analyse time from ﬁrst exposure to spiro-
nolactone to ﬁrst diagnosis of each pre-speciﬁed
cancer. Only conditions with >500 cases in the dataset
were retained as primary outcomes (excluded pharyn-
geal and myelomonoblastic/cytic leukaemia). Hazard
ratios (HR) were adjusted for age, sex and statistically
signiﬁcant covariates.
Results: There was no evidence of increased risk
associated with spironolactone use in the remaining 7
pre-speciﬁed primary outcomes. The risks of colorec-
tal cancer (HR 0.843; p = 0.002) and prostate cancer
(HR 0.769; p< 0.001) were lower with spironolactone
use. The risk of pancreatic cancer was signiﬁcantly
lower in some sensitivity analyses but not in the
primary analysis (HR 0.800; p = 0.066). There
was a dose-response relationship with incidence
of prostate cancer.
Conclusions: Spironolactone use was associated with
lower incidence of colorectal, prostate and possibly pan-
creatic cancers in this observational study. Of particular
interest is the lower incidence of prostate cancer, the
most common cancer in men in the UK. Further work
is needed to investigate this association.
662. Use of Statins and Prostate Cancer Mortality
Christian Dehlendorff,1 Charlotte Skriver,1 Christina G
Jespersen,2 Michael Borre,2 Mette Nørgård,3 Henrik T
Sørensen,3 Klaus Brasso,4 Jesper Hallas,5 Klaus K
Andersen,1 Søren Friis.1 1Danish Cancer Society
Research Center, Danish Cancer Society, Copenhagen,
Denmark; 2Department of Urology, Aarhus University
Hospital, Aarhus, Denmark; 3Department of Clinical
Epidemiology, Aarhus University Hospital, Aarhus,
Denmark; 4Department of Urology and Copenhagen Pros-
tate Cancer Center, Rigshospitalet, Copenhagen, Denmark;
5Clinical Pharmacology, Institute of Public Health, Univer-
sity of Southern Denmark, Odense, Denmark.
Background: Recent observational studies indicate
that statin use is associated with decreased mortality
from prostate cancer. Studies of statin use in relation
to prostate cancer prognosis are warranted.
Objectives: To evaluate whether use of statins im-
proves the prognosis of prostate cancer.
Methods: We conducted a population-based cohort
study by combining Danish nationwide administrative
and health registers. The cohort consisted of all Danish
men aged 35-85 years with a ﬁrst-time diagnosis of
prostate cancer between January 1997 and December
2010. Use of statins, aspirin, 5-alpha-reductase inhibi-
tors, non-aspirin NSAIDs, ACE-inhibitors and angio-
tensin-II antagonists were deﬁned as time-varying
covariates starting from date of diagnosis. Exposure
was deﬁned from the date of the second prescription.
Hazard ratios (HR) and 95% conﬁdence intervals
(CI) were computed for prostate cancer and all-cause
mortality based on a Cox proportional hazards model
using 1 year after diagnosis as baseline for follow-up.
HRs for prostate cancer or overall death with use of
statins were adjusted for age, year of prostate cancer
diagnosis, stage (localized, non-localized or un-
known), education, income, Charlson Comorbidity
Index score, diabetes, chronic obstructive lung disease
and the above drugs. Effect measure modiﬁcation was
estimated by including an interaction term between
pre-diagnostic and post-diagnostic statin use, as well
as between post-diagnostic statins use and age
(below/above 65 years) and stage, respectively.
Results: Among 34,284 patients with prostate cancer,
we identiﬁed 9,558 prostate cancer deaths and 13,124
deaths of any cause during a mean follow-up of 4 years
(maximum, 15 years). 11,815 patients used statins
following the prostate cancer diagnosis, and 6,715 pa-
tients had used statins within 2 years prior to diagno-
sis. We observed a 26% reduced prostate cancer
mortality rate among users of statins (HR= 0.74, CI
0.70-0.79). Likewise, a substantially reduced all-cause
mortality was observed (HR= 0.79, CI 0.75-0.83). No
substantial effect measure modiﬁcations by pre-
diagnostic use of statins, stage or age were observed.
Conclusions: Our ﬁndings support that use of statins
may improve the prognosis of prostate cancer.
663. Effectiveness of Herpes Zoster Vaccination
for Prevention of Post-Herpetic Neuralgia among
Individuals with Herpes Zoster
Hung Fu Tseng,1 Sara Tartof,1 Bruno Lewin,3 Craig Hales,2
Lina Sy,1 Rafael Harpaz,2 Stephanie Bialek,2 Kavya
Reddy,3 Po-ying Huang,3 Jeff Zhang,3 Sean Anand,1 Erin
Mary Bauer,3 Jennifer Chang,3 Steven Jacobsen.1
1Research and Evaluation, Kaiser Permanente, Pasadena,
CA, United States; 2Division of Viral Diseases, Centers for
Disease Control and Prevention, Atlanta, GA, United
States; 3Los Angeles Medical Center, Kaiser Permanente,
Los Angeles, CA, United States.
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Background: Post-herpetic neuralgia (PHN) is the per-
sistence of pain after resolution of herpes zoster (HZ) le-
sions. A large clinical trial showed that HZ vaccination
reduces HZ incidence by 51% in adults ≥60 years with
further reductions of PHN in subjects aged 70-79 years
who developed HZ despite vaccination. The effective-
ness of HZ vaccine in preventing PHN among persons
with HZ has not been evaluated in real world.
Objectives: Evaluate HZ vaccine effectiveness against
PHN among individuals with HZ.
Methods: The cohort study, conducted at Kaiser
Permanente (KP), consisted of immunocompetent
adults identiﬁed from electronic health records. The
vaccinated cohort consisted of 1,200 individuals who
were vaccinated against HZ at age ≥60 after 1/1/2007
and had an episode of HZ after vaccination. Unvacci-
nated individual were sex- and age- matched (1:1) to
vaccinated individuals and also had a documented
episode of HZ. Trained medical residents reviewed
medical record to determine the presence of HZ-
related pain at 30, 60, 90, and 180 days after HZ onset.
We deﬁned PHN as HZ-related pain lasting ≥ 90 days.
We compared the proportion of HZ cases progressing
to PHN between cohorts and calculated adjusted odds
ratios (aOR) and 95% conﬁdence intervals (CI) using
logistic regression.
Results: PHN occurred in 49 (4.08%) vaccinated and
90 (7.50%) unvaccinated individuals with HZ, with
an adjusted OR of 0.49 (95% CI: 0.34-0.72). The
estimate differed between sex. Twenty-six (3.45%)
vaccinated women experienced PHN, compared to
67 (8.90%) unvaccinated women (aOR 0.33, 95%
CI: 0.21-0.55). PHN occurred in 23 (5.15%) vacci-
nated men compared to 23 (5.15%) unvaccinated
men (aOR: 0.92, 95% CI: 0.49-1.72). The estimates
did not differ signiﬁcantly by age.
Conclusions: Previous HZ vaccination signiﬁcantly
reduced the proportion of HZ cases that progressed to
PHN in women, but not in men. This difference could
be explained in part by different patterns of health seek-
ing behavior, or by an as yet unrecognized biological
mechanism. Vaccination protects against painful se-
quelae of HZ through not only prevention of HZ but
may also prevent PHN when breakthrough HZ occurs.
664.Herpes Zoster InfectionRisk inAuto-Immune and
Inflammatory Diseases: Implications for Vaccination
HuifengYun,1,2 ShuoYang,2 LangChen,2KevinWinthrop,3
Fenglong Xie,2 John W Baddley,4 Kenneth G Saag,2 Singh
Jasvinder,2 Jeffrey R Curtis.1,2 1Department of Epidemio-
logy, University of Alabama at Birmingham, Birmingham,
AL, United States; 2Division of Clinical Immunology and
Rheumatology, University of Alabama at Birmingham,
Birmingham, AL, United States; 3Division of Infectious
Disease, Oregon Health & Science University, Portland,
OR,United States; 4Division of InfectiousDisease, University
of Alabama at Birmingham, Birmingham, AL, United States.
Background: Herpes zoster (HZ) vaccine is recom-
mended for healthy people age ≥ 60 years in US. It is
unclear whether the absolute risk for younger patients
with autoimmune or inﬂammatory (AI) diseases is
high enough to warrant vaccination.
Objectives: To evaluate the overall and age-stratiﬁed
absolute incidence of HZ infection associated with dif-
ferent AI diseases compared to healthy older adults
who are recommended for vaccination by the CDC.
Methods: Using 2007-2010 Multi-Payer Claims Data-
base, we assembled 7 AI disease cohorts who had ≥ 13
months continuous medical and pharmacy coverage.
Patients with at least one prescription and two diagno-
ses of rheumatoid arthritis (RA), psoriasis arthritis
(PsA), psoriasis (PsO), ankylosing spondylitis (AS),
inﬂammatory bowel disease (IBD), Lupus (SLE), gout
were included and compared with healthy patients with-
out any AI diseases. We identiﬁed HZ using diagnosis
codes and antiviral agent + - 30 days. Age-adjusted
incidence rates (AAIR) per 1,000 person-years were
calculated. Multivariable Cox regression models
determined the hazard ratio (HR) for HZ across cohorts.
Results: We identiﬁed 59,000 patients with RA, 2,742
with PsA, 4,422 with PsO, 1,192 with AS, 8,710 with
IBD, 11,342 with SLE, 70,736 with gout, 176,868 with
diabetes and 188,621 in the healthy cohort. The AAIRs
among the 7 disease cohorts ranged from a high of 14.1
per 1,000 person years (SLE) to a low of 3.9 (gout).
AAIR was 3.0/1000for healthy cohort. The age-speciﬁc
rate of HZ for RA and SLE patients age>=40 (with or
without the use of glucocorticoid (GC)) were greater
than the corresponding rate in healthy cohort age>=60.
Compared with the healthy cohort, the adjusted HR for
RA (1.4, 95% CI: 1.2-1.5), Gout (1.4,1.2-1.5), IBD
(1.8,1.5-2.1) and SLE (2.1,1.8-2.4) were increased sig-
niﬁcantly. HR for Biologic use was 1.4 (1.2-1.6). HZ
vaccination (HR: 0.68) and lack of use of GC (HR:
0.60) were inversely associated with HZ.
Conclusions: RA, Gout, IBD and SLE are associated
with an increased risk of HZ infection compared to
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healthy people. Based on absolute risk compared to
healthy people age ≥ 60, RA and SLE patients age
=40 may beneﬁt from vaccination for HZ.
665. Utilization of Nordic Countries National Regis-
tries to Monitor the Impact of HPV Vaccination
Kai-Li Liaw,1 Susanne Kruger Kjaer,2 Mari Nygard,3
Joakim Dillner.4 1Epidemiology, Merck Research Labora-
tories, North Wales, PA, United States; 2Virus, Lifestyle
and Genes, Danish Cancer Society Research Center,
Copenhagen, Denmark; 3Cancer Registry of Norway,
Oslo, Norway; 4Medicine; Medical Epidemiology and
Biostatistics, Karolinska Institute, Stockholm, Sweden.
Background: A quadrivalent vaccine HPV vaccine
(qHPV), GARDASILTM, was licensed in 2006 to pre-
vent HPV 6, 11, 16, and 18-related diseases.
Objectives: A multi-country surveillance study was im-
plemented to evaluate national HPV vaccination programs
between 2007 and 2011 following the licensure of qHPV.
Methods: In Denmark, Norway and Sweden, where
qHPV vaccination programs have been implemented,
nationwide registries were linked using unique per-
sonal identiﬁcation numbers to evaluate incidence of
cervical cancer and precursors by vaccination status.
Furthermore, HPV typing was performed on existing
cervical cytology and histology samples collected
through routine cervical screening, immediately before
and 5 years after qHPV licensure to monitor potential
changes in HPV types.
Results: Preliminary data showed that, in Denmark, the
country with the highest and earliest vaccine uptake, the
incidence rates of abnormal Pap smear in vaccinated
females decreased, especially in the younger birth co-
horts that had a higher vaccine uptake and lower likeli-
hood of pre-vaccination HPV exposure (relative risk
(RR) = 0.51, 95% CI 0.37-0.70 in the 1993-1994 birth
cohort and RR= 0.59, 95% CI 0.58-0.82 in the 1991-
1992 birth cohort). Five years after qHPV licensure, a
30% and 46% reduction in HPV 16/18 and HPV 6/11
(the 4 types included in qHPV) were observed respec-
tively in the nationally representative cytology samples
from women under 26 years of age, compared to a 16%
reduction for any HPV types. Data from Norway and
Sweden, where organized vaccination started later,
trended similarly but less pronounced.
Conclusions: HPV vaccine impact on cervical lesions
can be detected as early as 5 years after program
implementation. As the vaccinated birth cohorts reach
the recommended age of organized cervical screening
(23-25 years of age in the Nordic region), the registry
systems can be used to further estimate the effective-
ness of HPV vaccination and evaluate the full popula-
tion impact of the vaccine.
666. Accuracy of Administrative Claims Data to
Identify Dose Specific Rotavirus Vaccination Infor-
mation: Implications for Studies of Vaccine Safety
T Christopher Mast,1 Scott Quinlan,2 Nancy Santanello,1
Steve Lanes.2 1Epidemiology, Merck Research Laborato-
ries, North Wales, PA, United States; 2HealthCore, Inc,
Alexandria, VA.
Background: Large claims databases have recently
been used to assess the safety of multi-dose pediatric
rotavirus vaccines. The analyses have focused on
health outcomes observed within 7-days after each
dose. However, little is known about the accuracy of
claims data to reﬂect vaccine timing and dose number.
Objectives: To compare rotavirus vaccination history
in claims data with that in medical records (MR).
Methods: A retrospective cohort study was conducted
using a US national longitudinal claims database. The
study population included infants who received ≥ 1
dose of RotaTeq® during the ﬁrst year of life from 2/
1/06 to 11/30/12; infants were randomly sampled
to obtain 129 completed MR abstractions of demo-
graphic and dose administration data. For each
claims-based RotaTeq® dose, MR review deter-
mined: 1) correct brand; 2) if the administration
date was within ± 7 days of the claims date; and 3)
if the vaccine dose number in the MR matched
the claims data. The study outcome was expressed
as positive predictive value (PPV) and 95% conﬁ-
dence interval (CI) for overall accuracy of 1st,
2nd, and 3rd claims-base dose data.
Results: 272,142 infants were found to have received
≥1 dose of RotaTeq® in the 1st year of life. Of 129
infants sampled for MR review, the brand was incor-
rect for 3(2.3%), 1(1%) and 0 of 1st (n = 129), 2nd
(n = 103), and 3rd (n = 77) doses of RotaTeq®, respec-
tively. The percent(n) of claims-based doses with
no RotaTeq® vaccination in the MR within ± 7 days
of the claims-based administration date was 7.8%
(10), 6.8% (7) and 1.3% (1) for 1st, 2nd and 3rd
doses of RotaTeq®, respectively. Of 129 claims-
based 1st doses, 94 (72.9%) were identiﬁed in MR
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as 1st doses, 13 were 2nd doses, 11 were 3rd
doses, and one was a 4th dose. Thus, PPV
for 1st dose = 72.9% (95% CI: 64.3-80.3%). The
PPV for claims-based 2nd and 3rd doses was
78.6% (95% CI: 69.5-86.1%) and 93.5% (95% CI:
85.5-97.9%), respectively.
Conclusions: Studies assessing health outcomes
associated with temporal risk windows after speciﬁc
rotavirus vaccine doses (especially dose 1) should
consider using chart validated exposure data to avoid
exposure misclassiﬁcation.
667. Narcolepsy and Pandemic H1N1 Vaccine: A
Simulation Study to Explore the Effect of Bias
Caitlin N Dodd,1 Leonoor Wijnans,1,2 Maria AJ de
Ridder,1 Silvana A Romio,1,3 Daniel Weibel,1 Jan
Bonhoeffer,4,5 Miriam CJM Sturkenboom.1 1Medical
Informatics, ErasmusUniversityMedical Center, Rotterdam,
Netherlands; 2Medicines Evaluation Board, Utrecht,
Netherlands; 3Statistics and Quantitative Methods, Uni-
versity of Milano-Bicocca, Milan, Italy; 4Paediatric
Infectious Diseases and Vaccines, University Children’s
Hospital, Basel, Switzerland; 5Brighton Collaboration,
Basel, Switzerland.
Background: In the summer of 2010, reports which
were widely covered in the media, were published
on a potential association between Pandemrix and
narcolepsy in children aged 5 to 19 years.
Narcolepsy is a rare and under-diagnosed disease,
with aspeciﬁc onset and a long onset to diagnosis
interval. Subsequent studies focused on rapid as-
sessment reported relative risks as high as 12. All
studies published so far included follow-up time
during which the media attention was present
leading to detection bias; in addition some studies
used unblinded case validation and assessment of
onset date.
Objectives: Through simulations we aim to explore
the effect of media attention on the strength of the
association between Pandemrix and narcolepsy.
Methods: We simulated a population of children to
whom we assigned a probability of developing
narcolepsy and a probability of being vaccinated based
upon reported narcolepsy incidence and vaccination cov-
erage. Given narcolepsy onset, we assigned an interval
between onset and diagnosis based upon published data
using a gamma distribution. We applied detection bias
by reducing, between zero and 90%, the time from onset
to diagnosis in vaccinated cases following the beginning
of media attention. We simulated misclassiﬁcation of
onset date by resetting the date of onset to the period fol-
lowing vaccination in a subset of cases using a range of
probabilities of misclassiﬁcation from zero to 60%. These
simulated data sets were analyzed using standard cohort
and case control methods.
Results: The application of detection bias and misclas-
siﬁcation of onset each increased the relative risk of
narcolepsy following vaccination. With a 90% reduc-
tion in time from onset to diagnosis, a 60% probability
of recall bias among vaccinees diagnosed following
media coverage, and including only those cases with
onset before media coverage, we obtained a relative
rate of 12.06 (95%CI 5.45, 26.79) in the absence of a
vaccine association.
Conclusions: Our simulations show that stimulated
diagnosis of vaccinated cases following media atten-
tion, combined with misclassiﬁcation of onset dates,
could inﬂate estimates of relative risk of narcolepsy
following Pandemrix vaccination.
668. Safety of Seasonal Influenza Vaccination in
Solid Organ Transplant Recipients
GaëlDos Santos,1 FrançoisHaguinet,1GermanoLCFerreira,1
Dave Webb,2 John Logie,2 Dominique Rosillon,1
Vivek Shinde,1 Catherine Cohet.1 1Global Epide-
miology, GlaxoSmithKline Vaccines, Wavre, Belgium;
2WW Epidemiology, GlaxoSmithKline R&D, Stockley
Park, United Kingdom.
Background: Seasonal inﬂuenza vaccination is an
important public health measure recommended for
transplant recipients, due to the elevated risk of com-
plications associated with inﬂuenza infection. Safety
data on the association between solid organ transplant
rejection and vaccination with a trivalent inﬂuenza
vaccine (TIV) are limited.
Objectives: To assess the risk of solid organ (liver,
kidney, lung, heart, pancreas) transplant rejection after
vaccination with a TIV.
Methods: Self-controlled case-series (SCCS) analysis
using the UK Clinical Practice Research Datalink
General Practitioner OnLine database (CPRD
GOLD) and the linked Hospital Episodes Statistics
(HES) database. Algorithms were developed to
identify rejection events and covariates of interest
(time since transplantation, previous rejections,
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bacterial/viral infections, malignancies). The end-
point was the occurrence of at least one rejection
during any of the three inﬂuenza seasons 2006/07,
2007/08 and 2008/09. The risk periods were 30
and 60 days after TIV vaccination. Analyses were
conducted using the SCCS method for perturbed
post-event exposure.
Results: A total of 132, 136, and 168 subjects had at
least one rejection in seasons 2006/07, 2007/08 and
2008/09, respectively; an overall 45-51% received a
TIV. The analysis included 218 subjects, of which 156
(72%) were exposed cases. Relative incidence (RI) of
rejection of any of the ﬁve organs, adjusted for time
since transplantation, was 1.01 (95%CI: 0.58, 1.76)
and 0.88 (95%CI: 0.56, 1.38), 30 and 60 days after vac-
cination, respectively. Results were mainly driven by
kidney, the most commonly transplanted organ, with
RIs of 0.91 (95%CI: 0.44, 1.87) and 0.59 (95%CI:
0.32, 1.08), in the 30- and 60-day risk periods, respec-
tively. Risk estimates remained in a range of 0.6 to 1.3
across seasons and various sensitivity analyses, with
upper 95%CI limits below 3.0.
Conclusions: These results suggest no increased risk
of rejection following TIV vaccination in solid organ
transplant recipients and inform the beneﬁt-risk assess-
ment for seasonal inﬂuenza vaccination recommenda-
tions in this risk group.
669. Modelling the Predicted Net Impact of Contra-
indication: the Example of Glaucoma Treatment
Andrew Maguire,1 Francisco J de Abajo.2 1OXON
Epidemiology Ltd, London, United Kingdom; 2Departa-
mento de Ciencias Biomédicas, Universidad de Alcala de
Henares, Madrid, Spain.
Background: When patients are contraindicated one
therapy an alternative treatment is required. The alter-
native may have its own safety issues and may also be
less effective than the original therapy. It is thus im-
portant to predict the net impact of contraindication
before it is enforced.
Objectives: To predict the net impact of a contraindi-
cation via a worked example of glaucoma treatment.
The objectives are to demonstrate how event simula-
tion models can quantify the beneﬁts and harms of
the treatment option given to the contraindicated
population. The outcomes are heart failure “HF” and
bronchoconstriction (COPD/asthma). Incident and
exacerbation, case fatality and overall mortality are
modelled. We also aim to demonstrate how uncer-
tainty is incorporated.
Methods: Rates of each outcome and the charact-
eristics of the patient population (n = 17632) were
obtained from the THIN database. Patients were
assigned risks for each event using random distribu-
tions and relative risks were used to deﬁne exposure
to timolol or latanoprost. The relative risk (timolol vs.
latanoprost) for COPD/asthma exacerbation was 1.47
(95% CI:1.04-2.09) and for HF was 0.85 (0.72-1.0).
Hence we assumed that timolol has a protective effect
on HF that is lost when latanoprost is used. Case-fatality
used randomly assigned rates from published rates and
SE. Other deaths were modelled using national rates.
Uncertainty is incorporated into all the input parameters
and then events were simulated using the Exponential
distribution. Two cohorts were simulated using the
identical set of patients: 1) no contraindication: timolol
only; 2) contraindication: timolol except for COPD/
asthma patients who are given latanoprost. Both cohorts
were simulated 1000 times.
Results: The prevalence of COPD/asthma was 15.7%.
Contraindication would reduce the number of COPD/
asthma cases by 54.0 (SD= 12.7) whilst increasing
the number of cases of HF by 3 (SD= 10.2). There is
a net reduction of 9.6 deaths (SD= 25.5).
Conclusions: This hypothetical worked example
would indicate that the contraindication decreases
COPD/asthma cases and this is not offset by the
increase in HF. This example is not a formal risk
assessment of glaucoma treatment.
670. Patients’ Preferences for Benefits and Risks of
Anticoagulant Therapy: A Discrete Choice Experi-
ment (DCE)
Mehdi Najafzadeh, Joshua J Gagne, Niteesh K Choudhry,
Jennifer M Polinski, Jerry L Avorn, Sebastian
Schneeweiss. Division of Pharmacoepidemiology and
Pharmacoeconomics, Department of Medicine, Harvard
Medical School, Boston, MA, United States.
Background: With proliferating treatment options for
anticoagulant therapy, physicians and patients must
choose among them based on their beneﬁts and risks.
Patients’ preferences can be integrated into these deci-
sions to help deﬁne net beneﬁts of medications.
Objectives: To elicit patients’ relative preferences for
speciﬁc beneﬁts and risks of anticoagulant therapy.
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Methods: We selected a sample of U.S. patients with
cardiovascular disease from an online panel and con-
ducted a DCE to elicit patients’ relative preferences
for beneﬁts and risks of anticoagulant therapy: non-
fatal stroke, non-fatal myocardial infarction (MI), car-
diovascular death, minor bleeding, major bleeding,
bleeding death, and need for international normalized
ratio (INR) monitoring. These attributes were used to
design scenarios describing hypothetical treatments
that were randomly labeled as “new drug”, “old drug”,
or “no drug” and presented in 14 consecutive choice
questions. Conditional logistic regression was used
to estimate relative preferences and latent class
analysis was used to identify groups of patients with
similar preferences. We calculated Maximum Ac-
ceptable Risks (MARs), the magnitude of risk that
patients were willing to accept for each attribute in
exchange for avoiding a 1% increase in risk of a
fatal bleeding event.
Results: 341 patients completed all DCE questions.
MARs suggested that on average, patients valued a
1% increased risk of a fatal bleeding event the same
as a 2% increase in non-fatal MI, a 3% increase in
non-fatal stroke, a 3% increase in cardiovascular
death, a 6% increase in major bleeding, and a 16%
increase in minor bleeding. Patients were disinclined
to choose a proﬁle labeled “no drug” or “old drug”
independent of the probabilities of beneﬁts and risks
it contained. Prior stroke or MI was associated with
membership in the class with larger negative prefer-
ences for these outcomes.
Conclusions: Patients’ preferences for various out-
comes of anticoagulant therapy vary and depend on
their prior experiences with MI or stroke. Incor-
porating these preferences into calculation of net
beneﬁts and treatment decisions can enhance patient-
centered care.
671. Comparing Incremental Net Benefit (INB)
of Apixaban, Dabigatran, Rivaroaxaban, and
Warfarin in Patients with Atrial Fibrillation (AF)
Mehdi Najafzadeh, Sebastian S Schneeweiss, Niteesh
K Choudhry, Amanda R Patrick, Jennifer M Polinski,
Jerry L Avorn, Joshua J Gagne. Division of Pharma-
coepidemiology and Pharmacoeconomics, Department
of Medicine, Harvard Medical School, Boston, MA,
United States.
Background: Quantitatively comparing the beneﬁts
and harms of anticoagulants is challenging, requiring
a uniﬁed framework to measure various outcomes on
a common scale. The INB approach incorporates pa-
tients’ stated preferences and enables quantitative ben-
eﬁt-risk analyses and head-to-head drug comparisons.
Objectives: To compare the INB of apixaban,
dabigatran (150mg), rivaroxaban, and warfarin in pa-
tients with AF.
Methods: We used the INB framework to simulta-
neously account for event probabilities and preference
weights of ischemic stroke and major hemorrhage.
Event probabilities were derived from indirect compari-
sons of the efﬁcacy and safety of the 3 drugs among
patients with CHADS(2) scores ≥3, based on data from
randomized trials against warfarin (RELY, ARIS-
TOTLE, ROCKET-AF). Relative weights of outcomes
were based on Maximum Acceptable Risks (MAR) es-
timated from a discrete choice experiment (DCE) in a
sample of 341 U.S. patients with cardiovascular disease
who completed an online survey. We used Monte Carlo
simulation to estimate 95% credible intervals (CIs).
Results: Patients were willing to accept a maximum
2.28% (95% CI: 1.79- 2.88) risk of major hemorrhage
to avoid 1% increase in risk of ischemic stroke.
Integrating these weights with differences in the drugs’
efﬁcacy and safety resulted in an INB of 1.48% (95%
CI: 0.7- 2.22), for apixaban vs. warfarin, equal to a
1.48% reduction in stroke equivalents. The INB was
0.68% (95% CI: -0.12 - 1.47) for dabigatran, and
0.29% (95% CI: -0.20- 0.78) for rivaroxaban, com-
pared to warfarin. The INB was 0.80% (95% CI: -
0.26- 1.88) for apixaban vs. dabigatran, 1.19% (95%
CI: 0.33- 2.06) for apixaban vs. rivaroxaban, and 0.39%
(95% CI: -0.55- 1.31) for dabigatran vs. rivaroxaban.
Conclusions:Apixaban has a signiﬁcantly positive INB
relative to warfarin and rivaroxaban. The INBs of
dabigatran vs. warfarin, rivaroxaban vs. warfarin,
apixaban vs. dabigatran, and dabigatran vs. rivaroxaban
were also positive but smaller and the CIs included zero.
The INB balances beneﬁts and risks of anticoagulants
and provide a quantitative, patient-centered aid for
treatment decisions among these agents.
672. Comparison of ATRIA and CHA2DS2-VASc
Risk Stratification Schemes for the Prediction of
Stroke in the Individual Patient with Atrial Fibrilla-
tion and the Impact on Treatment Decisions
Hendrika A van den Ham,1 Olaf H Klungel,1 Daniel
E Singer,2 Hubert GM Leufkens,1 Tjeerd P van Staa.1,3
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1Pharmacoepidemiology and Clinical Pharmacology,
Utrecht Institute for Pharmaceutical Sciences,
Utrecht University, Utrecht, Netherlands; 2De-
partment of Epidemiology, Massachusetts General
Hospital, Boston, MA, United States; 3Department
of Epidemiology and Population Health, London
School of Hygiene & Tropical Medicine, London,
United Kingdom.
Background: Atrial ﬁbrillation (AF) increases the risk
of ischaemic stroke and treatment with anticoagulants
should be prescribed according to stroke risk.
Objectives: To compare the predictive ability of the
currently recommended CHA2DS2-VASc ischaemic
stroke risk score with the new ATRIA stroke risk score
in patients with atrial ﬁbrillation (AF). Furthermore,
we assessed how treatment decisions would be altered
when different risk stratiﬁcation would be used in
daily practice.
Methods: Patients with AF, not using warfarin, were
assembled from the Clinical Practice Research
Datalink (CPRD) database. Patients were followed
from date of AF diagnosis until occurrence of ischae-
mic stroke, prescription of warfarin, death or the end
of study. Independent predictors of ischaemic stroke
were identiﬁed with a Cox proportional hazard model
by stepwise backward selection. The c-index assessed
the discriminative ability of the risk schemes. Net
reclassiﬁcation improvement (NRI) assessed net
correct risk reclassiﬁcation using ATRIA versus
CHA2DS2-VASc, using published point score cut-
offs. As correct stroke risk thresholds for low/
moderate/high risk, 1% and 2% per year were used.
Results: A total of 60,594 patients were included. The
overall stroke rate was 2.45% per year. Age and
previous stroke were the strongest predictors of
ischaemic stroke. Other independent predictors were
hypertension (HR 1.25 CI 95%, 1.15-1.35) and
diabetes (HR 1.27 CI 95%, 1.14-1.41). Vascular
disease and heart failure were not signiﬁcant predic-
tors. For the full point scores, the c-index was 0.71
(CI 95%, 0.70-0.72) for the ATRIA score and 0.69
(CI 95%, 0.68-0.70) for the CHA2DS2-VASc score.
The NRI was 0.38 for ATRIA compared to the
CHA2DS2-VASc-score, resulting entirely from down-
ward reclassiﬁcation.
Conclusions: The ATRIA score had better discrimina-
tive ability than CHA2DS2-VASc. The CHA2DS2-
VASc-score assigns most AF patients to the moderate
and high risk categories, which could lead to overtreat-
ment. In this community-based, low-risk cohort, the
ATRIA score correctly reclassiﬁed patients as
lower risk.
673. Testosterone Laboratory Testing and
Testosterone Supplementation Use among Adult
Males in Denmark
Thomas Bøjer Rasmussen,1 Helene Nørrelund,1
Sinna Pilgaard Ulrichsen,1 J Bradley Layton,2
M Alan Brookhart,2 Henrik Toft Sørensen,1
Christian Fynbo Christiansen.1 1Department of Clinical
Epidemiology, Aarhus University Hospital, Aarhus N,
Denmark; 2Department of Epidemiology, UNC Gillings
School of Global Public Health, University of North
Carolina, Chapel Hill, NC, United States.
Background: Testosterone testing and supplementa-
tion is increasing, but population-based data character-
izing patients with testosterone testing are limited.
Objectives: To characterize patients with a ﬁrst testos-
terone laboratory test by testosterone level, in terms of
concurrent disease, testosterone and other drug use,
and other laboratory tests.
Methods: We used population-based databases to
conduct a cross-sectional study in Northern Denmark
during 2002-2011 among all male citizens aged 18+
(0.8 million adult male) who had ﬁrst testosterone test
and survived at least 90 days after the test. We assessed
concurrent (+/- 90 days) diagnoses, laboratory tests, and
prescriptions ﬁlled at community pharmacies, including
any prescriptions for testosterone within 90 days after a
test. We categorized patients according to testosterone
levels, using age-speciﬁc reference ranges. Patient
characteristics were described by proportions.
Results: A total of 12,756 patients had a testosterone
laboratory test during the study period (median age:
54 years). Among 10,982 patients with available mea-
surement results, 3,729 patients (34%) had a low level,
7,148 (65%) had a normal level, and 105 (1%) had a high
testosterone level. Only 82 (2%) of patients with a low
testosterone level ﬁlled any prescription for testosterone
at a community pharmacy ; 31 (0.8%) were new users.
Among patients with a testosterone test, 21% had a
cancer diagnosis and 17% received opioids. Out of
295 patients (2%) diagnosed with a pituitary disease,
117 had a low testosterone level and thus could receive
testosterone from a hospital pharmacy (not captured in
the records of community pharmacies). Only 62 of
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patients with low testosterone level were diagnosed
with a primary testicular disease.
Measurement of luteinizing hormone to distinguish
primary and secondary hypogonadism was performed
in 29% of patients with low testosterone level.
Conclusions: In Denmark, many testosterone mea-
surements are performed in patients with cancer, and
less commonly in patients with pituitary and testicular
disease. Compared with the US and the UK, only few
patients with low testosterone levels ﬁlled a prescrip-
tion for testosterone.
674. Time-Dependent Impact of Pre-Infarction An-
gina Pectoris and Intermittent Claudication on Mor-
tality Following Myocardial Infarction as Measures
of Inherent Local and Remote Ischemic Precondi-
tioning: A Danish Nationwide Cohort Study
Morten Schmidt,1,2 Erzsébet Hovath-Puho,1 Lars
Pedersen,1 Hans E Bøtker,1 Henrik T Sørensen.2
1Department of Clinical Epidemiology, Aarhus University
Hospital, Aarhus, Denmark; 2Department of Cardiology,
Aarhus University Hospital, Aarhus, Denmark.
Background: Local and remote ischemic precondi-
tioning are cardioprotective mechanisms.
Objectives: To examine the time-dependent impact of
pre-infarction angina pectoris and intermittent claudi-
cation on short- and long-term mortality from myocar-
dial infarction (MI).
Methods: We conducted a nationwide population-
based cohort study using medical registries. We
identiﬁed all ﬁrst-time hospitalizations for MI in
Denmark between 1996 and 2012 (n = 150,480).
We used Cox regression to compute mortality rate
ratios (MRRs) within 30 days, 31-365 days, 1-5
years, and 6-10 years comparing patients with and
without previous angina or intermittent claudication.
We repeated the analyses according to time
between angina or intermittent claudication and
subsequent MI (7 days or less, 8-14 days, 15-30
days, 31-90 days, and more than 90 days). We
adjusted for age, sex, calendar period of diagnosis,
and comorbidities.
Results: Compared to patients without previous sta-
ble or unstable angina, the adjusted 30-day MRR
was 0.85 (95% CI: 0.82-0.88) for patients with
prior stable angina and 0.67 (95% CI: 0.61-0.74)
for patients with prior unstable angina. The
mortality reduction was higher the shorter time in-
terval between angina presentation and MI and
higher for unstable than stable angina. Thus, the
30-day MRR was 0.33 (95% CI: 0.20-0.55) for pa-
tients presenting with unstable angina within 7 days
before MI compared to MI patients without previ-
ous angina. Beyond 30-days of follow-up, there
was no additional survival beneﬁt of pre-infarction
angina. Independent of time to MI, patients with
intermittent claudication had increased short- and
long-term mortality.
Conclusions: Pre-infarction angina, but not inter-
mittent claudication, improved 30-day mortality
following MI. The dependency of time and angina
type, suggests an effect of endogenous local ische-
mic preconditioning. The results for intermittent
claudication may reﬂect an absent remote precondi-
tioning effect or the higher comorbidity burden
among these patients.
675. The Common Data Model: Lessons from Past
Projects and Ongoing Initiatives
Patrick Ryan,1 Morten Anderson,2 Martijn Schuemie,3
Alison Burke,4 Kevin Haynes,5 Kenneth Man,6 Helga
Gardarsdottir,7 Marie L De Bruin.8 1Epidemiology,
Janssen Research and Development, Titusville, United
States; 2Karolinska Institutet, Stockholm, Sweden;
3Epidemiology, Janssen Research and Development,
Rotterdam, The Netherlands; 4CSD MR UK, CSD
Medical Research, London, United Kingdom;
5University of Pennsylvania, Philadelphia, United
States; 6Department of Pharmacology and Pharmacy,
University of Hong Kong, Hong Kong, Hong Kong;
7UMCUtrecht, Utrecht, The Netherlands; 8Utrecht
Institute for Pharmaceutical Sciences, Utrecht
University, Utrecht, The Netherlands.
Background: Multi-database studies face unique
challenges beyond the routine epidemiological
studies.
Observational research initiatives, like OMOP,
MiniSentinel, EUADR, PROTECT, EMIF and ASPEN,
have demonstrated the value of collaborative research
and offer potential for improving the power and relia-
bility of epidemiologic studies.
Objectives: In this workshop we will give an
overview of the methods applied and challenges
encountered in multi-database drug effect studies.
Practical experiences from Europe, the US and Asia
will be shared.
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Description: (1) Overview of data standardization
methods used in common data models (Patrick Ryan,
20min)
(2) Overview of methods applied to combine data,
results from a systematic review of the CARING
consortium (Morten Anderson, 20min)
(3) Perspectives from ongoing initiatives (10min each)
(a) EU – Martijn Schuemie
(b) US – Kevin Haynes
(c) Asia – Kenneth Man
(4) Open panel discussion – all panelists (chaired by
Marie L De Bruin, 20min)
In this workshop, we will present experiences of
implementing a common data model, and engage the
audience in an open discussion about the expectations
and challenges for standardizing data for collaborative
network–based analyses.
676. Comparisons in Pharmacoepidemiology: New
Challenges and Limitations of Current Approaches
Saad AW Shakir,1,2 Deborah Layton,1,2 Olaf H Klungel,3
Tjeerd Van Staa.4 1Drug Safety Research Unit,
Southampton, United Kingdom; 2School of Pharmacy
and Biomedical Science, University of Portsmouth,
Portsmouth, United Kingdom; 3Utrecht Institute for
Pharmaceutical Sciences, Utrecht University, Utrecht,
Netherlands; 4London School of Hygeine and Tropical
Medicine, London, United Kingdom.
Background: Undertaking robust comparisons in
pharmacoepidemiological (PE) and comparative effec-
tiveness (CE) studies are a major challenge. In these
designs certain subject characteristics may inﬂuence
the probability of exposure and the researcher cannot
control allocation to treatment or the conditions under
which treatment is given. Hence there is the potential
for non-random selection into a cohort, and if
appropriate, the comparator group(s). Methodological
advances in statistical analyses allow exploration of
observed (and unobserved) characteristics affecting
selection, but have their limitations. Problems with
comparisons have become more difﬁcult with the wide-
spread application of clinical guidelines (national/
regional), pharmacoeconomic policies and policies for
reimbursement, all of which determine treatment
choices thus introducing selection biases which are
beyond the capabilities of existing methods to handle.
Objectives: To explore current challenges to the de-
sign of postmarketing studies of medicines for which
there are signiﬁcant external inﬂuences governing
use and discuss possible solutions.
Description: There will be a series of four didactic
presentations from pharmacoepidemiologists covering
the challenges of study designs where inference
regarding differences between new and existing
agents is of interest, as well as proposing approaches
to handle the problems using real world-examples.
The session will also include a substantial time for
panel discussion.
The session will feature the following topics and
presenters (shown by initials)
(1) How guidelines and other external factors e.g.
pharmacoeconomic policies limit (and sometimes
prohibit) the use of comparators in PE studies
with examples of approaches to handle these
challenges (SAWS)
(2) Pragmatic Trials and Propensity Matching:
Methods to minimise the confounding problems
of observational research (TVS)
(3) Lessons from Social Science: The contextual com-
parator to characterise adoption vs counterfactual
comparator to compare risks (DL)
(4) Using guidelines to identify a prognostically com-
parable untreated comparator group (OK).
677. How to Bridge the Gap between Requirements
of Regulatory and Health Technology Assessment
Authorities for Post Authorization Studies? Exam-
ples from Europe and Asia
Massoud Toussi,1 Nicholas Moor,2 K Arnold Chan,3
Ian CK Wong.4 1Epidemiology and Safety, Europe,
IMS Health, Paris La Défense, Ile-de-France, France;
2Department of Pharmacology, University of Bordeaux,
Bordeaux, France; 3Department of Medical Research,
NTU Hospital, Taipei, Taiwan; 4Department Pharmacol-
ogy and Pharmacy, University of Hong Kong, Hong Kong,
Hong Kong.
Background: Health technology assessment (HTA)
authorities generally explore additional characteristics
of medicines and complete the efﬁcacy and safety
assessment carried out by regulatory authorities. This
pattern is changing and the overlap between the
requirements of regulatory and HTA bodies is
growing. As an example, the introduction of post
authorization efﬁcacy studies (PAES) on top of post
authorization safety studies (PASS) in the European
regulatory guidelines presents methodological and
logistic challenges for addressing both objectives in
post authorisation studies.
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Objectives: To review the requirements of regulatory
and HTA authorities for real life evidence with
examples of collaborative initiatives across the world,
especially in the European Union (EU) and Asia,
which facilitate bridging the gaps between these
requirements. To debate on the possibility and per-
spectives of a global harmonization of methodological
standards for post authorization studies.
Description: Four speakers from EU and Asia with
academic and research industry background will
review and discuss examples of ongoing collaborative
initiatives between regulatory and HTA bodies across
the world. Examples of collaboration such as the
HTA working group of the European Network of
Centres for Pharmacoepidemiology and Pharma-
covigilance (ENCePP-HTA), and the use of the National
Health Insurance database in Taiwan and Clinical
Data Analysis & Reporting System (CDARS) in
Hong Kong will be presented. Speakers will dem-
onstrate the helpful role of scientiﬁc networks in
bridging the gap between health authorities’
requirements for addressing safety and effectiveness
endpoints in post authorization studies. They will
debate in an interactive session on the perspectives
of an internationally acceptable set of vocuabulary
and standards for post authorization studies, similar
to those of the International Conference for
Harmonisation (ICH) on clinical trials.
678. Multi-National Pharmacoepidemiological
Studies in Asia - Methodological Challenges and
Potential Cross-Continental Collaboration
Edward Chia-Cheng Lai,1,2 Ian Douglas,3 Kiyoshi Kubota,4
Byung Joo Park,5 Nicole Pratt,6 Ian Wong,7 Yea-Huei Kao
Yang,1 Soko Setoguchi.2 1Institute of Clinical Pharmacy
and Pharmaceutical Sciences, National Cheng- Kung Uni-
versity, Tainan, Taiwan; 2Duke Clinical Research Institute,
Duke University School of Medicine, Durham, NC, United
States; 3Epidemiology and Population Health, London
School of Hygiene and Tropical Medicine, London, United
Kingdom; 4Department of Pharmacoepidemiology, Univer-
sity of Tokyo, Tokyo, Japan; 5Ofﬁce of Drug Utilization
Review, Korea Institute of Drug Safety and Risk Manage-
ment, Seoul, Republic of Korea; 6Quality Use of Medicines
and Pharmacy Research Centre, Sansom Institute for
Health Research, University of South Australia, Adelaide,
Australia; 7Department of Pharmacology and Pharmacy,
University of Hong Kong, Hong Kong, Hong Kong.
Background: Collaborative research networks exist to
facilitate the prompt identiﬁcation and validation of
emerging safety issues nationally and internationally.
Multi-databases studies, across countries and conti-
nents, would provide great opportunities but also
challenges for pharmacoepidemiologists to precisely
assess medication safety and effectiveness.
Objectives: To outline opportunities and chal-
lenges faced by pharmacoepidemiologists when
conducting multi-national databases studies. We
will also address 1) differences in databases and
health policy that affect the analysis and interpreta-
tion of safety or effectiveness results as well as
opportunities using our recent experiences, and 2)
practical issues and potential solutions to pool
and compare database speciﬁc results.
Description: Five presenters will address the topics
described below. The session will end with panel
discussion to answer questions and elaborate on the
feasibility and future opportunities about collaborative
database researches in pharmacoepidemiology across
countries and continents.
Moderators: Yea-Huei Kao Yang, Soko Setoguchi,
and Byung Joo Park (total 90 mins)
(1) Recent experiences and opportunities in Asia
and Europe
(1-1) Challenges of cross-continental studies assessing
drug safety in Asia (Nicole Pratt: 12 mins)
(1-2) Challenges in cross-country database studies for
pediatric pharmacoepidemiology in Europe
(Ian Wong: 12 mins)
(1-3) Opportunities of cross-continental databases stud-
ies (Ian Douglas: 12 mins)
(2) Data pooling and comparisons from multi-na-
tional databases studies
(2-1) Challenges before methodology: data privacy
and health policy related issues (Kiyoshi
Kubota: 12 mins)
(2-2) Methodology to pool country speciﬁc results
and proposed solutions (Edward Chia-Cheng
Lai: 12 mins)
(3) Panel discussion (30 mins): all speakers and
moderators.
679. Special Issues in Pharmacovigilance in
Emerging Countries
Syed Rizwanuddin Ahmad,1 David Lee,2 Gloria Shalviri,3
Marie Lindquist.4 1Georgetown University, Washington,
DC, United States; 2Global Technical Lead, Pharma-
ceutical Management, Center for Pharmaceutical
Management, Management Science for Health, Arlington,
VA; 3Food and Drug Organization, Iranian ADR
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Monitoring Center, Tehran; 4WHO Uppsala Monitoring
Centre, Uppsala.
Background: The increase in access to and use of
medicines on a massive scale in low and middle
income countries to treat diseases such as HIV/AIDS,
malaria, and tuberculosis has underscored the impor-
tance of fully functional pharmacovigilance systems
in these countries. These have begun to develop over
the last decade or so.
Objectives: The objectives of this session are two-fold
(1.) to provide an overview of the state of phar-
macovigilance systems in low and middle income coun-
tries with particular emphasis on how areas of immediate
need such as deﬁning and addressing the scope, human
resource needs, information sharing, and sustainability;
And (2.) to present the challenges being faced by
emerging countries and how these are being tackled.
Description: Rational use of medicines has the poten-
tial to save lives and relieve suffering but when used
inappropriately medicines can increase the burden of
disease by contributing to morbidity and mortality.
Low and middle income countries bear approximately
90% of the disease burden but access to essential med-
icines remains a major problem. A number of global
strategies are underway to support public health pro-
grams in these countries for the treatment of HIV/
AIDS, malaria, and tuberculosis. Most of these initia-
tives require the establishment of a pharmacovigilance
(PV) system to monitor adverse events associated with
the use of medicines. However, not all emerging coun-
tries have a fully operational PV system with trained pro-
fessionals. This session discusses the state of PV systems
in low and middle-income countries; the nature of support
needed to build PV system capacity in these countries to
effective levels; global and regional strategies and efforts
to develop institutional and professional capacity in re-
source-limited settings; remaining gaps; and the chal-
lenges being faced by a representative from one of these
countries and how these are being tackled. Perspectives
on the topic will be provided by representatives from aca-
demia/technical assistance providers; PV center; and the
World Health Organization/Uppsala Monitoring Center.
680. The Patient’s Voice in the Heart of BRACE
(Benefit-Risk Assessment, Communication and
Evaluation)
Meredith Smith,1 Priya Bahri,2 Gerald Dal Pan,3 Swapu
Banerjee,4 Peter Mol,5 Debashish Dey.6 1Drug Safety
Strategy & Science, EMD Serono Inc., Rockalnd, MA,
United States; 2Best Evidence Development, European
Medicine Agency, London, United Kingdom; 3Ofﬁce of
Surveillance and Epidemiology/CDER, US Food and
Drug Administration, Silver Spring, MD, United States;
4Regulatory, Risk & Cinical Development, Pope
Woodhead and Associates Ltd., St. Ives, Cambridgeshire,
United Kingdom; 5Clinical Pharmacy and Pharmacol-
ogy, University of Groningen, Groningen, Netherlands;
6Global Patient Safety, Eli Lilly and Company, Indianapolis,
IN, United States.
Background: Patients’ perspective in the drug devel-
opment and evaluation of beneﬁt-risk is acknowledged
as being of fundamental importance by key stake-
holders. Empirical research from the USA and Europe
revealed the promise and challenges of incorporating
patient’s voice in risk minimization and beneﬁt-risk
assessment. Patient-reported outcomes are already
widely used in clinical trials and drug safety. However,
their potential in capturing what patients’ value most in
the context of beneﬁts versus harms of medicines is an
emerging science. The Patient-Focused Drug Develop-
ment initiative by the U.S. Food and Drug Administration
(FDA) aims to more systematically gather patients’
perspectives regarding available therapies to treat their
condition. The European Medicine Agency (EMA) is
working to bring together representatives of patients,
consumers, and healthcare professionals to get a better
understanding of their role in the development of
medicines and regulatory process.
Objectives: To highlight current and possible future
role of patients in the development of medicines and,
in particular, to identify what patients can contribute
in the process of beneﬁt- risks assessment, risk mini-
mization, communication and evaluation.
Description: The symposium will consist of 5 talks
providing perspectives from different stakeholders
Speakers:
The promise and challenge of patient-centered ap-
proaches to risk minimization. Meredith Smith, EMD
Serono Inc. (15min).
Patient-reported outcomes of adverse events (PRO-
AEs) in real world beneﬁt-risk assessment. Swapu
Banerjee, Pope Woodhead & Associates Ltd. (15min).
How patients contribute to the assessment of bene-
ﬁts and risks at the EMA. Priya Bahri, EMA (15min).
Lessons learned from the FDA’s patient-focused
drug development initiative. Gerald Dal Pan, FDA
(15min).
Do patients value drug beneﬁts and risks differently
than their healthcare providers or regulators? An
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empirical study from the Netherlands. Peter Mol,
University of Groningen (15min)
Discussion (15min): Moderated open discussion.
Moderators: Debashish Dey, Eli Lilly; Peter Mol,
University of Groningen.
681. Using Pharmaceutical Data for Evaluating
Medicines Policy and Informing Quality Use of
Medicines
Libby Roughead,1 Flora Haaijer-Ruskamp,2 Veronika
Wirtz,3 Parthasarathi Gurumurthy,4 Lisa G Pont.5
1Samson Institute, University of South Australia, Adelaide,
Australia; 2Clinical Pharmacy and Pharmacology,
University Medical Centre Groningen, Groningen,
Netherlands; 3Centre for Global Health and Development,
Boston University, Boston, United States; 4Faculty of
Pharmacy, JSS University, Mysore, India; 5Sydney
Nursing School, University of Sydney, Sydney, Australia.
Background: National medicines utilisation data are
available in many countries and provide a valuable tool
for assessing the appropriateness of medicine use and
pharmaceutical policy. These data are particularly valu-
able where electronic health claims data are unavailable.
Objectives: In this symposium we will explore the use
of aggregated drug utilisation data to inform medicines
policy and drive quality use of medicines at the Inter-
national, National and Local levels. This symposium is
of interest to researchers, regulators and clinicians in-
terested in using non-traditional data sources to inform
policy and quality.
Description: Case studies from Europe, Oceania, Latin
America and Asia will be presented to stimulate discus-
sion around the use of aggregated data. A 30-minute
open debate and panel discussion will explore the
challenges of interpreting and using aggregated data as
well as practical issues around data collection process.
Using examples from Europe and the OECD, Using
examples from the OECD, Professor Flora Haaijer-
Ruskamp will demonstrate how cross country compar-
isons can assist in identifying potential problem areas
of medicine use and discuss the challenges in
collecting and interpret international prescribing qual-
ity data. Professor Libby Roughead will demonstrate
how comparisons of medicine use trends within coun-
tries can also be used to inform pharmaceutical policy
development and identify potential problems with
examples from Australia and Malaysia. In many
countries, sales data are available, and Professor
Veronika Wirtz will demonstrate how sales data have
been utilised for medicine assessments in Latin
America. Equally important is evaluation of medicine
use at the institutional level and Professor Parthasarathi
Gurumurthy will use examples from hospitals in India
to demonstrate methods for monitoring medicine use
at the local level.
Speakers: Professor Flora Haiijer-Ruskamp, Gro-
ningen, The Netherlands
Professor Libby Roughead, Adelaide, Australia
Professor Veronika Wirtz, Boston, USA
Professor Parthasarathi Gurumurthy, Mysore, India
Chair: Dr Lisa Pont, Sydney, Australia.
682. Combination Vildagliptin Use: Analysis from the
Vildagliptin Prescription-Event Monitoring Study
Naseer Qayum,1,2 Deborah Layton,1,2 Saad AW Shakir.1,2
1Drug Safety Research Unit, Southampton, United
Kingdom; 2School of Pharmacy and Biomedical Sciences,
University of Portsmouth, Portsmouth, United Kingdom.
Background: Vildagliptin is an anti-diabetic drug that
enhances glucose dependent insulin secretion as well as
targeting blood glucose levels, and is primarily used in
combination with other anti-diabetics drugs. Peripheral
oedema (PO) was identiﬁed as adverse events during
clinical trials and is of clinical interest.
Objectives: To investigate the effect of combination
vildagliptin use on PO reported in the Prescription-
Event Monitoring (PEM) study.
Methods: PEM is an observational cohort technique;
demographic and event data were collected from primary
care physicians whose patients had been dispensed
vildagliptin in combinationwith other anti-diabetic drugs.
A Cox regression model was used to assess the relation-
ship between the patients’ variables at baseline and PO.
Results: The PEM cohort comprised of 4828 patients
(median age 63 yrs; IQR 54 to 71); 2692 were male
(55.76%).
Male patients of average age (62 years) were esti-
mated to have approx. 13 times the hazard of having
PO if they had a PMHx of PO (HR 12.84 [95%CI
4.96, 33.23]) whilst this relationship was not observed
in females (HR 1.44 [95%CI 0.32, 6.40]). Patients
>60 years had 16 (male) and 6 (female) times the
hazard of having PO with a previous history of PO
vs. patients <60 years (HR 16.29 [95%CI 6.40,
41.50]; HR 5.64 [95%CI 1.29, 24.59]).
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Conclusions: Patients prescribed vildagliptin in
combination with other anti-diabetic medications
appear to be more likely of having PO if they have
had a previous history, particularly if the patient is of
an elderly age. These differences may need to be
taken in consideration when prescribing vildagliptin
in this fashion.
683. Impact of a Metoprolol Shortage on Post-
Myocardial Infarction beta-Blocker Utilization
Joshua J Gagne, Katsiaryna Bykov, Bo Wang, Niteesh K
Choudhry.1 1Division of Pharmacoepidemiology and
Pharmacoeconomics, Department of Medicine, Brigham
andWomen’s Hospital and HarvardMedical School, Boston.
Background: Drug shortages are an increasingly com-
mon problem in many countries, yet little is known
about their impact on subsequent drug utilization. In
the US, a shortage of metoprolol succinate extended
release tablets (metoprolol ER) affected multiple manu-
facturers beginning in late 2008 and early 2009.
Objectives: To investigate whether the metoprolol ER
shortage inﬂuenced post-myocardial infarction (MI)
beta-blocker use and adherence in a commercially
insured US population.
Methods: In each month from January 2006 to Decem-
ber 2011, we identiﬁed all patients discharged from the
hospital after MI. We determined whether patients ﬁlled
a beta-blocker prescription within 30 days of discharge
and determined one-year adherence (estimated using
the proportion of days covered [PDC] by any beta-
blocker) among those that ﬁlled. We conducted an
interrupted time series analysis using segmented regres-
sion with a change point corresponding to February
2009, after three manufacturers announced shortages
of metoprolol ER. We also examined trends in use of
other beta-blockers around the shortage period.
Results: The cohort comprised 34,702 patients, of
whom 66% ﬁlled a prescription for a beta-blocker
within 30 days, with a mean PDC of 78%. Prior to the
shortage, 22% of all patients who ﬁlled prescriptions
for beta-blockers following the MI used metoprolol
ER products that were subsequently affected by the
shortage. We observed increases in use of immediate
release metoprolol tartrate tablets and brand-name ver-
sions of metoprolol ER, neither of which were affected
by the shortage. We observed a 3.3% (p< 0.01) reduc-
tion in the proportion of all post-MI patients that used
any beta-blocker and a 2.3% (p< 0.01) reduction in
average PDC in the shortage period. We did not observe
substantial changes in slope for either outcome.
Conclusions: A shortage of metoprolol ER affecting
multiple manufacturers in the US was associated with
fewer patients receiving any post-MI beta-blocker and
lower adherence to beta-blocker therapy for those who
did receive it.
684. The Use of Oral Isotretinoin in France: Assess-
ment of Appropriate Use as a Second Line Treatment
Aurore Tricotel, Sara Miranda, Mahmoud Zureik.
Department of Epidemiology of Health Products, French
National Agency for Medicines and Health Products
Safety (ANSM), Saint-Denis, France.
Background: Systemic isotretinoin is a very effective
drug for the treatment of acne. Given its safety proﬁle
including teratogenicity and potential psychiatric ad-
verse events, isotretinoin should be reserved to severe
acne unresponsive to systemic antibiotics. Its use and
beneﬁt-risk ratio are kept under close monitoring.
Objectives: To assess the compliance with thera-
peutic indication and French guidelines, notably
the respect of second-line and duration of prior
antibiotic exposure.
Methods: A cohort of 3 245 subjects initiating an
oral isotretinoin treatment from January, 1st
2007 to December, 31th 2012 was identiﬁed using
EGB database, a representative sample of the
population protected by the French National Health
Insurance. An appropriate 3-months antibiotic
cure was deﬁned as at least 3 reimbursements of
systemic doxycycline, lymecycline, minocycline
and/or erythromycine within a 100 days-window in
the year preceding isotretinoin initiation. Patient
demographics, prescriber’s specialty and treatment
patterns were also described.
Results: Men were more frequently treated with
isotretinoine (57.6%) and signiﬁcantly younger than
women at treatment initiation (median age of 18 ver-
sus 26 years old). Isotretinoin initiation was more
often prescribed by dermatologists (86.5%) and
mean treatment duration was 22weeks. In 2012,
use of antibiotics in the year preceding initiation
was retrieved for 74% of subjects; for 64% of them
antibiotic cure was appropriate (66.0% for derma-
tologists versus 46.6% for general practitioners,
p< 0.0001). The respect of a 3-months cure of
abstract366
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
systemic antibiotic prior to isotretinoin initiation
was observed for 47% of the cohort.
Conclusions: Only half of subjects had a proper anti-
biotic cure before isotretinoin initiation. Communica-
tion on the appropriate conditions of use could be
necessary, particularly targeted to general
practitioners.
685. Impact of Abuse-Deterrent OxyContin on Pre-
scription Opioid Utilization in the United States
Catherine S Hwang,1,2 Hsien-Yen Chang,1,3G Caleb
Alexander.1,4,5 1Center for Drug Safety and Effectiveness,
Johns Hopkins Bloomberg School of Public Health,
Baltimore, MD, United States; 2Department of Interna-
tional Health, Johns Hopkins Bloomberg School of Public
Health, Baltimore, MD, United States; 3Department of
Health Policy and Management, Johns Hopkins
Bloomberg School of Public Health, Baltimore, MD,
United States; 4Department of Epidemiology, Johns Hop-
kins Bloomberg School of Public Health, Baltimore, MD,
United States; 5Division of General Internal Medicine,
Johns Hopkins Medicine, Baltimore, MD, United States.
Background: Although some evidence suggests
that the abuse-deterrent formulation of extended-
release (ER) oxycodone (OxyContin) may be
associated with reduced OxyContin abuse, little
is known about how this formulation has
impacted OxyContin sales or sales of common
alternative therapies.
Objectives: We quantiﬁed the degree to which
OxyContin reformulation affected its use as well
as the use of immediate-release (IR) oxycodone
and hydrocodone.
Methods: We used the IMS Health National Prescrip-
tion Audit, a nationally representative source of re-
tail and mail order prescription activity in the
United States, to conduct a segmented time-series
analysis of the use of OxyContin and other
prescription opioids. Our primary time period of in-
terest was 12months prior to and following August
2010. We performed model checks and sensitivity
analyses, such as adjusting for marketing and
promotion, using alternative lag periods, and adding
additional data points.
Results: OxyContin sales were similar before and
after the August 2010 reformulation, with ~550K
prescriptions per month. After adjusting for declines
in the generic ER oxycodone market, the formulation
change was associated with a reduction of ~18K
OxyContin prescription sales per month (p = 0.02,
95% CI = 3K to 32K). This decline corresponded to
a change in the annual growth rate of OxyContin use,
from 4% prior to reformulation to -24% during the year
after reformulation. There were no statistically signiﬁ-
cant changes associated with the sales of alternative opi-
oids, such as IR oxycodone (p= 0.30) or hydrocodone
(p = 0.91). Multiple sensitivity analyses supported these
ﬁndings and their substantive interpretation.
Conclusions: The market debut of abuse-deterrent
OxyContin was associated with declines in its use af-
ter accounting for the simultaneous contraction of the
generic ER oxycodone market. The failure of
reformulated OxyContin to absorb decreases in the
generic market share may be due to various factors, in-
cluding pricing differences and a perceived lack of
substitutability between generic and branded prod-
ucts. Further scrutiny into the effect of abuse-deterrent
formulations is vital given their popularity in opioid
drug development.
686. Survival of Elderly Australian Men Initiating
Hormone Therapy for Prostate Cancer
Svetla Gadzanova, Libby Roughead. QUMPRC,
University of South Australia, Adelaide, Australia.
Background: Prostate cancer causes the second
highest number of cancer deaths in men (after lung
cancer) and the most cancer cases in Australia. Andro-
gen deprivation therapy is used in treatment to reduce
the levels of male hormones, which stimulate cancer
cell growth.
Objectives: This study examined the survival rate of
elderly men who initiated androgen deprivation therapy
for prostate cancer.
Methods: An observational retrospective study was
undertaken using Australian Government Department
of Veterans’ Affairs dataset with pharmacy claims
for approximately 300,000 veterans and their depen-
dants. The veteran population have slightly more visits
to general practitioners (RR: 1.17, p< 0.05) and
hospitalisations (RR: 1.21, p< 0.05) annually than
the general Australian population aged ≥40 years.
The cohort included men who initiated androgen
deprivation therapy (with anti-androgens or gonado-
tropin releasing hormone analogues) between 2008
and 2010. Patients were followed to 31 Dec 2012.
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The observed (all-cause) survival rates were deter-
mined using Kaplan-Meier method. The relative sur-
vival rates were calculated as the ratio of the
observed to the expected survival rates of a similar
“cancer-free” group of people from the general popu-
lation using Ederer and Heise method. Results were
stratiﬁed by ten year age cohorts and Z-test statistics
applied to compare age speciﬁc rates at 1 to 5 years
of follow-up.
Results: There were 3,611 male veterans who initiated
hormone therapy with mean age 84 years (SD 7.5).
The observed median survival time was around three
and a half years (1290 days, 95% CI 1246-1366).
The cohort 1-year relative survival was 91.6% (95%
CI 90.2-92.9) declining to 79.4% (77.1-81.7) at 3 years
and to 57.0% (55.4-58.6) at 5 years post initiation of
hormone therapy. Age speciﬁc rates at 1, 3, and 5 year
follow-up were similar for those aged under 80 years
and signiﬁcantly lower for those aged 80 and over.
Conclusions: Relative survival rates after initiation of
androgen deprivation therapy show the majority of
men survive ﬁve years.
687. Genomic Determinants of Prognosis in Esopha-
geal Adenocarcinoma: Using Computational
Methods to Account for Gene-Gene Interactions
Eric Morgen,1 Xiaowei Shen,1 Thomas L Vaughan,3 David
Whiteman,4 Anna Wu,5 Marilie Gammon,6 Wong-Ho
Chow,7 Daniel O Stram,8 Yvonne Romero,2 Wei Xu,1
Geoffrey Liu.1 1PMH/OCI, University of Toronto, Toronto,
ON; 2Mayo Clinic, Rochester, MN; 3Fred Hutchinson
Cancer Center, Seattle, WA; 4QIMR Berghofer Research
Institute, Herston, Austria; 5USC/Norris Comprehensive
Cancer Centre, Los Angeles, CA; 6UNC-Chapel Hill,
Chapel Hill, NC; 7MD Anderson Cancer Center, Houston,
TX; 8University of Southern California, Los Angeles, CA.
Background: Esophageal adenocarcinoma carries a
poor prognosis, despite modern therapy. Methods of
stratifying patients into risk groups are needed, as are
new insights into genetic determinants of disease
behaviour. Prognosis is likely to have non-negligible
genetic inﬂuences, as mediated by host responses to
tumor, resistance to therapeutic side-effects, and/or
an inﬂuence on tumor development. Prior studies have
used candidate-gene approaches, but resulting ﬁndings
have fared poorly in validation.
Objectives: In an effort to improve this situation, we
attempted to consider gene-gene interactions by (1)
taking an unbiased, genome-wide approach, and (2)
using innovative methods that are better able to detect
multi-gene interactions.
Methods: A Toronto-based cohort of EAC patients
(n = 270) was genotyped via blood samples using the
Illumina Omni1_Quad DNA microarray as part of
the BEAGESS initiative. Quality control and analysis
was performed using PLINK, R, and GenABEL. Anal-
ysis used a Cox proportional hazards model testing for
independent effects at p< 1e-7. Because classical
analysis has no ability to detect gene-gene interactions,
the Random Survival Forest algorithm was used to de-
tect effects based on analysis of the top 1000 polymor-
phisms by on p-value ranking.
Results: All 270 patients were successfully genotyped
After data cleaning and standard GWAS quality control
procedures, there were 735,309 SNPs and 245 patients
remaining for analysis. The CPH model, adjusted for
population stratiﬁcation, produced a satisfactory Q-Q
plot, and showed one SNP (rs7844673, Chr 8) that
was signiﬁcant at p = 7.8E-8. In addition, Random
Forest based variable selection produced a set of 20 poly-
morphisms that (1) reproduced 86% of the predictive
ability of the full 1000 variables, and (2) also included
the #3 ranked polymorphism by CPH modeling
(rs9290822, Chr 3) upstream of the IGF2BP2 gene.
Conclusions: A genome-wide approach has discov-
ered two previously undescribed SNPs with a potential
inﬂuence on EAC prognosis via a combination of
independent and interactive effects. Validation in an
independent cohort is currently being planned.
688. Clinical Factors Associated with Prescription
Filling of Mood-Stabilizers in Bipolar Disorder – A
Population-Based Cohort Study
Louise Scheen,1 Robert Bodén,2 LenaBrandt,1 Jari Tiihonen,3
Morten Andersen,1 Helle Kieler,1 Johan Reutfors.1 1Centre
for Pharmacoepidemiology, Department of Medicine Solna,
Karolinska Institutet, Stockholm, Sweden; 2Department of
Neuroscience, Psychiatry, Uppsala University, Akademiska
Sjukhuset, Uppsala, Sweden; 3Department of Clinical Neuro-
science, Karolinska Institutet, Stockholm, Sweden.
Background: Non-adherence with mood-stabilizers
(MS) is known to be substantial in bipolar disorder
(BD) patients, and is associated with a worse outcome.
Although data suggests that medication effectiveness
is higher early in the course of BD, adherence rates in
newly diagnosed patients have not previously been
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investigated. In addition, a better understanding of the
risk-factors for non-adherence is needed to help identify
high-risk patients, guiding adherence interventions.
Objectives: To describe the pattern of prescription ﬁll-
ings of MS in newly diagnosed BD patients and to as-
sess clinical factors inﬂuencing MS prescription ﬁlling.
Methods: We performed a nationwide, population-
based cohort study in Sweden, using data from Swedish
national registers. We used the Swedish Patient Register
to identify patients aged 18 to 75 with a ﬁrst time diagno-
sis of BD between 2006 and 2011 (n =26 732). Data on
prescription ﬁlls for MS was obtained from the Pre-
scribed Drug Register. In multivariate Cox regression
models, we studied gender, age, previous use of mood-
stabilizers, psychiatric comorbidity, substance abuse,
affective state at diagnosis, psychotic symptoms at
diagnosis, previous psychiatric care and the duration of
hospitalization as predictors for MS ﬁlls.
Results: Among outpatients and inpatients, 54.4%
(95% conﬁdence interval [CI] 53.8%-55.1%) and
72.9% (95% CI, 71.7%-74.1%), respectively, ﬁlled a
MS prescription within one month after diagnosis. For
outpatients, prescription ﬁlling was primarily associated
with previous use of any MS (hazard ratio [HR], 1.86;
95% CI 1.80-1.92), whereas manic state at diagnosis
lowered the likelihood of prescription ﬁlling (HR, 0.51;
95% CI 0.46-0.56). For inpatients, prescription ﬁlling
was mainly associated with longer duration of the hospi-
talization (HR, 2.26; 95% CI 2.08-2.45 for a duration of
28 days compared to< 7days).
Conclusions: The proportion of patients with BD not
ﬁlling a prescription of aMS after diagnosis is substantial.
Previous MS use and longer hospitalizations were found
to be the strongest predictors for prescription ﬁlling.
689. Databases in Asia: The Potential for Distrib-
uted Network Approach
Edward Chia-Cheng Lai,1,2 Nathorn Chaiyakunapruk,3
Yinghong Zhang,2 Chantelle Hardy,2 Kiyoshi Kubota,4
Elizabeth E Roughead,5 Byung Joo Park,6 Ju-Young Shin,6
Ian CK Wong,7 Jin Wen,8 Sawaeng Watcharathanakij,9
Yea-Huei Kao Yang,1,10 Soko Setoguchi.2 1Institute of
Clinical Pharmacy and Pharmaceutical Sciences, National
Cheng- Kung University, Tainan, Taiwan; 2Duke Clinical
Research Institute, Duke University School of Medicine,
Durham, NC, United States; 3School of Pharmacy, Monash
University Malaysia, Selangor, Malaysia; 4Department of
Pharmacoepidemiology, University of Tokyo, Tokyo,
Japan; 5Quality Use of Medicines and Pharmacy Research
Centre, Ansom Institute for Health Research, University of
South Australia, Adelaide, Australia; 6Seoul National Uni-
versity College of Medicine, Korea Institute of Drug Safety
and Risk Management, Seoul, Republic of Korea; 7Depart-
ment of Pharmacology and Pharmacy, University of Hong
Kong, Hong Kong, China; 8Institute of Hospital Manage-
ment, West China Hospital, Sichuan University, Sichuan,
China; 9Pharmacy Practice, Faculty of Pharmaceutical
Sciences, Ubon Ratchathani University, Ubon Ratchathani,
Thailand; 10Health Outcome Research Center, National
Cheng-Kung University, Tainan, Taiwan.
Background: One of the initial steps to establish a
distributed network approach for collaborative multi-
national studies in Asia is to understand the applicabil-
ity of a common data model (CDM) to heterogeneous
data sources. However, the capacity of database in
Asian countries and the feasibility to build or apply
existing CDM has not been well described.
Objectives: To describe database availability and
characteristics of the databases in Asian countries
and to assess the feasibility to apply a CDM in Asian
database environments.
Methods: A web-based survey was conducted among
investigators using healthcare databases in Asia. The
potential survey participants were identiﬁed through
the Asian Pharmacoepidemiology Network. The survey
included questions: 1) characteristics of database, 2)
patients demographics, 3) data components and coding
system 4) medical expenditure, and 5) the traditional
Chinese medicine (TCM) or complementary medicine.
Results: A total of 10 data sources from Asian countries
participated in the survey, including nationwide data-
bases form Japan, Korea, Taiwan, and Hong Kong.
These contained data on approximately 128, 50, 23,
and 7 million individuals, respectively, covering all age
groups and the majority was Asian. One claims database
includes all veterans and dependents (approximately
330,000 individuals) from Australia with predominantly
elderly and Caucasian. Others included a hospital based
EHR from China (5 million individuals) and two EHRs
from Thailand (1 million and 300,000 individuals).
Two registries for cancer and stroke were from Taiwan.
The majority of databases possesses diagnoses informa-
tion with the date by either ICD9 or ICD10 codes; and
encompasses procedures and prescriptions records with
the date by domestic coding systems. Three databases
contain dispensing data for TCMs. One EHR includes
information of Thai herbal medicine.
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Conclusions: There are numerous Asian databases
with comprehensive healthcare information to provide
an opportunity for applying distributed network
approach in Asia. Harmonization of the coding
systems as well as understanding practice patterns
affecting the interpretation of results will be challenges
for multinational database studies.
690. Realistic Power Estimation for New User,
Active Comparator Studies: An Empirical Example
Mugdha N Gokhale,1 John B Buse,2 Til Sturmer.3 1Epi-
demiology, University of North Carolina, Chapel Hill,
NC, United States; 2Medicine, University of North
Carolina, Chapel Hill, NC, United States.
Background: Studies using large databases are ex-
pected to be sufﬁciently powered to study rare outcomes,
but often there is sequential loss of power due to steps
taken to increase internal validity.
Objectives: We illustrate this using a new-user cohort
study comparing pancreatic cancer incidence after
initiating dipeptidyl peptidase 4 inhibitors (DPP) or
thiazolidinediones (TZD).
Methods: Using a 20% sample of the Medicare claims
we ﬁrst identiﬁed patients with at least one claim of DPP
or TZD during 2007–2011 and sequentially narrowed
down to a population of new-users as follows:1) Ex-
clude prevalent users of DPP or TZD in the 6months
pre-initiation 2) Require another claim of the same drug
within 180 days of initiation 3) Exclude prevalent
cancers 4) Exclude patients age <66 yrs at initiation.
At each step we calculated power to detect literature
based relative risks of 1.5 and 3 using α 0.05, pa-
tients meeting criteria, ratio of TZD to DPP patients
and the reference risk of pancreatic cancer assuming
no loss to follow-up. Once the ﬁnal cohort was cre-
ated we estimated power assuming an as-treated
time-to-event model, where follow-up started from
the 2nd prescription and person-time was censored
at the earliest of the outcome, stopping/switching,
any incident cancer or death.
Results: There were 74930 and 237251 patients
with at least one script of DPP or TZD with
100% power to detect a RR of 1.5. Power was
99% after excluding prevalent users and requiring
2 scripts. Excluding prevalent cancers lowered the
power to 91% and exclusion of patients <66 yrs re-
sulted in ﬁnal cohort of 29695 DPP and 26390 TZD
new-users and a power of 88%. Power was further
reduced to 67% accounting for censoring (mainly
stopping). The power to detect a RR of 3 remained
>90% at all steps.
Conclusions: In designing new-user active comparator
studies, one should be mindful how steps increasing
internal validity affect sample size and person-time.
Examples with other drugs and outcomes will also be
presented.While actual numbers will depend on speciﬁc
settings, application of generic percentages of loss in
sample size and person-time may improve estimates
of power.
691. Use of Thiazolidinedione and Risk of Urothelial
Cancer among Taiwan Diabetes Patients
Jo-Yen Chao,1,3 Tzu-Chieh Lin,3 Ming-Cheng Wang,2,3
Yea-Huei Kao Yang.3 1Division of Nephrology, Depart-
ment of Internal Medicine, National Cheng Kung University
Hospital, Dou-Liu Branch, Yunlin County, Taiwan;
2Division of Nephrology, Department of Internal
Medicine, National Cheng Kung University Hospital,
Tainan, Taiwan; 3Institute of Clinical Pharmacy
and Pharmaceutical Science, National Cheng Kung
University, Tainan, Taiwan.
Background: The use of pioglitazone may increase
the risk of bladder cancer in patients with type 2
diabetes. The association between thiazolidinedione
(TZD), including pioglitazone and rosiglitazone,
and urothelial cancer is still controversial.
Objectives: Our aim was to ascertain whether
thiazolidinedione increases urothelial cancer risk
in patients with type 2 diabetes in Taiwanese
population.
Methods: A retrospective cohort study was conducted
in patients with type 2 diabetes mellitus who initiated
hypoglycemic treatment between Jan 1, 2001, and
Dec 31, 2010, using the National Health Insurance
Research Database (NHIRD) in Taiwan. Patients who
were younger than 18 years, with history of malignancy
or ever underwent organ transplant were excluded.
Information of baseline comorbidities and co-medi-
cations were retrieved from outpatient and inpatient
claims in the previous year before cohort entry.
Patients who were ever prescribed at least twice
with TZD, including pioglitazone and rosiglitazone,
were classiﬁed as TZD exposure group. Patients
were followed from cohort entry until diagnosis of
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urothelial cancer or the end of study, whichever
came ﬁrst. Time-dependent Cox proportional hazard
regression models were used to calculate hazard ratios
(HR) of bladder or urothelial cancer risk in patients
exposed to TZDs compared with patients without expo-
sure, adjusted for potential confounders. All statistical
tests were conducted using SAS version 9.3.
Results: From 2001 to 2010, there were 1,179,352
type 2 diabetic patients, age above 18 years, were
recruited. TZD users were younger than non-users
(53.9 ± 12.1 vs. 57.8 ± 13.7, p< 0.0001) and had
less baseline comorbidities, including hypertension,
coronary artery disease, heart failure, renal failure, cir-
rhosis, hyperlipidemia and cerebrovascular disease. A
total of 3,427 urothelial cancer cases were identiﬁed
during the study period. Results of time-dependent
Cox proportional hazard model showed that TZD
users were not associated with increased risk of
urothelial cancer (HR 0.652, 95% CI 0.590-0.721).
Conclusions: The use of pioglitazone and rosiglitazone
is not associated with increased risk of urothelial cancer
in Taiwan diabetic patients.
692. Comparing the Risk for Atrial Fibrillation in
Patients with Diabetes Initiating Metformin or Sul-
fonylureas: A Nationwide Population-Based Cohort
Study in Taiwan
Ying Ling Liu,1 Chi Wen Chiang,2 Tong Rong Tsai,3
Wei Chung Tsai.4 1Kaohsiung Medical University,
Kaohsiung City, Taiwan; 2Ministry of Health and
Welfare Pingtung Hosipital, Pingtung County, Taiwan;
3Kaohsiung Medical University, Kaohsiung City,
Taiwan; 4Kaohsiung Medical University Chung-Ho
Memorial Hospital, Kaohsiung City, Taiwan.
Background: Diabetes mellitus (DM) are associated
with increasing atrial ﬁbrillation/ﬂutter (AF), but lack of
studies to evaluate the association between these hypo-
glycemic agents and AF risk. Moreover, patients with
combination therapy means that they have uncontrolled
DM. In order to minimize the effect of other hypoglyce-
mic agent, we evaluate the effects of sulfonylureas(SU)
or metformin(Met) monotherapy on outcomes of AF in
type 2 diabetes(T2DM).
Objectives: To compare the effects of SU and Met on
incidence of AF.
Methods:A retrospective cohort study was conducted by
analyzing the TaiwanNational Health Insurance Research
Database. There are 5147 patients with T2DM newly
diagnosed at least 2 times in the same year from
1997-2009, 18years of age or above, and without history
of cardiovascular events, AF, and dysrhythmia at the base-
line. Patients with cancer, liver cirrhosis, chronic kidney
disease were excluded. Based on the prescription, patients
with SU or Met monotherapy for at least six months.
Descriptive statistics were used to summarize the
characteristics of two groups. The Kaplan-Meier
method was used for survival analysis and log-rank
test was used to compare the differences between
two groups. In addition, we used Cox proportional
hazards regression to adjust confounders.
Results: There were 5147 patients included with aver-
age follow-up duration of 4.34 (standard deviation
[SD]:3.44) years. The main characteristics were: the
mean age 56.54 (SD: 14.68) vs. 59.63 (SD: 14.68)
(Met vs. SU); male 45% vs. 54%.
Kaplan-Meier curve showed that lower risk of AF in
Met than SU group (5-years: 0.94%, 1.12%, p=0.05;
7-years: 1.11%, 1.87%, p=0.022). As compare with
Met monotherapy, patient with gliclazide monotherapy
has higher associated with newly diagnosed AF during
5 years and 7 years follow up, (adjusted hazard ratio
(aHR)=3.052, 95% CI 1.282-7.262, p =0.01 and aHR=
3.994, 95% CI 1.881-8.480, p =0.0003, respectively).
Conclusions: Treatment of newly diagnosed DM patient
with SU group, especially gliclazide, was associated with
increased AF incidence as compared to patients treated
with Met.
693. Statins and Risk of Pulmonary Complications
and Mortality after Gastric Bypass Surgery
Sigrid B Gribsholt,1 Elisabeth Svensson,2 Stine Skovbo,2
Reimar W Thomsen,2 Bjørn Richelsen,1 Henrik T
Sørensen.2 1Department of Endocrinology and Internal
Medicine, Aarhus University Hospital, Aarhus C, Den-
mark; 2Department of Clinical Epidemiology, Aarhus
University Hospital, Aarhus N, Denmark.
Background: Roux-en-Y gastric bypass (RYGB) sur-
gery results in pronounced weight loss in severely
obese people, but also may be associated with compli-
cations and elevated mortality. Former research has
suggested that patients using glucocorticoids are at
higher risk of postoperative bleeding than patients
without such drug use.
Objectives: To investigate the association between
recent glucocorticoid use and risk of postoperative
bleeding after RYGB.
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Methods: We conducted a nationwide cohort study
of all RYGB surgery patients in Denmark from
2006 through 2010. Using Danish medical databases,
we linked data on age, gender, surgical procedure,
current glucocorticoid use (redeemed prescription
60 days before surgery) or no current use (no
prescription <60 days before surgery), preoperative
comorbidity level assessed by the Charlson Comor-
bidity Index, and postoperative bleeding (within
30 days of surgery). We computed odds ratios (ORs)
for the association between glucocorticoid use and
bleeding with corresponding 95% conﬁdence intervals
(95% CIs), adjusting for sex, age and comorbidity using
logistic regression.
Results: In total, 9,855 patients underwent RYGB. Of
these, 247 (2.5 %) were current glucocorticoid users
and 9,608 (97.5%) were non-users. A higher risk of
bleeding was observed among the glucocorticoid users
(2.4%) than among non-users (1.2%), the adjusted OR
was 2.0 (95% CI 1.1-3.6).
Conclusions: Use of glucocorticoids within 60 days
before RYGB was associated with a higher risk of
postoperative bleeding during 30 days follow up.
694. Use of N-Methylthiotetrazole (NMTT) - Ceph-
alosporin Antibiotics and the Risk of Hemorrhagic
Events: A Nationwide Nested Case-Control Study
Li-Ju Chen,1 Fei-Yuan Hsiao,1,2 Li-Jiuan Shen,1,2 Shu-
Wen Lin.1,2 1Graduate Institute of Clinical Pharmacy,
School of Pharmacy, National Taiwan University,
Taipei, Taiwan; 2Department of Pharmacy, National
Taiwan University Hospital, Taipei, Taiwan.
Background: Several case reports and case series have
suggested a potential correlation between N-methyl-
thiotetrazole (NMTT) - cephalosporin (cepha) antibiotics
and coagulopathy. Nevertheless, there is a lack of
population-based empirical data.
Objectives: The objective of this nested case-control
study is to examine the association between the use
of antibiotics of interest and the risk of hemorrhagic
events using Taiwan’s National Health Insurance
Research Database (NHIRD).
Methods: Through the usage of Longitudinal Health
Insurance Database 2000 (LHID 2000) derived from
the original claim data of NHIRD, we identiﬁed
adult patients who received anti-infective treatment
with cefmetazole, cefoxitin, ﬂomoxef, moxalactam,
cefamandole, cefoperazone, which were deﬁned as ex-
posure group, and amoxicillin/ clavulanate, ampicillin/
sulbactam, cefuroxime, cefotaxime, ceftriaxone, which
were identiﬁed as non-exposure group, for more than
48 hours between year 2000 and 2011. The association
between the exposure to NMTT cepha and the risk of
hemorrhagic events identiﬁed through ICD-9-CM code
was examined using conditional logistic regression
models.
Results: Within the cohort consisting of 625 patients,
the average age was 65 years old and 57 %were males.
NMTT cepha accounted for 29.6 % of antibiotics expo-
sure among total study samples and ﬂomoxef was the
most frequently prescribed (24.8 %). We identiﬁed 40
cases who admitted for hemorrhagic events and 160
matched controls (1:4 by gender, age, and index date).
Overall, 14 cases were exposed to NMTT cepha while
40 controls were exposed to NMTT cepha prior to the in-
dex date. Results of conditional logistic regressionmodel
showed that exposure to NMTT cepha was associated
with a non-statistically increased risk of hemorrhagic
events (OR 1.67, 95% CI 0.77-3.64, p = 0.19).
Conclusions: Although limited by small sample size,
the preliminary results of this population-based study
provides further insight in the potential association
between use of NMTT antibiotics and risk of hemor-
rhagic events.
695. The Risk of Acute Liver Injury among Users of
Antibiotic Medications in the PROTECT Project:
The Results of a Nested Case-Control Study Using
European Outpatient Healthcare Data
RuthBrauer,1 IanDouglas,1 LuisAlbertoGarcia Rodriguez,2
Andrew Bate,3 Liam Smeeth,1 Robert Reynolds,3 Olaf
Klungel,4 Ana Ruigomez.2 1London School of Hygiene and
Tropical Medicine, London; 2Fundación Centro Español
de Investigación Farmacoepidemiológica, Madrid; 3Pﬁzer
Ltd, New York; 4Utrecht University, Utrecht.
Background: The estimated incidence of antibiotic
induced acute liver injury (ALI) varies widely, depend-
ing on the case deﬁnition and source population used.
Objectives: We aimed to compare the risk of ALI
associated with exposure to any type of antibiotic in a
Spanish and United Kingdom (UK) database with ac-
cess to outpatient data using the same case deﬁnitions.
Methods: The case-control studies in the Clinical
Practice Research Datalink (CPRD) and “Base de
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datos para la Investigacion Farmacoepidemiologica
en Atencion Primaria” (BIFAP) were nested in two
cohorts: A cohort for whom the date of the ﬁrst antibiotic
prescription deﬁned the start of follow-up and a non-
using control cohort for whom a random start-date was
generated. After exclusion criteria were applied, cases
with ALI were identiﬁed usingmedical codes, laboratory
test results and referrals to specialists. Up to 5 controls
were matched to cases by age, sex, calendar date and,
in CPRD only, practice. We used conditional logistic
regression to compute odds ratios (OR) and 95% conﬁ-
dence intervals of ALI associated with current use of
antibiotics compared to non-use. Results were adjusted
for potential confounding variables, including smoking
status, underlying diseases such as diabetes, and use of
concurrent medications. A secondary analysis was
performed using a broader case deﬁnition.
Results: In CPRD, 263 ALI cases could be matched to
1284 controls in CPRD. In BIFAP, 124 cases were
matched to 620 controls. The results of the adjusted
analyses showed qualitatively similar evidence of an
increased risk of ALI up to 14 days after the receipt
of an antibiotic in CPRD (OR 5.7, 95% CI 3.46-9.36)
and BIFAP (OR 2.6, 95%CI 1.26-5.37). Using a broader
case deﬁnition, the OR was 3.59 (95% CI 2.79-4.61) in
CPRD and 3.08 (95% CI 2.05-4.62) in BIFAP.
Conclusions: Whilst we acknowledge the potential
inaccuracy in capturing ALI using observational data,
we found that the use of a robust case deﬁnition led
to comparable ﬁndings regardless of the source
population used.
696. A Structured Database Approach for Addressing
Pharmacoepidemiologic Research Needs Concerning
Cancer
Jinghua He, Edward A Bortnichak, Mellissa Yong.
Epidemiology, Merck Sharp & Dohme, North Wales,
PA, United States.
Background: Cancer is not only a condition targeted
by many pharmacological agents, but also can be a
safety outcome for medications used to treat other
diseases. Population based cancer research using large
databases are challenging but essential in drug devel-
opment and post-marketing safety evaluations.
Objectives: To summarize frequently encountered
pharmacoepidemiologic questions concerning cancer,
review currently available data sources, and propose a
structured database approach for addressing these issues.
Methods: A focus group discussion was conducted
among drug research and development experts at
Merck Research Labs, including clinicians, epidemiol-
ogists, and database specialists. Results from this
discussion were summarized and presented.
Results: The most often encountered cancer research
questions include general epidemiology (incidence,
prevalence, etc.); characterizing populations of interest
(comorbidity, concomitant drug use, etc.); trial planning
and recruitment; treatment pattern; patient reported
outcomes; comparative effectiveness of treatments, and
post-marketing safety studies. Currently available data-
bases can be classiﬁed hierarchically based on their
accessibility, generalizability, and richness: 1) aggregated
public databases; 2) claims and electronic medical record
(EMR) databases; 3) cancer registries; 4) cancer registry
linked to claims/EMR data; and 5) tumor biobanks linked
to clinical data. The aggregated public databases provide
the most accessible information in large populations, but
often lack patient level details. Biobank linked to clinical
data present rich information on individual patients, but
are difﬁcult to construct and often limited to small sample
sizes. Considering the strengths and limitations of various
data types, a structured strategic database approach is
proposed. Common research needs are mapped to one
or multiple database hierarchy levels that likely offer
appropriate and practical solutions.
Conclusions: In spite of limitations, currently available
healthcare databases together offer ample research
opportunities to address cancer pharmacoepidemiologic
questions encountered during the drug development
lifecycle.
697. Increasing Risks of Stroke in Oral Cancer
Patients Treated with Radiotherapy or Chemotherapy:
A Nationwide Cohort Study
Yu-Ting Wu,1 Chung-Yu Chen,1 Yaw-Bin Huang,1,2
Cheng-Chiun Kuo.2 1Kaohsiung Medical University,
Kaohsiung, Taiwan; 2Kaohsiung Medical University
Chung-Ho Memorial Hospital, Kaohsiung, Taiwan.
Background: Several studies investigated the associa-
tion between cancers and stroke, especially in patients
who received radiotherapy or chemotherapy. However
the study evaluated the risks of stroke in oral cancer is
limited.
Objectives: The study intends to investigate the epide-
miology and hazard of stroke in oral cancer patients
treated with radiotherapy or chemotherapy.
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Methods: We conducted a population based retrospec-
tive cohort study in National Health Insurance Research
Database (NHIRD) in Taiwan from 1999 to 2009.
Our study included patients newly diagnosed with oral
cancer (ICD-9:141, 143, 144, 145) in 2000 to 2008. Pa-
tients aged less than 20years, with prior stroke, or prior
cancer history were excluded. All the populations were di-
vided into four subgroups: surgery-only, radiotherapy(RT)
-only, chemotherapy(CT)-only, both radiotherapy/chemo-
therapy, surgery plus radiotherapy or chemotherapy.
Each subject was followed from index date (diag-
nosed date of oral cancer) to the occurrence of stroke
(ICD-9 CM 430-438), death, withdrawn from the
insurance policy, or until 31 December 2009.
Cox proportional hazard model was used to estimate
hazard ratios (HR) of stroke and adjusted for age, sex,
Charlson comorbidity index, and chemotherapy. We
also calculate the stroke-free survival rate by using
Kaplan-Meier method following 5 years, with occur-
rence of stroke or death.
Results: From long term follow-up, there were 2511
patients had stroke (9.04%) from NHIRD. The hazard
ratio of stroke was 1.72-fold (95% CI: 1.517-1.956)
higher in patients treated with RT-only group and
1.847-fold (95% CI: 1.48-2.306) in CT-only group
compared to reference group (surgery-only group).
Interestingly, patients aged less than 40 had approx-
imate 3-fold high risk of stroke compared to surgery-
only group. There was no signiﬁcant difference in
stroke risk between different treatment modalities in
patients aged 50 and more.
Conclusions: Younger oral cancer patients treated
with radiotherapy or chemotherapy have higher risks
for stroke. Different modalities strategies and comor-
bidities may also elevate the risk.
698. Algorithm to Identify Malignant Lymphoma
Patients Extracted from an Electronic Hospital Da-
tabase and Its Application in Japan
Sumiko Okubo,1 Shuko Nojiri,1 Stepehn Paul Motsko,4
Yu Yan,4 Masanori Taketsuna,2 Haru Nakasawa,1 Hiroya
Asou,3 Rei Maeda.1 1Global Patient Safety, Eli Lilly
Japan KK, Kobe, Japan; 2Statistical Sciences, Eli Lilly
Japan KK, Kobe, Japan; 3Japan Medical Oncology, Eli
Lilly Japan KK, Kobe, Japan; 4Global Patient Safety,
Eli Lilly and Company, Indianapolis, United States.
Background: Malignant lymphoma is a group of hae-
matological malignancies with various clinical fea-
tures. Gemzar® was approved for the indication of
recurrent or refractory malignant lymphoma by the
Ministry of Health and Labor and Welfare in 2013.
There are few epidemiological studies using electronic
databases looking at malignant lymphoma patient pro-
ﬁle and prescription data in Japan.
Objectives: The purpose of this study was to develop an
algorithm to identify malignant lymphoma patients pre-
scribed with Gemzar® from electronic databases in Japan.
Methods: Patients with an ICD-10 code for malignant
lymphoma, whowere prescribed with Gemzar®, were se-
lected between 2008 April and 2013 Jan from an elec-
tronic hospital database. Two experienced oncologists
reviewed each potential malignant lymphoma patient’s
electronic medical claims proﬁle to decide on the true
malignant lymphoma cases. Based on this clinical re-
view, an algorithm with ICD-10 codes in combination
with procedure codes (procedure history for stem cell
transplantation) or prescriptions (rituximab or cyclophos-
phamide or vincristine) was developed. The sensitivity
and speciﬁcity of this algorithm were calculated based
on medical claims review.
Results: A total of 75 potential malignant lymphoma
patients with Gemzar® use were identiﬁed and under-
gone medical claims review. The deﬁned algorithm
was applied to these patients, yielding 24 patients with
malignant lymphoma. Based on medical claims review,
the algorithm yielded a sensitivity of 81.8% and speciﬁc-
ity of 88.7%.We also applied our algorithm to a different
time frame, and similar results were noted.
Conclusions: To our knowledge, this is the ﬁrst algo-
rithm developed to improve the validity for identifying
malignant lymphoma patients within an electronic
hospital database in Japan. The integrated approach
used in this study is a feasible method in the study of
patient proﬁles and treatment patterns.
699. The Disproportionate Analysis of Intravenous
Iron-Containing Medicines Related Adverse Reac-
tions in Taiwan
Yu Jie Huang,1 Wei Ming Ke,1 Wei I Huang,1 Wen Wen
Chen.1 1Taiwan National ADR Reporting Center,
Taiwan Drug Relief Foundation, Taipei, Taiwan.
Background: Intravenous iron-containing medicines
are the primary treatment for iron deﬁciency anemia
patients who are intolerant or failure to oral therapy.
All intravenous iron-containing products have the
risk of causing hypersensitivity reactions which
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can be life-threatening if not treated properly.
In June 2013, the EMA gave new recommendations
to manage the risk of allergic reactions of
these products.
Objectives: To examine the disproportional reporting
ratio of intravenous iron-containing medicines related
adverse reactions.
Methods: By using Taiwan National ADR Reporting
System database, we reviewed all ADR reports related
to intravenous iron-containing medicines from July
2008 to June 2013. The drug-reaction pairs were
coded with WHO-ATC code and MedDRA
dictionary. Signals of disproportional reporting were
identiﬁed by Proportional Reporting Ratio (PRR)
method at MedDRA preferred term (PT) level. Signals
were deﬁned as the lower bound of the 95% conﬁdential
interval (95%CI) of PRR≥ 1 and the number of reported
cases ≥3.
Results:We identiﬁed 116 ADR cases associated with
intravenous iron-containing products in the database
during the study period, including 88 (76%) females
and 28 (24%) males. Among these cases, the most
frequently reported reactions were dyspnea (8%),
followed by rash (7%), rash pruritic (7%), injection
site pain (6%) and pruritus (5%). The disproportion-
ate analysis identiﬁed 18 signals, where anaphylac-
toid reactions (PRR=92.7, 95% CI= 39.1-219.8,
n = 4), injection site pain (PRR=44, 95% CI=27-71.7,
n = 11), pain (PRR=23.2, 95% CI= 8.9-60.1, n = 3),
and injection site reaction (PRR=18.8, 95% CI= 8.3-
42.7,n = 4) appeared to be stronger signals during the
study period.
Conclusions: The disproportionate analysis of intra-
venous iron-containing medicines related ADR reports
indicated that anaphylactoid reaction was a potential
safety signal in Taiwan, which was corresponded with
the EMA warnings. Our ﬁndings provided essential
information for further signal reﬁnement and manage-
ment activities.
700. Use of Antihypertensive Drugs and Risk of Skin
Cancer
Sigrun A Johannesdottir,1,2 Morten Schmidt,1,2 Frank
Mehnert,1 Stanley Lemeshow,1,2 Henrik T Sørensen.1
1Department of Clinical Epidemiology, Aarhus Univer-
sity Hospital, Aarhus N, Denmark; 2Division of Biostatis-
tics, College of Public Health, Ohio State University,
Columbus, OH, United States.
Background: Several antihypertensives are photos-
ensitizing and may act as co-carcinogens with ultravi-
olet radiation.
Objectives: To determine whether angiotensin-
converting enzyme (ACE) inhibitors, angiotensin re-
ceptor blockers (ARBs), β-blockers, calcium channel
blockers (CCBs), and diuretics increase the risk of
squamous cell carcinoma (SCC), basal cell carcinoma
(BCC), and malignant melanoma (MM).
Methods: We used medical databases to conduct a
case-control study including all ﬁrst-time cases of
SCC (n = 2,282), BCC (n = 17,242), and MM
(n = 3,660) in northern Denmark 1991–2010. We
matched approximately ten controls (n = 231,743) to
each case by age, gender, and county of residence
using risk-set sampling. We used conditional logistic
regression to compute odds ratios (ORs) for skin
cancer with 95% conﬁdence intervals, comparing
ever users of antihypertensives (>2 previous
prescriptions) with non-users (≤2 previous prescriptions).
We adjusted for comorbidity and comedications. We
further analyzed ever use by duration (short-term:
<5 years; long-term: ≥5 years) and intensity (low-
intensity or high-intensity: <50% or ≥50% prescrip-
tion coverage during total duration of use,
respectively).
Results: Ever users of diuretics were at increased risk of
SCC (OR 1.19; 1.06–1.33), driven by potassium-spar-
ing agents alone (OR 1.40; 1.16–1.90) or
combined with low-ceiling diuretics (OR 2.68;
2.24–3.21) and by long-term use (OR 1.46 for both
low-intensity and high-intensity use). Ever users of
sulfonamides (OR 1.49; 1.04–2.12) and non-aldo-
sterone antagonist potassium-sparing agents (OR
2.26; 0.85–6.01) were at increased MM risk. The
latter also increased BCC risk (OR 1.47; 1.00–
2.17), as did low-ceiling diuretics combined with
potassium-sparing agents (OR 1.23; 1.12–1.35).
Use of some β-blockers increased the risk of MM
(20% for β1-selective), SCC (76% for non-selective
α- adrenergic), and BCC (21% for non-selective
β-blockers). Depending on intensity, long-term
ARB users had a 40–50% increased risk of MM.
Associations for CCBs and ACE inhibitors were
weak or inconsistent.
Conclusions: Use of some antihypertensives was
associated with an increased risk of skin cancer,
especially when used at long-term.
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701. Cancer Prognosis Following the Usage of Angio-
tensin-Converting Enzyme Inhibitors or Angiotensin
Receptor Blockers on Lung Cancer Patients with
Hypertension History
Pei-Jung Sha,1 Jong-Rung Tsai,2,3 Kun-Pin Hsieh,4,5
Yi-Hsin Yang.4 1Master Program in Clinical Pharmacy,
School of Pharmacy, College of Pharmacy, Kaohsiung
Medical University, Kaohsiung, Taiwan; 2Department
of Internal Medicine, Kaohsiung Medical University
Hospital, Kaohsiung, Taiwan; 3Department of
Respiratory Therapy, College of Medicine, Kaohsiung
Medical University, Kaohsiung, Taiwan; 4School of
Pharmacy, College of Pharmacy, Kaohsiung Medical
University, Kaohsiung, Taiwan; 5Department of
Pharmacy, Kaohsiung Medical University Hospital,
Kaohsiung, Taiwan.
Background: The use of angiotensin-converting
enzyme inhibitors (ACEIs) or angiotensin receptor
blockers (ARBs) is associated with longer survival
time because of its antiangiogenesis effect in lung
cancer patients.
Objectives: To further investigate whether there is
a dose-response association on the overall survival
(OS) and progression-free survival (PFS) rates from
the use of ACEIs, ARBs or other anti-hypertensive
medication in lung cancer patients with hyperten-
sion history.
Methods: We conducted a population-based retro-
spective cohort study using the Taiwan Health
Insurance Research Database (NHIRD). The cohort
consisted of newly-diagnosed lung cancer patients
during 2003-2010 with a hypertension history and
using anti-hypertensive medication in the year before
lung cancer diagnosis. OS and PFS rates and the
medication possession ratios (MPR) at the year
before or at the ﬁrst 6 month after diagnosis were
computed for ACEI/ARB groups. The COX regres-
sion was used to estimate the hazard ratios (HR) for
various groups of ACEI/ARB after adjusting for
covariates.
Results: Among 19,592 newly-diagnosed patients
with hypertension and using anti-hypertensive medica-
tion prior to the cancer diagnosis, there are 57.2%
patients belonged to ACEI/ARB group. The HRs de-
creased from 0.870 (95%CI = 0.819-0.924, p< 0.001)
to 0.846 (95%CI = 0.789-0.907, p< 0.001) for OS
and 0.895 (95%CI = 0.845-0.948, p< 0.001) to 0.878
(95% CI=0.821-0.938, p< 0.001) for PFS in increasing
MPRs from 50% to 90% at the post usage of ACEI/ARB.
While considering pre- and post-diagnostic usage of
ACEI/ARB, patients who used ACEI/ARB at both
periods has signiﬁcant protection in OS (HR=0.928,
95%CI=0.883-0.976) and PFS (HR=0.926, 95%CI=
0.882-0.971).
Conclusions: Post-diagnostic ACEI/ARBs use was
associated with signiﬁcant lower HRs for OS and
PFS in patients with lung cancer and had a history of
hypertension. Our results provide contribution on the
dose-responsive association in MPRs of ACEI/ARBs
after lung cancer diagnosis.
702. Stroke Epidemiology in China over the Past
Ten Years, a Study on Subtype Distribution and
Case Fatality
Lei Yan,1 Jiapeng Lu,2 Yadong Cui,3 Dena R Ramey,3
Jing Li,2 Lixin Jiang.2 1Epidemiology-Asia Paciﬁc Unit,
Merck Research Laboratories, MSD China, Beijing,
China; 2National Clinical Research Center of Cardiovas-
cular Diseases, State Key Laboratory of Cardiovascular
Disease, Fuwai Hospital, National Center for Cardiovas-
cular Diseases, Chinese Academy of Medical Sciences
and Peking Union Medical College, Be; 3Department of
Epidemiology, Merck Research Laboratories, Merck,
Whitehouse Station, NJ, United States.
Background: In China, stroke accounts for ~20% of
all adult deaths, and there are approximately 2
million new cases annually. However, there is
limited recent information on the distribution of
different subtypes and fatality rates for stroke in
the Chinese population.
Objectives: To understand the current distribution
of stroke subtypes in the Chinese population and
changes over the past 10 years.
Methods: This is a hospital-based, retrospective,
epidemiological study among inpatients diagnosed
with stroke (both incident and recurrent stroke) in the
past 10 years. 20 hospitals were selected from different
cities in the Northern and Southern part of China, with
one urban hospital and one rural hospital paired in
each city. Cases were randomly selected from the
stroke inpatients in each hospital in 2002, 2005,
2008 and 2011, respectively. All information, includ-
ing demographics, medical histories, tests, treatments,
diagnosis, and patient outcomes w abstracted from
medical records. Chi-square test was used for statisti-
cal analysis.
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Results: The total number of cases was 11,182, in-
cluding 2508 in 2002, 2744 in 2005, 2941 in 2008,
and 2989 in 2011. The average age was 64.9 years
and 40.5% were females. Most cases (96%) were
diagnosed by CT and/ or MRI, and the diagnosis rate
by MRI increased from 11% in 2002 to 41.3% in
2011. Overall, 69.2% of strokes were ischaemic,
22.1% were haemorrhagic, 2.6% were ischaemic
with haemorrhagic transformation, and 6.1% were
transient ischaemic attacks or others. The proportion
of haemorrhagic subtype was higher in rural
areas than in the urban areas (28.2% vs. 18.1%,
P< 0.05). The proportion of haemorrhagic strokes
signiﬁcantly decreased from 2002 to 2011,
with 26.6%, 22.2%, 22.7%, and 17.5%, respectively
in 2002, 2005, 2008, and 2011 (P< 0.01). The in-
hospital fatality rate of all strokes also decreased over
the past 10 years, with 6.1%, 4.6%, 3.4% and 2.9%
respectively, in 2002, 2005, 2008 and 2011 (P< 0.05).
Conclusions: The proportion of haemorrhagic strokes
and fatality rate for all strokes decreased signiﬁcantly
over the past 10 years. The use of MRI for stroke diag-
nosis has increased signiﬁcantly over the years.
703. The Effect of Using Statin for Cardiovascular
Prevention in Peritoneal Dialysis Patients
Ping-Hsun Wu,1,4 Yi-Ting Lin,2,3 Mei-Chuan Kuo,1,5 Yi-
WenChiu,1,5 Hung-ChunChen.1,5 1Division of Nephrology,
Department of Internal Medicine, Kaohsiung Medical
University Hospital, Kaohsiung, Taiwan; 2Department of
Family Medicine, Kaohsiung Medical University Hospital,
Kaohsiung, Taiwan; 3Department of Public Health, College
of Life Science, Kaohsiung Medical University, Kaohsiung,
Taiwan; 4Graduate Institute of Medicine, College of Medi-
cine, Kaohsiung Medical University, Kaohsiung, Taiwan;
5Faculty of Renal Care, College of Medicine, Kaohsiung
Medical University, Kaohsiung, Taiwan.
Background: End-stage renal disease is associated
with a high risk of cardiovascular event, which is
one of the leading causes of death among peritoneal
dialysis patients. However, most of the statin treatment
randomized studies focus on hemodialysis or chronic
kidney disease. The study of statin use for cardiovas-
cular prevention in peritoneal dialysis patients is still
sparse and need further investigate.
Objectives: This study aimed to evaluate the efﬁcacy
of statin in reducing the subsequent risk of cardiovas-
cular event in a national cohort of Taiwan peritoneal
dialysis patients.
Methods: We conducted a nationwide follow-up
study, based on the Taiwan National Health Insurance
Research Database. We identiﬁed 7114 incident
peritoneal dialysis patients between during 1998 and
2006. After excluding age< 18 years, renal transplan-
tation, acute coronary syndrome and all type of stroke
within 3months after dialysis, and switch from perito-
neal dialysis to hemodialysis for more than 3months,
there were remain 5466 patients. Of the peritoneal di-
alysis patients, there were 2839 patients received statin
treatment for hyperlipidemia control (725 received
statin with medication possession ratio (MPR) more
than 80% in the ﬁrst year and 2,114 received statin
with MPR less than 80%). During the 3 years follow
up, the primary outcomes of the study was major
cardiovascular event, which include hospitalization
for acute coronary syndrome and ischemic stroke.
Results: Statin with MPR more than 80% users were
not signiﬁcantly lower hospitalization for major car-
diovascular event than statin with MPR less than
80% users (6.34% vs. 7.05%), whereas full adjusted
hazard ratio [HR] was 0.91 (95% conﬁdence interval
[CI]: 0.65 to 1.27) after age, sex, comorbidities and
medications prescription during study period. The full
adjusted HRs of hospitalization for acute coronary
syndrome and ischemic stroke were 0.9 (95% CI:
0.61 to 1.32) and 0.98 (95% CI: 0.5 to 1.89).
Conclusions: In this retrospective analysis, statin use
in patients undergoing peritoneal dialysis had no
statistically signiﬁcant effect on the composite end
point of hospitalization for acute coronary syndrome
and ischemic stroke.
704. Statin Use and Risk of New-Onset Diabetes in
the Young Population with Hyperlipidemia
Yi-Ting Lin,1,4 Ping-Hsun Wu,2,5 Tsung-Hsien Lin.3,6 1De-
partment of Family Medicine, KaohsiungMedical University
Hospital, Kaohsiung, Taiwan; 2Division of Nephrology,
Department of Internal Medicine, Kaohsiung Medical Uni-
versity Hospital, Kaohsiung, Taiwan; 3Division of Cardiol-
ogy, Department of Internal Medicine, Kaohsiung Medical
University Hospital, Kaohsiung, Taiwan; 4Department of
Public Health, College of Life Science, Kaohsiung Medical
University, Kaohsiung, Taiwan; 5Graduate Institute of Med-
icine, College of Medicine, Kaohsiung Medical University,
Kaohsiung, Taiwan; 6Faculty of Medicine, College of Medi-
cine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Background: Statins use and risk of new-onset diabetes
(NOD) are demonstrated in clinical trial and cohort
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studies in the elderly patients. The association between
statin use and incident diabetes risk on young population
was not evaluated and also lack of data from randomized
control trial or meta-analysis. It remains unclear whether
statin use increases diabetes risk in the young population.
Objectives: The study aimed to evaluate the association
of statin exposure and diabetes risk in young patients.
Methods: From Taiwan National Health Insurance
beneﬁciaries we enrolled patients with age< 45 years
in men and <55 years in women between Janunary
1, 1997 and December 31, 2004 and continuously
treated with statins ≥30 days. Non-statin users were
matched to statin users on a 3:1 ratio by age, sex, ur-
banization level, socioeconomic status, and calendar
year. The study cohort was followed up until the oc-
currence of NOD, death, or until December 31, 2008.
Results: The risk of NOD in young patients treated
with statin were signiﬁcantly higher than non-users
(adjusted hazard ratio [aHR]: 4.90, 95% conﬁdence in-
terval [CI]: 4.10-5.84, p< 0.001). Regarding the statin
treatment duration, the higher NOD risk was found in
longer statin users (≥3months vs control, aHR: 5.47,
95% CI: 4.57-6.55, p< 0.001; ≥6months vs control,
aHR: 6.34, 95% CI: 5.29-7.61, p< 0.001; ≥3 years vs
control, aHR: 8.23, 95% CI: 6.59-10.29, p< 0.001).
The risk of incident diabetes in the statin group com-
pared with the control group was still higher than
control, even stratiﬁed by the baseline characteristics.
Conclusions: NOD and statin use was signiﬁcant
associated in young patients. Blood glucose should
be closely monitored in the young population with
long-term statin use.
705. Statin Use and the Risk of Incident Diabetes
Mellitus: A Population-Based Retrospective Cohort
Study in Taiwan
Zhen-Fang Lin,1 Fe-Lin Wu Lin.2 1School of Pharmacy,
National Taiwan University, Taipei, Taiwan; 2Graduate
Institute of Clinical Pharmacy, National Taiwan University,
Taipei, Taiwan.
Background: The effectiveness of statins in reducing
the risk of cardiovascular mortality and morbidity in
acute coronary syndrome (ACS) patient is well-
established. Although, statins are widely used and well
tolerated in ACS patients, an association with an
increased risk of new-onset diabetes mellitus has been
reported in various population groups.
Objectives: The objective of this study is to examine
the association between individual statin use and the
risk of incident diabetes mellitus in ACS patients
following percutaneous coronary intervention (PCI).
Methods: We conducted a retrospective cohort study
of patients who were hospitalized for ACS between 1
January 2006 and 31 December 2007 retrieved from
the Taiwan National Health Insurance Research
Database (NHIRD) and who were underwent PCI
(n = 18550). A propensity score technique was used
to establish a matched cohort for statin and non-statin
users in 1:1 (n = 6459 for each group). The relative risk
of statin users compared to non-statin users on the
occurrence of the incident diabetes mellitus for ACS
patients after PCI was analyzed by multivariable Cox
proportional hazards regression model.
Results: The statin users were signiﬁcantly associated
with a 19% increase in the risk of new onset diabetes
mellitus with the adjusted hazard ratio (HR) of 1.19
(95% CI, 1.07-1.33, p = 0.002) and the deﬁned daily
dose (DDD) adjusted HR of 1.27 (95% CI, 1.11-
1.45, p = 0.001) compared to non-statin users in the
matched cohort. In the matched cohort analysis for
these statin subgroups indicated that ﬂuvastatin and
simvastatin were associated with a statistically signiﬁ-
cant increase in the risk of new onset diabetes mellitus
with the adjusted HR of 1.33 (95% CI, 1.06 to 1.67);
DDD-adjusted HR of 1.98 (95% CI, 1.42-2.75) and
adjusted HR of 1.52 (95% CI, 1.24 to 1.87); DDD-
adjusted HR of 1.68 (95% CI, 1.23-2.28) respectively.
Conclusions:Our study indicated statistically signiﬁcant
increased risk of new onset diabetes mellitus and statin
use. Among individual statins, only ﬂuvastatin and
simvastatin were found to be statistically signiﬁcantly as-
sociatedwith increased risk of new onset diabetesmellitus.
706. ACE-Inhibitors and the Risk of Urinary Tract
Infections: Comparison of a Case-Crossover and
Prescription Sequence Symmetry Design
Koen B Pouwels, Jens HJ Bos, Eelko Hak. Unit of
PharmacoEpidemiology & PharmacoEconomics, De-
partment of Pharmacy, University of Groningen,
Groningen, Netherlands.
Background: In a post-hoc analysis of a randomized
controlled trial (RCT) (HR 1.82, 95%CI, 1.16-2.88)
and a prescription sequence symmetry analysis
(PSSA) (SR 1.56, 95%CI 1.11-2.20), we observed that
angiotensin-converting enzyme inhibitor (ACEi) use
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was associated with an increased risk of urinary tract
infections (UTIs).
Objectives: To evaluate the association between
ACEi and UTIs using a case-crossover design and
compare the results obtained with the previously
published PSSA and RCT.
Methods: A population-based case-crossover design
was performed with a pharmacy prescription database
(IADB.nl). The date of incident use of nitrofurantoin
(a proxy for UTIs) was deﬁned as the index date.
The risk period was deﬁned as 30 days before the
index date and the control period as 60-90 days before
that date. A person was considered exposed to ACEi if
there was at least 3 days’ supply within the window.
The following drugs were considered as time-varying
confounders: β-blockers, calcium channel blockers,
angiotensin-receptor blockers, diuretics, lipid-modifying
agents, non-steroidal anti-inﬂammatory drugs and glucose-
lowering drugs. In secondary analysis the deﬁnitions were
set similar to the PSSA. Conditional logistic regressionwas
used for all analyses.
Results: There were 51,249 patients that received a ﬁrst
nitrofurantoin prescription and met eligibility criteria. Of
these, 276 patients were only exposed to ACEi during
the risk window and 150 patients only during the control
window (crude OR 1.84, 95%CI 1.51-2.25; adjusted OR
1.74, 95%CI 1.42-2.13). Restricting the analysis to individ-
uals within the same age-category as the previous RCT, the
adjusted OR increased to 1.90 (95%CI 1.44-2.50). When
using similar deﬁnitions and criteria as in the PSSA, the
case-crossover estimates were slightly higher (adjusted
OR 2.09, 95%CI 1.68-2.61).
Conclusions: ACEi were associated with an increased
risk of developing ﬁrst UTIs. Despite the similarities
between the case-crossover design and the PSSA, the
PSSA led to slightly lower effect estimates than the
case-crossover analysis and the RCT.
707. Discontinuation of Angiotensin Converting
Enzyme Inhibitors (ACEIs) as a Potential Marker
for Adverse Drug Reactions (ADRs)
Seyed Hamidreza Mahmoud Pour,1 Catherine E de
Keyser,2,3 Patrick C Souverein,1 Folkert W Asselbergs,4
Albert Hofman,2 Bruno H Stricker,2,3 Anthonius de
Boer,1 Anke-Hilse Maitland-van der Zee.1 1Division of
Pharmacoepidemiology and Clinical Pharmacology,
Utrecht Institute for Pharmaceutical Sciences (UIPS),
Utrecht University, Utrecht, Netherlands; 2Department
of Epidemiology, Erasmus Medical Center, Rotterdam,
Netherlands; 3Department of Pharmacovigilance, The
Health Care Inspectorate, The Hague, Netherlands; 4Di-
vision of Heart and Lungs, Department of Cardiology,
University Medical Center, Utrecht, Netherlands.
Background: ACEI-induced ADRs are the main rea-
son to discontinue ACEI treatment. In prescription
databases, information on ADRs is not available;
therefore it is necessary to identify proxies for ADRs
in such databases to study risk factors for ADRs.
Objectives: To study prescription patterns for ACEIs
as potential marker for ACEI-induced ADRs.
Methods: A cohort of patients starting ACEI from
2000 to 2011 was identiﬁed within the Rotterdam
Study, (a prospective population-based cohort study
of approximately 15,000 individuals aged 45 years
and older). Medication dispensing data on daily basis
were obtained from the fully computerized linked
pharmacies. Participants were followed from the start
of ACEI treatment until the end of study period, death
or moving out of the area, whichever came ﬁrst.
Patients were classiﬁed into 4 mutually exclusive
groups: continuous users, discontinued users, switchers
to angiotensin receptor blockers (ARBs), and switchers
to other antihypertensives. For continuous use or
switching, the maximum time interval between two
prescription periods was set at 3 or 6months. Patients
without a prescription for antihypertensives, 3 or
6months after the end date of the last ACEI prescription
were classiﬁed as discontinued users. Primary care
physician ﬁles were searched for reasons of ACEI dis-
continuation for patients who discontinued or switched
ACEIs. Clinical events were classiﬁed as deﬁnite ADRs
(73.5% cough, 3% angioedema, 23.5% others), probable
ADRs, possible ADRs and deﬁnite non-ADRs. Positive
predictive values (PPVs) of the prescription patters of the
3 groups for ADRs were calculated.
Results: Totally 1132 patients were included. The PPV
for a deﬁnite ADR was 56.1% in switchers to ARBs,
while the PPVs for switchers to other antihypertensives,
and discontinued users were 39.5% and 19.5%. Includ-
ing probable and possible ADRs, increased the PPVs for
switchers to ARBs to 68.3% and 90.5%. A 6-month
time interval gave slightly higher PPVs compared to a
3-month interval (maximum 6.1% higher).
Conclusions: This study showed that switching from
ACEI to ARB is the best marker for ACEI-induced
ADRs in prescription databases.
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708. Epidemiology of Psoriasis in Japan: Results
from a Descriptive Study Using National Database
Yukari Kamijima,1,2 Nobuhiro Ooba,1 Tsugumichi Sato,1,3
Kiyoshi Kubota.1,2 1Department of Pharmacoepid-
emiology, Faculty of Medicine, University of Tokyo, Tokyo,
Japan; 2NPO Drug Safety Research Unit Japan, Tokyo,
Japan; 3Department of Pharmacy, Faculty of Pharmaceutical
Sciences, Tokyo University of Science, Chiba, Japan.
Background: The prevalence of patients with psoriasis
is not known in Japan. We report the results of a
descriptive study on patients with Psoriasis, one of the
ﬁrst research projects using the National Data Base
(NDB) of claims covering the whole Japanese
population.
Objectives: To know the prevalence, treatments and
comorbidity of psoriasis in Japan.
Methods: All the patients with a diagnostic code of
psoriasis in outpatient or inpatient claims issued dur-
ing the period from April 2010 to March 2011 were
identiﬁed in the NDB. Patients were classiﬁed into
those with palmoplanter pustulosis only (PPP) and
psoriasis with or without PPP (PSO). As a surrogate
for severity of psoriasis, treatments for PSO
and PPP were classiﬁed as systemic therapy (ST),
phototherapy without ST (PT) and topical therapy
only (TT). Patients with diagnostic code of
hyperlipidemia (HL), hypertension (HT) and
diabetes mellitus (DM) were deﬁned as having
those comorbidities if they also received lipid-low-
ering drug, antihypertensive drug and anti-diabetic
drug, respectively. We calculated and compared
the prevalence of comorbidities between patients
with different severities.
Results: A total of 565,903 patients (prevalence =
0.44%) were identiﬁed and classiﬁed into 429,679
(0.33%) with PSO and 136,224 (0.11%) with PPP.
The median age (given at intervals of 5 years) was
55-59 years old for both PSO and PPP. Males were
predominant with PSO (male: 59.1%) while females
were predominant with PPP (male: 34.7%). As
treatments for skin diseases, 9.3, 4.4, 77.5 and 8.9
% of patients with PSO and 1.9, 7.5, 75.1 and
15.6% of patients with PPP had ST, PT, TT and
no treatment, respectively. In both of the patients
with PSO and PPP, the prevalence of comorbidities
was higher (P< 0.0001 by chi-square test for all of HL,
HT and DM) in those with ST compared to those with
PT or TT.
Conclusions: This is the ﬁrst descriptive study using
the NDB about the patients with psoriasis in Japan
and provide full picture of the characteristics of those
patients. The NDB may be useful for descriptive
epidemiological study of diseases.
709. Risk of Cardiac Valve Disorders with Use of
Bisphosphonates
Preciosa M Coloma,1 Maria de Ridder,1 Peter Rijnbeek,1
Mees Mosseveld,1 Irene Bezemer,2 Ron MC Herings,2
Rosa Gini,3 Serena Pecchioli,4 Lorenza Scotti,5 Johan van
der Lei,1 Gianluca Triﬁrò,6 Miriam CJM Sturkenboom.1
1Medical Informatics, Erasmus MC University Medical
Center, Rotterdam, Netherlands; 2PHARMO Institute N.
V., Utrecht, Netherlands; 3Agenzia Regionale di Sanità
della Toscana, Florence, Italy; 4Società Italiana di
Medicina Generale, Florence, Italy; 5Università di
Milano-Bicocca, Milan, Italy; 6Clinical and Experimental
Medicine, University of Messina, Messina, Italy.
Background: A signal of cardiac valve disorders with
use of bisphosphonates was found in literature and in
Eudravigilance database, which contains reports of
suspected ADRs from worldwide sources.
Objectives: To evaluate risk of cardiac valve (CV)
disorders with use of bisphosphonates (BI).
Methods: Design/Setting:Case control study nested in
cohort of new users of BI from 6 electronic healthcare
databases in 3 countries (Italy,Netherlands,UK) in
1996-2012.Data extraction was done locally using
standardized protocol and software,followed by cen-
tralized analyses.
Exposures:Drug prescription/dispensing data were
used to evaluate drug exposure to BI and to other
drugs used for osteoporosis.Drug exposure was
characterized by recency and duration of use,with
180-day carry-over period.
Outcomes:All potential cases of CV disorders,
with separate subsets for valve regurgitation and
valve calciﬁcation,were identiﬁed using database-
speciﬁc disease codes/free-text search.Controls were
matched to each case by age, sex,database,index date.
Analyses:Adjusted odds ratios (ORs) were esti-
mated using conditional logistic regression.Analyses
were performed for the pooled data and for each
database separately,followed by meta-analysis.Same
analyses were performed in extended cohort of users
of drugs for osteoporosis,the main indication of use
for BI.
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Results: A very small but signiﬁcant association
was found between exposure to BI as a class and
risk of CV disorders.Overall, the risk of CV disor-
ders was 18% higher (95%CI 12%-23%) in current
users of any BI as compared with distant past
users.Speciﬁc risk of valve regurgitation was 14%
higher (95%CI 7%-22%),while no increased risk
of valve calciﬁcation was found.There was no sig-
niﬁcant heterogeneity (p = 0.13) in overall results
across databases.Sensitivity analyses showed no
increased risk of CV disorders for current use of
BI vs. current use of other anti-osteoporosis
drugs.Alendronate and risedronate were consis-
tently associated with small increased risk of
CV disorders in general and valve regurgitation
in particular.
Conclusions: Current use of BI as a class (and
alendronate and risedronate in particular) is associ-
ated with a small but signiﬁcant increased risk of
CV disorders.
710. Marginal Structural Model (MSM) to
Estimate the Effect of Cumulative Osteoporosis
Medication (OPM) on Serious Infection (SI) Using
Claims Data
Fei Xue,1 Vamshidar Goli,1 Paul Petraro,1 Trevor
McMullan,2 Eric Tchetgen Tchetgen.3 1Center for
Observational Research (CfOR), Amgen Inc., Thousand
Oaks, CA, United States; 2Global Biostatistics, Amgen
Inc., Thousand Oaks, CA, United States; 3Department
of Biostatistics and Epidemiology, Harvard School of
Public Health, Boston, MA, United States.
Background: The suboptimal persistence to OPM
may complicate the assessment of treatment effect.
Factors (e.g., fragility fracture) that trigger treatment
discontinuation/switching may be affected by
prior treatment and also confound the subsequent
treatment effect, causing time-varying (TV)
confounding. MSM is a useful tool to adjust for
TV confounding.
Objectives: To estimate the causal effect of cumula-
tive exposure to bisphosphonate (BP) and other OPM
on incidence rate (IR) of SI in women with PMO.
Methods: Women 55+ years old with a diagnosis or
treatment related to OP were identiﬁed from the
MarketScan database (2004 – 2011) and followed
for incident SI and general infection (GI). Cumula-
tive BP treatment from the start of follow-up was
assessed in 2 ways: 1) current and past treatment
with BP and other OPM; 2) cumulative BP dose
converted to alendronate-equivalent dose. Stabilized
weights (SW) were estimated by modeling treat-
ment and censoring processes conditional on past
treatment, baseline and TV covariates (updated upon
initiating, switching or ending treatment, censoring or
diagnosis of fragility fracture). Treatment effect was
estimated by unweighted Cox models and MSM
weighted by SW.
Results: Infection risk factors were less prevalent in
the BP-treated patients than other women with PMO.
Relative to the untreated, current or past BP treatment
was associated with lower IR of SI in the unweighted
models [IRR (95% CI): 0.85 (0.82 – 0.89) to 0.78
(0.76 – 0.80)] and MSM [0.84 (0.77 – 0.90) to 0.62
(0.59 – 0.63)], regardless of the status of other OPM.
When GI was assessed, treatment with current or past
BP treatment was associated with a similar or higher
IR [IRR (95% CI): 0.98 (0.96 – 0.99) to 1.12 (1.10 –
1.14)] in unweighted model, but a decreased IR [0.85
(0.84 – 0.87) to 0.69 (0.68 – 0.71)] in MSM. Analysis
of BP cumulative dose generated similar results.
Conclusions: The discrepancy of effect estimates for GI
but not SI comparing unweighted vs. weighted MSM
models suggested the analysis of combo outcomes with
a wide range of disease severity may be more susceptible
to TV confounding which can be adjusted for by MSM.
711. Case Report: Stevens-Johnson Syndrome
Following Exposure to Valproate
Hui-Hsia Hsieh, Ching-Yi Chang, Yung-Ta Lin,
Chi-Hua Chen. Pharmacy, Taichung Tzu Chi Hospital,
Buddhist Tzu Chi Medical Foundation, Taichung.
Background: Valproate can reduce abnormal brain
nerve discharge for the treatment of grand mal, petit
mal, hybrid and common temporal lobe epilepsy.
Stevens-Johnson Syndrome (SJS) is a severe life-
threatening adverse drug reaction that may manifest
within a few days to several months after exposure.
Objectives: Case Description: A 29-year-old woman
with a history of epilepsy and intellectual development
retardation, had previously received valproate and
other anticonvulsant drugs to manage seizures. She
developed good seizure control, and discontinued all
anticonvulsants 25 years ago. Due to recurrent
seizures, she reinitiated valproate treatment (600mg
BID) on Nov. 2013. One week later, she suffered
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common cold symptoms such as fever, dysphagia, and
poor appetite. On November 23rd, she was admitted
via emergency department due to fever, red, swollen
eyes and lots secretions of her eyes, severe oral ulcers
and an obvious skin rash over her trunk and limbs.
SJS was suspected and valproate was discontinued
immediately. During hospitalization, she was treated
with steroids and antihistamines for symptomatic
treatment and infection prevention. She was discharged
on December 9th. The patient received a score of 7 on
the Naranjo Adverse Drug Reaction (ADR) Probability
Scale, indicating that this was a “probable” ADR.
Results: Discussion: The initial time of symptoms is
common in drug-induced SJS within 1-3 weeks of
initiation as immune responses are triggered by metabo-
lism of the drug. If health professionals do not stop using
suspected drugs immediately, it may lead to serious
complications such as hepatitis, nephropathy, or death.
Anti-epileptic drugs such as valproate are known to cause
SJS. The patient had taken valproate for about two years
in childhood without incident and developed SJS with
few weeks of reinitiating the drug 20 years later.
Conclusions: We hope this case can enhance the sen-
sitivity of medical staff for SJS, reporting immediately
and allowing pharmacists involved in assessment.
712. Co-Morbid Medical Conditions in Vascular
Dementia: A Case-Control Study
Ruby C Castilla-Puentes,1 Miguel E Habeych.2 1Strategic
Medical Affairs &Medical Sciences, Codman Neuro-DePuy
Synthes, West Chester, PA, United States; 2Neurological
Surgery, Clinical Neurophysiology, University of Pittsburgh,
Medical Center, Pittsburgh, PA, United States.
Background: Despite availability of new knowledge
about Vascular Dementia (VaD), there are still a lot
of queries about the course and evolution of this entity.
Objectives: To compare the prevalence of co-morbid
medical conditions between patients with VaD and a
control group, from the Integrated Healthcare Informa-
tion Services (IHCIS) database.
Methods: VaD was deﬁned by the International
Classiﬁcation of Diseases 9th revision, clinical modiﬁca-
tion (ICD-9-CM) codes 290.40, 290.4, 290.41, 290.42,
and, 290.43. Case and controls’ data used was extracted
from the IHCIS database, made up of more than 35
Managed Care health plans within the US, covering
seven census regions. The matched case-control method
was used to compare for medical comorbidity. Controls
were matched to cases by age, gender, type of health
plan and pharmacy beneﬁts on a 15:1 ratio.
Results: Among the 604,364 patients 60 years of age
or older with full year of eligibility, (from January
1st to December 31, 2010), there were 898 patients with
VaD, from which 63.6% were women. A concurrent di-
agnosis of Alzheimer’s Disease or any other dementia
was considered an exclusion criteria. Cerebro-vascular
disease, atherosclerosis and atrial ﬁbrillation were found
12.6, 4.6 and 1.7 times higher, respectively, in VaD pa-
tients. Compared to controls VaD patients had more
septicemia (OR=6.5, 95% CI= 2.7-15.5); hypotension
(OR=4.6, 95% CI=2.0-1052); injuries (OR=4.0, 95%
CI=2.6-6.1); heart failure (OR=2.8, 95% CI=1.6-4.7);
lung diseases (OR=2.4, 95% CI=1.6-3.9); COPD
(OR= 1.8, 95% CI = 1.2-2.7); and urinary diseases
(OR = 1.6, 95% CI = 1.1-2.3).
Conclusions: The present study conﬁrms that medical
comorbidities are frequent complications of VaD and
physicians should be alert to the presence of these dis-
eases in patients with VaD.
713. Effectiveness and Safety of Aspirin in Taiwan
Special Population
Chung-Yu Chen,1 Yaw-Bin Huang,1,4 Wen-Ter Lai,2
Tzu-Chi Lee.3 1School of Pharmacy, Department of
Pharmacy, Kaohsiung Medical University, Kaohsiung,
Taiwan; 2Division of Cardiology, Department of Inter-
nal Medicine, Kaohsiung Medical University Hospital,
Kaohsiung, Taiwan; 3Department of Public Health,
Kaohsiung Medical University, Kaohsiung, Taiwan;
4Department of Pharmacy, Kaohsiung Medical Univer-
sity Hospital, Kaohsiung, Taiwan.
Background: Antiplatelet agents are known to de-
crease the hazard of secondary ischemic stroke (IS).
In particular, aspirin is the most commonly used anti-
platelet agent in the world and Taiwan. Nevertheless,
the therapeutic safety and effectiveness of aspirin in
special patients with stroke is uncertain, especially in
abnormal liver or renal function.
Objectives: Our study evaluated the effectiveness and
safety of low dose aspirin for the prevention of recur-
rent IS in liver cirrhosis and ESRD patients during
11 years follow-up after ﬁrst-time IS.
Methods: This retrospective study identiﬁed cases of
ESRD and liver cirrhosis from the National Health
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Insurance Research Database (NHIRD). Low dose as-
pirin was administered for 11 years to patients who
had experienced a ﬁrst IS between 1998 and 2006. Pri-
mary outcomes, including death and readmission to
hospital for stroke, and secondary outcomes, including
death, stroke, andmyocardial infarction or bleeding, were
examined. A Cox proportional hazards model was used
to assess the association of outcomes with aspirin
exposure (time-dependent covariate) during follow-up.
Results: In total, 1245 liver cirrhosis and 1936 patients
experienced a ﬁrst IS during the follow-up. According
to time-dependent analysis, the hazard ratio (HR) for
primary outcomes in patients treated with aspirin was
0.854 (95%CI: 0.784-0.960) in liver cirrhosis and
0.671 (95% CI: 0.452-0.836). At secondary outcomes,
hazard ratio for readmission for stroke was 0.857
(95%CI: 0.737-0.879) and that for bleeding was 0.901
(95%CI: 0.846-1.157) in cirrhosis patients treated with
aspirin. Otherwise, ESRD patients treated with aspirin,
HR for readmission for stroke was 0.783 (95%CI:
0.648-0.876) and that for bleeding was 0.812 (95%CI:
0.695-1.567). Moreover, independent risk factors for
decreasing the efﬁcacy of aspirin included DM, and
administration of proton pump inhibitors or statins.
Conclusions: In summary, from a large national popula-
tion database, using time-dependent analysis, and
deﬁning aspirin use as ﬁlling of prescriptions, we found
that aspirin was still safe and effective for use in patients
with ESRD or liver cirrhosis for preventing recurrent IS.
714. Analysis of Adverse Drug Reactions of Antiep-
ileptic Drugs by Using Spontaneous Reporting
System in Medical Center in Taiwan
Shi- LiWang,1 Chun-Ching Chiu,2 Sock-Ping Ng,1 Su-Yu
Chien.1 1Department of Pharmacy, Changhua Christian
Hospital, Changhua, Taiwan; 2Department of Neurology,
Changhua Christian Hospital, Changhua, Taiwan.
Background: Adverse effects of antiepileptic drugs
(AEDs) are common, can have a considerable impact
on quality of life and contribute to treatment failure.
The adverse effect proﬁles of AEDs differ greatly
and are often a determining factor in drug selection
because of the similar efﬁcacy rates shown by most
AEDs.By using spontaneous reporting system, we
can ﬁnd out the real world condition.
Objectives: To analyze AEDs adverse reactions from
hospital-based spontaneous reporting systems to iden-
tify type and severity of reactions reported.
Methods: A retrospective analysis of hospital-based
spontaneous reporting systems databases in Changhua
Christian Hospital over a period of up to four years
during 2010 to 2013. We extracted AEDs reporting cases,
which included phenytoin, valproate, levetiracetam,
phenobarbital, carbamazepine, oxcarbazepine, gabapentin,
lamotrigine, topiramate, pregabalin, vigabatrin, acetazol-
amide clonazepam and diazepam. Type and severity of
reactions was analyzed. Serious reaction deﬁned as
death or life-threathening, moderate reaction deﬁned as
permanent disability/incapacity, results in hospitalization
or prolongation of an existing hospitalization and
needs further management.
Results: A total of 167 cases were reported with mean
age 56.3 ± 21.7 years; 51% were female and 49% were
male ( F:M ; 1:0.9). Most common AEDs reported was
gabapentin, phenytoin and valproate with the case
number of 36.5% (61), 21.6% (36) and 18.6% (31)
respectively.The most frequent reaction reported was
dermatologic effects 71.3 % (119), central nervous sys-
tem (CNS)12.3% (21) and gastrointestinal effects 5.4%
(9).AEDs which reported CNS effects included phenyt-
oin(6), gabapentin (6) topiramate(4) and vigabatrin(3).
GI effects included valproate(3), phenytoin(2), and
gabapentin(2).No serious cases was reported, 13 cases
(7.5%) reported as moderate, in which phenytoin
accounted for 6 (46%) and 154 cases (92.5%) reported
as mild.
Conclusions: Our study revealed that gabapentin, the
new generation AEDs, was the most common
reporting agents, but all of the reactions were mild.
Phenytoin remains the common reporting agent and
lead to moderate reaction.
715. Risk ofHip Fractures Associated with Benzodiaz-
epines: CommonMethodology But Different Results in
a Multi-Site Cohort Study. The PROTECT Project
Gema Requena,1 Consuelo Huerta,2 Helga Gardarsdottir,3,4
Montserrat Miret,5 Elisa Martin,2 Patrick C Souverein,3
Cornelia Schneider,6 Rocío González-González,2 Andrew
Bate,7 Yolanda Alvarez,8 Dolores Montero,2 Luis A
García-Rodríguez,9 Robert Reynolds,10 Raymond G
Schlienger,11 Mark CH de Groot,3 Olaf H Klungel,3
Francisco J de Abajo.1,12 1Unit of Pharmacology, Depart-
ment of Biomedical Sciences, University of Alcalá, Madrid,
Spain; 2BIFAP Research Unit, Spanish Agency of Medi-
cines and Medical Devices, Madrid, Spain; 3Division of
Pharmacoepidemiology &Clinical Pharmacology, Utrecht
University, Utrecht, Netherlands; 4Department of Clinical
Pharmacy, University Medical Center Utrecht, Utrecht,
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Netherlands; 5Pharmacoepidemiology, Merck KGaA,
Geneva, Switzerland; 6Division Clinical Pharmacy &
Epidemiology, University of Basel, Basel, Switzerland; 7Epi-
demiology, Pﬁzer Ltd, Tadworth, United Kingdom; 8Signal
Detection and Risk Management, European Medicines
Agency, London, UnitedKingdom; 9Pharmacoepidemiology,
Spanish Center for Pharmacoepidemiological Research
(CEIFE), Madrid, Spain; 10Epidemiology, Pﬁzer Research
& Development, New York, United States; 11Global Clinical
Epidemiology, Novartis Pharma AG, Basel, Switzerland;
12Clinical Pharmacology Unit, University Hospital Príncipe
de Asturias, Madrid, Spain.
Background: The association between benzodiaze-
pines (BZD) and hip fractures has been estimated in
several observational studies in different countries or
regions, using diverse methodologies and deﬁnitions
limiting comparability.
Objectives: To estimate the risk of hip/femur fractures
associated with BZD prescribing in 3 European
primary care databases, using a common protocol,
and minimizing inter-database variation through
harmonization of deﬁnitions and coding.
Methods: A new user cohort study examining BZD and
related drug prescribing, and the risk of hip/femur frac-
ture between 2001 and 2009, was performedwithin 3 pri-
mary care databases from the Netherlands (Mondriaan),
Spain (BIFAP) and the UK (CPRD). Age, comorbity
and comedication were considered as covariates. Inci-
dence Rates (IRs) were calculated. Hazard ratios (HRs)
and 95% conﬁdence intervals (Cl) were also estimated
for current use versus past use using time-dependent
multivariable Cox proportional hazard models.
Results: We observed an increase in IRs by age, across
all exposure categories and among all databases. The in-
crease by age was much higher in females than in males
in BIFAP and CPRD. Crude HRs for current use of BZD
were similar for all databases and ranged from 2.83 (CI:
2.60-3.09) in BIFAP to 3.32 (CI: 3.10-3.56) and 3.32
(CI: 2.31-4.75) in CPRD and Mondriaan, respectively.
Adjusted HRs were however disparate: namely, 1.19
(CI: 1.08-1.30) in BIFAP; 1.52 (CI: 1.41-1.63) in CPRD,
and 2.03 (CI: 1.40-2.94) in Mondriaan.
Conclusions: Applying the same protocol to estimated
risk of hip/femur fractures associated to BZD resulted in
different estimates in the 3 databases. The most important
confounder was age in all 3 databases, while the effect of
other factors was minimal. This study allowed a compar-
ison across countries following a common methodology.
Our ﬁndings might be explained by intrinsic differences
between populations and pattern of use of BZD.
Acknowledgments: This research received support
from the Innovative Medicine Initiative Joint Under-
taking through the PROTECT project.
716. No Impact of Adjusting for Lifestyle Factors or
General Practice on Risk Estimates for the Associa-
tion betweenAntidepressants andHip/Femur Fracture
Patrick C Souverein,1 Mark CH De Groot,1 Elisa
Martin,2 Consuelo Huerta,2 Gianmario Candore,3
Yolanda Alvarez,3 Jim Slattery,3 Raymond G
Schlienger,5 Robert Reynolds,6 Olaf H Klungel,1 Helga
Gardarsdottir.1 1Pharmacoepidemiology and Clinical
Pharmacology, Utrecht Institute for Pharmaceutical
Sciences, Utrecht University, Utrecht; 2BIFAP Re-
search Unit, Agencia Española de Medicamentos y
Productos Sanitarios, Madrid, Spain; 3Signal Detection
and Data Analysis, Pharmacovigilance and Risk Manage-
ment, European Medicines Agency, London, United
Kingdom; 4Wordwide Epidemiology, GlaxoSmithKline,
Southall, United Kingdom; 5Global Clinical Epidemiology,
Novartis Pharma AG, Basel, Switzerland; 6Epidemiology,
Pﬁzer Inc., New York, United States.
Background: Routinely collected data from electronic
health record databases often lack information on rele-
vant risk factors, like lifestyle-factors (LSF, smoking,
alcohol use, body mass index) or socioeconomic factors
that may be needed for confounder adjustment in
epidemiogical studies.
Objectives: In the context of the Pharmacoe-
pidemiological Research on Outcomes of Therapeutics
by a European Consortium (PROTECT) project, the
impact of confounder adjustment on the risk of antide-
pressant (AD) use on hip/femur fracture (HF) and
compared results across three primary care databases
was assessed.
Methods: We conducted a case-control study nested
within 3 new AD user cohorts of adult patients
(2001-2009) in three databases (Spanish BIFAP,
Dutch Mondriaan and UK THIN. Cases were deﬁned
as a ﬁrst HF during the study period. Up to 4 controls
were matched by sex, age (+/-2 years) and time since
cohort entry (+/- 6months). Exposure to AD was clas-
siﬁed into current, recent and past use. We adjusted for
comedication and comorbidities, using same models
for all data sources. The impact of matching on prac-
tice (marker for socioeconomic factors) and additional
adjustment for LSF was done in THIN. Odds ratios
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(OR) were estimated using conditional logistic regres-
sion analysis.
Results: Current use of AD was associated with an
signiﬁcantly increased risk of HF in all data sources.
Adjusted ORs were 1.52 in BIFAP (1535 cases),
1.59 in THIN (3756 cases) and 3.32 in Mondriaan
(79 cases). In BIFAP/THIN, adjustment resulted in
<10% change of crude ORs. In Mondriaan, a 36%
change is probably explained by violation of model
assumptions by including too many variables. Further
adjustment for LSF in THIN did not yield different
estimates compared to the model without: OR 1.59.
Results were similar after including GP practice in
the matching algorithm: adjusted OR 1.64.
Conclusions: Matching on GP-practice and adjust-
ment for LSF had no impact on adjusted risk estimates,
suggesting that non-availability of such data does not
necessarily lead to bias. This could be reassuring for
datasets lacking such data or struggling with sample
size issues.
717. Antidepressant Use and the Risk of Hip Fracture:
A Self-Controlled Case Series Approach in Two
Primary Care Databases
MSanni Ali,1,2 Mark De Groot,1 Giammario Candore,3 Rolf
HH Groenwold,1,2 Patrick C Souverein,1 Yolanda Alvarez,3
Md JUddin,1 ArnoWHoes,2 A de Boer,1 Olaf HKlungel,1,2
Helga Gardarsdottir.1,4 1Division of Pharmacoepidemiology
and Clinical Pharmacology, Utrecht Institute for Pharma-
ceutical Sciences, University of Utrecht, Utrecht,
Netherlands; 2Julius Center for Health Sciences and Primary
Care, University Medical Center Utrecht, Utrecht,
Netherlands; 3European Medicines Agency, EMA, London,
United Kingdom; 4Department of Clinical Pharmacy,
Division of Laboratory and Pharmacy, University Medical
Center Utrecht, Utrecht, Netherlands.
Background: The use of antidepressants(AD,selec-
tive serotonin reuptake inhibitors,SSRI, or tricyclic
antidepressants,TCA) has been associated with hip
fractures(HF) in observational studies.However, it has
been suggested that such results may be confounded
by unmeasured patient characteristics.
Objectives: To assess the effect of AD use on the risk
of HF using self-controlled case series design.
Methods: A self-controlled case series study was
conducted in two primary care databases among
patients with a ﬁrst HF and a prescription for AD at
any time during observation.Data were extracted
from the UK THIN and the Dutch Mondriaan GP
databases of the period 2001-2009.The incidence
rate ratio(IRR) of HF for periods of AD use versus
no AD use was estimated using conditional Poisson
regression.
Results: There were 6,632 and 136 HF patients for
analysis in THIN and Mondriaan, respectively.After
adjustment for age, an increased risk of HF was ob-
served during the 30 day period after AD initiation:
IRR 1.57 (95% CI, 1.39-1.78) in THIN and 3.22
(1.51-6.84) in Mondriaan.The increased risk was also
observed during the next six months of AD use: IRR
1.52(1.39-1.65) in THIN and 2.76 (1.69-4.50) in
Mondriaan.In the period after six months, the risk
remained higher in THIN (IRR: 1.47; 1.31-1.65) but
not signiﬁcant in Mondriaan (IRR 1.94; 0.84-4.47).
Furthermore, an increased risk of HF was observed
during the 30 day period prior to AD initiation (IRR
1.22; 1.06-1.41) in THIN and (IRR 2.51; 1.00-6.33)
in Mondriaan.In both THIN and Mondriaan, when
cases were censored at the event times (HF) there ap-
peared to be a substantial bias in IRR in all the periods:
IRR during the 30 day period after AD initiation: 3.07
(2.66-3.54) in THIN and 12.34 (2.13-71.54) in
Mondriaan.The risk of HF was higher in SSRI users
than TCA users (4.39; 2.42-7.99 vs. 1.39; 0.58-2.41)
in Mondriaan but was similar in THIN (1.49; 1.36-
1.63 vs. 1.49; 1.33-1.66).
Conclusions: The incidence rate of hip fractures was
higher in the periods both immediately after the start
of AD use and during the ﬁrst six months of AD use
compared to periods of no use, although the magnitude
of the risk varied between databases.
718. Evaluation of “Pre-Treated” Bipolar Disorder
Patients Receiving Atypical Antipsychotics in the
UK Using an Electronic Health Record Database
Mellissa Yong,1 Jane Liao,1 Herve Besson,2 Zhiwen Lui,1
Pearson Jay.1 1Center for Observational and Real-World
Evidence, Merck&Co Inc, NorthWales, PA, United States;
2Center for Observational and Real-World Evidence,
Merck Sharp & Dohme, Oss, Netherlands.
Background: The clinical practice of initiating
therapy with atypical antipsychotics (AAs) while
the diagnostic evaluation of a patient (pt) proceeds
over a period of time is common. These pts are
not strictly “on” or “off” label, but classiﬁed as
“pre-treated”.
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Objectives: To characterize “pre-treated” pts receiv-
ing a bipolar disorder (BD) diagnosis (dx) within
180, 365, and 730 days after a new AA prescription
(Rx) and to compare these pts with “on” label BD
pts receiving AAs on or after a BD dx.
Methods: We identiﬁed pts receiving a new AA Rx
and BD dx between 1/1/2008 and 12/31/2012 in the
Clinical Practice Research Datalink and categorized
them as 1) “on” label – BD dx date<AA Rx date;
and 2) “pre-treated_180, _365, and _730” – BD dx date
180, 365, and 730days>AA Rx date, respectively. A
baseline period for each pt was deﬁned as 365 days
continuous enrollment prior to AA initiation. Descriptive
statistics were calculated for demographics, co-morbidities,
and psychiatric Rxs.
Results: A total of 56,284 pts received an AA Rx during
the study period, of which 5.2% received a BD dx. Ap-
proximately half of the BD pts received an AARx 2years
BD dx. In both “on” label and “pre-treated” groups,
median age was 44years and >60% were female. At
baseline, a lower proportion of “pre-treated” compared
to “on” label pts had diagnoses of substance depen-
dence/abuse (21% vs. 37%), dyslipidemia and cardiovas-
cular disease (1.1% vs. 3.9%), developmental disorders
(0.5% vs. 1.6%), and pain (20% vs. 32%). In pts who
received BD dx 1-2 years after AA Rx, almost half
of them received antiepileptics, followed by 40%
SSRIs, and 32% anxiolytics prior to their BD dx. Over
90% of “pre-treated” pts with BD dx 6months-1 year
and 1-2 years received an AA Rx suggesting that these
pts are likely to remain taking AAs once they are
prescribed.
Conclusions: Differences in comorbid conditions
between “on” label and “pre-treated” groups and
medications prescribed in “pre-treated” BD pts need
to be carefully considered in developing a BD-
treated pt cohort. Comparability by antipsychotic
medication would help to further understand these sub-
groups of BD pts.
719. Deprivation and Cancer Incidence in Southern
Europe: A Nation-Wide Ecological Study
Maria Garcia-Gil,1 Josep-Maria Elorza-Ricart,1 Marta
Banque-Navarro,2 Bonaventura Bolibar,1 Rafel Ramos,3
Daniel Prieto-Alhambra.4 1IDIAP Jordi Gol, Girona;
2Unitat de Prevenció i Registre del Càncer, Servei
d’Epidemiologia i Avaluació, Hospital del Mar, Barcelona;
3Catalan Institute of Health, Girona; 4IDIAP Jordi Gol and
NDORMS, University of Oxford, Barcelona and Oxford.
Background: Data on the association between depriva-
tion and cancer incidence from primary care electronical
medical records are scarce.
Objectives: To study the association between depriva-
tion and the incidence of common cancer types in a
Southern European region.
Methods: Retrospective ecological study using data
from SIDIAP, a database of longitudinal patient
electronical medical records for representative 5 million
people in Catalonia (Spain). The main exposure was the
MEDEA index, based on census-based socio-economic
indicators. Individuals living in rural areas were ex-
cluded, as MEDEA has not been validated for such
populations. The study outcomes were incident 1.cervix,
2.breast, 3.colo-rectal, 4.prostate, and 5.lung cancer in
2009-2012. The completeness of cancer recording in
SIDIAP was evaluated through linkage to a local cancer
register. The association between MEDEA quintiles
(the higher, the more deprived) and cancer incidence
was evaluated using zero-inﬂated Poisson regression
adjusted for sex, age, smoking, alcoholism, obesity,
and comorbidities (hypertension, diabetes).
Results: The sensitivity of SIDIAP for the 5 cancers
ranged from 84% to 95%. We found a direct associa-
tion between deprivation and lung and cervix cancer:
IRR 1.82 [1.64-2.01], IRR 1.25 [1.11-1.42] respectively
for most deprived compared to afﬂuent areas. Prostate
(men) and breast (women) cancers were more common
in wealthy areas: IRR 0.79 [0.73-0.85], IRR 0.83 [0.71-
0.96]. No association was found with colo-rectal cancer:
IRR 1.07 (0.99-1.15). Adjustment for confounders
attenuated the association with lung cancer risk (fully ad-
justed IRR 1.16 [1.08-1.25]), reversed the direction of
the association with colo-rectal cancer (IRR 0.90 [0.84-
0.95]), and did not modify the associations with cervix
(IRR 1.27 [1.11-1.45]), prostate (0.74 [0.69-0.80]) and
breast (0.76 [0.71-0.81]) cancer.
Conclusions: Deprivation is associated differently with
the occurrence of various cancer types. This information
will be useful to improve screening programmes as well
as cancer prevention and management strategies which
may be less successful in deprived areas.
720. Antidepressants and Valvular Heart Disease: A
Nested Case-Control Study in Taiwan
CH Lin,1 FY Hsiao,1,2,3 FLL Wu,1,2,3 LJ Shen.1,2,3
1Graduate Institute of Clinical Pharmacy, College of
Medicine, National Taiwan University, Taipei, Taiwan;
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pital and College of Medicine, Taipei, Taiwan; 3Depart-
ment of Pharmacy, College of Medicine, National
Taiwan University, Taipei, Taiwan.
Background: No clinical study shows a potential link
between use of antidepressants and risk of valvular
heart disease (VHD) which may be due to limited
studied population.
Objectives: The objective of this study was to assess
the association between use of different antidepres-
sants and VHD among patients who used at least three
prescriptions of antidepressants.
Methods: Using Taiwan’s National Health Insurance
Research Database (NHIRD), we conducted a nested
case-control study and identiﬁed 59,989 patients aged
over 20 years with newly prescribed antidepressants
during 2000-2010. Among the antidepressants users,
we further identiﬁed 356 cases of incident VHD and
1424 matched controls (1:4 ratio). Exposure to antide-
pressants were classiﬁed as high (HA group), moder-
ate (MA group), or low (LA group) based on the
afﬁnity of serotonin transporter antagonists. Condi-
tional logistic regression models were used to examine
the association between the use of antidepressants and
risk of incident VHD.
Results: We found that patients in the MA group were
associated with a 1.5-fold risk of VHD (unadjusted odds
ratio (OR) 1.50, 95% conﬁdence interval (CI) 1.13-1.98,
p< 0.01) as compared to non-users. An increased risk of
VHD was found to be associated with the LA group
(unadjusted OR 1.368 (95% CI 0.977-1.917, p=0.0681)
although non-statistically signiﬁcant. In contrast, the HA
group was associated with a lower risk of VHD (unad-
justed OR 0.74, 95% CI 0.45-1.22, p=0.2432).
Conclusions: Our study suggests that exposure to anti-
depressants with moderate afﬁnity for serotonin trans-
porter may be associated with an increased risk of VHD.
721. Distinguishing an Optimal Risk Modeling
Framework for Predicting Adverse Events
Zuoyi Zhang,1 Xiaochun Li,2 JonDuke.1,2 1Regenstrief Insti-
tute, Indianapolis, IN, United States; 2Biostatistics, Indiana
University, Indianapolis, IN, United States; 3Regenstrief
Institute, Indiana University, Indianapolis, IN, United States.
Background: The traditional approach for predicting
the patient-level probability of adverse events is
regression models. The binary partitioning approach in
Classiﬁcation and regression tree (CART) and random
forest (RF) is a data-driven modeling of interactions
and functional form through multiple splitting, which
is an advantage over the traditional approach.
Objectives: To identify an optimal risk modeling
framework for predicting adverse events.
Methods: For each pair of drug of interest (DOI) and
health outcome of interest (HOI), we generated a new-
user cohort comprising patients who initiated the DOI,
and a general cohort with the indicated outcome for
the DOI. Follow-up periods for HOIs were 30, 90
and 365 days from the DOI initiation. Each DOI-HOI
data set was randomly split into a training data set
and a test data set in the ratio of 2:1. Three modeling
approaches, LR, CART, and RF were applied to the
training data set and tested on the test set. The models
were later applied to the general cohorts (unexposed
cohorts) to assess their predictive capabilities. We gen-
erated ROC curves on the test sets and calculated
AUCs for overall appraisals of the methods.
Results: The AUCs (area under the curve) rank from
highest to the lowest in this order, RF, LR and CART
for all 3 exposure cohorts. Models for ACE inhibitors,
SSRIs have higher AUCs (range 69%-86%) than
models for Statins (AUC range 51%-77%). Using the
models built on the training set from an exposed
cohort to predict its corresponding general cohort, we
observed the similar AUCs (Amlodipine, 72%-85%;
bupropion, 72%-84%; Niacin, 57%-76%) to those on
the test sets of the exposed cohorts.
Conclusions: An optimal, practical framework for
personalized clinical decision support regarding
adverse drug events will feature: 1) use of RF for
model creation; 2) reliance on outcome-based models
rather than individual models for each drug-outcome
pair; and 3) apply models with higher PPV (even if
slightly lower AUC than the optimized model) to reduce
alert fatigue.
722. Safety of GlaxoSmithKline’s Inactivated
Adjuvanted (AS03) A/H1N1pdm09 Pandemic Influ-
enza Vaccine in Solid Organ Transplant Recipients
Catherine Cohet,1 François Haguinet,1 Germano LC Ferreira,1
Dave Webb,2 John Logie,2 Dominique Rosillon,1 Vivek
Shinde,1 Gaël Dos Santos.1 1Global Epidemiology,
GlaxoSmithKlineVaccines,Wavre, Belgium; 2WWEpidemiol-
ogy, GlaxoSmithKline R&D, Stockley Park, United Kingdom.
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Background: Solid organ transplant recipients are a
recommended priority group for inﬂuenza vaccination
due to the increased risk of complications associated
with inﬂuenza infection. Pandemic A/H1N1pdm09 in-
ﬂuenza vaccine safety data in this population are limited.
Objectives: To assess the risk of solid organ (liver, kid-
ney, lung, heart, pancreas) transplant rejection after vacci-
nation with GlaxoSmithKline’s A/H1N1pdm09 vaccine.
Methods: Self-controlled case-series (SCCS) in the UK
Clinical Practice Research Datalink General Practitioner
OnLine database (CPRDGOLD) and the linked Hospital
Episodes Statistics (HES) database. Algorithms were
developed to identify rejection events and covariates of
interest. The endpoint was the occurrence of at least one
rejection during the study period 01 October 2009 to 31
October 2010. The risk periods were 30 and 60days after
any vaccine dose. Analyses were conducted using the
SCCS method for perturbed post-event exposure.
Covariates included time since transplantation, seasonal
inﬂuenza vaccination, previous rejections, bacterial/viral
infections, and malignancies, provided that information
was available.
Results: The overall study population included 184
transplant recipients with at least one rejection in the
study period, of which 91 participated in the analysis,
including 71 exposed cases. Relative incidence (RI) of
rejection of any of the ﬁve organs, adjusted for time
since transplantation, was 1.05 (95%CI: 0.52, 2.14)
and 0.80 (95%CI: 0.42, 1.50), 30 and 60 days after
vaccination, respectively. Risk estimates remained
stable across various sensitivity analyses. Results were
mainly driven by kidney, the most commonly
transplanted organ (RI: 0.85; 95%CI: 0.38, 1.90).
Conclusions: The consistent range of risk estimates
around 1.0 with upper 95%CI limits below 2.0 suggests
no changes to the safety proﬁle of GlaxoSmithKline’s
A/H1N1pdm09 vaccine with regard to the risk of rejec-
tion in solid organ transplant recipients in the UK. These
results inform the beneﬁt-risk of AS03-adjuvanted
pandemic inﬂuenza vaccines in transplanted patients in
the event of future pandemics.
723. Comparative Safety of Antimuscarinics among
Adults in the United States, 2000–2011
Alan Kinlaw,1 Jennifer Wu,2 Mitchell Conover,1
Michele Jonsson Funk.1 1Department of Epidemiology,
University of North Carolina at Chapel Hill, Chapel
Hill, NC, United States; 2Department of Obstetrics and
Gynecology, University of North Carolina at Chapel
Hill, Chapel Hill, NC, United States.
Background:Antimuscarinics are ﬁrst line pharmacother-
apy for overactive bladder. There are limited population-
based comparative safety data for antimuscarinics,
particularly among older adults who are at increased risk
of adverse effects.
Objectives: To compare rates of cognitive decline and
constipation diagnosis codes among new users of
antimuscarinics.
Methods: Using longitudinal healthcare claims from
Truven Health Analytics’ MarketScan and Medicare
Supplemental databases from 2000–2011, we identi-
ﬁed new users of antimuscarinics age 50 years and
over. We excluded those with a diagnosis of cogni-
tive dysfunction, constipation, intestinal malabsorp-
tion or dry mouth during the prior year. Outcomes
included ICD-9 diagnosis codes for cognitive decline
or constipation within 1 year. We used Kaplan-Meier
curves to estimate cumulative risks at 1 year, and Cox
proportional hazards models to estimate hazard ratios
(HR) and 95% conﬁdence intervals (CI) adjusted for
sex and age.
Results: We identiﬁed 590,500 eligible new users of
antimuscarinics; 69% were female and median age
was 67 years (interquartile range: 59–78). Formulations
comprised extended-release (ER, 78% of the cohort)
and immediate-release (IR, 22%) antimuscarinics.
The 1-year cumulative risks of codes for cognitive
decline and constipation were 2.1% and 1.3%, re-
spectively. Incidence of codes for cognitive decline
was similar among ERs compared to ER oxybutynin
(tolterodine HR 1.03, CI: 0.97–1.09; solifenacin HR
1.04, CI: 0.97–1.12; darifenacin HR 1.06, CI: 0.97–
1.15; trospium HR 1.12, CI: 0.94–1.34; fesoterodine
HR 1.24, CI: 0.66–2.07) and comparing IRs to
ERs (HR 0.96, CI: 0.92–1.00). Among ERs com-
pared to ER oxybutynin, incidence of constipation
codes was similar for tolterodine but higher for
solifenacin (HR 1.18, CI: 1.08–1.29), darifenacin
(HR 1.36, CI: 1.23–1.51) and trospium (HR 1.93,
CI: 1.61–2.32); IRs and ERs had similar rates for
constipation.
Conclusions: We found similarities in rates of cogni-
tive decline diagnosis codes among antimuscarinics
and meaningful differences in rates of constipation
codes between different ER medications with lowest
levels for oxybutynin and tolterodine.
abstract388
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
724. Comparative Risk of Post-Operative Mortality
between Taiwan Dialysis and Non-Dialysis Patients
Receiving First-Time Surgery
Tzu Chieh Lin,1 Hung Chun Chen,2 Yen Chin Liu,2 Yea
Huei Kao Yang.1 1Institute of Clinical Pharmacy and
Pharmaceutical Sciences, College of Medicine, National
Cheng Kung, Tainan, Taiwan; 2Department of Anesthesi-
ology, National Cheng Kung University Medical College
and Hospital, Tainan, Taiwan.
Background: Clinical outcome of patients receiving
long-term dialysis showed an increased risk for
postoperative mortality rate. However, limited studies
examined the impact of anesthesia factors on surgical
outcomes.
Objectives: To compare the relative risk of postopera-
tive mortality among different anesthesia factors in
dialysis and non-dialysis patients who receive their
ﬁrst-time surgery.
Methods: From 2007-2009, incident dialysis patients
were identiﬁed from the Registry of Catastrophic Illness
Database, and non-dialysis patients were retrieved from
the longitudinal health insurance database in Taiwan. Pa-
tients were excluded if they were less than 18 years old,
not in long-term dialysis condition and receiving surgery
before dialysis. The relative risk of post-operativemortality
was compared with multivariate Cox regression analysis.
Further, the associations between patients’ demographics,
types of dialysis, type of anesthesia, duration of anesthesia
and preoperative comorbidities and post-operative mortal-
ity were examined as well. We tested the robustness of our
ﬁndings with series sensitivity analyses.
Results: There were 9,140 incident dialysis patients
and 45,725 control patients were identiﬁed from
NHIRD. Postoperative mortality was signiﬁcantly
higher in dialysis patients (84.0/1000 person-years).
Cox regression analyses also showed that dialysis pa-
tients had signiﬁcantly higher risk for postoperative
mortality (HR 15.0, 95% CI 11.9 to 18.9) than controls.
General anesthesia (HR 1.4, 95% CI 1.0 to 1.8) and lon-
ger duration of general anesthesia (HR 1.1, 95% CI 1.1
to 1.1) also increase postoperative mortality in both dial-
ysis and non-dialysis patients. Series subgroup analyses
further demonstrated that risk of postoperative mortality
in peritoneal dialysis patients was more pronounced
than in hemodialysis patients (HR 19.5 vs. HR 15.2).
Conclusions: Patients’ demographic, different anes-
thesia techniques and various comorbidities were
associated with increased mortality in dialysis patients.
These results provided an important information to
anesthesiologists for evaluating the possible surgical
outcome in dialysis patients.
725. Factors Associated with Exposure of Potential
Interactions between Chinese Herbal Medicines
and Western Medications
Hsin-Hui Tsai,1,2 Hsiang-Wen Lin,1,3 Chu-Ling Tsai,1
Yow-Wen Hsieh,1,3 Shyh-Shyan Jan,1 Ching-Yeh Tu.1
1Department of Pharmacy, China Medical University
Hospital, Taichung, Taiwan; 2Department of Cosmetic
Science, Providence University, Taichung, Taiwan;
3Graduate Institute and School of Pharmacy, College of
Pharmacy, China Medical University, Taichung, Taiwan.
Background: While concurrent use of Chinese herbal
medicines (CHM) and Western medications (WM) are
common in Taiwan, potential interactions between
CHM and WM might occur.
Objectives: To examine the prevalence of potential in-
teractions between CHM andWM and further to explore
the contributing factors associated with the occurrence of
potential interactions in a medical center in Taiwan.
Methods: A cross-sectional study was conducted to as-
sess the prevalence of exposure to the pre-identiﬁed
interactions between the CHM and WM among the out-
patients in China Medical University Hospital (CMUH),
providing Western and Traditional Chinese Medicine
practice, in Taiwan. The characteristics among those
exposed patients and non-exposed patients were com-
pared using student t and Chi square tests. Both univari-
ate and multivariate logistic regression analyses were
performed to explore the contributing factors of potential
major interactions.
Results: Of 10,814 outpatients prescribed with CHM in
CMUH in 2013, approximately 70% (n=7,276) were pre-
scribed with WM concurrently. A total of 101concurrent
users (1.4%) had been exposed to at least one combination
of potential interactions. Of them, 5% were exposure to 2
pairs of interactions. The concomitant use of Asian
ginseng and Donquai with antiplatelets or anticoagulants
were more prevalent than the others. After comparing
the characteristics with the 392 randomly selected patients
without potential interactions, those exposed patients were
more likely to be older, have higher number of outpatient
visits, distinct prescribed medications, and more comor-
bidities. While those patients with previous diagnosis of
cardiovascular diseases were more likely to expose to
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CHM-WM interactions, those who had previous history
of liver diseases were less likely to expose.
Conclusions:With more than two third of CHM users
ever exposed to the concurrent use of CHM and WM,
relatively low patients ever exposed to the concerned
potential interactions. While patients with cardiovascu-
lar diseases tended to expose to CHM-WM interactions,
further research is needed to investigate the outcomes
associated with such combinations.
726. Utilization of Immunosuppressive Drugs in
Post-Heart Transplant Recipients in Taiwan
Chia-Lin Chou,1 Chia-Yu Chou,1 Yin-Yu Huang,2 Chia-
Chen Hsu,1 Yueh-Ching Chou.1 1Department of Pharmacy,
Taipei Veterans General Hospital, Taipei, Taiwan;
2Department of Critical Care, Taipei Veterans General
Hospital, Taipei, Taiwan.
Background: Signiﬁcantly increasing heart transplanta-
tions have been performed in Taiwan in the past decades,
but the trends of maintenance immunosuppression for
heart transplant recipients have not been well known.
Objectives: We aim to explore the trends of immuno-
suppressive therapy maintenance for heart transplant
recipients in Taiwan by analyzing the Taiwan National
Health Insurance Research Database (NHIRD).
Methods: We retrospectively analyzed ambulatory
prescriptions in 488 heart transplant recipients for the
period 2000-2009. Patient complications after heart
transplantation were also identiﬁed.
Results: The annual number of new case heart transplant
recipients ranged from 18 to 68. The 5-year survival rate
was 77.9%. The total number of regimens was 10 in
2000, increasing to 28 in 2009. Most prescriptions were
immunosuppressive combinations (95.5%-89.5%). The
majority of immunosuppressive regimenswere a triple reg-
imen: cyclosporine, mycophenolic acid and corticosteroid
in 2009. Cyclosporine was a predominant calcineurin in-
hibitor with a decreasing trend from 73.9% to 59.1%,
whereas the use of tacrolimus signiﬁcantly increased from
11.9% to 38.4%. Mycophenolic acid was the most
frequently used antimetabolite (60.1%-80.3%), while the
use of azathioprine was reduced (21.6%-2.3%). From
2008, the launch of everolimus initiated a new era in the
utilization of mammalian target of rapamycin inhibitors
for maintenance immunosuppression.
Conclusions: Tacrolimus seemed likely to gradually
replace cyclosporine. Mycophenolic acid was the most
popular antimetabolite. The rapid increased use of evero-
limus may change the trends in maintenance immunosup-
pression. The increasing number of combination therapies
indicates a tendency towards tailored individual therapies.
727. Association between Inhaled Long-Acting beta-2-
Agonists and the Risk of AcuteMyocardial Infarction:
A Methodological Comparison of Two Databases
Ana SM Afonso,1 Sven Schmiedl,2,3 Claudia Becker,4 Paola
Primatesta,5 Estel Plana,6 Patrick C Souverin,1 Joke C
Korevaar,7 Joerg Hasford,8 Robert Reynolds,9 Mark CH de
Groot,1 Raymond G Schlienger,5 Olaf H Klungel,1 Marietta
Rottenkolber.8 1Division Pharmacoepidemiology and Clinical
Pharmacology, Utrecht Institute for Pharmaceutical Sciences,
Utrecht, Netherlands; 2Department of Clinical Pharmacology,
School of Medicine, Faculty of Health, Witten/Herdecke Uni-
versity, Witten, Germany; 3Philipp Klee-Institute for Clinical
Pharmacology, Helios Clinic Wuppertal, Wuppertal,
Germany; 4BaselPharmacoepidemiologyUnit,DivisionClinical
Pharmacy & Epidemiology, Department of Pharmaceutical
Sciences, University of Basel, Basel, Switzerland; 5Global Ep-
idemiology, Novartis Pharma AG, Basel, Switzerland;
6Global Epidemiology, Novartis Pharma AG, Barcelona,
Spain; 7NIVEL, Netherlands institute for Health Services
Research, Utrecht, Netherlands; 8Institute for Medical
Information Sciences, Biometry, and Epidemiology,
Ludwig-Maximilians-Universitaet, Munich, Germany;
9Epidemiology, Pﬁzer, New York, NY, United States.
Background: Results from multiple observational
studies on inhaled long-acting beta-2-agonists
(LABA) and the risk of acute myocardial infarction
(AMI) are conﬂicting, due to variations in methodo-
logical, clinical and health care characteristics. To
some extent, the discrepancies in the design might
limit the comparability of the results encountered.
Objectives: To determine the risk of AMI in inhaled
LABA users in two European electronic primary care
databases using a common study protocol.
Methods: Patients from the Dutch Mondriaan (1.4
Million) and the UK CPRD (5 Million) databases were
included if they had a diagnosis of asthma and/or
COPD, and were prescribed at least one inhaled
LABA, a short-acting beta-2-agonist (SABA), or a
short- or long-acting muscarinic antagonist (SAMA,
LAMA) during the study period (2002 to 2009).
LABA episodes were divided into current, recent
(<91 days after the prescription end date) and past
use (≥91 days after the prescription end date). Hazard
ratios (HR) and 95% conﬁdence intervals (CI) were
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estimated by using time-dependent multivariable Cox
regression models and adjusted for confounders
(age, sex, co-morbidities, co-medications). Adjusted
HR (HRadj) for current versus recent, and current
versus past use associated with the risk of AMI and
95%CI were calculated and stratiﬁed by indication
(asthma, COPD, and asthma&COPD).
Results: Overall, 656,414 patients in the CPRD and
36,188 patients in the Mondriaan database were
included. Patients in the CPRD database had more
comorbidities and co-medications when compared to
Mondriaan patients. In both Mondriaan and CPRD,
among asthma and asthma&COPD patients, no signif-
icant differences in the HRadj were found. Among
asthma&COPD patients, a signiﬁcantly decreased
AMI risk with HRadj 0.78; 95%CI 0.68–0.90, was
only found for the comparison of current LABA ver-
sus recent LABA use in the CPRD database, but not
signiﬁcant in the Mondriaan database, HRadj 0.55,
95%CI 0.28–1.08.
Conclusions: Despite potential differences between
databases, using a common protocol that reduced
methodological disparities, we found similar AMI
HRadj in the two cohorts.
728. Long-Acting beta Agonist Containing Therapies
and the Risk of Serious Adverse Events in Subjects
with Persistent Asthma
Pingsheng Wu,1 Tebeb Gebretsadik,2 William D
Dupont,2 Robert L Davis,3 Kelly Horan,4 Carlos
Iribarren,5 Elyse O Kharbanda,6 Emma Larkin,1 Tracy
Lieu,5 Irina Miroshnik,4 Edwards Mitchel,7 William M
Vollmer,8 Ann C Wu,4 Tina Hartert.1 1Department of
Medicine, Vanderbilt University School of Medicine,
Nashville, TN, United States; 2Department of Biostatis-
tics, Vanderbilt University School of Medicine, Nashville,
TN, United States; 3Department of Pediatrics, UTHSC-
ORNL Center in Biomedical Informatics, Memphis, TN,
United States; 4Department of Population Medicine,
Harvard Pilgrim Health Care Institute & Harvard Med-
ical School, Boston, MA, United States; 5Division of Re-
search, Kaiser Permanente, Oakland, CA, United States;
6HealthPartners Institute for Education and Research,
Minneapolis, MN, United States; 7Department of Health
Policy, Vanderbilt University School of Medicine, Nashville,
TN, United States; 8Kaiser Permanente Center for Health
Research, Portland, OR, United States.
Background: Long-acting beta agonists (LABAs) are
recommended to be used only in combination with an
inhaled corticosteroid (ICS). Whether combined ICS +
LABA is associated with an increased risk of serious
adverse events (SAE) is not known. It is also unclear
whether such risk is race speciﬁc.
Objectives: To determine whether ICS +LABA is as-
sociated with an increased risk of SAE in asthmatics.
Methods: We studied persistent asthmatics aged 4 to
50 years and continuously enrolled in 5 commercial
health plans of the Population-Based Effectiveness in
Asthma and Lung Disease Network from 2004 to
2010. Subjects were classiﬁed as users of ICS, LABA,
ICS +LABA, leukotriene antagonists (LTRA), other
medications, or non-initiators at the index date. A
SAE was deﬁned as an asthma hospitalization with
intensive care unit admission and/or mechanical
ventilation or death. Subjects were followed until
disenrollment, SAE, or end of study, whichever came
ﬁrst. We assessed the risk of SAE associated with
medication groups using Cox proportional hazard
regression analysis and further stratiﬁed by race.
Results: The majority (72387, 60.0%) of the 135016
persistent asthmatics did not initiate medication ther-
apy at the index date. Among those who did use med-
ications, 21854 (16.0%) used ICS, 1690 (1.3%) used
LABA, 7245 (5.4%) used ICS +LABA, 3846 (2.9%)
used LTRA, and 18796 (13.9%) used other medica-
tions. There were 472 (0.35%) SAE in the followup
time. Compared to non-initiators, subjects with either
LABA (adjusted hazard ratio [aHR]: 1.23, 95% conﬁ-
dence interval [CI]: 0.72, 2.12) or ICS+LABA (aHR:
1.00, 95%CI: 0.61, 1.64) did not have an increased risk
of SAE after adjusting for covariates. Both LABA and
ICS+LABA therapies were not associated with an
increased risk of SAE in African Americans (LABA:
aHR: 2.65, 95%CI: 0.81, 8.71; ICS+LABA: aHR:
2.12, 95%CI: 0.75, 5.99) or Caucasians (LABA: aHR:
1.38, 95%CI: 0.73, 2.65; ICS+LABA: aHR: 1.25,
95%CI: 0.67, 2.33).
Conclusions: We did not detect an increased risk of
SAE associated with LABA and ICS+LABA in a
large cohort of persistent asthmatics. The results were
consistent when stratiﬁed by race.
729. Concurrent Use of Chinese Herbal Products
Among Hormonal Users Aged 55-79 in Taiwan: A
Population-Based Study
Yueh-Ting Tsai,1,3 Jung-Nien Lai,1,2,3 Chien-Tung Wu,1,3
Shun-Gu Lin.1,4 1Institute of Traditional Medicine, School
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of Medicine, National Yang-Ming University, Taipei,
Taiwan, Taiwan; 2Department of Chinese Medicine, Taipei
City Hospital, Yangming Branch, Taipei, Taiwan, Taiwan;
3Taiwan Association for Traditional Chinese Medicine of
Family, Taipei, Taiwan, Taiwan; 4Department of Chinese
Medicine, Taipei City Hospital, Renai Branch, Taipei,
Taiwan, Taiwan.
Background: The increased practice of traditional
Chinese medicine (TCM) worldwide has raised con-
cerns regarding herb-drug interactions. The purpose
of our study is to analyze the concurrent use of
Chinese herbal products (CHPs) among women aged
55 to 79 years taking hormonal therapies (HT) in
Taiwan.
Objectives: Our study aimed to describe the patterns
of CHP usage and to explore the risk of breast cancer
among HT users in a nationwide cohort in Taiwan.
Our ﬁndings provide evidence-based information for
formulating appropriate management strategies for
drug safety and integrative medicine.
Methods: We selected a random sample of women
who were prescribed HT in Taiwan during a 7-year
study period from 1 million beneﬁciaries in the
National Health Insurance Research Database. The
usage, frequency of services, and CHP prescribed
were evaluated among 17,583 HT users. Logistic
regression was used to model factors associated
with the co-prescription of a CHP and a HT.
Cox proportional hazards regression was performed
to estimate adjusted hazard ratios (HRs) for inva-
sive breast cancer between TCM non users and
climacteric women who co-administered HT and
CHPs.
Results: More than 1 of every 5 study subjects used a
CHP concurrently (CHTCHP patients). Shu-jing-huo-
xie-tang was the most commonly co-administered
CHP. The adjusted hazard ratios for breast cancer
was increased by 1.29-fold (95% CI 0.22-7.70) for
CHTCHP patients who no longer received E-alone
HT for at least one year, by 1.37-fold (95% CI 0.75-
2.51) for current users of mixed regimen, but it was
even higher for CHTCHP patient who no longer
received mixed regimen for at least one year (HR 2.19,
95% CI 0.27-17.47).
Conclusions: Exploring potential CHP-drug interac-
tions and integrating both healthcare approaches might
be beneﬁcial for the overall health outcome of climac-
teric women.
730. Using Oncology Electronic Medical Records in
the Study of Non-Melanoma Skin Cancer in the
United States: Opportunities and Challenges
Lei Chen, Yuer Yan, James A Michael, Dale Quentin
Marmaduke, Yiu-Keung Lau, Nayan Acharya. Eli Lilly
and Company, Indianapolis, IN, United States.
Background: Non-melanoma skin cancer (NMSC) is
the most commonly diagnosed cancer in the United
States, of which metastatic NMSC has a poor long-term
prognosis. It is estimated that 0.5%-5% of NMSC cases
were metastatic based on studies dated back to the
1990’s. However, this data may not reﬂect the current
epidemiology and disease burden. Furthermore, the
US cancer registries do not collect NMSC cases, and
medical claims usually do not collect cancer stage
and histology. These gaps substantiate the importance
of exploring electronic medical records (EMR) in the
study of NMSC.
Objectives: To explore the opportunities and chal-
lenges of using the US-based IMS Oncology EMR
database in the study of NMSC.
Methods: NMSC patients with at least one invasive
NMSC diagnosis and no other primary cancer diagnoses
during 2000-2012 were selected. Medical claims of a
random sample of 100 patients were reviewed, and can-
cer epidemiology, histology and stage were described.
Results: Among 743,564 cancer patients, 4,761
NMSC patients were identiﬁed. The most commonly
observed characteristics were male gender (58.7%),
age ≥70 (55.4%), Caucasian race (90.9%), and South-
ern state residency (47.3%). Of NMSC patients with a
conﬁrmed cancer stage (n = 606), 9.6% (58) were met-
astatic. The proportion of NMSC patients with histol-
ogy available increased from 5% (204/3965) to 71%
(566/796) after 1 Oct 2011 when a digit for histology
was added to NMSC ICD-9 codes.
Conclusions: The higher rate of metastasis observed
in this oncology EMR database is reﬂective of higher
likelihood of metastatic NMSC patients being treated
in oncology clinic settings. Most NMSC cases are di-
agnosed at earlier stages and treated by dermatologists,
and are less likely to be captured in an oncology EMR
database. Whilst patients captured in an oncology
EMR may not be representative of NMSC patients in
general, they could be a good source to study metastatic
NMSC to better understand patient proﬁles, comorbidi-
ties, treatment patters, health outcomes and resource
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utilization – which should be the focus of much needed
research in the future.
731. Validating aMultipleMyeloma AlgorithmUsing
a SEER Tumor Registry and Administrative Data
Nancy A Brandenburg,1 Syd Phillips,2 Karen E Well,3
Kimberley J Woodcroft,3 Kandace Amend,4 Cheryl
Enger,4 Susan A Oliveria.2 1Global Drug Safety and Risk
Management, Celgene Corporation, Berkeley Heights,
NJ, United States; 2Epidemiology Research Group,
New York, NY, United States; 3Department of Public
Health Sciences, Henry Ford Health System, Detroit,
MI, United States; 4Epidemiology, Optum, Ann Arbor,
MI, United States.
Background: Large numbers of patients with multiple
myeloma (MM) can be studied in real world clinical
settings for outcomes and treatment patterns using ad-
ministrative databases. The validity of these studies is
contingent upon accurately identifying MM patients.
Currently, there are no validated published algorithms
to identify cases of MM using administrative data.
Objectives: Develop and evaluate algorithms to use
with administrative data to identify cases of MM.
Methods: Patients aged ≥18 years with ≥1 Interna-
tional Classiﬁcation of Diseases, 9th revision (ICD-9)
code for MM (203.0x) were identiﬁed in the Henry
Ford Health System (HFHS) from 1/1/2005 to 2/28/
2011 and in the Optum Research Database (ORD)
from 1/1/2008 to 3/31/2012. At HFHS, multiple al-
gorithms were tested and results compared to
morphologically conﬁrmed MM cases from a
tumor registry whose data are included in the
Surveillance, Epidemiology and End Results
(SEER) Program.
Applied the HFHS algorithm with reasonable posi-
tive predictive value (PPV) (81%) and high sensitivity
(79%) to the ORD, and results compared to medical
chart data. The algorithm required that the ICD-9
codes 203.0x, occur before and after the diagnostic
procedure codes for MM.
Results: At HFHS identiﬁed 1,432 patients; mean age
was 65.9 years (standard deviation (SD) = 13.9) and
51% were male (n = 726). The PPVs of 5 algorithms
tested ranged from 54% (95% conﬁdence interval
(CI); 50–58%) to 88% (95% CI; 83–91%). Sensitivity
ranged from 30% (95% CI; 26–34%) to 88% (95% CI,
85–91%). In the ORD, 3,866 patients with ≥1 ICD-9
codes for MM were identiﬁed, a random sample
(n = 400) was selected, and medical charts were
reviewed for 105 patients. Mean age was 57.1 years
(SD= 8.9) and 69% (n = 48) were male. Algorithm
PPV was 86% (95% CI; 79–92%).
Conclusions: At least two initial ICD-9 codes 203.0x
preceding diagnostic procedure codes for MM
followed by ICD-9 codes for MM within a speciﬁc
time window were required to achieve reasonable
algorithm performance. The PPV of our selected
algorithm at HFHS was 81% and sensitivity was
79%. In the ORD, the PPV was 86%. This algorithm
identiﬁes patients with MM with adequate validity
for claims database analyses.
732. Risk ofMortality withVenous Thromboembolism
in CPRD GOLD: The Impact of Using Linked Data
Arlene M Gallagher,1,2 Tim Williams,1 Hubert GM
Leufkens,2 Frank de Vries.2,3 1CPRD, Medicines and
Healthcare Products Regulatory Agency, London,
United Kingdom; 2Utrecht Institute for Pharmaceutical
Sciences, Utrecht University, Utrecht, Netherlands;
3Clinical Pharmacy and Toxicology, Maastricht Univer-
sity Medical Centre, Maastricht, Netherlands.
Background: The Clinical Practice Research Datalink
(CPRD) GOLD (formerly the General Practice Research
Database or GPRD) is widely used and is representative
for 8% of the UK population. Individual-level linkage to
death certiﬁcates from the Ofﬁce of National Statistics
(ONS) is limited to a proportion of GP practices from
England. Researchers choose different deﬁnitions for
the start and end of follow up for an individual studywith
linked data. There is currently no clear consensus on the
best choice. The impact of using different deﬁnitions of
follow-up on an existing study design in CPRD has not
been evaluated.
Objectives: To assess the risk of mortality following
venous thromboembolism, comparing different
methods of linking CPRD GOLD data with ONS data.
Methods: We included patients aged 18+ with a
diagnosis of venous thromboembolism (VTE) be-
tween 1995 and 2009. These older data were used
in order to replicate a previous study (Gallagher A
et al., Clin Appl Thromb Hemost. 2012 Jul;18
(4):370-8). At this point 40% of the patients in
GOLD had been linked individually and anony-
mously to ONS data. Cox regression estimated
relative rates (RRs) of all-cause mortality. We sta-
tistically adjusted for age, sex, lifestyle and VTE
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risk category. We compared basing the outcome
data on GOLD only or events eligible for GOLD-
ONS linkage while only looking at the time where
the two sources overlap.
Results: When the coverage period for all sources
was taken into account the average follow-up de-
creased (2.86 years vs. 3.81) and patients were more
likely to have information on risk factors for VTE
and lifestyle information (smoking, alcohol and
BMI). All-cause mortality rates were lower for the
unlinked GOLD population compared (140/1000
person years [pys]) vs. the GOLD-ONS linkage
(176/1000 pys). The relative risks of mortality in
men vs. women (reference) were comparable between
both populations: adj RR 0.90; 95% CI 0.85 - 0.95 in
GOLD vs. GOLD-ONS (0.88; 95% CI 0.81 - 0.95).
Findings were similar after stratiﬁcation to age or
time in range.
Conclusions: Mortality rates in VTE were
substantially higher in linked GOLD-ONS versus
GOLD only. The relative risks of mortality were
comparable.
733. Identification of Heart Failure by Diagnoses
and Cardiac Tests in a U.S. Electronic Health
Records Database
Hoa V Le,1 Chi TL Truong,1 Julie Priest,1 Julia
DiBello,2 Carlyne Averell.1 1Worldwide Epidemiol-
ogy, GlaxoSmithKline, Durham, NC, United States;
2Worldwide Epidemiology, GlaxoSmithKline, Philadelphia,
PA, United States.
Background: Development of a coding algorithm to
accurately identify heart failure (HF) in U.S. elec-
tronic health records (EHR) databases is useful for
pharmacoepidemiology research. It is unclear whether
using cardiac tests (LVEF, BNP, proBNP) in addition
to diagnosis codes can improve the accuracy in identi-
fying HF.
Objectives: To develop and evaluate a coding algo-
rithm to identify HF using the Humedica de-identiﬁed
EHR database.
Methods: In patients afﬁliated with integrated deliv-
ery network providers in the Humedica EHR dataset
in 2011, we selected those aged ≥50 years; with ≥ one
year of activity, ≥1 HF diagnoses [ICD-9 428.xx,
785.51] and test results for LVEF, BNP and proBNP.
Distributions of LVEF, BNP and proBNP were
estimated for three HF groups identiﬁed by diagnoses
only: (i) very likely: LVEF <40% or BNP >500 pg/
mL or proBNP >900 pg/mL; (ii) unlikely: LVEF
≥40% and BNP ≤100 pg/mL and proBNP <300 pg/
mL; (iii) probably: all others; as well as for three very
likely subgroups: LVEF <35% (severe), <40% and
≥40% (per the American Heart Association). Very
likely cases served as a gold standard to calculate
positive predictive value (PPV) of the algorithm.
Results: Overall 13,621 patients were identiﬁed by
HF diagnosis codes alone. Their median age was
74 years, 49.2% were females, 10.3% had acute MI
and 64.2% arrhythmias. Of these, 9,983 (73.3%) were
very likely; 2,852 (20.9%) were probably; and 786
(5.8%) were unlikely to have HF based on cardiac test
results. Using very likely as the gold standard, the PPV
was 0.73. Median LVEF, BNP and proBNP values for
the very likely group were 33%, 917 pg/mL and
4,368 pg/mL vs. 55%, 257 pg/mL and 532 pg/mL
for the probably group; and 57%, 48 pg/mL and
152 pg/mL for the unlikely group, respectively.
Median LVEF, BNP and proBNP values for very
likely HF subgroups were, for severe HF: 20%,
848 pg/mL and 4,737 pg/mL; LVEF <40% group:
23%, 815 pg/mL and 4,725 pg/mL; and LVEF
≥40% group: 55%, 1,072 pg/mL and 3,976 pg/mL,
respectively.
Conclusions: Researchers should consider combining
diagnosis codes with LVEF, BNP and proBNP to
improve the accuracy of ascertaining HF in pharm-
acoepidemiology studies.
734. Validation of Major Adverse Cardiovascular
Events (MACE) in US Claims Databases
Kevin Haynes,1 Melissa S Nezamzadeh,1 Craig W
Newcomb,1 Jason Roy,1 Whitney Kite,1 Dena M Carbonari,1
Serena Cardillo,2 Sean Hennessy,1 Cristin P Freeman,1
Crystal N Holick,3 Daina B Esposito,3 Brian L Strom,4
Lo Re Vincent.1 1Biostatistics and Epidemiology, Perel-
man School of Medicine, University of Pennsylvania,
Philadelphia, PA, United States; 2Medicine, Perelman
School of Medicine, University of Pennsylvania,
Philadelphia, PA, United States; 3HealthCore, Wilming-
ton, DE, United States; 4Rutgers Biomedical & Health
Sciences, Rutgers, The State University of New Jersey,
New Brunswick, NJ, United States.
Background: Post-marketing safety studies often rely
on claims-based algorithms for identifying MACE,
which require validation.
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Objectives: To validate an electronic algorithm for
MACE as part of an observational safety study of
saxagliptin.
Methods: Retrospective cohort study using 2009-
2011 data from US Medicare and the HealthCore
Integrated Research Database (HIRD). Inclusion
criteria: ≥18 years of age, enrolled in the database
for at least 180 days, and newly prescribed
saxagliptin or an OAD in a class other than DPP-4
inhibitor. MACE was deﬁned as a composite of
hospitalization with acute myocardial infarction
(AMI), hospitalization with acute stroke, or death
from cardiovascular causes, including AMI, acute
stroke, congestive heart failure, dysrhythmia, sudden
death, or coronary revascularization. Within each
data source, we conﬁrmed events through medical
record review. Endpoints arbitrators with clinical
expertise in cardiovascular disease adjudicated the
outcomes. The positive predictive value (PPV) and
95% CI were determined.
Results: After excluding non-participating hospitals,
we randomly selected and requested 95 medical re-
cords from a sample of eligible patients from each data
source. In US Medicare, the estimated PPV of the
AMI or stroke ICD-9 diagnostic coding algorithm
among 57 charts obtained and the 41 outcomes
conﬁrmed was 80.6% (62.5-92.5%) for principal
diagnoses listing and 61.5% (40.6-79.8%) for non-
principal listing. In the HIRDSM patients under
age 65, the estimated PPV of the AMI or stroke
ICD-9 diagnostic coding algorithm among 65
charts obtained and the 31 outcomes conﬁrmed
was 54.9% (40.3-68.9%) for principal diagnoses
listing and 21.4% (4.7-50.8%) for non-principal
listing.
Conclusions: In two US claims databases, an elec-
tronic algorithm to identify MACE resulting in hospi-
talization was developed among diabetic patients.
Further reﬁnement of the electronic algorithm is
needed to improve the PPV and will continue as
additional medical records are accumulated.
735. Concordance of Myocardial Infarction (MI)
betweenMedicare Administrative Data and Physician
Review Panel. The Atherosclerosis Risk in Communi-
ties (ARIC) Study
Montika Bush,1 Til Stürmer,1 Sally Stearns,2 Ross J
Simpson, Jr,3 Alan Brookhart,1 Anna Kucharska-Newton.1
1Epidemiology, University of North Carolina at Chapel HIll,
Chapel Hill, NC,United States; 2Health Policy andManage-
ment, University of North Carolina at Chapel HIll, Chapel
Hill, NC, United States; 3Medicine, University of North
Carolina at Chapel HIll, Chapel Hill, NC, United States.
Background:Medicare claims data are routinely used
in pharmacoepidemiology studies to identify out-
comes and comorbidities. Assessment of the validity
of claims to identify these conditions is necessary to
understand the extent of potential misclassiﬁcation
bias.
Objectives: To validate algorithms used to identify MI
in Medicare claims.
Methods:Data from ARIC, a longitudinal cardiovascu-
lar disease cohort study, were linked with healthcare
encounter data from Centers for Medicare andMedicaid
Services (CMS). The study population consisted of
7289 ARIC participants who were Medicare beneﬁcia-
ries and had ≥1 hospital claim between 2001-2010. All
CMS MedPAR hospital records meeting study criteria
(27,631) were compared to hospital records abstracted
by ARIC study personnel. A panel of ARIC physician
reviewers classiﬁes MI using chest pain, ECG, and
biomarker results. For the claims basedMI classiﬁcation
algorithms, we used discharge codes, discharge code
position, hospital length of stay (LOS), use of medical
procedures (revascularization or angiocardiography),
and type of stay. For each algorithm, sensitivity,
speciﬁcity, and positive predictive value (PPV) were
calculated using ARIC deﬁnite or probable MI as the
gold standard.
Results: The claims-based algorithm based on ICD9
discharge code 410.xx in any position had sensitivity
of 0.65 and speciﬁcity of 0.98. Adding additional
conditions to this algorithm did little to alter speciﬁcity
(range 0.98 to 0.99). Sensitivity decreased when adding
a single additional factor (short term stay, restricting 410.
xx discharge codes to ﬁrst or second position, or LOS of
>3 days) to the algorithm (0.65, 0.57, 0.49 respectively).
Using discharge code 410.x1 and short term stay to
classify MI, decreased sensitivity to 0.64. PPV ranged
from 0.52 to 0.66.
Conclusions: Claims based algorithms identifying
hospitalized MI had high speciﬁcity and moderate
PPV, as well as large variation in sensitivity based
upon criteria used in the deﬁnition. An algorithm
based on diagnosis codes alone performs well to
deﬁne cases of MI in claims data given the low false
positive rate.
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736. Comparing the Influence of Month of Birth and
Gender in Two Academic Years on Attention Deficit
Hyperactivity Disorder Diagnoses (ADHD) Among
Children in the Health Improvement Network
(THIN) UK Data
Caroline O’Leary, Alison Bourke, David Ansell. CSD
Medical Research UK, London.
Background: Long-term costs follow a diagnosis of
ADHD; therefore it is important to examine factors
inﬂuencing diagnosis.
Objectives: This study determines the prevalence of
ADHD among children according to month of birth
and gender across two academic years.
Methods: Children aged 5-15 years in the academic
years Sep 2010-Aug 2011 (Year 1) and Sep 2011-
Aug 2012 (Year 2) in The Health Improvement
Network (THIN) were assessed for ADHD using diag-
noses and prescriptions. Percentages were calculated
and differences across month of birth assessed using
chi squared tests for trend. Children with later months
of birth (Mar-Aug) were compared to earlier months
of birth (Sep-Feb), and males to females using relative
risks (RR).
Results: 436,299 children in Year 1 and 398,718 in
Year 2 were included with 0.75% and 0.76% diag-
nosed with ADHD respectively.
There was evidence at the 5% level of an increasing
trend in ADHD prevalence in both academic years
(p< 0.001, p = 0.005 in Year 1, Year 2 respectively).
Younger children were 14% more likely (RR= 1.14,
95% CI 1.07-1.23) in Year 1 and 12% more likely
(RR= 1.12 95% CI 1.04-1.20) in Year 2 to have
ADHD than older children.
Males were around ﬁve times more likely to have an
ADHD diagnosis in both years (RR = 5.00 95% CI
4.56-5.49, RR = 4.92 95% CI 4.47-5.42 in Year 1,
Year 2 respectively).
Conclusions: There was good agreement across
academic years both in the percentage with ADHD di-
agnosis, and the increasing trend through the academic
year. Younger children were more likely to be
diagnosed with ADHD than their older peers. This
may partly be due to them appearing to lack the matu-
rity of their older classmates. Males were more likely
to have an ADHD diagnosis than females in both
years. Further work could assess the differences in
different age groups and be extended to include
other conditions.
737. The Surveillance of Metoclopramide-Induced
Extra-Pyramidal Symptoms and Movement Disor-
ders Reported in Samsung Medical Center in Korea
Su Mi Lee,1 Ji Eun Park,1 Yong Seok Lee,1 Hu Kyung
Lee,1 Young Mee Lee,1 Byung Jae Lee.2 1Department
of Pharmacy, Samsung Medical Center, Seoul, Republic
of Korea; 2Division of Allergy, Department of Medicine,
Samsung Medical Center, Seoul, Republic of Korea.
Background: Metoclopramide, a dopamine receptor
antagonist used for various gastrointestinal disorders,
may cause extrapyramidal movement disorders.
Recently, European Medicines Agency (EMA) and
Ministry of Food and Drug Safety (MFDS) in Korea
announced restrictions on metoclopramide-containing
medicines tominimize serious neurological adverse effects.
Objectives: This study was aimed to investigate
metoclopramide-induced extrapyramidal symptoms
and movement disorders reported in Samsung Medical
Center (SMC).
Methods: Between August 14, 2011 and August
13, 2013, 90 metoclopramide-related adverse drug
reaction (ADR) reports were submitted to the
SMC pharmacy department. 59 ADR reports were
associated with extrapyramidal symptoms and
movement disorders. Retrospective electronic medi-
cal records (EMR) review was conducted on 44
patients who received metoclopramide in SMC. 15
ADR reports not occurred in SMC were excluded,
because detailed information was not available.
Causality assessment of ADR was performed by
WHO probability scale.
Results: Of 59 ADR reports, 57 cases (97 %) occurred
after intravenous metoclopramide administration. The
mean age was 41.7 years and 33 cases (56 %) occurred
in female. As a result of retrospective chart review of
44 patients, chemotherapy-induced nausea and
vomiting was the most common indication (68 %).
22 patients (50 %) received higher dose than EMA/
MFDS recommendation (≤0.5mg/kg/day), 5 patients
(11 %) received longer duration than EMA/MFDS
recommendation (≤5 days). 16 patients (36 %) were
rechallenged and neurological ADRs reappeared in 5
patients (31 %). Causality assessment showed that 4
cases were ‘certain’, 35 cases were ‘probable’, 5 cases
were ‘possible’.
Conclusions: Metoclopramide-related neurological
ADRs has been consistently reported. And in many
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cases, metoclopramide was not used in accordance
with recommended dose and duration of the EMA
and the MFDS. Therefore clinical pharmacist’s role
in monitoring, detecting, evaluating, documenting
ADRs and providing feedback to healthcare provider
is important to ensure the appropriate usage of
metoclopramide and improve the patient’s safety.
738. Osteoporosis in the Community: Findings from
a Novel Computerized Registry in a Large Health
Organization in Israel
Inbal Goldshtein,1 Allison Martin Nguyen,2 Gabriel
Chodick,1,3 Varda Shalev,1,3 Soﬁa Ish -Shalom,4 Julie
Chandler.2 1Medical Division, Maccabi Healthcare
Services, Tel Aviv, Israel; 2Epidemiology, Merck and
Co, North Wales, PA, United States; 3Sackler Faculty
of Medicine, Tel Aviv University, Tel Aviv, Israel;
4Faculty of Medicine, Technion, Haifa, Israel.
Background: Osteoporosis is an important public
health issue due to its rising prevalence and excess
morbidity and mortality among this population.
Objectives: To construct a registry of osteoporosis pa-
tients using the electronic medical records of Maccabi
Healthcare Services, a 2 million members health main-
tenance organization (HMO), operating in Israel. The
registry will be used to investigate the epidemiology
and burden of the disease, detect high risk populations,
and to assess quality of care and gaps in provision of
preventive medicine.
Methods: Included in the registry are patients with
history of osteoporosis diagnosis, typical fractures
(e.g. closed fractures of proximal femur, vertebral,
Colles’ and proximal humerus) and or purchases of
relevant medications, documented since 2000. In ad-
dition, we included patients with low bone density
from over 140,000 measurements, using an auto-
mated Optical Character Recognition (OCR) system.
Patients younger than 18 years of age, diagnosed
with Paget’s disease or purchasing pamidronic or
zoledrnic acid due to cancer were excluded. Registry
entry date was deﬁned as the ﬁrst medical event
consistent with any of inclusion and all exclusion criteria.
Results: We identiﬁed over 100,000 patients with
osteoporosis, with an average incidence of approxi-
mately 7,000 cases a year. Average age at registry
entry was 62 y/o for women and 66 y/o for men. Most
of the patients had more than one qualifying criteria. A
substantial proportion of the registry patients are untreated.
Conclusions: This is one of the world’s ﬁrst auto-
mated registries of osteoporosis, and it provides a
model for the development of a well-standardized,
highly validated source of information to support
clinicians, investigators, and decision-makers in the
ﬁeld of osteoporosis in the community.
739. What Does Natural Language Processing Add to
the Structured Data Available in Medical Records?
X Zhou,1 L Weiss,1 AM Walker,2 AN Ananthakrishnan,3
R Shen,1 R E Sobel,1 A Bate,1 R F Reynolds.1 1Epidemi-
ology, Pﬁzer Inc., NYC, NY, United States; 2WHISCON,
Newton, MA, United States; 3Massachusetts General
Hospital, Boston, MA, United States.
Background: Settings that offer machine-readable
medical text for research typically also contain struc-
tured data, such as diagnoses, laboratory results and
service types. Structured data have traditionally been
used in pharmacoepidemiology research. An important
question in natural language processing (NLP) of medi-
cal texts is the further contribution of NLP-derived
terms to what is knowable from structured data alone.
Objectives: To assess the contribution of NLP in the
detection of hepatic disorders in patients undergoing
care for inﬂammatory bowel disease (IBD).
Methods: From the records of 32,299 patients with di-
agnoses of IBD and for whom both text and structured
data were available, Humedica provided both com-
plete structured data and a wide range of extracted
NLP terms from clinical narrative notes related to the
signs, symptoms and diagnoses of hepatic disorders.
We used supervised learning with a clinical expert to
develop algorithms for the diagnosis and determination
of onset for hepatic disease.We compared diagnosis and
timing for the complete algorithm against those of the
algorithm with NLP terms deleted, and tested the sensi-
tivity and positive predictive value of the algorithm with
or without NLP against with the clinical evaluation.
Results: At the time of abstract writing, the coded
diagnoses and laboratory values of the structured data
appear to carry almost all of the information necessary
to deﬁne the type and onset of hepatic diseases in the
IBD patients. NLP’s contributions, in fewer than 10 per-
cent of cases, affect timing and type of hepatic disease.
Conclusions: The preliminary results indicated that
the added value of NLP in medical records may be
inversely related to the completeness with which
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providers use diagnostic terms in the structured data
ﬁelds. For this example of deﬁning hepatic disease in
IBD patients in records supplied by Humedica, the
additional contribution of NLP beyond that which
was available in the structured data was marginal.
740. Risk of Hospitalization and HealthCare Cost
Associated with Diabetic Complication Severity
Index in Taiwan’s National Health Insurance
Research Database
Hung-Lin Chen,1 Fei-Yuan Hsiao.1 1Graduate Institute
of Clinical Pharmacy, National Taiwan University,
College of Medicine, Taipei.
Background: The adapted Diabetes Complication
Severity Index (aDCSI) has been found to be an useful
tool for prediction of risk of hospitalization and
healthcare cost among diabetic patients. However, the
aDCSI has not been validated in external claims data-
bases, which may limit the generalizability of the index.
Objectives: To test the validity of aDCSI in predicting
the risk of hospitalization and healthcare cost in type 2
diabetic patients using a nationally-representative
claims database in Taiwan.
Methods: A retrospective cohort study was conducted
using Taiwan’s National Health Insurance Research
Database (NHIRD).Type 2 diabetic patients who had
4-years of enrollment were identiﬁed as study subjects
(n = 136,372). The aDCSI score (sum of diabetic compli-
cation with severity levels, range 0-13) and complication
count (sum of diabetic complications, range 0-7) were
generated using diagnostic codes for each patient.
Poisson model and linear regression models were con-
ducted to predict risk of hospitalization and healthcare
costs associated with aDSCI score and count of diabetic
complications.
Results: The aDCSI score (risk ratio 1.51 to 10.32
categorically, and 1.41 linearly) and count of diabetic
complications (risk ratio 1.56 to 12.20 categorically,
and 1.66 linearly) were signiﬁcantly positively associ-
ated with risk of hospitalization. A one-point increase
in the aDCSI score was positively associated with
increased healthcare costs.
Conclusions: The performance of aDCSI in predicting
risk of hospitalization and healthcare cost in the na-
tionally-representative claims database is similar to
those reported in the original study. It may serve as
an efﬁcient tool for stratifying type 2 diabetic patients
for disease management programs and population-
based studies.
741. Validation of Serious Hospitalized Infection
Events in US Claims Databases
Kevin Haynes,1 Melissa Nezamzadeh,1 Craig W
Newcomb,1 JasonRoy,1WhitneyKite,1 DenaMCarbonari,1
Serena Cardillo,2 Sean Hennessy,1 Cristin P Freeman,1
Crystal N Holick,3 Daina B Esposito,3 Brian L Strom,4
LoReVincent.1 1Biostatistics and Epidemiology, Perelman
School of Medicine, University of Pennsylvania,
Philadelphia, PA, United States; 2Medicine, Perelman School
of Medicine, University of Pennsylvania, Philadelphia, PA,
United States; 3HealthCore, Wilmington, DE; 4Rutgers
Biomedical & Health Sciences, Rutgers, The State University
of New Jersey, New Brunswick, NJ.
Background: The validity of a claims algorithm to
identify hospitalized infections for post-marketing
safety surveillance is unknown.
Objectives: To validate an electronic algorithm for
hospitalized infections as part of an observational
safety study of saxagliptin.
Methods: Retrospective cohort study using 2009-
2011 data from US Medicare and the HealthCore Inte-
grated Research DatabaseSM (HIRDSM). Inclusion
criteria: ≥18 years of age, enrolled in the database for
at least 180 days, and newly prescribed saxagliptin
or an OAD in a class other than DPP-4 inhibitor.
We identiﬁed incident hospitalizations for infection
by using a hospital diagnosis of an infection plus
at least one of the following recorded within 7 days
prior to the hospital admission: 1) a pharmacy claim
for an antimicrobial agent, 2) an outpatient visit
with an infection diagnosis, or 3) an emergency de-
partment visit with an infection diagnosis. Within
each data source, we sought medical record data
relevant to the outcomes of interest and conﬁrmed
events through medical record review. Endpoints ar-
bitrators with clinical expertise in infectious disease
adjudicated the outcomes. The positive predictive
value (PPV) and 95% CI were determined.
Results: After excluding non-participating hospitals,
we randomly selected and requested 95 medical re-
cords from a sample of eligible patients from each data
source. In US Medicare, we received 57 charts, of
which 49 validated. The estimated PPV of the infec-
tious ICD-9 diagnostic coding algorithm was 93.3%
(77.9-99.2%) for principal diagnoses listing and
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77.8% (57.7-91.4%) for non-principal listing. In
HIRDSM, we requested 95 charts of patients with an
eligible saxagliptin or other OAD index date. We re-
ceived 58 charts, of which 52 validated. The estimated
PPV of the infectious ICD-9 diagnostic coding algo-
rithm was 87.0% (74.7-95.1%) for principal diagnoses
listing and 92.3% (64.0-99.8%) for non-principal
listing.
Conclusions: In two US claims databases, a PPV
>85% was calculated for an electronic algorithm to
identify severe infections resulting in hospitalization
among diabetic patients newly initiating an OAD.
742. Evaluation of Methods for Identifying Chemo-
therapy Induced Febrile Neutropenia among Cancer
Patients in Denmark
Hairong Xu,1 Mette Nørgaard,2 Uffe Heide-Jørgensen,2
Lars Pedersen,2 John H Page,1 Vera Ehrenstein.2 1Center
For Observational Research, Amgen Inc., Thousand
Oaks; 2Department of Clinical Epidemiology, Aarhus
University Hospital, Aarhus, Denmark.
Background: Developing and validating algorithms
for identifying febrile neutropenia (FN) in administra-
tive databases is important for use of these databases to
characterize the risk and burden of chemotherapy
induced FN.
Objectives: To validate registry-based algorithms for
identifying neutropenia and FN in adult patients
diagnosed with breast cancer and non-Hodgkin’s
lymphoma (NHL) treated with myelosuppressive
chemotherapy.
Methods: This case control validation study was con-
ducted in Central Denmark. We sampled all cancer pa-
tients treated with myelosuppressive chemotherapy
who had potential evidence of neutropenia within a
year after cancer diagnosis, deﬁned as at least one
ICD-10 code for agranulocytosis or neutropenic fever
in the Danish National Registry of Patients (DNRP),
or a laboratory measurement of absolute neutrophil
count (ANC) of <2.0 × 109 cells/L in the Laboratory
Information Systems (LABKA) database. We also ran-
domly selected patients without evidence of potential
neutropenia, matching with the ratio of up to 1.5 to
the patients with potential neutropenia. Evidence on
the presence of FN from medical chart review was
used as the reference standard and was evaluated in
up to six chemotherapy cycles by clinicians blinded
to the registry-based algorithms. We calculated
sensitivity and speciﬁcity and standard error was esti-
mated using the generalized estimating equations
approach.
Results: Among 112 NHL and 116 breast cancer pa-
tients, 40 patients developed FN based on medical
chart review, corresponding to 73 cycles with FN.
The ICD-10 code of agranulocytosis (D70) had zero
sensitivity for identifying FN. The sensitivity was
0.63 (95% CI: 0.49-0.77) for neutropenic fever
(T88.8N) and 0.08 (95% CI: 0.01-0.15) for fever
(R50). The speciﬁcity for absence of FN was 1.00
for the code D70, 0.99 (0.98-0.99) for ICD-code
R50; 0.97 (95% CI: 0.96-0.99) for ICD-10 code
T88.8N. The infection diagnosis codes and the sys-
temic antibiotic administration yielded sensitivities of
0.27 (0.16-0.39) and 0.03 (0.00-0.07), respectively
for identifying FN.
Conclusions: ICD-10-based algorithms performed
poorly for identifying FN in the DNRP.
743. How Far Is Estimated Creatinine Clearance
(eClcr) and Estimated Glomerular Filtration Rate
(eGFR) from Measured Creatinine Clearance
(mClcr) in Taiwanese
Yu-Hui Wu, Fe-Lin Lin Wu. Graduate Institute of Clin-
ical Pharmacy, College of Medicine, National Taiwan
University, Taipei, Taiwan.
Background: Estimated creatinine clearance (eClcr)
by Cockroft-Gault (CG) equation is often used for dos-
age adjustment while estimated glomerular ﬁltration
rate (eGFR) by Modiﬁcation of Diet in Renal Disease
(MDRD) equation is used in chronic kidney disease
(CKD) staging. The measured creatinine clearance
(mClcr) based on 24 hour urine collection is a clinical
applicable renal function measurement.
Objectives: To evaluate the correlation between
mClcr and eClcr/eGFR values, as well as the need
for weight/Scr adjustments in the CG equation for spe-
cial patients.
Methods: We identiﬁed 80542 patients who had se-
rum creatinine (Scr) data in 2012 in National Taiwan
University Hospital electronic database, and exclude
those with Scr beyond the linear test range, extreme
weight or height, acute kidney injury or speciﬁc diag-
nosis (pregnancy, cachexia etc…), or lack of weight or
height, After screening, 268 patients with ensured ad-
equate 24 hour urine collection and urine creatinine
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(Ucr) measurements were included. Using mClcr as a
reference, the correlation, bias, precision, relative bias,
and accuracy of eClcr or eGFRwere calculated. Subgroup
analyses between patients with different body size or Scr
were performed to identify adjustment requirement.
Results: Both eClcr and eGFR had good correlation
with mClcr, but both showed approximately 20%
lower than mClcr. In subgroup analysis, obese patients
had greater bias than non-obese patients. Substituting
actual weight by ideal body weight in CG equation
in obese patients increased relative bias from 17.7%
to 37.2%. Patients with Scr< 0.8mg/dL had less bias
and better precision than those with Scr ≥ 0.8mg/dL.
Using Scr = 0.8mg/dL to substitute the actual Scr in
patients with Scr< 0.8mg/dL resulted in greater bias
and inaccuracy.
Conclusions: All eClcr and eGFR equations
underestimated mClcr by about 20% and had poor ac-
curacy. Adjustment of Scr and body weight in special
populations did not improve the performance of CG
estimation equations.
744. A Review of Dental Adverse Events Using the
FDA Adverse Event Reporting System
Keith Altman,1 Renata Budny.2 1The Law Ofﬁce of Keith
Altman, Massapequa Park, NY, United States; 2Restor-
ative Dentistry, New York City College of Technology,
Brooklyn, NY, United States.
Background: In the United States, dentists generally
practice separately from medical doctors. As a result,
dentists may be less informed concerning adverse
events associated with drugs prescribed to their pa-
tients. The risk of osteonecrosis of the jaw from the
use of bisphosphonates is now well known. Unfortu-
nately, in the past, dentists were not aware of this risk
and how invasive dental work could lead to such seri-
ous consequences.
Dentists routinely perform invasive dental work
when placing dental prostheses. As populations age
and new drugs are developed to treat this aging popu-
lation, dentists need to become more aware of the
drugs used by their patients and possible risks associ-
ated with invasive dental work.
Objectives: To determine whether there were any pat-
terns associated with dental adverse effects. Particu-
larly, classes of drugs were assessed to see if there
may be previously unknown relationships with dental
adverse effects.
Methods: The FDA AERS database was searched for
all reports containing the HLGT “Dental and gingival
conditions”. After these reports were identiﬁed, the
last best cases were used to select and segregate
serious and non-serious events. Suspect drugs for each
report were accumulated and the most frequent drugs
were combined into classes and their labels were
reviewed to determine whether dental adverse events
were discussed.
Results: There were a relatively small number of den-
tal effects in the FDA AERS database. As expected,
there were a large number of reports associated with
bisphoshonates. Curiously, there seem to be a large
number of reports associated with TNF drugs such as
Enbrel, Remicade, and Humira. A review of the labels
for these three drugs suggests that stronger warnings
for dental adverse effects similar to the bisphosphonate
labels may be warranted.
Conclusions: Reviewing the FDA AERS database can
provide useful insight into patterns of adverse effects.
A review of dental adverse effects shows that there
may be risks associated with invasive dental work that
are not well characterized in product labels. Dentists
need to be more aware of these risks.
745. Socio-Economic Status and Hip Fracture Risk:
A Region-Wide Ecological Study
Carlen Reyes,1,2 Maria Garcia-Gil,3 Josep M Elorza-Ricart,4
Rafael Ramos,3 Cyrus Cooper,5 Daniel Prieto-
Alhambra.2,5,6,7 1Primary Health Care Eap Sardenya-
Biomedical Research Institute Sant Pau (IIB Sant Pau),
Barcelona, Spain; 2GREMPAL Research Group. IDIAP
Jordi Gol Primary Care Research Institute, Universitat
Autònoma de Barcelona, Barcelona, Spain; 3Unidad de
Investigación en Atención Primaria de Girona, IDIAP
Jordi Gol, Institut Català de la Salut, Girona, Spain;
4System for the Development of Research in Primary Care
(SIDIAP), IDIAP Jordi Gol Primary Care Research
Institute, Barcelona, Spain; 5MRC Lifecourse Epidemiol-
ogy Unit, University of Southampton, Southampton,
United Kingdom; 6Oxford NIHR Musculoskeletal Bio-
medical Research Unit, Nufﬁeld Department of Ortho-
paedics, Rheumatology and Musculoskeletal Sciences,
University of Oxford, Oxford, United Kingdom; 7Unitat
de Recerca en Fisiopatologia Òssia i Articular (URFOA)
and RETICEF, IMIM Research Foundation, Parc de Salut
Mar and Instituto de Salud Carlos III, Barcelona, Spain.
Background: Hip fractures are a burden for health
care systems.
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Objectives: To determine the association between
socio-economic status (SES) and risk of hip fracture.
Methods: Design: Retrospective cohort study.
Setting: Data was obtained from the SIDIAP data-
base (primary care anonymized records for 5,8 million
people in Catalonia (Spain)). Anyone registered in
SIDIAP in 2009-2012 was eligible.
Exclusion criteria: population residing in rural areas.
Exposures: MEDEA scores (validated SES compos-
ite index), accounting for proportion of unemployed,
insufﬁciently educated, temporary workers, manual
workers, and insufﬁciently educated youngsters, was
estimated for each area based on census data.
Outcomemeasure: hip fracture (ICD-10) in 2009-2012.
Statistics: Zero-inﬂated Poisson models were ﬁtted
to study the association between SES quintiles and hip
fracture rates after adjustment (age, gender, obesity,
smoking and alcohol drinking).
Results: Compared to the most deprived, wealthy
areas had a older population (46.83 (18.49) versus
43.29 (17.59), mean years (SD)), had more women
(54.8% versus 49.1%), had a lower percentage of
obese (8.4% versus 16.2%), smokers (11.9% versus
16.9%) and high alcohol consumption (1.3% versus
1.5%). Afﬂuent areas had a higher incidence of hip
fracture compared to the most deprived (Age-sex ad-
justed incidence 38.57 (37.14-40.00) and 34.33
(32.90-35.76) per 10,000 persons-year respectively).
When compared to the wealthiest, deprived areas had
lower hip fracture rates (unadjusted RR 0.71 [95%CI
0.65-0.78]), although age-gender (RR 0.90 [95%CI
0.85-0.95]) adjustment and further adjustment for
obesity (RR 0.96 [95%CI 0.90-1.01]) attenuated this
association. Further adjustment for smoking and alco-
holism did not make a difference (RR 0.96 [95%CI
0.91-1.02]).
Conclusions: Wealthiest areas had a 30% increased
risk of hip fracture. Differences in age-gender compo-
sition, maybe due to a previously described higher
mortality associated with deprivation, and a higher
prevalence of obesity explain the observed risk reduc-
tion in these deprived areas. This information should
be used for health-care planning and commissioning.
746. Socio-Economic Status and the Risk of Devel-
oping Osteoarthritis: A Region-Wide Ecological
Study
Carlen Reyes,1,2 Maria Garcia-Gil,3 Josep M Elorza-
Ricart,4 Bonaventura Bolibar,3 Rafael Ramos,3 Daniel
Prieto-Alhambra.2,5,6,7 1Primary Health Care Center
Eap Sardenya-Biomedical Resarch Institute Sant Pau
(IIB Sant Pau), Barcelona, Spain; 2GREMPAL Research
Group, IDIAP Jordi Gol Primary Care Research Insti-
tute, Universitat Autònoma de Barcelona, Barcelona,
Spain; 3Institut Universitari d’Investigació en Atenció
Primària (IDIAP) Jordi Gol, Barcelona, España, Barce-
lona, Spain; 4System for the Development of Research in
Primary Care (SIDIAP), IDIAP Jordi Gol Primary Care
Research Institute, Barcelona, Spain; 5MRC Lifecourse
Epidemiology Unit, University of Southampton, South-
ampton, United Kingdom; 6Oxford NIHR Musculoskele-
tal Biomedical Research Unit, Nufﬁeld Department of
Orthopaedics, Rheumatology and Musculoskeletal Sci-
ences, University of Oxford, Oxford, United Kingdom;
7Unitat de Recerca en Fisiopatologia Òssia i Articular
(URFOA) and RETICEF, IMIM Research Foundation,
Parc de Salut Mar and Instituto de Salud Carlos III,
Barcelona, Spain.
Background: Osteoarthritis is one of the most com-
mon musculoskeletal disorders, with a great impact
on quality of life and healthcare costs.
Objectives: To determine the association between
socio-economic status (SES) and risk of osteoarthritis
at a population level.
Methods: Design: Retrospective ecological study.
Setting: Data was obtained from the SIDIAP data-
base (primary care anonymized records for ﬁve million
people living in Catalonia (Spain)). Anyone registered
in SIDIAP in 2009-2012 was eligible.
Exclusion criteria: population residing in rural areas.
Exposures: MEDEA scores (validated SES compos-
ite index) were estimated for each area based on
census data after linkage to the ofﬁcial census and
harmonization of participants’ addresses. MEDEA
accounts for the proportion of unemployed, insufﬁ-
ciently educated, temporary workers, manual workers,
and insufﬁciently educated youngsters.
Outcomes: incident diagnoses (ICD-10 codes) of
hand, hip or knee osteoarthritis in 2009-2012.
Statistical analysis: Zero-inﬂated Poisson models
were ﬁtted to study the association between MEDEA
quintiles and risk of each of the outcomes.
Results: Compared to the most deprived, wealthy
areas had a older population (46.83 (18.49) versus
43.29 (17.59), mean years (SD)), had more women
(54.8% versus 49.1%), and a lower percentage of
obese (8.4% versus 16.2%), smokers (11.9% versus
16.9%) and alcoholics (1.3% versus 1.5%). Compared
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to the wealthy areas, the most deprived has an in-
creased risk of osteoarthritis: age-gender-adjusted RR
1.23 (1.17-1.29) for hand, 1.26 (1.11-1.42) for hip,
and 1.51 (1.45-1.57) for knee osteoarthritis respec-
tively. After adjustment for obesity this association
was attenuated: 1.06 (0.93-1.20), 1.04 (0.99-1.09),
and 1.23 (1.19-1.28) respectively.
Conclusions: People living in deprived areas have
higher rates of knee, hand, and hip osteoarthritis. An
increased prevalence of obesity accounts for 50% of
the excess risk of osteoarthritis observed in deprived
areas. Public health interventions to reduce the preva-
lence of obesity in these populations would have the
potential to reduce health inequalities.
747. Acute Mortality among Psychiatric Patients
with Acute Agitation Using a Japanese Hospital
Database
KoNakajo,1 Shuko Nojiri,1 Meghan E Jones,2 Keiji Kido,1
Masanori Taketsuna,3 Rei Maeda.1 1Global Patient Safety
Japan, Eli Lilly Japan KK, Kobe, Japan; 2Global Patient
Safety, Eli Lilly andCompany, Indianapolis, United States;
3Global APSS, Eli Lilly Japan KK, Kobe, Japan.
Background: Psychiatric patients are reported to have
an increased mortality compared with general popula-
tion. Moreover, agitation in psychiatric patients is
thought to lead to poorer outcomes. Several studies have
been done to assess mortality of psychiatric patients
globally. However, there is limited data focusing onmor-
tality of patients in Japan as well as the risk of agitation.
Objectives: To assess acute in-hospital mortality
among psychiatric patients with agitation admitted to
Japanese hospitals.
Methods: Data was used from a large-scale hospital
administrative database that included approximately
4.5 million patients from Japanese 125 DPC hospitals
and contains demographic characteristics, diagnoses
(ICD-10 codes) and prescription information. The pri-
mary cohort was deﬁned as patients hospitalized
with a primary or admitting diagnosis of schizo-
phrenia, manic episode or bipolar disorder from
2008 Apr to 2012 Sep. Information of emergent
hospitalization was used as a proxy to agitation, as
it is a required item to be checked for DPC hospi-
tals in Japan. Observation period started from the
ﬁrst hospitalization date and ended at the date of
death or ﬁnal discharge from hospital. The primary
analysis was to calculate a crude mortality by
Kaplan-Meier method. As a sensitivity analysis,
prescription data of parenteral antipsychotics at ad-
mission was utilized to identify agitated patients
from the cohort and examine its robustness.
Results: Primary cohort consisted of 1426 patients ad-
mitted to hospital in an emergent setting. The mean
days of hospitalization were 57 days. 11 deaths were
observed in the follow-up period and 5 deaths were
observed in one month after admission.
Conclusions: We assessed acute in-hospital mortality
among psychiatric patients using a large Japanese da-
tabase. This is the ﬁrst study to estimate mortality rate
of death among psychiatric patients with agitation in
Japan. Our study showed the database would be of
value for having estimate of local background rate of
important disease.
748. Under-Recording of Endometriosis in the
Health Improvement Network (THIN) Primary
Care Database: A Validation Study
Renate Schulze-Rath,1 Lucia Cea Soriano,2 Esther
Lopez-Garcia,3 Montse Soriano-Gabarró,1 Luis A Garcia
Rodriguez.2 1Global Epidemiology, Bayer Pharma AG,
Berlin, Germany; 2Spanish Centre for Pharmaco-
epidemiological Research (CEIFE), Madrid, Spain;
3Universidad Autónoma de Madrid, Madrid, Spain.
Background: The incidence of endometriosis (EDM)
is difﬁcult to establish because diagnosis requires lap-
aroscopy and women with mild or moderate symp-
toms may not undergo this procedure.
Objectives: To estimate the incidence of EDM in the
UK and to study the potential for under-recording of
EDM, by validation studies using information on
dysmenorrhea and menorrhagia (two symptoms of
EDM), and hysterectomy (potentially used to treat
EDM).
Methods: We identiﬁed women in THIN aged 12–54
years between January 2000 and December 2010 with
a ﬁrst recording of a Read code indicating EDM. To
evaluate the level of under-recording, we performed
three separate follow-ups to identify all women with
a Read code for hysterectomy (N= 15,028), dysmen-
orrhea (N = 27,134) and menorrhagia (N = 60,915),
with no record of a diagnosis of EDM. For a random
sample of women in each of these groups, a validation
exercise was undertaken to ascertain the rate of false
negatives. This included the manual review of patient
proﬁles (free text comments from medical records)
abstract402
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
(N = 200) and responses to questionnaires (N = 50)
sent to primary care physicians (PCPs).
Results: From a cohort of 866,295 women, 5,087
women had a Read code for EDM, incidence 1.02
(95% conﬁdence interval [CI]: 0.99–1.05) per 1,000
person-years. The proportion of women with EDM
among those with a code for hysterectomy, dysme-
norrhea and menorrhagia was 9.5%, 3.5% and 0%, re-
spectively. Extrapolating these percentages, we
estimated that the number of women with EDM
among those with a code for hysterectomy and dys-
menorrhea was 1,428 and 950, respectively. Based
on this, the resulting incidence of EDM was estimated
to be 1.50 (95% CI: 1.46–1.53) per 1,000 person-
years.
Conclusions: Using Read codes as the only strategy to
identify women with EDM in THIN results in underes-
timation of the incidence. This study shows the utility
of complementing Read codes with additional data
such as free text comments and information from
PCPs.
749. Performance of an Algorithm for Identifying
Primary Hypocalcemia in Commercial Health Plan
Claims Data
Florence T Wang,1 Fei Xue,2 Eva Ng,1 Cathy W
Critchlow,2 David D Dore.1,3 1Epidemiology, Optum,
Waltham, MA, United States; 2Center for Observational
Research, Amgen, Thousand Oaks, CA, United States;
3Health Services, Policy & Practice, Brown University
School of Public Health, Providence, RI, United States.
Background: Post-licensure pharmacovigilance often
relies on electronic healthcare data to evaluate potential
occurrence of adverse events following drug exposure.
The accuracy of identifying hypocalcemia among those
with osteoporosis using diagnosis codes is not known.
Objectives: To assess performance of an algorithm for
identiﬁcation of hypocalcemia leading to hospitaliza-
tions or emergency room (ER) visits among women
with postmenopausal osteoporosis (PMO) within a
commercial insurer’s administrative database as com-
pared with medical records.
Methods: Women with PMO were identiﬁed from a
claims database of a large United States healthcare in-
surer. Potential hypocalcemia events were identiﬁed
by ICD-9 diagnosis code 275.41 in the primary posi-
tion on ER or inpatient claims from June 2005 through
May 2010. Hypocalcemia was conﬁrmed through
medical record review. The positive predictive value
(PPV) of the algorithm was estimated.
Results: Among 165,729 women with PMO, medical
records were sought for 55 potential hypocalcemia cases;
40 (73%) charts were received. Chart retrieval was 92%
in ER setting and 67% for hospitalizations. A clinician
conﬁrmed 16 of 40 potential hypocalcemia events
(PPV=40%, 95%, conﬁdence interval [CI]: 24.9%-
56.7%). PPV was higher for the ER setting (PPV=
81.8%, 95% CI: 48.2%-97.7%) as compared with inpa-
tient setting (PPV=24.1%, 95% CI: 10.3%-43.5%).
PPVs restricted to women without cancer were similar.
Conclusions: Our algorithm for identiﬁcation of pri-
mary hypocalcemia performed better in the ER setting
as compared with the inpatient setting.
750. Predicting the Need for Prolonged Mechanical
Ventilation Following the First Hospital Admission
Due to Chronic Obstructive Pulmonary Disease with
Acute Exacerbation
Kuang-Ming Liao,1,2 Wei-Chieh Lin,3 Chung-Yi Li,4
Yea-Huei Kao Yang.2 1Department of Internal Medicine,
Chi Mei Hospital Chia-Li Branch, Tainan, Taiwan;
2Institute of Clinical Pharmacy and Pharmaceutical
Sciences, National Cheng Kung University, Tainan,
Taiwan; 3Medical Intensive Care Unit, Department of In-
ternal Medicine, National Cheng Kung University Medi-
cal College and Hospital, Tainan, Taiwan; 4Department
of Public Health, College of Medicine, National Cheng
Kung University, Tainan, Taiwan.
Background: Chronic obstructive pulmonary disease
(COPD) patients may suffer from acute exacerbation
(AE) and lead to respiratory failure with ventilator
dependent. The growing burden of COPD raises the
needs for the research of the epidemiology of COPD.
Objectives: To clarify the disease course requiring
prolonged mechanical ventilation after the ﬁrst hospi-
tal admission due to COPD with AE.
Methods: The National Health Insurance Research
Data (NHIRD) is a medical claims database. The
claims data of 1,000,000 beneﬁciaries were randomly
sampled from the Year 2005 Registry for Beneﬁciaries
of the NHIRD covered the period from January 1,
1997 to December 31, 2010. Eligible cases were sub-
jects who had diagnoses of COPD (ICD-9-CM codes:
490-492, 496) from inpatient claims data and
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prescription bronchodilating drugs are beta 2-agonists,
anticholinergics, and theophylline between January 1,
2005 and December 31, 2009. The exclusion criteria
were: age younger than 40 years of age and cancer his-
tory. In order to retrieve ﬁrst hospital admission, pa-
tient ever hospitalization in January 1, 1997 and
December 31, 2004 also excluded. Patients followed
until respiratory failure and prolong mechanical venti-
lation ( more than 21 days) with catastrophic illness
document, end of study or time of death.
Results: There are18,042 COPD patients and mean
age and corresponding standard deviation was
73.89 ±12.01 years, with a male gender predominant
distribution (68.05% male). The mean of hospital visit
per year is 8.64 and their average of hospital length of
stay is 19.42 days. The average of medical expenditure
is 35589 NTD per visit. The incidence density is in-
creased in 60-69 years old and rapidly increased in more
than 70 years old group with 21.44 and 56.8 per 1000 pa-
tient-years, respectively. During the followed up period,
most PMV cases occurred in the ﬁrst 2 years (77.52%).
Conclusions: COPD patients older than 70 years old
increase the risk of PMV after ﬁrst hospitalization.
The incidence rate of PMV increased with age in
COPD patients. The cumulative incidence rate of
PMV most occurred in the ﬁrst two years.
751. Performance of an Algorithm for Identifying
Serious Dermatologic Adverse Events in Commer-
cial Health Plan Claims Data
Florence T Wang,1 Fei Xue,2 Eva Ng,1 Cathy W
Critchlow,2 David D Dore.1,3 1Epidemiology, Optum,
Waltham, MA, United States; 2Center for Observational
Research, Amgen, Thousand Oaks, CA, United States;
3Health Services, Policy & Practice, Brown University
School of Public Health, Providence, RI, United States.
Background: Post-licensure pharmacovigilance often
relies on electronic healthcare data to evaluate poten-
tial occurrence of adverse events following drug expo-
sure. The accuracy of identifying serious dermatologic
events among those with osteoporosis using diagnosis
codes is not known.
Objectives: To assess performance of an algorithm for
identiﬁcation of dermatologic adverse events leading
to hospitalizations or emergency room (ER) visits
among women with postmenopausal osteoporosis
(PMO) within a commercial insurer’s administrative
database as compared with medical records.
Methods: Women with PMO were identiﬁed from a
claims database of a large United States healthcare
insurer. Potential dermatologic adverse events were
identiﬁed by ICD-9 diagnosis codes 694.xx, 695.1x,
695.5x,708.xx, or 782.1 in the primary position on
ER or inpatient claims from June 2005 through May
2010. Cases were conﬁrmed through medical record
review. The positive predictive value (PPV) of the
algorithm was estimated.
Results: Among 165,729 women with PMO, medical
records were sought for 265 potential dermatologic
events (15 erythematous events, 6 bullous dermatoses,
247 other dermatologic events; 3 had qualifying codes
for multiple subtypes); 184 (69%) charts were re-
ceived. A clinician conﬁrmed 128 of 184 potential
cases (PPV= 70%, 95%, conﬁdence interval [CI]:
62%-76%). PPV was higher for the ER setting (PPV=
77%, 95% CI: 69%-84%) as compared with inpatient
setting (PPV= 39%, 95% CI: 23%-57%). PPVs re-
stricted to women without cancer were slightly higher.
Conclusions: Our algorithm for identiﬁcation of pri-
mary dermatologic adverse events performed better in
the ER setting as compared with the inpatient setting.
752. A Normalization Method for Clinical Labora-
tory Test Results between Distributed Electronic
Healthcare Databases
Dukyong Yoon,1 Man Young Park,1 Eun Kyoung Ahn,1
Martijn J Schuemie,2 Rae Woong Park,1,3,4 on Behalf of
the Surveillance of Health Care in Asian Network
(SCAN) project.5 1Department of Biomedical Informat-
ics, Ajou University School of Medicine, Suwon, Repub-
lic of Korea; 2Janssen Research and Development LLC,
Titusville, NJ, United States; 3Center for Clinical Epide-
miology and Biostatistics and Department of Biostatistics
and Epidemiology, Perelman School of Medicine at the
University of Pennsylvania, Philadelphia, PA, United
States; 4Center for Pharmacoepidemiology Research
and Training, Erelman School of Medicine at the Univer-
sity of Pennsylvania, Philadelphia, PA, United States; 5.
Background: Combining clinical laboratory test results
across sites of care for pharmacoepidemiologic studies
is challenging because of different assay methods and
patient populations. There is no established method to
normalize laboratory test results to make them analyz-
able across distributed databases.
Objectives: The aim of the study is to develop a nor-
malization method for clinical laboratory test results
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from different data sources in distributed research net-
works (DRNs).
Methods: We developed a normalization method
called subgroup adjustment standardization (SAS) that
considers population structure based on variables such
as age and sex. In contrast to conventional standardiza-
tion methods, the SAS makes the means of two distri-
butions identical when patient counts in each subgroup
of two datasets are same. Subgroups can be deﬁned by
variables selected by researcher.
We evaluated usefulness of SAS by performing sim-
ulations with assumption that an ideal method will
makes two distributions identical when two dataset
have same population structure. We applied standard-
ization and SAS method (subgrouping by age and
sex) to 100 simulated dataset pairs from the same orig-
inal datasets (hemoglobin results, n = 2,038,043) with
randomly generated different errors and population
structures in age and sex. We measured absolute
differences of mean between each normalized distribu-
tion pair.
Results: Before normalization, differences of mean
were 0.69 ± 0.48 g/dl in average. After normalization
by standardization and SAS method, average
differences were 0.07 ± 0.06 g/dl and 0.02 ± 0.02 g/dl
respectively. SAS method showed smaller difference
than standardization in 85 datasets among 100
simulations.
Conclusions: SAS method shows more ideal normal-
ized result than traditional standardization. Although
age and sex were used for classifying subgroup in this
simulation, any variables affecting laboratory test
results, e.g. disease state or speciﬁc exposure, can be
applied according to purpose of research or data
sources. The method is applicable to the normalization
of clinical laboratory test results over the DRN,
because it requires only mean and standard deviation
of each dataset.
753. The Predictive Values in Validation Studies:
Misleading Statistics?
Hairong Xu, Yanli Li, John H Page. Center For
Observational Research, Amgen Inc., Thousand Oaks.
Background: The validity of ﬁndings in epidemio-
logic studies depends in part on the validity of
algorithms to accurately measure exposures and health
outcomes. However, many validation studies limit
estimation to positive predictive values (PPV) only.
Objectives: We conducted a Monte Carlo simulation
study to estimate the effect of exposure on the out-
come under different misclassiﬁcation probabilities
for exposure, outcome and confounder.
Methods: We simulated a scenario where a binary co-
variate (Z) is a common cause of a binary exposure (X)
and a binary outcome (Y, true log odds ratio = 0.7) in
20000 subjects. We conducted 1000 simulations for each
of different sensitivities, speciﬁcities and prevalence for
X, Y and Z. We estimated logistic regression models
for each scenario. We estimated Monte Carlo mean bias
and coverage probability (CP) of the log odds ratio (true
CP=0.95) associated with X on Y for each situation.
Results: Mean bias of the log odds ratio was -0.04, -
0.07, -0.27 and CP was 0.88, 0.84, 0.43, respectively,
when prevalence of Y was 10%, 5%, and 1% for mea-
sured Y with sensitivity = 0.99 and speciﬁcity = 0.99.
Mean bias was -0.06, -0.08,-0.1 and CP was 0.83,
0.76, 0.68, respectively, when sensitivity was 0.9, 0.8,
and 0.7 for prevalence of Y= 10% (PPV=0.91, 0.90,
and 0.89 respectively). Mean bias was -0.18, -0.27, -
0.53 and CP was 0.06, 0.01, 0.00, respectively, when
prevalence of Y was 10%, 5%, and 1% for measured
Y with sensitivity = 0.95 and speciﬁcity = 0.95. Similar
patterns were observed when X was misclassiﬁed.
Conclusions:Modest imperfections in sensitivity and/
or speciﬁcity may result in signiﬁcant bias in both
effect estimates and conﬁdence intervals in epidemio-
logic studies. These effects are ampliﬁed with decreasing
prevalence. Despite wide use in validation studies, pre-
dictive values do not provide sufﬁcient information to
understand the likely impact of misclassiﬁcation.
754. A Novel Broadly Applicable Risk Score for
Predicting Mortality of Patients with Circulatory
System Diseases Within Hospitalization Duration
Zhi Qu,1 Jingchen Song,2 Siyan Zhan,1 Xiemin Ma.2
1Department of Epidemiology and Bio-statistics, Peking
University Health Science Center, Beijing, China; 2De-
partment of Health Policy and Management, Peking Uni-
versity Health Science Center, Beijing, China.
Background: The common comorbidity indexes was
developed about two decades ago and were not appro-
priate for inpatients risk adjustment nowadays.
Objectives: To develop a risk stratiﬁcation model that
broadly predicts mortality risks in hospitalized patients
with circulatory system diseases.
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Methods: The risk score model was generated by
using inpatient summary report of electronic medical
record dataset from 2006 to 2010 among 50 tertiary
hospitals in Beijing, and validated by same dataset of
65 tertiary hospitals in the whole country in 2012.
The patient diagnosis as identiﬁed by using the
International Classiﬁcation of Diseases, 10th Revision.
Risk score was developed with individual major
diagnostic codes. Receiver operating characteristic
(ROC) analysis was used to evaluated the predictive
effect of risk score, and the Charlson Comorbidity
Index (CCI) was used to compare with the risk score
in validation data sets.
Results: The diagnosis code of total 4,216,375
patients were used to generate the risk scores which
comprise 293 items out of more than 4,000 categories
and ranged from 96 to 1. In the validation data set, the
ROC was 0.845 compared with the CCI ROC of 0.748
among myocardial infarction inpatients, and in
coronary artery bypass grafting(CABG) inpatients
the ROC was 0.729 to CCI ROC of 0.626, in percu-
taneous coronary intervention(PCI) inpatients the
ROC was 0.847 and 0.648 respectively. The ROC
of novel risk score was improved 12.7, 16.4 and
30.1 percent among inpatients with circulatory sys-
tem disease.
Conclusions: This study generated a broadly applica-
ble tool for risk adjustment that predicts circulatory
system diseases inpatient mortality with more reliabil-
ity than current risk indexes. This risk index will allow
comorbidity-adjusted outcomes broadly in surgery,
hospitalization and drug efﬁcacy evaluation.
755. Applying STROBE in Renal Journals, Is There
Any Difference in the Quality of Reporting Observa-
tional Studies?
Mahmoud E Elrggal, Abdulhaseeb M Hanif. Clinical
Pharmacy Department, Umm Al Qura University,
Makkah, Saudi Arabia.
Background: Although Randomized clinical trials are
the gold standard in clinical research, Observational
studies have great advantages by evaluating rare or
late side effects associated with certain treatments
and providing a more accurate indication of what can
be achieved in routine clinical practice. Unfortunately,
they are more borne to several types of bias
(confounding bias, sampling bias and recall bias).
Therefore, Quality of reporting in observational
studies is crucial to eliminate such bias.
Objectives: Our aim is to compare the quality of
reporting observational studies in three nephrology
journals before and after the implementation of
STROBE (Strengthening the Reporting of Observa-
tional studies in Epidemiology).
Methods: Researchers independently identiﬁed, criti-
cally appraised and extracted data from studies in Kid-
ney International, NDT and JASN journals in 2004 and
2011. Study quality was assessed using STROBE check-
list. T-test was used to differentiate between the rate of
completion of reporting between the two years. One
wayANOVAwas used to differentiate between the three
journals in the adherence to STROBE recommendations.
Results:We reviewed 150 observational studies in the
three journals. We checked Methods and results items
from the STROBE checklist. T–test showed that there
is a signiﬁcant improvement (P = .002) in the comple-
tion of reporting from (43% completion) in 2004 to
(59% completion) in 2011. ANOVA showed no sig-
niﬁcant difference between the three journals in the
level of compliance to STROBE reporting.
Conclusions: Reporting of observational studies has
improved signiﬁcantly over the years in nephrology
journals after the introduction of STROBE statement.
Difference in the impact factor of journals does not re-
ﬂect any difference in the rate of compliance. Observa-
tional studies still under-reported and efforts should be
made to enhance the quality of reporting.
756. An Evaluation of Sequential Analysis Methods
for Active Drug Safety Surveillance Using Observa-
tional Data
Xiaofeng Zhou, Warren Bao, Mike Gaffney, Rongjun
Shen, Sara Young, Andrew Bate. Epidemiology, Pﬁzer,
NYC, NY, United States.
Background: There have been increasing interests
in applying sequential methods that were well
established in clinical studies, to prospectively monitor
the safety of newly approved drugs through accrual of
real world data. However, the application to marketed
drugs using observational data has been limited.
Several different sequential approaches have been
suggested but work is needed to determine which ap-
proaches are most suited to observational data.
Objectives: To assess performance of Conditional
Sequential Sampling Procedure (CSSP) and compare
with the SAS GENMOD Procedure (GP).
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Methods: Age and gender adjusted CSSP and GP
were compared under three alpha spending functions
(O’Brien-Fleming, Pocock, Uniform) with three
alpha levels (0.01, 0.05, 0.10), using Optum, a US
claims database between 2005 to 2010 split into 6
time periods. Concordance was assessed for the
OMOP reference set of 50 drug-outcome pairs for
true associations (9 positive pairs and 41 negative
controls). Four comparator groups deﬁned by OMOP
were used.
Results: Overall, GP had higher/comparable sensitiv-
ity and slightly lower/comparable speciﬁcity than
CSSP, varying by setting of comparator drug deﬁni-
tion, alpha spending function and alpha level. The set-
ting for best sensitivity in GP (56%) resulted in a
speciﬁcity of 59% while the same setting for CSSP re-
sulted in a sensitivity of 33% and speciﬁcity of 66%;
the setting for best sensitivity in CSSP (44%) resulted
in a speciﬁcity of 83% while the same setting for GP
resulted in a sensitivity of 44% and speciﬁcity of
80%. Across all settings, GP tends to pick up signals
faster than CSSP: 60-100% pairs in CSSP were picked
up at a later period compared with GP. Computation
time for both methods are comparable.
Conclusions: Our results suggest that GP performance
is comparable to CSSP and both methods showed po-
tential for safety surveillance. With the features of ﬂex-
ible confounding control and fewer assumptions, GP
may be a strong alternative to CSSP. Further study to
understand the capacity of GP to handle rare events
and assess the generalizability of our ﬁndings is needed.
757. Considerations for Using Electronic Medical
Record Data for Pharmacoepidemiology
Scott L DuVall,1,2 Corinne H Halls,1,2 Olga V
Patterson.1,2 1VA Salt Lake City Health Care System, Salt
Lake City, UT, United States; 2University of Utah, Salt
Lake City, UT, United States.
Background: A recent article in Medical Care pro-
vides a list of caveats for using electronic health record
(EHR) data in comparative effectiveness research
(CER), including EHRs may contain inaccurate data,
often do not tell a complete patient story, and have
been collected or coded for purposes other than re-
search and clinical care. Many researchers are not
closely involved in patient care or may conduct studies
spanning multiple clinical disciplines. Especially in
these cases, understanding the caveats of using EHR
data can be a challenge.
Objectives: To describe a 3-step process that helps en-
sure the availability, accuracy, and representativeness
of EHR data used in studies.
Methods: The ﬁrst step in the process is to investigate
the target study population. It includes gathering in-
formation about the common demographic proﬁle af-
fected, the ways the disease commonly manifests
itself, and diagnostic tests and treatments given. This
provides a baseline of the data that can be expected.
Institution-speciﬁc numbers should be compared with
national estimates and previous publications so any
differences can be explored and explained. The second
step is to discover the care workﬂow. It usually in-
volves discussing with care providers the types of inter-
actions patients in the target population have with the
health care system. Medical record data reﬂects these
interactions, so the goal is to ensure all points of data
entry are identiﬁed and understood. The third is to un-
derstand the underlying data. It requires iteratively
pulling and validating data to ensure the study popula-
tion is represented, that all relevant data are available,
and that the medical record data adequately represents
the real-world interactions of patients with providers.
Any deviations can be identiﬁed and addressed to en-
sure not only the data, but the study results are com-
plete, accurate, and reﬂective of clinical practice.
Results: This process has been tested and adopted by
our research team as we’ve performed studies in health
domains ranging from mental health to oncology to
cardiovascular health to surgery.
Conclusions: This 3-step process allows research teams
to conﬁdently conduct CER studies using EHR data.
758. Impact of Varying Control Moment Selection
in a Case-Crossover (CCO) Study on Antidepres-
sant Drug (AD) Use and Hip/Femur Fracture
(HFF) in PROTECT
Mark CH de Groot,1 Svetlana V Belitser,1 Patrick C
Souverein,1 Rolf HH Groenwold,2 Gianmario Candore,3
Yolanda Alvarez,3 Raymond G Schlienger,4 Robert
Reynolds,5 Olaf H Klungel,1 Helga Gardarsdottir.1 1Fac-
ulty of Science Division of Pharmacoepidemiology and
Clinical Pharmacology, Utrecht Institute for Pharmaceu-
tical Sciences, Utrecht University, Utrecht, Netherlands;
2Julius Center for Health Sciences and Primary
Care, University Medical Center Utrecht, Utrecht,
Netherlands; 3Signal Detection and Data Analysis,
Pharmacovigilance and Risk Management, European
Medicines Agency, London, United Kingdom; 4Global
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Clinical Epidemiology – Drug Safety & Epidemiology,
Novartis Pharma AG, Basel, Switzerland; 5Epidemiol-
ogy, Pﬁzer Inc., New York, United States.
Background: The CCO design is appealing because it
eliminates time-invariant person related confounding.
A prerequisite is that exposure in real life drug use is
sufﬁciently transient to allow for independence of ex-
posure states. The impact of variation in time of con-
trol moment selection is relatively unknown.
Objectives: To assess the inﬂuence of selection of
control moments at different times in a CCO study of
AD and HFF on variation in effect estimates.
Methods: Adult patients with HFF who received an
AD prescription during 2001-2009 were identiﬁed
from the Dutch Mondriaan GP database. For each pa-
tient, a case moment (the date of HFF) and four control
moments at 3, 6, 9, and 12months before the HFF
(M3, M6, M9, M12) were deﬁned. Each AD prescrip-
tion had a pre-deﬁned duration of 90 days. AD treatment
episodes were constructed and divided into current, re-
cent (0-2 months following current use) and past use
(>2months follow current use).We used conditional lo-
gistic regression to compute odds ratios (ORs) and 95%
conﬁdence intervals CI between AD use and HFF.
Results: Pairwise (1:1) comparisons of 82 case mo-
ments to varied control moments for current versus
no use resulted in ORs for HFF-M3 of 16.3 (95%CI:
2.2-123), M6: 7.8 (2.3-26), M9: 5.9 (2.1-16.1), and
M12: 4.1 (1.8-9.4). Including all (1:4), M3-M12, resulted
in OR 7.0 (3.2-15.2). For recent use even higher ORs
were found; M3: 49.7 (3.9-637), M6: 17.6 (2.5-136),
M9: 2.6 (0.7-9.5), M12: 3.7 (0.7-20), All 8.6 (2.7-27).
Discordancy of exposure and thus number of strata
contributing to the analyses increased from 32% in
M3 to 50% in M12.
Conclusions: Selection of control moments at differ-
ent times in CCO has considerable impact on effect es-
timates in this particular setting. CCO studies should
be designed with sufﬁcient time between case and
control moments to allow for sufﬁcient discordancy
in exposure to get reliable estimates.
759. Study Designs in Pharmacoepidemiologic
Studies on Electronic Healthcare Databases: A Sys-
tematic Review
Nathalie Gault,1 Stéphanie Foulon,1 Sylvie Guillo,2 Florence
Tubach.1 1Epidemiology and Clinical Research, APHP,
Hôpital Bichat, Paris, France; 2CIC1425-EC, UMR 1123
ECEVE, INSERM, Paris, France.
Background: Observational studies are widely used in
the real life pharmacoepidemiologic studies. Several
designs are available, such as cohort (C), case-control
(CC), or self-controlled (SC) designs, of which case-
crossover (CCO), case-time-control (CTC) and self-
controlled case-series (SCCS). Recommendations on
their use in medical products (MP) safety monitoring
on electronic healthcare databases (EHDB) have been
recently published.
Objectives:We aimed at describing which designs are
used in pharmacoepidemiologic studies on EHDB,
whether they ﬁt the recent recommendations, and
how frequent are the situations in which CO could
have been applied.
Methods: We searched Medline for articles published
in the second part of 2011. Terms referring to 1)
EHDB, 2) effect of MP, and 3) observational designs,
were combined. More SC were added after enlarging
the search between 01-2011 and 12-2012. Data fo-
cusing on designs, exposures (EXP) and events
(EV) characteristics were collected using a standard-
ized extraction form by two independent readers. In
papers reporting more than one design, the SC was
considered. 15% of papers were read by both
readers. SC could be applied in case of abrupt onset
and rare or recurrent event, and intermittent or acute
exposure. Speciﬁc assumptions for CCO and SCCS
were explored in papers using each design
respectively.
Results: In the initial search, 94 papers were analysed.
Of these, 48 (51%) used data of administrative DB, 19
(20%) of pharmacy records, 16 (17%) of primary care
records, other DB were less common. Safety was
assessed in 49 (52%) papers, effectiveness in others.
Study designs used were 67 C, 25 CC, and 2 SC. Basic
assumptions for SC use were met in 18% of papers
using a different design. The enlarged search found
13 CCO and 5 SCCS. The formers were always used
adequately concerning speciﬁc assumptions, except 1
article. Speciﬁc assumptions for SCCS use were less
often fulﬁlled.
Conclusions: SC designs have advantages, but their
use is subjected to key assumptions fulﬁlment. When
they are used, key assumptions are often fulﬁlled.
However, they could be employed more frequently
and their use should be encouraged.
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760. RCT Participants and Real Life Drug Users: A
Population-Based Cohort Study
Daniel Prieto-Alhambra,1,2,4M Kassim Javaid,1,5 Tjeerd
Van Staa,3 Cyrus Cooper,1,5 Adolfo Diez-Perez.4
1NDORMS, University of Oxford, Oxford, United
Kingdom; 2SIDIAP Database/Musculoskeletal Research
Unit, Idiap Jordi Gol Primary Care Research Institute,
Universitat Autonoma de Barcelona, Barcelona, Spain;
3Department of Non-Communicable Diseases, London
School of Hygiene & Tropical Medicine, London, United
Kingdom; 4Musculoskeletal Research Unit, IMIM-Parc
de Salut Mar, Universitat Autonoma de Barcelona,
Barcelona, Spain; 5MRC Lifecourse Epidemiology Unit,
University of Southampton, Southampton, United Kingdom.
Background: Translation of trial ﬁndings into routine
clinical practice remains a key issue for improving pa-
tient outcomes. The FIT randomized controlled trial
(RCT) showed that Alendronate is effective at reduc-
ing fractures in 3,658 women. There is little data on
its use in real life settings.
Objectives: To compare the baseline characteristics
and 3 years persistence amongst incident users of
Alendronate in 2006-2011 in primary care settings
with ﬁndings from FIT.
Methods: Design: Retrospective cohort study.
Setting: Data was obtained from the SIDIAP data-
base, containing primary care records and pharmacy
invoice data for >5 million people in Catalonia, Spain.
Inclusion criteria: users of Alendronate in 2006-
2011, deﬁned by dispensation of ≥2 prescriptions in
the study period.
Exclusion criteria: use of any anti-osteoporosis drug
in the previous year
Measurements:
Exclusion criteria for FIT: age (<55 or >80 years),
male gender, co-morbidities, oral steroid use, and alco-
holism. All other criteria, for which no data were avail-
able, were assumed to be fulﬁlled.
Therapy cessation was deﬁned as a 6-month reﬁll
gap in pharmacy dispensations.
Statistics: n and % of Alendronate users fulﬁlling
each inclusion criteria for FIT are reported. Kaplan-
Meier models were ﬁtted to estimate persistence.
Results: 42,974 new users of Alendronate were
identiﬁed. Amongst these, 12,795 (29.8%) and 7,847
(18.3%) would not be eligible for FIT due to age and
gender reasons respectively. 2,576 (6.0%) were previ-
ous steroid users, and 4,539 (10.6%) had some of the
co-morbidities listed as exclusion criteria. Overall,
only 21,705/42,974 (50.5%) users of Alendronate
would have been eligible for FIT.
3-year persistence in FIT was 89%, compared to
23.3% in SIDIAP Alendronate users.
Conclusions: In this conservative study, which as-
sumed (amongst other criteria) that all Alendronate
users had a densitometric diagnosis of osteoporosis,
only half of them were comparable to the FIT trial par-
ticipants. Persistence is also much lower in actual
practice than in RCT settings. Routinely collected data
are essential for the evaluation of the use of anti-
osteoporosis (and likely other) drugs in the community.
761. MM Optimization in Massive Observational
Analysis
Trevor R Shaddox,1 Kenneth L Lange,1,2,3 David
Madigan,4 Marc A Suchard.1,2,5 1Biomathematics, David
Geffen School of Medicine at UCLA, Los Angeles, CA,
United States; 2Human Genetics, David Geffen School
of Medicine at UCLA, Los Angeles, CA, United States;
3Statistics, UCLA, Los Angeles, CA, United States; 4Sta-
tistics, Columbia University, New York, NY, United
States; 5Biostatistics, Fielding School of Public Health
at UCLA, Los Angeles, CA, United States.
Background: Adverse drug events (ADEs) remain a
serious public health risk. Identifying dangerous
drugs from the emerging national patient claims
and electronic health record databases is a non-trivial
statistical challenge. Speciﬁcally, ﬁtting models in
the context of datasets with tens of thousands of co-
variates and millions of observations always perches
on the edge between computationally expensive and
intractable.
Objectives: New techniques for optimization in this
setting add to the arsenal of strategies that can push so-
phisticated, meaningful modeling toward feasiblity.
Here, we incorporate ideas from the Majorization-
Minimization and Minorization-Maximization (MM)
approach to develop two novel MM algorithms in the
context of the Bayesian self-controlled case series
(BSCCS) regression model.
Methods: In the ﬁrst algorithm, we take two
minorization transformations of the BSCCS likelihood
and optimize with sequential Newton steps. In the
second algorithm, we take a single minorization
transformation and solve the resulting minorizing
quadratics.
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Results: The result of both techniques is parameter
separation in the surrogate at each optimization step,
at the cost of an increase in the number of iterations re-
quired. This opens a possibility for transforming what
is currently a sequential iterative algorithm into a
parallel iterative algorithm.
Conclusions: The computational cost-beneﬁt analysis
then balances the number of steps takenwith the resulting
increase in computational efﬁciency. These implemen-
tations invite further research into the beneﬁts of using
MM algorithms in massive observational settings.
762. Understanding of the Clinical Course of Breast
Cancer in Japanese Women Using Health Insurance
Claims Database
Kenji Hamada, Terumi Nakayama. Drug Safety Div.,
Drug Safety Data Manegement Dept., Chugai Pharma-
ceutical Co.,Ltd., 1-1, Nihonbashi-Muromachi 2-chome,
Chuo-ku, Tokyo, Japan.
Background: Understanding the clinical course of a
disease is particularly helpful for risk surveillance
and management of drugs during the postmarketing
phase. Temporal information on medical procedures,
medications, and complications after ﬁrst diagnosis is
not only applicable to planning and monitoring appro-
priate use but also provides basic criteria for identify-
ing adverse drug reactions.
Objectives: Understanding the clinical course of
breast cancer in Japanese women after ﬁrst diagnosis.
Methods: For this descriptive epidemiological study,
we extracted data on breast cancer patients from July
2008 to June 2013 using a large Japanese health insur-
ance claims database provided by Japan Medical Data
Center Co., Ltd. We examined mean age at initial on-
set and temporal information on laboratory testing;
surgical, radiation, and hormone therapy; drug admin-
istration; and occurrence of complications. Breast
cancer was deﬁned according to diagnosis, whether
testing was performed, and treatment. Initial onset
was assumed in patients not diagnosed with breast
cancer in the 12months before meeting these criteria.
ICD-10, ATC, and Japanese medical service payment
codes were used for the deﬁnitions.
Results: During the period, 1,413 breast cancer pa-
tients were classiﬁed from 1,196,344 insured women.
Mean age at initial onset was 48.35 years. Mean fol-
low-up time was 18.24months (59months max.), but
567 patients dropped their insurance midway. During
the period, 1,289 patients had surgery (1.83 proce-
dures per patient who had surgery), 745 received
radiation therapy (49.12 treatments per patient
receiving radiation therapy), 486 received chemo-
therapy, and 888 received hormone therapy. On av-
erage, 1.84 agents were administrated per patient
treated with anticancer agents, including hormone
therapy. Nausea or emesis, constipation, skin in-
ﬂammation, and allergic rhinitis were the most com-
mon complications.
Conclusions: We were able to look at the clinical
course of breast cancer in Japanese women. The infor-
mation obtained can be helpful in risk surveillance and
management of drugs.
763. Simvastatin and Its Potential Drug Interac-
tions: An Analysis of Safety Signal Based on FDA
AERS Database
Amarsinh M Desai,1 Teresa M Cavanaugh,1 Christina
MLKelton,2 Pamela CHeaton,1 Jeff J Guo.1 1Department
of Health Outcomes, College of Pharmacy, University of
Cincinnati, Cincinnati, OH, United States; 2College of
Business, University of Cincinnati, Cincinnati, OH,
United States.
Background: Simvastatin is an antihyperlipidemic
agent used to lower serum cholesterol. Simvastatin
has been associated with rhabdomyolysis, a rare but
potentially life-threatening Adverse Drug Event
(ADE). Recently, the FDA created a black box warn-
ing limiting use of simvastatin at higher doses.
Objectives: The objective of this study was to
evaluate the data in the FDA Adverse Event Reporting
System (FAERS) to describe and proﬁle the cases that
led to this decision.
Methods: A retrospective analysis of all domestic and
foreign reports of simvastatin-associated rhabdomyol-
ysis between October 1997 and September 2011 was
conducted using FAERS database. The frequency of
the following outcomes was examined: congenital
anomaly, death, life-threatening reaction, hospitaliza-
tion, disability, others and required intervention. The
percentage of role codes (primary suspect, secondary
suspect, concomitant drug, or interacting drug) was
analyzed. Separate analysis was conducted to report
frequency of doses associated with rhabdomyolysis.
Drug dosages associated with both ADEs and speciﬁ-
cally rhabdomyolysis were evaluated.
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Results: A total of 3,014,229 simvastatin-associated
reports were identiﬁed over a 14-year period in the
FAERS database. Hospitalization occurred in 41.1%
and death was reported in 8.16% of the cases. Remark-
ably, 40.4% of ADE were reported for the 40mg dose
and 13.4% for the 80mg dose. Simvastatin was
designated as concomitant in 73.6% and as a secondary
suspect in 16.0% of the cases. A total of 25,701 reports
of simvastatin-associated rhabdomyolysis were
reported. Of these, 6,673 rhabdomyolysis reports had
dose information avaialble. Whereas, 44.1% were
associated with the 40mg dose; 26.7% were reported
for 80mg dose.
Conclusions: Simvastatin-associated ADE were
demonstrated in the FAERS database with severe clinical
outcomes including hospitalization and death. The
increased risk associated with higher simvastatin doses
provides evidence to support the FDA’s black box
warning.
764. Validity of Coding and Descriptive Epidemiol-
ogy of Rheumatoid Arthritis in Catalonia, Spain: A
Population-Based Cohort Study
Francesc Fina-Aviles,1 Bonaventura Bolibar,2 Daniel Prieto-
Alhambra.2,3 1Primary Care, Institut Catala de la Salut,
Barcelona, Catalonia, Spain; 2SIDIAP Database, Idiap
Jordi Gol Primary Care Research Institute, Universitat
Autonoma de Barcelona, Barcelona, Catalonia, Spain;
3NDORMS, University of Oxford, Oxford, United Kingdom.
Background: Information on the epidemiology of
rheumatoid arthritis (RA) in Southern Europe is scarce
and often historical. SIDIAP is a potential source for
such data, but RA coding has not been validated yet.
Objectives: We studied the results of rheumatoid fac-
tor (RF) testing amongst newly diagnosed RA cases in
SIDIAP. Secondly, we estimated the age and gender-
adjusted incidence and prevalence of RA in Catalonia,
Spain, and compared these to previous literature.
Methods: Design: Retrospective cohort study.
Setting: Data was obtained from the SIDIAP data-
base, which gathers primary care anonymized records
and laboratory tests data for ﬁve million people in
Catalonia (Spain). Anyone registered in SIDIAP in
2009-2012 was eligible.
Exclusion criteria: prevalent cases of RA were ex-
cluded for the study of incidence
Exposures:
Age, gender, and RF test results in the study period.
Outcomes were diagnoses of rheumatoid arthritis
according to GP coding (ICD-10).
Statistical analysis: age (5-year groups) and gender-
speciﬁc, and standardized incidence and prevalence of
RA and conﬁdence intervals (95%CI) were estimated
assuming a Poisson distribution.
Results: 20,091 prevalent (among whom 5,796 inci-
dent) cases of RA were identiﬁed among 4,796,498
study participants observed for up to 4 years. Rheuma-
toid factor was positive (≥10 IU/mL) in 1,833 (73.9%)
of 2,482 cases with a test performed in primary care.
Rates of RA increased with age in both genders,
peaking at the age of 65-70 years. Age and gender-
standardized incidence and prevalence rates were
19.95/100,000 person-years (95%CI 19.42-20.49)
and 4.17/1,000 (4.11-4.23) respectively.
Conclusions: Over 70% of the newly coded cases of
RA tested for RF in SIDIAP were sero-positive, equiv-
alent to what has been described for RA patients
worldwide. The incidence and prevalence of RA in
Catalonia is similar to that expected based on previous
literature. SIDIAP is a useful source of data for studies
of RA epidemiology and related therapies.
765. Lessons Learned from a Survey for Hospitalized
Influenza Using a Japanese Administrative Database
Tomomi Kimura. Infectious Diseases and Vaccine Thera-
peutic Area, Janssen Pharmaceutical K.K., Tokyo, Japan.
Background: Diagnosis-Procedure Combination
(DPC) is a ﬂat-fee payment system for hospitalized
patients in Japan and has 12 columns for diagnosis
codes (primary [PRI], condition triggering admission
[TRI], most costly, second costly, 4 comorbidities at
admission [COM], and 4 hospital onset conditions
[HP]). PRI and TRI are often considered as reasons
for admission but literature from the United States sug-
gested that the use of primary only did not fully cap-
ture inﬂuenza-associated hospitalizations.
Objectives: To evaluate the sensitivity of PRI/TRI in
identifying hospitalized inﬂuenza patients compared
to capturing it with any of the 12 diagnosis columns
in a Japanese hospital-based administrative database.
Methods: Individual billing records during 2008-2012
seasons (Sep-Aug) were extracted for patients having
at least one inﬂuenza code (ICD10 J10 or J11) in any
of the 12 diagnosis columns. PRI and TRI were highly
correlated and considered as one group.
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Results: Only 36.4% among 10,694 identiﬁed patients
had inﬂuenza code in PRI/TRI and had milder clinical
characteristics. The sensitivity was higher in younger
patients (46% for <17 yrs vs. 25% for 18 yrs or older)
and in neuraminidase inhibitors (NAI) treated patients
(n = 5,523, 47.4% vs. 24.6% for non-treatment group).
Nearly half of inﬂuenza was rather reported as a COM
for complications of inﬂuenza (e.g., pneumonia) or
other conditions. In addition, 19.2% had reported in-
ﬂuenza as HP but 27% of them had actually started
NAI within 3 days from the admission and considered
as rather community acquired.
Conclusions: Deﬁning hospitalized inﬂuenza as PRI/
TRI would overlook more than half of the inﬂuenza-
associated hospitalizations, especially for sicker pa-
tients, in this database. Laboratory conﬁrmation data
was not available and the patients should be consid-
ered as inﬂuenza-like illness. No source veriﬁcation
was done but HP might include some community-
acquired inﬂuenza patients. Coding patterns need to
be reviewed before assessing the magnitude of disease
burden using an administrative database.
766. The Association of Neovascular Age-Related
Macular Degeneration with Cardiovascular Dis-
eases: A Study Using the NHIRD in Taiwan
Wan-ju Lee,1,2 Yea-Huei Kao Yang,1 Ching-lan Cheng,1
Yi-sheng Willis Chang,2 Chung-yi Li.3 1Institute of Clin-
ical Pharmacy and Pharmaceutical Science, College of
Medicine, National Cheng Kung University, Tainan,
Taiwan; 2Department of Ophthalmology, National
Cheng Kung University Hospital, Tainan, Taiwan; 3De-
partment of Public Health, College of Medicine, National
Cheng Kung University, Tainan, Taiwan.
Background: Neovascular age-relatedmacular degener-
ation (nAMD) was the leading cause of blindness in the
elderly inmany developed countries. Although the causes
of nAMD are not well understood, studies revealed that it
shares many same risk factors with cardiovascular
diseases, such as myocardial infarction (MI) and stroke.
Objectives: To investigate the association between nAMD
and cardiovascular diseases in Taiwanese population.
Methods: We conducted a retrospective cohort by
means of National Health Insurance Research Data-
base (NHIRD) which contains about three million
population from year 2001 to 2008. We ﬁrst selected
970 patients who ﬁrst sought outpatient care for
nAMD during study period. The comparison group
consisted of 3,784 age- and sex-matched subjects ran-
domly selected from all beneﬁciaries registered in the
same period. The patients had MI or stroke history
within one year before enrolled in cohort would be ex-
cluded. The primary outcome was new events of MI or
stroke. Chronic conditions (Diabetes, hypertension, hy-
perlipidemia and rheumatic arthritis) or co-medications
related to MI or stroke were sought in both groups.
Results: Both groups showed slightly predominance
of male gender (nAMD, 59.48%; control, 59.80%).
In the nAMD group, more people of over 75-year-old
were collected compared to the control group (nAMD:
34.55%, control: 18.37%). The nAMD group showed
higher prevalence of diabetes, hypertension and
hyperlipidemia, prescriptions of medications (NSAID,
HMG-CoA reductase inhibitor, beta-blocker, calcium
channel blocker, ACEI andARB, Aspirin and anti-plate-
let). The rate of MI was 1.75% in the nAMD group and
1.90% in the comparison group. [nAMD: control = 17
(1.75%): 72 (1.90%); RR=0.9985, 95% CI= 0.989 to
1.008]. The rate of stroke was 17.01% in nAMDpatients
and 11.97% in the control groups, which had statistical
signiﬁcance. [nAMD: control = 165 (17.01%): 453
(11.97%), RR=1.0607, 95% CI= 1.0285 to 1.0939].
Conclusions: nAMD is associated with older age, male
gender, higher prevalence of diabetes, hypertension and
hyperlipidemia. Presence of nAMD is prospectively as-
sociated with a higher risk of incident stroke event.
767. Race-SpecificPrevalence andRisk Factors forCu-
taneous Psoriasis in a U.S. Population-Based Cohort
Hoa V Le, Chi TL Truong, Julie Priest, Carlyne Averell,
Charlotte Carroll, Martin Crane. Worldwide Epidemiology,
GlaxoSmithKline, Durham, NC, United States.
Background: Data on prevalence of cutaneous psori-
asis in the U.S. by race are limited, especially in the
context of other disease factors.
Objectives: To determine race-speciﬁc prevalence and
potential risk factors for skin psoriasis using the
Humedica de-identiﬁed electronic health records
(EHR) database.
Methods: We created a cohort of patients with a skin
psoriasis diagnosis [ICD-9 696.1] in 2011 among
those afﬁliated with integrated delivery network pro-
viders, and that had at least one year of follow-up in
the Humedica EHR database. Crude annual prevalence
of skin psoriasis was estimated overall as well as by race
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(per HIPAA restrictions), age group and gender. A ran-
dom sample of 100,000 patients without a psoriasis di-
agnosis was selected as controls. Multivariate logistic
regression was used to assess risk factors for psoriasis
controlling for demographics and Charlson comorbidi-
ties. Backward variable selection and two-sided p-value
<0.05 for statistical signiﬁcance were used.
Results: Overall prevalence, based on 44,365 skin
psoriasis patients, was 0.8%, lower in African-Ameri-
cans (0.3%) than Asians (0.8%) or Whites (0.9%);
5.8% were prescribed systemic drugs. Whites and
Asians had 2.5 fold greater risk of psoriasis than Afri-
can-Americans. Prevalence in the ﬁrst decade was
similar across race, but increased more rapidly with
age in Asians and Whites than African-Americans.
Compared to the 20-29 year old group, psoriasis
monotonically increased with age: ORadj = 0.3-0.6 for
the 0-9 and 11-19 year age groups, and ORadj = 1.5-
2.2 for the 30-39 through 60-69 age groups. Current
smoking was signiﬁcantly associated with psoriasis
(ORadj = 1.2, 95% CI: 1.2-1.3) and severe psoriasis
(ORadj = 3.9, 95% CI: 3.3-4.7). Severe diabetes,
connective tissue diseases, COPD and liver diseases
were signiﬁcantly associated with overall and severe
skin psoriasis.
Conclusions: Skin psoriasis prevalence in Whites and
Asians was more than double that in African-Americans.
White/Asian race, older ages, smoking, diabetes, con-
nective tissue diseases, COPD and liver diseases were
factors associated with increased risk of skin psoriasis.
768. InteractiveWeb-Based Tool for Cohort Creation
and Disease Outcome Feasibility
Scott L DuVall,1,2 Aaron WC Kamauu,3 Jonathan R
Nebeker.1,2 1VA Salt Lake City Health Care System, Salt
Lake City, UT, United States; 2University of Utah, Salt
Lake City, UT, United States; 3Anolinx LLC, Salt Lake
City, UT, United States.
Background: Building upon a web-based tool de-
scribed at the 28th ICPE that allowed patient charac-
teristics to be visualized from a variety of patient
populations and data sources, new functionality was
added to allow the interactive creation of patient
cohorts and real-time query and descriptive statistic
display of clinical outcomes.
Objectives: To develop an interactive tool to create
patients cohorts of interest and explore their speciﬁed
clinical outcomes.
Methods: A data mart of patient medical record data
in the Department of Veterans Affairs (VA) was cre-
ated to support the underlying query functionality.
This effort involved creating the the best representa-
tion of the most current, most correct demographic
variables (date of birth, sex, race, vital status, date of
death, residential zip code and state) for each patient
compared and combined across different sources and
from structured and text data sources. Summary tables
were created and indexed on the most commonly used
structured data (ICD9, medications, labs, and proce-
dures) which produced sub-second response time.
Users can iteratively deﬁne characteristics of the target
patient population and are provided the number of pa-
tients meeting each criterion in an attrition table for-
mat. The interface walks a user through the process
of taking a real-world concept, such as type II diabe-
tes, and translating it into queryable criterion, such as
ICD codes 250.x0 and 250.x2. A user can browse for
concepts by data domain – demographics, diag-
noses, procedures, medications, labs, vitals, and
text – or search for concepts with codes or key-
words. In this way, users are able to create data dic-
tionaries for their studies on the ﬂy. At any time,
the population can be explored through a set of
aggregate descriptive statistics and visualizations of
demographic and clinical characteristics. A set of clin-
ical outcomes can be speciﬁed and a Kaplan-Meier
curve will be generated.
Results: This system was developed and tested in VA
and has been used to support more than 100 feasibility
requests in the past year.
Conclusions: This tool supports feasibility, prelimi-
nary to research questions, and exploration of patient
characteristics and clinical outcomes.
769. Comorbidities in Patients with Thyroid Cancer
Evaluated Using US Administrative Claims Data
Ceri Hirst,1 James Ryan,1 Ozgur Tunceli,2 Siting Zhou,2
Kern David.2 1Payer and Real World Evidence,
AstraZeneca, Macclesﬁeld, Cheshire, United Kingdom;
2HealthCore Inc, Wilmington, DE, United States.
Background: Thyroid cancer is a rare and heteroge-
neous disease. While many patients have a good
prognosis, a subset of 5-20% experience recurrence
and progressive disease. Comorbidities in patients
with thyroid cancer, and speciﬁc subtypes such as
medullary thyroid cancer (MTC) and differentiated
thyroid cancer (DTC), are not well characterized.
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Objectives: To describe the demographic and clinical
characteristics of patients with thyroid cancer, includ-
ing speciﬁc subtypes.
Methods: Patients with at least 2 diagnosis codes for
thyroid cancer and 12months pre-index history
were identiﬁed using the HealthCore Integrated
Research Environment during 1/1/2007-8/31/2012.
Descriptive analyses were performed for pre- and
post-index presence of pre-speciﬁed comorbidities.
Stratiﬁed analyses were conducted using algorithms
deﬁning histologic subtypes (medullary thyroid
cancer (MTC), differentiated thyroid cancer (DTC),
or ‘other’).
Results: A total of 6,823 thyroid cancer patients were
included in this analysis; 280 in the MTC, 3,238 in the
DTC, and 3305 in the unclassiﬁed categories. The
MTC cohort consisted of slightly older patients, rela-
tive to the DTC group (49.7 years vs. 47.3 years),
and had a lower proportion of females (70.7% vs.
74.3%), respectively. At baseline, the most common
comorbidities were infection (45.3%), hypertension
(33.3%), hypothyroidism (32.2%) and chronic fatigue
(21.0%), and prevalence was similar across the sub-
groups. After thyroid cancer diagnosis, incidence was
highest for cardiovascular (0.23/patient year), pain
(0.24/patient year), infection (0.23/patient year), and
hypothyroidism (0.93/patient year) comordibities,
with similar patterns between subgroups.
Conclusions: Thyroid cancer represents a signiﬁcant
medical burden both to the individual and healthcare
system, with high levels of comorbidity. While sub-
groups differ in some characteristics, the most com-
mon comorbidities are broadly similar.
770. Suspected Adverse Drug Reactions Caused by
Herb Ephedrae Case Study
Ju-Hui Chen, Tsung-Hsiu Wu, Lih-Chi Chen. Pharmacy,
Taipei City Hospital, Taipei, Taiwan.
Background: Herb Ephedrae have the main effect to
promote sweating to release the exterior, diffuse the
lung to calm panting and induce diuresis to alleviate
edema. It causes adverse reactions in cardiac symp-
toms and stimulating sympathetic, parasympathetic
nervous system.
Objectives: Case statement: a 48-year-old female pa-
tient, on September 25, 2012 to the internal medicine
clinics, the main complaint of insomnia, but 2-3 hours
ﬁtfully, lumbar pain for 20 years, avertion to cold with
cold extremitis, fatigue, thirsty, thin and white coating
with string pluse. Physician prescribed of Radix
Puerariae, Ephedrae, Ramulus Cinnamomi, Radix
Paeoniae Alba, Radix Glycyrrhizae, Rhizoma
Zingiberis, Fructus Jujubae, Cortex Eucommiae,
Rhizomae Curcumae Longae, Radix Dipsaci, Semen
Ziziphi Spinosae, Radix Trichsothanhis, water decoc-
tion. On September 29, the patient felt nausea,
vomiting, and described that the stomach is very tight
and there is something sick after taking ﬁrst post drug.
Pharmacist recommended to be discontinued and back
to the clinics. On October 2, physician changed to pre-
scribing of Radix Bupleuri, Radix Scutellariae,
Rhizoma Pinelliae etc. The patient’s symptoms had
not occurred after stop taking medicine.
Methods: (A) The dosage of the drugs is in the rea-
sonable therapeutic dose scope. They do not have the
incompatibility. (B) The patient was not sick after
withdrawal or taking new prescription drugs.(C) From
the main complaint with the four diagnostic records,
the disease type of the patient is not clear. On 9/25,
she complained that the X-rays have long lumbar spine
bone spurs. Physician may be changed from the previ-
ous XiaochaihuTang to Ge Gen Tang. (D) According
to veriﬁcation of documents and journals, taking
Ephedrae may cause to be nausea, vomiting, abdomi-
nal discomfort.
Results: Based on the above assessment, suspected
drugs Ephedrae, Naranjo Scale assessment result is
likely (4 points), which belongs to type B.
Conclusions: A single herb contains a variety of
chemical components. As opposed to Western medi-
cine, the mechanisms of adverse reactions of TCM
are complex and difﬁcult to assess. We should enthu-
siastically report the cases of adverse reactions of
TCM as clinical references.
771. A Comparison between Chinese and US
Electronic Health Records Database Structures
Anokhi J Kapasi, Varinder Singh, Sharmila A Kamani,
Bao Nguyen-Khoa, Judith K Jones. , DGI, LLC, Arlington,
VA, United States.
Background: Electronic health records (EHRs) facili-
tate the delivery and quality of healthcare services.
The American Society for Testing andMaterials Standard
Practice for Content and Structure of EHRs E1384
(ASTM Standard) is one US standard for designing
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EHRs. The US has also adopted a standard for EHR
functionality, referred to as Meaningful Use (MU),
which promotes clinical and safety quality. As part
of its 2009 national health reform, China is also de-
veloping EHR standards.
Objectives: In this study we compared data elements
and concordance with EHR data categories in Chinese
and US EHR databases (DBs).
Methods: We identiﬁed DBs proﬁled in an online re-
source, B.R.I.D.G.E. TO DATA by: (1) searching for:
Database Type: longitudinal population database AND
electronic records, Database Source: electronic health
OR medical records; and (2) manually screening results
for inclusion of US/Chinese EHRs. We excluded other
DB types, e.g., registries. Relevant China EHR stan-
dards, ASTM Standard, and MU core objectives were
mapped to ≥1 DB ﬁeld in B.R.I.D.G.E. The EHR struc-
tures were compared to their respective national stan-
dards, to MU core objectives, and between countries.
Results: Our search led to 217 DBs, with a ﬁnal
screen yielding 1 Chinese (Shanghai FDA Hospital
Medical Record DB) and 10 US EHRs. All 10 US
EHRs had ≥50% concordance with ASTM Standards
(2 met 100%), while 3 had ≥50% of MU. The Chinese
EHR utilized 96% of the China standards and 33% of
MU. Chinese and US EHRs largely conformed to their
respective country’s standards, but MU adoption was
incomplete. Currently, cross-country comparisons
showed that US EHRs capture more details on death
data, behavioral data, and drug manufacturer. This is
a limited EHR sampling, and future analyses can pro-
vide a more fair comparison.
Conclusions: EHR standards are still a work in prog-
ress worldwide. B.R.I.D.G.E. served as a screening
tool to categorize data ﬁelds used in EHRs and identify
additional ﬁelds to complement China EHR standards.
B.R.I.D.G.E. may help EHR developers identify data
categories that would ultimately apply in a global sys-
tem and allow cross-country data comparisons.
772. Reducing the Manual Burden of Medical
Record Review through Informatics
Scott L DuVall,1,2 Tyler B Forbush,1 Ryan C Cornia,1,2
Thomas Ginter,1,2 Brad Adams,1,2 Miland N Palmer,1
Olga V Patterson,1,2 Jonathan R Nebeker.1,2 1VA Salt
Lake City Health Care System, Salt Lake City, UT,
United States; 2University of Utah, Salt Lake City, UT,
United States.
Background: A patient medical record contains rich
detail about disease state and progression, treatment
decisions, and outcomes, but much of this information
is stored in narrative text. Medical record review
(MRR) is a time consuming and costly process used
to extract clinical measures from patient charts not
available in administrative data.
Objectives: To show how informatics methods can
provide approaches to increase efﬁciency and accu-
racy of MRR.
Methods: Our team analyzed the MRR process over
the course of a dozen projects. We identiﬁed four po-
tential areas of improvement: workﬂow management,
informative displays, intuitive interfaces, and auto-
mated assistance. We developed VINCI ChartReview,
a light-weight MRR tool with functionality to address
these challenges. Administrative functions allow man-
agement of users, data, and assignment of patient charts
to users. Each task can use information from previous
tasks, pre-speciﬁed variables, or patient data to provide
a customized view of which parts of the chart to display,
what order to display data elements, and how to ﬁlter the
data (i.e., only data 30-days prior to index date). The dis-
play and review capability are split into three interfaces,
each supporting a distinct task (validation, clinical note
markup, full patient chart review). In each of the inter-
faces, annotation and markup capability is overlaid di-
rectly on the patient chart, eliminating the need to read
from one tool and perform data entry in another.
ChartReview incorporates natural language processing
and administrative data query capability to pre-annotate
and ﬁnd similar wording in other parts of the chart or
across charts. ChartReview can be conﬁgured to display
patient records from different database models.
Results: Identifying and addressing each bottleneck in
the MRR workﬂow has reduced administrative bur-
den, increased reviewer efﬁciency, and supports con-
sistency across review tasks. Speciﬁc examples of
reduction of number of ﬁles to manage, simpliﬁcation
of task tracking, reduction in number of clicks, and re-
viewer perception of ease of use will be presented.
Conclusions: Automated and information-driven ap-
proaches can greatly reduce the burden of manualMRR.
773. Use of Hydroxyethyl Starch Solutions in Taiwan
Wei-I Huang, Wei-Ming Ke, Wen-Wen Chen. Taiwan
National ADR Reporting Center, Taiwan Drug Relief
Foundation, Taipei, Taiwan.
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Background: Recent data have indicated that
hydroxyethyl starch (HES) solutions are associated
with an increased risk of mortality and renal injury
requiring dialysis when used in critically ill patients
including those with sepsis, and those admitted to the
ICU. The EMA and U.S FDA therefore warned against
the use of HES solutions in these clinical scenarios.
Objectives: To explore the prescription patterns of
HES solutions and to estimate the risk associated with
HES uses in contraindicated conditions in Taiwan.
Methods: We used the longitudinal cohort dataset of
one-million insurants that randomly sampled in 2005
from Taiwan National Health Insurance Research
Database (NHIRD) to describe usage patterns of
HES solution between 2005 and 2011. HES solutions
were categorized by molecular weight (MW, kDa)
and degree of substitution (DS) [200/0.5; 130/0.4;
70/0.5]. ICU admission episodes were deﬁned as inpa-
tient ICU claims where two claims with an interruption
≤3 days were considered as one episode. Sepsis condi-
tions were identiﬁed using ICD-9-CM diagnostic code
(038) or deﬁned as any IV antibiotic uses ≥7 days
during hospitalization. The usage of HES solutions
was thereafter calculated based on the above clinical
settings.
Results: We identiﬁed 5,760 patients received 7,154
HES solution prescriptions in 2011. 59% of the HES
solutions were prescribed in medical centers. HES
130/0.4 were prescribed most frequently (78%),
followed by HES 200/0.5 (20%) and HES 70/0.5
(2%). We also observed a slightly increasing trend of
HES solutions usage during the 7 years observational
period. During the observational period, 53% of HES
solutions were prescribed while patient was admitted
to ICU; 26% of HES solutions were prescribed under
sepsis conditions.
Conclusions: The ﬁndings suggest that HES solutions
were commonly prescribed for ICU patients under
sepsis conditions in clinical practice in Taiwan. Cau-
tions should be addressed to health care professionals
and further domestic regulatory actions should be
taken for this potential risk.
774. Impact of Subgroup Analyses and Adjustment
by Stratification on Safety Signal Detection for
Individual Case Reports
Suzie Seabroke,1 Kristina Juhlin,2 Gianmario Candore,3
Antoni Wisniewski,4 Naashika Quarcoo,5 Jeffery
L Painter,5 Daniel Soeria-Atmadja,2 Phil Tregunno,1
G Niklas Norén,2,6 Jim Slattery.3 1Medicines and
Healthcare Products Regulatory Agency, London, United
Kingdom; 2Uppsala Monitoring Centre, Uppsala, Sweden;
3European Medicines Agency, London, United Kingdom;
4AstraZeneca, Alderley Edge, United Kingdom;
5GlaxoSmithKline, London, United Kingdom; 6Department
of Mathematics, Stockholm University, Stockholm, Sweden.
Background: Many organisations use dispropor-
tionality analysis to identify suspected safety signals
in collections of individual case reports. Reporting pat-
terns vary over time, between regions, and with patient
demographics, but the relative merits of subgroup
analyses and adjustment by stratiﬁcation are not well
understood.
Objectives: Determine to what extent subgroup analy-
ses and stratiﬁcation improve accuracy for labelled ad-
verse drug reactions (ADR).
Methods:We evaluated 220 drug substances. Positive
controls were ADRs listed in the SPCs or in the core
data sheets. Statistics of disproportionate reporting
were identiﬁed with shrinkage disproportionality mea-
sures in three databases (EBGM for United Kingdom’s
Sentinel, and IC for EudraVigilance and VigiBase).
We compared the precision (positive predictive value)
and recall (sensitivity) of subgroup analyses and ad-
justment by stratiﬁcation with crude analysis. Three
covariates were considered separately: patient age,
sex, and continent of origin.
Results: Across all three databases and covariates,
subgroup analysis increased precision over crude and
adjusted analysis, with greatest increases by patient
age. In UK Sentinel, subgroup analysis yielded lower
recall for all covariates, but in EudraVigilance and
VigiBase recall increased. Greatest increases in recall
were observed for subgroup analysis by continent;
for VigiBase, recall increased from 0.33 to 0.38 and
precision from 0.12 to 0.13. Adjustment by stratiﬁca-
tion led to modest increases in precision and to de-
creases in recall.
Conclusions: Interestingly, subgroup analyses simul-
taneously increased precision and recall relative to
crude and adjusted analysis, in two international data-
bases. Adjustment by stratiﬁcation had limited impact
on precision and recall. Positive controls in this study
were labelled ADRs and future work should explore
whether the ﬁndings generalize to emerging safety
signals.
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775. Structured Assessment for Prospective Identifi-
cation of Potential Safety Signals in Electronic
Health Records
Susanna Cederholm,1 Alex Asiimwe,2 Andrew Bate,3
Fatima Bhayat,4 Gunnar Brobert,5 Geraldine Hill,1
Kristina Star,1 G Niklas Norén.1 1Uppsala Monitoring
Centre, Uppsala, Sweden; 2Eli Lilly UK, Windlesham,
United Kingdom; 3Pﬁzer, Inc, Walton Oaks, United
Kingdom; 4Takeda, London, United Kingdom; 5Bayer
Pharma, Berlin, Germany.
Background: Post-marketing surveillance aims to
identify and characterize risks of medicines. At pres-
ent, signal detection is predominantly based on indi-
vidual case reports, but the use of electronic health
records (EHR) and insurance claims to detect adverse
drug reactions (ADR) is an area of active research.
Most studies to date have focused on statistical evalu-
ation of well-established ADRs and not sought to de-
ﬁne processes for effective identiﬁcation of emerging
safety signals in EHRs.
Objectives: Evaluate a process for structured assess-
ment of potential safety signals from EHRs.
Methods: Six assessors trained in pharmacovigilance
and/or epidemiology evaluated seven drugs each with
20 medical events per drug, according to a pre-speciﬁed
questionnaire. Drug-event pairs temporally associated
according to a calibrated self-controlled cohort analysis
in THIN had been randomly selected for review. The
questionnaire for manual review considered aspects
such as the nature of the temporal pattern, the presence
of co-medications associated with the medical event,
the likelihood of confounding by underlying disease,
and other alternative explanations for observed temporal
associations.
Results: 820 temporally associated drugs and medical
events were assessed. 311 (38%) were excluded on the
grounds that the event was considered irrelevant as a
suspected ADR (e.g. ‘Medication review due’), 127
were classiﬁed as already labelled (25% of the relevant
events), and 91 were classiﬁed as meriting in-depth re-
view (24% of the relevant, non-labelled events). The
most common reasons that drug-event pairs were
dismissed were presence of similar events in the previ-
ous medical history or confounding by the underlying
disease.
Conclusions: Effective detection of safety signals in
EHRs requires a process for expert manual review of
highlighted associations. Even for more conservative
screening methods such as the one considered here, a
substantial proportion of detected associations could
be dismissed.
This research received support from the IMI Joint
Undertaking through the PROTECT project.
776. Evaluating Survival Outcome for Chemotherapy
in Advanced Lung Cancer Patients
PeiYi Lin, MeiFan Lin. Pharmacy, E-Da Hospital,
Kaohsiung, Taiwan.
Background: Lung cancer is the leading cause of can-
cer mortality in the world. Majority of lung cancer
death is mainly due to being diagnosed at an advanced
stage, and hence, one cannot apply effective treatment
to improve the survival rate of patients. The preferred
treatment approach for advanced or metastatic disease
lung cancer patients is, a single chemotherapy drugs.
Objectives: The purpose of this study is to explore the
association of monochemotherapy and survival rates
of lung cancer patients.
Methods: The study adopts a retrospective cohort
study design based on the National Health Insurance
Research Database (NHIRD) from 2002 to 2011.
Medical records of newly diagnosed lung cancer
(ICD-9-CM 162.0-162.9) patients from 2003-2010 were
extracted. Demographic characteristics, comorbidi-
ties, treatment patterns, and pattern of chemotherapy
were analyzed. The total medical utilization was
evaluated using descriptive statistics which incorpo-
rates sex, age and single agent therapy. Kaplan-
Meier estimates were used to construct survival
curves, and Cox proportional hazard model was used
to evaluate hazard ratios.
Results: There were 55,136 newly diagnosed lung
cancer patients during 2003-2010 identiﬁed from
NHIRD. Among them, 2,345 patients were treated by
single therapy. There were 1,695 (72.3%) males and,
650 (27.7%) females. The average age was 71.1
(60.7-81.5) years old. Treatment patterns are received
chemotherapy only based. Most chemotherapy pre-
scriptions were divided into three groups, 375 patients
in docetaxel, 1253 patients in gemcitabine, and 336
patients in vinorelbine group. Using vinorelbine group
has higher average of survival time 31.4 (23.6-39.1)
weeks than other groups. Elderly patients had a longer
survival time than younger patients. Median and
1-year survival were 16.8weeks and 34% in docetaxel
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group, 21.1weeks and 31% in gemcitabine group, and
31.4weeks and 37% in vinorelbine group.
Conclusions: The study found that gender, age, treat-
ment, and chemotherapy regimens are signiﬁcant factors
for the survival of NSCLC patients. Vinorelbine of three
chemotherapy regimens offered a signiﬁcant advantage
over the others in the treatment of advanced lung cancer.
778. Incidence of Intussusception in Early Childhood
in the Netherlands as a Baseline to the Introduction
of New Rotavirus Vaccines
Kartini Gadroen,1 Silvia Pérez-Vilar,3 Daniel Weibel,1
Sabine Straus,1 Jeanet Kemmeren,2 Nicoline van der
Maas,2 Hester de Melker,2 Miriam Sturkenboom.1
1Medical Informatics, Erasmus University Medical Cen-
ter, Rotterdam, Netherlands; 2Department of Epidemiol-
ogy and Surveillance, Center for Infectious Disease
Control, National Institute for Public Health and the
Environment, Bilthoven, Netherlands; 3Vaccine Research,
Centre for Public Health Research CSISP-FISABIO,
Valencia, Spain.
Background: In 1999, only one year after having re-
ceived marketing authorization in the USA, the ﬁrst
rotavirus vaccine Rotashield was withdrawn from the
market following the identiﬁcation of an unexpected
association between intussusception and the vaccine.
Since then, a new generation of rotavirus vaccines
have been licensed after large pre-licensure trials. A
recently updated Cochrane evaluation of currently ap-
proved rotavirus vaccines, excluded a risk of intussus-
ception of the magnitude observed with RotaShield,
however International data show a low-level increased
risk of intussusception. The purpose of our study is to
set the basis for future safety evaluations of rotavirus
vaccines and to validate database search criteria for in-
tussusception in a Dutch GP based database.
Objectives: Our primary objective is to estimate the
background incidence of intussusception in infants in
The Netherlands aged less than 12months of age. The
secondary objective is to validate, in a primary care da-
tabase the detection of intussusception cases in infants
less than 12months of age. In order to be able to com-
pare the incidence rates compared to other countries,
the third objective is estimate the background incidence
of intussusception in infants less than 36months of age.
Methods: We conducted a retrospective cohort study
within the Integrated Primary Care Information (IPCI)
database, a general practitioners database in The
Netherlands. The study population consisted of all in-
fants <36months of age with valid data in the data-
base between January 2003 until January 2013. The
primary outcome of interest is new cases of
intussusception.
Results: In the source population, 16 case of intussus-
ception were identiﬁed. The incidence rate in children
less than 12months of age was 23.4/100,000 person
years. The incidence rate in children less than
36months 9 of age was 19.0/100,000 person years.
Conclusions: Intussusception is rare in the Netherlands.
779. Identification of Drug-Induced Liver Injury in
Medical Information Databases Using the Japanese
Diagnostic Scale
Tadaaki Hanatani,1,2 Kimie Sai,1 Masahiro Tohkin,2
Katsunori Segawa,1 Michio Kimura,3 Katsuhito Hori,4
Junichi Kawakami,4 Yoshiro Saito.1 1Division of Medicinal
Safety Science, National Institute of Health Sciences, Tokyo,
Japan; 2Department of Regulatory Science, Graduate
School of Pharmaceutical Sciences, Nagoya City Univer-
sity, Nagoya, Japan; 3Department of Medical Informatics,
Hamamatsu University School of Medicine, Hamamatsu,
Japan; 4Department of Hospital Pharmacy, Hamamatsu
University School of Medicine, Hamamatsu, Japan.
Background: Challenges using medical information
databases (MIDs) for identifying drug-induced liver
injury (DILI) have been addressed worldwide. Be-
cause of diagnostic complexity, a standardized method
for DILI detection has not yet been established.
Objectives: We aimed to develop a DILI detection al-
gorithm based on the Digestive Disease Week Japan
2004 (DDW-J) scale, a Japanese clinical diagnostic
criteria for DILI. We then compared the ﬁndings be-
tween the DDW-J and the Council for International
Organizations of Medical Sciences/the Roussel Uclaf
Causality Assessment Method (CIOMS/RUCAM)
scales to conﬁrm its consistency. Possible risk factors
for DILI were assessed using the DDW-J algorithm.
Methods: Using an MID from Hamamatsu University
Hospital, we constructed DDW-J and CIOMS/RUCAM
algorithms and compared the judgments based on the
two algorithms. We examined characteristics of DILI
cases identiﬁed by the DDW-J algorithm after antibiotic
treatment, and evaluated possible risk factors for DILI
by multivariate logistic regression analysis in the
Hamamatsu population and a second population that
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included data from 124 hospitals, which was derived
from an MID from Medical Data Vision Co., Ltd.
Results: The concordance rate was 79.4% between
DILI patients identiﬁed by the DDW-J and CIOMS/
RUCAM algorithms; the Spearman rank correlation
coefﬁcient was 0.952 (P< 0.0001). Men showed a sig-
niﬁcantly higher risk for DILI after antibiotic treat-
ments in both MID populations.
Conclusions: We have developed a useful DILI detec-
tion method based on the DDW-J scale using MIDs,
whichwas compatible with the international standardized
scale. This study provides evidence for the utility of
MID-based research for improving pharmacovigilance.
780. Validation of Diagnostic Algorithms to Identify
AIDS Status, Hepatitis C Infection, Alcohol Abuse
and Illicit Drug Use in HIV Positive Individuals in
the Database of the Regie de l’Assurance-Maladie
du Quebec
Madeleine Durand,1 YishuWang,2 François Venne,1 Jason
R Guertin,1 Cécile L Tremblay,1 Michal Abrahamovicz.2
1Medecine, CHUM Research Center, Montreal, QC,
Canada; 2Epidemiology and Biostatistics, McGill University,
Montreal, QC, Canada.
Background: With increasing incidence of chronic
diseases in patients living with HIV, administrative
health care databases, which contain vast amount of
data on large cohorts, are a precious tool for research.
As these databases were not designed to study HIV,
several key variables to the study of HIV must be val-
idated to optimize their use for research.
Objectives: To establish and validate algorithms to
diagnose AIDS, Hepatitis C infection, alcohol abuse
and illicit drug use for HIV positive individuals in
the Regie de l’Assurance Maladie du Québec (RAMQ)
database, using a local database as gold standard
for diagnosis.
Methods: We used the HIV database of the Centre
Hospitalier Universitaire de Montreal as gold standard.
We developed diagnostic algorithms using medical
billing claims, discharge summaries, pharmacological
dispensations and length of follow-up to identify
the conditions in RAMQ. We identiﬁed individuals
present in both databases via unique identiﬁers. We cal-
culated sensitivity, speciﬁcity, positive predictive value
(PPV) and negative predictive value(NPV) of diagnostic
algorithms, along with exact 95% conﬁdence intervals.
Results: 420 HIV positive individuals had available
data in both databases. Results [95%CI] for the best di-
agnostic algorithms are as follows. For AIDS status,
sensitivity was 52[45-49]%, speciﬁcity 85[78-90]%,
PPV 82[74-88]%, and NPV 58[51-64]%. For Hepatitis
C, sensitivity was 30[21-41]%, speciﬁcity 96[93-98]%,
PPV 71[54-85]%, and NPV 81[77-86]%. For alco-
hol abuse, sensitivity was 52[41-63]%, speciﬁcity 92
[88-95]%, PPV 70[58-81]%, and NPV 85[80-89]%.
For illicit drug use, sensitivity was 68[59-76]%,
speciﬁcity 94[90-97]%, PPV 85[76-92]% and NPV 85
[80-89]%. Test characteristics were optimized when
individuals had available data for at least 2 years of
follow-up in RAMQ.
Conclusions: RAMQ database had low sensitivity but
high speciﬁcity to detect AIDS status, Hepatitis C in-
fection, alcohol abuse and illicit drug use. Additional
methods must be used to handle residual confounding
when using RAMQ data to study HIV.
781. Signal Detection for Potential Drug-Drug
Interactions Using Inpatient Electronic Health
Records with Laboratory Data
Rae Woong Park,1,2,3 Man Young Park,2 Dukyong
Yoon,2 Eun Kyoung Ahn,2 Martijn Schuemie,3 Sean
Hennessy.1,2 1Center for Clinical Epidemiology and Bio-
statistics and Department of Biostatistics and Epidemiol-
ogy, Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, PA, United States; 2Center
for Pharmacoepidemiology Research and Training,
Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, PA, United States; 3Biomedical
Informatics, Ajou University School of Medicine, Suwon,
Republic of Korea; 4Janssen Research and Development
LLC, Titusville, NJ, United States.
Background: There is often a long delay between
drug approval and the detection of clinically important
drug-drug interactions (DDIs). We are aware of no sig-
nal detection methods for identifying potential DDIs
using inpatient electronic health records (EHR) with
laboratory data.
Objectives: To develop and test a quantitative DDI sig-
nal detection method using EHRs with laboratory data.
Methods: Using inpatient EHR data, we identiﬁed
four cohorts: 1) exposed to both drug A and drug B
(A+B+); 2) exposed to A but not B (A +B-); 3) ex-
posed to B but not A (A-B+); and 4) exposed to nei-
ther A nor B (A-B-). The last three groups were
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matched to group (A+B+) with propensity scores that
included number of prior outcomes, admitting depart-
ment, age, sex, baseline liver and kidney function,
etc. The outcome was an abnormally high or low clin-
ical laboratory test result. The Relative Excess Risk
due to Interaction [RERI, = relative risk (RR)(A +B
+)-RR(A+B-)-RR(A-B+) + 1] (reported previously)
was calculated. A signal was as the lower 95% conﬁ-
dence limit for RERI exceeding 0.We examinedwarfarin
with all other drugs, using international normalization
ratio (INR)> 4.0 as the outcome. Drugs identiﬁed from
a review paper as increasing INR when used concomi-
tantly with warfarin (n =22) were used positive controls,
and all others were used as negative controls. Concomitant
drugs having group (A +B+)< 30 were excluded
from analysis. Sixteen years of EHR data of a large
hospital were used for this proof of concept study.
Results: A total of 27 drugs had positive signals. Of
the 11 included positive controls, 7 drugs had positive
signal (64% sensitivity). Of the 91 included negative
controls, 71 had a negative signal (78% speciﬁcity).
The positive predictive value was 26% and the nega-
tive predictive value was 95%. Many of the positive
signals not reported previously seem associated with
conditions that may increase INR, such as congestive
heart failure (furosemide), fever (cefoperazone), etc.
Conclusions: We developed and evaluated a method
to use inpatient EHR with laboratory data to identify
potential DDIs. Such methods are a promising ap-
proach to identifying unknown DDIs.
782. Flumazenil as Trigger Tool for Measuring
Adverse Drug Events
Sock Ping Ng,1 Hsiu Ling Wu,2 Alan Ronaldmp Talbot,2
Su Yu Chien.1 1Pharmacy, Changhua Christian Hospital,
Changhua, Taiwan; 2Medical Quality and Safety Depart-
ment, Changhua Christian Hospital, Changhua, Taiwan.
Background: Flumazenil is indicated for the reversal
of conscious sedation induced with benzodiazepines.
Administration of a reversal agent may an indicator
that patients are being over-sedated due to improper
doses or errors in administration.
Objectives: To determine why the drug was used and
calculate number of patients receiving ﬂumazenil to
counteract effects of midazolam.
Methods: Retrospective data analysis was performed
at a medical center Changhua Christian Hospital from
an electronic database derived from the Hospital’s
computerized physician order entry system. We select
patients receiving ﬂumazenil during Jan 2013 to Dec
2013. Patient orders were check for the injectable mid-
azolam before ﬂumazenil use or oral benzodiazepine
prescribed in the previous outpatient prescription. Data
analysis involved descriptive statistical analysis.
Results: Flumazenil was administered to 51 patients
during the study period. The mean age was
63.8 ± 19.4 years; 41% were female and 59% were
male ( F:M ; 1:1.4). Five patients (10%) received mid-
azolam followed by ﬂumazenil during examination,
included 3 patients during colonoscopy, 2 patients
during endoscopy and 1 patient during Endoscopic ret-
rograde cholangiopancreatography (ERCP). During
the study period, patient undergoing colonoscopy and
endoscopy was 2089 and 5122 respectively. The inci-
dence rate of midazolam reversal during colonoscopy
and endoscopy was 0.14% (3/2089) and 0.04%
(2/5122) respectively. Most of the patients (90%)
administered ﬂumazenil at emergency room for oral
benzodiazepine overdose. Ten patients (22%) have
outpatient prescription with oral benzodiazepine in
Changhua Christian Hospital.
Conclusions: Flumazenil may serve as trigger tool for
measuring benzodiazepine adverse drug events.
According to our results, most of patients (90%) re-
ceiving ﬂumazenil was due to self-poisoning by drug
overdose, 22% of them get the medications from
outpatient visit. Another 10% of patients were suffering
medication –related harm due to routine procedure, espe-
cially for colonoscopy (0.14%) and endoscopy (0.04%).
783. Clinical Burden of ANCA Associated Vasculitis
Scott L DuVall,1,2,3 Stephen Agbor,4 Andrew Wilson,4
Aaron WC Kamauu,4 Thomas Ginter,1,2 Tyler Forbush,1
Tmirah Haselkorn,5 Pavel Napalkov,5 Iain D Tatt,6 Curry
K Koening.1,2 1VA Salt Lake City Health Care System,
Salt Lake City, UT, United States; 2University of Utah
School of Medicine, Salt Lake City, UT, United States;
3Univeristy of Utah College of Pharmacy, Salt Lake City,
UT, United States; 4Anolinx, LLC, Salt Lake City, UT,
United States; 5Genentech, Inc, South San Francisco, CA,
United States; 6F Hoffman La Roche, Basel, Switzerland.
Background: Prior to use of glucocorticoids and cy-
clophosphamides, the mean survival from diagnosis
of granulomatosis with polyangitis was 5months.
Presently, however, a 10-year survival of 75% can be
expected. Though effective treatments have been
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developed, the clinical burden of ANCA Associated
Vasculitis (AAV) is still high. Due to the rarity of
the condition (incidence of 13-21 per million per year),
and lack of diagnostic codes which reliably distinguish
between AAV subtypes, virtually no data describing
the disease burden or natural history of disease in pa-
tients with AAV are available.
Objectives: Examine and compare the disease burden
of patients diagnosed with AAV in the Department of
Veterans Affairs (VA).
Methods: Natural language processing was applied to
identify patients with AAV between 1999 and 2011.
An AAV-matched control cohort was created during
that same time period, deﬁned as patient’s age ≥ 18
with no diagnosis of vasculitis or autoimmune disor-
der. Prevalence of comorbidities documented within
180 days after the ﬁrst AAV diagnosis were captured
and calculated. Crude prevalence relative risks (RR;
95% conﬁdence intervals (CIs)) were calculated and
compared between the AAV and control cohorts.
Results: NLP identiﬁed 3,774 unique AAV patients,
which were matched to 4,127 controls. Patients with
AAV had a signiﬁcantly higher crude RR compared
with controls for a number of conditions, including
the following ﬁve conditions with the highest RR:
end stage renal disease (RR= 28.7; 95% CI: 12.7-
64.8), pneumonia (RR=25.1; 95% CI: 16.1-39.2), mus-
cle weakness (RR=20.0; 95% CI: 10.2-39.1),
cardiomegaly (RR=14.1; 95% CI: 6.1-32.4), and diabe-
tes with other speciﬁed manifestations (RR=9.1; 95%
CI: 4.6-18.2).
Conclusions: Patients with AAV have high risks of
developing comorbid conditions. Direct damage from
vasculitis and medication side effects may contribute
to these risks. Quantifying risk and disease burden in
this understudied population is valuable in understand-
ing the natural history of disease and improving
clinical management of patients with AAV.
The burden of comorbidities is decidedly elevated
among AAV patients in the Department of Veterans
Affairs.
784. Is Information on Medication Use and Occur-
rence of Drug Related Problems Obtained by Means
of a Patient Questionnaire Useful When Conducting
Clinical Medication Reviews in Older Patients?
Floor Willeboordse,1 Lucienne Grundeken,1 Lisanne van
den Eyckel,1 Petra JM Elders,1 Francois G Schellevis,1
Jacqueline G Hugtenburg.2 1Department of General
Practice, EMGO+ Institution, VU University Medical
Center, Amsterdam, Netherlands; 2Department of Clini-
cal Pharmacology & Pharmacy, VU University Medical
Center, Amsterdam, Netherlands.
Background: Medication reviews are used to identify
(potential) drug-related problems (DRP). In the case of a
clinical meciation review (CMR), information on
actual medicine use and problems with drug taking
and adverse effects can only be obtained by asking
patients. Interviewing patients is a time consuming
and costly effort. Alternatively, patient information
needed to conduct a CMR can be obtained by means
of a questionnaire.
Objectives: Comparison of patient information on the
use ofmedication and occurrence of DRP in older patients
obtained by means of an interview and a questionnaire.
Methods: A two construct questionnaire was devel-
oped aimed to obtain information on knowledge and
use of medication, and occurrence of DRP. Face and
content validity were assessed by using expert and pa-
tient panels. The questionnaire was targeted at older
patients with polypharmacy and patients with one or
more predeﬁned geriatric symptoms who visited their
GP over a 1 year period.
Patients from 9 GP city practices were asked to
participate and complete the questionnaire. Each
patient was also interviewed at home. Per subject the
results obtained by means of questionnaire and inter-
view were compared. Sensitivity and speciﬁcity were
calculated.
Results: Ninety eight patients participated. In 41 and
44% of cases the use of medicines as reported in ques-
tionnaires matched the data stated in interviews,
respectively.
In the case of DRP questionnaire and interview data
corresponded between 70 and 90%. However, the
number of DRP identiﬁed was limited. Although being
highly speciﬁc, the questionnaire method was only of
moderate sensitivity.
Conclusions: Results obtained by means of a
questionnaire resembled those obtained by using the
questionnaire. This method of collecting patient infor-
mation as needed to conduct CMR therefore seems a
suitable tool that may replace the patient interview.
There remain certain (sub-)groups of older patients
from whom information can only be obtained by
means of an interview. Nevertheless, the use of
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questionnaires increases the feasibility of CMR in
daily practice.
785. Performance of Claims-Based Algorithms for
Identifying Thyroid Cancer in Commercial Health
Plan Enrollees Receiving Antidiabetic Therapies
Donnie P Funch,1 Douglas S Ross,2,3 Betsey M
Gardstein,1 Heather S Norman,1 Lauren A Sanders,1
Atheline Major-Pedersen,4 Soﬁa II Kring,5 David D
Dore.1,6 1Epidemiology, Optum, Waltham, MA, United
States; 2Massachusetts General Hospital, Boston, MA,
United States; 3Harvard Mediical School, Boston, MA,
United States; 4Global Safety, Novo Nordisk A/S,
Bagsværd, Denmark; 5Epidemiology, Novo Nordisk A/S,
Søborg, Denmark; 6School of Public Health, Brown
University, Providence, RI, United States.
Background: Thyroid cancer (TC) incidence is in-
creasing in the U.S. and many other countries. Large
administrative databases can be used to increase our
understanding of risk factors associated with this can-
cer, but relying only on diagnosis codes may lead to
outcome misclassiﬁcation.
Objectives: To develop and validate algorithms for TC.
Methods: The population came from a retrospective co-
hort study of adults who initiated therapy on antidiabetic
drugs conducted with administrative data from a large
commercial health insurer in the U.S. Patients had
6months of continuous enrollment prior to initiation of
antidiabetic drugs from Feb 2010 to Dec 2012; follow-
up went through March, 2013. Potential incident TCs
were identiﬁed using ICD9 diagnosis code 193. Medical
records were requested for each potential case and a TC
specialist adjudicated those received. Algorithms were
developed including important predictors of outcomes
and variables suggested in consultation with a TC spe-
cialist. Positive predictive values (PPVs) and 95% con-
ﬁdence intervals (CIs) were calculated to estimate the
fraction of potential cases that were true cases.
Results: Charts were requested for 126 patients and
112 were received (89%); 14 had insufﬁcient informa-
tion and were not used. Of the remaining 98 potential
cases, 52 were conﬁrmed as incident TC, yielding a
PPV of 53.1% (95% CI 42.8 – 63.1) for the ICD-9
code 193 alone. Additionally requiring a thyroidec-
tomy identiﬁed 50 of 52 cases but also captured 16
non-cases (PPV 75.8%; 95% CI 63.4-85.1). Requiring
a primary inpatient visit with the ICD9 code removed
41 of the 46 non-cases but only identiﬁed 16 of the
cases (PPV 76.2%; 95% CI 52.5-90.9). One algorithm
yielded a PPV of 91.5% (95% CI 78.7-97.2%). This
algorithm required cases to have a thyroidectomy dur-
ing follow-up and ≥2 ICD9 193 codes ≤ 90 days of this
event, identifying 43 cases and 4 non-cases.
Conclusions: These ﬁndings suggest a signiﬁcant de-
gree of misclassiﬁcation is present when relying only
on ICD-9 codes to detect this outcome. An algorithm
was developed that performs well in identifying TC
cases in an administrative claims database.
786. Predictive Analysis for Identifying Post Stroke
Spasticity Patients in UK Primary Care Data
Jerome Dinet,2 Andrew P Cox,1 Mireia Raluy,1 Sylvie
Gabriel,2 Meng Wang,1 Abdel Magid O Bakheit,3 A
Peter Moore.4 1Evidera, London, United Kingdom;
2Ipsen Pharma, Boulogne Billancourt, France; 3Moseley
Hall Hospital, Birmingham, United Kingdom; 4Walton
Center, Liverpool, United Kingdom.
Background: The prevalence of post stroke spasticity
(PSS) is widely reported to be around 30%. Yet within
UK Primary Care (PC) data the prevalence of patients
with a diagnostic code for spasticity as identiﬁed
through Read codes in the 12months following the
stroke event was less than 3%. We speculated that
many PSS patients receive care for the condition in
primary care as part of post stroke management, but
do not receive a diagnostic code.
Objectives: To determine if a substantial number of
PSS patients without a speciﬁc diagnostic code are
present in ‘The Health Improvement Network’ data-
base (THIN).
Methods: This was a retrospective predictive analysis
using PC data from THIN. Statistically validated
predictive analysis (a selection machine learning algo-
rithms) was used to predict the PSS status of PC pa-
tients. Further validation of the predictions was made
through reference to specialist clinicians. The study
population was all patients aged >18 years with a di-
agnostic code for stroke between 2007 and 2011. 852
patients with a diagnostic code for spasticity within
the 12month period following the stroke event were
considered positive cases of PSS.
Results: Through the use of the Random Forest algo-
rithm an additional 1,423 patient records consistent
with a treatment pattern for PSS in the 12months
following a stroke event were identiﬁed. Statistical
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validation of the Random Forest algorithm showed a
predictive accuracy of 80% with a false positive rate
of 8%. The Kappa coefﬁcient for the statistical valida-
tion was 0.32.
Conclusions: Even though, due to methodological is-
sues, the Random Forest algorithm did not directly use
the records of treatments commonly associated with
PSS, a signiﬁcant number of additional PSS patients
were identiﬁed. Accuracy of the statistical test was ad-
equate. The method was conservative and showed a
low false positive rate. This work shows the potential
for under-reporting of PSS in primary care data, and
provides a method for improved identiﬁcation of cases
and control records for future studies.
787. The Feasibility of Using Administrative Claims
Data to Study Pure Red Cell Aplasia (PRCA) in a
Cohort of Chronic Hepatitis C (CHC) Patients
Vinay Mehta,1 Scott Quinlan,2 Shirin Ahmed,1 Jennifer
Hawes,2 Chris Mast,1 Dan Mines,1 Nancy Santanello.1
1Merck and Co, Inc, North Wales, PA; 2Healthcore,
Inc, Alexandria, VA.
Background: Case reports of PRCA have been linked
to treatment of anemia in patients also receiving ther-
apy for CHC. The incidence rate of this very rare he-
matologic disorder would help evaluate the safety of
newer hepatitis C virus (HCV) treatments.While admin-
istrative claims databases may present a large enough
sample size to estimate the incidence of PRCA, no spe-
ciﬁc ICD-9-CM diagnosis code exists for PRCA.
Objectives:We sought to evaluate the positive predic-
tive value (PPV) of an automated algorithm for PRCA,
using medical records as a reference standard.
Methods: Using the HealthCore Integrated Research
claims DatabaseSM (HIRDSM), we identiﬁed a CHC
cohort from January 2006 through August 2012 using
ICD-9-CM diagnosis, CPT procedure, and GPI prod-
uct codes. In consultation with clinical experts, we de-
veloped two automated algorithms to identify PRCA
using claims data. Possible PRCA required at least
one medically attended encounter with ICD-9-CM di-
agnosis codes for aplastic anemia and evidence of a
bone marrow biopsy in the 30 days prior to and includ-
ing the aplastic anemia diagnosis date. Probable
PRCA included possible PRCA cases who also had
evidence of a chest computed tomography scan, red
blood cell transfusion, or initiation of immunosuppres-
sive therapy. Medical records were requested for all
possible PRCA cases and independently adjudicated
using pre-deﬁned criteria by three practicing hematol-
ogists/oncologists.
Results: A total of 36,164 CHC patients (mean age
51.2 years; 61% males) and 25 possible PRCA cases
were identiﬁed from the claims database. Medical re-
cords were available and adjudicated for 17 possible
cases (15 probable). None of the adjudicated cases
was conﬁrmed as true PRCA; most false positive cases
were hematologic malignancies.
Conclusions: Both possible and probable automated
case deﬁnitions for PRCA performed very poorly in
identifying true PRCA. Contributing factors likely in-
cluded the lack of a speciﬁc diagnosis code or signa-
ture pattern of clinical care, as well as the rarity of
the condition. Our results suggest that it is not feasible
to study the incidence of PRCA using claims data.
788. Validation of Diagnosis of Age-RelatedMacular
Degeneration in a Computer Database of Primary
Care
Zdravko P Vassilev,1 Luis A García Rodríguez,2 Montse
Soriano-Gabarró,3 Ana Ruigómez.2 1Bayer Healthcare
Pharmaceuticals, Whippany, NJ, United States; 2Spanish
Centre for Pharmacoepidemiologic Research (CEIFE),
Madrid, Spain; 3Bayer Pharma AG, Berlin, Germany.
Background: Age-related macular degeneration
(AMD) is the most common cause of legal blindness
in Western patients over the age of 50. There are
two types of AMD, dry (atrophic), that is the more
frequent and wet (neo-vascular), only 10% of all
AMD cases.
Objectives: To validate the recorded diagnosis of
AMD by manual review of the additionally requested
free text comments.
Methods:We used a random sample of 140 patients
out of 10,674 AMD patients registered in The
Health Improvement Network (THIN), and previously
identiﬁed by READ codes recorded. The ﬁrst step of
validation included a manual review of patient com-
puterized records without the free text comments.
The second step of validation consisted of additional
review of these records after incorporating the free
text comments to the patient proﬁles.
The manual review of patient proﬁles included all
clinical information from one year prior to one year
after the date of computer-detected Read code, as
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well as any test procedure codes within 30 days of
that date. We reviewed all recorded information of
each patient (e.g. referrals to ophthalmology clinics,
test procedures and frequency of visits to optician,
etc) to conﬁrm the diagnosis and type of AMD.If a
patient had wet AMD in one eye and dry in the other,
he was classiﬁed as wet AMD. If no mention of wet
or dry was found in the text section and the Read code
was unspeciﬁc AMD, patient was classiﬁed as unde-
ﬁned AMD.
Results: Of the 140 AMD patients identiﬁed through
READ codes, n = 136 were conﬁrmed as having
AMD and n = 4 were past events of AMD, after the
two steps of validation described above. This
amounted to a conﬁrmation rate of 97%. Before the re-
view of free text comments, 80% of patients were clas-
siﬁed as undeﬁned AMD, and only 5% were classiﬁed
as wet AMD. After reviewing the patient proﬁles with
free text comments, we found 21% of patients to
have wet AMD, and patients with undeﬁned AMD
decreased to 50%.
Conclusions: Conﬁrmation rate of incident AMD is
very high, but assignment of AMD type was not
always complete. Information in the free text ﬁelds
proved to be of great additional value to correctly
classify the AMD subtypes (wet or dry AMD).
789. Validation of Health Insurance Claims in Iden-
tification of Sudden Cardiac Death or Hospitalized
Myocardial Infarction (MI) Death through US
National Death Index (NDI) Search
Caihua Liang,1 C Robin Clifford,1 Alexander M
Walker.2 1Epidemiology, Optum, Waltham, MA, United
States; 2WHISCON, Newton, United States.
Background: Little is known about the accuracy of
mortality status inferred from health insurance claims
data in the US.
Objectives: To evaluate the performance of claims-
based algorithms in identiﬁcation of all-cause, sudden
cardiac and hospitalized MI death through the NDI.
Methods: In a study of cardiac mortality in 2002-2009
(Pharmacoepidemiol Drug Saf. 2013 Dec 23. doi:
10.1002/pds.3558), potential sudden cardiac deaths
were deﬁned in persons with insurance claims bearing
ICD-9 code 427.5 and emergency room or ambulance
services, and with no claims ≥7 days after. Hospital-
ized MI deaths were deﬁned by discharge vital status
as dead and a principal discharge diagnosis of ICD-9
410x, with no claims ≥ 7 days after. All-cause deaths
were also ascertained from claims. Cohort members
who left the insurance plan were submitted for NDI
search to determine possible fact and cause of death.
After a variety of consistency checks in the claims data
and special adjudication by two adjudicators, NDI
matches were considered true matches.
Results: There were 187 claims-deﬁned sudden car-
diac deaths, 104 (55.6%) of which were veriﬁed as
cardiac using the NDI; of 21 hospitalized deaths
classed as MI 12 (57.1%) were conﬁrmed as such in
the NDI; 97.3% (474/487) of all-cause deaths identi-
ﬁed from claims were also identiﬁed in the NDI.
Deaths identiﬁed from hospital discharge vital status
were almost always in the NDI (98.0%, 149/152).
Deaths not matched in NDI were mostly from patients
without Social Security numbers.
Conclusions: Claims alone can be used to identify
deaths with high predictive value, but are insensitive
for both cardiac and all-cause of death. NDI search
supplemented by insurance claims and hospital dis-
charge information is necessary for the identiﬁcation
of cause mortality.
[1] Walker AM, Liang C, Clifford CR, et al.
Pharmacoepidemiol Drug Saf. 2013 Dec 23. doi:
10.1002/pds.3558.
790. A Comparison of Disproportionality Analysis
Methods in National Adverse Drug Reaction Data-
bases of China
Jia He,2 Yongfang Hou,1 Xiaofei Ye,2 Guizhi Wu,1 Gang
Cheng,1 Xiaoxi Du.1 1National Center for ADRMonitoring,
Beijing, China; 2Department of Health Statistics, Second
Military Medical University, Shanghai, China.
Background: Several disproportionality analysis
methods are widely used for signal detection, but there
is no gold standard method.
Objectives: The goal of this study was to compare
the concordance of the performance characteristics
of these methods in spontaneous reporting system
of China.
Methods: Algorithms including reporting odds ratio
(ROR), proportional reporting ratio (PRR), information
component (IC), measure used by the Medicines and
Healthcare Products Regulatory Agency (MHRA),
was compared. Kappa coefﬁcient was used as the
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gauge to test the concordance. Reports received in the
year 2004 and 2005 were extracted for analysis in this
study.
Results: After data processing, 361872 reports
representing 52769 combinations were analyzed. The
analysis generated 24022, 22646, 5637 and 5302 sig-
nals of disproportionality by PRR, ROR, MHRA, IC,
respectively. The kappa coefﬁcient increased with the
threshold of number of drug-ADR combination and
the coefﬁcient exceeded 0.7 when the number of
suspected drug-ADR exceeded 2.
Conclusions: This study shows that different mea-
sures used are broadly comparable in spontaneous
reporting system in China when two or more cases
per combination have been collected.
791. Signal Detection from Spontaneous Reporting
System: An Evaluation of Disproportionality Analy-
sis in China
Jia He,1 Yongfang Hou,2 Xiaofei Ye,1 Guizhi Wu,2 Gang
Cheng,2 Xiaoxi Du.2 1Department of Health Statistics,
Second Military Medical University, Shanghai, China;
2National Center for ADR Monitoring, Beijing, China.
Background: Adverse drug reaction signals are usu-
ally announced by the authorities. Once a signal was
detected, label changes or drug withdrawal would be
required by the regulatory action. Disproportionality
analysis methods are widely used for signal detection.
However, there was no report about the signals
detected in China.
Objectives: In this article, we report the signals
detected in recent years and explored the effect of
different disproportionality methods for signal
detection.
Methods: Algorithms including reporting odds ratio
(ROR), proportional reporting ratio (PRR), informa-
tion component (IC), measure used by the Medicines
and Healthcare Products Regulatory Agency (MHRA),
was compared. Reports collected from the beginning of
the year 2004 and end of the year 2011 were extracted
for analysis in this study.
Results: Totally 17 signals were detected during this
period. 6 traditional Chinese medicines were included,
leading to 8 signals together. For 15 signals, the detec-
tion time was earlier than the bulletin time, with a me-
dian of 30months ahead of time.
Conclusions: The results demonstrated that dispro-
portionality analysis could be applied in the national
database of China. PRR and ROR detected signals
more sensitively. The issued signals included both
chemical medicines and traditional Chinese medicines.
Though the authorities have made great progress,
more effort should be made into the ﬁeld of pharma-
covigilance in China.
792. Feasibility of Alternative Methods for Health
Outcomes of Interest Algorithm Validation
Wan-Ju Lee,1 Todd A Lee,1,2 Simon Pickard,1,2 Azadeh
Shoaibi,3 Glen T Schumock.1,2 1Department of Phar-
macy Systems, Outcomes and Policy, University of
Illinois at Chicago, Chicago, IL, United States; 2Center
for Pharmacoepidemiology and Pharmacoeconomic
Research, University of Illinois at Chicago, Chicago,
IL, United States; 3Center for Drug Evaluation and Re-
search, Ofﬁce of Medical Policy, US Food and Drug
Administration, Silver Spring, MD, United States.
Background: The validity of algorithms used to iden-
tify cases in claims-based and administrative data is
crucial in medical product safety surveillance. The
traditional approach to algorithm validation using
medical charts is expensive and time-consuming. An
alternative method is to use an external, linkable
electronic data source that contains information on
case status.
Objectives: To identify and determine the feasibility
of the use of alternative electronic data sources to val-
idate algorithms for designated HOIs in the FDA
Mini-Sentinel Distributed Database (MSDD).
Methods: The approach involved multiple, iterative
steps, including 1) clariﬁcation of HOIs to be consid-
ered, 2) review of previous validation studies, and 3)
literature and web searches to identify potential elec-
tronic data sources (e.g., registries, electronic medical
records) for each HOI. The HOIs were initially catego-
rized as “not feasible”, “unlikely”, “potentially feasi-
ble”, and “feasible” for alternative database validation
based on criteria developed by the investigators. Poten-
tially feasible and feasible HOIs were ranked based on
priority to the FDA; then, further veriﬁcation of the al-
ternative data source and recommendations were made
for highly ranked HOIs.
Results: Among the 99 HOIs evaluated, 16 had well-
validated algorithms and were excluded. An additional
38 HOIs were considered not feasible or unlikely for
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the alternative validation approach. Among the
remaining 45 HOIs that were considered potentially
feasible or feasible, 6 were determined to be the
highest priority. These were suicide, type 1 diabetes,
hypertension crisis, pulmonary ﬁbrosis, pulmonary
hypertension and spontaneous abortion. Finally, sui-
cide (using the National Death Index data) and type
1 diabetes mellitus (using the T1D Exchange Registry)
were considered the best candidates for alternative
validation.
Conclusions: We identiﬁed 45 HOIs whose algo-
rithms, for detection of cases in MSDD, may be feasi-
bly validated using the alternative method. This
approach, including the criteria to assess feasibility,
and the ﬁndings may be of value to others developing
electronic safety surveillance systems.
793. Validation of Clinical Diagnoses, Medi-
cation Use, and Health System Utilization in
Taiwan’s National Health Insurance Research
Database
Chi-Shin Wu,1,2,3 Mei-Shu Lai,2 Susan Shur-Fen Gau,2,3
Sheng-Chang Wang,4 Hui-Ju Tsai.5,6,7 1Department of
Psychiatry, Far Eastern Memorial Hospital, New Taipei
City, Taiwan; 2College of Public Health, National
Taiwan University, Taipei, Taiwan; 3Department of
Psychiatry, National Taiwan University Hospital and Col-
lege ofMedicine, Taipei, Taiwan; 4Center of Neuropsychiat-
ric Research, National Health Research Institutes, Zhunan,
Taiwan; 5Division of Biostatistics and Bioinformatics,
Institute of Population Health Sciences, National Health
Research Institutes, Zhunan, Taiwan; 6Department of
Medical Genetics, College of Medicine, Kaohsiung Med-
ical University, Kaohsiung, Taiwan; 7Department of Pe-
diatrics, Feinberg School of Medicine, Northwestern
University, Chicago, United States.
Background: Taiwan’s National Health Insurance
Research Database (NHIRD) is one of the largest
available claims database; however, the validity of
the claims records in the NHIRD is still under
investigation.
Objectives: To evaluate the validity of claims records
for clinical diagnoses, medication use, and health
system utilization in the National Health Insurance
Research Database (NHIRD).
Methods: Design: The 2005 Taiwan National
Health Interview Survey (NHIS), which is a na-
tionwide cross-sectional survey investigating the
health status of non-institutionalized residents in
Taiwan
Setting: A total of 15,574 participants aged 12 and
above and consented to linkage with the data of
Taiwan’s NHIRD for research purposes were enrolled.
Main outcome measures: The self-reports in clinical
diagnoses, medication use, and health system utiliza-
tion were used to validate the accuracy of claims re-
cords in the in the NHIRD.
Statistic analysis: We used Cohen’s kappa statistics
and prevalence-adjusted bias-adjusted kappa to exam-
ine the concordance between claims records and pa-
tient self-reports. In addition, we used the self-report
as the reference standard to test the sensitivity, speci-
ﬁcity, positive predictive value, and negative predic-
tive value of claims records.
Results:We found the overall concordance of the kappa
statistics was moderate for clinical diagnosis and sub-
stantial for medication use and health system utilization.
The prevalence-adjusted bias-adjusted kappa for all con-
ditions was substantial to almost perfect. Using a strict
algorithm to identify the clinical diagnoses of claims
records could improve the prevalence-adjusted bias-
adjusted kappa, speciﬁcity and positive predictive value.
Conclusions: The concordance between the claims re-
cords and self-report survey results was moderate in
clinical diagnoses, and substantial in medication use
and health system utilization.
794. What Can Affect the Agreement between Patient
and General Practitioner Data on Medicine Use?
Hélène Peyrouzet,1,2,3 Sylvie Blazejewski,1,2,3 Julien
Bezin,2,3 Jean-Louis Montastruc,4 Marie-Laure Laroche,5
Nicholas Moore.1,2,3 1CIC-P 0005, Bordeaux, France;
2Bordeaux University, Bordeaux, France; 3Bordeaux
Hospital, Bordeaux, France; 4Toulouse Hospital,
Toulouse, France; 5Limoges Hospital, Limoges, France.
Background: In pharmacoepidemiology, several
sources of data are available for drug exposure assess-
ment including patient interview and physician ques-
tionnaire. Each source presents some advantages and
disadvantages that may induce misclassiﬁcation bias.
Comparison of different sources in assessing drug ex-
posure can have different results and the concordance
of data sources can vary between drugs family.
Objectives: To determine what factors can affect the
agreement between drug exposure measured from pa-
tient interviews and general practitioner (GP) data.
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Methods: This study was conducted within the
CESIR-U cohort that included adult drivers hospital-
ized after a serious crash. Information on drug expo-
sure during the week preceding the crash was
collected by two data sources: patient and GP. Patient
data were collected by face-to-face interviews. GP data
were collected by self-administered questionnaires.
Agreement between patient and GP data was deﬁned
as follow: we considered agreement when the same
drugs families were present in both sources, if not
we considered non-agreement. Presumed predictors
(patient sociodemographic characteristics, health sta-
tus, drug use) were analysed using a logistic regression
in order to assess the inﬂuence of each factor.
Results: Among the 679 patients of the CESIR-U co-
hort, 139 patients exposed to one or more drugs in one
of both sources were considered for analysis. The
prevalence of good concordance was only 18,7%.
Among the presumed predictors, the patient exposure
to nervous system drugs or respiratory system drugs
was related to a poorer concordance: ORs [95%CI] were
respectively 0,27 [0,09-0,79] and 0,27 [0,08-0,97]. The
number of drugs prescribed by the GP also affected
the concordance of data: a larger number of drugs
prescribed was related to a better concordance (OR: 1,49
[1,11–1,99]).
Conclusions: Good agreement between patient and
GP data on drug exposure seems very difﬁcult to ob-
tain particularly when patients are exposed to nervous
or respiratory system drugs. Since we cannot assume
that one data source is the gold standard, the best
way to collect the most complete data on drug expo-
sure is probably to use several data sources.
795. Agreement between Patient and General Prac-
titioner Data on Medicine Use
Hélène Peyrouzet,1,2,3 Sylvie Blazejewski,1,2,3 Julien
Bezin,2,3 Jean-Louis Montastruc,4 Marie-Laure Laroche,5
Nicholas Moore.1,2,3 1CIC-P 0005, Bordeaux, France;
2Bordeaux University, Bordeaux, France; 3Bordeaux
Hospital, Bordeaux, France; 4Toulouse Hospital,
Toulouse, France; 5Limoges Hospital, Limoges, France.
Background: Patient interviews are often used to ob-
tain information on drug exposure but this source may
be affected by information bias that is a potential
source of exposure misclassiﬁcation. General practi-
tioner (GP) data are less subject to information bias
but present also some limits, for example a lack of in-
formation on over the counter drugs.
Objectives: To compare drug exposure measured
from patient interviews and GP data.
Methods: This study was conducted within the
CESIR-U cohort that included adult drivers hospital-
ized after a serious crash. Information on drug
exposure during the week preceding the crash was col-
lected by two data sources: patient and GP. Patient
data were collected by face-to-face interviews. General
practitioner data were collected by self-administered
questionnaires. Comparisons between drug exposures
assessed using patient interviews and GP question-
naires were studied for each anatomical main group
(e.g. ﬁrst level of the Anatomical Therapeutic Chemi-
cal classiﬁcation). The agreement between those two
data sources was analysed using the kappa statistic
(k). Concordance was considered poor for k< 0.40,
moderate between k ≥ 0.40 and k< 0.60 and good
for k ≥ 0.60.
Results: Among the 679 patients of the CESIR-U co-
hort, 263 patients with data available from the two
sources were considered for analysis. The prevalence
of drug exposure based on the patient source was
47,5% and that reported from GP was 33.8%. Accord-
ing to the drug class, the kappa statistic varied from
0.19 for dermatology drugs to 0.76 for blood forming
organs drugs. The agreement was poor for dermatology
drugs, anti-infectives, systemic hormonal preparations,
respiratory and nervous system drugs. The agreement
was moderate for musculo-skeletal system drugs,
genito-urinary system and alimentary tract drugs. A
good agreement was observed for cardiovascular and
blood forming organs drugs.
Conclusions: Concordance between patient and GP
data regarding drug exposure varied greatly according
to the therapeutic group. Discrepancies between those
two sources could be attributed to recall or stigmatiza-
tion bias in patient data. It could also be due to a GP
lack of knowledge of drugs prescribed by others phy-
sicians.
796. Beyond Crude Cohort Designs: Large-Scale
Adjustment Approaches for Pharmacoepidemiology
Marc Suchard,1 Martijn Schuemie,2 Patrick Ryan.2
1UCLA, Los Angeles, CA, United States; 2Epidemiology,
Janssen Research and Development, Titusville, NJ,
United States.
Background: Massive longitudinal healthcare data-
bases enable development of surveillance solutions to
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identify and evaluate drug risk at unprecedented scale.
Recent comparative drug safety analyses using admin-
istrative claims data continue to rely on unadjusted
incidence rate ratios.
Objectives: We develop a large-scale regularized regre-
ssion framework to control for drug exposure-assignment
and estimate adjusted incidence rate ratios at scale.
Methods: In this framework, we include all clinical
information available about patients up to their time
of indication diagnosis and treatment exposure, such
as all possible drug prescriptions, medical conditions,
procedures and other demographics. The number of
covariates stands in the 10,000 s, regularization helps
us avoid overﬁtting and algorithmic optimization pro-
vides estimates in real-time. We apply our method to
examine incidence rates of in-patient gastrointestinal
bleeding among atrial ﬁbrillation patients taking
dabigatran or warfarin in the Truven MarketScan Com-
mercial Claims and Encounters database (2003 - 2011)
that covers over 227M patient-years.
Results: Using a new-user cohort design with a 6-month
washout period, there are 5845 dabigatran-exposed and
6165 warfarin-exposed patients with atrial ﬁbrillation
diagnoses. From these cohorts, the crude incidence
rate ratio is 0.38 (95% conﬁdence interval 0.25 - 0.57,
dabigatran/warfarin) consistent with recent observational
reports but strongly inconsistent with limited randomized
controlled trials. Regularized regression identiﬁes that
warfarin-exposed patients are generally sicker than
dabigatran-exposed patients, with larger numbers of
prescriptions for indication, number of in-patient visits
and comorbid conditions. After exposure-assignment
adjustment, patients demonstrate improved clinical
equipoise and the adjusted incidence rate ratio becomes
0.63 (0.38 - 1.05). Not signiﬁcantly different from 1,
the result is more consistent with randomized con-
trolled trials.
Conclusions: Large-scale adjustment is possible at
scale and greatly expands the promise of pharmaco-
epidemiology.
797. Refill Variables in Administrative Claims Data –
Potential Implications for Defining New Medication
User Cohorts
Jane S Der,1M Alan Brookhart,1 Fei Xue.2 1Epidemiol-
ogy, University of North Carolina, Chapel Hill, NC,
United States; 2Center for Observational Research,
Amgen, Inc., Thousand Oaks, CA, United States.
Background: Reﬁll information is available in many
of the U.S. insurance claims databases but has not
been used in previous studies to determine incident
medication use. This information could be used to re-
ﬁne how cohorts of new medication users are deﬁned.
Objectives: To obtain frequency distributions of the
REFILL variable in the MarketScan database (where
0 indicates a new prescription (Rx) ﬁll and discrete
numbers >0 indicate subsequent reﬁlls) in a cohort
deﬁned under customary methods of new user design
(i.e., washout period and baseline period of continuous
enrollment during which covariates are deﬁned prior
to index date). To evaluate the pattern of missingness
of this variable for patients over time.
Methods: Women ≥55 years old initiating an osteopo-
rosis (OP) medication (index treatment) with ≥6months
of continuous enrollment and no use of any similar OP
medication for ≥6months prior to index treatment were
identiﬁed from the database (2000-10). The pattern of
REFILL by received OP medications over time and
the distribution of REFILL for the index treatment were
evaluated.
Results: REFILL for the OP medication of each pa-
tient in the cohort (N = 125,623) generally followed
two patterns: (1) REFILL started at 0, increased by 1
consecutively at regular intervals, restarted at 0 and in-
creased consecutively again, (2) irregular time inter-
vals with nonconsecutive values. REFILL of the
index treatment ranged from 0 to 13. On the index
date, 90% of the cohort had REFILL= 0, while 5%,
2%, 1%, and 2% had REFILL equal to 1, 2, 3, and
≥4, respectively.
Conclusions: The pattern of changes in REFILL over
time suggests that REFILL not equal to 0 is likely ev-
idence that a Rx is not new, though REFILL = 0 may
not necessarily indicate a new Rx ﬁll as the value
may be reset by change of pharmacy or other reasons.
The distribution of REFILL of the index treatment sug-
gests that patients who would have been considered
new medication users based on customary new user de-
sign methods may have obtained ﬁlls for the drug
previously. The REFILL variable may be used to com-
plement customary new user design to determine if a
Rx is new, especially for long-term treatments.
798. How toCombine Evidence in aDatabaseNetwork
Martijn J Schuemie,1,6 Rave Harpaz,2,6 Patrick B
Ryan,1,6 William DuMouchel,3,6 David Madigan,4,6
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Marc A Suchard.5,6 1Epidemiology, Janssen Research
and Development, Titusville, NJ, United States;
2Stanford Center for Biomedical Informatics Research,
Stanford University, Stanford, CA, United States;
3Oracle Health Sciences, Burlington, MA, United States;
4Department of Statistics, Columbia University, New
York, NY, United States; 5Department of Biostatistics,
UCLA School of Public Health, Los Angeles, CA, United
States; 6Observational Health Data Sciences and Infor-
matics (OHDSI), New York, NY, United States.
Background: An increasing number of pharmaco-
epidemiology studies are being performed in a distrib-
uted network of databases (DBs), rather than in a
single DB. The standard approach for combining evi-
dence across the network is usually to perform the
same analysis in each DB, and combine estimates
using meta-analysis. However, it is unclear whether
this is the best approach.
Objectives: To empirically evaluate various ways of
conducting studies and combining evidence across
distributed DB networks.
Methods: We used a large reference set of negative
and positive control drug-outcome pairs including 4
health outcomes of interest (HOIs) to evaluate various
evidence combination techniques in 2 networks of
DBs: the 5 US DBs in the OMOP research lab, and 6
European DBs in the EU-ADR network. In both net-
works, each DB executed a large set of analyses, in-
cluding different methods and different variations of
methods. Combination techniques that were evaluated
include various meta-analysis techniques, running the
same analysis everywhere or selecting the optimal
method per DB.
Performance was evaluated based on the Area
Under the Receiver Operating Curve (AUC) using
leave-pair-out cross-validation.
Results: Running the same analysis in each DB
and combining evidence through meta-analysis
(e.g. AUC= .75, .78, .74, .84 resp. for the 4 HOIs in
the OMOP network) did not signiﬁcantly outperform
selecting a single, best DB whilst discarding all
others (AUC= .72, .75, .76, .78 resp.). Running the
optimal (often different) analysis per DB and combin-
ing evidence using sequential Bayesian updating did
show improved performance in both DB networks
(AUC = .76, .74, .83, .86 in the OMOP network).
Conclusions: Possibly due to between-DB heteroge-
neity, performing the same analysis in every DB in a
network does not seem to be the optimal approach.
The additional power gained by combining DBs ap-
pears to be offset by the loss in performance due to
using a study design that is suboptimal in some if not
all DBs. Instead, tailoring the analysis to each DB
and using a combination technique that ﬁrst normal-
izes estimates can turn the diversity in a DB network
to an advantage.
799. Measuring Frailty Using Claims Data for
Pharmacoepidemiologic Studies of Mortality in
Older Adults: Evidence and Recommendations
Dae Hyun Kim,1 Sebastian Schneeweiss.2 1Gerontology,
Beth Israel Deaconess Medical Center, Boston, MA, United
States; 2Pharmacoepidemiology and Pharmacoeconomics,
Brigham and Women’s Hospital, Boston, MA, United
States.
Background: Pharmacoepidemiologic studies in older
adults that rely on administrative claims are often lim-
ited by confounding by frailty. A model that uses
claims to predict a gold standard frailty can be devel-
oped and applied to estimate a frailty score (claim-
based frailty score) in another claims database without
detailed clinical information.
Objectives: To evaluate the existing claim-based pre-
diction models of frailty in the literature.
Methods: We searched MEDLINE and EMBASE
from inception to January 2014, without language re-
striction, to identify multivariable models that pre-
dicted frailty or its related outcome, disability, using
claims data. We critically appraised their approach,
including population, predictor selection, outcome
deﬁnition, and model performance.
Results: Of 140 reports, 3 models were identiﬁed. One
model that predicted poor functional status using
health care service claims in a representative sample
of community-dwelling and institutionalized older
adults showed an excellent discrimination (C statistic,
0.92). The other 2 models that predicted disability
using either diagnosis codes or prescription claims
alone in institutionalized or frail adults had limited
generalizability and modest model performance. None
of the models have been applied to reduce confound-
ing bias in pharmacoepidemiologic studies of a drug
treatment.
Conclusions: Confounding adjustment using a pre-
dicted frailty score is an innovative, potentially useful
approach that should be further developed to improve
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the validity of pharmacoepidemiologic studies of older
adults. We made the following recommendations for
developing and evaluating claim-based frailty scores
by incorporating knowledge from frailty research in
geriatrics and gerontology: 1) using the frailty index,
the count of health deﬁcits, as a gold standard
deﬁnition; 2) considering a prior diagnosis codes that
are characteristic of frailty as well as other diagnosis,
prescription, and health service claims; and 3) evaluating
the transportability to different databases and additional
confounding reduction beyond comorbidity adjustment.
800. A Critical Review of Pharmacoepidemiological
Observational Post-Authorisation Safety Study
(PASS) Design Used in the European Union and
Its Applicability in Latin America (LA)
Pedro A Lima-Filho,2 David Brown,1,2 Deborah
Layton.1,2 1Drug Safety Research Unit, Southampton,
United Kingdom; 2School of Pharmacy and Biomedical
Sciences, University of Portsmouth, Portsmouth, United
Kingdom.
Background: Currently, PASS are predominantly
conducted in the EU and rarely in LA. Lack of elec-
tronic health records databases (EHD), different medi-
cal practices and regulations can be obstacles to the
conduct of PASS as currently designed for the EU in LA.
Objectives: Primary: to evaluate if EU PASSs could
be conducted in its current design in Argentina and/or
Brazil and/or Mexico, considering: 1)if same source of
data could be used, 2)if medical condition (MC) studied
had similar local medical practice and 3)approval by lo-
cal regulations. Secondary: if any of these 3 factors
could be deemed relevant, individually or in combina-
tion, to the applicability of PASS.
Methods: Cross sectional survey of PASS in ENCePP
e-register of studies (ERS). Inclusion criteria: 1)regis-
tered at ERS, 2)risk assessment scope, 3)observational
or active surveillance, 4)conduct in EU country.
Excluded: 1)interventional clinical trials or follow
ups and 2)no assessment of drug safety. 91 studies
obtained, 74 selected. For each PASS, key data was:
study drug(s), MC, study population, source of data,
main objective(s) and design. Literature searches
were conducted for LA data: EHDs, applicable regula-
tions and MC management, then PASS reviewed
regarding applicability for LA conduct. Descriptive
statistics and univariate (Mantel-Haenszel) methods to
explore key variables relationship with conduct in LA
(Yes/No).
Results: 43/74 (58.1%) were feasible in LA. There
was a statistically signiﬁcant negative association be-
tween EHD use (n = 39) and feasibility in LA
(x2 = 47.9, p< 0.001; 20.5% EHD vs 79.5% No
EHD), but a positive association between prospective
data collection (PC) (n = 44) and PASSs feasibility in
LA (x2 = 54.8, p< 0.001; 93.2% PC vs 6.8% no PC).
Regional HAs do not regulate observational studies
currently and were not considered a limiting factor.
Local medical practices were similar and guidance
documents would not prevent PASS conduct.
Conclusions: Study ﬁndings suggest that a high pro-
portion of EU PASSs can be applied in LA, however
PASS designs based on sole use of pre-established
EHDs cannot currently be undertaken.
801. Bayesian Computation on Graphics Processing
Units Expands the Reach and Practicability of
Bayesian Methods in Pharmacoepidemiology
David C Norris. David Norris Consulting, LLC, Seattle,
WA, United States.
Background: Although celebrated for their conceptual
coherence and potent generality, Bayesian methods are
feared for their attendant computational difﬁculties.
Long run-times for Markov chain Monte Carlo
(MCMC) simulation remain a particularly vexing im-
pediment to Bayesian methods in many otherwise
highly suitable problem settings. General-purpose com-
puting on graphics processing units (GPGPU) has been
recognized as powerfully enabling to Bayesian methods
in certain special contexts, such as medical image pro-
cessing and massive mixture models. But the relevance
of GPGPU to Bayesian pharmacoepidemiology is not
widely appreciated.
Objectives: Characterize the gains achievable by
GPGPU for Bayesian inference in regimes of model
complexity and sample size typical for pharmaco-
epidemiology.
Methods: Developed in the Compute Uniﬁed Device
Architecture (CUDA) programming model, C and
Fortran codes are presented that exploit several forms
of parallelism in a generic MCMC application with
experimentally adjustable sample size and likelihood
complexity. Fine-grained parallelism is attained on
the size dimension, and coarse-grained parallelism
is readily achieved across independent Markov
chains. These parallelized codes are compared
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experimentally for their performance on a GPU,
against equivalent serial algorithms running on all
available threads of a similarly-priced modern
multicore processor. The speedups achieved by
GPGPU are compared to predictions from an ana-
lytic model of GPU architecture.
Results: In problems with sample sizes of 103–105,
and likelihood functions of moderate complexity,
GPGPU can accelerate Bayesian methods by more
than an order of magnitude. A properly calibrated an-
alytic model predicts these speedups reliably.
Conclusions: Despite the inherently serial nature of
Markov chains, MCMC retains several forms of paral-
lelism that, in applications of sufﬁcient complexity and
size, are highly exploitable on the massively parallel
architecture of modern GPUs. This fact shifts the fea-
sibility frontier for Bayesian methods, expanding their
reach in pharmacoepidemiology.
802. Feasibility of Adjusted Parametric Methods to
Model Survival Data as a Tool for Signal Strength-
ening: An Example in Modified Prescription-Event
Monitoring (M-PEM)
Deborah Layton,1,2 Alan C Kimber.3 1Drug Safety Re-
search Unit, Southampton, United Kingdom; 2University
of Portsmouth, Portsmouth, United Kingdom; 3Univer-
sity of Southampton, Southampton, United Kingdom.
Background: Survival methods have been used to
characterize crude hazards to support signal detection
and strengthening in M-PEM post-marketing studies.
A feasibility study examined the utility of applying
parametric methods with common predictors that in-
ﬂuence survival to produce adjusted hazards across
multiple events for signalling.
Objectives: To model a motivational example: the
TTO of extrapyramidal symptoms (EPS) reported
within a simulated cohort of 12816 patients derived
from an M-PEM study of an atypical antipsychotic
(AP).
Methods: The functional form, distributions of var-
iables and missingness were examined. A univariate
case/non-case analysis characterised those 100 EPS
cases identiﬁed <365 days post AP index date, with
calculation of crude OR (+95%CI). The semi-
parametric Kaplan-Meier method estimated survival
functions; Log-Rank test compared survival equal-
ity. Parametric models explored survival distribution
with model of best ﬁt chosen. The impact of
predictors on hazard was explored. Multiple imputa-
tion (MI) using STATA ICE explored sensitivity of
estimates.
Results: Data appeared missing at random; demo-
graphic variables (age,sex) had 4% missing. The crude
cumulative incidence estimate was 1.1% (0.0, 1.4);
crude OR for EPS in patients with a prior medical
history (pmh) EPS vs. no pmh was 23.7 (15.2,
37.1). Both semi-parametric and parametric
approaches found pmh EPS to have a non-propor-
tional and time-dependent effect. For those with a
pmh EPS, effect modiﬁcation by gender and pmh
depression was observed plus the underlying hazard
function was monotonically decreasing [shape
parameter 0.5 (0.4, 0.6)]. MI suggested complete
case analysis underestimated association with possi-
ble model misspeciﬁcation.
Conclusions: This analysis suggests use of adjusted
parametric modelling techniques should be reserved
for investigation of speciﬁc drug-event relationships
with methods that appropriately adjust for time-depen-
dent effects. If adjusted rates are desired across
multiple events for signal strengthening then use of
semi-parametric methods is feasible. Further work on
performance is still needed.
803. Calibration of Statistics from Observational
Studies Using Control Drug-Outcome Pairs: Incor-
porating Uncertainty about Controls
Martijn J Schuemie,1,6 Sander Greenland,2 Patrick B
Ryan,1,6 Marc A Suchard,3,6 William DuMouchel,4,6 David
Madigan.5,6 1Epidemiology, Janssen Research and
Development, Titusville, NJ, United States; 2Department
of Epidemiology, UCLA School of Public Health, Los
Angeles, CA, United States; 3Department of Biostatistics,
UCLA School of Public Health, Los Angeles, CA, United
States; 4Oracle Health Sciences, Burlington, MA, United
States; 5Department of Statistics, Columbia University,
New York, NY, United States; 6Observational Health
Data Sciences and Informatics (OHDSI), New York,
NY, United States.
Background: Observational studies are prone to
biases. Much research has focused on developing
methods to correct for these biases, such as propensity
scores and self-controlled designs. Complete adjust-
ment is rarely if ever possible, however, and residual
bias typically remains, e.g., due to mismeasurement
or lack of covariate measurements.
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One way to address this residual-bias problem is to
compare observed associations with control expo-
sure-outcome pairs, i.e., pairs for which the associa-
tion is presumed known with some degree of
certainty. When the control association is expected to
be null, the pair is said to form a null or “negative”
control. Our group previously published a technique
for using a set of null controls to estimate the potential
for systematic error in a study setup, and use this to
calibrate the p-value to more accurately reﬂect the
probability of seeing the observed estimate or larger
when the null hypothesis is true. However, this tech-
nique assumed that for the controls the null hypothesis
is certainly true, which is hard to defend.
Objectives: To attempt to quantify the uncertainty
about the effect sizes of exposure-outcome controls
based on existing evidence and to incorporate this un-
certainty in a calibration framework for statistics de-
rived from observational studies.
Methods: We use the literature and structured product
labels to infer uncertainty about effect sizes, and modify
our existing approach to incorporate this uncertainty.
Results: For outcomes with high background preva-
lence we can have some conﬁdence that the effect
sizes for our null controls are indeed small, but for rare
outcomes even large effect sizes are possible. We de-
scribe how this uncertainty can be added to our p-
value calibration methodology using a hierarchical
Bayesian framework. We then discuss options for ex-
tending to testing hypothesis other than the null, thus
providing calibrated interval estimates of effect.
Conclusions: Measuring the operating characteristics
of an observational study setup can help detect
residual bias, and through calibration can provide ad-
justments for residual bias in statistics derived from
observational studies.
804. Use of a Bayesian Approach to Design and
Evaluation of NCE2
Lien-Cheng Chang,1,2 Ming-Kung Yeh,1 Min-Shung
Lin,3 Chin-Fu Hsiao.4 1Center for Science and Technol-
ogy, Food and Drug Administration, Ministry of Health
and Welfare, Taipei, Taiwan; 2Institute of Biopharma-
ceutical Sciences, National Yang-Ming University,
Taipei, Taiwan; 3Department of Family Medicine,
Cathay General Hospital, Taipei, Taiwan; 4Institute of
Population Health Sciences, National Health Research
Institutes, Miaoli County, Taiwan.
Background: The regulatory agencies in Taiwan
deﬁnes NCE2 (New Chemical Entity 2) as those com-
pound drugs that have been approved and marketed
for ﬁve years in the top ten pharmaceutically advanced
countries but are new in Taiwan. To apply registration
of NCE2 in Taiwan, a clinical trial may be conducted
in Taiwan to evaluate the efﬁcacy and safety.
However, if the trial design is based conventional
signiﬁcance testing, the requirement of large sample
is inevitable.
Objectives: We will design a clinical trial to evaluate
the efﬁcacy and safety of NCE2 based on the concept
of consistency.
Methods: We propose a Bayeian approach to design
and evaluation of NCE2 trial. More speciﬁcally, an
empirical Bayes method with a mixture prior informa-
tion is suggested to synthesize the data from both
Taiwan and other countries to assess the consistency
of the treatment effect of NCE2 in Taiwan with other
countries.
Results: Since the NCE2 has been approved in at least
one of in the top ten pharmaceutically advanced coun-
tries, we can construct the empirical prior information
for the treatment effect for the NCE2 trial on the basis
of all of the observed data from other countries. We
will conclude similarity between the NCE2 trial and
the results from other countries if the posterior proba-
bility of deriving a positive treatment effect in the
NCE2 trial is large, say 80%. Numerical examples
illustrate applications of the proposed approach in dif-
ferent scenarios. Methods for sample size determina-
tion for the NCE2 trial are also proposed.
Conclusions: We have developed a Bayeian approach
to design and evaluation of NCE2 trial. For assessment
of the treatment effect of NCE2, the similarity criterion
is established by a Bayesian approach. The concept of
similarity is based on statistical prediction instead of
conventional signiﬁcance testing. With this approach,
the total sample size required for the NCE2 trial might
be reduced. That is, shortening the total duration of
conducting the NCE2 trial may be possible.
805. Reporting of Confounding Bias in Observational
Intervention Studies: Are We Making Progress?
Koen B Pouwels, Eelko Hak. Unit of Pharmaco-
Epidemiology & PharmacoEconomics, Department of
Pharmacy, University of Groningen, Groningen,
Netherlands.
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Background: Previously, poor quality of reporting of
confounding in articles on observational medical
interventions has been observed in a systematic
review. Included articles were published before the
STROBE statement and it was suggested that this
statement could have a considerable impact on the
reporting of such studies.
Objectives: To assess the quality of reporting of con-
founding in articles on observational medical
interventions.
Methods: Articles on observational studies on medical
interventions in ﬁve general medical and ﬁve
epidemiological journals published between January
2011 and December 2012 were systematically
reviewed. Relevant items related to confounding bias
were scored for each article. Overall quality of
reporting was based on a 7-point score. A comparison
was made with the previously published systematic
review based on articles published before the STROBE
statement. Risk ratios (RR) with 95% conﬁdence
intervals (CI) were calculated to represent changes in
two prespeciﬁed items: reporting on likelihood of
unobserved confounding and reporting on sensitivity
analysis to estimate the potential impact of unobserved
confounders.
Results: Preliminary results are based on 153 included
articles. The majority of studies provided details on the
distribution of key confounders (81%), methods used
to control for observed confounding (99%) and the po-
tential for unobserved confounding (90%). Details on
the selection and inclusion of confounders for the ﬁnal
model were provided in 22% and 41%, respectively.
The overall quality of reporting was moderate (median
4 points; interquartile range 3 to 5). Articles published
after the STROBE statement commented more often
on the potential for unobserved confounding (RR
1.52, 95% CI 1.33-1.75). Sensitivity analyses to esti-
mate the potential impact of unobserved confounders
were not signiﬁcantly more reported after the
STROBE statement (4.6% vs. 2.3%; RR 1.99, 95%
CI 0.59-6.67).
Conclusions: The quality of reporting of confounding
in articles on observational medical interventions
remains suboptimal and further efforts are needed to
improve reporting.
806. Withdrawn by Author
807. Validation of Indonesian Version of Short For-
mulary-36 Questionnaire in Hypertension Patients
Yuli Rahmawati, Dyah A Perwitasari. Faculty of Phar-
macy, University of Ahmad Dahlan, UAD, Yogyakarta,
Indonesia.
Background: According to National Health Survey
by Health Department of Indonesia, the prevalence
of hypertension in Indonesia is predicted getting
higher in the future, due to the life style change.
Currently, among the 31.7% hypertension patients,
only 0.4% patients taking antihypertension as the med-
ication. For sure, this can cause signiﬁcant impact to
the health problem and patients’ daily living. To un-
derstand the impact of hypertension disease and/or
the treatment of hypertension disease on patients’
daily living, we shall use a quality of life instrument
which has been translated and validated in Indonesian
language.
Objectives: Our study was aimed to validate the
Indonesian version of Short Formulary-36 (SF-36)
questionnaire in hypertension patients.
Methods: Our study was conducted in the Primary
Health Care located in rural area by observational de-
sign study. The inclusion criteria of the participants
were adult hypertension outpatients in the Primary
Health Care of Yogyakarta, Indonesia with the ﬁrst
or second stage of hypertension with or without com-
plications and taking the antihypertension medicine.
We performed the reliability test, construct validity
and known group validity.
Results: We recruited 30 patients who 77% and 67%
among them were female and ﬁrst stage of hyperten-
sion, respectively. All 8 domains in Indonesian version
of SF-36 questionnaire met the reliability criteria
(Cronbach α value> 0.7). All the items in the Indone-
sian version of SF-36 met the convergent validity,
which was each item were correlated with each do-
main (r ≥ 0.4) and met the discriminant validity, which
was items correlation within their domains were higher
than their correlation with other domains. The known
group validity resulted that there were no signiﬁcant
differences of 8 domains between the hypertension
group and hypertension with complications group
(p> 0.05).
Conclusions: The Indonesian version of SF-36 can be
used in hypertension patients started from the patients
who visite the primary health care in rural area.
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808. Association between Hospitalizations Due to
Cardiovascular and/or Neurologic Diseases and Ex-
posure of High Alert Chinese Medications: Nested
Case-Control Study
Hsiang-Wen Lin,1,2 Hsin-Hui Tsai,1,2,3 Chu-Ling Tsai,2,3
Yow-Wen Hsieh,2 Sheng-Shing Lin,4 Wen-Ling Lin,2,3
Shyh-Shyan Jan,2,3 Ching-Yeh Tu,2,3 Kun-Lung
Chang.2,3 1School of Pharmacy and Graduate Institute,
China Medical University, Taichung, Taiwan; 2Depart-
ment of Pharmacy, China Medical University Hospital,
Taichung, Taiwan; 3Division of Chinese Medicine, De-
partment of Pharmacy, China Medical University Hospi-
tal, Taichung, Taiwan; 4Division of Chinese Medicine,
China Medical University Hospital, Taichung, Taiwan.
Background: Chinese medications (CMs) are
recognized as safe and effective treatments in Chinese
society. Thus, the utilization of National Health
Insurance (NHI) covered CMs increased in recently
one decade.
Objectives: This study aimed to assess the risks of
hospitalization associated with exposure of high alert
Chinese Medications (HACMs).
Methods: The six CMs (Màn Tuó Luó, Qian Niú Zi,
Chuan Wu, Tian Nán Xing, Fù Zi, Bàn Xià) were rec-
ognized as the potential HACMs. The nested case con-
trol study of the patient cohort who ever received at
least 30 days continuously of NHI covered CMs in
2007 (CM users) was conducted using two million
random samples of Taiwan NHI Research Data-
bases. Those CM users who had hospitalized due
to cardiovascular (CV) or neurologic (NS) diseases
were identiﬁed as the cases. Those corresponding
control CM users were matched using the pre-speciﬁed
propensity scores. The conditional logisitic regressions
was performed to evaluate the associations of hospi-
talizations due to CV and NS diseases and the
exposure of HACMs within one month before the
events, controlling for the co-morbidities and
concurrent CV and NS related Western medications.
Results: Of 77,920 patients ever prescribed with CMs
in 2007, 579 patients ever hospitalized due to CV or
NS diseases (0.743%). After adjusting for the
concurrent medications and comorbidities, Bàn Xià
would increase 3% to 754% likelihood of hospitaliza-
tions due to any of CV and/or NS diseases. The
adjusted odds ratios were all greater than one for
Chuan Wu, Tian Nán Xing, Fù Zi but not statistically
signiﬁcant.
Conclusions: The exposures of speciﬁed HACMs,
especially Bàn Xià, were associated with signiﬁcant
incremental hospitalizations due to cardiovascular
and/or neurologic diseases compared with the other
treatments among CM users. More attention should
be made toward those who used HACMs as well as
those who possessed speciﬁc diseases.
809. Assessment of Affect of Geriatric Conditions on
Activities of Daily Living in the Elderly
Krishna Undela,1 Ancy Varghese,1 Parthasarathi
Gurumurthy,1 Narahari Mg.2 1Pharmacy Practice, JSS
College of Pharmacy, Mysore, Karnataka, India; 2Gen-
eral Medicine, JSS Medical College Hospital, Mysore,
Karnataka, India.
Background: Half of elderly people suffer from at
least one common geriatric condition (GC). GCs are
important consequences in elderly, may have a strong
negative impact on daily life.
Objectives: To investigate the prevalence of GCs and
their association with dependency in activities of daily
living (ADL).
Methods: A cross-sectional observational study was
conducted between June 2013 and February 2014 in
a tertiary care teaching hospital from southern parts
of India. A total of 1150 hospitalized patients with ≥60
years of age were included. Cognitive impairment,
falls, depression, urinary incontinence, dizziness,
lower body mass index, visual and hearing impairment
were identiﬁed as GCs. The Katz Index of Indepen-
dence in ADL was used to assess ADL disability,
which includes bathing, dressing, toileting, transfer-
ring, continence and feeding. Binary logistic regres-
sion analysis was applied to assess the relationship
between GCs and dependency in ADL.
Results: Mean (SD) age of the included patients was
68.4 (7.5) years. The prevalence of GCs was found
to be 73.9% (71.5% in males and 78.4% in females).
Commonly observed GCs were dizziness (30.7%),
followed by visual impairment (28.2%) and cognitive
impairment (20.4%). Among all patients 12.6% were
dependent in at least in one ADL, majority in transfer-
ring (7.5%), followed by continence (5.8%) and
toileting (5.7%). After adjustment for basic demo-
graphic variables, comorbidities and medications re-
ceived, we found that the patients with at least one GC
having 88% increased risk of dependency in at least
one ADL (RR 1.88; 95% CI 1.06-3.33; p = 0.02). By
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considering individual activity, elderly with GCs were
found to have signiﬁcant difﬁculty in transferring (RR
2.30; 95% CI 1.06-5.00; p = 0.03), than any other ADL.
Conclusions: Geriatric conditions in elderly people
associated with dependency in ADL. It is feasible to
reduce this problem by early detection and treatment
of chronic diseases result in GCs.
810. The Risk of Geriatric Conditions in Patient
with Diabetes Mellitus and Hypertension
Parthasarathi Gurumurthy,1 Ancy Varghese,1 Krishna
Undela,1 Narahari Mg,2 Krishna Undela.1 1Pharmacy
Practice, JSS College of Pharmacy, Mysore, Karnataka,
India; 2General Medicine, JSS Medical College Hospi-
tal, Mysore, Karnataka, India.
Background: Geriatric conditions (GC) are associated
with poor quality of life, higher morbidity and mortal-
ity among elderly. Chronic diseases like diabetes
mellitus (DM) and hypertension (HT) may predispose
the development of GC among elderly people.
Objectives: To assess the risk of DM and HT on GC
and the effect of gender differences on this association.
Methods: A cross-sectional observational study was
conducted in a tertiary care teaching hospital for a
period of nine months. Geriatric patients were assessed
for cognitive impairment (CI), falls, depression, urinary
incontinence, dizziness, lower body mass index (BMI),
visual and hearing impairment. Mini mental state exam-
ination questionnaire and geriatric depression scale
were used to assess CI and depression, respectively.
Other GC were self reported. Binary logistic regres-
sion analysis was used to identify the risk of GC.
Results: A total of 1150 patients were included; 65%
were males and 60% aged between 60-69 years. After
adjustment for basic demographics and comorbid con-
ditions, DM and HT were associated with increased
risk of overall GC (RR 1.41, 95% CI 1.01-1.96, and
RR 1.51, 95% CI 1.05-2.1, respectively) and spe-
ciﬁcally for urinary incontinence (RR 2.91; 95% CI
2.09-4.04) and visual impairment (RR 1.59; 95% CI
1.16-2.18) among diabetics and for depression (RR
2.06; 95% CI 1.02-4.25) and dizziness (RR 1.45;
95% CI 1.05-2.00) among hypertensive patients. We
found less risk of lower BMI among diabetics as well
as hypertensive patients (RR 0.49, 95% CI 0.32-0.77,
and RR 0.42; 95% CI 0.18-0.98, respectively). No in-
creased risk was observed among patients with both
DM and HT (RR 0.54, 95% CI 0.28-1.04). In the sub-
group analysis, diabetic males were found to have
more risk (RR 1.60; 95% CI 1.05-2.44) and hyperten-
sive female patients (RR 1.86; 95% CI 1.08-3.20) to
develop GC than their counterparts.
Conclusions: DM and HT were associated with exces-
sive risk for GC, especially urinary incontinence, vi-
sual impairment, depression and dizziness. Male
diabetics and female hypertensives are at more risk
of developing GC.
811. The Effectiveness and Safety of Febuxostat for
Chronic Kidney Disease Patients with Gout and
Hyperuricemia
Chien-Huei Huang,1 Ming-Cheng Wang,2,3 Chi-Tai
Yen,2,4 Ching-Lan Cheng,2 Pheng-Ying Yeh Liu,1 Hui-
Jen Chang.1 1Department of Pharmacy, National Cheng
Kung University Hospital, Tainan, Taiwan; 2Institution
of Clinical Pharmacy and Pharmaceutical Sciences, Na-
tional Cheng Kung University, Tainan, Taiwan; 3Depart-
ment of Internal Medicine, National Cheng Kung
University Hospital, Tainan, Taiwan; 4Department of In-
ternal Medicine, Ministry of Health and Welfare Tainan
Hospital, Tainan, Taiwan.
Background: Febuxostat is a novel xanthine oxidase
inhibitor introduced in Taiwan in 2012. It has been
used to treat hyperuricemia and gout but no sufﬁcient
evidence regarding its effectiveness and safety in
chronic kidney disease (CKD) patients.
Objectives: This study aimed to evaluate the effec-
tiveness and safety of febuxostat in CKD patients with
hyperuricemia and gout.
Methods: This is a prospective, observational study con-
ducted at a single medical center in southern Taiwan. We
enrolled patients in CKD stage 1 to 5 who received
febuxostat at entry of the study since July 2013. Primary
outcome was the gout attack no more than once or serum
uric acid (UA) level≤ 6.0mg/dL within 6months.
Secondary outcome was the safety of febuxostat.
Results: A total of 287 CKD patients were included.
The baseline demographic characteristics were: mean
age 62.5 years, men 84%, and mean serum creatinine
2.1 (±0.6) mg/dL, CKD stage 3 to 5 79%, hemodialy-
sis therapy 5%, hypertension 60%, and diabetes
mellitus 50%. The mean UA level decreased from
9.2 (±4.5) mg/dL to 6.3 (±2.1) mg/dL; 51.5% of pa-
tients achieved a level ≤ 6.0mg/dL, and 56% had gout
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attack no more than once. Dosage range of febuxostat
was 20-40mg/day in advanced CKD patients (eGFR
<30ml/min/1.73m2). Overall 5% of patients had skin
rash and drug eruption related to febuxostat, 30% of
whom had history of allergy to allopurinol.
Conclusions: Febuxostat effectively reduced the se-
rum UA level and frequency of gout attacks in CKD
patients. But the further comparison study between
allopurinol and febuxostat was needed to evaluate its
effectiveness and safety in these populations.
812. Non-PrescriptionMedicine Purchasing Behavior
Among Community Pharmacy Patrons in Malaysia
Abdul Haniff Bin Mohamad Yahaya, Mohamed Azmi
Bin Hassali, Asrul Akmal Bin Shaﬁe. Discipline of
Social Pharmacy, School of Pharmaceutical Sciences,
Universiti Sains Malaysia, Penang, Malaysia.
Background: Understanding consumer decision mak-
ing in health care is key to confronting the societal
health care challenges especially in self-medication.
Objectives: To evaluate non-prescription medicines
purchasing behaviour among community pharmacy
consumers in Malaysia.
Methods: A cross sectional nationwide study design
was undertaken. A pharmacy ‘exit survey’ was
conducted over a six month period across Malaysia.
One stage random cluster sampling technique was
employed. Face-to-face interview using validated and
pre-tested questionnaire was used by trained data col-
lectors. The non-prescription medicines purchasing
behaviour was explored and analysed descriptively.
Chi-squared test was used to determine the association
between non-prescription medicines purchasing be-
haviour and selected demographic determinants.
Results: A total of 2729 out of 2950 (93%) pharmacy
patrons agreed to participate in 59 selected pharmacy
outlets. A total of 3462 NPM purchased during study
period. Majority of the medicines were purchased for
self used (56.6%) followed by someone else (33.9%)
and shared (9.5%). It was found that female customers
were more likely to purchase for sharing purposes as
compared to male customers (χ2 = 30.665, p< 0.01).
There was high proportion of medicine that had been
purchased before (76.3%). Neuromuscular system
medicines such as NSAIDs and analgesics found to
be medicine were repeatedly purchases. Most of the
customers who purchased for the ﬁrst time (83.2%)
had no speciﬁc brand in mind. The selection of medi-
cines were carried out by describing the problem and
let the staff recommend. In contrary, the customers
who had particular brand in mind, they tend to chose
the product from the shelf by themselves (20.4%) or
ask for a product by the drug name (49.7%). The
location of pharmacy, price and services provided
were the major factors customers chose to purchase
their non-prescription medicines from community
pharmacy.
Conclusions: The ﬁndings provided insights surround-
ing the purchasing of non-prescription medicines in
Malaysia. It shows that there is a role of pharmacy staff
to ensure appropriate choice and use of medicines.
813. Outcomes of Earlier Use of Inhaled Corticoste-
roids among Patients Diagnosed with Moderate
Chronic Obstructive Pulmonary Diseases
Shan-Chieh Wu,1 Wei-Erh Cheng,3 Hsiang-Wen
Lin,1,2 Yow-Wen Hsieh.1,2 1School of Pharmacy
and Graduate Institute, China Medical University,
Taichung, ROC, Taiwan; 2Department of Pharmacy,
China Medical University Hospital, Taichung, ROC,
Taiwan; 3Division of Pulmonary and Critical Care,
Department of Internal Medicine, China Medical
University, Taichung, Taiwan.
Background: The inhaled corticosteroids (ICSs) were
recommended to use for Chronic Obstructive Pulmonary
Diseases (COPD) patients with FEV1 less than predicted
value of 50% (i.e., severe or Group C or D), following
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) guidelines. In the real practice, some physicians
prescribed ICSs with long-acting bronchodilators for
moderate or Group A or B patients (i.e., FEV1 predic-
tion: 50%-80%), in terms of earlier use of ICSs.
Objectives: The main objective of this study was to
assess the outcomes of earlier use ICSs for moderate
COPD patients.
Methods: A retrospective cohort study using the med-
ication databases and electronic medical records ob-
tained from China Medical University Hospital were
conducted. The moderate COPD patients were identi-
ﬁed upon their lung function following 2009 GOLD
guideline. Those moderate COPD patients were
grouped into either single therapy group (i.e., used
long-acting bronchodilators [LAB] only) or combo ther-
apy group (i.e., used LABwith ICS) based upon their re-
spiratory medication use patterns since the index date in
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2009. Their use of rescuemedications and the number of
patients occurred COPD exacerbation events (e.g., out-
patient visits, ER visits, hospitalizations) were evaluated
afterward for up to one year and compared using de-
scriptive and inferential analysis approaches.
Results: Of 175 moderate COPD patients, 77 (44%)
were in combo therapy group and their demographic
and disease status were not statistically signiﬁcant dif-
ferent from that in single therapy group. Those patients
in the combo therapy group were prescribed with more
rescue medications, especially oral steroids, and en-
countered more events of COPD exacerbation, espe-
cially ER visits and hospitalizations.
Conclusions: Those moderated COPD patients pre-
scribed with combo therapy were prescribed with more
rescue medications and occurred more COPD exacerba-
tions than those who received recommended treatments.
Further researches are needed to explore the contributing
factors of disease exacerbation and other outcomes among
moderate COPD patients receiving earlier use of ICSs.
814. Assessment on the Risk of Pneumonia Associ-
ated with Inhaled Corticosteroids in COPD Patients
in Taiwan
Ya-Chuan Chang,1 Tzu-Chieh Lin,1 Jih-Shuin Jerng,2
Yea-Huei Kao Yang.1 1Institute of Clinical Pharmacy
and Pharmaceutical Sciences, College of Medicine,
Health Outcome Research Center, National Cheng Kung
University, Tainan, Taiwan; 2Department of Internal Med-
icine, National Taiwan University Hospital and National
Taiwan University College of Medicine, Taipei, Taiwan.
Background: An increased risk of pneumonia, associ-
ated with inhaled Corticosteroids (ICS) in COPD pa-
tients, has been reported in some clinical trials.
However, it is not well documented in the real-life set-
ting, especially in Asia.
Objectives: To examine whether the use of ICS in
COPD patients in Taiwan is associated with a potential
increased risk of pneumonia.
Methods: We conducted a retrospective (2004 – 2010)
cohort study, including of COPD patients who had re-
ceived at least two prescriptions of bronchodilator within
30 days. The study outcome was the ﬁrst hospitalization
for pneumonia of any cause including inﬂuenza during
cohort follow-up. Exposure of inhaled corticosteroids
were retrieved from in-patient, outpatient and contracted
pharmacy claims in the NHIRD and categorized as ICS
(beclometasone, budesonide, and ﬂuticasone) alone or
in combination with beta agonist, which include. A
uni-directional time-dependent Cox analysis was used
to assess the pneumonia risk between patients who had
received ICS and those who had not.
Results: There were 30,646 COPD patients in our co-
hort. Of these, 2,083 (6.8%) had received ICS. The
crude incidence rate of pneumonia was 5.3 and 2.9
per 100 person-year in patients that had received ICS
ever and those that had not, respectively. Results of
time-dependent Cox analysis found use of ICS was
associated with a 2-fold increased risk in pneumonia
(adjusted hazard ratio: 2.44; 95%CI, 2.16-2.77).
Conclusions: In this preliminary report, a higher risk
for developing pneumonia was seen in COPD patients
that had received ICS than in those that had not used
ICS. In the future, we plan to do a proper control of
the baseline disease characteristics, such as severity
of COPD, and to explore the relationship between
ICS dose and potential risk of pneumonia.
815. The Prescription Analysis of Sedative Hyp-
notics in Nursing Home of Hospital
Meei Shure Kuo,1 Huei Ming Pan,2 Wen Ching Lin.3
1Pharmacy, St Joseph Hospital, Kaohsiung, Taiwan,
China; 2Family Medicine Deparment, St Joseph Hospi-
tal, Kaohsiung, Taiwan, China; 3Community Deparment,
St Joseph Hospital, Kaohsiung, Taiwan, China.
Background: Purpose:
The old age residents in nursing home besides hav-
ing chronic diseases, some residents can also suffer
with combination of psychiatric and psychotic disor-
ders. The patients who suffer with these signs and
symptoms can easily received sedative hypnotics
through doctor’s prescriptions when requested.
Objectives: These patients can develop addiction and
become dependent to the drugs after long-term used,
under comprehensive care coordination, we try to
evaluate the suitability of drugs.
Methods: We collected the prescription data within
six months, from July to December of 2013. Reviews
and discussion happened once every month in regards
of the kind of sedative hypnotic and the doses pre-
scribed to our nursing home residents.
Results: Our nursing home residents were 166 person.
About 60 people (36%) were prescribed with sedative
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hypnotics, Long-term used over 6months were 41.7%,
used less than 6months were 25%, frequently chang-
ing the kind of drugs were 18.3%. Within the sleep
disturbance group, residents use 1 drug belonging to
Benzodiazepam and non-Benzodiazepam were 27
people (45%), there were Alprazolam,Clonazepam,Es-
tazolam,Fludiazepam,Lorazepam,Oxazolam,
Zolpidem,etc. Detail of one drug used prescriptions:
most prescribed was Lorazepam 1mg were 12 people
(44%),least prescribed Zolpidem was 1 person (0.37%).
Combine use of BZD+non-BZD were 6 people,2 kinds
of BZD were 2 people, and 3 kinds of BZD+non BZD
were 1 person. In the other 2 groups were combined with
psychological & anxiolytic drugswere 25 people (38.3%).
Within half year period, We reviewed 3630 pre-
scriptions, that there were 8 people who was pre-
scribed with repeats and overdose of drugs, and 5 of
them discontinued or changed prescriptions after
discussion with doctors.
Conclusions: We can review and discuss the suitabil-
ity of those prescriptions with the doctors, nurses and
other workers in nursing home to help advises and up-
date information of the side effects of the drugs pre-
scribed. The result of analysis provides a safer way
for other members of the caretaker team, provide help-
ful knowledge, and achieve the best beneﬁt and good
care quality in nursing home.
816. Assessment of Diabetic Care Pay-for-Perfor-
mance Program
Mei-Chieh Chen,1 Yea-Huei Kao Yang,1,2 Shwu-Jiuan
Sheu.3 1Institute of Clinical Pharmacy and Pharmaceuti-
cal Sciences, College of Medicine, National Cheng Kung
University, Tainan, Taiwan; 2Health Outcome Research
Center, National Cheng Kung University, Tainan,
Taiwan; 3Department of Ophthalmology, Kaohsiung Vet-
erans General Hospital, National Yang-Ming University,
Kaohsiung, Taiwan.
Background: Diabetic retinopathy (DR) is one of the
major complications highly concerned in diabetic care.
The Pay-for-Performance (P4P) program for diabetic
care in Taiwan is implemented to provide ﬁnancial
incentives for healthcare providers to increase
follow-up visits. Previous study showed that
patients in P4P program received more guideline-
recommended examinations and P4P program was
cost-effective for diabetes care.
Objectives: Assess the effect of P4P program by in-
vestigating the difference between P4P and non-P4P
groups in patient compliance to ofﬁce visits, DR inci-
dence, and time to DR.
Methods: A retrospective cohort study was con-
ducted, based on the claims data in Taiwan from
1998 to 2011. Patients with newly diagnosed type 2
diabetes mellitus without retinopathy during 2002-
2006 were included and divided into P4P or non-P4P
group. We matched P4P patients with non-P4P patients
in 1:1 using propensity score by age, gender and
Charlson comorbidity index. All patients were followed
at least 5 years to observe the occurrence of DR. SAS
9.3 and STATA 13 statistical packages were used.
Results: There were 3,133 patients in P4P group and
33,656 patients in non-P4P group identiﬁed. The mean
incidence of DR was higher in P4P group (0.22 vs.
0.1%), but it was slightly decreasing after 2006. Com-
pared to non-P4P, P4P group had better compliance to
ofﬁce visits (7.95 vs. 2.73 visits/year) but slightly
quick progressed to DR (4.12 vs. 4.41 years).
Conclusions: Although patients in P4P program had
better care in terms of more frequent visits, they
seemed to have higher DR incidence and were earlier
diagnosed with DR.
817. Common Data Model Conversion in AsPEN
for SCAN Project
Yinghong Zhang,1 Edward Chia Cheng Lai,2 Chantelle
Hardy,1 Li Lin,1 Paul Stang,3 Patrick Ryan,3 Martijn
Schuemie,3 Soko Setoguchi.1 1Duke Clinicial Research
Institute, Durham, NC, United States; 2Institute of Clini-
cal Pharmacy and Pharmaceutical Sciences, National
Cheng Kung University, Tainan; 3Janssen Research
and Development, NJ, United States.
Background: Asian Pharmacoepidemiology Network
(AsPEN) is a multinational research network
established to provide a mechanism to support the con-
duct of pharmacoepidemiological research and to as-
sess safety and effectiveness of medications and
other therapeutic modalities in participating countries.
The AsPEN employs a distributed network approach
and the Surveillance of Health Care in Asian Network
(SCAN) project have decided to adopt the common
data model (CDM) developed by OMOP.
Objectives: To reﬁne and adapt an existing CDM for
healthcare data sources among AsPEN sites participat-
ing in the SCAN project, and create crosswalks among
the coding systems used in each country or region.
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Methods: The participating site/databases included
US Medicare claims data, Japan Medical Data Center
(JMDC) data, Taiwan National Health Insurance Re-
search Database (NHIRD) data, and Hong Kong Clin-
ical Data Analysis and Reporting System (CDARS)
data. We used the OMOP CDM as the standard data
model. We created a logic map that describes the rela-
tionship between the raw data from each database and
CDM. Then, we developed the extraction, transforma-
tion and loading (ETL) process. We initiated conver-
sion of Medicare data to the CDM and supported
each site by sharing the approach and conversion ex-
perience. Non-US sites underwent a mapping process
from the national drug code (NDC) to RxNorm
through drug generic name (in English), dosage
strength, and route of administration.
Results: Two years of US Medicare claims data has
been transformed to the CDM. About 83.2% condition
occurrence records, 99.6% procedure occurrence re-
cords, and 97.2% drug exposure records have been
mapped to the standard vocabulary. 94.1% of Taiwan-
ese NDC was mapped to RxNorm and proportion of
the unmapped drug was 5.5% of all prescriptions in
NHIRD. CDM/NDC conversions of other sites are
currently in progress.
Conclusions: We demonstrated the feasibility of
adopting and modifying OMOP for US Medicare data.
Further evaluation and revision is needed to directly
map Taiwanese NDC to RxNorm with accuracy.
The diversity and unique drug coding system from
each database is a major challenge in CDM conver-
sion. Further discussions on coding standardization
are needed.
818. Evaluation of Drug Safety Monitoring System
in the Republic of Armenia
Naira Romanova, Albert Sahakyan. Scientiﬁc Center of
Drug andMedical Technology Expertise, Yerevan, Armenia.
Background: Adverse drug reactions (ADR) are some
of the important issues in pharmacotherapy, and often
can cause inpatient hospitalization or its prolongation,
and even can cause patient’s death. For this reason
studies directed to reduce pharmacotherapy complications
and their costs, and to improve the management of drug
safety monitoring system remains an important issue in
Armenia.
Objectives: The aim of this study is to identify current
situation of drug safety monitoring system, to point out
the weaknesses of monitoring process and develop a
reformation concept paper for ADR monitoring system.
Methods: It was performed a retrospective observa-
tional study of ADR spontaneous reports and their
structures received from Armenian hospitals for the pe-
riod from 2008 to 2011. An analytical and comparative
review of legislative documents managing drug safety
monitoring system was conducted. During the study a
systematic, documentation, survey, historical and com-
parative analyses methods were used. ADR reports
were evaluated according to the ICH guidelines.
Results: During 2011, 223 cases of development of
ADRs in Armenia were registered. Based on WHO
statement Armenian NPC, to be considered as optimal,
has to send over 600 reports. Whereas in Armenia the
number of reports per one million inhabitants per year
is 70, which is 3 times less than an optimal NPC has to
send. Besides this, there are numerous weaknesses and
problems inhibiting NPC’s activities in Armenia. The
only one legislative document for managing drug
safety monitoring system is the “Law on medicines”.
There are no any other legally approved regulations
or legislative acts, and also there is an absence of nec-
essary guidelines and recommendations. Meantime,
the motivations ensuring healthcare professionals’ ac-
tive participation in ADR collecting and reporting pro-
cesses are not enough.
Conclusions: The results of the study showed, that
there are serious weaknesses in legal framework of
drug safety monitoring system in Armenia.
To strengthen drug safety monitoring system and to
eliminate barriers inhibiting its activities in Armenia a ref-
ormation concept paper was developed. Also, a strategy
for improvement NPC’s activities has to be developed.
819. Framework Proposal for Post-Marketing Sur-
veillance (PMS) from Taiwan National ADR
Reporting Center
Pi-Hui Chao, Wen-Wen Chen, Tsui-Min Tsai, Wei-Ming
Ke.1 1Taiwan Drug Relief Foundation, Taipei, Taiwan.
Background: Pharmacovigilance (PV) plays an im-
portant role in the lifecycle of drug development
which specially focuses on PMS. Traditionally, spon-
taneous reporting system (SRS) is the major tool for
drug safety monitoring. However, due to some innate
limitations of SRS and extensive growth of the health
claim databases, integrating difference sources of in-
formation into PV becomes the trend of the world,
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especially in Taiwan who has the large national health
insurance research (NHIR) database.
Objectives: In order to construct a more complete
PMS system, we intend to incorporate all accessible
resources, health claim database particularly, for drug
safety monitoring.
Methods: PV framework and methods of data
queries & analysis of advanced countries are taken as
references.
Results: We divided post-marketing surveillance in
three sequential stages: signal generation, reﬁnement
and evaluation. In the ﬁrst stage, three types of infor-
mation source were indentiﬁed, including warning/
news from media/regulatory bodies, high-alert medi-
cations from new drug application (NDA) process
and Taiwan drug relief system, and signals from
ADR reporting system detected by traditional or quan-
titative methods. In the next stage, ADR reports were
analyzed by SAS program and literature review is ini-
tiated. Simultaneously, utilization patterns of drugs
can be examined by longitudinal cohort datasets with
3 million individuals randomly sampled from NHIR
database. Simple outcome researches are also carried
out in this phase. Between these two stages, we de-
signed a checklist to prioritize all signals due to huge
quantities generated from the ﬁrst step. Then, we
cooperated with academics as need to implement a for-
mal epidemiological study for deﬁnitively evidences
in the last stage. All results will be provided to our reg-
ulatory authority or Safety Advisory Committee as
suggestions of risk management.
Conclusions: This framework help us manage signals
more efﬁciency and thoroughly in the pilot test.
Modiﬁcation and checkup are needed to improve
the system.
820. The Association between Oral Fluoroquinolones
and Incident Seizure Event
Celine SL Chui, Esther W Chan, Ian CK Wong.
Centre for Safe Medication Practice and Research,
Department of Pharmacology and Pharmacy, The
University of Hong Kong, Hong Kong, Hong Kong.
Background: Fluoroquinolones are a class of antibi-
otics prescribed for various infections. Several case re-
ports have indicated the potential association between
the use of oral ﬂuoroquinolones and the development
of incident seizure event.
Objectives: The objectives of this study were to: 1)
investigate the association between the use of oral
ﬂuoroquinolones and the development of incident
seizure event; 2) to estimate the crude absolute risk
of developing incident seizure event whilst prescribed
with oral ﬂuoroquinolones.
Methods: A self-controlled case series study design
was used to investigate the association. Patients were
retrieved from an electronic patient record database
called the Clinical Data Analysis and Reporting
System in Hong Kong from the year of 2001 to 2013.
Patients who had an incident seizure event and were pre-
scribed with oral ﬂuoroquinolones in the out-patients
setting during the study period were included. Those
with a history of post-traumatic or febrile convulsion
were excluded. The rate of having incident seizure event
during the exposure period was compared with the non-
exposed period. Conditional Poisson regression was
used to estimate the incidence rate ratio at a 5% signiﬁ-
cance level. A sensitivity analysis was conducted by ex-
cluding patients who died within 30 days after the
incident seizure event.
Results: A total of 291,751 prescriptions of oral
ﬂuoroquinolones were identiﬁed among 166,325 pa-
tients. A total of 2,206 patients met the case deﬁnition
and were included in the analysis. An incidence rate
ratio of 0.89 (0.52, 1.53) was estimated. Fourteen
cases of incident seizure event occurred during the
exposure period. The crude absolute risk of having
incident seizure event whilst prescribed with oral
ﬂuoroquinolones was approximately 4.8x10^-5
(2.9x10^-5, 8.1x10^-5). No statistically signiﬁcant as-
sociation was observed between the use of oral
ﬂuoroquinolones and the development of incident sei-
zure event in the sensitivity analysis.
Conclusions: This study does not support the associa-
tion between the use of oral ﬂuoroquinolones and the
development of incident seizure event.
821. Trastuzumab-Related Cardiotoxicity Among
Breast Cancer Patients in Taiwan
Hsu-Chih Chien,1 Yea-Huei Kao Yang,1,2 Jane PF Bai.3
1Institute of Clinical Pharmacy and Pharmaceutical Sci-
ences, National Cheng- Kung University, Tainan,
Taiwan; 2Health Outcome Research Center, National
Cheng- Kung University, Tainan, Taiwan; 3Predictive
Drug Safety Group, Ofﬁce of Clinical Pharmacology,
Center for Drug Evaluation and Research, U.S. Food and
Drug Administration, Silver Spring, MD, United States.
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Background: Use of trastuzumab improves outcomes
for patients with HER2-overexpressing breast cancer
but is associated with cardiotoxicity including conges-
tive heart failure and/or cardiomyopathy (CHF/CM).
The rates associated with trastuzumab-related cardio-
toxicity in Taiwanese breast cancer population are
not yet investigated.
Objectives: To quantify the risk of trastuzumab-related
cardiotoxicity in Taiwanese breast cancer population.
Methods: We identiﬁed breast cancer patients treated
with chemotherapy from the one million cohort of the
National Health Insurance Research Database (NHIRD)
between 2004 and 2009. We further conﬁrmed the
diagnosis of female breast cancer (ICD9-CM-code:
174) with the Registry for Catastrophic Illness Patient
Database, a subset of the NHIRD. Patients with
congestive heart failure and cancer history prior to breast
cancer diagnosis were excluded.
The rate for individual with CHF/CM (ICD9-CM-
code: 402.x1, 402.x3, 404.x1, 404.x3, 425, 428, and
785.51) were estimated. Descriptive statistics and
Cox proportional hazard model were employed for
data analysis, using trastuzumab as a unidirectional
time dependent variable.
Results: A total of 1857 breast cancer patients were
included (mean age = 50.52 years, range = 21-88
years). Patients were followed until documented
CHF or death or end of observation (2010/12/31).
The mean following time was 4.61 years (range
0.09-7.18 years). Among the patients, 137 (7.38%)
received trastuzumab. The rates of heart failure in
trastuzumab users (n = 137) and non-trastuzumab
users (n = 1720) were 2.92% and 2.38% (p = .57),
respectively. Compared with non-trastuzumab users,
the risk of CHF/CM was higher in trastuzumab users
after adjustment for age, for doxorubicin use and for
pre-existing risk factors for CHF with 1 year prior to
the diagnosis of breast cancer (include hypertension,
diabetes, coronary artery disease and dyslipidemia)
(aHR= 3.15; 95% CI, 1.12-8.85).
Conclusions: Trastuzumab was associated with in-
creased CHF/CM risk, compared with other chemo-
therapy. Further studies on risk factors associated
with trastuzumab-related cardiotoxicity in the Taiwan-
ese breast cancer population are warranted to provide
critical information for patient care.
822. Withdrawn by Author
823. Comparative Risk of Oral Ulcerations among
Antipsychotic Users with Schizophrenia or Bipolar
Disorder
Edward Chia-Cheng Lai,1,2 Cheng-Yang Hsieh,3 Soko
Setoguchi,2 Yea-Huei Kao Yang.1,4 1Institute of Clinical
Pharmacy and Pharmaceutical Sciences, National
Cheng- Kung University, Tainan, Taiwan; 2Duke
Clinical Research Institute, Duke University School of
Medicine, Durham, United States; 3Department of
Neurology, Tainan Sin-Lau Hospital, Tainan, Taiwan;
4Health Outcome Research Center, National Cheng-
Kung University, Tainan, Taiwan.
Background: Few reports indicated that antipsy-
chotics may associate with oral ulcerations. However,
no formal pharmacoepidemiolog studies examined
the association or compared risks among various
antipsychotics.
Objectives: To evaluate the comparative risk of oral
ulcerations among antipsychotics.
Methods: We conducted a retrospective cohort study
using Taiwan’s National Health Insurance Research
Database. Patients with schizophrenia or bipolar disor-
der were included if they were newly prescribed a sin-
gle antipsychotic medication including haloperidol,
sulpiride, olanzapine, quetiapine, risperidone, and
amisulpride during 2002 to 2010. The outcome of
interest was oral ulceration, which was deﬁned by
diagnosis with ICD-9 codes 528.0 (stomatitis and mu-
cositis), 528.2 (aphthous-like ulceration), or 947.0
(oral burns), followed by dispensing of stomatological
corticosteroids. We conducted Cox proportional
hazards regression to compare the risks among
antipyschotics. Potential confounding was adjusted
by inverse probability weighting using high dimen-
sional propensity score.
Results: Among 12,455 patients with schizophrenia or
bipolar disorder who were newly prescribed antipsy-
chotics with mean age of 44.5 years and 44% male,
3,422 were sulpiride users followed by 3194 quetiapine,
2478 risperidone, 2083 haloperidol, 787 olanzapine,
and 491 amisulpride users. The rate of oral ulcerations
was highest in olanzapine users (121 per 1000 person-
year) followed by risperidone (106), sulpiride (87),
amisulpride (84), haloperidol (80), and quetiapine (80).
Compared to quetiapine users, the adjusted hazard
ratio was 1.57 (95% CI, 1.14-2.18) in olanzapine, 1.43
(1.11-1.84) in risperidone, 1.29 (1.01-1.66) in haloperidol,
1.27 (0.81-2.00) in amisulpride, and 1.15 (0.92-1.45) in
sulpiride users.
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Conclusions: The use of quetiapine posed the lowest
risk of oral ulceration among haloperidol, sulpiride,
olanzapine, quetiapine, risperidone, amisulpride. Until
otherwise proven, practitioners should be aware of the
possibility of differential risks for oral ulcerations
among antipsychotics and consider it when choosing
a medical treatment for patients with schizophrenia
or bipolar disorders.
824. The Utilization of Pharmacovigilance Databases
for the Safety of Health Products: A Systematic
Review
Nathorn Chaiyakunapruk,1,2 Surasak Saokaew,2,3
Unchalee Permsuwan,4 Piyameth Dilokthornsakul,2
Mingkwan Na Takuathung,4 Gary Oderda,5 Wimon
Suwankesawong.6 1Discipline of Pharmacy, Monash
University Malaysia, Selangor, Malaysia; 2Center of
Pharmaceutical Outcomes Research, Naresuan Univer-
sity, Muang, Phitsanulok, Thailand; 3Faculty of Pharma-
ceutical Sciences, University of Phayao, Muang, Phayao,
Thailand; 4Faculty of Pharmacy, Chiang Mai University,
Muang, Chiang Mai, Thailand; 5College of Pharmacy,
University of Utah, Salt Lake, UT, United States; 6Health
Product Vigilance Center, Thai Food and Drug Adminis-
tration, Ministry of Public Health, Muang, Nonthaburi,
Thailand.
Background: Pharmacovigilance system is crucial for
a better understanding of safety proﬁles of health prod-
ucts. Governments of several countries have launched
pharmacovigilance databases for collecting informa-
tion on health products. Little is known regarding per-
spective the databases have been used for drug safety
policy and development of signal detection system.
Objectives: This study aimed to systematically review
literatures using pharmacovigilance databases as data
sources for investigation of safety of health products.
Methods: We performed systematic searches using
PubMed from January 2010 to July 2013. Key words
included “Pharmacovigilance” OR “vigilance data-
base” OR “vigibase”. We limited our searching with
only human studies and reporting in English. All human
studies using pharmacovigilance database were in-
cluded. A standardized form was used to extract charac-
teristics of databases, and study design from each study.
Results: Out of 708 articles identiﬁed from searching,
113 articles met inclusion criteria. About 88% used da-
tabases which are publicly available, while 12% used
databases owned by a private organization. Most of
articles (92%) used data from spontaneous reports,
while 8% used data from intensive-monitoring reports.
Thirty articles (27%) reported data of French
Pharmacovigilance Database, 26 articles (23%) of
WHO vigibase®, 12 articles (11%) of US-FDA Ad-
verse Event Reporting System (FAERS), 2 articles
(2%) of combination of WHO vigibase® and FAERS,
and 43 articles (38%) of others. Most articles (73%)
were studies investigating both exposure and out-
comes, while 19% and 8% were studies focused on
outcomes only and exposure only, respectively.
Based on geographical distribution, 59 articles
(52%) were conducted using databases from Euro-
pean’s countries, while only 5% and 1% were con-
ducted using databases from Asia-Paciﬁc and Africa
regions.
Conclusions: Pharmacovigilance databases are useful
for observing safety of health products. Most pub-
lished articles are from Western countries. Utilization
of the pharmacovigilance databases in Asia-paciﬁc
and Africa countries should be encouraged.
825. Adverse Drug Reactions Leading to Hospital
Admissions: A Prospective Study
Anand Kunchanur,1 Gurumurthy Parthasarathi.2 1Drug
Safety and Epidemiology, Novartis Healthcare Pvt.
Ltd., Hyderabad, Andhra Pradesh, India; 2Pharmacy,
JSS University, Mysore, Karnataka, India.
Background: Adverse drug reaction (ADR)s are iden-
tiﬁed as ﬁfth leading cause of death in USA and esti-
mated approx 2.9%-5.6% of the hospital admissions
are due to ADRs.
Objectives: To identify and assess the hospital admis-
sions due to adverse drug reactions and their cost in-
volved in managing each adverse drug reaction, in a
tertiary care teaching hospital.
Methods: The study was conducted in a tertiary care
teaching hospital in southern state of Karnataka,
India for the period of 8months. WHO deﬁnition of
an ADR was adopted. ADRs were reported through
spontaneous reporting by healthcare professionals
from the study units. The causality assessment of
each suspected ADR was performed by using WHO
probability scale, and the preventability was assessed
using modiﬁed Hartwig and Siegel scale. The cost
incurred in treating the ADRs of each individual
was calculated by considering direct and indirect
costs.
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Results: Amongst 6449 patient admissions, a total of
89 reactions were reported and evaluated from 82
(1.2%) patients who were attributed to ADR-related
hospital admission. Female predominance (54%)
was noted over male (45%) with the median age of
38.11years. The drug class most commonly implicated
was NSAIDs [32 (35.9%)] and diclofenac was found
common [13 (14.6%)] drug involved in causing these
reactions. Most commonly involved WHO-ART
system organ class (SOC) in the reported ADRs was
gastrointestinal system disorder [30 (36.5%)]. Most
of the reported ADRs were probable [48 (53.9%)].
Most of the ADRs were predictable [60 (73.1%)] and
70 (85.3%) were preventable. Patients admitted with
an ADR had an average hospital stay of 9.32 days
and the average cost incurred in managing each ADR
was found to be Rs 2,388 per patient.
Conclusions: The incidence of hospital admissions
due to ADRs was found 1.2%. Our study revealed
that majorities of the ADRs were predictable and
preventable, and the average cost incurred in manag-
ing each ADR was found Rs. 2,388. A successful
ADR surveillance system in a country like India can
have a greater impact on the medication use system
to improve the quality of patient care and in reducing
the occurrence of devastating and costly events.
826. Baseline Characteristics of COPD Clinical
Trial Subjects: An Inter-Ethnic Comparison
Christine S Clifton,1 Sophie L Stocker,1 Jaeyeon Shin,2
Annette S Gross.1 1Ethnopharmacology, GlaxoSmithKline
R&D, Sydney, NSW, Australia; 2Faculty of Pharmacy,
University of Sydney, Sydney, NSW, Australia.
Background:Multiregional clinical trials increasingly
include East Asian subjects. Differences in intrinsic
and extrinsic factors between East Asian and White
COPD populations may inﬂuence apparent response
to COPD therapies. Proﬁling these factors may assist
decision making when considering pooling regional
clinical study results.
Objectives: To compare baseline factors in COPD
subjects of 4 East Asian (EA) ethnic groups, as well
as with White COPD subjects, to inform future multi-
regional clinical study design.
Methods: Datasets were collated from 11 clinical
studies in COPD subjects. Demographic, baseline
disease and extrinsic factors were compared in EA (sub-
jects from Korea, Japan, Taiwan, China) and White
COPD subjects using ANOVA or Chi-square tests. All
studies received Institutional Review Board approval
and re-use of anonymised data was permitted.
Results: Data (median: 25th,75th percentiles) were
proﬁled in 6643 male COPD subjects. Post salbutamol
forced expiratory volume in 1 second (L) showed sta-
tistically signiﬁcant differences among the 5 ethnic
groups (p< 0.001, Kruskal-Wallis): Korea n = 351,
1.32 (1.07,1.56), Japan n = 381, 1.27 (0.91,1.61);
China n=832, 1.14 (0.88,1.47), Taiwan n=203, 1.02
(0.80,1.30); White n=4875, 1.54 (1.19,1.94). Demo-
graphic factors (age, weight and height) also demonstrated
statistically signiﬁcant differences among the 5 ethnic
groups (p< 0.001, Kruskal-Wallis). Among EA popula-
tions the small magnitude of differences in demographic
factors would generally not be considered clinically sig-
niﬁcant. Some variations in the pattern of smoking status
and background COPD therapy were observed among the
EA groups as well as relative to White COPD subjects.
Conclusions: The results conﬁrmed known differences
in demographics between White and EA populations.
The proﬁle of demographic factors among EA COPD
subjects supports the pooling of clinical trial results
across East Asia. However, some lung function and
extrinsic factors can vary between EA populations and
between EA and White populations and these factors
should be considered when assessing and pooling
regional clinical trial results.
827. Pharmacoepidemiolgy Studies in China: Are
There Gaps in Databases, Training Programs or
Both?
Hu Li, Natasha Stohlman, Lei Chen, Ken Hornbuckle.
Eli Lilly, Indianapolis.
Background: It is predicted that China will become the
second largest pharmaceutical market in the next decade.
At the beginning of 2009, the Chinese government
proposed to establish electronic health records to support
the national health system reform. Since then, a number
of healthcare databases have been initiated in China.
Objectives: To highlight the current status of
pharmacoepidemiology studies in China and in partic-
ular, to identify what are the gaps in conducting
pharmacopeidemiology research.
Methods: A literature review was conducted using
Embase: Excerpta Medica database from 1974 to
January 2014. The abstracts were initially assessed
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and followed by a full text review for all relevant
articles published in English. Three epidemiologists
independently reviewed these studies regarding study
design, outcome of interest, data sources, sample size
strength and limitations. A web search was also con-
ducted for epidemiological training programs.
Results: There were no publications in Embase using
claims-based data analyses. There was one study pub-
lished in Aug 2013, utilizing electronic health record
data. Overall, a number of disease epidemiological
studies were conducted in China ranging from acute
infectious disease (e.g. HIV) to long latency chronic
conditions (e.g. diabetes, cancer). Majority of the
studies (>90%) used diverse data resources (survey,
registry and surveillance) and utilized local/regional
hospital medical records. These ﬁndings could be attri-
buted to the decentralized data collection in hospital
systems, absence of any published national standards
and limited access to government owned data systems,
resulting in non-integrated, localized electronic data
sources. There are limited pharmacoepidemiology train-
ing programs in China and these need to be incorporated
into existing public health training programs to increase
expertise in this emerging area of science in China.
Conclusions: Healthcare databases are rapidly growing
in China. However, very few pharmacoepidemiology
studies have been published from these data sources.
There are a number of reasons for this gap including
lack of integrated databases and pharmacoepidemiology
training programs.
828. Psoriasis and the Risk of Myocardial Infarc-
tion: A Population-Based Cohort Study Using the
Clinical Practice Research Datalink
Rosa Parisi,1 Martin K Rutter,2 Mark Lunt,3 Helen S
Young,4 Deborah PM Symmons,3 Christopher EM
Grifﬁths,4 Darren M Ashcroft.1 1Centre for Pharmaco-
epidemiolgy & Drug Safety, Manchester Pharmacy
School, University of Manchester, Manchester, United
Kingdom; 2Manchester Diabetes Centre, Central Man-
chester University Hospitals NHS Foundation Trust; En-
docrinology and Diabetes Research Group, Institute
of Human Development, University of Manchester,
Manchester, United Kingdom; 3Arthritis Research UK
Centre for Epidemiology, Centre for Musculoskeletal
Research, Institute of Inﬂammation and Repair, University
of Manchester, Manchester, United Kingdom; 4The
Dermatology Research Centre, Salford Royal Hospital,
Institute of Inﬂammation and Repair, University of
Manchester, Manchester, United Kingdom.
Background: The association between psoriasis and
the risk of myocardial infarction (MI) is not clearly
understood.
Objectives: To investigate whether psoriasis is inde-
pendently associated with risk for MI after adjusting
for cardiovascular disease (CVD) risk factors.
Methods: An inception cohort of patients with psoria-
sis and matched controls (1:5) was identiﬁed for the in-
terval 1994-2009 using the Clinical Practice Research
Datalink. Patients were at least 20 years old with no
history of CVD or diabetes. Risk factors explored in-
cluded psoriasis, severe psoriasis (exposure to systemic
therapy or biologics), inﬂammatory arthritis (IA), dia-
betes, chronic kidney disease (CKD), hypertension, hy-
perlipidaemia and smoking as time-varying covariates;
depression, age, gender and calendar year as baseline
characteristics. Cox proportional hazard regression
using shared frailty models estimated hazard ratios
(HRs) with 95% conﬁdence intervals for the risk of inci-
dent (fatal and non-fatal) MI associated with psoriasis.
Results: 48,523 patients with psoriasis and 208,187
controls were identiﬁed. Mean (SD) age at index date
was 48 years (16); 56.40% were female. During a me-
dian follow-up of 5.2 years, 664 (1.37%) incident MI
events occurred in patients with psoriasis and 2,601
(1.25%) in controls. In the multivariable analysis all
risk factors (IA HR 1.60 (1.32-1.94); diabetes HR
1.26 (1.09-1.44); CKD HR 1.29 (1.12-1.48); hyperten-
sion HR 1.30 (1.21-1.41); hyperlipidaemia HR 1.14
(1.03-1.26); current smoker HR 2.58 (2.34-2.83);
age HR 1.07 (1.07-1.07); male gender HR 2.46
(2.20-2.73); and calendar year HR 0.95 (0.94-0.95))
were highly signiﬁcant except for depression HR
1.05 (0.97-1.15), psoriasis and severe psoriasis. The
crude HRs of MI for psoriasis were 1.05 (0.97-1.15)
and for severe psoriasis 1.45 (1.02-2.20), while the ad-
justed HRs were attenuated to 0.96(0.88-1.05) and to
1.22 (0.81-1.83).
Conclusions: Neither psoriasis nor severe psoriasis
were associated with an increased risk of MI after
adjusting for known CVD risk factors. However, IA
was associated with a 60% increased risk of MI.
829. Psoriasis and the Risk of Stroke: A Population-
Based Cohort Study Using the Clinical Practice
Research Datalink (CPRD)
Rosa Parisi,1 Martin K Rutter,2 Mark Lunt,3 Helen S
Young,4 Deborah PM Symmons,3 Christopher EM
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Grifﬁths,4 Darren M Ashcroft.1 1Centre for Pharmaco-
epidemiolgy & Drug Safety, Manchester Pharmacy
School, University of Manchester, Manchester, United
Kingdom; 2Manchester Diabetes Centre, Central
Manchester University Hospitals NHS Foundation Trust;
Endocrinology and Diabetes Research Group, Institute
of Human Development, University of Manchester,
Manchester, United Kingdom; 3Arthritis Research UK
Centre for Epidemiology, Centre for Musculoskeletal Re-
search, Institute of Inﬂammation and Repair, University
of Manchester, Manchester, United Kingdom; 4The
Dermatology Research Centre, Salford Royal Hospital,
Institute of Inﬂammation and Repair, University of
Manchester, Manchester, United Kingdom.
Background: The association between psoriasis and
the risk of stroke is not clearly understood.
Objectives: To investigate whether psoriasis is indepen-
dently associated with stroke after adjusting for risk factors.
Methods: An inception cohort of patients with psoria-
sis and matched controls (1:5) was identiﬁed for the
interval 1994-2009 using the CPRD. Patients were at
least 20 years old with no history of cardiovascular
disease (CVD) or diabetes. Risk factors explored in-
cluded psoriasis, severe psoriasis (exposure to sys-
temic therapy or biologics), inﬂammatory arthritis,
diabetes, chronic kidney disease, hypertension, hyper-
lipidaemia, transient ischaemic attack (TIA), myocar-
dial infarction (MI), atrial ﬁbrillation (AF), angina,
valvular heart disease, thromboembolic disease, con-
gestive heart failure and smoking as time-varying co-
variates; depression, age, gender and calendar year as
baseline characteristics. Cox proportional hazard re-
gression using shared frailty models and a stepwise
forward approach (p = 0.05) estimated hazard ratios
(HRs) with 95% conﬁdence intervals for the risk of in-
cident (fatal and non-fatal) stroke.
Results: 48,523 psoriasis patients and 208,187 con-
trols were identiﬁed (mean (SD) age at diagnosis
48 years (16); 56% female). During a median follow-
up of 5.2 years, 522 (1.08%) incident stroke events oc-
curred in patients with psoriasis and 2,018 (0.97%) in
controls. Crude HRs associated with psoriasis and
severe psoriasis were 1.10 (1.00-1.21) and 1.21
(0.74-1.98) respectively. The stepwise regression
model included: age HR 1.08 (1.08-1.08); TIA HR
4.85 (4.18-5.62); smoking HR 1.68 (1.53-1.85);
AF HR 2.13 (1.84; 2.48); calendar year HR 0.95
(0.94-0.96); hypertension HR 1.45 (1.34-1.57); male
gender HR 1.40 (1.29-1.51); MI HR 1.81 (1.45-2.25);
and thromboembolic disease HR 1.40 (1.18-1.66).
Neither psoriasis nor severe psoriasis were selected in
the multivariable model as important predictors for
stroke. When entered, their adjusted HRs were 1.05
(0.95-1.16) and 1.21 (0.73- 1.99) respectively.
Conclusions: Neither psoriasis nor severe psoriasis
were associated with an increased risk of stroke after
adjusting for known risk factors.
830. Spontaneous Reports of Thromboembolic Events
Associated with Cyproterone/Ethinylestradiol after
Media Attention
Florence van Hunsel, Eugene van Puijenbroek, Agnes
Kant. Netherlands Pharmacovigilance Centre Lareb,
‘s Hertogenbosch, Netherlands.
Background: After extensive media attention on
thromboembolic adverse drug reactions (TE-ADRs)
and the use of cyproterone/ethinylestradiol (CE), the
Netherlands Pharmacovigilance Centre Lareb received
a high number of reports about this association, which
prompted for detailed analyses.
Objectives: To analyse reports of thromboembolic
events associated with the use of cyproterone/
ethinylestradiol submitted to Lareb, focusing on the in-
dication of use, presence of risk factors and time be-
tween the initial symptoms and the actual diagnosis
of the TE.
Methods: Reports submitted to Lareb till 11 February
2014 were analysed. The analysis was focussed on re-
porter type, seriousness of the reaction, age of the pa-
tient, BMI, indication, ADRs classiﬁed as arterial
thrombosis and venous thrombosis, pulmonary embo-
lism, latency period, outcome of the reaction, treat-
ment of the ADR, delay between the ﬁrst symptoms
and diagnosis of the ADR, presence of risk factors.
Results: On 11 February 2014, Lareb had received a
total of 786 reports about CE, including 41 cases with
a fatal outcome. Of all reports, 438 reports considered
TE-ADRs which were analysed in more detail. Re-
ported ADRs consisted of arterial thrombosis
(N = 74), venous thrombosis (N = 63), pulmonary em-
bolism (N= 219) and thrombosis with an unspeciﬁed
location (N= 172). Patient’s mean age was 30.5 years
(range 14-57 years). The primary indications for use
were acne (N = 193), oral contraceptive (N= 181), hir-
sutism (N= 13), other (N = 18) or the indication was
unknown (N= 33). The median time to onset was
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4 years, although many patients reported a longer la-
tency period. There was no distinction between the
time of onset in respect to the reported ADR. No dif-
ferences in risk factors seem to exist between labeled
and off-label indications. In 382 out of 438 reports
(87%), the reporter was a consumer. Some reports
mentioned the fact that thrombosis or embolism were
not recognized in an early stage.
Conclusions: The reported thromboembolic ADRs are
a known risk related to the use of CE, but may be
misdiagnosed initially. From the reports that Lareb re-
ceived it is evident that off-label use is frequent.
831. Bisphosphonate and Adverse Cardiovascular
Events: Meta-Analysis of Randomized Placebo-
Controlled Trials
Dae Hyun Kim,1 James R Rogers,2 Lisa A Fulchino,2
Daniel H Solomon,2 Seoyoung C Kim.2 1Gerontology,
Beth Israel Deaconess Medical Center, Boston, MA,
United States; 2Pharmacoepidemiology and Pharmaco-
economics, Brigham and Women’s Hospital, Boston,
MA, United States.
Background: Some animal experiments and random-
ized controlled trials in humans suggest that
bisphosphonates may inhibit progression of athero-
sclerosis. Whether bisphosphonates reduce clinical
cardiovascular (CV) events is not known.
Objectives: To evaluate the cardiovascular effects of
bisphosphonate treatment.
Methods: We conducted a systematic search of
MEDLINE and EMBASE, from inception to August
2013, without language restriction, to identify random-
ized placebo-controlled trials of bisphosphonates that
had longer than 6-month duration and reported adverse
CV events. Two independent reviewers screened pa-
pers and extracted data on any CV events, atrial ﬁbril-
lation (AF), myocardial infarction (MI), stroke, and
CV death. The effect of bisphosphonates was com-
bined using the Mantel-Haenszel risk difference (RD)
over 7-12 months, 13-24 months, and ≥25months.
Results: Of 2,520 records, 34 records reported at least
one type of CV events from 22,213 patients treated
with bisphosphonate and 18,965 placebo patients
(mean age: 63.8 years; female: 81.7%) in 31 trials.
Per 1,000 patients treated for 7-12 months, bisphos-
phonate use may cause 21 excess any CV events
(95% conﬁdence interval: 2, 39), including 15 strokes
(95%CI: 0, 30), and 8 CV deaths (95%CI: 0, 17). There
was no clear link with AF (RD: 12; 95% CI: -5, 30) or
MI (RD: 4; 95% CI: -6, 14). There was no statistically
signiﬁcant difference in CV events over 13-24 months
or ≥25months, except an excess of 5 cases of AF
(95%CI: 2, 8) per 1,000 patients treated with zoledronic
acid for ≥25months.
Conclusions: We found no evidence of reduction in
CV events with bisphosphonate treatment. A possible
excess risk of stroke and CV deaths was observed in
the ﬁrst 7-12 months of treatment and AF among
long-term users. These data warrant a large-scale sur-
veillance study to better estimate possible risks.
832. Potential Signals for Cardiovascular-Related
Adverse Events with COX Inhibitor Use: Analysis of
the WHOGlobal ICSR Database System (VigiBase)
David Prieto-Merino,1 Joseph Kim,1,2 Stephen JW Evans.1
1Faculty of Epidemiology and Population Health, London
School of Hygiene and Tropical Medicine, London,
England, United Kingdom; 2Real-world Evidence Solu-
tions, IMS Health, London, England, United Kingdom.
Background: Recent meta-analyses of RCTs and ob-
servational studies have suggested a positive associa-
tion between the use of Cox-2 inhibitors and the risk of
myocardial infarction (MI). It remains unclear whether
an early detection of signals for CV events would have
been possible through the disproportionality analysis
(DA) of spontaneous reporting databases (SRDs) such
as the WHO Global ICSR Database System (VigiBase).
Objectives: To examine how soon the positive associ-
ation between MI and Cox-2 inhibitors could have
been detected in VigiBase.
Methods: We identiﬁed all ADR-drug combinations
that contain the ATC code for coxibs ( M01AHxx:
celecoxib, etoricoxib, lumiracoxib, rofecoxib, valde-
coxib, parecoxib). DA was performed for the 6 sub-
stances separately and the entire class (M01AH) against
other NSAIDS (ATC code M01A). Reporting odd ratios
(ROR) adjusted for sex and age (<41, 41-60, 61-80,
>80) were calculated for MI which was performed se-
quentially for each year (1999-2013). A positive signal
(PS) and a strong PS were deﬁned as the absolute value
of the standardised ROR >2 or >3 respectively.
Results: A total of 20,712,802 ADR-drug combina-
tions with 83,877 MIs were found. Of the 484,792 re-
ports that contained coxib substances, 21,044 had MI.
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Given that 60% of the reports were from the US, strat-
iﬁed the analysis by region: US, rest of the world
(ROW), and all the world (W). Strong signals for
coxib-MI was detected for these years and regions by
drug: celecoxib USA=2001, ROW =2001, W=2000;
etoricoxib USA=never, ROW =2002, W =2002;
lumiracoxib USA=never, ROW =2004, W =2008;
rofecoxib USA=2000, ROW =2000, W =2000;
valdecoxib USA=2006, ROW =2005, W =2005;
parecoxib USA=never, ROW =2003, W =2003; All
N01AH: USA=2000, ROW =2001, W =2000.
Conclusions: The ﬁndings from this study illustrates
the importance of SRDs for the early detection of sig-
nals for potentially rare but serious unanticipated AEs.
833. Temporal Changes in the Prescribing Propensity
Following Safety Warnings
Elizabeth M Garry,1 John B Buse,2 Virginia Pate,1 Til
Sturmer.1 1Department of Epidemiology, University of
North Carolina at Chapel Hill, Chapel Hill, NC, United
States; 2Department of Medicine, University of North
Carolina School of Medicine, Chapel Hill, NC, United
States.
Background: Channeling occurs when preferential
drug prescribing is inﬂuenced by calendar-time events.
Calendar time-speciﬁc propensity scores (PS) can be
used to address calendar time-speciﬁc channeling that
may occur after a black box warning is issued by the
Food and Drug Administration (FDA) or a safety con-
cern is publicized by the media.
Objectives: Evaluate changes in channeling away
from rosiglitazone (ROSI), an oral hypoglycemic
thiazolidinedione (TZD), that received a black box
warning for myocardial infarction (MI) in November
2007, six months after a highly publicized meta-analysis
suggested MI concern.
Methods: An incident-user design identiﬁed 35,313 pa-
tients> age 65 from 2006-2008 Medicare claims who
initiated a TZD [ROSI or Pioglitazone (PIO)], Dipeptidyl
peptidase-4 inhibitors (DPP), or Sulfonylureas (SU) in
\the six-month periods before (Period 1) and after
(Period 2) the FDA warning. Periods were compared
to evaluate changes in the propensity to prescribe a
TZD, as a function of preexisting cardiovascular
disease and other patient characteristics.
Results: Of those included, 3%(412) and 18%(2449)
initiated ROSI or PIO in Period 1; this was 3%(711)
and 17%(3787) in Period 2. The fully adjusted model
yielded no change in the propensity to prescribe TZD
vs. SU or DPP in Period 2 vs. 1 [OR(95% CI) for
ROSI vs. DPP:0.98(:0.86-1.12); ROSI vs. SU: 1.01
(0.90-1.13); TZD vs. DPP:0.97(0.89-1.05); TZD vs.
SU: 0.98(0.93-1.03)].
Conclusions: The distribution of PIO initiation was
three times that of ROSI in both periods, despite previ-
ous reports of near-equal distribution, suggesting that a
prescribing shift occurred prior to FDA action. Given
the limitation of available Medicare data, we were un-
able to account for claims prior to the publicized safety
concern. We will further compare these results to
MarketScan commercial claims data to demonstrate
the propensity to prescribe before and after a publi-
cized safety concern, as it compares to that of a subse-
quent FDA warning. Use of calendar time-speciﬁc PS
may be beneﬁcial to assess calendar-time differences
related to media and regulatory events, and may help
with respect to confounding control.
834. A Comparison of Cardiac Event Rates in
Patients with orWithoutMultipleMyeloma in the US
Kristin D Kistler,1 Brian Murphy,1 Jill Kalman,2 Gagan
Sahni,2WinifredWerther,3 Kanya Rajangam,3 Ajai Chari.2
1Evidera, Lexington, MA, United States; 2Mount Sinai, NY,
NY, United States; 3Onyx Pharmaceuticals, Inc., an Amgen
Subsidiary, South San Francisco, CA, United States.
Background: Multiple myeloma (MM) patients have
age-, disease-, and treatment-related risk factors for
cardiac events.
Objectives: To determine if the risk of cardiac events
is greater in MM patients vs. non-MM patients.
Methods: Retrospective observational study utilizing
the 2006–2011 MarketScan® database. Two patient
cohorts were identiﬁed: 1) MM patients treated with
corticosteroids and ≥3 drugs (bortezomib, IMiDs,
and alkylating agents or anthracyclines), where the in-
dex date (ID) was the date criteria of exposure to the 3
drugs was met; and 2) age and sex matched No-MM
patients (5:1); the distribution of No-MM patients’
IDs matched MM patients. Baseline was 6months
prior to the ID. Followup was from ID to study end
(i.e., 2011 or end of enrollment or prescription drug
coverage). Incidence of inpatient and/or outpatient car-
diac events was examined. Diagnosis, procedure and
treatment codes (ICD-9, HCPCS, and NDC) were used
to classify patients. Baseline variables included age,
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sex, geographic area, comorbidities (e.g., cardiac
events), and Charlson Comorbidity Index. Incidence
was calculated for patients without the event(s) at
baseline. Hazard ratios (HR) and 95% conﬁdence in-
tervals (CI) were adjusted for baseline variables when
univariate analyses showed a 10% difference.
Results: 1,723 MM patients and 8,615 comparators
were analyzed. Median (range) months of observation
were: MM, 9 (0–60); no-MM, 19 (0–66). Prevalence of
cardiac events was greater in the MM (52%) vs. no-MM
group (35%), P< 0.0001. Risk (HR [95% CI]) of any
cardiac event (2.2 [1.9–2.5]), arrhythmia (4.1 [3.5–4.8]),
congestive heart failure (2.9 [2.2–3.7]), cardiomyopathy
(2.6 [1.8–3.8]) and conduction disorders (1.7 [1.2–2.5])
was also signiﬁcantly greater among MM vs. no-MM
patients; the incidence of hypertensive/arterial events
and ischemic heart disease was similar between groups.
Conclusions: This study provides the ﬁrst comparison
of cardiac event risk in MM patients vs. age- and sex-
matched patients without MM. Cardiac event preva-
lence and risk was greater in MM patients with ≥3
prior drugs for any cardiac event, arrhythmia, CHF,
cardiomyopathy, and conduction disorders compared
to patients with no MM.
835. Rates of Cardiovascular Disease and Major Ad-
verse Cardiovascular Events in Psoriatic Arthritis Pa-
tients Compared to Non-Psoriatic Arthritis Patients
Lin Li,1 Katrina W Hagberg,1 Michael M Peng,2 Susan
Jick.1 1Boston Collaborative Drug Surveillance
Program, Boston University School of Public Health,
Lexington, MA, United States; 2PV and Epidemiology,
Celgene, Berkeley Heights, NJ, United States.
Background: There are few treatments available for
psoriatic arthritis (PA). This study was conducted in
support of a NDA ﬁling for a new PA drug.
Objectives: To estimate the rate of incident cardiovas-
cular disease (CVD) and Major Adverse Cardiovascu-
lar Events (MACE) in patients with psoriatic arthritis
(PA) in comparison to non-PA patients.
Methods: We conducted a cohort study using the
United Kingdom Clinical Practice Research Datalink
(CPRD) that included patients with a ﬁrst PA diagno-
sis recorded in 1988-2012 and up to 10 non-PA pa-
tients matched on age, sex, general practice, and
calendar time. All patients were required to have ≥1
year of recorded history prior to cohort entry (ﬁrst
PA diagnosis or matched date). We created two sepa-
rate cohorts (CVD and MACE) and excluded patients
who had a diagnosis of that outcome prior to cohort
entry. Cases were patients with a ﬁrst time diagnosis
of CVD (arrhythmias, ischemic heart disease, myocar-
dial infarction, stroke, pericardial disease, pulmonary
hypertension and sudden death) or MACE (myocar-
dial infarction, stroke, and sudden death) recorded dur-
ing follow-up. Patients were followed until the end of
the study period, end of practice registration, death, or
until ﬁrst diagnosis of interest. We estimated cumula-
tive incidence rates with 95% conﬁdence intervals
(CI) and risk (cumulative hazard function) using the
Kaplan Meier method for each cohort and tested risk
differences using a log-rank test.
Results: There were 7,982 PA patients and 74,583
non-PA patients in the CVD cohorts. The IR of CVD
was slightly higher in the PA compared to the non-
PA cohort [12.8/1,000 person-years (PY) (95% CI
11.9–13.7) and 9.6/1,000 PY (95% CI 9.3–9.0)].
There were 8,454 PA and 82,308 non-PA patients in
the MACE cohorts. The IR was slightly higher in the
PA compared to the non-PA cohort [4.6/1,000 PY
(95% CI 4.1–5.1) and 3.5/1,000 PY (95% CI 3.4–3.7,].
The analyses of cumulative hazards yielded statistically
signiﬁcant differences between the PA and non-PA co-
horts (p< 0.0001) for both outcomes.
Conclusions: The rates of CVD and MACE were
slightly higher in PA compared to non-PA patients.
836. Comparative Safety of NSAIDs on Myocardial
Infarction According to the COX-2 Selectivity
Sun-Young Jung,1 Eunmi Choi,1 Hyun-Joo Jung,1
Byung-Joo Park.1,2 1Korea Institute of Drug Safety and
Risk Management, Seoul, Republic of Korea; 2Depart-
ment of Preventive Medicine, Seoul National University
College of Medicine, Seoul, Republic of Korea.
Background: COX-2 selective inhibitors are known
to increase the risk of cardiovascular thrombotic
event. Recently, concerns about the risk of myocardial
infarction (MI) of non-selective nonsteroidal anti-in-
ﬂammatory drugs (NSAIDs) with higher COX-2
selectivity than naproxen, especially diclofenac, have
been raised in several studies.
Objectives: To compare the risk of MI in patients who
used several NSAIDs compared to naproxen.
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Methods: This was a retrospective cohort study using
the Korea Health Insurance Review and Assessment
Service-National Patients Sample (HIRA-NPS) data-
base of 2009. Patients aged 40 to 84 years with
NSAIDs prescription were included between April to
September 2009, with no history of CV disease for at
least 3months. As study drugs, etodolac, meloxicam,
nimesulide, celecoxib, diclofenac (higher COX-2
selectivity group), naproxen (reference drug),
piroxicam and ibuprofen (lower COX-2 selectivity
group) were included. Incidence rates of acute
myocardial infarction (ICD10, I21) after NSAIDs
use were estimated. Rate ratios (RR) and their 95%
conﬁdence intervals (CIs) for MI risk associated with
the use of NSAIDs were estimated from Cox’s propor-
tional hazards model.
Results: We identiﬁed 43,448 patients with NSAIDs
prescription, 4,511 patients with naproxen, 29,211
with higher COX-2 selectivity group, 9,726 with lower
COX-2 selectivity group. Compared to naproxen users,
the adjusted RR of MI was 1.32 (95% CI, 0.94-1.86)
for higher COX-2 selectivity group, and 1.22 (95%
CI, 0.84-1.78) for lower COX-2 selectivity group. For
the individual drugs, the adjusted RR for celecoxib
and diclofenac was 1.36 (95% CI, 0.73-2.53) and
1.42 (95% CI, 1.01-2.00), respectively.
Conclusions: The patients with higher COX-2 selec-
tivity NSAIDs showed no signiﬁcant increased risk
of MI. However, diclofenac users showed marginally
increased risk. Further studies to reveal the factors
affecting MI risk other than COX-2 selectivity will
be needed.
837. Risk of Aortic Aneurysm or Aortic Dissection
Associated with Fluoroquinolone Therapy
Chien-Chang Lee,1,2,3 Yueh-Sheng Chen,4 Shih-Hao
Lee,1 Meng-tse Gabriel Lee,1 Yi-Hsian Lin,1 Tse-Chih
Chou.5 1Department of Emergency Medicine, National
Taiwan University Hospital, Taipei; 2Department of
Emergency Medicine and Department of General Medi-
cine, National Taiwan University Hospital Yunlin
Branch; 3Department of Epidemiology, Harvard School
of Public Health, Boston; 4Division of General Medicine,
Department of Internal Medicine, Kaohsiung Chang
Gung Memorial Hospital, Kaohsiung; 5Clinical Infor-
matics and Medical Statistics Research Center, Chang
Gung University, Tao-Yuan.
Background: Fluoroquinolones (FQs), a broadly used
antibacterial agents, have been shown to associate
with collagen degradation in animal studies and
tendinopathies clinically. It is well known that colla-
gens possess the characteristic of load-bearing ele-
ments in aortic tissue. This raises the concern of
FQs’ association with more serious disorders such as
aortic aneurysm (AA) and aortic dissection (AD).
Objectives: We aimed to examine the relationship be-
tween FQ therapy and the development of AA or AD.
Methods: We conducted a population-based case-
control study nested in national health insurance re-
search database (NHIRD) of Taiwan between January
2000 and December 2009. One hundred controls were
selected for each one case matched on age and gender
using risk-set sampling scheme. We deﬁned case as
hospitalized patients with a primary or secondary diag-
nosis of AA or AD. We classiﬁed users of FQs as cur-
rent and past users dependent on the exposure to FQs
within 3months of index dates of AA or AD diagno-
sis. We used propensity score for adjustment of unbal-
anced covariates between users and nonusers. We
included β-lactams as an active comparator and exam-
ine their association with AA or AD.
Results: From a cohort of two million patients with
10 years follow-up, 1754 cases of AA or AD were
identiﬁed. After propensity score adjustment, current
use of FQs was at increased risk for developing AA
or AD (adjusted rate ratio [ARR], 1.87[95%CI, 1.28
- 2.73]) while past use did not show signiﬁcant associ-
ation (RR, 1.18[95%CI, 0.89 – 1.56]). We did not ﬁnd
signiﬁcant association between use of β-lactams and
development of AA or AD. Sensitivity analysis using
AA or AD undergoing operation as the primary case
deﬁnition also ﬁnd a signiﬁcant association (RR,
2.09 [95%CI 1.13 - 3.85]).
Conclusions:We ﬁnd a non-negligible association be-
tween current use of FQs and development of AA and
AD. Further studies are needed to validate our ﬁnd-
ings. Physicians should be alert of the potential associ-
ation when selecting antimicrobials for patients at high
risk for AA or AD.
838. Ranibizumab Associated with Increased Risk of
Ischaemic Stroke but Not Myocardial Infarct: A
Self-Controlled Case Series Analysis
Nicole Pratt,1 Emmae Ramsay,1 Anna Kemp,2 Lisa
Kalisch Ellett,1 Sepehr Shakib,3 Gillian Caughey,1 Philip
Ryan,4 Stephen Graves,5 Elizabeth Roughead.1 1Univer-
sity of South Australia, Adelaide; 2The University of
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Western Australia, Perth; 3Royal Adelaide Hospital,
Adelaide; 4University of Adelaide, Adelaide; 5Flinders
University, Adelaide.
Background: Ischaemic stroke and myocardial
infarction (MI) are potential adverse effects of
vascular endothelial growth factor (VEGF) inhibition.
Randomised controlled trials assessing these outcomes
in people who use VEGF inhibitors for macular degen-
eration have been under-powered to detect these ef-
fects, while cohort studies have been subject to bias
due to differences across groups.
Objectives: To assess the association between use of
the VEGF inhibitor, ranibizumab, and risk of: ischae-
mic stroke and MI, using the self-controlled case series
method, which uses a within person design to control
for unmeasured confounding.
Methods: An administrative claims database was
used to identify subjects exposed to ranibizumab
who had an ischaemic stroke or MI between August
2007 and March 2013. Person time was divided
into risk periods of unexposed, 1 to 30 days, 30 to
60 days and greater than 60 days exposure. A wash-
out period of 30 days and two 42-day pre-risk periods
were included. Rate ratios were calculated using
conditional Poisson regression, with results pre-
sented as adjusted rate ratios and 95% conﬁdence
intervals.
Results: There were 322 subjects who received
ranibizumab and experienced an ischaemic stroke
and 391 who had the outcome of MI. Median duration
of exposure was 8 to 9months with follow-up times of
approximately 2.8 years. No elevated risk of ischaemic
stroke was seen in the 1 to 30 days post initiation
(Incidence Rate Ratio (IRR) 1.33 [95% Conﬁdence
Interval (CI) 0.96 - 1.84]); however elevated risk was
observed for those who received therapy for 30 to
60 days (RR 1.89 [95% CI 1.12 - 3.21]). No associa-
tion was seen for MI in either time period (1 to 30 days
IRR 0.90 [95% CI 0.65 - 1.23], 30 to 60 days IRR 0.98
[95% CI 0.54 - 1.79]).
Conclusions: This case-series analysis suggests when
used intermittently there is no increased risk of ischae-
mic stroke for patients receiving ranibizumab therapy.
However, the risk was elevated when ranibizumab was
used as two consecutive injections. No evidence of
increased risk of MI was observed.
839. Methods and Guidelines for Integrity of Multi-
variable Analysis of Real World (observational)
Data
Drew G Levy,1 David C Norris,2 Aaron WC Kamauu,3
AndrewWilson.3 1Genentech, Inc., South San Francisco,
CA, United States; 2David Norris Consulting, LLC,
Seattle, Washington, United States; 3Anolinx LLC, Salt
Lake City, UT, United States.
Background: A consequence of the proliferation of
real world data (RWD; e.g., electronic health records,
claims data, public-use data, ACO’s, etc.) and the ur-
gency to use them to inform clinical decision making
is that the prevalence of observational data analyses
(ODA) is increasing dramatically. The methods, stan-
dards and guidelines for multivariable ODA currently
borrow substantially from those for randomized
clinical trials, and do not speciﬁcally address idiosyncra-
sies of ODA important for reproducible and scientiﬁcally
meaningful results.
Objectives: To critically examine standard practice of
ODA and survey the manifold opportunities for misdi-
rection of reproducible valid inference. Guidelines for
conducting ODA and corresponding standards for
evaluating ODA are proposed that integrate corrective
measures.
Methods: A multiple bias simulation model for the
prevalent ODA process is used to illustrate issues.
The entire process of multivariable modeling in ODA
is deconstructed and analyzed for prevalent sources
of potential distortion of inference, and recommenda-
tions for remediation at critical points are made. Major
points of focus include (a) explicit speciﬁcation of the
underlying causal and modeling assumptions; (b)
uncertainties due to model speciﬁcation, over-ﬁtting,
predictive optimism; (c) formally incorporating repro-
ducibility and expectation for reproduction of research
into ODA; and (d) expression and evaluation of results
in terms of reduction of uncertainty and altering prior
belief.
Results: This perspective connects multiple-bias
modeling, causal graph theory, modeling strategies, re-
producible research methods and Bayesian epistemol-
ogy for a coherent approach to ODA that optimizes
inferential integrity. The economics and behavioral
economics of various approaches are also contrasted.
Conclusions: The value of ODA for clinical decision-
making is constrained by uncertainties above and
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beyond that represented in estimated standard errors.
Various authors and methodologists have made impor-
tant contributions to various aspects of the problem.
Integrating these into a methodologic thesis suggests
guidelines for ODA practice and a standard for ODA
evaluation.
840. Validity of Claims-Based Stroke Algorithms in
Contemporary Medicare Data: REGARDS Study
Linked with Medicare Claims
Hiraku Kumamaru,1,2 Suzanne E Judd,3 Jeffrey R
Curtis,3,4 Rekha Ramachandran,4 N Chantelle Hardy,5 J
David Rhodes,3 Monika M Safford,4 Brett M Kissela,6
George Howard,3 Jessica J Jalbert,2,7 Thomas G Brott,8
Soko Setoguchi.5 1Epidemiology, Harvard School of
Public Health, Boston, MA, United States; 2Division
of Pharmacoepidemiology and Pharmacoeconomics,
Brigham and Women’s Hospital, Harvard Medical
School, Boston, MA, United States; 3University of
Alabama at Birmingham School of Public Health,
Birmingham, AL, United States; 4University of Alabama
at Birmingham School of Medicine, Birmingham, AL,
United States; 5Duke Clinical Research Institute, Dur-
ham, NC, United States; 6Department of Neurology, Uni-
versity of Cincinnati, Cincinnati, OH, United States;
7LA-SER Analytica, NY, NY, United States; 8Department
of Neurology, Mayo Clinic, Jacksonville, FL, United States.
Background: For validity of etiological and compara-
tive effectiveness and safety studies, outcomes of
interest must be captured with high speciﬁcity. How-
ever, stroke algorithms have not been validated in the
contemporary Medicare population.
Objectives: To assess the validity of stroke algorithms
in the contemporary Medicare population.
Methods: We linked the Reasons for Geographic and
Racial Differences in Stroke (REGARDS) study data
to 2003-2009 Medicare claims using SSN, birth date
and sex. In addition to events captured by REGARDS
phone interviews, medical charts were pursued for
strokes identiﬁed only in Medicare. Stroke specialists
adjudicated events using the retrieved medical charts.
Using adjudicated strokes as the gold standard, we cal-
culated the sensitivity, speciﬁcity, positive predictive
value (PPV) and negative predictive value of inpatient
stroke algorithms using ICD-9-CM codes for stroke as
the primary discharge diagnosis.
Results: We successfully linked 17,942 REGARDS
participants (91.2% linkage among age ≥65), and
15,089 had ≥1month continuous fee-for-service en-
rollment period available for study (mean age 69.3,
52% women, 37% black). We adjudicated 457 strokes,
of which 48 were identiﬁed by claims only. The ische-
mic stroke algorithm [codes 433.x1, 434.x1, 436] had
99.8% (95% conﬁdence interval: 99.7-99.9) speciﬁc-
ity, 88.8% (84.7-92.6) PPV and 58.6% (53.6-63.6)
sensitivity. The intracerebral hemorrhage algorithm
[codes 430, 431] had 100% (99.9-100) speciﬁcity,
88.6% (78.9-98.3) PPV and 67.4% (54.8-79.9) sensi-
tivity. The combined stroke algorithm [codes 430,
431, 433.x1, 434.x1, 436] had 99.8% (99.6-99.9) spec-
iﬁcity, 90.5% (87.1-94.0) PPV and 60.4% (55.8-65.1)
sensitivity. Speciﬁcity and PPV were consistently high
across the subgroups of age, sex and race.
Conclusions: High speciﬁcity and PPV of our inpa-
tient stroke algorithms support their use in etiologic
and comparative studies in contemporary Medicare
populations. However, low sensitivity limits their use
for estimating incidence rates or healthcare utilizations.
Further studies need to explore more sensitive algo-
rithms including outpatient diagnoses and procedures.
841. Performance of ICD-10 Codes in a Computer-
ized Hospital Database for Identification of Acute
Coronary Syndrome
Julien Bezin,1 Paul Ferreira,1 Maëlys Touya,1 Véronique
Gilleron,2 Sahondra Rambelomanana,1 Pierre-Olivier
Girodet,1 Nicholas Moore,1 Antoine Pariente.1 1Univ.
de Bordeaux, INSERM U657, CHU de Bordeaux, CIC
Bordeaux CIC1401, Bordeaux, France; 2CHU de Bor-
deaux, Service d’Information Médicale, Pôle de Santé
Publique, Bordeaux, France.
Background: One limitation of the use of computer-
ized hospital database for identiﬁcation of clinical
event is the validity of the recorded information.
Objectives: To evaluate, in the electronic database
of a French teaching hospital (Programme de
Médicalisation du Système d’Information, PMSI), the
adequacy of the coding of acute coronary syndrome
(ACS) events, and to develop and test a code combina-
tion for the identiﬁcation of these events in such
databases.
Methods: Inclusion criteria were hospitalizations to
Bordeaux teaching hospital between January 1, 2011
and December 31, 2011 and one of the following
ICD-10 (10th International Classiﬁcation of Diseases)
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main diagnosis code: I200 (unstable angina pectoris),
I208 (other forms of angina pectoris), I209 (angina
pectoris unspeciﬁed), I21 (acute myocardial infarc-
tion), I24 (others acute ischemic heart disorders) or
I25 (chronic ischemic heart disorders, with exception
of I252 “old myocardial infarction”). Among these,
100 hospitalizations were randomly selected; for each,
ACS was conﬁrmed/eliminated by inspection of
medical ﬁles by an independent events validation com-
mittee composed of a cardiologist, two clinical phar-
macologists and an expert in event validation, using
criteria of the European Society of Cardiology. The
concordance between coding and diagnosis was then
evaluated independently to identify ACS events from
electronic hospitalization data using each code, a com-
bination of two codes: a sensitive combination consid-
ering all codes and a speciﬁc combination considering
I200, I21 and I24 codes only.
Results: The adequacy of ACS coding differed within
codes. The Positive Predictive Value (PPV) for ACS
was 67% for the I200 code, 14% for codes I208 or
I209, 90% for I21, 100% for I24 (only two events),
and 21% for I25. It was 56% for the sensitive code
combination, and 84% for the speciﬁc one.
Conclusions: This study shows a high variability
between codes used to identify ACS with a com-
puterized hospital database. The speciﬁc code
combination showed better performances with re-
gard to the PPV and should thus be preferred in
studies focusing on ACS using electronic hospita-
lization data.
842. Prevalence of Cardiovascular Risk Factors and
Estimated 10 Year Cardiovascular Risk for Patients
in the Febuxostat Versus Allopurinol Streamlined
Trial (FAST)
Claudine G Jennings,1 Isla S Mackenzie,1 Rob Flynn,1
Ian Ford,2 George Nuki,3 Thomas MMacDonald.1 1Med-
icines Monitoring Unit, University of Dundee, Dundee,
United Kingdom; 2Robertson Centre for Biostatistics,
University of Glasgow, Glasgow, United Kingdom; 3In-
stitute of Genetics and Molecular Medicine, University
of Edinburgh, Edinburgh, United Kingdom.
Background: Gout patients have increased cardiovas-
cular risk compared to the general population. The
FAST trial is evaluating long term cardiovascular
safety of febuxostat versus allopurinol in patients with
gout. Recruited patients are over 60 years old, already
prescribed allopurinol and must have at least one addi-
tional cardiovascular risk factor.
Objectives: To review cardiovascular risk factors
present in FAST patients and calculate 10 year cardio-
vascular risk using ASSIGN and QRISK scores.
Methods: Pre-randomisation data for 1490 patients
recruited into FAST were collected and analysed to
determine predominant cardiovascular risk factors in
this population.
Results: 84.7% of FAST patients were male, mean
age 71 years, mean BMI 31.2 kg/m2. 7.8% of patients
were current smokers. Mean blood pressure at FAST
screening was 138/75mmHg (with 42.9% having sys-
tolic blood pressure≥ 140mmHg). Past medical history
included myocardial infarction (11.3%), ischaemic heart
disease (26.4%), stroke/TIA (10.5%), hypertension
(78.1%), peripheral vascular disease (PVD) (7.1%),
chronic kidney disease (CKD) (12.9%) and diabetes
(25.0%).
Cardiovascular risk factors used as inclusion criteria
for FAST were: age (>70 male,>75 female), smoking,
diabetes/impaired glucose tolerance, hypertension,
dyslipidaemia, CKD, family history of cardiovascular
disease, inﬂammatory arthritis, chronic NSAID use, pre-
vious cardiovascular event, PVD, COPD and BMI
>30 kg/m2. The commonest cardiovascular risk factor
was hypertension (80.0%), followed by dyslipidaemia
(59.0%), BMI >30 kg/m2 (54.2%) and diabetes
(25.0%). 8% of patients had a single risk factor while
30% had at least 5 risk factors (mean 3.7 risk factors
per patient).
Cardiovascular risk scoring in 1165 FAST patients
with no prior cardiovascular event gave an average
10 year risk of 33% using ASSIGN and 28% using
QRISK. 94% of patients using ASSIGN and 80%
using QRISK would be considered high risk.
Conclusions: Gout patients are a high risk group for
cardiovascular disease and data from the FAST trial il-
lustrates the high burden of cardiovascular risk factors
present in this population.
843. Cardiovascular Risk Management of Patients
in the Febuxostat Versus Allopurinol Streamlined
Trial (FAST)
Claudine G Jennings,1 Isla S Mackenzie,1 Rob Flynn,1
Ian Ford,2 George Nuki,3 Thomas MMacDonald.1 1Med-
icines Monitoring Unit, University of Dundee, Dundee,
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United Kingdom; 2Robertson Centre for Biostatistics,
University of Glasgow, Glasgow, United Kingdom;
3Institute of Genetics and Molecular Medicine, Univer-
sity of Edinburgh, Edinburgh, United Kingdom.
Background: Gout patients have increased cardiovas-
cular morbidity and mortality compared with the gen-
eral population. Management of cardiovascular risk
factors and secondary prevention after cardiovascular
events have a high priority in this population. The
FAST trial is evaluating the cardiovascular safety of
febuxostat versus allopurinol in patients with gout. Re-
cruited patients are aged over 60 years, already taking
allopurinol and must have at least one additional car-
diovascular risk factor.
Objectives: To review prescribing for cardiovascular
risk management in patients with hypertension, ischae-
mic heart disease and stroke recruited into the FAST
trial.
Methods: Pre-randomisation data for 1490 recruited
FAST patients was analysed. Hypertension manage-
ment was assessed by number and class of anti-hyper-
tensive medication used. Prescribing in patients with a
history of ischaemic heart disease or stroke was
reviewed for compliance with current guidance in
use of lipid lowering drugs, anti-platelet agents, blood
pressure management and cardioprotective drugs.
Results: 78.1% of FAST patients had a history of hy-
pertension. Blood pressure at the FAST screening visit
was above recommended targets (>140/90mmHg) in
43.4% of patients with hypertension and 41.1% of
patients without a diagnosis of hypertension. Treated
hypertensive patients were taking on average 2 antihy-
pertensive drugs with ACEi/ARB’s being most
commonly prescribed, followed by diuretics.
26.4% of FAST patients had ischaemic heart dis-
ease. 85.5% were prescribed lipid lowering therapy,
77.6% an antiplatelet agent and 97.0% antihyperten-
sive medication (mean 2.2 anti-hypertensive drugs
per patient). 72.1% were taking an ACEi/ARB and
67.3% a beta blocker.
10.5% of FAST patients had a history of stroke or
TIA. 80.3% were prescribed lipid lowering therapy,
79.6% an anti-platelet agent (with a further 17.2% on
oral anticoagulation) and 89.2% anti-hypertensive med-
ication (most commonly ACEi/ARB and diuretics).
Conclusions: The FAST trial population are at high
risk for cardiovascular events. Our data shows that
there is scope to improve outcomes particularly
through improved management of hypertension.
844. Incidence of Heart Failure: A Population-Based
Study in General Practice Setting
Ana Ruigomez,1 Luis A Garcia Rodriguez,1 Alexander
Michel.2 1CEIFE, Madrid, Spain; 2Global Epidemiology,
Bayer Pharma, Berlin, Germany.
Background: Owing to an ageing population, Heart
Failure (HF) is a public health problem with increasing
importance.
Objectives: To estimate the incidence rate of HF in
general practice and to describe the health care status
at time of diagnosis.
Methods: Population-based cohort study using The
Health Improvement Network database (THIN) in the
UK. We identiﬁed all patients aged 1-89 years with a
ﬁrst ever diagnosis of HF in 2000-2005. We did not in-
clude HF cases when the 1st diagnosis was recorded at
death or post-mortem ﬁnding. Cases with a previous
diagnosis of cancer were excluded as well. Question-
naires were sent to the general practitioners (GP) for
a sample of patients, to validate diagnosis. We further
assessed the signs and symptoms at presentation
and ascertained referral/hospitalization status among
the incident cases of HF at time of diagnosis
(+/- 15 days).
Results: 19,194 incident HF patients were identiﬁed.
The unweighted incidence rate of permanent HF was
1.9 per 1000 person-years (95%CI: 1.88-1.94) and
was higher in men than in women. Incidence markedly
increased with age. The incidence was below 1 per
1000 person-years for individuals younger than
40 years old, and increased steeply after this age for
men and women, reaching 22.5 (95%CI: 21.6-23.3)
in elderly men over 79 years old and 17.4 (95%CI:
16.9-18.0) for elderly women the same age. A Vali-
dation study is still ongoing with more than 80% of
the questionnaires received. Review of the computer
proﬁles of HF patients showed that dyspnea/fatigue
was the most frequently recorded symptom at presen-
tation (35% of the cases), and for the majority of
cases (88%) the record of HF was accompanied with
information on symptoms, sings and diagnostic test
performed. At the time of diagnosis half of the patients
were managed by the GP only (54.1%), while 27.3%
were referred to a specialist and 18.6% had a related
hospitalization. There were no major differences in
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age and sex of patients with respect to their health care
status.
Conclusions: HF is a frequent condition among the el-
derly and women have a lower incidence rate than
men. In a UK care setting, at the time of diagnosis
ca. half of the patients are treated by the GP only.
845. Risk of Death in a Cohort of Newly Diagnosed
Heart Failure Patients
Ana Ruigomez,1 Luis A Garcia Rodriguez,1 Alexander
Michel.2 1CEIFE, Madrid, Spain; 2Global Epidemiology,
Bayer Pharma, Berlin, Germany.
Background: Data on mortality in an incident Heart
Failure (HF) cohort are sparse.
Objectives: To estimate the mortality rate among a co-
hort of incident HF patients compared with a cohort
free of HF from the general population.
Methods: We identiﬁed 19,194 patients aged 1-89
years with a 1st ever diagnosis of HF in 2000-2005,
using The Health Improvement Network database
(THIN) in the UK. Patients in whom the 1st HF diag-
nosis was recorded at death or patients with a previous
cancer diagnosis were excluded. The HF cohort and
the control cohort were followed-up until end of
2011. Comparison individuals were individually
matched (ratio 1:5) by exact age at start date, sex and
number of GP visits. Short term mortality (1st year)
and long-term mortality (among survivors at 1 year)
were evaluated in both cohorts. Cox proportional haz-
ards regression analyses was used to calculate hazard
ratio (HRR) of death compared with the general popu-
lation (control cohort), adjusted for age, sex, calendar
year, number of GP visits and referral in year prior,
smoking, alcohol consumption, body mass index and
socioeconomic indexes.
Results: The mortality rate in the HF cohort was 12.5/
100 person-years compared to 4.4 /100 person-years in
the comparison cohort (hazard rate ratio: 2.32 (95%CI:
2.24-2.40). During a mean follow-up period of
4.5 years, 56 % of patients (10,745) in the HF cohort
died.
Those patients cared by specialists without a hospi-
talization (at the time of HF 1st diagnosis) carried a
similar risk of mortality as those managed by GP only,
while patients hospitalized had an increased risk of
mortality (HRR: 1.40; 95%CI: 1.33-1.46) compared
to patients seen only in primary care setting.
Short-term mortality (1st year) in HF patients was
ca. 17 % and more than double compared to individ-
uals free of HF (HRR: 2.33; 95%CI: 2.19-2.49). The
long-term mortality excess risk among HF patients
was similar to the estimates during the 1st-year of fol-
low-up (HRR: 2.31; 95% CI: 2.22-2.41).
Conclusions: Patients with newly diagnosed HF have
a high risk of mortality during the subsequent years.
This excess mortality risk is constant over time and
more pronounced in patients who were hospitalized
close to the initial diagnosis.
846. Cardiac Dysfunction among Soft Tissue
Sarcoma Patients in Denmark
Sumitra Shantakumar,1 Morten Olsen,2 Mette Norgaard,2
Lars Pedersen.2 1Worldwide Epidemiology, GlaxoSmithKline,
Singapore, Singapore; 2Department of Clinical Epidemiol-
ogy, Aarhaus University, Aarhaus, Denmark.
Background: Soft tissue sarcoma (STS) patients may
experience cardiotoxicity following treatment with che-
motherapy, yet no population-based data are available.
Objectives: To examine the incidence of left ventricu-
lar ejection fraction (LVEF) decrease, heart failure,
and cardiac death following STS diagnosis.
Methods: Using the Danish Pathology Registry and
Danish National Patient Registry, we identiﬁed all
STS patients diagnosed at age 18+ years during
1998-2011 who visited the oncology department man-
aging STS patients in Western Denmark. Clinically
meaningful LVEF decline was deﬁned as a>=15%
absolute decline compared to baseline, or a>=10%
drop with the follow up LVEF below the lower limit
of normal, as seen on chart review and cardiac imag-
ing. These patients, and a separate nationwide cohort
diagnosed during 2000-2009, were followed from
STS diagnosis until heart failure diagnoses, cardiac
death, emigration or 2012, using the Danish National
Patient Registry and Causes of Death Registry. Predic-
tors for heart failure were examined using Cox propor-
tional hazards regression models.
Results: At STS diagnosis, 45% of patients were
60+ years. Before STS diagnosis, 191 (39 %) patients
had underlying cardiovascular disease, including hy-
pertension. 70 (14 %) patients had cardiac imaging
prior to and following chemotherapy, and 8 (11%)
of these patients experienced LVEF decrease.
Doxorubin treatment was the strongest predictor of
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heart failure (hazard ratio: 2.4 (95% CI:0.5-11)). In
the nationwide cohort (n = 1193), 41 (3%) developed
heart failure, and cardiac death was listed as a cause
of death for 15 (1.3%), during 5510 person years of
follow up.
Conclusions: Low cumulative incidences of heart
failure and cardiac-related deaths were observed in a
nationally representative cohort of Danish STS pa-
tients. The available data on LVEF decease may not
be generalizable to the entire STS population.
847. Risk of QT Prolongation Induced by Atypical
Antipsychotics: A Case-Control Study
Nam-Kyong Choi,1 Joongyub Lee,1 Bo Ram Yang,1,2
Ye-Jee Kim,2 Mi-Sook Kim,2 Xue-Mei Jin,2 Jungmee
Kim,2 Rae Woong Park,3 Jin-Ho Lee,4 Byung-Joo
Park.2,5 1Seoul National University Hospital and Seoul
National University College of Medicine, Seoul; 2Seoul
National University College of Medicine, Seoul; 3Ajou
University School of Medicine, Suwon; 4Dongguk Uni-
versity College of Medicine, Seoul; 5Korea Institute of
Drug Safety and Risk Management, Seoul.
Background: Although atypical antipsychotics
(AAPs) were suspected to cause QT prolongation
(QTP), epidemiologic investigations were limited due
to the lack of the digitalized electrocardiography data
for a large population. We performed a case-control
study aiming to quantify the risk of QTP related to tor-
sade de pointes (TdP) by use of AAPs.
Objectives: To evaluate the risk of QTP by SSRIs.
Methods: Electrocardiogram Vigilance with Elec-
tronic data Warehouse (ECG-ViEW) was used, which
was constructed for 710,369 ECGs of 371,401 patients
with diagnosis and laboratory data for all patients who
ever visited a teaching hospital in Korea over a 17-
year study period. We included patients with at least
2 ECG and heart rate between 31 ~ 155. Cases were
patients without QTP at baseline and with QTP at
follow-up, where QTP was deﬁned using the QT no-
mogram. For each case, up to four controls were
matched by age and gender. We evaluated exposure
to all marketed AAPs prior to QTP among cases and
controls. We considered QT prolonging medications,
comorbidities and the most recent laboratory data to
the follow-up ECG as possible confounders. We
calculated the adjusted odds ratio (aOR) and its 95%
conﬁdence intervals (CIs) using the conditional logis-
tic regression.
Results: A total of 6,541 cases were identiﬁed and
26,305 controls were matched to the cases. The crude
OR of QTP by AAPs was 4.3 (95% CI: 2.19-8.45) and
the adjusted OR was 2.9 (95% CI: 1.23-6.68).
Conclusions: The use of AAPs increased risk of QT
prolongation to the level which was related to the
incident TdP.
848. Cardiac Adverse Events Associated with
Macrolide and Fluoroquinolone Antibiotics
Yizhou Ye,1 Aisling R Caffrey.1,2 1Department of Phar-
macy Practice, University of Rhode Island, Kingston, RI,
United States; 2Infectious Diseases Research Program,
Providence Veterans Affairs Medical Center, Providence,
RI, United States.
Background: There are concerns regarding torsadogenic
risk with macrolides (MLs) and ﬂuoroquinolones
(FQs), which can lead to serious complications includ-
ing sudden cardiac death.
Objectives: We quantiﬁed the association of cardiac
adverse events (CAEs) with MLs and FQs in the
United States Food and Drug Administration Adverse
Event Reporting System (FAERS).
Methods: This retrospective case/non-case study used
FAERS data from 2004 to 2012. Cases were identiﬁed
with Medical Dictionary for Regulatory Activities
terms from reports of torsades de pointes, sudden car-
diac death, ventricular ﬁbrillation, tachycardia, long
QT syndrome, ventricular tachycardia, electrocardio-
gram QT prolongation, cardiac arrest, and bradycardia.
Other non-cardiac adverse events were considered
non-cases. We included initial, non-duplicate reports
with complete age, gender, and event date. ML or
FQ exposures were identiﬁed from either primary, sec-
ondary suspected or interaction drug ﬁelds. Crude
reporting odds ratio (ROR) and proportional reporting
ratio (PRR) were calculated for each drug.
Results: Over the 9-year period, MLs were listed in
146 cases (one case with two MLs): azithromycin 74
(AZI), clarithromycin 54 (CLA), and erythromycin
19 (ERY). FQs were listed in 335 cases (130 cases
with two FQs and one case with three FQs): oﬂoxacin
143 (OFL), levoﬂoxacin 132 (LEV), moxiﬂoxacin 116
(MOX), ciproﬂoxacin 69 (CIP), and 7 others for
norﬂoxacin and gemiﬂoxacin together. Odds of ML
exposure was signiﬁcantly greater among CAE cases
compared to non-cases: AZI, ROR 1.9, 95% conﬁdence
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interval [CI] 1.5-2.4, PRR 1.9, 95% CI 1.5-2.4; CLA,
ROR 1.9, 95% CI 1.4-2.5, PRR 1.9, 95% CI 1.4-2.4;
ERY, ROR 2.3, CI 1.5-3.6, PRR 2.3, 95% CI 1.4-3.5.
Odds of FQ exposure was higher for MOX (ROR 2.2,
95% CI 1.9-2.7, PRR 2.2, 95% CI 1.8-2.6), OFL
(ROR 1.6, 95% CI 1.4-2.0, PRR 1.6, 95% CI 1.4-1.9),
and LEV (ROR 1.4, 95% CI 1.2-1.6, PRR 1.4, 95%
CI 1.2-1.6). The ROR and PRR for CIP were non-
signiﬁcant.
Conclusions: All MLs and most FQs demonstrated an
elevated risk for CAEs. Monitoring of the safety
proﬁle of MLs and FQs should be continued and ben-
eﬁt-risk should be considered.
849. Pulse Pressure and Stroke Risk: Development
and Validation of a New Stroke Risk Model
Francis Vekeman,1 Rajeev Ayyagari,2 Patrick Lefebvre,1
Siew Hwa Ong,3 Elizabeth Faust,2 Alex Trahey,2
Gerardo Machnicki,4 Mei Sheng Duh.2 1Groupe
d’Analyse Ltée, Montréal, QC, Canada; 2Analysis
Group, Boston, MA, United States; 3Novartis Pharma
AG, Basel, Switzerland; 4Novartis Pharma AG, Buenos
Aires, Argentina.
Background: Previous stroke risk models identiﬁed
systolic blood pressure (SBP) as a key predictive fac-
tor. Recent evidence suggests that pulse pressure
(PP), deﬁned as the difference between SBP and dia-
stolic blood pressure (DBP), could be a contributing
risk factor beyond SBP.
Objectives: This study aims to develop and validate a
new stroke risk model incorporating PP as a potential
risk factor.
Methods: Electronic medical records, including
laboratory data, of hypertensive patients from a US
integrated health delivery system were analyzed
(01/2004-05/2012). Patients with ≥1 PP reading and
≥6months of observation (baseline period) prior to
the ﬁrst observed diagnosis of hypertension were ran-
domly split into the development (two-thirds of sam-
ple) and validation (one-third of sample) datasets.
Stroke events were identiﬁed using ICD-9-CM 433.
xx-436.xx. Cox proportional hazards models assessed
time-to-ﬁrst-stroke-event within 3-years of ﬁrst con-
ﬁrmed hypertension diagnosis based on baseline risk
factors, including PP, age, gender, diabetes, and
cardiac comorbidities. The optimal risk model was se-
lected using the least absolute shrinkage and selection
operator (LASSO); performance was evaluated by the
c-statistic.
Results: Among 34,797 patients selected (mean age
59.3 years old, 48% male), average duration of obser-
vation was 3.9 years, and 4,272 patients (12.3%) had
a stroke. PP was higher among patients who developed
stroke (mean [SD] PP, stroke: 62.0 [15.3] mmHg;
non-stroke: 58.1 [14.0] mmHg, p< .001). The best
performing risk model (c-statistic, development: 0.730;
validation: 0.729) included PP (hazard ratio per mmHg
increase: 1.0037, p< .001) as a signiﬁcant risk factor
for stroke in addition to age and diabetes, among others.
Conclusions: This stroke risk model shows that
greater PP is a signiﬁcant predictive factor for in-
creased stroke risk, even in the presence of known risk
factors. PP should be considered by practitioners along
with established risk factors in treatment strategies to
prevent stroke.
850. Impact of Concomitant Use of Proton Pump In-
hibitors and Dual Antiplatelet Therapy on Recurrent
Myocardial Infarction: A Population-Based Case
Cross-Over Study
Ye-Jee Kim,1 Nam-Kyong Choi,2 Jong-Mi Seong,3
Joongyub Lee,2 Mi-Sook Kim,1 Ju-Young Shin,3
Sun-Young Jung,3 Hong-Ji Song,4 Byung-Joo Park.1,3
1Department of Preventive Medicine, Seoul National
University College of Medicine, Seoul, Republic of
Korea; 2Medical Research Collaborating Center, Seoul
National University Hospital, Seoul, Republic of Korea;
3Korea Institute of Drug Safety and Risk Management,
Seoul, Republic of Korea; 4Department of Family Med-
icine, Hallym University Sacred Heart Hospital, Anyang,
Republic of Korea.
Background: Concomitant use of proton pump inhib-
itor (PPI) is recommended to reduce the gastrointesti-
nal bleeding events in high risk patients received
anti-platelet therapy. In recent years, some or all PPIs
might decrease the platelet inhibitory effects of anti-
platelet drugs there has been controversy about the
impact of clinical outcomes. Case-based design
accounted for confounding between patients such as
the genetic and functional variability in the hepatic
CYP P450 isoenzymes.
Objectives: To investigate the association between
use of PPI and risk of recurrent MI in patients
receiving dual anti-platelet therapy (DAPT) consisting
aspirin and clopidogrel.
Methods: We conducted a population-based case-
crossover study using the Korean Health Insurance
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Review and Assessment Service database in patients
aged 30 to 99 years old, received DAPT from January
1, 2008 to December 31, 2010 after hospitalization for
acute myocardial infarction (AMI). We identiﬁed
recurrent MI cases as principal and subsidiary diag-
nosis of hospitalization or emergency department
visit including AMI (I21) and subsidiary MI (I22).
For each case, PPI use in 14 day period prior to
the ﬁrst recurrent date for MI was compared with
PPI use in four earlier 14 day control period. Condi-
tional logistic regression was used to calculate odds
ratio (OR) and 95% conﬁdence interval (CI),
adjusting for concomitant medications that could
affect recurrent MI.
Results: We identiﬁed 43,822 AMI patients received
DAPT consisting aspirin and clopidogrel. Among the
AMI patients 3,583 cases were found. After adjust-
ment, use of PPI was associated with an increased
the risk of recurrent MI (adjusted OR 1.35, 95%CI,
1.05-1.75). In a stratiﬁed analysis, all PPIs except
pantoprazole increased the risk of recurrent MI (1.56,
95%CI, 1.16-2.10). However, the aORs of recurrent
MI for omeprazole, pantoprazole, lansoprazole, and
esomeprazole were not statistically signiﬁcant.
Conclusions: The study result suggests careful moni-
torings are needed when concomitant use of PPI in
AMI patients receiving DAPT particularly within
14 days after initiation.
851. Long-Term Evaluation of the Effectiveness of
Warfarin Interactions Prescription Warning System
in a Medical Center
Pili Chih-Min Mao,1 Mei-Ing Chung,1 Eric Kin-Lap
Lee,2 Pi-Lai Tseng.2 1Graduate Institute of Pharmaceuti-
cal Sciences, School of Pharmacy, Kaohsiung Medical
University, Kaohsiung, Taiwan; 2Department of
Pharmacy, Kaohsiung Veterans General Hospital,
Kaohsiung, Taiwan.
Background: When we reviewed warfarin and drug
interactions relevant literature, The majority of drug
interactions was not absolute hanged, recognized the
need to the clinical use, it is recommended the physi-
cian to adjust warfarin dose and regular monitoring,
especially these patients just start to take for a few
days or was stopped just now.
Objectives: We planned to assess the long-term effec-
tiveness of warfarin interactions prescription warning
system, and to explore the choices between different
specialists facing the alert.
Methods: Our study based on the prescription alert
system database of the Kaohsiung Veterans General
Hospital (VGHKS), a 1300 bed medical center for
the period 2007-2012. Either physician stopped to
use or changed the prescriber were considered
“acceptable”, they decided to use was considered
“rejected”. We tried to put the main related special-
ties (i.e. cardiology, cardiac surgery, neurology and
neurosurgery) and other divisions (non-specialist)
divided into two groups. Conduct an independent
sample t-test to compare the number of decision by
specialist and non-specialist. All the batch analysis
was managed and performed using the SPSS version
20 for Windows.
Results: Our study included 845 patients (510 men,
age median: 64.6 years; 335 females, age median:
62.4 years); total warning times were 6557; these only
once warning times were 552. The decision to accept
were 231 (41.8%); excluding these alert data only
once, the decision to accept after repeatedly reminded
the recipients were 440 (44.5%).
Conclusions: The aim to import prescription drug in-
teraction warning system is to alert physicians use
these drugs should be considered, and make comple-
mentary measures to both efﬁcacy and drug safety.
This study presents a systematic assisted by physicians
make effective decisions. We also understood the
choices facing the alerts were signiﬁcant differences
between different specialists. These results could
transform the computer warning system in the future.
852. Use of Warfarin and Risk of Stroke and
Mortality in Chronic Dialysis Patients with Atrial
Fibrillation in Taiwan
Chiu-Ying Chen, Tzu-Chieh Lin, Yea-Huei Kao
Yang. Institute of Clinical Pharmacy and Pharmaceuti-
cal Sciences, National Cheng Kung University, Tainan,
Taiwan.
Background: Atrial ﬁbrillation (AF) is common
among patients undergoing dialysis. Both AF and
end-stage renal disease increase the risk of stroke and
systemic thromboembolism. Although warfarin is
recommended for stroke prevention in general popula-
tion, the effectiveness and safety of warfarin in dialy-
sis patients remains controversial.
Objectives: To investigate the associations between
warfarin use and stroke and mortality in Taiwanese
chronic dialysis patients with AF.
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Methods: A retrospective cohort study was conducted
by identifying chronic renal failure patients with
regular dialysis from Taiwan’s National Health Insur-
ance Research Database (NHIRD) during 2001 to
2007. Patients aged 18 years and older were eligible
if having at least two diagnoses of AF within 90days in
outpatients and once in inpatients. Utilization of warfarin
was determined by any use of warfarin after AF
diagnosis, and was treated as a time-dependent variable
during follow-up period. The study outcomes included is-
chemic stroke, hemorrhagic stroke, combined endpoint of
any stroke, and mortality. The crude rate ratio and 95%
conﬁdence interval of each adverse outcome between
warfarin users and non-users was calculated.
Results: Among 3,695 dialysis patients with pre-
existing AF, 568 (15.37%) ﬁlled a prescription for
warfarin. Comparing 528 warfarin exposure and
3,524 warfarin non-exposure over 14,088 person-
years of follow up, warfarin use was not associated
with statistically signiﬁcant reduction in ischemic
stroke (RR 1.11; 95% CI 0.83 to 1.49), hemorrhagic
stroke (RR 1.08; 95% CI 0.77 to 1.53), combined end-
point of any stroke (RR 1.20; 95% CI 0.68 to 2.11),
and mortality (RR 0.59; 95% CI 0.27 to 1.28).
Conclusions: In this preliminary analysis, we found
no association between warfarin use and risk of stroke
and mortality among dialysis patients with AF. Further
analyses with adequately controlled confounders are
needed to determine the risk and beneﬁt of warfarin
therapy in these patients.
853. Risk of Peripheral Neuropathy for Dronedarone
Compared to Other Antiarrhythmics
Chuntao Wu,1 Stephanie Tcherny-Lessenot,2 Wanju Dai,1
Yunxun Wang,1 Hayet Kechemir,2 Laurent Auclert,2
Jasmanda Wu,1 Patrick Caubel,1 Juhaeri Juhaeri.1 1Global
Phamacovigilance and Epidemiology, Sanoﬁ, Bridgewater,
NJ, United States; 2Global Phamacovigilance and
Epidemiology, Sanoﬁ, Chilly-Mazarin, France.
Background: Dronedarone has been used in the U.S
since 2009 to treat atrial ﬁbrillation (AF) or atrial ﬂut-
ter (AFL). It is unknown whether dronedarone in-
creases the risk of peripheral neuropathy compared to
other antiarrhythmics.
Objectives: To evaluate whether dronedarone is asso-
ciated with higher risk of peripheral neuropathy than
other antiarrhythmics including amiodarone, sotalol,
ﬂecainide and propafenone.
Methods: In this retrospective cohort study, the
MarketScan database was used to identify patients with
AF or AFLwho were at least 18 years old and ﬁlled pre-
scriptions of antiarrhythmics between July 20, 2009 and
December 31, 2011. Patients excluded from the analysis
were those who had shorter than 6months of enrollment
or had been diagnosed with peripheral neuropathy in the
6months prior to the ﬁrst prescription. The exposure
was the use of antiarrhythmics identiﬁed using the
National Drug Code. Peripheral neuropathy, the
outcome of interest, that developed on treatment with
antiarrhythmics from cohort entry to the end of 2011
were ascertained using the ICD-9-CM diagnosis codes.
The incidence rate of peripheral neuropathy was calcu-
lated for each antiarrhythmic. Controlling for baselines
risk factors including age, sex, history of diabetes
mellitus and other comorbidities in Cox proportional
hazards modelling, adjusted hazard ratios (aHRs) for
peripheral neuropathy for dronedarone compared to
each of the other antiarrhythmics were obtained.
Results: A total of 106,933 patients were treated by
antiarrhythmics including dronedarone (n= 12,989),
amiodarone (n = 45,173), sotalol (n = 22,036), ﬂecainide
(n = 14,244) or propafenone (n= 12,491). The incidence
rates (per 1,000 person-years) of peripheral neuropathy
were 1.33 for dronedarone, 2.38 for amiodarone, 1.20
for sotalol, 1.08 for ﬂecainide, and 1.97 for propafenone.
The aHRs for peripheral neuropathy for dronedarone
relative to other drugs ranged from 0.53 (95% conﬁ-
dence interval (CI), 0.21-1.34) vs. propafenone to 0.94
(95% CI, 0.38-2.30) vs. sotalol. The P values for all
aHRs were> 0.05.
Conclusions: There was no evidence suggesting that
the risk of peripheral neuropathy with dronedarone
was higher than other antiarrhythmics.
854. Risk of New-Onset Diabetes in Users of Lipid
Lowering Drugs (LLDs)
Nobuhiro Ooba,1,2,3 Soko Setoguchi,2,4 Tsugumichi
Sato,3,5 Kiyoshi Kubota.2,3 1Clinical Pharmacy, The
Nihon University School of Pharmacy, Chiba, Japan;
2Pharmacoepidemiology, Faculty of Medicine, Univer-
sity of Tokyo, Tokyo, Japan; 3NPO Drug Safety Research
Unit Japan, Tokyo, Japan; 4Duke Clinical Research
Institute, North Carolina, United States; 5Pharmacy,
Faculty of Pharmaceutical Sciences, Tokyo University
of Science, Chiba, Japan.
Background: Statins may increase the risk of new on-
set diabetes in trial patients. Although results from
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observational studies were conﬂicting, most studies
failed to adjust for important confounders such as cho-
lesterol level (CHOL), blood pressure (BP), body mass
index (BMI), A1c and fasting blood glucose (FBG).
Objectives: To assess the association between LLDs
and new onset diabetes after adjusting for important
clinical parameters that might have confounded the
previous studies.
Methods: A retrospective cohort study for new users
of LLDs was conducted using claims data combined
with health screening data from several large private
health insurers (2005- 2011). The data from manda-
tory annual health screenings included CHOL, BP,
BMI, A1c and FBG. All subjects met criteria for hy-
perlipidemia (Tchol ≥220, LDL ≥140, HDL <40 or
TG ≥150mg/dL). Subjects with previous LLDs, anti-
diabetics, diagnosis of diabetes, HbA1c ≥6.5% or
FBG ≥126mg/dL were excluded. Exposure to LLDs
were categorized into high potency statins (atorva-
statin, pitavastatin, rosuvastatin), low potency statins
(ﬂuvastatin, simvastatin, pravastatin), ﬁbrates
(bezaﬁbrate, fenoﬁbrate). Incident diabetes was identi-
ﬁed as new antidiabetic use or diagnosis of diabetes.
Cox regression models were used to estimate the risk
of diabetes in new users of various LLDs compared
to hyperlipidemia patients with no LLD after adjusting
for all baseline data including laboratory data.
Results: Among 68,620 hyperlipidemic patients (mean
age 42, 70% male), 3,674 were new users of a low
potency statin (979), a high potency statin (2,208) or a
ﬁbrate (487). During the mean follow-up of 2 years,
3,206 new diabetes was identiﬁed. The incidence rate
per 1,000 person-years was 23 in non LLD users com-
pared to 99 to 133 in LLD users. In multivariate analy-
ses, the risk of diabetes was highest with high potency
statins (HR 2.8; 95%CI: 2.3-3.4) followed by ﬁbrates
(2.0; 1.2-3.2) and low potency statins (1.9; 1.4-2.7).
Conclusions: The use of LLDs was associated with
increase of risk of incident diabetes by 2 to 2.6 folds
in Japanese population. Further studies need to con-
ﬁrm the ﬁndings in other populations and assess the
risk in each LLD.
855. Development of a Collaborative European
Post-Authorization Safety Study (PASS) Program
ExaminingRivaroxabanUse inRoutineClinicalPractice
Luis García Rodríguez,1 Edeltraut Garbe,2 Irene
Bezemer,3 Deborah Layton,4 Kiliana Suzart-Woischnik,5
Gunnar Brobert,5 JesseAlderson,6 ChristopherWinchester,6
Ron Herings,3 Kathrin Jobski,2 Tania Schink,2 Saad
Shakir,4 Montse Soriano-Gabarró,5 Mari-Ann Wallander.7
1Spanish Centre for Pharmacoepidemiologic Research
(CEIFE), Madrid, Spain; 2Leibniz Institute for Epidemiol-
ogy and Prevention Research – BIPS GmbH, Bremen,
Germany; 3PHARMO Institute for Drug Outcomes
Research, Utrecht, Netherlands; 4Drug Safety Research
Unit, Southampton, United Kingdom; 5Bayer Pharma AG,
Berlin, Germany; 6Research Evaluation Unit, Oxford
PharmaGenesis Ltd, Oxford, United Kingdom; 7Depart-
ment of Public Health and Caring Science, Uppsala
University, Uppsala, Sweden.
Background: Pro-active, post-authorization monitor-
ing of drug safety is of increasing importance.
Rivaroxaban is a Factor Xa inhibitor with multiple in-
dications, including: treatment of venous thromboem-
bolism (VTE) and prevention of recurrent VTE;
stroke prevention in atrial ﬁbrillation; and prevention
of atherothrombotic events (when combined with anti-
platelet therapy) following an acute coronary syndrome.
The use of anticoagulants is associated with the risk of
bleeding, and monitoring of the safety proﬁle and pat-
terns of rivaroxaban use in routine care is required.
Objectives: To develop a PASS program that will
provide post-authorization data to characterize
rivaroxaban use and relevant safety events (intracranial,
gastrointestinal, and urogenital hemorrhage).
Methods: European sources of longitudinal obser-
vational healthcare data were identiﬁed that met
pre-deﬁned criteria: population-based data on demo-
graphics, comorbidities and co-medications; and medi-
cal charts for outcome validation. Additional studies
were designed to capture drug utilization and safety data
in primary and secondary care via physician question-
naire. With an emphasis on the consistent deﬁnition of
end-points, protocols were developed and tailored for
each study for submission to regulatory authorities and
relevant ethics committees.
Results: A PASS program of 6 studies was designed.
Drug utilization of rivaroxaban, followed by safety
and effectiveness, in comparison with standard of care,
are being assessed using The Health Improvement Net-
work (UK), the PHARMO Database Network (The
Netherlands) and the German Pharmacoepidemiological
Research Database. The program also includes 2 Spe-
cialist Cohort Event Monitoring studies to collect data
on short-term use from treatment started in secondary
abstract 459
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
care, and a Modiﬁed Prescription-Event Monitoring
study that evaluates long-term use in primary care.
Conclusions: This PASS program, with its unique and
complementary approach, will monitor and characterize
the real-world beneﬁt–risk proﬁle of rivaroxaban.
A ﬂexible design allows the accommodation of any
new indications for rivaroxaban approved during
the study.
856. Comparative Safety of New Oral Anticoagu-
lants in Nonvalvular Atrial Fibrillation – A Single
Medical Center Experience
Ying-Hsuan Lai,1 Chien-Huei Huang,2 Ching-Lan
Cheng,1 Yea-Huei Kao Yang.1 1Institute of Clinical
Pharmacy and Pharmaceutical Sciences, National
Cheng Kung University, Tainan, Taiwan; 2Department
of Pharmacy, National Cheng Kung University Hospital,
Tainan, Taiwan.
Background: New oral anticoagulants (NOACs) are
recommended as prevention of thromboembolism in
patients with atrial ﬁbrillation (AF) especially those
who cannot tolerate warfarin, but absence of head-to-
head studies makes it inappropriate to deﬁnitive on
which NOAC has less bleeding rate.
Objectives: The aim of this study was to compare
safety between dabigatran and rivaroxaban, includingma-
jor bleeding (cerebral, respiratory, gastrointestinal and uri-
nary hemorrhage), minor bleeding (bleeding events other
than major bleeding) and other adverse events.
Methods: We conducted a retrospective cohort study
in patients with nonvalvular AF and those who had
history of valvular disease or inadequate data were ex-
cluded. The patients were ﬁrst prescribed dabigatran
(110mg daily) or rivaroxaban (15mg daily) between
March 1,2013 to October 30, 2013 in one medical cen-
ter in Taiwan. Primary endpoint is the total bleeding
rate. Hazard ratios and conﬁdence intervals (CI) were
calculated with Cox proportional hazard model.
Results: In total, we reviewed 121 patients and 8 of
them were excluded. There are 56 patients (male,
57.1%) in dabigatran group and 57 (male, 52.6%) in
rivaroxaban. The mean (SD) age in dabigatran and
rivaroxaban group were 77.1 (7.92) and 74.8 (10.9);
mean (SD) CHADS2 score were 3.09 (1.54) and 3.0
(1.29), respectively. The baseline characteristics were
not signiﬁcantly different between the two groups.
The medium follow-up duration was 176.5 days in
dabigatran group and 136 days in rivaroxaban. The
crude rate of total bleeding is 19.1 per 100 person-years
in dabigatran group and 29.1 per 100 person-years in
rivaroxaban group; hazard ratio was 0.74 (95% CI,
0.22 to 2.46) in dabigatran group compared to
rivaroxaban. There were two (3.5%) major bleeding in
rivaroxaban group and one (1.8%) ischemic stroke in
dabigatran group. The rate of other adverse events was
19.6% in dabigatran grouop and 1.75% in rivaroxaban.
Conclusions: In current study, dabigatran seems to
have relatively lower bleeding rate than rivaroxaban
but short follow-up duration and small sample size
made the results underpowered.
857. Minor Bleedings and Associated Risk Factors
Within Patients Initiating Warfarin Therapy:
Population-Based Study
Stéphanie Dumas,1 Payman Shahabi,2 Étienne Rouleau-
Mailloux,3 Jean-Claude Tardif,4,5 Sylvie Perreault,1
Marie-Pierre Dubé.2,4 1Faculty of Pharmacy, University
of Montréal, Montréal, QC, Canada; 2Beaulieu-Saucier
Pharmacogenomics Centre, University of Montreal-
Montreal Heart Institute, Montreal, QC, Canada; 3Department
of Pharmacology, Faculty of Medicine, University of
Montreal, Montreal, QC, Canada; 4Montreal Heart
Institute, University of Montreal, Montreal, QC, Canada.
Background:Warfarin is a commonly prescribed oral
anticoagulant well known for its narrow therapeutic
index. Bleeding events are a constant source of
worries among patients taking warfarin and clinicians.
Major bleeding events have been largely studied in
the past, but less is known about minor bleeding
events.
Objectives: Our goal is to investigate the occurrence
of minor bleeding events as well as their potential
risk factors.
Methods: This study was based on a prospective co-
hort of new warfarin-users whose objectives are to as-
sess the genetic, clinical and environmental risks
associated with the effectiveness and safety of warfa-
rin. Data was collected on 880 patients who began
the treatment between May 1st, 2010 and Dec. 31st,
2012. Patients were followed-up each three months
for a year. The primary outcome was the occurrence
of a ﬁrst minor bleeding and secondary outcome was
the occurrence of a bleeding requiring a hospitaliza-
tion, as reported by the patient. In this preliminary
work, we used a Cox regression analysis.
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Results: Mean age was 71.1, 61.6% of patients were
men, 68.0% had a history of hypertension and 60.0%
of dyslipidemia and 78.3% had atrial ﬁbrillation as a
primary indication for warfarin. Overall, 41.6% of pa-
tients reported at least one event of bleeding and 7.4%
had a least one hospitalization following a bleeding
event. Factors associated with bleedings requiring a
hospitalization included CYP2C9*2 allele count (HR
2.07; 95%CI 1.21-3.53), Time in Therapeutic Range
(TTR) (HR 0.97; 95%CI 0.96-0.98), a history of
angina (HR 2.55; 95%CI 1.36-4.78) and weekly
consumption of green vegetables (HR 0.83; 95%CI
0.72-0.96). Factors associated with minor bleedings
included the TTR (HR 0.99; 95%CI 0.99-1.00) and a
history of angina (HR 1.50; 95%CI 1.15-1.97).
Conclusions: Preliminary data suggest that a low TTR
is not only an indicator for major bleedings, but also
an indicator for minor bleedings. We also observed
that the occurrence of minor bleedings was high and
it might have an impact on health-related costs and
quality of life of patients. Further analysis including
comedication will be completed.
858. Clinical Outcomes of Pharmacists Providing
Medication Education to Inpatients New on Warfarin
Therapy
Yu- Chun Hwang, Chuei- Fen Yee, Kuei-Ju Cheng,
YF Lee, YT Tsai, KL Chu, Cy Chen. Department of
Pharmacy, Taipei Medical University-Municipal
Wanfang Hospital, Taipei.
Background: Warfarin was approved in 1954, and
has become the most commonly used oral anticoagu-
lant worldwide over the past sixty years. The main ad-
verse effect associated with warfarin is bleeding and
thrombolytic events. The aim of this study was to de-
termine if pharmacists-provided patient education to
those initiating warfarin therapy have better clinical
outcomes than those who receive regular care before
discharge.
Objectives: The objective was to identify clinical out-
comes of pharmacists providing medication education
to inpatients new on warfarin therapy in Wang-Fang
hospital in Taiwan.
Methods: From Sep 2013 to Oct 2013, we enrolled
ﬁrst-time prescribed warfarin inpatients (N = 56) and
excluded patient who has history of taking warfarin,
age below 18 years old and has active cancer. Phar-
macists reviewed patient’s information and detail;
provided medication education concerning anticoagu-
lants and anticoagulation booklet were given .Question-
naire was performed to evaluate patient’s satisfaction.
Information related bleeding and thrombosis events were
collected and evaluated through telephone interviews
after patient were discharged about one month later.
Results: Warning signs of thrombosis events in
control group (educated by nurses) are more than phar-
macist education group (16 events versus 5 events).
Warning signs of bleeding between control group
and pharmacist education group was not signiﬁcant.
In pharmacist education group, result of questionnaire,
average 4.67 points (out of 5 points) in patients’
self-assessment and average 4.78 points (out of
5 points) in satisfaction evaluation. The secondary out-
come, TTRs (Time in Therapeutic Range) in control
group and education group was 27.3% and 24.1%
(p = 0.467) respectively.
Conclusions: The study showed that pharmacists
providing medication education cannot directly im-
prove TTRs but improve thrombosis events. The
overall patient knowledge towards anticoagulants
and satisfaction after pharmacist education was
high. Further study of larger population and longer
duration of continue follow-up is required to obtain
available and valuable results of inpatients pharma-
cists’ intervention.
859. Comparing Individual Angiotensin-Converting
Enzyme Inhibitors with Angiotensin Receptor Blockers
on the Risk of Pneumonia: ANationwide Cohort Study
Sheng-Yuan Ruan,1,2 Chia-Hsuin Chang,1,2 Yen-Chieh
Lee,3 Li-Chiu Wu,1 Mei-Shu Lai.1 1Institute of Preven-
tive Medicine, College of Public Health, National
Taiwan University, Taipei, Taiwan; 2Department of In-
ternal Medicine, National Taiwan University Hospital,
Taipei, Taiwan; 3Department of Family Medicine,
Cathay General Hospital, Taipei, Taiwan.
Background: Previous studies suggested that angio-
tensin-converting enzyme (ACE) inhibitors may de-
crease the risk of pneumonia comparing with other
antihypertensive treatments. However, the data about
head-to-head comparison for ACE inhibitors and an-
giotensin receptor blockers (ARB) remained limited.
Objectives: To evaluate the risk of pneumonia inci-
dence and mortality for different ACE inhibitors as
compared with a common reference group, losartan,
which has a similar indication as ACE inhibitors.
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Methods:We conducted a retrospective cohort study
using the Taiwan National Health Insurance Re-
search Database. Adult patients aged more than
20 years who initiated ACE inhibitors and losartan
between January 1, 2004 and December 31, 2009
were identiﬁed. The measured outcomes were hospi-
talized pneumonia and pneumonia-related mortality.
Participants were followed from treatment initiation
to the earliest of outcome occurrence, death or
disenrollment from the National Health Insurance,
treatment discontinuation or switching to other
ACE inhibitors or ARBs, or December 31 2010. Cox
proportional hazards regressionmodel was used to calcu-
late the hazard ratios (HR) and their 95% conﬁdence
intervals (95% CI).
Results: A total of 1,192,082 ACE inhibitors initiators
and 175,668 losartan initiators were included. The
mean treatment duration ranged from 35.2 days for
captopril, to 87.3 days for imidapril, and 96.2 days
for losartan. In the multivariable regression analysis,
the risk of hospitalized pneumonia was signiﬁcantly
higher for captopril (adjusted HR 1.94; 95% CI: 1.82 -
2.07), enalapril (aHR 1.14; 95% CI: 1.07 - 1.22),
fosinopril (aHR 1.11; 95% CI: 1.02 -1.21), perindopril
(aHR 1.14; 95% CI: 1.04 - 1.25), and ramipril (aHR
1.11; 95% CI: 1.02 - 1.22), as compared with losartan.
Captopril was also associated with a signiﬁcantly in-
creased risk of pneumonia mortality (aHR 2.43; 95%
CI: 1.79 - 3.31).
Conclusions: Treatment with ACE inhibitors is not
associated with a lower risk of pneumonia incidence
and mortality comparing with losartan.
860. Does Use of Angiotensin Converting Enzyme
Inhibitors or Angiotensin Receptor Blockers
Decrease the Risk of Incident Active Tuberculosis
Disease? A Nested Case-Control Study on a
National Health Claim Database
Meng-tse Gabriel Lee,1 Shih-Hao Lee,1 Yi-Hsian Lin,1
Chien-Chang Lee.1,2 1Department of Emergency
Medicine, National Taiwan University Hospital, Taipei,
Taiwan; 2Department of Emergency Medicine and De-
partment of General Medicine, National Taiwan Univer-
sity Hospital Yunlin Branch, Taipei, Taiwan.
Background: Tuberculosis (TB) is one of the most
important global health issues. Our goal is to evaluate
new drugs to prevent the onset of TB.
Objectives: To evaluate whether the use of angioten-
sin converting enzyme inhibitors (ACEis) or angioten-
sin receptor blockers (ARBs) decrease the risk of
incident active TB disease.
Methods: A Nested case control study was carried out
using the claims data from National Health Insurance
Research Database (NHIRD) of Taiwan. 1 million pa-
tients from the NHIRD were longitudinally followed
from January 1997 to December 2011. New onset of
active TB was deﬁned as, the record of the ﬁrst diag-
nostic codes of TB plus the prescription of more than
two anti-TB medications for more than 28 days.
Results: 7,720 cases of new active TB (59.4 cases per
100,000 person-year) and 772,000 controls were iden-
tiﬁed. Current use, but not recent and past use of
ACEis was associated with a decreased risk of devel-
oping TB, with a disease risk score adjusted rate ratio
[ARR] of 0.87 (95% CI, 0.78 – 0.97). Consistently,
higher current cumulative days of ACEis usage
was associated with further decrease in the risk of
active TB ( P< 0.0001). Current use of ACEis only
signiﬁcantly decreased the risk of active TB onset
for patients >70 years old, with a disease risk score
[ARR] of 0.90 (95% CI, 0.81 – 0.99). However,
current use of ARBs, which is a similar drug as
ACEis in lowering blood pressure, did not signiﬁ-
cantly decrease risk of active TB, the disease risk
score [ARR] is 0.93 (95% CI, 0.83 – 1.04).
Conclusions:We are the ﬁrst group to report the novel
ﬁnding that current use of ACEis but not ARBs may
be associated with a decreased risk of active TB. This
data supports the current view that ACEis can decrease
the rate of pneumonia by improving the cough reﬂex.
Hence, it might be more beneﬁcial for elderly Chinese
patients with cardiovascular problems to use ACEis
instead of ARBs. However, more studies are necessary
before recommending ACEis to other patients at high
risk of TB.
861. Does Use of Calcium Channel Blockers Affect
the Risk of Incident Active Tuberculosis Disease?
A Nested Case Control Study on a National Health
Claim Database
Meng-tse Gabriel Lee,1 Yi-Hsian Lin,1 Shih-Hao Lee,1
Chien-Chang Lee.1 1Department of Emergency Medi-
cine, National Taiwan University Hospital, Taipei; 2De-
partment of Emergency Medicine and Department of
General Medicine, National Taiwan University Hospital
Yunlin Branch, Douliou.
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Background: It is World Health Organization’s
Global Plan to eradicate Tuberculosis (TB) disease
by the year of 2050, but it is difﬁcult to achieve that
goal by the current rate of infection decrease. Our goal
is to evaluate whether calcium channel blocker, an
existing cardiovascular drug can affect the onset of
active TB.
Objectives: To evaluate whether the use of calcium
channel blockers (CCBs) affect the risk of incident ac-
tive tuberculosis disease.
Methods: A nested case control study was carried out
using the claims data from National Health Insurance
Research Database of Taiwan from January 1997 to
December 2011. Index date referred to the ﬁrst date
of TB diagnosis. Patients with CCBs exposure were
deﬁned by receiving ≥ 7 days of prescription ending
in 3 different time frames. First, current use, refer
to prescription that ended within 30 days of the
index date. Second, recent use, refer to prescription
that ended 31 to 90 days prior to the index date.
Third, past use, refer to prescription that ended
between 91 days and 1 year prior to the index date.
Multivariate regression and a disease risk score
(DRS) technique were used to calculate risk of
active TB disease.
Results: From a cohort of one million patients with
13 years follow-up, 7164 cases of new active TB
and 716,400 controls were identiﬁed. Decrease in
the risk of active TB is inversely proportional to
the time from the last use of calcium channel
blockers. Patients under current use of CCBs had
28% lowered DRS adjusted decrease (0.72; 95%
CI, 0.66 – 0.78) in risk of active TB, while recent
use of CCBs had 12% lowered DRS adjusted
decrease (0.88; 95% CI, 0.77 – 0.99) in risk of
TB. However, past use of CCBs had no statistical
signiﬁcant inﬂuence on risk of active TB.
Conclusions: Our novel results suggest that current
and recent use of calcium channel blockers decrease
the risk of active TB. However, more studies are re-
quired to validate our results before recommending
CCBs to cardiovascular patients at high risk of TB.
862. Is Statin Use Associated with Reduced Risk of
Incident Active Tuberculosis? A Population-Based
Nested Case-Control Study
Chien-Chang Lee,1,2,3 Shih-Hao Lee,1 Yi-Hsian Lin,1
Meng-tse Gabriel Lee.1 1Department of Emergency
Medicine, National Taiwan University Hospital, Taipei;
2Department of Emergency Medicine and Department
of General Medicine, National Taiwan University Hospi-
tal Yunlin Branch, Douliou; 3Department of Epidemiol-
ogy, Harvard School of Public Health, Boston.
Background: Statins possess non-lipid-lowering
properties that mitigate inﬂammatory pathways. Re-
cent epidemiological data suggest that statins improve
clinical outcomes of pneumonia.
Objectives: To determine whether statin therapy is
associated with decreased risk of active tuberculosis (TB).
Methods: We conducted a nested case-control study
using the claims data from National Health Insurance
Research Database of Taiwan from January 1997 to
December 2011. Cases were deﬁned as incident TB
during, sampled. One hundred controls were selected
to match each case on age and sex by using risk-set
sampling scheme. We classiﬁed the use of statins into
current (<30 days), recent (31 to 90 days), and past
(>90 days) based on the time between new TB diag-
nosis and statin prescription. We used multivariable
conditional logistic regression model to estimate rate
ratios (RRs) after adjusting for individual confounding
variables or a summary disease risk score. Stratiﬁed
analyses by preplanned susceptible subgroups were
conducted for potential effect modiﬁers.
Results: From a cohort of 1 million patients, a total of
8098 cases and 809,800 controls were examined. The
mean age was 60.3 years, and the majority of patients
were male (68%). On crude analysis, statin therapy
was associated with decreased incidence of active TB
(RR: 0.78; 95% CI: 0.66 – 0.91). This inverse associ-
ation remained signiﬁcant after adjusting for demo-
graphic characteristics, cardiovascular and respiratory
comorbidities, intensity of health service utilization,
and use of various medications. (RR: 0.76, 95%CI:
0.65–0.90). Recent use or past use was associated
with attenuated protective effects. Longer duration of
statin use was associated with signiﬁcant incremental
protective effect (trend P = 0.027). Age or gender did
not appear to modify the effect of statin on active TB.
Conclusions: The use of statins was associated with an
approximately 25% reduction in the risk of active TB.
However, the precise effect of statins on active TB re-
mains unclear due to concerns about a “healthy-user” ef-
fect and residual confounding by variables that are
frequently absent from administrative datasets.
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863. Impact of Diuretic Use on Serum Urate Level
in the Febuxostat Versus Allopurinol Streamlined
Trial (FAST)
RobertW Flynn,1 Claudine G Jennings,1 Isla SMackenzie,1
George Nuki,2 Ian Ford,3 Thomas M MacDonald.1 1Medi-
cines Monitoring Unit, University of Dundee, Dundee,
United Kingdom; 2University of Edinburgh, Edinburgh,
United Kingdom; 3Robertson Centre for Biostatistics,
University of Glasgow, Glasgow.
Background: The use of some diuretics is cautioned
in gout as they can increase serum urate and worsen
symptoms. FAST is an international randomised trial
in gout patients at cardiovascular risk.
Objectives: To determine the level of diuretic use and
their impact on serum urate level in patients screened
for FAST.
Methods: This study used cross-sectional data col-
lected at screening as part of FAST. Patients were re-
cruited from 6 regions of the UK and Southern
Denmark. Eligible patients are aged 60 or over with
at least one additional cardiovascular risk factor and
take allopurinol for chronic hyperuricaemia. Patients
were classiﬁed as receiving thiazide, loop, “other” or
no diuretics. The primary outcome measure was serum
urate measured in μmol/L at screening. The propor-
tions of patients receiving diuretics are given as
percentages. A regression model was used to model
serum urate adjusted for other lifestyle & medical fac-
tors collected at baseline. The proportion of patients
with controlled serum urate (<357μmol/L) was
compared between diuretic users and non-users with
a χ2-test.
Results: By January 2014, 1490 patients had been
screened & were eligible for FAST. Of these 38.7%
were taking a diuretic (23.4% on thiazide, 17.0% on
loop & 5.4% on “other” diuretics with some using
more than one of each). Patients on diuretics had
higher serum urate at baseline than then non-users
(349 vs 322μmol/L; p< 0.0001) a difference of
26.3μmol/L (95% CI 17.7 to 34.8). In a multivariate
analysis, compared to no diuretic use, thiazide use
was associated with a 25.5μmol/L (95% CI 17.5 to
33.5) higher serum urate, loop diuretics 30.4μmol/L
(95% CI 20.7 to 40.0) & other diuretics 5.7μmol/L
(95% CI -8.9 to 20.3). Covariates signiﬁcantly associ-
ated with serum urate were allopurinol dose, BMI, age,
sex, renal impairment & losartan use. 42.6% of pa-
tients on diuretics had uncontrolled serum urate at
baseline compared to 31.0% of patient not on diuretics
(p< 0.0001).
Conclusions: Thiazide and loop diuretic use was asso-
ciated with increased serum urate. Despite being cau-
tioned for use in gout, these drugs are widely used in
this patient group with an associated worsening of
serum urate control.
864. Is There Less Interaction with Atorvastatin and
Rosuvastatin?
Baptiste Demailly, Malak Abou Taam, Marie-Laure
Duchenois, François Krabansky, Marie-Paule Roux,
Thierry Trenque. Regional Center of Pharmacovigilance
and Pharmacoepidemiology, Reims University Hospitals,
Reims, France.
Background: Statins are used in hypercholesterol-
emia and have adverse effects on skeletal muscle.
The symptoms of these effects range from slight
myalgia to severe rhabdomyolysis. Rhabdomyolysis
precipitated by multitherapy is most frequently de-
scribed during those treatment, due to impairment of
statin clearance by drugs sharing cytochrome P450
biotransformation pathway. Some statins like atorva-
statin and rosuvastatin are presented as having little
potential for drug interaction.
Objectives: To analyze each cases of rhabdomyolysis
under statin and assess the interaction potential of each
one which can lead to the rhabdomyolysis.
Methods: We used a retrospective and descriptive
study in the French PharmacoVigilance Database
(FPVD). Cases were all the observations with the
LLT term “rhabdomyolysis” registered into the FPVD
from Jan 1985 to Jan 2014. Interaction assessment was
realized according to the French Summary Medical
Product.
Results: 1600 reports of rhabdomyolysis was recorded
between 1985 and 2014, 506 are with statins (31.6%).
The mean age is 64.2 ± 13.3. Sex ratio is 1.72. Out-
come is mostly reported as recovered (356 cases), as
recovering (71 cases), or not recovered (61 cases), 35
deaths were reported and 24 are unknown. We noted
49 drug interactions, mostly with fusidic acid (20%),
colchicine (17%), cyclosporine and amiodarone (13%
each). Drug interaction is suspected in 24% (n = 12).
Interaction is possible in 37 (76%). We have 21 cases
of acute renal failure (ARF) added to rhabdomyolysis.
Among these 49 cases, the statin most implicated is
abstract464
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
simvastatin (44.6%), rosuvastatin (26.8%), atorva-
statin (17.8%), ﬂuvastatin (7.1%) and pravastatin
(3.6%). In the top sailed ranking, between 2008 and
2012, in France, there are ﬁrstly atorvastatin and the
last one is rosuvastatin.
Conclusions: We can see a difference between ex-
pected and reported drug interactions. ARF can lead
to rhabdomyolysis but it can be also induced by this
adverse event. More accuracy in those observations
is necessary to evaluate them. Anyway, we can ob-
serve signiﬁcant interaction with rosuvastatin which
is also the last commercialized statin. Better knowl-
edge of drug interaction is needed and caution is es-
sential whatever the statin.
865. Early Intervention of Skin Toxicities by
Panitumumab and Clinical Outcomes in the Clinical
Setting
Hagit Bergman,2 Tara Walton,4 Ryan Del Bel,3 Jack
Seki,6 Wei Xu,3 Gideon Koren,2 Neil Shear,5 Monika
Krzyzanowska,1,4 Doris Howell,4 Geoffrey Liu.1,4 1Med-
ical Oncology and Hematology, Princess Margaret
Cancer Centre, University Health Network, Toronto,
ON, Canada; 2Pharmacology and Toxicology, Univer-
sity Health Network, Toronto; 3Department of Biostatis-
tics, Princess Margaret Cancer Centre, Toronto;
4Ontario Patient Reported Outcomes of Symptoms and
Toxicity (ON-PROST), Princess Margaret Cancer Centre,
Toronto; 5Dermatology, Sunnybrook Hospital, Toronto;
6Pharmacy, Princess Margaret Cancer Centre, Toronto.
Background: Dermatologic toxicities from panitu-
mumab can interfere with consistent cancer treatment.
While treatment algorithms have been proposed for
managing dermatologic toxicities, they are only strin-
gently followed within a clinical trial setting.
Objectives: We assessed the impact of early versus
late intervention of rash by initial grade in a cohort
of patients treated outside of a clinical trial setting.
Methods: We evaluated retrospectively the assessment
andmanagement of skin toxicities related to panitumumab
in a consecutive cohort of patients receiving panitumumab
for the treatment of metastatic colorectal cancer outside of
a clinical trial from April 2009-August 2012.
Results: Of 34 patients, 32 (94%) had a reported
panitumumab-related skin toxicity (papulopustular
rash). 85% developed the rash by the end of the second
infusion cycle. A severity grading system was reported
for 65% of patients: 31% used the CTCAE grading
system, while 34% used mild/moderate/severe termi-
nology; the remaining 34%, grading was performed
by rash description in medical records. Rash was not
related to clinicodemographic data. Among patients
who initially presented with a mild rash (41%), the ma-
jority progressed when just observed without interven-
tion, but all who received at least topical ointment
(steroids or antimicrobial) remained stable or improved.
The majority of patients presenting with a moderate rash
(38%) were likely to get worse if they did not receive
oral antimicrobials. Alternatively, among those present-
ing with a severe rash (21%), all improved to moderate
rash after receiving oral antimicrobials (+/- topicals)
but dose reductions and delays were also required.
Conclusions: Dermatologic toxicities related to
panitumumab are common. Early intervention, even
with mild rash, reduces the risk of progression to more
severe grades of skin toxicities.
866. Do Pharmaceutical Claims Accurately Reflect
Oncology Prescribing Practice: Evidence from an
Australian HER2+ Early Breast Cancer Cohort
(HER2EBC)
Carole Harris,1 Benjamin Daniels,1 Robyn Ward,1 Sallie-
Anne Pearson.2 1Prince of Wales Clnical School, The
University of New South Wales, Sydney, NSW, Australia;
2Pharmacy, The University of Sydney, NSW, Australia.
Background: Pharmaceutical claims are used increas-
ingly to investigate the real-world use of prescribed
medicines. Claims databases are established for pay-
ment purposes, lack clinical data and only capture pre-
scriptions for which insurers pay a contribution.
Objectives: We compare Pharmaceutical Beneﬁts
Scheme (PBS) dispensing claims with prescriptions
written in oncology clinics to determine the accuracy
of dispensing data to: identify treatment protocols; es-
timate treatment cycles; estimate duration of therapy.
Methods: Our cohort comprised 110 female
HER2EBC patients commencing treatment at 4 Syd-
ney cancer centres between 2008 and 2011. Patients
consented to medical chart audit and linkage to PBS
claims. We constructed protocols from prescribing
and dispensing records independently, based on the
timing of trastuzumab and cytotoxic treatments;
estimated the median number of treatment cycles and
duration of therapy by protocol; and compared pre-
scription and dispensing data.
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Results: The median age of the cohort was 53 years
(range 21.1-86.2). Based on prescribing data, 67 pa-
tients received anthracycline-containing protocols, 43
received taxane only protocols. ACTH and TCH
accounted for 90% of all protocols. 75 patients
(68.2%) were assigned the same protocols based on
prescribing and claims data; 26 did not match as cyclo-
phosphamide falls below the patient copayment for
general PBS beneﬁciaries and is not captured in the
claims data. Compared with prescription data, number
of treatment cycles was underestimated in dispensing
data (ACTH: median 30 vs 44; TCH 26 vs 29);
trastuzumab-based treatment is administered weekly
in ACTH but only dispensed 3-weekly. Durations of
therapy differed by ≤5% in dispensing versus prescrip-
tion data (ACTH 422 days vs 466; TCH 368 vs 367).
Conclusions: PBS dispensing data is reliable for
establishing treatment protocols in concessional
beneﬁciaries and duration of therapy in all patients.
Claims data underestimates treatment cycles as
administration occurs more frequently than dispens-
ing. These limitations must be considered when
undertaking population-based studies using claims
data in HER2EBC.
867. Analysis of Human Recombinant Somatropins,
Erythropoietins and Granulocyte Colony Stimulat-
ing Factors in Pharmaceutical Formulations
Jia-Chuan Hsu, Bo-Yin Lai, Der-Yuan Wang, Daniel
Yang-Chih Shih. Division of Research and Analysis,
Food and Drug Administration, Ministry of Health and
Welfare, Taipei City, Taiwan.
Background: The quality, safety and efﬁcacy of
biopharmaceuticals are highly dependent on the pro-
cess of production, puriﬁcation and formulation.
Objectives: The aim of this project is to establish rou-
tine and robust methods for analyzing recombinant
proteins such as somatropins (growth hormone), eryth-
ropoietins (EPO), and granulocyte colony stimulating
factors (G-CSF) in pharmaceutical formulations,
biosimilars, and counterfeits.
Methods: Five somatropin, two EPO, and three
G-CSF products including one biosimilar and one prod-
uct in clinical trial from manufacturers were tested by
several analytical methods according to the Minimum
Requirement for Biological Products I & II (Taiwan
FDA), United States Pharmacopeia (USP) 35 edition
and European Pharmacopeia (EP) 7.0th edition. The
methods include peptide mapping, RP-HPLC, isoelectric
focusing (IEF), size-exclusion chromatography, capil-
lary electrophoresis, SDS-PAGE, native PAGE, western
blot, potency assay, and bacterial endotoxin test.
Results: Our data showed that the qualities of tested
products were all corresponding to the requirements
of USP, EP or in-house speciﬁcations. However, some
compendial analytical methods may not be suitable for
analyzing particular formulations or glycoproteins so
these methods need to be modiﬁed slightly or we had
to conﬁrm these testing results by in-house methods.
Conclusions: We have established standard test proce-
dures for recombinant proteins and we hope these analyt-
ical tools could also apply to the identiﬁcation of the
counterfeits and biosimilars andmake an effort to monitor
the long-term stability of biopharmaceuticals in the future.
868. Hepatotoxicity with Pazopanib for Renal Cell
Carcinoma in the Post-Approval Setting
Sumitra Shantakumar,1 Beth Nordstrom,2 Luc Djousse,3
Susan A Hall,4 Myrthe van-Herk Sukel,5 Kathy Fraeman,2
David R Gagnon,3 Karen Chagin,1 Jeanenne J Nelson.1
1Worldwide Epidemiology, GlaxoSmithKline, Singapore;
2Evidera, Lexington, United States; 3VA Healthcare,
Boston; 4NERI, Watertown; 5PHARMO, Utrecht.
Background: Clinical trials of pazopanib for treat-
ment of advanced renal cell carcinoma indicated a risk
of hepatotoxicity.
Objectives: To quantify the hepatic safety of
pazopanib in clinical practice across the ﬁrst four years
post-approval.
Methods: A sequential cohort study of new users of
pazopanib was conducted in three electronic health re-
cord (EHR) databases: the US Department of Veterans
Affairs (VA), the Altos outpatient oncology clinic
database, and the PHARMO database from the
Netherlands. Each data holder conducted analyses of
liver chemistry elevations during use of pazopanib.
Suspected Hy’s Law and drug-induced liver injury
outcomes were investigated via chart review, with ad-
judication by a committee of hepatologists using
methods established by the Drug Induced Liver Injury
Network. Periodic regulatory reports provided sum-
mary statistics on cumulatively accrued patients.
Results: A total of 156 from Altos and 243 pazopanib
users from the VA qualiﬁed for the analysis;
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PHARMO contained too few users for inclusion in the
ﬁnal analyses. ALT elevations >3x upper limit of nor-
mal (ULN) occurred at rates of 19.7 (95% conﬁdence
interval 16.7-23.1) per 100 person-years (py) in Altos
and 25.9 (22.4-29.7) per 100py in the VA; correspond-
ing rates of ALT >8xULN were 8.2 (6.9-9.6) per
100py and 2.1 (1.8-2.4) per 100py. Incidence of total
bilirubin elevations >1xULN was 40.3 (34.2-47.3) per
100py in Altos and 38.0 (32.9-43.7) per 100py in the
VA. Total bilirubin ≥2xULN occurred at 8.1 (6.8-9.4)
and 6.5 (5.6-7.5) per 100py in Altos and the VA, respec-
tively. There were no conﬁrmed Hy’s law-related
drug-induced liver injury events.
Conclusions: Severe liver chemistry elevations oc-
curred infrequently during pazopanib exposure, and
no cases of pazopanib-associated drug-induced
liver injury were observed over the four years of
patient accrual. This study illustrates an innovative
approach to ensure the timely dissemination of
safety monitoring results to regulators for a newly
approved oncology medication.
869. A Systematic Review of Progressive Multifocal
Leukoencephalopathy Case Reports Associated with
Monoclonal Antibody Treatment
Alicia Brunssen, Niklas Schmedt, Edeltraut Garbe.
Leibniz Institute for Prevention Research and Epidemi-
ology - BIPS GmbH, Bremen, Germany.
Background: In HIV-negative patients, progressive
multifocal leukoencephalopathy (PML) has been asso-
ciated with the use of monoclonal antibodies (MABs)
such as natalizumab, efalizumab and rituximab.
Objectives: To assess the characteristics of HIV-negative
PML cases associated with MAB treatment.
Methods: We conducted a systematic review of PML
case reports in HIV-negative patients treated with
MABs that were published in Medline between
January 1st, 1985 andMay 21st, 2013. Only cases ﬁtting
the highest level of diagnostic certainty according to
Mentzer et al. were considered. Data on baseline charac-
teristics, underlying diseases, immunosuppressive drug
(ID) treatment and PML treatment were assessed. In ad-
dition, we carried out a causality assessment according
to the WHO causality assessment system.
Results: Of 182 included PML cases reported in 90 ar-
ticles, 51.7%were female. The median age was 47 years.
Death was noted in 48.9%. Frequently reported
underlying diseases were multiple sclerosis (48.4%),
lympho- and myeloproliferative disorders (29.7%), trans-
plantations (13.2%) and rheumatic diseases (7.7%). Prior
to PML symptoms, treatment with natalizumab (49.5%),
rituximab (39.6%) and efalizumab (4.4%) was frequent.
Further reported MABs were inﬂiximab, alemtuzumab,
basiliximab, brentuximab vedotin, ibritumomab tiuxetan,
adalimumab and cetuximab. Other frequently used
IDs included cyclophosphamide, prednisone, metho-
trexate, vincristine, mitoxantrone and azathioprine.
The causality assessment revealed a probable causal
relationship in 57.8% of all natalizumab-associated
cases. In contrast, only possible relationships were
found for rituximab, efalizumab, brentuximab
vedotin, inﬂiximab, alemtuzumab, basiliximab and
ibritumomab tiuxetan. Commonly reported PML
treatments were plasmapheresis (43.4%), meﬂoquine
(33.0%) and mirtazapine (30.8%).
Conclusions: Probable relationships were only found
for natalizumab, since other IDs and underlying dis-
eases were often considered as alternative causes in
the causality assessment of other MABs. The role of
such interactions has to be investigated more closely
in further research on PML.
870. Adverse Reactions Associated To Biologics for
Psoriasis in Brazil
Luciane Cruz Lopes,1 Miriam Sanches Silviera,2 Claudia
Garcia Serpa Osorio-De-Castro,3 Tatiana Chama
Borges,4 Gordon Henry Guyatt.5 1Pharmaceutical
Science, University of Sorocaba, Sorocaba, Sao Paulo,
Brazil; 2Pharmaceutical Science, University of Sorocaba,
Sorocaba, Sao Paulo, Brazil; 3Núcelo de Assistência
Farmacêutica, Escola Nacional de Saúde Pública Sérgio
Arouca -, Fundação Oswaldo Cruz – Fiocruz, Rio de
Janeiro, Brazil; 4Laboratório de Educação em Saúde e
Ambiente, Centro de Pesquisas René Rachou, Fundação
Oswaldo Cruz – Fiocruz, Belo Horizonte, Minas
Gerais, Brazil; 5Department of Clinical Epidemiology
and Biostatistics, McMaster University, Hamilton, ON,
Canada.
Background: The safety of biological agents used for
treatment of psoriasis remains uncertain.
Objectives:We determined the frequency and severity
of adverse effect associated with use of biologic agents
for psoriasis obtained by lawsuits to the government of
Sao Paulo, Brazil.
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Methods: Using a descriptive cross-sectional design,
study sources of information included legal records,
dispensing pharmacy data and interviews with patients.
Research staff conducted telephone interviews with
patients suffering from psoriasis (ICD-L40) who used
biologic drug during the study period (2003 – 2010),
inquiring about [Outcome] any apparently medica-
tion-related adverse drug reactions (ADRs) or serious
adverse reactions (SAEs). The association of predis-
posing factors for ADRs was analyzed using logistic
regression analysis with the dependent variable being
the presence or absence of ADRs.
Results: Of the 218 patients identiﬁed, 15 proved inel-
igible; we interviewed 203 patients. From this total of
patient, 111 (54.7%) were taking inﬂiximab, 43
(21.2%) efalizumab, 35 (17.2%) etanercept and 14
(6.9%) adalimumab. Of the 203 patients 84 (41.4%)
experienced one or more adverse events related to bio-
logical agents (1.6 events/patients who had an event)
and of these 57 (67.9%) experienced one or more
SAE. We found no signiﬁcant associations of age,
public vs private health care, adequate vs inadequate
clinical follow up, or adherence to guidelines with oc-
currence of ADR. The risk of ADR was increased
when patients had one or more versus no comorbidity
OR= 6.54 (95% IC 3.20-13.32), p< 0.0001.
Conclusions: Biologic agents were associated with
high rates of ADRs, withdrawals due to adverse events
and SAEs. Patients contemplating use of biologic in-
terventions should be aware of these risks and should
undergo careful monitoring in the ﬁrst months of ther-
apy to avoid deterioration in the face of early manifes-
tations of an ADR. Our data suggests in patients with
comorbidity, warnings of possible adverse events and
enhanced surveillance is warranted.
871. HER2 Positive Early Breast Cancer
(HER2EBC): An Australian Patterns of Care Study
Carole Harris, Sallie-Anne Pearson, Ben Daniels, Robyn
Ward. , The University of New South Wales, Sydney,
NSW, Australia.
Background: Clinical trials have demonstrated the ben-
eﬁts of trastuzumab in treating HER2EBC. However, in
routine care it is unclear which patients are recommended
treatment, what chemotherapy partners are used and
whether patients receive all of their intended treatments.
Objectives: In this study we describe real world treat-
ment patterns in HER2EBC patients.
Methods: We undertook a clinical audit of patients di-
agnosed with HER2EBC (stage I-III) at 4 Sydney-based
cancer centres between 2008 and 2011. We identiﬁed
patients from pathology records and extracted informa-
tion on patient and cancer characteristics, treatments
planned and received from medical notes and medica-
tion charts.
Results: 203 patients formed the study cohort; median
age 55 years (range: 21-91), all but one patient was fe-
male. 77 patients had stage 1 disease, 84 stage 2 and
42 stage 3. 176 patients (86.7%) were recommended
trastuzumab-based treatment and 168 patients initiated
therapy. 96 were treated with anthracycline-based che-
motherapy and 70 with taxane-based chemotherapy.
76.7% completed the planned number of taxane-based
treatments compared with than the 60% receiving
anthracycline-based therapies; toxicity being the main
reason for not completing treatment. Younger patients
(OR 0.89, 95%CI 0.84-0.93, p< 0.001) and those with
grade 3 tumours compared to grade 1 and 2 combined
(OR 3.99, 95%CI 1.31-12.08, p0.014) were more
likely to be recommended trastuzumab-based treat-
ment. Younger patients (OR 0.85, 95%CI 0.81-0.90,
p <0.001) with a high HER2 gene copy number (OR
4.10, 95%CI 1.06-15.81, p 0.041) multifocal disease
(OR 3.53, 95%CI 1.06- 15.82 p 0.023) and stage 2
and 3 disease (OR 0.73, 95%CI 0.25-0.90) were more
likely to be recommended anthracycline over taxane-
based therapy.
Conclusions: Trastuzumab-based therapy is standard
of care for patients with HER2EBC regardless of pa-
tient or cancer characteristics. Our ﬁndings demon-
strate that chemotherapy partners may be inﬂuenced
by patient and cancer characteristics, however treat-
ment limiting toxicities also need to be considered in
order to maximise patient beneﬁt.
872. Bypassing Agents and Risk of Thromboembolic
Events in Patients with Hemophilia and Inhibitors
Katsiaryna Bykov,1 Rhonda L Bohn,2 Bruce M
Ewenstein,3 Jerry Avorn,1 John D Seeger.1 1Division of
Pharmacoepidemiology and Pharmacoeconomics, De-
partment of Medicine, Brigham and Women’s Hospital
and Harvard Medical School, Boston, MA, United
States; 2Independent Consultant, Waban, MA, United
States; 3Research and Development, Baxter Healthcare,
Westlake Village, CA, United States.
Background: Hemophilia patients with inhibitors to
factors VIII or IX require bypassing agents for
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bleeding management or prophylaxis. Thromboem-
bolic events (TEs) are a safety concern with the use
of these agents; however, the incidence of such events in
hemophilia patients with inhibitors remains poorly char-
acterized as both the disease and the outcomes are rare.
Objectives: To assess the incidence of TEs following
exposure to inhibitor bypassing agents in hemophilia
patients with inhibitors using a Medicaid Analytic
Extract (MAX) database.
Methods: In patients enrolled in Medicaid (2000-2006),
we identiﬁed males with a diagnosis code for hemo-
philia A or B and use of either recombinant factor VIIa
(rFVIIa) or activated prothrombin complex concentrate
(aPCC). Patients were followed until death, dis-
enrollment for> 3months, or end of study period to
measure exposure to bypassing agents and the occur-
rence of TEs. Exposure was assessed on an as-treated
basis with the assumption that a dispensing of a prod-
uct provides potential exposure for up to 3months.
Outcomes were adjudicated through review of chrono-
logical listings of claims over the period of 3months
before and 3months after an event. Incidence rates
were calculated as the number of events divided by
the corresponding person-time.
Results: The cohort included 408 patients (mean age
at cohort entry 11 years) who contributed 1,254 per-
son-years (PYs) of follow-up. There were 5,514 aPCC
and 8,782 rFVIIa dispensings recorded, which repre-
sented 405 aPCC-exposed and 420 rFVIIa-exposed
PYs. Of 21 potential outcomes identiﬁed, fewer than
11 were classiﬁed as probable outcomes on adjudica-
tion. The incidence of TEs was 12.5 events (95% CI:
6.2-22.8) per 1,000 PYs exposed to any bypassing
agent, 17.3 events (95% CI: 7.7 – 34.0) per 1,000
aPCC PYs and 9.5 events (95% CI: 3.2 – 22.6) per
1,000 rVIIa PYs.
Conclusions: The small number of TEs identiﬁed un-
derscores the rarity of this outcome among hemophilia
patients with inhibitors; however, coupled with com-
plicated exposure patterns to these products, it also
limits the strength of inference regarding relative risk
of the outcomes.
873. Factors Associated with Denosumab Initiation
among Postmenopausal Osteoporosis Patients in
Medicare
Huifeng Yun,1,2 Rui Chen,1 Nicole C Wright,1 Robert
Matthews,1 Torun Arora,1 Ashley N Milford,1 Fei
Xue,3 Elizabeth Delzell,1 Jeffrey R Curtis.1,2 1Depart-
ment of Epidemiology, University of Alabama at
Birmingham, Birmingham, AL, United States; 2Division
of Clinical Immunology and Rheumatology, University
of Alabama at Birmingham, Birmingham, AL, United
States; 3Global Observational Research, Amgen, Inc,
Los Angeles, CA, United States.
Background: Denosumab 60mg (DMAb), which re-
duces the risk of vertebral and non-vertebral fractures
in osteoporosis patients, was launched in the U.S. on
May 26, 2010. Characteristics of DMAb users and fac-
tors inﬂuencing the choice of initiation of Dmab have
not been described.
Objectives: To compare characteristics of DMAb, zo-
ledronic acid (ZOL) and oral bisphosphonates (BP)
(alendronate, risedronate and oral ibandronate) initia-
tors and to identify factors associated with DMAb
initiation.
Methods: Using data on all women with postmeno-
pausal osteoporosis (PMO) in Medicare, we identiﬁed
new users of DMAb, ZOL and oral BPs during 05/26/
2010-12/31/2010 based on procedure and pharmacy
claims. New users had no prior claims for the same
drug during the 18-month baseline period before initi-
ation. Eligible subjects were ≥65 years of age and con-
tinuously enrolled in Medicare medical and pharmacy
coverage during baseline. Logistic regression analyses
evaluated the relation between DMAb initiation and
demographic factors, co-morbidity, concurrent medi-
cations, health services utilization, physician specialty,
nursing home residency, history of fractures, and prior
use of anti-osteoporotic medications.
Results: During the study period, 5,796, 24,249 and
103,139 patients initiated DMAb, ZOL and oral BP,
respectively, at mean ages ranging from 77 to79 years.
Of DMAb and ZOL users, 22% were initiated by rheu-
matologists, whereas only 7% of oral BP users were
initiated by a rheumatologist. Referent to ZOL, odds
of initiating DMAb were 3.2 times greater (95% CI:
2.7-3.7) for Asians vs non Hispanic Whites, 2.9 (CI:
2.6-3.2) for renal disease history and 1.9 (CI: 1.8-2.0)
for prior use of BP. Referent to oral BPs, rheumatologist
(OR: 5.1, CI: 4.7-5.6) and family practice (OR: 1.8, CI:
1.7-2.0) specialties (vs internal medicine) were more
likely to initiate DMAb.
Conclusions: Among women with PMO in Medicare,
characteristics of initiators of DMAb and ZOL differed
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from those of initiators of oral BPs. Asian race, history
of renal disease, prior use of BP and physician special-
ties played signiﬁcant roles in DMAb initiation.
874. Safety Profile of Ophthalmic Biologics: Review
of Safety Data
Ana Penedones,1 Carlos Alves,1,2,3 Francisco Batel
Marques.1,2 1Central Portugal Regional Pharmaco-
vigilance Unit, Centre for Health Technology Assessment
and Drug Research (CHAD), AIBILI - Association for In-
novation and Biomedical Research on Light and Image,
Coimbra, Portugal; 2School of Pharmacy, University of
Coimbra, Coimbra, Portugal; 3Health Sciences Research
Centre, University of Beira Interior, Covilha, Portugal.
Background: New biologic drugs have been developed
for ophthalmic therapeutic indications, representing real
innovations in this medical ﬁeld. Due to the eye pharma-
cokinetics their administration is intravitreous. Their
safety proﬁle is not fully established.
Objectives: This study aimed to characterize the
safety proﬁle of biologics used in ophthalmologic ther-
apeutic indications.
Methods: The European medicines agency website
was searched to identify biologics with approved
ophthalmologic therapeutic indications. A systematic
literature search was performed using MEDLINE, the
Cochrane Central Register of Controlled Trials
(CENTRAL) and the International Clinical Trials Reg-
istry Platform up to December 2013. Pre-marketing,
phase III, and post marketing randomised controlled
trials (RCT), observational longitudinal studies and
clinical case reports involving adverse reactions were
included. Risk for bias was assessed by Downs &
Black checklist. Additionally, all European spontane-
ous reports of adverse reactions included in the
EudraVigilance up to December 2013, were considered.
Adverse events (AE) were classiﬁed as local (local re-
lated and non-related with the injection procedure) and
systemic (related or non-related with VEGF inhibition).
Results: Pegaptanib, ranibizumab and aﬂibercept were
identiﬁed as biologic drugs approved for ophthalmo-
logic use. Thirty clinical trials and 35 observational
longitudinal studies, along with 30 clinical case reports
and 7720 pharmacovigilance spontaneous reports
were identiﬁed and included in this study. Post-mar-
keting data provided new information by identifying
adverse events not described in pre-marketing data,
such as ‘retinal pigmented epithelium tears’,
‘hypersensitivity reactions’ and ‘intraocular inﬂamma-
tion’. Local AE not related with the injection proce-
dure were found to be the most frequent adverse
events. Non VEGF inhibition related AE were more
frequent amongst the systemic AE.
Conclusions: This systematic review of safety data of
biologics used in ophthalmology provides evidence on
new adverse drug events and on the frequency and se-
verity of those previously described.
875. Characteristics of Rheumatoid Arthritis
Patients Initiating Abatacept Therapy
Veena Thyagarajan,1 Teresa A Simon,2 Nan Liu,3 Nancy
D Lin.3 1Epidemiology, Optum, Ann Arbor, MI, United
States; 2Global Epidemiology, Bristol-Myers Squibb
Company, Hopewell, NJ, United States; 3Epidemiology,
Optum, Waltham, MA, United States.
Background: Prior studies suggest that baseline char-
acteristics of patients with rheumatoid arthritis (RA) ini-
tiating abatacept (ABA) therapy differ from RA patients
initiating other biologics (BDMs) and non-biologic dis-
ease modifying anti-rheumatic drugs (DMARDs).
Objectives: To evaluate baseline characteristics of RA
patients initiating ABA, BDMs, and DMARDs followed
for select infections as part of an ongoing post-marketing
safety evaluation of ABA.
Methods: A prospective cohort study of adult RA initi-
ators of ABA, BDMs, and DMARDs from December 1,
2005 –March 31, 2013 was conducted in administrative
claims data from a large United States healthcare in-
surer. Initiators were required to have at least 6months
continuous health plan enrollment prior to drug initiation
(baseline period), a baseline inpatient or outpatient
physician claim for RA (ICD-9 diagnosis code 714.xx),
and no baseline administration of the same drug.
Cohort assignment of patients with multiple study
drugs was based on the ﬁrst qualifying drug initi-
ated. Descriptive comparisons of demographics and
clinical characteristics were ascertained during the
baseline period.
Results: 4,702 abatacept users were identiﬁed, of
which 2,722 were classiﬁed as BDM or DMARD ini-
tiators and 984 failed to meet study inclusion criteria,
leading to the ﬁnal cohort assignment of 996 ABA,
14,187 BDMs, and 50,492 DMARD initiators. Hyper-
tension was the most common co-morbid condition
and was similar across the groups (ABA: 39%, BDMs:
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33%, DMARDs: 36%). A higher proportion of ABA
initiators than BDM and DMARD initiators had
history of BDM use (ABA: 48%, BDMs: 18%,
DMARDs: 9%) and a slightly higher proportion had
baseline history of: hospitalized infection (ABA: 5%,
BDMs: 3%, DMARDs: 4%), IV antibiotic use
(ABA: 4%, BDMs: 2%, DMARDs: 3%) and non-
melanoma skin cancer (ABA: 1%, BDMs andDMARDs:
less than 1%).
Conclusions: ABA initiators appear to have a higher
level of prior BDM exposure and a slightly higher
prevalence of select co-morbid conditions. These ﬁnd-
ings highlight the need for careful evaluation of base-
line characteristics in order to identify appropriate
comparator groups and address potential confounding
in assessments of ABA safety.
876. Utilization Pattern of Tumor Necrosis Factor
alpha Inhibitors among Patients with Rheumatologic
Arthritis in Korea
Joongyub Lee,1 Nam-Kyong Choi,1 Bo Ram Yang,1
Xue-Mei Jin,2 Byung-Joo Park.2,3 1Seoul National
University Hospital, Seoul; 2Seoul National University
College of Medicine, Seoul; 3Korea Institute of Drug
Safety and Risk Management, Seoul.
Background: Strategy for optimal management of
rheumatoid arthritis (RA) includes use of tumor necro-
sis factor alpha-α (TNF-α) inhibitors.
Objectives: To evaluate the utilization patterns including
persistency, switching among the TNF-α inhibitors.
Methods: We analyzed the 2006-2010 Korean Health
Insurance Review and Assessment Service databases
which covered all Korean RA patients. RA patients
were deﬁned as those with at least 2 prescriptions in-
volving disease modifying anti-rheumatic agents
(DMARD) under the diagnosis of RA. Among the RA
patients, we included adult RA patients (Age> 15) with
etanercept (ETA), inﬂiximab (IFX), or adalimumab
(ADA). We excluded patients with any prescription of
cyclophosphamide, or codes of diagnosis for cancers,
renal failures, liver failures, and organ transplantation.
To include new cases, we excluded those with prescrip-
tions of any DMARD during 2006. To evaluate the per-
sistency of TNF-α inhibitors, enrollees were followed
from the day of ﬁrst prescription of the TNF-α inhibitors
to the cessation of the TNF-α inhibitors which was de-
ﬁned as the no further prescription after the half of the
days supply from the last day of the previous prescription,
switching to other TNF-α inhibitors, 31 December 2010,
or death of the patient whichever came ﬁrst. Persistency
was compared using Cox proportional hazard model.
Results: Through the inclusion and exclusion criteria,
we enrolled 2,203 patients, whose mean age was 39.0
(SD 15.0) with proportion of female patients 40.1%.
ADA was used as the 1st TNF-α inhibitors in 1202 pa-
tients (54.6%), ETA 543 (24.6), IFX 458 (20.8%), re-
spectively. Among the patients who initiated TNF-α
inhibitors treatment with ADA, 108 (9.0%) patients
switched to other TNF-α inhibitors, ETA 61 (11.2%),
IFX 36 (7.9%). With reference to the IFX, ADA
showed 3.20 (95% CI: 2.10-4.86) times higher risk
of cessation of prescription, ETA 2.90 (95% CI:
1.88-4.50) after adjusting age and sex.
Conclusions: ADA was the most frequently initiated
TNF-α inhibitors during the study periods. However,
IFX showed the most persistent TNF-α inhibitors. Fur-
ther study to evaluate the factor related to the persis-
tency is needed.
877. Drug Safety Evaluation of Linezolid Injection
Inducing Thrombocytopenia
Mei-Ying Lu,1 Chih-I Lee,2 Yao-Jen Yang,1 Li-Hsiang
Liao.1 1Department of Pharmacy, Tainan Hospital, Minis-
try of Health and Walfare, Tainan, Taiwan; 2Section of In-
fectious Disease, Department of Internal Medicine, Tainan
Hospital, Ministry of Health andWalfare, Tainan, Taiwan.
Background: Reporting of adverse drug reactions is
an important measure to promote patient safety for
medicine. Several suspicious cases of parenteral ad-
ministration of linezolid (Zyvox®) inducing thrombo-
cytopenia were reported in our hospital.
Objectives: In this study, we try to evaluate the rela-
tionship between linezolid and occurrence of thrombo-
cytopenia, and hope to avoid serious adverse drug
reactions and improve patient safety.
Methods: This retrospective study assessed drug use
evaluation (DUE) manner.Several members of depart-
ment of Pharmacy and section of Infectious Disease
formulated the evaluation criteria, and patients re-
ceived parenteral linezolid treatment during November
2012 to April 2013 were embraced. The main assess-
ment projects included: the indications of linezolid
use, bacterial culture and blood cell counts tracing
before and after linezolid administration, and if the
occurrence of adverse reactions during therapy. These
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results are recorded in a written collection for further
analysis.
Results: The total 25 cases were involved, and the ma-
jor patients, twenty two (88%), were in medical ward.
Twenty ﬁve (100%) of them accorded with indication,
and bacteria cultures were obtained from all of our pa-
tients before and after administration of linezolid. In
the assessment of adverse reactions, eighteen patients
(72%) had adverse reactions in blood, gastrointestinal
system or liver function, and among them, eight pa-
tients (44%) had thrombocytopenia.
Conclusions: The use of linezolid is suitable for
criteria in our hospital. However, high occurrence rate
of adverse drug reactions of thrombocytopenia is de-
tected. Analysis of existing results can not ﬁnd out
the leading causes, and it may due to small case num-
bers. We will continue the safety assessment of linez-
olid, hoping to ﬁnd the factors of drug-related adverse
reactions. In addition, we will also strengthen advo-
cacy of monitoring blood cell and platelet counts dur-
ing linezolid therapy. If necessary, stop using the drug
immediately to ensure patient safety for medicine.
878. Challenges of a Post-Authorisation Safety
Study (PASS) in an Orphan Oncology Indication
Jane B Porter, Matthew Desmond, Marie O’Donnell,
Patrick McNamara, Manfred Lehnert, Bingxia Wang,
Hnin Hnin Ko. Takeda Pharmaceuticals International
Co., Cambridge, MA, United States.
Background: Mifamurtide was granted marketing
authorization by the European Medicines Agency
(EMA) in March 2009 for treatment of non-metastatic
osteosarcoma and the Market Authorisation Holder
(MAH) was required to conduct a Post-Authorisation
Safety Study (PASS).
Objectives: To describe the PASS design, the chal-
lenges in conduct, and the ﬁnal Committee for Medicinal
Products for Human Use (CHMP) recommendations to
Takeda.
Methods: The focus of the 300 patient single arm ob-
servational study was on short- and long-term safety of
patients administered mifamurtide according to the
product label.
Results: The protocol was approved by the CHMP in
July 2010 and the ﬁrst patient enrolled in December
2011; 25 patients were enrolled by December 2013.
Takeda encountered critical challenges in recruit-
ment, including the orphan disease status, low interest
from physicians due to perceived administrative burden,
and limited academic interest. Delays in reimbursement
and competing osteosarcoma studies impacted enroll-
ment. Takeda worked to expand country access and en-
gage relevant research groups. After consideration of
these challenges, the CHMP agreed to allow enrollment
of patients who had started mifamurtide treatment. Sub-
sequently, Takeda provided a comprehensive analysis
of safety data in clinical studies conducted during and
following marketing approval, as well as postmarketing
safety data, to the EMA’s Pharmacovigilance Risk
Assessment Committee (PRAC). Safety results were sim-
ilar to those reported in earlier clinical studies and the
product label; there were no new safety signals identiﬁed.
Based on Takeda’s extensive, yet ultimately futile,
efforts to increase patient accrual and upon review of
the cumulative safety data analyses, the CHMP ac-
cepted the PRAC’s recommendation that the PASS
could be discontinued.
Conclusions: Despite Takeda’s diligence, only 25
patients were enrolled over 2 years. Analysis of addi-
tional safety data led the CHMP to conclude that the
safety proﬁle of mifamurtide was adequately reﬂected
in the product label, the PASS could not be completed,
and Takeda should continue to monitor and report
adverse events.
879. Assessment of Patient Characteristics of Selective
Serotonin Reuptake Inhibitor (SSRI) Plus Add-On
Treatment Users in a United States Claims Database
Meghan E Jones, Elsie Grace, Dale Marmaduke,
James Martinez, Mark Bangs. Eli Lilly and Company,
Indianapolis, IN, United States.
Background: A potential next step for patients with
depression who do not achieve remission on their
initial antidepressant is the use of an adjunctive
treatment. Patients whose depression is not managed
on ﬁrst line therapy may be different than patients
who respond to initial treatment.
Objectives: To characterize patients treated with a se-
lective serotonin reuptake inhibitor (SSRI) plus add-on
treatment in terms of demographics, comorbidities,
and co-medications, and compare to patients treated
only with a SSRI.
Methods: A cohort study was conducted using Truven
Health MarketScan® data from 2004-2012 on adults
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with a diagnosis of major depressive disorder (ICD-9-
CM 296.2x or 296.3x) and a prescription for an antide-
pressant within 90 days of the diagnosis. Patients for
the add-on cohort were identiﬁed by at least one pre-
scription for quetiapine or aripiprazole that was pre-
ceded by at least two prescriptions and follwed by
one prescription for the same SSRI. The add-on cohort
was matched 1:4 to the SSRI cohort on age, sex and
insurance status. Cumulative incidence of comorbidi-
ties and medication use was calculated for one-year
follow-up. Rate ratios (RR) and 95% conﬁdence inter-
vals (95% CI) were calculated.
Results: 13,499 patients were identiﬁed for the add-on
cohort. Compared to the SSRI cohort, drug depen-
dence and substance abuse were higher in the add-on
cohort with RRs of 4.14 (95% CI = 4.00-4.28) and
3.26 (95% CI = 3.17-3.34) respectively. An increase
in prescriptions in sedatives and anxiolytics was seen
in the add-on cohort where also the mean insurance
co-pay was higher compared to the SSRI cohort. The
incidence of the majority of comorbidities and medica-
tion use was similar between the add-on cohort and the
SSRI cohort.
Conclusions: Although patients in the cohorts had
similar comorbidities and medication use, there was
an increase in the incidence of certain mental health
conditions, medications and resource utilization in
the add-on cohort compared to the SSRI cohort. It
is important to understand if there are differences
between the populations when considering future
treatments.
880. Types ofAdverse Reactions ofNon-Steroidal Anti-
Inflammatory Drugs. Multiclassificational Approach
Oleksandr V Matvieiev,1,2 Oleksandr Y Ezernitskiy.13
1Clinical Pharmacology and Pharmacotherapy, Crimea
State Medical University, Simferopol, Crimea, Ukraine;
2Regional Pharmacovigilance Ofﬁce in Crimea and
Sevastopol, State Expert Center of Ministry of Health of
Ukraine, Simferopol, Crimea, Ukraine; 3Crimea Republic
Institution “University Clinic”, Simferopol, Crimea, Ukraine.
Background: The ﬁrst attempts to classify adverse re-
actions (ADR) were made in 1958. Although some of
classiﬁcations are permanently revised and extended
there is still no universal one that covers all aspects
of ADR and distinguishes them precisely.
Objectives: The aim of our work was to determine
ratios of different types of reactions from a few
basic classiﬁcations used by specialists of local
pharmacovigilance ofﬁce in Crimea, Ukraine.
Methods: This work is a part of pharmaco-
epidemiological study of non-steroidal anti-inﬂammatory
drugs (NSAID) use in our region. We divided ADRs of
NSAIDs accordingly to classiﬁcations of Rawlins and
Thompson (RT), Will and Brown (WB) and DoTS.
Results: In 2011-January 2014 period 314 spontane-
ous reports about ADR of NSAID were recorded in lo-
cal database ARCADe. Accordingly to RT 67 (21.3%)
ADR belonged to type A reactions, 244 (77.7%) to
type B and 3 (0.95%) to type F while in WB 65
(20.7%) belonged to A type, 237 (75.5%) to type H,
8 (2.5%) to type C and 4 (1.3%) were not classiﬁed
(type U). A concurrence in approach to augmented
ADR was 97%, in bizarre ADR – 97.1%. In DoTS
228 (72.6%) cases were hypersusceptibility reactions,
85 (27.1%) – collateral and 1 (0.3%) - toxic ADRs.
Concurrence with WB and RT types for hypersuscep-
tibility - WB: A – 2, H – 226 and RT: A – 2, B - 226;
for collateral - WB: A – 63; C – 7; H – 11; U – 4 and
RT: A – 65, B – 17, F - 3); and 1 toxic ADR was C
type in WB and B type in RT. Hypersusceptibility
ADRs were ﬁrst-dose (65.8%), intermediate (33.8%)
and delayed (0.4%) reactions. Collateral ones included
all types of time-dependent ADR and intermediate
(32.9%), early and ﬁrst-dose (24.7% both) reactions
were registered more often. Only in 55 (17.5%) cases
we were able to determine susceptibility factors, age
(35; 63.6%) and co-morbidities (26; 47.3%) were
more frequent.
Conclusions: While the overall agreement for chosen
classiﬁcations in determining of allergic and mechanism-
dose dependent ADR is very good (Cohen’s κ=0.89
and 0.86), the agreement in pairs “DoTS-RT” and
“DoTS-WB” for allergic ADR stronger than for non-
allergic ADR (κ=0.8 and 0.79 versus κ =0.83 and 0.98).
881. Effectiveness of Multidisciplinary Care for
Chronic Kidney Disease Stage I to IV: An Experience
of CCPC-CKD Program
Yi-Shan Wang,1 Yuan-Ting Yang,1 Ping-Fang Chiu,2
Sock-Ping Ng,1 Su-Yu Chien.1 1Department of
Pharmacy, Changhua Christian Hospital, Changhua,
Taiwan; 2Division of Nephrology, Changhua Christian
Hospital, Changhua, Taiwan.
Background: Chronic kidney disease (CKD) is a con-
dition characterized by a gradual loss of kidney
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function over time. A multidisciplinary team approach
to CKD may help optimize care of CKD and comorbid-
ities. Clinical Care Program Certiﬁcation (CCPC) dem-
onstrates excellence in the integration and coordination
of care for treatment of a speciﬁc disease.
Objectives: The aim of this studywas to determine the ef-
fectiveness of multidisciplinary care for CKD stage I to IV.
Methods: CCPC-CKD program was implemented
since 2010. CKD stage I to IV patients with aged
18-65 years, willing to follow up by care team and
sign the inform consent will join the program. Trained
and experienced kidney disease care managers provide
patient education and disease management. Prescription
review by pharmacist for appropriateness and communi-
cate with doctor for any unreasonable medication use.
Pharmacist provides information of current drugs by giv-
ing leaﬂet which contain ﬁgure of themedication, assessed
patient’s adherence to the medication regimen. Dietitian
provides individualized dietetic education. Social worker
assess the social needs of individuals, families and groups,
assist people to develop and use the skills and resources
needed to resolve social problems. Certiﬁed spiritual care
specialist provides psychological and spiritual support.
Assess the ﬂuctuation of serum creatinine, LDL,
Triglyceride, uric acid (UA) and hemoglobin (Hb).
Results: A total of 130 patients includedwith the aged of
56.1 ±9years; There were 55 female and 75 male ( F:M ;
1:1.3). The average follow up was 23.8±13.9months
(range 3 to 49months). 112 (86.1%)patients with
hypertension, 26(20%) patients with diabetes. During
the follow up period, serum creatinine decrease
0.14 ± 0.004mg/dl ( 1.72 ± 0.005 vs 1.86 ± 0.006 ).
LDL and Triglyceride decrease 9 ± 0.6mg/dl
(84 ± 0.5 vs 75.1± 0.3) and 2.4± 0.8mg/dl (120 ± 0.9
vs 117.9 ± 1.1) respectively. UA decrease
0.2± 0.02mg/dl (6.8 ± 0.01 vs 6.7 ±0.01) and Hb in-
crease 0.3±0.04 g/dl (11.8 ±0.01vs 12.1±0.02).
Conclusions: Multidisciplinary team care may slow
the rate of decline in renal function and improve
patient comorbidities.
882. Pharmacist Role in Diabetes Clinical Care
Program Certification (CCPC-DM)
Shui-MuLin,1 Li-HsuanKuo,1 Yi-ShanWang,1 Sock-PingNg,1
Su-Yu Chien.1 1Department of Phamacy, Changhua
Christian Hospital, Changhua, Taiwan.
Background: Clinical Care Program Certiﬁcation
(CCPC) demonstrates excellence in the integration
and coordination of care for treatment of a speciﬁc dis-
ease. Pharmacist can be valuable members of CCPC
multidisciplinary diabetes team.
Objectives: The aim of this study was to quantify the
contribution of a pharmacist in CCPC multidisciplin-
ary diabetes team.
Methods: CCPC-DM program was implemented in
Changhua Christian Hospital since 2010. Newly
diagnosed and poorly controlled DM patients were in-
cluded. Poorly controlled was deﬁned as HbA1c> 10%
in 2 consecutive visit. Pharmacist provides information
of current drugs by giving leaﬂet which contain ﬁgure
of the medication, assessed patient’s medication know-
ledge (8-item questionnaire) and adherence (9-item
modiﬁed Hill Bone scale) to the medication regimen.
The maximum score on the scale is 36, with higher
scores indicative of worse adherence. Monitoring the
HbA1c, LDL and adverse drug reaction. Patients with
at least one year follow up were included in the analysis.
Results: A total of 53 patients included with the aged
of 46.6 ± 11.3 years; 21 patients were female and 32
patients were male ( F:M ; 1:1.5). For medication
knowledge,only 15 (28.3%) patients were know the
adverse drug reaction. and 13 (24.5% ) patients have
knowledge of oral hypoglycemic agents drug interac-
tion. At the baseline, the 3 patients have the highest score
with 14. After pharmacist intervention, the score de-
crease to 11. Average Hill Bone scores was decrease
from 11.7 ±0.9 to 9.2 ± 0.5. During the follow up
period, HbA1c decrease from 7.4% to 5.8%, LDL
decrease from 107.6mg/dL to 81mg/dL. For poorly
controlled DM patients, HbA1c and LDL decrease from
10% to 9% and 88.4mg/dL to 80.7mg/dL respectively.
The most adverse drug reaction monitor by pharmacist
was Metformin related GI effects (14.3%).
Conclusions: The individualized pharmaceutical care
provided by pharmacist will improve the patient
adherence, and demonstrated to be an effective to
manage patients in order to reduce HbA1c and the
complications associated with DM.
883. Characterization of Patients with Type 1 and
Type 2 Diabetes and Availability of Clinical Mea-
sures Within the Humedica Research Database
Anthony P Nunes, Donnie P Funch, Yan Ding, Robin
C Clifford, Jing Yang, Michael C Doherty, Jeanne
Loughlin. Epidemiology, Optum, Waltham, MA, United
States.
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Background: Observational studies of patients with dia-
betes often rely on administrative claims or electronic
health records (EHR).Administrative claims afford the op-
portunity to utilize large and diverse patient populations
with near complete capture of medical encounters. EHR
data systems are typically limited to a narrower subset of
potential medical encounters based on inclusion of speciﬁc
practices; however, these systems often include clinical
measures that are unavailable in a claims environment.
Objectives: Using diabetes as a motivating example, we
assess the research potential of the Humedica Research
Database, a resource pooling EHR from over 195
hospitals, 40,000 physicians, and 28.6 million patients.
Methods: From among a de-identiﬁed random 5%
sample of Humedica, we identify all patients with a di-
agnosis of type 1 diabetes (T1D) or type 2 diabetes
(T2D). We describe demographic and clinical charac-
teristics and compare with the Optum Research Data-
base (ORD), a large nationally representative claims
database, and with NHANES.
Results: Among the 987,538 sampled patients, we
identiﬁed 7,530 patients with T1D (0.8%) and
64,640 patients with T2D (6.5%). As compared to
NHANES and the ORD, patients with diabetes in
Humedica had similar distributions of gender and race,
with a greater proportion of patients over age 65.
Claims data yielded a higher proportion of patients re-
ceiving care from an endocrinologist (12.5%) as com-
pared to the patients within Humedica (4.8%). Most
patients in Humedica had an available BMI (79.1%
for T1D, 76.1% for T2D), blood pressure (84.5% for
T1D, 82.3% for T2D), HbA1c (72.4% for T1D, 61.9%
for T2D), random blood glucose (79.0% for T1D,
75.1% for T2D) and eGFR (78.6% for T1D, 75.3% for
T2D). Few patients had a fasting blood glucose (11.0%
for T1D, 9.3% for T2D) or an oral glucose tolerance test
(0.5% for T1D, 1.3% for T2D).
Conclusions:While the claims based environment may
offer more complete capture of all medical encounters
for covered patients, Humedica offers a complimentary
data source including a broad source population with
access to clinical notes and observations.
884. The Impact of Clinical Pharmacist on the Medi-
cine Expenditure in the Surgical Intensive Care Unit
Pei-Tzu Lin, Ching-Ling Tai. Pharmacy, Chiayi
Chang Gung Memorial Hospital of the C.G.M.F, Chiayi,
ROC, Taiwan.
Background: Multidisciplinary team could improve
medical quality and reduce medicine expenditure
waste in clinical. There is an essential role for pharma-
cists in the medical team. The clinical pharmacist at
surgical intensive care unit (SICU) takes charge of
the appropriate for all medications on all admitted
patients to reduce inappropriate medication and
improve therapy outcomes.
Objectives: To analyze the impact of clinical pharma-
cist on acceptability of clinical suggestions and medical
cost.
Methods: This was a retrospective study to assess the
impact of clinical pharmacist on a 20-bed SICU
from Jan 2013 to Feb 2013. The clinical pharmacist
preformed medical team rounds and provided medical
suggestions to surgeons. The data were documented at
Hospital Information System (HIS) of a regional
teaching hospital.
The medical suggestions associated drug related
problems could divide into three parts, including
recommendation on the medicine, monitoring the
efﬁcacy of therapy, consultation from medical
personnel.
Results: The clinical pharmacist provided 64 pharma-
ceutical services. 81.3% of them were recommendation
on the medicine, 14.1% of them were consultation from
medical personnel and others were monitoring the efﬁ-
cacy of therapy. The overall acceptability of interven-
tion is 89.1%.
The main interventions of recommendation on the
medicine were the following: inappropriate high dose
(26.9%), no indication for dug (17.3%) and duplicate
medication (15.4%). They made cost saving for
NTD 10603.7. Other interventions induced spend
more money (NTD 1258.92) to therapy, including
inappropriate low dose (13.5%), need drug to treat-
ment (7.7%) and shift to other mediation (7.7%).
But some interventions, such as inappropriate medi-
cation administration, didn’t cause any effect on
cost, even if surgeons accepted the recommendation.
On the whole, the medicine expenditure diminished
NTD 9354.79 and saved NTD179.9 per one
intervention.
Conclusions: Surgeons had high acceptability on clin-
ical pharmacist recommendations. Clinical pharmacist
could assist medical team to care patients and reduce
the unnecessary medicine expenditure. Clinical phar-
macist had a positive impact at SICU.
abstract 475
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
885. Cost-Effectiveness Analysis between Rocephin
and Ceftrixone in Hospitalized Patient with Com-
munity-Acquired Pneumonia
Min-Hsin Chao,1 Shun-Jin Lin.2 1Pharmacy, Kaohslung
Chang Gung Memorial Hospital, Kaohsiung; 2Graduate
Institute of Clinical Pharmacy, Kaohsiung Medical
University, Kaohsiung.
Background: In recent years, it has become a trend
that using the relatively inexpensive price of generic
drugs to replace the brand drugs. The previous studies
of substitutability between the brand drugs and generic
drugs widely used to treat community-acquired pneu-
monia (CAP) by antibiotics, ceftriaxone, were focused
on comparing the efﬁciency and safety.
Objectives: This study was to assess the differences of
total treatment costs and effects between generic and
brand ceftriaxone in inpatients with CAP by using
cost-effectiveness analysis model.
Methods: Observational retrospective study was used
to collect the patients ﬁt the criteria from Jan 1 to Dem
31, 2010. Furthermore, the cost-effectiveness of generic
and brand ceftriaxone (Rocephin® and Ceftriaxone®)
for CAP in hospitalized patients was evaluated.
Results: The results showed that failure treatment of
Rocephin® and Ceftriaxone® group were 5 and 10
people, respectively, and maintained the original treat-
ment regimen till to dead were 1 and 3 people, respec-
tively. Patients using Ceftriaxone® need to pay more
than NT 17,516 of alternative antibiotic cost after the
ﬁrst treatment failure as compare to Rocephin® cohort
(Rocephin® Group NT 6,530; Ceftriaxone® Group NT
24,046). Regardless of economic strata, the cost of ward
in Ceftriaxone® group was higher than Rocephin®
group. The average total treatment cost of Rocephin®
group was NT 46,015 and Ceftriaxone® group was NT
54,134. The incremental cost-effectiveness ratio (ICER)
of Ceftriaxone® group is NT 227,106.
Conclusions: Rocephin® is better than Ceftriaxone® in
the cost-effectiveness analysis for treatment of CAP
though it’s unit price has higher than Ceftriaxone®.
886. Teaching Pharmacoepidemiology in the GCC
Countries: Survey of Pharmacy Schools
Hisham Aljadhey,1 Mohamed Izham Ibrahim,2 Nouf
Almeshal,1 Yasser Albogami.1 1Medication Safety
Research Chair, College of Pharmacy, King Saud Uni-
versity, Riyadh, Saudi Arabia; 2College of Pharmacy,
Qatar University, Doha, Qatar.
Background: Pharmacoepidemiology practices are
limited in some developing countries. And in the
Gulf Region, a chapter of the International Society
for Pharmacoepidemiology was established in 2013
to promote pharmacoepidemiology in the region. To
promote pharmacoepidemiology, it is important to
include it in the curriculum of health colleges.
Objectives: To assess the current practices in teaching
pharmacoepidemiology in pharmacy schools in the
gulf region countries.
Methods: A validated survey was administered to as-
sess the teaching of pharmacoepidemiology and pres-
ence of expertise in pharmacoepidemiology. The
survey was sent via electronic mail to 35 schools in
ﬁve GCC countries. The survey assess school’s
background information and information related to
pharmacoepidemiology teaching. A second electronic
mail was followed after two weeks of no response,
followed by a phone call to request the response.
The survey were asked to be ﬁlled by the Dean, Vice
Dean, or pharmacoepidemiology course coordinator.
Descriptive analysis was conducted using the SPSS
statistical package.
Results: Eighteen out of 35 schools completed the sur-
vey (response rate of 51%). Of those 13 (72%) from
Saudi Arabia, 2 (11%) from United Arab Emirates
and one school from Qatar, Kuwait and Oman. Fifteen
(83%) are public/government schools. For the under-
graduate program, 8 schools offer baccalaureate pro-
gram and 10 schools offer PharmD program while
only one school offer both programs. Only 5 (28%)
schools offer postgraduate program but not in
pharmacoepidemiology. Median average of faculty
members is 31. When asked about pharmaco-
epidemiology course offered by the schools, 15 (83%)
claimed that the schools provide pharmacoepidemiology
education. Twelve schools have a dedicated course
teaching pharmacoepidemiology at either 4th or
5th year. Median average number of student enroll-
ing in the course is 55. Eleven (11/18) schools
claimed that they have faculty trained/specialized in
the area and most of them have PhD degree.
Conclusions: Teaching pharmacoepidemiology in
pharmacy schools in gulf region is common. However,
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no postgraduate programs in pharmacoepidemiology
are offered in the region.
887. Experience of Joint Post-Authorization Safety
Studies (PASS) through an Example
Marie-Laure Kurzinger, Juhaeri Juhaeri, Cristina
Chang, Laurent Auclert. Pharmacovigilance, Sanoﬁ,
Chilly-Mazarin, Bridgwater, Taipei, France.
Background: Joint Post-Authorization Safety Studies
are studies conducted by more than one marketing au-
thorization holder (MAH). They are especially rele-
vant when a safety concern applies to more than one
medicinal product, when the recruitment of patients
may be challenging (rare disease) or when the adverse
reaction is rare. Following consultation with the
Pharmacovigilance Risk Assessment Committee
(PRAC), the European Medicines Agency (EMA) or
the national competent authority can encourage MAHs
to conduct a joint PASS.
Objectives: The objective is to demonstrate how Joint
PASS can be set up and conducted through an example.
Methods: In 2010 EMA requested a study to evaluate
the risk and beneﬁt proﬁle of topical ketoprofen and rec-
ommended a joint initiative. A Joint epidemiological
case-control PASS was proposed focusing on severe
photosensitivity reactions leading to hospitalization
and exposure to topical ketoprofen.
Results: Twelve MAHs signed a temporary associa-
tion of companies. The contract reﬂected the European
Network of Centres for Pharmacoepidemiology and
Pharmacovigilance (ENCePP) rules to facilitate the
conduct of collaborative pharmacoepidemiology stud-
ies and uphold high standards throughout the research
process based on the principles of transparency and
scientiﬁc independence.
A ﬁnancial agreement between MAHs was reached
and the costs of the study were shared according to
the market shares.
An independent investigation center was selected to
conduct the study and developed a joint scientiﬁc
protocol.
A Joint Scientiﬁc Committee was set up to supervise
the scientiﬁc activities and ensure optimal coordination
amongst MAHs and the investigation center with
respect to the study.
Conclusions:Within a Joint initiative, the responsibil-
ities should be shared and distribution of tasks should
be clearly described. Although a Joint PASS may be
complex to set-up because of the numerous involved
MAHs, Joint PASS are an interesting setting for
MAHs collaboration and joining MAHs scientiﬁc
and ﬁnancial efforts should enhance the feasibility
and quality of such studies. Within the new EU legis-
lation, Joint studies are likely to be encouraged more
and more.
888. Safety Practices of Compounded Sterile Paren-
teral Preparations: An International Cross-Sectional
Study
Hisham Aljadhey,1 Nouf Al-Fadel,1 Rabih Dabliz,2
Osama Tabbara,2 Mansour A Mahmoud.1 1Medication
Safety Research Chair, College of Pharmacy, King Saud
University, Riyadh, Saudi Arabia; 2Pharmacy Service
Division, Cleveland Clinic, Abu Dhabi, United Arab
Emirates.
Background: Parenteral preparations are most com-
monly used in critical care settings, therefore it must
be properly diluted, labeled and administered cau-
tiously to ensure patient safety and avoid serious inju-
ries associated with these products.
Objectives: To evaluate pharmacists practice toward
the safety of compounding sterile preparations.
Methods: This was a cross-sectional study conducted
among pharmacists with expertise in compounded par-
enteral preparations. A Survey was developed based
on the recommendations from the Institute for Safe
Medication Practices and distributed through Intrave-
nous and Parenteral Nutrition experts network (IV
PN experts network) in the gulf region and beyond
using SurveyMonkey© software in December 2013.
An email message was sent to one pharmacist from
each hospital to participate in the survey. Data was an-
alyzed using Statistical Package for Social Science
(SPSS).
Results: One hundred twenty-four pharmacists were
invited to participate, out of which 40 (32%) pharma-
cists responded. Half of the pharmacists were
employed in tertiary hospitals. Thirty ﬁve percent of
the respondents were pharmacy supervisors and 57.5
% had more than 10 years of experience. Well-deﬁned
policies and procedures that guide the compounding of
sterile preparations and written guidelines for drug sta-
bility and compatibility were available in 92.5% hospi-
tals. Chemotherapy, Parenteral Nutrition (PN), other
selected high-alert medications order is veriﬁed by a
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second pharmacist in 77% of the hospitals. Removal
of concentrated electrolytes solutions from all patient
care areas is accomplished in 72% hospitals and
clearly identiﬁed as High Alert Medications in 77%
of the hospitals. Sixty-eight percent of the hospitals
did not utilize advanced practices such as bar code
veriﬁcation or intravenous robotics for the sterile
products service.
Conclusions: Minimum standards to ensure safety of
sterile compounds and recommended standards for
best practice were not implemented in many hospitals
in different countries.
889. An Assessment of the Current Medication
Safety Practices in the Primary Care Settings in
Riyadh, Saudi Arabia
Hisham Aljadhey,1 Rawan Alenizi,1 Mansour A
Mahmoud,1 Mohamed Azmi Hassali.2 1Medication
Safety Research Chair, College of Pharmacy, King Saud
University, Riyadh, Saudi Arabia; 2Discipline of Social
and Administrative Pharmacy, School of Pharmaceutical
Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Background: Medication errors are the main cause of
preventable adverse drug events (ADEs). Policy and
procedures that prevent medication errors are very im-
portant to ensure patient safety. However, little is
known about medication safety practices and precau-
tions undertaken to minimize or prevent medication
errors in the Saudi primary care settings.
Objectives: To assess the current medication safety
practices in primary care centers in Riyadh.
Methods: We conducted a cross-sectional study in a
random sample of primary care centers in Riyadh,
Saudi Arabia. We used a validated questionnaire that
consist of two main sections; general information
about the centers and questions assessing the imple-
mentation of medication safety standards modiﬁed
using components of ISMP standard of medication
safety practice. Data were analyzed using the Statisti-
cal Package for Social Science (SPSS) and the study
results are presented as count and percentages.
Results: A total of 27 primary care centers from
Riyadh participated in the study. Majority of the cen-
ters 13 (48%) deliver care to 100 patients or more
and none of the centers had medication errors
reporting system. Pregnancy status were not usually
checked when dispensing medication to females in
11 (41%) of the centers. Basic patients demographic
information such as, age, weight, height, past and cur-
rent medications and patient history were not routinely
gathered in 24 (88.9%) of the centers. Vital informa-
tion such blood glucose levels, liver enzymes, renal
functions, blood pressure and cholesterol levels were
not available for pharmacists to monitor drugs and ad-
just the doses in all primary care centers. Twenty-six
(93%) of the centers did not have systems that
automatically perform adult and pediatric dosages
check and warn practitioners about overdoses and un-
der doses for targeted high-alert or narrow therapeutic
index medications.
Conclusions: Majority of the core medication safety
standards were not implemented in most of the
primary care centers in Riyadh. We recommend that
policy makers should encourage primary care centers
to set standards to improve medication safety practices
in the primary care settings.
890. Compounding Training in Singapore: Are Final
Year Pharmacy Students Ready in Ensuring Quality
and Safety of Compounded Medications?
Yuen-Teng Choo,1 Cheong Hian Goh,2 Mui-Ling Tan,1
Wai-Ping Yau.1 1Department of Pharmacy, National
University of Singapore, Singapore, Singapore; 2Health
Sciences Authority, Singapore, Singapore.
Background: Pharmacy compounding is a profes-
sional service provided by pharmacists. In Singapore,
formal training on compounding remains by and large
an integral aspect of the curriculum in the pharmacist
professional training.
Objectives: To assess the perception of compounding
training in pharmacy education among ﬁnal year phar-
macy students in Singapore and their self-perceived
readiness in ensuring quality and safety of compounded
medications.
Methods: A cross-sectional survey was conducted
using self-administered questionnaire among ﬁnal year
pharmacy students in Singapore. The pilot-tested
questionnaire was developed based on available litera-
ture and consisted of predominantly closed-ended (in-
cluding Likert scale) questions. Descriptive statistics
were generated to summarize the data.
Results: Of 150 ﬁnal year pharmacy students in
Singapore, 134 were surveyed in November 2013.
Most respondents agreed that compounding should
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be included in the pharmacy curriculum (83.6%) as it
is an important part of pharmacy education (78.3%)
and pharmacy profession (61.2%). Majority under-
stood the beneﬁts (82.9%) and potential risks
(e.g. contamination) (80.6%) associated with
compounded medications. Nonetheless, only 15.7%
were aware of the report of fungal meningitis out-
break associated with the use of contaminated
compounded medication in the United States. While
more than half of the respondents agreed that they
were equipped with the knowledge (53.7%) and
skills (60.4%) needed to compound medications,
with adequate breadth (76.9%) and depth (63.4%) of
content taught in compounding, only a minority felt
that they were able to compound medications of good
quality (32.1%) and ensure their compounded medica-
tions are free from contamination (17.9%).
Conclusions: There is a place for compounding train-
ing in pharmacy education. While the breadth and
depth of content taught in compounding in the
pharmacy curriculum in Singapore are generally
adequate from students’ perspective, there is a need to
build students’ conﬁdence and to better prepare them
in ensuring quality and safety of their compounded
medications, thereby safeguarding public health.
891. We’ve Got Your Clinical Data – What’s in It
for Clinicians?
Nancy Huang,1 Isla Hains,1 Jane London,1 Clare Delaney,1
Margaret Williamson,1 Malcolm B Gillies,1 Catherine
Marshall.2 1MedicineInsight, NPS MedicineWise,
Melbourne, Victoria, Australia; 2Independent Health and
Guideline Advisor, Gisborne & Hawkes Bay, New
Zealand.
Background: Pharmacovigilance methods have been
advanced by the ability to collect and interpret real
world data from primary care electronic health records
(EHRs). Once collected, this can also be a source of
valuable information to improve clinical practice in
primary care by identifying trends, gaps or unintended
harm.
Objectives: MedicineInsight, a novel Australian
program to establish a longitudinal EHR database,
has designed a delivery model for EHR-data-driven
interventions. This paper explores the acceptability of
this model with contributing practices.
Methods: We conducted a review of current best
practice approaches to using real world data to drive
behaviour change and deﬁned a framework for inter-
vention design. The resulting framework contained
six steps informed by the Theoretical Domains Frame-
work. An intervention using this framework was
delivered via facilitated whole of practice meetings to
50 practices across Australia. This was evaluated to
assess acceptability, utility and practices’ intention to
improve clinical measures.
Results: Participants in the practice meetings include
practice managers, nurses and general practitioners.
Evaluation data collected from each practice meeting
show the intervention to be well received and useful
to identify relevant treatment gaps and priority areas.
The majority of practices indicated they would under-
take improvement activities as a result of the interven-
tion such as reviewing and recalling patients,
improving data completeness and changing patient
management. Despite the inevitable challenge prac-
tices have with limited time, value was seen in partic-
ipating in the intervention, which participants stated
was delivered in a comprehensive and concise manner.
Conclusions: To be successful, use of EHR data in
Australia has to be linked to tangible beneﬁts for clinicians
and patients at an early stage. MedicineInsight interven-
tions taking a holistic and systematic view of practices,
systems and processes for improvement have been well
accepted and show early signs of success. Considering
how clinical data can be translated into useful and usable
information to inﬂuence primary care outcomes is
paramount for the success of programs of this nature.
892. Analysis of Barriers to Patient Recruitment: A
Poster Advertising Campaign for Two Online-Only
Clinical Studies
David A Rorie, Rob Flynn, Lewis McConnachie, Tom M
MacDonald, Isla Mackenzie, Claudine Jennings.
Medicines Monitoring Unit, University of Dundee,
Dundee, Angus.
Background: Engaging public interest in clinical and
medical research continues to be a challenge.
Objectives: To examine the effect of poster advertise-
ment on registration rates in two online-only clinical
studies.
Methods: Posters were sent to every general medical
practice in Scotland, England, Wales and Northern
Ireland. Each practice was sent one of two posters
(randomly) for the MEMO project (www.
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memosafety.org) and one poster for the TIME study
(www.timestudy.co.uk). Practices were asked to dis-
play these. They were asked to reply stating whether
they had displayed the posters and what their reasons
were if they did not.
A second mailing of posters was sent to approxi-
mately 20% of the practices who did not respond to
the initial mailing. On this occasion the letter was ad-
dressed (randomly) to the GP or the practice nurse to
see if there was a difference in the number of replies.
Results: For the initial mailing, 15,158 practices were
sent posters, 1,155 responded (7.6%). 26 respondents
submitted an incomplete reply form.
14,003 practices failed to respond. 753 practices
responded and agreed to display at least one project
poster. 376 responded but chose to display no posters.
326 out of 7,496 poster v1 and 389 out of 7662 poster
v2 were displayed (Chi-square=4.47; df =1; p=0.0345)
suggesting that poster design had some inﬂuence on dis-
play rates.
For mailing two, 2,330 letters were sent and 106 out
of 1,220 to the practice nurses and 87 out of 1,110 to a
GP of the practice resulted in any response (p = 0.457;
overall response rate 8.7%). However, only 122
practices displayed at least one project poster and 66
practices chose to display no poster.
Conclusions: The response from general practices
was low. Sending posters to primary care practices
resulted in relatively few posters displayed. Poster
design had a small inﬂuence on display rates.
893. A Novel Approach to Pharmacogenomic and
Pharmacoepidemiologic Evidence Synthesis for Pre-
dictive Analysis and Regulatory Decision-Making
on Medical Device Performance
Yelizaveta Torosyan, Danica Marinac-Dabic. CDRH,
FDA, Silver Spring, United States.
Background: The CDRH’s vision to provide access
to safe and effective medical devices implies the
need for device evaluation tools that can accurately
predict device performance in various patient
subpopulations.
Objectives: The current regulatory research lacks
biomarker-based data that can be used for predictive
analysis of device performance. To address the
existing gap, we used non-conventional data sources
and tools for developing a new biomarker-based
approach to assessing device performance.
Methods: In this study, we focused on identiﬁcation of
device-related and gender/ethnicity-dependent genetic
markers (SNPs). Using in silico design, we employed
bioinformatics tools and population genetics/genomics
data from open sources such as PubMed/NCBI,
GenePattern/IGV, 1000 Genomes, and Ensembl.
Putative biomarkers were identiﬁed based on the
synthesis of device-related pharmacogenomic and
pharmacoepidemiologic evidence. Functional plau-
sibility and potential detectability of biomarker
candidates were tested using Ingenuity Knowledge
Database.
Results: The current presentation features some exam-
ples of IVD test effectiveness markers and arthroplasty
safety markers in gender/ethnicity-stratiﬁed subpopu-
lations. The biomarker-based prediction for device
safety or effectiveness was juxtaposed to the epidemi-
ological data on device performance from clinical
studies and registries. This pharmaco-genomic/
epidemiologic evidence synthesis validated the bio-
marker role of identiﬁed candidates and showed their
potential for identifying the risk groups with expected
poor device performance.
Conclusions: This novel methodological approach to
evidence synthesis based on device-related biomarkers
can enable predictive performance analysis on various
devices. The in silico identiﬁed and experimentally
validated biomarkers can facilitate clinical and regula-
tory decision-making, thus enhancing device safety
and effectiveness.
894. Impact, in Real Life Conditions, of the Use of a
Purifier Spray on Allergy Care in Dust Mite Allergic
Subjects
Charles Taieb,1 Christophe Ripoll.2 1Public Health,
PFSA, Paris, France; 2Medical, Naturactive, Castres,
France.
Background: Quality of life, quality of sleep are
altered in allergic patients.
Objectives: The study has been set-up in order to
evaluate in real life conditions the perceived efﬁcacy
of a spray containing essential oils on allergy related
symptoms, day sleepiness and quality of life of allergic
subjects.
Methods: Women and men with a known history of
dust mite allergy were recruited in the study. They
were asked to use in their house twice a day, the
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puriﬁer spray for a period of 28 days. The perceived
efﬁcacy was evaluated via self-validated question-
naires on allergy symptoms (discomfort generated by
sneezing, itchy eyes, stuffy nose, nasal ﬂow, tiredness,
ear itching), on daytime sleepiness (Epworth
Sleepiness Scale) and on qol (SF12). For the study
outcomes, each subject was evaluated at inclusion,
at day 7 and day 28. The satisfaction of subjects
through the CSQ8 questionnaire was also evaluated
at day 28.
Results: Forty two subjects, with an history of allergy
of 21.4 ± 11.2 years, were included. They present a
symptom score at inclusion of 6.63 ± 3.5 which was
signiﬁcantly reduced after 7 days of spray use with a
value of 3.87 ± 3.5 (p< 0,001). The improvement
was conﬁrmed at day 28 : 1.85 ± 1.6 (p< 0,001).
The data were also evaluated according to symptom
severity, i.e. low, moderate or severe symptoms. For
the three subpopulations, a signiﬁcant improvement
was observed on the symptoms score since 7 days of
spray use. Moreover, for the subjects showing severe
symptoms, an improvement was also observed on
daytime sleepiness (p< 0,04) with the Epworth score
going from 8.18 to 4.36 after 28 days, and on the
SF12 mental dimension score (p< 0,03) with a score
of 42.8 at inclusion vs 48.2 at day 28.
For the studied population the overall satisfaction
evaluated by the CSQ8 was above 75% after 28 days.
Conclusions: By using self-validated questionnaires,
the evaluation shows the interest of the use of the es-
sential oils spray in allergy care for dust mite allergic
subjects. The improvement on symptoms is observed
whatever the severity of symptoms is, and it is notice-
able that for subjects showing severe symptoms, the
quality of life and the sleep is also improved.
895. Comparative Safety of Endovascular and Open
Surgical Repair of Abdominal Aortic Aneurysms in
Low-Risk Patients
Jeffrey J Siracuse,1 Darren B Schneider,1 Peter H
Connoly,1 Art Sedrakyan,2 Andrew J Meltzer.1
1Vascular and Endovascular Surgery, Weill Cornell
Medical College, New York, NY, United States;
2Healthcare Policy and Research, Weill Cornell Medical
College, New York, NY, United States.
Background: The prevalence of signiﬁcant comorbid-
ities among patients with abdominal aortic aneurysms
(AAA) has contributed to widespread enthusiasm for
endovascular AAA repair (EVAR). However, the
advantages of EVAR in patients at low risk for open
surgical repair (OSR) remain unclear.
Objectives: Our objective is to compare perioperative
outcomes of EVAR to OSR in low-risk patients.
Methods: Patients undergoing EVAR and OSR for
infrarenal AAA were identiﬁed in the 2007-2010
National Surgical Quality Improvement Program
datasets. AAA-speciﬁc risk stratiﬁcation, using the
Medicare Aneurysm Score, was used to create
matched low-risk cohorts. Perioperative morbidity
and mortality were assessed via crude comparisons
of matched groups and regression models.
Results: Of 11753 patients undergoing EVAR, 4339
(37%) were deemed low risk. A matched cohort of
1576 patients was developed from 3804 (41%) under-
going OSR. By deﬁnition, the low-risk cohorts in-
cluded only men aged <75 without signiﬁcant
cardiac, pulmonary, or vascular comorbidities. Mean
age was 67+/-6 years. EVAR patients were more likely
to be obese (40.8% vs. 30.4%, P< .001), diabetic
(16.2% vs. 13.1%, p = .005), and have a history of car-
diac intervention (24.3% vs. 19.2%, P< .001), and/or
surgery (22.6% vs. 19.7%, p = .02), steroid use (3.6%
vs. 2.0%, p = .002), and bleeding disorders (8.7% vs.
5.9%, p = .001). EVAR was associated with reduced
30-day mortality (0.6% vs. 1.5%, p< 0.01), and re-
duced rates of major complications including: sepsis
(0.7% vs. 3.2%, p< 0.01), unplanned intubation (1.0
vs. 5.4%, p< .001), pneumonia (0.8% vs. 6.1%,
p< .001), acute renal failure (0.4% vs. 2.7%, p< .001),
early reoperation (3.7% vs. 6.0%, p 4 units (2.0% vs.
13.0%, p< .001), cardiac arrest (0.2 vs. 0.8, p = .001),
neurological deﬁcits (0.2% vs. 0.5%, p = .032), and uri-
nary tracts infections (1.2% vs. 2%, p= .02).
Conclusions: Our results demonstrate that even among
patients at low risk for OSR, EVAR is associated with
reduced perioperative mortality andmajor complications.
While clinical decisions must account for safety and
long-term effectiveness, the short-term beneﬁt of EVAR
is evident among patients at the lowest risk for OSR.
896. Cardiac Resynchronization Devices with and
Without Defibrillation: A Quantitative Systematic
Review and Assessment of National Use
Art Sedrakyan,1 Jennifer E Moon,1 Lauren Kuntz,2
Sharon-Lise T Normand,2,3 Abby J Isaacs,1 Bethany
Roell,4 Denica Marinac-Dabic.5 1Healthcare Policy and
Research, Weill Cornell Medical College, New York,
NY, United States; 2Harvard School of Public Health,
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Boston, MA, United States; 3Harvard Medical School,
Boston, MA, United States; 4University of Toledo
College of Medicine, Toledo, OH, United States; 5Center
for Devices and Radiological Health, US Food and Drug
Administration (FDA), Silver Spring, MD, United States.
Background: Evidence regarding the comparative ef-
fectiveness of CRT-P and CRT-D devices is lacking.
Objectives: We performed a systematic review of
randomized trials and observational studies to evaluate
the comparative effectiveness of cardiac resynchro-
nization therapy devices for heart failure with pacing
capacity only (CRT-P) versus those with deﬁbrillating
capacity (CRT-D). Additionally, we estimated the na-
tional use of CRT-P and CRT-D devices.
Methods: Randomized controlled trials of any size
and observational studies involving at least 100 sub-
jects were included if they were comparative in design,
enrolled adult subjects, and included clinical end-
points, speciﬁcally mortality, all-cause hospitalizations,
and infections/complications. National estimates of the
use of CRT-P and CRT-D devices were obtained from
the 2002-2009 Healthcare Cost and Utilization Project
Nationwide Inpatient Sample.
Results: Two randomized controlled trials and six ob-
servational studies representing a total of 4,153 pa-
tients contributed data to the efﬁcacy review. Of the
2,320 patients implanted with a CRT-D device, 371
(16.0%) died during follow-up. Among 1,833 patients
receiving a CRT-P device, 423 (23.1%) died. The
overall mortality rate ratio is 0.71 (0.49, 0.96). Three
studies that reported the total number of all-cause hos-
pitalizations showed no differences in patients receiv-
ing these devices (40.6% CRT-D vs 40.1% CRT-P).
Currently, one in eight patients receives CRT-P, and
there are many hospitals and physicians in the country
that prefer and use CRT-P frequently.
Conclusions: We found moderately strong evidence
that CRT-D devices are associated with decreased
all-cause mortality when compared to CRT-P. New
and larger trials are needed to support the use of
CRT-P in appropriate subgroups.
897. Comparative Safety and Effectiveness of
Robotic-Assisted Mitral Valve Repair
Subroto Paul,1 Abby J Isaacs,2 Jessica J Jalbert,2,3 Art
Sedrakyan.2 1Cardiothoracic Surgery, New York
Presbyterian-Weill Cornell Medical College, New York,
NY, United States; 2Healthcare Policy and Research, Weill
Cornell Medical College, New York, NY, United States;
3LA-SER Analytica, New York, NY, United States.
Background: Robotic-assisted mitral valve repair
(MVR) is a device based therapy that has been used
increasingly in cardiothoracic surgery. Little is known
about its use, performance, and costs relative to non-
robotic MVR on a national-level.
Objectives: To compare utilization, safety, effective-
ness, and costs of robotic device assisted MVR relative
to conventional surgical approaches to MVR.
Methods: Using the National Inpatient Sample data,
we identiﬁed patients 18 years of age or older un-
dergoing isolated elective MVR between 2008 and
2011 in the US. We compared robotic-assisted to
non-robotic MVR for the outcomes of in-hospital
mortality, major complications and a composite
outcome consisting of mortality and stroke using
hierarchical logistic regression. Non-parametric tests
were used to compare length of stay and cost. We
adjusted for clinically-relevant variables in the
logistic regression models and accounted for the
stratiﬁed design and clustering of patients within
hospitals.
Results: Of 48,546 elective MVRs, 2,286 (4.7%; 95%
CI: 4.5%-4.9%) were performed with robotic device
assistance. Robotic device-assisted procedures in-
creased from 2008 to 2011 (from 0.6%-4.6%) and
were more likely to be performed in large (90.6%)
and teaching (87.2%) hospitals. Robotic volume dif-
fered by region, with the largest volume performed
in the Mid-West (41.6%). Patients who underwent
robotic device-assisted surgery were younger
(median age 59 vs 65) with a higher proportion of
males (48.4% vs. 43.2%). While robotic-assisted
MVR was associated with a shorter median length
of stay [4 vs. 7 days, p< 0.001] and more routine
discharges [65.2% vs. 43.5%, p< 0.001], there
was no difference in median total costs [$116,828
vs $119,123, p = 0.70]. We found no differences be-
tween the robotic-assisted and conventional MVR
with respect to in-hospital mortality (OR= 1.2.;
95%CI: 0.55-2.6), complications (OR: 1.14 95%
CI: 0.68-1.91), or composite outcome (OR 1.3
95% CI: 0.77-2.21).
Conclusions: Costs of care and complications are
similar among patients undergoing MVR with and
without robotic-assistance, however, robotic-assisted
MVR led to shorter hospitalizations.
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898. The Selection of Prosthetics Aortic Valves for
Elderly Medicare Patients from 2006 to 2011 – A
Population Based Cross-Sectional Study
Dongyi(Tony) Du,1 Stephen McKean,2 Jeffrey Kelman,3
John Laschinger,1 Chris Johnson,2 Rob Warnock,2 Chris
Worrall,3 Thomas E MaCurdy,2 Hector Izurieta.4 1Center
for Devices and Radiological Healh, Food and Drug Ad-
ministration, Silver Spring, MD, United States; 2Acumen
LLC, Burlingame, CA, United States; 3Center for Medi-
care and Medicaid, Washington DC, United States;
4Center for Biologics Evaluation and Research, Food
and Drug Administration, Rockville, MD, United States.
Background: Both biological and mechanical pros-
thetic valves are treatment choices for Aortic Valve re-
placement (AVR). A recent study suggested that
mechanical valves were associated with higher risk
of death on the day of surgery than biological valves.
Objectives: The objective of this study is to character-
ize the selection of prosthetic aortic valves for elderly
Medicare patients.
Methods: This is a retrospective analysis of patients
65 years or older in the 2006-2011 Medicare databases
who underwent AVR alone or in combination with
other procedures. Patients were continuously enrolled
in Medicare Part A, B and D for at least six months
prior to the index surgery. We characterized the trends
and regional variation of the selection of prosthetic
valves. Multivariate logistic regression was used to
evaluate the determinants that inﬂuenced the selection
of prosthetic valves while controlling for demographic
characteristics and Charlson Comorbidities.
Results: A total of 66,453 Medicare patients 65 years
or older who underwent AVR met the inclusion and
exclusion criteria for the ﬁve and a half years period.
The selection of mechanical aortic valves decreased
from 32.6% in 2006 to 27.0% in 2011 (P value
<0.0001). In comparison with 18.9% from northeast-
ern states, 36.0% of patients from southern states se-
lected mechanical valves (P value <0.0001). Major
determinants of the selection of prosthetic valves in-
clude age, gender, region, hospital characteristics and
physician experience.
Conclusions: We saw a 17.2% decrease in the selec-
tion of mechanical aortic valves among elderly
Medicare patients from 2006 to 2011. Dramatic regional
difference was observed in the choice of prosthetic
valves across the nation. Future research is warranted
to evaluate whether there are differences in the quality
of care for prosthetic valve recipients across regions.
899. Long Term Safety of Sacral Nerve Modulation
in Medicare Beneficiaries
Bilal Chughtai,1 Abby J Isaacs,2 Art Sedrakyan.2 1Urol-
ogy, Weill Cornell Medical College, New York, NY,
United States; 2Healthcare Policy and Research, Weill
Cornell Medical College, New York, NY, United States.
Background: Sacral nerve stimulation (SNS) device
(InterStim®, Medtronic, Inc., Minneapolis, MN) has
been FDA approved and is used as a second-line
therapy for both urinary and bowel control. However,
there is limited evidence regarding long term safety
of SNS.
Objectives: We sought to determine short and long
term adverse events associated with SNS among
Medicare beneﬁciaries.
Methods: We used the 5% random sample of all
Medicare claims for 2001-2011 to identify patients of
interest. All patients diagnosed with neurogenic blad-
der, interstitial cystitis, overactive bladder, or fecal in-
continence that underwent SNS implantation were
included. We determined the safety of the SNS using
in depth analysis of complication occurrences on the
day of surgery and during the 5 years following initial
procedure, including time until device replacement or
removal. SAS 9.3 was used for all analyses.
Results: A cohort of 1,475 patients representing
29,480 individuals nationally underwent treatment
with SNS in the 11 year period. The cohort was repre-
sentative of real world patients undergoing SNS sur-
gery with high prevalence of certain comorbidities
such as hypertension (69.3 %), diabetes (29.4%),
chronic pulmonary disease (25.5%), hypothyroidism
(25.2%), and depression (22.7%).
There were few complications on the day of sur-
gery. However, at 90 days 3.7% of patients had bowel
complications, 2.0% urological, 12.9% infectious, and
1.6% had a stroke. Overall, bowel, neurological com-
plication occurrences were consistent with those in
prior year rates, while infectious complications
decreased over time. At 5-years post-implantation,
17.3% had their devices removed and 11.3%
replaced, leaving 73.9% with their original devices.
Conclusions: The urological, infectious, and bowel
complication occurrences were low after SNS among
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Medicare beneﬁciaries with multiple comorbidities.
There were infrequent serious complications such as
hemorrhage and stroke post operatively and a substan-
tial number of patients had their device removed or re-
placed. Although SNS appears safe in this high-risk
population, a comprehensive registry will ensure con-
tinuous safety of this technology.
900. Trend, Utilization, and Outcomes of Male
Incontinence Devices
Bilal Chughtai,1 Abby J Isaacs,2 Jialin Mao,2 Art
Sedrakyan.2 1Urology, Weill Cornell Medical College,
New York, NY, United States; 2Healthcare Policy and
Research, Weill Cornell Medical College, New York,
NY, United States.
Background: Post prostatectomy incontinence (PPI)
is a serious consequence of surgery for prostate cancer.
Several device and non-device based therapies are cur-
rently used by surgeons.
Objectives: To determine occurrence of short and
long term adverse events and re-interventions associ-
ated with devices for PPI as compared to non-device
based intervention among Medicare beneﬁciaries.
Methods: All male PPI patients were identiﬁed from a
nationally representative random sample of Medicare
claims for 2000-2011. Artiﬁcial urinary sphincter
(AUS) device recipients, patients who underwent a
sling device operation and those receiving an injection
of a bulking agent were determined. Survival analysis
was used to describe freedom from re-intervention.
Results: Of the entire cohort of 26,180 patients between
2001 and 2011, 35% received an AUS, 28% a bulking
agent, and 37% a sling. There were more obese patients
in the sling group (p= 0.01) and fewer patients with dia-
betes in the bulking group (p = 0.04). The volume of pro-
cedures has increased from 2001 to 2011. Use of bulking
agents has decreased over time, while sling use has in-
creased, and AUS remained consistent (p< 0.01).
Over the entire follow-up, patients treated with
bulking agents had the most subsequent interventions
(40% and 53%), followed by sling (10% and 16%),
and AUS (8% and 20%)(p< 0.01). Patients who re-
ceived AUS at initial procedure were least likely to
convert to another device (2%), compared to sling
(11%) and bulk (40%) (p< 0.01). Post-operative and
90 day complications were rare. On the procedure
day, urologic complications were most common
(AUS: 16%, Bulk: 4%, Sling: 9%). UTI and cystitis
were the most common adverse effects at 90 days
(AUS: 8%, Bulk: 5%, Sling: 6%).
Conclusions: Sling procedures have been more widely
performed over the decade. Device based procedures are
associated with lower rate of re-interventions compared
to endoscopic therapy in this high-risk population. All
three treatments seem to be safe among Medicare bene-
ﬁciaries with multiple comorbidities. The urological, in-
fectious, and neurological complication occurrences
were low. A device registry will ensure long-term safety
of various technologies used for male incontinence.
901. Comparative Effectiveness of Robotic Device
Assisted vs. Thoracoscopic Lobectomy
Subroto Paul,2 Abby J Isaacs,1 Jessica Jalbert,1,3 Art
Sedrakyan.1 1Healthcare Policy and Research, Weill
Cornell Medical College, New York, NY, United States;
2Cardiothoracic Surgery, New York Presbyterian-Weill
Cornell Medical College, New York, NY, United States;
3LA-SER Analytica, New York, NY, United States.
Background: Robotic-assisted device lobectomy
(RADL) use is growing, but little is known about its perfor-
mance, and costs relative to thoracoscopic lobectomy (TL).
Objectives: To compare safety, effectiveness, and
costs of RADL to TL.
Methods: Using the National Inpatient Sample (NIS)
data, we identiﬁed patients 18 years of age or older un-
dergoing elective RDAL or TL between 2008 and
2011. We compared RADL to TL for the in-hospital
and intra-operative outcomes of mortality and any
complication (cardiovascular, pulmonary, infectious,
or iatrogenic bleeding).We used weighted hierarchical
logistic regression models to account for clinically-
relevant covariates, stratiﬁed survey design, and clus-
tering. Length of stay and costs were compared using
Wilcoxon tests.
Results: We identiﬁed 2,498 RADLs and 37,595 TLs
performed from 2008 to 2011. RADL patients were
more likely to be male (48.4% vs 43.2%) and to have
coronary artery (22.5% vs 18.2%) and chronic pulmo-
nary diseases (47.7% vs 41.3%). RADLs were less
likely to be used in large bed-size (60.0% vs 77.3%)
and teaching hospitals (64.7% vs 69.3%). Compared
to TL, crude mortality risk was similar with RDAL
(0.7% vs. 1.3%; adjusted OR [aOR]: 0.58 (95% CI:
0.21-1.56]) but RDAL patients had a higher risk of
complications (50.1% vs. 45.2%; aOR= 1.20 [95%
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CI: 0.95-1.50]), experiencing more cardiovascular
(23.3% vs. 20.0%; aOR= 1.22 [95% CI: 0.97-1.55]),
pulmonary (33.9% vs. 31.8%; aOR= 1.07 [95% CI:
0.82-1.40]), and iatrogenic bleeding (5.0% vs. 2.0%;
aOR= 2.64 [95% CI: 1.58-4.43]) complications.
RDAL patients had higher costs than TL patients
[$22,582 vs. $17,874, p< 0.05] with no differences
in length of stay (median: 5 IQR: 3-7 days) but less
routine discharges (60.8% vs. 70.3%).
Conclusions: RDAL seems to be associated with sim-
ilar mortality and higher complications risks than TL,
at a signiﬁcantly higher cost.
902. Taiwan Post-Market Surveillance of Medical
Devices in Recent 5 Years
Ya-Hui Cheng,1 Ming-Chan Sung,2,3 Pei-Weng Tu,2
Ming-Kung Yeh,2 Tsui-Min Tsai,1 Yi-You Huang.4 1Na-
tional ADR Reporting Center, Taiwan Drug Relief Foun-
dation, Taipei, Taiwan; 2Food and Drug Administration,
Ministry of Health and Welfare, Taipei, Taiwan; 3Insti-
tute of Health Policy and Management, National Taiwan
University, Taipei, Taiwan; 4Institute of Biomedical En-
gineering, National Taiwan University, Taipei, Taiwan.
Background: Recently, there are many attractions in
post-market surveillance on Medical Devices. All
competent authorities try to foster post-market surveil-
lance for medical devices safety to compensate the
policy of speeding approvals for pre-market evalua-
tion. The medical device event reporting system
(MDRS) is the key fundamental for post-market sur-
veillance worldwide. In Taiwan, the MDRS was
established in 2003. In 2005, the medical device defect
reporting systemwas included. The ﬁrst case of periodic
safety update report (PSUR) of medical device was re-
quested in 2008. From then on, the numbers and quality
of reporting cases are growing and improving.
Objectives: Assessing the data of medical device
events (N = 383) and the defect reports (N = 4,273) re-
ceived by National ADR Reporting Center through
MDRS in Taiwan from 2009 to 2013.
Methods: MDRS in Taiwan from 2009 to 2013.
Reporting cases were analyzed in terms of the reporting
source, quality, category, event issues or defects.
Results: The reporting number increases each year re-
gardless of MDRS or medical device defect reported
cases. It is almost two digit growth rate per year.
The results reveal that after almost ten year efforts,
people have much awareness in the safety of medical
devices. In Taiwan, the major source of ADR came from
medical companies; however, the defect reported cases
were come from end users, including hospitals and pa-
tients. Most of ADR cases were high risk medical de-
vices, such as drug eluting stents, breast implants et al.
Based on the result analysis, TFDA had been issued
the PSUR for stents for several years.
Conclusions: It is obviously that the reported cases
of MDRS increase quickly each year. This poster
deciphers the results of MDRS and will provide some
key cues for the improvement of Medical Device re-
evaluation in the future. Based on these efforts, Post-
Market Surveillance of Medical Devices in Taiwan
has been recognized worldwide and Taiwan also par-
ticipated to be a member of the National Competent
Authority Report (NCAR) exchange program in
December 2010. Some efforts still needed to foster
the safety of medical devices in the future.
903. Anti-Coagulation After Hip or Knee Joint
Replacement: Assessment of the Benefits and Risks
in an Elderly Cohort
Nicole Pratt,1 Stephen Graves,2 Kara Cashman,3 Gillian
Caughey,1 Elizabeth Roughead.1 1University of South
Australia, South Australia; 2Flinders University, South
Australia; 3Adelaide University, South Australia.
Background: Deep Vein Thrombosis (DVT) and Pul-
monary Embolism (PE) is a risk after major hip or knee
arthroplasty. Limited head-to-head trials of the new anti-
coagulantsmean that their efﬁcacy in routine clinical prac-
tice after joint replacement is uncertain. Prevention of
DVT and PEmust be weighed against the risk of bleeding
events as bleeding into joints can result in complications
such as prolonged healing time and wound infections.
Objectives: To examine the beneﬁts and risks associ-
ated with anticoagulant use following total hip
replacement (THR) or total knee replacement (TKR).
Methods: A retrospective cohort study was used to ex-
amine the risk of DVT (ICD10: I80.2), PE (ICD10: I26),
wound infection (T81.4) and death in the 3months after
THR or TKR. Major bleeding was also examined in the
1month after surgery. Patients with a procedure be-
tween August 2007 and February 2013 who were aged
over 18 years at the time of their surgery and who were
eligible for subsidy of all health care services in the year
prior to their procedure were included. Exposure was
determined on 1 day before surgery to 2 days after
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surgery: enoxaparin (ATC: B01AB05) or rivaroxaban
(ATC: B01AX06). Cox proportional hazard models
with enoxaparin as the reference and adjusting for age,
gender, prior hospitalizations, prior medicine use, and
Rx-Risk comorbidity score, were used.
Results: No difference in the risk of DVT, PE or death
was found between the anticoagulants. Bleeding risk
was lower but not signiﬁcantly different with rivaroxaban
compared to enoxaparin after THR (Hazard Ratio (HR):
0.60; 95% CI 0.18-1.94). Wound infection was the most
prevalent outcome occurring in 4% of THR and 5% of
TKR patients.Wound infectionwas signiﬁcantly reduced
in the rivaroxaban group after THR (HR: 0.30; 95% CI
0.09 to 0.96) but no difference was identiﬁed after TKR.
Conclusions: Overall, no beneﬁt was observed with
rivaroxaban compared to enoxaparin for DVT or PE pre-
vention. While no difference in major bleeding risk was
observed between the anticoagulants, rivaroxaban was
associated with less wound infection after THR which
may be a consequence of differences in minor bleeds.
904. 12-Year Implantation and Survival Rates of
Patients with Implantable Cardioverter-Defibrillator
in Routine Clinical Practice Compared with the
Background Population, and the Prognostic Impact
of Age, Sex, and Comorbidity: A Danish Nationwide
Population-Based Cohort Study
Morten Schmidt,1,2 Susanne B Pedersen,2 Dorá K Farkas,1
Søren P Hjortshøj,3 Hans E Bøtker,2 Jens C Nielsen,2
Henrik T Sørensen.1 1Department of Clinical
Epidemiology, Aarhus University Hospital, Aarhus,
Denmark; 2Department of Cardiology, Aarhus Uni-
versity Hospital, Aarhus N, Denmark; 3Department
of Cardiology, Aalborg University Hospital, Aalborg,
Denmark.
Background: Trends on implantation and survival rates
of patients with implantable cardioverter-deﬁbrillator
(ICD) are lacking.
Objectives: To examine long-term implantation and
survival rates of ICD patients in routine clinical prac-
tice compared with the background population, and
the prognostic impact of age, sex, and comorbidity.
Methods: We conducted a nationwide population-
based cohort study. Using medical databases, we
identiﬁed all ﬁrst-time ICD implantations during
2000-2012 (n = 8,460), an age-, sex-, and comorbid-
ity-matched comparison cohort (n = 84,600), and
complete mortality. Comorbidity categories were
deﬁned by Charlson Comorbidity Index scores of
0 (low), 1 (moderate), 2 (severe), and 3 or more
(very severe). We computed standardized implanta-
tion rates and assessed mortality rate ratios (MRRs)
within 12 years using a comparison cohort from the
general population. Within the ICD cohort, we
compared mortality rates associated with age, sex,
and comorbidity.
Results: The implantation rate (per million people) in-
creased 5-fold from 2000 to 2012, both overall (from
42 to 213) and for men (from 34 to 174) and women
(from 8 to 39). Controlling for age-, sex- and comor-
bidity, ICD patients had a 70% increased MRR within
the ﬁrst and the remaining ﬁve years compared with
the general population. However, no increased mortal-
ity was observed when adjusting additionally for
cardiovascular morbidity (1-year MRR=1.05, 95%
CI: 0.92-1.20; 1-5-year MRR= 1.01, 95% CI: 0.92-
1.10). Old age and increasing comorbidity burden
were poor prognostic factors for both short- and
long-term mortality. One-year mortality rate was equal
for men and women.
Conclusions: The rate of ICD implantation increased
ﬁve-fold in Denmark between 2000-2012. ICD pa-
tients had the same 5-year survival probability as the
background population when taking cardiovascular
and other comorbidity into account. Age and comor-
bidity were strong prognostic factors for short-term
mortality, while sex was not.
905. Comparative Effectiveness of Peripheral
Vascular Stents and Surgical Bypass for Critical
Limb Ischemia in the Vascular Study Group of
Greater New York
Andrew J Meltzer,1 Abby J Isaacs,2 Art Sedrakyan.2
1Vascular and Endovascular Surgery, Weill Cornell
Medical College, New York, NY, United States;
2Healthcare Policy and Research, Weill Cornell Medical
College, New York, NY, United States.
Background: Revascularization using peripheral vas-
cular stents (PVS) is a less invasive alternative to open
surgical bypass (BPG) for patients with critical limb
ischemia (CLI), however, there are concerns over its
safety and effectiveness.
Objectives: The purpose of this multi-institutional
study is to compare the effectiveness of peripheral vas-
cular stents (PVS) to surgical bypass (BPG) for critical
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limb ischemia (CLI) in the Vascular Study Group of
Greater New York (VSGGNY).
Methods: Patients undergoing BPG or PVS for CLI at
VSGGNY centers (2011-2013) were included. Using
the Society for Vascular Surgery’s Objective Perfor-
mance Goals (OPGs) for CLI, safety and effectiveness
of PVS and BPG were initially assessed by direct
comparison. Propensity scores were created using
logistic regression including 25 potential confounders
(demographics, comorbidities, anatomic and clinical
risk factors, medications). Nearest neighbor 1:1
matching enabled risk-adjusted comparisons between
treatment modalities in a balanced cohort.
Results: 414 patients (268 PVS, 146 BPG) were
treated for tissue loss (69%) or ischemic rest pain
(31%). Patients undergoing PVS were more likely to
have tissue loss (74.6% vs. 57.5%; P< 0.001), and
co-morbidities including: diabetes (69.3% vs. 57.5%;
P = 0.02), heart failure (22% vs. 13.7%; P = 0.04),
and end-stage renal disease (13.1% vs. 4.1%;
P = 0.004). At 1 year, direct comparison of cohorts
suggested superior outcomes with BPG: freedom from
re-intervention, amputation, or restenosis (RAS)
(90.4% vs. 81.7%; P = 0.02) and freedom from re-
intervention or amputation (RAO) (92.5% vs. 85.8%,
P = 0.045). After accounting for differences between
the BPG and PVS cohorts by 1:1 propensity score
matching, PVS compared favorably to BPG, with
greater freedom from major adverse limb events +
post-operative death (MALE+POD) at 1 year
(95.6% vs. 88.5%; P< 0.05).
Conclusions: By crude comparison, early re-
intervention and restenosis are more prevalent with
PVS. However, risk-adjusted comparison afﬁrms the
safety and effectiveness of PVS in the treatment of CLI.
906. How Do Routine Care Carotid Artery Stenting
Patients Fare Compared to Those Enrolled in
Trials?
Jessica J Jalbert,1,2 Louis L Nguyen,3 Marie D Gerhard-
Herman,4 Michael R Jaff,5 John D Seeger,1,6 Hiraku
Kumamaru,1 Lauren A Williams,1 Jun Liu,1 Chih-Ying
Chen,1 Soko Setoguchi.1,7 1Division of Pharmaco-
epidemiology and Pharmacoeconomics, Brigham and
Women’s Hospital/Harvard Medical School, Boston,
MA, United States; 2LA-SER Analytica, New York, NY,
United States; 3Division of Vascular and Endovascular
Surgery, Brigham and Women’s Hospital, Boston, MA,
United States; 4Division of Cardiovascular Medicine,
Brigham andWomen’s Hospital, Boston, MA, United States;
5Division of Cardiovascular Medicine, Massachusetts
General Hospital, Boston, MA, United States; 6OptumInsight
Epidemiology, Waltham, MA, United States; 7Duke Clinical
Research Institute, Durham, NC, United States.
Background: Clinicians base clinical decisions on
randomized controlled trial (RCT) evidence but
routine care settings may differ from RCTs in terms
of provider proﬁciency and patient factors, which
may alter risks and beneﬁts of a treatment.
Objectives: To compare 30-day mortality in carotid
artery stenting (CAS) patients enrolled in landmark
RCTs, contemporary US registries, or Medicare.
Methods: We linked Medicare data (2000-2009) to
CMS’s CAS Database (CAS-D; 2005-2009) and the
Society for Vascular Surgery’s Vascular Registry
(SVS-VR; 2005-2008) to estimate 30-day mortality
among fee-for service beneﬁciaries ≥66 years of age
undergoing CAS. The 30-day mortality risk among
Medicare-linked registry patients was compared to
those of landmark CAS RCTs (CREST, ICSS, SAP-
PHIRE, SPACE, EVA-3S) and large post-marketing
registries (SAPPHIRE Worldwide, CASES-PMS,
CAPTURE-2, CAPTURE).
Results: Mean age was lower among RCT patients
(67.6 for SPACE to 72.5 for SAPPHIRE) than among
post-marketing registries (72-73) or Medicare-linked
registry patients (~76). Post-marketing registries had
fewer symptomatic patients than Medicare-linked reg-
istries or RCTs. SAPPHIRE was the only RCT enroll-
ing high-surgical risk (HSR) patients but the majority
of routine care patients were HSR (range: 91.2% to
100%). RCTs had minimum provider proﬁciency re-
quirements and post-marketing surveillance registries
had mandatory provider training, while the CAS-D
and SVS-VR had neither. The 30-day mortality risk
among Medicare-linked CAS-D (n = 22,516) was
1.7% (95% CI: 1.5-1.8%) and was 1.8% (95% CI:
1.2-2.4%) among SVS-VR (n = 1,999). The 30-day
mortality risk among RCT patients was lower than
among Medicare-linked asymptomatic patients, while
symptomatic Medicare patients had 1.6 to 3.8 times
the risk of dying compared to RCT CAS patients.
30-day mortality risks among registries were ~1%,
which is between that of RCTs and Medicare-linked
registry patients.
Conclusions: Medicare CAS patients have higher
30-day mortality than RCT or registry patients that
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relate to differences in age, comorbidity burden, and
provider proﬁciency. This underscore the importance
of evaluating CAS effectiveness in routine care.
907. Use of Optional ICD-9-CM Articulating
Surface Codes for Total Hip Arthroplasty in US
Claims Data
Jonathan Schelfhout, Chao Chen, Abraham Hartzema.
Pharmaceutical Outcomes and Policy, University of
Florida, Gainesville, FL, United States.
Background: International Classiﬁcation of Diseases,
Ninth Revision, Clinical Modiﬁcation (ICD-9-CM)
codes for total hip arthroplasty articulating surfaces
were introduced October 2005. These optional codes
have a great potential to facilitate comparative effec-
tiveness analyses of THA articulating surfaces in
claims data; however, little is known about the use of
these codes in the US.
Objectives: Our primary objective is to identify
national trends in the utilization of THA articulating
surface codes. We also aim to test for correlation
between use of the codes and patient and institutional
characteristics.
Methods: We used data from the National Inpatient
Sample (NIS) and included all records with an ICD-
9-CM code for THA. Each claim was classiﬁed ac-
cording to the presence of an articulating surface code
as follows: metal-on-polyethylene (MoP), metal-on-
metal (MoM), ceramic-on-ceramic (CoC), ceramic-
on-polyethylene (CoP), or missing. Trends in utiliza-
tion were divided into 3 time periods (2006-2007,
2008-2009, 2010-2011) to and stratiﬁed by patient and
institutional characteristics test for changes over time.
Results: Use of ICD-9-CM codes for articulating sur-
face were low (40-46%) throughout the study period
and did not signiﬁcantly increase. Appearance of
MoM codes peaked in 2008 while CoP codes became
more frequent over the study period. Increased use of
any code was correlated with younger age, male
gender, osteoarthritis primary diagnosis, and increased
annual THA volume of the hospital. We also found
evidence of clustering of code use by hospital.
Conclusions: Optional ICD-9-CM codes identifying
articulating surface were missing in more than 50%
of THA claims, and this alone may hinder any analysis
of comparative safety in claims data. The use of these
codes does not appear to be increasing. We found
correlations between appearance of any code and pa-
tient/institutional characteristics, and this needs to be
accurately controlled for in any potential analysis.
While there are plausible reasons for many trends seen
in use of articulating surface codes, these codes have
never been validated and their accuracy is unknown.
908. Hospital Volume and Outcomes for Total Hip
Arthroplasty
Chao Chen,1 Efe Eworuke,1,2 Jonathan Schelfhout,1
Abraham Hartzema.1 1Pharmaceutical Outcomes and
Policy, University of Florida, Gainesville, FL, United
States; 2Ofﬁce of Surveillance and Epidemiology, Food
and Drug Administration (FDA), Silver Spring, Washington
DC, United States.
Background: Studies have shown that higher hospital
volume is likely to be associated with better patient
outcomes for highly specialized surgical procedures.
Therefore, some health plans encouraged their mem-
bers to choose hospitals with larger procedure volume.
Total hip arthroplasty (THA) is a procedure of great
interest because of its large medical costs and potential
for postoperative complications.
Objectives: This study examines the relationship be-
tween hospital volume and in-hospital mortality for
THA patients in the United States using Nationwide
Inpatient Sample data.
Methods: The 2006-2008 Healthcare Cost and Utili-
zation Project (HCUP) Nationwide Inpatient Sample
(NIS) used in this study represents a stratiﬁed, 20%
sample of community hospitals in the United States.
Patients with total hip replacement were identiﬁed by
ICD-9-CM codes. The primary outcome was in-hospital
mortality. Secondary endpoints included length of stay
and postoperative complication rates of deep venous
thrombosis, postoperative wound infection, and pulmo-
nary embolism. Logistic regression and multivariate
linear regression models were used for binary and
continuous outcomes respectively, adjusting for age,
gender, income, Charlson comorbidity index, and pro-
cedure type (primary or revision) using a propensity
score method.
Results: 155,442 primary and 1,954 revisions of total
hip replacement records were included in the study.
Most patients are white (86.70%) and female
(56.45%) with a mean age of 65.27. In-hospital death
was signiﬁcantly associated with lower hospital
volume (adjusted odds ratio, 0.659; 95% conﬁdence
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interval, 0.504, 0.861). A signiﬁcant negative correla-
tion between hospital volume and length of stay was
observed (p-value, 0.001).
Conclusions: Higher hospital volumes in our study
were associated with lower in-hospital mortality rates
for total hip arthroplasty patients in the United States.
More research is needed to determine the exact causes
of this correlation.
Disclaimer:
This work was completed while all authors were
afﬁliated with the University of Florida.
The views expressed are those of the authors and do
not necessarily express the opinions of the US Food
and Drug Administration.
909. Evaluation of Implant Stabilization andMobility
in Total Knee Arthroplasty
Art Sedrakyan,1 Elixabeth W Paxton,2 Steven E Graves,3
Guy Cafri,2 Abby J Isaacs,1 Barbara Bordini,4 Otto
Robertsson,5 Alejandro Allepuz,6 Ove Furnace,7 Denica
Marinac-Dabic.8 1Healthcare Policy and Research, Weill
Cornell Medical College, New York, NY, United States;
2Surgical Outcomes and Analysis, Kaiser Permanente,
San Diego, CA, United States; 3Australian Orthopaedic
Association’s National Joint Replacement Registry, Ade-
laide, Australia; 4Emilia Romagna Joint Registry, Istituto
Ortopedico Rizzoli, Bologna, Italy; 5Swedish Knee
Arthroplasty Register, Gothenburg, Sweden; 6Catalan
Arthroplasty Register - Registre d’Artroplàsties de
Catalunya (RACat), Barcelona, Spain; 7The Norwegian
Arthroplasty Register, Department of Orthopaedic Sur-
gery, Haukeland University Hospital, Bergen, Norway;
8Ofﬁce of Surveillance and Biometrics, Center for
Device and Radiological Health, United States Food
and Drug Administration (FDA), Silver Spring, MD,
United States.
Background: Total knee arthroplasty (TKA) is one of
the three most common major surgeries in the USA.
Growth in demand worldwide and the increased cost
burden of these procedures have fueled the long
standing debate over the superiority of cruciate
retaining (Non-PS), posterior stabilized (PS), and
mobile bearing implants.
Objectives: We sought to determine the effects of
knee implant stabilization and mobility on device
failure and identify other risk factors for revision.
Methods: Using the International Consortium of
Orthopedic Registry (ICOR) distributed registry
network, primary TKA procedures performed for oste-
oarthritis were identiﬁed from six national registries
(2001-2010). We used linear mixed models with
implant survival probability as the unit of analysis.
We compared mobile to ﬁxed bearing designs and
examined the effects of stabilization.
Results: The cohort consisted of 448705 TKAs.
Mobile bearing non-PS devices had a higher risk of re-
vision than ﬁxed bearing non-PS designs (HR: 1.45,
95% CI: 1.18-1.78). Mobile bearing PS designs also
had higher risk of revision than ﬁxed bearing PS de-
signs (HR: 1.79, 95% CI: 1.23-2.76). Additionally,
we found that PS knee devices were inferior to non-
PS devices. This effect was consistent in the two
subgroups of resurfaced or non-resurfaced patella and
was stronger in the ﬁrst two years after surgery (year
two HR: 1.75, 95% CI: 1.27-2.41 for resurfaced and
HR: 1.31, 95% CI: 1.19-1.45 for non-resurfaced
patella). We also found reduced risk of device failure
with age> 65 (HR: 0.57, 95% CI: 0.55-0.60) and a
strong interaction of gender with resurfacing. Females
that have their patella resurfaced have a reduced risk
compared to males with non-resurfaced patella
(HR: 0.66, 95% CI: 0.60-0.72).
Conclusions: Our unprecedented multinational study
is based on the largest cohort of TKA ever assembled.
We found that mobile bearing non-PS designs present
a greater risk of failure than ﬁxed. Our study also
demonstrated a signiﬁcantly higher revision rate in
PS knees compared to Non-PS knees, particularly in
the ﬁrst two years. The risk of failure was modiﬁed
by age, gender and patella resurfacing.
910. Creation and Use of a “Lag Time” Variable for
Comparative Effectiveness Research Using Claims
Data
Sarah R Hoffman,1 Nilsa Loyo-Berríos,2 Megan Gatski,2
Manuel Bayona,2 Veronica Price.3 1Oak Ridge Institute
for Science and Education (ORISE) Research Fellow,
Food and Drug Administration, Silver Spring, MD,
United States; 2Division of Epidemiology, Center for
Devices and Radiological Health, Food and Drug Ad-
ministration, Silver Spring, MD, United States; 3Division
of Reproductive, Gastro-Renal and Urology Devices, Of-
ﬁce of Device Evaluation, Food and Drug Administra-
tion, Silver Spring, MD, United States.
Background: The Multi-Payer Claims Database
(MPCD) consists of nationally representative data
from public and private payer claims. Meaningful
abstract 489
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
use of claims data is sometimes limited by the need to
distinguish unique interventions from billing adjustments.
Objectives: (1) Demonstrate the use of a “lag time”
variable for distinguishing true re-interventions from
billing adjustments in a large claims database. (2) Ex-
plore the effects of “lag time” thresholds on CER
results.
Methods: Using the Multi-Payer Claims Database
(MPCD), women with uterine ﬁbroids who received
treatments of interest (uterine artery embolization, en-
dometrial ablation, hysterectomy, myomectomy) dur-
ing the four-year study period, were identiﬁed using
ICD-9-CM codes. A total of 131,884 women repre-
sented by 17.4 million procedures were included. Data
were sorted in SAS 9.3. Lag time (date of re-interven-
tion claim minus date of previous procedure claim)
was calculated for all procedures, except for baseline.
Statistics concerning re-intervention were computed
four ways: 1) overall, 2) excluding procedures with a
lag time of 0 days, 3) excluding procedures with a lag
time< 30 days, or 4) excluding procedures with a lag
time< 90 days.
Results: Most women (80%) underwent hysterectomy
as their initial procedure, 14% of which were subtotal
hysterectomies. When no minimum lag time threshold
was applied, 27,528 repeat hysterectomies were identi-
ﬁed. Setting minimum lag times of> 0 days, 30 days,
and 90 days reduced the number of repeat hysterecto-
mies detected to 1,427, 50, and 24 respectively. When
no minimum lag time was applied, uterine artery
embolization patients required more re-interventions
per person than patients receiving other baseline
interventions (1.51). When a minimum lag time of> 0
days was applied, endometrial ablation patients
required more re-interventions per person than other
groups (0.14).
Conclusions: Lag time thresholds can have powerful
implications for comparative effectiveness ﬁndings.
Claims data researchers must clarify to their audience
how true re-interventions were distinguished from bill-
ing adjustments and what effect this may have had on
study ﬁndings.
911. Identifying Important Sensitivity Analyses
Empirically for Pre-Specification in CER Protocols
Cynthia J Girman,1 Douglas Faries,2 Patrick Ryan,3 Matt
Rotelli,4 Mark Belger,2 Bruce Binkowitz,5 Robert
O’Neill.6 1Comparative & Outcomes Evidence, Center
for Observational & Real-world Evidence, Merck Sharp
& Dohme, North Wales, PA, United States; 2Global Sta-
tistical Sciences, Eli Lilly & Co., Indianapolis, IN, United
States; 3Epidemiology Analytics, Janssen Research &
Development, Titusville, NJ, United States; 4Global
PK/PD& Pharmacometrics, Eli Lilly & Co., Indianapolis,
IN, United States; 5Late Development Statistics, Merck
Sharp & Dohme, Rahay, NJ, United States; 6The Ofﬁce
of Translational Sciences, CDER, Food and Drug
Administration, Rockville, MD, United States.
Background: The use of healthcare databases for
comparative effectiveness research (CER) is increas-
ing dramatically but such studies can be challenging.
To minimize bias and confounding to allow valid, re-
producible results, study design and analytic decisions
are critical. Researchers sometimes apply sensitivity
analyses to certain study features, but other design
considerations may also impact results. In addition,
sensitivity analyses are usually performed post-hoc,
and the AHRQ Users Guide recommends an a priori
plan to assess robustness of results to potential sources
of bias with study design choices as part of a CER
protocol.
Objectives: We sought to develop pre-study steps to
empirically identify sensitivity analyses of design fea-
tures that might be most impactful at completion of the
study, using simple analyses of baseline or aggregate
treatment data conducted before study initiation.
Methods: The number of possible sensitivity analyses
for study design decisions and operational aspects of
CER can be extensive, and prone to spurious
ﬁndings and interpretation difﬁculties if all were
conducted. The DIA CER scientiﬁc working group
proposes an approach to empirically identify important
sensitivity analyses that could be pre-speciﬁed in CER
a protocool.
Results: Univariate analyses for basic design consid-
erations such as outcome algorithms, exposure deﬁni-
tions, time windows and handling of exposure
anomolies can be applied to aggregate data (prior to
therapy initiation in a new user design, or data without
associating treatment with outcome) to assess how
much prevalence or median person-time changes with
different deﬁnitions. This can identify sensitivity
analyses that may be most likely to inﬂuence the
results, and such analyses could be done at the time
of other feasibility analyses.Over time, a library of
such analyses could help researchers easily identify
sensitivity analyses to pre-specify in CER protocols.
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Conclusions: Pre-study analyses to empirically
identify the more important sensitivity analyses for
pre-speciﬁcation in a CER protocol could help
improve the integrity and interpretability of CER, and
potentially help reduce the chance of spurious ﬁndings.
912. Withdrawn by Author
913. Risk of Spontaneous Abortion in Young
Women Exposed to Human Papillomavirus (HPV)-
16/18 AS04-Adjuvanted Vaccine in the United King-
dom: An Observational Cohort Study
Laurence Baril,1 Dominique Rosillon,1 Corinne
Willame,1 Maria-Genalin Angelo,1 Julia Zima,1 Judith
H van den Bosch,2 Tjeerd van Staa,3 Rachel Boggon,3
Eveline Bunge,2 Sonia Hernandez-Diaz,4 Christina
Chambers.5 1GlaxoSmithKline Vaccines, Wavre,
Belgium; 2Pallas Health Research and Consultancy,
Rotterdam, Netherlands; 3CPRDResearchGroup, London,
United Kingdom; 4Harvard School of Public Health,
Boston, United States; 5University of California San Diego
School of Medicine, La Jolla, United States.
Background: The HPV-16/18 AS04-adjuvanted vac-
cine is indicated for protection against cervical cancer
in >100 countries. Safety of inadvertent exposure to
any dose of this vaccine during pregnancy needs to
be further investigated.
Objectives: To assess the relative risk of spontaneous
abortion (SA) during weeks 1–23 of gestation in women
aged 15–25 years after HPV-16/18 vaccination.
Methods: Two cohorts were deﬁned in the UK
Clinical Practice Research Datalink General Practice
OnLine Database (CPRD GOLD; pregnancies
Sep2008–Jun2011): 1) exposed pregnant women with
last menstrual period (LMP) between 30 days before
and 45 days after any dose of HPV-16/18 AS04-
adjuvanted vaccine; 2) non-exposed pregnant women
with LMP between 120 days and 18months after the
last vaccine dose (NCT01905462). The risk of SA
was compared between cohorts using a Cox propor-
tional hazards model. Sensitivity analysis considered
the number of doses during the risk period.
Results: Of 161,849 HPV-16/18 vaccinated women in
CPRD GOLD, 207 exposed and 632 non-exposed
women were eligible. SA occurred in 11.6% of the ex-
posed and 9.0% of the non-exposed cohort. The age-
adjusted hazard ratio (HR) for SA in exposed versus
non-exposed women during the risk period was 1.30
(95% CI: 0.79; 2.12, p-value = 0.30). Sensitivity anal-
ysis showed a higher risk of SA among women receiv-
ing 2 doses (n = 29) during the risk period, with an
adjusted HR of 2.55 (1.09; 5.93, p-value = 0.03) but
not when receiving only 1 dose (n = 178, HR 1.11
(0.64; 1.91), p-value = 0.71). Similar results were ob-
tained when an extended risk period (-30/+90 days)
was considered.
Conclusions: There was no evidence of an increased
risk of SA in women with LMP 30 days before to
45 days after any dose of HPV-16/18 AS04-
adjuvanted vaccine. However, in sensitivity analyses,
there was an increased risk in the small subgroup
of women (<0.05%) receiving 2 doses in the risk
period.
Funding: GlaxoSmithKline Biologicals SA
914. Withdrawn by Author
915. Risk of Microscopic Colitis during Use of PPIs,
NSAIDs, beta-Blockers and Other Drugs
Gwen MC Masclee,1,2 Preci M Coloma,1 Ernst J
Kuipers,2 Miriam CJM Sturkenboom.1 1Medical Infor-
matics, Erasmus University Medical Center, Rotterdam,
Netherlands; 2Gastroenterology and Hepatology, Erasmus
University Medical Center, Rotterdam, Netherlands.
Background: Microscopic colitis (MC) is increas-
ingly recognized as important cause of chronic diar-
rhea in the elderly. In recent years, several drugs
were reported to increase the risk of MC. However,
studies lacked a clear exposure deﬁnition or did not
address dose- and duration-relationships.
Objectives: To estimate the risk of MC during use of
several drugs, such as NSAIDs, PPIs, beta-blockers
(BBL) and low-dose aspirin (LDA).
Methods: Design: Nested case-control study within a
population based cohort.
Setting: Dutch general practice (GP) database (IPCI).
Outcomes: Incident MC cases (aged≥ 18 years) iden-
tiﬁed by free text search with manual validation to en-
sure histological conﬁrmation. Controls: 1)community-
based; 2)patients with negative colonoscopy results
were matched on age, sex and GP practice.
Exposure: Drug use was determined within 1
and 2years prior to index date (date of earliest symptoms).
abstract 491
© 2014 The Authors Pharmacoepidemiology and Drug Safety
© 2014 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety, 2014; 23(S1): 1–497
DOI: 10.1002/pds
Statistical analysis: Matched (OR) and adjusted
odds ratios (ORa) by conditional logistic regression.
Results: Out of 1,458,410 subjects we matched 218
incident MC cases to 15,045 community controls.
Current use (≤3months) of proton pump inhibitors
(PPIs), NSAIDs, selective serotonin re-uptake inhibi-
tors (SSRIs), LDA, BBL and ACE-inhibitors (ACEI)
increased the risk of MC compared to never use, with
ORa between 2.6 (95%CI:1.5-4.4) for BBL and 7.2
(95%CI:4.4-11.9) for PPIs evaluating ≤1 year prior to
index date. Accounting for diagnostic delay (≤2 year
prior to index date) only current use of NSAIDs, PPIs,
SSRIs, LDA and ACEI increased the risk of MC.
Statins did not increase the risk of MC. Higher doses
did not show higher risks for MC. When estimating
the risk of MC compared to colonoscopy-test negative
controls, only current use of PPIs and BBL signiﬁ-
cantly increased the risk of MC (ORa 4.3 and 6.8,
respectively).
Conclusions: The risk of MC increased from 3 up to
7-fold with current use of NSAIDS, PPIs, low-dose
aspirin, ACE-inhibitors and beta-blockers when
compared to community-based controls. This in-
creased risk is likely explained by diagnostic bias
since only PPIs and beta-blockers remained to
signiﬁcantly increase the risk when compared to
colonoscopy negative controls.
916. A Descriptive Analysis to Compare the
Occurrence of Myocardial Infarction (MI) in
Testosterone-Treated and Untreated Hypogonadal
Males and PDE5-Inhibitor Users
Hu Li,1 Karin Benoit,2 James Michael,3 Stephen
Motsko.4 1GPS, Eli Lilly and Company, Indianapolis;
2Eli Lilly and Company, Indianapolis; 3Eli Lilly and
Company, Indianapolis; 4Eli Lilly and Company,
Indianapolis.
Background: Finkle et al. 2014, using the Truven
Health MarketScan database, concluded that the risk
of MI increased after patients received a prescription
for testosterone replacement therapy (TRT). The study
did not compare the MI risk between TRT patients and
untreated hypogonadal (HG) men, but rather used
PDE-5 inhibitor (PDE5i) patients as the comparator.
Objectives: To investigate the risk of MI among adult
men receiving TRT prescriptions (w/o PDE5i) vs. HG
men not receiving TRT vs. patients receiving PDE5i.
Methods: The study used the 2006 to 2010 US-based
Truven Health MarketScan Databases. The index date
was the ﬁrst prescription or ﬁrst randomly assigned
HG diagnosis date. The pre-index period was
12months. The MI event rate (inpatient ICD-9 410)
was calculated during the pre-index period, and during
90, 180, 365 post-index days, using mean and condi-
tional probability divided into 30-day time-windows
for 365 days. Analyses were stratiﬁed by age.
Results: 142,358 TRT patients, 86,643 untreated HG
men and 359,321 PDE5i patients (without TRT pre-
scriptions) were identiﬁed. Compared to untreated men
(aged 51.5 ± 12.96), the TRT patients (aged
53.0± 11.45), and PDE5i patients (aged 54.9 ± 10.82)
were, on average, slightly older. Among TRT patients,
an increase in the MI incidence rate was found during
the 90-day post-index period (5.61, 95%CI: 4.76 -
6.45 per 1,000 PY) as compared to the pre-index period
(4.59, 4.24 – 4.95), especially among elderly patients
(>65 years). This increase trend was not found among
PDE5i patients, consistent with Finkle. Among un-
treated HG men, a similar increase was observed during
the 90-day post-index period (6.57, 5.40- 7.73),
compared to the pre-index period (4.48, 4.03-4.92). A
similar increase in MI incidence rate was also observed
when compared to PDE5i patients.
Conclusions: As literature indicates that HG is a risk
factor for CV events, this unadjusted analysis suggests
that HG, rather than TRT, may contribute to the in-
creased MI risk in this population. Future adjusted
studies are warranted to further understand MI risk in
treated and untreated HG patients.
917. Risk of Sudden Sensorineural Hearing Loss in
Adults Using Phosphodiesterase Type 5 Inhibitors
Wei Liu,1 Patrick J Antonelli,2 Philipp Dahm,3 Tobias
Gerhard,4 Joseph AC Delaney,5 Richard Segal,1 Stephen
Crystal,4 Almut G Winterstein.1 1Pharmaceutical Out-
come and Policy, University of Florida, Gainesville,
FL, United States; 2Otolaryngology, University of
Florida, Gainesville, FL, United States; 3Urology,
University of Florida,Gainesville, FL,United States; 4Institute
of Health, Health Care Policy and Aging Research, Rutgers
University, New Brunswick, NJ, United States; 5Epidemiol-
ogy, University of Washington, Seattle, WA, United States.
Background: Phosphodiesterase type 5 (PDE5) inhib-
itors are the ﬁrst line therapy for erectile dysfunction
(ED). There has been accumulating evidence from
case reports and animal studies suggesting that PDE5
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inhibitor exposure might increase the risk of sudden
sensorineural hearing loss (SSHL).
Objectives: To evaluate the risk for SSHL associated
with the use of PDE5 inhibitors.
Methods: We conducted a cohort study in the
MarketScan Commercial Claims and Encounter Data-
base between 1998 and 2007. The primary analysis in-
volved 377,722 male adults who initiated treatment
with a PDE5 inhibitor and 1,957,233 nonusers. Pe-
riods of use were measured time-dependently for 3
PDE5 inhibitors using varying assumptions regarding
utilization pattern. SSHL was deﬁned based on
ICD9-CM codes combined with 2 CPT codes for au-
diometric hearing tests. We used Cox PH models to
evaluate the risk of SSHL during periods of PDE5 in-
hibitor use against nonuse, adjusting for propensity
score and age as a time-dependent variable. We con-
ducted sensitivity analyses included, besides varying
exposure deﬁnitions, restriction to cases treated with
systemic steroids after SSHL diagnosis, PS matching,
and inclusion of additional time-dependent covariates
to reduce residual confounding.
Results: The cohort included 1,233 SSHL cases with
4,652,265 person-years of follow-up. In the primary
analysis (where patients were assumed to use 1 PDE5 in-
hibitor dose per week), current users had higher rates of
SSHL than did nonusers (adjusted HR=1.29, [95% CI,
1.01, 1.55]; excess risk = 1.97 SSHL cases per 1,000 ex-
posure-years). The HR for SSHL was 1.60 (1.33, 1.94)
comparing recent use with nonuse. When patients were
assumed to take 1 PDE5 inhibitor every 2weeks, the
HR was 1.24 (1.02, 1.50) and 1.66 (1.34, 2.06) compar-
ing current and recent use with nonuse. When we
restricted SSHL cases to subsequent treatment with oral
or intra-tympanic steroids, the HR was 1.36 (1.11,
1.72) and 1.54 (1.17, 1.86) respectively. The results were
not meaningfully altered in most sensitivity analyses.
Conclusions: PDE5 inhibitors are associated with a
small but signiﬁcant increased risk of SSHL in male
adults treated with these drugs for ED.
918. An Innovative Approach to Benefit-Risk As-
sessment Addressing Quality and Efficiency with
Transformative Technology: Insights and Lessons
from a Pilot Initiative
Mondira Bhattacharya,1 Tobias Sayre,2 Jeff Frimpter,2
Scott Snyder.1 1Pharmacovigilance and Patient Safety,
AbbVie, Inc., North Chicago, IL, United States; 2Doctor
Evidence LLC, Santa Monica, CA, United States.
Background: Beneﬁt-risk (B-R) assessments con-
ducted by manufacturers in line with regulatory
standards require focused review of large amounts of
data and a structured, disciplined approach to deci-
sion-making. An evidence-based medicine (EBM)
technology platform was applied to this process.
Objectives: To demonstrate the application of an EBM
technology platform to the B-R assessment process uti-
lizing the FDA structured framework by a biopharma-
ceutical research and development organization.
Methods: The Doctor Evidence (DRE) systematic
literature review and synthesis platform was utilized
to identify, organize, and aggregate evidence related
to assessment of existing treatments for efﬁcacy and
safety within the “Current Treatment Options” of the
FDA’s B-R framework. Sixteen published studies were
identiﬁed and examined using the DRE EBM platform
allowing AbbVie scientists and medical professionals
to coordinate longitudinally on a B-R project.
Results: The DRE platform provided strong, intuitive
data aggregation capabilities, producing reports across
pertinent studies within a disease state. Analyses pro-
vided a more quantitative perspective to the tradition-
ally qualitative representations in B-R assessments.
Graphical outputs improved the visualization of the ef-
ﬁcacy and safety proﬁle of a developmental compound
with marketed treatments. The EBM technology plat-
form allowed for presentation of synthesized safety
and efﬁcacy data to multidisciplinary stakeholders fa-
cilitating development of B-R conclusions. Depth of
the meta-analysis functionality within the EBM plat-
form was limited by differences in published terminol-
ogies; however, the platform is being reﬁned to
account for diverse ontologies.
Conclusions: This technology and application enabled
an AbbVie B-R team to efﬁciently gain collective per-
spective on the plethora of published and internal data
generated for a developmental compound. Feedback
was implemented by DRE to allow the B-R team to im-
prove the depth of their analyses. This pilot effort has
provided a standardized approach to the operational
considerations for conducting B-R in the future.
919. Educational Intervention to Improve the
Practice of Pharmacovigilance among Traditional
Medicine Practitioners
IbrahimOreagba, IwalewaOgunleye.Pharmacology, College
of Medicine, University of Lagos, Idiaraba, Lagos, Nigeria.
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Background: In the face of the growing usage of
herbs, pharmacovigilance of herbal medicine is still
in its infancy. Literatures have indicated lack of aware-
ness as one of the major barriers to pharmacovigilance.
Objectives: To improve the practice of pharma-
covigilance among traditional medicine practitioners in
Lagos State through an educational intervention.
Methods: A total of 237 traditional medicine practi-
tioners attended a one day workshop on pharma-
covigilance. A well structured questionnaire consisting
of questions to test knowledge of pharmacovigilance, at-
titude and knowledge of practice of pharmacovigilance
was ﬁlled by the participants at the start of the workshop
and the same set of questionnaire was also ﬁlled at the
end of the training. Data collected were analysed using
SPSS 17.0. The impact of the training on the knowledge
and attitude was determined using the paired t-test.
Results: A comparison of TMPs knowledge, attitude
and knowledge of practice scores before and after the
intervention showed signiﬁcant differences. The mean
knowledge score at baseline increased from 15.2 ± 4.6
to 16.5 ± 4.9 with (p-value of 0.063).
The mean attitude score at baseline increased from
4.1 ± 0.6 to 4.5 ± 0.6 (p value of 0.001).
The mean knowledge of practice score at baseline
increased from 8.4 ± 1.3 to 9.1 ± 1.3 (p value of 0.04).
Gender and educational qualiﬁcation inﬂuenced
knowledge of practice and attitude of TMPs to
pharmacovigilance.
Conclusions: The educational intervention had a great
impact on the attitude and knowledge of practice of
pharmacovigilance amongst the practitioners. More
training sessions might be needed for the overall effect
to be seen in their knowledge and practice. It is impor-
tant to emphasize the need for traditional medicine
practitioners to associate with a regulatory authority
so as to checkmate their activities. Educational inter-
ventions like this should be carried out from time to
time in order to sustain their knowledge and hence
ensure the safe use of herbs since herbal medicine is
popular and there is a greater acceptance of herbal
medicine in Nigeria and the world over.
920. Natural Language Processing of Clinical Notes
in Electronic Health Records to Improve Capture of
Hypoglycemia
Anthony P Nunes,1 Shengsheng Yu,2 Karen Kurtyka,2
Cynthia Senerchia,3 Jefffrey Hill,3 Kimberly G
Brodovicz,2 Larry Radican,2 Samuel S Engel,2 Sean R
Calvo,3 David D Dore.1,4 1Optum, Waltham, MA, United
States; 2Merck Sharp & Dohme Co., Whitehouse Station,
NJ, United States; 3Humedica, Boston, MA, United
States; 4Brown University, Providence, RI, United States.
Background: Hypoglycemia is under ascertained in
healthcare billing data, especially for mild or moderate
events. Clinical notes in electronic health records
(EHR) include details of medical encounters that
may not be represented in structured data ﬁelds.
Objectives: We assessed whether natural language
processing (NLP) of clinical notes increases capture
of hypoglycemia events and hypoglycemia severity.
Methods: The Humedica statistically deidentiﬁed
EHR database includes information on over 25 million
patients from 195 hospitals throughout the United
States. We identiﬁed all patients in Humedica with
an International Classiﬁcation of Diseases, Ninth Re-
vision (ICD-9) diagnosis code for diabetes mellitus
between January 2007 and September 2013. Hypogly-
cemia was identiﬁed via NLP of clinical notes and
ICD-9 codes within structured data ﬁelds. The hypo-
glycemia NLP algorithm was developed iteratively
by specifying, reviewing, and updating term lists that
originated from standard clinical nomenclature. Term
analogs were included to account for differences in
spacing, hyphenation, and spelling. A clinical nurse spe-
cialist manually identiﬁed additional terms from notes
and the algorithm searched for expressions that were
highly correlated with known hypoglycemia terms.
Results: Of 1,914,324 patients with diabetes, 286,386
(15.0%) had ≥ 1 hypoglycemia event identiﬁed via
NLP and 148,158 (7.7%) had ≥ 1 event identiﬁed via
ICD-9. Only 49,544 patients had an event identiﬁed
by both NLP and ICD-9. Information on severity
was available for ≥ 1 event for 38,241 patients
(13.4%) with NLP-identiﬁed hypoglycemia; 19,984
patients had ≥ 1 event described as mild to moderate
and 23,237 had ≥ 1 event described as severe.
Conclusions: NLP of clinical notes broadened the
capture of hypoglycemia events relative to ICD-9
diagnoses alone and identiﬁed a largely different set
of events. Mild-moderate events were underrepre-
sented and may not be reported to providers or may
not include descriptions of severity when noted.
921. Incidence Rate of Microscopic Colitis in the
Netherlands
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Gwen MCMasclee,1,2 Preci M Coloma,1 Ernst J Kuipers,2
Miriam CJM Sturkenboom.1 1Medical Informatics, Erasmus
University Medical Center, Rotterdam, Netherlands;
2Gastroenterology and Hepatology, Erasmus University
Medical Center, Rotterdam, Netherlands.
Background: Chronic diarrhea is a common problem
and affects quality of life. Microscopic colitis (MC) is
increasingly recognized as important cause of chronic
diarrhea in the elderly. The incidence rate (IR) of
MC, including two entities: lymphocytic (LC) and
collagenous colitis (CC), increased in recent years.
This may be due to detection bias because more
diagnostic colonoscopies are being performed. Up to
date incidence studies accounting for this are lacking.
Objectives: To estimate the IR of MC in the general
population in the Netherlands.
Methods: Design: Cohort study, study period from 1st
January 2003 to May 2013.
Setting: Dutch general practice database (IPCI).
Outcomes: Microscopic colitis (CC, LC and
unspeciﬁed) identiﬁed by free text search and
manual validation of medical records from general
practitioners
Statistical analysis: Standardized software provided
age- and sex-speciﬁc IR for LC and CC separately.
Results: The study population of 1,458,410 subjects
contributed to 4,158,573 person-years (PYS). We
identiﬁed 210 incident MC cases (LC: 122; CC: 88; un-
speciﬁed: 54), yielding an overall IR of 5.1/100,000
PYS; 2.1/100,000 PYS for CC; 1.6/100,000 PYS for
LC and 1.3/100,000 PYs for unspeciﬁed MC. IR of
MC overall, CC and LC separately remained stable from
2003 (IR MC overall: 3.5/100,000 PYS) until 2013 (IR
MC overall: 2.5/100,000 PYS). IR of LC increased after
the age of 50-54 years (3.0/100,000 PYS) until 75-79
years (7.2/100,000 PYS), whereas for CC the IR
increased already from the age of 45-49 years
(1.2/100,000 PYS) until 80-84 years of age (7.9/100,000
PYS). However, across age groups IRs of CC, and LC
were comparable. Across all ages and calendar years, IR
was 2-4 times higher for females than males. Accounting
for possible detection bias: IR of MC decreased from
5.6/1,000 colonoscopies in 2003 to 2.4 in 2012.
Conclusions: Incidence rates of MC remained fairly
stable during a 10-year period from 2003-2013 in the
Netherlands, taking into account the increase in the
total number of colonoscopies over this period. IR of
MC increased with ageing, for CC at 50 years and
for LC at 60 years of age and was 2-4 times higher
for females than males across all ages.
922. The Positive Impact of Pharmacist on Appropri-
ateness of Ambulatory Prescriptions inMedical Center
Wen Chuan Lin, Huei Chuan Lee, Wen Liang Lin,
Shu Hua Tai, Feng Ying Yeh, Hui Hui-Jen Chang.
Department of Pharmacy, National Cheng Kung
University Hospital, Tainan.
Background: Health care service is highly afﬁnity in
Taiwan. Many patients intend to go to medical center
for better care and may follow up in different doctors.
It makes physician prescribed drugs in extreme time.
In other side, Taiwan is aging society, multiple
medication use is common in older adults. Multiple med-
ication use is a major risk factor for prescribing error,
drug related problems and other adverse health outcomes.
Pharmacist is the specialist in medication use, so we cre-
ated an integrated service model for ambulatory patients
to improve their appropriateness of prescriptions.
Objectives: Pharmacist took active intervention to
improve patient health care and decrease unnecessary
medication use.
Methods: Patients mainly followed in National Cheng
Kung University Hospital (NCKUH) clinics were
included during 2010-2012. Pharmacists collected re-
lated data from medical chart prospectively and inter-
view patient as needed focusing on drug utilization.
Then we consulted doctors for dissolving drug related
problems. Finally, the economic impact and prescrip-
tion pattern were estimated by cooperation with
National Health Insurance Administration.
Results: A total of 7871 patients were recruited. 366
drug related problems were consulted during the three
years. Male (n = 213) was much more than female
(n = 153). Most of them are geriatric patients (65-84
years old). The top three DRP were duplication of
same pharmacology class, medication use without in-
dication, and non-adherence/ drug-disease interaction.
The common offending drugs was metformin (n = 28).
The medical cost and medication number per person
were all decreased ﬁnally.
Conclusions: The aggressively intervention of phar-
macists had positive impact on ambulatory patients
medication use in NCKUH, not only improving
appropriateness of prescription, but also decreasing
the burden of Nation Health Insurance.
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923. Risk of Diabetes among Patients Exposed
to Primary Androgen Deprivation Therapy for
Clinically Localized Prostate Cancer
Huei-Ting Tsai,1 Nancy L Keating,2 Marianne Ulcickas
Yood,3 Stephen K Van Den Eeden,4 Reina Haque,5
Andrea E Cassidy-Bushrow,6 Matthew R Smith,7 Arnold
L Potosky.1 1Department of Oncology, Lombardi
Comprehensive Cancer Center, Georgetown University
Medical Center, Washington, DC, United States;
2Department of Health Care Policy, Division of General
Internal Medicine, Harvard Medical School, Brigham
and Women’s Hospital, Boston, MA, United States;
3Department of Epidemiology, Boston University
School of Public Health, Boston, MA, United States;
4Division of Research, Kaiser Permanente Northern
California, Oakland, CA, United States; 5Division of
Research & Evaluation, Kaiser Permanente Southern Cali-
fornia, Pasadena, CA, United States; 6Department of Public
Health Sciences, Henry Ford Hospital, Detroit, MI, United
States; 7Genitorurinary Oncology Program, Massachusetts
General Hospital, Boston, MA, United States.
Background: The use of primary androgen depriva-
tion therapy (PADT) to treat localized prostate cancer
remains controversial due to lack of evidence regarding
survival beneﬁt and concern of harmful effects. This
study quantiﬁed risk of diabetes mellitus (DM) in
patients with localized prostate cancer receiving PADT.
Objectives: To understand risk of diabetes associated
with PADT among men with clinically localized
prostate cancer.
Methods: Using data from three health plans in the
Health Maintenance Organization (HMO) Cancer Re-
search Network, we conducted a retrospective cohort
study of 12,191 men with clinically localized prostate
cancer, without DM diagnosis before and 90 days after
prostate cancer diagnosis, and who hadn’t received
curative intent treatment one year after prostate
cancer diagnosis. We deﬁned PADT as gonadotropin -
releasing hormone (GnRH) agonists use within
12months after prostate cancer diagnosis without
surgery or radiation. Incident DM was deﬁned by ﬁrst
record of DM at least 90 days after prostate cancer
diagnosis from inpatient and outpatient diagnoses
codes, anti-diabetic medication prescriptions, or a
hemoglobin A1c greater than 7%. We conducted
Cox-proportional hazards models with conventional
and propensity score analyses to estimate DM risk
associated with PADT use in clinically localzied
prostate cancer.
Results: 1,203 (9.9%) patients developed incident
DM; DM incidence rate was 2.48 events per 100
person-years in the PADT group and 1.61 per 100
person-years in the non-PADT group. PADT was
associated with 1.6 fold increased risk of DM (95%
C.I. = 1.4, 1.9) after adjusting for patient age, race,
diagnosis year, history of other cancer, hypertension,
hyperlipidemia, and obesity in the multivariable
models. Propensity score analyses results were
similar.
Conclusions: PADT may be associated with an
increased rate of DM in prostate cancer patients.
Further study of the relative risks and beneﬁts of
PADT for early-stage prostate cancer are needed.
Physicians and patients should consider the PADT-
associated risk of DM before use.
924. Study of Ursodeoxycholic Acid Influence on
Efficacy and Safety of Statin Therapy in Patients
with Liver, Gall Bladder and/or Biliary Tract
Diseases (the RAKURS Study)
Sergey Martsevich,1 Nataly Kutishenko,2 Lyubov
Drozdova,3 Olga Lerman.4 1Department for Preventive Phar-
macotherapy, State ResearchCenter for PreventiveMedicine,
Moscow, Russian Federation; 2Department for Preventive
Pharmacotherapy, State Research Center for Preventive
Medicine, Moscow, Russian Federation; 3Department for
Preventive Pharmacotherapy, State Research Center for Pre-
ventiveMedicine,Moscow, Russian Federation; 4Department
for Preventive Pharmacotherapy, State Research Center for
Preventive Medicine, Moscow, Russian Federation.
Background: Patients with a high risk of cardiovascu-
lar complications and liver disease often do not receive
the necessary treatment with statins.
Objectives: To assess the potential of ursode-
oxycholic acid (UDCA) in the prevention of liver
dysfunction in patients with cardiovascular diseases
(CVD) and high risk of cardiovascular events (CVE)
with indications for statins use.
Methods: Patients (n = 262, age 60.1 ± 8.9 years)
took statins for secondary prevention of CVE in
observational cohort study. The follow-up duration
was 6months. UDCA was recommended for all
patients because of liver diseases and/or biliary tract.
Some of the patients with high treatment compliance
strictly followed recommendations to take UDCA,
and another part of the patients with low treatment
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compliance did not take UDCA. Comparison of these
groups allowed highlighting UDCA effects.
Results: Controlled lipid-lowering therapy in combina-
tionwith UDCA resulted in a signiﬁcant reduction in total
cholesterol (TC) and low density lipoprotein cholesterol
(LDL) levels after 6months of follow-up to 4.3mmol/L
and 2.3mmol/L, respectively (p< 0.001). Deterioration
in the dynamics of alanineaminotransferase (ALT), as-
partate aminotransferase (AST), creatinphosphokinase
(CPK) and gamma glutamine transferase (GGT), as well
as increase in serum bilirubin was not found. Moreover,
in general signiﬁcant decrease inALT, AST,GGT and al-
kaline phosphatase (p< 0.001) was observed, the levels
of total serum bilirubin and CPK did not change at the
end of the study (p=0.65 and p=0.16, respectively).
Taking UDCA simultaneously with statins led to addi-
tional reduction in TC and LDL compared with statin
monotherapy (p=0.01).
Conclusions: One of the affordable and effective ways
to deal with a wider statin use in patients with liver
and biliary tract disorders is their co-administration
with UDCA.
925. A Comparative Analysis of Signal Detection in
Electronic Healthcare Databases vs. Spontaneous
Reporting Databases
Alexandra C Pacurariu,1,2 Preciosa M Coloma,1 Gianluca
Triﬁro,1,3 Sabine M Straus,1,2 Martijn J Schuemie,1 Rosa
Gini,4 Ron Herings,5 Giampiero Mazzaglia,6 Gino
Picelli,7 Lorenza Scotti,8 Lars Pedersen,9 Johan van der
Lei,1 Miriam C Sturkenboom.1 1Medical Informatics,
Erasmus University Medical Center, Rotterdam,
Netherlands; 2Pharmacovigilance, Dutch Medicines
Evaluation Board, Utrecht, Netherlands; 3Clinical and
Experimental Medicine, University of Messina, Messina,
Italy; 4Agenzia Regionale di Sanità della Toscana,
Florence, Italy; 5PHARMO Institute, Utrecht,
Netherlands; 6Società Italiana di Medicina Generale,
Florence, Italy; 7Pedianet-Società Servizi Telematici
SRL, Padova, Italy; 8Statistics, Università diMilano-Bicocca,
Milan, Italy; 9Clinical Epidemiology, Aarhus University
Hospital, Aarhus, Denmark.
Background: Electronic healthcare records (EHR) da-
tabases are now increasingly being considered as a
source of information for signal detection and validation
activities, complementary to spontaneous reporting
systems (SRS).
Objectives: The objective of this study was to investi-
gate the degree of complementarity of signal detection
in the two different systems.
Methods: A retrospective evaluation was performed
in an European EHR database network (EU-ADR)
and a SRS database (Eudravigilance) for the time pe-
riod 2000-2009. We focused on two different adverse
events: bullous eruptions (BE) and acute myocardial
infarction (AMI). A disproportionality-based method,
the proportional reporting ratio (PRR), was used in
Eudravigilance (PRR lower CI95%> 1) and a co-
hort-based method, Longitudinal Gamma Poisson
Shrinker (LGPS) (lower CI95%> 1), in EU-ADR for
the purpose of initial screening for signals. A set of
positive and negative test cases was constructed using
data available literature and in the product information
leaﬂet. The performance of the systems was assessed
by means of diagnostic-test related methods.
Results: For AMI, 221 potential signals were found in
the two systems, out of which 33 (15%) were identi-
ﬁed only in Eudravigilance and 174 (78.7%) only in
EU-ADR. Sensitivity for AMI detection was greater
in EU-ADR compared to Eudravigilance (29.2% vs.
17.5%) at a cost of slightly decreased speciﬁcity
(80.3% vs. 96.7%). For bullous eruption, 116 signals
were found, 60 (51.8%) in Eudravigilance and 28
(24.1%) in EU-ADR. For this event, Eudravigilance
was more sensitive (61.1% vs. 27.8%), again with a
loss in speciﬁcity (74.6% vs. 82.0%).
Conclusions: Signal detection in EHR databases has
better sensitivity for more common events such as
myocardial infarction and this feature can be exploited
for ﬁnding additional signals if the drawback of low
speciﬁcity can be overcome. In contrast, SRS appears
to be a better source for detection of rare events.
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